PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	PG	WC	SC	GA	UT	PM
J	Zhou, L; Ohashi, Y; Yoshida, M				Zhou, Liang; Ohashi, Yoji; Yoshida, Makoto			Low Complexity Millimeter-Wave LOS-MIMO Systems with Uniform Circular Arrays for Small CellsWireless Backhaul	IEICE TRANSACTIONS ON COMMUNICATIONS			English	Article						channel capacity; BER; LOS-MIMO; millimeter-wave; precoding; spatial interleaver; 5G; small cells; wireless backhaul; uniform circular arrays (UCAs)	CHANNELS; CAPACITY; DESIGN; 5G	The dramatic growth in wireless data traffic has triggered the investigation of fifth generation (5G) wireless communication systems. Small cells will play a very important role in 5G to meet the 5G requirements in spectral efficiency, energy savings, etc. In this paper, we investigate low complexity millimeter-wave communication systems with uniform circular arrays (UCAs) in line-of-sight (LOS) multiple-input multiple-output (MIMO) channels, which are used in fixed wireless access such as small cell wireless backhaul for 5G. First, we demonstrate that the MIMO channel matrices for UCAs in LOS-MIMO channels are circulant matrices. Next, we provide a detailed derivation of the unified optimal antenna placement which makes MIMO channel matrices orthogonal for 3 x 3 and 4x4 UCAs in LOS channels. We also derive simple analytical expressions of eigenvalues and capacity as a function of array design (link range and array diameters) for the concerned systems. Finally, based on the properties of circulant matrices, we propose a high performance low complexity LOS-MIMO precoding system that combines forward error correction (FEC) codes and spatial interleaver with the fixed IDFT precoding matrix. The proposed precoding system for UCAs does not require the channel knowledge for estimating the precoding matrix at the transmitter under the LOS condition, since the channel matrices are circulant ones for UCAs. Simulation results show that the proposed low complexity system is robust to various link ranges and can attain excellent performance in strong LOS environments and channel estimation errors.	[Zhou, Liang; Ohashi, Yoji] Fujitsu Labs Ltd, Kawasaki, Kanagawa 2118588, Japan; [Yoshida, Makoto] Fujitsu Labs Ltd, Adv Wireless Technol Lab, Kawasaki, Kanagawa 2118588, Japan	Zhou, L (reprint author), Fujitsu Labs Ltd, Kawasaki, Kanagawa 2118588, Japan.	lzhou@jp.fujitsu.com					Ali I., 2011, BEAM DIVISION MULTIP; [Anonymous], 2012, 80211AD IEEE; [Anonymous], 2014, 5G RAD ACC REQ CONC; Boccardi F, 2014, IEEE COMMUN MAG, V52, P74, DOI 10.1109/MCOM.2014.6736746; [Anonymous], 2009, 802153C IEEE; Hur S, 2013, IEEE T COMMUN, V61, P4391, DOI 10.1109/TCOMM.2013.090513.120848; Scaglione A, 2002, IEEE T SIGNAL PROCES, V50, P1051, DOI 10.1109/78.995062; [Anonymous], 2010, ECMA387; Zhou L, 2007, IEEE VTS VEH TECHNOL, P2078, DOI 10.1109/VETECS.2007.430; [Anonymous], 2009, P IEEE MTT S INT MIC; Telatar E, 1999, EUR T TELECOMMUN, V10, P585, DOI 10.1002/ett.4460100604; Bohagen F, 2007, IEEE T WIREL COMMUN, V6, P1420, DOI 10.1109/TWC.2007.05548; Driessen PF, 1999, IEEE T COMMUN, V47, P173, DOI 10.1109/26.752119; Love DJ, 2005, IEEE T INFORM THEORY, V51, P2967, DOI 10.1109/TIT.2005.850152; Zhou L, 2013, UEEE INT SYM PERS IN, P1397; Sarris I, 2007, IEEE T VEH TECHNOL, V56, P2194, DOI 10.1109/TVT.2007.897240; Muhi-Eldeen Z, 2010, IET MICROW ANTENNA P, V4, P1300, DOI 10.1049/iet-map.2009.0431; Zhou L, 2012, UEEE INT SYM PERS IN, P1885; Chen SZ, 2014, IEEE COMMUN MAG, V52, P36; Wang JY, 2009, IEEE J SEL AREA COMM, V27, P1390, DOI 10.1109/JSAC.2009.091009; Au E.K.S., 2006, P IEEE ISIT JUL; Foschini G. J., 1998, Wireless Personal Communications, V6, DOI 10.1023/A:1008889222784; Gray R.M., 2001, STANFORD U ISL, V2, P155; Li Z.Y., 2014, P IEICE 2014 SOC C S, P146; Matthaiou M., 2010, P INT ICST C COMM NE, P1; Moon TK, 2005, ERROR CORRECTION CODING: MATHEMATICAL METHODS AND ALGORITHMS, P1, DOI 10.1002/0471739219; Raleigh GG, 1998, IEEE T COMMUN, V46, P357, DOI 10.1109/26.662641; Shelly C. C., 2010, P IEEE APSURSI 2010, DOI 10.1145/1805986.1806002; Torkildson E., 2006, P 44 ALL C COMM CONT; Yeh C.J., 2011, P EOS ESD S, P1; Zhou L., 2014, P IEICE 2014 GEN C M, P189; Zhou L., 2014, P IEEE WCNC 2014 APR, P1293; Zhou L., 2013, P IEICE 2013 SOC C S, P195	33	0	0	IEICE-INST ELECTRONICS INFORMATION COMMUNICATIONS ENG	TOKYO	KIKAI-SHINKO-KAIKAN BLDG, 3-5-8, SHIBA-KOEN, MINATO-KU, TOKYO, 105-0011, JAPAN	1745-1345			IEICE T COMMUN	IEICE Trans. Commun.	NOV	2015	E98B	11					2348	2358		10.1587/transcom.E98.B.2348		11	Engineering, Electrical & Electronic; Telecommunications	Engineering; Telecommunications	CV6YP	WOS:000364418600027		
J	Kimura, M				Kimura, Mutsumi			Special Section on Electronic Displays FOREWORD	IEICE TRANSACTIONS ON ELECTRONICS			English	Editorial Material									Ryukoku Univ, Kyoto, Japan	Kimura, M (reprint author), Ryukoku Univ, Kyoto, Japan.							0	0	0	IEICE-INST ELECTRONICS INFORMATION COMMUNICATIONS ENG	TOKYO	KIKAI-SHINKO-KAIKAN BLDG, 3-5-8, SHIBA-KOEN, MINATO-KU, TOKYO, 105-0011, JAPAN	1745-1353			IEICE T ELECTRON	IEICE Trans. Electron.	NOV	2015	E98C	11					999	999				1	Engineering, Electrical & Electronic	Engineering	CV6ZG	WOS:000364420500001		
J	Ochi, M; Shida, Y; Okuno, H; Goto, H; Kugimiya, T; Kanamaru, M				Ochi, Mototaka; Shida, Yoko; Okuno, Hiroyuki; Goto, Hiroshi; Kugimiya, Toshihiro; Kanamaru, Moriyoshi			Al-Based Metal Mesh Electrodes for Advanced Touch Screen Panels Using Aluminum Nitride System Optical Absorption Layer	IEICE TRANSACTIONS ON ELECTRONICS			English	Article						touch screen panel; metal mesh electrode; projected capacitive; invisible; etching property	THIN-FILMS	An Al-N system optical absorption layer has been developed, to be used for Al-based metal mesh electrodes on touch screen panels. The triple-layered electrode effectively suppresses the optical reflection in both visible light and the blue color region and exhibits excellent wet etching property that accommodates micro-fabrication. Due to its high noise immunity and contact sensitivity originating from its low electrical resistivity, the proposed metal mesh electrodes are useful for touch-sensitive panels in the next generation ultra-high-resolution displays.	[Ochi, Mototaka; Shida, Yoko; Goto, Hiroshi; Kugimiya, Toshihiro] Kobe Steel Ltd, Elect Res Lab, Kobe, Hyogo 6512271, Japan; [Okuno, Hiroyuki; Kanamaru, Moriyoshi] Kobelco Res Inst Inc, Tech Engn Dept, Kobe, Hyogo 6512271, Japan	Ochi, M (reprint author), Kobe Steel Ltd, Elect Res Lab, Kobe, Hyogo 6512271, Japan.	ochi.mototaka@kobelco.com					Joo HY, 1999, J VAC SCI TECHNOL A, V17, P862, DOI 10.1116/1.582035; Chen H, 2000, APPL PHYS LETT, V77, P1117, DOI 10.1063/1.1289496; LOH WM, 1985, IEEE ELECTR DEVICE L, V6, P441, DOI 10.1109/EDL.1985.26185; Jadwisienczak WM, 2000, APPL PHYS LETT, V76, P3376, DOI 10.1063/1.126652; Tsujimura T, 2002, J VAC SCI TECHNOL B, V20, P1907, DOI 10.1116/1.1502704; Khoshman JM, 2005, J NON-CRYST SOLIDS, V351, P3334, DOI 10.1016/j.jnoncrysol.2005.08.009; Caldwell M.L., 2000, P MRS, V639; Gurumurugan K, 1999, APPL PHYS LETT, V74, P3008, DOI 10.1063/1.123995; Haga H., 2012, SID S, V43, P489; Hattori R., 2012, NIKKEI ELECT, P40; Mitani Y., 2011, NIPPON GOMU KYOKAISH, V84, P256; Nakatani N., 2012, P IDW 12, P807; Ochi M., 2013, P IDW 13, P371; Pan Der Pauw L.J., 1959, PHILIPS TECH REV, V20, P220; Pan Der Pauw L.J., 1958, PHILIPS RES REP, V13, P1; Smith T., 1931, T OPTICAL SOC, V33; Takahashi S., 2010, SID S, V41, P544	17	0	0	IEICE-INST ELECTRONICS INFORMATION COMMUNICATIONS ENG	TOKYO	KIKAI-SHINKO-KAIKAN BLDG, 3-5-8, SHIBA-KOEN, MINATO-KU, TOKYO, 105-0011, JAPAN	1745-1353			IEICE T ELECTRON	IEICE Trans. Electron.	NOV	2015	E98C	11					1000	1007		10.1587/transele.E98.C.1000		8	Engineering, Electrical & Electronic	Engineering	CV6ZG	WOS:000364420500002		
J	Haga, H; Yoshinaga, K; Yanase, J; Sugimoto, D; Takatori, K; Asada, H				Haga, Hiroshi; Yoshinaga, Kazuhide; Yanase, Jiro; Sugimoto, Daisuke; Takatori, Kenichi; Asada, Hideki			Electrostatic Tactile Display Using Beat Phenomenon for Stimulus Localization	IEICE TRANSACTIONS ON ELECTRONICS			English	Article						tactile display; electrostatic force; beat phenomenon; multi touch; user experience		We present an electrostatic tactile display for stimulus localization. The 240-Hz electrostatic force was generated by the beat phenomenon in a region where excited X electrodes cross excited Y electrodes, which presents localized tactile sensation out of the entire surface. A 10.4-in. visual-tactile integrated display was successfully demonstrated.	[Haga, Hiroshi; Yoshinaga, Kazuhide; Yanase, Jiro; Sugimoto, Daisuke; Takatori, Kenichi; Asada, Hideki] NLT Technol Ltd, Kawasaki, Kanagawa 2118666, Japan	Haga, H (reprint author), NLT Technol Ltd, Kawasaki, Kanagawa 2118666, Japan.	h-haga@nlt-technologies.com					Kaczmarek KA, 2006, IEEE T BIO-MED ENG, V53, P2047, DOI 10.1109/TBME.2006.881804; MALLINCKRODT E, 1953, SCIENCE, V118, P277, DOI 10.1126/science.118.3062.277; STRONG RM, 1970, IEEE T MAN MACHINE, VMM11, P72, DOI 10.1109/TMMS.1970.299965; Bau O., 2010, UIST 2010, P283; Fukumoto M., 2001, CHI 01, P121; Kajimoto H., 2012, SIGGRAPH AS 2012 EM, P1; Poupyrev I., 2003, UIST 03, P217; Tang H, 1998, IEEE Trans Rehabil Eng, V6, P241	8	0	0	IEICE-INST ELECTRONICS INFORMATION COMMUNICATIONS ENG	TOKYO	KIKAI-SHINKO-KAIKAN BLDG, 3-5-8, SHIBA-KOEN, MINATO-KU, TOKYO, 105-0011, JAPAN	1745-1353			IEICE T ELECTRON	IEICE Trans. Electron.	NOV	2015	E98C	11					1008	1014		10.1587/transele.E98.C.1008		7	Engineering, Electrical & Electronic	Engineering	CV6ZG	WOS:000364420500003		
J	Manabe, H; Date, M; Takada, H; Inamura, H				Manabe, Hiroyuki; Date, Munekazu; Takada, Hideaki; Inamura, Hiroshi			Low-Power Driving Technique for 1-Pixel Display Using an External Capacitor	IEICE TRANSACTIONS ON ELECTRONICS			English	Article						LCD; PDLC; 1-pixel; low power; capacitor	LIQUID-CRYSTAL	Liquid crystal displays (LCDs) are suitable as elements underlying wearable and ubiquitous computing thanks to their low power consumption. A technique that uses less power to drive 1-pixel LCDs is proposed. It harvests the charges on the LCD and stores them in an external capacitor for reuse when the polarity changes. A simulation shows that the charge reduction depends on the ratio of the capacitance of the external capacitor to that of the LCD and can reach 50%. An experiment on a prototype demonstrates an almost 30% reduction with large 1-pixel LCDs. With a small 10 x 10 mm(2) LCD, the overhead of the micro-controller matches the reduction so no improvement could be measured. Though the technique requires longer time for polarity reversal, we confirm that it does not significantly degrade visual quality.	[Manabe, Hiroyuki; Inamura, Hiroshi] NTT DOCOMO, Res Labs, Yokosuka, Kanagawa 2398536, Japan; [Date, Munekazu; Takada, Hideaki] NTT Corp, NTT Media Intelligence Labs, Yokosuka, Kanagawa 2390847, Japan	Manabe, H (reprint author), NTT DOCOMO, Res Labs, Yokosuka, Kanagawa 2398536, Japan.	manabehiroyuki@acm.org					Choi I, 2002, ISLPED'02: PROCEEDINGS OF THE 2002 INTERNATIONAL SYMPOSIUM ON LOW POWER ELECTRONICS AND DESIGN, P112; Izadi S, 2008, UIST 2008: PROCEEDINGS OF THE 21ST ANNUAL ACM SYMPOSIUM ON USER INTERFACE SOFTWARE AND TECHNOLOGY, P269, DOI 10.1145/1449715.1449760; Wong KV, 2014, J ENERG RESOUR-ASME, V136, DOI 10.1115/1.4024768; Lampert CM, 1999, P SOC PHOTO-OPT INS, V3788, P2, DOI 10.1117/12.365772; DRZAIC PS, 1986, J APPL PHYS, V60, P2142, DOI 10.1063/1.337167; Asaoka Y, 2009, 2009 SID INTERNATIONAL SYMPOSIUM DIGEST OF TECHNICAL PAPERS, VOL XL, BOOKS I - III, P395; Macchione M, 2000, LIQ CRYST, V27, P1337; Lampert CM, 2003, SOL ENERG MAT SOL C, V76, P489, DOI 10.1016/S0927-0248(02)00259-3; Xu P, 2006, APPL OPTICS, V45, P4020, DOI 10.1364/AO.45.004020; Hsu HB, 2000, IEEE T IND ELECTRON, V47, P1118, DOI 10.1109/41.873221; Choi BD, 2000, IEEE T CONSUM ELECTR, V46, P1155; Kim JS, 2000, IEEE J SOLID-ST CIRC, V35, P74; Rekimoto J, 2012, PROCEEDINGS OF THE INTERNATIONAL WORKING CONFERENCE ON ADVANCED VISUAL INTERFACES, P168, DOI 10.1145/2254556.2254587; Erhart A., 1997, SID, P23; Gatti F., 2002, P INT C COMP ARCH SY, P218; Kim S.T., 1997, P INT DISPL WORKSH, P155; Manabe H., 2014, P IDW 14, P1343; Manabe H., 2014, P UIST 14, V14, P373; Masunaga optical, WINK GLASS 2013; Pastoor S, 1997, DISPLAYS, V17, P100, DOI 10.1016/S0141-9382(96)01040-2; Seiko electric, SILF; Sung Y.C., 2000, SID S, V31, P142, DOI 10.1889/1.1832902; Yang S. S., 2003, P ISCAS 03, V5, P365	23	0	0	IEICE-INST ELECTRONICS INFORMATION COMMUNICATIONS ENG	TOKYO	KIKAI-SHINKO-KAIKAN BLDG, 3-5-8, SHIBA-KOEN, MINATO-KU, TOKYO, 105-0011, JAPAN	1745-1353			IEICE T ELECTRON	IEICE Trans. Electron.	NOV	2015	E98C	11					1015	1022		10.1587/transele.E98.C.1015		8	Engineering, Electrical & Electronic	Engineering	CV6ZG	WOS:000364420500004		
J	Ishizuka, S; Mukai, T; Kakeya, H				Ishizuka, Shuta; Mukai, Takuya; Kakeya, Hideki			Multi-Phase Convex Lens Array for Directional Backlights to Improve Luminance Distribution of Autostereoscopic Display	IEICE TRANSACTIONS ON ELECTRONICS			English	Article						autostereoscopic display; homogeneous brightness; liner Fresnel lens array		We realize homogenous luminance of the directional backlight for the time-division multiplexing autostereoscopic display using a convex lens array with the elemental lenses whose phase of placement in each row differs from one another. The validity of the proposed optical design is confirmed by a prototype system.	[Ishizuka, Shuta; Mukai, Takuya] Univ Tsukuba, Informat Engn, Tsukuba, Ibaraki 3058573, Japan; [Kakeya, Hideki] Univ Tsukuba, Tsukuba, Ibaraki 3058573, Japan	Ishizuka, S (reprint author), Univ Tsukuba, Informat Engn, Tsukuba, Ibaraki 3058573, Japan.	s1430191@u.tsukuba.ac.jp			JSPS, Japan [25280070]	This research is partially supported by the Grant-in-Aid for Scientific Research, JSPS, Japan, Grant number: 25280070.	Surman P, 2008, J SOC INF DISPLAY, V16, P743, DOI 10.1889/1.2953481; [Anonymous], 2014, P SOC PHOTO-OPT INS; Ishizuka S, 2014, J ELECTRON IMAGING, V23, DOI 10.1117/1.JEI.23.1.011002; Hayashi A, 2010, J SOC INF DISPLAY, V18, P507, DOI 10.1889/JSID18.7.507; Perlin K, 2000, COMP GRAPH, P319; Schultz JC, 2009, 2009 SID INTERNATIONAL SYMPOSIUM DIGEST OF TECHNICAL PAPERS, VOL XL, BOOKS I - III, P127; Gaudreau J.E., 2012, SPIE P, V8288-70; Hattori T., 1996, JP Patent, Patent No. [08-160556, A, 08160556]; Hattori T., 1996, JP Patent, Patent No. [08-160356, A, 16035608]; Hattori T., 1996, JP Patent, Patent No. [08-163603, A, 08163603]; Hattori T., 1996, JP Patent, Patent No. [08-160355, A, 160355]; Hattori T., 1999, SPIE P, V3639, P66; Huang Y.-P., 2012, P IDW AD 12, P1889; Ishizuka S., 2013, SID 13, V44, P1173; Kwon H, 2012, PROC SPIE, V8288, DOI 10.1117/12.907793; Lee H. J., 2006, SID S, V37, P81, DOI 10.1889/1.2433641; Sykora M.J., 2011, SPIE P, V7863-29; Ting C. H., 2011, SID DIGEST, V42, P460; Travis A., 2010, SID 10, V41, P215	19	0	0	IEICE-INST ELECTRONICS INFORMATION COMMUNICATIONS ENG	TOKYO	KIKAI-SHINKO-KAIKAN BLDG, 3-5-8, SHIBA-KOEN, MINATO-KU, TOKYO, 105-0011, JAPAN	1745-1353			IEICE T ELECTRON	IEICE Trans. Electron.	NOV	2015	E98C	11					1023	1027		10.1587/transele.E98.C.1023		5	Engineering, Electrical & Electronic	Engineering	CV6ZG	WOS:000364420500005		
J	Koga, Y; Matsuda, T; Kimura, M; Wang, DP; Furuta, M; Kasami, M; Tomai, S; Yano, K				Koga, Yuki; Matsuda, Tokiyoshi; Kimura, Mutsumi; Wang, Dapeng; Furuta, Mamoru; Kasami, Masashi; Tomai, Shigekazu; Yano, Koki			Capacitance Sensor of Frequency Modulation for Integrated Touchpanels Using Amorphous In-Sn-Zn-O Thin-Film Transistors	IEICE TRANSACTIONS ON ELECTRONICS			English	Article						capacitance sensor; frequency modulation; integrated touch-panel; amorphous In-Sn-Zn-O (alpha-ITZO); thin-film transistor (TFT)		We have developed a capacitance sensor of frequency modulation for integrated touchpanels using amorphous In-Sn-Zn-O (alpha-ITZO) thin-film transistors (TFTs). This capacitance sensor consists of a ring oscillator, whose one stage is replaced by a reset transistor, sensing transistor, and sensing electrode. The sensing electrode is prepared as one terminal to form a sensing capacitor when the other terminal is added by a finger. The ring oscillator consists of pseudo CMOS inverters. We confirm that the oscillation frequency changes when the other terminal is added. This result suggests that this capacitance sensor can be applied to integrated touchpanels on flatpanel displays.	[Koga, Yuki; Matsuda, Tokiyoshi; Kimura, Mutsumi] Ryukoku Univ, Dept Elect & Informat, Otsu, Shiga 5202194, Japan; [Matsuda, Tokiyoshi; Kimura, Mutsumi] Ryukoku Univ, Joint Res Ctr Sci & Technol, Otsu, Shiga 5202194, Japan; [Matsuda, Tokiyoshi; Kimura, Mutsumi] Ryukoku Univ, High Tech Res Ctr, Otsu, Shiga 5202194, Japan; [Wang, Dapeng; Furuta, Mamoru] Kochi Univ Technol, Sch Environm Sci & Engn, Kamaishi, Iwate 7828502, Japan; [Kasami, Masashi] Idemitsu Kosan Co Ltd, Elect Mat Dept, Sodegaura, Chiba 2990293, Japan; [Tomai, Shigekazu; Yano, Koki] Idemitsu Kosan Co Ltd, Adv Technol Res Labs, Sodegaura, Chiba 2990293, Japan	Koga, Y (reprint author), Ryukoku Univ, Dept Elect & Informat, Otsu, Shiga 5202194, Japan.	mutsu@rins.ryukoku.ac.jp			Idemitsu Kosan Co. Ltd.; Joint Research Center for Science and Technology at Ryukoku University; High-Tech Research Center Program for private universities from the Ministry of Education, Culture, Sports, Science and Technology (MEXT); MEXT; Faculty of Science and Technology of Ryukoku University	This work is partially supported by a collaborative research with Idemitsu Kosan Co. Ltd., research project of the Joint Research Center for Science and Technology at Ryukoku University, grant from the High-Tech Research Center Program for private universities from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), grant for research facility equipment for private universities from MEXT, and grant for special research facilities from the Faculty of Science and Technology of Ryukoku University.	Nomura K, 2004, NATURE, V432, P488, DOI 10.1038/nature03090; Fukuda K, 2011, IEEE ELECTR DEVICE L, V32, P1448, DOI 10.1109/LED.2011.2161747; Kanda E, 2008, SID INT SYMP DIG TEC, V39, P834; Kimura M, 2003, IEICE T ELECTRON, VE86C, P63; Bhowmik A.K., 2014, INTERACTIVE DISPLAYS; Kimura M., 2014, SID 14, V45, P960; Tomai S, 2012, JPN J APPL PHYS, V51, DOI 10.1143/JJAP.51.03CB01	7	0	0	IEICE-INST ELECTRONICS INFORMATION COMMUNICATIONS ENG	TOKYO	KIKAI-SHINKO-KAIKAN BLDG, 3-5-8, SHIBA-KOEN, MINATO-KU, TOKYO, 105-0011, JAPAN	1745-1353			IEICE T ELECTRON	IEICE Trans. Electron.	NOV	2015	E98C	11					1028	1031		10.1587/transele.E98.C.1028		4	Engineering, Electrical & Electronic	Engineering	CV6ZG	WOS:000364420500006		
J	Matsuzaki, T; Ishinabe, T; Fujikake, H				Matsuzaki, Tomoya; Ishinabe, Takahiro; Fujikake, Hideo			Crystal Axis Control of Soluble Organic Semiconductors in Nematic Liquid Crystal Solvents Based on Electric Field	IEICE TRANSACTIONS ON ELECTRONICS			English	Article						organic semiconductor; liquid crystal solvents; single crystal; electric field		We investigated a control of the crystalline orientation of soluble organic semiconductor single crystals using liquid crystal solvents aligned by the electric field to improve the performance of organic thin-film transistors. We clarified that the semiconductor single crystal grows to the direction parallel to the liquid crystal alignment oriented by the lateral electric field.	[Matsuzaki, Tomoya; Ishinabe, Takahiro; Fujikake, Hideo] Tohoku Univ, Grad Sch Engn, Dept Elect, Sendai, Miyagi 9808579, Japan	Matsuzaki, T (reprint author), Tohoku Univ, Grad Sch Engn, Dept Elect, Sendai, Miyagi 9808579, Japan.	matsuzaki.tomoya@ecei.tohoku.ac.jp					Minemawari H, 2011, NATURE, V475, P364, DOI 10.1038/nature10313; Jeon JH, 2001, IEEE ELECTR DEVICE L, V22, P429; Ebata H, 2007, J AM CHEM SOC, V129, P15732, DOI 10.1021/ja074841i; Sugimoto A, 2004, IEEE J SEL TOP QUANT, V10, P107, DOI 10.1109/JSTQE.2004.824112; Uemura T, 2009, APPL PHYS EXPRESS, V2, DOI 10.1143/APEX.2.111501; Fujikake H., 2008, SPIE NEWSROOM, DOI [10.1117/2.1200811.1376, DOI 10.1117/2.1200811.1376]; Fujikake H., 2004, JPN J APPL PHYS, V43, P536; Matsuzaki T., 2014, 61 SPRING M 2014 JSA; Onodera A., 2009, RICOH TECH REP, P73; Souk J.H., 1990, I IMAGE INF TELEVISI, VIDY90-157, P17	10	0	0	IEICE-INST ELECTRONICS INFORMATION COMMUNICATIONS ENG	TOKYO	KIKAI-SHINKO-KAIKAN BLDG, 3-5-8, SHIBA-KOEN, MINATO-KU, TOKYO, 105-0011, JAPAN	1745-1353			IEICE T ELECTRON	IEICE Trans. Electron.	NOV	2015	E98C	11					1032	1034		10.1587/transele.E98.C.1032		3	Engineering, Electrical & Electronic	Engineering	CV6ZG	WOS:000364420500007		
J	Sano, H; Ishida, R; Kura, T; Fujita, S; Naka, S; Okada, H; Takai, T				Sano, Hironao; Ishida, Ryota; Kura, Tatsuya; Fujita, Shunsuke; Naka, Shigeki; Okada, Hiroyuki; Takai, Takeshi			Transparent Organic Light-Emitting Diodes with Top Electrode Using Ion-Plating Method	IEICE TRANSACTIONS ON ELECTRONICS			English	Article						organic light-emitting diode; ion-plating; transparent electrode; high deposition rate; low temperature deposition	OXIDE-FILMS; LAYER; DAMAGES	Transparent organic light-emitting diodes (TOLEDs) were investigated with top electrode of indium-tin-oxide (ITO) by ion-plating method. High deposition rate of 4.4 nm/s was realized without plasma damage of under organic layer. In the TOLEDs with inverted structure, high transmittance of over 75% at 550 nm and bright emission of 1,850 and 1,410 cd/m(2), from bottom and top side at 163 mA/cm(2), respectively, were obtained.	[Sano, Hironao; Ishida, Ryota; Kura, Tatsuya; Fujita, Shunsuke; Naka, Shigeki; Okada, Hiroyuki] Toyama Univ, Toyama 9308555, Japan; [Takai, Takeshi] NACHI FUJIKOSHI, Namerikawa Shi 9360802, Japan	Sano, H (reprint author), Toyama Univ, Toyama 9308555, Japan.	nak@eng.u-toyama.ac.jp					Kim SY, 2008, JPN J APPL PHYS, V47, P862, DOI 10.1143/JJAP.47.8621; Uchida T, 2008, THIN SOLID FILMS, V516, P5907, DOI 10.1016/j.tsf.2007.10.042; Miyashita T, 2005, JPN J APPL PHYS 1, V44, P3682, DOI 10.1143/JJAP.44.3682; Meyer J, 2008, APPL PHYS LETT, V93, DOI 10.1063/1.2975176; Park CH, 2015, ACS APPL MATER INTER, V7, P6047, DOI 10.1021/am5091066; Lei H, 2013, APPL SURF SCI, V285, P389, DOI 10.1016/j.apsusc.2013.08.065; Liao LS, 1999, APPL PHYS LETT, V75, P1619, DOI 10.1063/1.124773; Bulovic V, 1997, APPL PHYS LETT, V70, P2954, DOI 10.1063/1.119260; Hoshi Y, 2003, THIN SOLID FILMS, V445, P245, DOI 10.1016/S0040-6090(03)01182-9; Lei H, 2010, JPN J APPL PHYS, V49, DOI 10.1143/JJAP.49.042103; Dangtip S, 2008, J PHYS CONF SER, V100, DOI 10.1088/1742-6596/100/4/042011; Yamamoto H, 2006, JPN J APPL PHYS 2, V45, pL213, DOI 10.1143/JJAP.45.L213; Leterrier Y, 2004, THIN SOLID FILMS, V460, P156, DOI 10.1016/j.tsf.2004.01.052; Takada N., 2011, MONTHLY DISPLAY, V17, P25	14	0	0	IEICE-INST ELECTRONICS INFORMATION COMMUNICATIONS ENG	TOKYO	KIKAI-SHINKO-KAIKAN BLDG, 3-5-8, SHIBA-KOEN, MINATO-KU, TOKYO, 105-0011, JAPAN	1745-1353			IEICE T ELECTRON	IEICE Trans. Electron.	NOV	2015	E98C	11					1035	1038		10.1587/transele.E98.C.1035		4	Engineering, Electrical & Electronic	Engineering	CV6ZG	WOS:000364420500008		
J	Sato, A; Ishinabe, T; Fujikake, H				Sato, Akihito; Ishinabe, Takahiro; Fujikake, Hideo			Flexible In-Plane-Switching Liquid Crystal Display Using Stretched Polycarbonate Substrates with Optical Positive A-Plate	IEICE TRANSACTIONS ON ELECTRONICS			English	Article						liquid crystal display; flexible display; wide viewing angle; IPS mode; uniaxial polycarbonate substrate	ANGLE	Optical compensation of flexible in-plane switching (IPS) mode liquid crystal display (LCD) using polycarbonate substrate with uniaxial optical anisotropy was achieved for wide viewing angle. We theoretically clarified that the slow axis of plastic substrate must be parallel to the absorption axis of polarizer and alignment direction of IPS mode LC. We successfully suppressed a light leakage in the dark state in a wide viewing angle range by fabricated device using uniaxial polycarbonate substrates. These results show that it is possible to realize a high quality flexible LCD using plastic substrates.	[Sato, Akihito; Ishinabe, Takahiro; Fujikake, Hideo] Tohoku Univ, Grad Sch Engn, Dept Elect, Sendai, Miyagi 9808579, Japan	Sato, A (reprint author), Tohoku Univ, Grad Sch Engn, Dept Elect, Sendai, Miyagi 9808579, Japan.	sato.akihito@ecei.tohoku.ac.jp					Ishinabe T, 2009, JPN J APPL PHYS, V48, DOI 10.1143/JJAP.48.092403; Ishinabe T, 2014, APPL PHYS EXPRESS, V7, DOI 10.7567/APEX.7.111701; Sato H, 2006, IDW '06: PROCEEDINGS OF THE 13TH INTERNATIONAL DISPLAY WORKSHOPS, VOLS 1-3, P605; Sato H, 2002, JPN J APPL PHYS 1, V41, P5302, DOI 10.1143/JJAP.41.5302; Ishinabe T, 2002, JPN J APPL PHYS 1, V41, P4553, DOI 10.1143/JJAP.41.4553; Lee GS, 2007, JPN J APPL PHYS 1, V46, P289, DOI 10.1143/JJAP.46.289; Fujikake H, 2005, IDW/AD '05: PROCEEDINGS OF THE 12TH INTERNATIONAL DISPLAY WORKSHOPS IN CONJUNCTION WITH ASIA DISPLAY 2005, VOLS 1 AND 2, P871; Chen Z.H., 2014, P INT DISPL WORKSH, P1461; Ishinabe T., 2005, P 12 INT DISPL WORKS, P1325; Ishinabe T., 2001, SID 01, P906; Kondo K., 1995, P INT DISPL WORKSH, P43; Kuzuhara N., 2006, KONICA MINOLTA TECHN, V3, P133; Mori H., 1996, P AM LCD 96 IDW 96, P189	13	0	0	IEICE-INST ELECTRONICS INFORMATION COMMUNICATIONS ENG	TOKYO	KIKAI-SHINKO-KAIKAN BLDG, 3-5-8, SHIBA-KOEN, MINATO-KU, TOKYO, 105-0011, JAPAN	1745-1353			IEICE T ELECTRON	IEICE Trans. Electron.	NOV	2015	E98C	11					1039	1042		10.1587/transele.E98.C.1039		4	Engineering, Electrical & Electronic	Engineering	CV6ZG	WOS:000364420500009		
J	Sakai, H; Ishinabe, T; Fujikake, H				Sakai, Hideki; Ishinabe, Takahiro; Fujikake, Hideo			Flexible Polymer-Wall-Stabilized Blue-Phase Liquid Crystal Cell Using Plastic Substrates	IEICE TRANSACTIONS ON ELECTRONICS			English	Article						liquid crystal display; flexible display; plastic substrate; cholesteric blue phase; polymer wall		To develop a flexible liquid crystal display (LCD) with a wide viewing angle range and high contrast ratio, we have proposed a flexible blue-phase LC device sustained by polymer walls inside the LC cell. We clarified that the polymer walls can maintain a constant cell gap and suppress the generation of alignment defects of the blue-phase LC in a bending state.	[Sakai, Hideki; Ishinabe, Takahiro; Fujikake, Hideo] Tohoku Univ, Grad Sch Engn, Dept Elect, Sendai, Miyagi 9808579, Japan	Sakai, H (reprint author), Tohoku Univ, Grad Sch Engn, Dept Elect, Sendai, Miyagi 9808579, Japan.	sakai.hideki@ecei.tohoku.ac.jp					Yan J, 2013, APPL PHYS LETT, V102, DOI 10.1063/1.4793750; Kikuchi H, 2002, NAT MATER, V1, P64, DOI 10.1038/nmat712; Ge ZB, 2009, J DISP TECHNOL, V5, P250, DOI 10.1109/JDT.2009.2022849; Sato H, 2002, JPN J APPL PHYS 1, V41, P5302, DOI 10.1143/JJAP.41.5302; Kimura M, 2013, PROCEEDINGS OF 2013 TWENTIETH INTERNATIONAL WORKSHOP ON ACTIVE-MATRIX FLATPANEL DISPLAYS AND DEVICES (AM-FPD 13): TFT TECHNOLOGIES AND FPD MATERIALS, P33; Chen Y, 2013, APPL PHYS LETT, V102, DOI 10.1063/1.4802090; Ishinabe T., 2002, JPN J APPL PHYS, V41, P5302; Rao LH, 2009, APPL PHYS LETT, V95, DOI 10.1063/1.3271771; Sakai H., 2014, 61 SPRING M JSAP, P12; Sakai H., 2014, INT DISPL WORKSH; Sakai T., 2013, IEICE T ELECT JAPA C, VJ96-C, P55	11	0	0	IEICE-INST ELECTRONICS INFORMATION COMMUNICATIONS ENG	TOKYO	KIKAI-SHINKO-KAIKAN BLDG, 3-5-8, SHIBA-KOEN, MINATO-KU, TOKYO, 105-0011, JAPAN	1745-1353			IEICE T ELECTRON	IEICE Trans. Electron.	NOV	2015	E98C	11					1043	1046		10.1587/transele.E98.C.1043		4	Engineering, Electrical & Electronic	Engineering	CV6ZG	WOS:000364420500010		
J	Kawashima, S; Morita, K; Nakazawa, M; Yamane, K; Ogai, M; Kawabata, K; Takai, K; Fujii, Y; Yasuda, R; Wang, W; Hikosaka, Y; Inoue, K				Kawashima, Shoichiro; Morita, Keizo; Nakazawa, Mitsuharu; Yamane, Kazuaki; Ogai, Mitsuhiro; Kawabata, Kuninori; Takai, Kazuaki; Fujii, Yasuhiro; Yasuda, Ryoji; Wang, Wensheng; Hikosaka, Yukinobu; Inoue, Ken'ichi			An 8-Mbit 0.18-mu m CMOS 1T1C FeRAM in Planar Technology	IEICE TRANSACTIONS ON ELECTRONICS			English	Article						1T1C-FeRAM; sectional cyclic word line; bit-line GND level sensing; planar FeRAM cell; temperature-bit distribution	CHAIN FERAM; BITLINE	An 8-Mbit 0.18-mu m CMOS 1T1C ferroelectric RAM (FeRAM) in a planar ferroelectric technology was developed. Even though the cell area of 2.48 mu m(2) is almost equal to that of a 4-Mbit stacked-capacitor FeRAM (STACK FeRAM) 2.32 mu m(2) [1], the chip size of the developed 8-Mbit FeRAM, including extra 2-Mbit parities for the error correction code (ECC), is just 52.37 mm(2), which is about 30% smaller than twice of the 4-Mbit STACK FeRAM device, 37.68 mm(2) x 2 [1]. This excellent characteristic can be attributed to the large cell matrix architectures of the sectional cyclic word line (WL) that was used to increase the column numbers, and to the 1T1C bit-line GND level sensing (BGS) [2], [3] circuit design intended to sense bit lines (BL) that have bit cells 1K long and a large capacitance. An access time of 52 ns and a cycle time of 77 ns in RT at a VDD of 1.8 V were achieved.	[Kawashima, Shoichiro; Morita, Keizo; Nakazawa, Mitsuharu; Yamane, Kazuaki; Ogai, Mitsuhiro; Kawabata, Kuninori; Takai, Kazuaki; Fujii, Yasuhiro; Yasuda, Ryoji; Wang, Wensheng; Inoue, Ken'ichi] Fujitsu Semicond Ltd, Yokohama, Kanagawa 2220033, Japan; [Hikosaka, Yukinobu] Fujitsu Semicond Ltd, Aizu Factory, Aizu Wakamatsu, Fukushima 9658502, Japan	Kawashima, S (reprint author), Fujitsu Semicond Ltd, Yokohama, Kanagawa 2220033, Japan.	kawashima@jp.fujitsu.com					McAdams HP, 2004, IEEE J SOLID-ST CIRC, V39, P667, DOI 10.1109/JSSC.2004.825241; Hoya K, 2010, IEEE T VLSI SYST, V18, P1745, DOI 10.1109/TVLSI.2009.2034380; Takashima D, 2011, IEEE J SOLID-ST CIRC, V46, P681, DOI 10.1109/JSSC.2010.2098210; Kawashima S, 2002, IEEE J SOLID-ST CIRC, V37, P592, DOI 10.1109/4.997852; Sheikholeslami A, 2000, P IEEE, V88, P667, DOI 10.1109/5.849164; Shiga H, 2010, IEEE J SOLID-ST CIRC, V45, P142, DOI 10.1109/JSSC.2009.2034414; Eliason J, 2005, IEEE CUST INTEGR CIR, P427; Kawashima S, 2007, IEICE T ELECTRON, VE90C, P1941, DOI 10.1093/ietele/e90-c.10.1941; Kawashima S., 2009, THESIS TOKYO I TECHN, P91; Kim JK, 2006, 2006 KDI-KAEA CONFERENCE ON ENHANCING PRODUCTIVITY AND SUSTAINING GROWTH, P1	10	0	0	IEICE-INST ELECTRONICS INFORMATION COMMUNICATIONS ENG	TOKYO	KIKAI-SHINKO-KAIKAN BLDG, 3-5-8, SHIBA-KOEN, MINATO-KU, TOKYO, 105-0011, JAPAN	1745-1353			IEICE T ELECTRON	IEICE Trans. Electron.	NOV	2015	E98C	11					1047	1057		10.1587/transele.E98.C.1047		11	Engineering, Electrical & Electronic	Engineering	CV6ZG	WOS:000364420500011		
J	Tanaka, H; Onoye, T				Tanaka, Hirokazu; Onoye, Takao			Special Section on Smart Multimedia & Communication Systems FOREWORD	IEICE TRANSACTIONS ON FUNDAMENTALS OF ELECTRONICS COMMUNICATIONS AND COMPUTER SCIENCES			English	Editorial Material									[Tanaka, Hirokazu] Hiroshima City Univ, Hiroshima, Japan; [Tanaka, Hirokazu] Toshiba Co Ltd, Tokyo, Japan; [Tanaka, Hirokazu] Hiroshima Univ, Hiroshima 730, Japan; [Tanaka, Hirokazu] Yokohama Natl Univ, Yokohama, Kanagawa 240, Japan	Tanaka, H (reprint author), Hiroshima City Univ, Hiroshima, Japan.							0	0	0	IEICE-INST ELECTRONICS INFORMATION COMMUNICATIONS ENG	TOKYO	KIKAI-SHINKO-KAIKAN BLDG, 3-5-8, SHIBA-KOEN, MINATO-KU, TOKYO, 105-0011, JAPAN	1745-1337			IEICE T FUND ELECTR	IEICE Trans. Fundam. Electron. Commun. Comput. Sci.	NOV	2015	E98A	11					2209	2210				2	Computer Science, Hardware & Architecture; Computer Science, Information Systems; Engineering, Electrical & Electronic	Computer Science; Engineering	CV6XH	WOS:000364414700001		
J	Higa, K; Funaki, K				Higa, Keita; Funaki, Keiichi			Robust ASR Based on ETSI Advanced Front-End Using Complex Speech Analysis	IEICE TRANSACTIONS ON FUNDAMENTALS OF ELECTRONICS COMMUNICATIONS AND COMPUTER SCIENCES			English	Article						robust ASR; ETSI AFE; iterative Wiener filter (IWF); complex speech analysis; analytic signal	RECOGNITION; ENHANCEMENT	The advanced front-end (AFE) for automatic speech recognition (ASR) was standardized by the European Telecommunications Standards Institute (ETSI). The AFE provides speech enhancement realized by an iterative Wiener filter (IWF) in which a smoothed FFT spectrum over adjacent frames is used to design the filter. We have previously proposed robust time-varying complex Auto-Regressive (TV-CAR) speech analysis for an analytic signal and evaluated the performance of speech processing such as F-0 estimation and speech enhancement. TV-CAR analysis can estimate more accurate spectrum than FFT, especially in low frequencies because of the nature of the analytic signal. In addition, TV-CAR can estimate more accurate speech spectrum against additive noise. In this paper, a time-invariant version of wide-band TV-CAR analysis is introduced to the IWF in the AFE and is evaluated using the CENSREC-2 database and its baseline script.	[Higa, Keita] Univ Ryukyus, Sch Engn & Sci, Nakagami, Okinawa 9030213, Japan; [Funaki, Keiichi] Univ Ryukyus, C&N Ctr, Nakagami, Okinawa 9030213, Japan	Higa, K (reprint author), Univ Ryukyus, Sch Engn & Sci, Nakagami, Okinawa 9030213, Japan.	funaki@cc.u-ryukyu.ac.jp					LIM JS, 1978, IEEE T ACOUST SPEECH, V26, P197; Yamamoto K, 2010, 11TH ANNUAL CONFERENCE OF THE INTERNATIONAL SPEECH COMMUNICATION ASSOCIATION 2010 (INTERSPEECH 2010), VOLS 1-2, P1189; HANSEN JHL, 1991, IEEE T SIGNAL PROCES, V39, P795, DOI 10.1109/78.80901; Moreno PJ, 1996, INT CONF ACOUST SPEE, P733, DOI 10.1109/ICASSP.1996.543225; Pardede HF, 2013, SPEECH COMMUN, V55, P587, DOI 10.1016/j.specom.2013.02.004; Kim W, 2012, 2012 IEEE INTERNATIONAL CONFERENCE ON ACOUSTICS, SPEECH AND SIGNAL PROCESSING (ICASSP), P4121; Kim C, 2012, 2012 IEEE INTERNATIONAL CONFERENCE ON ACOUSTICS, SPEECH AND SIGNAL PROCESSING (ICASSP), P4101; BOLL SF, 1979, IEEE T ACOUST SPEECH, V27, P113, DOI 10.1109/TASSP.1979.1163209; Nakamura S, 2006, INTERSPEECH 2006 AND 9TH INTERNATIONAL CONFERENCE ON SPOKEN LANGUAGE PROCESSING, VOLS 1-5, P2330; Hermansky H, 1994, IEEE T SPEECH AUDI P, V2, P578, DOI 10.1109/89.326616; Shimamura T, 2010, 11TH ANNUAL CONFERENCE OF THE INTERNATIONAL SPEECH COMMUNICATION ASSOCIATION 2010 (INTERSPEECH 2010), VOLS 3 AND 4, P1712; EPHRAIM Y, 1985, IEEE T ACOUST SPEECH, V33, P443, DOI 10.1109/TASSP.1985.1164550; ETSI Advanced Front-End, 2007, 202050 ES ETSI; Funaki K., 2001, EUROSPEECH 2001, P2649; Funaki K., 1998, EUSIPCO 98, P1177; Funaki K., 2008, EUSIPCO 2008; Keronen S., 2011, P INTERSPEECH, P1265; Nakagawa S., 1994, ACOUSTICAL SCI TECHN, V50, P849; Paliwal K., P EUROSPEECH2003	19	0	0	IEICE-INST ELECTRONICS INFORMATION COMMUNICATIONS ENG	TOKYO	KIKAI-SHINKO-KAIKAN BLDG, 3-5-8, SHIBA-KOEN, MINATO-KU, TOKYO, 105-0011, JAPAN	1745-1337			IEICE T FUND ELECTR	IEICE Trans. Fundam. Electron. Commun. Comput. Sci.	NOV	2015	E98A	11					2211	2219		10.1587/transfun.E98.A.2211		9	Computer Science, Hardware & Architecture; Computer Science, Information Systems; Engineering, Electrical & Electronic	Computer Science; Engineering	CV6XH	WOS:000364414700002		
J	Ueda, C; Ibata, M; Azetsu, T; Suetake, N; Uchino, E				Ueda, Chiaki; Ibata, Minami; Azetsu, Tadahiro; Suetake, Noriaki; Uchino, Eiji			Food Image Enhancement by Adjusting Intensity and Saturation in RGB Color Space	IEICE TRANSACTIONS ON FUNDAMENTALS OF ELECTRONICS COMMUNICATIONS AND COMPUTER SCIENCES			English	Article						RGB color space; intensity enhancement; saturation enhancement; food image		In a food image acquired by a digital camera, its intensity and saturation components are sometimes decreased depending on the illumination environment. In this case, the food image does not look delicious. In general, RGB components are transformed into hue, saturation and intensity components, and then the saturation and intensity components are enhanced so that the food image looks delicious. However, these processes are complex and involve a gamut problem. In this paper, we propose an intensity and saturation enhancement method while preserving the hue in the RGB color space for the food image. In this method, at first, the intensity components are enhanced avoiding the saturation deterioration. Then the saturation components of the regions having the hue components frequently appeared in foods are enhanced. In order to illustrate the effectiveness of the proposed method, the enhancement experiments using several food images are done.	[Ueda, Chiaki; Ibata, Minami; Suetake, Noriaki; Uchino, Eiji] Yamaguchi Univ, Grad Sch Sci & Engn, Yamaguchi 7538512, Japan; [Azetsu, Tadahiro] Yamaguchi Prefectural Univ, Off Informat & Technol, Yamaguchi 7538502, Japan; [Uchino, Eiji] Fuzzy Log Syst Inst, Iizuka, Fukuoka 8200064, Japan	Ueda, C (reprint author), Yamaguchi Univ, Grad Sch Sci & Engn, Yamaguchi 7538512, Japan.	azetsu@yamaguchi-pu.ac.jp					Yang S, 2013, ELECTRON LETT, V49, P1221, DOI 10.1049/el.2013.0221; Naik SK, 2003, IEEE T IMAGE PROCESS, V12, P1591, DOI 10.1109/TIP.2003.819231; Bassiou N, 2007, COMPUT VIS IMAGE UND, V107, P108, DOI 10.1016/j.cviu.2006.11.012; Chien CL, 2011, INT J INNOV COMPUT I, V7, P6691; Gunasekaran S, 1996, TRENDS FOOD SCI TECH, V7, P245, DOI 10.1016/0924-2244(96)10028-5; Mery D, 2005, J FOOD ENG, V66, P353, DOI 10.1016/j.jfoodeng.2004.04.001; FAIRCHILD MD, 1991, COLOR RES APPL, V16, P385, DOI 10.1002/col.5080160608; Azetsu T., 2014, J I IMAGE INF TV ENG, V68, pJ482; Foley J.D., 1983, FUNDAMENTALS INTERAC, P613; Gonzalez R.C., 2002, DIGITAL IMAGE PROCES, P295; Inoue K., 2013, P ITE ANN CONV 2013, P1; Murahira K., 2013, IEICE T FUNDAMEN J A, VJ96-A, P264; Pitas I., 2000, DIGITAL IMAGE PROCES, P31	13	0	0	IEICE-INST ELECTRONICS INFORMATION COMMUNICATIONS ENG	TOKYO	KIKAI-SHINKO-KAIKAN BLDG, 3-5-8, SHIBA-KOEN, MINATO-KU, TOKYO, 105-0011, JAPAN	1745-1337			IEICE T FUND ELECTR	IEICE Trans. Fundam. Electron. Commun. Comput. Sci.	NOV	2015	E98A	11					2220	2228		10.1587/transfun.E98.A.2220		9	Computer Science, Hardware & Architecture; Computer Science, Information Systems; Engineering, Electrical & Electronic	Computer Science; Engineering	CV6XH	WOS:000364414700003		
J	Jiang, XT; Song, T; Shimamoto, T; Shi, W; Wang, LS				Jiang, Xiantao; Song, Tian; Shimamoto, Takashi; Shi, Wen; Wang, Lisheng			Spatio-Temporal Prediction Based Algorithm for Parallel Improvement of HEVC	IEICE TRANSACTIONS ON FUNDAMENTALS OF ELECTRONICS COMMUNICATIONS AND COMPUTER SCIENCES			English	Article						HEVC; spatio-temporal prediction; parallel processing; complexity	MOTION ESTIMATION; STANDARD; DECISION; VIDEOS	The next generation high efficiency video coding (HEVC) standard achieves high performance by extending the encoding block to 64 x 64. There are some parallel tools to improve the efficiency for encoder and decoder. However, owing to the dependence of the current prediction block and surrounding block, parallel processing at CU level and Sub-CU level are hard to achieve. In this paper, focusing on the spatial motion vector prediction (SMVP) and temporal motion vector prediction (TMVP), parallel improvement for spatio-temporal prediction algorithms are presented, which can remove the dependency between prediction coding units and neighboring coding units. Using this proposal, it is convenient to process motion estimation in parallel, which is suitable for different parallel platforms such as multi-core platform, compute unified device architecture (CUDA) and so on. The simulation experiment results demonstrate that based on HM12.0 test model for different test sequences, the proposed algorithm can improve the advanced motion vector prediction with only 0.01% BD-rate increase that result is better than previous work, and the BDPSNR is almost the same as the HEVC reference software.	[Jiang, Xiantao; Wang, Lisheng] Tongji Univ, Dept Elect & Informat Engn, Shanghai 200092, Peoples R China; [Jiang, Xiantao; Song, Tian; Shimamoto, Takashi; Shi, Wen] Univ Tokushima, Dept Elect & Elect Engn, Tokushima 7708506, Japan	Jiang, XT (reprint author), Tongji Univ, Dept Elect & Informat Engn, Shanghai 200092, Peoples R China.	xiantao@ee.tokushima-u.ac.jp; tiansong@ee.tokushima-u.ac.jp			National High Technology Research and Development Program of China (863 Program) [2013AA040302]; Shanghai Economic and Information commission major technical equipment development project [ZB-ZBYZ-03-12-1067-1]; JSPS KAKENHI [26330066]	This research was supported by a grant from the National High Technology Research and Development Program of China (863 Program) (NO:2013AA040302), and the Shanghai Economic and Information commission major technical equipment development project (NO: ZB-ZBYZ-03-12-1067-1). It also was supported by JSPS KAKENHI Grant Number 26330066.	Inoue K, 2013, IEICE T FUND ELECTR, VE96A, P2191, DOI 10.1587/transfun.E96.A.2191; Tian GF, 2013, IEICE T FUND ELECTR, VE96A, P780, DOI 10.1587/transfun.E96.A.780; Sinangil ME, 2013, IEEE J-STSP, V7, P1017, DOI 10.1109/JSTSP.2013.2273658; Sullivan GJ, 2012, IEEE T CIRC SYST VID, V22, P1649, DOI 10.1109/TCSVT.2012.2221191; Lin JL, 2013, IEEE J-STSP, V7, P957, DOI 10.1109/JSTSP.2013.2271975; Sinangil ME, 2012, IEEE IMAGE PROC, P1529, DOI 10.1109/ICIP.2012.6467163; Yan CG, 2014, IEEE T CIRC SYST VID, V24, P2077, DOI 10.1109/TCSVT.2014.2335852; Shen LQ, 2013, IEEE T MULTIMEDIA, V15, P465, DOI 10.1109/TMM.2012.2231060; Bjontegaard G., 2001, SG16Q6 ITUT; Jiang X., 2014, 2014 IEEE INT C CONS, P115; Kazui K., 2011, JCTVCE062; Park J., 2011, JCTVCD095; Sanchez G, 2015, ANALOG INTEGR CIRC S, V82, P135, DOI 10.1007/s10470-014-0342-9; Yu Q., 2012, 2012 INT JOINT C NEU, P1; Zhang J., 2013, 2013 PICT COD S PCS, P281	15	0	0	IEICE-INST ELECTRONICS INFORMATION COMMUNICATIONS ENG	TOKYO	KIKAI-SHINKO-KAIKAN BLDG, 3-5-8, SHIBA-KOEN, MINATO-KU, TOKYO, 105-0011, JAPAN	1745-1337			IEICE T FUND ELECTR	IEICE Trans. Fundam. Electron. Commun. Comput. Sci.	NOV	2015	E98A	11					2229	2237		10.1587/transfun.E98.A.2229		9	Computer Science, Hardware & Architecture; Computer Science, Information Systems; Engineering, Electrical & Electronic	Computer Science; Engineering	CV6XH	WOS:000364414700004		
J	Kurihara, K; Kikuchi, M; Imaizumi, S; Shiota, S; Kiya, H				Kurihara, Kenta; Kikuchi, Masanori; Imaizumi, Shoko; Shiota, Sayaka; Kiya, Hitoshi			An Encryption-then-Compression System for JPEG/Motion JPEG Standard	IEICE TRANSACTIONS ON FUNDAMENTALS OF ELECTRONICS COMMUNICATIONS AND COMPUTER SCIENCES			English	Article						Encryption-then-Compression system; perceptual encryption; JPEG; color image; cryptographic hash function	IMAGE	In many multimedia applications, image encryption has to be conducted prior to image compression. This paper proposes a JPEG-friendly perceptual encryption method, which enables to be conducted prior to JPEG and Motion JPEG compressions. The proposed encryption scheme can provides approximately the same compression performance as that of JPEG compression without any encryption, where both gray scale images and color ones are considered. It is also shown that the proposed scheme consists of four block-based encryption steps, and provide a reasonably high level of security. Most of conventional perceptual encryption schemes have not been designed for international compression standards, but this paper focuses on applying the JPEG and Motion JPEG standards, as one of the most widely used image compression standards. In addition, this paper considers an efficient key management scheme, which enables an encryption with multiple keys to be easy to manage its keys.	[Kurihara, Kenta; Kikuchi, Masanori; Shiota, Sayaka; Kiya, Hitoshi] Tokyo Metropolitan Univ, Fac Syst Design, Hino, Tokyo 1910065, Japan; [Imaizumi, Shoko] Chiba Univ, Grad Sch Adv Integrat Sci, Chiba 2638522, Japan	Kurihara, K (reprint author), Tokyo Metropolitan Univ, Fac Syst Design, Hino, Tokyo 1910065, Japan.	kiya@sd.tmu.ac.jp					Li SJ, 2007, IEEE T CIRC SYST VID, V17, P214, DOI 10.1109/TCSVT.2006.888840; Zhou JT, 2014, IEEE T INF FOREN SEC, V9, P39, DOI 10.1109/TIFS.2013.2291625; Imaizumi S, 2009, ISCAS: 2009 IEEE INTERNATIONAL SYMPOSIUM ON CIRCUITS AND SYSTEMS, VOLS 1-5, P505; Johnson M, 2004, IEEE T SIGNAL PROCES, V52, P2992, DOI 10.1109/TSP.2004.833860; [Anonymous], 2013, 1SC29WG1N6402 ISOIEC; Fujiyoshi M, 2007, IEICE T FUND ELECTR, VE90A, P590, DOI 10.1093/ietfec/e90-a.3.590; Lagendijk RL, 2013, IEEE SIGNAL PROC MAG, V30, P82, DOI 10.1109/MSP.2012.2219653; [Anonymous], 2008, IEEE IMAGE PROC; Zhang XP, 2012, IEEE T IMAGE PROCESS, V21, P3108, DOI 10.1109/TIP.2012.2187671; Liu W, 2010, IEEE T IMAGE PROCESS, V19, P1097, DOI 10.1109/TIP.2009.2038773; Zhang XP, 2011, IEEE T INF FOREN SEC, V6, P53, DOI 10.1109/TIFS.2010.2099114; Watanabe O, 2004, IEEE IMAGE PROC, P3435; Engel D, 2009, MULTIMEDIA SYST, V15, P243, DOI 10.1007/s00530-008-0150-0; Klinc D, 2012, IEEE T INFORM THEORY, V58, P6989, DOI 10.1109/TIT.2012.2210752; Engel D., 2012, EURASIP J INF SECUR, V2012, P1; Hu R., 2014, 2014 IEEE INT C AC S, P7387; Huang C.-T., 2014, APSIPA T SIGNAL INFO, V3, pe7; Imaizumi S., 2007, IM PROC 2007 ICIP 20, V2, pII; Ito I., 2009, EURASIP J INFORM SEC, V2009, P1, DOI 10.1155/2009/841045; Jain A.K., 2008, EURASIP J ADV SIG PR, V8, P1, DOI DOI 10.1155/2008/657081; Khan M.I., 2010, 2010 INT C INT ADV S, P1; Kiya H., 2003, P IEEE INT C IM PROC; Schelkens P., 2014, P 2 ACM WORKSH INF H, P1; Tang ZJ, 2015, MULTIMED TOOLS APPL, V74, P5429, DOI 10.1007/s11042-014-1861-1; WALLACE GK, 1991, COMMUN ACM, V34, P30, DOI 10.1145/103085.103089; Yasuda K., 2010, IEICE ESS FUNDAMENTA, V4, P57	26	0	0	IEICE-INST ELECTRONICS INFORMATION COMMUNICATIONS ENG	TOKYO	KIKAI-SHINKO-KAIKAN BLDG, 3-5-8, SHIBA-KOEN, MINATO-KU, TOKYO, 105-0011, JAPAN	1745-1337			IEICE T FUND ELECTR	IEICE Trans. Fundam. Electron. Commun. Comput. Sci.	NOV	2015	E98A	11					2238	2245		10.1587/transfun.E98.A.2238		8	Computer Science, Hardware & Architecture; Computer Science, Information Systems; Engineering, Electrical & Electronic	Computer Science; Engineering	CV6XH	WOS:000364414700005		
J	Tomita, K; Hatanaka, M; Onoye, T				Tomita, Kosuke; Hatanaka, Masahide; Onoye, Takao			Implementation of Viterbi Decoder toward GPU-Based SDR Receiver	IEICE TRANSACTIONS ON FUNDAMENTALS OF ELECTRONICS COMMUNICATIONS AND COMPUTER SCIENCES			English	Article						Viterbi decoder; TVDA; GPU; CUDA; SDR		Viterbi decoding is commonly used for several protocols, but computational cost is quite high and thus it is necessary to implement it effectively. This paper describes GPU implementation of Viterbi decoder utilizing three-point Viterbi decoding algorithm (TVDA), in which the received bits are divided into multiple chunks and several chunks are decoded simultaneously. Coalesced access and Warp Shuffle, which is new instruction introduced are also utilized in order to improve decoder performance. In addition, iterative execution of parallel chunks decoding reduces the latency of proposed Viterbi decoder in order to utilize the decoder as a part of GPU-based SDR transceiver. As the result, the throughput of proposed Viterbi decoder is improved by 23.1%.	[Tomita, Kosuke; Hatanaka, Masahide; Onoye, Takao] Osaka Univ, Dept Informat Syst Engn, Suita, Osaka 5650871, Japan	Tomita, K (reprint author), Osaka Univ, Dept Informat Syst Engn, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	tomita.kosuke@ist.osaka-u.ac.jp; masahide@ist.osaka-u.ac.jp; onoye@ist.osaka-u.ac.jp					Li RC, 2014, CONCURR COMP-PRACT E, V26, P821, DOI 10.1002/cpe.3093; Li RC, 2013, 2013 IEEE WIRELESS COMMUNICATIONS AND NETWORKING CONFERENCE (WCNC), P4305; Ulversoy T, 2010, IEEE COMMUN SURV TUT, V12, P531, DOI 10.1109/SURV.2010.032910.00019; [Anonymous], 2007, 802112007 IEEE; IEEE Computer Society, 2007, 802162004 IEEE; Kim June, 2010, IEEE Communications Magazine, V48, DOI 10.1109/MCOM.2010.5434388; Lin C.-P, 2011, 2011 IEEE 38th International Conference on Plasma Sciences (ICOPS), DOI 10.1109/PLASMA.2011.5993280	7	0	0	IEICE-INST ELECTRONICS INFORMATION COMMUNICATIONS ENG	TOKYO	KIKAI-SHINKO-KAIKAN BLDG, 3-5-8, SHIBA-KOEN, MINATO-KU, TOKYO, 105-0011, JAPAN	1745-1337			IEICE T FUND ELECTR	IEICE Trans. Fundam. Electron. Commun. Comput. Sci.	NOV	2015	E98A	11					2246	2253		10.1587/transfun.E98.A.2246		8	Computer Science, Hardware & Architecture; Computer Science, Information Systems; Engineering, Electrical & Electronic	Computer Science; Engineering	CV6XH	WOS:000364414700006		
J	Ida, Y; Ahn, CJ; Matsumoto, T; Matsufuji, S				Ida, Yuta; Ahn, Chang-Jun; Matsumoto, Takahiro; Matsufuji, Shinya			Achievement Accurate CSI for AF Relay MIMO/OFDM Based on Complex HTRCI Pilot Signal with Enhanced MMSE Equalization	IEICE TRANSACTIONS ON FUNDAMENTALS OF ELECTRONICS COMMUNICATIONS AND COMPUTER SCIENCES			English	Article						AF relay transmissions; MIMO; OFDM; complex HTRCI pilot signal; enhanced MMSE equalization	NETWORKS; MIMO; DESIGN; AMPLIFY; SYSTEMS	Amplify-and-forward (AF) relay multiple-input multiple-output (MIMO) orthogonal frequency division multiplexing (OFDM) systems can achieve high data rate and high quality communications. On the other hand, it has to estimate all channels between the source-relay and relay-destination nodes in the destination node. In MIMO/OFDM systems, high time resolution carrier interferometry (HTRCI) has been proposed to achieve an accurate channel estimation (CE) with a small number of pilot signals. However, since it has many interferences, an accurate CE is not obtained and the system performance is degraded in AF relay MIMO/OFDM systems. Therefore, in this paper, we propose the complex HTRCI (C-HTRCI) pilot signal and the enhanced minimum mean square error (E-MMSE) equalization to achieve an accurate CE and to improve the system performance for AF relay MIMO/OFDM systems.	[Ida, Yuta; Matsumoto, Takahiro; Matsufuji, Shinya] Yamaguchi Univ, Grad Sch Sci & Engn, Ube, Yamaguchi 7558611, Japan; [Ahn, Chang-Jun] Chiba Univ, Grad Sch Engn, Chiba 2638522, Japan	Ida, Y (reprint author), Yamaguchi Univ, Grad Sch Sci & Engn, Ube, Yamaguchi 7558611, Japan.	y.ida@yamaguchi-u.ac.jp					Abeta S., 2010, P IEEE INT C COMM SY, P146; Jungnickel V, 2014, IEEE COMMUN MAG, V52, P44, DOI 10.1109/MCOM.2014.6815892; Laneman JN, 2004, IEEE T INFORM THEORY, V50, P3062, DOI 10.1109/TIT.2004.838089; Ma J, 2011, IEEE T WIREL COMMUN, V10, P1956, DOI 10.1109/TWC.2011.041311.101477; Zhang Y, 2010, IEEE T VEH TECHNOL, V59, P4192, DOI 10.1109/TVT.2010.2065249; Gao FF, 2008, IEEE T WIREL COMMUN, V7, P1907, DOI 10.1109/TWC.2008.070118; Zhang GC, 2012, WIRELESS PERS COMMUN, V62, P879, DOI 10.1007/s11277-010-0098-1; Zhang Y, 2013, WIREL COMMUN MOB COM, V13, P1571, DOI 10.1002/wcm.2213; Adachi K, 2012, IEEE T WIREL COMMUN, V11, P2520, DOI 10.1109/TWC.2012.050112.111372; Amarasuriya G, 2012, IEEE T COMMUN, V60, P1823, DOI 10.1109/TCOMM.2012.051012.100594; Zou J, 2011, IEICE T COMMUN, VE94B, P848, DOI 10.1587/transcom.E94.B.848; Wang N, 2014, IEICE T COMMUN, VE97B, P702, DOI 10.1587/transcom.E97.B.702; Sheu JS, 2013, IEICE T COMMUN, VE96B, P254, DOI 10.1587/transcom.E96.B.254; Feng W, 2014, IEICE T COMMUN, VE97B, P746, DOI 10.1587/transcom.E97.B.746; Kong T, 2011, IEEE T SIGNAL PROCES, V59, P4438, DOI 10.1109/TSP.2011.2158429; Ahn CJ, 2010, DIGIT SIGNAL PROCESS, V20, P1447, DOI 10.1016/j.dsp.2010.01.005; Ida Y., 2013, P 6 INT WORKSH SIGN, P130; Iwamura M., 2010, NTT DOCOMO TECHNICAL, V12, P29; Ni Y., 2014, EURASIP J ADV SIG PR, V2014, P1; Park S, 2008, PROCEEDINGS OF THE ASME INTERNATIONAL MECHANICAL ENGINEERING CONGRESS AND EXPOSITION 2007, VOL 5, P1; Van Zelst A., 2000, P IEEE VTC2000 SPRIN, V2, P1070	21	0	0	IEICE-INST ELECTRONICS INFORMATION COMMUNICATIONS ENG	TOKYO	KIKAI-SHINKO-KAIKAN BLDG, 3-5-8, SHIBA-KOEN, MINATO-KU, TOKYO, 105-0011, JAPAN	1745-1337			IEICE T FUND ELECTR	IEICE Trans. Fundam. Electron. Commun. Comput. Sci.	NOV	2015	E98A	11					2254	2262		10.1587/transfun.E98.A.2254		9	Computer Science, Hardware & Architecture; Computer Science, Information Systems; Engineering, Electrical & Electronic	Computer Science; Engineering	CV6XH	WOS:000364414700007		
J	Natori, T; Tanabe, N; Furukawa, T				Natori, Takahiro; Tanabe, Nari; Furukawa, Toshihiro			MIMO MC-CDMA Channel Estimation for Various Mobile Velocities	IEICE TRANSACTIONS ON FUNDAMENTALS OF ELECTRONICS COMMUNICATIONS AND COMPUTER SCIENCES			English	Article						MIMO MC-CDMA; Kalman filter; mobile environment; colored driving source		This paper proposes the MIMO MC-CDMA channel estimation method for the various mobile environments. The distinctive feature of the proposed method is possible to robustly estimate with respect to the mobile velocity using the Kalman filter with the colored driving source. Effectiveness of the proposed method are shown by computer simulations.	[Natori, Takahiro; Furukawa, Toshihiro] Tokyo Univ Sci, Tokyo 1628601, Japan; [Tanabe, Nari] Tokyo Univ Sci, SUWA, Chino 3910292, Japan	Natori, T (reprint author), Tokyo Univ Sci, Tokyo 1628601, Japan.	t.natori@ms.kagu.tus.ac.jp; nari@rs.suwa.tus.ac.jp; furukawa@ms.kagu.tus.ac.jp					Tanabe N, 2008, IEICE T FUND ELECTR, VE91A, P818, DOI 10.1093/ietfec/e91-a.3.818; Wang ZY, 2005, IEICE T COMMUN, VE88B, P1282, DOI 10.1093/ietcom/e88-b.3.1282; Chen BS, 2007, IEEE T WIREL COMMUN, V6, P2328, DOI 10.1109/TWC.2007.05860; Baddour KE, 2005, IEEE T WIREL COMMUN, V4, P1650, DOI 10.1109/TWC.2005.850327; Haykin S., 2001, ADAPTIVE FILTER THEO	5	0	0	IEICE-INST ELECTRONICS INFORMATION COMMUNICATIONS ENG	TOKYO	KIKAI-SHINKO-KAIKAN BLDG, 3-5-8, SHIBA-KOEN, MINATO-KU, TOKYO, 105-0011, JAPAN	1745-1337			IEICE T FUND ELECTR	IEICE Trans. Fundam. Electron. Commun. Comput. Sci.	NOV	2015	E98A	11					2267	2269		10.1587/transfun.E98.A.2267		3	Computer Science, Hardware & Architecture; Computer Science, Information Systems; Engineering, Electrical & Electronic	Computer Science; Engineering	CV6XH	WOS:000364414700009		
J	Wu, X; Jin, Z; Niu, D; Inoue, Y				Wu, Xiao; Jin, Zhou; Niu, Dan; Inoue, Yasuaki			An Effective Time-Step Control Method in Damped Pseudo-Transient Analysis for Solving Nonlinear DC Circuit Equations	IEICE TRANSACTIONS ON FUNDAMENTALS OF ELECTRONICS COMMUNICATIONS AND COMPUTER SCIENCES			English	Article						pseudo transient analysis; step-control; DC operating point; switched evolution/relaxation	ALGORITHMS	An effective time-step control method is proposed for the damped pseudo-transient analysis (DPTA). This method is based on the idea of the switched evolution/relaxation method which can automatically adapt the step size for different circuit states. Considering the number of iterations needed for the convergence of the Newton-Raphson method, the new method adapts the suitable time-step size with the status of previous steps. By numerical examples, it is proved that this method can improve the simulation efficiency and convergence for the DPTA method to solve nonlinear DC circuits.	[Wu, Xiao; Jin, Zhou; Inoue, Yasuaki] Waseda Univ, Grad Sch Informat Prod & Syst, Kitakyushu, Fukuoka 210096, Japan; [Niu, Dan] Southeast Univ, Sch Automat, Nanjing 210096, Jiangsu, Peoples R China	Wu, X (reprint author), Waseda Univ, Grad Sch Informat Prod & Syst, Kitakyushu, Fukuoka 210096, Japan.	wuxiao@asagi.waseda.jp; jinzhou@fuji.waseda.jp; niudan2010@akane.waseda.jp; inoue_yasuaki@waseda.jp					Keyes DE, 1995, LECT NOTES PHYS, V453, P1; MULDER WA, 1985, J COMPUT PHYS, V59, P232, DOI 10.1016/0021-9991(85)90144-5; Jin Z, 2013, IEICE T FUND ELECTR, VE96A, P2524, DOI 10.1587/transfun.E96.A.2524; WEEKS WT, 1973, IEEE T CIRCUITS SYST, VCT20, P628; Kelley CT, 1998, SIAM J NUMER ANAL, V35, P508, DOI 10.1137/S0036142996304796; VENKATAKRISHNAN V, 1989, AIAA J, V27, P885, DOI 10.2514/3.10196; Goldgeisser L., 2001, P IEEE INT S CIRC SY, V5, P307; Nagel L. W., 1975, ERLM520 U CAL; Orkwis P.D., 1990, NEWTONS METHOD SOLVE, P90; Ortega J., 1970, ITERATIVE SOLUTION N; Wilton R., 1993, IEECOLLOQUIUM SPICE, p3/1; Wu X., 2013, ITC CSCC2013 YEOS KO, P922; Wu X., 2014, IEICE T NOLTA N, VE5-N, P512; Yu H, 2006, IEICE T FUND ELECTR, VE89A, P2724, DOI 10.1093/ietfec/e89-a.10.2724	14	0	0	IEICE-INST ELECTRONICS INFORMATION COMMUNICATIONS ENG	TOKYO	KIKAI-SHINKO-KAIKAN BLDG, 3-5-8, SHIBA-KOEN, MINATO-KU, TOKYO, 105-0011, JAPAN	1745-1337			IEICE T FUND ELECTR	IEICE Trans. Fundam. Electron. Commun. Comput. Sci.	NOV	2015	E98A	11					2274	2282		10.1587/transfun.E98.A.2274		9	Computer Science, Hardware & Architecture; Computer Science, Information Systems; Engineering, Electrical & Electronic	Computer Science; Engineering	CV6XH	WOS:000364414700011		
J	Kikuchi, H; Itoh, K; Ushida, M; Tsuda, H; Yamaoka, Y				Kikuchi, Hiroaki; Itoh, Kouichi; Ushida, Mebae; Tsuda, Hiroshi; Yamaoka, Yuji			Privacy-Preserving Decision Tree Learning with Boolean Target Class	IEICE TRANSACTIONS ON FUNDAMENTALS OF ELECTRONICS COMMUNICATIONS AND COMPUTER SCIENCES			English	Article						privacy; decision tree learning; Boolean query; piecewise linear function		This paper studies a privacy-preserving decision tree learning protocol (PPDT) for vertically partitioned datasets. In vertically partitioned datasets, a single class (target) attribute is shared by both parities or carefully treated by either party in existing studies. The proposed scheme allows both parties to have independent class attributes in a secure way and to combine multiple class attributes in arbitrary boolean function, which gives parties some flexibility in data-mining. Our proposed PPDT protocol reduces the CPU-intensive computation of logarithms by approximating with a piecewise linear function defined by light-weight fundamental operations of addition and constant multiplication so that information gain for attributes can be evaluated in a secure function evaluation scheme. Using the UCI Machine Learning dataset and a synthesized dataset, the proposed protocol is evaluated in terms of its accuracy and the sizes of trees*.	[Kikuchi, Hiroaki] Meiji Univ, Sch Interdisciplinary Math Sci, Tokyo 1648525, Japan; [Itoh, Kouichi; Ushida, Mebae; Tsuda, Hiroshi; Yamaoka, Yuji] Fujitsu Labs Ltd, Kawasaki, Kanagawa 2118588, Japan	Kikuchi, H (reprint author), Meiji Univ, Sch Interdisciplinary Math Sci, Tokyo 1648525, Japan.	kikn@meiji.ac.jp					Jagannathan G, 2009, 2009 IEEE INTERNATIONAL CONFERENCE ON DATA MINING WORKSHOPS (ICDMW 2009), P114, DOI 10.1109/ICDMW.2009.93; [Anonymous], 2004, P 7 ANN INT C INF SE; Lindell Y, 2000, LECT NOTES COMPUT SC, V1880, P36; Kikuchi H, 2013, IEICE T FUND ELECTR, VE96A, P111, DOI 10.1587/transfun.E96.A.111; Vaidya J, 2005, LECT NOTES COMPUT SC, V3654, P139; Du W., 2002, IEEE INT C DAT MIN W, V14, P1; Malkhi D., 2004, US SEC S; Paillier P, 1999, LECT NOTES COMPUT SC, V1592, P223; Quinlan J. R., 1986, Machine Learning, V1, DOI 10.1023/A:1022643204877; Yasunaga H., 2012, ANN SURG, V257, P640	10	0	0	IEICE-INST ELECTRONICS INFORMATION COMMUNICATIONS ENG	TOKYO	KIKAI-SHINKO-KAIKAN BLDG, 3-5-8, SHIBA-KOEN, MINATO-KU, TOKYO, 105-0011, JAPAN	1745-1337			IEICE T FUND ELECTR	IEICE Trans. Fundam. Electron. Commun. Comput. Sci.	NOV	2015	E98A	11					2291	2300		10.1587/transfun.E98.A.2291		10	Computer Science, Hardware & Architecture; Computer Science, Information Systems; Engineering, Electrical & Electronic	Computer Science; Engineering	CV6XH	WOS:000364414700013		
J	Beaugendre, A; Goto, S				Beaugendre, Axel; Goto, Satoshi			Adaptive Block-Propagative Background Subtraction Method for UHDTV Foreground Detection	IEICE TRANSACTIONS ON FUNDAMENTALS OF ELECTRONICS COMMUNICATIONS AND COMPUTER SCIENCES			English	Article						foreground detection; block-propagation; UHDTV; ABPBGS; 8K; 4K; moving object; super hi-vision		This paper presents an Adapting Block-Propagative Background Subtraction (ABPBGS) designed for Ultra High Definition Television (UHDTV) foreground detection. The main idea is to detect block after block along the objects in order to skip all areas of the image in which there is no moving object. This is particularly interesting for UHDTV when the objects of interest could represent not even 0.1% of the total area. From a seed block which is determined in a previous iteration, the detection will spread along an object as long as it detects a part of that object. A block history map guaranties that each block is processed only once. Moreover, only small blocks are loaded and processed, thus saving computational time and memory usage. The process of each block is independent enough to be easily parallelized. Compared to 9 state-of-the-art works, the ABPBGS achieved the best results with an average global quality score of 0.57 (1 being the maximum) on a dataset of 4K and 8K UHDTV sequences developed for this work. None of the state-of-the-art methods could process 4K videos in reasonable time while the ABPBGS has shown an average speed of 5.18 fps. In comparison, 5 of the 9 state-of-the-art methods performed slower on 270p down-scale version of the same videos. The experiments have also shown that for the process an 8K UHDTV video the ABPBGS can divide the memory required by about 24 for a total of 450 MB.	[Beaugendre, Axel; Goto, Satoshi] Waseda Univ, Grad Sch Informat Prod & Syst, Kitakyushu, Fukuoka 8080135, Japan	Beaugendre, A (reprint author), Waseda Univ, Grad Sch Informat Prod & Syst, Kitakyushu, Fukuoka 8080135, Japan.	axel.beaugendre@fuji.waseda.jp					Oliver NM, 2000, IEEE T PATTERN ANAL, V22, P831, DOI 10.1109/34.868684; Song L, 2013, 2013 FIFTH INTERNATIONAL WORKSHOP ON QUALITY OF MULTIMEDIA EXPERIENCE (QOMEX), P34; Reddy V, 2013, IEEE T CIRC SYST VID, V23, P83, DOI 10.1109/TCSVT.2012.2203199; Wren CR, 1997, IEEE T PATTERN ANAL, V19, P780, DOI 10.1109/34.598236; Bloisi D, 2012, COMPUTATIONAL MODELLING OF OBJECTS REPRESENTED IN IMAGES: FUNDAMENTALS, METHODS AND APPLICATIONS III, P39; Zivkovic Z, 2006, PATTERN RECOGN LETT, V27, P773, DOI 10.1016/j.patrec.2005.11.005; Sobral A, 2014, COMPUT VIS IMAGE UND, V122, P4, DOI 10.1016/j.cviu.2013.12.005; Wang Z, 2004, IEEE T IMAGE PROCESS, V13, P600, DOI 10.1109/TIP.2003.819861; Berjon D., 2014, INT C CONS EL ICCE I, P359; Calderara S., 2006, P 4 ACM INT WORKSH V, V4, P211, DOI DOI 10.1145/1178782.1178814; Hofmann M., 2012, COMP VIS PATT REC WO, P38; KaewTraKulPong P., 2001, EUR WORKSH ADV VID B, P135; Le Feuvre J., 2014, P 5 ACM MULT SYST C, P7; McFarlane N ., 1995, MACH VISION APPL, V83, P187; Shishikui Y., 2009, EBU TECHNICAL REV; Sobral A., 2013, 9 WORKSH VIS COMP WV; Sugawara M., 2012, P IEEE, V101, P8; Toyama K., 1999, P IEEE INT C COMP VI, V1, P255, DOI DOI 10.1109/ICCV.1999.791228; Tsai W. K., 2012, IEEE EMBEDDED SYSTEM, V4, P49, DOI [10.1109/LES.2012.2195710.10.1109/LES.2012.2195710, DOI 10.1109/LES.2012.2195710]; Vacavant A., 2012, LNCS, V7728, P291; Yao J., 2007, IEEE C COMP VIS PATT, P1; Zivkovic Z, 2004, INT C PATT RECOG, P28, DOI 10.1109/ICPR.2004.1333992	22	0	0	IEICE-INST ELECTRONICS INFORMATION COMMUNICATIONS ENG	TOKYO	KIKAI-SHINKO-KAIKAN BLDG, 3-5-8, SHIBA-KOEN, MINATO-KU, TOKYO, 105-0011, JAPAN	1745-1337			IEICE T FUND ELECTR	IEICE Trans. Fundam. Electron. Commun. Comput. Sci.	NOV	2015	E98A	11					2307	2314		10.1587/transfun.E98.A.2307		8	Computer Science, Hardware & Architecture; Computer Science, Information Systems; Engineering, Electrical & Electronic	Computer Science; Engineering	CV6XH	WOS:000364414700015		
J	Tanaka, A; Takebayashi, H; Takigawa, I; Imai, H; Kudo, M				Tanaka, Akira; Takebayashi, Hirofumi; Takigawa, Ichigaku; Imai, Hideyuki; Kudo, Mineichi			Ensemble and Multiple Kernel Regressors: Which Is Better?	IEICE TRANSACTIONS ON FUNDAMENTALS OF ELECTRONICS COMMUNICATIONS AND COMPUTER SCIENCES			English	Article						kernel regression; ensemble kernel regressor; multiple kernel regressor; generalization error; reproducing kernel Hilbert spaces	SUBSPACE INFORMATION CRITERION; MODEL SELECTION	For the last few decades, learning with multiple kernels, represented by the ensemble kernel regressor and the multiple kernel regressor, has attracted much attention in the field of kernel-based machine learning. Although their efficacy was investigated numerically in many works, their theoretical ground is not investigated sufficiently, since we do not have a theoretical framework to evaluate them. In this paper, we introduce a unified framework for evaluating kernel regressors with multiple kernels. On the basis of the framework, we analyze the generalization errors of the ensemble kernel regressor and the multiple kernel regressor, and give a sufficient condition for the ensemble kernel regressor to outperform the multiple kernel regressor in terms of the generalization error in noise-free case. We also show that each kernel regressor can be better than the other without the sufficient condition by giving examples, which supports the importance of the sufficient condition.	[Tanaka, Akira; Takebayashi, Hirofumi; Takigawa, Ichigaku; Imai, Hideyuki; Kudo, Mineichi] Hokkaido Univ, Grad Sch Informat Sci & Technol, Div Comp Sci & Informat Technol, Sapporo, Hokkaido 0600814, Japan	Tanaka, A (reprint author), Hokkaido Univ, Grad Sch Informat Sci & Technol, Div Comp Sci & Informat Technol, Sapporo, Hokkaido 0600814, Japan.	takira@main.ist.hokudai.ac.jp					Tanaka A, 2011, INT CONF ACOUST SPEE, P2072; Sugiyama M, 2001, IEICE T FUND ELECTR, VE84A, P2319; Muller KR, 2001, IEEE T NEURAL NETWOR, V12, P181, DOI 10.1109/72.914517; Tanaka A, 2008, LECT NOTES COMPUT SC, V5342, P530, DOI 10.1007/978-3-540-89689-0_57; Sugiyama M, 2000, NEURAL COMPUT, V12, P2909, DOI 10.1162/089976600300014773; Sugiyama M, 2001, NEURAL COMPUT, V13, P1863, DOI 10.1162/08997660152469387; Mercer J, 1909, PHILOS T R SOC LOND, V209, P415, DOI 10.1098/rsta.1909.0016; Tanaka A, 2010, INT CONF ACOUST SPEE, P2074, DOI 10.1109/ICASSP.2010.5495065; ARONSZAJN N, 1950, T AM MATH SOC, V68, P337; Sonnenburg S, 2006, J MACH LEARN RES, V7, P1531; Tanaka A, 2012, LECT NOTES COMPUT SC, V7626, P345, DOI 10.1007/978-3-642-34166-3_38; Sugiyama M, 2004, NEURAL COMPUT, V16, P1077, DOI 10.1162/089976604773135113; Cristianini N, 2000, INTRO SUPPORT VECTOR; Hardy G.-H., 1952, INEQUALITIES; Ogawa H., 1995, NC958 IEICE; Rao C.R., 1971, GEN INVERSE MATRICES; Reed M., 1980, METHODS MODERN MATH; Saitoh S., 1997, INTEGRAL TRANSFORMS; Schatten R., 1960, NORM IDEALS COMPLETE; Takebayashi H., 2014, 29 SIGN PROC S, P120; Tanaka A., 2014, 29 SIGN PROC S, P425; Tanaka A., 2013, 28 SIGN PROC S, P350; Tanaka A., 2014, 6 AS C MACH LEARN AC; Vapnik V., 1999, NATURE STAT LEARNING	24	0	0	IEICE-INST ELECTRONICS INFORMATION COMMUNICATIONS ENG	TOKYO	KIKAI-SHINKO-KAIKAN BLDG, 3-5-8, SHIBA-KOEN, MINATO-KU, TOKYO, 105-0011, JAPAN	1745-1337			IEICE T FUND ELECTR	IEICE Trans. Fundam. Electron. Commun. Comput. Sci.	NOV	2015	E98A	11					2315	2324		10.1587/transfun.E98.A.2315		10	Computer Science, Hardware & Architecture; Computer Science, Information Systems; Engineering, Electrical & Electronic	Computer Science; Engineering	CV6XH	WOS:000364414700016		
J	Uchida, M				Uchida, Masato			Unsupervised Weight Parameter Estimation for Exponential Mixture Distribution Based on Symmetric Kullback-Leibler Divergence	IEICE TRANSACTIONS ON FUNDAMENTALS OF ELECTRONICS COMMUNICATIONS AND COMPUTER SCIENCES			English	Article						ensemble learning; parameter estimation; exponential mixture model; symmetric Kullback-Leibler divergence		When there are multiple component predictors, it is promising to integrate them into one predictor for advanced reasoning. If each component predictor is given as a stochastic model in the form of probability distribution, an exponential mixture of the component probability distributions provides a good way to integrate them. However, weight parameters used in the exponential mixture model are difficult to estimate if there is no training samples for performance evaluation. As a suboptimal way to solve this problem, weight parameters may be estimated so that the exponential mixture model should be a balance point that is defined as an equilibrium point with respect to the distance from/to all component probability distributions. In this paper, we propose a weight parameter estimation method that represents this concept using a symmetric Kullback-Leibler divergence and generalize this method.	Chiba Inst Technol, Dept Elect Elect & Comp Engn, Narashino, Chiba 275016, Japan	Uchida, M (reprint author), Chiba Inst Technol, Dept Elect Elect & Comp Engn, Narashino, Chiba 275016, Japan.	masato.uchida@ieee.org			Japan Society for the Promotion of Science [26330112]	This work was supported in part by the Japan Society for the Promotion of Science through Grants-in-Aid for Scientific Research (C) (26330112).	Friedman J, 2000, ANN STAT, V28, P337, DOI 10.1214/aos/1016218223; SCHAPIRE RE, 1990, MACH LEARN, V5, P197, DOI 10.1023/A:1022648800760; Breiman L, 1996, MACH LEARN, V24, P123, DOI 10.1023/A:1018054314350; Ueda N, 1996, IEEE IJCNN, P90, DOI 10.1109/ICNN.1996.548872; Domingo C., 2000, P 13 ANN C COMP LEAR, P180; Freund Y, 1997, J COMPUT SYST SCI, V55, P119, DOI 10.1006/jcss.1997.1504; Uchida M., 2001, IEICE T INF SYST D2, P1537; Uchida M., 2014, P JOINT 7 INT C SOFT, P1126; Uchida M., 2011, J MATH MODELLING ALG, V10, P307; Uchida M., 2003, IEICE T INF SYST D2, VJ86-D-II, P1131	10	0	0	IEICE-INST ELECTRONICS INFORMATION COMMUNICATIONS ENG	TOKYO	KIKAI-SHINKO-KAIKAN BLDG, 3-5-8, SHIBA-KOEN, MINATO-KU, TOKYO, 105-0011, JAPAN	1745-1337			IEICE T FUND ELECTR	IEICE Trans. Fundam. Electron. Commun. Comput. Sci.	NOV	2015	E98A	11					2349	2353		10.1587/transfun.E98.A.2349		5	Computer Science, Hardware & Architecture; Computer Science, Information Systems; Engineering, Electrical & Electronic	Computer Science; Engineering	CV6XH	WOS:000364414700021		
J	Chen, ZY; Muramatsu, S				Chen, Zhiyu; Muramatsu, Shogo			Multi-Focus Image Fusion Based on Multiple Directional LOTs	IEICE TRANSACTIONS ON FUNDAMENTALS OF ELECTRONICS COMMUNICATIONS AND COMPUTER SCIENCES			English	Article						multiple DirLOTs; image fusion; mutual information	NONSUBSAMPLED CONTOURLET TRANSFORM; PERFORMANCE; DESIGN	This letter proposes an image fusion method which adopts a union of multiple directional lapped orthogonal transforms (DirLOTs). DirLOTs are used to generate symmetric orthogonal discrete wavelet transforms and then to construct a union of unitary transforms as a redundant dictionary with a multiple directional property. The multiple DirLOTs can overcome a disadvantage of separable wavelets to represent images which contain slant textures and edges. We analyse the characteristic of local luminance contrast, and propose a fusion rule based on interscale relation of wavelet coefficients. Relying on the above, a novel image fusion method is proposed. Some experimental results show that the proposed method is able to significantly improve the fusion performance from those with the conventional discrete wavelet transforms.	[Chen, Zhiyu] Niigata Univ, Grad Sch Sci & Technol, Niigata 9502181, Japan; [Muramatsu, Shogo] Niigata Univ, Dept Elect & Elect Engn, Niigata 9502181, Japan	Chen, ZY (reprint author), Niigata Univ, Grad Sch Sci & Technol, Niigata 9502181, Japan.	chenzhiyu@telecom0.eng.niigata-u.ac.jp; shogo@eng.niigata-u.ac.jp			JSPS KAKENHI [26420347]	This work was supported in part by JSPS KAKENHI Grant Number 26420347.	Petrovic V, 2005, IEEE I CONF COMP VIS, P1866; Zhang Z, 1999, P IEEE, V87, P1315; Goshtasby AA, 2007, INFORM FUSION, V8, P114, DOI 10.1016/j.inffus.2006.04.001; da Cunha AL, 2006, IEEE T IMAGE PROCESS, V15, P3089, DOI 10.1109/TIP.2006.877507; Muramatsu S, 2012, IEEE T IMAGE PROCESS, V21, P2434, DOI 10.1109/TIP.2011.2182055; [Anonymous], 1997, IEEE T IMAGE PROCESS, DOI DOI 10.1109/ICIP.1997.632093; Li HF, 2013, OPTIK, V124, P40, DOI 10.1016/j.ijleo.2011.11.088; Easley G, 2008, APPL COMPUT HARMON A, V25, P25, DOI 10.1016/j.acha.2007.09.003; Lewis JJ, 2007, INFORM FUSION, V8, P119, DOI 10.1016/j.inffus.2005.09.006; TOET A, 1989, OPT ENG, V28, P789, DOI 10.1117/12.7977034; Muramatsu S, 2012, 2012 IEEE INTERNATIONAL CONFERENCE ON ACOUSTICS, SPEECH AND SIGNAL PROCESSING (ICASSP), P1089; Aslantas V, 2014, OPT COMMUN, V332, P350, DOI 10.1016/j.optcom.2014.07.044; Guorong G., 2013, IET IMAGE PROCESS, V7, P633, DOI [10.1049/iet-ipr.2012.0558, DOI 10.1049/IET-IPR.2012.0558]; Huang W., 2007, PATTERN RECOGN, V28, P493, DOI DOI 10.1016/J.PATREC.2006.09.005; Liu Y, 2015, INFORM FUSION, V23, P139, DOI 10.1016/j.inffus.2014.05.004; Stathaki T, 2008, IMAGE FUSION: ALGORITHMS AND APPLICATIONS, P1; Viola P, 1997, INT J COMPUT VISION, V24, P137, DOI 10.1023/A:1007958904918; WATSON AB, 1987, J OPT SOC AM A, V4, P2401, DOI 10.1364/JOSAA.4.002401; Yong Yang, 2014, Sensors, V14, DOI 10.3390/s141222408	19	0	0	IEICE-INST ELECTRONICS INFORMATION COMMUNICATIONS ENG	TOKYO	KIKAI-SHINKO-KAIKAN BLDG, 3-5-8, SHIBA-KOEN, MINATO-KU, TOKYO, 105-0011, JAPAN	1745-1337			IEICE T FUND ELECTR	IEICE Trans. Fundam. Electron. Commun. Comput. Sci.	NOV	2015	E98A	11					2360	U157		10.1587/transfun.E98.A.2360		6	Computer Science, Hardware & Architecture; Computer Science, Information Systems; Engineering, Electrical & Electronic	Computer Science; Engineering	CV6XH	WOS:000364414700024		
J	Wu, SQ; Nagahashi, H				Wu, Shuqiong; Nagahashi, Hiroshi			Penalized AdaBoost: Improving the Generalization Error of Gentle AdaBoost through a Margin Distribution	IEICE TRANSACTIONS ON INFORMATION AND SYSTEMS			English	Article						Gentle AdaBoost; generalization error; machine learning; modest AdaBoost; training error		Gentle AdaBoost is widely used in object detection and pattern recognition due to its efficiency and stability. To focus on instances with small margins, Gentle AdaBoost assigns larger weights to these instances during the training. However, misclassification of small-margin instances can still occur, which will cause the weights of these instances to become larger and larger. Eventually, several large-weight instances might dominate the whole data distribution, encouraging Gentle AdaBoost to choose weak hypotheses that fit only these instances in the late training phase. This phenomenon, known as "classifier distortion", degrades the generalization error and can easily lead to overfitting since the deviation of all selected weak hypotheses is increased by the late-selected ones. To solve this problem, we propose a new variant which we call "Penalized AdaBoost". In each iteration, our approach not only penalizes the misclassification of instances with small margins but also restrains the weight increase for instances with minimal margins. Our method performs better than Gentle AdaBoost because it avoids the "classifier distortion" effectively. Experiments show that our method achieves far lower generalization errors and a similar training speed compared with Gentle AdaBoost.	[Wu, Shuqiong] Tokyo Inst Technol, Dept Computat Intelligence & Syst Sci, Yokohama, Kanagawa 2268503, Japan; [Nagahashi, Hiroshi] Tokyo Inst Technol, Imaging Sci & Engn Lab, Yokohama, Kanagawa 2268503, Japan	Wu, SQ (reprint author), Tokyo Inst Technol, Dept Computat Intelligence & Syst Sci, Yokohama, Kanagawa 2268503, Japan.	bu.s.aa@m.titech.ac.jp; longb@isl.titech.ac.jp					Friedman J, 2000, ANN STAT, V28, P337, DOI 10.1214/aos/1016218223; Viola P, 2001, PROC CVPR IEEE, P511; Chen K, 2011, IEEE T PATTERN ANAL, V33, P129, DOI 10.1109/TPAMI.2010.92; Schapire RE, 1999, MACH LEARN, V37, P297, DOI 10.1023/A:1007614523901; Paul B, 2009, ICAPR 2009: SEVENTH INTERNATIONAL CONFERENCE ON ADVANCES IN PATTERN RECOGNITION, PROCEEDINGS, P251, DOI 10.1109/ICAPR.2009.67; Mallapragada Pavan Kumar, 2009, IEEE Trans Pattern Anal Mach Intell, V31, P2000, DOI 10.1109/TPAMI.2008.235; Sun YJ, 2004, PROCEEDINGS OF THE 2004 INTERNATIONAL CONFERENCE ON MACHINE LEARNING AND APPLICATIONS (ICMLA'04), P41; Ferreira AJ, 2012, ENSEMBLE MACHINE LEARNING: METHODS AND APPLICATIONS, P35, DOI 10.1007/978-1-4419-9326-7_2; Demiriz A, 2002, MACH LEARN, V46, P225, DOI 10.1023/A:1012470815092; Rodriguez JJ, 2008, PATTERN RECOGN LETT, V29, P1049, DOI 10.1016/j.patrec.2007.06.019; Schapire RE, 1998, ANN STAT, V26, P1651; Seyedhosseini M, 2011, 2011 INTERNATIONAL JOINT CONFERENCE ON NEURAL NETWORKS (IJCNN), P1245, DOI 10.1109/IJCNN.2011.6033366; Bache K., 2013, UCI MACHINE LEARNING; Bradley J. K., 2007, NIPS, P185; Domingo C., 2000, 13 ANN C COMP LEARN, P180; Freund Y., 1999, Journal of Japanese Society for Artificial Intelligence, V14; Freund Y., 1999, Proceedings of the Twelfth Annual Conference on Computational Learning Theory, DOI 10.1145/307400.307419; Freund Y., 2009, PREPRINT; Grossmann E., 2004, IEEE WORKSH LEARN CO, P105; Gunnar O. T. R., 2001, MACH LEARN, V42, P287; Hegazy D., 2008, WORLD ACAD SCI ENG T, P70; Li H., 2008, DIGITAL IMAGE COULPU, P533; Li SZ, 2004, IEEE T PATTERN ANAL, V26, P1112, DOI 10.1109/TPAMI.2004.68; Lu Y., 2007, P 7 INT C MULT CLASS, P180; Servedio R.A., 2003, J MACHINE LEARNING R, V4, P633; Sun C., 2011, IEEE GLOB 2011 DEC, P1; Thongkam Y. Z. J., 2008, AUSTR WORKSH HLTH DA, P55; Vezhnevets A., GML ADABOOST MATLAB, P1; Vezhnevets A., 2005, GRAPHICON, V12, P987; Warmuth M., 2007, ADV NEURAL INFORM PR, P1; Warmuth M. K., 2008, P INT C ALG LEARN TH, P256; Wu S., 2014, SPIE, V9069, P1	32	0	0	IEICE-INST ELECTRONICS INFORMATION COMMUNICATIONS ENG	TOKYO	KIKAI-SHINKO-KAIKAN BLDG, 3-5-8, SHIBA-KOEN, MINATO-KU, TOKYO, 105-0011, JAPAN	1745-1361			IEICE T INF SYST	IEICE Trans. Inf. Syst.	NOV	2015	E98D	11					1906	1915		10.1587/transinf.2015EDP7069		10	Computer Science, Information Systems; Computer Science, Software Engineering	Computer Science	CV7AA	WOS:000364422600002		
J	Ogata, K; Mita, T; Shimizu, T; Yamasaki, N				Ogata, Kunihiro; Mita, Tomoki; Shimizu, Takeshi; Yamasaki, Nobuya			Training Assist System of a Lower Limb Prosthetic Visualizing Floor-Reaction Forces Using a Color-Depth Sensing Camera	IEICE TRANSACTIONS ON INFORMATION AND SYSTEMS			English	Article						rehabilitation; visualization; prosthetic leg; zero moment point	REAL-TIME; FEEDBACK; AMPUTATION; KINECT	Some unilateral lower-limb amputees, have through continued exertion, increase the foot reaction force of the sound leg. The asymmetric gait with a prosthetic leg may thus negatively affect the musculoskeletal health of the leg on the healthy side. Therefore, it is important for these amputees to learn how to adjust the balance of each foot load in training. The aim of this study is to develop a training support system visualizing floor-reaction forces using a color-depth sensor. The pose of the entire body of the amputee is measured by the depth sensor, and the floor reaction force is estimated based on Zero Moment Point (ZMP), which is calculated using the center of mass of the amputee. Evaluation experiments of the proposed method were performed and they confirmed the effectiveness of the estimation method and the training with the visualization of reaction force.	[Ogata, Kunihiro; Mita, Tomoki; Yamasaki, Nobuya] Natl Rehabil Ctr Persons Disabil, Res Inst, Tokorozawa, Saitama 3590042, Japan; [Shimizu, Takeshi] Natl Rehabil Ctr Persons Disabil, Rehabil Serv Bur, Tokorozawa, Saitama 3590042, Japan	Ogata, K (reprint author), Saitama Univ, Grad Sch Sci & Engn, Saitama, Japan.	kuniogata@mail.saitama-u.ac.jp					Miura K, 2011, IEEE INT C INT ROBOT, P4428, DOI 10.1109/IROS.2011.6048511; Kitsunezaki N, 2013, 2013 IEEE INTERNATIONAL SYMPOSIUM ON MEDICAL MEASUREMENTS AND APPLICATIONS PROCEEDINGS (MEMEA), P294; Darter BJ, 2011, PHYS THER, V91, P1385, DOI 10.2522/ptj.20100360; Clark RA, 2013, GAIT POSTURE, V38, P1064, DOI 10.1016/j.gaitpost.2013.03.029; Shotton J, 2011, PROC CVPR IEEE, P1297, DOI 10.1109/CVPR.2011.5995316; Sabe R, 2012, 2012 IEEE/SICE INTERNATIONAL SYMPOSIUM ON SYSTEM INTEGRATION (SII), P337, DOI 10.1109/SII.2012.6427371; ROSSI SA, 1995, J REHABIL RES DEV, V32, P120; Llorens R, 2012, STUD HEALTH TECHNOL, V181, P108, DOI 10.3233/978-1-61499-121-2-108; Bowker J.H., 1992, ATLAS LIMB PROSTHETI; Davis B.L., 2004, AAOP, V16, P49; Dingwell JB, 1996, PROSTHET ORTHOT INT, V20, P101; Kajita S., 2014, INTRO HUMANOID ROBOT; Kajita S., 2010, P IEEE RSJ INT C INT, P4489; Kajita S., 2006, P IEEE RSJ INT C INT, P2993; Murai A, 2010, PROG BIOPHYS MOL BIO, V103, P310, DOI 10.1016/j.pbiomolbio.2010.09.006; Nakagawa A., 2002, DEV PROSTHETIC GAIT, P158; Sugihara T., 2009, P 2009 IEEE INT C RO, P1966; VUKOBRATOVIC M, 1972, Mathematical Biosciences, V15, P1, DOI 10.1016/0025-5564(72)90061-2	18	0	0	IEICE-INST ELECTRONICS INFORMATION COMMUNICATIONS ENG	TOKYO	KIKAI-SHINKO-KAIKAN BLDG, 3-5-8, SHIBA-KOEN, MINATO-KU, TOKYO, 105-0011, JAPAN	1745-1361			IEICE T INF SYST	IEICE Trans. Inf. Syst.	NOV	2015	E98D	11					1916	1922		10.1587/transinf.2015EDP7089		7	Computer Science, Information Systems; Computer Science, Software Engineering	Computer Science	CV7AA	WOS:000364422600003		
J	Komatani, K; Hotta, N; Sato, S; Nakano, M				Komatani, Kazunori; Hotta, Naoki; Sato, Satoshi; Nakano, Mikio			Posteriori Restoration of Turn-Taking and ASR Results for Incorrectly Segmented Utterances	IEICE TRANSACTIONS ON INFORMATION AND SYSTEMS			English	Article						spoken dialogue system; VAD error; turn taking; a posteriori restoration	SPOKEN DIALOGUE	Appropriate turn-taking is important in spoken dialogue systems as well as generating correct responses. Especially if the dialogue features quick responses, a user utterance is often incorrectly segmented due to short pauses within it by voice activity detection (VAD). Incorrectly segmented utterances cause problems both in the automatic speech recognition (ASR) results and turn-taking: i.e., an incorrect VAD result leads to ASR errors and causes the system to start responding though the user is still speaking. We develop a method that performs a posteriori restoration for incorrectly segmented utterances and implement it as a plug-in for the MMDAgent open-source software. A crucial part of the method is to classify whether the restoration is required or not. We cast it as a binary classification problem of detecting originally single utterances from pairs of utterance fragments. Various features are used representing timing, prosody, and ASR result information. Experiments show that the proposed method outperformed a baseline with manually-selected features by 4.8% and 3.9% in cross-domain evaluations with two domains. More detailed analysis revealed that the dominant and domain-independent features were utterance intervals and results from the Gaussian mixture model (GMM).	[Komatani, Kazunori] Osaka Univ, Inst Sci & Ind Res, Ibaraki 5670047, Japan; [Hotta, Naoki; Sato, Satoshi] Nagoya Univ, Grad Sch Engn, Nagoya, Aichi 4648603, Japan; [Nakano, Mikio] Honda Res Inst Japan Co Ltd, Wako, Saitama 3510188, Japan	Komatani, K (reprint author), Osaka Univ, Inst Sci & Ind Res, Ibaraki 5670047, Japan.	komatani@sanken.osaka-u.ac.jp			JST PRESTO; Naito Science & Engineering Foundation	This work was partly supported by JST PRESTO and the Naito Science & Engineering Foundation.	Katsumaru M, 2009, LECT NOTES ARTIF INT, V5579, P481, DOI 10.1007/978-3-642-02568-6_49; Benyassine A, 1997, IEEE COMMUN MAG, V35, P64, DOI 10.1109/35.620527; Heeman PA, 1999, COMPUT LINGUIST, V25, P527; Liu Y, 2006, IEEE T AUDIO SPEECH, V14, P1526, DOI 10.1109/TASL.2006.878255; Lee A, 2013, INT CONF ACOUST SPEE, P8382, DOI 10.1109/ICASSP.2013.6639300; Baumann T., 2011, P SIGDIAL PORTL US J, P120; Bell L., 2001, P NAACL WORKSH AD DI, P2; Core M.G., 1999, P 37 ANN M ASS COMP, P413, DOI 10.3115/1034678.1034742; Edlund J., 2005, COMPUTER STUDIES LAN, P576; Georgila K., 2010, P ANN M SPEC INT GRO, P237; Hotta N., 2014, P ANN C INT SPEECH C, P313; Jan E.E., 2003, P EUR, P1249; Kitaoka N., 2005, T JAPANESE SOC ARTIF, V20, P220, DOI 10.1527/tjsai.20.220; Komatani K., 2014, P INT WORKSH SPOK DI, P27; Lee A., 2009, P APSIPA ASC, P131; Lee A., 2004, P ICSLP, P173; Nakano M., 2011, P SIGDIAL C JUN, P18; Nakano M., 1999, P 37 ANN M ASS COMP, P200, DOI 10.3115/1034678.1034715; Ohsuga T., 2005, P EUR C SPEECH COMM; Raux A., 2008, P 9 SIGDIAL WORKSH D, P1, DOI 10.3115/1622064.1622066; Raux A., 2009, P HUM LANG TECHN 200, P629, DOI 10.3115/1620754.1620846; Sakai H., 2007, P 1 INT C ROB COMM C; Sato R., 2002, P ICSLP 2002 DENV US, P861; Selfridge E., 2011, P SIGDIAL PORTL OR J, P110; Shneiderman B., 1997, DESIGNING USER INTER; Skantze G., 2010, P SIGDIAL TOK JAP SE, P1; Traum D., 2012, LECT NOTES COMPUTER, V7502, P275	27	0	0	IEICE-INST ELECTRONICS INFORMATION COMMUNICATIONS ENG	TOKYO	KIKAI-SHINKO-KAIKAN BLDG, 3-5-8, SHIBA-KOEN, MINATO-KU, TOKYO, 105-0011, JAPAN	1745-1361			IEICE T INF SYST	IEICE Trans. Inf. Syst.	NOV	2015	E98D	11					1923	1931		10.1587/transinf.2015EDP7014		9	Computer Science, Information Systems; Computer Science, Software Engineering	Computer Science	CV7AA	WOS:000364422600004		
J	Liang, Y; Iwano, K; Shinoda, K				Liang, Yuan; Iwano, Koji; Shinoda, Koichi			Error Correction Using Long Context Match for Smartphone Speech Recognition	IEICE TRANSACTIONS ON INFORMATION AND SYSTEMS			English	Article						speech recognition; error correction; multimodal interface; word confusion network; context match	CONFUSION NETWORKS; RECOVERY	Most error correction interfaces for speech recognition applications on smartphones require the user to first mark an error region and choose the correct word from a candidate list. We propose a simple multimodal interface to make the process more efficient. We develop Long Context Match (LCM) to get candidates that complement the conventional word confusion network (WCN). Assuming that not only the preceding words but also the succeeding words of the error region are validated by users, we use such contexts to search higher-order n-grams corpora for matching word sequences. For this purpose, we also utilize the Web text data. Furthermore, we propose a combination of LCM andWCN ("LCM + WCN") to provide users with candidate lists that are more relevant than those yielded by WCN alone. We compare our interface with the WCN-based interface on the Corpus of Spontaneous Japanese (CSJ). Our proposed "LCM + WCN" method improved the 1-best accuracy by 23%, improved the Mean Reciprocal Rank (MRR) by 28%, and our interface reduced the user's load by 12%.	[Liang, Yuan; Shinoda, Koichi] Tokyo Inst Technol, Dept Comp Sci, Tokyo 1528552, Japan; [Iwano, Koji] Tokyo City Univ, Dept Informat Ecol Studies, Yokohama, Kanagawa 2248551, Japan	Liang, Y (reprint author), Tokyo Inst Technol, Dept Comp Sci, Tokyo 1528552, Japan.	yuan@ks.cs.titech.ac.jp; iwano@tcu.ac.jp; shinoda@cs.titech.ac.jp					Laurent A, 2011, INT CONF ACOUST SPEE, P4884; Yoshino K, 2013, INT CONF ACOUST SPEE, P8252, DOI 10.1109/ICASSP.2013.6639274; Vertanen K, 2006, INTERSPEECH 2006 AND 9TH INTERNATIONAL CONFERENCE ON SPOKEN LANGUAGE PROCESSING, VOLS 1-5, P1890; Kristensson PO, 2009, AI MAG, V30, P85; Parada C, 2010, 11TH ANNUAL CONFERENCE OF THE INTERNATIONAL SPEECH COMMUNICATION ASSOCIATION 2010 (INTERSPEECH 2010), VOLS 1-2, P1269; Lecorve G, 2012, 13TH ANNUAL CONFERENCE OF THE INTERNATIONAL SPEECH COMMUNICATION ASSOCIATION 2012 (INTERSPEECH 2012), VOLS 1-3, P182; Shinoda K, 2011, SPEECH COMMUN, V53, P283, DOI 10.1016/j.specom.2010.10.001; Wang LJ, 2008, INTERSPEECH 2008: 9TH ANNUAL CONFERENCE OF THE INTERNATIONAL SPEECH COMMUNICATION ASSOCIATION 2008, VOLS 1-5, P2659; Mangu L, 2000, COMPUT SPEECH LANG, V14, P373, DOI 10.1006/csla.2000.0152; Sturm J, 2005, SPEECH COMMUN, V45, P289, DOI 10.1016/j.specom.2004.11.007; BABER C, 1993, INT J MAN MACH STUD, V39, P495, DOI 10.1006/imms.1993.1070; [Anonymous], 2001, ACOUST SPEECH SIG PR; Lewis JR, 1999, HUM FAC ERG SOC P, P457; [Anonymous], 2012, P ICASSP; Burke M., 2006, P ACM SIGCHI C HUM F, P339, DOI 10.1145/1124772.1124823; Civera J, 2004, LECT NOTES COMPUT SC, V3138, P207; Dixon P. R., 2007, P IEEE ASRU, P443; Hakkani-Tur D, 2006, COMPUT SPEECH LANG, V20, P495, DOI 10.1016/j.csl.2005.07.005; Huggins-Daines D., 2008, P 46 ANN M ASS COMP, P17, DOI 10.3115/1564144.1564149; Kudo T., 2009, JAPANESE WEB N GRAM; Liang Y., 2014, P SLT, P454; Liang Y., 2014, P INTERSPEECH, P1194; Maekawa K., 2000, P 2 INT C LANG RES E, P947; Mankoff J., 1999, ERROR CORRECTION TEC; Matsumoto Y., 2007, CHASEN MORPHOLOGICAL; Nishizaki H., 2006, P ICCPOL, P213; Ogata J., 2005, P EUR 2005, P133; Rodriguez L, 2007, LECT NOTES COMPUT SC, V4477, P241; Schlippe T., 2013, P INTERSPEECH, P2698; Stolcke A., 2011, P ASRU; Suhm B., 2001, ACM Transactions on Computer-Human Interaction, V8, DOI 10.1145/371127.371166; Vertanen K., 2010, P AAAI, P1698; Vertanen K., 2009, P 14 ACM INT C INT U, P237; Vidal E., 2007, P MLMI, P60	34	0	0	IEICE-INST ELECTRONICS INFORMATION COMMUNICATIONS ENG	TOKYO	KIKAI-SHINKO-KAIKAN BLDG, 3-5-8, SHIBA-KOEN, MINATO-KU, TOKYO, 105-0011, JAPAN	1745-1361			IEICE T INF SYST	IEICE Trans. Inf. Syst.	NOV	2015	E98D	11					1932	1942		10.1587/transinf.2015EDP7179		11	Computer Science, Information Systems; Computer Science, Software Engineering	Computer Science	CV7AA	WOS:000364422600005		
J	Mishiba, K; Yoshitome, T				Mishiba, Kazu; Yoshitome, Takeshi			Improvement of Colorization-Based Coding Using Optimization by Novel Colorization Matrix Construction and Adaptive Color Conversion	IEICE TRANSACTIONS ON INFORMATION AND SYSTEMS			English	Article						colorization-based coding; image compression; colorization matrix; edge-preserving filtering; adaptive color conversion		This study improves the compression efficiency of Lee's colorization-based coding framework by introducing a novel colorization matrix construction and an adaptive color conversion. Colorization-based coding methods reconstruct color components in the decoder by colorization, which adds color to a base component (a grayscale image) using scant color information. The colorization process can be expressed as a linear combination of a few column vectors of a colorization matrix. Thus it is important for colorization-based coding to make a colorization matrix whose column vectors effectively approximate color components. To make a colorization matrix, Lee's colorization-based coding framework first obtains a base and color components by RGB-YCbCr color conversion, and then performs a segmentation method on the base component. Finally, the entries of a colorization matrix are created using the segmentation results. To improve compression efficiency on this framework, we construct a colorization matrix based on a correlation of base-color components. Furthermore, we embed an edge-preserving smoothing filtering process into the colorization matrix to reduce artifacts. To achieve more improvement, our method uses adaptive color conversion instead of RGB-YCbCr color conversion. Our proposed color conversion maximizes the sum of the local variance of a base component, which resulted in increment of the difference of intensities at region boundaries. Since segmentation methods partition images based on the difference, our adaptive color conversion leads to better segmentation results. Experiments showed that our method has higher compression efficiency compared with the conventional method.	[Mishiba, Kazu; Yoshitome, Takeshi] Tottori Univ, Dept Elect & Elect Engn, Tottori 6808550, Japan	Mishiba, K (reprint author), Tottori Univ, Dept Elect & Elect Engn, Tottori 6808550, Japan.	mishiba@ele.tottori-u.ac.jp					Comaniciu D, 2002, IEEE T PATTERN ANAL, V24, P603, DOI 10.1109/34.1000236; Lee S, 2013, IEEE T IMAGE PROCESS, V22, P2627, DOI 10.1109/TIP.2013.2253486; Miyata T, 2009, PCS: 2009 PICTURE CODING SYMPOSIUM, P101; He XF, 2009, PROC CVPR IEEE, P65; Petschnigg G, 2004, ACM T GRAPHIC, V23, P664, DOI 10.1145/1015706.1015777; Levin A, 2004, ACM T GRAPHIC, V23, P689, DOI 10.1145/1015706.1015780; He KM, 2013, IEEE T PATTERN ANAL, V35, P1397, DOI 10.1109/TPAMI.2012.213; Cheng L., 2007, P 24 INT C MACH LEAR, P161, DOI 10.1145/1273496.1273517; Mishiba K., 2014, P IEEE INT C IM PROC, P5551; Ono S., 2010, COLORIZATION BASED C, P230; Pati YC, 1993, P 27 AS C SIGN SYST, P40, DOI DOI 10.1109/ACSSC.1993.342465	11	0	0	IEICE-INST ELECTRONICS INFORMATION COMMUNICATIONS ENG	TOKYO	KIKAI-SHINKO-KAIKAN BLDG, 3-5-8, SHIBA-KOEN, MINATO-KU, TOKYO, 105-0011, JAPAN	1745-1361			IEICE T INF SYST	IEICE Trans. Inf. Syst.	NOV	2015	E98D	11					1943	1949		10.1587/transinf.2015EDP7106		7	Computer Science, Information Systems; Computer Science, Software Engineering	Computer Science	CV7AA	WOS:000364422600006		
J	Zhang, C; Akashi, T				Zhang, Chao; Akashi, Takuya			High-Speed and Local-Changes Invariant Image Matching	IEICE TRANSACTIONS ON INFORMATION AND SYSTEMS			English	Article						local-changes invariant; image matching; feature compression; random projection indexed KD-tree forests	FEATURES	In recent years, many variants of key point based image descriptors have been designed for the image matching, and they have achieved remarkable performances. However, to some images, local features appear to be inapplicable. Since theses images usually have many local changes around key points compared with a normal image, we define this special image category as the image with local changes (IL). An IL pair (ILP) refers to an image pair which contains a normal image and its IL. ILP usually loses local visual similarities between two images while still holding global visual similarity. When an IL is given as a query image, the purpose of this work is to match the corresponding ILP in a large scale image set. As a solution, we use a compressed HOG feature descriptor to extract global visual similarity. For the nearest neighbor search problem, we propose random projection indexed KD-tree forests (rKDFs) to match ILP efficiently instead of exhaustive linear search. rKDFs is built with large scale low-dimensional KD-trees. Each KD-tree is built in a random projection indexed subspace and contributes to the final result equally through a voting mechanism. We evaluated our method by a benchmark which contains 35,000 candidate images and 5,000 query images. The results show that our method is efficient for solving local-changes invariant image matching problems.	[Zhang, Chao] Iwate Univ, Grad Sch Engn, Design & Media Technol, Morioka, Iwate 0208551, Japan; [Akashi, Takuya] Iwate Univ, Fac Engn, Morioka, Iwate 0208551, Japan	Zhang, C (reprint author), Iwate Univ, Grad Sch Engn, Design & Media Technol, Morioka, Iwate 0208551, Japan.	zhang@scv.cis.iwate-u.ac.jp; akashi@iwate-u.ac.jp					Achlioptas D, 2003, J COMPUT SYST SCI, V66, P671, DOI 10.1016/S0022-0000(03)00025-4; Grauman K, 2005, PROC CVPR IEEE, P627; Wu PC, 2011, LECT NOTES COMPUT SC, V6524, P371; [Anonymous], 2007, 2007 IEEE C COMP VIS; Baraniuk R, 2008, CONSTR APPROX, V28, P253, DOI 10.1007/s00365-007-9003-x; Hauagge DC, 2012, PROC CVPR IEEE, P206, DOI 10.1109/CVPR.2012.6247677; Eitz M, 2011, IEEE T VIS COMPUT GR, V17, P1624, DOI 10.1109/TVCG.2010.266; Dalal N, 2005, PROC CVPR IEEE, P886; Muja M, 2009, VISAPP 2009: PROCEEDINGS OF THE FOURTH INTERNATIONAL CONFERENCE ON COMPUTER VISION THEORY AND APPLICATIONS, VOL 1, P331; Lowe DG, 2004, INT J COMPUT VISION, V60, P91, DOI 10.1023/B:VISI.0000029664.99615.94; Arthur D., 2007, ACM SIAM S DISCR ALG, P1027; Bay H, 2006, LECT NOTES COMPUT SC, V3951, P404; Chong HY, 2008, ACM T GRAPHIC, V27, DOI 10.1145/1360612.1360660; Csurka G., 2004, ECCV, P1; Delhumeau J., 2013, ACM INT C MULT ACMMM, P653; Friedman J. H., 1977, ACM Transactions on Mathematical Software, V3; Gionis A., 1999, INT C VER LARG DAT B, P518; Ke Y., 2004, ACM MULTIMEDIA ACMMM, P5; Lazebnik S., 2006, 2006 IEEE COMP SOC C, V2, P2169, DOI DOI 10.1109/CVPR.2006.68; Li P., 2012, 2012 IEEE INT C INF, P627; Liu C, 2011, IEEE T PATTERN ANAL, V33, P978, DOI 10.1109/TPAMI.2010.147; Oliva A, 2006, PROG BRAIN RES, V155, P23, DOI 10.1016/S0079-6123(06)55002-2; Robinson J. T., 1981, ACM SIGMOD INT C MAN, P10; Russell B. C., 2011, 2011 IEEE International Conference on Computer Vision Workshops (ICCV Workshops), DOI 10.1109/ICCVW.2011.6130291; Shrivastava A., 2011, ACM T GRAPHIC, V30; Silpa-Anan C., 2008, 2008 IEEE C COMP VIS, P1, DOI 10.1109/CVPR.2008.4587638; Torralba A., 2008, 2008 33 INT C INFR M, P1; Vedaldi A., 2010, ACM MULTIMEDIA, P1469; Zhang C., 2015, AS CONTR C ASCC IEEE, P814; Zhang C., 2015, IEICE T INF SYST, VE98-D, P1080	30	0	0	IEICE-INST ELECTRONICS INFORMATION COMMUNICATIONS ENG	TOKYO	KIKAI-SHINKO-KAIKAN BLDG, 3-5-8, SHIBA-KOEN, MINATO-KU, TOKYO, 105-0011, JAPAN	1745-1361			IEICE T INF SYST	IEICE Trans. Inf. Syst.	NOV	2015	E98D	11					1958	1966		10.1587/transinf.2015EDP7093		9	Computer Science, Information Systems; Computer Science, Software Engineering	Computer Science	CV7AA	WOS:000364422600008		
J	Takimoto, H; Kokui, T; Yamauchi, H; Kishihara, M; Okubo, K				Takimoto, Hironori; Kokui, Tatsuhiko; Yamauchi, Hitoshi; Kishihara, Mitsuyoshi; Okubo, Kensuke			Image Modification Based on a Visual Saliency Map for Guiding Visual Attention	IEICE TRANSACTIONS ON INFORMATION AND SYSTEMS			English	Article						visual attention; saliency map; image processing; guiding attention		It is commonly believed that improved interaction between humans and electronic device, it is effective to draw the viewer's attention to a particular object. Augmented reality (AR) applications can call attention to real objects by overlaying highlight effects or visual stimuli (such as arrows) on a physical scene. Sometimes, more subtle effects would be desirable, in which case it would be necessary to smoothly and naturally guide the user's gaze without external stimuli. Here, a novel image modification method is proposed for directing a viewer's gaze to specific regions of interest. The proposed method uses saliency analysis and color modulation to create modified images in which the region of interest is the most salient region in the entire image. The proposed saliency map model that is used during saliency analysis reduces computational costs and improves the naturalness of the image using the LAB color space and simplified normalization. During color modulation, the modulation value of each LAB component is determined in order to consider the relationship between the LAB components and the saliency value. With the image obtained in this manner, the viewer's attention is smoothly attracted to a specific region very naturally. Gaze measurements as well as a subjective experiments were conducted to prove the effectiveness of the proposed method. These results show that a viewer's visual attention is indeed attracted toward the specified region without any sense of discomfort or disruption when the proposed method is used.	[Takimoto, Hironori; Kokui, Tatsuhiko; Yamauchi, Hitoshi; Kishihara, Mitsuyoshi; Okubo, Kensuke] Okayama Prefectural Univ, Fac Comp Sci & Syst Engn, Soja 7191197, Japan	Takimoto, H (reprint author), Okayama Prefectural Univ, Fac Comp Sci & Syst Engn, Soja 7191197, Japan.	takimoto@c.oka-pu.ac.jp			Wesco Scientific Promotion Foundation; Japan Society for the Promotion of Science [24500653]	This research was partially supported by the Wesco Scientific Promotion Foundation and a Grant-in-Aid for Scientific Research (C) from the Japan Society for the Promotion of Science (grant no. 24500653).	Achanta R., 2008, P INT C COMP VIS SYS, P66; Achanta R, 2009, PROC CVPR IEEE, P1597; Pang D, 2008, 2008 IEEE INTERNATIONAL CONFERENCE ON MULTIMEDIA AND EXPO, VOLS 1-4, P1073, DOI 10.1109/ICME.2008.4607624; Nguyen TV, 2013, IEEE T MULTIMEDIA, V15, P1910, DOI 10.1109/TMM.2013.2272919; Kimura A, 2013, IEICE T INF SYST, VE96D, P562, DOI 10.1587/transinf.E96.D.562; Shen JY, 2000, PERCEPTION, V29, P241, DOI 10.1068/p2933; TREISMAN AM, 1980, COGNITIVE PSYCHOL, V12, P97, DOI 10.1016/0010-0285(80)90005-5; Engel S, 1997, NATURE, V388, P68, DOI 10.1038/40398; POSNER MI, 1980, Q J EXP PSYCHOL, V32, P3, DOI 10.1080/00335558008248231; Itti L, 1998, IEEE T PATTERN ANAL, V20, P1254, DOI 10.1109/34.730558; Mendez E, 2010, LECT NOTES COMPUT SC, V6133, P232, DOI 10.1007/978-3-642-13544-6_22; [Anonymous], 2002, BT50011 ITUR; Bailey R, 2009, ACM T GRAPHIC, V28, DOI 10.1145/1559755.1559757; Chuang YL, 2014, IEICE T INF SYST, VE97D, P160, DOI 10.1587/transinf.E97.D.160; Hagiwara A., 2011, P INT WORKSH PERV EY, P43; Hata H., 2014, P IPSJ INT 2014, P57; Hitomi S., 2015, P RISP INT WORKSH NC, P90; Inome H., 2010, J I IMAGE INFORM TEL, V34, P89; KOCH C, 1985, HUM NEUROBIOL, V4, P219; Kokui T., 2013, P 22 IEEE INT S RO M, P467; Mateescu V.A., 2014, P ACM MULT PIVP, P15; Mateescu V.A., 2013, P 2013 IEEE INT C MU, P1; Peters R.J., 2008, ACM T APPL PERCEPTIO, V5; Shi T., 2013, P PAC RIM S IM VID T, V8333, P206; Su Z., 2010, VISAPP, V2, P370; Veas E.E., 2011, P SIGCHI C HUM FACT, P1471	26	0	0	IEICE-INST ELECTRONICS INFORMATION COMMUNICATIONS ENG	TOKYO	KIKAI-SHINKO-KAIKAN BLDG, 3-5-8, SHIBA-KOEN, MINATO-KU, TOKYO, 105-0011, JAPAN	1745-1361			IEICE T INF SYST	IEICE Trans. Inf. Syst.	NOV	2015	E98D	11					1967	1975		10.1587/transinf.2015EDP7087		9	Computer Science, Information Systems; Computer Science, Software Engineering	Computer Science	CV7AA	WOS:000364422600009		
J	Sakamoto, M; Yamaguchi, H; Yamazaki, T; Kamijo, K; Yamanoi, T				Sakamoto, Maiko; Yamaguchi, Hiromi; Yamazaki, Toshimasa; Kamijo, Ken-ichi; Yamanoi, Takahiro			Performance of a Bayesian-Network-Model-Based BCI Using Single-Trial EEGs	IEICE TRANSACTIONS ON INFORMATION AND SYSTEMS			English	Article						BCI; Bayesian network; single-trial EEG; ICA; ECDL	INDEPENDENT COMPONENT ANALYSIS; MOTOR IMAGERY; CORTEX; CONNECTIVITY; LOCALIZATION; PATTERNS	We have proposed a new Bayesian network model (BNM) framework for single-trial-EEG-based Brain-Computer Interface (BCI). The BNM was constructed in the following. In order to discriminate between left and right hands to be imaged from single-trial EEGs measured during the movement imagery tasks, the BNM has the following three steps: (1) independent component analysis (ICA) for each of the single-trial EEGs; (2) equivalent current dipole source localization (ECDL) for projections of each IC on the scalp surface; (3) BNM construction using the ECDL results. The BNMs were composed of nodes and edges which correspond to the brain sites where ECDs are located, and their connections, respectively. The connections were quantified as node activities by conditional probabilities calculated by probabilistic inference in each trial. The BNM-based BCI is compared with the common spatial pattern (CSP) method. For ten healthy subjects, there was no significant difference between the two methods. Our BNM might reflect each subject's strategy for task execution.	[Sakamoto, Maiko] Hitachi Publ Syst Serv Co Ltd, Tokyo 1360075, Japan; [Yamaguchi, Hiromi] NEC Corp Ltd, Knowledge Discovery Res Labs, Kawasaki, Kanagawa 2118666, Japan; [Yamazaki, Toshimasa] Kyushu Inst Technol, Dept Biosci & Bioinformat, Iizuka, Fukuoka 8208502, Japan; [Kamijo, Ken-ichi] NEC Corp Ltd, Med Solut Div, Tokyo 1088558, Japan; [Yamanoi, Takahiro] Hokkai Gakuen Univ, Fac Engn, Div Life Sci & Technol, Sapporo, Hokkaido 0640926, Japan	Sakamoto, M (reprint author), Hitachi Publ Syst Serv Co Ltd, Tokyo 1360075, Japan.	t-ymzk@bio.kyutech.ac.jp			Japan Society for the Promotion of Science [20300196]	This research was partly supported by a Grants-in-Aid for Scientific Research (B) (20300196) - The Japan Society for the Promotion of Science.	SOUFFLET L, 1991, ELECTROEN CLIN NEURO, V79, P393, DOI 10.1016/0013-4694(91)90204-H; Hyvarinen A, 1997, NEURAL COMPUT, V9, P1483, DOI 10.1162/neco.1997.9.7.1483; Blankertz B, 2008, IEEE SIGNAL PROC MAG, V25, P41, DOI [10.1109/MSP.2008.4408441, 10.1109/MSP.200790.900,9]; Gong GL, 2009, CEREB CORTEX, V19, P524, DOI 10.1093/cercor/bhn102; Yamazaki T, 2000, BRAIN TOPOGR, V12, P159, DOI 10.1023/A:1023467806268; Honey CJ, 2007, P NATL ACAD SCI USA, V104, P10240, DOI 10.1073/pnas.0701519104; Yamazaki T, 2013, BRAIN-COMPUTER INTERFACE SYSTEMS - RECENT PROGRESS AND FUTURE PROSPECTS, P155, DOI 10.5772/55805; HALLETT M, 1994, BEHAV BRAIN SCI, V17, P210; Bai O, 2005, CLIN NEUROPHYSIOL, V116, P1213, DOI 10.1016/j.clinph.2005.01.006; Micheloyannis S, 2006, NEUROSCI LETT, V402, P273, DOI 10.1016/j.neulet.2006.04.006; Xu N, 2004, IEEE T BIO-MED ENG, V51, P1067, DOI 10.1109/TBME.2004.826699; Shibasaki H, 2006, CLIN NEUROPHYSIOL, V117, P2341, DOI 10.1016/j.clinph.2006.04.025; Pfurtscheller G, 2006, NEUROIMAGE, V31, P153, DOI 10.1016/j.neuroimage.2005.12.003; Cheng J, 2002, ARTIF INTELL, V137, P43, DOI 10.1016/S0004-3702(02)00191-1; Cichocki A., 2007, ICALAB VERSION 3 TOO; Delorme A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030135; Hagmann P., 2007, PLOS BIOL, V7, pe597; Kadie C.M., 2001, MSRTR200167; Kamijo K, 2001, Front Med Biol Eng, V10, P285; Kretschmann H.-J., 2003, KLIN NEUROANATOMIE K; Makeig S, 1996, ADV NEUR IN, V8, P145; MOSHER JC, 1992, IEEE T BIO-MED ENG, V39, P541, DOI 10.1109/10.141192; Shigemasu K., 2009, INTRO BAYESIAN NETWO; Sporns O., 2011, NETWORKS BRAIN; Tanaka K., 2010, CLIN NEUR 2010 ICCN; Tung L., 2002, THESIS U BRIT COLUMB; Wang YJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037665; Yamazaki T., 2014, NEUROLOGICAL MED, V81, P204; Yamazaki T., 2014, J REHABILITATION ROB, V1, P1	29	0	0	IEICE-INST ELECTRONICS INFORMATION COMMUNICATIONS ENG	TOKYO	KIKAI-SHINKO-KAIKAN BLDG, 3-5-8, SHIBA-KOEN, MINATO-KU, TOKYO, 105-0011, JAPAN	1745-1361			IEICE T INF SYST	IEICE Trans. Inf. Syst.	NOV	2015	E98D	11					1976	1981		10.1587/transinf.2015EDP7017		6	Computer Science, Information Systems; Computer Science, Software Engineering	Computer Science	CV7AA	WOS:000364422600010		
J	Kashiwabara, Y; Ishio, T; Inoue, K				Kashiwabara, Yuki; Ishio, Takashi; Inoue, Katsuro			Improvement in Method Verb Recommendation Technique Using Association Rule Mining	IEICE TRANSACTIONS ON INFORMATION AND SYSTEMS			English	Article						recommendation; verb in method name; association rule	SOURCE CODE	In a previous study, we proposed a technique to recommend candidate verbs for a method name so that developers can consistently use various verbs. In this study, we improve the rule extraction technique proposed in this previous study. Moreover, we confirm that the rank of each correct verb recommended by the new technique is higher than that by the previous technique.	[Kashiwabara, Yuki; Ishio, Takashi; Inoue, Katsuro] Osaka Univ, Suita, Osaka 5650871, Japan	Kashiwabara, Y (reprint author), Osaka Univ, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	k-yuki@ist.osaka-u.ac.jp			JSPS KAKENHI [25220003, 26280021]	This work was supported by JSPS KAKENHI Grant Numbers 25220003 and 26280021.	Agrawal R., 1993, ACM SIGMOD RECORD, V22, P207, DOI DOI 10.1145/170035.170072; Hayase Y, 2011, EUR CON SFTWR MTNCE, P93, DOI 10.1109/CSMR.2011.15; Hill E, 2009, PROC INT CONF SOFTW, P232, DOI 10.1109/ICSE.2009.5070524; Kashiwabara Y, 2014, 2014 SOFTWARE EVOLUTION WEEK - IEEE CONFERENCE ON SOFTWARE MAINTENANCE, REENGINEERING, AND REVERSE ENGINEERING (CSMR-WCRE), P323, DOI 10.1109/CSMR-WCRE.2014.6747186; Host EW, 2009, LECT NOTES COMPUT SC, V5653, P294; Lawrie D, 2006, INT C PROGRAM COMPRE, P3, DOI 10.1109/ICPC.2006.51; Karlsen E.K., 2012, P WORKSH PART EV PRO, P35; Sridhara Giriprasad, 2010, P 25 ASE, P43, DOI 10.1145/1858996.1859006; Yu S., 2012, LECT NOTES COMPUTER, V7713, P235	9	0	0	IEICE-INST ELECTRONICS INFORMATION COMMUNICATIONS ENG	TOKYO	KIKAI-SHINKO-KAIKAN BLDG, 3-5-8, SHIBA-KOEN, MINATO-KU, TOKYO, 105-0011, JAPAN	1745-1361			IEICE T INF SYST	IEICE Trans. Inf. Syst.	NOV	2015	E98D	11					1982	1985		10.1587/transinf.2015EDL8069		4	Computer Science, Information Systems; Computer Science, Software Engineering	Computer Science	CV7AA	WOS:000364422600011		
J	Zhao, X; He, LF; Yao, B; Chao, YY				Zhao, Xiao; He, Lifeng; Yao, Bin; Chao, Yuyan			A New Connected-Component Labeling Algorithm	IEICE TRANSACTIONS ON INFORMATION AND SYSTEMS			English	Article						connected component; labeling; pattern recognition; image analysis		This paper presents a new connected component labeling algorithm. The proposed algorithm scans image lines every three lines and processes pixels three by three. When processing the current three pixels, we also utilize the information obtained before to reduce the repeated work for checking pixels in the mask. Experimental results demonstrated that our method is more efficient than the fastest conventional labeling algorithm.	[Zhao, Xiao; He, Lifeng; Yao, Bin] Shaanxi Univ Sci & Technol, Coll Elect & Informat Engn, Artificial Intelligence Inst, Xian 710021, Shaanxi, Peoples R China; [He, Lifeng] Aichi Prefectural Univ, Grad Sch Informat Sci & Technol, Nagakute, Aichi 4801198, Japan; [Chao, Yuyan] Nagoya Sangyo Univ, Grad Sch Environm Management, Owariasahi 4888711, Japan	He, LF (reprint author), Shaanxi Univ Sci & Technol, Coll Elect & Informat Engn, Artificial Intelligence Inst, Xian 710021, Shaanxi, Peoples R China.	helifeng@ist.aichi-pu.ac.jp	Liu, Guojun/A-9459-2015	Liu, Guojun/0000-0003-1816-6239	National Natural Science Foundation of China [61471227]; Ministry of Education, Science, Sports and Culture of Japan [26330200]; Scientific Research of Shaanxi Province of China [2014K11-02-01-13]	This work was supported in part by the Grant-in-Aid for the National Natural Science Foundation of China under Grant No. 61471227, the Scientific Research (C) of the Ministry of Education, Science, Sports and Culture of Japan under Grant No. 26330200, and the Scientific Research of Shaanxi Province of China under Grant No. 2014K11-02-01-13.	OTSU N, 1979, IEEE T SYST MAN CYB, V9, P62; Wu KS, 2009, PATTERN ANAL APPL, V12, P117, DOI 10.1007/s10044-008-0109-y; He LF, 2009, PATTERN RECOGN, V42, P1977, DOI 10.1016/j.patcog.2008.10.013; He LF, 2010, PATTERN RECOGN LETT, V31, P28, DOI 10.1016/j.patrec.2009.08.012; Grana C, 2010, IEEE T IMAGE PROCESS, V19, P1596, DOI 10.1109/TIP.2010.2044963; He LF, 2014, IEEE T IMAGE PROCESS, V23, P943, DOI 10.1109/TIP.2013.2289968; He LF, 2008, IEEE T IMAGE PROCESS, V17, P749, DOI 10.1109/TIP.2008.919369; Trein J., 2008, MPC WORKSH RAV WEING, P71; Woods R. E., 1992, DIGITAL IMAGE PROCES	9	0	0	IEICE-INST ELECTRONICS INFORMATION COMMUNICATIONS ENG	TOKYO	KIKAI-SHINKO-KAIKAN BLDG, 3-5-8, SHIBA-KOEN, MINATO-KU, TOKYO, 105-0011, JAPAN	1745-1361			IEICE T INF SYST	IEICE Trans. Inf. Syst.	NOV	2015	E98D	11					2013	2016		10.1587/transinf.2015EDL8135		4	Computer Science, Information Systems; Computer Science, Software Engineering	Computer Science	CV7AA	WOS:000364422600018		
J	Takebe, H; Uehara, Y; Uchida, S				Takebe, Hiroaki; Uehara, Yusuke; Uchida, Seiichi			Efficient Anchor Graph Hashing with Data-Dependent Anchor Selection	IEICE TRANSACTIONS ON INFORMATION AND SYSTEMS			English	Article						nearest neighbor search; anchor graph hashing; similarity space; principal component analysis		Anchor graph hashing (AGH) is a promising hashing method for nearest neighbor (NN) search. AGH realizes efficient search by generating and utilizing a small number of points that are called anchors. In this paper, we propose a method for improving AGH, which considers data distribution in a similarity space and selects suitable anchors by performing principal component analysis (PCA) in the similarity space.	[Takebe, Hiroaki; Uehara, Yusuke] Fujitsu Labs Ltd, Kawasaki, Kanagawa 2118588, Japan; [Uchida, Seiichi] Kyushu Univ, Fukuoka 8190395, Japan	Takebe, H (reprint author), Fujitsu Labs Ltd, Kawasaki, Kanagawa 2118588, Japan.	takebe.hiroaki@jp.fujitsu.com					Liu Wei, 2011, Reports in Parasitology, V1, P1; Zhang D, 2010, SIGIR 2010: PROCEEDINGS OF THE 33RD ANNUAL INTERNATIONAL ACM SIGIR CONFERENCE ON RESEARCH DEVELOPMENT IN INFORMATION RETRIEVAL, P18; Kimura F, 1997, PATTERN RECOGN, V30, P1329, DOI 10.1016/S0031-3203(96)00153-7; Belkin M, 2003, NEURAL COMPUT, V15, P1373, DOI 10.1162/089976603321780317; Datar Mayur, 2004, P 20 ANN S COMP GEOM, P253, DOI DOI 10.1145/997817.997857; Indyk P., 1999, P 13 ANN ACM S THEOR, P604; Iwamura M., 2010, P DAS2010, P89, DOI 10.1145/1815330.1815342; Liu W., 2010, P 27 INT C MACH LEAR, P679; Weiss Y., 2008, ADV NEURAL INFORM PR, V21, P1753	9	0	0	IEICE-INST ELECTRONICS INFORMATION COMMUNICATIONS ENG	TOKYO	KIKAI-SHINKO-KAIKAN BLDG, 3-5-8, SHIBA-KOEN, MINATO-KU, TOKYO, 105-0011, JAPAN	1745-1361			IEICE T INF SYST	IEICE Trans. Inf. Syst.	NOV	2015	E98D	11					2030	2033		10.1587/transinf.2015EDL8060		4	Computer Science, Information Systems; Computer Science, Software Engineering	Computer Science	CV7AA	WOS:000364422600022		
J	Kawaguchi, T; Dobashi, Y; Yamamoto, T				Kawaguchi, Tatsuki; Dobashi, Yoshinori; Yamamoto, Tsuyoshi			Controlling the Simulation of Cumuliform Clouds Based on Fluid Dynamics	IEICE TRANSACTIONS ON INFORMATION AND SYSTEMS			English	Article						cloud; fluid simulation; control; computer graphics		Controlling fluid simulation is one of the important research topics in computer graphics. In this paper, we focus on controlling the simulation of cumuliform cloud formation. Using a previously proposed method for controlling cloud simulation the convergence speed is very slow; therefore, it takes a long time before the clouds form the desired shapes. We improved the method and accelerated the convergence by introducing a new mechanism for controlling the amount of water vapor added. We demonstrate the effectiveness of the proposed method by several examples.	[Kawaguchi, Tatsuki; Dobashi, Yoshinori; Yamamoto, Tsuyoshi] Hokkaido Univ, Fac Engn, Sapporo, Hokkaido 0608628, Japan	Kawaguchi, T (reprint author), Hokkaido Univ, Fac Engn, Sapporo, Hokkaido 0608628, Japan.	kawaguchi@ime.ist.hokudai.ac.jp					Hong JM, 2004, COMPUT ANIMAT VIRT W, V15, P147, DOI 10.1002/cav.17; Dobashi Y., 2008, P SIGGRAPH 08; Fattal R., 2004, SIGGRAPH 04 ACM SIGG, P441; Jakob Wenzel, 2010, MITSUBA RENDERER; Miyazaki R., 2001, Proceedings Ninth Pacific Conference on Computer Graphics and Applications. Pacific Graphics 2001, DOI 10.1109/PCCGA.2001.962893; Thurey N., 2006, SCA 06, P7	6	0	0	IEICE-INST ELECTRONICS INFORMATION COMMUNICATIONS ENG	TOKYO	KIKAI-SHINKO-KAIKAN BLDG, 3-5-8, SHIBA-KOEN, MINATO-KU, TOKYO, 105-0011, JAPAN	1745-1361			IEICE T INF SYST	IEICE Trans. Inf. Syst.	NOV	2015	E98D	11					2034	2037		10.1587/transinf.2015EDL8085		4	Computer Science, Information Systems; Computer Science, Software Engineering	Computer Science	CV7AA	WOS:000364422600023		
J	Hargreaves, CE; Rose-Zerilli, MJJ; Machado, LR; Iriyama, C; Hollox, EJ; Cragg, MS; Strefford, JC				Hargreaves, Chantal E.; Rose-Zerilli, Matthew J. J.; Machado, Lee R.; Iriyama, Chisako; Hollox, Edward J.; Cragg, Mark S.; Strefford, Jonathan C.			Fc receptors: genetic variation, function, and disease	IMMUNOLOGICAL REVIEWS			English	Review						Fc receptors; genetics; immunotherapy; antibodies	SYSTEMIC-LUPUS-ERYTHEMATOSUS; COPY-NUMBER VARIATION; METASTATIC COLORECTAL-CANCER; SINGLE AMINO-ACID; HIGH-AFFINITY IGG; B-CELL RECEPTOR; CETUXIMAB PLUS IRINOTECAN; PRIMARY SJOGRENS-SYNDROME; GENOME-WIDE ASSOCIATION; NATURAL-KILLER-CELLS	Fc receptors (FcRs) are key immune receptors responsible for the effective control of both humoral and innate immunity and are central to maintaining the balance between generating appropriate responses to infection and preventing autoimmunity. When this balance is lost, pathology results in increased susceptibility to cancer, autoimmunity, and infection. In contrast, optimal FcR engagement facilitates effective disease resolution and response to monoclonal antibody immunotherapy. The underlying genetics of the FcR gene family are a central component of this careful balance. Complex in humans and generated through ancestral duplication events, here we review the evolution of the gene family in mammals, the potential importance of copy number, and functionally relevant single nucleotide polymorphisms, as well as discussing current approaches and limitations when exploring genetic variation in this region.	[Hargreaves, Chantal E.; Rose-Zerilli, Matthew J. J.; Strefford, Jonathan C.] Univ Southampton, Fac Med, Canc Genom Grp, Canc Sci, Southampton SO9 5NH, Hants, England; [Hargreaves, Chantal E.; Cragg, Mark S.] Univ Southampton, Fac Med, Canc Sci, Antibody & Vaccine Grp, Southampton SO9 5NH, Hants, England; [Machado, Lee R.; Hollox, Edward J.] Univ Leicester, Dept Genet, Leicester LE1 7RH, Leics, England; [Machado, Lee R.] Univ Northampton, Sch Hlth, Northampton, England; [Iriyama, Chisako] Nagoya Univ, Dept Hematol & Oncol, Grad Sch Med, Nagoya, Aichi 4648601, Japan	Strefford, JC (reprint author), Southampton Gen Hosp, Canc Genom Grp, Canc Sci Unit, Tremona Rd, Southampton SO16 6YD, Hants, England.	jcs@soton.ac.uk	Iriyama, Chisako/P-9811-2015		Experimental Cancer Medicine Centre (ECMC); Leukaemia and Lymphoma Research [11052, 12050]; Wellcome Trust [087663]; United Kingdom National Centre for the Replacement, Refinement and Reduction of Animals in Research CRACK IT Programme [NC/C011204/1]; Kay Kendall Leukaemia Fund [KKL687]; Uehara Memorial Foundation; Roche; GSK biopharm; Pfizer, Inc.	We thank the Experimental Cancer Medicine Centre (ECMC)-funded University of Southampton, Faculty of Medicine Human Tissue Bank (Human Tissue Authority licence 12009) for the sample storage critical for our work. We also thank the molecular pathology unit for their assistance with the Fc gamma R genotyping performed in their facility, in particular Drs Elizabeth Hodges, Rosalind Ganderton, and Miss Charlotte Lee. The contributors were funded by grants from Leukaemia and Lymphoma Research (11052, 12050), Wellcome Trust (087663), the United Kingdom National Centre for the Replacement, Refinement and Reduction of Animals in Research CRACK IT Programme (NC/C011204/1), Kay Kendall Leukaemia Fund (KKL687) and the Uehara Memorial Foundation. M. S. C. acts as a consultant for BioInvent and has received research funding from them as well as from Roche and GSK biopharm for oncology-related antibody projects. J. C. S. received research funding from Roche. E. J. H. currently receives research funding from Pfizer, Inc. The other authors declare no conflict of interest.	Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632; Akula S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096903; Mueller M, 2013, AM J HUM GENET, V92, P28, DOI 10.1016/j.ajhg.2012.11.013; Willcocks LC, 2010, P NATL ACAD SCI USA, V107, P7881, DOI 10.1073/pnas.0915133107; Breunis WB, 2009, HUM MUTAT, V30, pE640, DOI 10.1002/humu.20997; CLARK MR, 1991, EUR J IMMUNOL, V21, P1911, DOI 10.1002/eji.1830210820; Su K, 2002, GENES IMMUN, V3, pS51, DOI 10.1038/sj.gene.6363879; Yuasa T, 1999, J EXP MED, V189, P187, DOI 10.1084/jem.189.1.187; Su KH, 2004, J IMMUNOL, V172, P7192; Sareneva I, 2009, TISSUE ANTIGENS, V73, P54, DOI 10.1111/j.1399-0039.2008.01179.x; Jiang Y, 1999, INT IMMUNOL, V11, P1685, DOI 10.1093/intimm/11.10.1685; STRONCEK DF, 1991, BLOOD, V77, P1572; ORY PA, 1989, J CLIN INVEST, V83, P1676, DOI 10.1172/JCI114067; Machado LR, 2012, AM J HUM GENET, V90, P973, DOI 10.1016/j.ajhg.2012.04.018; Espeli M, 2012, J EXP MED, V209, P2307, DOI 10.1084/jem.20121752; Bruhns P, 2000, J BIOL CHEM, V275, P37357, DOI 10.1074/jbc.M003518200; Blank MC, 2005, HUM GENET, V117, P220, DOI 10.1007/s00439-005-1302-3; Metes D, 1998, BLOOD, V91, P2369; Bux J, 1997, BLOOD, V89, P1027; Lassauniere R, 2013, HUM IMMUNOL, V74, P627, DOI 10.1016/j.humimm.2013.01.020; Alizadeh BZ, 2010, J RHEUMATOL, V37, P1673, DOI 10.3899/jrheum.091259; AMIGORENA S, 1992, SCIENCE, V256, P1808, DOI 10.1126/science.1535455; QIU WQ, 1990, SCIENCE, V248, P732, DOI 10.1126/science.2139735; Thabet MM, 2009, ANN RHEUM DIS, V68, P1775, DOI 10.1136/ard.2008.099309; Ernst LK, 2002, J MOL MED-JMM, V80, P248, DOI 10.1007/s00109-001-0294-2; Ernst LK, 1998, MOL IMMUNOL, V35, P943, DOI 10.1016/S0161-5890(98)00079-0; KULCZYCKI A, 1990, P NATL ACAD SCI USA, V87, P2856, DOI 10.1073/pnas.87.7.2856; Baerenwaldt A, 2011, P NATL ACAD SCI USA, V108, P18772, DOI 10.1073/pnas.1111810108; Treangen TJ, 2012, NAT REV GENET, V13, P36, DOI 10.1038/nrg3117; Flesch BK, 2002, TRANSFUSION, V42, P469, DOI 10.1046/j.1525-1438.2002.00087.x; Hollox EJ, 2009, HUM MUTAT, V30, P477, DOI 10.1002/humu.20911; Nimmerjahn F, 2008, NAT REV IMMUNOL, V8, P34, DOI 10.1038/nri2206; van der Poel CE, 2010, BLOOD, V116, P5327, DOI 10.1182/blood-2010-04-280214; Hollox EJ, 2014, HUM GENET, V133, P1217, DOI 10.1007/s00439-014-1457-x; Morris DL, 2010, EUR J HUM GENET, V18, P1027, DOI 10.1038/ejhg.2010.56; McKinney C, 2012, HUM MOL GENET, V21, P2370, DOI 10.1093/hmg/dds039; Su KH, 2004, J IMMUNOL, V172, P7186; Minskoff SA, 1998, J IMMUNOL, V161, P2079; Niederer HA, 2010, ANN NY ACAD SCI, V1183, P69, DOI 10.1111/j.1749-6632.2009.05132.x; Xiu Y, 2002, J IMMUNOL, V169, P4340; Bolland S, 2000, IMMUNITY, V13, P277, DOI 10.1016/S1074-7613(00)00027-3; Hindson BJ, 2011, ANAL CHEM, V83, P8604, DOI 10.1021/ac202028g; Mittal R, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001203; Aitman TJ, 2006, NATURE, V439, P851, DOI 10.1038/nature04489; Sharp AJ, 2005, AM J HUM GENET, V77, P78, DOI 10.1086/431652; Molokhia M, 2011, RHEUMATOLOGY, V50, P1206, DOI 10.1093/rheumatology/keq456; Maresco DL, 1998, CYTOGENET CELL GENET, V82, P71, DOI 10.1159/000015067; Prochazka V, 2011, NEOPLASMA, V58, P263, DOI 10.4149/neo_2011_03_263; SALMON JE, 1992, J CLIN INVEST, V89, P1274, DOI 10.1172/JCI115712; Hastings PJ, 2009, NAT REV GENET, V10, P551, DOI 10.1038/nrg2593; TAKAI S, 1994, HUM GENET, V93, P13; Bibeau F, 2009, J CLIN ONCOL, V27, P1122, DOI 10.1200/JCO.2008.18.0463; Breunis WB, 2008, BLOOD, V111, P1029, DOI 10.1182/blood-2007-03-079913; Hoshino T, 2012, SYST APPL MICROBIOL, V35, P390, DOI 10.1016/j.syapm.2012.06.006; Nagelkerke SQ, 2015, GENES IMMUN, V16, P422, DOI 10.1038/gene.2015.25; Xu LL, 2014, J IMMUNOL, V192, P5179, DOI 10.4049/jimmunol.1400101; Hurvitz SA, 2012, CLIN CANCER RES, V18, P3478, DOI 10.1158/1078-0432.CCR-11-2294; Edberg JC, 2002, ARTHRITIS RHEUM, V46, P2132, DOI 10.1002/art.10438; Bailey JA, 2002, SCIENCE, V297, P1003, DOI 10.1126/science.1072047; ORY PA, 1989, J CLIN INVEST, V84, P1688, DOI 10.1172/JCI114350; Khor CC, 2011, NAT GENET, V43, P1241, DOI 10.1038/ng.981; Nimmerjahn F, 2015, TRENDS IMMUNOL, V36, P325, DOI 10.1016/j.it.2015.04.005; Sudmant PH, 2010, SCIENCE, V330, P641, DOI 10.1126/science.1197005; Quartuccio L, 2014, ANN RHEUM DIS, V73, P716, DOI 10.1136/annrheumdis-2012-202435; Vaughan AT, 2014, BLOOD, V123, P669, DOI 10.1182/blood-2013-04-490821; Weng WK, 2003, J CLIN ONCOL, V21, P3940, DOI 10.1200/JCO.2003.05.013; Carlotti E, 2007, HAEMATOL-HEMATOL J, V92, P1127, DOI 10.3324/haematol.11288; Ghesquieres H, 2012, BLOOD, V120, P2650, DOI 10.1182/blood-2012-05-431825; Asano K, 2013, INFLAMM BOWEL DIS, V19, P2061, DOI 10.1097/MIB.0b013e318298118e; BROOKS DG, 1989, J EXP MED, V170, P1369, DOI 10.1084/jem.170.4.1369; Jiang Y, 2000, IMMUNOGENETICS, V51, P429, DOI 10.1007/s002510050641; van der Poel CE, 2011, J IMMUNOL, V186, P2699, DOI 10.4049/jimmunol.1003526; Wang M, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1370-2; van der Heijden J, 2012, J IMMUNOL, V188, P1318, DOI 10.4049/jimmunol.1003945; Li LH, 2010, SCAND J RHEUMATOL, V39, P148, DOI 10.3109/03009740903292304; RAVETCH JV, 1989, J EXP MED, V170, P481, DOI 10.1084/jem.170.2.481; McGovern DPB, 2010, NAT GENET, V42, P332, DOI 10.1038/ng.549; Musolino A, 2008, J CLIN ONCOL, V26, P1789, DOI 10.1200/JCO.2007.14.8957; Boross P, 2011, J IMMUNOL, V187, P1304, DOI 10.4049/jimmunol.1101194; Ottolini B, 2014, GENOME BIOL EVOL, V6, P3025, DOI 10.1093/gbe/evu236; YUNIS JJ, 1982, SCIENCE, V215, P1525, DOI 10.1126/science.7063861; Nossent JC, 2012, J RHEUMATOL, V39, P2142, DOI 10.3899/jrheum.120294; Weng WK, 2009, LEUKEMIA LYMPHOMA, V50, P723, DOI 10.1080/10428190902829441; Park SJ, 2012, ONCOLOGY-BASEL, V82, P83, DOI 10.1159/000335959; Haldorsen K, 2013, GENES IMMUN, V14, P234, DOI 10.1038/gene.2013.12; Zhang W, 2007, J CLIN ONCOL, V25, P3712, DOI 10.1200/JCO.2006.08.8021; Smith KGC, 2010, NAT REV IMMUNOL, V10, P328, DOI 10.1038/nri2762; Niederer HA, 2010, HUM MOL GENET, V19, P3282, DOI 10.1093/hmg/ddq216; Reil A, 2013, TRANSFUSION, V53, P2145, DOI 10.1111/trf.12086; Bruhns P, 2009, BLOOD, V113, P3716, DOI 10.1182/blood-2008-09-179754; SALMON JE, 1990, J CLIN INVEST, V85, P1287, DOI 10.1172/JCI114566; Clynes R, 2005, CLIN EXP IMMUNOL, V141, P230, DOI 10.1111/j.1365-2249.2005.02847.x; KUROSAKI T, 1989, NATURE, V342, P805, DOI 10.1038/342805a0; Fanciulli M, 2007, NAT GENET, V39, P721, DOI 10.1038/ng2046; WARMERDAM PAM, 1993, J BIOL CHEM, V268, P7346; Kyogoku C, 2002, ARTHRITIS RHEUM, V46, P1242, DOI 10.1002/art.10257; Dong CL, 2014, ARTHRITIS RHEUMATOL, V66, P1291, DOI 10.1002/art.38337; Metes D, 1999, EUR J IMMUNOL, V29, P2842, DOI 10.1002/(SICI)1521-4141(199909)29:09<2842::AID-IMMU2842>3.0.CO;2-5; Kono H, 2005, HUM MOL GENET, V14, P2881, DOI 10.1093/hmg/ddi320; Fayngerts SA, 2007, IMMUNOGENETICS, V59, P493, DOI 10.1007/s00251-007-0208-8; Pritchard NR, 2000, CURR BIOL, V10, P227, DOI 10.1016/S0960-9822(00)00344-4; BREDIUS RGM, 1994, IMMUNOLOGY, V83, P624; Robinson JI, 2012, HUM MUTAT, V33, P741, DOI 10.1002/humu.22031; Ioan-Facsinay A, 2002, IMMUNITY, V16, P391, DOI 10.1016/S1074-7613(02)00294-7; McGaha TL, 2005, SCIENCE, V307, P590, DOI 10.1126/science.1105160; Magnusson V, 2004, GENES IMMUN, V5, P130, DOI 10.1038/sj.gene.6364052; Conrad DF, 2010, NATURE, V464, P704, DOI 10.1038/nature08516; Tamura K, 2011, ANN ONCOL, V22, P1302, DOI 10.1093/annonc/mdq585; STUART SG, 1989, EMBO J, V8, P3657; Koene HR, 1998, BLOOD, V91, P673; Redon R, 2006, NATURE, V444, P444, DOI 10.1038/nature05329; Tse WY, 2000, CLIN EXP IMMUNOL, V119, P574, DOI 10.1046/j.1365-2249.2000.01182.x; Metes D, 2001, J IMMUNOL METHODS, V258, P85, DOI 10.1016/S0022-1759(01)00472-0; Nimmerjahn F, 2011, CURR TOP MICROBIOL, V350, P105, DOI 10.1007/82_2010_86; TROUNSTINE ML, 1990, INT IMMUNOL, V2, P303, DOI 10.1093/intimm/2.4.303; SAMMARTINO L, 1988, IMMUNOGENETICS, V28, P380, DOI 10.1007/BF00364238; Cartron G, 2002, BLOOD, V99, P754, DOI 10.1182/blood.V99.3.754; Brownlie RJ, 2008, J EXP MED, V205, P883, DOI 10.1084/jem.20072565; Chen JY, 2006, ARTHRITIS RHEUM, V54, P3908, DOI 10.1002/art.22220; Lu JH, 2015, P NATL ACAD SCI USA, V112, P833, DOI 10.1073/pnas.1418812112; Lindsay SJ, 2006, AM J HUM GENET, V79, P890, DOI 10.1086/508709; GESSNER JE, 1995, J BIOL CHEM, V270, P1350; Lau CS, 2006, LUPUS, V15, P715, DOI 10.1177/0961203306072311; Pinheiro LB, 2012, ANAL CHEM, V84, P1003, DOI 10.1021/ac202578x; Huggett JF, 2013, CLIN CHEM, V59, P892, DOI 10.1373/clinchem.2013.206375; Willcocks LC, 2008, J EXP MED, V205, P1573, DOI 10.1084/jem.20072413; Li SYS, 2014, J CLIN INVEST, V124, P3879, DOI 10.1172/JCI75539; Nimmerjahn F, 2005, IMMUNITY, V23, P41, DOI 10.1016/j.immuni.2005.05.010; Floto RA, 2005, NAT MED, V11, P1056, DOI 10.1038/nm1288; Maxwell KF, 1999, NAT STRUCT BIOL, V6, P437; Stewart-Akers AM, 2004, GENES IMMUN, V5, P521, DOI 10.1038/sj.gene.6364121; MUTA T, 1994, NATURE, V369, P340; Takai T, 1996, NATURE, V379, P346, DOI 10.1038/379346a0; Li XL, 2003, ARTHRITIS RHEUM, V48, P3242, DOI 10.1002/art.11313; Nimmerjahn F, 2007, CURR OPIN IMMUNOL, V19, P239, DOI 10.1016/j.coi.2007.01.005; Meknache N, 2009, J IMMUNOL, V182, P2542, DOI 10.4049/jimmunol.0801665; CLARK MR, 1989, J IMMUNOL, V143, P1731; FROMONT P, 1992, BLOOD, V79, P2131; Nimmerjahn F, 2007, ADV IMMUNOL, V96, P179, DOI 10.1016/S0065-2776(07)96005-8; Bux J, 2008, VOX SANG, V94, P277, DOI 10.1111/j.1423-0410.2007.01031.x; OSMAN N, 1992, J IMMUNOL, V148, P1570; Mackay M, 2006, J EXP MED, V203, P2157, DOI 10.1084/jem.20051503; Wu JM, 1997, J CLIN INVEST, V100, P1059, DOI 10.1172/JCI119616; Bournazos S, 2011, RESPIRATION, V81, P142, DOI 10.1159/000321997; Siriboonrit U, 2003, TISSUE ANTIGENS, V61, P374, DOI 10.1034/j.1399-0039.2003.00047.x; Maresco DL, 1996, CYTOGENET CELL GENET, V73, P157, DOI 10.1159/000134330; Clatworthy MR, 2007, P NATL ACAD SCI USA, V104, P7169, DOI 10.1073/pnas.0608889104; Yesmin K, 2010, CLIN ENDOCRINOL, V73, P119, DOI 10.1111/j.1365-2265.2010.03780.x; Liu F, 2014, DNA CELL BIOL, V33, P616, DOI 10.1089/dna.2013.2333; Ruyssen-Witrand A, 2012, ANN RHEUM DIS, V71, P875, DOI 10.1136/annrheumdis-2011-200337; Chen JY, 2014, ARTHRITIS RHEUMATOL, V66, P3113, DOI 10.1002/art.38813; Dahal LN, 2015, IMMUNOL REV, V268, P104, DOI 10.1111/imr.12342; desHaas M, 1996, J IMMUNOL, V156, P2948; desHaas M, 1995, BLOOD, V86, P2403; Duan JY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103329; Flinsenberg TWH, 2014, CLIN IMMUNOL, V155, P108, DOI 10.1016/j.clim.2014.09.006; Franke L, 2015, EUR J HUM GENET, DOI [10.1038/ejhg.2015.95, DOI 10.1038/EJHG.2015.95]; Guilliams M, 2014, NAT REV IMMUNOL, V14, P94, DOI 10.1038/nri3582; Gupta RM, 2014, J CLIN INVEST, V124, P4154, DOI 10.1172/JCI72992; HUIZINGA TWJ, 1990, BLOOD, V76, P1927; Kuo HC, 2015, ARTHRITIS RHEUMATOL, V67, P828, DOI 10.1002/art.38976; Lee YH, 2014, RHEUMATOL INT, V34, P1409, DOI 10.1007/s00296-014-3015-1; Li XR, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3007097; Li Y, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2590; Marques RB, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013173; McIntosh RS, 2007, PLOS PATHOG, V3, P647, DOI 10.1371/journal.ppat.0030072; Mellor JD, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-1; Nadauld L, 2012, TRANSL MED, V2, P107; Nguyen HT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063219; Nimmerjahn Falk, 2012, Cancer Immun, V12, P13; Nossent JC, 2013, AUTOIMMUNE DIS, V2013, P6; Persky DO, 2012, HAEMATOL-HEMATOL J, V97, P937, DOI 10.3324/haematol.2011.050419; SYKES PJ, 1992, BIOTECHNIQUES, V13, P444; VANDENHERIKOUDIJK IE, 1995, BLOOD, V85, P2202; van dersHeijden J, 2013, J ALLERGY CLIN IMMUN, V131, p[1408, e1405]; VANDEWINKEL JGJ, 1995, J IMMUNOL, V154, P2896; vansMirre E, 2006, BLOOD, V108, P584; vansVugt MJ, 1999, EUR J IMMUNOL, V29, P143; Vogelpoel LTC, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00079; WARMERDAM PAM, 1991, J IMMUNOL, V147, P1338	180	5	5	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0105-2896	1600-065X		IMMUNOL REV	Immunol. Rev.	NOV	2015	268	1			SI		6	24		10.1111/imr.12341		19	Immunology	Immunology	CU9TJ	WOS:000363887900002		
J	Caaveiro, JMM; Kiyoshi, M; Tsumoto, K				Caaveiro, Jose M. M.; Kiyoshi, Masato; Tsumoto, Kouhei			Structural analysis of Fc/FcR complexes: a blueprint for antibody design	IMMUNOLOGICAL REVIEWS			English	Review						immunoglobulin G gamma receptor; X-ray crystallography; immunoglobulin G; therapeutic antibodies; biomolecular recognition; protein engineering	FC-GAMMA-RI; DEPENDENT CELLULAR CYTOTOXICITY; HUMAN-IGG-FC; INTRAVENOUS IMMUNOGLOBULIN THERAPY; PERSISTENT VIRAL-INFECTION; HIGH-AFFINITY BINDING; CRYSTAL-STRUCTURE; EFFECTOR FUNCTIONS; IN-VIVO; MONOCLONAL-ANTIBODIES	The number of studies and the quality of the structural data of Fc receptors (FcRs) has rapidly increased in the last few years. Upon critical examination of the literature, we have extracted general conclusions that could explain differences in affinity and selectivity of FcRs for immunoglobulin G (IgG) based on structural considerations. FcRs employ a little conserved asymmetric surface of domain D2 composed of two distinct subsites to recognize the well-conserved lower hinge region of IgG1-Fc. The extent of the contact interface with the antibody in subsite 1 of the receptor (but not in subsite 2), the geometrical complementarity between antibody and receptor, and the number of polar interactions contribute decisively toward strengthening the binding affinity of the antibody for the receptor. In addition, the uncertain role of the N-linked glycan of IgG for the binding and effector responses elicited by FcRs is discussed. The available data suggest that not only the non-covalent interactions between IgG and FcRs but also their dynamic features are essential for the immune response elicited through these receptors. We believe that the integration of structural, thermodynamic, and kinetic data will be critical for the design and validation of the next generation of therapeutic antibodies with enhanced effector capabilities.	[Caaveiro, Jose M. M.; Kiyoshi, Masato; Tsumoto, Kouhei] Univ Tokyo, Sch Engn, Dept Bioengn, Tokyo 1088639, Japan; [Kiyoshi, Masato] Natl Inst Hlth Sci, Div Biol Chem & Biol, Tokyo, Japan; [Tsumoto, Kouhei] Univ Tokyo, Inst Med Sci, Tokyo 1088639, Japan	Tsumoto, K (reprint author), Univ Tokyo, Inst Med Sci, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	tsumoto@bioeng.t.u-tokyo.ac.jp	Caaveiro, Jose M.M./J-2790-2013	Caaveiro, Jose M.M./0000-0001-5568-2369	Platform for Drug Discovery, Informatics, and Structural Life Science from the Ministry of Education, Culture, Sports, Science and Technology, Japan; Japan Society for the Promotion of Science [25249115, 15K06962]	We thank Dr. Koldo Morante for critical readership of the manuscript. This work was supported by the Platform for Drug Discovery, Informatics, and Structural Life Science from the Ministry of Education, Culture, Sports, Science and Technology, Japan, and by Grants-in-Aid for Scientific Research A (grant number 25249115 to K. T.) and Scientific Research C (grant number 15K06962 to J. M. M. C.) from the Japan Society for the Promotion of Science. The authors declare no competing financial interest.	Krissinel E, 2007, J MOL BIOL, V372, P774, DOI 10.1016/j.jmb.2007.05.022; Schwab I, 2013, NAT REV IMMUNOL, V13, P176, DOI 10.1038/nri3401; Presta LG, 2008, CURR OPIN IMMUNOL, V20, P460, DOI 10.1016/j.coi.2008.06.012; Borrok MJ, 2012, ACS CHEM BIOL, V7, P1596, DOI 10.1021/cb300130k; KIMBERLY RP, 1990, J EXP MED, V171, P1239, DOI 10.1084/jem.171.4.1239; Stavenhagen JB, 2008, ADV ENZYME REGUL, V48, P152, DOI 10.1016/j.advenzreg.2007.11.011; Roux KH, 1997, J IMMUNOL, V159, P3372; Garman SC, 1998, CELL, V95, P951, DOI 10.1016/S0092-8674(00)81719-5; Pietersz GA, 2009, IMMUNOL CELL BIOL, V87, P3, DOI 10.1038/icb.2008.82; Shinkawa T, 2003, J BIOL CHEM, V278, P3466, DOI 10.1074/jbc.M210665200; GHIRLANDO R, 1995, BIOCHEMISTRY-US, V34, P13320, DOI 10.1021/bi00041a007; Sazinsky SL, 2008, P NATL ACAD SCI USA, V105, P20167, DOI 10.1073/pnas.0809257105; Sondermann P, 2000, NATURE, V406, P267, DOI 10.1038/35018508; Stamos J, 2004, STRUCTURE, V12, P1289, DOI 10.1016/j.str.2004.04.015; Halper-Stromberg A, 2014, CELL, V158, P989, DOI 10.1016/j.cell.2014.07.043; Takai T, 2002, NAT REV IMMUNOL, V2, P580, DOI 10.1038/nri856; Radaev S, 2001, J BIOL CHEM, V276, P16469, DOI 10.1074/jbc.M100350200; Koene HR, 1997, BLOOD, V90, P1109; Stavenhagen JB, 2007, CANCER RES, V67, P8882, DOI 10.1158/0008-54/2.CAN-07-0696; BREKKE OH, 1995, IMMUNOL TODAY, V16, P85, DOI 10.1016/0167-5699(95)80094-8; Lu JH, 2011, J BIOL CHEM, V286, P40608, DOI 10.1074/jbc.M111.257550; Bonetto S, 2009, FASEB J, V23, P575, DOI 10.1096/fj.08-117069; Ernst LK, 1998, MOL IMMUNOL, V35, P943, DOI 10.1016/S0161-5890(98)00079-0; PAREKH RB, 1985, NATURE, V316, P452, DOI 10.1038/316452a0; Suzuki M, 2013, BIOCHEM BIOPH RES CO, V436, P519, DOI 10.1016/j.bbrc.2013.05.137; Baruah K, 2012, J MOL BIOL, V420, P1, DOI 10.1016/j.jmb.2012.04.002; Hatayama K, 2012, APPL MICROBIOL BIOT, V94, P1051, DOI 10.1007/s00253-012-3902-x; Nimmerjahn F, 2008, NAT REV IMMUNOL, V8, P34, DOI 10.1038/nri2206; Radaev S, 2002, MOL IMMUNOL, V38, P1073, DOI 10.1016/S0161-5890(02)00036-6; Lu JH, 2008, NATURE, V456, P989, DOI 10.1038/nature07468; Karsten CM, 2012, IMMUNOBIOLOGY, V217, P1067, DOI 10.1016/j.imbio.2012.07.015; Pincetic A, 2014, NAT IMMUNOL, V15, P707, DOI 10.1038/ni.2939; Ferrara C, 2011, P NATL ACAD SCI USA, V108, P12669, DOI 10.1073/pnas.1108455108; BERKEN A, 1966, J EXP MED, V123, P119, DOI 10.1084/jem.123.1.119; Graille M, 2000, P NATL ACAD SCI USA, V97, P5399, DOI 10.1073/pnas.97.10.5399; van Sorge NM, 2003, TISSUE ANTIGENS, V61, P189, DOI 10.1034/j.1399-0039.2003.00037.x; Hogarth PM, 2012, NAT REV DRUG DISCOV, V11, P311, DOI 10.1038/nrd2909; Vafa O, 2014, METHODS, V65, P114, DOI 10.1016/j.ymeth.2013.06.035; Raju TS, 2008, CURR OPIN IMMUNOL, V20, P471, DOI 10.1016/j.coi.2008.06.007; Matsumiya S, 2007, J MOL BIOL, V368, P767, DOI 10.1016/j.jmb.2007.02.034; Takai T, 2005, J CLIN IMMUNOL, V25, P1, DOI 10.1007/s10875-005-0353-8; Crispin M, 2013, P NATL ACAD SCI USA, V110, pE3544, DOI 10.1073/pnas.1310657110; Bevaart L, 2006, CANCER RES, V66, P1261, DOI 10.1158/0008-5472.CAN-05-2856; Heyman B, 2000, ANNU REV IMMUNOL, V18, P709, DOI 10.1146/annurev.immunol.18.1.709; Shields RL, 2002, J BIOL CHEM, V277, P26733, DOI 10.1074/jbc.M202069200; Lu JH, 2012, IMMUNOL REV, V250, P230, DOI 10.1111/j.1600-065X.2012.01162.x; Sondermann P, 1999, EMBO J, V18, P1095, DOI 10.1093/emboj/18.5.1095; Kaneko Y, 2006, SCIENCE, V313, P670, DOI 10.1126/science.1129594; Herr AB, 2003, NATURE, V423, P614, DOI 10.1038/nature01685; Krapp S, 2003, J MOL BIOL, V325, P979, DOI 10.1016/S0022-2836(02)01250-0; SARMAY G, 1992, MOL IMMUNOL, V29, P633, DOI 10.1016/0161-5890(92)90200-H; MORGAN A, 1995, IMMUNOLOGY, V86, P319; Nimmerjahn F, 2015, TRENDS IMMUNOL, V36, P325, DOI 10.1016/j.it.2015.04.005; Powell MS, 2006, J IMMUNOL, V176, P7489; Yu XJ, 2013, J AM CHEM SOC, V135, P9723, DOI 10.1021/ja4014375; Cady CT, 2010, IMMUNOL LETT, V130, P57, DOI 10.1016/j.imlet.2009.12.001; Otten MA, 2008, J IMMUNOL, V181, P6829; van der Poel CE, 2011, J IMMUNOL, V186, P2699, DOI 10.4049/jimmunol.1003526; Ferrara C, 2006, J BIOL CHEM, V281, P5032, DOI 10.1074/jbc.MS10171200; Anthony RM, 2008, SCIENCE, V320, P373, DOI 10.1126/science.1154315; Hayward S, 1998, PROTEINS, V30, P144, DOI 10.1002/(SICI)1097-0134(19980201)30:2<144::AID-PROT4>3.0.CO;2-N; Li X, 2009, GENES IMMUN, V10, P380, DOI 10.1038/gene.2009.35; Sondermann P, 2013, P NATL ACAD SCI USA, V110, P9868, DOI 10.1073/pnas.1307864110; Lim SH, 2010, HAEMATOL-HEMATOL J, V95, P135, DOI 10.3324/haematol.2008.001628; Albanesi M, 2012, IMMUNOL LETT, V143, P20, DOI 10.1016/j.imlet.2012.02.005; Oflazoglu E, 2010, MABS-AUSTIN, V2, P14; Keeble AH, 2008, P NATL ACAD SCI USA, V105, P6045, DOI 10.1073/pnas.0800159105; Ghirlando R, 1999, IMMUNOL LETT, V68, P47, DOI 10.1016/S0165-2478(99)00029-2; Asaoka Y, 2012, PROTEIN ENG DES SEL, V25, P835, DOI 10.1093/protein/gzs053; DUNCAN AR, 1988, NATURE, V332, P563, DOI 10.1038/332563a0; Kato K, 2000, J MOL BIOL, V295, P213, DOI 10.1006/jmbi.1999.3351; Ahmed AA, 2014, J MOL BIOL, V426, P3166, DOI 10.1016/j.jmb.2014.07.006; Ding Y, 2003, J BIOL CHEM, V278, P27966, DOI 10.1074/jbc.C300223200; Jefferis R, 2009, TRENDS PHARMACOL SCI, V30, P356, DOI 10.1016/j.tips.2009.04.007; Yamaguchi Y, 2006, BBA-GEN SUBJECTS, V1760, P693, DOI 10.1016/j.bbagen.2005.10.002; Oganesyan V, 2008, MOL IMMUNOL, V45, P1872, DOI 10.1016/j.molimm.2007.10.042; Asaoka Y, 2013, MOL IMMUNOL, V54, P403, DOI 10.1016/j.molimm.2013.01.007; Bruhns P, 2009, BLOOD, V113, P3716, DOI 10.1182/blood-2008-09-179754; Okazaki A, 2004, J MOL BIOL, V336, P1239, DOI 10.1016/j.jmb.2004.01.007; Shields RL, 2001, J BIOL CHEM, V276, P6591, DOI 10.1074/jbc.M009483200; Davies AM, 2014, J MOL BIOL, V426, P630, DOI 10.1016/j.jmb.2013.10.039; Zhang YH, 2000, IMMUNITY, V13, P387, DOI 10.1016/S1074-7613(00)00038-8; HULETT MD, 1994, ADV IMMUNOL, V57, P1, DOI 10.1016/S0065-2776(08)60671-9; Mossner E, 2010, BLOOD, V115, P4393, DOI 10.1182/blood-2009-06-225979; Barb AW, 2011, NAT CHEM BIOL, V7, P147, DOI [10.1038/nchembio.511, 10.1038/NCHEMBIO.511]; Mancardi DA, 2013, BLOOD, V121, P1563, DOI 10.1182/blood-2012-07-442541; Lazar GA, 2006, P NATL ACAD SCI USA, V103, P4005, DOI 10.1073/pnas.0508123103; West AP, 2000, BIOCHEMISTRY-US, V39, P9698, DOI 10.1021/bi000749m; Mimoto F, 2013, PROTEIN ENG DES SEL, V26, P589, DOI 10.1093/protein/gzt022; van de Winkel JGJ, 2010, IMMUNOL LETT, V128, P4, DOI 10.1016/j.imlet.2009.09.005; Fiebiger BM, 2015, P NATL ACAD SCI USA, V112, pE2385, DOI 10.1073/pnas.1505292112; Minard-Colin V, 2008, BLOOD, V112, P1205, DOI 10.1182/blood-2008-01-135160; Horton HM, 2010, BLOOD, V116, P3004, DOI 10.1182/blood-2010-01-265280; Mimoto F, 2014, MOL IMMUNOL, V58, P132, DOI 10.1016/j.molimm.2013.11.017; DiLillo DJ, 2015, CELL, V161, P1035, DOI 10.1016/j.cell.2015.04.016; DiLillo DJ, 2014, NAT MED, V20, P143, DOI 10.1038/nm.3443; Garman SC, 2001, J MOL BIOL, V311, P1049, DOI 10.1006/jmbi.2001.4929; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; Mimura Y, 2001, J BIOL CHEM, V276, P45539, DOI 10.1074/jbc.M107478200; Ioan-Facsinay A, 2002, IMMUNITY, V16, P391, DOI 10.1016/S1074-7613(02)00294-7; LUND J, 1990, MOL IMMUNOL, V27, P1145, DOI 10.1016/0161-5890(90)90103-7; Natsume A, 2005, J IMMUNOL METHODS, V306, P93, DOI 10.1016/j.jim.2005.07.025; Idusogie EE, 2000, J IMMUNOL, V164, P4178; Mizushima T, 2011, GENES CELLS, V16, P1071, DOI 10.1111/j.1365-2443.2011.01552.x; Saphire EO, 2001, SCIENCE, V293, P1155, DOI 10.1126/science.1061692; James LC, 2007, P NATL ACAD SCI USA, V104, P6200, DOI 10.1073/pnas.0609174104; Arnold JN, 2007, ANNU REV IMMUNOL, V25, P21, DOI 10.1146/annurev.immunol.25.022106.141702; Ramsland PA, 2011, J IMMUNOL, V187, P3208, DOI 10.4049/jimmunol.1101467; Rayner LE, 2015, J BIOL CHEM, V290, P8420, DOI 10.1074/jbc.M114.631002; Ravetch JV, 2001, ANNU REV IMMUNOL, V19, P275, DOI 10.1146/annurev.immunol.19.1.275; Ercan A, 2010, ARTHRITIS RHEUM-US, V62, P2239, DOI 10.1002/art.27533; Goede V, 2014, NEW ENGL J MED, V370, P1101, DOI 10.1056/NEJMoa1313984; Lu JH, 2015, P NATL ACAD SCI USA, V112, P833, DOI 10.1073/pnas.1418812112; Berntzen G, 2006, PROTEIN ENG DES SEL, V19, P121, DOI 10.1093/protein/gzj011; Teplyakov A, 2013, MOL IMMUNOL, V56, P131, DOI 10.1016/j.molimm.2013.03.018; Kubota T, 2009, CANCER SCI, V100, P1566, DOI 10.1111/j.1349-7006.2009.01222.x; Mimoto F, 2013, MABS-AUSTIN, V5, P229, DOI 10.4161/mabs.23452; Nimmerjahn F, 2006, IMMUNITY, V24, P19, DOI 10.1016/j.immuni.2005.11.010; Umana P, 1999, NAT BIOTECHNOL, V17, P176; Maenaka K, 2001, J BIOL CHEM, V276, P44898, DOI 10.1074/jbc.M106819200; Jefferis R, 2002, IMMUNOL LETT, V82, P57, DOI 10.1016/S0165-2478(02)00019-6; Maxwell KF, 1999, NAT STRUCT BIOL, V6, P437; Sondermann P, 2001, J MOL BIOL, V309, P737, DOI 10.1006/jmbi.2001.4670; Frank M, 2014, J MOL BIOL, V426, P1799, DOI 10.1016/j.jmb.2014.01.011; Barb AW, 2015, BIOCHEMISTRY-US, V54, P313, DOI 10.1021/bi501380t; Holdom MD, 2011, NAT STRUCT MOL BIOL, V18, P571, DOI 10.1038/nsmb.2044; Wormald MR, 1997, BIOCHEMISTRY-US, V36, P1370, DOI 10.1021/bi9621472; Nimmerjahn F, 2007, CURR OPIN IMMUNOL, V19, P239, DOI 10.1016/j.coi.2007.01.005; Ellsworth JL, 2010, PROTEIN ENG DES SEL, V23, P299, DOI 10.1093/protein/gzq007; Oganesyan V, 2008, ACTA CRYSTALLOGR D, V64, P700, DOI 10.1107/S0907444908007877; Hanson QM, 2015, BIOCHEMISTRY-US, V54, P2931, DOI 10.1021/acs.biochem.5b00299; Liu Z, 2014, J BIOL CHEM, V289, P3571, DOI 10.1074/jbc.M113.513366; Garman SC, 2000, NATURE, V406, P259; Oganesyan V, 2014, J BIOL CHEM, V289, P7812, DOI 10.1074/jbc.M113.537563; Hogarth PM, 2002, CURR OPIN IMMUNOL, V14, P798, DOI 10.1016/S0952-7915(02)00409-0; Bournazos S, 2014, CELL, V158, P1243, DOI 10.1016/j.cell.2014.08.023; Daeron M, 2014, CURR TOP MICROBIOL, V382, pV; Dalziel M, 2014, SCIENCE, V343, P37, DOI 10.1126/science.1235681; dasSilva FP, 2007, NAT MED, V13, P1368; Davies AM, 2014, MOL IMMUNOL, V62, P46, DOI 10.1016/j.molimm.2014.05.015; Getahun A, 2015, IMMUNOL REV, V268, P66, DOI 10.1111/imr.12336; Guilliams M, 2014, NAT REV IMMUNOL, V14, P94, DOI 10.1038/nri3582; Harre U, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7651; Jefferis R, 2009, NAT REV DRUG DISCOV, V8, P226, DOI 10.1038/nrd2804; Kiyoshi M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7866; Lu JH, 2015, IMMUNOL REV, V268, P192, DOI 10.1111/imr.12346; McIntosh RS, 2007, PLOS PATHOG, V3, P647, DOI 10.1371/journal.ppat.0030072; Negishi-Koga T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7637; Subedi GP, 2014, STRUCTURE, V22, P1478, DOI 10.1016/j.str.2014.08.002; Bateman A, 2015, NUCLEIC ACIDS RES, V43, pD204, DOI 10.1093/nar/gku989; Unkeless J C, 1995, Semin Immunol, V7, P37, DOI 10.1016/1044-5323(95)90006-3; Wieland A, 2015, IMMUNITY, V42, P367, DOI 10.1016/j.immuni.2015.01.009; Yamada DH, 2015, IMMUNITY, V42, P379, DOI 10.1016/j.immuni.2015.01.005; Zhang X, 2015, SCI REP-UK, V5, DOI 10.1038/srep09803	154	2	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0105-2896	1600-065X		IMMUNOL REV	Immunol. Rev.	NOV	2015	268	1			SI		201	221		10.1111/imr.12365		21	Immunology	Immunology	CU9TJ	WOS:000363887900014		
J	Shibuya, A; Honda, S				Shibuya, Akira; Honda, Shin-ichiro			Immune regulation by Fc alpha/mu receptor (CD351) on marginal zone B cells and follicular dendritic cells	IMMUNOLOGICAL REVIEWS			English	Review						Fc receptor; IgA; IgM; Fc; receptor; follicular dendritic cells; marginal zone B cells	ALPHA/MU-RECEPTOR; ANTIGEN PRESENTATION; IGG AUTOANTIBODIES; GAMMA RECEPTORS; DEFICIENT MICE; MU-RECEPTORS; T-CELLS; EXPRESSION; RESPONSES; ENDOCYTOSIS	Although both Fc/ receptor (Fc/R) and polymeric Ig receptor (poly-IgR) are Fc receptors for IgA and IgM and are functionally and genetically related, the expression profile of Fc/R is unique. Unlike poly-IgR, Fc/R is expressed on marginal zone (MZ) B cells and follicular dendritic cells, suggesting that Fc/R plays an important role in humoral immune responses. Fc/R mediates endocytosis of the IgM immune complex (IC). Recent research demonstrated that Fc/R downregulated retention of the IgM IC with a T-independent (TI) antigen on MZ B cells and follicular dendritic cells due to endocytosis of the IgM IC, suppressing germinal center formation, affinity maturation, and memory B-cell generation in response to TI antigen challenge. In addition, Fc/R physically associates with Toll-like receptor 4 (TLR4) and augments TLR4 oligomerization and signaling in MZ B cells upon lipopolysaccharide (LPS) challenge, leading to increased proinflammatory cytokine production by MZ B cells. Thus, Fc/R is a unique Fc receptor that is involved in humoral immune responses and inflammation.	[Shibuya, Akira; Honda, Shin-ichiro] Univ Tsukuba, Dept Immunol, Fac Med, Tsukuba, Ibaraki 3058575, Japan; [Shibuya, Akira] Univ Tsukuba, Life Sci Ctr Tsukuba Adv Res Alliance TARA, Dept Immunol, Tsukuba, Ibaraki 3058575, Japan; [Shibuya, Akira] Univ Tsukuba, Dept Immunol, Japan Sci & Technol Agcy, CREST, Tsukuba, Ibaraki 3058575, Japan	Shibuya, A (reprint author), Univ Tsukuba, CREST, Japan Sci & Technol Agcy, 1-1-1 Tennohdai, Tsukuba, Ibaraki 3058575, Japan.	ashibuya@md.tsukuba.ac.jp					Shibuya A, 2000, NAT IMMUNOL, V1, P441, DOI 10.1038/80886; Shimizu Y, 2001, IMMUNOGENETICS, V53, P709, DOI 10.1007/s00251-001-0375-y; Takai T, 2002, NAT REV IMMUNOL, V2, P580, DOI 10.1038/nri856; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; MALISZEWSKI CR, 1990, J EXP MED, V172, P1665, DOI 10.1084/jem.172.6.1665; Rubtsov A, 2005, IMMUNITY, V23, P527, DOI 10.1016/j.immuni.2005.09.018; NAKAMURA T, 1993, J IMMUNOL, V151, P6933; Nimmerjahn F, 2008, NAT REV IMMUNOL, V8, P34, DOI 10.1038/nri2206; MATHUR A, 1988, J IMMUNOL, V141, P1855; OHNO T, 1990, J EXP MED, V172, P1165, DOI 10.1084/jem.172.4.1165; Kurita N, 2009, MOL IMMUNOL, V46, P749, DOI 10.1016/j.molimm.2008.10.002; Sakamoto N, 2001, EUR J IMMUNOL, V31, P1310, DOI 10.1002/1521-4141(200105)31:5<1310::AID-IMMU1310>3.0.CO;2-N; Martin F, 2002, NAT REV IMMUNOL, V2, P323, DOI 10.1038/nri799; Kubagawa H, 2009, J EXP MED, V206, P2779, DOI 10.1084/jem.20091107; Arai S, 2013, CELL REP, V3, P1187, DOI 10.1016/j.celrep.2013.03.006; Carroll MC, 1998, ANNU REV IMMUNOL, V16, P545, DOI 10.1146/annurev.immunol.16.1.545; Shibuya A, 2006, SPRINGER SEMIN IMMUN, V28, P377, DOI 10.1007/s00281-006-0050-3; Honda S, 2009, P NATL ACAD SCI USA, V106, P11230, DOI 10.1073/pnas.0809917106; Ghumra A, 2009, EUR J IMMUNOL, V39, P1147, DOI 10.1002/eji.200839184; MOSTOV KE, 1994, ANNU REV IMMUNOL, V12, P63, DOI 10.1146/annurev.immunol.12.1.63; DOMBROWICZ D, 1993, CELL, V75, P969, DOI 10.1016/0092-8674(93)90540-7; Groom JR, 2007, J EXP MED, V204, P1959, DOI 10.1084/jem.20062567; AMIGORENA S, 1992, NATURE, V358, P337, DOI 10.1038/358337a0; Boes M, 2000, P NATL ACAD SCI USA, V97, P1184, DOI 10.1073/pnas.97.3.1184; Takagaki K, 2013, MOL IMMUNOL, V56, P23, DOI 10.1016/j.molimm.2013.04.003; GOSSELIN EJ, 1992, J IMMUNOL, V149, P3477; WHELAN CA, 1981, IMMUNOL LETT, V3, P249, DOI 10.1016/0165-2478(81)90083-3; Richards HB, 1999, CLIN EXP IMMUNOL, V115, P547; Joseph SB, 2004, CELL, V119, P299, DOI 10.1016/j.cell.2004.09.032; Cho Y, 2010, MOL IMMUNOL, V47, P878, DOI 10.1016/j.molimm.2009.10.016; Ehrenstein MR, 2000, J EXP MED, V191, P1253, DOI 10.1084/jem.191.7.1253; LOIZOU S, 1992, CLIN EXP IMMUNOL, V90, P434; Girkontaite I, 2001, NAT IMMUNOL, V2, P855, DOI 10.1038/ni0901-855; Ouchida R, 2012, P NATL ACAD SCI USA, V109, pE2699, DOI 10.1073/pnas.1210706109; Yoo EM, 2011, MOL IMMUNOL, V48, P1818, DOI 10.1016/j.molimm.2011.05.011; SYLVESTRE DL, 1994, SCIENCE, V265, P1095, DOI 10.1126/science.8066448; Shima H, 2010, INT IMMUNOL, V22, P149, DOI 10.1093/intimm/dxp121; PRICOP L, 1993, J IMMUNOL, V151, P3018; SILVAIN C, 1995, J IMMUNOL, V155, P1606; ERCOLANI L, 1981, J IMMUNOL, V127, P2044; DAVIS W, 1995, EMBO J, V14, P432; Miyazaki T, 1999, J EXP MED, V189, P413, DOI 10.1084/jem.189.2.413; Boes M, 2000, MOL IMMUNOL, V37, P1141, DOI 10.1016/S0161-5890(01)00025-6; Guinamard R, 2000, NAT IMMUNOL, V1, P31; Takai T, 1996, NATURE, V379, P346, DOI 10.1038/379346a0; Herlands RA, 2008, IMMUNITY, V29, P249, DOI 10.1016/j.immuni.2008.06.009; Cerutti A, 2013, NAT REV IMMUNOL, V13, P118, DOI 10.1038/nri3383; Heesters BA, 2013, IMMUNITY, V38, P1164, DOI 10.1016/j.immuni.2013.02.023; MAO SY, 1991, J IMMUNOL, V146, P958; Kikuno K, 2007, EUR J IMMUNOL, V37, P3540, DOI 10.1002/eji.2007376551; Guilliams M, 2014, NAT REV IMMUNOL, V14, P94, DOI 10.1038/nri3582; Tanigakik K, 2002, NAT IMMUNOL, V3, P443, DOI 10.1038/ni793	52	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0105-2896	1600-065X		IMMUNOL REV	Immunol. Rev.	NOV	2015	268	1			SI		288	295		10.1111/imr.12345		8	Immunology	Immunology	CU9TJ	WOS:000363887900020		
J	Inagaki, T; Abe, K; Takahashi, K; Mochida, T				Inagaki, Takashi; Abe, Ken-ichi; Takahashi, Kazuyuki; Mochida, Tomoyuki			Organometallic ionic liquids from half-sandwich Ru(II) complexes with various chelating ligands	INORGANICA CHIMICA ACTA			English	Article						Ionic liquids; Half-sandwich complexes; Ruthenium complexes; Crystal structures; Thermal properties; Catalytic activity	ARENE-RUTHENIUM COMPLEXES; CRYSTAL-STRUCTURES; MAGNETIC-PROPERTIES; THERMAL-PROPERTIES; ORGANIC-SYNTHESIS; SALTS; COORDINATION; CATIONS; SOLUBILITY; CATALYSTS	Salts comprising of cationic half-sandwich Ru(II) complexes with various chelating ligands and the bis (trifluoromethanesulfonyl) amide anion (Tf2N-) were prepared. These salts can be represented as [(arene) RuCl(L-L)][Tf2N] (arene = C6Me5Bu, C6Me6, p-cymene, C6H6; L-L = 2-Py-CH2NHCMe2Et, 2-Py-CH= NC6H13, H13C6NHCH2CH2NHC6H13, Me2NCH2CH2SC4H9, Me2CN=CHCH=NCMe2). Two of the eight salts are liquids at room temperature (similar to 20 degrees C), while the other salts are solids with melting points of 60-130 degrees C. Upon cooling from the melt, most salts exhibited glass transitions between -30 degrees C and -5 degrees C. The salts were found to catalyze the oxidation of cyclohexanol although decomposition occurred during the reaction. Crystal structures of related salts were also determined. (C) 2015 Elsevier B.V. All rights reserved.	[Inagaki, Takashi; Abe, Ken-ichi; Takahashi, Kazuyuki; Mochida, Tomoyuki] Kobe Univ, Grad Sch Sci, Dept Chem, Nada, Hyogo 6578501, Japan	Mochida, T (reprint author), Kobe Univ, Grad Sch Sci, Dept Chem, Nada, Hyogo 6578501, Japan.	tmochida@platinum.kobe-u.ac.jp	Mochida, Tomoyuki/F-8555-2012	Mochida, Tomoyuki/0000-0002-3446-2145	KAKENHI [24655126, 24350073]	We thank Dr. Y. Furuie (Kobe University) for the elemental analysis. This work was financially supported by KAKENHI (Nos. 24655126 and 24350073).	Okuhata M, 2013, CHEM COMMUN, V49, P7662, DOI 10.1039/c3cc44199g; Shi ZJ, 2004, J AM CHEM SOC, V126, P13596, DOI 10.1021/ja046890q; Plechkova NV, 2008, CHEM SOC REV, V37, P123, DOI 10.1039/b006677j; Masui H, 1997, INORG CHEM, V36, P5118, DOI 10.1021/ic9706111; Yoshimura T, 2004, J COLLOID INTERF SCI, V276, P231, DOI 10.1016/j.jcis.2004.03.045; Kiprof P, 2001, J ORGANOMET CHEM, V620, P113, DOI 10.1016/S0022-328X(00)00852-4; Mallick B, 2008, ANGEW CHEM INT EDIT, V47, P7635, DOI 10.1002/anie.200802390; Miura Y, 2010, INORG CHEM, V49, P10032, DOI 10.1021/ic1013363; Srivastava PK, 2012, J APPL POLYM SCI, V125, P31, DOI 10.1002/app.34594; Inagaki T, 2012, CHEM-EUR J, V18, P6795, DOI 10.1002/chem.201200151; Del Sesto RE, 2005, J ORGANOMET CHEM, V690, P2536, DOI 10.1016/j.jorganchem.2004.09.060; Mori S, 2013, ORGANOMETALLICS, V32, P283, DOI 10.1021/om301073z; Funasako Y, 2013, DALTON T, V42, P10138, DOI 10.1039/c3dt50976a; Krossing I, 2006, J AM CHEM SOC, V128, P13427, DOI 10.1021/ja0619612; Zuccaccia D, 2005, ORGANOMETALLICS, V24, P3476, DOI 10.1021/om050145k; Lee SG, 2006, CHEM COMMUN, P1049, DOI 10.1039/b514140k; Lin IJB, 2005, J ORGANOMET CHEM, V690, P3498, DOI 10.1016/j.jorganchem.2005.03.007; Canivet J, 2005, J ORGANOMET CHEM, V690, P3202, DOI 10.1016/j.jorganchem.2005.02.050; Branco A, 2011, CHEM COMMUN, V47, P2300, DOI 10.1039/c0cc03892j; Funasako Y, 2013, DALTON T, V42, P8317, DOI 10.1039/c3dt00084b; Brooks NR, 2011, CHEM-EUR J, V17, P5054, DOI 10.1002/chem.201003209; Kohno Y, 2014, CHEM COMMUN, V50, P6633, DOI 10.1039/c4cc01023j; MCCORMICK FB, 1993, ORGANOMETALLICS, V12, P610, DOI 10.1021/om00027a006; Shirase H, 2009, B CHEM SOC JPN, V82, P230, DOI 10.1246/bcsj.82.230; Handy ST, 2001, ORG LETT, V3, P233, DOI 10.1021/ol0068849; Armand M, 2009, NAT MATER, V8, P621, DOI [10.1038/nmat2448, 10.1038/NMAT2448]; Komurasaki A, 2015, DALTON T, V44, P7595, DOI 10.1039/c5dt00723b; JAIN VK, 1993, POLYHEDRON, V12, P2377, DOI 10.1016/S0277-5387(00)83057-0; Funasako Y, 2011, CHEM COMMUN, V47, P4475, DOI 10.1039/c0cc05820c; Yoshida Y, 2010, PHYS CHEM CHEM PHYS, V12, P1675, DOI 10.1039/b920046k; Nockemann P, 2006, J AM CHEM SOC, V128, P13658, DOI 10.1021/ja0640391; Inagaki T, 2012, CHEM-EUR J, V18, P8070, DOI 10.1002/chem.201200157; BENNETT MA, 1982, INORG SYN, V21, P74, DOI 10.1002/9780470132524.ch16; Funasako Y, 2012, CHEM-EUR J, V18, P11929, DOI 10.1002/chem.201201778; Iida M, 2008, CHEM-EUR J, V14, P5047, DOI 10.1002/chem.200701764; Davis JH, 2004, CHEM LETT, V33, P1072; Dickson SJ, 2008, CHEM-EUR J, V14, P7296, DOI 10.1002/chem.200800772; Pratt HD, 2011, DALTON T, V40, P11396, DOI 10.1039/c1dt10973a; Zhang PF, 2012, CHEM COMMUN, V48, P2334, DOI 10.1039/c2cc16906a; Zhu BL, 2007, ORGANOMETALLICS, V26, P1721, DOI 10.1021/om0610795; Churchill AJ, 2011, INORG CHIM ACTA, V369, P120, DOI 10.1016/j.ica.2011.01.014; Cole AC, 2002, J AM CHEM SOC, V124, P5962, DOI 10.1021/ja026290w; Ogo S, 2002, ORGANOMETALLICS, V21, P2964, DOI 10.1021/om011059x; Mori S, 2013, ORGANOMETALLICS, V32, P780, DOI 10.1021/om300847s; Sawant AD, 2011, GREEN CHEM LETT REV, V4, P41, DOI 10.1080/17518253.2010.500622; Himeda Y, 2007, ORGANOMETALLICS, V26, P702, DOI 10.1021/om060899e; Huang JF, 2006, J ELECTROCHEM SOC, V153, pJ9, DOI 10.1149/1.2150161; Aliende C, 2012, ORGANOMETALLICS, V31, P6106, DOI 10.1021/om3004702; Boulaire V. L., 2000, CHEM COMMUN, P2195; Brown R. J. C., 2001, CHEM COMMUN, P1863; Brown RJC, 2001, CHEM COMMUN, P1862, DOI 10.1039/b104601m; Dixneuf P. H., 2013, METAL CATALYZED REAC; Farrugia J., 1997, J APPL CRYSTALLOGR, V30, P565, DOI DOI 10.1107/S0021889897003117; Inagaki T., UNPUB; Mathews CJ, 2000, CHEM COMMUN, P1249, DOI 10.1039/b002755n; Prodius D., 2015, CHEM COMMUN, V49, P1915; Pucheault Mathieu, 2010, Top Curr Chem, V290, P83, DOI 10.1007/128_2008_33; Rongers R. D., 2002, ACS S SERIES, V818; Scheldrick G. M., 1997, SHELXL PROGRAM SOLUT; Sheldrick GM, 2008, ACTA CRYSTALLOGR A, V64, P112, DOI 10.1107/S0108767307043930; Singh P, 2010, EUR J INORG CHEM, P4187, DOI 10.1002/ejic.201000319; Stark A., 2007, KIRK OTHMER ENCY CHE, V26, P836; Turnbull D., 1960, MOD ASPECT VITR, V1, P38; Weingaertner H, 2008, ANGEW CHEM INT EDIT, V47, P654, DOI 10.1002/anie.200604951; Yamamuro O, 2006, CHEM PHYS LETT, V423, P371, DOI 10.1016/j.cplett.2006.03.074; Yoshida Y., 2011, IONIC LIQUIDS THEORY, P1862; Zhang P., 2012, CHEM COMMUN, P2334	67	0	0	ELSEVIER SCIENCE SA	LAUSANNE	PO BOX 564, 1001 LAUSANNE, SWITZERLAND	0020-1693	1873-3255		INORG CHIM ACTA	Inorg. Chim. Acta	NOV 1	2015	438						112	117		10.1016/j.ica.2015.09.009		6	Chemistry, Inorganic & Nuclear	Chemistry	CU9MB	WOS:000363867500016		
J	Elreedy, A; Tawfik, A; Kubota, K; Shimada, Y; Harada, H				Elreedy, Ahmed; Tawfik, Ahmed; Kubota, Kengo; Shimada, Yusuke; Harada, Hideki			Hythane (H-2 + CH4) production from petrochemical wastewater containing mono-ethylene glycol via stepped anaerobic baffled reactor	INTERNATIONAL BIODETERIORATION & BIODEGRADATION			English	Article						Hythane; Stepped anaerobic baffled reactor; Petrochemical wastewater; Mono-ethylene glycol; Organic loading rate; Microbial community	ANAEROBIC BAFFLED REACTOR; AIRCRAFT DEICING FLUID; SYNTHETIC WASTE-WATER; OIL MILL EFFLUENT; RICE STRAW WASTE; ETHYLENE-GLYCOL; HYDROGEN-PRODUCTION; UASB REACTOR; PILOT-SCALE; LIGNOCELLULOSIC BIOMASS	Hythane (H-2 + CH4) production from petrochemical wastewater containing mono-ethylene glycol (MEG) via a novel stepped anaerobic baffled (SAB) reactor was investigated. The reactor was continuously operated for five months at constant hydraulic retention time (HRT) of 72 h and different organic loading rates (OLRs) of 0.33, 0.67 and 1.67 gCOD l(-1) d(-1). The maximum H-2 yield of 359.01 +/- 33.46 ml H-2 gCOD(removed)(-1) and H-2 production rate of 5.12 +/- 0.48 l d(-1) were obtained at OLR of 1.67 gCOD l(-1) d(-1). Nevertheless, the maximum methane yield of 159.11 +/- 14.72 ml CH4 gCOD(removed)(-1) and methane production rate of 2.48 +/- 0.22 l d(-1) were recorded at OLR of 0.67 gCOD l(-1) d(-1). The maximum CH4 and H-2 content of 52.08 and 49.84% were achieved at OLR of 0.33 and 1.67 gCOD l(-1) d(-1), respectively. Compartment-wise hythane profiles were assessed to optimize the production rate. Microbial community analysis was conducted and showed the dominant bacteria of Proteobacteria (44.3%), Firmicutes (28.9%), Chloroflexi (8.9%), Actinobacteria (5.7%), and Bacteroidetes (5.6%). (C) 2015 Elsevier Ltd. All rights reserved.	[Elreedy, Ahmed; Tawfik, Ahmed] E JUST, Dept Environm Engn, Alexandria 21934, Egypt; [Kubota, Kengo] Tohoku Univ, Dept Civil & Environm Engn, Aoba Ku, Sendai, Miyagi 9808579, Japan; [Shimada, Yusuke] Tohoku Univ, Grad Sch Environm Studies, Aoba Ku, Sendai, Miyagi 9808579, Japan; [Harada, Hideki] Tohoku Univ, New Ind Creat Hatchery Ctr NICHe, Aoba Ku, Sendai, Miyagi 9808579, Japan	Elreedy, A (reprint author), E JUST, Dept Environm Engn, POB 179, Alexandria 21934, Egypt.	Ahmed.elreedy@ejust.edu.sg			Ministry of Higher Education (MOHE)	The first author is very grateful for Ministry of Higher Education (MOHE) for giving him a PhD scholarship to study at Egypt-Japan University of Science and Technology (E-JUST).	Fang HHP, 2002, BIORESOURCE TECHNOL, V82, P87, DOI 10.1016/S0960-8524(01)00110-9; Tawfik A, 2013, RENEW ENERG, V50, P402, DOI 10.1016/j.renene.2012.06.038; Rincon B, 2006, INT BIODETER BIODEGR, V57, P114, DOI 10.1016/j.ibiod.2005.12.004; Liu XL, 2009, BIORESOURCE TECHNOL, V100, P104, DOI 10.1016/j.biortech.2008.06.007; Sreethawong T, 2010, CHEM ENG J, V160, P322, DOI 10.1016/j.cej.2010.03.037; Krishna GVTG, 2008, BIORESOURCE TECHNOL, V99, P8193, DOI 10.1016/j.biortech.2008.03.016; Mohammadi T, 2005, DESALINATION, V181, P35, DOI 10.1016/j.desal.2005.01.012; Orecki A, 2006, DESALINATION, V200, P358, DOI 10.1016/j.desal.2006.03.364; Darlington C, 1998, J ENVIRON SCI HEAL A, V33, P339; Dama P, 2002, WATER SCI TECHNOL, V46, P263; Wahab MA, 2014, BIORESOURCE TECHNOL, V172, P150, DOI 10.1016/j.biortech.2014.08.127; Debik E, 2009, BIORESOURCE TECHNOL, V100, P2777, DOI 10.1016/j.biortech.2008.12.058; Kim KN, 2008, KOREAN J CHEM ENG, V25, P89, DOI 10.1007/s11814-008-0015-4; Shakerkhatibi M, 2013, INT J ENVIRON RES, V7, P195; Leth PM, 2005, FORENSIC SCI INT, V155, P179, DOI 10.1016/j.forsciint.2004.11.012; Tawfik A, 2012, BIORESOURCE TECHNOL, V107, P186, DOI 10.1016/j.biortech.2011.11.086; Elsamadony M, 2015, INT J ENERG RES, V39, P929, DOI 10.1002/er.3297; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Liu GH, 2013, BIOCHEM ENG J, V72, P48, DOI 10.1016/j.bej.2012.12.017; Coskun T, 2012, BIORESOURCE TECHNOL, V121, P31, DOI 10.1016/j.biortech.2012.06.102; Sundberg C, 2013, FEMS MICROBIOL ECOL, V85, P612, DOI 10.1111/1574-6941.12148; Elsamadony M, 2015, APPL ENERG, V149, P272, DOI 10.1016/j.apenergy.2015.03.127; GASTON LW, 1963, J BACTERIOL, V85, P356; Mizzouri NS, 2013, INT BIODETER BIODEGR, V83, P1, DOI 10.1016/j.ibiod.2013.03.026; Zerva C, 2003, J HAZARD MATER, V97, P257, DOI 10.1016/S0304-3894(02)00265-0; Kennedy K, 2005, WATER SA, V31, P377; Tawfik A, 2014, INT J ENERG RES, V38, P1155, DOI 10.1002/er.3128; Baloch MI, 2003, J ENVIRON ENG-ASCE, V129, P1015, DOI 10.1016/(ASCE)0733-9372(2003)129:11(1015); Intanoo P, 2014, INT J HYDROGEN ENERG, V39, P9611, DOI 10.1016/j.ijhydene.2014.04.105; Wang JL, 2004, BIORESOURCE TECHNOL, V93, P205, DOI 10.1016/j.biortech.2003.06.004; Kuscu OS, 2009, J HAZARD MATER, V161, P787, DOI 10.1016/j.jhazmat.2008.04.039; Shin JW, 2014, INT BIODETER BIODEGR, V95, P89, DOI 10.1016/j.ibiod.2014.05.005; Dincer I, 2007, INT J ENERG RES, V31, P29, DOI 10.1002/er.1226; Ghaniyari-Benis S, 2010, PROCESS BIOCHEM, V45, P1616, DOI 10.1016/j.procbio.2010.06.016; DWYER DF, 1983, APPL ENVIRON MICROB, V46, P185; Yetilmezsoy K, 2012, BIORESOURCE TECHNOL, V118, P89, DOI 10.1016/j.biortech.2012.05.088; Marin J, 2010, BIORESOURCE TECHNOL, V101, P2217, DOI 10.1016/j.biortech.2009.11.055; Schoenberg T, 2001, BIODEGRADATION, V12, P59, DOI 10.1023/A:1011961214180; APHA, 2005, STANDARD METHODS EXA; Aydinol F.I, 2011, BIOPROC BIOSYST ENG, V34, P153; Dutta K., 2014, INT BIODETER BIODEGR, P1; Ginkel S V, 2001, Environ Sci Technol, V35, P4726, DOI 10.1021/es001979r; Hassan S.R., 2014, CENTRAL EUROPEAN J E, V3, P389, DOI DOI 10.2478/S13531-013-0107-8; Hassani A.H., 2013, ENVIRON TECHNOL, V35, P499, DOI DOI 10.1080/09593330.2013.834947; Komisar S., 1998, 71 ANN C WAT ENV FED; Lee J, 1997, J BIOTECHNOL, V56, P1, DOI 10.1016/S0168-1656(97)00073-4; Li WC, 2015, INT BIODETER BIODEGR, V98, P81, DOI 10.1016/j.ibiod.2014.09.002; Malakahmad A, 2014, WATER AIR SOIL POLL, V225, DOI 10.1007/s11270-014-1883-3; Nasr Mahmoud, 2014, Sustainable Environment Research, V24; Nasr M., 2014, J IND ENG CHEM; Raja P. K., 2009, CHEM ENG J, V148, P212, DOI DOI 10.1016/J.CEJ.2008.08.036; Ratanatamskul C., 2015, INT BIODETERIOR BIOD	52	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0964-8305	1879-0208		INT BIODETER BIODEGR	Int. Biodeterior. Biodegrad.	NOV	2015	105						252	261		10.1016/j.ibiod.2015.09.015		10	Biotechnology & Applied Microbiology; Environmental Sciences	Biotechnology & Applied Microbiology; Environmental Sciences & Ecology	CV4VJ	WOS:000364264300032		
J	Umezaki, Y; Ito, M; Nakashima, M; Mihara, Y; Kurohama, H; Yatsunami, N; Yasuhi, I				Umezaki, Yasushi; Ito, Masahiro; Nakashima, Masahiro; Mihara, Yumi; Kurohama, Hirokazu; Yatsunami, Naoko; Yasuhi, Ichiro			Low Expression of S100P Is Associated With Poor Prognosis in Patients With Clear Cell Adenocarcinoma of the Ovary	INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER			English	Article						Clear cell adenocarcinoma; Immunohistochemistry; Ovary; Prognosis; S100P	CLINICAL CHARACTERISTICS; GENE-EXPRESSION; CARCINOMA; CANCER; RESISTANCE; LINES	Objective The S100P protein stimulates cell proliferation and survival, thereby contributing to cancer progression. The purposes of this study were to evaluate S100P expression in ovarian clear cell adenocarcinoma and to determine whether S100P expression was correlated with the clinicopathological features or prognoses of patients with clear cell adenocarcinoma. Methods We examined S100P expression in 30 ovarian clear cell adenocarcinoma specimens using immunohistochemistry analysis. The Kaplan-Meier method was used for analysis of overall survival, and comparisons were made based on the log-rank test. Results Negative staining for nuclear S100P was associated with a poor prognosis as compared with that of positive staining for nuclear S100P in specimens from patients with clear cell adenocarcinoma. Conclusions These data suggested that S100P may serve as an independent prognostic factor and marker for acquired resistance to chemotherapeutic drugs in clear cell adenocarcinoma.	[Umezaki, Yasushi; Ito, Masahiro; Mihara, Yumi; Kurohama, Hirokazu] Natl Hosp Org Nagasaki Med Ctr, Dept Pathol, Nagasaki 8560835, Japan; [Nakashima, Masahiro] Nagasaki Univ, Grad Sch Biomed Sci, Atom Bomb Dis Inst, Dept Tumour & Diagnost Pathol, Nagasaki 852, Japan; [Yatsunami, Naoko; Yasuhi, Ichiro] Natl Hosp Org Nagasaki Med Ctr, Dept Obstet & Gynecol, Nagasaki 8560835, Japan	Umezaki, Y (reprint author), Natl Hosp Org Nagasaki Med Ctr, 2-1001-1 Kubara, Nagasaki 8560835, Japan.	umezaki@nagasaki-mc.com					Wang Q, 2008, CANCER LETT, V272, P277, DOI 10.1016/j.canlet.2008.07.017; Sugiyama T, 2000, CANCER, V88, P2584, DOI 10.1002/1097-0142(20000601)88:11<2584::AID-CNCR22>3.0.CO;2-5; Bertram J, 1998, ANTI-CANCER DRUG, V9, P311, DOI 10.1097/00001813-199804000-00004; Streicher WW, 2010, BIOPHYS CHEM, V151, P181, DOI 10.1016/j.bpc.2010.06.003; Logsdon CD, 2003, CANCER RES, V63, P2649; Behbakht K, 1998, GYNECOL ONCOL, V70, P255, DOI 10.1006/gyno.1998.5071; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Umezaki Y, 2015, EUR J GYNAECOL ONCOL, V36, P138; Surowiak P, 2007, HISTOPATHOLOGY, V51, P125, DOI 10.1111/j.1365-2559.2007.02714.x; Sekiya R, 2012, HUM PATHOL, V43, P904, DOI 10.1016/j.humpath.2011.08.002; Averboukh L, 1996, PROSTATE, V29, P350; Jiang F, 2005, LEUKEMIA RES, V29, P1181, DOI 10.1016/j.leukres.2005.03.012; BECKER T, 1992, EUR J BIOCHEM, V207, P541, DOI 10.1111/j.1432-1033.1992.tb17080.x; Gao JH, 2008, CHINESE MED J-PEKING, V121, P1563; Guerreiro Da Silva ID, 2000, INT J ONCOL, V16, P231; Rusell PBP., 1989, SURG PATHOLOGY OVARI; Serov SF, 1973, INT HISTOLOGICAL CLA; Shiota M, 2010, BJU INT, V107, P1148	18	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1048-891X	1525-1438		INT J GYNECOL CANCER	Int. J. Gynecol. Cancer	NOV	2015	25	9					1582	1586		10.1097/IGC.0000000000000544		5	Oncology; Obstetrics & Gynecology	Oncology; Obstetrics & Gynecology	CV4AX	WOS:000364208900006		
J	Yamaguchi, M; Erdenebaatar, C; Saito, F; Motohara, T; Miyahara, Y; Tashiro, H; Katabuchi, H				Yamaguchi, Munekage; Erdenebaatar, Chimeddulam; Saito, Fumitaka; Motohara, Takeshi; Miyahara, Yo; Tashiro, Hironori; Katabuchi, Hidetaka			Long-Term Outcome of Aromatase Inhibitor Therapy With Letrozole in Patients With Advanced Low-Grade Endometrial Stromal Sarcoma	INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER			English	Article						Endometrial stromal sarcoma; Aromatase inhibitor; Letrozole; Estrogen receptor; Hormonal treatment	OF-THE-LITERATURE; HORMONAL-THERAPY; UTERINE SARCOMAS; CENTER EXPERIENCE; MANAGEMENT; RECURRENCE; SURVIVAL; ACETATE; LGESS	Background There has been no consensus on the indications for the treatment of advanced low-grade endometrial stromal sarcoma (LGESS), and the possible effects of hormonal treatment including progestins and aromatase inhibitors have been reported. The aim of this study was to investigate the efficacy of aromatase inhibitor therapy with letrozole for patients with residual or recurrent LGESS. Methods We retrospectively reviewed the clinical response of patients with advanced LGESS who had been treated with letrozole. We also analyzed the adverse effects after the administration of letrozole. The expression levels of estrogen receptor and aromatase in the tumors were immunohistochemically examined. Results In 5 patients who had been treated for unresectable LGESS lesions after initial or repeat surgical procedures, residual lesions in 3 patients and recurrence lesions in 2 patients were the indications for hormonal therapy with letrozole. The median duration of letrozole exposure at retrospective analysis was 53 (10-96) months. The clinical outcomes were classified as complete response in 2 patients, partial response in 1 patient, and stable disease in 2 patients. Myalgias, hot flashes, and arthralgias were not observed during the follow-up period in any patients. The median serum levels of estradiol were <5.0 (cutoff value, <0.5-11.8) pg/mL. The median age-matched bone mineral densities were 92% (79%-123%). The LGESS tissues in all 5 patients were positive for estrogen receptor and aromatase expression. Conclusions Letrozole as well as progestins could be the first choice of treatment for patients with recurrent or residual LGESS, which is difficult to resect surgically because of its efficacy and minimal adverse effects.	[Yamaguchi, Munekage; Erdenebaatar, Chimeddulam; Saito, Fumitaka; Motohara, Takeshi; Katabuchi, Hidetaka] Kumamoto Univ, Fac Life Sci, Dept Obstet & Gynecol, Kumamoto, Kumamoto 8608556, Japan; [Miyahara, Yo] Japan Community Hlth Care Org, Kumamoto Gen Hosp, Dept Obstet & Gynecol, Yatsushiro, Japan; [Tashiro, Hironori] Kumamoto Univ, Fac Life Sci, Dept Mother Child Nursing, Kumamoto, Kumamoto 8608556, Japan	Yamaguchi, M (reprint author), Kumamoto Univ, Fac Life Sci, Dept Obstet & Gynecol, Chuo Ku, 1-1-1 Honjo, Kumamoto, Kumamoto 8608556, Japan.	munekage@hotmail.co.jp					Amant F, 2014, INT J GYNECOL CANCER, V24, pS67, DOI 10.1097/IGC.0000000000000205; Abeler VM, 2009, HISTOPATHOLOGY, V54, P355, DOI 10.1111/j.1365-2559.2009.03231.x; Miller WR, 2001, J STEROID BIOCHEM, V79, P93, DOI 10.1016/S0960-0760(01)00148-0; Jordan VC, 2005, J NATL CANCER I, V97, P619, DOI 10.1093/jnci/djil26; Cheng X, 2011, GYNECOL ONCOL, V121, P323, DOI 10.1016/j.ygyno.2010.12.360; Dahhan T, 2009, EUR J OBSTET GYN R B, V144, P80, DOI 10.1016/j.ejogrb.2009.02.005; Shoji K, 2011, MED ONCOL, V28, P771, DOI 10.1007/s12032-010-9511-6; Nakayama K, 2010, INT J CLIN ONCOL, V15, P179, DOI 10.1007/s10147-010-0040-2; Maluf FC, 2001, GYNECOL ONCOL, V82, P384, DOI 10.1006/gyno.2001.6238; Altman AD, 2012, INT J GYNECOL CANCER, V22, P1006, DOI 10.1097/IGC.0b013e31825b7de8; Tzakas E, 2009, J OBSTET GYNAECOL, V29, P778, DOI 10.3109/01443610903165552; Alkasi O, 2009, ARCH GYNECOL OBSTET, V279, P57, DOI 10.1007/s00404-008-0631-6; Spano JP, 2003, MED ONCOL, V20, P87, DOI 10.1385/MO:20:1:87; Beck TL, 2012, GYNECOL ONCOL, V125, P141, DOI 10.1016/j.ygyno.2011.10.010; dos Santos LA, 2011, GYNECOL ONCOL, V121, P319, DOI 10.1016/j.ygyno.2010.12.363; Mesia AF, 2000, AM J OBSTET GYNECOL, V182, P1140, DOI 10.1067/mob.2000.103939; THIJSSEN JHH, 1989, EUR J CANCER CLIN ON, V25, P1953, DOI 10.1016/0277-5379(89)90377-5; Rauh-Hain JA, 2013, OBSTET GYNECOL, V122, P676, DOI 10.1097/AOG.0b013e3182a189ac; Geisler J, 2011, BRIT J CANCER, V104, P1059, DOI 10.1038/bjc.2011.58; Reich O, 2007, CURR OPIN ONCOL, V19, P347, DOI 10.1097/CCO.0b013e3281a7ef3a; Reich O, 2004, MODERN PATHOL, V17, P104, DOI 10.1038/modpathol.3800031; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Pink D, 2006, GYNECOL ONCOL, V101, P464, DOI 10.1016/j.ygyno.2005.11.010; Burke C, 2004, OBSTET GYNECOL, V104, P1182, DOI 10.1097/01.AOG.0000133533.05148.aa; Tse KY, 2011, BEST PRACT RES CL OB, V25, P733, DOI 10.1016/j.bpobgyn.2011.05.011; Ioffe YJ, 2009, GYNECOL ONCOL, V115, P466, DOI 10.1016/j.ygyno.2009.08.014; Krauss K, 2007, ANTICANCER RES, V27, P3477; Amant F, 2009, LANCET ONCOL, V10, P1188, DOI 10.1016/S1470-2045(09)70226-8; Leunen M, 2004, GYNECOL ONCOL, V95, P769, DOI 10.1016/j.ygyno.2004.07.063; Chew I, 2010, ADV ANAT PATHOL, V17, P113, DOI 10.1097/PAP.0b013e3181cfb7c2; Charles JZ, 2014, TUMOURS FEMALE GENIT, P455; Sylvestre Vonetta T., 2010, Hormones & Cancer, V1, P112, DOI 10.1007/s12672-010-0007-9; Yang KH, 2015, CANC RES TREAT	33	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1048-891X	1525-1438		INT J GYNECOL CANCER	Int. J. Gynecol. Cancer	NOV	2015	25	9					1645	1651		10.1097/IGC.0000000000000557		7	Oncology; Obstetrics & Gynecology	Oncology; Obstetrics & Gynecology	CV4AX	WOS:000364208900015		
J	Kawano, M; Mabuchi, S; Matsumoto, Y; Sasano, T; Takahashi, R; Kuroda, H; Kozasa, K; Isohashi, F; Ogawa, K; Kimura, T				Kawano, Mahiru; Mabuchi, Seiji; Matsumoto, Yuri; Sasano, Tomoyuki; Takahashi, Ryoko; Kuroda, Hiromasa; Kozasa, Katsumi; Isohashi, Fumiaki; Ogawa, Kazuhiko; Kimura, Tadashi			Prognostic Significance of Pretreatment Thrombocytosis in Cervical Cancer Patients Treated With Definitive Radiotherapy	INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER			English	Article						Thrombocytosis; Cervical cancer; Radiotherapy; Survival	GYNECOLOGIC-ONCOLOGY-GROUP; EPITHELIAL OVARIAN-CANCER; PARANEOPLASTIC THROMBOCYTOSIS; ENDOMETRIAL CARCINOMA; PLATELETS; INTERLEUKIN-6; METASTASIS; CELLS; CHEMOTHERAPY; PROGRESSION	Objective The aim of this study was to investigate the prevalence and prognostic significance of an elevated platelet count at the time of the initial diagnosis in patients with cervical cancer who are treated with definitive radiotherapy. Methods The baseline characteristics and outcome data of cervical cancer patients who were treated with definitive radiotherapy between November 1993 and December 2011 were collected and retrospectively reviewed. The patients were separated into 2 groups according to their platelet counts. The clinicopathological characteristics and overall survival rates of the 2 groups were compared. A Cox proportional hazards regression model was used to investigate the prognostic significance of an elevated platelet count. Results An elevated platelet count was found to be associated with younger age (P = 0.0003), an advanced clinical stage (P < 0.0001), larger tumors (P = 0.0025), lower hemoglobin levels (P < 0.0001), and more frequent treatment failure (P = 0.0015). Multivariate analysis demonstrated that an advanced clinical stage (hazards ratio [HR], 2.93; 95% confidence interval [CI], 1.47-6.70; P = 0.0015), nonsquamous cell carcinoma histology (HR, 2.67; 95% CI, 1.52-4.42; P = 0.0011), larger tumors (HR, 3.86; 95% CI, 2.18-7.03; P < 0.0001), lower hemoglobin levels (HR, 1.99; 95% CI, 1.34-2.93; P = 0.0008), and an elevated platelet count (HR, 1.65; 95% CI, 1.03-2.56; P = 0.0395) were significant predictors of survival. Conclusions An elevated platelet count at the time of the initial diagnosis is an independent prognostic factor in cervical cancer patients who are treated with definitive radiotherapy.	[Kawano, Mahiru; Mabuchi, Seiji; Matsumoto, Yuri; Sasano, Tomoyuki; Takahashi, Ryoko; Kuroda, Hiromasa; Kozasa, Katsumi; Kimura, Tadashi] Osaka Univ, Dept Obstet & Gynecol, Grad Sch Med, Suita, Osaka 5650871, Japan; [Isohashi, Fumiaki; Ogawa, Kazuhiko] Osaka Univ, Dept Radiat Oncol, Grad Sch Med, Suita, Osaka 5650871, Japan	Kawano, M (reprint author), Osaka Univ, Dept Obstet & Gynecol, Grad Sch Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	smabuchi@gyne.med.osaka-u.ac.jp					Chopra V, 1998, CANCER INVEST, V16, P152, DOI 10.3109/07357909809050029; Eifel PJ, 2004, J CLIN ONCOL, V22, P872, DOI 10.1200/JCO.2004.07.197; Borsig L, 2001, P NATL ACAD SCI USA, V98, P3352, DOI 10.1073/pnas.061615598; Nash GF, 2002, LANCET ONCOL, V3, P425, DOI 10.1016/S1470-2045(02)00789-1; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107; ROSS R, 1974, P NATL ACAD SCI USA, V71, P1207, DOI 10.1073/pnas.71.4.1207; Srivani R, 2003, INT J GYNECOL CANCER, V13, P331, DOI 10.1046/j.1525-1438.2003.13197.x; Ma L, 2005, P NATL ACAD SCI USA, V102, P216, DOI 10.1073/pnas.0406682102; Buergy D, 2012, INT J CANCER, V130, P2747, DOI 10.1002/ijc.27441; Mabuchi S, 2010, GYNECOL OBSTET INVES, V69, P224, DOI 10.1159/000273207; Lee M, 2011, GYNECOL ONCOL, V122, P238, DOI 10.1016/j.ygyno.2011.04.012; Labelle M, 2011, CANCER CELL, V20, P576, DOI 10.1016/j.ccr.2011.09.009; Heusinkveld M, 2011, J IMMUNOL, V187, P1157, DOI 10.4049/jimmunol.1100889; HERNANDEZ E, 1994, GYNECOL ONCOL, V55, P328, DOI 10.1006/gyno.1994.1300; Wei LH, 2003, ONCOGENE, V22, P1517, DOI 10.1038/sj.onc.1206226; Smorenburg SM, 2001, PHARMACOL REV, V53, P93; Gucer F, 1998, GYNECOL ONCOL, V70, P210, DOI 10.1006/gyno.1998.5078; HERNANDEZ E, 1992, CANCER, V69, P2975, DOI 10.1002/1097-0142(19920615)69:12<2975::AID-CNCR2820691218>3.0.CO;2-A; Tamussino KF, 2001, INT J GYNECOL CANCER, V11, P236, DOI 10.1046/j.1525-1438.2001.01024.x; Stone RL, 2012, NEW ENGL J MED, V366, P610, DOI 10.1056/NEJMoa1110352; Niers TMH, 2007, CRIT REV ONCOL HEMAT, V61, P195, DOI 10.1016/j.critrevonc.2006.07.007; FERDEGHINI M, 1994, ANTICANCER RES, V14, P735; Ajiki W, 2004, JPN J CLIN ONCOL, V34, P352; LOPES A, 1994, CANCER, V74, P90, DOI 10.1002/1097-0142(19940701)74:1<90::AID-CNCR2820740116>3.0.CO;2-0; RODRIGUEZ GC, 1994, OBSTET GYNECOL, V83, P445; Hernandez E, 2000, GYNECOL ONCOL, V78, P137, DOI 10.1006/gyno.2000.5838; Mabuchi S, 2009, GYNECOL ONCOL, V113, P200, DOI 10.1016/j.ygyno.2009.02.008; de Jonge ETM, 1999, INT J GYNECOL CANCER, V9, P198; Boucharaba A, 2004, J CLIN INVEST, V114, P1714, DOI 10.1172/JCI200422123; Allensworth SK, 2013, GYNECOL ONCOL, V130, P499, DOI 10.1016/j.ygyno.2013.05.038; Mabuchi S, 2010, INT J GYNECOL CANCER, V20, P834, DOI 10.1111/IGC.0b013e3181dcadd1; Lin RJ, 2014, BLOOD, V124, P184, DOI 10.1182/blood-2014-03-562538; Riess L., 1872, ARCH ANAT PHYSL WISS, V39, P237	33	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1048-891X	1525-1438		INT J GYNECOL CANCER	Int. J. Gynecol. Cancer	NOV	2015	25	9					1656	1662		10.1097/IGC.0000000000000533		7	Oncology; Obstetrics & Gynecology	Oncology; Obstetrics & Gynecology	CV4AX	WOS:000364208900017		
J	Mabuchi, Y; Yahata, T; Kobayashi, A; Tanizaki, Y; Shiro, M; Ota, N; Yagi, S; Minami, S; Ino, K				Mabuchi, Yasushi; Yahata, Tamaki; Kobayashi, Aya; Tanizaki, Yuko; Shiro, Michihisa; Ota, Nami; Yagi, Shigetaka; Minami, Sawako; Ino, Kazuhiko			Clinicopathologic Factors of Cervical Adenocarcinoma Stages IB to IIB	INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER			English	Article						Adenocarcinoma; Cervical carcinoma; Clinicopathologic factor; Human papillomavirus	RADICAL HYSTERECTOMY; UTERINE CERVIX; ASSOCIATION; GYNECOLOGY; OBSTETRICS; CARCINOMA; CANCER	Objective The aim of this study was to clarify the clinicopathologic factors of stages IB to IIB cervical adenocarcinoma. Methods Several clinicopathologic factors were compared between 35 patients who underwent radical hysterectomy and pelvic lymphadenectomy due to cervical adenocarcinoma stages IB to IIB and 77 patients with squamous cell carcinoma (SCC). Results In patients with adenocarcinoma, univariate analysis demonstrated that International Federation of Gynecology and Obstetrics stage, tumor size, and lymphovascular space invasion were significantly associated with progression-free survival (PFS), whereas FIGO stage, lymphovascular space invasion, and lymph node metastasis were significantly associated with overall survival (OS). However, multivariate analysis revealed that FIGO stage was the only significant factor for PFS in patients with adenocarcinoma. In patients with SCC, univariate analysis demonstrated that FIGO stage and lymph node metastasis were significantly associated with PFS, whereas FIGO stage, lymphovascular space invasion, and lymph node metastasis were significantly associated with OS. Multivariate analysis revealed that lymph node metastasis was the only significant factor for PFS and OS in patients with SCC. In 26 patients who were positive for high-risk human papillomavirus (HPV), including both adenocarcinoma and SCC patients, univariate and multivariate analyses revealed that HPV18 was significantly associated with poorer PFS compared with non-HPV18. There was a significant difference in distribution of HPV genotype between adenocarcinoma and SCC. Conclusions Careful treatment may be necessary for the patients with lymphovascular space invasion in early-stage cervical adenocarcinoma. The presence of HPV18 may have an influence on the prognosis of early-stage cervical carcinoma.	[Mabuchi, Yasushi; Yahata, Tamaki; Kobayashi, Aya; Tanizaki, Yuko; Shiro, Michihisa; Ota, Nami; Yagi, Shigetaka; Minami, Sawako; Ino, Kazuhiko] Wakayama Med Univ, Dept Obstet & Gynecol, Sch Med, Wakayama 6410012, Japan	Mabuchi, Y (reprint author), Wakayama Med Univ, Dept Obstet & Gynecol, Sch Med, 811-1 Kimiidera, Wakayama 6410012, Japan.	booyan@wakayama-med.ac.jp					Sedlis A, 1999, GYNECOL ONCOL, V73, P177, DOI 10.1006/gyno.1999.5387; Burger RA, 1996, J NATL CANCER I, V88, P1361, DOI 10.1093/jnci/88.19.1361; Kim JY, 2011, J GYNECOL ONCOL, V22, P32, DOI 10.3802/jgo.2011.22.1.32; Pilch H, 2001, INT J GYNECOL CANCER, V11, P39, DOI 10.1046/j.1525-1438.2001.011001039.x; Nishiwaki M, 2008, J CLIN MICROBIOL, V46, P1161, DOI 10.1128/JCM.00793-07; Kasamatsu T, 2009, BRIT J CANCER, V100, P1400, DOI 10.1038/sj.bjc.6605048; Nakanishi T, 2000, GYNECOL ONCOL, V79, P289, DOI 10.1006/gyno.2000.5935; Park JY, 2010, BRIT J CANCER, V102, P1692, DOI 10.1038/sj.bjc.6605705; Aoki D, 2014, J OBSTET GYNAECOL RE, V40, P338, DOI 10.1111/jog.12360; Yang Sun-Hye, 2014, Obstet Gynecol Sci, V57, P492, DOI 10.5468/ogs.2014.57.6.492; Yoshida T, 2008, VIRCHOWS ARCH, V455, P253	11	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1048-891X	1525-1438		INT J GYNECOL CANCER	Int. J. Gynecol. Cancer	NOV	2015	25	9					1677	1682		10.1097/IGC.0000000000000542		6	Oncology; Obstetrics & Gynecology	Oncology; Obstetrics & Gynecology	CV4AX	WOS:000364208900020		
J	Kawatsu, L; Lzumi, K; Uchimura, K; Urakawa, M; Ohkado, A; Takahashi, I				Kawatsu, L.; Lzumi, K.; Uchimura, K.; Urakawa, M.; Ohkado, A.; Takahashi, I.			Can social network analysis assist in the prioritisation of contacts in a tuberculosis contact investigation?	INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE			English	Article						TB; social network analysis; contact investigation	RESISTANT TUBERCULOSIS; TRANSMISSION; OUTBREAK	OBJECTIVES: To evaluate the effectiveness of social network analysis (SNA) in prioritising contacts in a tuberculosis (TB) contact investigation. METHOD: We reviewed and analysed patient and contact investigation data from a large outbreak that occurred in Tokyo, Japan, between 2010 and 2012. Relevant data were extracted to create a social matrix, which was then analysed using SNA software to visualise the network and calculate SNA metrics (degree and betweenness) for all patients and contacts. Statistical analyses were conducted to examine whether degree and betweenness centrality scores could prioritise contacts for in-depth investigation by calculating the odds of latent tuberculous infection (LTBI) being diagnosed among contacts with high scores compared to those with low scores. RESULTS: The data on a total of 8 patients and 376 contacts, of whom 56 were diagnosed with LTBI, were analysed. Centrality scores did not show a statistically significant association with the risk of contacts being diagnosed with LTBI. However, contacts with high betweenness scores were more likely to be diagnosed with LTBI than contacts with lower scores (OR 2.88, 95%CI 1.31-5.83, P = 0.007). CONCLUSION: Our results showed the potential of a betweenness score in prioritising contacts during TB contact investigation.	[Kawatsu, L.; Lzumi, K.; Uchimura, K.; Ohkado, A.] Japan Anti TB Assoc, Res Inst TB, Dept Epidemiol & Clin Res, Tokyo 2048533, Japan; [Lzumi, K.; Ohkado, A.] Nagasaki Univ, Grad Sch Biomed Sci, Nagasaki 852, Japan; [Urakawa, M.] RIT JATA, Dept Program Support, Tokyo, Japan; [Takahashi, I.] Shinjuku City Publ Hlth Ctr, Shinjuku Ku, Tokyo, Japan	Kawatsu, L (reprint author), Japan Anti TB Assoc, Res Inst TB, Dept Epidemiol & Clin Res, 3-1-24 Matsuyama, Tokyo 2048533, Japan.	kawatsu@jata.or.jp			Ministry of Health Labor and Welfare, Tokyo, Japan	The study was funded by The Ministry of Health Labor and Welfare, Grant-in-Aid for Scientific Research, Tokyo, Japan.	Ahiko T, 2014, KEKKAKU SESSHOKUSHA; Gandhi NR, 2013, J INFECT DIS, V207, P9, DOI 10.1093/infdis/jis631; Klovdahl AS, 2001, SOC SCI MED, V52, P681, DOI 10.1016/S0277-9536(00)00170-2; Sterling TR, 2000, INT J TUBERC LUNG D, V4, P1066; Bishai WR, 1998, JAMA-J AM MED ASSOC, V280, P1679, DOI 10.1001/jama.280.19.1679; Hollm-Delgado MG, 2009, SOC SCI MED, V69, P747, DOI 10.1016/j.socscimed.2009.06.043; Barnes PF, 1997, JAMA-J AM MED ASSOC, V278, P1159, DOI 10.1001/jama.278.14.1159; STORK D, 1992, GROUP ORGAN MANAGE, V17, P193, DOI 10.1177/1059601192172006; Mohle-Boetani JC, 2002, JAMA-J AM MED ASSOC, V287, P1040, DOI 10.1001/jama.287.8.1040; Rothenberg RB, 1998, SEX TRANSM DIS, V25, P154, DOI 10.1097/00007435-199803000-00009; Asghar RJ, 2009, J URBAN HEALTH, V86, P776, DOI 10.1007/s11524-009-9378-z; Wylie JL, 2005, J INFECT DIS, V191, P899, DOI 10.1086/427661; Cook VJ, 2007, J INFECT DIS, V196, P1517, DOI 10.1086/523109; Gardy JL, 2011, NEW ENGL J MED, V364, P730, DOI 10.1056/NEJMoa1003176; Fitzpatrick LK, 2001, CLIN INFECT DIS, V33, P1801, DOI 10.1086/323671; Cook VJ, 2012, INT J TUBERC LUNG D, V16, P297, DOI 10.5588/ijtld.11.0350; Weis SE, 2002, AM J RESP CRIT CARE, V166, P36, DOI 10.1164/rccm.2109089; KLOVDAHL AS, 1994, SOC SCI MED, V38, P79, DOI 10.1016/0277-9536(94)90302-6; Jackson AD, 2009, INT J TUBERC LUNG D, V13, P486; Anderson LF, 2014, LANCET INFECT DIS, V14, P406, DOI [10.1016/S1473-3099(14)70022-2, 10.1016/S1473-3099(14)20022-2]; Fujiyama Riyo, 2011, Kekkaku, V86, P869; Hanneman R., 2005, INTRO SOCIAL NETWORK; Hernandez-Garduno E, 2002, CAN MED ASSOC J, V167, P349; Lambregts-van Weezenbeek CSB, 2003, INT J TUBERC LUNG D, V7, pS463; McKenzie A, 2007, AM J PUBLIC HEALTH, V97, P470; Nagamine Michiko, 2008, Kekkaku, V83, P379; Reichler MR, 2003, INT J TUBERC LUNG D, V7, pS325; Tamaru Aki, 2013, Kekkaku, V88, P399; VEEN J, 1992, TUBERCLE LUNG DIS, V73, P73, DOI 10.1016/0962-8479(92)90058-R	29	0	0	INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)	PARIS	68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE	1027-3719	1815-7920		INT J TUBERC LUNG D	Int. J. Tuberc. Lung Dis.	NOV	2015	19	11					1293	1299		10.5588/ijtld.15.0378		7	Infectious Diseases; Respiratory System	Infectious Diseases; Respiratory System	CV4XQ	WOS:000364270200006		
J	Hatsuda, K; Takeuchi, M; Ogata, K; Sasaki, Y; Kagawa, T; Nakatsuji, H; Ibaraki, M; Sakaguchi, M; Kurata, M; Hayashi, S				Hatsuda, K.; Takeuchi, M.; Ogata, K.; Sasaki, Y.; Kagawa, T.; Nakatsuji, H.; Ibaraki, M.; Sakaguchi, M.; Kurata, M.; Hayashi, S.			The impact of nutritional state on the duration of sputum positivity of Mycobacterium tuberculosis	INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE			English	Article						body mass index; glucose intolerance; white blood cells	DIABETES-MELLITUS; PULMONARY TUBERCULOSIS; TREATMENT OUTCOMES; PREVALENCE; MORTALITY; DEFICIT; JAPAN	BACKGROUND: The outcome of anti-tuberculosis treatment varies according to patient factors. OBJECTIVE: To retrospectively identify risks related to the extension of time to negative sputum culture (T-n) and to determine their clinical significance. DESIGN: Patients with bacilli susceptible to isoniazid and rifampicin who received initial standard treatment without cessation were recruited into the study. A total of 630 consecutive in-patients were included in the risk development analysis (development cohort) and another 611 consecutive in-patients in the risk validation analysis (validation cohort). RESULTS: Univariate analysis showed that T-n was related to sex, body mass index (BMI), white blood cell count (WBC), serum albumin, fasting blood sugar, haemoglobin A1c, C-reactive protein and total cholesterol levels and sputum smear positivity (SSP). Multivariate analysis showed that BMI, WBC and SSP were significant risk factors related to extended T-n. Optimal cut-offs of BMI and WBC for predicting good (T-n < 46 days) and poor responders (T-n >= 46 days) according to each risk were determined by receiver operating characteristics analysis. Risks were verified with the validation cohort. T-n increased according to the number of risks; the median T-n for patients with three risks was 21 days longer than that of patients with none. CONCLUSION: The nutritional state of a TB patient can be used to predict T-n.	[Hatsuda, K.] Natl Hosp Org, Kinki Chuo Chest Med Ctr, Dept Clin Lab, Sakai, Osaka 5918555, Japan; [Takeuchi, M.; Kurata, M.] Mukogawa Womens Univ, Grad Sch Human Environm Sci, Nishinomiya, Hyogo, Japan; [Ogata, K.; Nakatsuji, H.; Ibaraki, M.; Sakaguchi, M.] Natl Hosp Org, Kinki Chuo Chest Med Ctr, Dept Food & Nutr, Sakai, Osaka 5918555, Japan; [Sasaki, Y.; Kagawa, T.; Hayashi, S.] Natl Hosp Org, Kinki Chuo Chest Med Ctr, Dept Internal Med, Sakai, Osaka 5918555, Japan	Hayashi, S (reprint author), Natl Hosp Org, Kinki Chuo Chest Med Ctr, Kita Ku, 1180 Nagasone Cho, Sakai, Osaka 5918555, Japan.	shayashi@kch.hosp.go.jp			Osaka Tuberculosis Foundation, Osaka, Japan	This study was supported by a Grant-in-Aid from the Osaka Tuberculosis Foundation, Osaka, Japan. The authors are grateful to R Hayashi for her linguistic assistance.	AKAZAWA Y, 1994, DIABETES RES CLIN PR, V24, pS23, DOI 10.1016/0168-8227(94)90223-2; Akhtar M, 2000, MANAGEMENT TUBERCULO, P14; Guler M, 2007, INT J CLIN PRACT, V61, P231, DOI 10.1111/j.1742-1241.2006.01131.x; Alisjahbana B, 2007, CLIN INFECT DIS, V45, P428, DOI 10.1086/519841; Isanaka S, 2012, J NUTR, V142, P350, DOI 10.3945/jn.111.144287; Hernandez-Pando R, 2009, ARCH IMMUNOL THER EX, V57, P355, DOI 10.1007/s00005-009-0042-9; WEINSIER RL, 1979, AM J CLIN NUTR, V32, P418; Pednekar MS, 2008, INT J EPIDEMIOL, V37, P524, DOI 10.1093/ije/dyn001; Kim HJ, 2010, INT J TUBERC LUNG D, V14, P79; Dooley KE, 2009, AM J TROP MED HYG, V80, P634; RILEY RL, 1995, AM J EPIDEMIOL, V142, P3; Kim DK, 2008, EUR RESPIR J, V32, P1031, DOI 10.1183/09031936.00174907; Baker MA, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-81; Dye C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021161; Hayashi S, 2014, INT J TUBERC LUNG D, V18, P84, DOI 10.5588/ijtld.13.0495; Nathan DM, 2009, DIABETES CARE, V32, P1327, DOI 10.2337/dc09-9033; Islam M M, 1999, J Epidemiol, V9, P155; ITO C, 1994, DIABETES RES CLIN PR, V24, pS29, DOI 10.1016/0168-8227(94)90224-0; KUZUYA T, 1994, DIABETES RES CLIN PR, V24, pS15, DOI 10.1016/0168-8227(94)90222-4; Lonnroth K, 2009, INT J EPIDEMIOL, V39, P149; Ministry of Health Labor and Welfare Japan, 2012, CHANG NUMB NEWL REG; Ministry of Health Labor and Welfare Japan, 1999, SUMM ACT REG INF DIS; Ministry of Health Labor and Welfare Japan, 2010, NUMB INC RAT NEWL RE; Ministry of Health Labour and Welfare, 2012, NAT HLTH NUTR SURV; Ministry of Health Law Japan, 2015, DIET REF INT JAP; Omori M, 1998, PRESENT STATUS DIAGN; Taylor Zachary, 2005, MMWR Recomm Rep, V54, P1; World Health Organization, 2013, WHOHTMTB201311; World Health Organization Expert Committee, 1995, WHO TECHN REP SER, V854, P362	29	0	0	INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)	PARIS	68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE	1027-3719	1815-7920		INT J TUBERC LUNG D	Int. J. Tuberc. Lung Dis.	NOV	2015	19	11					1369	1375		10.5588/ijtld.14.0963		7	Infectious Diseases; Respiratory System	Infectious Diseases; Respiratory System	CV4XQ	WOS:000364270200016		
J	Tachibana, H; Iida, S; Kondo, T; Fukuda, H; Takagi, T; Iizuka, J; Hashimoto, Y; Tanabe, K				Tachibana, Hidekazu; Iida, Shoichi; Kondo, Tsunenori; Fukuda, Hironori; Takagi, Toshio; Iizuka, Junpei; Hashimoto, Yasunobu; Tanabe, Kazunari			Possible impact of continuous drainage after minimally invasive partial nephrectomy	INTERNATIONAL UROLOGY AND NEPHROLOGY			English	Article						Drain placement; Partial nephrectomy; Renal neoplasms; Minimally invasive surgery; Continuous drainage	DRESSINGS; PLACEMENT	Postoperative management of minimally invasive partial nephrectomy (MIPN) without drain placement is common, but the effects on patients are unclear. We investigated the impact of no drain placement after MIPN. We retrospectively studied 194 consecutive patients who underwent laparoscopic and robotic partial nephrectomy at one academic center. The study group included 46 evaluable patients without drain placement. The quantity of postoperative fluid collection in the perirenal space was calculated using computed tomography. The preoperative and postoperative serum concentrations of total protein, albumin, neutrophils, lymphocytes, monocytes numbers, and C-reactive protein (CRP) levels in the blood were compared between groups. Drains were placed in 148 (76.3 %) patients who underwent MIPN. The remaining 46 (23.7 %) patients did not have drain placement. Although the average total quantity of fluid discharged from the drain was 214 mL, the average fluid remaining in the perirenal space did not significantly differ with or without drain placement (20.3 vs. 16.8 mL, p = 0.64). The decrease in serum total protein and albumin was significantly greater with drain placement than without (total protein: 18.9 vs. 12.2 %, p < 0.001; and albumin: 24.7 vs. 22 %, p = 0.038). No drain placement also caused markedly greater decreases in lymphocytes and monocytes than did drain placement, whereas neutrophils and CRP did not differ based on drain placement. Analysis of the quantity of fluid collection showed little need for routine drain placement. Not placing a drain after MIPN prevented serum protein loss and possibly accelerated wound-healing immune responses.	[Tachibana, Hidekazu; Iida, Shoichi; Kondo, Tsunenori; Fukuda, Hironori; Takagi, Toshio; Iizuka, Junpei; Hashimoto, Yasunobu; Tanabe, Kazunari] Tokyo Womens Med Univ, Dept Urol, Shinjuku Ku, Tokyo 1628666, Japan	Iida, S (reprint author), Tokyo Womens Med Univ, Dept Urol, Shinjuku Ku, 8-1 Kawada Cho, Tokyo 1628666, Japan.	setogawacho@yahoo.co.jp					Takagi T, 2014, INT J UROL, V21, P880, DOI 10.1111/iju.12462; Poon CM, 2009, JSLS-J SOC LAPAROEND, V13, P625; ABRAMSON DJ, 1976, SURG GYNECOL OBSTET, V143, P285; CERISE EJ, 1970, ANN SURG, V171, P764, DOI 10.1097/00000658-197005000-00016; ROMM S, 1982, PLAST RECONSTR SURG, V70, P397, DOI 10.1097/00006534-198209000-00023; Abaza R, 2013, J UROLOGY, V189, P823, DOI 10.1016/j.juro.2012.08.236; Lane BR, 2013, J UROLOGY, V190, P44, DOI 10.1016/j.juro.2012.12.102; Mir MC, 2014, J UROLOGY, V192, P665, DOI 10.1016/j.juro.2014.03.036; Stawicki SP, 2009, SCAND J SURG, V98, P8; Meeks JJ, 2008, J UROLOGY, V180, P2375, DOI 10.1016/j.juro.2008.08.018; KANNON GA, 1995, DERMATOL SURG, V21, P583; Ubbink DT, 2008, ARCH SURG-CHICAGO, V143, P950, DOI 10.1001/archsurg.143.10.950; EAGLSTEIN WH, 1988, ARCH DERMATOL, V124, P392, DOI 10.1001/archderm.124.3.392; Kosuga T, 2014, ANN SURG ONCOL, V21, P2028, DOI 10.1245/s10434-014-3520-1; Godoy G, 2011, J UROLOGY, V186, P411, DOI 10.1016/j.juro.2011.03.151; Abreu ALD, 2013, J UROLOGY, V189, P462, DOI 10.1016/j.juro.2012.09.039; Diez JA, 1990, HPB SURG, V3; Diez J A, 1990, HPB Surg, V3, P5, DOI 10.1155/1990/37926; Robb I, 1890, ANN SUR, V12, P425; Shiroki R, 2011, JPN J UROL, V102, P679; Zadeh Farahani RM, 2009, J TISSUE VIABILITY, V18, P57, DOI 10.1016/j.jtv.2008.11.005	21	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0301-1623	1573-2584		INT UROL NEPHROL	Int. Urol. Nephrol.	NOV	2015	47	11					1763	1769		10.1007/s11255-015-1094-x		7	Urology & Nephrology	Urology & Nephrology	CV0KY	WOS:000363940800002		
J	Kaneko, T; Arai, M; Ikeda, M; Morita, M; Watanabe, Y; Hirama, A; Shimizu, A; Tsuruoka, S				Kaneko, Tomohiro; Arai, Momoko; Ikeda, Mariko; Morita, Megumi; Watanabe, Yoko; Hirama, Akio; Shimizu, Akira; Tsuruoka, Shuichi			Comparison of immunosuppressive therapies for IgA nephropathy after tonsillectomy: three-course versus one-course steroid pulse combined with mizoribine	INTERNATIONAL UROLOGY AND NEPHROLOGY			English	Article						IgA nephropathy; Tonsillectomy; Steroid pulse; Mizoribine	IMMUNOGLOBULIN-A NEPHROPATHY; RANDOMIZED CONTROLLED-TRIAL; CLINICAL REMISSION; CORTICOSTEROIDS; PREDNISOLONE; COMBINATION; EFFICACY; STAGE; RATS	It has been reported that steroid pulse therapy for IgA nephropathy improves renal prognosis. However, because of the side effects, steroid dose must be restricted to some cases. Treatment effects of steroid on cases already presenting with reduced renal function are unknown. In this study, we performed tonsillectomy in patients with IgA nephropathy and conducted a comparative study about subsequent immunosuppressive therapy. Subjects were patients younger than 70 years of age diagnosed with IgA nephropathy by renal biopsy. Treatment protocols were a single-course steroid pulse combined with mizoribine during a period from August 2006 to June 2010 (Group A; n = 34) and a three-course steroid pulse during a period from July 2010 to March 2013 (Group B; n = 32). Primary end points were excretory amounts of proteinuria, disappearance of proteinuria and hematuria, and exacerbation of renal function. In both the groups, proteinuria decreased significantly 12 months after treatment, and no significant difference in alleviation effects on proteinuria was found between groups. eGFR increased significantly 12 months after treatment in Group A, whereas it tended to decrease in Group B. As for the preservation effect on eGFR, Group A showed significantly higher preservation of eGFR. Similar results were shown in the patients whose eGFR at the start of the treatment was less than 60 mL/min/1.73 m(2). Single-course steroid pulse therapy combined with mizoribine was considered to have a protective effect on the renal function in IgA nephropathy, especially accompanying renal dysfunction.	[Kaneko, Tomohiro; Arai, Momoko; Ikeda, Mariko; Morita, Megumi; Watanabe, Yoko; Hirama, Akio; Tsuruoka, Shuichi] Nippon Med Sch, Div Nephrol, Dept Internal Med, Bunkyo Ku, Tokyo 1138603, Japan; [Shimizu, Akira] Nippon Med Sch, Dept Analyt Human Pathol, Tokyo 1138603, Japan	Kaneko, T (reprint author), Nippon Med Sch, Div Nephrol, Dept Internal Med, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138603, Japan.	tomohiro@nms.ac.jp; takemomoko@nms.ac.jp; maripon0107@yahoo.co.jp; f-megumi@nms.ac.jp; s9100@nms.ac.jp; ahirama@nms.ac.jp; ashimizu@nms.ac.jp; tsuruoka@nms.ac.jp					Xie YS, 2011, AM J MED SCI, V341, P367, DOI 10.1097/MAJ.0b013e318207e02d; Kawamura T, 2013, J NEPHROL, V26, P350, DOI 10.5301/jn.5000151; Kaneko T, 2013, J NIPPON MED SCH, V80, P279; Kwon S, 2013, AM J MED SCI, V345, P274, DOI 10.1097/MAJ.0b013e31828a6a01; Hirsch IB, 1997, ENDOCRIN METAB CLIN, V26, P631, DOI 10.1016/S0889-8529(05)70271-1; Sakuraya K, 2014, J UROLOGY, V191, P1139, DOI 10.1016/j.juro.2013.10.053; Sonda K, 1996, TRANSPLANT P, V28, P3643; Hotta O, 2001, AM J KIDNEY DIS, V38, P736, DOI 10.1053/ajkd.2001.27690; Kobayashi Y, 1996, NEPHRON, V72, P237; Ochi A, 2013, INT UROL NEPHROL, V45, P469, DOI 10.1007/s11255-012-0251-8; Komatsu H, 2008, CLIN J AM SOC NEPHRO, V3, P1301, DOI 10.2215/CJN.00310108; Takahashi S, 2000, BIOCHEM BIOPH RES CO, V274, P87, DOI 10.1006/bbrc.2000.3104; Ikezumi Y, 2011, HISTOPATHOLOGY, V58, P198, DOI 10.1111/j.1365-2559.2011.03742.x; Kaneko T, 2011, CLIN EXP NEPHROL, V15, P73, DOI 10.1007/s10157-010-0356-2; Russo D, 2001, AM J KIDNEY DIS, V38, P18, DOI 10.1053/ajkd.2001.25176; Itoh H, 1999, J BIOL CHEM, V274, P35147, DOI 10.1074/jbc.274.49.35147; Praga M, 2003, J AM SOC NEPHROL, V14, P1578, DOI 10.1097/01.ASN.0000068460.37369.DC; van Staa TP, 2000, RHEUMATOLOGY, V39, P1383, DOI 10.1093/rheumatology/39.12.1383; Yun SI, 2009, J BONE MINER METAB, V27, P140, DOI 10.1007/s00774-008-0019-5; Li PKT, 2006, AM J KIDNEY DIS, V47, P751, DOI 10.1053/a.ajkd.2006.01.017; JULIAN BA, 1993, CONTRIB NEPHROL, V104, P198; Pozzi C, 1999, LANCET, V353, P883, DOI 10.1016/S0140-6736(98)03563-6; Katafuchi R, 2003, AM J KIDNEY DIS, V41, P972, DOI 10.1016/S0272-6386(03)00194-X; Kikuchi Y, 2005, NEPHROL DIAL TRANSPL, V20, P1573, DOI 10.1093/ndt/gfh888; Kawamura T, 2014, NEPHROL DIAL TRANSPL, V29, P1546, DOI 10.1093/ndt/gfu020; Nishitani Y, 2005, KIDNEY INT, V68, P1078, DOI 10.1111/j.1523-1755.2005.00500.x; Ikezumi Y, 2010, AM J NEPHROL, V31, P273, DOI 10.1159/000279163; Ballardie FW, 2002, J AM SOC NEPHROL, V13, P142; Kawasaki Y, 2004, AM J NEPHROL, V24, P576, DOI 10.1159/000082202; Berger J, 1968, J Urol Nephrol (Paris), V74, P694; Berl Tomas, 2009, J Renin Angiotensin Aldosterone Syst, V10, P1, DOI 10.1177/1470320309102747; Ito T, 2015, INT UROL NEPHROL, V47, P131, DOI 10.1007/s11255-014-0850-7	32	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0301-1623	1573-2584		INT UROL NEPHROL	Int. Urol. Nephrol.	NOV	2015	47	11					1823	1830		10.1007/s11255-015-1118-6		8	Urology & Nephrology	Urology & Nephrology	CV0KY	WOS:000363940800011		
J	Sato, Y; White, S; Winter, W				Sato, Yasuhiko; White, Stuart; Winter, Wilhelm			Nuclear dimension and Z-stability	INVENTIONES MATHEMATICAE			English	Article							C-ASTERISK-ALGEBRAS; JIANG-SU ALGEBRA; STAR-ALGEBRAS; INDUCTIVE LIMITS; DECOMPOSITION RANK; CENTRAL-SEQUENCES; CLASSIFICATION; FINITE	Simple, separable, unital, monotracial and nuclear C*-algebras are shown to have finite nuclear dimension whenever they absorb the Jiang-Su algebra Z tensorially. This completes the proof of the Toms-Winter conjecture in the unique trace case. The structure theory of simple nuclear C*-algebras is currently undergoing revolutionary progress, driven by the discovery of regularity properties of various flavours: topological, functional analytic and algebraic. Despite the diverse nature of these regularity properties, they are all satisfied by those classes of C*-algebras which have been successfully classified by K-theoretic data, and they all fail spectacularly for the "exotic" algebras in [30,40] which provide counterexamples to Elliott's classification conjecture. The observation that there are deep connections between these disparate properties was crystallised in the following conjecture of Toms and the third named author.	[Sato, Yasuhiko] Kyoto Univ, Grad Sch Sci, Sakyo Ku, Kyoto 6068502, Japan; [White, Stuart] Univ Glasgow, Sch Math & Stat, Glasgow Q12 8QW, Lanark, Scotland; [Winter, Wilhelm] WWU Munster, Math Inst, D-48149 Munster, Germany	Winter, W (reprint author), WWU Munster, Math Inst, Einsteinstr 62, D-48149 Munster, Germany.	ysato@math.kyoto-u.ac.jp; stuart.white@glasgow.ac.uk; wwinter@uni-muenster.de			JSPS [25887031]; EPSRC [I019227/1-2]; DFG [SFB 878]	Research partially supported by JSPS (the Grant-in-Aid for Research Activity Start-up 25887031), by EPSRC (Grant no. I019227/1-2), and by the DFG (SFB 878).	BLACKADAR B, 1982, J FUNCT ANAL, V45, P297, DOI 10.1016/0022-1236(82)90009-X; HANDELMAN D, 1981, MICH MATH J, V28, P229; Winter W, 2010, ADV MATH, V224, P461, DOI 10.1016/j.aim.2009.12.005; Hirshberg I, 2012, ADV MATH, V230, P1029, DOI 10.1016/j.aim.2012.03.028; MCDUFF D, 1970, P LOND MATH SOC, V21, P443; Winter W, 2010, INVENT MATH, V179, P229, DOI 10.1007/s00222-009-0216-4; VOICULESCU D, 1991, DUKE MATH J, V62, P267, DOI 10.1215/S0012-7094-91-06211-3; WOLFF M, 1994, ARCH MATH, V62, P248, DOI 10.1007/BF01261365; Rordam M, 2010, J REINE ANGEW MATH, V642, P129, DOI 10.1515/CRELLE.2010.039; Ara P, 2011, CONTEMP MATH, V534, P1; Matui H, 2014, DUKE MATH J, V163, P2687, DOI 10.1215/00127094-2826908; Toms AS, 2007, T AM MATH SOC, V359, P3999, DOI 10.1090/S0002-9947-07-04173-6; Toms AS, 2008, ANN MATH, V167, P1029; Rordam M, 2004, INT J MATH, V15, P1065, DOI 10.1142/S0129167X04002661; CONNES A, 1976, ANN MATH, V104, P73, DOI 10.2307/1971057; Winter W, 2014, J REINE ANGEW MATH, V692, P193, DOI 10.1515/crelle-2012-0082; HAAGERUP U, 1985, J FUNCT ANAL, V62, P160, DOI 10.1016/0022-1236(85)90002-3; Blackadar B, 1997, MATH ANN, V307, P343, DOI 10.1007/s002080050039; ELLIOTT GA, 1976, J ALGEBRA, V38, P29, DOI 10.1016/0021-8693(76)90242-8; Kirchberg E, 2005, GEOM FUNCT ANAL, V15, P377, DOI 10.1007/s00039-005-0510-2; Winter W, 2012, INVENT MATH, V187, P259, DOI 10.1007/s00222-011-0334-7; Matui H, 2012, ACTA MATH-DJURSHOLM, V209, P179, DOI 10.1007/s11511-012-0084-4; Winter W, 2011, J NONCOMMUT GEOM, V5, P253, DOI 10.4171/JNCG/74; Coward KT, 2008, J REINE ANGEW MATH, V623, P161, DOI 10.1515/CRELLE.2008.075; Kirchberg E, 2004, INT J MATH, V15, P63, DOI 10.1142/S0129167X04002119; Tikuisis A, 2014, ANAL PDE, V7, P673, DOI 10.2140/apde.2014.7.673; Tikuisis A, 2014, MATH ANN, V358, P729, DOI 10.1007/s00208-013-0951-0; Toms AS, 2009, P NATL ACAD SCI USA, V106, P16942, DOI 10.1073/pnas.0903629106; EFFROS EG, 1978, PAC J MATH, V77, P417; Robert L, 2012, ADV MATH, V231, P2802, DOI 10.1016/j.aim.2012.07.010; Rordam M, 2003, ACTA MATH-DJURSHOLM, V191, P109, DOI 10.1007/BF02392697; RORDAM M, 1991, J FUNCT ANAL, V100, P1, DOI 10.1016/0022-1236(91)90098-P; CHOI MD, 1976, ANN MATH, V104, P585, DOI 10.2307/1970968; Toms AS, 2008, CAN J MATH, V60, P703, DOI 10.4153/CJM-2008-031-6; Jiang XH, 1999, AM J MATH, V121, P359; Kirchberg E, 2006, ABEL SYMP, V1, P175, DOI 10.1007/978-3-540-34197-0_10; Barlak S., 2014, J NONCOMM G IN PRESS; Ciuperca A, 2008, INT MATH RES NOTICES, DOI 10.1093/imrn/rnm158; Elliott G.A., 2014, ARXIV14062382; Haagerup U., 2014, C R MATH ACAD SCI SO, V36, P67; Kirchberg E, 2014, J REINE ANGEW MATH, V695, P175, DOI 10.1515/crelle-2012-0118; Kirchberg E., 1995, P INT C MATH ZUR 199, V1, P943; Lin H., 2008, INT MATH RES PAP IMR, V3; Loring T., 1997, FIELDS I MONOGRAPHS, V8; Rordam M., 2002, CLASSIFICATION NUCL, V126, P1; Sato Y., 2012, ARXIV12093000; Sato Y., 2011, ARXIV11044339; Sinclair A., 2008, LONDON MATH SOC LECT, V351; Szabo G., 2013, P LOND MATH IN PRESS; Takesaki Masamichi, 1979, THEORY OPERATOR ALGE, V1; Toms AS, 2015, INT MATH RES NOTICES, P2702, DOI 10.1093/imrn/rnu001; Winter W., 2009, MUNSTER J MATH, V2, P311; Winter W., 2013, ARXIV13085084	53	1	1	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0020-9910	1432-1297		INVENT MATH	Invent. Math.	NOV	2015	202	2					893	921		10.1007/s00222-015-0580-1		29	Mathematics	Mathematics	CV4GG	WOS:000364224400007		
J	Lee, H; Ueno, T; Saito, N				Lee, Hoonseung; Ueno, Tomonaga; Saito, Nagahiro			The Effect of Electrode Gap Distance on the Synthesis of Carbon Materials by Using Solution Plasma Process	JOM			English	Article							OXYGEN REDUCTION; NANOPARTICLES; GRAPHENE; NANOTUBES; BATTERIES; GRAPHITE; VEHICLES	Carbon nanomaterials were synthesized by using the solution plasma process and the carbon structure was precisely controlled through adjusting electrode gap distances. Transmission electron microscope and diffraction images showed ordered graphitic layers and clear ring patterns when the electrode distance was wider. The measurement of conductive properties has been improved approximately 400 times from 19 k Omega cm to 47 Omega cm, and the C/H ratio from the result of elemental analysis decreased from 0.31 to 0.18 with decreasing resistivity of carbon. These results showed that the electrode distance was an important factor to control the energy input during the synthesis of carbon materials in the plasma/gas zone generated by solution plasma processing and strongly affect the properties of synthesized carbon materials.	[Lee, Hoonseung; Ueno, Tomonaga; Saito, Nagahiro] Nagoya Univ, Grad Sch Engn, Chikusa Ku, Nagoya, Aichi 4648603, Japan; [Ueno, Tomonaga; Saito, Nagahiro] Nagoya Univ, Green Mobil Collaborat Res Ctr, Chikusa Ku, Nagoya, Aichi 4648603, Japan; [Ueno, Tomonaga; Saito, Nagahiro] Japan Sci & Technol Agcy JST, CREST, Tokyo 1020076, Japan	Lee, H (reprint author), Nagoya Univ, Grad Sch Engn, Chikusa Ku, Furo Cho, Nagoya, Aichi 4648603, Japan.	hiro@rd.numse.nagoya-u.ac.jp			Core Research for Evolutional Science and Technology (CREST) of Japan Science and Technology (JST) Agency	This work was supported in part by Core Research for Evolutional Science and Technology (CREST) of Japan Science and Technology (JST) Agency.	Kang J, 2015, RSC ADV, V5, P29131, DOI 10.1039/c5ra04220h; Kim DW, 2015, PHYS CHEM CHEM PHYS, V17, P407, DOI 10.1039/c4cp03868a; [Anonymous], 2006, J IND ENG CHEM; Vaseashta A, 2005, SCI TECHNOL ADV MAT, V6, P312, DOI 10.1016/j.stam.2005.02.018; Ferrari AC, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.075414; Panomsuwan G, 2015, PHYS CHEM CHEM PHYS, V17, P6227, DOI 10.1039/c4cp05995f; Broussely M, 2005, J POWER SOURCES, V146, P90, DOI 10.1016/j.jpowsour.2005.03.172; Scrosati B, 2005, CHEM REC, V5, P286, DOI 10.1002/tcr.20054; SCHABEL MC, 1992, PHYS REV B, V46, P7185, DOI 10.1103/PhysRevB.46.7185; Sinha N, 2005, IEEE T NANOBIOSCI, V4, P180, DOI 10.1109/TNB.2005.850478; Panomsuwan G, 2015, J MATER CHEM A, V3, P9972, DOI 10.1039/c5ta00244c; Lee H, 2014, RSC ADV, V4, P51758, DOI 10.1039/c4ra03253e; Kang J, 2013, CARBON, V60, P292, DOI 10.1016/j.carbon.2013.04.040; Kam NWS, 2005, J AM CHEM SOC, V127, P6021, DOI 10.1021/ja050062v; Bratescu MA, 2011, J PHYS CHEM C, V115, P24569, DOI 10.1021/jp207447c; Lee C, 2008, SCIENCE, V321, P385, DOI 10.1126/science.1157996; Fellner C, 2000, J POWER SOURCES, V85, P229, DOI 10.1016/S0378-7753(99)00344-4; Ajayan PM, 1999, CHEM REV, V99, P1787, DOI 10.1021/cr970102g; Su DS, 2010, CHEMSUSCHEM, V3, P136, DOI 10.1002/cssc.200900182; Stoller MD, 2008, NANO LETT, V8, P3498, DOI 10.1021/nl802558y; Cho SP, 2011, NANOTECHNOLOGY, V22, DOI 10.1088/0957-4484/22/45/455701; Pootawang P, 2012, NANOTECHNOLOGY, V23, DOI 10.1088/0957-4484/23/39/395602; Xu Z, 2012, ACS NANO, V6, P7103, DOI 10.1021/nn3021772; Bechtold D., 1998, 38 P POW SOURC C, P508; Broussely M, 2004, LITHIUM BATTERIES: SCIENCE AND TECHNOLOGY, P645; Chen R.J., 2002, APPL PHYS SCI, V100, P4984; Koehler U., 1997, 32 P INT EN CONV ENG, P93; Li O.L., 2013, J I ELECTROSTAT JPN, V37, P22; Liu J., 2008, CANCER RES, V68, P6652; Nishi Y, 1998, THIRTEENTH ANNUAL BATTERY CONFERENCE ON APPLICATIONS AND ADVANCES, P31, DOI 10.1109/BCAA.1998.653834; Watanaphanit A., 2013, POLYM DEGRAD STABIL, V98, P1072; Watanaphanit A., 2013, RSC ADV, DOI [10.1039/c3ra45029e, DOI 10.1039/C3RA45029E]	32	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1047-4838	1543-1851		JOM-US	JOM	NOV	2015	67	11					2550	2556		10.1007/s11837-015-1660-9		7	Materials Science, Multidisciplinary; Metallurgy & Metallurgical Engineering; Mineralogy; Mining & Mineral Processing	Materials Science; Metallurgy & Metallurgical Engineering; Mineralogy; Mining & Mineral Processing	CV0JG	WOS:000363936400009		
J	Akceoglu, GA; Li, OL; Saito, N				Akceoglu, Garbis Atam; Li, Oi Lun; Saito, Nagahiro			Innovative Graphite Oxide-Cellulose Based Material Specific for Genomic DNA Extraction	JOM			English	Article							DOUBLE-STRANDED DNA; GRAPHENE OXIDE; SAMPLES; FILMS; NANOMATERIALS; VALIDATION; ADSORPTION; COHORT	Extraction of genomic DNA from various types of samples is often challenging for commercial silica spin column. In this study, we proposed graphite oxide (GO)/cellulose composite as an alternative material for genomic DNA extraction. The purity of DNA and extraction efficiency were compared to that of commercial silica product. In this study, the total weight % of GO was fixed at 4.15% in GO/Cellulose composite. Chewed gum, nail clip, cigarette bud paper, animal tissue and hair sample were used as various genomic DNA sources for extraction experiments. Among all types of samples, the extraction efficiencies were 4 to 12 times higher than that of commercial silica spin column. The absorbance ratio of 260 nm to 280 nm (A260/A280) of all samples ranged between 1.6 and 2.0. The results demonstrated that GO/Cellulose composites might serve as an innovative solid support material for genomic DNA extraction.	[Akceoglu, Garbis Atam; Li, Oi Lun; Saito, Nagahiro] Nagoya Univ, Grad Sch Engn, Dept Mat Phys & Energy Engn, Chikusa Ku, Nagoya, Aichi 4648603, Japan; [Li, Oi Lun; Saito, Nagahiro] Nagoya Univ, Green Mobil Collaborat Res Ctr, Chikusa Ku, Nagoya, Aichi 4648603, Japan; [Saito, Nagahiro] Nagoya Univ, Inst Innovat Future Soc, SIDC, Chikusa Ku, Nagoya, Aichi 4648603, Japan	Akceoglu, GA (reprint author), Nagoya Univ, Grad Sch Engn, Dept Mat Phys & Energy Engn, Chikusa Ku, Furo Cho, Nagoya, Aichi 4648603, Japan.	hiro@rd.numse.nagoya-u.ac.jp					Akceoglu G.A., 2015, COLLOIDS B IN PRESS; Khriachtchev LY, 1997, DIAM RELAT MATER, V6, P694, DOI 10.1016/S0925-9635(96)00719-4; Tang LH, 2012, ADV FUNCT MATER, V22, P3083, DOI 10.1002/adfm.201102892; BOOM R, 1990, J CLIN MICROBIOL, V28, P495; Greenspoon SA, 2004, J FORENSIC SCI, V49, P29; Bourke MT, 1999, J FORENSIC SCI, V44, P1046; Eigler S, 2012, CARBON, V50, P3666, DOI 10.1016/j.carbon.2012.03.039; Nii D, 2013, COLLOID SURFACE B, V106, P234, DOI 10.1016/j.colsurfb.2013.01.054; Lei HZ, 2011, NANOSCALE, V3, P3888, DOI 10.1039/c1nr10617a; Premkumar T, 2012, PROG POLYM SCI, V37, P515, DOI 10.1016/j.progpolymsci.2011.08.003; Hansen TVO, 2007, CANCER EPIDEM BIOMAR, V16, P2072, DOI 10.1158/1055-9965.EPI-07-0611; Le Marchand L, 2001, CANCER EPIDEM BIOMAR, V10, P701; Wang Y, 2011, TRENDS BIOTECHNOL, V29, P205, DOI 10.1016/j.tibtech.2011.01.008; Dimiev A, 2012, J AM CHEM SOC, V134, P2815, DOI 10.1021/ja211531y; Pinto AM, 2013, COLLOID SURFACE B, V111, P188, DOI 10.1016/j.colsurfb.2013.05.022; Witt S, 2012, FORENSIC SCI INT-GEN, V6, P539, DOI 10.1016/j.fsigen.2012.01.002; Stanishevsky AV, 1996, DIAM RELAT MATER, V5, P1355, DOI 10.1016/0925-9635(96)00553-5; Goenka S, 2014, J CONTROL RELEASE, V173, P75, DOI 10.1016/j.jconrel.2013.10.017; Castella V, 2006, FORENSIC SCI INT, V156, P70, DOI 10.1016/j.forsciint.2005.11.012; Tang ZW, 2010, SMALL, V6, P1205, DOI 10.1002/smll.201000024; Crouse C, 2005, CROAT MED J, V46, P563; Han DL, 2011, CARBOHYD POLYM, V83, P966, DOI 10.1016/j.carbpol.2010.09.006; Marcano DC, 2010, ACS NANO, V4, P4806, DOI 10.1021/nn1006368; WILSON MR, 1995, INT J LEGAL MED, V108, P68, DOI 10.1007/BF01369907; Dahotre NB, 2004, JOM-US, V56, P35, DOI 10.1007/s11837-004-0287-z; Shao YY, 2010, ELECTROANAL, V22, P1027, DOI 10.1002/elan.200900571; Anslinger Katja, 2005, Legal Medicine, V7, P164, DOI 10.1016/j.legalmed.2005.01.002; Barbaro A., 2011, FORENSIC SCI INT, V3, pe61; Franke N., 2008, FORENSIC SCI INT-GEN, V1, P423, DOI 10.1016/j.fsigss.2007.08.006; Ghatak Souvik, 2013, J Biomol Tech, V24, P224, DOI 10.7171/jbt.13-2404-001; Ip S.C.Y., 2015, SCI JUSTICE; Khriachtchev LY, 1997, NATO ASI 3 HIGH TECH, V38, P309; Stray J., 2009, FORENSIC SCI INT-GEN, V2, P159; Truong L., 2015, OPEN J EPIDEMIOL, V05, P41; Watanabe Yoshihisa, 2003, Leg Med (Tokyo), V5 Suppl 1, pS177, DOI 10.1016/S1344-6223(02)00104-9; Wittmann C., 2005, IMMOBILISATION DNA C, P4	36	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1047-4838	1543-1851		JOM-US	JOM	NOV	2015	67	11					2557	2563		10.1007/s11837-015-1610-6		7	Materials Science, Multidisciplinary; Metallurgy & Metallurgical Engineering; Mineralogy; Mining & Mineral Processing	Materials Science; Metallurgy & Metallurgical Engineering; Mineralogy; Mining & Mineral Processing	CV0JG	WOS:000363936400010		
J	Hai, Y; Liao, LB; Lv, GC; Qin, FX; Mei, LF; Wei, YZ				Hai, Yun; Liao, Libing; Lv, Guocheng; Qin, Faxiang; Mei, Lefu; Wei, Yaozu			Application of Composite Powders Recycled from Graphite Tailings in Styrene-Butadiene Rubber	JOM			English	Article							CARBON-BLACK	With styrene-butadiene rubber (SBR) as matrix and composite powders recycled from graphite tailings as fillers, the influence of the particle size and content of the composite powders on the tensile strength and electrical conductivity of the composite powder-filled SBR were studied. The results showed that composite powder recycled from graphite tailings could reinforce SBR, whose tensile strength was significantly increased with reducing the particle size of the composite powder, but it had little effect on the conductivity of the system. With composite powders as fillers in conjunction with conductive carbon black, the tensile strength and electrical conductivity of the system were greatly improved. The maximum tensile strength of the SBR filled with composite powder and conductive carbon black increased by 47% compared to that of the single composite powder-filled SBR. When the filling content of conductive carbon black was 10 phr and that of composite powder was above 30 phr, the volume resistivity of SBR showed a sharp decline, reaching a minimum about 10(6) Omega cm at 40 phr. All the results indicated that composite powder recycled from graphite tailings can be applied effectively as filler in SBR. It has great economic and environmental benefits.	[Hai, Yun; Liao, Libing; Lv, Guocheng; Mei, Lefu; Wei, Yaozu] China Univ Geosci, Sch Mat Sci & Technol, Beijing 10083, Peoples R China; [Qin, Faxiang] Natl Inst Mat Sci, Nanomat Grp 1D, Tsukuba, Ibaraki 3050047, Japan	Hai, Y (reprint author), China Univ Geosci, Sch Mat Sci & Technol, Beijing 10083, Peoples R China.	lbliao@cugb.edu.cn; guochenglv@cugb.edu.cn			National High Technology Research and Development Program of China ("863" Program) [2012AA062403]; Fundamental Research Funds for the Central Universities [2-9-2014-102]	This research was jointly supported by National High Technology Research and Development Program of China ("863" Program, No. 2012AA062403), and the Fundamental Research Funds for the Central Universities (2-9-2014-102).	Zou H, 2010, J APPL POLYM SCI, V115, P2710, DOI 10.1002/app.29901; MEDALIA AI, 1986, RUBBER CHEM TECHNOL, V59, P432, DOI 10.5254/1.3538209; Rico M, 2008, J HAZARD MATER, V152, P846, DOI 10.1016/j.jhazmat.2007.07.050; Ahmari S, 2013, CONSTR BUILD MATER, V40, P1002, DOI 10.1016/j.conbuildmat.2012.11.069; Kimura H, 2010, J APPL POLYM SCI, V117, P1711, DOI 10.1002/app.32057; Rofer CK, 2000, SCIENCE, V288, P439; Sharma RS, 2001, ENG GEOL, V60, P235, DOI 10.1016/S0013-7952(00)00104-6; RUSCHAU GR, 1992, J APPL PHYS, V72, P953, DOI 10.1063/1.352350; SUMITA M, 1991, POLYM BULL, V25, P265, DOI 10.1007/BF00310802; Wang XT, 2004, NAT MATER, V3, P539, DOI 10.1038/nmat1161; Escocio VA, 2008, INT J POLYM MATER, V57, P374, DOI 10.1080/00914030701420202; Fandrich R, 2007, INT J MINER PROCESS, V84, P310, DOI 10.1016/j.minpro.2006.07.018; Sandmann D., 2013, J MINERAL MAT CHARAC, V1, P285, DOI DOI 10.4236/JMMCE.2013.16043; Shcheglov S.I., 1970, REFRACTORIES, V10, P469; Sichel E.K., 1982, CARBON BLACK POLYM C	15	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1047-4838	1543-1851		JOM-US	JOM	NOV	2015	67	11					2733	2738		10.1007/s11837-015-1492-7		6	Materials Science, Multidisciplinary; Metallurgy & Metallurgical Engineering; Mineralogy; Mining & Mineral Processing	Materials Science; Metallurgy & Metallurgical Engineering; Mineralogy; Mining & Mineral Processing	CV0JG	WOS:000363936400031		
J	Xu, J; Mori, N; Kawashima, S				Xu, Jiang; Mori, Naofumi; Kawashima, Shuichi			L-p-L-q-L-r estimates and minimal decay regularity for compressible Euler-Maxwell equations	JOURNAL DE MATHEMATIQUES PURES ET APPLIQUEES			English	Article						L-p-L-q-L-r estimates; Regularity-loss; Minimal decay regularity; Euler-Maxwell equations	DISSIPATIVE HYPERBOLIC SYSTEMS; TIMOSHENKO SYSTEM; GLOBAL EXISTENCE; SMOOTH SOLUTIONS; BALANCE LAWS; CONVEX ENTROPY; CAUCHY-PROBLEM; BESOV-SPACES; PROPERTY; BEHAVIOR	Due to the dissipative structure of regularity-loss, extra higher regularity than that for the global-in-time existence is usually imposed to obtain the optimal decay rates of classical solutions to dissipative systems. The aim of this paper is to seek the lowest regularity index for the optimal decay rate of L-1(R-n)-L-2(R-n). Consequently, a notion of minimal decay regularity for dissipative systems of regularity-loss is firstly proposed. To do this, we develop a new time-decay estimate of L-p(R-n)-L-q(R-n)-L-r(R-n) type by using the low-frequency and high-frequency analysis in Fourier spaces. As an application, for compressible Euler-Maxwell equations with the weaker dissipative mechanism, it is shown that the minimal decay regularity coincides with the critical regularity for global classical solutions. Moreover, the recent decay property for symmetric hyperbolic systems with non-symmetric dissipation is also extended to be the L-p-version. (C) 2015 Elsevier Masson SAS. All rights reserved.	[Xu, Jiang] Nanjing Univ Aeronaut & Astronaut, Dept Math, Nanjing 211106, Jiangsu, Peoples R China; [Xu, Jiang; Kawashima, Shuichi] Kyushu Univ, Fac Math, Fukuoka 8190395, Japan; [Mori, Naofumi] Kyushu Univ, Grad Sch Math, Fukuoka 8190395, Japan	Xu, J (reprint author), Nanjing Univ Aeronaut & Astronaut, Dept Math, Jiangjun Rd 29, Nanjing 211106, Jiangsu, Peoples R China.	jiangxu_79@nuaa.edu.cn; n-mori@math.kyushu-u.ac.jp; kawashim@math.kyushu-u.ac.jp			National Natural Science Foundation of China [11471158]; Program for New Century Excellent Talents in University [NCET-13-0857]; Fundamental Research Funds for the Central Universities [NE2015005];  [25220702];  [22244009]	J. Xu is partially supported by the National Natural Science Foundation of China (11471158), the Program for New Century Excellent Talents in University (NCET-13-0857) and the Fundamental Research Funds for the Central Universities (NE2015005). He would like to thank Professor Kawashima for giving him much help when he was visiting Kyushu University in Japan. The work is also partially supported by Grant-in-Aid for Scientific Researches (S) 25220702 and (A) 22244009.	Hanouzet B, 2003, ARCH RATION MECH AN, V169, P89, DOI 10.1007/s00205-003-0257-6; Yong WA, 2004, ARCH RATION MECH AN, V172, P247, DOI 10.1007/s00205-003-0304-3; Xu J, 2011, SIAM J MATH ANAL, V43, P2688, DOI 10.1137/100812768; Sugitani Y, 2010, J HYPERBOL DIFFER EQ, V7, P471, DOI 10.1142/S0219891610002207; Duan RJ, 2011, COMMUN PUR APPL MATH, V64, P1497, DOI 10.1002/cpa.20381; Hosono T, 2006, MATH MOD METH APPL S, V16, P1839, DOI 10.1142/S021820250600173X; Dharmawardane PMN, 2012, SIAM J MATH ANAL, V44, P1976, DOI 10.1137/11083900X; Ide K, 2008, MATH MOD METH APPL S, V18, P1001, DOI 10.1142/S0218202508002930; Kawashima S, 2004, ARCH RATION MECH AN, V174, P345, DOI 10.1007/s00205-004-0330-9; Kawashima S, 2009, Z ANAL ANWEND, V28, P1; Xu J, 2013, SIAM J MATH ANAL, V45, P1422, DOI 10.1137/120888673; Xu J, 2014, ARCH RATION MECH AN, V211, P513, DOI 10.1007/s00205-013-0679-8; Tan Z, 2014, J DIFFER EQUATIONS, V257, P2846, DOI 10.1016/j.jde.2014.05.056; Ueda Y, 2012, SIAM J MATH ANAL, V44, P2002, DOI 10.1137/100806515; Duan RJ, 2011, J HYPERBOL DIFFER EQ, V8, P375, DOI 10.1142/S0219891611002421; Dharmawardane PMN, 2013, J HYPERBOL DIFFER EQ, V10, P37, DOI 10.1142/S0219891613500021; Duan RJ, 2012, SIAM J MATH ANAL, V44, P102, DOI 10.1137/110838406; Xu J, 2015, ARCH RATION MECH AN, V218, P275, DOI 10.1007/s00205-015-0860-3; Ide K, 2008, MATH MOD METH APPL S, V18, P647, DOI 10.1142/S0218202508002802; Chen GQ, 2000, TRANSPORT THEOR STAT, V29, P311, DOI 10.1080/00411450008205877; Peng YJ, 2011, SIAM J MATH ANAL, V43, P944, DOI 10.1137/100786927; Liu YQ, 2013, NONLINEAR ANAL-THEOR, V84, P1, DOI 10.1016/j.na.2013.02.005; Ueda Y, 2012, ARCH RATION MECH AN, V205, P239, DOI 10.1007/s00205-012-0508-5; Mori N, 2014, J HYPERBOL DIFFER EQ, V11, P135, DOI 10.1142/S0219891614500039; Bianchini S, 2007, COMMUN PUR APPL MATH, V60, P1559, DOI 10.1002/cpa.20195; KATO T, 1975, ARCH RATION MECH AN, V58, P181, DOI 10.1007/BF00280740; Kawashima S., 1984, THESIS KYOTO U; Kawashima S., 1983, LECT NOTES NUMER APP, V6, P59; Majda A, 1984, COMPRESSIBLE FLUID F; Markowich P.A., 1990, SEMICONDUCTOR EQUATI; Nirenberg L., 1959, ANN SCUOLA NORM SUP, P115; Peng YJ, 2015, J MATH PURE APPL, V103, P39, DOI 10.1016/j.matpur.2014.03.007; Shizuta Y., 1985, HOKKAIDO MATH J, V14, P249; Ueda Y., 2011, METHODS APPL ANAL, V18, P245; Umeda T., 1984, JAPAN J APPL MATH, V1, P435	35	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0021-7824	1776-3371		J MATH PURE APPL	J. Math. Pures Appl.	NOV	2015	104	5					965	981		10.1016/j.matpur.2015.07.001		17	Mathematics, Applied; Mathematics	Mathematics	CV4RM	WOS:000364254200006		
J	Saibi, H; Aboud, E; Gottsmann, J				Saibi, H.; Aboud, E.; Gottsmann, J.			Curie point depth from spectral analysis of aeromagnetic data for geothermal reconnaissance in Afghanistan	JOURNAL OF AFRICAN EARTH SCIENCES			English	Article						Aeromagnetic anomalies; Curie-point depth; Geothermal gradient; Heat flow; Hot spring; Western Afghanistan	MAGNETIC-ANOMALIES; JAPAN; MAP	The geologic setting of Afghanistan has the potential to contain significant mineral, petroleum and geothermal resources. However, much of the country's potential remains unknown due to limited exploration surveys. Here, we present countrywide aeromagnetic data to estimate the Curie point depth (CPD) and to evaluate the geothermal exploration potential. CPD is an isothermal surface at which magnetic minerals lose their magnetization and as such outlines an isotherm of about 580 degrees C. We use spectral analysis on the aeromagnetic data to estimate the CPD spatial distribution and compare our findings with known geothermal fields in the western part of Afghanistan. The results outline four regions with geothermal potential: 1) regions of shallow Curie point depths (similar to 16-21 km) are located in the Helmand basin. 2) regions of intermediate depths (similar to 21-27 km) are located in the southern Helmand basin and the Baluchistan area. 3) Regions of great depths (similar to 25-35 km) are located in the Farad block. 4) Regions of greatest depths (similar to 35-40 km) are located in the western part of the northern Afghanistan platform. The deduced thermal structure in western Afghanistan relates to the collision of the Eurasian and Indian plates, while the shallow CPDs are related to crustal thinning. This study also shows that the geothermal systems are associated with complex magmatic and tectonic association of major intrusions and fault systems. Our results imply geothermal gradients ranging from 14 degrees C/km to 36 degrees C/km and heat-flow values ranging from 36 to 90 mW/m(2) for the study area. (C) 2015 Elsevier Ltd. All rights reserved.	[Saibi, H.] Kyushu Univ, Fac Engn, Dept Earth Resources Engn, Fukuoka 812, Japan; [Aboud, E.] King Abdulaziz Univ, Geohazards Res Ctr, Jeddah 21413, Saudi Arabia; [Aboud, E.] Natl Res Inst Astron & Geophys, Helwan, Egypt; [Gottsmann, J.] Univ Bristol, Dept Earth Sci, Bristol, Avon, England	Saibi, H (reprint author), Kyushu Univ, Fac Engn, Dept Earth Resources Engn, 6-10-1 Hakozaki, Fukuoka 812, Japan.	saibi-hakim@mine.kyushu-u.ac.jp			Royal Society [UF090006]	The authors are grateful to Dr. Daud Shah Saba (Governor of Herat Province, Afghanistan) for geothermal data. J.G. acknowledges support from the Royal Society (UF090006).	OKUBO Y, 1994, J GEOPHYS RES-SOL EA, V99, P22363, DOI 10.1029/94JB01336; Stampolidis A, 2005, SURV GEOPHYS, V26, P461, DOI 10.1007/s10712-005-7886-2; Espinosa-Cardena JM, 2008, J VOLCANOL GEOTH RES, V176, P601, DOI 10.1016/j.jvolgeores.2008.04.014; HAGGERTY SE, 1978, GEOPHYS RES LETT, V5, P105, DOI 10.1029/GL005i002p00105; Dunlop DJ, 2001, PHYS EARTH PLANET IN, V126, P43, DOI 10.1016/S0031-9201(01)00243-6; Maden N, 2010, PURE APPL GEOPHYS, V167, P349, DOI 10.1007/s00024-009-0017-0; SHUEY RT, 1977, GEOPHYS J ROY ASTR S, V50, P75, DOI 10.1111/j.1365-246X.1977.tb01325.x; OKUBO Y, 1985, GEOPHYSICS, V50, P481, DOI 10.1190/1.1441926; Tanaka A, 1999, TECTONOPHYSICS, V306, P461, DOI 10.1016/S0040-1951(99)00072-4; Rajaram M, 2009, EARTH PLANET SC LETT, V281, P147, DOI 10.1016/j.epsl.2009.02.013; Aboud E, 2011, TECTONOPHYSICS, V506, P46, DOI 10.1016/j.tecto.2011.04.010; WASILEWSKI PJ, 1979, GEOPHYS RES LETT, V6, P541, DOI 10.1029/GL006i007p00541; BHATTACHARYYA BK, 1975, J GEOPHYS RES, V80, P4461, DOI 10.1029/JB080i032p04461; Blakely R. J., 1995, POTENTIAL THEORY GRA; Bouligand C., 2009, J GEOPHYS RES, V114, P1, DOI DOI 10.1029/2009113006494; Caine J.S., 1999, FAULTS SUBSURFACE FL; Mihalasky M.J., 2007, 20071214 US GEOL SUR; Musazai A., 1994, RES ULTRABASITES AFG, P127; De Ritis R, 2013, B VOLCANOL, V75, DOI 10.1007/s00445-013-0710-9; Saba D.S., 2004, GEOTHERMAL ENERGY AF; Said Ashan, 2007, 20071247 US GEOL SUR; Schindler J.S., 2002, GEOTIMES; Shareq A., 1980, GEOLOGY MINERAL RESO, P535; Shenwary GS, 2011, 20111055 US GEOL SUR, P8; Stacey F.O., 1977, PHYS EARTH; Tapponnier M., 1981, EARTH PLANET SC LETT, V52, P355; Turcotte D.L., 1982, GEODYNAMICS; U.S. Geological Survey, 2011, 20111055 US GEOL SUR; Wheeler R., 2005, 20051264 USGS	29	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	1464-343X	1879-1956		J AFR EARTH SCI	J. Afr. Earth Sci.	NOV	2015	111						92	99		10.1016/j.jafrearsci.2015.07.019		8	Geosciences, Multidisciplinary	Geology	CU8WD	WOS:000363823900007		
J	Nakajima, S; Caravaggio, F; Boileau, I; Chung, JK; Plitman, E; Gerretsen, P; Wilson, AA; Houle, S; Mamo, DC; Graff-Guerrero, A				Nakajima, Shinichiro; Caravaggio, Fernando; Boileau, Isabelle; Chung, Jun K.; Plitman, Eric; Gerretsen, Philip; Wilson, Alan A.; Houle, Sylvain; Mamo, David C.; Graff-Guerrero, Ariel			Lack of age-dependent decrease in dopamine D-3 receptor availability: a [C-11]-(+)-PHNO and [C-11]-raclopride positron emission tomography study	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						aging; dopamine; D-2 receptor; D-3 receptor; positron emission tomography; [C-11]-(+)-PHNO; [C-11]-Raclopride	HUMAN-BRAIN; SUBSTANTIA-NIGRA; HEALTHY HUMANS; BINDING; PET; DECLINE; COGNITION; DENSITY; AGONIST; LIGAND	Positron emission tomography with antagonist radiotracers has showed that striatal dopamine D-2/3 receptor (D2/3R) availability decreases with age. However, no study has specifically assessed whether D2/3R availability decreases with age in healthy persons as measured with agonist radiotracers. Moreover, it is unknown whether D3R availability changes with age in healthy humans. Thus, we explored the relationship between age and D2/3R availability in healthy humans using the D-3 receptor (D3R)-preferential agonist radiotracer [C-11]-(+)-PHNO (n=72, mean s.d. age = 40 +/- 15, range =18 to 73) and the antagonist [C-11]-Raclopride (n=70, mean s.d. age = 40 +/- 14, range = 18 to 73) (both, n=33). The contribution of D3R to the [C-11]-(+)-PHNO signal varies across regions of interest; the substantia nigra and hypothalamus represent D3R-specific regions, the ventral pallidum, globus pallidus, and ventral striatum represent D2/3R-mixed regions, and the caudate and putamen represent D-2 receptor (D2R)-specific regions. With [C-11]-(+)-PHNO, a negative correlation was observed between age and nondisplaceable. binding potential (BPND) in the caudate (r(70)=-0.32, P=0.005). No correlations were observed in the other regions. With [C-11]-Raclopride, negative correlations were observed between age and BPND in the caudate (r(68)=-0.50, P < 0.001), putamen (r(68)=-0.41, P <0.001), and ventral striatum (r(68)=-0.43, P < 0.001). In conclusion, in contrast with the age-dependent decrease in D2R availability, these findings suggest that D3R availability does not change with age.	[Nakajima, Shinichiro; Caravaggio, Fernando; Chung, Jun K.; Plitman, Eric; Gerretsen, Philip; Mamo, David C.; Graff-Guerrero, Ariel] Ctr Addict & Mental Hlth, Multimodal Imaging Grp, Res Imaging Ctr, Toronto, ON M5T 1R8, Canada; [Nakajima, Shinichiro; Gerretsen, Philip; Mamo, David C.; Graff-Guerrero, Ariel] Ctr Addict & Mental Hlth, Geriatr Mental Hlth Div, Toronto, ON M5T 1R8, Canada; [Nakajima, Shinichiro; Boileau, Isabelle; Gerretsen, Philip; Wilson, Alan A.; Houle, Sylvain; Mamo, David C.; Graff-Guerrero, Ariel] Univ Toronto, Dept Psychiat, Toronto, ON, Canada; [Nakajima, Shinichiro] Keio Univ, Sch Med, Dept Neuropsychiat, Tokyo, Japan; [Caravaggio, Fernando; Chung, Jun K.; Plitman, Eric; Gerretsen, Philip; Wilson, Alan A.] Univ Toronto, Inst Med Sci, Toronto, ON, Canada; [Boileau, Isabelle; Wilson, Alan A.; Houle, Sylvain; Graff-Guerrero, Ariel] Campbell Res Inst, Ctr Addict & Mental Hlth, Toronto, ON, Canada; [Mamo, David C.] Univ Malta, Dept Psychiat, Valletta, Malta	Graff-Guerrero, A (reprint author), Ctr Addict & Mental Hlth, Multimodal Imaging Grp, Res Imaging Ctr, 250 Coll St, Toronto, ON M5T 1R8, Canada.	ariel_graff@yahoo.com.mx			Canadian Institutes of Health Research (CIHR) [MOP-114989, MOP-157739, MOP-97946, MOP 102731]; National Institutes of Health (NIH) [RO1MH084886-01A2]; Ontario Mental Health Foundation (OMHF); Parkinson Society Canada (PSC)	This study was supported by the Canadian Institutes of Health Research (CIHR): MOP-114989, MOP-157739, MOP-97946 MOP 102731; the National Institutes of Health (NIH): RO1MH084886-01A2; the Ontario Mental Health Foundation (OMHF); and Parkinson Society Canada (PSC): 2010-04.	Nakajima S, 2013, EUR NEUROPSYCHOPHARM, V23, P799, DOI 10.1016/j.euroneuro.2013.05.006; Tziortzi AC, 2011, NEUROIMAGE, V54, P264, DOI 10.1016/j.neuroimage.2010.06.044; Ricci A, 1996, NEUROBIOL AGING, V17, P45, DOI 10.1016/0197-4580(95)02029-2; Rinne JO, 1998, NEUROLOGY, V50, P152; Wang Y, 1998, SYNAPSE, V30, P56, DOI 10.1002/(SICI)1098-2396(199809)30:1<56::AID-SYN7>3.0.CO;2-J; Graff-Guerrero A, 2008, HUM BRAIN MAPP, V29, P400, DOI 10.1002/hbm.20392; Pohjalainen T, 1998, AM J PSYCHIAT, V155, P768; Ichise M, 1998, J NUCL MED, V39, P1511; CORDES M, 1994, ANN NEUROL, V36, P667, DOI 10.1002/ana.410360420; Payer DE, 2014, NEUROPSYCHOPHARMACOL, V39, P311, DOI 10.1038/npp.2013.192; Nakano M, 1996, MECH AGEING DEV, V86, P95, DOI 10.1016/0047-6374(95)01680-5; Backman L, 2006, NEUROSCI BIOBEHAV R, V30, P791, DOI 10.1016/j.neubiorev.2006.06.005; VANDYCK CH, 1995, J NUCL MED, V36, P1175; Lane HY, 2008, J PSYCHIATR NEUROSCI, V33, P47; Gunn RN, 1997, NEUROIMAGE, V6, P279, DOI 10.1006/nimg.1997.0303; CORTES R, 1989, NEUROSCIENCE, V28, P263, DOI 10.1016/0306-4522(89)90178-4; Volkow ND, 1998, ANN NEUROL, V44, P143, DOI 10.1002/ana.410440125; Volkow ND, 1996, PSYCHIAT RES-NEUROIM, V67, P11, DOI 10.1016/0925-4927(96)02809-0; WASSEF M, 1981, NEUROSCIENCE, V6, P2125, DOI 10.1016/0306-4522(81)90003-8; WONG DF, 1988, ANN NY ACAD SCI, V515, P203, DOI 10.1111/j.1749-6632.1988.tb32986.x; SEVERSON JA, 1982, J NEUROCHEM, V39, P1623, DOI 10.1111/j.1471-4159.1982.tb07996.x; Inoue M, 2001, LIFE SCI, V69, P1079, DOI 10.1016/S0024-3205(01)01205-X; Kaasinen V, 2000, NEUROBIOL AGING, V21, P683, DOI 10.1016/S0197-4580(00)00149-4; Girgis RR, 2011, NEUROPSYCHOPHARMACOL, V36, P887, DOI 10.1038/npp.2010.228; Wallace DR, 1996, EUR J PHARMACOL, V308, P283, DOI 10.1016/0014-2999(96)00354-8; Wong DF, 1997, J CEREBR BLOOD F MET, V17, P316; Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007; Graff-Guerrero A, 2010, INT J NEUROPSYCHOPH, V13, P273, DOI 10.1017/S1461145709990642; Lammertsma AA, 1996, NEUROIMAGE, V4, P153, DOI 10.1006/nimg.1996.0066; BANNON MJ, 1992, P NATL ACAD SCI USA, V89, P7095, DOI 10.1073/pnas.89.15.7095; KISH SJ, 1995, ANN NEUROL, V38, P260, DOI 10.1002/ana.410380220; Shotbolt P, 2012, J CEREBR BLOOD F MET, V32, P127, DOI 10.1038/jcbfm.2011.115; Uchida H, 2011, INT J GERIATR PSYCH, V26, P1300, DOI 10.1002/gps.2682; DEKEYSER J, 1990, BRAIN RES, V528, P308, DOI 10.1016/0006-8993(90)91672-4; Studholme C, 1997, MED PHYS, V24, P25, DOI 10.1118/1.598130; Mawlawi O, 2001, J CEREBR BLOOD F MET, V21, P1034; Caravaggio F, 2014, NEUROPSYCHOPHARMACOL, V39, P2769, DOI 10.1038/npp.2014.125; Caravaggio F., 2013, BIOL PSYCHIAT, V77, P196; Cole DM, 2011, CEREB CORTEX, V22, P2784; Pieramico V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043901	40	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	NOV	2015	35	11					1812	1818		10.1038/jcbfm.2015.129		7	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	CV4TR	WOS:000364259900013		
J	Gu, YH; Kanazawa, M; Hung, SY; Wang, XY; Fukuda, S; Koziol, JA; del Zoppo, GJ				Gu, Yu-Huan; Kanazawa, Masato; Hung, Stephanie Y.; Wang, Xiaoyun; Fukuda, Shunichi; Koziol, James A.; del Zoppo, Gregory J.			Cathepsin L acutely alters microvessel integrity within the neurovascular unit during focal cerebral ischemia	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						cathepsin L; extracellular matrix; focal ischemia; microglia; microvessel	INVARIANT CHAIN; HEMORRHAGIC TRANSFORMATION; ENDOTHELIAL-CELL; BRAIN ISCHEMIA; PROCATHEPSIN-L; IN-VITRO; EXPRESSION; DEGRADATION; ACTIVATION; PROTEASES	During focal cerebral ischemia, the degradation of microvessel basal lamina matrix occurs acutely and is associated with edema formation and microhemorrhage. These events have been attributed to matrix metalloproteinases (MMPs). However, both known protease generation and ligand specificities suggest other participants. Using cerebral tissues from a non-human primate focal ischemia model and primary murine brain endothelial cells, astrocytes, and microglia in culture, the effects of active cathepsin L have been defined. Within 2 hours of ischemia onset cathepsin L, but not cathepsin B, activity appears in the ischemic core, around microvessels, within regions of neuron injury and cathepsin L expression. In in vitro studies, cathepsin L activity is generated during experimental ischemia in microglia, but not astrocytes or endothelial cells. In the acidic ischemic core, cathepsin L release is significantly increased with time. A novel ex vivo assay showed that cathepsin L released from microglia during ischemia degrades microvessel matrix, and interacts with MMP activity. Hence, the loss of microvessel matrix during ischemia is explained by microglial cathepsin L release in the acidic core during injury evolution. The roles of cathepsin L and its interactions with specific MMP activities during ischemia are relevant to strategies to reduce microvessel injury and hemorrhage.	[Gu, Yu-Huan; Kanazawa, Masato; del Zoppo, Gregory J.] Univ Washington, Sch Med, Dept Med, Div Hematol, Seattle, WA 98104 USA; [Gu, Yu-Huan; Kanazawa, Masato; del Zoppo, Gregory J.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98104 USA; [Kanazawa, Masato] Niigata Univ, Brain Res Inst, Dept Neurol, Niigata 951, Japan; [Hung, Stephanie Y.] Univ Arkansas Med Sci, Coll Med, Dept Surg, Little Rock, AR 72205 USA; [Wang, Xiaoyun] Scripps Translat Sci Inst, Scripps Genom Med, La Jolla, CA USA; [Fukuda, Shunichi] Natl Hosp Org, Kyoto Med Ctr, Dept Neurosurg, Kyoto, Japan; [Koziol, James A.; del Zoppo, Gregory J.] Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	del Zoppo, GJ (reprint author), Univ Washington, Harborview Med Ctr, Sch Med, Dept Med,Div Hematol,Dept Neurol, Box 359756,325 Ninth Ave, Seattle, WA 98104 USA.	grgdlzop@u.washington.edu			NIH [NS 053716, NS 038710]; Astellas Foundation for Research on Metabolic Disorders; Mochida Memorial Foundation	This work was supported by research grants NS 053716 and NS 038710 from the NIH (GJdZ). Support from the Astellas Foundation for Research on Metabolic Disorders and the Mochida Memorial Foundation are gratefully acknowledged. The laboratory also received funds from Mr and Mrs A Gonsalves whom it thanks.	Lecaille F, 2007, PROTEIN SCI, V16, P662, DOI 10.1110/ps.06266607; Hamann GF, 1996, J CEREBR BLOOD F MET, V16, P1373; del Zoppo GJ, 2012, J CEREBR BLOOD F MET, V32, P919, DOI 10.1038/jcbfm.2012.11; SHEAHAN K, 1989, CANCER RES, V49, P3809; Milner R, 2008, STROKE, V39, P191, DOI 10.1161/STROKEAHA.107.486134; Cailhier JF, 2008, J BIOL CHEM, V283, P27220, DOI 10.1074/jbc.M801164200; Boland B, 2004, NEUROBIOL AGING, V25, P83, DOI 10.1016/S0197-4580(03)00034-4; KIRSCHKE H, 1982, BIOCHEM J, V201, P367; Lee B, 2011, J CLIN INVEST, V121, P3005, DOI 10.1172/JCI46358; Kohda Y, 1996, BIOCHEM BIOPH RES CO, V228, P616, DOI 10.1006/bbrc.1996.1706; ISHIDOH K, 1994, FEBS LETT, V352, P281, DOI 10.1016/0014-5793(94)00924-4; Robker RL, 2000, P NATL ACAD SCI USA, V97, P4689, DOI 10.1073/pnas.080073497; GUINEC N, 1993, BIOL CHEM H-S, V374, P1135, DOI 10.1515/bchm3.1993.374.7-12.1135; Haring HP, 1996, J NEUROPATH EXP NEUR, V55, P236, DOI 10.1097/00005072-199602000-00012; Manship BM, 2008, MAR BIOL, V153, P473, DOI 10.1007/s00227-007-0834-6; Godiksen H, 2007, INT J FOOD SCI TECH, V42, P102, DOI 10.1111/j.1365-2621.2006.01254.x; Honey K, 2002, J EXP MED, V195, P1349, DOI 10.1084/jem.20011904; Sun M, 2011, CARDIOVASC RES, V89, P374, DOI 10.1093/cvr/cvq328; Whitelock JM, 1996, J BIOL CHEM, V271, P10079; Heo JH, 1999, J CEREBR BLOOD F MET, V19, P624, DOI 10.1097/00004647-199906000-00005; ROZHIN J, 1994, CANCER RES, V54, P6517; Seyfried DM, 2001, BRAIN RES, V901, P94, DOI 10.1016/S0006-8993(01)02289-2; Ishidoh K, 1998, BIOCHEM BIOPH RES CO, V252, P202, DOI 10.1006/bbrc.1998.9613; Hosomi N, 2001, STROKE, V32, P1341; ASTRUP J, 1977, STROKE, V8, P51; HAMANN GF, 1995, STROKE, V26, P2120; NAKANISHI H, 1994, EXP NEUROL, V126, P119, DOI 10.1006/exnr.1994.1048; Gresser O, 2001, EUR J IMMUNOL, V31, P1813, DOI 10.1002/1521-4141(200106)31:6<1813::AID-IMMU1813>3.0.CO;2-8; van Hinsbergh VWM, 2006, ARTERIOSCL THROM VAS, V26, P716, DOI 10.1161/01.ATV.0000209518.58252.17; Stypmann J, 2002, P NATL ACAD SCI USA, V99, P6234, DOI 10.1073/pnas.092637699; TOMLINSON FH, 1993, STROKE, V24, P2030; Yamashima T, 1998, EUR J NEUROSCI, V10, P1723, DOI 10.1046/j.1460-9568.1998.00184.x; del Zoppo GJ, 2010, J INTERN MED, V267, P156, DOI 10.1111/j.1365-2796.2009.02199.x; Tagaya M, 1997, STROKE, V28, P1245; Nishimura T, 1999, J ANIM SCI, V77, P93; Fukuda S, 2004, STROKE, V35, P998, DOI 10.1161/01.STR.0000119383.76447.05; WANG XK, 1994, MOL CHEM NEUROPATHOL, V23, P103, DOI 10.1007/BF02815404; Felbor U, 2002, P NATL ACAD SCI USA, V99, P7883, DOI 10.1073/pnas.112632299; HAYASHI K, 1992, J CELL BIOL, V119, P945, DOI 10.1083/jcb.119.4.945; Jolivel V, 2015, ACTA NEUROPATHOL, V129, P279, DOI 10.1007/s00401-014-1372-1; Yoshiyama Y, 2000, NEUROSCI LETT, V290, P125, DOI 10.1016/S0304-3940(00)01326-4	41	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	NOV	2015	35	11					1888	1900		10.1038/jcbfm.2015.170		13	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	CV4TR	WOS:000364259900022		
J	Otoki, Y; Nakagawa, K; Kato, S; Miyazawa, T				Otoki, Yurika; Nakagawa, Kiyotaka; Kato, Shunji; Miyazawa, Teruo			MS/MS and LC-MS/MS analysis of choline/ethanolamine plasmalogens via promotion of alkali metal adduct formation	JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES			English	Article						Plasmalogen; Choline plasmalogen; Ethanolamine plasmalogen; Tandem mass spectrometry; Rat tissues	PERFORMANCE LIQUID-CHROMATOGRAPHY; TANDEM MASS-SPECTROMETRY; ALZHEIMERS-DISEASE; ELECTROSPRAY-IONIZATION; PHOSPHOLIPIDS; DEFICIENCY; TISSUES; BRAIN; ACID; PLASMENYLETHANOLAMINE	Tandem mass spectrometry (MS/MS) has been used for the analysis of plasmalogen (Pis), a physiologically important class of vinyl ether-linked phospholipid. However, MS/MS generally causes little fragmentation of Pls, especially choline Pls (PC-Pis). Previous MS/MS studies reported an increased formation of product ions of PC-Pls (and also ethanolamine Pls (PE-Pis)) in the presence of 'alkali metals.' Therefore, use of alkali metals considerably leads to the development of a method for analysis of both PC- and PE-Pls. In this study, this notion was evaluated using quadrupole-time-of-flight MS/MS and liquid chromatography (LC) coupled with MS/MS. Results from MS/MS confirmed that alkali metals (e.g., sodium) produced significant fragmentation of PC-Pls and PE-Pls. A number of structure-diagnostic product ions exhibiting high intensities were observed under optimized MS/MS conditions using alkali metals. Moreover, the ability to selectively and sensitively identify PC-Pls and PE-Pls at the molecular species level in biological samples (rat brain and heart) was demonstrated using LC-MS/MS. Therefore, the herein developed method appears to be a powerful tool for analyzing Pls and may provide a better understanding of their physiological roles in vivo. (C) 2015 Elsevier B.V. All rights reserved.	[Otoki, Yurika; Nakagawa, Kiyotaka; Kato, Shunji; Miyazawa, Teruo] Tohoku Univ, Grad Sch Agr Sci, Food & Biodynam Chem Lab, Aoba Ku, Sendai, Miyagi 9818555, Japan; [Miyazawa, Teruo] Tohoku Univ, Food Biotechnol Innovat Project NICHe, Sendai, Miyagi 9808579, Japan	Nakagawa, K (reprint author), Tohoku Univ, Grad Sch Agr Sci, Food & Biodynam Chem Lab, Aoba Ku, 1-1 Tsutsumidori Amamiyamachi, Sendai, Miyagi 9818555, Japan.	nkgw@m.tohoku.ac.jp					Reiss D, 1997, BIOCHEM J, V323, P807; MURPHY EJ, 1993, LIPIDS, V28, P565, DOI 10.1007/BF02536090; Goodenowe DB, 2007, J LIPID RES, V48, P2485, DOI 10.1194/jlr.M700023-JLR200; Hsu FF, 2003, J MASS SPECTROM, V38, P752, DOI 10.1002/jms.491; Igarashi M, 2011, J ALZHEIMERS DIS, V24, P507, DOI 10.3233/JAD-2011-101608; Yamashita S, 2014, J OLEO SCI, V63, P423, DOI 10.5650/jos.ess13188; Huczynski A, 2006, BIOPOLYMERS, V82, P491, DOI 10.1002/bip.20502; FOLCH J, 1957, J BIOL CHEM, V226, P497; HEYMANS HSA, 1983, NATURE, V306, P69, DOI 10.1038/306069a0; Brites P, 2004, BBA-MOL CELL BIOL L, V1636, P219, DOI 10.1016/j.bbalip.2003.12.010; Dacremont G, 1995, J INHERIT METAB DIS, V18, P84, DOI 10.1007/BF00711431; Donato P, 2012, MASS SPECTROM REV, V31, P523, DOI 10.1002/mas.20353; HERMETTER A, 1989, BIOCHIM BIOPHYS ACTA, V978, P151, DOI 10.1016/0005-2736(89)90510-5; GINSBERG L, 1995, BRAIN RES, V698, P223, DOI 10.1016/0006-8993(95)00931-F; Braverman NE, 2012, BBA-MOL BASIS DIS, V1822, P1442, DOI 10.1016/j.bbadis.2012.05.008; Hsu FF, 2000, J MASS SPECTROM, V35, P596; FORD DA, 1989, P NATL ACAD SCI USA, V86, P3479, DOI 10.1073/pnas.86.10.3479; Rezanka T, 2011, LIPIDS, V46, P765, DOI 10.1007/s11745-011-3556-y; ZOELLER RA, 1988, J BIOL CHEM, V263, P11590; Yang K, 2009, J CHROMATOGR B, V877, P2924, DOI 10.1016/j.jchromb.2009.01.016; Han XL, 1995, J AM SOC MASS SPECTR, V6, P1202, DOI 10.1016/1044-0305(95)00568-4; Mawatari S, 2007, ANAL BIOCHEM, V370, P54, DOI 10.1016/j.ab.2007.05.020; Han XL, 2001, J NEUROCHEM, V77, P1168, DOI 10.1046/j.1471-4159.2001.00332.x; GLASER PE, 1994, BIOCHEMISTRY-US, V33, P5805, DOI 10.1021/bi00185a019; Nishimukai M, 2014, CLIN CHIM ACTA, V437, P147, DOI 10.1016/j.cca.2014.07.024; PANGANAM.RV, 1971, CHEM PHYS LIPIDS, V6, P97, DOI 10.1016/0009-3084(71)90031-4; Tajima Y, 2013, LIPIDS HEALTH DIS, V12, DOI 10.1186/1476-511X-12-68; Zemski B.K.A., 2004, J AM SOC MASS SPECTR, V15, P1499	28	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1570-0232	1873-376X		J CHROMATOGR B	J. Chromatogr. B	NOV 1	2015	1004						85	92		10.1016/j.jchromb.2015.09.012		8	Biochemical Research Methods; Chemistry, Analytical	Biochemistry & Molecular Biology; Chemistry	CV4OL	WOS:000364246300012		
J	Markle, J; Okada, S; Deenick, E; Mele, F; Averbuch, D; Lagos, M; Gonzalez, M; Alzahrani, M; Soudais, C; Henderson, L; Deswarte, C; Jabot-Hanin, F; Martinez-Barricarte, R; Itan, Y; Boisson, B; Cooper, A; Picard, C; Abel, L; Notarangelo, L; Boisson-Dupuis, S; Puel, A; Sallusto, F; Bustamante, J; Tangye, S; Casanova, JL				Markle, Janet; Okada, Satoshi; Deenick, Elissa; Mele, Federico; Averbuch, Dina; Lagos, Macarena; Gonzalez, Marcela; Alzahrani, Mohammed; Soudais, Claire; Henderson, Lauren; Deswarte, Caroline; Jabot-Hanin, Fabienne; Martinez-Barricarte, Ruben; Itan, Yuval; Boisson, Bertrand; Cooper, Andrea; Picard, Capucine; Abel, Laurent; Notarangelo, Luigi; Boisson-Dupuis, Stephanie; Puel, Anne; Sallusto, Federica; Bustamante, Jacinta; Tangye, Stuart; Casanova, Jean-Laurent			Impairment of IL-17A/F Immunity to Candida and IFN-g Immunity to Mycobacterium in Patients with RORC Deficiency	JOURNAL OF CLINICAL IMMUNOLOGY			English	Meeting Abstract	4th Meeting of the Latin-American-Society-for-Immunodeficiencies (LASID)	NOV 18-21, 2015	Buenos Aires, ARGENTINA	Latin Amer Soc Immunodeficiencies					[Markle, Janet; Martinez-Barricarte, Ruben; Itan, Yuval; Boisson, Bertrand; Picard, Capucine; Abel, Laurent; Boisson-Dupuis, Stephanie; Puel, Anne; Bustamante, Jacinta; Casanova, Jean-Laurent] Rockefeller Univ, St Giles Lab Human Genet Infect Dis, Rockefeller Branch, New York, NY 10021 USA; [Okada, Satoshi] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Pediat, Hiroshima, Japan; [Deenick, Elissa; Tangye, Stuart] St Vincents Hosp, Garvan Inst Med Res, Div Immunol, Darlinghurst, NSW 2010, Australia; [Deenick, Elissa; Tangye, Stuart] Univ NSW Australia, St Vincents Clin Sch, Sydney, NSW, Australia; [Mele, Federico; Sallusto, Federica] Univ Svizzera Italiana, Inst Res Biomed, Bellinzona, Switzerland; [Averbuch, Dina] Hadassah Univ Hosp, Dept Pediat, IL-91120 Jerusalem, Israel; [Lagos, Macarena; Gonzalez, Marcela] Univ Valparaiso, Sch Med, Dept Immunol, Valparaiso, Chile; [Lagos, Macarena; Gonzalez, Marcela] Padre Hurtado Hosp, Dept Pediat, Santiago, Chile; [Lagos, Macarena; Gonzalez, Marcela] Clin Alemana, Santiago, Chile; [Alzahrani, Mohammed] King Faisal Specialist Hosp & Res Ctr, Dept Pediat, Riyadh 11211, Saudi Arabia; [Soudais, Claire] Inst Curie, INSERM, U932, Paris, France; [Henderson, Lauren; Notarangelo, Luigi] Boston Childrens Hosp, Div Immunol, Boston, MA USA; [Deswarte, Caroline; Jabot-Hanin, Fabienne] Imagine Inst, Lab Human Genet Infect Dis, INSERM, Necker Branch,UMR 1163, Paris, France; [Deswarte, Caroline; Jabot-Hanin, Fabienne; Picard, Capucine; Abel, Laurent; Boisson-Dupuis, Stephanie; Puel, Anne; Bustamante, Jacinta; Casanova, Jean-Laurent] Paris Descartes Univ, Imagine Inst, Paris, France; [Cooper, Andrea] Trudeau Inst Inc, Saranac Lake, NY USA; [Picard, Capucine; Abel, Laurent; Boisson-Dupuis, Stephanie; Puel, Anne; Bustamante, Jacinta; Casanova, Jean-Laurent] Imagine Inst, INSERM, UMR 1163, Necker Branch, Paris, France; [Picard, Capucine; Casanova, Jean-Laurent] Necker Hosp Sick Children, Pediat Hematol Immunol Unit, Paris, France; [Picard, Capucine; Bustamante, Jacinta] Necker Hosp Sick Children, Paris AP HP, Ctr Study Primary Immunodeficiencies, Paris, France; [Notarangelo, Luigi] Childrens Hosp, Manton Ctr Orphan Dis Res, Boston, MA 02115 USA; [Casanova, Jean-Laurent] Howard Hughes Med Inst, New York, NY USA								0	0	0	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0271-9142	1573-2592		J CLIN IMMUNOL	J. Clin. Immunol.	NOV	2015	35			1		PL033	S13	S14				2	Immunology	Immunology	CV0XR	WOS:000363977700030		
J	Huang, ZP; Kataoka, M; Chen, JH; Wu, GZ; Ding, J; Nie, M; Lin, ZQ; Liu, JM; Hu, XY; Ma, LX; Zhou, B; Wakimoto, H; Zeng, CY; Kyselovic, J; Deng, ZL; Seidman, CE; Seidman, JG; Pu, WT; Wang, DZ				Huang, Zhan-Peng; Kataoka, Masaharu; Chen, Jinghai; Wu, Gengze; Ding, Jian; Nie, Mao; Lin, Zhiqiang; Liu, Jianming; Hu, Xiaoyun; Ma, Lixin; Zhou, Bin; Wakimoto, Hiroko; Zeng, Chunyu; Kyselovic, Jan; Deng, Zhong-Liang; Seidman, Christine E.; Seidman, J. G.; Pu, William T.; Wang, Da-Zhi			Cardiomyocyte-enriched protein CIP protects against pathophysiological stresses and regulates cardiac homeostasis	JOURNAL OF CLINICAL INVESTIGATION			English	Article							EMBRYONIC STEM-CELLS; HEART-FAILURE; HYPERTROPHY; MECHANISMS; VECTORS; DISEASE; MODELS; MICE	Cardiomyopathy is a common human disorder that is characterized by contractile dysfunction and cardiac remodeling. Genetic mutations and altered expression of genes encoding many signaling molecules and contractile proteins are associated with cardiomyopathy; however, how cardiomyocytes sense pathophysiological stresses in order to then modulate cardiac remodeling remains poorly understood. Here, we have described a regulator in the heart that harmonizes the progression of cardiac hypertrophy and dilation. We determined that expression of the myocyte-enriched protein cardiac ISL1-interacting protein (CIP, also known as MLIP) is reduced in patients with dilated cardiomyopathy. As CIP is highly conserved between human and mouse, we evaluated the effects of CIP deficiency on cardiac remodeling in mice. Deletion of the CIP-encoding gene accelerated progress from hypertrophy to heart failure in several cardiomyopathy models. Conversely, transgenic and AAV-mediated CIP overexpression prevented pathologic remodeling and preserved cardiac function. CIP deficiency combined with lam in A/C deletion resulted in severe dilated cardiomyopathy and cardiac dysfunction in the absence of stress. Transcriptome analyses of CIP-deficient hearts revealed that the p53- and FOX01-mediated gene networks related to homeostasis are disturbed upon pressure overload stress. Moreover, FOX01 overexpression suppressed stress-induced cardiomyocyte hypertrophy in CIP-deficient cardiomyocytes. Our studies identify CIP as a key regulator of cardiomyopathy that has potential as a therapeutic target to attenuate heart failure progression.	[Huang, Zhan-Peng; Kataoka, Masaharu; Chen, Jinghai; Wu, Gengze; Ding, Jian; Nie, Mao; Lin, Zhiqiang; Liu, Jianming; Hu, Xiaoyun; Ma, Lixin; Zhou, Bin; Pu, William T.; Wang, Da-Zhi] Harvard Univ, Boston Childrens Hosp, Sch Med, Dept Cardiol, Boston, MA 02115 USA; [Kataoka, Masaharu] Keio Univ, Sch Med, Dept Cardiol, Tokyo, Japan; [Wu, Gengze; Zeng, Chunyu] Third Mil Med Univ, Daping Hosp, Dept Cardiol, Chongqing, Peoples R China; [Nie, Mao; Deng, Zhong-Liang] Chongqing Med Univ, Affiliated Hosp 2, Dept Orthopaed Surg, Chongqing, Peoples R China; [Ma, Lixin] Hubei Univ, Coll Life Sci, Wuhan, Peoples R China; [Zhou, Bin] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Nutr Sci, Shanghai, Peoples R China; [Wakimoto, Hiroko; Seidman, Christine E.; Seidman, J. G.] Harvard Univ, Dept Genet, Sch Med, Boston, MA 02115 USA; [Kyselovic, Jan] Comenius Univ, Fac Pharm, Bratislava, Slovakia; [Seidman, Christine E.; Seidman, J. G.] Howard Hughes Med Inst, Chevy Chase, MD USA; [Pu, William T.; Wang, Da-Zhi] Harvard Univ, Harvard Stem Cell Inst, Cambridge, MA 02138 USA	Wang, DZ (reprint author), Harvard Univ, Boston Childrens Hosp, Sch Med, Dept Cardiol, 300 Longwood Ave, Boston, MA 02115 USA.	dwang@enders.tch.harvard.edu	Ding, Jian/F-6996-2015		March of Dimes Foundation; Muscular Dystrophy Association; NIH [HL085635, HL116919, T32HL007572]; Banyu Life Science Foundation International	We thank members of the Wang laboratory for advice and support. Work in the Wang laboratory is supported by the March of Dimes Foundation, the Muscular Dystrophy Association, and the NIH (HL085635, HL116919). M. Kataoka was supported by Banyu Life Science Foundation International. Z.-P. Huang is supported by NIH grant T32HL007572.	Maillet M, 2013, NAT REV MOL CELL BIO, V14, P38, DOI 10.1038/nrm3495; Grieger JC, 2006, NAT PROTOC, V1, P1412, DOI 10.1038/nprot.2006.207; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Ni YG, 2006, CIRCULATION, V114, P1159, DOI 10.1161/CIRCULATIONAHA.106.637124; Hill JA, 2008, NEW ENGL J MED, V358, P1370, DOI 10.1056/NEJMra072139; Nikolova V, 2004, J CLIN INVEST, V113, P357, DOI 10.1172/JCI200419448; Jiao K, 2003, GENE DEV, V17, P2362, DOI 10.1101/gad.1124803; Harvey PA, 2011, J CELL BIOL, V194, P355, DOI 10.1083/jcb.201101100; Sullivan T, 1999, J CELL BIOL, V147, P913, DOI 10.1083/jcb.147.5.913; CLARKE K, 1983, INT J BIOCHEM, V15, P1267, DOI 10.1016/0020-711X(83)90217-3; Xing WB, 2006, CIRC RES, V98, P1089, DOI 10.1161/01.RES.0000218781.23144.3e; Yutzey KE, 2007, CIRCULATION, V115, P792, DOI 10.1161/CIRCULATIONAHA.106.682534; Frey N, 2003, ANNU REV PHYSIOL, V65, P45, DOI 10.1146/annurev.physiol.65.092101.142243; Ahmad F, 2005, ANNU REV GENOM HUM G, V6, P185, DOI 10.1146/annurev.genom.6.080604.162132; Olson EN, 2006, SCIENCE, V313, P1922, DOI 10.1126/science.1132292; Koitabashi N, 2012, NAT REV CARDIOL, V9, P147, DOI 10.1038/nrcardio.2011.172; Ahmad F, 2005, CIRCULATION, V112, P3140, DOI 10.1161/CIRCULATIONAHA.105.550806; Hill JA, 2000, CIRCULATION, V101, P2863; Gao GP, 2005, CURR GENE THER, V5, P285, DOI 10.2174/1566523054065057; Houser SR, 2012, CIRC RES, V111, P131, DOI 10.1161/RES.0b013e3182582523; Prasad KMR, 2011, GENE THER, V18, P43, DOI 10.1038/gt.2010.105; Frey N, 2004, CIRCULATION, V109, P1580, DOI 10.1161/01.CIR.0000120390.68287.BB; Morita H, 2005, J CLIN INVEST, V115, P518, DOI 10.1172/JCI200524351; Xin M, 2013, NAT REV MOL CELL BIO, V14, P529, DOI 10.1038/nrm3619; Huang ZP, 2012, CIRC RES, V110, P818, DOI 10.1161/CIRCRESAHA.111.259663; Hansen GM, 2008, GENOME RES, V18, P1670, DOI 10.1101/gr.078352.108; Ahmady E, 2011, J BIOL CHEM, V286, P19702, DOI 10.1074/jbc.M110.165548; Zhou PZ, 2013, P NATL ACAD SCI USA, V110, P15395, DOI 10.1073/pnas.1304124110; FANBURG BL, 1970, NEW ENGL J MED, V282, P723, DOI 10.1056/NEJM197003262821306; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513	30	0	0	AMER SOC CLINICAL INVESTIGATION INC	ANN ARBOR	35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA	0021-9738	1558-8238		J CLIN INVEST	J. Clin. Invest.	NOV	2015	125	11					4122	4134		10.1172/JCI82423		13	Medicine, Research & Experimental	Research & Experimental Medicine	CV2TL	WOS:000364110000016		
J	Nakashima, H; Kaufmann, JK; Wang, PY; Nguyen, T; Speranza, MC; Kasai, K; Okemoto, K; Otsuki, A; Nakano, I; Fernandez, S; Goins, WF; Grandi, P; Glorioso, JC; Lawler, S; Cripe, TP; Chiocca, EA				Nakashima, Hiroshi; Kaufmann, Johanna K.; Wang, Pin-Yi; Tran Nguyen; Speranza, Maria-Carmela; Kasai, Kazue; Okemoto, Kazuo; Otsuki, Akihiro; Nakano, Ichiro; Fernandez, Soledad; Goins, William F.; Grandi, Paola; Glorioso, Joseph C.; Lawler, Sean; Cripe, Timothy P.; Chiocca, E. Antonio			Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma	JOURNAL OF CLINICAL INVESTIGATION			English	Article							HERPES-SIMPLEX-VIRUS; INNATE ANTIVIRAL RESPONSE; GENE-EXPRESSION; STEM-CELLS; MICROTUBULE REORGANIZATION; NUCLEAR-LOCALIZATION; COMBINATION THERAPY; TEGUMENT PROTEIN; TYPE-1 INFECTION; MAMMALIAN-CELLS	Oncolytic viral (OV) therapy, which uses genetically engineered tumor-targeting viruses, is being increasingly used in cancer clinical trials due to the direct cytolytic effects of this treatment that appear to provoke a robust immune response against the tumor. As OVs enter tumor cells, intrinsic host defenses have the potential to hinder viral replication and spread within the tumor mass. In this report, we show that histone deacetylase 6 (HDAC6) in tumor cells appears to alter the trafficking of post-entry OVs from the nucleus toward lysosomes. In glioma cell lines and glioma-stem-like cells, HDAC6 inhibition (HDAC6i) by either pharmacologic or genetic means substantially increased replication of oncolytic herpes simplex virus type 1 (oHSV). Moreover, HDAC6i increased shuttling of post-entry oHSV to the nucleus. In addition, electron microscopic analysis revealed that post-entry oHSVs are preferentially taken up into glioma cells through the endosomal pathway rather than via fusion at the cell surface. Together, these findings illustrate a mechanism of glioma cell defense against an incoming infection by oHSV and identify possible approaches to enhance oHSV replication and subsequent lysis of tumor cells.	[Nakashima, Hiroshi; Kaufmann, Johanna K.; Tran Nguyen; Speranza, Maria-Carmela; Kasai, Kazue; Lawler, Sean; Chiocca, E. Antonio] Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA; [Wang, Pin-Yi; Cripe, Timothy P.] Nationwide Childrens Hosp, Div Hematol Oncol Blood & Marrow Transplant, Columbus, OH USA; [Okemoto, Kazuo; Nakano, Ichiro] Ohio State Univ, Med Ctr, Dept Neurosurg, Columbus, OH 43210 USA; [Otsuki, Akihiro] Tottori Univ, Fac Med, Div Anesthesiol & Crit Care Med, Yonago, Tottori 683, Japan; [Fernandez, Soledad] Ohio State Univ, Dept Biomed Informat, Columbus, OH 43210 USA; [Goins, William F.; Grandi, Paola; Glorioso, Joseph C.] Univ Pittsburgh, Inst Canc, Dept Neurosurg, Pittsburgh, PA USA	Chiocca, EA (reprint author), PBB-301,75 Francis St, Boston, MA 02115 USA.	eachiocca@partners.org			NCI grant [P01CA163205]	This work was supported by NCI grant P01CA163205.	Ahluwalia MS, 2014, J NEURO-ONCOL, V119, P503, DOI 10.1007/s11060-014-1495-1; Haggarty SJ, 2003, P NATL ACAD SCI USA, V100, P4389, DOI 10.1073/pnas.0430973100; Kambara H, 2005, CANCER RES, V65, P2832, DOI 10.1158/0008-5472.CAN-04-3227; Zilberman Y, 2009, J CELL SCI, V122, P3531, DOI 10.1242/jcs.046813; Husain M, 2014, J VIROL, V88, P11229, DOI 10.1128/JVI.00727-14; Kurozumi K, 2007, J NATL CANCER I, V99, P1768, DOI 10.1093/jnci/djm229; Akella JS, 2010, NATURE, V467, P218, DOI 10.1038/nature09324; Elliott G, 1998, J VIROL, V72, P6448; Janke C, 2014, J CELL BIOL, V206, P461, DOI 10.1083/jcb.201406055; Marks PA, 2010, EXPERT OPIN INV DRUG, V19, P1049, DOI 10.1517/13543784.2010.510514; Donnelly O, 2013, J ROY SOC MED, V106, P310, DOI 10.1177/0141076813494196; FULLER AO, 1987, P NATL ACAD SCI USA, V84, P5454, DOI 10.1073/pnas.84.15.5454; Nicola AV, 2003, J VIROL, V77, P5324, DOI 10.1128/JVI.77.9.5324-5332.2003; Vaughan EE, 2008, MOL THER, V16, P1841, DOI 10.1038/mt.2008.190; Nguyen TLA, 2008, P NATL ACAD SCI USA, V105, P14981, DOI 10.1073/pnas.0803988105; White MC, 2013, CANCER GENE THER, V20, P88, DOI 10.1038/cgt.2012.89; Peruzzi P, 2013, NEURO-ONCOLOGY, V15, P1212, DOI 10.1093/neuonc/not055; Butler KV, 2010, J AM CHEM SOC, V132, P10842, DOI 10.1021/ja102758v; Kotsakis A, 2001, J VIROL, V75, P8697, DOI 10.1128/JVI.75.18.8697-8711.2001; Poon APW, 2003, J VIROL, V77, P12671, DOI 10.1128/JVI.77.23.12671-12678.2003; Lyman MG, 2009, J VIROL, V83, P2058, DOI 10.1128/JVI.01718-08; Kambara H, 2005, CANCER RES, V65, P11255, DOI 10.1158/0008-5472.CAN-05-2278; Ostrom QT, 2014, NEURO-ONCOLOGY, V16, P896, DOI 10.1093/neuonc/nou087; Verhey KJ, 2007, CELL CYCLE, V6, P2152; Chiocca EA, 2008, CURR OPIN MOL THER, V10, P38; Desai P, 1998, J VIROL, V72, P7563; Nusinzon I, 2006, MOL CELL BIOL, V26, P3106, DOI 10.1128/MCB.26.8.3106-3113.2006; Liu TC, 2008, MOL THER, V16, P1041, DOI 10.1038/mt.2008.58; Chiocca EA, 2014, CANCER IMMUNOL RES, V2, P295, DOI 10.1158/2326-6066.CIR-14-0015; Kim DR, 2012, INT J MOL MED, V29, P218, DOI 10.3892/ijmm.2011.831; Garner JA, 2003, ADV DRUG DELIVER REV, V55, P1497, DOI 10.1016/j.addr.2003.07.006; Yedowitz JC, 2005, J VIROL, V79, P4730, DOI 10.1128/JVI.79.8.4730-4743.2005; KOYAMA AH, 1987, MICROBIOL IMMUNOL, V31, P123; Mao P, 2013, P NATL ACAD SCI USA, V110, P8644, DOI 10.1073/pnas.1221478110; Kirkin V, 2009, MOL CELL, V34, P259, DOI 10.1016/j.molcel.2009.04.026; Goins WF, 2014, METHODS MOL BIOL, V1144, P63, DOI 10.1007/978-1-4939-0428-0_5; Wang PY, 2013, GENE THER, V20, P761, DOI 10.1038/gt.2012.93; Krisky DM, 1998, GENE THER, V5, P1593, DOI 10.1038/sj.gt.3300766; Marks PA, 2009, J CELL BIOCHEM, V107, P600, DOI 10.1002/jcb.22185; Matthias P, 2008, CELL CYCLE, V7, P7; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Barua S, 2010, BIOMATERIALS, V31, P5894, DOI 10.1016/j.biomaterials.2010.04.007; Otsuki A, 2008, MOL THER, V16, P1546, DOI 10.1038/mt.2008.155; Chiocca EA, 2014, CANCER RES, V74, P3396, DOI 10.1158/0008-5472.CAN-14-0290; Milne RSB, 2005, J VIROL, V79, P6655, DOI 10.1128/JVI.79.11.6655-6663.2005; Gao YS, 2010, J BIOL CHEM, V285, P11219, DOI 10.1074/jbc.M109.042754; Mak AB, 2012, CELL REP, V2, P951, DOI 10.1016/j.celrep.2012.09.016; Stiles KM, 2010, VIROLOGY, V399, P109, DOI 10.1016/j.virol.2009.12.034; Nicola AV, 2004, J VIROL, V78, P7508, DOI 10.1128/JVI.78.14.7508-7517.2004; Lee JY, 2010, EMBO J, V29, P969, DOI 10.1038/emboj.2009.405; Heldwein EE, 2008, CELL MOL LIFE SCI, V65, P1653, DOI 10.1007/s00018-008-7570-z; Uchida H, 2013, MOL THER, V21, P561, DOI 10.1038/mt.2012.211; Saeki Y, 2001, MOL THER, V3, P591, DOI 10.1006/mthe.2001.0294; Jovasevic V, 2008, J VIROL, V82, P3311, DOI 10.1128/JVI.01919-07; Abaitua F, 2012, J VIROL, V86, P8998, DOI 10.1128/JVI.01209-12; Banerjee I, 2014, SCIENCE, V346, P473, DOI 10.1126/science.1257037; Brencicova E, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2013.00037; Cody JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092919; Kaufmann JK, 2014, NEURO-ONCOLOGY, V16, P334, DOI 10.1093/neuonc/not310; Kovacs Jeffery J, 2004, Novartis Found Symp, V259, P170; Nakashima H, 2015, J BIOL CHEM, V290, P1485, DOI 10.1074/jbc.M114.593871; Reardon DA, 1458, NEURO-ONCOLOGY, V16, P1441; Sturm D, 2014, NAT REV CANCER, V14, P92, DOI 10.1038/nrc3655; Thomas AA, 2014, JAMA NEUROL, V71, P1437, DOI 10.1001/jamaneurol.2014.1701; Valenzuela-Fernandez A, 2005, MOL BIOL CELL, V16, P5445, DOI 10.1091/mbc.E05-04-0354; Valenzuela-Fernandez A, 2008, TRENDS CELL BIOL, V18, P291, DOI 10.1016/j.tcb.2008.04.003	66	0	0	AMER SOC CLINICAL INVESTIGATION INC	ANN ARBOR	35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA	0021-9738	1558-8238		J CLIN INVEST	J. Clin. Invest.	NOV	2015	125	11					4269	4280		10.1172/JCI80713		12	Medicine, Research & Experimental	Research & Experimental Medicine	CV2TL	WOS:000364110000027		
J	Moroi, A; Yoshizawa, K; Iguchi, R; Ikawa, H; Kosaka, A; Hotta, A; Tsutsui, T; Saida, Y; Ueki, K				Moroi, Akinori; Yoshizawa, Kunio; Iguchi, Ran; Ikawa, Hiroumi; Kosaka, Akihiko; Hotta, Asami; Tsutsui, Takamitsu; Saida, Yuriko; Ueki, Koichiro			The amount of mandibular setback influence on occlusal force following sagittal split ramus osteotomy	JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY			English	Article						Amount of setback; Occlusal contact area; Bite force	ORTHOGNATHIC SURGICAL-CORRECTION; CONTACT AREA; BITE FORCE; PROGNATHISM; SURGERY; FIXATION; MORPHOLOGY; ASYMMETRY; PRESSURE; MUSCLES	Purpose: The purpose of this study was to examine the influence between the magnitude of setback in sagittal split ramus osteotomy (SSRO) and occlusal contact area and bite force without relapse after surgery. Patients and methods: Sixty female patients with a diagnosis of mandibular prognathism were divided into 3 groups according to the magnitude of setback: group 1 (<= 5 mm), group 2 (>5 mm but <10 mm), and group 3 (>= 10 mm). All patients underwent skeletal analysis by lateral and frontal cephalogrammetry and measured the occlusal contact area and bite force by the pressure-sensitive system (Dental Prescale, Dental Occlusion Pressuregraph FDP-705; Fuji Photo Film Co., Tokyo, Japan) preoperatively and post-operatively at 1 month, 3 months, 6 months, and 1 year. Results: There were no significant differences in occlusal contact area and bite force between the 3 groups. Only group 3 showed a significant difference in occlusal contact area and bite force between the preoperative and 1-year measurements. Conclusion: The results indicate that the magnitude of setback did not influence the bite force or occlusal contact area in SSRO. (C) 2015 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.	[Moroi, Akinori; Yoshizawa, Kunio; Iguchi, Ran; Ikawa, Hiroumi; Kosaka, Akihiko; Hotta, Asami; Tsutsui, Takamitsu; Saida, Yuriko; Ueki, Koichiro] Univ Yamanashi, Interdisciplinary Grad Sch Med & Engn, Div Med, Dept Oral & Maxillofacial Surg,Chuo Ku, Yamanashi 4093898, Japan	Moroi, A (reprint author), Univ Yamanashi, Interdisciplinary Grad Sch Med & Engn, Div Med, Dept Oral & Maxillofacial Surg,Chuo Ku, 1110 Shimokato, Yamanashi 4093898, Japan.	amoroi@yamanashi.ac.jp					Paeng JY, 2012, J CRANIO MAXILL SURG, V40, P660, DOI 10.1016/j.jcms.2011.11.001; Kim YG, 1997, J ORAL MAXIL SURG, V55, P121, DOI 10.1016/S0278-2391(97)90224-X; Dicker GJ, 2012, INT J ORAL MAX SURG, V41, P1131, DOI 10.1016/j.ijom.2012.03.013; Nagai I, 2001, BRIT J ORAL MAX SURG, V39, P429, DOI 10.1054/bjom.2001.0681; Goto TK, 2008, J ORAL REHABIL, V35, P594, DOI 10.1111/j.1365-2842.2007.01837.x; Moroi A, 2015, INT J ORAL MAX SURG, V44, P971, DOI 10.1016/j.ijom.2015.03.015; Ueki K, 2006, J ORAL MAXIL SURG, V64, P1480, DOI 10.1016/j.joms.2006.03.036; XU JA, 1994, DENTOMAXILLOFAC RAD, V23, P154; FRANCO JE, 1989, J ORAL MAXIL SURG, V47, P451, DOI 10.1016/0278-2391(89)90276-0; Throckmorton GS, 2000, J ORAL MAXIL SURG, V58, P515, DOI 10.1016/S0278-2391(00)90014-4; [Anonymous], 1991, J NATL MED COLL; Iwase M, 2006, INT J ORAL MAX SURG, V35, P1102, DOI 10.1016/j.ijom.2006.08.014; SHIRATSUCHI Y, 1991, J CRANIO MAXILL SURG, V19, P299, DOI 10.1016/S1010-5182(05)80336-1; Ueki K, 2009, ORAL SURG ORAL MED O, V108, P679, DOI 10.1016/j.tripleo.2009.05.042; Ueki K, 2001, INT J ORAL MAX SURG, V30, P490, DOI 10.1054/ijom.2001.0171; Harada K, 2000, J ORAL MAXIL SURG, V58, P370, DOI 10.1016/S0278-2391(00)90913-3; Harada K, 2003, ORAL SURG ORAL MED O, V95, P649, DOI 10.1067/moe.2003.239; Ellis E, 1996, J ORAL MAXIL SURG, V54, P176, DOI 10.1016/S0278-2391(96)90443-7; Mobarak K A, 2000, Int J Adult Orthodon Orthognath Surg, V15, P83; Oh JS, 2015, J CRANIO MAXILL SURG, V43, P186, DOI 10.1016/j.jcms.2014.10.023; Ueki K, 2014, J CRANIOMAXILLOFAC S, V42, P210; Ueki K, 2014, J CRANIO MAXILL SURG, V42, P1808, DOI 10.1016/j.jcms.2014.06.019	22	0	0	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	1010-5182	1878-4119		J CRANIO MAXILL SURG	J. Cranio-MaxilloFac. Surg.	NOV	2015	43	9					1743	1748		10.1016/j.jcms.2015.08.015		6	Dentistry, Oral Surgery & Medicine; Surgery	Dentistry, Oral Surgery & Medicine; Surgery	CV3DM	WOS:000364138600007		
J	Watanuki, S; Honda, H; Minemura, N; Manesh, RS; Raoult, D; Tokuda, Y				Watanuki, Satoshi; Honda, Hitoshi; Minemura, Nobuyoshi; Manesh, Reza Sedighi; Raoult, Didier; Tokuda, Yasuharu			Sutton's Law: Keep Going Where The Money Is	JOURNAL OF GENERAL INTERNAL MEDICINE			English	Article							WHIPPLES-DISEASE		[Watanuki, Satoshi] Tokyo Metropolitan Tama Med Ctr, Dept Rheumatol, Fuchu, Tokyo 1838524, Japan; [Honda, Hitoshi] Tokyo Metropolitan Tama Med Ctr, Div Infect Dis, Fuchu, Tokyo 1838524, Japan; [Minemura, Nobuyoshi] Nagoya Med Ctr, Div Rheumatol, Nagoya, Aichi, Japan; [Manesh, Reza Sedighi] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Raoult, Didier] Unite Rickettsies, Fac Med, Marseille, France; [Tokuda, Yasuharu] Japan Community Healthcare Org, Tokyo, Japan	Watanuki, S (reprint author), Tokyo Metropolitan Tama Med Ctr, Dept Rheumatol, Fuchu, Tokyo 1838524, Japan.	sat.watanuki@gmail.com					Coderre S, 2003, MED EDUC, V37, P695, DOI 10.1046/j.1365-2923.2003.01577.x; Whipple GH, 1907, B JOHNS HOPKINS HOSP, V18, P382; Fenollar F, 2007, NEW ENGL J MED, V356, P55, DOI 10.1056/NEJMra062477; Schneider T, 2008, LANCET INFECT DIS, V8, P179, DOI 10.1016/S1473-3099(08)70042-2; PETERSDORF R, 1961, MEDICINE, V40, P1, DOI 10.1097/00005792-196102000-00001; Fenollar F, 2014, J INFECTION, V69, P103, DOI 10.1016/j.jinf.2014.05.008	6	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0884-8734	1525-1497		J GEN INTERN MED	J. Gen. Intern. Med.	NOV	2015	30	11					1711	1715		10.1007/s11606-015-3425-0		5	Health Care Sciences & Services; Medicine, General & Internal	Health Care Sciences & Services; General & Internal Medicine	CU7LT	WOS:000363721100037		
J	Frost, AE; Barst, RJ; Hoeper, MM; Chang, HJ; Frantz, RP; Fukumoto, Y; Galie, N; Hassoun, PM; Klose, H; Matsubara, H; Morrell, NW; Peacock, AJ; Pfeifer, M; Simonneau, G; Tapson, VF; Torres, F; Vizza, CD; Lawrence, D; Yang, W; Felser, JM; Quinn, DA; Ghofrani, HA				Frost, Adaani E.; Barst, Robyn J.; Hoeper, Marius M.; Chang, Hyuk-Jae; Frantz, Robert P.; Fukumoto, Yoshihiro; Galie, Nazzareno; Hassoun, Paul M.; Klose, Hans; Matsubara, Hiromi; Morrell, Nicholas W.; Peacock, Andrew J.; Pfeifer, Michael; Simonneau, Gerald; Tapson, Victor F.; Torres, Fernando; Vizza, Carmine Dario; Lawrence, David; Yang, Wei; Felser, James M.; Quinn, Deborah A.; Ghofrani, Hossein-Ardeschir			Long-term safety and efficacy of imatinib in pulmonary arterial hypertension	JOURNAL OF HEART AND LUNG TRANSPLANTATION			English	Article						pulmonary arterial hypertension; imatinib; safety; long-term; efficacy	GROWTH-FACTOR EXPRESSION; 6-MINUTE WALK TEST; CONTROLLED-TRIAL; DOUBLE-BLIND; OPEN-LABEL; THERAPY; TREPROSTINIL; SURVIVAL; MESYLATE; PROSTACYCLIN	BACKGROUND: Imatinib is an oral inhibitor of several protein kinases implicated in the pathophysiology of pulmonary hypertension. Treatment with imatinib resulted in improved hemodynamics and exercise capacity in a controlled trial (Imatinib [QTI571] in Pulmonary Arterial Hypertension, a Randomized Efficacy Study [IMPRES]), among pulmonary arterial hypertension (PAH) patients inadequately responsive to 2 to 3 PAH-specific therapies. METHODS: The long-term (up to 204 weeks) safety and efficacy of imatinib in this open-label extension study were reviewed until early study termination on April 16, 2014. Of 202 IMPRES-enrolled patients, 66 imatinib and 78 placebo recipients entered the extension. RESULTS: Overall, 93.8% (135 of 144) of patients discontinued the extension study; administrative issues (i.e., sponsor termination; 32.6%) and adverse events (31.3%) were the primary 'reasons for discontinuation. Nine patients completed the extension study before it was terminated. Serious and unexpected adverse events were frequent. These included 6 subdural hematomas in the extension study and 17 deaths during or within 30 days of study end. Although the patients who tolerated imatinib and remained in the extension for a longer duration did experience an improvement in functional class and walk distance, most discontinued the drug and the study. CONCLUSIONS: Severe adverse events, significant side effects, and a high discontinuation rate limit the utility of imatinib in the treatment of PAH. These risks outweigh any possible improvements in hemodynamics and walk distance seen in those patients able to remain on drug. The off-label use of this compound in PAH is discouraged. (C) 2015 International Society for Heart and Lung Transplantation. All rights reserved.	[Frost, Adaani E.] Baylor Coll Med, Houston, TX 77030 USA; [Frost, Adaani E.] Houston Methodist Hosp, Lung Ctr, Houston, TX 77030 USA; [Barst, Robyn J.] Columbia Univ, Coll Phys & Surg, New York, NY USA; [Hoeper, Marius M.] Hannover Med Sch, Dept Resp Med, D-30623 Hannover, Germany; [Hoeper, Marius M.] German Ctr Lung Res DZL, Hannover, Germany; [Chang, Hyuk-Jae] Yonsei Univ Hlth Syst, Severance Cardiovasc Hosp, Div Cardiol, Seoul, South Korea; [Frantz, Robert P.] Mayo Clin, Coll Med, Div Cardiovasc Dis & Internal Med, Rochester, MN USA; [Fukumoto, Yoshihiro] Tohoku Univ, Grad Sch Med, Dept Cardiovasc Med, Sendai, Miyagi 980, Japan; [Galie, Nazzareno] Univ Bologna, Dept Specialised Expt & Diagnost Med, Bologna, Italy; [Hassoun, Paul M.] Johns Hopkins Univ, John Hopkins Bayview Med Ctr, Baltimore, MD USA; [Klose, Hans] Univ Med Ctr Hamburg, Dept Pulmonol, Hamburg, Germany; [Matsubara, Hiromi] Natl Hosp Org, Okayama Med Ctr, Div Cardiol, Okayama, Japan; [Morrell, Nicholas W.] Univ Cambridge, Sch Clin Med, Dept Med, Addenbrookes & Papworth Hosp, Cambridge, England; Golden Jubilee Natl Hosp, Scottish Pulm Vasc Unit, Glasgow, Lanark, Scotland; [Pfeifer, Michael] Univ Regensburg, Clin Internal Med, D-93053 Regensburg, Germany; [Simonneau, Gerald] Hop Bicetre, Dept Pneumol, Paris, France; [Simonneau, Gerald] Hop Bicetre, ICU, Paris, France; [Tapson, Victor F.] Duke Univ, Med Ctr, Duke Pulm Vasc Dis Ctr, Durham, NC USA; [Torres, Fernando] Univ Texas SW Med Ctr Dallas, SW Adv Lung Dis & Lung Transplant Clin, Dallas, TX USA; [Vizza, Carmine Dario] Univ Roma La Sapienza, Dept Cardiovasc & Resp Dis, Rome, Italy; [Lawrence, David; Yang, Wei; Felser, James M.; Quinn, Deborah A.] Novartis Pharmaceut, Dept Global Clin Dev, E Hanover, NJ USA; [Ghofrani, Hossein-Ardeschir] Univ Giessen, D-35390 Giessen, Germany; [Ghofrani, Hossein-Ardeschir] Univ Hosp Giessen, Marburg Lung Ctr, Giessen, Germany; [Ghofrani, Hossein-Ardeschir] Marburg GmbH, Giessen, Germany	Frost, AE (reprint author), Houston Methodist Hosp, Lung Ctr, Suite 1001,Smith Tower,6550 Fannin, Houston, TX 77030 USA.	afrost@houstonmethodist.org		vizza, carmine dario/0000-0002-3540-4983; Galie, Nazzareno/0000-0003-4271-8670	Novartis Pharrna AG; Actelion; United Therapeutics/Lung LLC; Gilead; Novartis; Bayer; Pfizer; United Therapeutics; Daiichi Sankyo; GlaxoSmithKline; Nippon Shinyaku; Lilly; Bayer-Schering; Lung LLC; Ikaria; Medtronic; Actelion Pharmaceuticals Japan; BMS; Ergonex	Novartis Pharrna AG funded the study and provided writing support for the manuscript.; A.E.F. has received honoraria for consultations and/or speaking about a product or about pulmonary hypertension from Actelion, United Therapeutics/Lung LLC, Gilead, Novartis, Bayer and Pfizer; and grant support from Actelion, United Therapeutics/Lung LLC, Gilead, Novartis, Bayer and Pfizer. R.J.B. (deceased) received honoraria for consultations/scientific advisory board activity from Actelion, Bayer, Lilly, Gilead, GlaxoSmithKline, Ikaria, Merck, Novartis, Pfizer, and VentriPoint Diagnostics. M.M.H. received honoraria for consultations and/or speaking at conferences from Actelion, Bayer, GlaxoSmithKline, Novartis, and Pfizer. R.P.F. has received research funding from United Therapeutics, served on advisory boards for United Therapeutics and Actelion, and has had a consultancy agreement with Pfizer. Y.F. has received lecturer fees from Bayer, Daiichi Sankyo, Pfizer, GlaxoSmithKline, Novartis, and Nippon Shinyaku. N.G. has been involved with Steering Committee activities for Lilly, Actelion, Pfizer, Bayer-Schering, GlaxoSmithKline, and Novartis, has received payment for lecturer fees from Actelion, Lilly, Pfizer, Bayer-Schering, and GlaxoSmithKline, and has also conducted contract research for Actelion, Pfizer, United Therapeutics, Bayer-Schering, and GlaxoSmithKline. P.M.H. has received honoraria for consultations and/or scientific advisory board activities from Gilead, Novartis, and Merck. H.K. has received fees from Actelion, Bayer, GlaxoSmithKline, Novartis, United Therapeutics, and Pfizer, and grant support from Actelion. H.M. has received lecturer fees from GlaxoSmithKline, Actelion Pharmaceuticals Japan, and Nippon Shinyaku. N.W.M. has received a research grant from Novartis. A.J.P. received personal fees from BMS during the conduct of the study and has received honoraria for advisory boards from Actelion, Bayer, GlaxoSmithKline, and United Therapeutics. V.F.T. has received research funds and consulting fees from Actelion, Bayer, Gilead, Lung LLC, United Therapeutics, and research funds only from Novartis. F.T. has received personal fees from Actelion, Gilead, Pfizer, and United Therapeutics, and grant support from Actelion, Gilead, Ikaria, Medtronic, Novartis, Pfizer, and United Therapeutics. C.D.V. has received fees for serving as a speaker, consultant, and an advisory board member from Actelion, Dompe, GlaxoSmithKline, Italfarmaco, Lilly, and Pfizer. W.Y., J.M.F., and D.A.Q. are employees of Novartis and all hold shares with Novartis. D.L. was a Novartis employee at the time the study was conducted. H.A.G. has received grants from Actelion, Bayer, Ergonex, and Pfizer during the conduct of the study; has received personal fees (outside of the submitted work) for board membership from Actelion, Bayer, Ergonex, GlaxoSmithKline, Novartis, and Pfizer, consultancy fees from Actelion, Bayer, Ergonex, Gilead, GlaxoSmithKline, Merck, Novartis, and Pfizer, payment for lectures (including speakers' bureaus) from Actelion, Bayer, Ergonex, Gilead, GlaxoSmithKline, Novartis, and Pfizer, and travel/accommodation/meeting expenses from Actelion, Bayer, Ergonex, GlaxoSmithKline, Merck, Novartis, and Pfizer. H-J.C., M.P. and G.S. do not have a financial	Hoeper MM, 2013, CIRCULATION, V127, P1128, DOI 10.1161/CIRCULATIONAHA.112.000765; Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111; Mathai SC, 2012, AM J RESP CRIT CARE, V186, P428, DOI 10.1164/rccm.201203-0480OC; Gambaryan N, 2011, EUR RESPIR J, V37, P1392, DOI 10.1183/09031936.00045710; Barst RJ, 2003, J AM COLL CARDIOL, V41, P2119, DOI 10.1016/S0735-1097(03)00463-7; Jing ZC, 2013, CIRCULATION, V127, P624, DOI 10.1161/CIRCULATIONAHA.112.124388; DALONZO GE, 1991, ANN INTERN MED, V115, P343; Rubin LJ, 2002, NEW ENGL J MED, V346, P896, DOI 10.1056/NEJMoa012212; Mucke H, 2013, DRUG TODAY, V49, P203, DOI 10.1358/dot.2013.49.3.1937430; Ghofrani HA, 2010, AM J RESP CRIT CARE, V182, P1171, DOI 10.1164/rccm.201001-0123OC; Galie N, 2005, NEW ENGL J MED, V353, P2148, DOI 10.1056/NEJMoa050010; Ghofrani HA, 2005, NEW ENGL J MED, V353, P1412, DOI 10.1056/NEJMc051946; McLaughlin VV, 2010, J AM COLL CARDIOL, V55, P1915, DOI 10.1016/j.jacc.2010.01.027; Ghofrani HA, 2013, NEW ENGL J MED, V369, P330, DOI 10.1056/NEJMoa1209655; Simonneau G, 2002, AM J RESP CRIT CARE, V165, P800, DOI 10.1164/rccm.2106079; Humbert M, 2010, CIRCULATION, V122, P156, DOI 10.1161/CIRCULATIONAHA.109.911818; Galie N, 2008, CIRCULATION, V117, P3010, DOI 10.1161/CIRCULATIONAHA.107.742510; Schermuly RT, 2005, J CLIN INVEST, V115, P2811, DOI 10.1172/JCI24838; Montani D, 2011, AM J RESP CRIT CARE, V184, P116, DOI 10.1164/rccm.201006-0905OC; Olschewski H, 2002, NEW ENGL J MED, V347, P322, DOI 10.1056/NEJMoa020204; Humbert M, 2013, CIRCULATION, V127, P1098, DOI 10.1161/CIRCULATIONAHA.113.001460; Galie N, 2009, CIRCULATION, V119, P2894, DOI 10.1161/CIRCULATIONAHA.108.839274; Benza RL, 2012, CHEST, V142, P448, DOI 10.1378/chest.11-1460; Patterson KC, 2006, ANN INTERN MED, V145, P152; RICH S, 1985, CIRCULATION, V71, P1191; Simonneau G, 2009, J AM COLL CARDIOL, V54, pS43, DOI 10.1016/j.jacc.2009.04.012; Perros F, 2008, AM J RESP CRIT CARE, V178, P81, DOI 10.1164/rccm.200707-1037OC; Tapson VF, 2006, CHEST, V129, P683, DOI 10.1378/chest.129.3.683; Pulido T, 2013, NEW ENGL J MED, V369, P809, DOI 10.1056/NEJMoa1213917; Humbert M, 1998, EUR RESPIR J, V11, P554; Souza R, 2006, THORAX, V61, P736, DOI 10.1136/thx.2006.064097; Song KW, 2004, LEUKEMIA LYMPHOMA, V45, P1633, DOI 10.1080/10428190310001615666; Barst RJ, 1996, NEW ENGL J MED, V334, P296, DOI 10.1056/NEJM199602013340504; Chin KM, 2014, AM HEART J, V167, P218, DOI 10.1016/j.ahj.2013.08.008; McLaughlin V V, 2011, Eur Respir Rev, V20, P262, DOI 10.1183/09059180.00006411	35	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1053-2498	1557-3117		J HEART LUNG TRANSPL	J. Heart Lung Transplant.	NOV	2015	34	11					1366	1375		10.1016/j.healun.2015.05.025		10	Cardiac & Cardiovascular Systems; Respiratory System; Surgery; Transplantation	Cardiovascular System & Cardiology; Respiratory System; Surgery; Transplantation	CV4YW	WOS:000364273400002		
J	Ohkusa, T; Koido, S				Ohkusa, Toshifumi; Koido, Shigeo			Intestinal microbiota and ulcerative colitis	JOURNAL OF INFECTION AND CHEMOTHERAPY			English	Review						Bacteria; Intestinal microbiota; Innate immunity; Inflammatory bowel disease; Ulcerative colitis; Crohn's disease	INFLAMMATORY-BOWEL-DISEASE; ANTIBIOTIC COMBINATION THERAPY; TOLL-LIKE RECEPTOR-2; NEONATAL NECROTIZING ENTEROCOLITIS; MUCOSA-ASSOCIATED MICROBIOTA; BUTYRATE-PRODUCING BACTERIA; ESCHERICHIA-COLI; FECAL MICROBIOTA; CROHNS-DISEASE; KAPPA-B	There is a close relationship between the human host and the intestinal microbiota, which is an assortment of microorganisms, protecting the intestine against colonization by exogenous pathogens. Moreover, the intestinal microbiota play a critical role in providing nutrition and the modulation of host immune homeostasis. Recent reports indicate that some strains of intestinal bacteria are responsible for intestinal ulceration and chronic inflammation in inflammatory bowel diseases (IBD) such as ulcerative colitis (UC) and Crohn's disease (CD). Understanding the interaction of the intestinal microbiota with pathogens and the human host might provide new strategies treating patients with IBD. This review focuses on the important role that the intestinal microbiota plays in maintaining innate immunity in the pathogenesis and etiology of UC and discusses new antibiotic therapies targeting the intestinal microbiota. (C) 2015, Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.	[Ohkusa, Toshifumi; Koido, Shigeo] Jikei Univ, Kashiwa Hosp, Dept Gastroenterol & Hepatol, Kashiwa, Chiba 2778567, Japan	Ohkusa, T (reprint author), Jikei Univ, Kashiwa Hosp, Dept Gastroenterol & Hepatol, 163-1 Kashiwashita, Kashiwa, Chiba 2778567, Japan.	ohkusa@jikei.ac.jp					Willing BP, 2010, GASTROENTEROLOGY, V139, P1844, DOI 10.1053/j.gastro.2010.08.049; Andoh A, 2007, INFLAMM BOWEL DIS, V13, P955, DOI 10.1002/ibd.20151; Rath HC, 1996, J CLIN INVEST, V98, P945, DOI 10.1172/JCI118878; Hemmi H, 2001, NATURE, V409, P646, DOI 10.1038/35054604; Panwala CM, 1998, J IMMUNOL, V161, P5733; Wang W, 2014, J CLIN MICROBIOL, V52, P398, DOI 10.1128/JCM.01500-13; Nemoto H, 2012, DIGEST DIS SCI, V57, P2955, DOI 10.1007/s10620-012-2236-y; SINGER RE, 1981, INFECT IMMUN, V32, P458; Sellon RK, 1998, INFECT IMMUN, V66, P5224; Underhill DM, 1999, P NATL ACAD SCI USA, V96, P14459, DOI 10.1073/pnas.96.25.14459; Ohkusa T, 2003, GUT, V52, P79, DOI 10.1136/gut.52.1.79; Vermeiren J, 2012, FEMS MICROBIOL ECOL, V79, P685, DOI 10.1111/j.1574-6941.2011.01252.x; Sha SM, 2013, DIAGN MICR INFEC DIS, V75, P245, DOI 10.1016/j.diagmicrobio.2012.11.022; Schwiertz A, 2010, J PEDIATR-US, V157, P240, DOI 10.1016/j.jpeds.2010.02.046; Eeckhaut V, 2013, GUT, V62, P1745, DOI 10.1136/gutjnl-2012-303611; Jobin C, 2000, INFLAMM BOWEL DIS, V6, P206; Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; Martinez C, 2008, AM J GASTROENTEROL, V103, P643, DOI 10.1111/j.1572-0241.2007.01592.x; Pitcher MCL, 1996, GUT, V39, P1, DOI 10.1136/gut.39.1.1; Nishikawa J, 2009, SCAND J GASTROENTERO, V44, P180, DOI 10.1080/00365520802433231; Bohr URM, 2004, J CLIN MICROBIOL, V42, P2766, DOI 10.1128/JCM.42.6.2766-2768.2004; Kato K, 2014, ALIMENT PHARM THER, V39, P949, DOI 10.1111/apt.12688; Fujita H, 2002, J GASTROENTEROL, V37, P509, DOI 10.1007/s005350200079; ROBERT A, 1977, PROSTAGLANDINS, V14, P333, DOI 10.1016/0090-6980(77)90178-2; Nomura T, 2005, ALIMENT PHARM THER, V21, P1017, DOI 10.1111/j.1365-2036.2005.02428.x; Segain JP, 2000, GUT, V47, P397, DOI 10.1136/gut.47.3.397; Ohkusa T, 2005, SCAND J GASTROENTERO, V40, P1334, DOI 10.1080/00365520510023648; Varela E, 2013, ALIMENT PHARM THER, V38, P151, DOI 10.1111/apt.12365; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Verma R, 2010, J CLIN MICROBIOL, V48, P4279, DOI 10.1128/JCM.01360-10; Ott SJ, 2008, J CLIN MICROBIOL, V46, P3510, DOI 10.1128/JCM.01512-08; Matsuda H, 2000, J GASTROEN HEPATOL, V15, P61, DOI 10.1046/j.1440-1746.2000.02045.x; Sokol H, 2006, INFLAMM BOWEL DIS, V12, P106, DOI 10.1097/01.MIB.0000200323.38139.c6; Machiels K, 2014, GUT, V63, P1275, DOI 10.1136/gutjnl-2013-304833; Rehman A, 2010, J MED MICROBIOL, V59, P1114, DOI 10.1099/jmm.0.021170-0; Swidsinski A, 2008, INFLAMM BOWEL DIS, V14, P147, DOI 10.1002/ibd.20330; OLUSANYA O, 1992, ZBL BAKT-INT J MED M, V276, P254; Michail S, 2012, INFLAMM BOWEL DIS, V18, P1799, DOI 10.1002/ibd.22860; POPOFF MR, 1985, INFECT IMMUN, V47, P697; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Swidsinski A, 2002, GASTROENTEROLOGY, V122, P44, DOI 10.1053/gast.2002.30294; Ohkusa T, 2010, AM J GASTROENTEROL, V105, P1820, DOI 10.1038/ajg.2010.84; Mylonaki M, 2005, INFLAMM BOWEL DIS, V11, P481, DOI 10.1097/01.MIB.0000159663.62651.4f; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Hausmann M, 2002, GASTROENTEROLOGY, V122, P1987, DOI 10.1053/gast.2002.33662; Kotlowski R, 2007, GUT, V56, P669, DOI 10.1136/gut.2006.099796; Fite A, 2013, J CLIN MICROBIOL, V51, P849, DOI 10.1128/JCM.02574-12; Hoshino K, 1999, J IMMUNOL, V162, P3749; Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097; BOUSSEBOUA H, 1989, INFECT IMMUN, V57, P932; Sokol H, 2008, P NATL ACAD SCI USA, V105, P16731, DOI 10.1073/pnas.0804812105; Lepage P, 2011, GASTROENTEROLOGY, V141, P227, DOI 10.1053/j.gastro.2011.04.011; Yoshida T, 2011, J GASTROENTEROL, V46, P339, DOI 10.1007/s00535-010-0355-9; Sartor RB, 2006, NAT CLIN PRACT GASTR, V3, P390, DOI 10.1038/ncpgasthep0528; Frank DN, 2007, P NATL ACAD SCI USA, V104, P13780, DOI 10.1073/pnas.0706625104; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; Sokol H, 2009, INFLAMM BOWEL DIS, V15, P1183, DOI 10.1002/ibd.20903; TOUW JJA, 1982, A VAN LEEUW J MICROB, V48, P315, DOI 10.1007/BF00418285; Dianda L, 1997, AM J PATHOL, V150, P91; Ohkusa T, 2002, J GASTROEN HEPATOL, V17, P849, DOI 10.1046/j.1440-1746.2002.02834.x; Kumari R, 2013, WORLD J GASTROENTERO, V19, P3404, DOI 10.3748/wjg.v19.i22.3404; Strauss J, 2011, INFLAMM BOWEL DIS, V17, P1971, DOI 10.1002/ibd.21606; Ohkusa T, 2009, J MED MICROBIOL, V58, P535, DOI 10.1099/jmm.0.005801-0; VONWULFFEN H, 1989, LANCET, V1, P1449; BURKE DA, 1988, BRIT MED J, V297, P102; GIAFFER MH, 1992, GUT, V33, P646, DOI 10.1136/gut.33.5.646; Kabeerdoss J, 2013, BMC GASTROENTEROL, V13, DOI 10.1186/1471-230X-13-20; Morgan XC, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-9-r79; Mukhopadhya I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021490; Rajilic-Stojanovic M, 2013, INFLAMM BOWEL DIS, V19, P481, DOI 10.1097/MIB.0b013e31827fec6d; Steenbergen van TJ, 1982, J MED MICROBIOL, V5, P253; Tahara T, 2015, DIGEST DIS SCI, V60, P205, DOI 10.1007/s10620-014-3316-y; Thomson JM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017184; Tong MM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080702; Walker AW, 2011, BMC MICROBIOL, V11, DOI 10.1186/1471-2180-11-7; Walujkar SA, 2014, GUT PATHOG, V6, DOI 10.1186/1757-4749-6-22	76	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1341-321X	1437-7780		J INFECT CHEMOTHER	J. Infect. Chemother.	NOV	2015	21	11					761	768		10.1016/j.jiac.2015.07.010		8	Infectious Diseases; Pharmacology & Pharmacy	Infectious Diseases; Pharmacology & Pharmacy	CV3FO	WOS:000364144400001		
J	Yanagisawa, K; Ogawa, Y; Uchiumi, H; Gohda, F; Mawatari, M; Ishizaki, T; Mitsui, T; Yokohama, A; Handa, H; Tsukamoto, N; Nojima, Y				Yanagisawa, Kunio; Ogawa, Yoshiyuki; Uchiumi, Hideki; Gohda, Fumito; Mawatari, Momoko; Ishizaki, Takuma; Mitsui, Takeki; Yokohama, Akihiko; Handa, Hiroshi; Tsukamoto, Norifumi; Nojima, Yoshihisa			Gene polymorphisms of mannose-binding lectin confer susceptibility to Pneumocystis pneumonia in HIV-infected patients	JOURNAL OF INFECTION AND CHEMOTHERAPY			English	Article						Mannose-binding lectin (MBL); Gene polymorphism; Pneumocystis pneumonia (PCP); Human immunodeficiency virus (HIV); Acquired immunodeficiency syndrome (AIDS)	ALVEOLAR MACROPHAGES; CARINII PNEUMONIA; IN-VITRO; PHAGOCYTOSIS; DEFICIENCY; PENTAMIDINE; INSIGHTS	Background: Mannose-binding lectin (MBL) plays an important role in innate immunity. The aim of this study was to determine whether genetic variants of MBL confer susceptibility to Pneumocystis pneumonia (PCP) in patients with advanced human immunodeficiency virus (HIV) infections. Objective: HIV patients (n = 53) having CD4 counts <200/mu L who were admitted to our hospital were analyzed. Of these 53 patients, 30 had PCP at admission, and 23 did not. Genotypes at six single nucleotide polymorphisms (SNP) in MBL2 gene and serum MBL levels were determined for each patient, and compared between patients with or without PCP. We also examined whether MBL enhances phagocytosis of macrophages against rat-type Pneumocystis organism in vitro. Results: Genotypes associated with low production of MBL were significantly more common in the PCP group than in the non-PCP group (P = 0.049, odds ratio 2.17,95% CI 1.02-4.63). Serum MBL levels were significantly higher in the non-PCP group (P = 0.039). Findings from in vitro experiments indicated that MBL act as a direct opsonin enhancing macrophage-mediated phagocytosis of Pneumocystis organisms. Conclusion: Genetic variation of MBL production influences susceptibility to PCP in patients with advanced HIV infection, and can be regarded as a risk factor for PCP. (C) 2015, Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.	[Yanagisawa, Kunio; Ogawa, Yoshiyuki; Uchiumi, Hideki; Gohda, Fumito; Mawatari, Momoko; Ishizaki, Takuma; Mitsui, Takeki; Handa, Hiroshi; Nojima, Yoshihisa] Gunma Univ, Grad Sch Med, Dept Med & Clin Sci, Maebashi, Gunma 3718511, Japan; [Yokohama, Akihiko; Tsukamoto, Norifumi] Gunma Univ Hosp, Div Blood Transfus Serv, Maebashi, Gumma, Japan; [Tsukamoto, Norifumi] Gunma Univ Hosp, Ctr Oncol, Maebashi, Gumma, Japan	Ogawa, Y (reprint author), Gunma Univ, Grad Sch Med, Dept Med & Clin Sci, 3-39-22 Showa, Maebashi, Gunma 3718511, Japan.	yo-ogawa@gunma-u.ac.jp					Schwarcz L, 2013, AIDS, V27, P597, DOI 10.1097/QAD.0b013e32835b0fa2; Grabar S, 2006, J ANTIMICROB CHEMOTH, V57, P4, DOI 10.1093/jac/dki411; Kerrigan AM, 2009, IMMUNOBIOLOGY, V214, P562, DOI 10.1016/j.imbio.2008.11.003; Koziel H, 1998, AM J RESP CELL MOL, V18, P834; Gomi K, 2004, CHEST, V126, P95, DOI 10.1378/chest.126.1.95; MASUR H, 1989, ANN INTERN MED, V111, P223; Garred P, 2006, GENES IMMUN, V7, P85, DOI 10.1038/sj.gene.6364283; Lawn SD, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-59; Huang Laurence, 2011, Proc Am Thorac Soc, V8, P294, DOI 10.1513/pats.201009-062WR; Koziel H, 2000, AM J RESP CELL MOL, V23, P452; MONK JP, 1990, DRUGS, V39, P741, DOI 10.2165/00003495-199039050-00008; Thomas CF, 2007, NAT REV MICROBIOL, V5, P298, DOI 10.1038/nrmicro1621; HARDY WD, 1992, NEW ENGL J MED, V327, P1842, DOI 10.1056/NEJM199212243272604; Eisen DP, 2003, CLIN INFECT DIS, V37, P1496, DOI 10.1086/379324; Thorisson GA, 2005, GENOME RES, V15, P1592, DOI 10.1101/gr.4413105; Koziel H, 1998, J CLIN INVEST, V102, P1332, DOI 10.1172/JCI560; Kaur S, 2007, CLIN EXP IMMUNOL, V148, P382, DOI 10.1111/j.1365-2249.2007.03351.x; Willment JA, 2008, TRENDS MICROBIOL, V16, P27, DOI 10.1016/j.tim.2007.10.012; Walenkamp AME, 2000, J MICROBIOL METH, V40, P39, DOI 10.1016/S0167-7012(99)00128-1; Ou XT, 2011, J INFECT DIS, V203, P1686, DOI 10.1093/infdis/jir152; Schurmann M, 2013, TRANSPL IMMUNOL, V28, P159, DOI 10.1016/j.trim.2013.05.003; Rajagopalan R, 2010, MOL IMMUNOL, V47, P2505, DOI 10.1016/j.molimm.2010.05.292; Verdu P, 2006, HUM MOL GENET, V15, P2650, DOI 10.1093/hmg/ddl193	23	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1341-321X	1437-7780		J INFECT CHEMOTHER	J. Infect. Chemother.	NOV	2015	21	11					769	775		10.1016/j.jiac.2015.07.006		7	Infectious Diseases; Pharmacology & Pharmacy	Infectious Diseases; Pharmacology & Pharmacy	CV3FO	WOS:000364144400002		
J	Nakamura, Y; Kawanohara, H; Kamei, M				Nakamura, Yuuki; Kawanohara, Hirokazu; Kamei, Miwako			Proposition of real-time precise prediction model of infectious disease patients from Prescription Surveillance using the National Database of Electronic Medical Claims	JOURNAL OF INFECTION AND CHEMOTHERAPY			English	Article						Prescription Surveillance; Pharmacy; Pediatric infectious disease	SALES; JAPAN	The incidence of common pediatric infectious diseases has been monitored officially at sentinel medical institutions in Japan. However, the numbers of affected patients are not provided. Prescription Surveillance (PS), which infers the number of patients with influenza, varicella, and gastrointestinal infections from data related to prescriptions at external pharmacies, provides estimates to the public the following morning. This study assessed the prediction ability of the incidence of common pediatric infectious diseases from PS information using the National Database of Electronic Medical Claims (NDBEMC): the number of patients prescribed neuraminidase inhibitors, anti-herpes virus drugs, antibiotic drugs, antipyretic analgesics, and multi-ingredient cold medications. The diseases include RS virus infection, pharyngoconjunctival fever, hand, foot and mouth disease, erythema infectiosum, exanthem subitum, pertussis, herpangina, influenza, varicella, and gastrointestinal infection. For comparison, we used the estimated number of patients who were prescribed neuraminidase inhibitor in PS, which had been confirmed already for precision, and provided estimates to the general public via the internet. The discrepancy rates of all considered diseases between the reported number in NDBEMC and the predicted numbers of patients from PS were less than the value in NI counts and the coefficients of determination in the estimation were from .8109 to .9825. These predictions were sufficiently precise to provide to the general public. (C) 2015, Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.	[Nakamura, Yuuki] Nihon Univ, Grad Sch Pharm, Funabashi, Chiba 2748555, Japan; [Kawanohara, Hirokazu] EM Syst Co Ltd, Osaka, Japan; [Kamei, Miwako] Nihon Univ, Sch Pharm, Funabashi, Chiba 2748555, Japan	Nakamura, Y (reprint author), Nihon Univ, Grad Sch Pharm, Hlth Commun, 7-7-1 Narashinodai, Funabashi, Chiba 2748555, Japan.	phyu14002@g.nihon-u.ac.jp					Hashimoto S, 2003, J EPIDEMIOL, V13, P136; Goldenberg A, 2002, P NATL ACAD SCI USA, V99, P5237, DOI 10.1073/pnas.042117499; Nakamura Y, 2015, JPN J INFECT DIS, V68, P27, DOI 10.7883/yoken.JJID.2014.092; Magruder SF, 2003, J HOPKINS APL TECH D, V24, P349; Shimatani N, 2015, JPN J INFECT DIS, V68, P288, DOI 10.7883/yoken.JJID.2014.233; Health Insurance Bureau Ministry of Health Labour and Welfare, 2013, PROC PROV INF MED CL; Health Insurance Bureau Ministry of Health Labour and Welfare, 2013, REP PROV INF MED CLA; Health Insurance Bureau Ministry of Health Labour and Welfare, 2011, GUID PROV INF MED CL; Magruder Steven F, 2004, MMWR Morb Mortal Wkly Rep, V53 Suppl, P117; Miura K, 2013, HOKEN IRYO KAGAKU, V62, P31; Nakamura Yuuki, 2015, Kansenshogaku Zasshi, V89, P388; Nakamura Y, 2015, KOUSEINOSHIHYOU, P23; Nakamura Yuuki, 2015, Kansenshogaku Zasshi, V89, P23; Ohkusa Y, REPORT ESTIMATED NUM; Sugawara T, 2012, J MED INTERNET RES, V14, DOI 10.2196/jmir.1881; Sugawara Tamie, 2011, Kansenshogaku Zasshi, V85, P632; Sugawara T., 2012, JPN J INFECT PREV CO, V27, P195; Suzue T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030639; Wagner Michael M, 2004, MMWR Morb Mortal Wkly Rep, V53 Suppl, P40	19	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1341-321X	1437-7780		J INFECT CHEMOTHER	J. Infect. Chemother.	NOV	2015	21	11					776	782		10.1016/j.jiac.2015.07.007		7	Infectious Diseases; Pharmacology & Pharmacy	Infectious Diseases; Pharmacology & Pharmacy	CV3FO	WOS:000364144400003		
J	Kawamata, R; Yokoyama, K; Sato, M; Goto, M; Nozaki, Y; Takagi, T; Kumagai, H; Yamagata, T				Kawamata, Ryou; Yokoyama, Koji; Sato, Miori; Goto, Masahide; Nozaki, Yasuyuki; Takagi, Takeshi; Kumagai, Hideki; Yamagata, Takanori			Utility of serum ferritin and lactate dehydrogenase as surrogate markers for steroid therapy for Mycoplasma pneumoniae pneumonia	JOURNAL OF INFECTION AND CHEMOTHERAPY			English	Article						Interleukin-18; Lactate dehydrogenase; Ferritin; Mycoplasma pneumoniae; Mycoplasma pneumonia; Children	INTERLEUKIN-18; INFECTION; CYTOKINES; CHILDREN	Introduction: Patients with severe mycoplasma pneumonia having very high serum interleukin-18 levels may require systemic corticosteroid treatment. However, we know of no laboratory markers that have been identified to assess the precise severity of Mycoplasma pneumoniae pneumonia. Thus, we investigated the usefulness of four clinical laboratory tests as severity indicators and surrogate markers for initiation of steroid therapy in these patients. Patients and methods: For 22 Japanese children (including 3 patients who needed systemic corticosteroid therapy) diagnosed with Mycoplasma pneumoniae pneumonia, white blood cell counts and serum concentrations of interleukin-18, C-reactive protein, lactate dehydrogenase, and ferritin were determined in the acute and recovery phases. Results: In total, 8 and 14 patients were classified as moderate and mild pneumonia, respectively, according to clinical manifestations. The serum interleukin-18 level in the acute phase of the pneumonia group was significantly higher than that of age-matched controls. Furthermore, serum interleukin-18, lactate dehydrogenase and ferritin levels in the acute phase increased in parallel with the severity of the pneumonia. The serum ferritin level was also higher in the acute phase than in the recovery phase. Positive correlations between the levels of serum interleukin-18, lactate dehydrogenase and ferritin were observed in the acute phase. Conclusions: Serum lactate dehydrogenase and ferritin levels may be useful as indicators of the severity of pediatric Mycoplasma pneumoniae pneumonia for initiation of corticosteroid therapy. (C) 2015, Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.	[Kawamata, Ryou; Sato, Miori; Goto, Masahide] Hitachiomiya Saiseikai Hosp, Dept Pediat, Hitachiomiya, Ibaraki 3192256, Japan; [Kawamata, Ryou; Yokoyama, Koji; Nozaki, Yasuyuki; Kumagai, Hideki; Yamagata, Takanori] Jichi Med Univ, Sch Med, Dept Pediat, Nagano, Tochigi, Japan; [Nozaki, Yasuyuki] Shin Oyama City Hosp, Dept Pediat, Nagano, Tochigi, Japan; [Takagi, Takeshi] Ibaraki Prefectural Inst Publ Hlth, Dept Bacteriol, Mito, Ibaraki, Japan	Kawamata, R (reprint author), Hitachiomiya Saiseikai Hosp, Dept Pediat, 3033-3 Tagouchi Cho, Hitachiomiya, Ibaraki 3192256, Japan.	kawamatar@jichi.ac.jp			Saisei Medical and Social Welfare Joint Research, Japan [42]	This study was supported by a grant from the Saisei Medical and Social Welfare Joint Research 2013 (No. 42), Japan.	Aggarwal BB, 2000, CYTOKINE REFERENCE, P337; Tamura A, 2008, J INFECTION, V57, P223, DOI 10.1016/j.jinf.2008.06.012; Shimizu M, 2010, RHEUMATOLOGY, V49, P1645, DOI 10.1093/rheumatology/keq133; Shimizu T, 2014, INFECT IMMUN, V82, P3076, DOI 10.1128/IAI.01961-14; Matsuoka M, 2004, ANTIMICROB AGENTS CH, V48, P4624, DOI 10.1128/AAC.48.12.4624-4630.2004; Oishi T, 2011, J INFECT CHEMOTHER, V17, P803, DOI 10.1007/s10156-011-0265-7; Lee KY, 2006, PEDIATR PULM, V41, P263, DOI 10.1002/ppul.20374; Okazaki N, 2001, MICROBIOL IMMUNOL, V45, P617; Narita M, 2007, PEDIATR PULM, V42, P397, DOI 10.1002/ppul.20445; Tanaka H, 2002, CHEST, V121, P1493, DOI 10.1378/chest.121.5.1493; Narita M, 2012, CYTOKINE, V59, P18, DOI 10.1016/j.cyto.2012.04.007; Oishi T, 2012, EMERG INFECT DIS, V18, P849, DOI 10.3201/eid1805.111149; Inamura N, 2014, J INFECT CHEMOTHER, V20, P270, DOI 10.1016/j.jiac.2014.01.001; Tagliabue C, 2008, J INFECT DIS, V198, P1180, DOI 10.1086/591915; Narita M, 2000, CLIN DIAGN LAB IMMUN, V7, P909, DOI 10.1128/CDLI.7.6.909-914.2000; Colafrancesco S, 2012, INT J INFLAM; Kawamata R, 2013, EVALUATION HOST IMMU, P29; Koike Y, 2013, CASE REP PEDIAT; Okamura H, 2000, CYTOKINE REFERENCE, P413; Ouchi K, 2011, GUIDELINES MANAGEMEN, P35	20	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1341-321X	1437-7780		J INFECT CHEMOTHER	J. Infect. Chemother.	NOV	2015	21	11					783	789		10.1016/j.jiac.2015.07.009		7	Infectious Diseases; Pharmacology & Pharmacy	Infectious Diseases; Pharmacology & Pharmacy	CV3FO	WOS:000364144400004		
J	Koyama, K; Ohshima, N; Suzuki, J; Kawashima, M; Okuda, K; Sato, R; Suzukawa, M; Nagai, H; Matsui, H; Ohta, K				Koyama, Kazuya; Ohshima, Nobuharu; Suzuki, Junko; Kawashima, Masahiro; Okuda, Kenichi; Sato, Ryota; Suzukawa, Maho; Nagai, Hideaki; Matsui, Hirotoshi; Ohta, Ken			Evaluation of clinical characteristics and prognosis of chronic pulmonary aspergillosis depending on the underlying lung diseases: Emphysema vs prior tuberculosis	JOURNAL OF INFECTION AND CHEMOTHERAPY			English	Article						Chronic pulmonary aspergillosis; Pulmonary emphysema; Previous pulmonary tuberculosis; Pneumonia; Prognosis	OXYGEN-THERAPY; OBSTRUCTION; FUMIGATUS	Purpose: There have been scarce data evaluating the differences of clinical characteristics and prognosis of chronic pulmonary aspergillosis (CPA) depending on underlying pulmonary diseases. We tried to clarify them in CPA patients who had pulmonary emphysema or previous pulmonary tuberculosis. Methods: We reviewed and evaluated CPA patients diagnosed between 2007 and 2013 with pulmonary emphysema (PE group; n = 29), with previous pulmonary tuberculosis (PT group; n = 47) and with combination of these 2 underlying conditions (CTE group; n = 24). Results: In CT findings, fungus balls were rare in PE group (7% in PE group and 36% in PT group; p = 0.006). Compared with PT group, PE group patients exhibited more frequent preceding antibiotics administration (45% vs 11%; p = 0.002) and fever (52% vs 17%; p = 0.002), less frequent hemosputum (24% vs 57%; p = 0.008), and more frequent consolidations in imaging (79% vs 38%; p = 0.001) and respiratory failure (34% vs 13%; p = 0.020), possibly suggesting more acute clinical manifestations of CPA in emphysematous patients. Trend of the differences between PT and PE group was not changed when patients with fungal balls were excluded. Multivariate Cox regression analysis of risks for all-cause mortality revealed age (HR, 1.079; p = 0.002) and emphysema (HR, 2.45; p = 0.040) as risk factors. Conclusions: Assessment of underlying lung diseases is needed when we estimate prognosis and consider treatment of CPA patients. Particularly, emphysematous patients can be presented as refractory pneumonia and show poor prognosis. (C) 2015, Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.	[Koyama, Kazuya; Suzuki, Junko; Kawashima, Masahiro; Okuda, Kenichi; Sato, Ryota; Suzukawa, Maho; Nagai, Hideaki; Matsui, Hirotoshi; Ohta, Ken] Natl Hosp Org Tokyo Natl Hosp, Ctr Pulm Dis, Tokyo 2048585, Japan; [Ohshima, Nobuharu; Ohta, Ken] Natl Hosp Org Tokyo Natl Hosp, Ctr Asthma & Allergy, Tokyo 2048585, Japan	Koyama, K (reprint author), Natl Hosp Org Tokyo Natl Hosp, Ctr Pulm Dis, 3-1-1 Kiyose Shi, Tokyo 2048585, Japan.	koyamak@tokyo-hosp.jp					GODDARD PR, 1982, CLIN RADIOL, V33, P379, DOI 10.1016/S0009-9260(82)80301-2; Chen JC, 1997, THORAX, V52, P810; SNIDER GL, 1985, AM REV RESPIR DIS, V132, P182; Kohno S, 2010, J INFECTION, V61, P410, DOI 10.1016/j.jinf.2010.08.005; Bafadhel M, 2014, EUR RESPIR J, V43, P64, DOI 10.1183/09031936.00162912; Leav BA, 2000, NEW ENGL J MED, V343, P586, DOI 10.1056/NEJM200008243430818; Nakamoto K, 2013, INTERNAL MED, V52, P727, DOI 10.2169/internalmedicine.52.9142; MIYAMOTO K, 1995, AM J RESP CRIT CARE, V152, P972; Celli BR, 2004, NEW ENGL J MED, V350, P1005, DOI 10.1056/NEJMoa021322; HOGG JC, 1968, NEW ENGL J MED, V278, P1355, DOI 10.1056/NEJM196806202782501; Ohba H, 2012, RESP MED, V106, P724, DOI 10.1016/j.rmed.2012.01.014; Kawamura S, 2000, INTERNAL MED, V39, P209, DOI 10.2169/internalmedicine.39.209; COLEMAN RM, 1972, APPL MICROBIOL, V23, P301; CAMPBELL MJ, 1964, AM REV RESPIR DIS, V89, P186; Meersseman W, 2004, AM J RESP CRIT CARE, V170, P621, DOI 10.1164/rccm.200401-093OC; Aida A, 1998, AM J RESP CRIT CARE, V158, P188; Smith NL, 2011, EUR RESPIR J, V37, P865, DOI 10.1183/09031936.00054810; Hunter RL, 2011, TUBERCULOSIS, V91, P497, DOI 10.1016/j.tube.2011.03.007; Bulpa P, 2007, EUR RESPIR J, V30, P782, DOI 10.1183/09031936.00062206; Limper AH, 2011, AM J RESP CRIT CARE, V183, P96, DOI 10.1164/rccm.2008-740ST; Ader F, 2005, CLIN MICROBIOL INFEC, V11, P427, DOI 10.1111/j.1469-0691.2005.01143.x; TRAVER GA, 1979, AM REV RESPIR DIS, V119, P895; Barouky R, 2003, EUR J INTERN MED, V14, P380, DOI 10.1016/S0953-6205(03)90006-9; Kousha M, 2011, Eur Respir Rev, V20, P156, DOI 10.1183/09059180.00001011; Noni M, 2014, MED MYCOL, V52, P715, DOI 10.1093/mmy/myu038; Samarakoon P, 2008, Chron Respir Dis, V5, P19, DOI 10.1177/1479972307085637	26	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1341-321X	1437-7780		J INFECT CHEMOTHER	J. Infect. Chemother.	NOV	2015	21	11					795	801		10.1016/j.jiac.2015.08.006		7	Infectious Diseases; Pharmacology & Pharmacy	Infectious Diseases; Pharmacology & Pharmacy	CV3FO	WOS:000364144400006		
J	Ikematsu, H; Kawai, N; Iwaki, N; Kashiwagi, S				Ikematsu, Hideyuki; Kawai, Naoki; Iwaki, Norio; Kashiwagi, Seizaburo			Clinical outcome of laninamivir octanoate hydrate for influenza in the 2013-2014 Japanese season	JOURNAL OF INFECTION AND CHEMOTHERAPY			English	Article						Long-acting neuraminidase inhibitor; Laninamivir; Effectiveness; IC50	NEURAMINIDASE INHIBITORY-ACTIVITY; OSELTAMIVIR; VIRUS	The clinical outcome of laninamivir octanoate hydrate (laninamivir) in the Japanese 2013-2014 influenza season was investigated. A total of 235 patients were enrolled, of whom 222 were evaluated for the duration of fever and other symptoms. The types/subtypes were 101 A(H1N1) pdm09 (45.5%), 37 A(H3N2) (16.7%), and 84 B (37.8%). The median durations of fever were 32.0, 41.0, and 50.0 h, and the median durations of symptoms were 74.5, 85.0, and 95.0 h for A(H1N1) pdm09, A(H3N2), and B, respectively. The differences among the three groups were not statistically significant. There was no significant difference in the duration of fever or symptoms between patients under 10 and 10 years or over. The median durations of fever were 46.0 and 58.0 h and the median durations of symptoms were 95.0 and 77.0 h for the Yamagata and Victoria lineages, respectively. The virus positive rates at day 5 were significantly different at 31.5% (28/89), 12.1% (4/33), and 34.7% (26/75) for the three type/subtypes, respectively. The virus positive rates for A(H1N1) pdm0(and B were significantly higher for the patients under 10 years than for the patients 10 years or older. (p = 0.037(and 0.0320, respectively). No significant increase was found between the IC50 of days 1 and 5. No adverse drug reactions associated with laninamivir were reported. These results indicate the continuing clinical utility of laninamivir against influenza, irrespective of the virus type/subtype or lineage, and that it is unlikely that the clinical use of laninamivir will lead to selection of resistant virus. (C) 2015, Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.	[Ikematsu, Hideyuki; Kawai, Naoki; Iwaki, Norio; Kashiwagi, Seizaburo] Japan Phys Assoc, Tokyo, Japan	Ikematsu, H (reprint author), 2-18-30 Hakataekihigashi,Hakata Ku, Fukuoka 8120013, Japan.	ikematsu@gray.plala.or.jp			DAIICHI SANKYO COMPANY, LIMITED	This investigation was sponsored by DAIICHI SANKYO COMPANY, LIMITED.	Watanabe A, 2010, CLIN INFECT DIS, V51, P1167, DOI 10.1086/656802; Nakauchi M, 2011, J VIROL METHODS, V171, P156, DOI 10.1016/j.jviromet.2010.10.018; Kawai N, 2009, J INFECTION, V59, P207, DOI 10.1016/j.jinf.2009.07.002; [Anonymous], 2009, WKLY EPIDEMIOL REC, V46, P481; Kawai N, 2009, CLIN INFECT DIS, V49, P1828, DOI 10.1086/648424; Kawai N, 2006, CLIN INFECT DIS, V43, P439, DOI 10.1086/505868; Yamashita M, 2009, ANTIMICROB AGENTS CH, V53, P186, DOI 10.1128/AAC.00333-08; Fiore Anthony E., 2011, Morbidity and Mortality Weekly Report, V60, P1; Kawai N, 2007, J INFECTION, V55, P267, DOI 10.1016/j.jinf.2007.05.176; Ikematsu H, 2014, J INFECT CHEMOTHER, V20, P77, DOI 10.1016/j.jiac.2013.07.002; Sugaya N, 2010, ANTIMICROB AGENTS CH, V54, P2575, DOI 10.1128/AAC.01755-09; Ikematsu H, 2014, J INFECT CHEMOTHER, V20, P81, DOI 10.1016/j.jiac.2013.07.013; Kashiwagi S, 2012, INT J ANTIMICROB AG, V40, P381, DOI 10.1016/j.ijantimicag.2012.06.017; Ikematsu H, 2012, J INFECT CHEMOTHER, V18, P529, DOI 10.1007/s10156-012-0377-8; Ikematsu H, 2015, J INFECT CHEMOTHER, V21, P39, DOI 10.1016/j.jiac.2014.08.030; Ikematsu H, 2014, J INFECT CHEMOTHER, V20, P799, DOI 10.1016/j.jiac.2014.08.023	16	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1341-321X	1437-7780		J INFECT CHEMOTHER	J. Infect. Chemother.	NOV	2015	21	11					802	807		10.1016/j.jiac.2015.08.013		6	Infectious Diseases; Pharmacology & Pharmacy	Infectious Diseases; Pharmacology & Pharmacy	CV3FO	WOS:000364144400007		
J	Kaneko, M; Maruta, M; Shikata, H; Hanayama, M; Ikebe, T				Kaneko, Masahiko; Maruta, Masaki; Shikata, Hisaharu; Hanayama, Masakazu; Ikebe, Tadayoshi			Acute abdomen due to group A streptococcus bacteremia caused by an isolate with a mutation in the csrS gene	JOURNAL OF INFECTION AND CHEMOTHERAPY			English	Article						Group A streptococcus bacteremia; Acute abdomen; Streptococcal toxic shock syndrome; csrS gene mutation	INFECTIONS; EPIDEMIOLOGY; PERITONITIS; MANAGEMENT; REGULATOR; VIRULENCE; DISEASE	Streptococcus pyogenes (group A streptococcus) is an aerobic gram-positive coccus that causes infections ranging from non-invasive pharyngitis to severely invasive necrotizing fasciitis. Mutations in csrS/csrR and rgg, negative regulator genes of group A streptococcus, are crucial factors in the pathogenesis of streptococcal toxic shock syndrome, which is a severe, invasive infection characterized by sudden onset of shock and multiorgan failure, resulting in a high mortality rate. Here we present a case of group A streptococcal bacteremia in a 28-year-old Japanese woman with no relevant previous medical history. The patient developed progressive abdominal symptoms that may have been due to spontaneous bacterial peritonitis, followed by a state of shock, which did not fulfill the proposed criteria for streptococcal toxic shock. The isolate was found to harbor a mutation in the negative regulator csrS gene, whereas the csrR and rgg genes were intact. It was noteworthy that this strain carrying a csrS mutation had caused group A streptococcal bacteremia characterized by acute abdomen as the presenting symptom in a young individual who had been previously healthy. This case indicates that group A streptococcus with csrS mutations has potential virulence factors that are associated with the onset of group A streptococcal bacteremia that does not meet the diagnostic criteria for streptococcal toxic shock syndrome. (C) 2015, Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.	[Kaneko, Masahiko; Maruta, Masaki; Shikata, Hisaharu; Hanayama, Masakazu] Uwajima City Hosp, Dept Internal Med, Uwajima, Ehime 7988510, Japan; [Ikebe, Tadayoshi] Natl Inst Infect Dis, Dept Bacteriol 1, Shinjuku Ku, Tokyo 1628640, Japan	Kaneko, M (reprint author), Uwajima City Hosp, Dept Internal Med, 1-1 Goten Machi, Uwajima, Ehime 7988510, Japan.	kaneko@uwajima-mh.jp					Ejlertsen T, 2001, SCAND J INFECT DIS, V33, P734, DOI 10.1080/003655401317074518; Miyoshi-Akiyama T, 2006, J INFECT DIS, V193, P1677, DOI 10.1086/504263; Walker MJ, 2007, NAT MED, V13, P981, DOI 10.1038/nm1612; Haap M, 2010, AM J CRIT CARE, V19, P454, DOI 10.4037/ajcc2009615; DEMERS B, 1993, CLIN INFECT DIS, V16, P792; Lamagni TL, 2008, J CLIN MICROBIOL, V46, P2359, DOI 10.1128/JCM.00422-08; Westwood DA, 2013, SURG INFECT, V14, P171, DOI 10.1089/sur.2012.038; Stevens DL, 2005, CLIN INFECT DIS, V41, P1373, DOI 10.1086/497143; STEVENS DL, 1988, J INFECT DIS, V158, P23; Factor SH, 2003, EMERG INFECT DIS, V9, P970; STEVENS DL, 1992, CLIN INFECT DIS, V14, P2; Bakleh M, 2005, CLIN INFECT DIS, V40, P410, DOI 10.1086/427286; Kiska DL, 1997, J INFECT DIS, V176, P992; Ato M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003455; Ikebe T, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000832; BREIMAN RF, 1993, JAMA-J AM MED ASSOC, V269, P390	16	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1341-321X	1437-7780		J INFECT CHEMOTHER	J. Infect. Chemother.	NOV	2015	21	11					816	819		10.1016/j.jiac.2015.06.010		4	Infectious Diseases; Pharmacology & Pharmacy	Infectious Diseases; Pharmacology & Pharmacy	CV3FO	WOS:000364144400009		
J	Tamaki, K; Kinjo, T; Aoyama, H; Tomoyose, T; Nakachi, S; Hanashiro, T; Shimabukuro, N; Tedokon, I; Morichika, K; Nishi, Y; Taira, N; Fujita, J; Yoshimi, N; Fukushima, T; Masuzaki, H				Tamaki, Keita; Kinjo, Takeshi; Aoyama, Hajime; Tomoyose, Takeaki; Nakachi, Sawako; Hanashiro, Taeko; Shimabukuro, Natsuki; Tedokon, Iori; Morichika, Kazuho; Nishi, Yukiko; Taira, Naoya; Fujita, Jiro; Yoshimi, Naoki; Fukushima, Takuya; Masuzaki, Hiroaki			Fatal pneumonia and viremia due to human parainfluenza virus type 1 in a patient with adult T-cell leukemia-lymphoma treated with mogamulizumab	JOURNAL OF INFECTION AND CHEMOTHERAPY			English	Article						Parainfluenza virus type 1; Viremia; Mogamulizumab; Adult T-cell leukemia-lymphoma; Viral pneumonia	RESPIRATORY VIRAL-INFECTIONS; PHASE-II; RECIPIENTS; TRANSPLANTATION; FEATURES	We report a case of fatal pneumonia and viremia due to human parainfluenza virus type 1 (HPIV-1) in a 65-year-old male patient with adult T-cell leukemia-lymphoma (ATL) treated with mogamulizumab, a brand-new therapeutic agent for ATL. To our knowledge, this is the first report describing viremia due to HPIV-1. After administering mogamulizumab, lymphocyte count in the blood was drastically decreased and the patient suffered from complicated infections including gram-negative bacterial sepsis, cytomegalovirus antigenemia and aspergillosis. Although these infections were successfully controlled by broad spectrum antimicrobial therapy, patchy ground-grass opacities in the both lungs were gradually worsened. He finally died due to acute respiratory failure. Since findings of the chest CT was consistent with typical patterns of viral pneumonia, we screened major respiratory viruses in the peripheral blood with multiplex PCR, and it turned out that RNA of HPIV-1 was positive. Although ATL cells were not detected in the autopsied lungs and a variety of other tissues, cytoplasmic inclusion bodies, which are commonly observed in RNA viral infection, were abundantly observed in the autopsied lung tissue. These findings suggest that mogamulizumab accomplished complete remission of ATL, while the chemotherapy-induced prolonged lymphopenia caused fatal pneumonia and viremia due to HPIV-1. As it has been well recognized that community respiratory viruses including HPIV-1 often cause fatal pneumonia in patients with leukemia, but also there is no specific treatment for HPIV-1, we have to enforce standard precautions especially when we treat leukemic patients with intensively immunosuppressive agents such as mogamulizumab. (C) 2015, Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.	[Tamaki, Keita; Tomoyose, Takeaki; Nakachi, Sawako; Hanashiro, Taeko; Shimabukuro, Natsuki; Tedokon, Iori; Morichika, Kazuho; Nishi, Yukiko; Masuzaki, Hiroaki] Univ Ryukyus, Grad Sch Med, Dept Med 2, Div Endocrinol Diabet & Metab Hematol & Rheumatol, Nishihara, Okinawa 9030215, Japan; [Kinjo, Takeshi; Fujita, Jiro] Univ Ryukyus, Fac Med, Dept Infect Dis Resp & Digest Med, Nishihara, Okinawa 90301, Japan; [Aoyama, Hajime; Yoshimi, Naoki] Univ Ryukyus, Grad Sch Med, Dept Pathol & Oncol, Nishihara, Okinawa 90301, Japan; [Aoyama, Hajime; Yoshimi, Naoki] Univ Ryukyus, Fac Med, Nishihara, Okinawa 90301, Japan; [Nakachi, Sawako; Shimabukuro, Natsuki] Ryukyu Univ Hosp, Bone Marrow Transplantat Ctr, Nakagami, Okinawa, Japan; [Taira, Naoya] Heartlife Hosp, Dept Internal Med, Nakagami, Japan; [Fukushima, Takuya] Univ Ryukyus, Fac Med, Sch Hlth Sci, Lab Immunohematol, Nishihara, Okinawa 90301, Japan	Masuzaki, H (reprint author), Univ Ryukyus, Grad Sch Med, Dept Med 2, Div Endocrinol Diabet & Metab Hematol & Rheumatol, 207 Uehara, Nishihara, Okinawa 9030215, Japan.	hiroaki@med.u-ryukyu.ac.jp			Takeda Science Foundation (Specified Research Grant); Metabolic Syndrome Foundation; project "Establishing a research hub toward the development of an intellectual cluster in Okinawa Prefecture, Japan"	This work was supported in part by the Takeda Science Foundation (Specified Research Grant), the Metabolic Syndrome Foundation and the project "Establishing a research hub toward the development of an intellectual cluster in Okinawa Prefecture, Japan." We thank M. Hirata, I. Asato, C. Noguchi, M. Shimoji and Y. Kuniyoshi for excellent secretarial assistance.	Jennings LC, 2008, THORAX, V63, P42, DOI 10.1136/thx.2006.075077; Chemaly RF, 2012, BLOOD, V119, P2738, DOI 10.1182/blood-2011-08-371112; Herbst T, 2013, AM J ROENTGENOL, V201, P550, DOI 10.2214/AJR.12.9613; Ruuskanen O, 2011, LANCET, V377, P1264, DOI 10.1016/S0140-6736(10)61459-6; Tsukasaki K, 2009, J CLIN ONCOL, V27, P453, DOI 10.1200/JCO.2008.18.2428; Ishida T, 2012, J CLIN ONCOL, V30, P837, DOI 10.1200/JCO.2011.37.3472; Kalimuddin S, 2013, J CLIN VIROL, V56, P37, DOI 10.1016/j.jcv.2012.10.005; Shiley KT, 2010, J THORAC IMAG, V25, P68, DOI 10.1097/RTI.0b013e3181b0ba8b; UCHIYAMA T, 1977, BLOOD, V50, P481; Chemaly RF, 2006, MEDICINE, V85, P278, DOI 10.1097/01.md.0000232560.22098.4e; SHIMOYAMA M, 1991, BRIT J HAEMATOL, V79, P428, DOI 10.1111/j.1365-2141.1991.tb08051.x; Hirsch HH, 2013, CLIN INFECT DIS, V56, P258, DOI 10.1093/cid/cis844; Renaud C, 2011, CURR OPIN INFECT DIS, V24, P333, DOI 10.1097/QCO.0b013e3283480440; Chun JY, 2007, NUCLEIC ACIDS RES, V35, pE40, DOI 10.1093/nar/gkm051; Duncan Michael D, 2005, Proc Am Thorac Soc, V2, P449, DOI 10.1513/pats.200507-073JS; Ishida T, 2015, BRIT J HAEMATOL, V169, P672, DOI 10.1111/bjh.13338; Ishitsuka K, 2014, LANCET ONCOL, V15, pE517, DOI 10.1016/S1470-2045(14)70202-5; Nakano N, 2014, HEPATOL RES, V44, P354, DOI 10.1111/hepr.12117; Shah Dimpy P, 2012, Am J Blood Res, V2, P203; Whimbey Estella, 1997, American Journal of Medicine, V102, P10, DOI 10.1016/S0002-9343(97)80004-6	20	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1341-321X	1437-7780		J INFECT CHEMOTHER	J. Infect. Chemother.	NOV	2015	21	11					820	823		10.1016/j.jiac.2015.07.001		4	Infectious Diseases; Pharmacology & Pharmacy	Infectious Diseases; Pharmacology & Pharmacy	CV3FO	WOS:000364144400010		
J	Endo, S; Nemoto, T; Yano, H; Kakuta, R; Kanamori, H; Inomata, S; Ishibashi, N; Aoyagi, T; Hatta, M; Gu, Y; Kitagawa, M; Kaku, M				Endo, Shiro; Nemoto, Tadanobu; Yano, Hisakazu; Kakuta, Risako; Kanamori, Hajime; Inomata, Shinya; Ishibashi, Noriomi; Aoyagi, Tetsuji; Hatta, Masumitsu; Gu, Yoshiaki; Kitagawa, Miho; Kaku, Mitsuo			First confirmed case of spondylodiscitis with epidural abscess caused by Parvimonas micra	JOURNAL OF INFECTION AND CHEMOTHERAPY			English	Article						Gram-positive anaerobic cocci; Parvimonas micra; Spondylodiscitis with epidural abscess; 16S ribosomal RNA	ANAEROBIC-BACTERIA; INFECTIONS	Parvimonas micra was renamed species as within Gram-positive anaerobic cocci and rarely causes severe infections in healthy people. We report the first confirmed case of spondylodiscitis with epidural abscess caused by P. micra in a healthy women. The patient has a pain in low back and anterior left thigh. Magnetic resonance imaging and computed tomography detected the affected lesion at the L2 and L3 vertebral bodies. All isolates from the surgical and needle biopsy specimens were identified as P. micra by 16S rRNA and MALDI-TOF. In this case, P. micra showed high sensitivity to antimicrobial therapy. She was successfully treated with debridement and sulbactam/ampicillin, followed by oral metronidazole for a total of 10 weeks. The causative microorganisms of spondylodiscitis are not often identified, especially anaerobic bacteria tend to be underestimated. On the other hand, antimicrobial therapy for spondylodiscitis is usually prolonged. Accordingly, we emphasize the importance of performing accurate identification including anaerobic bacteria. (C) 2015, Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.	[Endo, Shiro; Yano, Hisakazu; Kanamori, Hajime; Inomata, Shinya; Ishibashi, Noriomi; Aoyagi, Tetsuji; Hatta, Masumitsu; Gu, Yoshiaki; Kitagawa, Miho; Kaku, Mitsuo] Tohoku Univ, Grad Sch Med, Dept Infect Control & Lab Diagnost, Aoba Ku, Sendai, Miyagi 9808575, Japan; [Nemoto, Tadanobu] Izumi Orthopaed Hosp, Izumi Ku, Sendai, Miyagi 9813121, Japan; [Kakuta, Risako] Tohoku Univ, Dept Otolaryngol Head & Neck Surg, Grad Sch Med, Aoba Ku, Sendai, Miyagi 9808575, Japan	Endo, S (reprint author), Tohoku Univ, Grad Sch Med, Dept Infect Control & Lab Diagnost, Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.	ain@med.tohoku.ac.jp					Flynn TR, 2012, J ORAL MAXIL SURG, V70, P1854, DOI 10.1016/j.joms.2011.09.009; Ulger-Toprak N, 2010, INT J SYST EVOL MICR, V60, P1013, DOI 10.1099/ijs.0.015909-0; Walter G, 2014, EUR J CLIN MICROBIOL, V33, P1355, DOI 10.1007/s10096-014-2073-3; Zimmerli W, 2010, NEW ENGL J MED, V362, P1022, DOI 10.1056/NEJMcp0910753; REIG M, 1994, J ANTIMICROB CHEMOTH, V33, P358, DOI 10.1093/jac/33.2.358; Murphy EC, 2013, FEMS MICROBIOL REV, V37, P520, DOI 10.1111/1574-6976.12005; Veloo ACM, 2011, ANTIMICROB AGENTS CH, V55, P1199, DOI 10.1128/AAC.01771-09; GARCIARODRIGUEZ JA, 1995, ANAEROBE, V1, P69, DOI 10.1006/anae.1995.1001; Minces LR, 2010, ANAEROBE, V16, P327, DOI 10.1016/j.anaerobe.2010.03.011; CLSI, 2012, M100S22 CLSI S; Dalke Krzysztof, 2011, Otolaryngol Pol, V65, P228, DOI 10.1016/S0030-6657(11)70680-1; Fraisse T, 2009, JOINT BONE SPINE, V76, P104, DOI 10.1016/j.jbspin.2008.01.029; Griffin AT, 2014, DIAGN MICR INFEC DIS, V78, P491, DOI 10.1016/j.diagmicrobio.2013.08.025; Taylor GK, 2012, BMJ CASE REP	14	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1341-321X	1437-7780		J INFECT CHEMOTHER	J. Infect. Chemother.	NOV	2015	21	11					828	830		10.1016/j.jiac.2015.06.002		3	Infectious Diseases; Pharmacology & Pharmacy	Infectious Diseases; Pharmacology & Pharmacy	CV3FO	WOS:000364144400012		
J	Kolker, S; Cazorla, AG; Valayannopoulos, V; Lund, AM; Burlina, AB; Sykut-Cegielska, J; Wijburg, FA; Teles, EL; Zeman, J; Dionisi-Vici, C; Baric, I; Karall, D; Augoustides-Savvopoulou, P; Aksglaede, L; Arnoux, JB; Avram, P; Baumgartner, MR; Blasco-Alonso, J; Chabrol, B; Chakrapani, A; Chapman, K; Saladelafont, ECI; Couce, ML; de Meirleir, L; Dobbelaere, D; Dvorakova, V; Furlan, F; Gleich, F; Gradowska, W; Grunewald, S; Jalan, A; Haberle, J; Haege, G; Lachmann, R; Laemmle, A; Langereis, E; de Lonlay, P; Martinelli, D; Matsumoto, S; Muhlhausen, C; de Baulny, HO; Ortez, C; Pena-Quintana, L; Ramadza, DP; Rodrigues, E; Scholl-Burgi, S; Sokal, E; Staufner, C; Summar, ML; Thompson, N; Vara, R; Pinera, IV; Walter, JH; Williams, M; Burgard, P				Koelker, Stefan; Garcia Cazorla, Angeles; Valayannopoulos, Vassili; Lund, Allan M.; Burlina, Alberto B.; Sykut-Cegielska, Jolanta; Wijburg, Frits A.; Teles, Elisa Leao; Zeman, Jiri; Dionisi-Vici, Carlo; Baric, Ivo; Karall, Daniela; Augoustides-Savvopoulou, Persephone; Aksglaede, Lise; Arnoux, Jean-Baptiste; Avram, Paula; Baumgartner, Matthias R.; Blasco-Alonso, Javier; Chabrol, Brigitte; Chakrapani, Anupam; Chapman, Kimberly; Cortes i Saladelafont, Elisenda; Couce, Maria L.; de Meirleir, Linda; Dobbelaere, Dries; Dvorakova, Veronika; Furlan, Francesca; Gleich, Florian; Gradowska, Wanda; Gruenewald, Stephanie; Jalan, Anil; Haeberle, Johannes; Haege, Gisela; Lachmann, Robin; Laemmle, Alexander; Langereis, Eveline; de Lonlay, Pascale; Martinelli, Diego; Matsumoto, Shirou; Muehlhausen, Chris; de Baulny, Helene Ogier; Ortez, Carlos; Pena-Quintana, Luis; Ramadza, Danijela Petkovic; Rodrigues, Esmeralda; Scholl-Buergi, Sabine; Sokal, Etienne; Staufner, Christian; Summar, Marshall L.; Thompson, Nicholas; Vara, Roshni; Vives Pinera, Inmaculada; Walter, John H.; Williams, Monique; Burgard, Peter			The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 1: the initial presentation	JOURNAL OF INHERITED METABOLIC DISEASE			English	Article							COA DEHYDROGENASE-DEFICIENCY; BLOOD-BRAIN-BARRIER; PROPIONIC ACIDEMIA; METHYLMALONIC ACIDURIA; ISOVALERIC ACIDEMIA; HEAD CIRCUMFERENCE; GLUTARYL-COENZYME; NATURAL-HISTORY; CLINICAL-COURSE; MANAGEMENT	Background The clinical presentation of patients with organic acidurias (OAD) and urea cycle disorders (UCD) is variable; symptoms are often non-specific. Aims/methods To improve the knowledge about OAD and UCD the E-IMD consortium established a web-based patient registry. Results We registered 795 patients with OAD (n = 452) and UCD (n = 343), with ornithine transcarbamylase (OTC) deficiency (n = 196), glutaric aciduria type 1 (GA1; n = 150) and methylmalonic aciduria (MMA; n = 149) being the most frequent diseases. Overall, 548 patients (69 %) were symptomatic. The majority of them (n = 463) presented with acute metabolic crisis during (n = 220) or after the newborn period (n = 243) frequently demonstrating impaired consciousness, vomiting and/or muscular hypotonia. Neonatal onset of symptoms was most frequent in argininosuccinic synthetase and lyase deficiency and carbamylphosphate 1 synthetase deficiency, unexpectedly low in male OTC deficiency, and least frequently in GA1 and female OTC deficiency. For patients with MMA, propionic aciduria (PA) and OTC deficiency (male and female), hyperammonemia was more severe in metabolic crises during than after the newborn period, whereas metabolic acidosis tended to be more severe in MMA and PA patients with late onset of symptoms. Symptomatic patients without metabolic crises (n = 94) often presented with a movement disorder, mental retardation, epilepsy and psychiatric disorders (the latter in UCD only). Conclusions The initial presentation varies widely in OAD and UCD patients. This is a challenge for rapid diagnosis and early start of treatment. Patients with a sepsis-like neonatal crisis and those with late-onset of symptoms are both at risk of delayed or missed diagnosis.	[Koelker, Stefan; Gleich, Florian; Haege, Gisela; Staufner, Christian; Burgard, Peter] Univ Childrens Hosp Heidelberg, Dept Gen Pediat, Div Inherited Metab Dis, D-69120 Heidelberg, Germany; [Garcia Cazorla, Angeles; Cortes i Saladelafont, Elisenda; Ortez, Carlos] Hosp San Joan de Deu, ISCIII, Serv Neurol, Barcelona, Spain; [Garcia Cazorla, Angeles; Cortes i Saladelafont, Elisenda; Ortez, Carlos] Hosp San Joan de Deu, ISCIII, CIBERER, Barcelona, Spain; [Valayannopoulos, Vassili; Arnoux, Jean-Baptiste; de Lonlay, Pascale] Necker Enfants Malad Univ Hosp, Reference Ctr Inherited Metab Dis, Hop Necker Enfants Malad, AP HP, Paris, France; [Valayannopoulos, Vassili; Arnoux, Jean-Baptiste; de Lonlay, Pascale] IMAGINE Inst, Paris, France; [Lund, Allan M.; Aksglaede, Lise] Copenhagen Univ Hosp, Rigshosp, Dept Clin Genet, Ctr Inherited Metab Dis, Copenhagen, Denmark; [Burlina, Alberto B.; Furlan, Francesca] Azienda Osped Padova, UOC Malattie Metab Ereditarie, Padua, Italy; [Sykut-Cegielska, Jolanta] Inst Mother & Child Hlth, Screening Dept, Warsaw, Poland; [Wijburg, Frits A.; Langereis, Eveline] Univ Amsterdam, Acad Med Ctr, Dept Pediat, NL-1105 AZ Amsterdam, Netherlands; [Teles, Elisa Leao; Rodrigues, Esmeralda] EPE, Hosp S Joao, Serv Pediat, Unidade Doencas Metab, Oporto, Portugal; [Zeman, Jiri; Dvorakova, Veronika] Charles Univ Prague, Fac Med 1, Prague, Czech Republic; [Zeman, Jiri; Dvorakova, Veronika] Gen Univ Prague, Prague, Czech Republic; [Dionisi-Vici, Carlo; Martinelli, Diego] Osped Pediat Bambino Gesu, UOC Patol Metab, Rome, Italy; [Baric, Ivo] Univ Hosp Ctr Zagreb, Sch Med, Zagreb, Croatia; [Baric, Ivo] Univ Zagreb, Zagreb 41000, Croatia; [Karall, Daniela; Scholl-Buergi, Sabine] Med Univ Innsbruck, Clin Pediat 1, Inherited Metab Disorders, A-6020 Innsbruck, Austria; [Augoustides-Savvopoulou, Persephone] Gen Hosp Thessaloniki Hippocration, Metab Lab, Dept Pediat 1, Thessaloniki, Greece; [Avram, Paula] Inst Mother & Child Care Alfred Rusescu, Bucharest, Romania; [Baumgartner, Matthias R.; Haeberle, Johannes; Laemmle, Alexander] Univ Childrens Hosp Zurich, Div Metab, CH-8032 Zurich, Switzerland; [Baumgartner, Matthias R.; Haeberle, Johannes; Laemmle, Alexander] Univ Childrens Hosp Zurich, Childrens Res Ctr, CH-8032 Zurich, Switzerland; [Blasco-Alonso, Javier] Hosp Maternoinfantil HRU Carlos Haya, Malaga, Spain; [Chabrol, Brigitte] CHU Timone, Hop Enfants, Serv Neurol, Ctr Reference Malad Hereditaires Metab, Marseilles, France; [Chakrapani, Anupam] Birmingham Childrens Hosp NHS Fdn Trust, Birmingham B4 6NH, W Midlands, England; [Chapman, Kimberly; Summar, Marshall L.] Childrens Natl Med Ctr, Washington, DC 20010 USA; [Couce, Maria L.] Hosp Clin Univ Santiago de Compostela, Dept Pediat, Metab Unit, Santiago De Compostela, Spain; [de Meirleir, Linda] Univ Hosp Vrije Univ Brussel, Brussels, Belgium; [Dobbelaere, Dries] Hop Jeanne de Flandre, Ctr Reference Malad Hereditaires Metab Enfant & A, Lille, France; [Gradowska, Wanda] Childrens Mem Hlth Inst, Dept Lab Diagnost, Warsaw, Poland; [Gruenewald, Stephanie; Thompson, Nicholas] UCL, Great Ormond St Hosp, Metab Unit, London, England; [Gruenewald, Stephanie; Thompson, Nicholas] UCL, Inst Child Hlth, London, England; [Jalan, Anil] NIRMAN, Om Rachna Soc, Mumbai, Maharashtra, India; [Lachmann, Robin] Natl Hosp Neurol & Neurosurg, Charles Dent Metab Unit, London WC1N 3BG, England; [Matsumoto, Shirou] Kumamoto Univ Hosp, Dept Pediat, Kumamoto, Japan; [Muehlhausen, Chris] Univ Klinikum Hamburg Eppendorf, Klin Kinder & Jugendmed, Hamburg, Germany; [de Baulny, Helene Ogier] Univ Paris, Hop Robert Debre, F-75252 Paris, France; [Ramadza, Danijela Petkovic] Univ Hosp Ctr Zagreb, Zagreb, Croatia; [Pena-Quintana, Luis] Univ Las Palmas Gran Canaria, Unit Pediat Gastroenterol Hepatol & Nutr, Hosp Univ Maternoinfantil Canarias, Las Palmas Gran Canaria, Spain; [Sokal, Etienne] Catholic Univ Louvain, Clin Univ St Luc, Serv Gastroenterol & Hepatol Pediat, B-1200 Brussels, Belgium; [Vara, Roshni] St Thomas Hosp, Evelina Childrens Hosp, London, England; [Vives Pinera, Inmaculada] Hosp Virgen Arrixaca Murcia, Inborn Metab Dis Unit, El Palmar, Spain; [Walter, John H.] Univ Manchester, Manchester Acad Hlth Sci Ctr, Willink Biochem Genet Unit, Genet Med, Manchester, Lancs, England; [Williams, Monique] Erasmus Univ, Erasmus MC Sophia Kinderziekenhuis, Rotterdam, Netherlands	Kolker, S (reprint author), Univ Childrens Hosp Heidelberg, Dept Gen Pediat, Div Inherited Metab Dis, Neuenheimer Feld 430, D-69120 Heidelberg, Germany.	Stefan.Koelker@med.uni-heidelberg.de		blasco-alonso, javier/0000-0003-4008-3747	European Union, in the framework of the Health Programme [201012 01]; Kindness-for-Kids Foundation (Munich, Germany); radiz - Rare Disease Initiative Zurich, a clinical research priority programme of the University of Zurich; National Institute for Health Research University College London Hospitals Biomedical Research Centre	This publication arises from the project "European registry and network for intoxication type metabolic diseases" (E-IMD; EAHC no 201012 01) which has received funding from the European Union, in the framework of the Health Programme. After the end of the EU funding period the E-IMD patient registry will be sustained by funding from the Kindness-for-Kids Foundation (Munich, Germany).; M. Baumgartner, J. Haberle and A. Laemmle (Zurich, Switzerland) are supported by radiz - Rare Disease Initiative Zurich, a clinical research priority programme of the University of Zurich.; Drs Murphy and Lachmann were supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre.	Ah Mew Nicholas, 2013, J Pediatr, V162, P324, DOI 10.1016/j.jpeds.2012.06.065; Kolker S, 2002, PEDIATR RES, V52, DOI 10.1023/01.PDR.0000023176.89966.45; Zwickler T, 2012, J INHERIT METAB DIS, V35, P797, DOI 10.1007/s10545-011-9426-1; Teufel U, 2011, PEDIATR TRANSPLANT, V15, pE110, DOI 10.1111/j.1399-3046.2009.01171.x; Boy N, 2013, J INHERIT METAB DIS, V36, P525, DOI 10.1007/s10545-012-9517-7; Cole TJ, 1998, STAT MED, V17, P407, DOI 10.1002/(SICI)1097-0258(19980228)17:4<407::AID-SIM742>3.0.CO;2-L; Sauer SW, 2010, BBA-MOL BASIS DIS, V1802, P552, DOI 10.1016/j.bbadis.2010.03.003; Harting I, 2009, BRAIN, V132, P1764, DOI 10.1093/brain/awp112; Junquera CG, 2009, EUR J PEDIATR, V168, P103, DOI 10.1007/s00431-008-0696-z; Cole TJ, 2011, ANN HUM BIOL, V38, P7, DOI 10.3109/03014460.2011.544139; Schwab MA, 2006, BIOCHEM J, V398, P107, DOI 10.1042/BJ20060221; VANDERMEER SB, 1994, J PEDIATR-US, V125, P903, DOI 10.1016/S0022-3476(05)82005-0; Chandler RJ, 2009, FASEB J, V23, P1252, DOI 10.1096/fj.08-121848; Kolker S, 2007, PEDIATR RES, V62, P357; Vockley J, 2006, AM J MED GENET C, V142C, P95, DOI 10.1002/ajmg.c.30089; Kolker S, 2011, J INHERIT METAB DIS, V34, P677, DOI 10.1007/s10545-011-9289-5; Gallagher RC, 2014, J PEDIATR-US, V164, P720, DOI 10.1016/j.jpeds.2013.12.024; Loeber JG, 2012, J INHERIT METAB DIS, V35, P603, DOI 10.1007/s10545-012-9483-0; Heringer J, 2010, ANN NEUROL, V68, P743, DOI 10.1002/ana.22095; Summar ML, 2008, ACTA PAEDIATR, V97, P1420, DOI 10.1111/j.1651-2227.2008.00952.x; Pena L, 2012, MOL GENET METAB, V105, P5, DOI 10.1016/j.ymgme.2011.09.022; Strauss KA, 2010, BRAIN, V133, P76, DOI 10.1093/brain/awp297; Leonard JV, 2003, EUR J PEDIATR, V162, pS21, DOI 10.1007/s00431-003-1345-1; Okun JG, 2002, J BIOL CHEM, V277, P14674, DOI 10.1074/jbc.M200997200; Nassogne M, 2005, J INHERIT METAB DIS, V28, P407, DOI 10.1007/s10545-005-0303-7; Olsen RKJ, 2003, HUM MUTAT, V22, P12, DOI 10.1002/humu.10226; Strauss AW, 1999, SEMIN PERINATOL, V23, P100, DOI 10.1016/S0146-0005(99)80044-5; Sauer SW, 2006, J NEUROCHEM, V97, P899, DOI 10.1111/j.1471-4159.2006.03813.x; Mcclelland VM, 2009, DEV MED CHILD NEUROL, V51, P235, DOI 10.1111/j.1469-8749.2008.03240.x; Engelhardt B, 2014, CELL TISSUE RES, V355, P687, DOI 10.1007/s00441-014-1811-2; Kolker S, 2013, J INHERIT METAB DIS, V36, P635, DOI 10.1007/s10545-013-9600-8; Sauer SW, 2005, J BIOL CHEM, V280, P21830, DOI 10.1074/jbc.M502845200; Kolker S, 2006, PEDIATR RES, V59, P840, DOI 10.1203/01.pdr.0000219387.79887.86; Enns GM, 2007, NEW ENGL J MED, V356, P2282, DOI 10.1056/NEJMoa066596; Gabbe SG, 2012, OBSTET GYNECOL, V119, P171, DOI 10.1097/AOG.0b013e3182393208; Mustafa A, 2006, J INHERIT METAB DIS, V29, P586, DOI 10.1007/s10545-006-0303-0; Hoffmann GF, 1996, NEUROPEDIATRICS, V27, P115, DOI 10.1055/s-2007-973761; Liu JH, 2014, ANN EPIDEMIOL, V24, P441, DOI 10.1016/j.annepidem.2014.02.009; Summar ML, 2013, MOL GENET METAB, V110, P179, DOI 10.1016/j.ymgme.2013.07.008; Kido J, 2012, J INHERIT METAB DIS, V35, P777, DOI 10.1007/s10545-011-9427-0; Burgard P, 2012, J INHERIT METAB DIS, V35, P613, DOI 10.1007/s10545-012-9484-z; Lamp J, 2011, J BIOL CHEM, V286, P17777, DOI 10.1074/jbc.M111.232744; Tavares MV, 2013, J INHERIT METAB DIS, V36, P805, DOI 10.1007/s10545-012-9567-x; Sutton VR, 2012, MOL GENET METAB, V105, P26, DOI 10.1016/j.ymgme.2011.08.034; de Keyzer Y, 2009, PEDIATR RES, V66, P91, DOI 10.1203/PDR.0b013e3181a7c270; Dionisi-Vici C, 2006, J INHERIT METAB DIS, V29, P383, DOI 10.1007/s10545-006-0278-z; Chapman KA, 2012, MOL GENET METAB, V105, P16, DOI 10.1016/j.ymgme.2011.09.026; Strauss KA, 2007, BRAIN, V130, P1905, DOI 10.1093/brain/awm058; Batshaw ML, 2014, MOL GENET METAB, V113, P127, DOI 10.1016/j.ymgme.2014.08.001; Baumgartner MR, 2014, ORPHANET J RARE DIS, V9, DOI 10.1186/s13023-014-0130-8; COLE TJ, 1990, EUR J CLIN NUTR, V44, P45; DeBrosse, 2012, MOL GENET METAB, V107, P394; Grunert SC, 2012, ORPHANET J RARE DIS, V7, DOI 10.1186/1750-1172-7-9; Grunert SC, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-6; Haberle J, 2012, ORPHANET J RARE DIS, V7, DOI 10.1186/1750-1172-7-32; Kolker S, 2015, J INHERIT M IN PRESS; Nettesheim S, 2013, MONATSSCHR KINDER S2, V161, P166; R Core Team, 2014, R LANG ENV STAT COMP; Richter SJ, 2007, J MODERN APPL STAT M, V6, P399; Ruegger CM, 2014, J INHERIT METAB DIS, V37, P21, DOI 10.1007/s10545-013-9624-0; Sachs L, 2012, ANGEW STAT; Smucker MD, 2007, CIKM 07, P623, DOI DOI 10.1145/1321440.1321528; Whitfield, 1996, AM J PERINAT, V13, P131; Zwickler T, 2014, J INHERIT METAB DIS, V37, P31, DOI 10.1007/s10545-013-9621-3	64	2	2	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0141-8955	1573-2665		J INHERIT METAB DIS	J. Inherit. Metab. Dis.	NOV	2015	38	6					1041	1057		10.1007/s10545-015-9839-3		17	Endocrinology & Metabolism; Genetics & Heredity	Endocrinology & Metabolism; Genetics & Heredity	CV0YV	WOS:000363980800005		
J	Kolker, S; Valayannopoulos, V; Burlina, AB; Sykut-Cegielska, J; Wijburg, FA; Teles, EL; Zeman, J; Dionisi-Vici, C; Baric, I; Karall, D; Arnoux, JB; Avram, P; Baumgartner, MR; Blasco-Alonso, J; Boy, SPN; Rasmussen, MB; Burgard, P; Chabrol, B; Chakrapani, A; Chapman, K; Saladelafont, ECI; Couce, ML; de Meirleir, L; Dobbelaere, D; Furlan, F; Gleich, F; Gonzalez, MJ; Gradowska, W; Grunewald, S; Honzik, T; Horster, F; Ioannou, H; Jalan, A; Haberle, J; Haege, G; Langereis, E; de Lonlay, P; Martinelli, D; Matsumoto, S; Muhlhausen, C; Murphy, E; de Baulny, HO; Ortez, C; Pedron, CC; Pintos-Morell, G; Pena-Quintana, L; Ramadza, DP; Rodrigues, E; Scholl-Burgi, S; Sokal, E; Summar, ML; Thompson, N; Vara, R; Pinera, IV; Walter, JH; Williams, M; Lund, AM; Cazorla, AG				Koelker, Stefan; Valayannopoulos, Vassili; Burlina, Alberto B.; Sykut-Cegielska, Jolanta; Wijburg, Frits A.; Teles, Elisa Leao; Zeman, Jiri; Dionisi-Vici, Carlo; Baric, Ivo; Karall, Daniela; Arnoux, Jean-Baptiste; Avram, Paula; Baumgartner, Matthias R.; Blasco-Alonso, Javier; Boy, S. P. Nikolas; Rasmussen, Marlene Bogehus; Burgard, Peter; Chabrol, Brigitte; Chakrapani, Anupam; Chapman, Kimberly; Cortes i Saladelafont, Elisenda; Couce, Maria L.; de Meirleir, Linda; Dobbelaere, Dries; Furlan, Francesca; Gleich, Florian; Julieta Gonzalez, Maria; Gradowska, Wanda; Gruenewald, Stephanie; Honzik, Tomas; Hoerster, Friederike; Ioannou, Hariklea; Jalan, Anil; Haeberle, Johannes; Haege, Gisela; Langereis, Eveline; de Lonlay, Pascale; Martinelli, Diego; Matsumoto, Shirou; Muehlhausen, Chris; Murphy, Elaine; de Baulny, Helene Ogier; Ortez, Carlos; Pedron, Consuelo C.; Pintos-Morell, Guillem; Pena-Quintana, Luis; Ramadza, Danijela Petkovic; Rodrigues, Esmeralda; Scholl-Buergi, Sabine; Sokal, Etienne; Summar, Marshall L.; Thompson, Nicholas; Vara, Roshni; Vives Pinera, Inmaculada; Walter, John H.; Williams, Monique; Lund, Allan M.; Garcia Cazorla, Angeles			The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 2: the evolving clinical phenotype	JOURNAL OF INHERITED METABOLIC DISEASE			English	Article							COA DEHYDROGENASE-DEFICIENCY; ARGININOSUCCINATE LYASE DEFICIENCY; GLUTARIC ACIDURIA; METHYLMALONIC ACIDURIA; PROPIONIC ACIDEMIA; COENZYME-A; 3-HYDROXYGLUTARIC ACID; ISOVALERIC ACIDEMIA; HEAD CIRCUMFERENCE; NATURAL-HISTORY	Background The disease course and long-term outcome of patients with organic acidurias (OAD) and urea cycle disorders (UCD) are incompletely understood. Aims To evaluate the complex clinical phenotype of OAD and UCD patients at different ages. Results Acquired microcephaly and movement disorders were common in OAD and UCD highlighting that the brain is the major organ involved in these diseases. Cardiomyopathy [methylmalonic (MMA) and propionic aciduria (PA)], prolonged QT(c) interval (PA), optic nerve atrophy [MMA, isovaleric aciduria (IVA)], pancytopenia (PA), and macrocephaly [glutaric aciduria type 1 (GA1)] were exclusively found in OAD patients, whereas hepatic involvement was more frequent in UCD patients, in particular in argininosuccinate lyase (ASL) deficiency. Chronic renal failure was often found in MMA, with highest frequency in mut(0) patients. Unexpectedly, chronic renal failure was also observed in adolescent and adult patients with GA1 and ASL deficiency. It had a similar frequency in patients with or without a movement disorder suggesting different pathophysiology. Thirteen patients (classic OAD: 3, UCD: 10) died during the study interval, ten of them during the initial metabolic crisis in the newborn period. Male patients with late-onset ornithine transcarbamylase deficiency were presumably overrepresented in the study population. Conclusions Neurologic impairment is common in OAD and UCD, whereas the involvement of other organs (heart, liver, kidneys, eyes) follows a disease-specific pattern. The identification of unexpected chronic renal failure in GA1 and ASL deficiency emphasizes the importance of a systematic follow-up in patients with rare diseases.	[Koelker, Stefan; Boy, S. P. Nikolas; Burgard, Peter; Gleich, Florian; Hoerster, Friederike; Haege, Gisela] Univ Childrens Hosp Heidelberg, Dept Gen Pediat, Div Inherited Metab Dis, D-69120 Heidelberg, Germany; [Valayannopoulos, Vassili; Arnoux, Jean-Baptiste; de Lonlay, Pascale] Necker Enfants Malad Univ Hosp, Reference Ctr Inherited Metab Dis, Hop Necker Enfants Malad, AP HP, Paris, France; [Valayannopoulos, Vassili; Arnoux, Jean-Baptiste; de Lonlay, Pascale] IMAGINE Inst, Paris, France; [Burlina, Alberto B.; Furlan, Francesca] UOC Malattie Metab Ereditarie, Azienda Osped Padova, Padua, Italy; [Sykut-Cegielska, Jolanta] Inst Mother & Child Hlth, Screening Dept, Warsaw, Poland; [Wijburg, Frits A.; Langereis, Eveline] Univ Amsterdam, Acad Med Ctr, Dept Pediat, NL-1105 AZ Amsterdam, Netherlands; [Teles, Elisa Leao; Rodrigues, Esmeralda] EPE, Hosp S Joao, Serv Pediat, Unidade Doencas Metab, Oporto, Portugal; [Zeman, Jiri; Honzik, Tomas] Charles Univ Prague, Fac Med 1, Prague, Czech Republic; [Zeman, Jiri; Honzik, Tomas] Gen Univ Prague, Prague, Czech Republic; [Dionisi-Vici, Carlo; Martinelli, Diego] UOC Patol Metab, Osped Pediat Bambino Gesu, Rome, Italy; [Baric, Ivo] Univ Hosp Ctr Zagreb, Sch Med, Zagreb, Croatia; [Baric, Ivo] Univ Zagreb, Zagreb 41000, Croatia; [Karall, Daniela; Scholl-Buergi, Sabine] Med Univ Innsbruck, Clin Pediat 1, Inherited Metab Disorders, A-6020 Innsbruck, Austria; [Rasmussen, Marlene Bogehus; Lund, Allan M.] Copenhagen Univ Hosp, Rigshosp, Dept Clin Genet, Ctr Inherited Metab Dis, Copenhagen, Denmark; [Avram, Paula] Inst Mother & Child Care Alfred Rusescu, Bucharest, Romania; [Baumgartner, Matthias R.; Haeberle, Johannes] Univ Childrens Hosp Zurich, Div Metab, CH-8032 Zurich, Switzerland; [Baumgartner, Matthias R.; Haeberle, Johannes] Univ Childrens Hosp Zurich, Childrens Res Ctr, CH-8032 Zurich, Switzerland; [Blasco-Alonso, Javier] Hosp Maternoinfantil HRU Carlos Haya, Malaga, Spain; [Chabrol, Brigitte] CHU Timone, Hop Enfants, Serv Neurol, Ctr Reference Malad Hereditaires Metab, Marseilles, France; [Chakrapani, Anupam] Birmingham Childrens Hosp NHS Fdn Trust, Birmingham B4 6NH, W Midlands, England; [Chapman, Kimberly; Summar, Marshall L.] Childrens Natl Med Ctr, Washington, DC 20010 USA; [Cortes i Saladelafont, Elisenda; Julieta Gonzalez, Maria; Ortez, Carlos; Garcia Cazorla, Angeles] ISCIII, Serv Neurol, Hosp San Joan de Deu, Barcelona, Spain; [Cortes i Saladelafont, Elisenda; Julieta Gonzalez, Maria; Ortez, Carlos; Garcia Cazorla, Angeles] ISCIII, CIBERER, Barcelona, Spain; [Couce, Maria L.] Hosp Clinico Univ Santiago de Compostela, Dept Pediat, Metab Unit, Santiago De Compostela, Spain; [de Meirleir, Linda] Univ Hosp Vrije Univ Brussel, Brussels, Belgium; [Dobbelaere, Dries] Hop Jeanne de Flandre, Ctr Reference Malad Hereditaires Metab Enfant & A, Lille, France; [Gradowska, Wanda] Childrens Mem Hlth Inst, Dept Lab Diagnost, Warsaw, Poland; [Gruenewald, Stephanie; Thompson, Nicholas] UCL, Great Ormond St Hosp, Metab Unit, London, England; [Gruenewald, Stephanie; Thompson, Nicholas] UCL, Inst Child Hlth, London, England; [Ioannou, Hariklea] Gen Hosp Thessaloniki Hippocration, Metab Lab, Dept Pediat 1, Thessaloniki, Greece; [Jalan, Anil] NIRMAN, Om Rachna Soc, Bombay, Maharashtra, India; [Matsumoto, Shirou] Kumamoto Univ Hosp, Dept Pediat, Kumamoto, Japan; [Williams, Monique] Univ Klinikum Hamburg Eppendorf, Klin Kinder & Jugendmed, Hamburg, Germany; [Murphy, Elaine] Natl Hosp Neurol & Neurosurg, Charles Dent Metab Unit, London WC1N 3BG, England; [de Baulny, Helene Ogier] Univ Paris, Hop Robert Debre, F-75252 Paris, France; [Pedron, Consuelo C.] Hosp Infantil Univ Nino Jesus, Dept Pediat, Metab Dis Unit, Madrid, Spain; [Pintos-Morell, Guillem] Hosp Badalona Germans Trias & Pujol, Dept Pediat, Badalona, Spain; [Pena-Quintana, Luis; Ramadza, Danijela Petkovic] Univ Hosp Ctr Zagreb, Zagreb, Croatia; [Sokal, Etienne] Catholic Univ Louvain, Clin Univ St Luc, Serv Gastroenterol & Hepatol Pediat, B-1200 Brussels, Belgium; [Vara, Roshni] St Thomas Hosp, Evelina Childrens Hosp, London, England; [Vives Pinera, Inmaculada] Hosp Virgen Arrixaca Murcia, Inborn Metab Dis Unit, El Palmar, Spain; [Walter, John H.] Univ Manchester, Manchester Acad Hlth Sci Ctr, Willink Biochem Genet Unit, Genet Med, Manchester, Lancs, England; [Williams, Monique] Erasmus Univ, Erasmus MC Sophia Kinderziekenhuis, Rotterdam, Netherlands	Kolker, S (reprint author), Univ Childrens Hosp Heidelberg, Dept Gen Pediat, Div Inherited Metab Dis, Neuenheimer Feld 430, D-69120 Heidelberg, Germany.	Stefan_Koelker@med.uni-heidelberg.de		blasco-alonso, javier/0000-0003-4008-3747	European Union, in the framework of the Health Programme [201012 01]; Kindness-for-Kids Foundation (Munich, Germany); Dietmar Hopp Foundation (St. Leon-Rot, Germany); radiz - Rare Disease Initiative Zurich, a clinical research priority program of the University of Zurich; National Institute for Health Research University College London Hospitals Biomedical Research Centre	This publication arises from the project "European registry and network for intoxication type metabolic diseases" (E-IMD; EAHC no 201012 01) which has received funding from the European Union, in the framework of the Health Programme. After the end of the EU funding period the E-IMD patient registry has been sustained by funding from the Kindness-for-Kids Foundation (Munich, Germany) and the Dietmar Hopp Foundation (St. Leon-Rot, Germany).; M. Baumgartner and J. Haberle (Zurich, Switzerland) are supported by radiz - Rare Disease Initiative Zurich, a clinical research priority program of the University of Zurich.; Drs Murphy and Lachmann were supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre	Mew NA, 2013, J PEDIATR-US, V162, P324, DOI 10.1016/j.jpeds.2012.06.065; Nagamani SCS, 2012, MOL GENET METAB, V107, P315, DOI 10.1016/j.ymgme.2012.09.016; Poge AP, 1997, ACTA PAEDIATR, V86, P1144, DOI 10.1111/j.1651-2227.1997.tb14827.x; Takanashi J, 2003, AM J NEURORADIOL, V24, P1184; GOODMAN SI, 1975, BIOCHEM MED METAB B, V12, P12, DOI 10.1016/0006-2944(75)90091-5; Jamuar SS, 2012, MOL GENET METAB, V106, P488, DOI 10.1016/j.ymgme.2012.05.018; Teufel U, 2011, PEDIATR TRANSPLANT, V15, pE110, DOI 10.1111/j.1399-3046.2009.01171.x; Baric I, 1999, J INHERIT METAB DIS, V22, P867, DOI 10.1023/A:1005683222187; Boy N, 2013, J INHERIT METAB DIS, V36, P525, DOI 10.1007/s10545-012-9517-7; Gropman A, 2010, MOL GENET METAB, V100, pS20, DOI 10.1016/j.ymgme.2010.01.017; Williams ZR, 2009, AM J OPHTHALMOL, V147, P929, DOI 10.1016/j.ajo.2008.12.024; Cole TJ, 1998, STAT MED, V17, P407, DOI 10.1002/(SICI)1097-0258(19980228)17:4<407::AID-SIM742>3.0.CO;2-L; Sauer SW, 2010, BBA-MOL BASIS DIS, V1802, P552, DOI 10.1016/j.bbadis.2010.03.003; Harting I, 2009, BRAIN, V132, P1764, DOI 10.1093/brain/awp112; Cole TJ, 2011, ANN HUM BIOL, V38, P7, DOI 10.3109/03014460.2011.544139; Braissant O, 2013, J INHERIT METAB DIS, V36, P595, DOI 10.1007/s10545-012-9546-2; Schwab MA, 2006, BIOCHEM J, V398, P107, DOI 10.1042/BJ20060221; Zinnanti WJ, 2007, J CLIN INVEST, V117, P3258, DOI 10.1172/JCI31617; Ensenauer R, 2004, AM J HUM GENET, V75, P1136, DOI 10.1086/426318; Marquard J, 2011, EUR J PEDIATR, V170, P241, DOI 10.1007/s00431-010-1313-5; Erez A, 2011, NAT MED, V17, P1619, DOI 10.1038/nm.2544; Chandler RJ, 2009, FASEB J, V23, P1252, DOI 10.1096/fj.08-121848; Tuchman M, 2008, MOL GENET METAB, V94, P397, DOI 10.1016/j.ymgme.2008.05.004; Gitiaux C, 2008, MOVEMENT DISORD, V23, P2392, DOI 10.1002/mds.22313; Kolker S, 2007, PEDIATR RES, V62, P357; Mirandola SR, 2008, J INHERIT METAB DIS, V31, P44, DOI 10.1007/s10545-007-0798-1; Kolker S, 2011, J INHERIT METAB DIS, V34, P677, DOI 10.1007/s10545-011-9289-5; Horster F, 2007, PEDIATR RES, V62, P225; Heringer J, 2010, ANN NEUROL, V68, P743, DOI 10.1002/ana.22095; Summar ML, 2008, ACTA PAEDIATR, V97, P1420, DOI 10.1111/j.1651-2227.2008.00952.x; Mori T, 2002, PEDIATR DEVEL PATHOL, V5, P597, DOI 10.1007/s10024-002-0109-7; Pena L, 2012, MOL GENET METAB, V105, P5, DOI 10.1016/j.ymgme.2011.09.022; Hassel B, 2002, J NEUROCHEM, V82, P410, DOI 10.1046/j.1471-4159.2002.00986.x; Garbade SF, 2014, J INHERIT METAB DIS, V37, P763, DOI 10.1007/s10545-014-9676-9; Stellmer F, 2007, J MOL MED-JMM, V85, P763, DOI 10.1007/s00109-007-0174-5; Horster F, 2009, J INHERIT METAB DIS, V32, P630, DOI 10.1007/s10545-009-1189-6; Strauss KA, 2010, BRAIN, V133, P76, DOI 10.1093/brain/awp297; Mitchell GA, 2008, MOL GENET METAB, V94, P4, DOI 10.1016/j.ymgme.2007.12.005; Brunengraber H, 2006, J INHERIT METAB DIS, V29, P327, DOI 10.1007/s10545-006-0320-1; Baruteau J, 2014, MITOCHONDRION, V17, P150, DOI 10.1016/j.mito.2014.07.001; Nassogne M, 2005, J INHERIT METAB DIS, V28, P407, DOI 10.1007/s10545-005-0303-7; Cosson MA, 2009, MOL GENET METAB, V97, P172, DOI 10.1016/j.ymgme.2009.03.006; Dewar D, 2003, J CEREBR BLOOD F MET, V23, P263, DOI 10.1097/01.WCB.0000053472.41007.F9; Morath MA, 2008, J INHERIT METAB DIS, V31, P35, DOI 10.1007/s10545-007-0571-5; Kolker S, 2013, J INHERIT METAB DIS, V36, P635, DOI 10.1007/s10545-013-9600-8; HAYASAKA K, 1982, TOHOKU J EXP MED, V137, P329, DOI 10.1620/tjem.137.329; Serrano M, 2010, J CHILD NEUROL, V25, P352, DOI 10.1177/0883073809340696; Sauer SW, 2005, J BIOL CHEM, V280, P21830, DOI 10.1074/jbc.M502845200; Kolker S, 2006, PEDIATR RES, V59, P840, DOI 10.1203/01.pdr.0000219387.79887.86; Enns GM, 2007, NEW ENGL J MED, V356, P2282, DOI 10.1056/NEJMoa066596; Prada CE, 2011, J PEDIATR-US, V159, P862, DOI 10.1016/j.jpeds.2011.06.005; COUDE FX, 1979, J CLIN INVEST, V64, P1544, DOI 10.1172/JCI109614; Mustafa A, 2006, J INHERIT METAB DIS, V29, P586, DOI 10.1007/s10545-006-0303-0; Komatsuzaki S, 2012, NEUROLOGY, V79, pE63, DOI 10.1212/WNL.0b013e3182648bb6; Seminara J, 2010, MOL GENET METAB, V100, pS97, DOI 10.1016/j.ymgme.2010.01.014; Traber G, 2011, J NEURO-OPHTHALMOL, V31, P344, DOI 10.1097/WNO.0b013e31822db480; Thies B, 2013, BBA-MOL BASIS DIS, V1832, P1463, DOI 10.1016/j.bbadis.2013.04.019; Lamp J, 2011, J BIOL CHEM, V286, P17777, DOI 10.1074/jbc.M111.232744; de Keyzer Y, 2009, PEDIATR RES, V66, P91, DOI 10.1203/PDR.0b013e3181a7c270; Nguyen NHT, 2007, J NEUROCHEM, V101, P806, DOI 10.1111/j.1471-4159.2006.04397.x; Chapman KA, 2012, MOL GENET METAB, V105, P16, DOI 10.1016/j.ymgme.2011.09.026; Strauss KA, 2007, BRAIN, V130, P1905, DOI 10.1093/brain/awm058; Batshaw ML, 2001, J PEDIATR-US, V138, pS46, DOI 10.1067/mpd.2001.111836; Butterworth RF, 2014, MOL GENET METAB, V113, P113, DOI 10.1016/j.ymgme.2014.06.003; Cavicchi C, 2014, ORPHANET J RARE DIS, V9, DOI 10.1186/s13023-014-0105-9; COLE TJ, 1990, EUR J CLIN NUTR, V44, P45; Grunert SC, 2012, ORPHANET J RARE DIS, V7, DOI 10.1186/1750-1172-7-9; Grunert SC, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-6; Hagos Y, 2008, PFLUGERS ARCH, V457, P225; Hawkins RA, 2006, J NUTR, V136, P218; Herskovitz M, 2013, NEUROLOGY, V81, P849, DOI 10.1212/WNL.0b013e3182a2cbf2; Kolker S, J INHERIT METAB DIS; Mercimek-Mahmutoglu S, 2010, MOL GENET METAB, V100, P24, DOI 10.1016/j.ymgme.2010.01.013; Nizon M, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-148; R Core Team, 2014, R LANG ENV STAT COMP; Romano S, 2010, J PEDIATR-US, V156, P128, DOI 10.1016/j.jpeds.2009.07.002; Ruegger CM, 2014, J INHERIT METAB DIS, V37, P31; Sokoloff L, 1960, HDB PHYSL 1, VII, P161; Strobl R, 2004, BIOMET J S1, V46, P90, DOI 10.1002/bimj.200490298; Therneau T.M., 2014, PACKAGE SURVIVAL ANA	80	2	2	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0141-8955	1573-2665		J INHERIT METAB DIS	J. Inherit. Metab. Dis.	NOV	2015	38	6					1059	1074		10.1007/s10545-015-9840-x		16	Endocrinology & Metabolism; Genetics & Heredity	Endocrinology & Metabolism; Genetics & Heredity	CV0YV	WOS:000363980800006		
J	Kolker, S; Garcia-Cazorla, A; Valayannopoulos, V; Lund, AM; Burlina, AB; Sykut-Cegielska, J; Wijburg, FA; Teles, EL; Zeman, J; Dionisi-Vici, C; Baric, I; Karall, D; Augoustides-Savvopoulou, P; Aksglaede, L; Arnoux, JB; Avram, P; Baumgartner, MR; Blasco-Alonso, J; Chabrol, B; Chakrapani, A; Chapman, K; Saladelafont, ECI; Couce, ML; de Meirleir, L; Dobbelaere, D; Dvorakova, V; Furlan, F; Gleich, F; Gradowska, W; Grunewald, S; Jalan, A; Haberle, J; Haege, G; Lachmann, R; Laemmle, A; Langereis, E; de Lonlay, P; Martinelli, D; Matsumoto, S; Muhlhausen, C; de Baulny, HO; Ortez, C; Pena-Quintana, L; Ramadza, DP; Rodrigues, E; Scholl-Burgi, S; Sokal, E; Staufner, C; Summar, ML; Thompson, N; Vara, R; Pinera, IV; Walter, JH; Williams, M; Burgard, P				Koelker, Stefan; Garcia-Cazorla, Angeles; Valayannopoulos, Vassili; Lund, Allan M.; Burlina, Alberto B.; Sykut-Cegielska, Jolanta; Wijburg, Frits A.; Teles, Elisa Leao; Zeman, Jiri; Dionisi-Vici, Carlo; Baric, Ivo; Karall, Daniela; Augoustides-Savvopoulou, Persephone; Aksglaede, Lise; Arnoux, Jean-Baptiste; Avram, Paula; Baumgartner, Matthias R.; Blasco-Alonso, Javier; Chabrol, Brigitte; Chakrapani, Anupam; Chapman, Kimberly; Cortes i Saladelafont, Elisenda; Couce, Maria L.; de Meirleir, Linda; Dobbelaere, Dries; Dvorakova, Veronika; Furlan, Francesca; Gleich, Florian; Gradowska, Wanda; Gruenewald, Stephanie; Jalan, Anil; Haeberle, Johannes; Haege, Gisela; Lachmann, Robin; Laemmle, Alexander; Langereis, Eveline; de Lonlay, Pascale; Martinelli, Diego; Matsumoto, Shirou; Muehlhausen, Chris; de Baulny, Helene Ogier; Ortez, Carlos; Pena-Quintana, Luis; Petkovic Ramadza, Danijela; Rodrigues, Esmeralda; Scholl-Buergi, Sabine; Sokal, Etienne; Staufner, Christian; Summar, Marshall L.; Thompson, Nicholas; Vara, Roshni; Vives Pinera, Inmaculada; Walter, John H.; Williams, Monique; Burgard, Peter			The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 1: the initial presentation (vol 38, pg 1041, 2015)	JOURNAL OF INHERITED METABOLIC DISEASE			English	Correction									[Koelker, Stefan; Gleich, Florian; Haege, Gisela; Staufner, Christian; Burgard, Peter] Univ Childrens Hosp, Div Inherited Metab Dis, Dept Gen Pediat, D-69120 Heidelberg, Germany; [Garcia-Cazorla, Angeles; Cortes i Saladelafont, Elisenda; Ortez, Carlos] Hosp San Joan de Deu, Serv Neurol, ISCIII, Barcelona, Spain; [Garcia-Cazorla, Angeles; Cortes i Saladelafont, Elisenda; Ortez, Carlos] Hosp San Joan de Deu, CIBERER, ISCIII, Barcelona, Spain; [Valayannopoulos, Vassili; Arnoux, Jean-Baptiste; de Lonlay, Pascale] Necker Enfants Malad Univ Hosp, Hop Necker Enfants Malad, AP HP, Reference Ctr Inherited Metab Dis, Paris, France; [Valayannopoulos, Vassili; Arnoux, Jean-Baptiste; de Lonlay, Pascale] IMAGINE Inst, Paris, France; [Lund, Allan M.; Aksglaede, Lise] Copenhagen Univ Hosp, Rigshosp, Dept Clin Genet, Ctr Inherited Metab Dis, Copenhagen, Denmark; [Burlina, Alberto B.; Furlan, Francesca] Azienda Osped Padova, UOC Malattie Metab Ereditarie, Padua, Italy; [Sykut-Cegielska, Jolanta] Inst Mother & Child Hlth, Screening Dept, Warsaw, Poland; [Wijburg, Frits A.; Langereis, Eveline] Univ Amsterdam, Acad Med Ctr, Dept Pediat, NL-1105 AZ Amsterdam, Netherlands; [Teles, Elisa Leao; Rodrigues, Esmeralda] Hosp Sao Joao, EPE, Serv Pediat, Unidade Doencas Metab, Oporto, Portugal; [Zeman, Jiri; Dvorakova, Veronika] Charles Univ Prague, Fac Med 1, Prague, Czech Republic; [Zeman, Jiri; Dvorakova, Veronika] Gen Univ Prague, Prague, Czech Republic; [Dionisi-Vici, Carlo; Martinelli, Diego] Osped Pediat Bambino Gesu, UOC Patol Metab, Rome, Italy; [Baric, Ivo] Univ Hosp Ctr Zagreb, Sch Med, Zagreb, Croatia; [Baric, Ivo] Univ Zagreb, Zagreb 41000, Croatia; [Karall, Daniela; Scholl-Buergi, Sabine] Med Univ Innsbruck, Clin Pediat 1, Inherited Metab Disorders, A-6020 Innsbruck, Austria; [Augoustides-Savvopoulou, Persephone] Gen Hosp Thessaloniki Hippocrat, Metab Lab, Dept Pediat 1, Thessaloniki, Greece; [Avram, Paula] Inst Mother & Child Care Alfred Rusescu, Bucharest, Romania; [Baumgartner, Matthias R.; Haeberle, Johannes; Laemmle, Alexander] Univ Childrens Hosp Zurich, Div Metab, CH-8032 Zurich, Switzerland; [Baumgartner, Matthias R.; Haeberle, Johannes; Laemmle, Alexander] Univ Childrens Hosp Zurich, Childrens Res Ctr, CH-8032 Zurich, Switzerland; [Blasco-Alonso, Javier] Hosp Materno Infantil, HRU Carlos Haya, Malaga, Spain; [Chabrol, Brigitte] CHU Timone, Hop Enfants, Serv Neurol, Ctr Reference Malad Hereditaires Metab, Marseilles, France; [Chakrapani, Anupam] Birmingham Childrens Hosp NHS Fdn Trust, Birmingham B4 6NH, W Midlands, England; [Chapman, Kimberly; Summar, Marshall L.] Childrens Natl Med Ctr, Washington, DC 20010 USA; [Couce, Maria L.] Univ Santiago de Compostela, Hosp Clin, Dept Pediat, Metab Unit, Santiago De Compostela, Spain; [de Meirleir, Linda] Vrije Univ Brussel, Univ Hosp, Brussels, Belgium; [Dobbelaere, Dries] Hop Jeanne de Flandre, Ctr Reference Malad Hereditaires Metab Enfant & A, Lille, France; [Gradowska, Wanda] Childrens Mem Hlth Inst, Dept Lab Diagnost, Warsaw, Poland; [Gruenewald, Stephanie; Thompson, Nicholas] UCL, Great Ormond St Hosp, Metab Unit, London, England; [Gruenewald, Stephanie; Thompson, Nicholas] UCL, Inst Child Hlth, London, England; [Jalan, Anil] Om Rachna Soc, NIRMAN, Bombay, Maharashtra, India; [Lachmann, Robin] Natl Hosp Neurol & Neurosurg, Charles Dent Metab Unit, London WC1N 3BG, England; [Matsumoto, Shirou] Kumamoto Univ Hosp, Dept Pediat, Kumamoto, Japan; [Muehlhausen, Chris] Univ Klinikum Hamburg Eppendorf, Klin Kinder & Jugendmed, Hamburg, Germany; [de Baulny, Helene Ogier] Univ Paris, Hop Robert Debre, F-75252 Paris, France; [Petkovic Ramadza, Danijela] Univ Hosp Ctr Zagreb, Zagreb, Croatia; [Pena-Quintana, Luis] Univ Las Palmas Gran Canaria, Unit Pediat Gastroenterol Hepatol & Nutr, Hosp Univ Materno Infantil Canarias, Las Palmas Gran Canaria, Spain; [Sokal, Etienne] Catholic Univ Louvain, Clin Univ St Luc, Serv Gastroenterol & Hepatol Pediat, B-1200 Brussels, Belgium; [Vara, Roshni] St Thomas Hosp, Evelina Childrens Hosp, London, England; [Vives Pinera, Inmaculada] Hosp Virgen de la Arrixaca Murcia, Inborn Metab Dis Unit, El Palmar, Spain; [Walter, John H.] Univ Manchester, Manchester Acad Hlth Sci Ctr, Willink Biochem Genet Unit, Genet Med, Manchester, Lancs, England; [Williams, Monique] Erasmus Univ, Erasmus MC Sophia Kinderziekenhuis, Rotterdam, Netherlands	Kolker, S (reprint author), Univ Childrens Hosp, Div Inherited Metab Dis, Dept Gen Pediat, Neuenheimer Feld 430, D-69120 Heidelberg, Germany.	Stefan.Koelker@med.uni-heidelberg.de					Kolker S, 2015, J INHERIT METAB DIS, V38, P1041, DOI 10.1007/s10545-015-9839-3	1	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0141-8955	1573-2665		J INHERIT METAB DIS	J. Inherit. Metab. Dis.	NOV	2015	38	6					1155	1156		10.1007/s10545-015-9867-z		2	Endocrinology & Metabolism; Genetics & Heredity	Endocrinology & Metabolism; Genetics & Heredity	CV0YV	WOS:000363980800016		
J	Kolker, S; Valayannopoulos, V; Burlina, AB; Sykut-Cegielska, J; Wijburg, FA; Teles, EL; Zeman, J; Dionisi-Vici, C; Baric, I; Karall, D; Arnoux, JB; Avram, P; Baumgartner, MR; Blasco-Alonso, J; Boy, SPN; Rasmussen, MB; Burgard, P; Chabrol, B; Chakrapani, A; Chapman, K; Saladelafont, ECI; Couce, ML; de Meirleir, L; Dobbelaere, D; Furlan, F; Gleich, F; Gonzalez, MJ; Gradowska, W; Grunewald, S; Honzik, T; Horster, F; Ioannou, H; Jalan, A; Haberle, J; Haege, G; Langereis, E; de Lonlay, P; Martinelli, D; Matsumoto, S; Muhlhausen, C; Murphy, E; de Baulny, HO; Ortez, C; Pedron, CC; Pintos-Morell, G; Pena-Quintana, L; Ramadza, DP; Rodrigues, E; Scholl-Burgi, S; Sokal, E; Summar, ML; Thompson, N; Vara, R; Pinera, IV; Walter, JH; Williams, M; Lund, AM; Garcia-Cazorla, A				Koelker, Stefan; Valayannopoulos, Vassili; Burlina, Alberto B.; Sykut-Cegielska, Jolanta; Wijburg, Frits A.; Teles, Elisa Leao; Zeman, Jiri; Dionisi-Vici, Carlo; Baric, Ivo; Karall, Daniela; Arnoux, Jean-Baptiste; Avram, Paula; Baumgartner, Matthias R.; Blasco-Alonso, Javier; Boy, S. P. Nikolas; Rasmussen, Marlene Bogehus; Burgard, Peter; Chabrol, Brigitte; Chakrapani, Anupam; Chapman, Kimberly; Cortes i Saladelafont, Elisenda; Couce, Maria L.; de Meirleir, Linda; Dobbelaere, Dries; Furlan, Francesca; Gleich, Florian; Julieta Gonzalez, Maria; Gradowska, Wanda; Gruenewald, Stephanie; Honzik, Tomas; Hoerster, Friederike; Ioannou, Hariklea; Jalan, Anil; Haeberle, Johannes; Haege, Gisela; Langereis, Eveline; de Lonlay, Pascale; Martinelli, Diego; Matsumoto, Shirou; Muehlhausen, Chris; Murphy, Elaine; de Baulny, Helesne Ogier; Ortez, Carlos; Pedron, Consuelo C.; Pintos-Morell, Guillem; Pena-Quintana, Luis; Petkovic Ramadza, Danijela; Rodrigues, Esmeralda; Scholl-Buergi, Sabine; Sokal, Etienne; Summar, Marshall L.; Thompson, Nicholas; Vara, Roshni; Vives Pinera, Inmaculada; Walter, John H.; Williams, Monique; Lund, Allan M.; Garcia-Cazorla, Angeles			The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 2: the evolving clinical phenotype (vol 38, pg 1059, 2015)	JOURNAL OF INHERITED METABOLIC DISEASE			English	Correction									[Koelker, Stefan; Boy, S. P. Nikolas; Burgard, Peter; Gleich, Florian; Hoerster, Friederike] Univ Childrens Hosp Heidelberg, Dept Gen Pediat, Div Inherited Metab Dis, D-69120 Heidelberg, Germany; [Valayannopoulos, Vassili; Arnoux, Jean-Baptiste; de Lonlay, Pascale] Necker Enfants Malad Univ Hosp, Hop Necker Enfants Malad, AP HP, Reference Ctr Inherited Metab Dis, Paris, France; [Burlina, Alberto B.; Furlan, Francesca] Azienda Osped Padova, UOC Malattie Metab Ereditarie, Padua, Italy; [Sykut-Cegielska, Jolanta] Inst Mother & Child Hlth, Screening Dept, Warsaw, Poland; [Wijburg, Frits A.; Langereis, Eveline] Univ Amsterdam, Acad Med Ctr, Dept Pediat, NL-1105 AZ Amsterdam, Netherlands; [Teles, Elisa Leao; Rodrigues, Esmeralda] Hosp Sao Joao, EPE, Serv Pediat, Unidade Doencas Metab, Oporto, Portugal; [Zeman, Jiri; Honzik, Tomas] Charles Univ Prague, Fac Med 1, Prague, Czech Republic; [Zeman, Jiri; Honzik, Tomas] Gen Univ Prague, Prague, Czech Republic; [Dionisi-Vici, Carlo; Martinelli, Diego] Osped Pediat Bambino Gesu, UOC Patol Metab, Rome, Italy; [Baric, Ivo] Univ Hosp Ctr Zagreb, Sch Med, Zagreb, Croatia; [Baric, Ivo] Univ Zagreb, Zagreb 41000, Croatia; [Karall, Daniela; Scholl-Buergi, Sabine] Med Univ Innsbruck, Clin Pediat 1, Inherited Metab Disorders, A-6020 Innsbruck, Austria; [Rasmussen, Marlene Bogehus] Copenhagen Univ Hosp, Rigshosp, Dept Clin Genet, Ctr Inherited Metab Dis, Copenhagen, Denmark; [Avram, Paula] Inst Mother & Child Care Alfred Rusescu, Bucharest, Romania; [Baumgartner, Matthias R.; Haeberle, Johannes] Univ Childrens Hosp Zurich, Div Metab, CH-8032 Zurich, Switzerland; [Baumgartner, Matthias R.; Haeberle, Johannes] Univ Childrens Hosp Zurich, Childrens Res Ctr, CH-8032 Zurich, Switzerland; [Blasco-Alonso, Javier] Hosp Materno Infantil, HRU Carlos Haya, Malaga, Spain; [Chabrol, Brigitte] CHU Timone, Hop Enfants, Serv Neurol, Ctr Reference Malad Hereditaires Metab, Marseilles, France; [Chakrapani, Anupam] Birmingham Childrens Hosp NHS Fdn Trust, Birmingham B4 6NH, W Midlands, England; [Chapman, Kimberly; Summar, Marshall L.] Childrens Natl Med Ctr, Washington, DC 20010 USA; [Cortes i Saladelafont, Elisenda; Julieta Gonzalez, Maria; Ortez, Carlos; Garcia-Cazorla, Angeles] Hosp San Joan de Deu, Serv Neurol, Barcelona, Spain; [Cortes i Saladelafont, Elisenda; Julieta Gonzalez, Maria; Garcia-Cazorla, Angeles] Hosp San Joan de Deu, CIBERER, ISCIII, Barcelona, Spain; [Couce, Maria L.] Univ Santiago de Compostela, Hosp Clinico, Dept Pediat, Metab Unit, Santiago De Compostela, Spain; [de Meirleir, Linda] Vrije Univ Brussel, Univ Hosp, Brussels, Belgium; [Dobbelaere, Dries] Hop Jeanne de Flandre, Ctr Reference Malad Hereditaires Metab Enfant & A, Lille, France; [Gradowska, Wanda] Childrens Mem Hlth Inst, Dept Lab Diagnost, Warsaw, Poland; [Gruenewald, Stephanie; Thompson, Nicholas] UCL, Great Ormond St Hosp, Metab Unit, London, England; [Gruenewald, Stephanie; Thompson, Nicholas] UCL, Inst Child Hlth, London, England; [Ioannou, Hariklea] Gen Hosp Thessaloniki Hippocrat, Metab Lab, Dept Pediat 1, Thessaloniki, Greece; [Jalan, Anil] Om Rachna Soc, NIRMAN, Bombay, Maharashtra, India; [Matsumoto, Shirou] Kumamoto Univ Hosp, Dept Pediat, Kumamoto, Japan; [Muehlhausen, Chris] Univ Klinikum Hamburg Eppendorf, Klin Kinder & Jugendmed, Hamburg, Germany; [Murphy, Elaine] Natl Hosp Neurol & Neurosurg, Charles Dent Metab Unit, London WC1N 3BG, England; [de Baulny, Helesne Ogier] Univ Paris, Hop Robert Debre, F-75252 Paris, France; [Pedron, Consuelo C.] Hosp Infantil Univ Nino Jesus, Metab Dis Unit, Dept Pediat, Madrid, Spain; [Pintos-Morell, Guillem] Hosp Badalona Germans Trias & Pujol, Dept Pediat, Badalona, Spain; [Pena-Quintana, Luis; Petkovic Ramadza, Danijela] Univ Hosp Ctr Zagreb, Zagreb, Croatia; Univ Las Palmas Gran Canaria, Hosp Univ Materno Infantil Canarias, Unit Pediat Gastroenterol Hepatol & Nutr, Las Palmas Gran Canaria, Spain; [Sokal, Etienne] Catholic Univ Louvain, Clin Univ St Luc, Serv Gastroenterol & Hepatol Pediat, B-1200 Brussels, Belgium; [Vara, Roshni] St Thomas Hosp, Evelina Childrens Hosp, London, ON, Canada; [Vives Pinera, Inmaculada] Hosp Virgen de la Arrixaca Murcia, Inborn Metab Dis Unit, El Palmar, Spain; [Walter, John H.] Univ Manchester, Manchester Acad Hlth Sci Ctr, Willink Biochem Genet Unit, Genet Med, Manchester, Lancs, England; [Williams, Monique] Erasmus Univ, Erasmus MC Sophia Kinderziekenhuis, Rotterdam, Netherlands	Kolker, S (reprint author), Univ Childrens Hosp Heidelberg, Dept Gen Pediat, Div Inherited Metab Dis, Neuenheimer Feld 430, D-69120 Heidelberg, Germany.	Stefan_Koelker@med.uni-heidelberg.de					Kolker S, 2015, J INHERIT METAB DIS, V38, P1059, DOI 10.1007/s10545-015-9840-x	1	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0141-8955	1573-2665		J INHERIT METAB DIS	J. Inherit. Metab. Dis.	NOV	2015	38	6					1157	1158		10.1007/s10545-015-9868-y		2	Endocrinology & Metabolism; Genetics & Heredity	Endocrinology & Metabolism; Genetics & Heredity	CV0YV	WOS:000363980800017		
J	Narumoto, K; Sugimura, M; Saga, K; Matsunaga, Y				Narumoto, Keiichiro; Sugimura, Motoi; Saga, Kozue; Matsunaga, Youichi			Changes in pelvic shape among Japanese pregnant women over the last 5 decades	JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH			English	Article						anthropoid; gynecoid; Japan; pelvis		AimPelvic shape affects the progression of labor. The gynecoid-type pelvis has been the most common in women, but a previous study reported that the anthropoid type has increased in Japan. The purpose of this study was to examine: (i) the current prevalence of different pelvic shapes in Japanese pregnant women; and (ii) the changes in the prevalence of the pelvic shapes over the past 50 years. Material and MethodsWe conducted a cross-sectional study using descriptive analysis for the prevalence of the pelvic shape and a historical comparison to assess the changes in the proportions of pelvic shapes with Japanese data from the 1960s to the 1980s. We reviewed a total of 517 delivery records from May 2010 to August 2012 at a rural Japanese hospital where prenatal X-ray pelvimetry had been routinely performed as local practice. We analyzed the readings of the digital imaging data in pregnant women who underwent X-ray pelvimetry. ResultsWe identified the X-ray data in 326 Japanese pregnant women. The prevalence of the anthropoid, gynecoid and flat types was 151 (46.3%), 142 (43.6%), and 33 (10.1%), respectively. There were no differences in the maternal characteristics according to the pelvic shapes. The prevalence of the anthropoid-type pelvis has increased by approximately 40% and that of the gynecoid type has decreased by 20% since the 1960s. ConclusionThe prevalence of the anthropoid-type pelvis have significantly increased in Japan. Identifying a determinant of this phenomenon requires further research.	[Narumoto, Keiichiro; Sugimura, Motoi] Hamamatsu Univ, Sch Med, Dept Obstet Gynecol & Family Med, Hamamatsu, Shizuoka 4313192, Japan; [Saga, Kozue] Juzen Kinen Hosp, Dept Obstet & Gynecol, Hamamatsu, Shizuoka, Japan; [Matsunaga, Youichi] Kikugawa Municipal Gen Hosp, Dept Obstet & Gynecol, Shizuoka, Japan	Narumoto, K (reprint author), Hamamatsu Univ, Sch Med, Dept Obstet Gynecol & Family Med, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan.	k-narunaru@hotmail.co.jp					Schulze-Rath R, 2008, RADIAT ENVIRON BIOPH, V47, P301, DOI 10.1007/s00411-008-0171-2; Walrath D, 2003, CURR ANTHROPOL, V44, P5, DOI 10.1086/344489; STODDART TG, 1946, CAN MED ASSOC J, V54, P50; ANGEL JL, 1982, AM J PHYS ANTHROPOL, V58, P297, DOI 10.1002/ajpa.1330580308; KALTREIDER DF, 1952, AM J OBSTET GYNECOL, V63, P392; Ponkey SE, 2003, OBSTET GYNECOL, V101, P915, DOI 10.1016/S0029-7844(03)00068-1; EICH GF, 1992, RADIOGRAPHICS, V12, P467; CALDWELL W. E., 1938, PROC ROY SOC MED, V32, P1; Cunningham FG, 2009, WILLIAMS OBSTET; LAVELLE M, 1995, AM J PHYS ANTHROPOL, V98, P59, DOI 10.1002/ajpa.1330980106; MENGERT WF, 1948, JAMA-J AM MED ASSOC, V138, P169; Moloy HC, 1975, MOLOYS EVALUATION PE; Pattinson RC, 1997, COCHRANE DATABASE SY; STEWART DB, 1984, BRIT J OBSTET GYNAEC, V91, P618, DOI 10.1111/j.1471-0528.1984.tb04819.x; Suzuki R, 2010, AM J OBSTET GYNECOL, V203; Takahashi N, 1985, BOSEIEISEI, V26, P269; Takahashi T, 1992, JOSANPU, V46, P18; Thoms H, 1939, Yale J Biol Med, V11, P179	18	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1341-8076	1447-0756		J OBSTET GYNAECOL RE	J. Obstet. Gynaecol. Res.	NOV	2015	41	11					1687	1692		10.1111/jog.12778		6	Obstetrics & Gynecology	Obstetrics & Gynecology	CU9SR	WOS:000363885900002		
J	Yamashita, M; Hayashi, S; Endo, M; Okuno, K; Fukui, O; Mimura, K; Tachibana, Y; Ishii, K; Mitsuda, N; Kimura, T				Yamashita, Michiko; Hayashi, Shusaku; Endo, Masayuki; Okuno, Kentaro; Fukui, On; Mimura, Kazuya; Tachibana, Yosuke; Ishii, Keisuke; Mitsuda, Nobuaki; Kimura, Tadashi		ORCO	Incidence and risk factors for recurrent spontaneous preterm birth: A retrospective cohort study in Japan	JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH			English	Article						interpregnancy interval; obstetric history; racial disparity; recurrence; spontaneous preterm birth	INTERPREGNANCY INTERVAL; GESTATIONAL-AGE; SHORT CERVIX; DELIVERY; PREGNANCY; EPIDEMIOLOGY; PREVENTION; PATTERNS; SMOKING; IMPACT	AimThe aim of this study was to assess the incidence and risk factors for recurrent spontaneous preterm birth (PTB) in Japan. Material and MethodsA retrospective cohort study was conducted at five tertiary perinatal centers in Osaka, Japan from 2008 through 2012. Perinatal data were collected from medical records of women with a singleton gestation and a previous spontaneous PTB. Exclusion criteria were first-trimester spontaneous abortion, first antenatal visit beyond 14weeks of gestation, and previous PTB with medical indications, placenta previa, abruptio placenta, multiple pregnancy, fetal anomaly, and antepartum fetal demise. The associations between recurrent spontaneous PTB and perinatal factors were evaluated by logistic regression analysis. ResultsOf 547 women with a previous spontaneous PTB, 89 (16.3%) suffered a recurrent spontaneous PTB. The risk factors for recurrence included multiple previous spontaneous PTB (adjusted odds ratio [aOR]: 2.26; 95% confidence interval [CI]: 1.19-4.30; P=0.013), no previous term birth (aOR: 2.08; 95%CI: 1.24-3.49; P=0.005), and interpregnancy interval<12months (aOR: 2.13; 95%CI: 1.17-3.85; P=0.013). ConclusionApproximately one in six women with a previous spontaneous PTB suffered a recurrent spontaneous PTB. Multiple previous spontaneous PTB, no previous term birth, and short interpregnancy interval were independent risk factors for recurrence.	[Yamashita, Michiko; Hayashi, Shusaku; Ishii, Keisuke; Mitsuda, Nobuaki] Osaka Univ, Osaka Med Ctr, Dept Maternal Fetal Med, Osaka, Japan; [Yamashita, Michiko; Hayashi, Shusaku; Ishii, Keisuke; Mitsuda, Nobuaki] Osaka Univ, Res Inst Maternal & Child Hlth, Osaka, Japan; [Yamashita, Michiko; Endo, Masayuki; Mimura, Kazuya; Kimura, Tadashi] Osaka Univ, Dept Obstet & Gynecol, Osaka, Japan; [Okuno, Kentaro] Aizenbashi Hosp, Dept Obstet & Gynecol, Osaka, Japan; [Fukui, On] Rinku Gen Med Ctr, Dept Obstet & Gynecol, Osaka, Japan; [Tachibana, Yosuke] Hyogo Prefectural Nishinomiya Hosp, Dept Obstet & Gynecol, Kobe, Hyogo, Japan	Hayashi, S (reprint author), Osaka Med Ctr, 840 Murodo Izumi, Osaka 5941101, Japan.	hayashis@mch.pref.osaka.jp			Ministry of Education, Culture, Sports, Science and Technology, Japan [24249080, 26670724]	This study was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology, Japan (24249080 and 26670724).	Andres R L, 2000, Semin Neonatol, V5, P231, DOI 10.1053/siny.2000.0025; Ananth CV, 2006, J MATERN-FETAL NEO M, V19, P773, DOI 10.1080/14767050600965882; Iams JD, 2010, AM J OBSTET GYNECOL, V203, P89, DOI 10.1016/j.ajog.2010.02.004; Romero R, 2006, BJOG-INT J OBSTET GY, V113, P17, DOI 10.1111/j.1471-0528.2006.01120.x; Smith GCS, 2003, BRIT MED J, V327, P313, DOI 10.1136/bmj.327.7410.313; Berghella V, 2005, OBSTET GYNECOL, V106, P181, DOI 10.1097/01.AOG.0000168435.17200.53; Simonsen SE, 2013, BJOG-INT J OBSTET GY, V120, P863, DOI 10.1111/1471-0528.12182; Pennell CE, 2007, AM J OBSTET GYNECOL, V196, P107, DOI 10.1016/j.ajog.2006.03.109; Olsen SF, 2002, BRIT MED J, V324, P447, DOI 10.1136/bmj.324.7335.447; Shavell VI, 2012, FERTIL STERIL, V97, P107, DOI 10.1016/j.fertnstert.2011.10.009; Winkvist A, 1998, INT J EPIDEMIOL, V27, P248, DOI 10.1093/ije/27.2.248; Mercer BM, 1999, AM J OBSTET GYNECOL, V181, P1216, DOI 10.1016/S0002-9378(99)70111-0; [Anonymous], 2014, MAT CHILD HLTH STAT, P49; Cnattingius S, 1999, NEW ENGL J MED, V341, P943, DOI 10.1056/NEJM199909233411303; Ananth CV, 2006, AM J OBSTET GYNECOL, V195, P643, DOI 10.1016/j.ajog.2006.05.022; Goldenberg RL, 2008, LANCET, V371, P75, DOI 10.1016/S0140-6736(08)60074-4; Markham KB, 2014, OBSTET GYNECOL, V123, P34, DOI 10.1097/AOG.0000000000000048; Adams MM, 2000, JAMA-J AM MED ASSOC, V283, P1591, DOI 10.1001/jama.283.12.1591; Matsuda Y, 2011, J OBSTET GYNAECOL RE, V37, P1409, DOI 10.1111/j.1447-0756.2011.01552.x; Shiozaki A, 2014, J OBSTET GYNAECOL RE, V40, P53, DOI 10.1111/jog.12120; SHIONO PH, 1986, JAMA-J AM MED ASSOC, V255, P82; Meis PJ, 2003, NEW ENGL J MED, V348, P2379, DOI 10.1056/NEJMoa035140; Bukowski R, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000061; DeFranco EA, 2014, BJOG-INT J OBSTET GY, V121, P1633, DOI 10.1111/1471-0528.12891; DeFranco EA, 2007, AM J OBSTET GYNECOL, V197; Englund-Ogge L, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g1446; Kistka ZA, 2007, AM J OBSTET GYNECOL, V196; Martin Joyce A, 2012, Natl Vital Stat Rep, V61, P1; McManemy J, 2007, AM J OBSTET GYNECOL, V196; Owen J, 2009, AM J OBSTET GYNECOL, V201; The American College of Obstetricians and Gynecologists; Committee on Practice Bulletins-Obstetrics, 2012, OBSTET GYNECOL, V120, P964	31	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1341-8076	1447-0756		J OBSTET GYNAECOL RE	J. Obstet. Gynaecol. Res.	NOV	2015	41	11					1708	1714		10.1111/jog.12786		7	Obstetrics & Gynecology	Obstetrics & Gynecology	CU9SR	WOS:000363885900005		
J	Ishii, K; Nakata, M; Wada, S; Murakoshi, T; Sago, H				Ishii, Keisuke; Nakata, Masahiko; Wada, Seiji; Murakoshi, Takeshi; Sago, Haruhiko			Feasibility and preliminary outcomes of fetoscopic laser photocoagulation for monochorionic twin gestation with selective intrauterine growth restriction accompanied by severe oligohydramnios	JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH			English	Article						fetal therapy; laser therapy; monochorionic twin; multiple gestation; oligohydramnios; selective intrauterine growth restriction	UMBILICAL ARTERY DOPPLER; END-DIASTOLIC FLOW; TRANSFUSION SYNDROME; INTERMITTENT ABSENT; SINGLE-CENTER; PREGNANCIES; COAGULATION; DEATH; MANAGEMENT; FETICIDE	AimThis study aimed to clarify the feasibility and perinatal outcomes of fetoscopic laser photocoagulation (FLP) for monochorionic twin gestation with selective intrauterine growth restriction (sIUGR) accompanied by both abnormal umbilical artery Doppler waveforms and isolated severe oligohydramnios of the sIUGR twin. MethodsIn this prospective clinical trial, which included 10 cases with absent or reversed end-diastolic flow in the umbilical artery and severe oligohydramnios of the sIUGR twin, the main outcomes investigated were the feasibility of FLP and the rate of severe FLP-related maternal complications. The survival rate and incidence of neurological abnormalities of the twins at 28days of age were also evaluated. ResultsFLP was completed for all cases without major intraoperative maternal complications, although one case experienced threatened preterm labor requiring intensive treatment after the procedure. Three sIUGR and 10 larger twins were alive without neurological abnormalities at 28days of age, while intrauterine fetal death occurred in the remaining seven sIUGR twins. ConclusionFLP for monochorionic twins with sIUGR, especially when accompanied by abnormal Doppler and severe oligohydramnios of the sIUGR twin, appears to be feasible and potentially beneficial for the larger twin, as well as for some sIUGR twins.	[Ishii, Keisuke] Osaka Med Ctr, Dept Maternal Fetal Med, Izumi, Japan; [Ishii, Keisuke] Res Inst Maternal & Child Hlth, Izumi, Japan; [Nakata, Masahiko] Tokuyama Cent Hosp, Dept Obstet & Gynecol, Shunan, Japan; [Wada, Seiji; Sago, Haruhiko] Natl Ctr Child Hlth & Dev, Ctr Maternal Fetal Neonatal & Reprod Med, Tokyo, Japan; [Murakoshi, Takeshi] Seirei Hamamatsu Gen Hosp, Dept Perinatol, Maternal & Perinatal Care Ctr, Hamamatsu, Shizuoka, Japan	Ishii, K (reprint author), Osaka Med Ctr, Dept Maternal Fetal Med, 840 Murodo Izumi, Osaka 5941101, Japan.	keisui@mch.pref.osaka.jp					Gratacos E, 2008, ULTRASOUND OBST GYN, V31, P669, DOI 10.1002/uog.5362; Ishii K, 2011, ULTRASOUND OBST GYN, V37, P22, DOI 10.1002/uog.8846; Chalouhi GE, 2013, PRENATAL DIAG, V33, P109, DOI 10.1002/pd.4031; Ishii K, 2012, J OBSTET GYNAECOL RE, V38, P1271, DOI 10.1111/j.1447-0756.2012.01940.x; Rossi AC, 2009, AM J OBSTET GYNECOL, V200, P123, DOI 10.1016/j.ajog.2008.08.039; van den Bos EM, 2013, ULTRASOUND OBST GYN, V41, P653, DOI 10.1002/uog.12408; Chang YL, 2009, PRENATAL DIAG, V29, P253, DOI 10.1002/pd.2193; Ishii K, 2009, FETAL DIAGN THER, V26, P157, DOI 10.1159/000253880; Slaghekke F, 2014, LANCET, V383, P2144, DOI 10.1016/S0140-6736(13)62419-8; Quintero RA, 2001, AM J OBSTET GYNECOL, V185, P689, DOI 10.1067/mob.2001.116724; OKAMURA K, 1994, OBSTET GYNECOL, V83, P975; Nakayama S, 2012, J OBSTET GYNAECOL RE, V38, P692, DOI 10.1111/j.1447-0756.2011.01759.x; Senat MV, 2003, AM J OBSTET GYNECOL, V189, P1320, DOI 10.1067/S0002-9378(03)00644-6; Lewi L, 2006, AM J OBSTET GYNECOL, V194, P782, DOI 10.1016/j.ajog.2005.09.013; Lanna MM, 2012, ULTRASOUND OBST GYN, V39, P407, DOI 10.1002/uog.11073; Gratacos E, 2007, ULTRASOUND OBST GYN, V30, P28, DOI 10.1002/uog.4046; Hillman SC, 2011, OBSTET GYNECOL, V118, P928, DOI 10.1097/AOG.0b013e31822f129d; Gratacos E, 2004, ULTRASOUND OBST GYN, V23, P456, DOI 10.1002/uog.1013; Sago H, 2010, PRENATAL DIAG, V30, P1185, DOI 10.1002/pd.2647; Lewi L, 2007, AM J OBSTET GYNECOL, V197, DOI DOI 10.1016/J.AJ0G.2007.05.009.PMID:18060944; Lewi L, 2008, AM J OBSTET GYNECOL, V199, P511; Lewi L., 2008, AM J OBSTET GYNECOL, V199; Roberts D, 2008, COCHRANE DB SYST REV, V23	23	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1341-8076	1447-0756		J OBSTET GYNAECOL RE	J. Obstet. Gynaecol. Res.	NOV	2015	41	11					1732	1737		10.1111/jog.12827		6	Obstetrics & Gynecology	Obstetrics & Gynecology	CU9SR	WOS:000363885900009		
J	Kodama, Y; Sameshima, H; Yamashita, R; Oohashi, M; Ikenoue, T				Kodama, Yuki; Sameshima, Hiroshi; Yamashita, Rie; Oohashi, Masanao; Ikenoue, Tsuyomu			Intrapartum fetal heart rate patterns preceding terminal bradycardia in infants (> 34weeks) with poor neurological outcome: A regional population-based study in Japan	JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH			English	Article						cerebral palsy; fetal bradycardia; fetal heart rate monitoring; intrauterine infection; non-reassuring patterns	SUBSEQUENT CEREBRAL-PALSY; CHORIOAMNIONITIS; PREGNANCIES; INFECTION; ASPHYXIA; DEATHS; LABOR	AimIntrapartum fetal bradycardia necessitates immediate operative delivery. Our aim was to investigate the hypothesis that some non-reassuring fetal heart rate (FHR) patterns were present before the onset of terminal bradycardia in infants who developed subsequent brain damage. Material and MethodsFrom a population-based study of 65197 deliveries, 190 stillbirths, 115 neonatal deaths, and 136 neurologically high-risk infants were registered by the Miyazaki Perinatal Conference. There were 15 cases of neurologically high-risk infants born at >34weeks of gestation exhibiting intrapartum terminal bradycardia. Focusing on the brain-damaged infants, we retrospectively analyzed FHR patterns for at least 1h prior to the bradycardia. ResultsBrain damage (cerebral palsy [n=11] and mental retardation [n=2]) was diagnosed at 2years old in 13 out of 15 neurologically high-risk infants. Two infants had bradycardia on admission. In the remaining 11 infants, FHR patterns were reassuring in six (55%) and non-reassuring in five (45%), including late decelerations (n=4) and variable decelerations (n=2). Clinically relevant factors in the non-reassuring group included intrauterine infection (n=3), malpresentation with umbilical cord coiling (n=1), and unknown causes (n=1). Clinically relevant features in the reassuring group included cord prolapse (n=1), vaginal breech delivery (n=1), shoulder dystocia (n=1), rupture of membranes (n=1), and unknown causes (n=2). ConclusionMore than half of the brain-damaged infants born at >34weeks of gestation who exhibited intrapartum terminal bradycardia had unremarkable FHR patterns before abrupt-onset bradycardia. For those with non-reassuring patterns preceding bradycardia, intrauterine infection was the major sentinel event.	[Kodama, Yuki] Miyazaki Univ, Fac Med, Dept Obstet & Gynecol, Kiyotake, Miyazaki 8891692, Japan; [Kodama, Yuki] Miyazaki Univ, Fac Med, Perinatal Ctr, Kiyotake, Miyazaki 8891692, Japan	Kodama, Y (reprint author), Miyazaki Univ, Fac Med, Dept Obstet & Gynecol, 5200 Kihara, Kiyotake, Miyazaki 8891692, Japan.	yuki_kodama@med.miyazaki-u.ac.jp					Okumura A, 2000, EARLY HUM DEV, V58, P111, DOI 10.1016/S0378-3782(00)00072-4; Sameshima H, 2004, AM J OBSTET GYNECOL, V190, P118, DOI 10.1016/j.ajog.2003.07.014; Sameshima H, 2007, EARLY HUM DEV, V83, P517, DOI 10.1016/j.earlhumdev.2006.09.040; Sameshima H, 2008, JPN J INFECT DIS, V61, P400; LENCKI SG, 1994, AM J OBSTET GYNECOL, V170, P1345; Wu YW, 2003, JAMA-J AM MED ASSOC, V290, P2677, DOI 10.1001/jama.290.20.2677; Kodama Y, 2009, EARLY HUM DEV, V85, P235, DOI 10.1016/j.earlhumdev.2008.10.007; Bax M, 2006, JAMA-J AM MED ASSOC, V296, P1602, DOI 10.1001/jama.296.13.1602; ROLAND EH, 1992, AM J NEURORADIOL, V13, P973; GRANT A, 1989, LANCET, V2, P1233; Kodama Y, 2007, J OBSTET GYNAECOL RE, V33, P45, DOI 10.1111/j.1447-0756.2007.00484.x; Pasternak JF, 1998, PEDIATR NEUROL, V18, P391, DOI 10.1016/S0887-8994(98)00002-2; Sameshima H, 2005, AM J PERINAT, V22, P181, DOI 10.1055/s-2005-867090; LEUNG AS, 1993, AM J OBSTET GYNECOL, V169, P945; Sameshima H, 2008, EARLY HUM DEV, V84, P319, DOI 10.1016/j.earlhumdev.2007.08.004; Macones GA, 2008, OBSTET GYNECOL, V112, P661, DOI 10.1097/AOG.0b013e3181841395; KUBLI FW, 1969, AM J OBSTET GYNECOL, V104, P1190; Myers R E, 1975, Adv Neurol, V10, P223; Neufeld Michael D, 2005, J Perinatol, V25, P108, DOI 10.1038/sj.jp.7211219; Volpe JJ, 2008, NEUROLOGY NEWBORN, P400	20	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1341-8076	1447-0756		J OBSTET GYNAECOL RE	J. Obstet. Gynaecol. Res.	NOV	2015	41	11					1738	1743		10.1111/jog.12797		6	Obstetrics & Gynecology	Obstetrics & Gynecology	CU9SR	WOS:000363885900010		
J	Shinohara, S; Hirai, M; Hirata, S; Suzuki, K				Shinohara, Satoshi; Hirai, Mitsuo; Hirata, Shuji; Suzuki, Kohta			Relation between low 50-g glucose challenge test results and small-for-gestational-age infants	JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH			English	Article						glucose challenge test; maternal weight; pregnancy outcome; screening; small for gestational age	FETAL-GROWTH; PREGNANCY; ASSOCIATION; OUTCOMES; BIRTH	AimThere is no consensus opinion regarding a possible relation between low 50-g glucose challenge test (GCT) results and small-for-gestational-age infants (SGA). This study aimed to clarify the relation between low 50-g GCT results and SGA, after adjusting for potential confounding factors, using a large clinical dataset. Material and MethodsOur retrospective cohort study evaluated the obstetric records of women who delivered at Kofu Municipal Hospital (Japan) between January 2011 and December 2013. The exclusion criteria were gestational diabetes mellitus, diabetes in pregnancy, and GCT results of 140mg/dL. Based on these criteria, we included 1603 women who had undergone a GCT between 24 and 28weeks of gestation, and divided the subjects into a low-GCT group (90mg/dL) and a non-low-GCT group (91-139mg/dL). The (2)-test and multivariate logistic regression analysis were used to investigate the association between low GCT results and SGA. ResultsThe mean subject age was 30.45.4years, with 45.1% nulliparity (n=723) and 1538 (96.0%) term deliveries. The incidence of SGA was 10.7% (172/1603), and 17.9% (287/1603) of the women had low GCT results. Low GCT results were significantly associated with an increased risk of SGA (odds ratio, 1.66; 95% confidence interval, 1.14-2.42), after controlling for maternal age, pre-pregnancy maternal weight, maternal weight gain during pregnancy, and pregnancy-induced hypertension. ConclusionIt appears that there is a significant association between low GCT results and SGA. However, further studies are needed to explore the detailed mechanisms of this association.	[Shinohara, Satoshi; Hirai, Mitsuo] Kofu Municipal Hosp, Dept Obstet & Gynecol, Kofu, Yamanashi, Japan; [Hirata, Shuji] Univ Yamanashi, Fac Med, Dept Obstet & Gynecol, Chuo Ku, Yamanashi 4093898, Japan; [Suzuki, Kohta] Univ Yamanashi, Interdisciplinary Grad Sch Med & Engn, Dept Hlth Sci, Chuo Ku, Yamanashi 4093898, Japan	Suzuki, K (reprint author), Univ Yamanashi, Interdisciplinary Grad Sch Med & Engn, Dept Hlth Sci, Chuo Ku, 1110 Shimokato, Yamanashi 4093898, Japan.	kohtas@yamanashi.ac.jp					American Diabetes Association, 2014, DIABETES CARE S1, V37, pS14, DOI [DOI 10.2337/DC14-S014, 10.2337/dc14-S014]; Yogev Y, 2009, SEMIN FETAL NEONAT M, V14, P77, DOI 10.1016/j.siny.2008.09.002; Dalfra MG, 2011, AM J PHYSIOL-ENDOC M, V301, pE25, DOI 10.1152/ajpendo.00024.2011; Melamed N, 2013, J MATERN-FETAL NEO M, V26, P1107, DOI 10.3109/14767058.2013.770460; DELOSMONTEROS AE, 1993, OBSTET GYNECOL, V82, P515; Bienstock JL, 2008, ULTRASOUND OBST GYN, V31, P517, DOI 10.1002/uog.5316; Chen XK, 2007, INT J EPIDEMIOL, V36, P368, DOI 10.1093/ije/dyl284; Scholl TO, 2001, AM J EPIDEMIOL, V154, P514, DOI 10.1093/aje/154.6.514; Ardilouze JL, 2012, BJOG-INT J OBSTET GY, V119, P1283, DOI 10.1111/j.1471-0528.2012.03423.x; Harita N, 2012, J OBSTET GYNAECOL RE, V38, P1137, DOI 10.1111/j.1447-0756.2012.01848.x; Feinberg Jeffrey H, 2005, J Perinatol, V25, P509, DOI 10.1038/sj.jp.7211336; Ma Kimberly K, 2013, Am J Perinatol, V30, P715, DOI 10.1055/s-0032-1331027; Minakami H, 2014, GUIDELINES OBSTET PR; Ogawa Y, 1998, ACTA NEONAT JPN, V34, P624; Vadakekut ES, 2010, J AM OSTEOPATH ASSOC, V111, P148; Wendland EM, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-23	16	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1341-8076	1447-0756		J OBSTET GYNAECOL RE	J. Obstet. Gynaecol. Res.	NOV	2015	41	11					1752	1756		10.1111/jog.12794		5	Obstetrics & Gynecology	Obstetrics & Gynecology	CU9SR	WOS:000363885900012		
J	Takano, M; Hirata, H; Kagawa, Y; Murata, S; Fujiwara, M; Nakata, M				Takano, Mayumi; Hirata, Hiroko; Kagawa, Yukiko; Murata, Susumu; Fujiwara, Michihisa; Nakata, Masahiko			Ratio of fetal anteroposterior to transverse cerebellar diameter for detection of the cerebellar hypoplasia in the second trimester and comparison with trisomy 18	JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH			English	Article						cerebellar diameter; cerebellar hypoplasia; fetal cerebellum; trisomy 18; ultrasonography	TRANSCEREBELLAR DIAMETER; GESTATIONAL-AGE; NOMOGRAMS; EMPHASIS; GROWTH	AimCerebellar hypoplasia, particularly, trisomy 18, represents a chromosomal abnormality. However, morphological assessment of the fetal cerebellum is yet to be established. The purpose of this study was to produce reference values for the fetal transverse cerebellar diameter (TCD), anteroposterior cerebellar diameter (APCD) and the ratio of APCD to TCD (APCD/TCD ratio) in normal fetuses, compared with cases of trisomy 18. MethodsThis retrospective study included 266 normal singleton pregnancies resulting in term delivery at our institution from 2012-2013. Patients had received ultrasound examinations in the second trimester. TCD and APCD measurements were performed and then APCD/TCD ratio was calculated. Consequently, three cases of trisomy 18 were compared with reference values. ResultsGestational age correlated with TCD (r(s)=0.766, P<0.0001) and APCD (r(s)=0.61, P<0.0001), but not with APCD/TCD ratio (r(s)=0.070, P=0.252). The median APCD/TCD ratio was 0.52 and the standard deviation was 0.05. In cases of trisomy 18, all TCD measurements were located within normal ranges. In contrast, both the APCD and APCD/ TCD ratio displayed lower values than that of normal fetuses. ConclusionsThis study showed that not only TCD but also APCD correlated with gestational age, and APCD/TCD ratio indicated a fixed value (almost 0.5) in normal fetuses. Furthermore, APCD and APCD/TCD ratio were deemed useful indicators for cerebellar hypoplasia. In particular, the APCD/TCD ratio proved more convenient, without requiring individual evaluation of TCD and APCD.	[Takano, Mayumi; Kagawa, Yukiko; Murata, Susumu; Fujiwara, Michihisa; Nakata, Masahiko] Kawasaki Med Univ, Dept Obstet & Gynecol, Okayama 7008505, Japan; [Takano, Mayumi; Hirata, Hiroko; Nakata, Masahiko] Tokuyama Cent Hosp, Dept Obstet & Gynecol, Shunan, Japan	Takano, M (reprint author), Kawasaki Med Univ, Dept Obstet & Gynecol, Kita Ku, 2-1-80 Nakasange, Okayama 7008505, Japan.	applelephantea@icloud.com					Vinkesteijn ASM, 2001, ULTRASOUND OBST GYN, V17, P502, DOI 10.1046/j.1469-0705.2001.00383.x; Chavez MR, 2003, AM J OBSTET GYNECOL, V189, P1021, DOI 10.1067/S0002-9378(03)00894-9; Chavez MR, 2007, J ULTRAS MED, V26, P1167; HILL LM, 1991, AM J OBSTET GYNECOL, V165, P72; GOLDSTEIN I, 1987, AM J OBSTET GYNECOL, V156, P1065; Sherer DM, 2007, ULTRASOUND OBST GYN, V29, P32, DOI 10.1002/uog.3879; Chavez MR, 2004, AM J OBSTET GYNECOL, V191, P979, DOI 10.1016/j.ajog.2004.06.046; Yeo L, 2003, J ULTRAS MED, V22, P581; STEIGER RM, 1995, ULTRASOUND OBST GYN, V5, P384, DOI 10.1046/j.1469-0705.1995.05060384.x; INAGAKI M, 1987, NEURORADIOLOGY, V29, P474; Nyberg DA, 2001, J ULTRAS MED, V20, P655; Malinger G, 2007, ULTRASOUND OBST GYN, V29, P109, DOI 10.1002/uog.3909	12	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1341-8076	1447-0756		J OBSTET GYNAECOL RE	J. Obstet. Gynaecol. Res.	NOV	2015	41	11					1757	1761		10.1111/jog.12795		5	Obstetrics & Gynecology	Obstetrics & Gynecology	CU9SR	WOS:000363885900013		
J	Nakamura, K; Nakayama, K; Ishikawa, M; Katagiri, H; Katagiri, A; Ishibashi, T; Sato, E; Asakawa, Y; Kyo, S				Nakamura, Kohei; Nakayama, Kentaro; Ishikawa, Masako; Katagiri, Hiroshi; Katagiri, Atsuko; Ishibashi, Tomoka; Sato, Emi; Asakawa, Yasuyuki; Kyo, Satoru			Efficacy of multiple microwave endometrial ablation technique for menorrhagia resulting from adenomyosis	JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH			English	Article						adenomyosis; dysmenorrhea; menorrhagia; microwave endometrial ablation; visual analog scale		AimConventional microwave endometrial ablation (MEA) can be insufficient to control menorrhagia resulting from adenomyosis. We compared the standard single ablation technique with multiple MEA - repeating ablation three times in the same region - in patients with adenomyosis and menorrhagia. Material and MethodsWe performed single MEA in 18 patients and multiple MEA in seven patients between 2007 and 2013. We compared the efficacy of single and multiple MEA using a visual analog scale (VAS) for menorrhagia, dysmenorrhea, and patient satisfaction. We also evaluated the incidence of menorrhagia recurrence, amenorrhea, and procedure complications in relation to patients' clinical factors. ResultsVAS scores for improved menorrhagia and patient satisfaction were significantly higher in the multiple MEA group than in the single MEA group; however, the operative time was longer in the multiple-treatment group. There were no statistical differences between groups in hemoglobin levels, VAS improvement for dysmenorrhea, menorrhagia recurrence, frequency of complications, or amenorrhea rate. ConclusionMultiple MEA successfully controls menorrhagia from adenomyosis and achieves a higher satisfaction rate than single MEA.	[Nakamura, Kohei; Nakayama, Kentaro; Ishikawa, Masako; Katagiri, Hiroshi; Katagiri, Atsuko; Ishibashi, Tomoka; Sato, Emi; Kyo, Satoru] Shimane Univ, Sch Med, Dept Obstet & Gynecol, Yokohama, Kanagawa, Japan; [Asakawa, Yasuyuki] Asakawa Matern Hosp, Yokohama, Kanagawa, Japan	Nakayama, K (reprint author), Shimane Univ, Dept Obstet & Gynecol, Sch Med, Enyacho 89-1, Izumo, Shimane 6938501, Japan.	kn88@med.shimane-u.ac.jp					Yeasmin S, 2009, ARCH GYNECOL OBSTET, V280, P279, DOI 10.1007/s00404-008-0885-z; MCCAUSLAND AM, 1992, AM J OBSTET GYNECOL, V166, P1619; Nakayama K, 2011, CLIN EXP OBSTET GYN, V38, P33; Nakayama K, 2014, J OBSTET GYNAECOL RE, V40, P224, DOI 10.1111/jog.12163; Nakayama K, 2011, ARCH GYNECOL OBSTET, V283, P1065, DOI 10.1007/s00404-010-1496-z; Goswami A, 1998, J Obstet Gynaecol Res, V24, P281; Kanaoka Yasushi, 2003, Archives of Gynecology and Obstetrics, V269, P30, DOI 10.1007/s00404-003-0480-2; Kanaoka Y, 2012, PRACTICE GUIDELINE M	8	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1341-8076	1447-0756		J OBSTET GYNAECOL RE	J. Obstet. Gynaecol. Res.	NOV	2015	41	11					1769	1772		10.1111/jog.12787		4	Obstetrics & Gynecology	Obstetrics & Gynecology	CU9SR	WOS:000363885900015		
J	Ishikawa, H; Sanada, M; Shozu, M				Ishikawa, Hiroshi; Sanada, Michio; Shozu, Makio			Ovarian pregnancy associated with a fresh blastocyst transfer following in vitro fertilization	JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH			English	Article						blastocyst; ectopic pregnancy; in vitro fertilization; laparoscopy; ovarian pregnancy	ECTOPIC PREGNANCY; MANAGEMENT; RISK	Ovarian pregnancy is a rare subtype of ectopic pregnancy, and its mechanisms have not been clarified. We report a case of ovarian pregnancy that supports a blastocyst migration mechanism. An infertile woman became pregnant after a single blastocyst transfer following in vitro fertilization during a fresh non-donor cycle. Transvaginal ultrasound revealed a gestational sac-like structure containing an active fetus that was located adjacent to the corpus luteum of the right ovary. Laparoscopy identified a red, swollen implantation site in the ovary, which was completely removed by wedge resection without damaging the remaining parenchyma. This case demonstrated that a fresh blastocyst transferred into the endometrial cavity migrated through the fallopian tube, implanted on an ovarian surface, and formed an ovarian pregnancy.	[Ishikawa, Hiroshi; Sanada, Michio; Shozu, Makio] Chiba Univ, Grad Sch Med, Dept Reprod Med, Chiba 2608670, Japan	Ishikawa, H (reprint author), Chiba Univ, Grad Sch Med, Dept Reprod Med, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	ishikawa@chiba-u.jp					Ishihara O, 2011, FERTIL STERIL, V95, P1966, DOI 10.1016/j.fertnstert.2011.02.015; Koo YJ, 2011, INT J GYNECOL OBSTET, V114, P97, DOI 10.1016/j.ijgo.2011.02.013; Fang C, 2015, FERTIL STERIL, V103, P655, DOI 10.1016/j.fertnstert.2014.11.023; Tsirigotis M, 1998, HUM REPROD, V13, P3285, DOI 10.1093/humrep/13.12.3285; Odejinmi F, 2009, J MINIM INVAS GYN, V16, P354, DOI 10.1016/j.jmig.2009.01.002; Decleer W, 2014, FERTIL STERIL, V101, P162, DOI 10.1016/j.fertnstert.2013.10.002; Scutiero G, 2012, JSLS-J SOC LAPAROEND, V16, P492, DOI 10.4293/108680812X13462882736385; Kashima K, 2013, J OBSTET GYNAECOL RE, V39, P375, DOI 10.1111/j.1447-0756.2012.01963.x; Jena Saubhagya Kumar, 2014, J Clin Diagn Res, V8, pOD06, DOI 10.7860/JCDR/2014/9169.5028; Li C, 2014, EUR J OBSTET GYN R B, V181, P176, DOI 10.1016/j.ejogrb.2014.07.049; Zhu Q, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-006447	11	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1341-8076	1447-0756		J OBSTET GYNAECOL RE	J. Obstet. Gynaecol. Res.	NOV	2015	41	11					1823	1825		10.1111/jog.12790		3	Obstetrics & Gynecology	Obstetrics & Gynecology	CU9SR	WOS:000363885900023		
J	Matsueda, S; Hidaka, N; Kondo, Y; Fujiwara, A; Fukushima, K; Kato, K				Matsueda, Sayaka; Hidaka, Nobuhiro; Kondo, Yukiko; Fujiwara, Arisa; Fukushima, Kotaro; Kato, Kiyoko			External iliac artery thrombosis after common iliac artery balloon occlusion during cesarean hysterectomy for placenta accreta in cervico-isthmic pregnancy	JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH			English	Article						arterial thrombosis; cervico-isthmic pregnancy; cesarean hysterectomy; interventional radiology; placenta accreta	PERCRETA; EMBOLIZATION; HEMORRHAGE	Although the role of interventional radiology in the field of obstetrical hemorrhage has been widely reported upon recently, the rate of procedure-related complications has not been fully determined. We present the case of a patient who developed an external iliac artery thrombosis, a rarely reported complication associated with prophylactic common iliac artery balloon occlusion (CIABO). After CIABO, we found that the dorsalis pedis artery of the right foot was weak and the foot was cold, despite the fact that the patient had no complaints. Computed tomography demonstrated a linear thrombus in the right external iliac artery. We managed the patient conservatively using a heparin drip without the need for thromboembolectomy. Our experience suggests that it is important to consider the risk of thrombosis formation after CIABO. Physical examination post-procedure is key to identifying this complication early.	[Matsueda, Sayaka; Hidaka, Nobuhiro; Kondo, Yukiko; Fujiwara, Arisa; Fukushima, Kotaro; Kato, Kiyoko] Kyushu Univ, Grad Sch Med Sci, Dept Obstet & Gynecol, Fukuoka 8128582, Japan	Hidaka, N (reprint author), Kyushu Univ, Grad Sch Med Sci, Dept Obstet & Gynecol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	hidaka.nobuhiro.484@m.kyushu-u.ac.jp					Hansch E, 1999, AM J OBSTET GYNECOL, V180, P1454, DOI 10.1016/S0002-9378(99)70036-0; Bishop S, 2011, INT J OBSTET ANESTH, V20, P70, DOI 10.1016/j.ijoa.2010.09.012; Sewell MF, 2006, OBSTET GYNECOL, V108, P746, DOI 10.1097/01.AOG.0000201992.80130.2c; Ozkan U, 2010, CARDIOVASC INTER RAD, V33, P18, DOI 10.1007/s00270-009-9691-7; Carnevale FC, 2011, CARDIOVASC INTER RAD, V34, P758, DOI 10.1007/s00270-011-0166-2; Avery DM, 2009, OBSTET GYNECOL SURV, V64, P335, DOI 10.1097/OGX.0b013e31819f95ff; Bodner LJ, 2006, CARDIOVASC INTER RAD, V29, P354, DOI 10.1007/s00270-005-0023-2; Dubois J, 1997, AM J OBSTET GYNECOL, V176, P723, DOI 10.1016/S0002-9378(97)70582-9; Shih JC, 2005, AM J OBSTET GYNECOL, V193, P1756, DOI 10.1016/j.ajog.2005.08.033; Greenberg JI, 2007, AM J OBSTET GYNECOL, V197, p[470, e1]; Manalo-Estrella P, 1967, ARCH PATHOL, V83, P226; Paull JD, 1995, ANAESTH INTENS CARE, V23, P731; Shrivastava V, 2007, AM J OBSTET GYNECOL, V197, P402; Teixidor Vinas M, 2014, CLIN RADIOL, V69, P345	14	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1341-8076	1447-0756		J OBSTET GYNAECOL RE	J. Obstet. Gynaecol. Res.	NOV	2015	41	11					1826	1830		10.1111/jog.12777		5	Obstetrics & Gynecology	Obstetrics & Gynecology	CU9SR	WOS:000363885900024		
J	Morisawa, H; Makino, S; Takahashi, H; Sorita, M; Matsubara, S				Morisawa, Hiroyuki; Makino, Shinji; Takahashi, Hironori; Sorita, Mari; Matsubara, Shigeki			Retinal detachment in hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome: Color vision abnormality as the first and predominant manifestation	JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH			English	Article						blurred vision; color vision; HELLP; optical coherence tomography; retinal detachment	CENTRAL SEROUS CHORIORETINOPATHY; PREECLAMPSIA; DIAGNOSIS; DEFECTS	Serous retinal detachment is sometimes caused by hypertensive disorders in pregnancy and its associated conditions, in which the predominant eye symptoms are blurred vision, distorted vision, and reduced visual acuity. To our best knowledge, this is the first report of a puerperal woman with hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome in whom color vision abnormality was the first and predominant manifestation of serous retinal detachment. At 32 weeks of gestation, the 34-year-old Japanese woman underwent cesarean section due to HELLP syndrome. She complained of color vision abnormality on day 1 post-partum and ophthalmological examination revealed serous retinal detachment of both eyes. The visual acuity was preserved. With supportive therapy, her color vision abnormality gradually ameliorated and retinal detachment completely resolved on day 34 post-partum without any sequelae. Obstetricians should be aware that color vision abnormality can be the first and predominant symptom of HELLP-related serous retinal detachment.	[Morisawa, Hiroyuki; Takahashi, Hironori; Matsubara, Shigeki] Jichi Med Univ, Dept Obstet & Gynecol, Shimotsuke, Tochigi 3290498, Japan; [Makino, Shinji; Sorita, Mari] Jichi Med Univ, Dept Ophthalmol, Shimotsuke, Tochigi 3290498, Japan	Matsubara, S (reprint author), Jichi Med Univ, Dept Obstet & Gynecol, 3311-1 Shimotsuke, Shimotsuke, Tochigi 3290498, Japan.	matsushi@jichi.ac.jp					Tranos PG, 2002, EYE, V16, P491, DOI 10.1038/sj.eye.670056; Sathish S, 2000, CLIN EXP OPHTHALMOL, V28, P387, DOI 10.1046/j.1442-9071.2000.00342.x; Bek T, 2000, ACTA OPHTHALMOL SCAN, V78, P632, DOI 10.1034/j.1600-0420.2000.078006632.x; Mayer WJ, 2012, ARCH GYNECOL OBSTET, V286, P819, DOI 10.1007/s00404-012-2343-1; Yamaguchi T, 1999, CURR EYE RES, V18, P417, DOI 10.1076/ceyr.18.6.417.5262; Maaranen TH, 2000, RETINA-J RET VIT DIS, V20, P633, DOI 10.1097/00006982-200011000-00008; Gogia V, 2014, CAN J OPHTHALMOL, V49, pE5, DOI 10.1016/j.jcjo.2013.09.009; Tranquilli AL, 2014, PREGNANCY HYPERTENS, V4, P97, DOI 10.1016/j.preghy.2014.02.001; POKORNY J, 1986, VISION RES, V26, P1573, DOI 10.1016/0042-6989(86)90176-8; Cunningham FG, 2014, WILLIAMS OBSTET, P728; Garg A, 2014, INVEST OPHTH VIS SCI, V55, P5723, DOI 10.1167/iovs.14-14143; Ogawa Y, 1998, ACTA NEONAT JPN, V34, P624; Vigil-De Gracia P, 2011, INT J GYNECOL OBSTET, V114, P223, DOI 10.1016/j.ijgo.2011.04.003; Watanabe K, 2013, HYPERTENS RES PREGNA, V1, P3	14	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1341-8076	1447-0756		J OBSTET GYNAECOL RE	J. Obstet. Gynaecol. Res.	NOV	2015	41	11					1835	1838		10.1111/jog.12781		4	Obstetrics & Gynecology	Obstetrics & Gynecology	CU9SR	WOS:000363885900026		
J	Kaneko, M; Yamauchi, A; Yamashita, R; Sato, Y; Kodama, Y; Sameshima, H				Kaneko, Masatoki; Yamauchi, Aya; Yamashita, Rie; Sato, Yuichiro; Kodama, Yuki; Sameshima, Hiroshi			Did antepartum hypoxic insult caused by fetal vessel thrombosis influence the procalcitonin level in umbilical blood? A case report	JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH			English	Article						fetal vessel thrombosis; hypoxic-ischemic encephalopathy; procalcitonin; quadriplegia	DIAGNOSIS; GUIDE	We report a case of marked elevation of the procalcitonin level in umbilical blood and neonatal blood at birth. The mother did not perceive fetal motion. Antepartum fetal heart rate monitoring showed a loss of variability and absence of acceleration. No fetal breathing movement, fetal movement, or fetal tone were observed by ultrasonography. The female neonate was delivered by cesarean section at 25weeks of gestation, with birthweight 774g. The umbilical arterial pH value at birth was 7.29. Mild elevation in interleukin-6 and tumor necrosis factor- in umbilical blood were observed. Cytochrome c showed a high level in umbilical and neonatal blood at birth. Placental histopathology revealed multiple fetal vessel thrombosis in the large stem villi and chorionic vessels. The neonate showed no infectious signs throughout the neonatal period. Computed tomography at 3months of age revealed atrophy in the cerebrum and cerebellum. At 1year after birth, the infant showed spastic quadriplegia. In this case, antepartum asphyxia due to fetal vessel thrombosis may have influenced the elevation of procalcitonin level in umbilical blood and neonatal blood at birth.	[Kaneko, Masatoki] Miyazaki Univ, Fac Med, Grad Sch Nursing Sci, Miyazaki, Japan; [Kaneko, Masatoki; Yamauchi, Aya; Yamashita, Rie; Kodama, Yuki; Sameshima, Hiroshi] Miyazaki Univ, Fac Med, Dept Obstet & Gynecol, Miyazaki, Japan; [Sato, Yuichiro] Miyazaki Univ, Fac Med, Dept Pathol, Miyazaki, Japan	Kaneko, M (reprint author), Miyazaki Univ, Fac Med, Dept Obstet & Gynecol, Grad Sch Nursing Sci, 5200 Kihara, Kiyotake, Miyazaki 8891692, Japan.	mkaneko@med.miyazaki-u.ac.jp			Japan Ministry of Education, Culture, Sports, Science and Technology [25462566]	This work was partly funded by a grant (25462566) from the Japan Ministry of Education, Culture, Sports, Science and Technology.	Meisner M, 2014, ANN LAB MED, V34, P263, DOI 10.3343/alm.2014.34.4.263; Hankey B, 2015, EMERG MED J, V32, P493, DOI 10.1136/emermed-2015-204865.1; Sato Y, 2006, PLACENTA, V27, P715, DOI 10.1016/j.placenta.2005.05.008; Marchini G, 2000, ACTA PAEDIATR, V89, P1082, DOI 10.1080/713794557; Joram N, 2011, EUR J CLIN MICROBIOL, V30, P1005, DOI 10.1007/s10096-011-1187-0; Polster BM, 2004, J NEUROCHEM, V90, P1281, DOI 10.1111/j.1471-4159.2004.02572.x; Chiesa C, 1998, CLIN INFECT DIS, V26, P664, DOI 10.1086/514576; Assumma M, 2000, CLIN CHEM, V46, P1583; HEIFETZ S A, 1988, Pediatric Pathology, V8, P37; Schuetz P, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-107; Walker Caroline, 2015, AACN Adv Crit Care, V26, P99, DOI 10.1097/NCI.0000000000000079	11	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1341-8076	1447-0756		J OBSTET GYNAECOL RE	J. Obstet. Gynaecol. Res.	NOV	2015	41	11					1839	1842		10.1111/jog.12828		4	Obstetrics & Gynecology	Obstetrics & Gynecology	CU9SR	WOS:000363885900027		
J	Tanaka, K; Matsushima, M; Matsuzawa, Y; Wachi, Y; Izawa, T; Sakai, K; Kobayashi, Y; Iwashita, M				Tanaka, Kei; Matsushima, Miho; Matsuzawa, Yukiko; Wachi, Yuichi; Izawa, Tomoko; Sakai, Keiji; Kobayashi, Yoichi; Iwashita, Mitsutoshi			Antepartum reversible cerebral vasoconstriction syndrome with pre-eclampsia and reversible posterior leukoencephalopathy	JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH			English	Article						antepartum; headache; pre-eclampsia; reversible cerebral vasoconstriction; reversible posterior leukoencephalopathy	POSTPARTUM ANGIOPATHY; PUERPERIUM; VASOSPASM; ANGIITIS	Reversible cerebral vasoconstriction syndrome (RCVS) is characterized by severe headache and diffuse segmental constriction of the cerebral arteries that resolves spontaneously within a few months. Pregnancy is one of the precipitating factors of RCVS and most of the reported cases occurred in the post-partum period. We report a case of RCVS that occurred in a pregnant women with pre-eclampsia during her antepartum period. A 34-year-old woman in full-term pregnancy presented with a severe and acute headache. Magnetic resonance angiography (MRA) showed multiple segmental constrictions of the cerebral arteries. Magnetic resonance imaging revealed a high-intensity lesion in the left occipital lobe, consistent with reversible posterior leukoencephalopathy syndrome, on fluid attenuated inversion recovery sequences. The case was also complicated by severe pre-eclampsia and the patient underwent emergency cesarean section. Although her symptoms resolved rapidly, MRA revealed new lesions of arterial constriction 4days after onset. The vasoconstriction completely resolved on MRA after 10days and the patient was discharged without neurological sequelae.	[Tanaka, Kei; Matsushima, Miho; Matsuzawa, Yukiko; Wachi, Yuichi; Izawa, Tomoko; Sakai, Keiji; Kobayashi, Yoichi; Iwashita, Mitsutoshi] Kyorin Univ, Sch Med, Dept Obstet & Gynecol, Mitaka, Tokyo 1818611, Japan	Tanaka, K (reprint author), Kyorin Univ, Sch Med, Dept Obstet & Gynecol, 6-20-2 Shinkawa, Mitaka, Tokyo 1818611, Japan.	kei49tanaka@gmail.com					Calabrese LH, 2007, ANN INTERN MED, V146, P34; Ducros A, 2007, BRAIN, V130, P3091, DOI 10.1093/brain/awm256; Albano B, 2011, NEUROL SCI, V32, P497, DOI 10.1007/s10072-011-0505-8; Singhal AB, 2004, ARCH NEUROL-CHICAGO, V61, P411, DOI 10.1001/archneur.61.3.411; FARINE D, 1984, OBSTET GYNECOL, V63, P586; RAROQUE HG, 1993, STROKE, V24, P2108; CALABRESE LH, 1993, J RHEUMATOL, V20, P2046; CALL GK, 1988, STROKE, V19, P1159; Hinchey J, 1996, NEW ENGL J MED, V334, P494, DOI 10.1056/NEJM199602223340803; SERDARU M, 1984, J NEUROL NEUROSUR PS, V47, P73, DOI 10.1136/jnnp.47.1.73; GERAGHTY JJ, 1991, NEUROLOGY, V41, P1145; Ishibashi T, 2011, J ANESTH, V25, P405, DOI 10.1007/s00540-011-1122-7; Neudecker S, 2006, OBSTET GYNECOL, V107, P446, DOI 10.1097/01.AOG.0000187945.61146.e6; Konstantinopoulos PA, 2004, AM J OBSTET GYNECOL, V191, P375, DOI 10.1016/j.ajog.2004.03.028; Sattar Ahsan, 2010, Expert Rev Cardiovasc Ther, V8, P1417, DOI 10.1586/erc.10.124	15	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1341-8076	1447-0756		J OBSTET GYNAECOL RE	J. Obstet. Gynaecol. Res.	NOV	2015	41	11					1843	1847		10.1111/jog.12788		5	Obstetrics & Gynecology	Obstetrics & Gynecology	CU9SR	WOS:000363885900028		
J	Mayama, M; Yoshihara, M; Ukai, M; Kondo, S; Kishigami, Y; Oguchi, H				Mayama, Michinori; Yoshihara, Masato; Ukai, Mayu; Kondo, Shinya; Kishigami, Yasuyuki; Oguchi, Hidenori			Sarcoid-like reaction mimicking vaginal cancer recurrence	JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH			English	Article						false positive; PET; CT; recurrence; sarcoid-like reaction; vaginal cancer	MALIGNANCY; PET/CT	A sarcoid-like reaction is a development of non-caseating granuloma in patients with underlying malignancy and represents a false positive finding on positron emission tomography/computed tomography (PET/CT). A sarcoid-like reaction is a benign condition; therefore, differentiating a sarcoid-like reaction from cancer recurrence is necessary. Only uterine and ovarian cancer related cases have been reported in the gynecological field and to the best of our knowledge, this is the first case of a sarcoid-like reaction in vaginal cancer. A 59-year-old vaginal cancer patient received concurrent chemoradiotherapy and achieved complete remission. Recurrence of vaginal cancer was suspected because of the elevation of serum squamous cell carcinoma antigen level. PET/CT revealed abnormal uptake at the bilateral mediastinal and hilar lymph nodes. A non-caseating granuloma was detected from the biopsy of the swollen lymph nodes. No evidence of cancer recurrence was observed. A sarcoid-like reaction should be considered when evaluating PET/CT in cancer patients to prevent unnecessary treatments.	[Mayama, Michinori; Yoshihara, Masato; Ukai, Mayu; Kondo, Shinya; Kishigami, Yasuyuki; Oguchi, Hidenori] Toyota Mem Hosp, Dept Obstet & Gynecol, Toyota, Japan	Mayama, M (reprint author), Toyota Mem Hosp, Dept Obstet & Gynecol, 20-2 Misato Cho, Toyota, Japan.	marimo.mayama@gmail.com					Kim MH, 2013, CANCER RES TREAT, V45, P354, DOI 10.4143/crt.2013.45.4.354; GORTON G, 1957, ACTA RADIOL, V47, P381; Chowdhury FU, 2009, CLIN RADIOL, V64, P675, DOI 10.1016/j.crad.2009.03.005; TANGEN JM, 1988, ACTA MED SCAND, V223, P83; BRINCKER H, 1986, CANCER TREAT REV, V13, P147, DOI 10.1016/0305-7372(86)90002-2; Lai CH, 2007, CURR OPIN OBSTET GYN, V19, P37, DOI 10.1097/GCO.0b013e32801195c9; Aide N, 2009, MOL IMAGING BIOL, V11, P224, DOI 10.1007/s11307-008-0191-y; Craun Jonathan B, 2012, J Nucl Med Technol, V40, P231, DOI 10.2967/jnmt.112.102814; Inoue K, 2013, SPRINGERPLUS, V2, DOI 10.1186/2193-1801-2-113; Tchernev Georgi, 2014, Wien Med Wochenschr, V164, P247, DOI 10.1007/s10354-014-0269-x	10	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1341-8076	1447-0756		J OBSTET GYNAECOL RE	J. Obstet. Gynaecol. Res.	NOV	2015	41	11					1855	1858		10.1111/jog.12829		4	Obstetrics & Gynecology	Obstetrics & Gynecology	CU9SR	WOS:000363885900031		
J	Akaishi, T; Shimazaki, A; Tonouchi, A; Ueda, K; Miyawaki, N; Kawazu, K				Akaishi, Takahiro; Shimazaki, Atsushi; Tonouchi, Asaka; Ueda, Kenji; Miyawaki, Nobuaki; Kawazu, Kouichi			Benefits of Tafluprost and Timolol Fixed-Dose Combination for the Treatment of Glaucoma Are Confirmed by Studies on Experimental Animal Models	JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS			English	Article							INTRAOCULAR-PRESSURE; ADHERENCE; TOLERABILITY; PILOCARPINE; 0.5-PERCENT; POPULATION; EFFICACY; THERAPY; SAFETY	Purpose: To assess the usefulness of 0.0015% tafluprost and 0.5% timolol fixed-dose combination (TT-FDC) for glaucoma, the ocular hypotensive effect of TT-FDC and concentration of tafluprost and timolol in the aqueous humor were compared with those of the concomitant administration of 0.0015% tafluprost and 0.5% timolol with or without an appropriate administration interval. Methods: The ocular hypotensive effect was assessed by intraocular pressure (IOP) measurement in cynomolgus monkeys. Drug penetration into the aqueous humor was estimated by the concentrations of tafluprost acid (active metabolic form of tafluprost) and timolol, which were measured using liquid chromatography-tandem mass spectrometry after administration of tafluprost and timolol to Sprague Dawley rats. Results: The ocular hypotensive effect of TT-FDC was equivalent to that of the concomitant administration of timolol and tafluprost at a more than 5-min interval in monkeys. However, the ocular hypotensive effect of the concomitant administration of timolol and tafluprost without an interval (-2.80.2mmHg at peak IOP reduction) was significantly weaker compared with TT-FDC (-4.3 +/- 0.5mmHg at peak IOP reduction, P=0.008 vs. concomitant administration of timolol and tafluprost) in monkeys. The aqueous humor concentration of the second administered drug (tafluprost) was not affected by the dosing conditions, whereas the concentration of the first instilled drug (timolol) without the interval was lower than that with a 5-min interval (1,200ngh/mL vs. 1,890ngh/mL in AUC(0-4)) in rats. Conclusion: TT-FDC demonstrates a clear benefit by preventing efficacy loss without an appropriate interval in experimental animal models.	[Akaishi, Takahiro; Shimazaki, Atsushi; Tonouchi, Asaka; Ueda, Kenji; Miyawaki, Nobuaki; Kawazu, Kouichi] Santen Pharmaceut Co Ltd, Div Res & Dev, Osaka 5308552, Japan	Akaishi, T (reprint author), Santen Pharmaceut Co Ltd, Div Res & Dev, Kita Ku, 4-20 Ofukacho, Osaka 5308552, Japan.	takahiro.akaishi@santen.co.jp					Abe H., 1999, J EYE, V16, P907; Ung C, 2013, OPHTHALMOLOGY, V120, P1150, DOI 10.1016/j.ophtha.2012.11.026; ZIMMERMAN TJ, 1977, ARCH OPHTHALMOL-CHIC, V95, P605; SCHMITT CJ, 1980, ARCH OPHTHALMOL-CHIC, V98, P547; Robin AL, 2007, AM J OPHTHALMOL, V144, P533, DOI 10.1016/j.ajo.2007.06.012; CHRAI SS, 1974, J PHARM SCI, V63, P333, DOI 10.1002/jps.2600630304; Takagi Y, 2004, EXP EYE RES, V78, P767, DOI 10.1016/j.exer.2003.12.007; MIICHI H, 1983, INVEST OPHTH VIS SCI, V24, P1269; Alward WL, 1998, AM J OPHTHALMOL, V126, P498; Dietlein TS, 2006, GRAEF ARCH CLIN EXP, V244, P859, DOI 10.1007/s00417-005-0142-0; Toris CB, 2010, CURR MOL MED, V10, P824; Hollo G, 2014, J OCUL PHARMACOL TH, V30, P468, DOI 10.1089/jop.2013.0229; [Anonymous], 2012, NIHON GANKA GAKKAI Z, V116, P3; ANDERSON DR, 1989, AM J OPHTHALMOL, V108, P485; SIEG JW, 1976, J PHARM SCI, V65, P1816, DOI 10.1002/jps.2600651230; Djafari F, 2009, J GLAUCOMA, V18, P238, DOI 10.1097/IJG.0b013e3181815421; Olthoff CMG, 2005, OPHTHALMOLOGY, V112, P953, DOI 10.1016/j.ophtha.2004.12.035; Robin AL, 2005, OPHTHALMOLOGY, V112, P863, DOI 10.1016/j.ophtha.2004.12.026; Inoue K., 2011, J EYE, V28, P874; Kuwayama Y., 2015, J EYE, V32, P133; Kuwayama Y., 2013, J EYE, V30, P1185; Pfeiffer N, 2014, ADV THER, V31, P1228, DOI 10.1007/s12325-014-0163-3; Van Veldhuisen PC, 2000, AM J OPHTHALMOL, V130, P429; Ueda K., 2013, J EYE, V30, P1761; Zimmerman T J, 1983, Surv Ophthalmol, V28 Suppl, P252, DOI 10.1016/0039-6257(83)90142-X	25	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1080-7683	1557-7732		J OCUL PHARMACOL TH	J. Ocular Pharmacol. Ther.	NOV 1	2015	31	9					518	524		10.1089/jop.2015.0031		7	Ophthalmology; Pharmacology & Pharmacy	Ophthalmology; Pharmacology & Pharmacy	CV4ID	WOS:000364229500003		
J	Fukuda, M; Sasaki, H				Fukuda, Masamichi; Sasaki, Hiroshi			Effects of Fluoroquinolone-Based Antibacterial Ophthalmic Solutions on Corneal Wound Healing	JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS			English	Article							CELLS IN-VITRO; 4TH-GENERATION FLUOROQUINOLONES; TOPICAL ANTIBIOTICS; EPITHELIAL-CELLS; TOXICITY; RESISTANCE; RABBIT; CYTOTOXICITY; KERATOCYTES; KERATITIS	Purpose: To evaluate the effects of fluoroquinolone-based antibacterial ophthalmic solutions on cell proliferation in vitro and corneal wound healing in vivo. Methods: Staten's Serum institute rabbit corneal cells were exposed to phosphate-buffered saline, 1.5% and 0.5% levofloxacin, 0.5% moxifloxacin, and 0.3% gatifloxacin, for 2min, following which the cells were incubated without the drug. The cell viability was evaluated after 24 or 72h of incubation. Rabbit corneal epithelial abrasion models created using n-heptanol were instilled with saline or fluoroquinolone-based solutions 7 times at 30-min intervals, following which corneal epithelial wound healing was evaluated from 30min to 48h by the measurement of electrical corneal resistance (CR) ratios. Results: The cell viability decreased over time; the lowest values were observed with 1.5% levofloxacin. Significant differences in cell viability were observed among the 4 solutions at 72h (P<0.05); the cell viabilities of 1.5% and 0.5% levofloxacin, 0.5% moxifloxacin, and 0.3% gatifloxacin were 21.6%, 97.9%, 39.1%, and 67.5%, respectively. The electrical CR ratios at 48h after instillation were 103.8% (saline), 78.2% (1.5% levofloxacin), 105.0% (0.5% levofloxacin), 74.9% (0.5% moxifloxacin), and 87.7% (0.3% gatifloxacin); the difference was significant between 1.5% levofloxacin or 0.5% moxifloxacin and saline (P<0.05). Conclusions: The cytotoxicities of 1.5% and 0.5% levofloxacin, 0.5% moxifloxacin, and 0.3% gatifloxacin were different, and 1.5% levofloxacin and 0.5% moxifloxacin resulted in delayed corneal wound healing. The results suggest that 1.5% levofloxacin exerts the greatest influence on corneal wound healing.	[Fukuda, Masamichi; Sasaki, Hiroshi] Kanazawa Med Univ, Dept Ophthalmol, Uchinada, Ishikawa 9200293, Japan	Fukuda, M (reprint author), Kanazawa Med Univ, Dept Ophthalmol, 1-1 Daigaku, Uchinada, Ishikawa 9200293, Japan.	fukuda@kanazawa-med.ac.jp					Fintelmann RE, 2011, ARCH OPHTHALMOL-CHIC, V129, P399, DOI 10.1001/archophthalmol.2011.45; Walter K, 2006, CORNEA, V25, P855, DOI 10.1097/01.ico.0000224642.43601.14; Ayaki M, 2012, BIOCONTROL SCI, V17, P93; Sosa AB, 2008, CORNEA, V27, P930, DOI 10.1097/ICO.0b013e31816f27ab; Clark L, 2004, J TOXICOL-CUTAN OCUL, V23, P1, DOI 10.1081/CUS-120029762; Dutot M, 2006, INVEST OPHTH VIS SCI, V47, P2812, DOI 10.1167/iovs.06-0224; Barequet IS, 2007, CORNEA, V26, P606; Moshirfar M, 2008, GRAEF ARCH CLIN EXP, V246, P1455, DOI 10.1007/s00417-008-0893-5; Tsuchiya Y, 2008, CURR EYE RES, V33, P868, DOI 10.1080/02713680802382971; Matsumoto S, 2006, CORNEA, V25, pS1, DOI 10.1097/01.ico.0000151543.15736.93; Bezwada P, 2008, CURR MED RES OPIN, V24, P419, DOI 10.1185/030079908X261005; Oum BS, 2014, OPHTHALMIC RES, V51, P216, DOI 10.1159/000357976; Goldstein MH, 1999, OPHTHALMOLOGY, V106, P1313; Mallari PLT, 2001, AM J OPHTHALMOL, V131, P131, DOI 10.1016/S0002-9394(00)00642-5; Williams KK, 2007, J OCUL PHARMACOL TH, V23, P517, DOI 10.1089/jop.2007.0008; Seitz B, 1996, INVEST OPHTH VIS SCI, V37, P656; CINTRON C, 1979, OPHTHALMIC RES, V11, P90; Ayaki Masahiko, 2010, Clin Ophthalmol, V4, P1019; Chen WS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040893; Fukuda Masamichi, 2012, Clin Ophthalmol, V6, P585, DOI 10.2147/OPTH.S30935; McDonald Marguerite B, 2006, Int Ophthalmol Clin, V46, P47, DOI 10.1097/01.iio.0000212132.98760.72; Milder E, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.01.016; MISHIMA S., 1966, INVEST OPHTHALMOL, V5, P264; Watanabe Ryou, 2010, Clin Ophthalmol, V4, P1181, DOI 10.2147/OPTH.S13672	24	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1080-7683	1557-7732		J OCUL PHARMACOL TH	J. Ocular Pharmacol. Ther.	NOV 1	2015	31	9					536	540		10.1089/jop.2014.0118		5	Ophthalmology; Pharmacology & Pharmacy	Ophthalmology; Pharmacology & Pharmacy	CV4ID	WOS:000364229500006		
J	Hirai, S; Kurashima, H; Nakamura, D; Komatsu, T; Yasuda, Y; Habashita-Obata, S; Ichikawa, S; Katsuta, O; Iwawaki, T; Kohno, K				Hirai, Shin-ichiro; Kurashima, Hiroaki; Nakamura, Daisuke; Komatsu, Tomoko; Yasuda, Yuki; Habashita-Obata, Sayo; Ichikawa, Sanae; Katsuta, Osamu; Iwawaki, Takao; Kohno, Kenji			2-Phenyl-APB-144-Induced Retinal Pigment Epithelium Degeneration and Its Underlying Mechanisms	JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS			English	Article							MACULAR DEGENERATION; CELL-DEATH; ER STRESS; AUTOPHAGY; MICE; CHLOROQUINE; INHIBITOR; TOXICITY; PATHOGENESIS; MACROPHAGES	Purpose: To investigate the efficacy of 2-phenyl-APB-144 (APB)-induced retinopathy in a rat model and its underlying mechanisms, with a particular focus on retinal pigment epithelium (RPE) degeneration. Methods: Electroretinograms (ERGs) were evaluated in APB-administered rats. In ARPE-19 cells, cathepsin, and autophagy marker LC3 were analyzed by western blotting or immunohistochemistry. Organelle pH alterations were detected by Acridine Orange Staining. Endoplasmic reticulum stress-dependent or -independent cell death signaling was analyzed by reporter gene assays of activating transcription factor 4 (ATF4), immunoglobulin heavy-chain binding protein (BiP), inositol-requiring enzyme 1 (IRE1), quantitative reverse transcription-polymerase chain reaction of CHOP mRNA, and the effects of pharmacological eukaryotic initiation factor 2 (eIF2) dephosphorylation inhibitor, Salubrinal. The pharmacological effects of Salubrinal were examined by fluorophotometry, electrophysiology, and histopathology. Results: APB-induced ERG amplitude reduction and fluorescein permeability enhancement into the vitreous body of rats were determined. In ARPE-19 cells, APB-induced organelle pH alterations, imbalances of procathepsin and cathepsin expression, the time-dependent accumulation of LC3-II, and the translational activation of ATF4 were determined. Salubrinal protected against APB-induced cell death and inhibited ATF4 downstream factor CHOP mRNA induction. In APB-induced rat retinopathy, systemic Salubrinal alleviated the enhanced fluorescein permeability into the vitreous body from the RPE, the reductions in ERG amplitudes, and RPE degeneration. Conclusions: Organelle pH alterations and autophagy impairments are involved in APB-induced RPE cell death. Inhibition of eIF2 dephosphorylation protected the RPE in vivo and in vitro. These findings suggested that APB-induced retinopathy is a valuable animal model for exploring the mechanism of RPE-driven retinopathy.	[Hirai, Shin-ichiro; Kurashima, Hiroaki; Habashita-Obata, Sayo; Ichikawa, Sanae; Katsuta, Osamu] Santen Pharmaceut Co Ltd, Nara Res & Dev Ctr, Nara 6300101, Japan; [Hirai, Shin-ichiro; Kurashima, Hiroaki; Nakamura, Daisuke; Komatsu, Tomoko; Yasuda, Yuki; Kohno, Kenji] Nara Inst Sci & Technol, Grad Sch Biol Sci, Lab Mol & Cell Genet, Nara, Japan; [Iwawaki, Takao] Gunma Univ, Adv Sci Res Leaders Dev Unit, Maebashi, Gunma, Japan	Hirai, S (reprint author), Santen Pharmaceut Co Ltd, Nara Res & Dev Ctr, 8916-16 Takayama, Nara 6300101, Japan.	shinichiro.hirai@santen.co.jp			Japan Society for the Promotion of Science (JSPS) KAKENHI [24228002]; Ministry of Education, Culture, Sports, Science, and Technology (MEXT) KAKENHI [19058010]	This work was supported by the Japan Society for the Promotion of Science (JSPS) KAKENHI (24228002 to K.K.) and the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) KAKENHI (19058010 to K.K.). The authors thank Drs. Daisuke Oikawa, Kazutoshi Mori, Hiroshi Enomoto, Kazuyuki Nishioka, Hiroyuki Aono, Kazuhiro Hosoi, Nobuaki Miyawaki, Minoru Sasano, and Masatsugu Nakamura for helpful technical and scientific support.	ROSENTHAL AR, 1978, INVEST OPHTH VIS SCI, V17, P1158; Iwawaki T, 2009, P NATL ACAD SCI USA, V106, P16657, DOI 10.1073/pnas.0903775106; Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004; Kaarniranta K, 2010, ACTA OPHTHALMOL, V88, P387, DOI 10.1111/j.1755-3768.2009.01840.x; POOLE B, 1981, J CELL BIOL, V90, P665, DOI 10.1083/jcb.90.3.665; Peters S, 2006, OPHTHAL RES, V38, P83, DOI 10.1159/000090268; Kilberg MS, 2009, TRENDS ENDOCRIN MET, V20, P436, DOI 10.1016/j.tem.2009.05.008; Rakoczy PE, 2002, AM J PATHOL, V161, P1515, DOI 10.1016/S0002-9440(10)64427-6; Mitter SK, 2012, ADV EXP MED BIOL, V723, P83, DOI 10.1007/978-1-4614-0631-0_12; GOODWIN LG, 1957, BRIT J PHARM CHEMOTH, V12, P468; Yoon YH, 2010, INVEST OPHTH VIS SCI, V51, P6030, DOI 10.1167/iovs.10-5278; Uchiyama Y, 2008, HISTOCHEM CELL BIOL, V129, P407, DOI 10.1007/s00418-008-0406-y; Ishiko S, 1996, JPN J OPHTHALMOL, V40, P310; LEE KP, 1990, ARCH TOXICOL, V64, P135, DOI 10.1007/BF01974399; DAMICO DJ, 1984, INVEST OPHTH VIS SCI, V25, P564; FURUCHI T, 1993, J BIOL CHEM, V268, P27345; Hetz C, 2012, NAT REV MOL CELL BIO, V13, P89, DOI 10.1038/nrm3270; Algvere PV, 2002, ACTA OPHTHALMOL SCAN, V80, P136, DOI 10.1034/j.1600-0420.2002.800204.x; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Tanaka Y, 2000, NATURE, V406, P902; TOIMELA T, 1995, OPHTHALMIC RES, V27, P150; Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546; LEE KP, 1991, ARCH TOXICOL, V65, P292, DOI 10.1007/BF01968963; Krohne TU, 2010, EXP EYE RES, V90, P465, DOI 10.1016/j.exer.2009.12.011; Hashizume K, 2008, AM J PATHOL, V172, P1325, DOI 10.2353/ajpath.2008.070730; Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028; Liu J, 2008, INVEST OPHTH VIS SCI, V49, P772, DOI 10.1167/iovs.07-0675; Kiuchi K, 2002, CURR EYE RES, V25, P373, DOI 10.1076/ceyr.25.6.373.14227; Miyamoto N, 2011, INVEST OPHTH VIS SCI, V52, P1226, DOI 10.1167/iovs.10-5775; Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje; Wang AL, 2009, AUTOPHAGY, V5, P563; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Oikawa D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051290; KATZ ML, 1989, MECH AGEING DEV, V49, P23, DOI 10.1016/0047-6374(89)90065-1; SORSBY A, 1958, Br J Ophthalmol, V42, P563, DOI 10.1136/bjo.42.9.563; Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456	36	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1080-7683	1557-7732		J OCUL PHARMACOL TH	J. Ocular Pharmacol. Ther.	NOV 1	2015	31	9					570	584		10.1089/jop.2014.0076		15	Ophthalmology; Pharmacology & Pharmacy	Ophthalmology; Pharmacology & Pharmacy	CV4ID	WOS:000364229500011		
J	Abe, T; Maruyama, S; Babkair, H; Yamazaki, M; Cheng, J; Saku, T				Abe, Tatsuya; Maruyama, Satoshi; Babkair, Hamzah; Yamazaki, Manabu; Cheng, Jun; Saku, Takashi			Simultaneous immunolocalization of desmoglein 3 and IgG4 in oral pemphigus vulgaris: IgG4 predominant autoantibodies in its pathogenesis	JOURNAL OF ORAL PATHOLOGY & MEDICINE			English	Article						desmoglein 3; IgG4; immunohistochemistry; oral mucosa; pemphigus vulgaris	IGG4-RELATED DISEASE; DIAGNOSTIC-CRITERIA; SERUM IGG4; FOLIACEUS; DESMOSOME; PANCREATITIS; ADHESION; SUBCLASS	BackgroundOral pemphigus vulgaris (PV), an autoimmune blistering disease, is mainly mediated by autoantibodies against desmoglein (Dsg) 3. However, no attention has been paid to IgG subclasses of the autoantibodies against Dsg3 in the diagnostic procedure for PV. Thus, our aim in this study was to investigate whether Dsg3 and any of IgG subclasses are immunohistochemically colocalized in tissue sections of PV oral mucosa. Materials and MethodsSerial sections cut from formalin-fixed paraffin blocks of biopsy specimens of 9 PV cases and those of normal buccal mucosa surgically removed for fibro-epithelial polyps were comparatively examined for immunohistochemical localizations for Dsg3, IgG4, and IgG. ResultsDsg3 was demonstrated in a dot-like pattern on the cell border and in the cytoplasm of the whole epithelial layer in both normal and PV specimens, while its staining was irregular among floating epithelial sheets of PV. IgG4 was also demonstrated in a punctuated fashion on the cell border among floating epithelial sheets, which was nearly identical to the immunohistochemical profile of Dsg3. In addition to being detected in the epithelial part, IgG4 signals were prominently localized in plasma cells scattered in the granulation tissue, where ratios of IgG4-positive (+) plasma cells to IgG+ cells were extraordinarily higher (mean 28%) than those in normal mucosa. DiscussionThese findings confirmed for the first time that autoantibodies against Dsg3 are mainly composed of IgG4 in oral PV and that the combined immunohistochemistry for Dsg3 and IgG4 can be a valuable aid in confirming a histopathological diagnosis of PV.	[Abe, Tatsuya; Babkair, Hamzah; Yamazaki, Manabu; Cheng, Jun; Saku, Takashi] Niigata Univ, Grad Sch Med & Dent Sci, Div Oral Pathol,Dept Tissue Regenerat & Reconstru, Chuo Ku, Niigata, Japan; [Abe, Tatsuya; Maruyama, Satoshi; Saku, Takashi] Niigata Univ Hosp, Dept Surg Pathol, Oral Pathol Sect, Chuo Ku, Niigata 9518520, Japan	Maruyama, S (reprint author), Niigata Univ Hosp, Dept Surg Pathol, Oral Pathol Sect, Chuo Ku, 1-754 Asahimachi Dori, Niigata 9518520, Japan.	maru@dent.niigata-u.ac.jp			Japan Society for the Promotion of Science [25861768]; Iwadare Scholarship Foundation, Japan	This work was supported in part by a Grant-in-Aid for Young Scientists (B) from the Japan Society for the Promotion of Science (25861768), with additional funding from the Iwadare Scholarship Foundation, Japan.	Alberse RC, 1993, ALLERGY, V48, P559; OKAHATA H, 1990, CLIN EXP ALLERGY, V20, P39, DOI 10.1111/j.1365-2222.1990.tb02773.x; Shirakata Y, 1998, J INVEST DERMATOL, V110, P76, DOI 10.1046/j.1523-1747.1998.00085.x; Stone JH, 2012, NEW ENGL J MED, V366, P539, DOI 10.1056/NEJMra1104650; Kottke MD, 2006, J CELL SCI, V119, P797, DOI 10.1242/jcs.02888; Waschke J, 2008, HISTOCHEM CELL BIOL, V130, P21, DOI 10.1007/s00418-008-0420-0; Hacker MK, 2002, CLIN IMMUNOL, V105, P64, DOI 10.1006/clim.2002.5259; Futei Y, 2001, J DERMATOL SCI, V26, P55, DOI 10.1016/S0923-1811(00)00158-4; SCHILTZ JR, 1976, J INVEST DERMATOL, V67, P254, DOI 10.1111/1523-1747.ep12513454; Umehara H, 2012, MOD RHEUMATOL, V22, P21, DOI 10.1007/s10165-011-0571-z; Deshpande V, 2012, MODERN PATHOL, V25, P1181, DOI 10.1038/modpathol.2012.72; Zhang XF, 2012, ARCH PATHOL LAB MED, V136, P1402, DOI 10.5858/arpa.2011-0425-OA; Kricheli D, 2000, BRIT J DERMATOL, V143, P337, DOI 10.1046/j.1365-2133.2000.03659.x; Ikeda S, 2003, ARCH DERMATOL RES, V295, pS12, DOI 10.1007/s00403-002-0367-2; AMAGAI M, 1994, J CLIN INVEST, V94, P59, DOI 10.1172/JCI117349; Nishikawa T, 1996, J DERMATOL SCI, V12, P1, DOI 10.1016/0923-1811(95)00459-9; Raina A, 2008, ARCH PATHOL LAB MED, V132, P48, DOI 10.1043/1543-2165(2008)132[48:SIGFLI]2.0.CO;2; Kljuic A, 2003, CELL, V113, P249, DOI 10.1016/S0092-8674(03)00273-3; Strehl JD, 2011, J CLIN PATHOL, V64, P237, DOI 10.1136/jcp.2010.085613; Mahoney MG, 1999, J CLIN INVEST, V103, P461, DOI 10.1172/JCI5252; Funakoshi T, 2012, BRIT J DERMATOL, V167, P1245, DOI 10.1111/j.1365-2133.2012.11144.x; Calkins CC, 2006, J BIOL CHEM, V281, P7623, DOI 10.1074/jbc.M512447200; Hamano H, 2001, NEW ENGL J MED, V344, P732, DOI 10.1056/NEJM200103083441005; Nousari HC, 1999, LANCET, V354, P667, DOI 10.1016/S0140-6736(99)03007-X; Khabiri AR, 2006, PARASITE IMMUNOL, V28, P357, DOI 10.1111/j.1365-3024.2006.00837.x; Koch PJ, 1997, J CELL BIOL, V137, P1091, DOI 10.1083/jcb.137.5.1091; Elder DE, 2008, LEVERS HISTOPATHOLOG, P245	27	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0904-2512	1600-0714		J ORAL PATHOL MED	J. Oral Pathol. Med.	NOV	2015	44	10					850	856		10.1111/jop.12290		7	Dentistry, Oral Surgery & Medicine; Pathology	Dentistry, Oral Surgery & Medicine; Pathology	CU9LN	WOS:000363866100012		
J	Tsukuura, H; Ando, Y; Gyawali, B; Matsumoto, M; Sugishita, M; Honda, K; Urakawa, H; Maeda, O; Hasegawa, Y				Tsukuura, Hiroaki; Ando, Yuichi; Gyawali, Bishal; Matsumoto, Masami; Sugishita, Mihoko; Honda, Kazunori; Urakawa, Hiroshi; Maeda, Osamu; Hasegawa, Yoshinori			Prophylactic Use of Antiemetics for Prevention of Opioid-Induced Nausea and Vomiting: A Questionnaire Survey among Japanese Physicians	JOURNAL OF PALLIATIVE MEDICINE			English	Article							PAIN MANAGEMENT; CANCER-PATIENTS; PROCHLORPERAZINE; OXYCODONE; MORPHINE	Background: Antiemetics are being used both for the treatment and prophylaxis of opioid-induced nausea and vomiting (OINV) in clinical practice, despite the lack of evidence for the prophylactic benefit. Data regarding the actual status of prophylactic antiemetic use for OINV remain to be elucidated. Objective: The objective of this study was to evaluate the practice among Japanese physicians of the prophylactic use of antiemetics when starting opioids prescription for the prevention of opioid-induced nausea and vomiting. Methods: This questionnaire survey was targeted among physicians experienced in cancer pain treatment at two institutions of Japan (Nagoya University Hospital and Ichinomiya City Municipal Hospital). The questionnaire assessed the physicians' practice and beliefs regarding the prophylactic antiemetics prescription when they start opioids in patients with cancer pain. Results: Questionnaires were filled in and received from 112 physicians from two institutions. Eighty-two percent of physicians prescribed prophylactic antiemetics at the beginning of opioid prescription, and the most commonly prescribed drug for this purpose was prochlorperazine (88%). Conclusion: Despite the lack of evidence, Japanese physicians commonly prescribe prophylactic antiemetics, most commonly prochlorperazine, for OINV. Prospective clinical trials are necessary to evaluate the efficacy of this practice.	[Tsukuura, Hiroaki; Ando, Yuichi; Gyawali, Bishal; Sugishita, Mihoko; Honda, Kazunori; Urakawa, Hiroshi; Maeda, Osamu] Nagoya Univ Hosp, Dept Clin Oncol & Chemotherapy, Nagoya, Aichi 4668550, Japan; [Hasegawa, Yoshinori] Nagoya Univ Hosp, Dept Respirol, Nagoya, Aichi 4668550, Japan; [Matsumoto, Masami] Ichinomiya City Hosp, Dept Respirol, Ichinomiya, Japan	Tsukuura, H (reprint author), Nagoya Univ Hosp, Dept Clin Oncol & Chemotherapy, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	tsuku@med.nagoya-u.ac.jp	MAEDA, Osamu/Q-1016-2015				Hardy J, 2002, SUPPORT CARE CANCER, V10, P231, DOI 10.1007/s00520-001-0332-1; Smith HS, 2014, EUR J PHARMACOL, V722, P67, DOI 10.1016/j.ejphar.2013.09.074; Kanbayashi Y, 2014, J PALLIAT MED, V17, P683, DOI 10.1089/jpm.2013.0613; Tashiro M, 2014, CLIN CHIM ACTA, V429, P175, DOI 10.1016/j.cca.2013.12.011; BHARGAVA KP, 1981, BRIT J PHARMACOL, V72, P471; Donnelly S, 2002, SUPPORT CARE CANCER, V10, P13, DOI 10.1007/s005200100274; Ishihara M, 2012, CLIN J PAIN, V28, P373, DOI 10.1097/AJP.0b013e318237d626; Nicholson B, 2003, DRUGS, V63, P17, DOI 10.2165/00003495-200363010-00002; Vignaroli E, 2012, J PALLIAT MED, V15, P186, DOI 10.1089/jpm.2011.0296; Williams PI, 1999, EUR J ANAESTH, V16, P638, DOI 10.1046/j.1365-2346.1999.00561.x; Japanese Society for Palliative Medicine, 2014, CLIN GUID CANC PAIN; National Comprehensive Cancer Network, 2015, CLIN PRACT GUID ONC; Okamoto Yoshiaki, 2010, J Opioid Manag, V6, P431	13	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1096-6218	1557-7740		J PALLIAT MED	J. Palliat. Med.	NOV 1	2015	18	11					977	980		10.1089/jpm.2015.0203		4	Health Care Sciences & Services	Health Care Sciences & Services	CV0LK	WOS:000363942000014		
J	Gaibulloev, K; George, J; Sandler, T; Shimizu, H				Gaibulloev, Khusrav; George, Justin; Sandler, Todd; Shimizu, Hirofumi			Personnel contributions to UN and non-UN peacekeeping missions: A public goods approach	JOURNAL OF PEACE RESEARCH			English	Article						endogeneity; joint product model; personnel contributions; spatial panel regressions; UN and non-UN peacekeeping	OPERATIONS; SYSTEM; PEACE; MODEL	Based on spatial panel regressions for 1990-2012, this article draws publicness differences between peacekeeping personnel contributions to UN and non-UN peacekeeping operations. The analysis shows that UN missions are much less responsive to personnel spillovers, derived from other contributors' peacekeepers, than is the case of non-UN missions. UN peacekeeping missions display either no response or free riding to these personnel spillovers, while non-UN missions indicate spillover complementarity. Moreover, a number of controls distinguish the two kinds of peacekeeping, where non-UN missions display income normality and UN missions' deployments increase with the number of concurrent peacekeeping missions. The latter suggests that some countries specialize in supplying UN peacekeepers as a money-making venture. The positive response to the population variable supports this conjecture for UN missions, because a greater population base provides the recruits for peacekeeping operations. Our spatial empirical analysis accounts for the endogeneity of peacekeeper spillovers. The article concludes with a host of robustness tests that account for the alternative classes of peacekeepers, African Union and ECOWAS missions, and other empirical variants.	[Gaibulloev, Khusrav] Amer Univ Sharjah, Dept Econ, Sharjah, U Arab Emirates; [George, Justin; Sandler, Todd] Univ Texas Dallas, Sch Econ Polit & Policy Sci, Richardson, TX 75083 USA; [Shimizu, Hirofumi] Natl Def Acad Japan, Dept Publ Policy, Yokosuka, Kanagawa, Japan	Sandler, T (reprint author), Univ Texas Dallas, Sch Econ Polit & Policy Sci, Richardson, TX 75083 USA.	tsandler@utdallas.edu					Bobrow DB, 1997, J CONFLICT RESOLUT, V41, P723, DOI 10.1177/0022002797041006001; [Anonymous], 2007, STATA J; Kelejian HH, 1998, J REAL ESTATE FINANC, V17, P99, DOI 10.1023/A:1007707430416; Kelejian HH, 2006, J REGIONAL SCI, V46, P507, DOI 10.1111/j.1467-9787.2006.00449.x; Dorussen H, 2013, J PEACE RES, V50, P691, DOI 10.1177/0022343313484953; Shimizu H, 2005, DEFENCE PEACE ECON, V16, P1, DOI 10.1080/1024269052000323515; Bove V, 2011, J PEACE RES, V48, P699, DOI 10.1177/0022343311418265; Gaibulloev K, 2009, J CONFLICT RESOLUT, V53, P827, DOI 10.1177/0022002709338509; Victor J, 2010, J PEACE RES, V47, P217, DOI 10.1177/0022343309354142; Lebovic JH, 2004, J CONFLICT RESOLUT, V48, P910, DOI 10.1177/002200270412269357; Hultman L, 2013, AM J POLIT SCI, V57, P875, DOI 10.1111/ajps.12036; CORNES R, 1994, J PUBLIC ECON, V54, P403, DOI 10.1016/0047-2727(94)90043-4; Khanna J, 1999, KYKLOS, V52, P345, DOI 10.1111/j.1467-6435.1999.tb00222.x; Salverda N, 2013, J PEACE RES, V50, P707, DOI 10.1177/0022343313498764; Bellamy Alex J, 2013, PROVIDING PEACEKEEPE; Binyam Solomon, 2007, HDB DEFENSE EC, V2, P741; Coleman Katharina P, 2014, POLITICAL EC UN PEAC; Doyle Michael W, 2006, MAKING WAR BUILDING; Elhorst Paul J, 2014, INT REGIONAL SCI REV, V37, P389; Hill Stephen M, 1996, PEACEKEEPING UN; International Institute for Strategic Studies, 1991, THE MIL BAL; Lisa Hultman, 2013, ANN M AM POL SCI ASS; North Atlantic Treaty Organization (NATO), 2014, FIN EC DAT REL NATO; Page Fortna Virginia, 2008, DOES PEACEKEEPING WO; Shimizu H., 2002, J PEACE RES, V39, P651, DOI 10.1177/0022343302039006001; Stockholm International Peace Research Institute (SIPRI), 2014, SIPRI MIL EXP DAT; Thierry Tardy, 2013, FUNDING PEACE OPERAT; Todd Sandler, 1999, POL EC NATO PRESENT; United Nations, 2014, MUCH DOES PEAC COST; United Nations, 2008, UN PEAC OP PRINC GUI; United Nations Department of Peacekeeping Operations, 1990, MONTHL SUMM COUNTR C; United Nations Office for Disarmament Affairs, 2014, UN REP MIL EXP; World Bank, 2013, WOR DEV REP, P1, DOI 10.1596/978-0-8213-9575-2	33	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0022-3433	1460-3578		J PEACE RES	J. Peace Res.	NOV	2015	52	6					727	742		10.1177/0022343315579245		16	International Relations; Political Science	International Relations; Government & Law	CV3MV	WOS:000364164200003		
J	Sato, Y; Oshiro, M; Takemoto, K; Hosono, H; Saito, A; Kondo, T; Aizu, K; Matsusawa, M; Futamura, Y; Asami, T; Terasaki, H; Hayakawa, M				Sato, Y.; Oshiro, M.; Takemoto, K.; Hosono, H.; Saito, A.; Kondo, T.; Aizu, K.; Matsusawa, M.; Futamura, Y.; Asami, T.; Terasaki, H.; Hayakawa, M.			Multicenter observational study comparing sedation/analgesia protocols for laser photocoagulation treatment of retinopathy of prematurity	JOURNAL OF PERINATOLOGY			English	Article							NEONATAL CIRCUMCISION; ANESTHESIA; PAIN; VACCINATION; ANALGESIA; CHILDREN; BRAIN; YOUNG	OBJECTIVE: The aim of this study was to identify the best sedation/analgesia protocol for laser photocoagulation (PC) of retinopathy of prematurity (ROP). STUDY DESIGN: This multicenter observational study included five hospitals, each using a specific sedation/analgesia protocol: local anesthesia with oxybuprocaine hydrochloride (Group L); intravenous pentazocine (Group P); intravenous fentanyl (Group F); air, oxygen and sevoflurane (AOS) inhalation (Group I). The groups were compared for pain responses, vital signs and adverse events. RESULTS: Heart rates and systemic blood pressures were elevated by PC in Groups L and P and Groups L, P and F, respectively. Moreover, poor analgesic efficacy was recognized in Groups L, P and F. In contrast, Group I experienced hypothermia, enteral feeding intolerance and apnea more frequently. CONCLUSION: From the viewpoint of sedation/pain relief, AOS anesthesia should be the best protocol. However, considering all the various factors together, the most reasonable one can be varied based on the patient's condition and hospital.	[Sato, Y.; Saito, A.; Kondo, T.; Hayakawa, M.] Nagoya Univ Hosp, Ctr Maternal Neonatal Care, Div Neonatol, Nagoya, Aichi 4668550, Japan; [Oshiro, M.; Saito, A.] Japanese Red Cross Nagoya Daiichi Hosp, Dept Pediat, Nagoya, Aichi, Japan; [Takemoto, K.] Anjo Kosei Hosp, Dept Pediat, Anjo, Aichi, Japan; [Takemoto, K.; Hosono, H.] Konan Kosei Hosp, Dept Pediat, Konan, Aichi, Japan; [Kondo, T.] Ogaki Municipal Hosp, Dept Pediat Cardiol & Neonatol, Ogaki, Gifu, Japan; [Aizu, K.] Toyota Mem Hosp, Dept Neonatol, Toyota, Aichi, Japan; [Matsusawa, M.] Okazaki City Hosp, Dept Pediat, Okazaki, Aichi, Japan; [Futamura, Y.; Asami, T.; Terasaki, H.] Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Nagoya, Aichi 4648601, Japan	Sato, Y (reprint author), Nagoya Univ Hosp, Ctr Maternal Neonatal Care, Div Neonatol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	yoshiaki@med.nagoya-u.ac.jp					Mellon RD, 2007, ANESTH ANALG, V104, P509, DOI 10.1213/01.ane.0000255729.96438.b0; Haigh PM, 1997, BRIT J OPHTHALMOL, V81, P283, DOI 10.1136/bjo.81.4.283; Zhu CL, 2010, J CEREBR BLOOD F MET, V30, P1017, DOI 10.1038/jcbfm.2009.274; Taddio A, 1997, LANCET, V349, P599, DOI 10.1016/S0140-6736(96)10316-0; Loepke AW, 2008, ANESTH ANALG, V106, P1681, DOI 10.1213/ane.0b013e318167ad77; TADDIO A, 1995, LANCET, V345, P291, DOI 10.1016/S0140-6736(95)90278-3; Chen SDM, 2007, EYE, V21, P1033, DOI 10.1038/sj.eye.2702499; Parulekar MV, 2008, EYE, V22, P375, DOI 10.1038/sj.eye.6702642; Laudenbach V, 2001, J CLIN INVEST, V107, P457, DOI 10.1172/JCI9716; ANAND KJS, 1989, PEDIATR CLIN N AM, V36, P795; Kirwan C, 2007, ACTA OPHTHALMOL SCAN, V85, P644, DOI 10.1111/j.1600-0420.2007.00900.x; Woodhead DD, 2007, J PERINATOL, V27, P209, DOI 10.1038/sj.jp.7211675; Dilli D, 2014, ACTA PAEDIATR, V103, pE76, DOI 10.1111/apa.12454; Batton DG, 2006, PEDIATRICS, V118, P2231, DOI [10.1542/peds.2006-2277., DOI 10.1542/PEDS.2006-2277]; GIANNAKOULOPOULOS X, 1994, LANCET, V344, P77, DOI 10.1016/S0140-6736(94)91279-3; Gole GA, 2005, ARCH OPHTHALMOL-CHIC, V123, P991; Lawrence J, 1993, Neonatal Netw, V12, P59; SCHULENBURG WE, 1995, ACTA OPHTHALMOL SCAN, V73, P14	18	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0743-8346	1476-5543		J PERINATOL	J. Perinatol.	NOV	2015	35	11					965	969		10.1038/jp.2015.112		5	Obstetrics & Gynecology; Pediatrics	Obstetrics & Gynecology; Pediatrics	CV0XB	WOS:000363976000015		
J	Mizumoto, A; Yamamoto, K; Nakayama, Y; Takara, K; Nakagawa, T; Hirano, T; Hirai, M				Mizumoto, Atsushi; Yamamoto, Kazuhiro; Nakayama, Yuko; Takara, Kohji; Nakagawa, Tsutomu; Hirano, Takeshi; Hirai, Midori			Induction of Epithelial-Mesenchymal Transition via Activation of Epidermal Growth Factor Receptor Contributes to Sunitinib Resistance in Human Renal Cell Carcinoma Cell Lines	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							LUNG-CANCER; TUMOR PROGRESSION; EXPRESSION; EGFR; EFFICACY; PATHWAY; KINASE; TRANSACTIVATION; PROLIFERATION; TUMORIGENESIS	Sunitinib is widely used for treating renal cell carcinoma (RCC). However, some patients do not respond to treatment with this drug. We aimed to study the association between sunitinib sensitivity and epithelial-mesenchymal transition (EMT) regulation via epidermal growth factor receptor (EGFR) signaling, which is a mechanism of resistance to anticancer drugs. Three RCC cell lines (786-O, ACHN, and Caki-1) were used, and then we evaluated cell viability, EMT regulatory proteins, and signal transduction with sunitinib treatment. Cell viability of 786-O cells was maintained after treatment with sunitinib. After treatment with sunitinib, EGFR phosphorylation increased in 786-O cells, resulting in an increase in the phosphorylation of extracellular signal-regulated kinase, nuclear translocation of beta-catenin, and expression of mesenchymal markers. These results suggest that sunitinib induced EMT via activation of EGFR in 786-O cells, but not in ACHN and Caki-1 cells. Caki-1/SN cells, a resistant cell line generated by continuous exposure to sunitinib, displayed increased phosphorylation of EGFR. Cell viability in the presence of sunitinib was decreased by erlotinib, as the selective inhibitor of EGFR, treatment in 786-O and Caki-1/SN cells. Similarly, erlotinib suppressed sunitinib-induced EGFR activation and upregulated mesenchymal markers. Thus, we postulate that resistance to sunitinib in RCC may be associated with EMT caused by activation of EGFR.	[Mizumoto, Atsushi; Nakagawa, Tsutomu; Hirano, Takeshi; Hirai, Midori] Kobe Univ, Dept Biochem & Mol Biol, Div Pharmacokinet, Grad Sch Med, Kobe, Hyogo, Japan; [Yamamoto, Kazuhiro; Nakagawa, Tsutomu; Hirano, Takeshi; Hirai, Midori] Kobe Univ Hosp, Dept Pharm, Kobe, Hyogo 6500017, Japan; [Nakayama, Yuko; Takara, Kohji] Himeji Dokkyo Univ, Dept Clin Pharmaceut, Fac Pharmaceut Sci, Himeji, Hyogo, Japan	Yamamoto, K (reprint author), Kobe Univ Hosp, Dept Pharm, Chuo Ku, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	yamakz@med.kobe-u.ac.jp			Kobe University Research Fund	This research was supported by the Kobe University Research Fund of 2013-2014.	Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Huang D, 2010, CANCER RES, V70, P1053, DOI 10.1158/0008-5472.CAN-09-3722; Ishimaru T, 2010, J UROLOGY, V184, P2143, DOI 10.1016/j.juro.2010.06.088; Dai HL, 2013, NEUROCHEM INT, V63, P610, DOI 10.1016/j.neuint.2013.09.005; Weygant N, 2015, ONCOTARGET, V6, P2193; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Makhov PB, 2012, MOL CANCER THER, V11, P1510, DOI 10.1158/1535-7163.MCT-11-0907; Katoh M, 2006, CANCER BIOL THER, V5, P1059, DOI 10.4161/cbt.5.9.3151; Stickle NH, 2005, MUTAT RES-FUND MOL M, V578, P23, DOI 10.1016/j.mrfmmm.2005.02.016; Bae GY, 2013, ONCOTARGET, V4, P2512; Klatte T, 2007, CLIN CANCER RES, V13, P7388, DOI 10.1158/1078-0432.CCR-07-0411; Dordevic G, 2012, J BIOMED SCI, V19, DOI 10.1186/1423-0127-19-40; Holland WS, 2012, CANCER CHEMOTH PHARM, V69, P185, DOI 10.1007/s00280-011-1684-y; Moreno-Caceres J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.294; Zhang ZF, 2012, NAT GENET, V44, P852, DOI 10.1038/ng.2330; Yang J, 2012, INT J CANCER, V130, P959, DOI 10.1002/ijc.26095; Uemura H, 2010, JPN J CLIN ONCOL, V40, P194, DOI 10.1093/jjco/hyp146; Roskoski R, 2007, BIOCHEM BIOPH RES CO, V356, P323, DOI 10.1016/j.bbre.2007.02.156; Sanchez-Tillo E, 2011, AM J CANCER RES, V1, P897; Sorkin A, 2001, BIOCHEM SOC T, V29, P480, DOI 10.1042/BST0290480; Witta SE, 2006, CANCER RES, V66, P944, DOI 10.1158/0008-5472.CAN-05-1988; Moch H, 1997, HUM PATHOL, V28, P1255; Faivre S, 2007, NAT REV DRUG DISCOV, V6, P734, DOI 10.1038/nrd2380; Lappano R, 2011, NAT REV DRUG DISCOV, V10, P47, DOI 10.1038/nrd3320; Wang Y, 2009, NAT MED, V15, P319, DOI 10.1038/nm.1922; Maille E, 2011, AM J PHYSIOL-LUNG C, V301, pL945, DOI 10.1152/ajplung.00149.2011; Shinojima T, 2007, CARCINOGENESIS, V28, P529, DOI 10.1093/carcin/bgl143; Santamaria PG, 2010, MOL CELL, V38, P3, DOI 10.1016/j.molcel.2010.03.012; Abouantoun TJ, 2011, J NEURO-ONCOL, V101, P215, DOI 10.1007/s11060-010-0259-9; Flaig TW, 2010, BRIT J CANCER, V103, P796, DOI 10.1038/sj.bjc.6605868; Ding G, 2007, AM J PHYSIOL-RENAL, V293, pF1889, DOI 10.1152/ajprenal.00112.2007; Hollier BG, 2009, J MAMMARY GLAND BIOL, V14, P29, DOI 10.1007/s10911-009-9110-3; Chang L, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.407; Dong PX, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0231-0; Duran M, 2013, INT BRAZ J UROL, V39, P768, DOI 10.1590/S1677-5538.IBJU.2013.06.02; Keitel Ulrike, 2014, Oncoscience, V1, P706; Leung HW, 2014, MOL CLIN ONCOL, V2, P858; Muriel LC, 2012, INVEST NEW DRUGS, V30, P2443; Paoli P, 2013, BBA-MOL CELL RES, V1833, P3481, DOI 10.1016/j.bbamcr.2013.06.026; Shorning BY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016209; Voon DCC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070427; Yamamoto K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102110	42	0	0	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA	0022-3565	1521-0103		J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	NOV	2015	355	2					152	158		10.1124/jpet.115.226639		7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CV3MT	WOS:000364164000003		
J	Lopez, AM; Chuang, JC; Posey, KS; Ohshiro, T; Tomoda, H; Rudel, LL; Turley, SD				Lopez, Adam M.; Chuang, Jen-Chieh; Posey, Kenneth S.; Ohshiro, Taichi; Tomoda, Hiroshi; Rudel, Lawrence L.; Turley, Stephen D.			PRD125, a Potent and Selective Inhibitor of Sterol O-Acyltransferase 2 Markedly Reduces Hepatic Cholesteryl Ester Accumulation and Improves Liver Function in Lysosomal Acid Lipase-Deficient Mice	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							LOW-DENSITY-LIPOPROTEIN; STORAGE-DISEASE; DIETARY-CHOLESTEROL; ACAT INHIBITION; SMALL-INTESTINE; ACYL-COENZYME; MOUSE; METABOLISM; ATHEROSCLEROSIS; HYPERCHOLESTEROLEMIA	In most organs, the bulk of cholesterol is unesterified, although nearly all possess a varying capability of esterifying cholesterol through the action of either sterol O-acyltransferase (SOAT) 1 or, in the case of hepatocytes and enterocytes, SOAT2. Esterified cholesterol (EC) carried in plasma lipoproteins is hydrolyzed by lysosomal acid lipase (LAL) when they are cleared from the circulation. Loss-of-function mutations in LIPA, the gene that encodes LAL, result in Wolman disease or cholesteryl ester storage disease (CESD). Hepatomegaly and a massive increase in tissue EC levels are hallmark features of both disorders. While these conditions can be corrected with enzyme replacement therapy, the question arose as to whether pharmacological inhibition of SOAT2 might reduce tissue EC accretion in CESD. When weaned at 21 days, Lal(-/-) mice, of either gender, had a whole liver cholesterol content that was 12- to 13-fold more than that of matching Lal(+/+) littermates (23 versus 1.8 mg, respectively). In Lal(-/-) males given the selective SOAT2 inhibitor PRD125 1,11-O-o-methylbenzylidene-7-O-p-cyanobenzoyl-1,7,11-trideacetylpyripyropene A in their diet (similar to 10 mg/day per kg body weight) from 21 to 53 days, whole liver cholesterol content was 48.6 versus 153.7 mg in untreated 53-day-old Lal(-/-) mice. This difference reflected a 59% reduction in hepatic EC concentration (mg/g), combined with a 28% fall in liver mass. The treated mice also showed a 63% reduction in plasma alanine aminotransferase activity, in parallel with decisive falls in hepatic mRNA expression levels for multiple proteins that reflect macrophage presence and inflammation. These data implicate SOAT2 as a potential target in CESD management.	[Lopez, Adam M.; Chuang, Jen-Chieh; Posey, Kenneth S.; Turley, Stephen D.] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA; [Ohshiro, Taichi; Tomoda, Hiroshi] Kitasato Univ, Grad Sch Pharmaceut Sci, Tokyo, Japan; [Ohshiro, Taichi; Rudel, Lawrence L.] Wake Forest Univ, Bowman Gray Sch Med, Dept Pathol, Winston Salem, NC 27103 USA	Turley, SD (reprint author), Univ Texas SW Med Ctr Dallas, Div Digest & Liver Dis, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	stephen.turley@utsouthwestern.edu			National Institutes of Health National Heart, Lung, and Blood Institute [R01HL009610, PO1HL049373]; Wake Forest Innovations; Japan Society for the Promotion of Science	This work was supported by the National Institutes of Health National Heart, Lung, and Blood Institute [Grant R01HL009610 to S.D.T.] and [Grant PO1HL049373 to L.L.R]. Dr. Ohshiro was supported by a grant from Wake Forest Innovations as well as a grant-in-aid for scientific research from the Japan Society for the Promotion of Science.	Valasek MA, 2005, ADV PHYSIOL EDUC, V29, P151, DOI 10.1152/advan.00019.2005; Du H, 2001, J LIPID RES, V42, P489; Peng SQ, 2000, ARTERIOSCL THROM VAS, V20, P2682; Turley SD, 2010, AM J PHYSIOL-GASTR L, V299, pG1012, DOI 10.1152/ajpgi.00190.2010; Taylor AM, 2012, J LIPID RES, V53, P2331, DOI 10.1194/jlr.M028241; GRUNDY SM, 1983, ANNU REV NUTR, V3, P71, DOI 10.1146/annurev.nu.03.070183.000443; SLOAN HR, 1972, J CLIN INVEST, V51, P1923, DOI 10.1172/JCI106997; Remaley AT, 1997, ARTERIOSCL THROM VAS, V17, P1813; Lee RG, 2000, J LIPID RES, V41, P1991; Schwarz M, 1998, J LIPID RES, V39, P1833; Chang C, 2006, ACTA BIOCH BIOPH SIN, V38, P151, DOI 10.1111/j.1745-7270.2006.00154.x; Rudel LL, 1997, J CLIN INVEST, V100, P74, DOI 10.1172/JCI119524; Farese RV, 2006, ARTERIOSCL THROM VAS, V26, P1684, DOI 10.1161/01.ATV.0000227511.35456.90; KURIYAMA M, 1990, J LIPID RES, V31, P1605; Balwani M, 2013, HEPATOLOGY, V58, P950, DOI 10.1002/hep.26289; Rousset X, 2011, CURR ATHEROSCLER REP, V13, P249, DOI 10.1007/s11883-011-0171-6; OSONO Y, 1995, J CLIN INVEST, V95, P1124, DOI 10.1172/JCI117760; Zhang J, 2012, J LIPID RES, V53, P1144, DOI 10.1194/jlr.M024356; Tardif JC, 2004, CIRCULATION, V110, P3372, DOI 10.1161/01.CIR.0000147777.12010.EF; Ohshiro T, 2011, ARTERIOSCL THROM VAS, V31, P1108, DOI 10.1161/ATVBAHA.111.223552; Xie CL, 2002, J LIPID RES, V43, P1508, DOI 10.1194/jlr.M200146-JLR200; Lopez AM, 2014, BIOCHEM BIOPH RES CO, V454, P162, DOI 10.1016/j.bbrc.2014.10.063; Rudel LL, 2005, ARTERIOSCL THROM VAS, V25, P1112, DOI 10.1161/01.ATV.0000166548.65753.1e; Dietschy JM, 2004, J LIPID RES, V45, P1375, DOI [10.1194/jlr.r400004, 10.1194/jlr.r400004-JLR200]; Lada AT, 2004, J LIPID RES, V45, P378, DOI 10.1194/jlr.D300037-JLR200; GOODMAN DS, 1965, PHYSIOL REV, V45, P747; Reiner Z, 2014, ATHEROSCLEROSIS, V235, P21, DOI 10.1016/j.atherosclerosis.2014.04.003; Chuang JC, 2014, BIOCHEM BIOPH RES CO, V443, P1073, DOI 10.1016/j.bbrc.2013.12.096; Sun Y, 2014, MOL GENET METAB, V112, P229, DOI 10.1016/j.ymgme.2014.04.006; Parini P, 2004, CIRCULATION, V110, P2017, DOI 10.1161/01.CIR.0000143163.76212.0B; HOEG JM, 1984, AM J HUM GENET, V36, P1190; Todoroki T, 2000, ANN CLIN BIOCHEM, V37, P187, DOI 10.1258/0004563001899195; Alger HM, 2010, J BIOL CHEM, V285, P14267, DOI 10.1074/jbc.M110.118422; GOLDSTEIN JL, 1975, J BIOL CHEM, V250, P8487; Ohtawa M, 2013, BIOORG MED CHEM LETT, V23, P3798, DOI 10.1016/j.bmcl.2013.04.075; Dong HQ, 2011, TRENDS ENDOCRIN MET, V22, P234, DOI 10.1016/j.tem.2011.02.003; Nissen SE, 2006, NEW ENGL J MED, V354, P1253, DOI 10.1056/NEJMoa054699; Rong JX, 2013, ARTERIOSCL THROM VAS, V33, P4, DOI 10.1161/ATVBAHA.112.252056; Cooper AD, 1997, J LIPID RES, V38, P2173; Beltroy EP, 2005, HEPATOLOGY, V42, P886, DOI 10.1002/hep.20868; Cases S, 1998, J BIOL CHEM, V273, P26755, DOI 10.1074/jbc.273.41.26755; Du H, 1998, HUM MOL GENET, V7, P1347, DOI 10.1093/hmg/7.9.1347; Aqul A, 2014, AM J PHYSIOL-GASTR L, V307, pG836, DOI 10.1152/ajpgi.00243.2014; DHOLLAND.F, 1969, BIOCHIM BIOPHYS ACTA, V176, P146, DOI 10.1016/0005-2760(69)90083-6; Grabowski GA, 2015, SCRIVERS ONLINE META; Lipkin M, 1981, PHYSL GASTROINTESTIN, P145; Tso Patrick, 1994, P1867; Turley SD, 1988, LIVER BIOL PATHOBIOL, P617	48	0	0	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA	0022-3565	1521-0103		J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	NOV	2015	355	2					159	167		10.1124/jpet.115.227207		9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CV3MT	WOS:000364164000004		
J	Littmann, T; Gottle, M; Reinartz, MT; Kalble, S; Wainer, IW; Ozawa, T; Seifert, R				Littmann, Timo; Goettle, Martin; Reinartz, Michael T.; Kaelble, Solveig; Wainer, Irving W.; Ozawa, Takeaki; Seifert, Roland			Recruitment of beta-Arrestin 1 and 2 to the beta(2)-Adrenoceptor: Analysis of 65 Ligands	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							PROTEIN-COUPLED RECEPTORS; AIRWAY SMOOTH-MUSCLE; 7-TRANSMEMBRANE RECEPTORS; FENOTEROL STEREOISOMERS; RACEMIC ALBUTEROL; CELLS; ADRENOCEPTOR; MICE; DESENSITIZATION; ACTIVATION	Beyond canonical signaling via G(alpha)s and cAMP, the concept of functional selectivity at beta(2)-adrenoceptors (beta(2)ARs) describes the ability of adrenergic drugs to stabilize ligand-specific receptor conformations to initiate further signaling cascades comprising additional G-protein classes or beta-arrestins (beta arr). A set of 65 adrenergic ligands including 40 agonists and 25 antagonists in either racemic or enantiopure forms was used for barr recruitment experiments based on a split-luciferase assay in a cellular system expressing beta(2)AR. Many agonists showed only (weak) partial agonism regarding barr recruitment. Potencies and/or efficacies increased depending on the number of chirality centers in (R) configuration; no (S)-configured distomer was more effective at inducing beta arr recruitment other than the eutomer. beta arr2 was recruited more effectively than beta arr1. The analysis of antagonists revealed no significant effects on barr recruitment. Several agonists showed preference for activation of G(alpha)s GTPase relative to beta arr recruitment, and no beta arr-biased ligand was identified. In conclusion: 1) agonists show strong bias for G(alpha)s activation relative to barr recruitment; 2) agonists recruit beta arr1 and beta arr2 with subtle differences; and 3) there is no evidence for beta arr recruitment by antagonists.	[Littmann, Timo; Goettle, Martin; Reinartz, Michael T.; Kaelble, Solveig; Seifert, Roland] Hannover Med Sch, Inst Pharmacol, D-30625 Hannover, Germany; [Wainer, Irving W.] NIA, Lab Clin Invest, Baltimore, MD 21224 USA; [Ozawa, Takeaki] Univ Tokyo, Dept Chem, Sch Sci, Tokyo 113, Japan	Seifert, R (reprint author), Hannover Med Sch, Inst Pharmacol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	seifert.roland@mh-hannover.de			internal funds of the Hannover Medical School	This work was supported by internal funds of the Hannover Medical School. The authors declare no conflict of interest.	Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Rajagopal S, 2011, MOL PHARMACOL, V80, P367, DOI 10.1124/mol.111.072801; Gawchik SM, 1999, J ALLERGY CLIN IMMUN, V103, P615, DOI 10.1016/S0091-6749(99)70233-2; HOCHHAUS G, 1992, INT J CLIN PHARM TH, V30, P342; Carter AA, 2005, J PHARMACOL EXP THER, V315, P839, DOI 10.1124/jpet.105.088914; Yin H, 2009, J BIOL CHEM, V284, P12328, DOI 10.1074/jbc.M806516200; Templeton AGB, 1998, PULM PHARMACOL THER, V11, P1, DOI 10.1006/pupt.1998.0110; Conner DA, 1997, CIRC RES, V81, P1021; Nelson HS, 1998, J ALLERGY CLIN IMMUN, V102, P943, DOI 10.1016/S0091-6749(98)70332-X; Reinartz MT, 2015, N-S ARCH PHARMACOL, V388, P517, DOI 10.1007/s00210-015-1086-5; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Mitra S, 1998, MOL PHARMACOL, V53, P347; Bohn LM, 2002, J NEUROSCI, V22, P10494; Toll L, 2011, J PHARMACOL EXP THER, V336, P524, DOI 10.1124/jpet.110.173971; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; Reiner S, 2010, J BIOL CHEM, V285, P36188, DOI 10.1074/jbc.M110.175604; Shukla AK, 2011, TRENDS BIOCHEM SCI, V36, P457, DOI 10.1016/j.tibs.2011.06.003; MAZZONI L, 1994, PULM PHARMACOL, V7, P367, DOI 10.1006/pulp.1994.1043; Plazinska A, 2014, BIOORGAN MED CHEM, V22, P234, DOI 10.1016/j.bmc.2013.11.030; HAGELUKEN A, 1994, BIOCHEM PHARMACOL, V47, P1789, DOI 10.1016/0006-2952(94)90307-7; Patel M, 2012, EXPERT OPIN PHARMACO, V13, P1069, DOI 10.1517/14656566.2012.662221; Reinartz MT, 2015, N-S ARCH PHARMACOL, V388, P51, DOI 10.1007/s00210-014-1054-5; Birnbaumer L, 2007, BBA-BIOMEMBRANES, V1768, P772, DOI 10.1016/j.bbamem.2006.12.002; Luttrell LM, 2010, PHARMACOL REV, V62, P305, DOI 10.1124/pr.109.002436; Beaulieu JM, 2005, CELL, V122, P261, DOI 10.1016/j.cell.2005.05.012; Reiter E, 2012, ANNU REV PHARMACOL, V52, P179, DOI 10.1146/annurev.pharmtox.010909.105800; Oakley RH, 2002, ASSAY DRUG DEV TECHN, V1, P21, DOI 10.1089/154065802761001275; Volcheck GW, 2005, CLIN EXP ALLERGY, V35, P1341, DOI 10.1111/j.1365-2222.2005.02347.x; Magocsi M, 2007, IMMUNOLOGY, V122, P503, DOI 10.1111/j.1365-2567.2007.02658.x; Seifert R, 2013, BIOCHEM PHARMACOL, V86, P853, DOI 10.1016/j.bcp.2013.07.029; Baramki D, 2002, J ALLERGY CLIN IMMUN, V109, P449, DOI 10.1067/mai.2002.122159; Baillie GS, 2003, P NATL ACAD SCI USA, V100, P940, DOI 10.1073/pnas.262787199; Seifert R, 2002, BIOCHEM BIOPH RES CO, V298, P824, DOI 10.1016/S0006-291X(02)02569-X; Evans BA, 2010, BRIT J PHARMACOL, V159, P1022, DOI 10.1111/j.1476-5381.2009.00602.x; Kopra K, 2013, ANAL CHEM, V85, P2276, DOI 10.1021/ac303215r; Wenzel-Seifert K, 2000, MOL PHARMACOL, V58, P954; Delmotte P, 2010, AM J RESP CELL MOL, V42, P373, DOI 10.1165/rcmb.2008-0403OC; Baker JG, 2010, BRIT J PHARMACOL, V160, P1048, DOI 10.1111/j.1476-5381.2010.00754.x; Shenoy SK, 2006, J BIOL CHEM, V281, P1261, DOI 10.1074/jbc.M506576200; BLACK JW, 1983, PROC R SOC SER B-BIO, V220, P141, DOI 10.1098/rspb.1983.0093; Pedersen ME, 2007, CURR HYPERTENS REP, V9, P269, DOI 10.1007/s11906-007-0050-2; Handley DA, 2002, PULM PHARMACOL THER, V15, P135, DOI 10.1006/pupt.2001.0327; Takakura H, 2012, ACS CHEM BIOL, V7, P901, DOI 10.1021/cb200360z; Wisler JW, 2007, P NATL ACAD SCI USA, V104, P16657, DOI 10.1073/pnas.0707936104; Johnson M, 1998, AM J RESP CRIT CARE, V158, pS146; Audet M, 2010, FASEB J, V24, P2829, DOI 10.1096/fj.09-144816; Hummel IB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064556; Erickson CE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071980; Handley D A, 2000, Curr Opin Pulm Med, V6, P43, DOI 10.1097/00063198-200001000-00009; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; van der Westhuizen ET, 2014, MOL PHARMACOL, V85, P492, DOI 10.1124/mol.113.088880; Zhang XY, 1998, AM J PHYSIOL-LUNG C, V274, pL32	53	0	0	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA	0022-3565	1521-0103		J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	NOV	2015	355	2					183	+		10.1124/jpet.115.227959		30	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CV3MT	WOS:000364164000007		
J	Ohshiro, T; Ohtawa, M; Nagamitsu, T; Matsuda, D; Yagyu, H; Davis, MA; Rudel, LL; Ishibashi, S; Tomoda, H				Ohshiro, Taichi; Ohtawa, Masaki; Nagamitsu, Tohru; Matsuda, Daisuke; Yagyu, Hiroaki; Davis, Matthew A.; Rudel, Lawrence L.; Ishibashi, Shun; Tomoda, Hiroshi			New Pyripyropene A Derivatives, Highly SOAT2-Selective Inhibitors, Improve Hypercholesterolemia and Atherosclerosis in Atherogenic Mouse Models	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							COACHOLESTEROL ACYLTRANSFERASE 2; E-DEFICIENT MICE; CHOLESTEROL ACYLTRANSFERASE; ACYL-COA; ASPERGILLUS-FUMIGATUS; CARDIOVASCULAR EVENTS; LDL CHOLESTEROL; REDUCING LIPIDS; ACAT INHIBITION; STATIN THERAPY	Sterol O-acyltransferase 2 (SOAT2; also known as ACAT2) is considered as a new therapeutic target for the treatment or prevention of hypercholesterolemia and atherosclerosis. Fungal pyripyropene A (PPPA: 1,7,11-triacyl type), the first SOAT2-selective inhibitor, proved orally active in vivo using atherogenic mouse models. The purpose of the present study was to demonstrate that the PPPA derivatives (PRDs) prove more effective in the mouse models than PPPA. Among 196 semisynthetic PPPA derivatives, potent, SOAT2-selective, and stable PRDs were selected. In vivo antiatherosclerotic activity of selected PRDs was tested in apolipoprotein E knockout (Apoe(-/-)) mice or low-density lipoprotein receptor knockout (Ldlr(-/-)) mice fed a cholesterol-enriched diet (0.2% cholesterol and 21% fat) for 12 weeks. During the PRD treatments, no detrimental side effects were observed. Among three PRDs, Apoe(-/-) mice treated with PRD125 (1-,11-O-benzylidene type) at 1 mg/kg/day had significantly lower total plasma cholesterol concentration by 57.9 +/- 9.3%; further, the ratio of cholesteryl oleate to cholesteryl linoleate in low-density lipoprotein was lower by 55.6 +/- 7.5%, respectively. The hepatic cholesteryl ester levels and SOAT2 activity in the small intestines and livers of the PRD-treated mice were selectively lowered. The atherosclerotic lesion areas in the aortae of PRD125-treated mice were significantly lower at 62.2 +/- 13.1%, respectively. Furthermore, both PRDs were also orally active in atherogenic Ldlr(-/-) mice. Among the PRDs tested, PRD125 was the most potent in both mouse models. These results suggest that SOAT2-selective inhibitors such as PRD125 have a high potential as poststatin agents for treatment and/or prevention in patients with atherosclerosis and hypercholesterolemia.	[Ohshiro, Taichi; Ohtawa, Masaki; Nagamitsu, Tohru; Matsuda, Daisuke; Tomoda, Hiroshi] Kitasato Univ, Grad Sch Pharmaceut Sci, Tokyo 1088641, Japan; [Ohshiro, Taichi; Yagyu, Hiroaki; Ishibashi, Shun] Jichi Med Univ, Dept Med, Shimotsuke, Tochigi, Japan; [Ohshiro, Taichi; Davis, Matthew A.; Rudel, Lawrence L.] Wake Forest Sch Med, Dept Internal Med, Sect Mol Med, Winston Salem, NC USA	Tomoda, H (reprint author), Kitasato Univ, Grad Sch Pharmaceut Sci, Minato Ku, 5-9-1 Shirokane, Tokyo 1088641, Japan.	tomodah@pharm.kitasato-u.ac.jp			Program for Promotion of Fundamental Studies in Health Sciences from the National Institute of Biomedical Innovation; Ministry of Education, Culture, Sports, Science and Technology [26253009]; Japan Society for the Promotion of Science (JSPS); U.S. National Institutes of Health National Heart Lung and Blood Institute [HL-49373]; Postdoctoral Fellowship for Research Abroad	This work was supported by the Program for Promotion of Fundamental Studies in Health Sciences from the National Institute of Biomedical Innovation (to H.T.); by a grant-in-aid for Scientific Research (A) 26253009 from the Ministry of Education, Culture, Sports, Science and Technology (to H.T.); by a grant-in-aid from Japan Society for the Promotion of Science (JSPS) and their Postdoctoral Fellowship for Research Abroad. (to T.O.); and by the U.S. National Institutes of Health National Heart Lung and Blood Institute [Grant HL-49373 to L.L.R.].	Bell TA, 2007, ARTERIOSCL THROM VAS, V27, P1396, DOI 10.1161/ATVBAHA.107.142802; Du H, 2001, J LIPID RES, V42, P489; Lee RG, 2004, CIRC RES, V95, P998, DOI 10.1161/01.RES.0000147558.15554.67; Ohshiro T, 2007, J ANTIBIOT, V60, P43; Terasaka N, 2007, ATHEROSCLEROSIS, V190, P239, DOI 10.1016/j.atherosclerosis.2006.03.007; Yagyu H, 2000, J BIOL CHEM, V275, P21324, DOI 10.1074/jbc.M002541200; Sabatine MS, 2015, NEW ENGL J MED, V372, P1500, DOI 10.1056/NEJMoa1500858; Das A, 2008, J BIOL CHEM, V283, P10453, DOI 10.1074/jbc.M709460200; Fazio S, 2006, NEW ENGL J MED, V354, P1307, DOI 10.1056/NEJMe068012; Buhman KK, 2000, NAT MED, V6, P1341; Zhang J, 2012, J LIPID RES, V53, P1144, DOI 10.1194/jlr.M024356; Tardif JC, 2004, CIRCULATION, V110, P3372, DOI 10.1161/01.CIR.0000147777.12010.EF; Ohshiro T, 2011, ARTERIOSCL THROM VAS, V31, P1108, DOI 10.1161/ATVBAHA.111.223552; Temel RE, 2007, J LIPID RES, V48, P1618, DOI 10.1194/jlr.M700109-JLR200; Miller CD, 2012, ACAD EMERG MED, V19, P673, DOI 10.1111/j.1553-2712.2012.01378.x; Lopez AM, 2014, BIOCHEM BIOPH RES CO, V454, P162, DOI 10.1016/j.bbrc.2014.10.063; Davis HR, 2001, ARTERIOSCL THROM VAS, V21, P2032, DOI 10.1161/hq1201.100260; KIM YK, 1994, J ANTIBIOT, V47, P154; Ikenoya M, 2007, ATHEROSCLEROSIS, V191, P290, DOI 10.1016/j.atherosclerosis.2006.05.048; Warensjo E, 2008, AM J CLIN NUTR, V88, P203; TOMODA H, 1994, J ANTIBIOT, V47, P148; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Ohshiro T, 2008, J ANTIBIOT, V61, P503, DOI 10.1038/ja.2008.67; Bell TA, 2006, ARTERIOSCL THROM VAS, V26, P1814, DOI 10.1161/01.ATV.0000225289.30767.06; Lada AT, 2004, J LIPID RES, V45, P378, DOI 10.1194/jlr.D300037-JLR200; Ohtawa M, 2013, BIOORG MED CHEM LETT, V23, P2659, DOI 10.1016/j.bmcl.2013.02.088; Libby P, 2005, J AM COLL CARDIOL, V46, P1225, DOI 10.1016/j.jacc.2005.07.006; Mihaylova B, 2012, LANCET, V380, P581, DOI 10.1016/S0140-6736(12)60367-5; Parini P, 2004, CIRCULATION, V110, P2017, DOI 10.1161/01.CIR.0000143163.76212.0B; Ohtawa M, 2013, BIOORG MED CHEM LETT, V23, P3798, DOI 10.1016/j.bmcl.2013.04.075; Robinson JG, 2015, NEW ENGL J MED, V372, P1489, DOI 10.1056/NEJMoa1501031; Accad M, 2000, J CLIN INVEST, V105, P711, DOI 10.1172/JCI9021; Cannon CP, 2015, NEW ENGL J MED, V372, P2387, DOI 10.1056/NEJMoa1410489; Nissen SE, 2006, NEW ENGL J MED, V354, P1253, DOI 10.1056/NEJMoa054699; Fazio S, 2001, J CLIN INVEST, V107, P163, DOI 10.1172/JCI10310; OMURA S, 1993, J ANTIBIOT, V46, P1168; Ohshiro T, 2011, FUTURE MED CHEM, V3, P2039, DOI [10.4155/fmc.11.158, 10.4155/FMC.11.158]; Usui S, 2002, J LIPID RES, V43, P805; Willner EL, 2003, P NATL ACAD SCI USA, V100, P1262, DOI 10.1073/pnas.0336398100; Du H, 1998, HUM MOL GENET, V7, P1347, DOI 10.1093/hmg/7.9.1347; Egan A, 2011, NEW ENGL J MED, V365, P285, DOI 10.1056/NEJMp1106689; Ohtawa M, 2013, BIOORG MED CHEM LETT, V23, P1285, DOI 10.1016/j.bmcl.2012.12.099; Ara~jo F. A., 2010, BIOMED PHARMACOTHER, V64, P29, DOI [10.1016/ j. biopha. 2009. 03.003, DOI 10.1016/J.BI0PHA.2009.03.003]; Arsenault BJ, 2012, CURR CARDIOL REP, V14, P443, DOI 10.1007/s11886-012-0285-7; Matsuda D, 2015, J ANTIBIOT, V68, P27, DOI 10.1038/ja.2014.91; Ohshiro T, 2015, EXPERT OPIN THER PAT, V25, P145, DOI 10.1517/13543776.2014.989833; Rudel LL, 2001, CURR OPIN LIPIDOL, V12, P121, DOI 10.1097/00041433-200104000-00005; Armitage J, 2010, LANCET, V376, P1658, DOI 10.1016/S0140-6736(10)60310-8; Valayannopoulos V, 2014, J HEPATOL, V61, P1135, DOI 10.1016/j.jhep.2014.06.022; Zhang J, 2014, CIRC RES, V115, P826, DOI 10.1161/CIRCRESAHA.115.304378	50	0	0	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA	0022-3565	1521-0103		J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	NOV	2015	355	2					297	+		10.1124/jpet.115.227348		28	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CV3MT	WOS:000364164000020		
J	Spati, J; Chumbley, J; Doerig, N; Brakowski, J; Holtforth, MG; Seifritz, E; Spinelli, S				Spaeti, Jakub; Chumbley, Justin; Doerig, Nadja; Brakowski, Janis; Holtforth, Martin Grosse; Seifritz, Erich; Spinelli, Simona			Valence and agency influence striatal response to feedback in patients with major depressive disorder	JOURNAL OF PSYCHIATRY & NEUROSCIENCE			English	Article							BDNF VAL66MET POLYMORPHISM; PREDICTION ERROR; LEARNED HELPLESSNESS; PERSONALITY-TRAITS; NEGATIVE FEEDBACK; REWARD; MONETARY; TASK; PERFORMANCE; INVENTORY	Background Reduced sensitivity to positive feedback is common in patients with major depressive disorder (MDD). However, findings regarding negative feedback are ambiguous, with both exaggerated and blunted responses being reported. The ventral striatum (VS) plays a major role in processing valenced feedback, and previous imaging studies have shown that the locus of controls (self agency v. external agency) over the outcome influences VS response to feedback. We investigated whether attributing the outcome to one's own action or to an external agent influences feedback processing in patients with MDD. We hypothesized that depressed participants would be less sensitive to the feedback attribution reflected by an altered VS response to self-attributed gains and losses. Methods Using functional MRI and a motion prediction task, we investigated the neural responses to self-attributed (SA) and externally attributed (EA) monetary gains and losses in unmedicated patients with MDD and healthy controls. Results We included 21 patients and 25 controls in our study. Consistent with our prediction, healthy controls showed a VS response influenced by feedback valence and attribution, whereas in depressed patients striatal activity was modulated by valence but was insensitive to attribution. This attribution insensitivity led to an altered ventral putamen response for SA - EA losses in patients with MDD compared with healthy controls. Limitations Depressed patients with comorbid anxiety disorder were included. Conclusion These results suggest an altered assignment of motivational salience to SA losses in patients with MDD. Altered striatal response to SA negative events may reinforce the belief of not being in control of negative outcomes contributing to a cycle of learned helplessness.	[Spaeti, Jakub] Natl Ctr Neurol & Psychiat, Dept Psychophysiol, NIMH, Tokyo, Japan; [Chumbley, Justin] Univ Zurich, Lab Social & Neural Syst Res, Dept Econ, CH-8008 Zurich, Switzerland; [Doerig, Nadja; Holtforth, Martin Grosse] Univ Zurich, Inst Psychol, CH-8008 Zurich, Switzerland; [Brakowski, Janis; Seifritz, Erich] Univ Zurich, Dept Psychiat Psychotherapy & Psychosomat, Hosp Psychiat, CH-8008 Zurich, Switzerland; [Holtforth, Martin Grosse] Univ Bern, Dept Psychol, Bern, Switzerland; [Spinelli, Simona] Univ Zurich, Preclin Lab Translat Res Affect Disorders, Dept Psychiat Psychotherapy & Psychosomat, Hosp Psychiat, CH-8008 Zurich, Switzerland; [Spinelli, Simona] Univ Zurich, Ctr Neurosci, CH-8008 Zurich, Switzerland; [Spinelli, Simona] ETH, Zurich, Switzerland; [Seifritz, Erich; Spinelli, Simona] Univ Zurich, Zurich Ctr Integrat Human Physiol, CH-8008 Zurich, Switzerland	Spinelli, S (reprint author), Univ Zurich, Preclin Lab Translat Res Affect Disorders, Dept Psychiat Psychotherapy & Psychosomat, Hosp Psychiat, August Forel Str 7, CH-8008 Zurich, Switzerland.	spinellisimona@gmail.com			Swiss National Science Foundation [PZ00P3_126363/1, PZ00P3_146001/1, PP00P1-123377/1]; FAN of the Zurich University Association (ZUNIV); Foundation for Research in Science and the Humanities at the University of Zurich; Clinical Research Priority Program "Molecular Imaging" at the University of Zurich	The authors thank Dr. Philipp Stampfli for his invaluable assistance in study procedures. S. Spinelli is funded by a Swiss National Science Foundation Ambizione Fellowship (grants PZ00P3_126363/1 and PZ00P3_146001/1). J. Chumbley is funded by a grant from FAN of the Zurich University Association (ZUNIV). M. Grosse Holtforth and N. Doerig are funded by a grant from the Swiss National Science Foundation (grant PP00P1-123377/1) and a research grant by the Foundation for Research in Science and the Humanities at the University of Zurich. We acknowledge support by the Clinical Research Priority Program "Molecular Imaging" at the University of Zurich.	Smoski MJ, 2009, J AFFECT DISORDERS, V118, P69, DOI 10.1016/j.jad.2009.01.034; Kumar P, 2008, BRAIN, V131, P2084, DOI 10.1093/brain/awn136; McFarland BR, 2009, DEPRESS ANXIETY, V26, P117, DOI 10.1002/da.20513; Ullsperger M, 2003, J NEUROSCI, V23, P4308; Menon V, 2010, BRAIN STRUCT FUNCT, V214, P655, DOI 10.1007/s00429-010-0262-0; Schrijvers D, 2008, CORTEX, V44, P569, DOI 10.1016/j.cortex.2007.08.014; Holmes AJ, 2010, COGN AFFECT BEHAV NE, V10, P119, DOI [10.3758/CABN.10.1.119, 10.3158/CABN.10.1.119]; Knutson B, 2001, NEUROREPORT, V12, P3683, DOI 10.1097/00001756-200112040-00016; Murphy FC, 1999, PSYCHOL MED, V29, P1307, DOI 10.1017/S0033291799001233; ABRAMSON LY, 1978, J ABNORM PSYCHOL, V87, P49, DOI 10.1037//0021-843X.87.1.49; Gradin VB, 2011, BRAIN, V134, P1751, DOI 10.1093/brain/awr059; Ruchsow M, 2006, J PSYCHIAT RES, V40, P37, DOI 10.1016/j.jpsychires.2005.02.002; Murphy FC, 2003, PSYCHOL MED, V33, P455, DOI 10.1017/S0033291702007018; Knutson B, 2008, BIOL PSYCHIAT, V63, P686, DOI 10.1016/j.biopsych.2007.07.023; Robinson OJ, 2012, AM J PSYCHIAT, V169, P152, DOI 10.1176/appi.ajp.2011.11010137; Helmreich I, 2011, EUR ARCH PSY CLIN N, V261, P357, DOI 10.1007/s00406-010-0175-1; Helfinstein SM, 2011, NEUROPSYCHOLOGIA, V49, P479, DOI 10.1016/j.neuropsychologia.2010.12.015; Steele JD, 2007, BRAIN, V130, P2367, DOI 10.1093/brain/awm150; Pizzagalli DA, 2005, BIOL PSYCHIAT, V57, P319, DOI 10.1016/j.biopsych.2004.11.026; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; Haruno M, 2006, J NEUROPHYSIOL, V95, P948, DOI 10.1152/jn.00382.2005; Tucker DM, 2003, J ABNORM PSYCHOL, V112, P667, DOI 10.1037/0021-843X.112.4.667; Pizzagalli DA, 2008, J PSYCHIATR RES, V43, P76, DOI 10.1016/j.jpsychires.2008.03.001; Eshel N, 2010, BIOL PSYCHIAT, V68, P118, DOI 10.1016/j.biopsych.2010.01.027; Spati J, 2014, HUM BRAIN MAPP, V35, P4428, DOI 10.1002/hbm.22484; Haggard P, 2012, CURR BIOL, V22, pR390, DOI 10.1016/j.cub.2012.02.040; Lang UE, 2005, PSYCHOPHARMACOLOGY, V180, P95, DOI 10.1007/s00213-004-2137-7; Douglas KM, 2009, J AFFECT DISORDERS, V119, P92, DOI 10.1016/j.jad.2009.02.018; Berridge KC, 2012, EUR J NEUROSCI, V35, P1124, DOI 10.1111/j.1460-9568.2012.07990.x; MAIER SF, 1976, J EXP PSYCHOL GEN, V105, P3, DOI 10.1037/0096-3445.105.1.3; Weiner B, 2010, EDUC PSYCHOL-US, V45, P28, DOI 10.1080/00461520903433596; Rush AJ, 1996, PSYCHOL MED, V26, P477; Sacchet MD, 2013, NEUROIMAGE, V66, P270, DOI 10.1016/j.neuroimage.2012.10.056; Elliott R, 1996, PSYCHOL MED, V26, P975; Olvet DM, 2010, PSYCHIAT RES, V179, P30, DOI 10.1016/j.psychres.2010.06.008; Chronis-Tuscano A, 2009, J AM ACAD CHILD PSY, V48, P928, DOI 10.1097/CHI.0b013e3181ae09df; Sen S, 2003, NEUROPSYCHOPHARMACOL, V28, P397, DOI 10.1038/sj.npp.1300053; Fales CL, 2008, BIOL PSYCHIAT, V63, P377, DOI 10.1016/j.biopsych.2007.06.012; Chiu PH, 2007, AM J PSYCHIAT, V164, P608, DOI 10.1176/appi.ajp.164.4.608; Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007; Bromberg-Martin ES, 2010, NEURON, V68, P815, DOI 10.1016/j.neuron.2010.11.022; van Tol MJ, 2013, NEUROIMAGE-CLIN, V2, P790, DOI 10.1016/j.nicl.2013.05.012; Holmes AJ, 2008, ARCH GEN PSYCHIAT, V65, P179, DOI 10.1001/archgenpsychiatry.2007.19; Pizzagalli DA, 2009, AM J PSYCHIAT, V166, P702, DOI 10.1176/appi.ajp.2008.08081201; Frustaci A, 2008, NEUROPSYCHOBIOLOGY, V58, P163, DOI 10.1159/000182892; Tavares JVT, 2008, NEUROIMAGE, V42, P1118, DOI 10.1016/j.neuroimage.2008.05.049; Franz M, 1998, FORTSCHR NEUROL PSYC, V66, P407, DOI 10.1055/s-2007-995279; Satterthwaite TD, 2012, NEUROIMAGE, V61, P723, DOI 10.1016/j.neuroimage.2012.03.060; Zink CF, 2004, NEURON, V42, P509, DOI 10.1016/S0896-6273(04)00183-7; Glascher J, 2010, NEURON, V66, P585, DOI 10.1016/j.neuron.2010.04.016; Smoski MJ, 2011, PSYCHIAT RES-NEUROIM, V194, P263, DOI 10.1016/j.pscychresns.2011.06.012; Pryce CR, 2011, PHARMACOL THERAPEUT, V132, P242, DOI 10.1016/j.pharmthera.2011.06.006; Beck AT, 1996, J PERS ASSESS, V67, P588, DOI 10.1207/s15327752jpa6703_13; Chumbley J, 2014, NEUROSCIENCE, V280, P130, DOI 10.1016/j.neuroscience.2014.09.014; Dayana P, 2008, CURR OPIN NEUROBIOL, V18, P185, DOI 10.1016/j.conb.2008.08.003; Friston K J, 1994, Hum Brain Mapp, V1, P210, DOI 10.1002/hbm.460010306; Hünnerkopf Regina, 2007, Neuropsychopharmacology, V32, P2552, DOI 10.1038/sj.npp.1301383; Kerr DL, 2012, FRONT PSYCHOL, V3, DOI 10.3389/fpsyg.2012.00557; Krampen G, 1994, DTSCH BEARBEITUNG WE; Laux L., 1981, STATE TRAIT ANGSTINV; Penny W., 2006, STAT PARAMETRIC MAPP; Studer B, 2012, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00046	62	0	0	CMA-CANADIAN MEDICAL ASSOC	OTTAWA	1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 5W8, CANADA	1180-4882	1488-2434		J PSYCHIATR NEUROSCI	J. Psychiatry Neurosci.	NOV	2015	40	6					394	400		10.1503/jpn.140225		7	Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	CV3HN	WOS:000364149900004		
J	Sakarunchai, I; Kato, Y; Yamada, Y; Inamasu, J				Sakarunchai, Ittichai; Kato, Yoko; Yamada, Yasuhiro; Inamasu, Joji			Ischemic Event and Risk Factors of Embolic Stroke in Atherosclerotic Cerebral Aneurysm Patients Treated with a New Clipping Technique	JOURNAL OF STROKE & CEREBROVASCULAR DISEASES			English	Article						Atherosclerotic cerebral aneurysm; ischemic event; thromboembolism; hemodynamics wall shear stress	UNRUPTURED INTRACRANIAL ANEURYSMS; ENDOVASCULAR TREATMENT; SURGERY	Background: We would like to know the exact rate of ischemic event and the risk factors associated with embolic stroke by treatment of atherosclerotic cerebral aneurysm with a new technique. Methods: This is a retrospective cohort study in patients diagnosed as unruptured atherosclerotic cerebral aneurysm who underwent microsurgical clipping between January 2012 and August 2014. All intraoperative video recordings were reviewed and chosen in patients who were identified as atherosclerotic lesion on the dome, neck, or parent artery of the aneurysm. The demographic, radiographic, operative, and postoperative data were collected. The primary end point was the incidence of cerebral infarction and the neurologic outcomes using the discharge modified Rankin Scale (mRS) score at postoperation time. A statistical analysis of the factors associated with embolic stroke was done by Fisher exact and Wilcoxon rank-sum tests. The individual surgical technique was demonstrated as an illustration for use as a guide. Results: Among 103 atherosclerotic cerebral aneurysms, only 3 patients (2.9%) were associated with postoperative cerebral infarction and 1 of them had permanent neurologic deficit. A good mRS score (0-2) was found in 99% of patients and only 1% had a fair mRS score (3-4). A factor associated with ischemic outcome was duration of operation (P = .046). The differences in the atherosclerotic location showed no statistical significance. Conclusions: We found a very low incidence of embolic infarction after clipping of an atherosclerotic cerebral aneurysm with our new technique. Only duration of the operation time was a dependent risk factor for embolic infarction.	[Sakarunchai, Ittichai] Prince Songkla Univ, Div Neurosurg, Dept Surg, Hat Yai 90110, Songkhla, Thailand; [Kato, Yoko; Yamada, Yasuhiro; Inamasu, Joji] Fujita Hlth Univ, Sch Med, Dept Neurosurg, Aichi, Japan	Sakarunchai, I (reprint author), Prince Songkla Univ, Fac Med, Dept Surg, Div Neurosurg, Hat Yai 90110, Songkhla, Thailand.	it_swu039@hotmail.com					Li J, 2009, NEUROL INDIA, V57, P453, DOI 10.4103/0028-3886.55607; Bhatia S, 2011, ACTA NEUROCHIR, V153, P905, DOI 10.1007/s00701-010-0846-8; Kulcsar Z, 2011, AM J NEURORADIOL, V32, P587, DOI 10.3174/ajnr.A2339; Wessels T, 2005, STROKE, V36, P757, DOI 10.1161/01.STR.0000158908.48022.d7; Sharma M, 2013, NEUROL INDIA, V61, P270, DOI 10.4103/0028-3886.115067; VANSWIETEN JC, 1988, STROKE, V19, P604; Sasaki T, 2007, J NEUROSURG, V107, P60, DOI 10.3171/JNS-07/07/0060; Inci S, 2000, SURG NEUROL, V53, P530, DOI 10.1016/S0090-3019(00)00244-5; Krayenbuhl N, 2009, STROKE, V40, P129, DOI 10.1161/STROKEAHA.108.524777; ADAMSON J, 1994, STROKE, V25, P963; SAMSON D, 1994, NEUROSURGERY, V34, P22; Gruber A, 2011, NEUROSURGERY, V68, P657, DOI 10.1227/NEU.0b013e31820777ee; Wiebers D, 2003, LANCET, V362, P103, DOI 10.1016/S0140-6736(03)13860-3; Ohno K, 1999, ACTA NEUROCHIR, V141, P699, DOI 10.1007/s007010050364; Altay T, 2011, J NEUROINTERV SURG, V3, P147, DOI 10.1136/jnis.2010.003616; Bederson BJ, 1992, J NEUROSURG, V77, P478; Defillo A, 2014, CUREUS, V6, pe203; Wiebers D, 1998, NEW ENGL J MED, V339, P1725; Lawton TM, 2005, NEUROSURGERY, V56, P441; Sano H, 1998, NEUROL MED-CHIR, V38, P58; Sugiyama S, 2014, 15 INT C BIOM ENG IF, V34, P738; Valk MH, 2011, LANCET NEUROL, V10, P626; Yamada Y, 2014, AUSTIN J CEREBROVASC, V1, P1; Yasargil MG., 1984, MICRONEUROSURGERY, P124	24	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1052-3057	1532-8511		J STROKE CEREBROVASC	J. Stroke Cerebrovasc. Dis.	NOV	2015	24	11					2497	2507		10.1016/j.jstrokecerebrovasdis.2015.06.032		11	Neurosciences; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	CV1VX	WOS:000364047300015		
J	Ohyama, S; Yokota, C; Miyashita, F; Amano, T; Inoue, Y; Shigehatake, Y; Sakamoto, Y; Toyoda, K; Minematsu, K				Ohyama, Satoshi; Yokota, Chiaki; Miyashita, Fumio; Amano, Tatsuo; Inoue, Yasuteru; Shigehatake, Yuya; Sakamoto, Yuki; Toyoda, Kazunori; Minematsu, Kazuo			Effective Education Materials to Advance Stroke Awareness Without Teacher Participation in Junior High School Students	JOURNAL OF STROKE & CEREBROVASCULAR DISEASES			English	Article						Stroke education; Manga; animated cartoon; comic; FAST	HIP-HOP STROKE; PUBLIC-EDUCATION; ISCHEMIC-STROKE; ACT FAST; JAPANESE POPULATION; KNOWLEDGE; SYMPTOMS; CAMPAIGNS; CHILDREN; PROGRAM	Background: Youth stroke education is promising for the spread of stroke awareness. The aim of this study was to examine whether our stroke awareness teaching materials without teacher's participation can increase student awareness to act fast on suspected stroke signs. Methods: We used the face, arm, speech, and time (FAST) mnemonic derived from the Cincinnati Prehospital Stroke Scale. Seventy-three students of the second grade and 72 students of the third grade (age range, 13-15 years) in a junior high school were enrolled in the study. The students were divided into 2 groups: students who received a teacher's lesson (group I) and those who did not receive a teacher's lesson (group II). Students in group II watched an animated cartoon and read a Manga comic in class. All students took the educational aids home, including the Manga comic and magnetic posters printed with the FAST message. Questionnaires on stroke knowledge were examined at baseline and immediately and 3 months after receiving the intervention. Results: At 3 months after the intervention, a significant improvement in understanding the FAST message was confirmed in both the groups (group I, 85%; group II, 94%). Significant increases in the knowledge of risk factors were not observed in each group. Conclusions: Our education materials include a Manga comic, an animated cartoon, and a magnetic poster, without an accompanying teacher's lesson can increase stroke awareness, including the FAST message, in junior high school students.	[Ohyama, Satoshi; Yokota, Chiaki; Miyashita, Fumio; Amano, Tatsuo; Inoue, Yasuteru; Shigehatake, Yuya; Sakamoto, Yuki; Toyoda, Kazunori; Minematsu, Kazuo] Natl Cerebral & Cardiovasc Ctr, Dept Cerebrovasc Med, Suita, Osaka 5658565, Japan	Yokota, C (reprint author), Natl Cerebral & Cardiovasc Ctr, Dept Cerebrovasc Med, 5-7-1 Fujishirodai, Suita, Osaka 5658565, Japan.	cyokota@ncvc.go.jp			National Cerebral and Cardiovascular Center [22-4-1]	This study was supported by the Intramural Research Fund of the National Cerebral and Cardiovascular Center (22-4-1).	Fogle CC, 2010, J STROKE CEREBROVASC, V19, P370, DOI 10.1016/j.jstrokecerebrovasdis.2009.06.007; Amano T, 2014, J STROKE CEREBROVASC, V23, P1040, DOI 10.1016/j.jstrokecerebrovasdis.2013.08.021; Williams O, 2008, STROKE, V39, P2809, DOI 10.1161/STROKEAHA.107.513143; Miyashita F, 2014, J STROKE CEREBROVASC, V23, P1385, DOI 10.1016/j.jstrokecerebrovasdis.2013.11.016; Williams O, 2012, STROKE, V43, P163, DOI 10.1161/STROKEAHA.111.621029; Fussman C, 2010, STROKE, V41, P1501, DOI 10.1161/STROKEAHA.110.578195; Matsuzono K, 2015, STROKE, V46, P572, DOI 10.1161/STROKEAHA.114.007907; Williams O, 2014, STROKE, V45, P889, DOI 10.1161/STROKEAHA.113.002906; Cai L, 2014, CIRCULATION, V129, P1832, DOI 10.1161/CIRCULATIONAHA.113.005666; Teuschl Y, 2010, INT J STROKE, V5, P187, DOI 10.1111/j.1747-4949.2010.00428.x; Morgenstern LB, 2007, STROKE, V38, P2972, DOI 10.1161/STROKEAHA.107.490078; Muller-Nordhorn J, 2009, ARCH INTERN MED, V169, P1484, DOI 10.1001/archinternmed.2009.232; Fortmann SP, 2000, AM J EPIDEMIOL, V152, P316, DOI 10.1093/aje/152.4.316; Silver FL, 2003, STROKE, V34, P1965, DOI 10.1161/01.STR.0000083175.01126.62; Morimoto A, 2013, STROKE, V44, P2829, DOI 10.1161/STROKEAHA.113.001537; Kothari RU, 1999, ANN EMERG MED, V33, P373, DOI 10.1016/S0196-0644(99)70299-4; Emberson J, 2014, LANCET, V384, P1929, DOI 10.1016/S0140-6736(14)60584-5; Lawlor M, 2015, J NEUROL NEUROSUR PS, V86, P818, DOI 10.1136/jnnp-2014-308812; Bray JE, 2011, STROKE, V42, P2154, DOI 10.1161/STROKEAHA.110.612036; Miyamatsu N, 2012, STROKE, V43, P545, DOI 10.1161/STROKEAHA.111.634196; Shigehatake Y, 2014, J STROKE CEREBROVASC, V23, P1623, DOI 10.1016/j.jstrokecerebrovasdis.2014.01.001; Berkhemer OA, 2015, NEW ENGL J MED, V372, P11, DOI 10.1056/NEJMoa1411587; Campbell BCV, 2015, NEW ENGL J MED, V372, P1009, DOI 10.1056/NEJMoa1414792; Goyal M, 2015, NEW ENGL J MED, V372, P1019, DOI 10.1056/NEJMoa1414905; Dombrowski SU, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-915; Baranowski T, 2010, NEW ENGL J MED, V363, P443, DOI 10.1056/NEJMoa1001933; Inoue Y, 2015, J STROKE CEREBROVASC, V24, P480, DOI 10.1016/j.jstrokecerebrovasdis.2014.09.022; Kawano H, 2014, J STROKE CEREBROVASC, V23, P2372, DOI 10.1016/j.jstrokecerebrovasdis.2014.05.010; Lecouturier J, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-784; Wall Hilary K, 2008, Prev Chronic Dis, V5, pA49	30	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1052-3057	1532-8511		J STROKE CEREBROVASC	J. Stroke Cerebrovasc. Dis.	NOV	2015	24	11					2533	2538		10.1016/j.jstrokecerebrovasdis.2015.07.001		6	Neurosciences; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	CV1VX	WOS:000364047300020		
J	Kamiya, A; Kamiya, K; Tatsumi, H; Suzuki, M; Horiguchi, S				Kamiya, Akane; Kamiya, Kentaro; Tatsumi, Hiroshi; Suzuki, Makihiko; Horiguchi, Satoshi			Japanese Adaptation of the Stroke and Aphasia Quality of Life Scale-39 (SAQOL-39): Comparative Study among Different Types of Aphasia	JOURNAL OF STROKE & CEREBROVASCULAR DISEASES			English	Article						Aphasia; quality of life; stroke; outcome	HEART-DISEASE	Background: We have developed a Japanese version of the Stroke and Aphasia Quality of Life Scale-39 (SAQOL-39), designated as SAQOL-39-J, and used psychometric methods to examine its acceptability and reliability. Methods: The acceptability and reliability of SAQOL-39-J, which was developed from the English version using a standard translation and back-translation method, were examined in 54 aphasia patients using standard psychometric methods. The acceptability and reliability of SAQOL-39-J were then compared among patients with different types of aphasia. Results: SAQOL-39-J showed good acceptability, internal consistency (Cronbach's a score 5.90), and test-retest reliability (intraclass correlation coefficient = .97). Broca's aphasia patients showed the lowest total scores and communication scores on SAQOL-39-J. Conclusions: The Japanese version of SAQOL-39, SAQOL-39-J, provides acceptable and reliable data in Japanese stroke patients with aphasia. Among different types of aphasia, Broca's aphasia patients had the lowest total and communication SAQOL-39-J scores. Further studies are needed to assess the effectiveness of health care interventions on health-related quality of life in this population.	[Kamiya, Akane] Sagamihara Minami Hosp, Dept Rehabil, Sagamihara, Kanagawa 2520331, Japan; [Kamiya, Kentaro] Kitasato Univ Hosp, Dept Rehabil, Sagamihara, Kanagawa, Japan; [Tatsumi, Hiroshi] Kitasato Univ, Coll Liberal Arts & Sci, Sagamihara, Kanagawa 228, Japan; [Suzuki, Makihiko] Aichi Gakuin Univ, Dept Hlth Sci, Nisshin, Aichi, Japan; [Horiguchi, Satoshi] Kitasato Univ, Sch Allied Hlth Sci, Dept Rehabil, Sagamihara, Kanagawa 228, Japan	Kamiya, A (reprint author), Sagamihara Minami Hosp, Dept Rehabil, Minami Ku, 7-10-7 Oonodai, Sagamihara, Kanagawa 2520331, Japan.	kamiya.akane.st@gmail.com					Kim AS, 2011, CIRCULATION, V124, P314, DOI 10.1161/CIRCULATIONAHA.111.018820; Lee JJ, 2012, PHYS THER, V92, P1546, DOI 10.2522/ptj.20110403; GUYATT GH, 1993, ANN INTERN MED, V118, P622; Mimura M, 1998, BRAIN, V121, P2083, DOI 10.1093/brain/121.11.2083; Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI 10.1161/CIR.0000000000000152; Lata-Caneda MC, 2009, EUR J PHYS REHAB MED, V45, P379; Rachpukdee S, 2013, J STROKE CEREBROVASC, V22, pE70, DOI 10.1016/j.jstrokecerebrovasdis.2012.05.005; Hilari K, 2003, STROKE, V34, P1944, DOI 10.1161/01.STR.0000081987.46660.ED; Guajardo VD, 2015, J STROKE CEREBROVASC, V24, P201, DOI 10.1016/j.jstrokecerebrovasdis.2014.08.020; GUILLEMIN F, 1993, J CLIN EPIDEMIOL, V46, P1417, DOI 10.1016/0895-4356(93)90142-N; Kartsona A, 2007, Eura Medicophys, V43, P27; Posteraro L, 2004, Eura Medicophys, V40, P257; Raven J. C., 1995, COLOURED PROGR MATRI	13	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1052-3057	1532-8511		J STROKE CEREBROVASC	J. Stroke Cerebrovasc. Dis.	NOV	2015	24	11					2561	2564		10.1016/j.jstrokecerebrovasdis.2015.07.007		4	Neurosciences; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	CV1VX	WOS:000364047300024		
J	Saji, N; Kimura, K; Yagita, Y; Uemura, J; Aoki, J; Sato, T; Sakurai, T				Saji, Naoki; Kimura, Kazumi; Yagita, Yoshiki; Uemura, Junichi; Aoki, Junya; Sato, Takahiro; Sakurai, Takashi			Deep Cerebral Microbleeds and Renal Dysfunction in Patients with Acute Lacunar Infarcts	JOURNAL OF STROKE & CEREBROVASCULAR DISEASES			English	Article						Cerebral microbleeds; chronic kidney disease; lacunar infarcts; renal dysfunction; small vessel disease; stroke	WHITE-MATTER HYPERINTENSITY; CHRONIC KIDNEY-DISEASE; PULSE-WAVE VELOCITY; SILENT BRAIN INFARCT; ANKLE VASCULAR INDEX; SMALL VESSEL DISEASE; ARTERIAL STIFFNESS; ISCHEMIC-STROKE; INTRACEREBRAL HEMORRHAGE; ASSOCIATION	Background: Cerebral small-vessel disease (SVD) is associated with renal dysfunction such as chronic kidney disease. Although cerebral microbleeds (CMBs) are common in patients with acute lacunar infarcts (ALI), the association between renal dysfunction and CMBs in such patients remains unclear. Methods: Between April 2007 and March 2013, we evaluated consecutive first-ever ALI patients, who were admitted to our hospital within 24 hours of stroke onset. CMBs were defined as focal areas of signal loss in brain parenchyma less than 5 mm on T2*-weighted gradient-echo imaging. Renal dysfunction was defined as an estimated glomerular filtration rate less than 60 mL/minute/1.73 m(2) on admission. Correlations between renal dysfunction and the presence (model 1) and location of CMBs (model 2; any deep or infratentorial CMBs) were determined by multivariable logistic regression analyses. Results: Among 152 patients (33.6% men; mean age, 67.6 years), 53 had CMBs. Patients with CMBs were older (69.9 versus 66.3 years, P = .03) and had a higher frequency of white matter hyperintensity (WMH; 62.3% versus 25.3%, P < .001), silent lacunar infarcts (SLI; 75.5% versus 43.3%, P < .001), and renal dysfunction (41.5% versus 22.2%, P = .015) than those without CMBs. On multivariable analyses, renal dysfunction (odds ratio, 95% confidence interval; model 1: 2.38, 1.02-5.66; model 2: 2.78, 1.16-6.81), WMH (3.87, 1.76-8.80; 3.72, 1.64-8.71), SLI (3.85, 1.71-9.14; 4.20, 1.77-10.8), and diabetes mellitus (. 26,.09-.63;.24,.08-.63) were independently associated with CMBs. Conclusions: In patients with ALI, renal dysfunction was positively associated with CMBs independent of cerebral SVD.	[Saji, Naoki; Yagita, Yoshiki; Uemura, Junichi] Kawasaki Med Univ, Dept Stroke Med, Kurashiki, Okayama, Japan; [Saji, Naoki; Sakurai, Takashi] Natl Ctr Geriatr & Gerontol, Ctr Comprehens Care & Res Memory Disorders, Obu, Aichi 4748511, Japan; [Kimura, Kazumi; Aoki, Junya; Sato, Takahiro] Nippon Med Sch, Grad Sch Med, Dept Neurol Sci, Tokyo 113, Japan	Saji, N (reprint author), Natl Ctr Geriatr & Gerontol, Ctr Comprehens Care & Res Memory Disorders, 7-430 Morioka, Obu, Aichi 4748511, Japan.	sajink@nifty.com			Japan Society for the Promotion of Science [26870765]	N.S. reports a research grant, Grants-in-Aid for Scientific Research (No. 26870765) from the Japan Society for the Promotion of Science.	Adams Jr HP, 1993, ARTERIOSCLER THROMB, V24, P35, DOI DOI 10.1161/01.STR.24.1.35; Saji N, 2012, STROKE, V43, P3088, DOI 10.1161/STROKEAHA.112.670737; Song TJ, 2014, EUR J NEUROL, V21, P463, DOI 10.1111/ene.12332; Khatri M, 2007, STROKE, V38, P3121, DOI 10.1161/STROKEAHA.107.493593; Cho AH, 2009, NEUROLOGY, V73, P1645, DOI 10.1212/WNL.0b013e3181c1defa; Kim BJ, 2008, J NEUROL, V255, P1176, DOI 10.1007/s00415-008-0864-0; Ryu WS, 2012, INT J STROKE, V7, P551, DOI 10.1111/j.1747-4949.2011.00732.x; Nakagawa K, 2011, AM J CARDIOL, V107, P912, DOI 10.1016/j.amjcard.2010.10.074; Otani H, 2010, CEREBROVASC DIS, V30, P43, DOI 10.1159/000313612; Ovbiagele B, 2013, STROKE, V44, P2409, DOI 10.1161/STROKEAHA.113.001958; Wardlaw JM, 2013, LANCET NEUROL, V12, P822, DOI 10.1016/S1474-4422(13)70124-8; Seo WK, 2008, CEREBROVASC DIS, V26, P618, DOI 10.1159/000166837; Ovbiagele B, 2010, ARCH NEUROL-CHICAGO, V67, P45, DOI 10.1001/archneurol.2009.310; Saji N, 2011, J STROKE CEREBROVASC, V20, P231, DOI 10.1016/j.jstrokecerebrovasdis.2009.12.005; Zhang CR, 2015, J STROKE CEREBROVASC, V24, P649, DOI 10.1016/j.jstrokecerebrovasdis.2014.10.016; Saji N, 2012, HYPERTENS RES, V35, P756, DOI 10.1038/hr.2012.20; Gregoire SM, 2010, J NEUROL NEUROSUR PS, V81, P679, DOI 10.1136/jnnp.2009.198994; Cordonnier C, 2007, BRAIN, V130, P1988, DOI 10.1093/brain/aw1387; Oksala NKJ, 2010, STROKE, V41, P1914, DOI 10.1161/STROKEAHA.110.587352; Imaizumi T, 2015, J STROKE CEREBROVASC, V24, P1855, DOI 10.1016/j.jstrokecerebrovasdis.2015.04.027; Saji N, 2011, NEUROEPIDEMIOLOGY, V36, P252, DOI 10.1159/000328260; Saji N, 2012, INTERNAL MED, V51, P1003, DOI 10.2169/internalmedicine.51.6852; Wiseman S, 2014, CEREBROVASC DIS, V37, P64, DOI 10.1159/000356789; Saji N, 2015, HYPERTENS RES, V38, P323, DOI 10.1038/hr.2015.8; Greenberg SM, 2009, LANCET NEUROL, V8, P165, DOI 10.1016/S1474-4422(09)70013-4; Staals J, 2009, STROKE, V40, P3264, DOI 10.1161/STROKEAHA.109.558049; Saba L, 2015, J STROKE CEREBROVASC, V24, P284, DOI 10.1016/j.jstrokecerebrovasdis.2014.07.035; Saji Naoki, 2014, Cerebrovasc Dis Extra, V4, P174, DOI 10.1159/000365565; Yakushiji Y, 2015, J STROKE CEREBROVASC, V24, P431, DOI 10.1016/j.jstrokecerebrovasdis.2014.09.015	29	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1052-3057	1532-8511		J STROKE CEREBROVASC	J. Stroke Cerebrovasc. Dis.	NOV	2015	24	11					2572	2579		10.1016/j.jstrokecerebrovasdis.2015.07.010		8	Neurosciences; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	CV1VX	WOS:000364047300026		
J	Tomita, H; Hagii, J; Metoki, N; Saito, S; Shiroto, H; Hitomi, H; Kamada, T; Seino, S; Takahashi, K; Baba, Y; Sasaki, S; Uchizawa, T; Iwata, M; Matsumoto, S; Shoji, Y; Tanno, T; Osanai, T; Yasujima, M; Okumura, K				Tomita, Hirofumi; Hagii, Joji; Metoki, Norifumi; Saito, Shin; Shiroto, Hiroshi; Hitomi, Hiroyasu; Kamada, Takaatsu; Seino, Satoshi; Takahashi, Koki; Baba, Yoshiko; Sasaki, Satoko; Uchizawa, Takamitsu; Iwata, Manabu; Matsumoto, Shigeo; Shoji, Yoshihiro; Tanno, Tomohiro; Osanai, Tomohiro; Yasujima, Minoru; Okumura, Ken			Impact of Sex Difference on Severity and Functional Outcome in Patients with Cardioembolic Stroke	JOURNAL OF STROKE & CEREBROVASCULAR DISEASES			English	Article						Female sex; cardioembolic stroke; stroke severity; functional outcome	NONVALVULAR ATRIAL-FIBRILLATION; ISCHEMIC-STROKE; GENDER; REGISTRY	Introduction: Female sex is a risk factor for thromboembolic events in Caucasian, but not in Japanese, patients with nonvalvular atrial fibrillation. However, it remains unclear whether the female sex is also a risk factor for severe stroke and unfavorable functional outcome in patients with cardioembolic (CE) stroke. Methods: Three hundred fifty-five consecutive patients with CE stroke within 48 hours after onset and with a modified Rankin Scale (mRS) score of 1 or lower before onset were studied. We compared basic characteristics, stroke severity, and functional outcome between female (n = 157) and male (n = 198) patients. Results: The mean age was higher in female than in male patients (80 +/- 8 versus 75 +/- 9 years, P < .00001). The congestive heart failure, hypertension, age [= 75 years], diabetes, stroke/transient ischemic attack [TIA] (CHADS(2)) score before onset was similar between the two groups (median, 3 [2-4] in both groups). Stroke severity on admission, assessed by the National Institutes of Health Stroke Scale (NIHSS), was higher in female than in male patients (13 [5-20] versus 8 [3-16], P = .0009). Functional outcome at discharge, assessed by mRS, was unfavorable in female than in male patients (3 [1-5] versus 2 [1-4], P = .005). An mRS score of 3 or higher at discharge was found more in female than in male patients (59% versus 39%, P = .0001). Multivariate analyses confirmed that female sex was a significant determinant of severe stroke (NIHSS = 8) on admission (odds ratio [OR] to male = 1.97; 95% confidence interval [CI]; 1.24-3.15, P = .004) and for the mRS score of 3 or higher at discharge (OR = 1.83; 95% CI, 1.16-2.89; P = .01). Similar results were obtained by propensity-score matching analysis. Conclusions: Female sex is a risk factor for severe stroke on admission and unfavorable functional outcome at discharge in Japanese patients with CE stroke.	[Tomita, Hirofumi; Shoji, Yoshihiro; Tanno, Tomohiro; Osanai, Tomohiro; Okumura, Ken] Hirosaki Univ, Grad Sch Med, Dept Cardiol, Hirosaki, Aomori 0368562, Japan; [Hagii, Joji; Metoki, Norifumi; Saito, Shin; Shiroto, Hiroshi; Hitomi, Hiroyasu; Kamada, Takaatsu; Seino, Satoshi; Takahashi, Koki; Baba, Yoshiko; Sasaki, Satoko; Uchizawa, Takamitsu; Iwata, Manabu; Matsumoto, Shigeo; Yasujima, Minoru] Hirosaki Stroke & Rehabil Ctr, Hirosaki, Aomori 0368104, Japan; [Osanai, Tomohiro; Okumura, Ken] Hirosaki Univ, Grad Sch Med, Dept Hypertens & Stroke Med, Hirosaki, Aomori 0368562, Japan	Okumura, K (reprint author), Hirosaki Univ, Grad Sch Med, Dept Cardiol, 5 Zaifu Cho, Hirosaki, Aomori 0368562, Japan.	okumura@hirosaki-u.ac.jp			Bayer HealthCare; Boehringer Ingelheim; Daiichi-Sankyo	Dr. Hirofumi Tomita received research funding from Bayer HealthCare; Dr. Joji Hagii received research funding from Bayer Healthcare, and Speakers' Bureau/Honorarium from Boehringer Ingelheim, Bayer Healthcare, Bristol-Myers Squibb, and Pfizer; Dr. Norifumi Metoki received Speakers' Bureau/Honorarium from Boehringer Ingelheim, Bayer Healthcare, Bristol-Myers Squibb, and Pfizer; Dr. Minoru Yasujima received Speakers' Bureau/Honorarium from Bristol-Myers Squibb and Pfizer; Dr. Ken Okumura received research funding from Boehringer Ingelheim, Bayer Healthcare, and Daiichi-Sankyo, and Speakers' Bureau/Honorarium from Boehringer Ingelheim, Bayer Healthcare, Bristol-Myers Squibb, Pfizer, and Eisai. The other authors have no disclosure.	Adams Jr HP, 1993, ARTERIOSCLER THROMB, V24, P35, DOI DOI 10.1161/01.STR.24.1.35; Eriksson M, 2009, STROKE, V40, P909, DOI 10.1161/STROKEAHA.108.517581; Lip GYH, 2010, CHEST, V137, P263, DOI 10.1378/chest.09-1584; Gall SL, 2010, NEUROLOGY, V74, P975, DOI 10.1212/WNL.0b013e3181d5a48f; Roquer J, 2003, STROKE, V34, P1581, DOI 10.1161/01.STR.0000078562.82918.F6; Irie F, 2015, STROKE, V46, P471, DOI 10.1161/STROKEAHA.114.006739; Inoue H, 2014, AM J CARDIOL, V113, P957, DOI 10.1016/j.amjcard.2013.11.057; Okumura K, 2014, CIRC J, V78, P1593, DOI 10.1253/circj.CJ-14-0144; Tian YF, 2012, J CEREBR BLOOD F MET, V32, P780, DOI 10.1038/jcbfm.2011.179; Alkayed NJ, 1998, STROKE, V29, P159; [Anonymous], 2005, JPN J STROKE, V26, P327; Camm AJ, 2012, EUR HEART J, V33, P2719, DOI 10.1093/eurheartj/ehs253; Siegel C, 2011, P NATL ACAD SCI USA, V108, P11662, DOI 10.1073/pnas.1102635108; January CT, 2014, CIRCULATION, V130, pE199, DOI 10.1161/CIR.0000000000000041	14	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1052-3057	1532-8511		J STROKE CEREBROVASC	J. Stroke Cerebrovasc. Dis.	NOV	2015	24	11					2613	2618		10.1016/j.jstrokecerebrovasdis.2015.07.016		6	Neurosciences; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	CV1VX	WOS:000364047300031		
J	Yao, H; Takashima, Y; Araki, Y; Uchino, A; Yuzuriha, T; Hashimoto, M				Yao, Hiroshi; Takashima, Yuki; Araki, Yuko; Uchino, Akira; Yuzuriha, Takefumi; Hashimoto, Manabu			Leisure-Time Physical Inactivity Associated with Vascular Depression or Apathy in Community-Dwelling Elderly Subjects: The Sefuri Study	JOURNAL OF STROKE & CEREBROVASCULAR DISEASES			English	Article						Physical activity; apathy; vascular depression; vascular cognitive impairment; white matter lesions; magnetic resonance imaging; small vessel	WHITE-MATTER LESIONS; SMALL-VESSEL DISEASE; OLDER PERSONS; BRAIN MRI; ALZHEIMERS-DISEASE; LIFE EXPECTANCY; BLOOD-PRESSURE; SYMPTOMS; DEMENTIA; IMPACT	Background: Although physical inactivity is a major public health problem, the causative factors for physical inactivity per se are poorly understood. To address this issue, we investigated the relationship between deep white matter lesions (DWMLs) on magnetic resonance imaging, apathy, and physical activities using structural equation modeling (SEM). Methods: We examined 317 community-dwelling elderly subjects (137 men and 180 women with a mean age of 64.5 years) without dementia or clinically apparent depression. Physical activity was assessed with a questionnaire consisting of 3 components (leisure-time, work, and sport activities). Results: The mean score from the apathy scale (a visual analogue version of Starkstein's apathy scale) of the Grades 2-3 DWML group was 420 (95% confidence interval [CI] 379-461), which was lower (more apathetic) than the Grade 0 DWML group score of 478 (95% CI 463-492) after adjustment for education as a covariate. SEM showed that the direct paths from DWMLs or education to apathy were significant, and the direct path from apathy to leisure-time activity was highly significant (beta =.25, P < .001). The degree of apathetic behavior was negatively associated with sport activity in female subjects and positively associated with TV watching in male subjects. Conclusions: The results of the study show that DWMLs are one of the major factors that cause apathetic behavior and that apathy has significant negative effects on leisure-time physical activity in community-dwelling elderly subjects. Even a minor level of apathy without major depression would have a significant impact on activities of daily living and quality of life.	[Yao, Hiroshi; Takashima, Yuki; Yuzuriha, Takefumi; Hashimoto, Manabu] Natl Hosp Org Hizen Psychiat Ctr, Ctr Emot & Behav Disorders, Kanzaki, Saga 8420192, Japan; [Araki, Yuko] Shizuoka Univ, Grad Sch Integrated Sci & Technol, Hamamatsu, Shizuoka, Japan; [Uchino, Akira] Saitama Med Univ, Int Med Ctr, Dept Diagnost Radiol, Saitama, Japan	Yao, H (reprint author), Natl Hosp Org Hizen Psychiat Ctr, Ctr Emot & Behav Disorders, Mitsu 160, Kanzaki, Saga 8420192, Japan.	rinkenyao@abelia.ocn.ne.jp			JSPS KAKENHI [24590909]	This work was supported by JSPS KAKENHI Grant Number 24590909.	Ainsworth BE, COMPENDIUM PHYS ACTI; Taylor WD, 2013, MOL PSYCHIATR, V18, P963, DOI 10.1038/mp.2013.20; Wen CP, 2011, LANCET, V378, P1244, DOI 10.1016/S0140-6736(11)60749-6; Gons RAR, 2013, NEUROLOGY, V81, P971, DOI 10.1212/WNL.0b013e3182a43e33; Fukuda K, 2014, J STROKE CEREBROVASC, V23, P817, DOI 10.1016/j.jstrokecerebrovasdis.2013.07.005; Lavretsky H, 2008, INT J GERIATR PSYCH, V23, P1040, DOI 10.1002/gps.2030; BRUCE ML, 1994, AM J PUBLIC HEALTH, V84, P1796, DOI 10.2105/AJPH.84.11.1796; Doi Y, 2009, STROKE, V40, P1187, DOI 10.1161/STROKEAHA.108.531319; Wardlaw JM, 2013, LANCET NEUROL, V12, P822, DOI 10.1016/S1474-4422(13)70124-8; Penninx BWJH, 1998, JAMA-J AM MED ASSOC, V279, P1720, DOI 10.1001/jama.279.21.1720; Hashimoto M, 2014, J STROKE CEREBROVASC, V23, P1770, DOI 10.1016/j.jstrokecerebrovasdis.2014.05.008; Grool AM, 2014, NEUROLOGY, V82, P1628, DOI 10.1212/WNL.0000000000000378; Firbank MJ, 2012, BRIT J PSYCHIAT, V201, P40, DOI 10.1192/bjp.bp.111.098897; Hybels CF, 2009, PSYCHOL MED, V39, P1677, DOI 10.1017/S0033291709005650; BAECKE JAH, 1982, AM J CLIN NUTR, V36, P936; Hajjar I, 2011, CIRCULATION, V123, P858, DOI 10.1161/CIRCULATIONAHA.110.978114; Taylor-Piliae RE, 2006, AM J EPIDEMIOL, V164, P598, DOI 10.1093/aje/kwj248; Levy R, 2012, REV NEUROL-FRANCE, V168, P585, DOI 10.1016/j.neurol.2012.05.003; Grool AM, 2013, BIOL PSYCHIAT, V73, P169, DOI 10.1016/j.biopsych.2012.08.024; Yao H, 2009, HYPERTENS RES, V32, P586, DOI 10.1038/hr.2009.65; YOSHITAKE T, 1995, NEUROLOGY, V45, P1161; Erickson KI, 2012, ARCH MED RES, V43, P615, DOI 10.1016/j.arcmed.2012.09.008; Clarke DE, 2010, INT PSYCHOGERIATR, V22, P819, DOI 10.1017/S1041610209991402; Lee IM, 2012, LANCET, V380, P219, DOI 10.1016/S0140-6736(12)61031-9; Moonen JEF, 2015, INT PSYCHOGERIATR, V27, P1485, DOI 10.1017/S1041610215000253; STARKSTEIN SE, 1992, J NEUROPSYCH CLIN N, V4, P134; FAZEKAS F, 1993, NEUROLOGY, V43, P1683; Zheng JJJ, 2011, STROKE, V42, P2086, DOI 10.1161/STROKEAHA.110.610360; Kloppenborg RP, 2014, NEUROLOGY, V82, P2127, DOI 10.1212/WNL.0000000000000505; Barry LC, 2011, AM J GERIAT PSYCHIAT, V19, P783, DOI 10.1097/JGP.0b013e3181ff6669; Belmaker RH, 2008, NEW ENGL J MED, V358, P55, DOI 10.1056/NEJMra073096; Brookes RL, 2014, NEUROLOGY, V83, P1417, DOI 10.1212/WNL.0000000000000882; Franco MR, 2015, BRIT J SPORT MED, V49, DOI 10.1136/bjsports-2014-094015; Hertogh EM, 2008, INT J BEHAV NUTR PHY, V5, DOI 10.1186/1479-5868-5-30; Reiner M, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-813; MARIN RS, 1991, J NEUROPSYCH CLIN N, V3, P243; Moonen JEF, 2015, J AM GERIATR SOC, V63, P112, DOI 10.1111/jgs.13199	37	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1052-3057	1532-8511		J STROKE CEREBROVASC	J. Stroke Cerebrovasc. Dis.	NOV	2015	24	11					2625	2631		10.1016/j.jstrokecerebrovasdis.2015.07.018		7	Neurosciences; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	CV1VX	WOS:000364047300033		
J	Sadahiro, H; Inamura, A; Sugimoto, K; Yamane, A; Ishihara, H; Shirao, S; Yoneda, H; Suzuki, M				Sadahiro, Hirokazu; Inamura, Akinori; Sugimoto, Kazutaka; Yamane, Akiko; Ishihara, Hideyuki; Shirao, Satoshi; Yoneda, Hiroshi; Suzuki, Michiyasu			Cranioplasty and Duraplasty with Transcranial Color-Coded Duplex Sonography after Aneurysmal Subarachnoid Hemorrhage	JOURNAL OF STROKE & CEREBROVASCULAR DISEASES			English	Article						TCCS; vasospasm; SAH; titanium mesh plate; Huygens principle; acoustic impedance	DOPPLER ULTRASONOGRAPHY; VASOSPASM; DIAGNOSIS; SPASM	Background: Transcranial color-coded duplex sonography (TCCS) is a noninvasive technique for monitoring of cerebral vasospasm after neurosurgery for aneurismal subarachnoid hemorrhage. In this surgery, surgical materials are used. The goal of the study was to identify materials that can be used with ultrasound and to propose methods for cranioplasty and duraplasty using materials that permit TCCS. Methods: The chosen neurosurgical materials were titanium mesh plate (TMP), Gore-tex, SEAMDURA, gelatinous sponge, and oxidized cellulose. B-mode imaging was recorded with the materials placed between urethane resin 10 mm in diameter and the urethane phantom model. TCCS was performed to detect middle cerebral artery flow through TMP and Gore-tex. Results: TMP and SEAMDURA permitted penetration of ultrasound in B-mode and Doppler imaging, but the other materials did not do so. Conclusions: A postcraniotomy window (PCW) on a line extending from the horizontal portion of M1 using only TMP permitted flow imaging with TCCS. In external decompression, TCCS was effective only without use of Gore-tex around the postcraniotomy window. This method allows the middle cerebral artery flow to be detected easily.	[Sadahiro, Hirokazu; Inamura, Akinori; Sugimoto, Kazutaka; Yamane, Akiko; Ishihara, Hideyuki; Shirao, Satoshi; Yoneda, Hiroshi; Suzuki, Michiyasu] Yamaguchi Univ, Sch Med, Dept Neurosurg & Clin Neurosci, Ube, Yamaguchi 755, Japan	Sadahiro, H (reprint author), Yamaguchi Univ, Sch Med, Dept Neurosurg & Clin Neurosci, 1-1-1 Minami Kogushi, Ube, Yamaguchi 755, Japan.	sadahiro@kenwakai.gr.jp					Krejza J, 2005, RADIOLOGY, V236, P621, DOI 10.1148/radiol.2362031662; Nakae R, 2011, NEUROSURGERY, V69, P876, DOI 10.1227/NEU.0b013e318222dc4c; Connolly ES, 2012, STROKE, V43, P1711, DOI 10.1161/STR.0b013e3182587839; SLOAN MA, 1989, NEUROLOGY, V39, P1514; Yagita Y, 1996, ULTRASOUND MED BIOL, V22, P701, DOI 10.1016/0301-5629(96)00032-4; ITOH T, 1993, STROKE, V24, P1192; AASLID R, 1986, NEURORADIOLOGY, V28, P11; Swiat M, 2009, CRIT CARE MED, V37, P963, DOI 10.1097/CCM.0b013e31819b8165; AbuRahma AF, 2005, J VASC SURG, V41, P789, DOI 10.1016/j.jvs.2005.02.025	9	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1052-3057	1532-8511		J STROKE CEREBROVASC	J. Stroke Cerebrovasc. Dis.	NOV	2015	24	11					2640	2645		10.1016/j.jstrokecerebrovasdis.2015.07.023		6	Neurosciences; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	CV1VX	WOS:000364047300035		
J	Katsumata, M; Oki, K; Nakahara, J; Izawa, Y; Abe, T; Takahashi, S; Suzuki, N				Katsumata, Masahiro; Oki, Koichi; Nakahara, Jin; Izawa, Yoshikane; Abe, Takato; Takahashi, Shinichi; Suzuki, Norihiro			Ipsilateral Facial Tactile Hypesthesia in a Patient with Lateral Medullary Syndrome	JOURNAL OF STROKE & CEREBROVASCULAR DISEASES			English	Article						Lateral medullary infarction; Wallenberg syndrome; tactile hypesthesia; ipsilateral face	INFARCTION	Background: Various sensory impairments have been reported in patients with lateral medullary syndrome, also known as Wallenberg syndrome. The typical sensory impairments experienced by patients with this condition are ipsilateral facial and contralateral trunk and limb thermal hypesthesia and hypoalgesia. Tactile (light touch) sensation is not generally diminished. Here we report the case of a 35-year-old man with lateral medullary infarction who had atypical sensory impairment. Methods: We examined the results from the neurological examination of the patient as well as findings from computed tomography of the head and magnetic resonance imaging. Results: Magnetic resonance imaging showed left lateral medullary infarction caused by left posterior inferior cerebellar artery dissection. Neurological examination revealed both tactile and thermal/pain hypesthesia on the left side of the patient's face, and thermal/pain hypesthesia on his right upper and lower limbs. Conclusion: There are two types of tactile sensation: epicritic and protopathic. Facial tactile sensation is usually thought to be associated with epicritic tactile sensation, which travels through principal sensory nuclei of the trigeminal nerve. The protopathic pathway travels down through the spinal tract via the trigeminal nerve and is not considered a primary pathway. However, in this case the protopathic tactile sensation pathway might be involved, and it caused facial tactile hypesthesia. Because most of previous case reports and literature reviews focused only on thermal/pain hypesthesia, we believe that this case provides critical information on the brainstem neuroanatomy, especially for the protopathic tactile sensation pathway in patients with stroke.	[Katsumata, Masahiro; Oki, Koichi; Nakahara, Jin; Izawa, Yoshikane; Abe, Takato; Takahashi, Shinichi; Suzuki, Norihiro] Keio Univ, Sch Med, Dept Neurol, Tokyo 1608582, Japan; [Abe, Takato] Osaka City Univ, Grad Sch Med, Dept Neurol, Osaka, Japan	Katsumata, M (reprint author), Keio Univ, Sch Med, Dept Neurol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	ktmasahiro@gmail.com	Abe, Takato/L-8393-2013; Takahashi, Shinichi/L-3454-2013; Oki, Koichi/L-9433-2013; Suzuki, Norihiro/J-5125-2013	Abe, Takato/0000-0002-4185-5254; 			Cerrato P, 2000, STROKE, V31, P3064; WILKINS RH, 1970, ARCH NEUROL-CHICAGO, V22, P379; Fukuoka T, 2012, J STROKE CEREBROVASC, V21, P594, DOI 10.1016/j.jstrokecerebrovasdis.2011.01.008; Kim JS, 2001, NEUROLOGY, V57, P1230; Hongo H, 2014, J STROKE CEREBROVASC, V23, P182, DOI 10.1016/j.jstrokecerebrovasdis.2012.09.011; Kim JS, 2003, BRAIN, V126, P1864, DOI 10.1093/brain/awg169; Sekine T, 2011, NEUROL SCI, V32, P321, DOI 10.1007/s10072-010-0456-5; Hirayama K., 2010, NEUROLOGICAL SEMEIOL, V1, P396; Ooe K, 2001, PROGR MED, V21, P2868; Vrettos A, 2013, BMJ CASE REP, DOI [10.1136/bcr-2012-006709, DOI 10.1136/BCR-2012-006709]	10	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1052-3057	1532-8511		J STROKE CEREBROVASC	J. Stroke Cerebrovasc. Dis.	NOV	2015	24	11					E315	E317		10.1016/j.jstrokecerebrovasdis.2015.07.027		3	Neurosciences; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	CV1VX	WOS:000364047300002		
J	Matsui, M; Uemura, S; Takeda, Y; Samejima, K; Matsumoto, T; Hasegawa, A; Tsushima, H; Hoshino, E; Ueda, T; Morimoto, K; Okamoto, K; Okada, S; Onoue, K; Okayama, S; Kawata, H; Kawakami, R; Maruyama, N; Akai, Y; Iwano, M; Shiiki, H; Saito, Y				Matsui, Masaru; Uemura, Shiro; Takeda, Yukiji; Samejima, Ken-ichi; Matsumoto, Takaki; Hasegawa, Ayako; Tsushima, Hideo; Hoshino, Ei; Ueda, Tomoya; Morimoto, Katsuhiko; Okamoto, Keisuke; Okada, Sadanori; Onoue, Kenji; Okayama, Satoshi; Kawata, Hiroyuki; Kawakami, Rika; Maruyama, Naoki; Akai, Yasuhiro; Iwano, Masayuki; Shiiki, Hideo; Saito, Yoshihiko		NARA-CKD Invest	Placental Growth Factor as a Predictor of Cardiovascular Events in Patients with CKD from the NARA-CKD Study	JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY			English	Article							CHRONIC KIDNEY-DISEASE; TYROSINE KINASE 1; ACUTE MYOCARDIAL-INFARCTION; GLOMERULAR-FILTRATION-RATE; CORONARY-HEART-DISEASE; ADVANCED SOLID TUMORS; ADVERSE OUTCOMES; TROPONIN-T; ALL-CAUSE; IN-VIVO	Placental growth factor (PIGF) contributes to atherogenesis through vascular inflammation and plaque destabilization. High levels of PIGF may be associated with mortality and cardiovascular disease, but the relationship between PIGF level and adverse outcomes in patients with CKD is unclear. We conducted a prospective cohort study of 1351 consecutive participants with CKD enrolled in the Novel Assessment of Risk management for Atherosclerotic diseases in CKD (NARA-CKD) study between April 1, 2004, and December 31, 2011. During a median follow-up of 3 years, 199 participants died and 383 had cardiovascular events, defined as atherosclerotic disease or heart failure requiring hospitalization. In adjusted analyses, mortality and cardiovascular risk increased in each successive quartile of serum PIGF level; hazard ratios (HRs) (95% confidence intervals [95% asp for mortality and cardiovascular risk, respectively, were 1.59 (0.83 to 3.16) and 1.55 (0.92 to 2.66) for the second quartile, 2.97 (1.67 to 5.59) and 3.39 (2.20 to 5.41) for the third quartile, and 3.87 (2.24 to 7.08) and 8.42 (5.54 to 13.3) for the fourth quartile. The composite end point of mortality and cardiovascular events occurred during the study period in 76.4% of patients in both the highest PIGF quartile (19.6 pg/ml) and the lowest eGFR tertile (<30 ml/min per 1.73 m2). The association between sPIGF and mortality or cardiovascular events was not attenuated when participants were stratified by age, sex, traditional risk factors, and eGFR. These data suggest elevated PIGF is an independent risk factor for all-cause mortality and cardiovascular events in patients with CKD.	[Matsui, Masaru; Uemura, Shiro; Takeda, Yukiji; Samejima, Ken-ichi; Matsumoto, Takaki; Hasegawa, Ayako; Ueda, Tomoya; Morimoto, Katsuhiko; Okamoto, Keisuke; Okada, Sadanori; Onoue, Kenji; Okayama, Satoshi; Kawata, Hiroyuki; Kawakami, Rika; Akai, Yasuhiro; Saito, Yoshihiko] Nara Med Univ, Dept Internal Med 1, Kashihara, Nara 6348533, Japan; [Saito, Yoshihiko] Nara Med Univ, Dept Regulatory Med Blood Pressure, Kashihara, Nara, Japan; [Samejima, Ken-ichi; Tsushima, Hideo] Ohyodo Town Hosp, Dept Med, Nara, Japan; [Hoshino, Ei] Saisei Kai Nara City Hosp, Dept Med, Nara, Japan; [Maruyama, Naoki] Nara City Gen Hosp, Dept Cardiol, Nara, Japan; [Iwano, Masayuki] Univ Fukui, Dept Nephrol, Fukui 910, Japan; [Shiiki, Hideo] Uda City Gen Hosp, Dept Med, Nara, Japan	Saito, Y (reprint author), Nara Med Univ, Dept Internal Med 1, 840 Shijo Cho, Kashihara, Nara 6348533, Japan.	saitonaramed@gmail.com			Ministry of Health, Labour and Welfare of Japan; Takeda Science Foundation	This work was supported in part by Grants-in-Aid from the Ministry of Health, Labour and Welfare of Japan, and the Takeda Science Foundation.	MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; Selvaraj SK, 2003, BLOOD, V102, P1515, DOI 10.1182/blood-2002-11-3423; Matsuo S, 2009, AM J KIDNEY DIS, V53, P982, DOI 10.1053/j.ajkd.2008.12.034; Theilade S, 2012, DIABETIC MED, V29, P337, DOI 10.1111/j.1464-5491.2011.03482.x; Sakuma M, 2010, CIRC J, V74, P792, DOI 10.1253/circj.CJ-09-0834; Dominguez JR, 2013, J AM SOC NEPHROL, V24, P647, DOI 10.1681/ASN.2012090894; PARK JE, 1994, J BIOL CHEM, V269, P25646; Luttun A, 2002, ANN NY ACAD SCI, V979, P80; Horio M, 2010, AM J KIDNEY DIS, V56, P32, DOI 10.1053/j.ajkd.2010.02.344; Ky B, 2011, J AM COLL CARDIOL, V58, P386, DOI 10.1016/j.jacc.2011.03.032; Hemmelgarn BR, 2010, JAMA-J AM MED ASSOC, V303, P423, DOI 10.1001/jama.2010.39; Dierkes J, 2000, CIRCULATION, V102, P1964; Onoue K, 2009, CIRCULATION, V120, P2470, DOI 10.1161/CIRCULATIONAHA.109.867929; Ito S, 2010, NAT REV NEPHROL, V6, P10, DOI 10.1038/nrneph.2009.203; Muller YA, 1997, STRUCTURE, V5, P1325, DOI 10.1016/S0969-2126(97)00284-0; Matsushita K, 2012, JAMA-J AM MED ASSOC, V307, P1941, DOI 10.1001/jama.2012.3954; Jaffe IZ, 2010, J CLIN INVEST, V120, P3891, DOI 10.1172/JCI40205; Pilarczyk K, 2008, ATHEROSCLEROSIS, V196, P333, DOI 10.1016/j.atherosclerosis.2006.10.038; Oemrawsingh RM, 2011, HEART, V97, P1061, DOI 10.1136/hrt.2010.197392; Hage FG, 2009, J AM COLL CARDIOL, V53, P2129, DOI 10.1016/j.jacc.2009.02.047; Gerstein HC, 2001, JAMA-J AM MED ASSOC, V286, P421, DOI 10.1001/jama.286.4.421; Sela S, 2011, CIRC RES, V108, P1063, DOI 10.1161/CIRCRESAHA.110.239665; Liu YM, 2004, JAMA-J AM MED ASSOC, V291, P451, DOI 10.1001/jama.291.4.451; Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731; Glaser R, 2011, AM J CARDIOL, V107, P821, DOI 10.1016/j.amjcard.2010.11.003; Searle J, 2011, ARTERIOSCL THROM VAS, V31, P2972, DOI 10.1161/ATVBAHA.111.237784; Hochholzer W, 2011, EUR HEART J, V32, P326, DOI 10.1093/eurheartj/ehq429; Matsushita K, 2010, LANCET, V375, P2073, DOI 10.1016/S0140-6736(10)60674-5; Herzog CA, 1998, NEW ENGL J MED, V339, P799, DOI 10.1056/NEJM199809173391203; Bertocchio JP, 2011, KIDNEY INT, V79, P1051, DOI 10.1038/ki.2011.48; Matsui M, 2014, KIDNEY INT, V85, P393, DOI 10.1038/ki.2013.339; Lockhart AC, 2010, J CLIN ONCOL, V28, P207, DOI 10.1200/JCO.2009.22.9237; Lenderink T, 2006, J AM COLL CARDIOL, V47, P307, DOI 10.1016/j.jacc.2005.08.063; Stenvinkel P, 1999, KIDNEY INT, V55, P1899, DOI 10.1046/j.1523-1755.1999.00422.x; Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904; Roncal C, 2010, CARDIOVASC RES, V86, P29, DOI 10.1093/cvr/cvp380; Kalogeropoulos A, 2009, ARCH INTERN MED, V169, P708, DOI 10.1001/archinternmed.2009.40; Cassidy A, 2009, ARTERIOSCL THROM VAS, V29, P134, DOI 10.1161/ATVBAHA.108.171066; Matsumoto T, 2013, INTERNAL MED, V52, P1019, DOI 10.2169/internalmedicine.52.9073; Khurana R, 2005, CIRCULATION, V111, P2828, DOI 10.1161/CIRCULATIONAHA.104.495887; Di Angelantonio E, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c4986; Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031; HO KKL, 1993, J AM COLL CARDIOL, V22, pA6; Isakova T, 2011, JAMA-J AM MED ASSOC, V305, P2432; Lassen U, 2012, BRIT J CANCER, V106, P678, DOI 10.1038/bjc.2011.609; McGraw AP, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.112.000018; Pan PX, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-36; Peiskerova M, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-142; Rambod M, 2014, ATHEROSCLEROSIS, V236, P360, DOI 10.1016/j.atherosclerosis.2014.07.026	49	0	0	AMER SOC NEPHROLOGY	WASHINGTON	1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA	1046-6673	1533-3450		J AM SOC NEPHROL	J. Am. Soc. Nephrol.	NOV	2015	26	11					2871	2881		10.1681/ASN.2014080772		11	Urology & Nephrology	Urology & Nephrology	CV0CR	WOS:000363915500030		
J	Xu, WX; Rutledge, SA; Schumacher, C; Katsumata, M				Xu, Weixin; Rutledge, Steven A.; Schumacher, Courtney; Katsumata, Masaki			Evolution, Properties, and Spatial Variability of MJO Convection near and off the Equator during DYNAMO	JOURNAL OF THE ATMOSPHERIC SCIENCES			English	Article						Convection; Madden-Julian oscillation; Radars; Radar observations	MADDEN-JULIAN OSCILLATION; SHIP-BORNE RADAR; INDIAN-OCEAN; TOGA COARE; RAINFALL CHARACTERISTICS; SCALE CIRCULATION; SUMATERA ISLAND; PRECIPITATION; CLOUD; TRMM	This study investigates the evolution, structure, and spatial variability of Madden-Julian oscillation (MJO) convection observed during the 2011/12 Dynamics of the MJO (DYNAMO) field campaign. Generally, the C-band radars located in the near-equatorial Indian OceanShared Mobile Atmospheric Research and Teaching Radar (SMART-R) on Addu Atoll (Gan) and NASA TOGA on the R/V Roger Revelle (Revelle)observed similar trends in echo-top heights, stratiform rain fraction, and precipitation feature size across the MJO life cycle. These trends are closely related to changes in mid- to upper-tropospheric moisture, sea surface temperature (SST), zonal wind, and diagnosed vertical air motions. However, the evolution of convection, moisture, and vertical air motion at the R/V Mirai (Mirai), located in the intertropical convergence zone (ITCZ) at 8 degrees S, exhibited a pattern nearly opposite to Gan and Revelle. When the MJO was active over the equator, convection was suppressed around Mirai owing to induced subsidence by the strong upward motion to the north. SST and zonal winds near Mirai were nearly invariant across the MJO life cycle, indicating little influence from the MJO in these fields. Compared to Gan and Revelle, Mirai had a significant amount of precipitation that fell from shallow and isolated convection. There were subtle differences in the evolution and properties of the convection observed between Gan and Revelle. Deep convection occurred slightly earlier at Gan compared to Revelle, consistent with the west-to-east progression of the MJO in the central Indian Ocean. Furthermore, convective deepening was more gradual over Revelle compared to Gan, especially during the October MJO event.	[Xu, Weixin; Rutledge, Steven A.] Colorado State Univ, Dept Atmospher Sci, Ft Collins, CO 80521 USA; [Schumacher, Courtney] Texas A&M Univ, Dept Atmospher Sci, College Stn, TX USA; [Katsumata, Masaki] Japan Agcy Marine Earth Sci & Technol, Yokosuka, Kanagawa 2370061, Japan	Xu, WX (reprint author), Colorado State Univ, Dept Atmospher Sci, 3915 West Laporte Ave, Ft Collins, CO 80521 USA.	wxinxu@atmos.colostate.edu			National Science Foundation DYNAMO Project [AGS-1063928]	This research was supported by the National Science Foundation DYNAMO Project Grant AGS-1063928. We thank the entire crew of the R/V Revelle and Mirai for their excellent support and Chief Scientists James Moum (Revelle) and Kunio Yoneyama (Mirai) for their dedication and leadership. Special thanks also go to Paul Ciesielski and Richard Johnson for providing the sounding data, sounding-associated products, and science discussion. We also thank Brandon Kerns for help in processing Meteosat satellite data.	Ciesielski PE, 2014, J ATMOS OCEAN TECH, V31, P741, DOI 10.1175/JTECH-D-13-00165.1; DePasquale A, 2014, J GEOPHYS RES-ATMOS, V119, P6347, DOI 10.1002/2013JD021031; Mori S, 2004, MON WEATHER REV, V132, P2021, DOI 10.1175/1520-0493(2004)132<2021:DLRPMO>2.0.CO;2; Guy N, 2014, MON WEATHER REV, V142, P1385, DOI 10.1175/MWR-D-13-00252.1; Saxen TR, 2000, MON WEATHER REV, V128, P407, DOI 10.1175/1520-0493(2000)128<0407:SRCCFC>2.0.CO;2; Said RK, 2010, J GEOPHYS RES-ATMOS, V115, DOI 10.1029/2010JD013863; Adams PJ, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD001010; Gentemann CL, 2004, J GEOPHYS RES-OCEANS, V109, DOI 10.1029/2003JC002092; Huffman GJ, 2007, J HYDROMETEOROL, V8, P38, DOI 10.1175/JHM560.1; Tian BJ, 2006, J ATMOS SCI, V63, P2462, DOI 10.1175/JAS3782.1; Deng M, 2014, J APPL METEOROL CLIM, V53, P2503, DOI 10.1175/JAMC-D-13-0311.1; McPhaden MJ, 2009, B AM METEOROL SOC, V90, P459, DOI 10.1175/2008BAMS2608.1; Xu WX, 2014, J ATMOS SCI, V71, P2859, DOI 10.1175/JAS-D-13-0372.1; Liu CT, 2008, J APPL METEOROL CLIM, V47, P2712, DOI 10.1175/2008JAMC1890.1; Vialard J, 2008, GEOPHYS RES LETT, V35, DOI 10.1029/2008GL035238; Nesbitt SW, 2006, MON WEATHER REV, V134, P2702, DOI 10.1175/MWR3200.1; Fujita M, 2011, J METEOROL SOC JPN, V89A, P317, DOI 10.2151/jmsj.2011-A22; Chen SS, 1996, J ATMOS SCI, V53, P1380, DOI 10.1175/1520-0469(1996)053<1380:MVODCI>2.0.CO;2; Johnson RH, 2013, J ATMOS SCI, V70, P3157, DOI 10.1175/JAS-D-13-065.1; Biggerstaff MI, 2005, B AM METEOROL SOC, V86, P1263, DOI 10.1175/BAMS-86-9-1263; Riley EM, 2011, J ATMOS SCI, V68, P3032, DOI 10.1175/JAS-D-11-030.1; Rosenfeld D, 1998, B AM METEOROL SOC, V79, P2457, DOI 10.1175/1520-0477(1998)079<2457:SBIIPF>2.0.CO;2; Powell SW, 2013, J GEOPHYS RES-ATMOS, V118, P11979, DOI 10.1002/2013JD020421; Gottschalck J, 2013, MON WEATHER REV, V141, P4173, DOI 10.1175/MWR-D-13-00022.1; Koren I, 2008, SCIENCE, V321, P946, DOI 10.1126/science.1159185; Lin JL, 2004, J ATMOS SCI, V61, P296, DOI 10.1175/1520-0469(2004)061<0296:SPVHPA>2.0.CO;2; Yoneyama K, 2013, B AM METEOROL SOC, V94, P1871, DOI 10.1175/BAMS-D-12-00157.1; Zuluaga MD, 2013, J ATMOS SCI, V70, P2713, DOI 10.1175/JAS-D-12-0311.1; Gentemann CL, 2010, IEEE T GEOSCI REMOTE, V48, P1009, DOI 10.1109/TGRS.2009.2030322; Kemball-Cook SR, 2001, J CLIMATE, V14, P780, DOI 10.1175/1520-0442(2001)014<0780:TOOCIT>2.0.CO;2; Said RK, 2013, J GEOPHYS RES-ATMOS, V118, P6905, DOI 10.1002/jgrd.50508; Webber BGM, 2010, Q J ROY METEOR SOC, V136, P740, DOI 10.1002/qj.604; ZIPSER EJ, 1994, MON WEATHER REV, V122, P1751, DOI 10.1175/1520-0493(1994)122<1751:TVPORR>2.0.CO;2; BLADE I, 1993, J ATMOS SCI, V50, P2922, DOI 10.1175/1520-0469(1993)050<2922:TIOIAS>2.0.CO;2; Seiki A, 2013, J GEOPHYS RES-OCEANS, V118, P5523, DOI 10.1002/jgrc.20381; Xie SP, 2002, J CLIMATE, V15, P864, DOI 10.1175/1520-0442(2002)015<0864:SAMOSI>2.0.CO;2; Kim D, 2009, J CLIMATE, V22, P6413, DOI 10.1175/2009JCLI3063.1; Williams E, 2002, CR PHYS, V3, P1277, DOI 10.1016/S1631-0705(02)01407-X; Katsumata M, 2008, SOLA, V4, P101, DOI 10.2151/sola.2008-026; STEINER M, 1995, J APPL METEOROL, V34, P1978, DOI 10.1175/1520-0450(1995)034<1978:CCOTDS>2.0.CO;2; MADDEN RA, 1972, J ATMOS SCI, V29, P1109, DOI 10.1175/1520-0469(1972)029<1109:DOGSCC>2.0.CO;2; Kiladis GN, 2005, J ATMOS SCI, V62, P2790, DOI 10.1175/JAS3520.1; Halverson JB, 1999, MON WEATHER REV, V127, P1208, DOI 10.1175/1520-0493(1999)127<1208:AEOCSO>2.0.CO;2; Bechtold P, 2008, Q J ROY METEOR SOC, V134, P1337, DOI 10.1002/qj.289; Zhang CD, 2005, REV GEOPHYS, V43, DOI 10.1029/2004RG000158; Sakurai N, 2005, J METEOROL SOC JPN, V83, P835, DOI 10.2151/jmsj.83.835; WALISER DE, 1993, J CLIMATE, V6, P2162, DOI 10.1175/1520-0442(1993)006<2162:ASDCOT>2.0.CO;2; Feng Z, 2014, J ATMOS OCEAN TECH, V31, P1021, DOI 10.1175/JTECH-D-13-00132.1; Lau KM, 2010, J CLIMATE, V23, P504, DOI 10.1175/2009JCLI2920.1; Wheeler MC, 2004, MON WEATHER REV, V132, P1917, DOI 10.1175/1520-0493(2004)132<1917:AARMMI>2.0.CO;2; Zhang CD, 2013, B AM METEOROL SOC, V94, P1849, DOI 10.1175/BAMS-D-12-00026.1; Vitart F, 2010, Q J ROY METEOR SOC, V136, P842, DOI 10.1002/qj.623; Rowe AK, 2014, J GEOPHYS RES-ATMOS, V119, P2543, DOI 10.1002/2013JD020799; DeWitt L. H., 2013, J GEOPHYS RES-ATMOS, V118, P5736, DOI [10.1002/jgrd.50419, DOI 10.1002/JGRD.50419]; Fliegel J., 2012, THESIS TEXAS A M U; Hu Q., 1994, J ATMOS SCI, V51, P1089, DOI [10.1175/1520-0469(1994)051<1089:LFOIRC>2.0.CO;2, DOI 10.1175/1520-0469(1994)051]; Kerns BW, 2014, MON WEATHER REV, V142, P1326, DOI 10.1175/MWR-D-13-00159.1; MADDEN RA, 1971, J ATMOS SCI, V28, P702, DOI 10.1175/1520-0469(1971)028<0702:DOADOI>2.0.CO;2; Moum JN, 2014, B AM METEOROL SOC, V95, P1185, DOI 10.1175/BAMS-D-12-00225.1; Oye D., 1995, REORDER PROGRAM GRID; Thompson J. E., 2015, J ATMOS SCI, V72, P4091, DOI [10.1175/JAS-D-14-0206.1, DOI 10.1175/JAS-D-14-0206.1]; Xu WX, 2015, J ATMOS SCI, V72, P623, DOI 10.1175/JAS-D-14-0130.1	62	0	0	AMER METEOROLOGICAL SOC	BOSTON	45 BEACON ST, BOSTON, MA 02108-3693 USA	0022-4928	1520-0469		J ATMOS SCI	J. Atmos. Sci.	NOV	2015	72	11					4126	4147		10.1175/JAS-D-15-0032.1		22	Meteorology & Atmospheric Sciences	Meteorology & Atmospheric Sciences	CV3UU	WOS:000364192700004		
J	Kanada, S; Wada, A				Kanada, Sachie; Wada, Akiyoshi			Numerical Study on the Extremely Rapid Intensification of an Intense Tropical Cyclone: Typhoon Ida (1958)	JOURNAL OF THE ATMOSPHERIC SCIENCES			English	Article						Tropical cyclones; Nonhydrostatic models	CONVECTIVE BURSTS; WARM-CORE; HURRICANE; MODEL; SIMULATION; EYEWALL; SURFACE; CLOUD; SHEAR; PARAMETERIZATION	Extremely rapid intensification (ERI) of Typhoon Ida (1958) was examined with a 2-km-mesh nonhydrostatic model initiated at three different times. Ida was an extremely intense tropical cyclone with a minimum central pressure of 877 hPa. The maximum central pressure drop in 24 h exceeded 90 hPa. ERI was successfully simulated in two of the three experiments. A factor crucial to simulating ERI was a combination of shallow-to-moderate convection and tall, upright convective bursts (CBs). Under a strong environmental vertical wind shear (>10 m s(-1)), shallow-to-moderate convection on the downshear side that occurred around the intense near-surface inflow moistened the inner-core area. Meanwhile, dry subsiding flows on the upshear side helped intensification of midlevel (8 km) inertial stability. First, a midlevel warm core appeared below 10 km in the shallow-to-moderate convection areas, being followed by the development of the upper-level warm core associated with tall convection. When tall, upright, rotating CBs formed from the leading edge of the intense near-surface inflow, ERI was triggered at the area in which the air became warm and humid. CBs penetrated into the upper troposphere, aligning the areas with high vertical vorticity at low to midlevels. The upper-level warm core developed rapidly in combination with the midlevel warm core. Under the preconditioned environment, the formation of the upright CBs inside the radius of maximum wind speeds led to an upright axis of the secondary circulation within high inertial stability, resulting in a very rapid central pressure deepening.	[Kanada, Sachie] Nagoya Univ, Hydrospher Atmospher Res Ctr, Nagoya, Aichi 4648601, Japan; [Wada, Akiyoshi] Japan Meteorol Agcy, Meteorol Res Inst, Tsukuba, Ibaraki, Japan	Kanada, S (reprint author), Nagoya Univ, Hydrospher Atmospher Res Ctr, Chikusa Ku, Furo Cho, Nagoya, Aichi 4648601, Japan.	skanada@rain.hyarc.nagoya-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan; JSPS-KAKENHI [26400466]; MEXT-KAKENHI [25106708]	The authors are grateful to three anonymous reviewers for instructive comments. This study was supported by the Ministry of Education, Culture, Sports, Science and Technology of Japan under the framework of the Sousei Program and JSPS-KAKENHI Grant 26400466 and MEXT-KAKENHI Grant 25106708. Numerical simulations were performed using the Earth Simulator.	[Anonymous], 1993, METEOR MON; OOYAMA K, 1969, J ATMOS SCI, V26, P3, DOI 10.1175/1520-0469(1969)026<0003:NSOTLC>2.0.CO;2; Hendricks EA, 2010, MON WEATHER REV, V138, P3243, DOI 10.1175/2010MWR3185.1; Nakanishi M, 2004, BOUND-LAY METEOROL, V112, P1, DOI 10.1023/B:BOUN.0000020164.04146.98; Wang Y, 2004, METEOROL ATMOS PHYS, V87, P257, DOI 10.1007/s00703-003-0055-6; HOLLIDAY CR, 1979, MON WEATHER REV, V107, P1022, DOI 10.1175/1520-0493(1979)107<1022:CCORIT>2.0.CO;2; HACK JJ, 1986, J ATMOS SCI, V43, P1559, DOI 10.1175/1520-0469(1986)043<1559:NROAVT>2.0.CO;2; DEARDORFF JW, 1980, BOUND-LAY METEOROL, V18, P495, DOI 10.1007/BF00119502; Guimond SR, 2010, J ATMOS SCI, V67, P633, DOI 10.1175/2009JAS3119.1; SHAPIRO LJ, 1982, J ATMOS SCI, V39, P378, DOI 10.1175/1520-0469(1982)039<0378:TROBHT>2.0.CO;2; Zagrodnik JP, 2014, J ATMOS SCI, V71, P2789, DOI 10.1175/JAS-D-13-0314.1; Kanada S, 2012, J GEOPHYS RES-ATMOS, V117, DOI 10.1029/2011JD016582; Rogers RF, 2015, MON WEATHER REV, V143, P536, DOI 10.1175/MWR-D-14-00175.1; Ebita A, 2011, SOLA, V7, P149, DOI 10.2151/sola.2011-038; CHARNEY JG, 1964, J ATMOS SCI, V21, P68, DOI 10.1175/1520-0469(1964)021<0068:OTGOTH>2.0.CO;2; STERANKA J, 1986, MON WEATHER REV, V114, P1539, DOI 10.1175/1520-0493(1986)114<1539:TRBSMC>2.0.CO;2; Reasor PD, 2013, MON WEATHER REV, V141, P2949, DOI 10.1175/MWR-D-12-00334.1; Riemer M, 2010, ATMOS CHEM PHYS, V10, P3163; Jiang HY, 2012, MON WEATHER REV, V140, P1164, DOI 10.1175/MWR-D-11-00134.1; Reasor PD, 2012, MON WEATHER REV, V140, P425, DOI 10.1175/MWR-D-11-00080.1; Chen H, 2013, J ATMOS SCI, V70, P146, DOI 10.1175/JAS-D-12-062.1; Sawada M, 2007, J METEOROL SOC JPN, V85, P479, DOI 10.2151/jmsj.85.479; Zhou XQ, 2011, J ATMOS SCI, V68, P972, DOI 10.1175/2011JAS3575.1; Vigh JL, 2009, J ATMOS SCI, V66, P3335, DOI 10.1175/2009JAS3092.1; Kieper ME, 2012, GEOPHYS RES LETT, V39, DOI 10.1029/2012GL052115; Chen H, 2011, WEATHER FORECAST, V26, P885, DOI 10.1175/WAF-D-11-00001.1; Montgomery MT, 1998, J ATMOS SCI, V55, P3176, DOI 10.1175/1520-0469(1998)055<3176:TCVCFV>2.0.CO;2; Kepert JD, 2012, MON WEATHER REV, V140, P1427, DOI 10.1175/MWR-D-11-00217.1; McFarquhar GM, 2012, J ATMOS SCI, V69, P3515, DOI 10.1175/JAS-D-12-016.1; Wissmeier U, 2011, Q J ROY METEOR SOC, V137, P845, DOI 10.1002/qj.819; Wada A, 2012, J GEOPHYS RES-ATMOS, V117, DOI 10.1029/2012JD017583; BLACKADAR AK, 1962, J GEOPHYS RES, V67, P3095, DOI 10.1029/JZ067i008p03095; Braun SA, 2002, MON WEATHER REV, V130, P1573, DOI 10.1175/1520-0493(2002)130<1573:ACRSOH>2.0.CO;2; Bryan GH, 2009, J ATMOS SCI, V66, P148, DOI 10.1175/2008JAS2707.1; Xu J, 2010, J ATMOS SCI, V67, P1831, DOI 10.1175/2010JAS3387.1; Montgomery MT, 2014, Q J ROY METEOR SOC, V140, P2132, DOI 10.1002/qj.2283; Nolan DS, 2007, J ATMOS SCI, V64, P3377, DOI 10.1175/JAS3988.1; Rogers R, 2013, MON WEATHER REV, V141, P2970, DOI 10.1175/MWR-D-12-00357.1; Kaplan J, 2003, WEATHER FORECAST, V18, P1093, DOI 10.1175/1520-0434(2003)018<1093:LCORIT>2.0.CO;2; Saito K, 2007, J METEOROL SOC JPN, V85B, P271, DOI 10.2151/jmsj.85B.271; Wang H, 2014, MON WEATHER REV, V142, P29, DOI 10.1175/MWR-D-13-00070.1; MURAKAMI M, 1990, J METEOROL SOC JPN, V68, P107; Montgomery MT, 2006, J ATMOS SCI, V63, P355, DOI 10.1175/JAS3604.1; Nakano M, 2012, J METEOROL SOC JPN, V90A, P339, DOI 10.2151/jmsj.2012-A19; Pendergrass AG, 2009, MON WEATHER REV, V137, P805, DOI 10.1175/2008MWR2657.1; Ito K, 2011, J ATMOS SCI, V68, P2250, DOI 10.1175/JAS-D-10-05022.1; Smith RK, 2009, Q J ROY METEOR SOC, V135, P1321, DOI 10.1002/qj.428; Sanger NT, 2014, MON WEATHER REV, V142, P3, DOI 10.1175/MWR-D-12-00306.1; Bui HH, 2009, Q J ROY METEOR SOC, V135, P1715, DOI 10.1002/qj.502; Kanada S, 2013, J CLIMATE, V26, P9986, DOI 10.1175/JCLI-D-12-00477.1; Heymsfield GM, 2001, J APPL METEOROL, V40, P1310, DOI 10.1175/1520-0450(2001)040<1310:EDRIOT>2.0.CO;2; GRAY WM, 1968, MON WEATHER REV, V96, P669, DOI 10.1175/1520-0493(1968)096<0669:GVOTOO>2.0.CO;2; Hazelton AT, 2015, MON WEATHER REV, V143, P883, DOI 10.1175/MWR-D-14-00122.1; Kitagawa H., 2000, 46 NPD JPN MET AG, P16; Kondo J., 1975, Boundary-Layer Meteorology, V9; Louis J. F., 1982, P ECMWF WORKSH PLAN, P59; Montgomery MT, 2014, AUST METEOROL OCEAN, V64, P37; Wada A., 2014, PROG EARTH PLANET SC, V1, P11, DOI [10.1186/2197-4284-1-11, DOI 10.1186/2197-4284-1-11]; Yabu S., 2005, 51 NPD JPN MET AG, P53	59	0	0	AMER METEOROLOGICAL SOC	BOSTON	45 BEACON ST, BOSTON, MA 02108-3693 USA	0022-4928	1520-0469		J ATMOS SCI	J. Atmos. Sci.	NOV	2015	72	11					4194	4217		10.1175/JAS-D-14-0247.1		24	Meteorology & Atmospheric Sciences	Meteorology & Atmospheric Sciences	CV3UU	WOS:000364192700007		
J	Takashima, S; Iwata, H; Sakata, M; Osawa, R; Nishie, W; Shimizu, H				Takashima, S.; Iwata, H.; Sakata, M.; Osawa, R.; Nishie, W.; Shimizu, H.			Widespread erythema ab igne caused by hot bathing	JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY			English	Letter									[Takashima, S.; Iwata, H.; Sakata, M.; Osawa, R.; Nishie, W.; Shimizu, H.] Hokkaido Univ, Grad Sch Med, Dept Dermatol, Sapporo, Hokkaido, Japan	Iwata, H (reprint author), Hokkaido Univ, Grad Sch Med, Dept Dermatol, Sapporo, Hokkaido, Japan.	hiroaki.iwata@med.hokudai.ac.jp					Lin SJ, 2002, ACTA DERM-VENEREOL, V82, P478, DOI 10.1080/000155502762064728; PAGE EH, 1988, J AM ACAD DERMATOL, V18, P1003, DOI 10.1016/S0190-9622(88)70098-5; Riahi RR, 2010, INT J DERMATOL, V49, P1314, DOI 10.1111/j.1365-4632.2009.04433.x; Huynh N, 2011, CUTIS, V88, P290; Cho S, 2011, DERMATOL SURG, V37, P551, DOI 10.1111/j.1524-4725.2011.01923.x; Riahi Ryan R, 2012, Dermatol Online J, V18, P5	6	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0926-9959	1468-3083		J EUR ACAD DERMATOL	J. Eur. Acad. Dermatol. Venereol.	NOV	2015	29	11					2259	2261		10.1111/jdv.12558		3	Dermatology	Dermatology	CV0ZQ	WOS:000363983000029		
J	Kasuya, A; Hoshino, T; Aoshima, M; Tatsuno, K; Fujiyama, T; Tokura, Y				Kasuya, A.; Hoshino, T.; Aoshima, M.; Tatsuno, K.; Fujiyama, T.; Tokura, Y.			TGF beta/SMAD4 signalling is inhibited in tumour cells and infiltrating lymphocytes of a patient with colon cancer-associated dermatomyositis	JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY			English	Letter							GROWTH-FACTOR-BETA; REGULATORY T-CELLS; PROLIFERATION		[Kasuya, A.; Hoshino, T.; Aoshima, M.; Tatsuno, K.; Fujiyama, T.; Tokura, Y.] Hamamatsu Univ, Dept Dermatol, Sch Med, Hamamatsu, Shizuoka, Japan	Kasuya, A (reprint author), Hamamatsu Univ, Dept Dermatol, Sch Med, Hamamatsu, Shizuoka, Japan.	casuaki@hama-med.ac.jp					Andrieux G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033761; WAHL SM, 1988, J IMMUNOL, V140, P3026; Kasuya A, 2013, ACTA DERM-VENEREOL, V93, P715, DOI 10.2340/00015555-1550; Inman GJ, 2011, CURR OPIN GENET DEV, V21, P93, DOI 10.1016/j.gde.2010.12.004; Fleming NI, 2013, CANCER RES, V73, P725, DOI 10.1158/0008-5472.CAN-12-2706; Beswick EJ, 2011, INFECT IMMUN, V79, P2737, DOI 10.1128/IAI.01146-10; Zhang HN, 2008, IMMUNOLOGY, V124, P304, DOI 10.1111/j.1365-2567.2007.02769.x; Kobie JJ, 2003, CANCER RES, V63, P1860; Fujimoto M, 2012, ARTHRITIS RHEUM-US, V64, P513, DOI 10.1002/art.33403	9	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0926-9959	1468-3083		J EUR ACAD DERMATOL	J. Eur. Acad. Dermatol. Venereol.	NOV	2015	29	11					2265	2267		10.1111/jdv.12569		3	Dermatology	Dermatology	CV0ZQ	WOS:000363983000033		
J	Tsujiwaki, M; Hata, H; Miyauchi, T; Homma, E; Aoyagi, S; Shimizu, H				Tsujiwaki, M.; Hata, H.; Miyauchi, T.; Homma, E.; Aoyagi, S.; Shimizu, H.			Warty intralymphatic histiocytosis successfully treated with topical tacrolimus	JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY			English	Letter							RHEUMATOID-ARTHRITIS		[Tsujiwaki, M.; Hata, H.; Miyauchi, T.; Homma, E.; Aoyagi, S.; Shimizu, H.] Hokkaido Univ, Dept Dermatol, Grad Sch Med, Sapporo, Hokkaido, Japan	Hata, H (reprint author), Hokkaido Univ, Dept Dermatol, Grad Sch Med, Sapporo, Hokkaido, Japan.	hata07jp@yahoo.co.jp					Saggar S, 2011, J DRUGS DERMATOL, V10, P1208; Wang Y, 2012, EUR J DERMATOL, V22, P814, DOI 10.1684/ejd.2012.1869; Requena L, 2009, AM J DERMATOPATH, V31, P140, DOI 10.1097/DAD.0b013e3181986cc2; Washio K, 2011, DERMATOLOGY, V223, P20, DOI 10.1159/000330561; Bakr F, 2014, J AM ACAD DERMATOL, V70, P927, DOI 10.1016/j.jaad.2013.11.024; Sakaguchi M, 2011, ARCH DERMATOL, V147, P131, DOI 10.1001/archdermatol.2010.407; OGRADY JT, 1994, HISTOPATHOLOGY, V24, P265, DOI 10.1111/j.1365-2559.1994.tb00519.x; de Unamuno Bustos Blanca, 2013, Int J Dermatol, V52, P547, DOI 10.1111/j.1365-4632.2012.05696.x; Korman JB, 2013, J AM ACAD DERMATOL, V69, pE314, DOI 10.1016/j.jaad.2013.08.020	9	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0926-9959	1468-3083		J EUR ACAD DERMATOL	J. Eur. Acad. Dermatol. Venereol.	NOV	2015	29	11					2267	2269		10.1111/jdv.12570		3	Dermatology	Dermatology	CV0ZQ	WOS:000363983000034		
J	Homma, E; Hata, H; Tsujiwaki, M; Aoyagi, S; Shimizu, H				Homma, E.; Hata, H.; Tsujiwaki, M.; Aoyagi, S.; Shimizu, H.			Nanoparticle albumin-bound paclitaxel can be useful agent to advanced primary mucinous carcinoma of the skin	JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY			English	Letter							ADENOCYSTIC CARCINOMA		[Homma, E.; Hata, H.; Tsujiwaki, M.; Aoyagi, S.; Shimizu, H.] Hokkaido Univ, Grad Sch Med, Dept Dermatol, Sapporo, Hokkaido, Japan	Hata, H (reprint author), Hokkaido Univ, Grad Sch Med, Dept Dermatol, Sapporo, Hokkaido, Japan.	hata07jp@yahoo.co.jp					MENDOZA S, 1971, ARCH DERMATOL, V103, P68, DOI 10.1001/archderm.103.1.68; Gradishar WJ, 2005, J CLIN ONCOL, V23, P7794, DOI 10.1200/JCO.2005.04.937; YEUNG KY, 1977, CANCER, V39, P2556, DOI 10.1002/1097-0142(197706)39:6<2556::AID-CNCR2820390637>3.0.CO;2-D; WRIGHT JD, 1979, CANCER, V44, P1757, DOI 10.1002/1097-0142(197911)44:5<1757::AID-CNCR2820440533>3.0.CO;2-8; RAO KV, 1978, INT SURG, V63, P168; Ajithkumar TV, 1999, AM J CLIN ONCOL-CANC, V22, P303, DOI 10.1097/00000421-199906000-00019; Breiting L, 2008, INT J DERMATOL, V47, P242, DOI 10.1111/j.1365-4632.2008.03558.x; Miyasaka M, 2009, EUR J PLAST SURG, V32, P189; Montero Alberto J, 2011, Expert Rev Clin Pharmacol, V4, P329, DOI 10.1586/ecp.11.7; Weedon D., 2009, WEEDONS SKIN PATHOLO, P757	10	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0926-9959	1468-3083		J EUR ACAD DERMATOL	J. Eur. Acad. Dermatol. Venereol.	NOV	2015	29	11					2271	2273		10.1111/jdv.12574		3	Dermatology	Dermatology	CV0ZQ	WOS:000363983000036		
J	Machino, R; Yamasaki, N; Miyazaki, T; Matsumoto, K; Tsuchiya, T; Tanaka, T; Hayashi, H; Ashizawa, K; Nagayasu, T				Machino, Ryusuke; Yamasaki, Naoya; Miyazaki, Takurou; Matsumoto, Keitarou; Tsuchiya, Tomoshi; Tanaka, Tomonori; Hayashi, Hideyuki; Ashizawa, Kazuto; Nagayasu, Takeshi			A Rare Case of Primary Pulmonary Glomus Tumor	JOURNAL OF THORACIC IMAGING			English	Article						lung; glomus tumor; computed tomography; magnetic resonance imaging			[Machino, Ryusuke; Yamasaki, Naoya; Miyazaki, Takurou; Matsumoto, Keitarou; Tsuchiya, Tomoshi; Nagayasu, Takeshi] Nagasaki Univ, Grad Sch Biomed Sci, Dept Surg Oncol, Nagasaki 8528501, Japan; [Tanaka, Tomonori] Nagasaki Univ, Grad Sch Biomed Sci, Dept Pathol, Nagasaki 8528501, Japan; [Hayashi, Hideyuki; Ashizawa, Kazuto] Nagasaki Univ, Grad Sch Biomed Sci, Dept Clin Oncol, Nagasaki 8528501, Japan	Yamasaki, N (reprint author), Nagasaki Univ, Grad Sch Biomed Sci, Dept Surg Oncol, 1-7-1 Sakamoto, Nagasaki 8528501, Japan.	ynaoya@nagasaki-u.ac.jp					Ueno M, 2004, J THORAC IMAG, V19, P131, DOI 10.1097/00005382-200404000-00015; Folpe AL, 2001, AM J SURG PATHOL, V25, P1, DOI 10.1097/00000478-200101000-00001; Gaertner EM, 2000, AM J SURG PATHOL, V24, P1105, DOI 10.1097/00000478-200008000-00008; De Cocker Jeroen, 2008, Interact Cardiovasc Thorac Surg, V7, P1191, DOI 10.1510/icvts.2007.172957; Enzinger FM, 2001, SOFT TISSUE TUMORS, P985	5	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0883-5993	1536-0237		J THORAC IMAG	J. Thorac. Imaging	NOV	2015	30	6					W76	W79		10.1097/RTI.0000000000000187		4	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CV5CB	WOS:000364282900006		
J	Sato, H; Ono, A; Okada, F; Maeda, T; Saburi, Y; Urabe, S; Mori, H				Sato, Haruka; Ono, Asami; Okada, Fumito; Maeda, Toru; Saburi, Yoshio; Urabe, Shogo; Mori, Hiromu			A Case of Diffuse Alveolar Septal Amyloidosis Associated With Multiple Myeloma	JOURNAL OF THORACIC IMAGING			English	Article						diffuse alveolar septal amyloidosis; multiple myeloma; computed tomography	PULMONARY AMYLOIDOSIS; RESPIRATORY-TRACT	Primary amyloidosis (amyloid light-chain amyloidosis [AL amyloidosis]) is a rare condition characterized by extracellular deposition of amyloid protein comprising immunoglobulin light chain in multiple organs. Clinically evident AL amyloidosis develops during the disease course in 10% to 15% of patients with multiple myeloma.(1) Thoracic manifestations of amyloidosis have 3 patterns: tracheobronchial, nodular, and diffuse alveolar septal. The diffuse alveolar septal pattern is the least common type of pulmonary amyloidosis.(2) This pattern is sometimes seen in patients with multiple myeloma and is associated with a poor prognosis. We report a case involving a patient with diffuse alveolar septal amyloidosis associated with multiple myeloma. High-resolution computed tomography (HRCT) showed ground-glass opacity (GGO), interlobular septal thickening, and intralobular reticular opacity in both lungs.	[Sato, Haruka; Ono, Asami; Okada, Fumito; Mori, Hiromu] Oita Univ, Fac Med, Dept Radiol, Oita 8795593, Japan; [Maeda, Toru] Oita Prefectural Hosp, Dept Radiol, Oita, Japan; [Saburi, Yoshio] Oita Prefectural Hosp, Dept Hematol, Oita, Japan; [Urabe, Shogo] Oita Prefectural Hosp, Dept Pathol Lab, Oita, Japan	Sato, H (reprint author), Oita Univ, Fac Med, Dept Radiol, 1-1 Idaigaoka,Hasama Machi, Oita 8795593, Japan.	sato-h@oita-u.ac.jp					Bahlis NJ, 2006, BONE MARROW TRANSPL, V38, P7, DOI 10.1038/sj.bmt.1705395; Cottin V, 2008, RESPIRATION, V75, P210, DOI 10.1159/000090249; SMITH RRL, 1979, AM J MED, V66, P96, DOI 10.1016/0002-9343(79)90488-1; URBAN BA, 1993, RADIOGRAPHICS, V13, P1295; GROSS BH, 1986, SEMIN ROENTGENOL, V21, P113, DOI 10.1016/0037-198X(86)90028-3; Higo H, 2014, INTERNAL MED, V53, P1809, DOI 10.2169/internalmedicine.53.1728; Kurahara Y, 2012, INTERNAL MED, V51, P1447, DOI 10.2169/internalmedicine.51.7050; Pickford HA, 1997, AM J ROENTGENOL, V168, P351; THOMPSON PJ, 1983, THORAX, V38, P84, DOI 10.1136/thx.38.2.84	9	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0883-5993	1536-0237		J THORAC IMAG	J. Thorac. Imaging	NOV	2015	30	6					W73	W75		10.1097/RTI.0000000000000183		3	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CV5CB	WOS:000364282900005		
J	Sato, Y; Oikado, K; Tominaga, J; Sakurada, A; Saito, R; Takase, K				Sato, Yoshinao; Oikado, Katsunori; Tominaga, Junya; Sakurada, Akira; Saito, Ryoko; Takase, Kei			A Case of Apparent Lung Adenocarcinoma Size Reduction During Steroid Therapy	JOURNAL OF THORACIC IMAGING			English	Article						lung cancer; spontaneous regression; computed tomography	SOLID TUMORS; CANCER	Spontaneous regression of lung cancer is a rare phenomenon. We described a case of lung adenocarcinoma size reduction during steroid therapy. In this case, histopathologic findings showed a lung adenocarcinoma surrounded by obstructive pneumonia and inflammatory cell infiltration. Steroid use might have diminished the inflammatory response around the lung cancer, resulting in the apparent shrinkage of the lung cancer. This phenomenon is a potential pitfall in lung cancer diagnosis.	[Sato, Yoshinao; Tominaga, Junya; Takase, Kei] Tohoku Univ, Grad Sch Med, Dept Diagnost Radiol, Sendai, Miyagi 9808574, Japan; [Saito, Ryoko] Tohoku Univ, Grad Sch Med, Dept Pathol, Sendai, Miyagi 9808574, Japan; [Sakurada, Akira] Tohoku Univ Hosp, Dept Thorac Surg, Sendai, Miyagi, Japan; [Oikado, Katsunori] Canc Inst Hosp, Dept Diagnost Radiol, Tokyo, Japan	Sato, Y (reprint author), Tohoku Univ, Grad Sch Med, Dept Diagnost Radiol, Aoba Ku, 1-1 Seiryo, Sendai, Miyagi 9808574, Japan.	yoshinao_s@rad.med.tohoku.ac.jp					Rutz HP, 2002, LANCET, V360, P1969, DOI 10.1016/S0140-6736(02)11922-2; Greenstein S, 2002, CLIN CANCER RES, V8, P1681; COLE WH, 1981, J SURG ONCOL, V17, P201, DOI 10.1002/jso.2930170302; Herr I, 2006, LANCET ONCOL, V7, P425, DOI 10.1016/S1470-2045(06)70694-5; Kappauf H, 1997, ANN ONCOL, V8, P1031, DOI 10.1023/A:1008209618128; Keith BD, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-84; Yang RM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060279	7	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0883-5993	1536-0237		J THORAC IMAG	J. Thorac. Imaging	NOV	2015	30	6					W80	W81		10.1097/RTI.0000000000000178		2	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CV5CB	WOS:000364282900007		
J	Kojima, M; Aiboshi, J; Shibata, M; Kobayashi, T; Otomo, Y				Kojima, Mitsuaki; Aiboshi, Junichi; Shibata, Masahiro; Kobayashi, Tetsuyuki; Otomo, Yasuhiro			Novel role of group VIB Ca2+-independent phospholipase A2 gamma in leukocyte-endothelial cell interactions: An intravital microscopic study in rat mesentery	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Calcium-independent phospholipase A(2); intravital microscopy; (2)-integrin; adherence; rats	ARACHIDONIC-ACID RELEASE; MULTIPLE ORGAN FAILURE; ACUTE LUNG INJURY; HUMAN NEUTROPHILS; A(2) INHIBITOR; HEMORRHAGIC-SHOCK; EXPRESSION; PYRROPHENONE; IPLA(2)GAMMA; INFLAMMATION	BACKGROUND Phospholipase A(2) (PLA(2)) is associated with a variety of inflammatory processes related to polymorphonuclear neutrophil (PMN)-endothelial cell interactions. However, the cellular and molecular mechanisms underlying the interactions and the causative isoform(s) of PLA(2) remain elusive. In addition, we recently showed that calcium-independent PLA(2) (iPLA(2)), but not cytosolic PLA(2) (cPLA(2)), is responsible for the cytotoxic functions of human PMN including respiratory bursts, degranulation, and chemotaxis. We therefore hypothesized that iPLA(2) is a prerequisite for the PMN recruitment cascade into the site of inflammation. The aim of this study was to elucidate the roles of the three major phospholipases A(2), iPLA(2), cPLA(2) and secretory PLA(2), in leukocyte rolling and adherence and in the surface expression of (2)-integrins in vivo and in vitro in response to well-defined stimuli. METHODS Male Wistar rats were pretreated with PLA(2) inhibitors selective for iPLA(2), iPLA(2), cPLA(2), or secretory PLA(2). Leukocyte rolling/adherence in the mesenteric venules superfused with platelet-activating factor (PAF) were quantified by intravital microscopy. Furthermore, isolated human PMNs or whole blood were incubated with each PLA(2) inhibitor and then activated with formyl-methionyl-leucyl-phenylalanine (fMLP) or PAF. PMN adherence was assessed by counting cells bound to purified fibrinogen, and the surface expression of lymphocyte function-associated antigen 1 and macrophage antigen 1 (Mac-1) was measured by flow cytometry. RESULTS The iPLA(2)-specific inhibitor almost completely inhibited the fMLP/PAF-induced leukocyte adherence in vivo and in vitro and also decreased the fMLP/PAF-stimulated surface expression of Mac-1 by 60% and 95%, respectively. In contrast, the other inhibitors did not affect these cellular functions. CONCLUSION iPLA(2) seems to be involved in leukocyte/PMN adherence in vivo and in vitro as well as in the up-regulation of Mac-1 in vitro in response to PAF/fMLP. This enzyme is therefore likely to be a major regulator in the PMN recruitment cascade.	[Kojima, Mitsuaki; Otomo, Yasuhiro] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Acute Crit Care & Disaster Med, Tokyo 1138510, Japan; [Aiboshi, Junichi] Tokyo Med & Dent Univ, Hosp Med, Trauma & Acute Crit Care Med Ctr, Tokyo 1138510, Japan; [Shibata, Masahiro] Shibaura Inst Technol, Dept Biosci & Engn, Tokyo 108, Japan; [Kobayashi, Tetsuyuki] Ochanomizu Univ, Fac Sci, Dept Biol, Tokyo 112, Japan	Aiboshi, J (reprint author), Tokyo Med & Dent Univ, Hosp Med, Trauma & Acute Crit Care Med Ctr, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	aiboshi.accm@tmd.ac.jp			JSPS KAKENHI from the Japan Society of the Promotion of Science [26462748]	This study was supported by JSPS KAKENHI Grant (No. 26462748) from the Japan Society of the Promotion of Science (to J.A.).	AmandiBurgermeister E, 1997, EUR J PHARMACOL, V326, P237, DOI 10.1016/S0014-2999(97)85419-2; Moon SH, 2012, J BIOL CHEM, V287, P14880, DOI 10.1074/jbc.M111.336776; Ono T, 2002, BIOCHEM J, V363, P727, DOI 10.1042/0264-6021:3630727; Morishita K, 2013, J TRAUMA ACUTE CARE, V75, P767, DOI 10.1097/TA.0b013e3182a924f2; Furue S, 2001, CRIT CARE MED, V29, P719, DOI 10.1097/00003246-200104000-00004; White MC, 2007, THROMB RES, V120, P597, DOI 10.1016/j.thromres.2006.11.007; Gilroy DW, 2004, FASEB J, V18, P489, DOI 10.1096/fj.03-0837com; Murakami M, 2005, J BIOL CHEM, V280, P14028, DOI 10.1074/jbc.M413766200; Balboa MA, 2003, J IMMUNOL, V170, P5276; Kuwata H, 2007, J BIOL CHEM, V282, P20124, DOI 10.1074/jbc.M611883200; Escrig V, 1997, J PHARMACOL EXP THER, V282, P123; KUIJPERS TW, 1991, BLOOD, V78, P1105; Wanten GJA, 2002, EUR J CLIN INVEST, V32, P285, DOI 10.1046/j.1365-2362.2002.00959.x; Ley K, 2007, NAT REV IMMUNOL, V7, P678, DOI 10.1038/nri2156; Morishita K, 2012, J TRAUMA ACUTE CARE, V72, P1541, DOI 10.1097/TA.0b013e318256df15; Snyder DW, 1999, J PHARMACOL EXP THER, V288, P1117; Rubin BB, 2005, J BIOL CHEM, V280, P7519, DOI 10.1074/jbc.M40738200; Flamand N, 2006, BRIT J PHARMACOL, V149, P385, DOI 10.1038/sj.bjp.0706879; Herter J, 2013, J IMMUNOL, V190, P4451, DOI 10.4049/jimmunol.1203179; Jenkins CM, 2002, J BIOL CHEM, V277, P32807, DOI 10.1074/jbc.M202568200; Tanaka H, 2000, BIOCHEM BIOPH RES CO, V272, P320, DOI 10.1006/bbrc.2000.2776; Yan W, 2005, J BIOL CHEM, V280, P26669, DOI 10.1074/jbc.M502358200; BATES EJ, 1993, J LEUKOCYTE BIOL, V53, P420; Murakami M, 2011, PROG LIPID RES, V50, P152, DOI 10.1016/j.plipres.2010.12.001; Bauer A, 2008, EUR J MED RES, V13, P568; Panes J, 1999, HEPATOLOGY, V30, P445, DOI 10.1002/hep.510300214; Yoda E, 2010, J LIPID RES, V51, P3003, DOI 10.1194/jlr.M008060; SENGELOV H, 1993, J CLIN INVEST, V92, P1467, DOI 10.1172/JCI116724; Seno K, 2001, BIOORG MED CHEM LETT, V11, P587, DOI 10.1016/S0960-894X(01)00003-8; Harvey KA, 2010, CLIN NUTR, V29, P492, DOI 10.1016/j.clnu.2009.10.008; KOIKE K, 1995, J TRAUMA, V39, P23, DOI 10.1097/00005373-199507000-00003; ASHIKAWA K, 1986, CIRC RES, V59, P704; Marshall J, 2000, J IMMUNOL, V164, P2084; Aiboshi J, 2001, SHOCK, V15, P302, DOI 10.1097/00024382-200115040-00009; Mikami S, 2015, J TRAUMA ACUTE CARE, V79, P238, DOI 10.1097/TA.0000000000000730; JACOBSON PB, 1993, J IMMUNOL, V151, P5639; Osakabe N, 2012, LIFE SCI, V91, P1196, DOI 10.1016/j.lfs.2012.08.031; MOORE EE, 1994, J TRAUMA, V37, P881, DOI 10.1097/00005373-199412000-00002; Meliton AY, 2010, EUR RESPIR J, V35, P402, DOI 10.1183/09031936.00009309; Curcic S, 2015, BBA-MOL CELL BIOL L, V1851, P184, DOI 10.1016/j.bbalip.2014.11.010; Leite JO, 2009, BMC CARDIOVASC DISOR, V9, DOI 10.1186/1471-2261-9-7	41	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	NOV	2015	79	5					782	789		10.1097/TA.0000000000000845		8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	CV3XX	WOS:000364201100012		
J	Uchida, T; Ohno, Y				Uchida, T.; Ohno, Y.			Defining the visual adaptation field for mesopic photometry: How does a high-luminance source affect peripheral adaptation?	LIGHTING RESEARCH & TECHNOLOGY			English	Article							BRIGHTNESS DIFFERENCE THRESHOLD; LIGHT-SOURCE; GLARE; VISIBILITY	CIE 191:2010 recommends a mesopic photometry system in which the luminous efficiency function is determined from the adaptation luminance. However, it cannot be practically implemented because the adaptation field used to determine the adaptation luminance is not defined. Surrounding luminance effect is a key factor in defining the adaptation field. Vision experiments have been conducted to measure the surrounding luminance effect on peripheral adaptation state with a point source at various intensities placed at different positions. The results reveal that the effect can be described as veiling luminance and that the magnitude of the effect is larger than that of the foveal veiling luminance. A model for the peripheral veiling luminance proposed by Stiles and Crawford in 1937 shows the best prediction for the surrounding luminance effect.	[Uchida, T.] Panasonic Corp, Kadoma, Osaka 5718686, Japan; [Uchida, T.; Ohno, Y.] Natl Inst Stand & Technol, Gaithersburg, MD 20899 USA	Uchida, T (reprint author), Panasonic Corp, 1048 Kadoma, Kadoma, Osaka 5718686, Japan.	uchida.tatsukiyo@jp.panasonic.com			New Energy and Industrial Technology Development Organization (NEDO) in Japan [P09024]	This study is a part of a project funded by the New Energy and Industrial Technology Development Organization (NEDO) in Japan (Project number P09024).	Goodman TM, 2012, PROCEEDINGS OF CIE 2012 LIGHTING QUALITY AND ENERGY EFFICIENCY, P503; Walkey H, 2007, LIGHTING RES TECHNOL, V39, P335, DOI 10.1177/1477153507080920; Uchida T, 2014, LIGHTING RES TECHNOL, V46, P520, DOI 10.1177/1477153513498084; Freiding A, 2007, LIGHTING RES TECHNOL, V39, P319, DOI 10.1177/1477153507080917; Puolakka M, 2012, PROCEEDINGS OF CIE 2012 LIGHTING QUALITY AND ENERGY EFFICIENCY, P64; Heynderickx I, 2013, PROCEEDINGS OF THE CIE CENTENARY CONFERENCE TOWARDS A NEW CENTURY OF LIGHT, P41; Stiles WS, 1937, PROC R SOC SER B-BIO, V122, P255, DOI 10.1098/rspb.1937.0024; Varady G, 2007, LIGHTING RES TECHNOL, V39, P355, DOI 10.1177/1477153507080922; Stiles WS, 1929, P R SOC LOND B-CONTA, V105, P131, DOI 10.1098/rspb.1929.0033; Holladay LL, 1926, J OPT SOC AM REV SCI, V12, P271, DOI 10.1364/JOSA.12.000271; BLACKWELL HR, 1946, J OPT SOC AM, V36, P624, DOI 10.1364/JOSA.36.000624; Blackwell O. M., 1971, Journal of the Illuminating Engineering Society, V1; CIE Internationale Beleuchtungskommission, 1942, SEKR ZEHNT TAG SCHEN, VI, P183; Commission Internationale de l'Eclairage, 2002, CIE PUBL, V146; Commission Internationale de l'Eclairage, 1972, CIE PUBL, V19; Commission Internationale de l'Eclairage, 2010, CIE PUBL, V191; Commission Internationale de l'Eclairage, 1997, CIE PUBL, V124; Commission Internationale de l'Eclairage, 2000, CIE PUBL, V140; He Y, 1998, LR T, V30, P175; He Y, 1997, J ILLUM ENG SOC, V26, P125; Holladay LL, 1927, J OPT SOC AM REV SCI, V14, P1, DOI 10.1364/JOSA.14.000001; IJSPEERT JK, 1990, VISION RES, V30, P699, DOI 10.1016/0042-6989(90)90096-4; Illuminating Engineering Society of North America, 2012, TM1212 IES; Narisada K, 1992, J LIGHT VISUAL ENV, V16, P81; Narisada K, 1995, J LIGHT VIS ENV, V19, P5, DOI 10.2150/jlve.19.2_5; Stills WS, 1929, P R SOC LOND B-CONTA, V104, P322, DOI 10.1098/rspb.1929.0012; Vos JJ, 2003, LIGHTING RES TECHNOL, V35, P163, DOI 10.1191/1477153503li083oa	27	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1477-1535	1477-0938		LIGHTING RES TECHNOL	Lighting Res. Technol.	NOV	2015	47	7					845	858		10.1177/1477153514558963		14	Construction & Building Technology; Optics	Construction & Building Technology; Optics	CV3KK	WOS:000364157900007		
J	Nomaki, H; Chikaraishi, Y; Tsuchiya, M; Toyofuku, T; Suga, H; Sasaki, Y; Uematsu, K; Tame, A; Ohkouchi, N				Nomaki, Hidetaka; Chikaraishi, Yoshito; Tsuchiya, Masashi; Toyofuku, Takashi; Suga, Hisami; Sasaki, Yoko; Uematsu, Katsuyuki; Tame, Akihiro; Ohkouchi, Naohiko			Variation in the nitrogen isotopic composition of amino acids in benthic foraminifera: Implications for their adaptation to oxygen-depleted environments	LIMNOLOGY AND OCEANOGRAPHY			English	Article							SEDIMENT SAGAMI BAY; ORGANIC-MATTER; NITRATE UPTAKE; MINIMUM ZONE; DENITRIFICATION; CARBON; JAPAN; PHYTODETRITUS; FRACTIONATION; PARTICULATE	We evaluated nitrate utilization by benthic foraminifera at the redox boundary around the sediment-water interface by examining the stable nitrogen isotopic composition (N-15, parts per thousand vs. AIR) of amino acids. Five foraminiferal species collected from bathyal Sagami Bay (water depth, 1430m) in three different sampling seasons were analyzed by determining the N-15 values of amino acids from whole cells and those in test (shell) proteins remaining after H2O2 treatment. The N-15 values of phenylalanine fell within a narrow range (typically 1-3 parts per thousand) in the test proteins of all five species, but the whole-cell N-15 values of phenylalanine were substantially different from those of the test proteins in two species, Globobulimina affinis (by 6.3 parts per thousand) and Uvigerina akitaensis (by 4.5 parts per thousand). These differences in the N-15 values of amino acids suggest that these species utilize nitrate in their cells probably for nitrate respiration (i.e., denitrification) to adapt to oxygen-depleted environments, as was previously observed in the shallow water benthic foraminifera Ammonia sp. Apparent trophic positions determined using the N-15 values of amino acids also differed between whole cells and tests in G. affinis, U. akitaensis, and Ammonia sp., perhaps because they have different microbial associations, as observed by cellular ultrastructural analysis. These differences in nitrate utilization and microbial associations among benthic foraminifera suggest that foraminifera adapt in diverse ways to conditions in dysoxic to anoxic sediments.	[Nomaki, Hidetaka; Chikaraishi, Yoshito; Suga, Hisami; Sasaki, Yoko; Ohkouchi, Naohiko] Japan Agcy Marine Earth Sci & Technol, Dept Biogeochem, Yokosuka, Kanagawa 2370061, Japan; [Tsuchiya, Masashi; Toyofuku, Takashi] Japan Agcy Marine Earth Sci & Technol, Dept Marine Biodivers Res, Yokosuka, Kanagawa 2370061, Japan; [Uematsu, Katsuyuki; Tame, Akihiro] Marine Works Japan, Dept Marine & Earth Sci, Yokosuka, Kanagawa, Japan	Nomaki, H (reprint author), Japan Agcy Marine Earth Sci & Technol, Dept Biogeochem, 2-15 Natsushimacho, Yokosuka, Kanagawa 2370061, Japan.	nomakih@jamstec.go.jp			Ministry of Education, Culture, Sports, Science and Technology, Japan [20740302, 22740340]	We are grateful to the crews and scientists of the R/V Tanseimaru during cruises KT04-04, KT04-26, KT05-18, KT06-13, KT08-06, and to those of R/V Shinseimaru cruise KS13-T2, for their collaboration. We thank Sachie Sugime for her help during foraminiferal isolation. We also thank the editors and two anonymous reviewers for their constructive comments on this manuscript. This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan (Young Scientists B No. 20740302 and 22740340).	McClelland JW, 2002, ECOLOGY, V83, P2173, DOI 10.1890/0012-9658(2002)083[2173:TRATNI]2.0.CO;2; Doane TA, 2003, ANAL LETT, V36, P2713, DOI 10.1081/AL-120024647; Maeda T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042024; Nomaki H, 2009, DEEP-SEA RES PT I, V56, P1488, DOI 10.1016/j.dsr.2009.04.013; Bernhard JM, 2012, J GEOPHYS RES-BIOGEO, V117, DOI 10.1029/2012JG001949; Moodley L, 2002, MAR ECOL PROG SER, V236, P23, DOI 10.3354/meps236023; Ohga T, 1997, TERRA NOVA, V9, P33, DOI 10.1046/j.1365-3121.1997.d01-6.x; McCarthy MD, 2007, GEOCHIM COSMOCHIM AC, V71, P4727, DOI 10.1016/j.gca.2007.06.061; Hogslund S, 2008, J EXP MAR BIOL ECOL, V359, P85, DOI 10.1016/j.jembe.2008.02.015; Glud RN, 2009, LIMNOL OCEANOGR, V54, P723, DOI 10.4319/lo.2009.54.3.0723; Gooday AJ, 2000, DEEP-SEA RES PT II, V47, P25, DOI 10.1016/S0967-0645(99)00099-5; Braeckman U, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059289; Koho KA, 2011, FEMS MICROBIOL ECOL, V75, P273, DOI 10.1111/j.1574-6941.2010.01010.x; Bernhard JM, 2001, DEEP-SEA RES PT I, V48, P2233, DOI 10.1016/S0967-0637(01)00017-6; Nomaki H, 2005, LIMNOL OCEANOGR, V50, P134; Popp BN, 2007, TERR ECOL SER, V1, P173; Nomaki H, 2014, LIMNOL OCEANOGR, V59, P1879, DOI 10.4319/lo.2014.59.6.1879; Stramma L, 2010, DEEP-SEA RES PT I, V57, P587, DOI 10.1016/j.dsr.2010.01.005; Bernhard JM, 2003, SCIENCE, V299, P861, DOI 10.1126/science.1077314; Toyofuku T, 2000, PALEOCEANOGRAPHY, V15, P456, DOI 10.1029/1999PA000460; Woulds C, 2007, LIMNOL OCEANOGR, V52, P1698, DOI 10.4319/lo.2007.52.4.1698; Bernhard JM, 2000, NATURE, V403, P77, DOI 10.1038/47476; Nomaki H, 2011, MAR ECOL PROG SER, V431, P11, DOI 10.3354/meps09144; Pina-Ochoa E, 2010, P NATL ACAD SCI USA, V107, P1148, DOI 10.1073/pnas.0908440107; Bernhard JM, 2008, J EUKARYOT MICROBIOL, V55, P135, DOI 10.1111/j.1550-7408.2008.00318.x; Chikaraishi Y, 2014, ECOL EVOL, V4, P2423, DOI 10.1002/ece3.1103; Shaffer G, 2009, NAT GEOSCI, V2, P105, DOI 10.1038/NGEO420; Glud RN, 2009, LIMNOL OCEANOGR, V54, P1, DOI 10.4319/lo.2009.54.1.0001; Bernhard JM, 2010, ENVIRON MICROBIOL, V12, P2107, DOI 10.1111/j.1462-2920.2009.02073.x; Nomaki H, 2008, MAR ECOL PROG SER, V357, P153, DOI 10.3354/meps07309; Jeffreys RM, 2015, BIOGEOSCIENCES, V12, P1781, DOI 10.5194/bg-12-1781-2015; Chikaraishi Y, 2010, EARTH LIFE ISOTOPES, P367; Chikaraishi Y, 2009, LIMNOL OCEANOGR-METH, V7, P740; Downs EE, 2014, MAR ECOL PROG SER, V516, P239, DOI 10.3354/meps11030; Koho KA, 2012, CELL ORIG LIFE EXTRE, V21, P251; Risgaard-Petersen N, 2006, NATURE, V443, P93, DOI 10.1038/nature05070; Steffan SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076152	37	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0024-3590	1939-5590		LIMNOL OCEANOGR	Limnol. Oceanogr.	NOV	2015	60	6					1906	1916		10.1002/lno.10140		11	Limnology; Oceanography	Marine & Freshwater Biology; Oceanography	CU9TO	WOS:000363888400004		
J	Gao, L; Li, DJ; Ishizaka, J; Zhang, YW; Zong, HB; Guo, LD				Gao, Lei; Li, Daoji; Ishizaka, Joji; Zhang, Yanwei; Zong, Haibo; Guo, Laodong			Nutrient dynamics across the river-sea interface in the Changjiang (Yangtze River) estuaryEast China Sea region	LIMNOLOGY AND OCEANOGRAPHY			English	Article							DILUTED WATER; YELLOW; CARBON; DISCHARGE; SEDIMENT; BEHAVIOR; BUDGETS; STRAIT; MATTER; PLUME	A total of 13 cruises were performed in different seasons between July 2010 and July 2012, and in various subsystems of the Changjiang (Yangtze River) Estuary and the adjacent East China Sea (ECS). Multiple vessels were deployed to conduct transect sampling, simultaneous and consecutive sampling, sampling with buoys, and sampling during phytoplankton bloom events, which allowed us to track detached patches of water masses and to collect discrete and time-series samples in different patches. We found that the river-derived nutrients from the Changjiang could be transported through the western ECS and reach as far as the northeastern ECS during summer, but in the form of isolated patches rather than continuous plumes. The concentrations of NO3-,SiO32-,andPO43- decreased with increasing seaward distance of these patches, showing largely nonconservative mixing behavior and the ECS being a sink for nutrients. During winter, conversely, all nutrient species showed mostly conservative behavior, with correlative coefficients (R-2) even reaching>0.97 in the salinity-nutrient correlations for both NO3- and SiO32- during the western ECS cruise in February 2012 and during the Changjiang mouth cruise in March 2012. In addition, a large variability in nutrient concentrations was observed within the Changjiang freshwaters and could be partly attributed to inputs from local tributaries. This study highlights the importance of simultaneous field sampling with multiple vessels for investigating the biogeochemical behavior of nutrients in highly dynamic ocean margin areas such as the Changjiang Estuary-ECS region.	[Gao, Lei; Li, Daoji; Zong, Haibo] E China Normal Univ, State Key Lab Estuarine & Coastal Res, Shanghai 200062, Peoples R China; [Ishizaka, Joji] Nagoya Univ, Hydrospher Atmospher Res Ctr, Nagoya, Aichi 4648601, Japan; [Zhang, Yanwei] Tongji Univ, State Key Lab Marine Geol, Shanghai 200092, Peoples R China; [Guo, Laodong] Univ Wisconsin, Sch Freshwater Sci, Milwaukee, WI 53201 USA	Gao, L (reprint author), E China Normal Univ, State Key Lab Estuarine & Coastal Res, Shanghai 200062, Peoples R China.	lgao@sklec.ecnu.edu.cn			Ministry of Science and Technology of China [2010CB951203]; National Natural Science Foundation of China [41106098]; State Key Laboratory of Estuarine and Coastal Research in East China Normal University [2009KYYW03, 2010RCDW14]	The authors would like to thank the captains and crews of T/V Nagasaki-maru, Zhepuyuyun 8381, Zhepuyu 42134, Haijian 47, Haijian 49 for their assistance during sampling. The authors also thank Jianrong Zhu, Guosen Zhang, Teng Wang, Weiqing Chen, Xu Han, Guangpeng Liu, and Qiang Fu for their technical assistance during both field and laboratory studies, and the Associate Editor, James Leichter, and two anonymous reviewers for their constructive comments, which improved the presentation of this work. This study was funded in part by Ministry of Science and Technology of China (2010CB951203), the National Natural Science Foundation of China (41106098), and the State Key Laboratory of Estuarine and Coastal Research in East China Normal University (2009KYYW03 and 2010RCDW14). The two cruises in the northeastern East China Sea were a part of activity of EAST-II (East Asian Sea Time Series-II) by CREAMS-AP (Circulation Research on East Asian Marginal Sea - Advisory Panel) of PICES (North Pacific Marine Science Organization).	Dore JE, 1996, MAR CHEM, V53, P173, DOI 10.1016/0304-4203(96)00004-7; Gao L, 2009, J MARINE SYST, V75, P265, DOI 10.1016/j.jmarsys.2008.10.006; Isobe A, 2002, J GEOPHYS RES-OCEANS, V107, DOI 10.1029/2000JC000702; Moon JH, 2010, J PHYS OCEANOGR, V40, P1035, DOI 10.1175/2010JPO4167.1; Zhu JR, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL019997; Chen CTA, 2000, GEOPHYS RES LETT, V27, P381, DOI 10.1029/1999GL002373; Gao L, 2011, J GEOPHYS RES-BIOGEO, V116, DOI 10.1029/2010JG001627; Moon JH, 2009, CONT SHELF RES, V29, P1549, DOI 10.1016/j.csr.2009.04.007; Shiozaki T, 2011, J GEOPHYS RES-OCEANS, V116, DOI 10.1029/2010JC006934; EDMOND JM, 1985, CONT SHELF RES, V4, P17, DOI 10.1016/0278-4343(85)90019-6; Lee SH, 1999, J GEOPHYS RES-OCEANS, V104, P15679, DOI 10.1029/1999JC900108; Chen CS, 2008, J GEOPHYS RES-OCEANS, V113, DOI 10.1029/2006JC003994; Chen CTA, 2006, J GEOPHYS RES-OCEANS, V111, DOI 10.1029/2005JC003281; Gong GC, 1996, CONT SHELF RES, V16, P1561, DOI 10.1016/0278-4343(96)00005-2; Liu XJ, 2009, ESTUAR COAST SHELF S, V85, P641, DOI 10.1016/j.ecss.2009.09.017; Chang PH, 2014, CONT SHELF RES, V81, P7, DOI 10.1016/j.csr.2014.03.007; WANG WS, 1988, PROG OCEANOGR, V21, P373; Senjyu T, 2006, J OCEANOGR, V62, P681, DOI 10.1007/s10872-006-0086-y; Yang HJ, 2007, J ENVIRON SCI-CHINA, V19, P1193, DOI 10.1016/S1001-0742(07)60195-8; Chang PH, 2003, J GEOPHYS RES-OCEANS, V108, P1, DOI 10.1029/2002JC001749; Ichikawa H, 2002, J OCEANOGR, V58, P77, DOI 10.1023/A:1015876701363; Gao L, 2014, J GEOPHYS RES-BIOGEO, V119, P1717, DOI 10.1002/2013JG002487; Gao L, 2012, J GEOPHYS RES-BIOGEO, V117, DOI 10.1029/2012JG001952; Zhang JZ, 1998, WATER RES, V32, P2553, DOI 10.1016/S0043-1354(98)00005-0; Gao L, 2008, ESTUAR COAST SHELF S, V77, P331, DOI 10.1016/j.ecss.2007.09.018; Yuan DL, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL023815; Gao L, 2008, CONT SHELF RES, V28, P2393, DOI 10.1016/j.csr.2008.05.004; Giraud X, 2008, GLOBAL BIOGEOCHEM CY, V22, DOI 10.1029/2006GB002717; Shan F, 2009, ACTA OCEANOL SIN, V28, P11; Shi Z, 2004, J HYDROL, V293, P180, DOI 10.1016/j.jhydrol.2004.01.014; Lie HJ, 2003, J GEOPHYS RES-OCEANS, V108, DOI 10.1029/2001JC001194; Chen CTA, 1999, J GEOPHYS RES-OCEANS, V104, P20675, DOI 10.1029/1999JC900055; MILLIMAN JD, 1992, J GEOL, V100, P525; Dittmar T, 2006, GLOBAL BIOGEOCHEM CY, V20, DOI 10.1029/2005GB002570; Lu X., 2006, J GEOPHYS RES, V111, DOI [10.1029/2005JC003250, DOI 10.1029/2005JC003250]; Shen H. T., 2003, SALTWATER INTRUSION; Zhang J, 1996, CONT SHELF RES, V16, P1023, DOI 10.1016/0278-4343(95)00055-0	37	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0024-3590	1939-5590		LIMNOL OCEANOGR	Limnol. Oceanogr.	NOV	2015	60	6					2207	2221		10.1002/lno.10196		15	Limnology; Oceanography	Marine & Freshwater Biology; Oceanography	CU9TO	WOS:000363888400026		
J	Natsume, T; Ishida, M; Kitagawa, K; Nagata, M; Sakuma, H; Ichihara, T				Natsume, Takahiro; Ishida, Masaki; Kitagawa, Kakuya; Nagata, Motonori; Sakuma, Hajime; Ichihara, Takashi			Theoretical considerations in measurement of time discrepancies between input and myocardial time-signal intensity curves in estimates of regional myocardial perfusion with first-pass contrast-enhanced MRI	MAGNETIC RESONANCE IMAGING			English	Article						Myocardial perfusion MRI; Myocardial blood flow; Patlak plot; Time delay; Upslope; Two-compartment model	POSITRON-EMISSION-TOMOGRAPHY; CARDIOVASCULAR MAGNETIC-RESONANCE; BLOOD-FLOW; INJECTION TECHNIQUE; QUANTIFICATION; RESERVE; MODEL; BOLUS; DECONVOLUTION	The purpose of this study was to develop a method to determine time discrepancies between input and myocardial time signal intensity (TSI) curves for accurate estimation of myocardial perfusion with first-pass contrast-enhanced MRI. Estimation of myocardial perfusion with contrast-enhanced MRI using kinetic models requires faithful recording of contrast content in the blood and myocardium. Typically, the arterial input function (AIF) is obtained by setting a region of interest in the left ventricular cavity. However, there is a small delay between the AIF and the myocardial curves, and such time discrepancies can lead to errors in flow estimation using Patlak plot analysis. In this study, the time discrepancies between the arterial TSI curve and the myocardial tissue TSI curve were estimated based on the compartment model. In the early phase after the arrival of the contrast agent in the myocardium, the relationship between rate constant K-1 and the concentrations of Gd-DTPA contrast agent in the myocardium and arterial blood (LV blood) can be described by the equation K-1 = {dC(myo)(t(peak))/dt}/C-a(t(peak)), where C-myo(t) and C-a(t) are the relative concentrations of Gd-DTPA contrast agent in the myocardium and in the LV blood, respectively, and t(peak) is the time corresponding to the peak of Ca(t). In the ideal case, the time corresponding to the maximum upslope of C-myo(t), t(max), is equal to t(peak). In practice, however, there is a small difference in the arrival times of the contrast agent into the LV and into the myocardium. This difference was estimated to correspond to the difference between t(peak) and t(max). The magnitudes of such time discrepancies and the effectiveness of the correction for these time discrepancies were measured in 18 subjects who underwent myocardial perfusion MRI under rest and stress conditions. The effects of the time discrepancies could be corrected effectively in the myocardial perfusion estimates. (C) 2015 Elsevier Inc. All rights reserved.	[Natsume, Takahiro; Ichihara, Takashi] Fujita Hlth Univ, Fac Radiol Technol, Sch Hlth Sci, Toyoake, Aichi 471192, Japan; [Ishida, Masaki; Kitagawa, Kakuya; Nagata, Motonori; Sakuma, Hajime] Mie Univ, Sch Med, Dept Radiol, Tsu, Mie 514, Japan	Ichihara, T (reprint author), Fujita Hlth Univ, Fac Radiol Technol, Sch Hlth Sci, 1-98 Dengakugakubo Kutsukake Cho, Toyoake, Aichi 471192, Japan.	ichihara@fujita-hu.ac.jp		Natsume, Takahiro/0000-0002-6744-4701			Christian TF, 2004, RADIOLOGY, V232, P677, DOI 10.1148/radiol.2323030573; Fritz-Hansen T, 2008, J MAGN RESON IMAGING, V27, P818, DOI 10.1002/jmri.21306; PATLAK CS, 1983, J CEREBR BLOOD F MET, V3, P1; Vallee JP, 1999, JMRI-J MAGN RESON IM, V9, P197, DOI 10.1002/(SICI)1522-2586(199902)9:2<197::AID-JMRI7>3.0.CO;2-X; Christian TF, 2008, J MAGN RESON IMAGING, V27, P1271, DOI 10.1002/jmri.21383; Kurita T, 2009, EUR HEART J, V30, P444, DOI 10.1093/eurheartj/ehn521; Jerosch-Herold M, 1998, MED PHYS, V25, P73, DOI 10.1118/1.598163; Ichihara T, 2011, IEEE T NUCL SCI, V58, P133, DOI 10.1109/TNS.2010.2084104; Ritter C, 2006, MAGN RESON MED, V56, P844, DOI 10.1002/mrm.21020; Ichihara T, 2009, MAGN RESON MED, V62, P373, DOI 10.1002/mrm.22018; Ichihara T, 2010, IEEE NUCL SCI CONF R, P2573, DOI 10.1109/NSSMIC.2010.5874252; Ichihara T, 2010, IEEE NUCL SCI CONF R, P2330, DOI 10.1109/NSSMIC.2010.5874200; KETY SS, 1951, PHARMACOL REV, V3, P1; Jerosch-Herold M, 2002, MED PHYS, V29, P886, DOI 10.1118/1.1473135; Al-Saadi N, 2000, J AM COLL CARDIOL, V36, P1557, DOI 10.1016/S0735-1097(00)00914-1; Ibrahim T, 2002, J AM COLL CARDIOL, V39, P864, DOI 10.1016/S0735-1097(01)01829-0; Ishida M, 2011, MAGN RESON MED, V66, P1391, DOI 10.1002/mrm.22936; Al-Saadi N, 2000, CIRCULATION, V101, P1379; Schwitter J, 2001, CIRCULATION, V103, P2230; Panting JR, 2002, NEW ENGL J MED, V346, P1948, DOI 10.1056/NEJMoa012369; Pruessmann KP, 1999, MAGNET RESON MED, V42, P952, DOI 10.1002/(SICI)1522-2594(199911)42:5<952::AID-MRM16>3.0.CO;2-S; RUTLAND MD, 1979, BRIT J RADIOL, V52, P134; Sipola P, 2003, RADIOLOGY, V226, P129, DOI 10.1148/radiol.2261011874	23	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0730-725X	1873-5894		MAGN RESON IMAGING	Magn. Reson. Imaging	NOV	2015	33	9					1059	1065		10.1016/j.mri.2015.06.015		7	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CU8YY	WOS:000363831200006		
J	Iwadate, Y; Miyoshi, K; Kabasawa, H				Iwadate, Yuji; Miyoshi, Kunihiro; Kabasawa, Hiroyuki			Motion detection improvement of a pencil-beam navigator echo using a gradient reversal technique	MAGNETIC RESONANCE IMAGING			English	Article						Magnetic resonance imaging; Pencil beam excitation; Navigator; Gradient reversal; Motion correction	PULSES; EXCITATION; SEQUENCE	Purpose: To develop and demonstrate the feasibility of a pencil-beam navigator using a gradient reversal technique for reducing signal contamination from undesired excitation for precise motion detection and correction. Materials and methods: The navigator echo was obtained using normal and reversed gradient waveforms sequentially in three-dimensional spoiled gradient-recalled echo imaging. These two signals were combined in the complex domain for generating the final navigator data, which were used for detecting the diaphragm motion to nullify the side lobe effects with the smallest radius from the beam center. The navigator signals were compared with and without the proposed technique in phantom and human scans. In addition, navigator-gated imaging was performed in the human scans. Results: In a phantom experiment, the proposed technique diminished signals from a phantom placed outside the beam's area. In human scans, the proposed technique reduced undesired signals in the navigator data for all subjects. The resultant images had fewer motion-induced ghosts than the images from the conventional technique for 8 subjects out of 10. Conclusions: We have demonstrated that the gradient reversal technique reduced undesired signals in a pencil-beam navigator. This technique can be an alternative for free-breathing abdominal scan when the conventional navigator technique cannot detect the patient's respiratory motion precisely. (C) 2015 Elsevier Inc. All rights reserved.	[Iwadate, Yuji; Kabasawa, Hiroyuki] GE Healthcare Japan, Global MR Applicat & Workflow, Hino, Tokyo 1930825, Japan; [Miyoshi, Kunihiro] GE Healthcare Japan, MR Engn, Hino, Tokyo 1930825, Japan	Iwadate, Y (reprint author), GE Healthcare Japan, Global MR Applicat & Workflow, 4-7-127 Asahigaoka, Hino, Tokyo 1930825, Japan.	yuji.iwadate@ge.com		Iwadate, Yuji/0000-0002-7848-8654			Wang Y, 1996, RADIOLOGY, V198, P55; Bornert P, 1998, MAGN RESON MATER PHY, V7, P166; Nehrke K, 1999, MAGN RESON IMAGING, V17, P1173, DOI 10.1016/S0730-725X(99)00043-0; Siegelman ES, 1996, RADIOLOGY, V199, P13; Wang Y, 1996, MAGNET RESON MED, V36, P117, DOI 10.1002/mrm.1910360120; Simmons A, 1999, MAGNET RESON MED, V41, P1274, DOI 10.1002/(SICI)1522-2594(199906)41:6<1274::AID-MRM27>3.0.CO;2-1; HARDY CJ, 1989, J APPL PHYS, V66, P1513, DOI 10.1063/1.344411; Young PM, 2010, AM J ROENTGENOL, V195, P687, DOI 10.2214/AJR.09.3892; Iwadate Y, 2014, MAGN RESON MED, V72, P172, DOI 10.1002/mrm.24902; PAULY J, 1989, J MAGN RESON, V81, P43, DOI 10.1016/0022-2364(89)90265-5; Vasanawala SS, 2010, PEDIATR RADIOL, V40, P340, DOI 10.1007/s00247-009-1502-4; Alley MT, 1997, MAGNET RESON MED, V37, P260, DOI 10.1002/mrm.1910370220; Katscher U, 2003, MAGNET RESON MED, V49, P144, DOI 10.1002/mrm.10353; Alexander AL, 1997, MAGNET RESON MED, V38, P1016, DOI 10.1002/mrm.1910380623	14	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0730-725X	1873-5894		MAGN RESON IMAGING	Magn. Reson. Imaging	NOV	2015	33	9					1168	1172		10.1016/j.mri.2015.06.020		5	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CU8YY	WOS:000363831200018		
J	Stevens, K; Iba, Y; Suzuki, A; Mutterlose, J				Stevens, Kevin; Iba, Yasuhiro; Suzuki, Akihiko; Mutterlose, Joerg			Biological and environmental signals recorded in shells of Argonauta argo (Cephalopoda, Octobrachia) from the Sea of Japan	MARINE BIOLOGY			English	Article							SCALLOP PECTEN-MAXIMUS; STABLE-ISOTOPE; LIFE-HISTORY; SPIRULA-SPIRULA; CORAL SKELETONS; GROWTH-RATE; CALCITE; RATIOS; MG/CA; FRACTIONATION	The argonauts (genus Argonauta) are enigmatic cephalopods. They have a cosmopolitan distribution in subtropical and tropical seas, where they inhabit the epipelagic zone. Their biology, ecology, and life cycle are poorly understood. It is for the first time that stable isotope (delta C-13, delta O-18) and element ratios (Mg/Ca, Sr/Ca, Ba/Ca) from three argonaut shells have been analyzed in order to test whether their life cycle and habitat are reflected in these data. The three studied shells have been collected in October 2012 from a mass stranding in Yoichi Bay, Hokkaido, Japan. The specimens were sampled along the keel of the shells to acquire ontogenetic records and along growth-sections of the shells to obtain synchronous data of differing shell growth rates. Carbon and oxygen isotope values as well as Mg/Ca ratios are in part controlled by the shell growth rate. Sr/Ca values show similar ontogenetic trends in the three shells. Comparison with measured sea surface temperature data indicates a temperature control on delta O-18, Mg/Ca, and Sr/Ca, and a fast growth of the argonaut shell. Ba/Ca ratios of the shells might record environmental parameters. These new data highlight the influence of vital effects, but they also demonstrate that argonaut shell isotopic and elemental records can be used to understand the life cycle of these animals better.	[Stevens, Kevin; Mutterlose, Joerg] Ruhr Univ Bochum, Inst Geol Mineral & Geophys, D-44801 Bochum, Germany; [Iba, Yasuhiro] Hokkaido Univ, Dept Earth & Planetary Sci, Sapporo, Hokkaido 0600810, Japan; [Suzuki, Akihiko] Hokkaido Univ, Dept Earth Sci, Kita Ku, Sapporo, Hokkaido 0028502, Japan	Stevens, K (reprint author), Ruhr Univ Bochum, Inst Geol Mineral & Geophys, Univ Str 150, D-44801 Bochum, Germany.	kevin.stevens@rub.de			DFG [Mu667/43-1]; JSPS [25800285]	This research is part of the DFG collaborative research group CHARON. We are grateful for funding provided by DFG Grant Mu667/43-1 to J. Mutterlose and JSPS Grant 25800285 to Y. Iba. We thank the staff of the laboratory of the GeoZentrum Nordbayern for performing the stable isotope analysis and the staff of the laboratory of the Ruhr-Universitat Bochum for performing the ICP-OES analysis. Y. Nishida from the Central Fisheries Research Institute, Hokkaido Research Institution is thanked for supplying the SST data for Yoichi Bay, Hokkaido; K. Moriwaki from the Shimane Prefectural Fisheries Technology Center is acknowledged for the Hamada, Shimane SST data. We are thankful to the members of the CHARON research group for comments and discussions and to R. Hoffmann for discussions and supplying literature. C. Moller is thanked for proofreading an earlier draft of the manuscript. We thank the associate editor A.G. Checa as well as K. De Baets and an anonymous reviewer for helpful comments on the manuscript.	Anderson T. F., 1983, SOC ECON PALEONT MIN, V10, P1; CHIVAS AR, 1986, PALAEOGEOGR PALAEOCL, V54, P43, DOI 10.1016/0031-0182(86)90117-3; Kim ST, 2007, CHEM GEOL, V246, P135, DOI 10.1016/j.chemgeo.2007.08.005; Hewitt RA, 2003, J PALEONTOL, V77, P792, DOI 10.1666/0022-3360(2003)077<0792:ROHAAA>2.0.CO;2; [Anonymous], 2001, PALAEONTOL ELECTRON, DOI DOI 10.1016/J.BCP.2008.05.025; Finn JK, 2013, MOLLUSCAN RES, V33, P143, DOI 10.1080/13235818.2013.824854; LAND LS, 1975, MAR BIOL, V33, P221, DOI 10.1007/BF00390926; Schone BR, 2008, GEO-MAR LETT, V28, P269, DOI 10.1007/s00367-008-0114-6; ODOR RK, 1986, CAN J ZOOL, V64, P1591, DOI 10.1139/z86-241; Marali S, 2013, PALAEOGEOGR PALAEOCL, V373, P25, DOI 10.1016/j.palaeo.2012.06.017; Robinson LF, 2014, DEEP-SEA RES PT II, V99, P184, DOI 10.1016/j.dsr2.2013.06.005; Immenhauser A, 2005, PALAEOGEOGR PALAEOCL, V215, P221, DOI 10.1016/j.palaeo.2004.09.005; Staudinger MD, 2013, DEEP-SEA RES PT II, V95, P182, DOI 10.1016/j.dsr2.2012.06.004; SWART PK, 1983, EARTH-SCI REV, V19, P51, DOI 10.1016/0012-8252(83)90076-4; McConnaughey TA, 2008, GEO-MAR LETT, V28, P287, DOI 10.1007/s00367-008-0116-4; UREY HC, 1951, GEOL SOC AM BULL, V62, P399, DOI 10.1130/0016-7606(1951)62[399:MOPATO]2.0.CO;2; Adkins JF, 2003, GEOCHIM COSMOCHIM AC, V67, P1129, DOI 10.1016/s0016-7037(00)01203-6; Chauvaud L, 2005, GEOCHEM GEOPHY GEOSY, V6, DOI 10.1029/2004GC000890; Lukeneder A, 2008, MAR BIOL, V154, P175, DOI 10.1007/s00227-008-0911-5; Dance MA, 2014, MAR BIOL, V161, P489, DOI 10.1007/s00227-013-2346-x; NESIS K N, 1977, Zoologicheskii Zhurnal, V56, P1004; Tang JW, 2008, GEOCHIM COSMOCHIM AC, V72, P3718, DOI 10.1016/j.gca.2008.05.031; LANDMAN NH, 1994, PALEOBIOLOGY, V20, P40; Reznick D, 2002, ECOLOGY, V83, P1509, DOI 10.2307/3071970; Nurnberg D, 1996, GEOCHIM COSMOCHIM AC, V60, P803, DOI 10.1016/0016-7037(95)00446-7; Freitas PS, 2006, GEOCHIM COSMOCHIM AC, V70, P5119, DOI 10.1016/j.gca.2006.07.029; Kim KR, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2004GL021211; Stevens K, 2015, PALAEOGEOGR PALAEOCL, V417, P164, DOI 10.1016/j.palaeo.2014.10.031; MITCHELL PR, 1994, SCANNING MICROSCOPY, V8, P35; Goodwin DH, 2013, PALAEOGEOGR PALAEOCL, V373, P88, DOI 10.1016/j.palaeo.2012.03.034; Strugnell J, 2010, MOL PHYLOGENET EVOL, V54, P701, DOI 10.1016/j.ympev.2009.11.017; Wolfe K, 2012, BIOL BULL-US, V223, P236; Schone BR, 2013, PALAEOGEOGR PALAEOCL, V373, P50, DOI 10.1016/j.palaeo.2011.05.013; Auclair AC, 2004, CHEM GEOL, V207, P91, DOI 10.1016/j.chemgeo.2004.02.006; Kimball JB, 2014, CHEM GEOL, V381, P223, DOI 10.1016/j.chemgeo.2014.05.008; Hahn S, 2012, BIOGEOSCIENCES, V9, P1897, DOI 10.5194/bg-9-1897-2012; Klein RT, 1996, GEOLOGY, V24, P415, DOI 10.1130/0091-7613(1996)024<0415:BSRSST>2.3.CO;2; Rexfort A, 2009, PALAEOGEOGR PALAEOCL, V284, P153, DOI 10.1016/j.palaeo.2009.09.021; Price GD, 2009, PALAIOS, V24, P273, DOI 10.2110/palo.2008.p08-067r; Watkins JM, 2014, EARTH PLANET SC LETT, V404, P332, DOI 10.1016/j.epsl.2014.07.036; Wanamaker AD, 2007, PALEOCEANOGRAPHY, V22, DOI 10.1029/2006PA001352; Lorrain A, 2005, GEOLOGY, V33, P965, DOI 10.1130/G22048.1; Owen R, 2002, GEOCHIM COSMOCHIM AC, V66, P1727, DOI 10.1016/S0016-7037(01)00882-1; Rexfort A, 2006, EARTH PLANET SC LETT, V247, P212, DOI 10.1016/j.epsl.2006.04.025; Hoving HJT, 2015, CURR BIOL, V25, pR322, DOI 10.1016/j.cub.2015.02.018; Finn JK, 2010, P ROY SOC B-BIOL SCI, V277, P2967, DOI 10.1098/rspb.2010.0155; Vander Putten E, 2000, GEOCHIM COSMOCHIM AC, V64, P997; Lazareth CE, 2003, ESTUAR COAST SHELF S, V57, P1103, DOI 10.1016/S0272-7714(03)00013-1; Aubert H, 1862, Z WISS ZOOL ABT A, V12; Bandel K., 1984, Natur und Mensch (Nuremberg), V1984, P33; Horibe Y, 1968, J GEOPHYS RES, V74, P1239; Lecuyer C., 2006, eEarth, V1, P1; McConnaughey T., 1989, PATTERNS GEOCHIM COS, V53, P151; MCCONNAUGHEY T, 1989, GEOCHIM COSMOCHIM AC, V53, P163, DOI 10.1016/0016-7037(89)90283-4; Moriyasu S, 1972, KUROSHIO ITS PHYSICA, P353; Nishimura S., 1968, Publications of the Seto Marine Biological Laboratory, V16, P61; OKUTANI T, 1983, Venus the Japanese Journal of Malacology, V41, P281; Poulain C, 2015, CHEM GEOL, V396, P42, DOI 10.1016/j.chemgeo.2014.12.019; Power J, 1839, MAG NAT HIST, V3, P101; Roper C F E, 1984, FAO FISH SYNOP, V125, P277; Sukhsangchan Charuay, 2007, Kasetsart Journal Natural Sciences, V41, P531; Suzuki A, 2013, J JPN DRIFT SOC, V11, P1; Taft BA, 1972, KUROSHIO ITS PHYSICA, P165; Uye Shin-Ichi, 1996, Journal of Oceanography, V52, P689, DOI 10.1007/BF02239460; Uye Shin-ichi, 1997, Journal of Oceanography, V53, P529; Warnke Kerstin, 2010, Ferrantia, V59, P191; Wolfe K, 2013, MAR BIOL, V160, P2271, DOI 10.1007/s00227-012-2032-4	67	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0025-3162	1432-1793		MAR BIOL	Mar. Biol.	NOV	2015	162	11					2203	2215		10.1007/s00227-015-2750-5		13	Marine & Freshwater Biology	Marine & Freshwater Biology	CV0PH	WOS:000363952400004		
J	Kacinskaite, R; Matsumoto, K				Kacinskaite, Roma; Matsumoto, Kohji			The mixed joint universality for a class of zeta-functions	MATHEMATISCHE NACHRICHTEN			English	Article						Euler product; periodic Hurwitz zeta-function; limit theorem; universality	HURWITZ	A mixed joint limit theorem in the space of holomorphic functions, and a mixed joint universality theorem are proved for a rather general class of Euler products and periodic Hurwitz zeta-functions. (C) 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim	[Kacinskaite, Roma] Siauliai Univ, Inst Informat Math & E Studies, Dept Math, LT-77156 Shiauliai, Lithuania; [Matsumoto, Kohji] Nagoya Univ, Grad Sch Math, Chikusa Ku, Nagoya, Aichi 4648602, Japan	Matsumoto, K (reprint author), Nagoya Univ, Grad Sch Math, Chikusa Ku, Nagoya, Aichi 4648602, Japan.	r.kacinskaite@fm.su.lt; kohjimat@math.nagoya-u.ac.jp					Kacinskaite R, 2011, STUD SCI MATH HUNG, V48, P257, DOI 10.1556/SScMath.48.2011.2.1162; Laurincikas A, 1998, ACTA ARITH, V84, P1; Janulis K, 2012, MATH MODEL ANAL, V17, P673, DOI 10.3846/13926292.2012.735260; Mishou H, 2007, LITH MATH J, V47, P32, DOI 10.1007/s10986-007-0003-0; Laurincikas A, 1997, ACTA ARITH, V79, P31; Laurincikas A, 2000, NAGOYA MATH J, V157, P211; Laurincikas A, 2001, ACTA ARITH, V98, P345, DOI 10.4064/aa98-4-2; MATSUMOTO K, 1990, LECT NOTES MATH, V1434, P178; Billingsley P., 1968, CONVERGENCE PROBABIL; Janulis K., 2013, ANN U SCI BUDAPEST S, V39, P203; Javtokas A., 2006, HARDY RAMANUJAN J, V29, P18, DOI DOI 10.1007/S10625-005-0242-Y; Laurincikas A, 2012, ANALYTIC AND PROBABILISTIC METHODS IN NUMBER THEORY, P185; Laurincikas A., 2011, CHEBYSHEVSKII SB, V12, P192; Macaitiene R., 2012, FUNCTIONS NUMBER THE, VB34, P217; Matsumoto K., 2015, NUMBER THEORY ITS AP, V11, P95; Mergelyan S. N., 1952, USP MAT NAUK, V7, P31; Mergelyan S. N., 1951, DOKL AKAD NAUK SSSR, V78, P405; Poceviciene V, 2014, MATH MODEL ANAL, V19, P52, DOI 10.3846/13926292.2014.893261; Sander J., 2006, ANALYSIS MUNICH, V26, P295, DOI 10.1524/anly.2006.26.99.295; Steuding J, 2007, LECT NOTES MATH, P2007; Steuding J., 2003, BONNER MATH SCHRIFTE, V360; Voronin S. M., 1975, ACTA ARITH, V27, P493, DOI DOI 10.1007/S10625-005-0242-Y; Voronin S. M., 1975, MATH USSR IZV, V9, P443, DOI DOI 10.1007/S10625-005-0242-Y; Walsh J. L., 1960, AM MATH SOC C PUBL, V20	24	0	0	WILEY-V C H VERLAG GMBH	WEINHEIM	POSTFACH 101161, 69451 WEINHEIM, GERMANY	0025-584X	1522-2616		MATH NACHR	Math. Nachr.	NOV	2015	288	16					1900	1909		10.1002/mana.201400366		10	Mathematics	Mathematics	CU9UZ	WOS:000363892800007		
J	Dal Berto, M; Bica, CG; de Sa, GP; Barbisan, F; Azzolin, VF; Rogalski, F; Duarte, MMMF; Da Cruz, IBM				Dal Berto, Maiquidieli; Bica, Claudia Giuliano; de Sa, Gustavo Pereira; Barbisan, Fernanda; Azzolin, Veronica Farina; Rogalski, Felipe; Medeiros Frescura Duarte, Marta Maria; Manica da Cruz, Ivana Beatrice			The effect of superoxide anion and hydrogen peroxide imbalance on prostate cancer: an integrative in vivo and in vitro analysis	MEDICAL ONCOLOGY			English	Article						DU-145; Genotypes; Paraquat; Porphyrin; Prostate cancer; Superoxide manganese dependent	MNSOD GENE POLYMORPHISM; DISMUTASE GENE; CELL LINES; ASSOCIATION; RISK; OVEREXPRESSION; DIMORPHISM; TOXICITY; SURVIVAL; THERAPY	The epidemiological impact of SOD2 imbalance on prostate cancer (PC) risk associated with genetic variations has previously been studied. However, we found no previous studies clarifying the nature of SOD2 effects on prostate cancer. Here, we performed integrated in vivo and in vitro protocols that analyzed the association between Ala16Val-SOD2 polymorphism and prostate cancer aggressiveness at the time of diagnosis and evaluated the effect of the imbalance on PC proliferation using the DU-145 PC cell line treated with paraquat and porphyrin. In the pharmacological model, paraquat was used to increase superoxide anion levels and porphyrin was the SOD2 analog. The results confirmed the impact of superoxide-hydrogen peroxide imbalance on PC cell biology since porphyrin decreased cell proliferation and both treatments modulated antioxidant genes. Therefore, our results corroborate previous suggestions that alteration of redox status could be exploited therapeutically in the treatment of PC.	[Dal Berto, Maiquidieli; Bica, Claudia Giuliano] Fed Univ Hlth Sci, Dept Basic Hlth Sci, BR-90050170 Porto Alegre, RS, Brazil; [de Sa, Gustavo Pereira; Barbisan, Fernanda; Azzolin, Veronica Farina; Medeiros Frescura Duarte, Marta Maria; Manica da Cruz, Ivana Beatrice] Univ Fed Santa Maria, Dept Hlth Sci Ctr, BR-97105900 Santa Maria, RS, Brazil; [Rogalski, Felipe] Tokyo Metropolitan Univ, Dept Biol Sci, Cellular Genet Lab, Tokyo 1920397, Japan	Bica, CG (reprint author), Fed Univ Hlth Sci, Dept Basic Hlth Sci, Rua Sarmento Leite 245, BR-90050170 Porto Alegre, RS, Brazil.	claudia@ufcspa.edu.br			CNPq; CAPES	The authors are grateful for the help of the Laboratory of Biogenomica-Federal University of Santa Maria, RS, Brazil. This study was funded by the following research grants and fellowships: CNPq and CAPES.	Ergen HA, 2007, ANTICANCER RES, V27, P1227; Bica C, 2009, PATHOL ONCOL RES, V15, P19, DOI 10.1007/s12253-008-9064-6; Mikhak B, 2008, CARCINOGENESIS, V29, P2335, DOI 10.1093/carcin/bgn212; Costa F, 2012, REPROD BIOMED ONLINE, V24, P474, DOI 10.1016/j.rbmo.2012.01.009; Oskina NA, 2014, PATHOL ONCOL RES, V20, P635, DOI 10.1007/s12253-014-9742-5; Choi WS, 2012, CELL IMMUNOL, V280, P164, DOI 10.1016/j.cellimm.2012.12.007; Margalit DN, 2015, CLIN GENITOURIN CANC, V13, P370, DOI 10.1016/j.clgc.2014.12.018; Oberley TD, 2000, PROSTATE, V44, P144, DOI 10.1002/1097-0045(20000701)44:2<144::AID-PROS7>3.0.CO;2-G; Miriyala S, 2012, BBA-MOL BASIS DIS, V1822, P794, DOI 10.1016/j.bbadis.2011.12.002; SPITZ DR, 1989, ANAL BIOCHEM, V179, P8, DOI 10.1016/0003-2697(89)90192-9; Bresciani G, 2013, FREE RADICAL RES, V47, P781, DOI 10.3109/10715762.2013.836275; Oberley LW, 2001, ANTIOXID REDOX SIGN, V3, P461, DOI 10.1089/15230860152409095; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; Chaiswing L, 2014, FREE RADICAL BIO MED, V67, P342, DOI 10.1016/j.freeradbiomed.2013.11.006; William-Faltaos S, 2006, ANTICANCER RES, V26, P2093; Pani G, 2004, CURR MED CHEM, V11, P1299; Chaiswing L, 2007, FREE RADICAL BIO MED, V43, P202, DOI 10.1016/j.freeradbiomed.2007.03.031; Sutton A, 2003, PHARMACOGENETICS, V13, P145, DOI 10.1097/01.fpc.0000054067.64000.8f; Oberley LW, 2005, BIOMED PHARMACOTHER, V59, P143, DOI 10.1016/j.biopha.2005.03.006; BUS JS, 1984, ENVIRON HEALTH PERSP, V55, P37, DOI 10.2307/3429690; Sun GG, 2013, ASIAN PAC J CANCER P, V14, P1937, DOI 10.7314/APJCP.2013.14.3.1937; Wang SM, 2009, EUR J CANCER, V45, P2874, DOI 10.1016/j.ejca.2009.04.024; Duan H, 2003, ANTIOXID REDOX SIGN, V5, P677, DOI 10.1089/152308603770310356; Mao C, 2010, J CANCER RES CLIN, V136, P975, DOI 10.1007/s00432-009-0742-x; Barbisan F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107299; Bresciani Guilherme, 2015, Adv Clin Chem, V68, P87, DOI 10.1016/bs.acc.2014.11.001; Cadona FC, 2014, ANAL METHODS-UK, V6, P8559, DOI 10.1039/c4ay01709a; Jentzsch AM, 1996, FREE RADICAL BIO MED, V20, P251, DOI 10.1016/0891-5849(95)02043-8; Liwei Liu, 2009, Urology, V74, P884, DOI 10.1016/j.urology.2008.11.016; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; ShimodaMatsubayashi S, 1996, BIOCHEM BIOPH RES CO, V226, P561, DOI 10.1006/bbrc.1996.1394; Sobin LH, 2002, TNM CLASSIFICATION M; Taufer M, 2005, J GERONTOL A-BIOL, V60, P145	33	0	0	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1357-0560	1559-131X		MED ONCOL	Med. Oncol.	NOV	2015	32	11							251	10.1007/s12032-015-0700-1		10	Oncology	Oncology	CU9FX	WOS:000363850900008		
J	Oh, CK; Lee, SW; Jeong, OC				Oh, Chang Kyu; Lee, Sang Wook; Jeong, Ok Chan			Fabrication of pneumatic valves with spherical dome-shape fluid chambers	MICROFLUIDICS AND NANOFLUIDICS			English	Article						Polydimethylsiloxane; Pneumatic valve; Spherical dome-shape fluidic chamber	LARGE-SCALE INTEGRATION; PIEZOELECTRIC MICROVALVE; MICROFLUIDIC DEVICES; SOFT LITHOGRAPHY; CELL SORTER; PUMPS; DELIVERY	This paper describes a simple fabrication method for pneumatic valves with spherical dome-shape fluidic chambers and channels. The proposed method is based on replicating a deformed polydimethylsiloxane (PDMS) diaphragm using a variable PDMS mold during the liquid PDMS curing process. A PDMS mold structure with a sealed cavity is prepared through a typical replica molding process and structural bonding with a glass substrate. The PDMS diaphragm inflates due to thermal expansion of air in the sealed cavity when it is placed on a hotplate during the thermal curing process, and this shape is transferred to liquid PDMS poured on the active PDMS structure. The proposed pneumatic valve can then be fabricated by bonding the valve chamber to the diaphragm. The effectiveness of the proposed valve was verified through optical observations of the valve pattern and measurements of the temporal response of the flow rate using pressurized liquid flow rectified by the fabricated valve. A finite element method was used to provide a structural analysis of the valve diaphragm to examine the characteristics of the rectified flow rate of the working fluid due to structural deformation of the valve diaphragm. The proposed fabricated valve effectively overcame the drawbacks of micro-fluid channels with rectangular cross sections and was also suitable for other micro-devices with spherical dome-shape cross sections.	[Oh, Chang Kyu; Jeong, Ok Chan] Inje Univ, Grad Sch Mech Engn, Gimhae, South Korea; [Lee, Sang Wook] Univ Tokyo, Dept Chem, Tokyo 113, Japan; [Jeong, Ok Chan] Inje Univ, Dept Biomed Engn, Gimhae, South Korea	Jeong, OC (reprint author), Inje Univ, Grad Sch Mech Engn, Gimhae, South Korea.	memsoku@inje.ac.kr			Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education [NRF-2013R1A1A2012537]	This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2013R1A1A2012537).	Fordyce PM, 2012, LAB CHIP, V12, P4287, DOI 10.1039/c2lc40414a; SATO K, 1994, J MICROMECH MICROENG, V4, P205, DOI 10.1088/0960-1317/4/4/005; Goll C, 1997, J MICROMECH MICROENG, V7, P224, DOI 10.1088/0960-1317/7/3/038; Cherng YS, 2014, J MICROMECH MICROENG, V24, DOI 10.1088/0960-1317/24/1/015016; Oh KW, 2005, J MICROMECH MICROENG, V15, P2449, DOI 10.1088/0960-1317/15/12/029; McDonald JC, 2002, ACCOUNTS CHEM RES, V35, P491, DOI 10.1021/ar010110q; Wang YC, 2004, ANAL CHEM, V76, P4426, DOI 10.1021/ac0497499; Park W, 2010, LAB CHIP, V10, P2814, DOI 10.1039/c005173j; Dy AJ, 2014, J MICROMECH MICROENG, V24, DOI 10.1088/0960-1317/24/5/057001; Lee S, 2013, BIOCHIP J, V7, P38, DOI 10.1007/s13206-013-7106-y; Huang SS, 2012, J MICROMECH MICROENG, V22, DOI 10.1088/0960-1317/22/8/085008; Bae B, 2002, J MICROELECTROMECH S, V11, P344, DOI 10.1109/JMEMS.2002.800921; Jeong OC, 2008, J MICROMECH MICROENG, V18, DOI 10.1088/0960-1317/18/2/025022; Goettsche T, 2005, SENSOR ACTUAT A-PHYS, V118, P70, DOI 10.1016/j.sna.2004.08.007; Studer V, 2004, J APPL PHYS, V95, P393, DOI 10.1063/1.1629781; Hosokawa K, 2000, J MICROMECH MICROENG, V10, P415, DOI 10.1088/0960-1317/10/3/317; Studer V, 2004, MICROELECTRON ENG, V73-4, P852, DOI 10.1016/j.mee.2004.03.064; Yang X, 2004, J MICROELECTROMECH S, V13, P660, DOI 10.1109/JMEMS.2004.832184; Unger MA, 2000, SCIENCE, V288, P113, DOI 10.1126/science.288.5463.113; Li HQ, 2004, SENSOR ACTUAT A-PHYS, V111, P51, DOI 10.1016/j.sna.2003.10.013; Kim TK, 2011, MICROELECTRON ENG, V88, P1982, DOI 10.1016/j.mee.2010.12.108; Liu J, 2002, ELECTROPHORESIS, V23, P1531, DOI 10.1002/1522-2683(200205)23:10<1531::AID-ELPS1531>3.0.CO;2-D; Whitesides GM, 2006, NATURE, V442, P368, DOI 10.1038/nature05058; Grover WH, 2003, SENSOR ACTUAT B-CHEM, V89, P315, DOI 10.1016/S0925-4005(02)00468-9; Fu AY, 2002, ANAL CHEM, V74, P2451, DOI 10.1021/ac0255330; Yang EH, 2004, J MICROELECTROMECH S, V13, P799, DOI 10.1107/JMEMS.2004.83567; Thorsen T, 2002, SCIENCE, V298, P580, DOI 10.1126/science.1076996; Sundararajan N, 2005, LAB CHIP, V5, P350, DOI 10.1039/b500792p; Jeong KH, 2004, OPT EXPRESS, V12, P2494, DOI 10.1364/OPEX.12.002494; Ho CM, 1998, SENSOR ACTUAT A-PHYS, V64, P8; Kim HT, 2011, JPN J APPL PHYS, V50, DOI 10.1143/JJAP.50.06GL04; Kim TK, 2011, JPN J APPL PHYS, V50, DOI 10.1143/JJAP.50.06GL05; Takao H, 2005, SENSOR ACTUAT A-PHYS, V119, P75; Wise KD, 2003, J MICROELECTROMECH S, V12, P8; Yanagisawa K, 1993, P TRANSDUCERS, V93, P102	35	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1613-4982	1613-4990		MICROFLUID NANOFLUID	Microfluid. Nanofluid.	NOV	2015	19	5			SI		1091	1099		10.1007/s10404-015-1627-8		9	Nanoscience & Nanotechnology; Instruments & Instrumentation; Physics, Fluids & Plasmas	Science & Technology - Other Topics; Instruments & Instrumentation; Physics	CV0YA	WOS:000363978600009		
J	Li, Z; Haward, SJ				Li, Zhuo; Haward, Simon J.			Viscoelastic flow development in planar microchannels	MICROFLUIDICS AND NANOFLUIDICS			English	Article						Microfluidics; Particle image velocimetry; Polymer solution; Entry length; Flow modification	VISCOSITY ELASTIC FLUIDS; DILUTE POLYMER-SOLUTIONS; PARTICLE IMAGE VELOCIMETRY; LOW-REYNOLDS-NUMBER; EXTENSIONAL FLOW; GRADUAL CONTRACTION; TRANSIENT-BEHAVIOR; MICRO-CONTRACTION; MOLECULAR-WEIGHT; ENTRANCE REGION	Microparticle image velocimetry is used to capture the flow development process for a Newtonian fluid (water) and a viscoelastic poly(ethylene oxide) (PEO) solution entering a microfabricated capillary entrance geometry. We show that the presence of polymers significantly modifies the developing flow field in the capillary region compared with the Newtonian solvent, resulting in a significantly increased entrance length (L (e)). For water over a range of Reynolds numbers 1.9 a parts per thousand currency sign Re a parts per thousand currency sign 37.5, we find fully developed parabolic velocity profiles are achieved within an entrance length given by L (e)/D (h) = 0.24 + 0.03Re, where D (h) is the hydraulic diameter of the capillary. However, the developing flow for PEO solution at modest Re a parts per thousand currency sign 11.5 strongly depends on the Weissenberg number (Wi), and the flow profile within the capillary region evolves from parabolic to flattened and finally concave with Wi increasing in the range 10.8 a parts per thousand currency sign Wi a parts per thousand currency sign 256.2. We observe a clear correlation between the evolution of flow profiles across the capillary and the development and growth of vortices in the region upstream of the capillary entrance. Measurements of the excess pressure drop across the contraction strongly suggest that an increase in the extensional viscosity in the central region of the channel is responsible for the generation of the complex flow kinematics. These quantitative results are expected to be useful in optimizing industrial processes and the design of "lab-on-a-chip" devices involving viscoelastic fluids and also have important implications for the applicability of microchannels in complex fluid rheometry.	[Li, Zhuo] Tongji Univ, State Key Lab Pollut Control & Resource Reuse, Shanghai 200092, Peoples R China; [Haward, Simon J.] Grad Univ, Okinawa Inst Sci & Technol, Okinawa 9040495, Japan	Haward, SJ (reprint author), Grad Univ, Okinawa Inst Sci & Technol, Okinawa 9040495, Japan.	zhuoli2013@tongji.edu.cn; simon.haward@oist.jp			National Natural Science Foundation of China [21307092]; Fundamental Research Funds for the Central Universities; Micro/Bio/Nanofluidics Unit of the Okinawa Institute of Science and Technology Graduate University (OIST)	ZL would like to acknowledge the financial supports of the National Natural Science Foundation of China (No. 21307092) and the Fundamental Research Funds for the Central Universities. SJH gratefully acknowledges the support of the Micro/Bio/Nanofluidics Unit of the Okinawa Institute of Science and Technology Graduate University (OIST).	Meinhart CD, 1999, EXP FLUIDS, V27, P414, DOI 10.1007/s003480050366; GOTTLIEB M, 1979, IND ENG CHEM FUND, V18, P357, DOI 10.1021/i160072a013; Arratia PE, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.144502; Haward SJ, 2010, J NON-NEWTON FLUID, V165, P1654, DOI 10.1016/j.jnnfm.2010.09.002; Oak J, 2004, MICROSCALE THERM ENG, V8, P111, DOI 10.1080/10893950490445289; Rodd LE, 2005, J NON-NEWTON FLUID, V129, P1, DOI 10.1016/j.jnnfm.2005.04.006; Poole RJ, 2005, P ROY SOC A-MATH PHY, V461, P3827, DOI 10.1098/rspa.2005.1535; BOGER DV, 1970, AICHE J, V16, P1088, DOI 10.1002/aic.690160637; Litvinov S, 2014, MICROFLUID NANOFLUID, V16, P257, DOI 10.1007/s10404-013-1207-8; Yapici K, 2012, J FLUID ENG-T ASME, V134, DOI 10.1115/1.4006696; Rothstein JP, 2001, J NON-NEWTON FLUID, V98, P33, DOI 10.1016/S0377-0257(01)00094-5; Rodd LE, 2010, J NON-NEWTON FLUID, V165, P1189, DOI 10.1016/j.jnnfm.2010.06.003; Schroeder CM, 2003, SCIENCE, V301, P1515, DOI 10.1126/science.1086070; Ookawara S, 2000, J CHEM ENG JPN, V33, P675, DOI 10.1252/jcej.33.675; Smith DE, 1998, SCIENCE, V281, P1335, DOI 10.1126/science.281.5381.1335; BEAVERS GS, 1970, INT J HEAT MASS TRAN, V13, P689, DOI 10.1016/0017-9310(70)90043-8; NGUYEN TQ, 1992, POLYMER, V33, P2611, DOI 10.1016/0032-3861(92)91145-R; Ober TJ, 2013, RHEOL ACTA, V52, P529, DOI 10.1007/s00397-013-0701-y; Rodd LE, 2007, J NON-NEWTON FLUID, V143, P170, DOI 10.1016/j.jnnfm.2007.02.006; Haward SJ, 2010, RHEOL ACTA, V49, P781, DOI 10.1007/s00397-010-0453-x; Meinhart CD, 2000, MEAS SCI TECHNOL, V11, P809, DOI 10.1088/0957-0233/11/6/326; Durst F, 2005, J FLUID ENG-T ASME, V127, P1154, DOI 10.1115/1.2063088; Lee SY, 2008, MICROFLUID NANOFLUID, V5, P1, DOI 10.1007/s10404-007-0179-y; Lubansky AS, 2015, J RHEOL, V59, P835, DOI 10.1122/1.4918976; Haward SJ, 2012, SOFT MATTER, V8, P536, DOI 10.1039/c1sm06494k; Haward SJ, 2011, SOFT MATTER, V7, P9908, DOI 10.1039/c1sm05493g; Alves MA, 2003, J NON-NEWTON FLUID, V110, P45, DOI 10.1016/S0377-0257(02)00191-X; DEVANAND K, 1991, MACROMOLECULES, V24, P5943, DOI 10.1021/ma00022a008; Poole RJ, 2009, J NON-NEWTON FLUID, V160, P47, DOI 10.1016/j.jnnfm.2009.03.005; Rodd LE, 2005, APPL RHEOL, V15, P12; Groisman A, 2003, SCIENCE, V300, P955, DOI 10.1126/science.1083694; GRAESSLEY WW, 1980, POLYMER, V21, P258, DOI 10.1016/0032-3861(80)90266-9; Stone HA, 2004, ANNU REV FLUID MECH, V36, P381, DOI 10.1146/annurev.fluid.36.050802.122124; Pipe CJ, 2008, RHEOL ACTA, V47, P621, DOI 10.1007/s00397-008-0268-1; Mackley M, 2010, RHEOL ACTA, V49, P443, DOI 10.1007/s00397-010-0435-z; Haward SJ, 2010, RHEOL ACTA, V49, P633, DOI 10.1007/s00397-009-0420-6; Entov VM, 1997, J NON-NEWTON FLUID, V72, P31, DOI 10.1016/S0377-0257(97)00022-0; Colby RH, 2010, RHEOL ACTA, V49, P425, DOI 10.1007/s00397-009-0413-5; Gulati S, 2008, J NON-NEWTON FLUID, V155, P51, DOI 10.1016/j.jnnfm.2008.05.005; ATKINSON B, 1969, AICHE J, V15, P548, DOI 10.1002/aic.690150414; Santiago JG, 1998, EXP FLUIDS, V25, P316, DOI 10.1007/s003480050235; Li Z, 2011, J NON-NEWTON FLUID, V166, P951, DOI 10.1016/j.jnnfm.2011.04.010; METZNER AB, 1965, AICHE J, V11, P989, DOI 10.1002/aic.690110609; Li Z, 2011, RHEOL ACTA, V50, P277, DOI 10.1007/s00397-011-0539-0; Klessinger UA, 2013, MICROFLUID NANOFLUID, V15, P533, DOI 10.1007/s10404-013-1171-3; PerezTrejo L, 1996, RHEOL ACTA, V35, P194, DOI 10.1007/BF00396046; VRADIS GC, 1993, INT J HEAT MASS TRAN, V36, P543, DOI 10.1016/0017-9310(93)80030-X; Anna SL, 2001, J RHEOL, V45, P115, DOI 10.1122/1.1332389; Tirtaatmadja V, 2006, PHYS FLUIDS, V18, DOI 10.1063/1.2190469; Beebe DJ, 2010, CHEM SOC REV, V39, P1036; CHEN RY, 1973, J FLUID ENG-T ASME, V95, P153; Hassan I, 2010, J FLUIDS ENG, V132, P1; Muchnik G. F., 1973, Journal of Engineering Physics, V25, DOI 10.1007/BF00834770; Ridley BS, 2007, J FLUIDS ENG, V139, P1281; Shah R.K., 1978, ADV HEAT TRANSFER; Tanner R.I., 1998, RHEOLOGY HIST PERSPE; White F.M., 2003, FLUID MECH	57	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1613-4982	1613-4990		MICROFLUID NANOFLUID	Microfluid. Nanofluid.	NOV	2015	19	5			SI		1123	1137		10.1007/s10404-015-1630-0		15	Nanoscience & Nanotechnology; Instruments & Instrumentation; Physics, Fluids & Plasmas	Science & Technology - Other Topics; Instruments & Instrumentation; Physics	CV0YA	WOS:000363978600012		
J	Sun, T; Huang, Q; Shi, Q; Wang, HP; Liu, XM; Seki, M; Nakajima, M; Fukuda, T				Sun, Tao; Huang, Qiang; Shi, Qing; Wang, Huaping; Liu, Xiaoming; Seki, Minoru; Nakajima, Masahiro; Fukuda, Toshio			Magnetic assembly of microfluidic spun alginate microfibers for fabricating three-dimensional cell-laden hydrogel constructs	MICROFLUIDICS AND NANOFLUIDICS			English	Article						Magnetic assembly; 3D cellular structures; Microfluidic "printing" method; Alginate microfibers; Magnetic nanoparticles	3D; SCAFFOLDS; FIBERS	Microfluidic devices employed as "printing" head provide a mild condition to fabricate cell-laden hydrogel modules for three-dimensional (3D) assembly to create cellular constructs. However, because of the poor controllability of hydrogels and unstable microfluidic fabrication process, it remains a challenge to fabricate morphologically accurate structures to mimic in vivo tissues, which hinders the building of in vitro models of organs. In this paper, we combine a magnetic-driven strategy into a microfluidic "printing" method to handle this challenge. To enhance the controllability, we encapsulate magnetic nanoparticles (MNPs) into cell-laden alginate hydrogel microfibers and then magnetically assemble these microfibers on the surface of designed support models. To keep a continuous spinning process, we immerse the spinning orifice of microfluidic device into phosphate-buffered saline filled in a Petri dish to eliminate the influence of droplets generated during microfibers ejection. Meanwhile, a dextran flow impulse is employed to prevent the blockage of microchannels. Interestingly, this impulse can achieve to temporarily cease the spinning process. Moreover, an optimized magnetic assembly is achieved by considering both the assembling area on a ring magnet and the MNPs concentration in microfibers. After the test of cell survival, a high cell viability of 97.2 % can be confirmed in assembled structures, which indicates that our method allows a biocompatible assembly of cell-laden hydrogels to build macroscopic 3D cellular structures similar to tissues observed in vivo.	[Sun, Tao; Huang, Qiang; Shi, Qing; Wang, Huaping; Liu, Xiaoming; Fukuda, Toshio] Beijing Inst Technol, Intelligent Robot Inst, Sch Mechatron Engn, Beijing 100081, Peoples R China; [Seki, Minoru] Chiba Univ, Dept Appl Chem & Bioengn, Inage Ku, Chiba 2638522, Japan; [Nakajima, Masahiro] Nagoya Univ, Dept Micronano Syst Engn, Chikusa Ku, Nagoya, Aichi 4648603, Japan	Shi, Q (reprint author), Beijing Inst Technol, Intelligent Robot Inst, Sch Mechatron Engn, 5 South Zhongguancun St, Beijing 100081, Peoples R China.	shiqing@bit.edu.cn			National Nature Science Foundation of China [61375108, 61520106011]; 111 project [B08043]	We thank Hasegawa Laboratory at Nagoya University for the help of the design of microfluidic device and cell experiments. This research was supported by the National Nature Science Foundation of China under Grants 61375108 and 61520106011, and "111 project" under Grant B08043.	Kang E, 2011, NAT MATER, V10, P877, DOI [10.1038/nmat3108, 10.1038/NMAT3108]; Xu F, 2011, ADV MATER, V23, P4254, DOI 10.1002/adma.201101962; Yu Y, 2014, ADV MATER, V26, P2494, DOI 10.1002/adma.201304974; Marga F, 2012, BIOFABRICATION, V4, DOI 10.1088/1758-5082/4/2/022001; Leng L, 2012, ADV MATER, V24, P3650, DOI 10.1002/adma.201201442; Liu J, 2012, APPL SURF SCI, V258, P7530, DOI 10.1016/j.apsusc.2012.04.077; THOMAS A, 1995, J CHEM TECHNOL BIOT, V64, P73, DOI 10.1002/jctb.280640112; Yamada M, 2012, BIOMATERIALS, V33, P8304, DOI 10.1016/j.biomaterials.2012.07.068; Agarwal P, 2013, LAB CHIP, V13, P4525, DOI 10.1039/c3lc50678a; Qin D, 2010, NAT PROTOC, V5, P491, DOI 10.1038/nprot.2009.234; Yamada KM, 2007, CELL, V130, P601, DOI 10.1016/j.cell.2007.08.006; Tamayol A, 2013, BIOTECHNOL ADV, V31, P669, DOI 10.1016/j.biotechadv.2012.11.007; Hu CZ, 2014, MICROFLUID NANOFLUID, V17, P457, DOI 10.1007/s10404-013-1325-3; Xu CX, 2012, BIOTECHNOL BIOENG, V109, P3152, DOI 10.1002/bit.24591; Ahn S, 2012, BIOMACROMOLECULES, V13, P2997, DOI 10.1021/bm3011352; Onoe H, 2013, NAT MATER, V12, P584, DOI [10.1038/nmat3606, 10.1038/NMAT3606]; Kang E, 2012, ADV MATER, V24, P4271, DOI 10.1002/adma.201201232; Li YH, 2013, ADV FUNCT MATER, V23, P660, DOI 10.1002/adfm.201201708; Cuadros TR, 2012, CARBOHYD POLYM, V89, P1198, DOI 10.1016/j.carbpol.2012.03.094; Yang K, 2010, APPL SURF SCI, V256, P3093, DOI 10.1016/j.apsusc.2009.11.079; Yamada M, 2012, SOFT MATTER, V8, P3122, DOI 10.1039/c2sm07263g; Ghorbanian S, 2014, BIOMED MICRODEVICES, V16, P387, DOI 10.1007/s10544-014-9842-8; Duan B, 2013, J BIOMED MATER RES A, V101, P1255, DOI 10.1002/jbm.a.34420; Sun T, 2015, MICROFLUID NANOFLUID, V18, P1177, DOI 10.1007/s10404-014-1511-y; Chung SE, 2015, LAB CHIP, V15, P1667, DOI 10.1039/c5lc00009b; Lin YS, 2012, PLOS ONE, DOI [10.1371/journal.pone.0033184, DOI 10.1371/J0URNAL.P0NE.0033184]; Matsunaga Y, 2012, ADV HEALTHC MATER, V23, P90, DOI [10.1002/adma.201004375, DOI 10.1002/ADMA.201004375]; Murphy SV, 2014, NAT BIOTECHNOL, V32, P773, DOI 10.1038/nbt.2958; Tasoglu S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4124; Wang Huaping, 2015, IEEE Trans Biomed Eng, V62, P2620, DOI 10.1109/TBME.2015.2437952; Yue T, 2014, LAB CHIP, V14, P1151, DOI 10.1039/c3lc51134k; Zhao Y, 2014, BIOFABRICATION, V6, DOI 10.1088/1758-5082/6/3/035001	32	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1613-4982	1613-4990		MICROFLUID NANOFLUID	Microfluid. Nanofluid.	NOV	2015	19	5			SI		1169	1180		10.1007/s10404-015-1633-x		12	Nanoscience & Nanotechnology; Instruments & Instrumentation; Physics, Fluids & Plasmas	Science & Technology - Other Topics; Instruments & Instrumentation; Physics	CV0YA	WOS:000363978600015		
J	Pallottini, A; Ferrara, A; Pacucci, F; Gallerani, S; Salvadori, S; Schneider, R; Schaerer, D; Sobral, D; Matthee, J				Pallottini, A.; Ferrara, A.; Pacucci, F.; Gallerani, S.; Salvadori, S.; Schneider, R.; Schaerer, D.; Sobral, D.; Matthee, J.			The brightest Ly alpha emitter: Pop III or black hole?	MONTHLY NOTICES OF THE ROYAL ASTRONOMICAL SOCIETY			English	Article						black hole physics; stars: Population III; galaxies: high-redshift	HIGH-REDSHIFT GALAXIES; POPULATION-III; STAR-FORMATION; DIRECT COLLAPSE; STELLAR POPULATIONS; PHYSICAL CONDITIONS; METAL ENRICHMENT; 1ST GALAXIES; REIONIZATION; EVOLUTION	CR7 is the brightest z = 6.6 Ly alpha emitter (LAE) known to date, and spectroscopic follow-up by Sobral et al. suggests that CR7 might host Population (Pop) III stars. We examine this interpretation using cosmological hydrodynamical simulations. Several simulated galaxies show the same 'Pop III wave' pattern observed in CR7. However, to reproduce the extreme CR7 Ly alpha/He II1640 line luminosities (L-alpha/He II) a top-heavy initial mass function and a massive (greater than or similar to 10(7)M(circle dot)) Pop III burst with age less than or similar to 2 Myr are required. Assuming that the observed properties of Ly alpha and He II emission are typical for Pop III, we predict that in the COSMOS/UDS/SA22 fields, 14 out of the 30 LAEs at z = 6.6 with L-alpha > 10(43.3) erg s(-1) should also host Pop III stars producing an observable L-He II greater than or similar to 10(42.7) erg s(-1). As an alternate explanation, we explore the possibility that CR7 is instead powered by accretion on to a direct collapse black hole. Our model predicts L-alpha, L-He II, and X-ray luminosities that are in agreement with the observations. In any case, the observed properties of CR7 indicate that this galaxy is most likely powered by sources formed from pristine gas. We propose that further X-ray observations can distinguish between the two above scenarios.	[Pallottini, A.; Ferrara, A.; Pacucci, F.; Gallerani, S.] Scuola Normale Super Pisa, I-56126 Pisa, Italy; [Ferrara, A.] Univ Tokyo, Kavli IPMU, Kashiwa, Chiba 2778583, Japan; [Salvadori, S.] Univ Groningen, Kapteyn Astron Inst, NL-9747 AD Groningen, Netherlands; [Schneider, R.] INAF, Osservatorio Astron Roma, I-00040 Monte Porzio Catone, Italy; [Schaerer, D.] Univ Geneva, Dept Astron, Observ Geneva, CH-1290 Versoix, Switzerland; [Schaerer, D.] CNRS, IRAP, F-31400 Toulouse, France; [Sobral, D.] Univ Lisbon, OAL, Inst Astrofis & Ciencias Espaco, P-1349018 Lisbon, Portugal; [Sobral, D.] Univ Lisbon, Fac Ciencias, Dept Fis, P-1749016 Lisbon, Portugal; [Sobral, D.; Matthee, J.] Leiden Univ, Leiden Observ, NL-2300 RA Leiden, Netherlands	Pallottini, A (reprint author), Scuola Normale Super Pisa, Piazza Cavalieri 7, I-56126 Pisa, Italy.	andrea.pallottini@sns.it		Schneider, Raffaella/0000-0001-9317-2888; Sobral, David/0000-0001-8823-4845	Netherlands Organization for Scientific research (NWO), VENI [639.041.233]; European Research Council under the European Union (FP)/ERC [306476]; NWO through a Veni fellowship; FCT through a FCT Investigator Starting Grant; FCT through a Start-up Grant [IF/01154/2012/CP0189/CT0010]; FCT [PEst-OE/FIS/UI2751/2014]	SS acknowledges support from the Netherlands Organization for Scientific research (NWO), VENI grant 639.041.233. RS acknowledges support from the European Research Council under the European Union (FP/2007-2013)/ERC grant agreement no. 306476. DS acknowledges (i) financial support from the NWO through a Veni fellowship and (ii) funding from FCT through a FCT Investigator Starting Grant and Start-up Grant (IF/01154/2012/CP0189/CT0010) and from FCT grant PEst-OE/FIS/UI2751/2014.	Dayal P, 2008, MON NOT R ASTRON SOC, V389, P1683, DOI 10.1111/j.1365-2966.2008.13721.x; Ma Q, 2015, MON NOT R ASTRON SOC, V449, P3006, DOI 10.1093/mnras/stv477; Greif TH, 2012, MON NOT R ASTRON SOC, V424, P399, DOI 10.1111/j.1365-2966.2012.21212.x; Erb DK, 2010, ASTROPHYS J, V719, P1168, DOI 10.1088/0004-637X/719/2/1168; Zheng W, 2012, NATURE, V489, P406, DOI 10.1038/nature11446; Volonteri M, 2008, MON NOT R ASTRON SOC, V383, P1079, DOI 10.1111/j.1365-2966.2007.12589.x; Brinchmann J, 2008, MON NOT R ASTRON SOC, V385, P769, DOI 10.1111/j.1365-2966.2008.12914.x; Trenti M, 2009, ASTROPHYS J, V700, P1672, DOI 10.1088/0004-637X/700/2/1672; Pacucci F, 2015, MON NOT R ASTRON SOC, V448, P104, DOI 10.1093/mnras/stv018; Salvadori S, 2014, MON NOT R ASTRON SOC, V437, pL26, DOI 10.1093/mnrasl/slt132; Shang C, 2010, MON NOT R ASTRON SOC, V402, P1249, DOI 10.1111/j.1365-2966.2009.15960.x; De Breuck C, 2000, ASTRON ASTROPHYS, V362, P519; Sugimura K, 2014, MON NOT R ASTRON SOC, V445, P544, DOI 10.1093/mnras/stu1778; Pallottini A, 2014, MON NOT R ASTRON SOC, V444, pL105, DOI 10.1093/mnrasl/slu126; Agarwal B, 2013, MON NOT R ASTRON SOC, V432, P3438, DOI 10.1093/mnras/stt696; Pallottini A, 2014, MON NOT R ASTRON SOC, V440, P2498, DOI 10.1093/mnras/stu451; Teyssier R, 2002, ASTRON ASTROPHYS, V385, P337, DOI 10.1051/0004-6361:20011817; Yoshida N, 2006, ASTROPHYS J, V652, P6, DOI 10.1086/507978; Ferland GJ, 2013, REV MEX ASTRON ASTR, V49, P137; Ouchi M, 2009, ASTROPHYS J, V696, P1164, DOI 10.1088/0004-637X/696/2/1164; Sheth RK, 1999, MON NOT R ASTRON SOC, V308, P119, DOI 10.1046/j.1365-8711.1999.02692.x; Latif MA, 2013, MON NOT R ASTRON SOC, V436, P2989, DOI 10.1093/mnras/stt1786; Turk MJ, 2009, SCIENCE, V325, P601, DOI 10.1126/science.1173540; Schneider R, 2006, MON NOT R ASTRON SOC, V369, P1437, DOI [10.1111/j.1365-2966.2006.10391.x, 10.1111/j.1365-2966.10391.x]; Ferrara A, 2014, MON NOT R ASTRON SOC, V443, P2410, DOI 10.1093/mnras/stu1280; Yue B, 2013, MON NOT R ASTRON SOC, V433, P1556, DOI 10.1093/mnras/stt826; Begelman MC, 2006, MON NOT R ASTRON SOC, V370, P289, DOI [10.1111/j.1365-2966.2006.10467.x, 10.1111/j.1365-2966.10467.x]; Bromm V, 2002, ASTROPHYS J, V564, P23, DOI 10.1086/323947; Yue B, 2014, MON NOT R ASTRON SOC, V440, P1263, DOI 10.1093/mnras/stu351; Schneider R, 2002, ASTROPHYS J, V571, P30, DOI 10.1086/339917; Salvadori S, 2009, MON NOT R ASTRON SOC, V395, pL6, DOI 10.1111/j.1745-3933.2009.00627.x; Zabl J, 2015, MON NOT R ASTRON SOC, V451, P2050, DOI 10.1093/mnras/stv1019; Tornatore L, 2007, MON NOT R ASTRON SOC, V382, P945, DOI 10.1111/j.1365-2966.2007.12215.x; Bouwens RJ, 2012, ASTROPHYS J, V754, DOI 10.1088/0004-637X/754/2/83; Cai Z, 2011, ASTROPHYS J LETT, V736, DOI 10.1088/2041-8205/736/2/L28; Cassata P, 2013, ASTRON ASTROPHYS, V556, DOI 10.1051/0004-6361/201220969; Daddi E, 2007, ASTROPHYS J, V670, P156, DOI 10.1086/521818; Elvis M, 2009, ASTROPHYS J SUPPL S, V184, P158, DOI 10.1088/0067-0049/184/1/158; Gonzalez V, 2011, ASTROPHYS J LETT, V735, DOI 10.1088/2041-8205/735/2/L34; Heap S., 2015, ARXIV150402742; Kashikawa N, 2012, ASTROPHYS J, V761, DOI 10.1088/0004-637X/761/2/85; Kehrig C, 2015, ASTROPHYS J LETT, V801, DOI 10.1088/2041-8205/801/2/L28; Larson D, 2011, ASTROPHYS J SUPPL S, V192, DOI 10.1088/0067-0049/192/2/16; Maio U, 2010, MON NOT R ASTRON SOC, V407, P1003, DOI 10.1111/j.1365-2966.2010.17003.x; Matthee J, 2015, MON NOT R ASTRON SOC, V451, P400, DOI 10.1093/mnras/stv947; McLure RJ, 2011, MON NOT R ASTRON SOC, V418, P2074, DOI 10.1111/j.1365-2966.2011.19626.x; Nagao T, 2008, ASTROPHYS J, V680, P100, DOI 10.1086/587888; Pacucci F., 2015, ARXIV150605299; Pallottini A., 2015, ARXIV150605803; Raiter A, 2010, ASTRON ASTROPHYS, V523, DOI 10.1051/0004-6361/201015236; Regan JA, 2014, ASTROPHYS J, V795, DOI 10.1088/0004-637X/795/2/137; Schaerer D, 2002, ASTRON ASTROPHYS, V382, P28, DOI 10.1051/0004-6361:20011619; Sobral David, 2015, Astrophysical Journal, V808, DOI 10.1088/0004-637X/808/2/139; Stark DP, 2013, ASTROPHYS J, V763, DOI 10.1088/0004-637X/763/2/129; Visbal E., 2015, ARXIV150506359; Wise JH, 2012, ASTROPHYS J, V745, DOI 10.1088/0004-637X/745/1/50; Xu H, 2013, ASTROPHYS J, V773, DOI 10.1088/0004-637X/773/2/83	57	1	1	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0035-8711	1365-2966		MON NOT R ASTRON SOC	Mon. Not. Roy. Astron. Soc.	NOV 1	2015	453	3					2465	2470		10.1093/mnras/stv1795		6	Astronomy & Astrophysics	Astronomy & Astrophysics	CU6NL	WOS:000363649000022		
J	Shirasaki, M; Hamana, T; Yoshida, N				Shirasaki, Masato; Hamana, Takashi; Yoshida, Naoki			Probing cosmology with weak lensing selected clusters - I. Halo approach and all-sky simulations	MONTHLY NOTICES OF THE ROYAL ASTRONOMICAL SOCIETY			English	Article						gravitational lensing: weak; cosmological parameters; cosmology: theory; large-scale structure of universe	BARYON ACOUSTIC-OSCILLATIONS; MATTER POWER SPECTRUM; GALAXY CLUSTERS; PEAK STATISTICS; COSMIC SHEAR; NONLINEAR EVOLUTION; EXCURSION ANGLES; DENSITY PROFILE; JOINT ANALYSIS; NUMBER COUNTS	We explore a variety of statistics of clusters selected with cosmic shear measurement by utilizing both analytic models and large numerical simulations. We first develop a halo model to predict the abundance and the clustering of weak lensing selected clusters. Observational effects such as galaxy shape noise are included in our model. We then generate realistic mock weak lensing catalogues to test the accuracy of our analytic model. To this end, we perform full-sky ray-tracing simulations that allow us to have multiple realizations of a large continuous area. We model the masked regions on the sky using the actual positions of bright stars, and generate 200 mock weak lensing catalogues with sky coverage of similar to 1000 deg(2). We show that our theoretical model agrees well with the ensemble average of statistics and their covariances calculated directly from the mock catalogues. With a typical selection threshold, ignoring shape noise correction causes overestimation of the clustering of weak lensing selected clusters with a level of about 10 per cent, and shape noise correction boosts the cluster abundance by a factor of a few. We calculate the cross-covariances using the halo model with accounting for the effective reduction of the survey area due to masks. The covariance of the cosmic shear auto power spectrum is affected by the mode-coupling effect that originates from sky masking. Our model and the results can be readily used for cosmological analysis with ongoing and future weak lensing surveys.	[Shirasaki, Masato; Hamana, Takashi] Natl Astron Observ Japan, Mitaka, Tokyo 1818588, Japan; [Yoshida, Naoki] Univ Tokyo, Sch Sci, Dept Phys, Bunkyo Ku, Tokyo 1130033, Japan; [Yoshida, Naoki] Univ Tokyo, Todai Inst Adv Study, Kavli Inst Phys & Math Universe WPI, Kashiwa, Chiba 2778583, Japan; [Yoshida, Naoki] Japan Sci & Technol Agcy, CREST, Kawaguchi, Saitama 3320012, Japan	Shirasaki, M (reprint author), Natl Astron Observ Japan, Mitaka, Tokyo 1818588, Japan.	masato.shirasaki@gmail.com			JSPS Promotion of Science [25287050, 26400285]; JST CREST	We would like to thank M. R. Becker for making the source program of CALCLENS available, and HEALPIX team for making HEALPIX software publicly available. This work is supported in part by Grant-in-Aid for Scientific Research from the JSPS Promotion of Science (25287050; 26400285). NY acknowledges financial support from JST CREST. MS is supported by Grant-in-Aid for JSPS Fellows. Numerical computations presented in this paper were in part carried out on the general-purpose PC farm at Center for Computational Astrophysics, CfCA, of National Astronomical Observatory of Japan.	Ade PAR, 2014, ASTRON ASTROPHYS, V571, DOI 10.1051/0004-6361/201321591; Allen SW, 2011, ANNU REV ASTRON ASTR, V49, P409, DOI 10.1146/annurev-astro-081710-102514; Hu W, 2003, ASTROPHYS J, V584, P702, DOI 10.1086/345846; Beutler F, 2011, MON NOT R ASTRON SOC, V416, P3017, DOI 10.1111/j.1365-2966.2011.19250.x; Oguri M, 2011, PHYS REV D, V83, DOI 10.1103/PhysRevD.83.023008; Crocce M, 2006, MON NOT R ASTRON SOC, V373, P369, DOI 10.1111/j.1365-2966.2006.11040.x; Jain B, 2000, ASTROPHYS J, V530, P547, DOI 10.1086/308384; Hu W, 2001, PHYS REV D, V64, DOI 10.1103/PhysRevD.64.083005; Duffy AR, 2008, MON NOT R ASTRON SOC, V390, pL64, DOI 10.1111/j.1745-3933.2008.00537.x; Lewis A, 2000, ASTROPHYS J, V538, P473, DOI 10.1086/309179; Shirasaki M, 2014, ASTROPHYS J, V786, DOI 10.1088/0004-637X/786/1/43; Sanchez AG, 2012, MON NOT R ASTRON SOC, V425, P415, DOI 10.1111/j.1365-2966.2012.21502.x; Marian L, 2012, MON NOT R ASTRON SOC, V423, P1711, DOI 10.1111/j.1365-2966.2012.20992.x; Bartelmann M, 2001, PHYS REP, V340, P291, DOI 10.1016/S0370-1573(00)00082-X; Beutler F, 2014, MON NOT R ASTRON SOC, V443, P1065, DOI 10.1093/mnras/stu1051; Yang XY, 2013, PHYS REV D, V87, DOI 10.1103/PhysRevD.87.023511; Kayo I, 2013, MON NOT R ASTRON SOC, V429, P344, DOI 10.1093/mnras/sts340; Hamana T, 2005, MON NOT R ASTRON SOC, V356, P829, DOI 10.1111/j.1365-2966.2004.08512.x; Hennawi JF, 2005, ASTROPHYS J, V624, P59, DOI 10.1086/428749; Hamana T, 2012, MON NOT R ASTRON SOC, V425, P2287, DOI 10.1111/j.1365-2966.2012.21582.x; Blake C, 2011, MON NOT R ASTRON SOC, V418, P1707, DOI 10.1111/j.1365-2966.2011.19592.x; Gorski KM, 2005, ASTROPHYS J, V622, P759, DOI 10.1086/427976; Zentner AR, 2013, PHYS REV D, V87, DOI 10.1103/PhysRevD.87.043509; Liu J, 2014, PHYS REV D, V89, DOI 10.1103/PhysRevD.89.023515; Takada M, 2014, MON NOT R ASTRON SOC, V441, P2456, DOI 10.1093/mnras/stu759; Kratochvil JM, 2010, PHYS REV D, V81, DOI 10.1103/PhysRevD.81.043519; Semboloni E, 2013, MON NOT R ASTRON SOC, V434, P148, DOI 10.1093/mnras/stt1013; Anderson L, 2014, MON NOT R ASTRON SOC, V441, P24, DOI 10.1093/mnras/stu523; Fan ZH, 2010, ASTROPHYS J, V719, P1408, DOI 10.1088/0004-637X/719/2/1408; Jeong D, 2009, PHYS REV D, V80, DOI 10.1103/PhysRevD.80.123527; Schirmer M, 2007, ASTRON ASTROPHYS, V462, P875, DOI 10.1051/0004-6361:20065955; Takada M, 2004, MON NOT R ASTRON SOC, V348, P897, DOI 10.1111/j.1365-2966.2004.07410.x; Heymans C, 2012, MON NOT R ASTRON SOC, V427, P146, DOI 10.1111/j.1365-2966.2012.21952.x; Miyazaki S, 2007, ASTROPHYS J, V669, P714, DOI 10.1086/521621; Marian L, 2013, MON NOT R ASTRON SOC, V432, P1338, DOI 10.1093/mnras/stt552; Oguri M, 2012, MON NOT R ASTRON SOC, V420, P3213, DOI 10.1111/j.1365-2966.2011.20248.x; Cooray A, 2001, ASTROPHYS J, V554, P56, DOI 10.1086/321376; Das S, 2008, ASTROPHYS J, V682, P1, DOI 10.1086/589638; Nishimichi T, 2009, PUBL ASTRON SOC JPN, V61, P321; Hamana T, 2002, MON NOT R ASTRON SOC, V330, P365, DOI 10.1046/j.1365-8711.2002.05103.x; Munshi D, 2008, PHYS REP, V462, P67, DOI 10.1016/j.physrep.2008.02.003; Duffy AR, 2010, MON NOT R ASTRON SOC, V405, P2161, DOI 10.1111/j.1365-2966.2010.16613.x; Heitmann K, 2010, ASTROPHYS J, V715, P104, DOI 10.1088/0004-637X/715/1/104; Hilbert S, 2012, MON NOT R ASTRON SOC, V426, P2870, DOI 10.1111/j.1365-2966.2012.21841.x; Sato M, 2009, ASTROPHYS J, V701, P945, DOI 10.1088/0004-637X/701/2/945; Hikage C, 2011, MON NOT R ASTRON SOC, V412, P65, DOI 10.1111/j.1365-2966.2010.17886.x; Brown ML, 2005, MON NOT R ASTRON SOC, V360, P1262, DOI 10.1111/j.1365-2966.2005.09111.x; Springel V, 2005, MON NOT R ASTRON SOC, V364, P1105, DOI 10.1111/j.1365-2966.2005.09655.x; Peacock JA, 1996, MON NOT R ASTRON SOC, V280, pL19; Maturi M, 2005, ASTRON ASTROPHYS, V442, P851, DOI 10.1051/0004-6361:20042600; Hamana T, 2004, MON NOT R ASTRON SOC, V350, P893, DOI 10.1111/j.1365-2966.2004.07691.x; Semboloni E, 2011, MON NOT R ASTRON SOC, V417, P2020, DOI 10.1111/j.1365-2966.2011.19385.x; Dietrich JP, 2010, MON NOT R ASTRON SOC, V402, P1049, DOI 10.1111/j.1365-2966.2009.15948.x; Yang XY, 2011, PHYS REV D, V84, DOI 10.1103/PhysRevD.84.043529; Hirata CM, 2004, PHYS REV D, V70, DOI 10.1103/PhysRevD.70.063526; Hilbert S, 2009, ASTRON ASTROPHYS, V499, P31, DOI 10.1051/0004-6361/200811054; Navarro JF, 1997, ASTROPHYS J, V490, P493, DOI 10.1086/304888; Becker MR, 2013, MON NOT R ASTRON SOC, V435, P115, DOI 10.1093/mnras/stt1352; Betoule M, 2014, ASTRON ASTROPHYS, V568, DOI 10.1051/0004-6361/201423413; Bhattacharya S, 2011, ASTROPHYS J, V732, DOI 10.1088/0004-637X/732/2/122; Hinshaw G, 2013, ASTROPHYS J SUPPL S, V208, DOI 10.1088/0067-0049/208/2/19; Covone G, 2014, ASTROPHYS J LETT, V784, DOI 10.1088/2041-8205/784/2/L25; Efstathiou G, 2004, MON NOT R ASTRON SOC, V349, P603, DOI 10.1111/j.1365-2966.2004.07530.x; Hamana T, 2001, MON NOT R ASTRON SOC, V327, P169, DOI 10.1046/j.1365-8711.2001.04685.x; Hansen FK, 2003, MON NOT R ASTRON SOC, V343, P559, DOI 10.1046/j.1365-8711.2003.06695.x; KAISER N, 1992, ASTROPHYS J, V388, P272, DOI 10.1086/171151; Kilbinger M, 2013, MON NOT R ASTRON SOC, V430, P2200, DOI 10.1093/mnras/stt041; LILJE PB, 1992, ASTROPHYS J, V386, pL33, DOI 10.1086/186286; LIMBER DN, 1954, ASTROPHYS J, V119, P655, DOI 10.1086/145870; Liu XK, 2014, ASTROPHYS J, V784, DOI 10.1088/0004-637X/784/1/31; Maturi M, 2010, ASTRON ASTROPHYS, V519, DOI 10.1051/0004-6361/200912866; Mohammed I., 2014, ARXIV14106826; Okabe N, 2013, ASTROPHYS J LETT, V769, DOI 10.1088/2041-8205/769/2/L35; Osato K., 2015, ARXIV E PRINTS; Schmidt F, 2011, ASTROPHYS J, V735, DOI 10.1088/0004-637X/735/2/119; Schneider P, 1996, MON NOT R ASTRON SOC, V283, P837; Shan HY, 2012, ASTROPHYS J, V748, DOI 10.1088/0004-637X/748/1/56; Smith RE, 2003, MON NOT R ASTRON SOC, V341, P1311, DOI 10.1046/j.1365-8711.2003.06503.x; Takada M, 2007, NEW J PHYS, V9, DOI 10.1088/1367-2630/9/12/446; Takahashi R, 2012, ASTROPHYS J, V761, DOI 10.1088/0004-637X/761/2/152; Teyssier R, 2009, ASTRON ASTROPHYS, V497, P335, DOI 10.1051/0004-6361/200810657; Valageas P, 2011, ASTRON ASTROPHYS, V527, DOI 10.1051/0004-6361/201015685; Van Waerbeke L, 2000, MON NOT R ASTRON SOC, V313, P524	83	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0035-8711	1365-2966		MON NOT R ASTRON SOC	Mon. Not. Roy. Astron. Soc.	NOV 1	2015	453	3					3043	3067		10.1093/mnras/stv1854		25	Astronomy & Astrophysics	Astronomy & Astrophysics	CU6NL	WOS:000363649000064		
J	Pan, HA; Fujimoto, Y; Tasker, EJ; Rosolowsky, E; Colombo, D; Benincasa, SM; Wadsley, J				Pan, Hsi-An; Fujimoto, Yusuke; Tasker, Elizabeth J.; Rosolowsky, Erik; Colombo, Dario; Benincasa, Samantha M.; Wadsley, James			What is a GMC? Are observers and simulators discussing the same star-forming clouds?	MONTHLY NOTICES OF THE ROYAL ASTRONOMICAL SOCIETY			English	Article						methods: numerical; techniques: image processing; ISM: clouds; ISM: structure; galaxies: ISM	GIANT MOLECULAR CLOUDS; INTERSTELLAR-MEDIUM; GALAXIES. I.; MASS; DENSITY; EMISSION; MODELS; CORES; GAS; IMF	As both simulations and observations reach the resolution of the star-forming molecular clouds, it becomes important to clarify if these two techniques are discussing the same objects in galaxies. We compare clouds formed in a high-resolution galaxy simulation identified as continuous structures within a contour, in the simulator's position-position-position (PPP) coordinate space and the observer's position-position-velocity space (PPV). Results indicate that the properties of the cloud populations are similar in both methods and up to 70 per cent of clouds have a single counterpart in the opposite data structure. Comparing individual clouds in a one-to-one match reveals a scatter in properties mostly within a factor of 2. However, the small variations in mass, radius and velocity dispersion produce significant differences in derived quantities such as the virial parameter. This makes it difficult to determine if a structure is truly gravitationally bound. The three cloud types originally found in the simulation in Fujimoto et al. are identified in both data sets, with around 80 per cent of the clouds retaining their type between identification methods. We also compared our results when using a peak decomposition method to identify clouds in both PPP and PPV space. The number of clouds increased with this technique, but the overall cloud properties remained similar. However, the more crowded environment lowered the ability to match clouds between techniques to 40 per cent. The three cloud types also became harder to separate, especially in the PPV data set. The method used for cloud identification therefore plays a critical role in determining cloud properties, but both PPP and PPV can potentially identify the same structures.	[Pan, Hsi-An; Fujimoto, Yusuke; Tasker, Elizabeth J.] Hokkaido Univ, Fac Sci, Dept Phys, Kita Ku, Sapporo, Hokkaido 0600810, Japan; [Rosolowsky, Erik; Colombo, Dario] Univ Alberta, Dept Phys, Edmonton, AB T6G 2E1, Canada; [Benincasa, Samantha M.; Wadsley, James] McMaster Univ, Dept Phys & Astron, Hamilton, ON L8S 4M1, Canada	Pan, HA (reprint author), Hokkaido Univ, Fac Sci, Dept Phys, Kita Ku, Kita 10 Nishi 8, Sapporo, Hokkaido 0600810, Japan.	hapan@astro1.sci.hokudai.ac.jp; yusuke@astro1.sci.hokudai.ac.jp; tasker@astro1.sci.hokudai.ac.jp			MEXT	The authors would like to thank the yt development team (Turk et al. 2011) for support during the analysis of these simulations and the anonymous referee for their helpful report. Numerical computations were carried out on the Cray XT4 and Cray XC30 at the Center for Computational Astrophysics (CfCA) of the National Astronomical Observatory of Japan. EJT is funded by the MEXT grant for the Tenure Track System.	Andre P, 2010, ASTRON ASTROPHYS, V518, DOI 10.1051/0004-6361/201014666; SOLOMON PM, 1987, ASTROPHYS J, V319, P730, DOI 10.1086/165493; Fujimoto Y, 2014, MON NOT R ASTRON SOC, V439, P936, DOI 10.1093/mnras/stu014; Heyer MH, 1998, ASTROPHYS J, V502, P265, DOI 10.1088/0004-637X/699/2/1092; LARSON RB, 1981, MON NOT R ASTRON SOC, V194, P809; Brunt CM, 2003, ASTROPHYS J SUPPL S, V144, P47, DOI 10.1086/344245; Jarrett TH, 2003, ASTRON J, V125, P525, DOI 10.1086/345794; Tasker EJ, 2006, ASTROPHYS J, V641, P878, DOI 10.1086/500567; Rosolowsky E, 2006, PUBL ASTRON SOC PAC, V118, P590, DOI 10.1086/502982; Alves J, 2007, ASTRON ASTROPHYS, V462, pL17, DOI 10.1051/0004-6361:20066389; Tasker EJ, 2009, ASTROPHYS J, V700, P358, DOI 10.1088/0004-637X/700/1/358; McMullin JP, 2007, ASTR SOC P, V376, P127; Goldsmith PF, 2008, ASTROPHYS J, V680, P428, DOI 10.1086/587166; Goodman AA, 2009, ASTROPHYS J, V692, P91, DOI 10.1088/0004-637X/692/1/91; Ostriker EC, 2001, ASTROPHYS J, V546, P980, DOI 10.1086/318290; Thim F, 2003, ASTROPHYS J, V590, P256, DOI 10.1086/374888; Dobbs CL, 2011, MON NOT R ASTRON SOC, V413, P2935, DOI 10.1111/j.1365-2966.2011.18371.x; Bolatto AD, 2013, ANNU REV ASTRON ASTR, V51, P207, DOI 10.1146/annurev-astro-082812-140944; Roman-Duval J, 2010, ASTROPHYS J, V723, P492, DOI 10.1088/0004-637X/723/1/492; Beuther H, 2002, ASTROPHYS J, V566, P945, DOI 10.1086/338334; Battisti AJ, 2014, ASTROPHYS J, V780, DOI 10.1088/0004-637X/780/2/173; Beaumont CN, 2013, ASTROPHYS J, V777, DOI 10.1088/0004-637X/777/2/173; Berne O, 2014, ASTROPHYS J, V795, DOI 10.1088/0004-637X/795/1/13; Bryan GL, 2014, ASTROPHYS J SUPPL S, V211, DOI 10.1088/0067-0049/211/2/19; Burton MG, 2013, PUBL ASTRON SOC AUST, V30, DOI 10.1017/pasa.2013.22; Colombo D, 2014, ASTROPHYS J, V784, DOI 10.1088/0004-637X/784/1/3; Meyer JD, 2013, ASTROPHYS J, V772, DOI 10.1088/0004-637X/772/2/107; Hughes A, 2013, ASTROPHYS J, V779, DOI 10.1088/0004-637X/779/1/46; Lada CJ, 2003, ANNU REV ASTRON ASTR, V41, P57, DOI 10.1146/annurev.astro.41.011802.094844; Schinnerer E, 2013, ASTROPHYS J, V779, DOI 10.1088/0004-637X/779/1/42; Ward RL, 2012, ASTROPHYS J, V756, DOI 10.1088/0004-637X/756/2/119; Whitmore BC, 2014, ASTROPHYS J, V795, DOI 10.1088/0004-637X/795/2/156; Wong T, 2011, ASTROPHYS J SUPPL S, V197, DOI 10.1088/0067-0049/197/2/16; Yim K, 2014, ASTRON J, V148, DOI 10.1088/0004-6256/148/6/127	34	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0035-8711	1365-2966		MON NOT R ASTRON SOC	Mon. Not. Roy. Astron. Soc.	NOV 1	2015	453	3					3082	3099		10.1093/mnras/stv1843		18	Astronomy & Astrophysics	Astronomy & Astrophysics	CU6NL	WOS:000363649000066		
J	Burns, RA; Imai, H; Handa, T; Omodaka, T; Nakagawa, A; Nagayama, T; Ueno, Y				Burns, R. A.; Imai, H.; Handa, T.; Omodaka, T.; Nakagawa, A.; Nagayama, T.; Ueno, Y.			A 'water spout' maser jet in S235AB-MIR	MONTHLY NOTICES OF THE ROYAL ASTRONOMICAL SOCIETY			English	Article						Masers; stars: individual: S235AB-MIR; ISM: jets and outflows	STAR-FORMING REGIONS; GALACTIC CONSTANTS; VLBA OBSERVATIONS; YOUNG STARS; VERA; ROTATION; OUTFLOW; SIMULATION; KINEMATICS; ASTROMETRY	We report on annual parallax and proper motion observations of H2O masers in S235AB-MIR, which is a massive young stellar object in the Perseus Arm. Using multi-epoch VLBI (very long baseline interferometry) astrometry we measured a parallax of pi = 0.63 +/- 0.03 mas, corresponding to a trigonometric distance of D = 1.56(-0.08)(+0.09) kpc, and source proper motion of (mu(alpha)cos delta, mu(delta)) = (0.79 +/- 0.12, -2.41 +/- 0.14) mas yr(-1). Water masers trace a jet of diameter 15 au which exhibits a definite radial velocity gradient perpendicular to its axis. 3D maser kinematics were well modelled by a rotating cylinder with physical parameters: v(out) = 45 +/- 2 km s(-1), v(rot) = 22 +/- 3 km s(-1), i = 12 degrees +/- 2 degrees, which are the outflow velocity, tangential rotation velocity and line-of-sight inclination, respectively. One maser feature exhibited steady acceleration which may be related to the jet rotation. During our 15-month VLBI programme there were three 'maser burst' events caught 'in the act' which were caused by the overlapping of masers along the line of sight.	[Burns, R. A.; Imai, H.; Handa, T.; Omodaka, T.; Nakagawa, A.] Kagoshima Univ, Grad Sch Sci & Engn, Kagoshima 8900065, Japan; [Nagayama, T.; Ueno, Y.] Natl Astron Observ Japan, Mizusawa VLBI Observ, Mizusawa, Iwate 0230861, Japan	Burns, RA (reprint author), Kagoshima Univ, Grad Sch Sci & Engn, 1-21-35 Korimoto, Kagoshima 8900065, Japan.	RossBurns88@googlemail.com; handa@sci.kagoshima-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan; Japan Society for the Promotion of Science (JSPS) [25610043]	RB would like to acknowledge the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan for financial support under the Monbukagakusho scholarship.; HI has been supported by Japan Society for the Promotion of Science (JSPS) Grant-in-Aid for Challenging Exploratory Research (25610043).	Ando K, 2011, PUBL ASTRON SOC JPN, V63, P45; Bacciotti F, 2002, ASTROPHYS J, V576, P222, DOI 10.1086/341725; Felli M, 2004, ASTRON ASTROPHYS, V420, P553, DOI 10.1051/0004-6361:20035905; Shimoikura T, 2005, ASTROPHYS J, V634, P459, DOI 10.1086/432865; PALLA F, 1993, ASTROPHYS J, V418, P414, DOI 10.1086/173402; Kurtz S, 2004, ASTROPHYS J SUPPL S, V155, P149, DOI 10.1086/423956; DEGUCHI SJ, 1989, ASTROPHYS J, V340, pL17, DOI 10.1086/185428; Motogi K, 2013, MON NOT R ASTRON SOC, V428, P349, DOI 10.1093/mnras/sts035; Saito H, 2007, ASTROPHYS J, V659, P459, DOI 10.1086/512058; Woitas J, 2005, ASTRON ASTROPHYS, V432, P149, DOI 10.1051/0004-6361:20034439; Coffey D, 2004, ASTROPHYS J, V604, P758, DOI 10.1086/382019; Dewangan LK, 2011, MON NOT R ASTRON SOC, V414, P1526, DOI 10.1111/j.1365-2966.2011.18487.x; Honma M, 2008, PUBL ASTRON SOC JPN, V60, P951; Moscadelli L, 2000, ASTRON ASTROPHYS, V360, P663; KERR FJ, 1986, MON NOT R ASTRON SOC, V221, P1023; TOFANI G, 1995, ASTRON ASTROPHYS SUP, V112, P299; Hachisuka K, 2009, ASTROPHYS J, V696, P1981, DOI 10.1088/0004-637X/696/2/1981; Pratap P, 2008, ASTRON J, V135, P1718, DOI 10.1088/0004-6256/135/5/1718; Felli M, 2006, ASTRON ASTROPHYS, V453, P911, DOI 10.1051/0004-6361:20054646; Cerqueira AH, 2006, ASTRON ASTROPHYS, V448, P231, DOI 10.1051/0004-6361:20054110; Iguchi S, 2005, PUBL ASTRON SOC JPN, V57, P259; Furuya RS, 2000, ASTROPHYS J, V542, pL135, DOI 10.1086/312925; Bally J, 2005, ASTRON J, V129, P2281, DOI 10.1086/429098; HENKEL C, 1986, ASTRON ASTROPHYS, V165, P197; Caswell JL, 2008, MON NOT R ASTRON SOC, V386, P1521, DOI 10.1111/j.1365-2966.2008.13129.x; Zinnecker H, 2007, ANNU REV ASTRON ASTR, V45, P481, DOI 10.1146/annurev.astro.44.051905.092549; Lee CF, 2000, ASTROPHYS J, V542, P925, DOI 10.1086/317056; Asaki Y, 2007, PUBL ASTRON SOC JPN, V59, P397; Beltran MT, 2004, ASTROPHYS J, V601, pL187, DOI 10.1086/382150; Garatti ACO, 2015, ASTRON ASTROPHYS, V573, DOI 10.1051/0004-6361/201423992; Cesaroni R., 2007, PROTOSTARS PLANETS, P197; Chikada Y., 1991, FRONTIERS VLBI, P79; Felli M, 2007, ASTRON ASTROPHYS, V476, P373, DOI 10.1051/0004-6361:20077804; Hirota T, 2014, ASTROPHYS J LETT, V782, DOI 10.1088/2041-8205/782/2/L28; Hogbom J. A., 1974, Astronomy and Astrophysics Supplement Series, V15; Imai H, 2012, PUBL ASTRON SOC JPN, V64; Kawaguchi N, 2000, P SOC PHOTO-OPT INS, V4015, P544, DOI 10.1117/12.390448; Kobayashi H., 2003, ASP C SER, V306, p48P; Konigl A., 2000, Protostars and planets 4; Moscadelli L, 2011, ASTRON ASTROPHYS, V526, DOI 10.1051/0004-6361/201015641; Motogi K., 2015, PASJ IN PRESS; Navarete F., 2015, P IAU S, V307, P431; Petrov L, 2012, MON NOT R ASTRON SOC, V419, P1097, DOI 10.1111/j.1365-2966.2011.19765.x; Reid MJ, 2014, ASTROPHYS J, V783, DOI 10.1088/0004-637X/783/2/130; Soker N, 2005, ASTRON ASTROPHYS, V435, P125, DOI 10.1051/0004-6361:20042225; Torrelles J. M., 2012, P IAU S, P377; Zapata LA, 2015, ASTROPHYS J, V798, DOI 10.1088/0004-637X/798/2/131; Zapata LA, 2010, ASTRON ASTROPHYS, V510, DOI 10.1051/0004-6361/200810245	48	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0035-8711	1365-2966		MON NOT R ASTRON SOC	Mon. Not. Roy. Astron. Soc.	NOV 1	2015	453	3					3163	3173		10.1093/mnras/stv1836		11	Astronomy & Astrophysics	Astronomy & Astrophysics	CU6NL	WOS:000363649000073		
J	Yang, HW; Oura, K; Wang, HY; Gan, ZY; Tokuda, K				Yang, Hongwu; Oura, Keiichiro; Wang, Haiyan; Gan, Zhenye; Tokuda, Keiichi			Using speaker adaptive training to realize Mandarin-Tibetan cross-lingual speech synthesis	MULTIMEDIA TOOLS AND APPLICATIONS			English	Article						HMM-based speech synthesis; Speaker adaptive training; Multi-lingual speech synthesis; Tibetan speech synthesis; Mandarin-Tibetan cross-lingual speech synthesis; Grapheme-to-phoneme conversion	MAPPING APPROACH; ENGLISH TTS; ADAPTATION	This paper presents a method to realize the hidden Markov model (HMM)-based Mandarin-Tibetan cross-lingual statistical speech synthesis using speaker adaptive training. A set of Speech Assessment Methods Phonetic Alphabet (SAMPA) is designed to label the pronunciation of the initial and the final of Mandarin and Tibetan syllables according to the similarities in pronunciation between Mandarin and Tibetan. A grapheme-to-phoneme conversion method is realized to convert Chinese or Tibetan sentences to SAMPA-based Pinyin sequences. A Mandarin statistical speech synthesis framework is employed to realize Mandarin-Tibetan cross-lingual speech synthesis. A set of context-dependent label format is designed to label the context information of Mandarin and Tibetan sentences. A question set is also realized for context dependent decision tree clustering. The initial and the finalare used as the synthesis units with training using a set of average mixed-lingual models from a large Mandarin multi-speaker-based corpus and a small Tibetan one-speaker-based corpus using speaker adaptive training (SAT). Then, the speaker adaptation transformation is applied to the speaker dependent (SD) training data to obtain a set of speaker dependent Mandarin or Tibetan models from the average mixed-lingual models. The Mandarin speech or Tibetan speech is then synthesized from the speaker dependent Mandarin or Tibetan models. Tests show that this method outperforms the method using only Tibetan SD models when only a small number of Tibetan training utterances are available. When the number of training Tibetan utterances is increased, the performances of the two methods tend to be the same. Mixed Tibetan training sentences have a small effect on the quality of synthesized Mandarin speech.	[Yang, Hongwu; Gan, Zhenye] Northwest Normal Univ, Coll Phys & Elect Engn, Key Lab Atom & Mol Phys & Funct Mat Gansu Prov, Lanzhou 730070, Peoples R China; [Oura, Keiichiro; Tokuda, Keiichi] Nagoya Inst Technol, Dept Comp Sci & Engn, Nagoya, Aichi, Japan; [Wang, Haiyan] Northwest Normal Univ, Coll Phys & Elect Engn, Lanzhou 730070, Peoples R China	Yang, HW (reprint author), Northwest Normal Univ, Coll Phys & Elect Engn, Key Lab Atom & Mol Phys & Funct Mat Gansu Prov, Lanzhou 730070, Peoples R China.	yanghw@nwnu.edu.cn; uratec@sp.nitech.ac.jp; why6715@163.com; ganzy@nwnu.edu.cn; tokuda@nitech.ac.jp			National Natural Science Foundation of China [61263036, 61262055]; Gansu Science Fund for Distinguished Young Scholars [1210RJDA007]; Core Research for Evolutional Science and Technology (CREST) from Japan Science and Technology Agency (JST)	The research leading to these results was partly funded by the National Natural Science Foundation of China (Grant No. 61263036, 61262055), Gansu Science Fund for Distinguished Young Scholars (Grant No. 1210RJDA007) and the Core Research for Evolutional Science and Technology (CREST) from Japan Science and Technology Agency (JST).	Peng XL, 2010, 2010 IEEE 10TH INTERNATIONAL CONFERENCE ON SIGNAL PROCESSING PROCEEDINGS (ICSP2010), VOLS I-III, P605; Yamagishi J, 2009, IEEE T AUDIO SPEECH, V17, P66, DOI 10.1109/TASL.2008.2006647; Siohan O, 2002, COMPUT SPEECH LANG, V16, P5, DOI 10.1006/csla.2001.0181; Zen H, 2009, SPEECH COMMUN, V51, P1039, DOI 10.1016/j.specom.2009.04.004; Wu YJ, 2008, 2008 6TH INTERNATIONAL SYMPOSIUM ON CHINESE SPOKEN LANGUAGE PROCESSING, PROCEEDINGS, P9; Bourlard H, 2011, SADHANA-ACAD P ENG S, V36, P885, DOI 10.1007/s12046-011-0050-4; Chen YN, 2009, INT CONF ACOUST SPEE, P4273, DOI 10.1109/ICASSP.2009.4960573; Qian Y, 2009, IEEE T AUDIO SPEECH, V17, P1231, DOI 10.1109/TASL.2009.2015708; Kawahara H, 1999, SPEECH COMMUN, V27, P187, DOI 10.1016/S0167-6393(98)00085-5; Latorre J, 2006, SPEECH COMMUN, V48, P1227, DOI 10.1016/j.specom.2006.05.003; Liang H, 2008, INT CONF ACOUST SPEE, P4641; [高定国 Gao Dingguo], 2005, [中文信息学报, Journal of Chinese Information Processing], V19, P71; Gao L, 2010, IEEE INT C INF AUT I, P817; Goldstein M, 1991, ESSENTIALS MODERN LI; Handel Z, 2008, LANGUAGE LINGUISTICS, V2, P422, DOI 10.1111/j.1749-818X.2008.00061.x; Li Y, 2008, J TSINGHUA U SCI TEC, V48, P621; Mirjam W, 2010, EDIINFRR1388 U ED; Qian Y, 2006, ISCSLP 2006, P223; Schrder M, 2007, BLIZZARD CHALLENGE 2; Wells J, 1997, HDB STANDARDS RESOUR; Wu YJ, 2009, INTERSPEECH 2009, P528; Yamagishi J, 2003, IEICE T FUND ELECTR, VE86A, P1956; Zen H, 2010, INT 2010, P186; Zhang Jialu, 2009, Acta Acustica, V34	24	1	1	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	1380-7501	1573-7721		MULTIMED TOOLS APPL	Multimed. Tools Appl.	NOV	2015	74	22					9927	9942		10.1007/s11042-014-2117-9		16	Computer Science, Information Systems; Computer Science, Software Engineering; Computer Science, Theory & Methods; Engineering, Electrical & Electronic	Computer Science; Engineering	CV1LQ	WOS:000364019400006		
J	Finucane, HK; Bulik-Sullivan, B; Gusev, A; Trynka, G; Reshef, Y; Loh, PR; Anttila, V; Xu, H; Zang, CZ; Farh, K; Ripke, S; Day, FR; Purcell, S; Stahl, E; Lindstrom, S; Perry, JRB; Okada, Y; Raychaudhuri, S; Daly, MJ; Patterson, N; Neale, BM; Price, AL				Finucane, Hilary K.; Bulik-Sullivan, Brendan; Gusev, Alexander; Trynka, Gosia; Reshef, Yakir; Loh, Po-Ru; Anttila, Verneri; Xu, Han; Zang, Chongzhi; Farh, Kyle; Ripke, Stephan; Day, Felix R.; Purcell, Shaun; Stahl, Eli; Lindstrom, Sara; Perry, John R. B.; Okada, Yukinori; Raychaudhuri, Soumya; Daly, Mark J.; Patterson, Nick; Neale, Benjamin M.; Price, Alkes L.		ReproGen Consortium; Psychiat Genomics Consortium; RACI Consortium	Partitioning heritability by functional annotation using genome-wide association summary statistics	NATURE GENETICS			English	Article							BODY-MASS INDEX; GENETIC ARCHITECTURE; HUMAN HEIGHT; COMMON SNPS; CELL-TYPES; VARIANTS; LOCI; DISEASE; SUSCEPTIBILITY; PROPORTION	Recent work has demonstrated that some functional categories of the genome contribute disproportionately to the heritability of complex diseases. Here we analyze a broad set of functional elements, including cell type-specific elements, to estimate their polygenic contributions to heritability in genome-wide association studies (GWAS) of 17 complex diseases and traits with an average sample size of 73,599. To enable this analysis, we introduce a new method, stratified LD score regression, for partitioning heritability from GWAS summary statistics while accounting for linked markers. This new method is computationally tractable at very large sample sizes and leverages genome-wide information. Our findings include a large enrichment of heritability in conserved regions across many traits, a very large immunological disease-specific enrichment of heritability in FANTOM5 enhancers and many cell type-specific enrichments, including significant enrichment of central nervous system cell types in the heritability of body mass index, age at menarche, educational attainment and smoking behavior.	[Finucane, Hilary K.] MIT, Dept Math, Cambridge, MA 02139 USA; [Finucane, Hilary K.; Gusev, Alexander; Loh, Po-Ru; Lindstrom, Sara; Price, Alkes L.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; [Bulik-Sullivan, Brendan; Anttila, Verneri; Farh, Kyle; Ripke, Stephan; Daly, Mark J.; Neale, Benjamin M.] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Boston, MA 02114 USA; [Bulik-Sullivan, Brendan; Anttila, Verneri; Farh, Kyle; Ripke, Stephan; Daly, Mark J.; Neale, Benjamin M.] Harvard Univ, Sch Med, Boston, MA USA; [Bulik-Sullivan, Brendan; Anttila, Verneri; Ripke, Stephan; Daly, Mark J.; Neale, Benjamin M.] Broad Inst MIT & Harvard, Stanley Ctr Psychiat Res, Cambridge, MA USA; [Trynka, Gosia; Purcell, Shaun; Raychaudhuri, Soumya] Harvard Univ, Sch Med, Div Genet, Brigham & Womens Hosp, Boston, MA USA; [Trynka, Gosia; Purcell, Shaun; Raychaudhuri, Soumya] Harvard Univ, Sch Med, Div Rheumatol, Brigham & Womens Hosp, Boston, MA USA; [Trynka, Gosia; Raychaudhuri, Soumya] Partners Ctr Personalized Genet Med, Boston, MA USA; [Trynka, Gosia; Anttila, Verneri; Raychaudhuri, Soumya; Daly, Mark J.; Patterson, Nick; Neale, Benjamin M.; Price, Alkes L.] Broad Inst MIT & Harvard, Program Med & Populat Genet, Cambridge, MA USA; [Trynka, Gosia] Wellcome Trust Sanger Inst, Cambridge, England; [Reshef, Yakir] Harvard Univ, Dept Comp Sci, Cambridge, MA 02138 USA; [Xu, Han; Zang, Chongzhi] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA; [Xu, Han; Zang, Chongzhi] Harvard Univ, TH Chan Sch Publ Hlth, Boston, MA 02115 USA; [Farh, Kyle] Broad Inst MIT & Harvard, Epigen Program, Cambridge, MA USA; [Day, Felix R.; Perry, John R. B.] Univ Cambridge, MRC, Epidemiol Unit, Sch Clin Med,Inst Metab Sci, Cambridge, England; [Purcell, Shaun; Stahl, Eli] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA; [Okada, Yukinori] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Human Genet & Dis Divers, Tokyo, Japan; [Okada, Yukinori] RIKEN, Ctr Integrat Med Sci, Lab Stat Anal, Yokohama, Kanagawa, Japan; [Raychaudhuri, Soumya] Univ Manchester, Fac Med & Human Sci, Manchester, Lancs, England	Finucane, HK (reprint author), MIT, Dept Math, Cambridge, MA 02139 USA.	hilaryf@mit.edu; bulik@broadinstitute.org; bneale@broadinstitute.org; aprice@hsph.harvard.edu	Hansen, Thomas Folkmann/O-5965-2014	Day, Felix/0000-0003-3789-7651; Hansen, Thomas Folkmann/0000-0001-6703-7762	US National Institutes of Health [R01 MH101244, R01 HG006399, R03 CA173785, R21 CA182821, F32 GM106584, U01 HG0070033]; Fannie and John Hertz Foundation; Wellcome Trust Sanger Institute [WT098051]; National Institute of General Medical Sciences [T32 GM007753]; Arthritis Foundation; Doris Duke Clinical Scientist Development Award; Wellcome Trust [076113]	We thank B. Bernstein, M. Finucane, A. Forrest, E. Hodis, D. Kotliar, X.S. Liu, M. Kellis, M. O'Donovan, B. Pasaniuc, A. Sandelin, A. Sarkar, P. Sullivan, B. Vilhjalmsson, A. Veres and the anonymous reviewers for helpful discussions and/or comments. This research was funded by US National Institutes of Health grants R01 MH101244, R01 HG006399, R03 CA173785, R21 CA182821, F32 GM106584 and U01 HG0070033. H.K.F. was also supported by the Fannie and John Hertz Foundation. G.T. is supported by the Wellcome Trust Sanger Institute (WT098051). Y.R. was supported by award T32 GM007753 from the National Institute of General Medical Sciences. S. Raychaudhuri is supported by funding from the Arthritis Foundation and by a Doris Duke Clinical Scientist Development Award. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of General Medical Sciences or the National Institutes of Health. This study made use of data generated by the Wellcome Trust Case Control Consortium (WTCCC) and the Wellcome Trust Sanger Institute. A full list of the investigators who contributed to the generation of the WTCCC data is available at http://www.wtccc.org.uk/. Funding for the WTCCC project was provided by the Wellcome Trust under award 076113.	Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632; Teslovich TM, 2010, NATURE, V466, P707, DOI 10.1038/nature09270; Liu DJJ, 2014, NAT GENET, V46, P200, DOI 10.1038/ng.2852; Speliotes EK, 2010, NAT GENET, V42, P937, DOI 10.1038/ng.686; Gusev A, 2014, AM J HUM GENET, V95, P535, DOI 10.1016/j.ajhg.2014.10.004; Yang JA, 2011, AM J HUM GENET, V88, P76, DOI 10.1016/j.ajhg.2010.11.011; Stahl EA, 2012, NAT GENET, V44, P483, DOI 10.1038/ng.2232; Hnisz D, 2013, CELL, V155, P934, DOI 10.1016/j.cell.2013.09.053; Schunkert H, 2011, NAT GENET, V43, P333, DOI 10.1038/ng.784; Lee SH, 2012, NAT GENET, V44, P247, DOI 10.1038/ng.1108; Hoffman MM, 2013, NUCLEIC ACIDS RES, V41, P827, DOI 10.1093/nar/gks1284; Lindblad-Toh K, 2011, NATURE, V478, P476, DOI 10.1038/nature10530; Ward LD, 2012, SCIENCE, V337, P1675, DOI 10.1126/science.1225057; Parker SCJ, 2013, P NATL ACAD SCI USA, V110, P17921, DOI 10.1073/pnas.1317023110; Trynka G, 2013, NAT GENET, V45, P124, DOI 10.1038/ng.2504; Allen HL, 2010, NATURE, V467, P832, DOI 10.1038/nature09410; Morris AP, 2012, NAT GENET, V44, P981, DOI 10.1038/ng.2383; Yang J, 2011, EUR J HUM GENET, V19, P807, DOI 10.1038/ejhg.2011.39; Jostins L, 2012, NATURE, V491, P119, DOI 10.1038/nature11582; Yang JA, 2010, NAT GENET, V42, P565, DOI 10.1038/ng.608; Pasquali L, 2014, NAT GENET, V46, P136, DOI 10.1038/ng.2870; Trynka G, 2015, AM J HUM GENET, V97, P139, DOI 10.1016/j.ajhg.2015.05.016; Yin LM, 2007, NATURE, V446, P661, DOI 10.1038/nature05682; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Wang WH, 2012, RHEUMATOL INT, V32, P887, DOI 10.1007/s00296-010-1710-0; Faroodi IS, 2014, CLIN MED, V14, P286, DOI 10.7861/clinmedicine.14-3-286; Okada Y, 2014, NATURE, V506, P376, DOI 10.1038/nature12873; Maurano MT, 2012, SCIENCE, V337, P1190, DOI 10.1126/science.1222794; Andersson R, 2014, NATURE, V507, P455, DOI 10.1038/nature12787; Manning AK, 2012, NAT GENET, V44, P659, DOI 10.1038/ng.2274; Bulik-Sullivan B, 2015, NAT GENET, V47, P1236, DOI 10.1038/ng.3406; Ripke S, 2014, NATURE, V511, P421, DOI 10.1038/nature13595; Pickrell JK, 2014, AM J HUM GENET, V94, P559, DOI 10.1016/j.ajhg.2014.03.004; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Boraska V, 2014, MOL PSYCHIATR, V19, P1085, DOI 10.1038/mp.2013.187; Bulik-Sullivan BK, 2015, NAT GENET, V47, P291, DOI 10.1038/ng.3211; Davis LK, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003864; Farh KKH, 2015, NATURE, V518, DOI 10.1038/nature13835; International HapMap 3 Consortium, 2010, NATURE, V467, P52; Kettyle W.M., 1998, ENDOCRINE PATHOPHYSI; Kichaev G, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004722; Lilly L.S., 2012, PATHOPHYSIOLOGY HEAR; Perry JRB, 2014, NATURE, V514, P92, DOI 10.1038/nature13545; Pott S, 2015, NAT GENET, V47, P8, DOI 10.1038/ng.3167; Psychiatric GWAS Consortium Bipolar Disorder Working Group, 2011, NAT GENET, V43, P977; Rietveld CA, 2013, SCIENCE, V340, P1467, DOI 10.1126/science.1235488; Roadmap Epigenomics Consortium, 2015, NATURE, V518, P317, DOI DOI 10.1038/NATURE14248; Stamatoyannopoulos JA, 2012, GENOME RES, V22, P1602, DOI 10.1101/gr.146506.112; Furberg H, 2010, NAT GENET, V42, P441, DOI 10.1038/ng.571	49	2	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2015	47	11					1228	+		10.1038/ng.3404		11	Genetics & Heredity	Genetics & Heredity	CV1BN	WOS:000363988200005		
J	Kato, N; Loh, M; Takeuchi, F; Verweij, N; Wang, X; Zhang, WH; Kelly, TN; Saleheen, D; Lehne, B; Leach, IM; Drong, AW; Abbott, J; Wahl, S; Tan, ST; Scott, WR; Campanella, G; Chadeau-Hyam, M; Afzal, U; Ahluwalia, TS; Bonder, MJ; Chen, P; Dehghan, A; Edwards, TL; Esko, T; Go, MJ; Harris, SE; Hartiala, J; Kasela, S; Kasturiratne, A; Khor, CC; Kleber, ME; Li, HX; Mok, ZY; Nakatochi, M; Sapari, NS; Saxena, R; Stewart, AFR; Stolk, L; Tabara, Y; Teh, AL; Wu, Y; Wu, JY; Zhang, Y; Aits, I; Alves, ADC; Das, S; Dorajoo, R; Hopewell, JC; Kim, YK; Koivula, RW; Luan, J; Lyytikainen, LP; Nguyen, QN; Pereira, MA; Postmus, I; Raitakari, OT; Bryan, MS; Scott, RA; Sorice, R; Tragante, V; Traglia, M; White, J; Yamamoto, K; Zhang, YH; Adair, LS; Ahmed, A; Akiyama, K; Asif, R; Aung, T; Barroso, I; Bjonnes, A; Braun, TR; Cai, H; Chang, LC; Chen, CH; Cheng, CY; Chong, YS; Collins, R; Courtney, R; Davies, G; Delgado, G; Do, LD; Doevendans, PA; Gansevoort, RT; Gao, YT; Grammer, TB; Grarup, N; Grewal, J; Gu, DF; Wander, GS; Hartikainen, AL; Hazen, SL; He, J; Heng, CK; Hixson, JE; Hofman, A; Hsu, C; Huang, W; Husemoen, LLN; Hwang, JY; Ichihara, S; Igase, M; Isono, M; Justesen, JM; Katsuy, T; Kibriya, MG; Kim, YJ; Kishimoto, M; Koh, WP; Kohara, K; Kumari, M; Kwek, K; Lee, NR; Lee, J; Liao, JM; Lieb, W; Liewald, DCM; Matsubara, T; Matsushita, Y; Meitinger, T; Mihailov, E; Milani, L; Mills, R; Mononen, N; Muller-Nurasyid, M; Nabika, T; Nakashima, E; Ng, HK; Nikus, K; Nutile, T; Ohkubo, T; Ohnaka, K; Parish, S; Paternoster, L; Peng, H; Peters, A; Pham, ST; Pinidiyapathirage, MJ; Rahman, M; Rakugi, H; Rolandsson, O; Rozario, MA; Ruggiero, D; Sala, CF; Sarju, R; Shimokawa, K; Snieder, H; Sparso, T; Spiering, W; Starr, JM; Stott, DJ; Stram, DO; Sugiyama, T; Szymczak, S; Tang, WHW; Tong, L; Trompet, S; Turjanmaa, V; Ueshima, H; Uitterlinden, AG; Umemura, S; Vaarasmaki, M; van Dam, RM; van Gilst, WH; van Veldhuisen, DJ; Viikari, JS; Waldenberger, M; Wang, YQ; Wang, AL; Wilson, R; Wong, TY; Xiang, YB; Yamaguchi, S; Ye, XW; Young, RD; Young, TL; Yuan, JM; Zhou, XY; Asselbergs, FW; Ciullo, M; Clarke, R; Deloukas, P; Franke, A; Franks, PW; Franks, S; Friedlander, Y; Gross, MD; Guo, ZR; Hansen, T; Jarvelin, MR; Jorgensen, T; Jukema, JW; Kahonen, M; Kajio, H; Kivimaki, M; Lee, JY; Lehtimaki, T; Linneberg, A; Miki, T; Pedersen, O; Samani, NJ; Sorensen, TIA; Takayanagi, R; Toniolo, D; Ahsan, H; Allayee, H; Chen, YT; Danesh, J; Deary, IJ; Franco, OH; Franke, L; Heijman, BT; Holbrook, JD; Isaacs, A; Kim, BJ; Lin, X; Liu, JJ; Marz, W; Metspalu, A; Mohlke, KL; Sanghera, DK; Shu, XO; van Meurs, JBJ; Vithana, E; Wickremasinghe, AR; Wijmenga, C; Wolffenbuttel, BHW; Yokota, M; Zheng, W; Zhu, DL; Vineis, P; Kyrtopoulos, SA; Kleinjans, JCS; McCarthy, MI; Soong, R; Gieger, C; Scott, J; Teo, YY; He, J; Elliott, P; Tai, ES; van der Harst, P; Kooner, JS; Chambers, JC				Kato, Norihiro; Loh, Marie; Takeuchi, Fumihiko; Verweij, Niek; Wang, Xu; Zhang, Weihua; Kelly, Tanika N.; Saleheen, Danish; Lehne, Benjamin; Leach, Irene Mateo; Drong, Alexander W.; Abbott, James; Wahl, Simone; Tan, Sian-Tsung; Scott, William R.; Campanella, Gianluca; Chadeau-Hyam, Marc; Afzal, Uzma; Ahluwalia, Tarunveer S.; Bonder, Marc Jan; Chen, Peng; Dehghan, Abbas; Edwards, Todd L.; Esko, Tonu; Go, Min Jin; Harris, Sarah E.; Hartiala, Jaana; Kasela, Silva; Kasturiratne, Anuradhani; Khor, Chiea-Chuen; Kleber, Marcus E.; Li, Huaixing; Mok, Zuan Yu; Nakatochi, Masahiro; Sapari, Nur Sabrina; Saxena, Richa; Stewart, Alexandre F. R.; Stolk, Lisette; Tabara, Yasuharu; Teh, Ai Ling; Wu, Ying; Wu, Jer-Yuarn; Zhang, Yi; Aits, Imke; Alves, Alexessander Da Silva Couto; Das, Shikta; Dorajoo, Rajkumar; Hopewell, Jemma C.; Kim, Yun Kyoung; Koivula, Robert W.; Luan, Jian'an; Lyytikainen, Leo-Pekka; Nguyen, Quang N.; Pereira, Mark A.; Postmus, Iris; Raitakari, Olli T.; Bryan, Molly Scannell; Scott, Robert A.; Sorice, Rossella; Tragante, Vinicius; Traglia, Michela; White, Jon; Yamamoto, Ken; Zhang, Yonghong; Adair, Linda S.; Ahmed, Alauddin; Akiyama, Koichi; Asif, Rasheed; Aung, Tin; Barroso, Ines; Bjonnes, Andrew; Braun, Timothy R.; Cai, Hui; Chang, Li-Ching; Chen, Chien-Hsiun; Cheng, Ching-Yu; Chong, Yap-Seng; Collins, Rory; Courtney, Regina; Davies, Gail; Delgado, Graciela; Do, Loi D.; Doevendans, Pieter A.; Gansevoort, Ron T.; Gao, Yu-Tang; Grammer, Tanja B.; Grarup, Niels; Grewal, Jagvir; Gu, Dongfeng; Wander, Gurpreet S.; Hartikainen, Anna-Liisa; Hazen, Stanley L.; He, Jing; Heng, Chew-Kiat; Hixson, James E.; Hofman, Albert; Hsu, Chris; Huang, Wei; Husemoen, Lise L. N.; Hwang, Joo-Yeon; Ichihara, Sahoko; Igase, Michiya; Isono, Masato; Justesen, Johanne M.; Katsuy, Tomohiro; Kibriya, Muhammad G.; Kim, Young Jin; Kishimoto, Miyako; Koh, Woon-Puay; Kohara, Katsuhiko; Kumari, Meena; Kwek, Kenneth; Lee, Nanette R.; Lee, Jeannette; Liao, Jiemin; Lieb, Wolfgang; Liewald, David C. M.; Matsubara, Tatsuaki; Matsushita, Yumi; Meitinger, Thomas; Mihailov, Evelin; Milani, Lili; Mills, Rebecca; Mononen, Nina; Mueller-Nurasyid, Martina; Nabika, Toru; Nakashima, Eitaro; Ng, Hong Kiat; Nikus, Kjell; Nutile, Teresa; Ohkubo, Takayoshi; Ohnaka, Keizo; Parish, Sarah; Paternoster, Lavinia; Peng, Hao; Peters, Annette; Pham, Son T.; Pinidiyapathirage, Mohitha J.; Rahman, Mahfuzar; Rakugi, Hiromi; Rolandsson, Olov; Rozario, Michelle Ann; Ruggiero, Daniela; Sala, Cinzia F.; Sarju, Ralhan; Shimokawa, Kazuro; Snieder, Harold; Sparso, Thomas; Spiering, Wilko; Starr, John M.; Stott, David J.; Stram, Daniel O.; Sugiyama, Takao; Szymczak, Silke; Tang, W. H. Wilson; Tong, Lin; Trompet, Stella; Turjanmaa, Vaino; Ueshima, Hirotsugu; Uitterlinden, Andre G.; Umemura, Satoshi; Vaarasmaki, Marja; van Dam, Rob M.; van Gilst, Wiek H.; van Veldhuisen, Dirk J.; Viikari, Jorma S.; Waldenberger, Melanie; Wang, Yiqin; Wang, Aili; Wilson, Rory; Wong, Tien-Yin; Xiang, Yong-Bing; Yamaguchi, Shuhei; Ye, Xingwang; Young, Robin D.; Young, Terri L.; Yuan, Jian-Min; Zhou, Xueya; Asselbergs, Folkert W.; Ciullo, Marina; Clarke, Robert; Deloukas, Panos; Franke, Andre; Franks, Paul W.; Franks, Steve; Friedlander, Yechiel; Gross, Myron D.; Guo, Zhirong; Hansen, Torben; Jarvelin, Marjo-Riitta; Jorgensen, Torben; Jukema, J. Wouter; Kahonen, Mika; Kajio, Hiroshi; Kivimaki, Mika; Lee, Jong-Young; Lehtimaki, Terho; Linneberg, Allan; Miki, Tetsuro; Pedersen, Oluf; Samani, Nilesh J.; Sorensen, Thorkild I. A.; Takayanagi, Ryoichi; Toniolo, Daniela; Ahsan, Habibul; Allayee, Hooman; Chen, Yuan-Tsong; Danesh, John; Deary, Ian J.; Franco, Oscar H.; Franke, Lude; Heijman, Bastiaan T.; Holbrook, Joanna D.; Isaacs, Aaron; Kim, Bong-Jo; Lin, Xu; Liu, Jianjun; Maerz, Winfried; Metspalu, Andres; Mohlke, Karen L.; Sanghera, Dharambir K.; Shu, Xiao-Ou; van Meurs, Joyce B. J.; Vithana, Eranga; Wickremasinghe, Ananda R.; Wijmenga, Cisca; Wolffenbuttel, Bruce H. W.; Yokota, Mitsuhiro; Zheng, Wei; Zhu, Dingliang; Vineis, Paolo; Kyrtopoulos, Soterios A.; Kleinjans, Jos C. S.; McCarthy, Mark I.; Soong, Richie; Gieger, Christian; Scott, James; Teo, Yik-Ying; He, Jiang; Elliott, Paul; Tai, E. Shyong; van der Harst, Pim; Kooner, Jaspal S.; Chambers, John C.		BIOS-consortium; CARDIo GRAMplusCD; LifeLines Cohort Study; InterAct Consortium	Trans-ancestry genome-wide association study identifies 12 genetic loci influencing blood pressure and implicates a role for DNA methylation	NATURE GENETICS			English	Article							PULMONARY ARTERIAL-HYPERTENSION; CENTRIC ARRAY; RISK-FACTORS; CARDIOVASCULAR-DISEASE; VARIANTS; REGIONS; KIDNEY; TISSUE; METAANALYSIS; INDIVIDUALS	We carried out a trans-ancestry genome-wide association and replication study of blood pressure phenotypes among up to 320,251 individuals of East Asian, European and South Asian ancestry. We find genetic variants at 12 new loci to be associated with blood pressure (P = 3.9 x 10(-11) to 5.0 x 10(-21)). The sentinel blood pressure SNPs are enriched for association with DNA methylation at multiple nearby CpG sites, suggesting that, at some of the loci identified, DNA methylation may lie on the regulatory pathway linking sequence variation to blood pressure. The sentinel SNPs at the 12 new loci point to genes involved in vascular smooth muscle (IGFBP3, KCNK3, PDE3A and PRDM6) and renal (ARHGAP24, OSR1, SLC22A7 and TBX2) function. The new and known genetic variants predict increased left ventricular mass, circulating levels of NT-proBNP, and cardiovascular and all-cause mortality (P = 0.04 to 8.6 x 10(-6)). Our results provide new evidence for the role of DNA methylation in blood pressure regulation.	[Kato, Norihiro; Takeuchi, Fumihiko; Akiyama, Koichi; Isono, Masato; Shimokawa, Kazuro] Natl Ctr Global Hlth & Med, Res Inst, Dept Gene Diagnost & Therapeut, Tokyo, Japan; [Loh, Marie; Jarvelin, Marjo-Riitta] Univ Oulu, Inst Hlth Sci, Oulu, Finland; [Loh, Marie; Zhang, Weihua; Lehne, Benjamin; Scott, William R.; Campanella, Gianluca; Chadeau-Hyam, Marc; Afzal, Uzma; Grewal, Jagvir; Vineis, Paolo; Elliott, Paul; Chambers, John C.] Univ London Imperial Coll Sci Technol & Med, Dept Epidemiol & Biostat, London, England; [Loh, Marie] ASTAR, Translat Lab Genet Med, Singapore, Singapore; [Verweij, Niek; Leach, Irene Mateo; van Gilst, Wiek H.; van Veldhuisen, Dirk J.; van der Harst, Pim] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands; [Wang, Xu; Chen, Peng; Khor, Chiea-Chuen; Cheng, Ching-Yu; Koh, Woon-Puay; Lee, Jeannette; van Dam, Rob M.; Liu, Jianjun; Teo, Yik-Ying; Tai, E. Shyong] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 117548, Singapore; [Wang, Xu; Chen, Peng; Khor, Chiea-Chuen; Cheng, Ching-Yu; Koh, Woon-Puay; Lee, Jeannette; van Dam, Rob M.; Liu, Jianjun; Teo, Yik-Ying; Tai, E. Shyong] Natl Univ Hlth Syst, Singapore, Singapore; [Zhang, Weihua; Tan, Sian-Tsung; Afzal, Uzma; Grewal, Jagvir; Mills, Rebecca; Kooner, Jaspal S.; Chambers, John C.] Ealing Hosp Natl Hlth Serv NHS Trust, Southall, Middx, England; [Kelly, Tanika N.; He, Jiang] Tulane Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, New Orleans, LA USA; [Saleheen, Danish; Asif, Rasheed] Ctr Non Communicable Dis, Karachi, Pakistan; [Saleheen, Danish; Young, Robin D.; Danesh, John] Univ Cambridge, Dept Publ Hlth & Primary Care, Strangeways Res Lab, Cambridge, England; [Saleheen, Danish] Univ Penn, Perelman Sch Med, Cardiovasc Inst, Philadelphia, PA 19104 USA; [Drong, Alexander W.; McCarthy, Mark I.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England; [Abbott, James] Univ London Imperial Coll Sci Technol & Med, Bioinformat Support Serv, London, England; [Wahl, Simone; Waldenberger, Melanie; Wilson, Rory; Gieger, Christian] Helmholtz Zentrum Munchen, German Res Ctr Environm Hlth, Res Unit Mol Epidemiol, Neuherberg, Germany; [Wahl, Simone; Peters, Annette; Waldenberger, Melanie; Wilson, Rory; Gieger, Christian] Helmholtz Zentrum Munchen, German Res Ctr Environm Hlth, Inst Epidemiol 2, Neuherberg, Germany; [Wahl, Simone] German Ctr Diabet Res DZD, Neuherberg, Germany; [Tan, Sian-Tsung; Scott, William R.; Scott, James; Kooner, Jaspal S.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England; [Ahluwalia, Tarunveer S.; Grarup, Niels; Justesen, Johanne M.; Sparso, Thomas; Hansen, Torben; Pedersen, Oluf; Sorensen, Thorkild I. A.] Univ Copenhagen, Fac Hlth & Med Sci, Sect Metab Genet, Novo Nordisk Fdn Ctr Basic Metab Res, Copenhagen, Denmark; [Ahluwalia, Tarunveer S.] Univ Copenhagen, Herlev & Gentofte Hosp, Copenhagen Prospect Studies Asthma Childhood COSP, Copenhagen, Denmark; [Ahluwalia, Tarunveer S.] Steno Diabet Ctr, DK-2820 Gentofte, Denmark; [Bonder, Marc Jan; Franke, Lude; Wijmenga, Cisca; van der Harst, Pim] Univ Groningen, Univ Med Ctr Groningen, Dept Genet, Groningen, Netherlands; [Dehghan, Abbas; Hofman, Albert; Uitterlinden, Andre G.; Franco, Oscar H.; Isaacs, Aaron] Erasmus Univ, Med Ctr, Dept Epidemiol, Rotterdam, Netherlands; [Edwards, Todd L.] Vanderbilt Univ, Dept Med, Div Epidemiol, Vanderbilt Epidemiol Ctr,Ctr Human Genet Res, Nashville, TN USA; [Esko, Tonu; Kasela, Silva; Mihailov, Evelin; Milani, Lili; Metspalu, Andres] Univ Tartu, Estonian Genome Ctr, EE-50090 Tartu, Estonia; [Esko, Tonu] Childrens Hosp, Div Endocrinol, Boston, MA 02115 USA; [Esko, Tonu] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA; [Esko, Tonu] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA; [Go, Min Jin; Kim, Yun Kyoung; Hwang, Joo-Yeon; Kim, Young Jin; Kim, Bong-Jo] Natl Inst Hlth, Ctr Genome Sci, Chungcheongbuk Do, South Korea; [Harris, Sarah E.] Univ Edinburgh, Med Genet Sect, Ctr Genom & Expt Med, Edinburgh, Midlothian, Scotland; [Harris, Sarah E.] Western Gen Hosp, Inst Genet & Mol Med, MRC, Edinburgh EH4 2XU, Midlothian, Scotland; [Harris, Sarah E.; Davies, Gail; Liewald, David C. M.; Starr, John M.; Deary, Ian J.] Univ Edinburgh, Ctr Cognit Aging & Cognit Epidemiol, Edinburgh, Midlothian, Scotland; [Hartiala, Jaana; Allayee, Hooman] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA; [Hartiala, Jaana; Allayee, Hooman] Univ So Calif, Keck Sch Med, Inst Med Genet, Los Angeles, CA 90033 USA; [Kasturiratne, Anuradhani; Pinidiyapathirage, Mohitha J.; Wickremasinghe, Ananda R.] Univ Kelaniya, Fac Med, Dept Publ Hlth, Ragama, Sri Lanka; [Khor, Chiea-Chuen; Dorajoo, Rajkumar; Liu, Jianjun; Teo, Yik-Ying] ASTAR, Genome Inst Singapore, Singapore, Singapore; [Khor, Chiea-Chuen; Cheng, Ching-Yu; Liao, Jiemin; Wong, Tien-Yin; Vithana, Eranga] Natl Univ Singapore, Dept Ophthalmol, Singapore 117548, Singapore; [Khor, Chiea-Chuen] Natl Univ Singapore, Dept Paediat, Singapore 117548, Singapore; [Kleber, Marcus E.; Delgado, Graciela; Grammer, Tanja B.; Maerz, Winfried] Heidelberg Univ, Mannheim Med Fac, Med Clin V, Mannheim, Germany; [Li, Huaixing; Wang, Yiqin; Ye, Xingwang; Lin, Xu] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Nutr Sci, Key Lab Nutr & Metab, Shanghai, Peoples R China; [Mok, Zuan Yu; Sapari, Nur Sabrina; Ng, Hong Kiat; Rozario, Michelle Ann; Soong, Richie] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore 117548, Singapore; [Nakatochi, Masahiro] Nagoya Univ Hosp, Ctr Adv Med & Clin Res, Nagoya, Aichi, Japan; [Saxena, Richa; Bjonnes, Andrew] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Human Genet Res, Boston, MA USA; [Stewart, Alexandre F. R.] Univ Ottawa, Inst Heart, Cardiovasc Res Methods Ctr, Ottawa, ON, Canada; [Stewart, Alexandre F. R.] Ruddy Canadian Cardiovasc Genet Ctr, Ottawa, ON, Canada; [Stolk, Lisette; Uitterlinden, Andre G.; van Meurs, Joyce B. J.] Erasmus Univ, Med Ctr, Dept Internal Med, Rotterdam, Netherlands; [Tabara, Yasuharu] Kyoto Univ, Grad Sch Med, Ctr Genom Med, Kyoto, Japan; [Teh, Ai Ling; Chong, Yap-Seng; Holbrook, Joanna D.] ASTAR, Singapore Inst Clin Sci, Singapore, Singapore; [Wu, Ying; Mohlke, Karen L.] Univ N Carolina, Dept Genet, Chapel Hill, NC USA; [Wu, Jer-Yuarn; Chang, Li-Ching; Chen, Chien-Hsiun; Chen, Yuan-Tsong] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan; [Wu, Jer-Yuarn; Chen, Chien-Hsiun] China Med Univ, Sch Chinese Med, Taichung, Taiwan; [Zhang, Yi; Zhu, Dingliang] Shanghai Jiao Tong Univ, Sch Med, Shanghai Ruijin Hosp, State Key Lab Med Genet, Shanghai 200030, Peoples R China; [Zhang, Yi; Zhu, Dingliang] Shanghai Res Inst Hypertens, Shanghai, Peoples R China; [Aits, Imke; Lieb, Wolfgang] Univ Kiel, Inst Epidemiol & Biobank Popgen, Kiel, Germany; [Alves, Alexessander Da Silva Couto; Das, Shikta; Jarvelin, Marjo-Riitta] Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, Dept Epidemiol & Biostat, MRC,Hlth Protect Agcy PHE,Ctr Environm & Hlth, London, England; [Hopewell, Jemma C.; Collins, Rory; Parish, Sarah; Clarke, Robert] Univ Oxford, Nuffield Dept Populat Hlth, Clin Trials Support Unit, Oxford, England; [Koivula, Robert W.; Franks, Paul W.] Skane Univ, Hosp Malmo, Dept Clin Sci, Genet & Mol Epidemiol Unit, Malmo, Sweden; [Luan, Jian'an; Scott, Robert A.] Univ Cambridge, Epidemiol Unit, MRC, Inst Metab Sci, Cambridge, England; [Lyytikainen, Leo-Pekka; Mononen, Nina; Lehtimaki, Terho] Fimlab Labs, Dept Clin Chem, Tampere, Finland; [Lyytikainen, Leo-Pekka; Mononen, Nina; Lehtimaki, Terho] Univ Tampere, Sch Med, Dept Clin Chem, FIN-33101 Tampere, Finland; [Nguyen, Quang N.; Do, Loi D.; Pham, Son T.] Bach Mai Hosp, Vietnam Natl Heart Inst, Hanoi, Vietnam; [Pereira, Mark A.] Univ Minnesota, Sch Publ Hlth, Minneapolis, MN USA; [Postmus, Iris] Leiden Univ, Med Ctr, Dept Gerontol & Geriatr, Leiden, Netherlands; [Postmus, Iris] Netherlands Consortium Hlth Ageing, Leiden, Netherlands; [Raitakari, Olli T.] Turku Univ Hosp, Dept Clin Physiol & Nucl Med, FIN-20520 Turku, Finland; [Raitakari, Olli T.] Univ Turku, Res Ctr Appl & Prevent Cardiovasc Med, Turku, Finland; [Bryan, Molly Scannell; Kibriya, Muhammad G.; Tong, Lin; Ahsan, Habibul] Univ Chicago, Dept Publ Hlth Sci, Chicago, IL 60637 USA; [Sorice, Rossella; Nutile, Teresa; Ruggiero, Daniela; Ciullo, Marina] CNR, Inst Genet & Biophys Buzzati Traverso, I-80125 Naples, Italy; [Tragante, Vinicius; Doevendans, Pieter A.; Asselbergs, Folkert W.] Univ Med Ctr Utrecht, Dept Cardiol, Div Heart & Lungs, Utrecht, Netherlands; [Traglia, Michela; Sala, Cinzia F.; Toniolo, Daniela] Ist Sci San Raffaele, Div Genet & Cell Biol, I-20132 Milan, Italy; [Traglia, Michela] Ist Ricovero & Cura Carattere Sci IRCCS Burlo Gar, Inst Maternal & Child Hlth, Trieste, Italy; [White, Jon] UCL, Genet Inst, Dept Genet Environm & Evolut, London, England; [Yamamoto, Ken] Kyushu Univ, Med Inst Bioregulat, Div Genom, Fukuoka 812, Japan; [Zhang, Yonghong; Peng, Hao; Wang, Aili; Guo, Zhirong] Soochow Univ, Coll Med, Sch Publ Hlth, Dept Epidemiol, Suzhou, Peoples R China; [Adair, Linda S.] Univ N Carolina, Dept Nutr, Chapel Hill, NC USA; [Ahmed, Alauddin; Rahman, Mahfuzar] UChicago Res Bangladesh, Dhaka, Bangladesh; [Aung, Tin; Cheng, Ching-Yu; Liao, Jiemin; Wong, Tien-Yin; Vithana, Eranga; Teo, Yik-Ying] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore; [Barroso, Ines] Wellcome Trust Sanger Inst, Metabol Dis Grp, Cambridge, England; [Barroso, Ines] Addenbrookes Hosp, Inst Metab Sci, Natl Inst Hlth Res, Cambridge Biomed Res Ctr, Cambridge, England; [Barroso, Ines] Univ Cambridge, Addenbrookes Hosp, Inst Metab Sci, Metab Res Labs, Cambridge CB2 2QQ, England; [Braun, Timothy R.; Sanghera, Dharambir K.] Univ Oklahoma, Hlth Sci Ctr, Dept Pediat, Oklahoma City, OK 73190 USA; [Cai, Hui; Courtney, Regina; Shu, Xiao-Ou; Zheng, Wei] Vanderbilt Univ, Dept Med, Div Epidemiol, Vanderbilt Epidemiol Ctr,Vanderbilt Genet Inst, Nashville, TN USA; [Cai, Hui; Courtney, Regina; Shu, Xiao-Ou; Zheng, Wei] Vanderbilt Univ, Dept Med, Div Epidemiol, Vanderbilt Ingram Canc Ctr, Nashville, TN USA; [Cheng, Ching-Yu] Duke Natl Univ Singapore, Grad Sch Med, Off Clin Sci, Ctr Quantitat Med, Singapore, Singapore; [Chong, Yap-Seng] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore 117595, Singapore; [Davies, Gail; Liewald, David C. M.; Deary, Ian J.] Univ Edinburgh, Dept Psychol, Edinburgh, Midlothian, Scotland; [Gansevoort, Ron T.] Univ Groningen, Univ Med Ctr Groningen, Dept Internal Med, Groningen, Netherlands; [Gao, Yu-Tang; Xiang, Yong-Bing] Shanghai Canc Inst, Dept Epidemiol, Shanghai, Peoples R China; [Gu, Dongfeng] Chinese Acad Med Sci, Fu Wai Hosp, Beijing 100730, Peoples R China; [Gu, Dongfeng] Chinese Acad Med Sci, Cardiovasc Inst, Beijing 100730, Peoples R China; [Gu, Dongfeng] Peking Union Med Coll, Beijing 100021, Peoples R China; [Wander, Gurpreet S.; Sarju, Ralhan] Hero DMC Heart Inst, Dayanand Med Coll & Hosp Unit, Ludhiana, Punjab, India; [Hartikainen, Anna-Liisa; Vaarasmaki, Marja] Oulu Univ Hosp, Dept Obstet & Gynecol, Oulu, Finland; [Hartikainen, Anna-Liisa; Vaarasmaki, Marja] Univ Oulu, Med Res Ctr, Oulu, Finland; [Hartikainen, Anna-Liisa; Vaarasmaki, Marja; Jarvelin, Marjo-Riitta] Oulu Univ Hosp, Unit Primary Care, Oulu, Finland; [Hazen, Stanley L.; Tang, W. H. Wilson] Cleveland Clin, Inst Heart & Vasc, Dept Cardiovasc Med, Cleveland, OH 44106 USA; [Hazen, Stanley L.] Cleveland Clin, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44106 USA; [He, Jing] Vanderbilt Univ, Dept Biostat, Nashville, TN 37235 USA; [Heng, Chew-Kiat] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pediat, Singapore 117595, Singapore; [Hixson, James E.] Univ Texas Houston, Sch Publ Hlth, Ctr Human Genet, Houston, TX USA; [Hsu, Chris; Stram, Daniel O.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA; [Huang, Wei] Chinese Natl Human Genom Ctr, Dept Genet, Shanghai, Peoples R China; [Husemoen, Lise L. N.; Jorgensen, Torben; Linneberg, Allan] Glostrup Univ Hosp, Res Ctr Prevent & Hlth, Glostrup, Denmark; [Ichihara, Sahoko] Mie Univ, Grad Sch Reg Innovat Studies, Tsu, Mie 514, Japan; [Igase, Michiya; Kohara, Katsuhiko; Miki, Tetsuro] Ehime Univ, Grad Sch Med, Dept Geriatr Med, Toon, Ehime, Japan; [Katsuy, Tomohiro; Tai, E. Shyong] Osaka Univ, Grad Sch Med, Dept Clin Gene Therapy, Suita, Osaka, Japan; [Katsuy, Tomohiro; Rakugi, Hiromi] Osaka Univ, Grad Sch Med, Dept Geriatr Med & Nephrol, Suita, Osaka, Japan; [Kishimoto, Miyako; Matsushita, Yumi; Kajio, Hiroshi] Natl Ctr Global Hlth & Med, Toyama, Japan; [Koh, Woon-Puay] Duke Natl Univ Singapore, Grad Sch Med, Singapore, Singapore; [Kumari, Meena; Kivimaki, Mika] UCL, Dept Epidemiol & Publ Hlth, London, England; [Kwek, Kenneth] KK Womens & Childrens Hosp, Singapore, Singapore; [Lee, Nanette R.] Univ San Carlos, Off Populat Studies Fdn, Cebu, Philippines; [Lee, Nanette R.] Univ San Carlos, Dept Anthropol Sociol & Hist, Cebu, Philippines; [Matsubara, Tatsuaki] Aichi Gakuin Univ, Sch Dent, Dept Internal Med, Nagoya, Aichi 464, Japan; [Meitinger, Thomas] Helmholtz Zenntrum Munchen, German Res Ctr Environm Hlth, Inst Human Genet, Neuherberg, Germany; [Meitinger, Thomas] Tech Univ Munich, Inst Human Genet, D-80290 Munich, Germany; [Mueller-Nurasyid, Martina] Helmholtz Zenntrum Munchen, German Res Ctr Environm Hlth, Inst Genet Epidemiol, Neuherberg, Germany; [Mueller-Nurasyid, Martina] Univ Munich, Dept Med 1, Munich, Germany; [Mueller-Nurasyid, Martina; Peters, Annette] German Ctr Cardiovasc Res DZHK, Munich, Germany; [Nabika, Toru] Shimane Univ, Fac Med, Dept Funct Pathol, Izumo, Shimane, Japan; [Nakashima, Eitaro] Nagoya Univ, Grad Sch Med, Dept Internal Med, Div Endocrinol & Diabet, Nagoya, Aichi 4648601, Japan; [Nakashima, Eitaro] Chubu Rosai Hosp, Dept Endocrinol & Diabet, Nagoya, Aichi, Japan; [Nikus, Kjell] Tampere Univ Hosp, Dept Cardiol, Ctr Heart, Tampere, Finland; [Nikus, Kjell] Univ Tampere, Sch Med, FIN-33101 Tampere, Finland; [Ohkubo, Takayoshi] Teikyo Univ, Sch Med, Dept Hyg & Publ Hlth, Tokyo 173, Japan; [Ohnaka, Keizo] Kyushu Univ, Grad Sch Med Sci, Dept Geriatr Med, Fukuoka, Japan; [Paternoster, Lavinia; Sorensen, Thorkild I. A.] Univ Bristol, MRC, Integrat Epidemiol Unit, Bristol, Avon, England; [Rahman, Mahfuzar] Bangladesh Rehabil Assistance Comm, Res & Evaluat Div, Dhaka, Bangladesh; [Rolandsson, Olov; Franks, Paul W.] Umea Univ, Sect Family Med, Dept Publ Hlth & Clin Med, Umea, Sweden; [Snieder, Harold] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands; [Spiering, Wilko] Univ Med Ctr Utrecht, Dept Vasc Med, Utrecht, Netherlands; [Starr, John M.] Univ Edinburgh, Alzheimer Scotland Dementia Res Ctr, Edinburgh, Midlothian, Scotland; [Stott, David J.] Univ Glasgow, Fac Med, Inst Cardiovasc & Med Sci, Acad Sect Geriatr Med, Glasgow, Lanark, Scotland; [Sugiyama, Takao] Asahi Life Fdn, Inst Adult Dis, Tokyo, Japan; [Szymczak, Silke; Franke, Andre] Univ Kiel, Inst Clin Mol Biol, Kiel, Germany; [Tang, W. H. Wilson] Cleveland Clin, Lerner Res Inst, Dept Cellular & Mol Med, Cleveland, OH 44106 USA; [Trompet, Stella; Jukema, J. Wouter] Leiden Univ, Med Ctr, Dept Cardiol, Leiden, Netherlands; [Turjanmaa, Vaino; Kahonen, Mika] Tampere Univ Hosp, Dept Clin Physiol, Tampere, Finland; [Turjanmaa, Vaino; Kahonen, Mika] Univ Tampere, Sch Med, Dept Clin Physiol, FIN-33101 Tampere, Finland; [Ueshima, Hirotsugu] Shiga Univ Med Sci, Dept Hlth Sci, Otsu, Shiga 52021, Japan; [Ueshima, Hirotsugu] Shiga Univ Med Sci, Ctr Epidemiol Res Asia, Otsu, Shiga 52021, Japan; [Umemura, Satoshi] Yokohama City Univ, Grad Sch Med, Dept Med Sci & Cardiorenal Med, Yokohama, Kanagawa 232, Japan; [Viikari, Jorma S.] Turku Univ Hosp, Div Med, FIN-20520 Turku, Finland; [Viikari, Jorma S.] Univ Turku, Dept Med, Turku, Finland; [Yamaguchi, Shuhei] Shimane Univ, Fac Med, Dept Internal Med 3, Izumo, Shimane, Japan; [Young, Terri L.; Vithana, Eranga] Duke Natl Univ Singapore, Grad Sch Med, Neurosci & Behav Disorders NBD Program, Singapore, Singapore; [Young, Terri L.] Duke Univ, Med Ctr, Duke Eye Ctr, Durham, NC USA; [Yuan, Jian-Min] Univ Pittsburgh, Inst Canc, Canc Control & Populat Sci, Pittsburgh, PA USA; [Zhou, Xueya] Tsinghua Univ, Tsinghua Natl Lab Informat Sci & Technol, Dept Automat, Bioinformat Div,Minist Educ,Key Lab Bioinformat, Beijing 100084, Peoples R China; [Zhou, Xueya] Tsinghua Univ, Dept Automat, Ctr Synthet & Syst Biol, TNLIST,Minist Educ,Key Lab Bioinformat, Beijing 100084, Peoples R China; [Zhou, Xueya] Univ Hong Kong, Dept Psychiat, Hong Kong, Hong Kong, Peoples R China; [Asselbergs, Folkert W.; Jukema, J. Wouter; van der Harst, Pim] Netherlands Heart Inst, Interuniv Cardiol Inst Netherlands, Durrer Ctr Cardiogenet Res, Utrecht, Netherlands; [Asselbergs, Folkert W.] UCL, Fac Populat Hlth Sci, Inst Cardiovasc Sci, London, England; [Deloukas, Panos] Queen Mary Univ London, William Harvey Res Inst, Barts & London Sch Med & Dent, London, England; [Deloukas, Panos] King Abdulaziz Univ, Jeddah 21413, Saudi Arabia; [Franks, Paul W.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; [Franks, Steve] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Inst Reprod & Dev Biol, London, England; [Friedlander, Yechiel] Hebrew Univ Jerusalem, Sch Publ Hlth, Jerusalem, Israel; [Gross, Myron D.] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA; [Jarvelin, Marjo-Riitta] Univ Oulu, Bioctr Oulu, Oulu, Finland; [Jarvelin, Marjo-Riitta] Univ Oulu, Fac Med, Ctr Life Course Epidemiol, Oulu, Finland; [Jukema, J. Wouter] ICIN, Utrecht, Netherlands; [Lee, Jong-Young] Minist Hlth & Welf, Seoul, South Korea; [Lee, Jong-Young] THERAGEN ETEX Bio Inst, Suwon, South Korea; [Linneberg, Allan] Rigshosp, Dept Clin Expt Res, DK-2100 Copenhagen, Denmark; [Linneberg, Allan] Univ Copenhagen, Fac Hlth & Med Sci, Dept Clin Med, Copenhagen, Denmark; [Samani, Nilesh J.] Univ Leicester, Glenfield Hosp, Dept Cardiovasc Sci, Leicester, Leics, England; [Samani, Nilesh J.] Glenfield Hosp, NIHR Leicester Cardiovasc Biomed Res Unit, Leicester, Leics, England; [Sorensen, Thorkild I. A.] Bispebjerg & Frederiksberg Hosp, Inst Prevent Med, Copenhagen, Denmark; [Takayanagi, Ryoichi] Kyushu Univ, Grad Sch Med Sci, Dept Med & Bioregulatory Sci, Kyushu, Japan; [Toniolo, Daniela] CNR, Inst Mol Genet, I-27100 Pavia, Italy; [Danesh, John] Wellcome Trust Sanger Inst, Hinxton, England; [Heijman, Bastiaan T.] Leiden Univ, Med Ctr, Mol Epidemiol, Leiden, Netherlands; [Maerz, Winfried] Med Univ Graz, Inst Clin Med, Graz, Austria; [Maerz, Winfried] Med Univ Graz, Chem Lab Diagnost, Graz, Austria; [Maerz, Winfried] Synlab Acad, Synlab Serv, Mannheim, Germany; [Wolffenbuttel, Bruce H. W.] Univ Groningen, Univ Med Ctr Groningen, Dept Endocrinol, Groningen, Netherlands; [Yokota, Mitsuhiro] Aichi Gakuin Univ, Sch Dent, Dept Genome Sci, Nagoya, Aichi 464, Japan; [Kyrtopoulos, Soterios A.] Natl Hellen Res Fdn, Inst Biol Med Chem & Biotechnol, GR-11635 Athens, Greece; [Kleinjans, Jos C. S.] Maastricht Univ, Dept Toxicogenom, Maastricht, Netherlands; [McCarthy, Mark I.] Univ Oxford, Oxford Ctr Diabet Endocrinol & Metab, Oxford, England; [Soong, Richie] Natl Univ Singapore, Dept Pathol, Singapore 117548, Singapore; [Teo, Yik-Ying] Natl Univ Singapore, Grad Sch Integrat Sci & Engn, Singapore 117548, Singapore; [Teo, Yik-Ying] Natl Univ Singapore, Inst Life Sci, Singapore 117548, Singapore; [Teo, Yik-Ying] Natl Univ Singapore, Dept Stat & Appl Probabil, Singapore 117548, Singapore; [Tai, E. Shyong] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore 117595, Singapore; [Kooner, Jaspal S.; Chambers, John C.] Imperial Coll Healthcare NHS Trust, London, England	Chambers, JC (reprint author), Univ London Imperial Coll Sci Technol & Med, Dept Epidemiol & Biostat, London, England.	nokato@ri.ncgm.go.jp; jhe@tulane.edu; p.elliott@ic.ac.uk; e_shyong_tai@nuhs.edu.sg; p.van.der.harst@umcg.nl; j.kooner@ic.ac.uk; john.chambers@ic.ac.uk	Deloukas, Panos/B-2922-2013; Meitinger, Thomas/O-1318-2015; Waldenberger, Melanie/B-5355-2014; Nakatochi, Masahiro/Q-1247-2015; Campanella, Gianluca/G-2617-2010	Deloukas, Panos/0000-0001-9251-070X; Waldenberger, Melanie/0000-0003-0583-5093; Nakatochi, Masahiro/0000-0002-1838-4837; NUTILE, TERESA/0000-0001-7062-8352; Campanella, Gianluca/0000-0002-5411-6338	Grants for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan [24390084, 21390099, 20390185, 22390186, 24591060, 25253059, 25461127]; Science and Technology Incubation Program in Advanced Regions, Japanese Science and Technology Agency; Japanese Atherosclerosis Prevention Fund; Takeda Medical Research Foundation; National Cardiovascular Research Grants; US National Institutes of Health (NIH) - National Institute of Diabetes and Digestive and Kidney Diseases [R01DK082766]; National Human Genome Research Institute [NOT-HG-11-009]; VPR bridge grant from the University of Oklahoma Health Sciences Center; BBMRI-NL; Netherlands Organization for Scientific Research (NWO project) [184.021.007]; Ministry of Education, Culture, Sports, Science and Technology of Japan; Japanese Society for the Promotion of Science; grants for Core Research for Evolutional Science and Technology (CREST) from the Japanese Science and Technology Agency; Program for the Promotion of Fundamental Studies in Health Sciences, National Institute of Biomedical Innovation Organization (NIBIO); KAKENHI on Priority Area 'Applied Genomics' from the Ministry of Education, Culture, Sports, Science and Technology of Japan; National Center for Global Health and Medicine; Okinaga Scholarship; Grants for International Health Research from the Ministry of Health, Labour and Welfare of Japan [17C-1, 20S-6]; National Center for Global Health and Medicine [22S-10, 25S-1]; Manpei Suzuki Diabetes Foundation; Italian Ministry of Universities (Interomics Flag project) [FIRB-RBNE08NKH7]; Assessorato Ricerca Regione Campania; Fondazione con il SUD [2011-PDR-13]; Fondazione Banco di Napoli; National Institutes of Health [DK078150, TW05596, HL085144, TW008288]; Novo Nordisk; Swedish Research Council; Pahlssons Foundation; Swedish Heart Lung Foundation; Skane Regional Health Authority; Estonian government [SF0180142s08]; Center of Excellence in Genomics (EXCEGEN); University of Tartu [SP1GVARENG]; Competitive Research Funding from Tampere University Hospital [9M048, 9N035]; Finnish Cultural Foundation; Finnish Foundation for Cardiovascular Research; Emil Aaltonen Foundation, Finland; Tampere Tuberculosis Foundation; US NIH [R01CA107431, P42ES10349, 2R01LM010098, NCI RO1CA55069, R35CA53890, R01CA80205, R01CA144034, RO1CA82729, UM1CA173640, R37CA70867]; National Heart, Lung, and Blood Institute [P01HL098055, P01HL076491, R01HL103866, P20HL113452, R01HL103931]; National Institute of Environmental Health Sciences [R01ES021801]; National Heart, Lung, and Blood Institute, US NIH [U01HL072507, R01HL087263, R01HL090682]; Velux Foundation; Danish Medical Research Council; Danish Agency for Science, Technology and Innovation; Aase and Ejner Danielsens Foundation; ALK-Abello (Horsholm, Denmark); Timber Merchant Vilhelm Bangs Foundation; MEKOS Laboratories Denmark; Research Centre for Prevention and Health; Capital Region of Denmark; Lundbeck Foundation; Lundbeck Foundation Centre for Applied Medical Genomics in Personalised Disease Prediction, Prevention and Care (LuCamp); Novo Nordisk Foundation; Korean Centers for Disease Control and Prevention [4845-301, 4851-302, 4851-307]; Korean National Institute of Health, Republic of Korea [2012-N73002-00]; UK Medical Research Council; British Heart Foundation; Merck Co.; Roche Vitamins, Ltd.; University of Oxford; Centre National de Genotypage from Merck Co.; Oxford British Heart Foundation Centre of Research Excellence; British Heart Foundation [FS/14/55/30806, RG/07/008/23674]; GENDINOB project; Singapore National Research Foundation under its Translational and Clinical Research (TCR) Flagship Programme [NMRC/TCR/012-NUHS/2014]; Singapore Institute for Clinical Sciences, A*STAR, Singapore; Compagnia di San Paolo (Torino, Italy); Fondazione Cariplo, Italy; Ministry of Health, Ricerca Finalizzata; CCM; Telethon, Italy; Danish Research Council; Danish Centre for Health Technology Assessment; Research Foundation of Copenhagen County; Ministry of Internal Affairs and Health; Danish Heart Foundation; Danish Pharmaceutical Association; Augustinus Foundation; Ib Henriksen Foundation; Becket Foundation; Danish Diabetes Association; European Union (Sixth Framework Programme of the European Community) [LSHM-CT-2006-037197]; Ministry of Education, Culture, Sports, Science and Technology of Japan [21390099, 20390185, 19659163, 16790336, 12204008, 15790293, 16590433, 17790381, 18390192, 18590265, 18590587, 18590811, 19590929, 19650188, 19790423, 17390186, 20390184, 21390223]; Ministry of Health, Labor and Welfare of Japan [H15-Longevity-005, H17-Longevity-003, H16-Kenko-001, H18-Longevity(kokusai), H11-Longevity-020, H17-Kenkou-007, H17-Pharmaco-common-003, H18-Junkankitou[Seishuu]-Ippan-012, H20-Junkankitou[Seishuu]-Ippan-009, 013]; Health and Labor Sciences Research Grants, Japan; Science and Technology Incubation Program in Advanced Regions; Japanese Science and Technology Agency; Japanese Society for the Promotion of Science [16.54041, 18.54042, 19.7152, 20.7198, 20.7477, 20.54043]; Health Science Research Grants and Medical Technology Evaluation Research Grants from the Ministry of Health, Labour and Welfare of Japan; Uehara Memorial Foundation; Biomedical Innovation Grants; Japanese Research Foundation for Clinical Pharmacology; Helmholtz Zentrum Munchen-German Research Center for Environmental Health; German Federal Ministry of Education and Research (BMBF); Federal Ministry of Health; Munich Center of Health Sciences (MC Health), LMUinnovativ; German-Israeli Foundation for Scientific Research and Development; European Union [305280, 279143, 201668, 305739, LSHM-CT-2004-503485]; Helmholtz-Russia Joint Research Group (HRJRG) [310]; German Center for Diabetes Research (DZD); EU [602936]; BMBF e:Med project e:AtheroSysMed-Systems Medicine of Myocardial Infarction and Stroke; UK Biotechnology and Biological Sciences Research Council (BBSRC); Royal Society; Chief Scientist Office of the Scottish government; BBSRC; Age UK (The Disconnected Mind project); Netherlands Organization for Scientific Research (NWO) [175.010.2007.006, 184021007]; Economic Structure-Enhancing Fund (FES) of the Dutch government; Ministry of Economic Affairs; Ministry of Education, Culture and Science; Ministry for Health, Welfare and Sports; Northern Netherlands Collaboration of Provinces (SNN); province of Groningen, University Medical Center Groningen; University of Groningen; Dutch Kidney Foundation; Dutch Diabetes Research Foundation; NIHR Comprehensive Biomedical Research Centre Imperial College Healthcare NHS Trust; Medical Research Council, UK [G0601966, G0700931, G0500539, G0600331, G0902037]; Wellcome Trust [084723/Z/08/Z]; NIHR [RP-PG-0407-10371]; Action on Hearing Loss [G51]; INTERREG IV Oberrhein Program (Genetic Mechanisms of Cardiovascular Diseases) [A28]; European Regional Development Fund (ERDF); Wissenschaftsoffensive TMO; Academy of Finland (Center of Excellence in Complex Disease Genetics) [104781, 120315, 129269]; University Hospital Oulu, Biocenter; University of Oulu, Finland [75617]; European Commission [QLG1-CT-2000-01643, 223004]; National Heart, Lung, and Blood Institute through the STAMPEED program [5R01HL087679-02, 1RL1MH083268-01]; US NIH/National Institute of Mental Health [5R01MH63706:02]; ENGAGE project; Academy of Finland [286284, 134309, 126925, 121584, 124282, 129378, 117787, 41071]; Biocentrum Helsinki; German Ministry of Education and Research (BMBF) through the National Genome Research Network (NGFN); Ministry of Science, Commerce and Transportation of the state of Schleswig-Holstein; German Ministry of Education and Research [01EY1103]; Dutch Kidney Foundation [E033]; European Union project grant GENECURE [FP-6 LSHM CT 2006 037697]; Netherlands Organization for Health Research and Development (NWO-Groot grant) [175.010.2007.006]; Netherlands Organization for Health Research and Development (NWO VENI grant) [916.761.70]; Netherlands Organization for Health Research and Development (ZonMw grant) [90.700.441]; Dutch Interuniversity Cardiology Institute Netherlands (ICIN); Pfizer; Bristol-Myers-Squibb; Netherlands Heart Foundation [2001 D 032]; Netherlands Genomics Initiative (Netherlands Consortium for Healthy Aging grant) [050-060-810]; Erasmus Medical Center; Erasmus University; Netherlands Organization for Health Research and Development (ZonMw); Research Institute for Diseases in the Elderly (RIDE); European Commission (DG XII); municipality of Rotterdam; Genetic Laboratory of the Department of Internal Medicine, Erasmus Medical Center; Biomedical Research Council of Singapore [08/1/35/19/550, 09/1/35/19/616]; NMRC, Singapore [STaR/0003/2008, CG/SERI/2010, NMRC/1270/2010, 0796/2003, IRG07nov013, IRG09nov014]; Genetic and Environmental Determinants of Type 2 Diabetes in Chinese Singaporeans, grant from the US NIH [R01DK080720]; NMRC of Singapore; Genome Institute of Singapore; A*STAR, Singapore; US NIH/National Cancer Institute [R35CA53890, R01CA80205, R01CA144034, RO1CA55069]; NUS-HUJ CREATE Programme of the National Research Foundation, Singapore [370062002]; Biomedical Research Council of Singapore (A*STAR, Singapore); Dutch government [NWO 184.021.007]; National Natural Science Foundation of China [81172761]; Project of the Priority Academic Program Development of Jiangsu Higher Education Institutions; Yong Loo Lin School of Medicine; National University Health System; Life Sciences Institute of the National University of Singapore; National Research Foundation of Singapore [NRF-RF-2010-05]; Biomedical Research Council of Singapore (under the individual research grants scheme); Chinese National Key Program for Basic Research (973) [2004CB518603, 2006CB503804, 2009CB521905]; Chinese National High-Tech Program (863) [2009AA022703, 2006AA022179]; Ministry of Science and Technology, National Natural Science Foundation of China [30871361]; Academia Sinica Genomic Medicine Multicenter Study, Taiwan [40-05-GMM]; Stroke Association; National Institute on Aging [5RO1AG13196]; Agency for Health Care Policy Research [HS06516]; John D. and Catherine T. MacArthur Foundation Research Networks on Successful Midlife Development and Socio-Economic Status and Health; Social Insurance Institution of Finland; Kuopio, Tampere and Turku University Hospital Medical Funds [X51001]; Juho Vainio Foundation; Paavo Nurmi Foundation; Finnish Foundation of Cardiovascular Research; Emil Aaltonen Foundation; Yrjo Jahnsson Foundation;  [RR20649];  [ES10126];  [DK56350];  [HEALTH-F4-2007-201413]	AASC. This work was supported by Grants for Scientific Research (24390084, 21390099 and 20390185) from the Ministry of Education, Culture, Sports, Science and Technology of Japan; a Science and Technology Incubation Program in Advanced Regions, Japanese Science and Technology Agency; the Japanese Atherosclerosis Prevention Fund; the Takeda Medical Research Foundation; and National Cardiovascular Research Grants.; AIDHS/SDS. This study was supported by US National Institutes of Health (NIH) grants R01DK082766 (D.K.S.) funded by the National Institute of Diabetes and Digestive and Kidney Diseases and NOT-HG-11-009 (D.K.S.) funded by the National Human Genome Research Institute (D.K.S.) and by a VPR bridge grant (D.K.S.) from the University of Oklahoma Health Sciences Center.; BIOS-consortium. The BIOS-consortium is funded by BBMRI-NL, a research infrastructure financed by the Netherlands Organization for Scientific Research (NWO project 184.021.007).; CAGE-Amagasaki. We acknowledge the outstanding contributions of the employees of the National Center for Global Health and Medicine who provided technical and infrastructural support for this work. Above all, we thank the participants who made this work possible and who gave it value. We also thank T. Ogihara, Y. Yamori, A. Fujioka, C. Makibayashi, S. Katsuya, K. Sugimoto, K. Kamide, R. Morishita and the many physicians of the participating hospitals and medical institutions in the Amagasaki Medical Association for their assistance in collecting the DNA samples and accompanying clinical information. This work was supported by Grants for Scientific Research (22390186, 24591060, 25253059 and 25461127) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.; CAGE-Fukuoka. This work was supported by Grants-in-Aid for the 21st Century Center of Excellence Program (Kyushu University) from the Ministry of Education, Culture, Sports, Science and Technology of Japan and Grants-in-Aid for Scientific Research (category A) from the Japanese Society for the Promotion of Science. We are grateful to all participants of this study. We also especially thank S. Kono for his management of the DNA samples and clinical information.; CAGE_GWAS1. The CAGE Network studies were supported by grants for Core Research for Evolutional Science and Technology (CREST) from the Japanese Science and Technology Agency; the Program for the Promotion of Fundamental Studies in Health Sciences, National Institute of Biomedical Innovation Organization (NIBIO); KAKENHI (Grant-in-Aid for Scientific Research) on Priority Area 'Applied Genomics' from the Ministry of Education, Culture, Sports, Science and Technology of Japan; and a grant from the National Center for Global Health and Medicine. N.K. is a recipient of the Okinaga Scholarship and thanks S. Okinaga, H. Okinaga and other staff at Teikyo University, Japan, for their considerable support of doctoral work.; CAGE-KING. This study was supported in part by Grants-in-Aid for Scientific Research, including ones from categories A and B and the NEXT program of the Japanese Society for the Promotion of Science and by Grants-in-Aid on Priority Areas 'Comprehensive Genomics' and 'Applied Genomics', from the Ministry of Education, Culture, Sports, Science and Technology of Japan.; CAGE-Vietnam. The CAGE-Vietnam study was supported by Grants for International Health Research (17C-1 and 20S-6) from the Ministry of Health, Labour and Welfare of Japan, grants for the National Center for Global Health and Medicine (22S-10 and 25S-1) and the Manpei Suzuki Diabetes Foundation. We acknowledge the following investigators and institutions for their substantial contribution to the current study: T. Sasazuki, M. Noda, N. Kato, S. Kanagawa, T. Mizoue, H. Ohara and Y. Takahashi (Japanese investigators); T. Quy, N. Lan Viet, P. Thi Hong Hoa, N. Hoa Dieu Van, N. Thi Lam, L. Bach Mai, N. Quang Bay, P. Thi Phuong Thuy and B. Minh Duc (Vietnamese investigators); the National Center for Global Health and Medicine (Japan), Bach Mai Hospital (Vietnam), the Vietnam National Institute of Nutrition and the NCGM-BMH Medical Collaboration Center.; Cilento. We thank the populations of Cilento, Italy, for their participation in the study. This work was supported by grants from the Italian Ministry of Universities (FIRB-RBNE08NKH7, Interomics Flag project), the Assessorato Ricerca Regione Campania, the Fondazione con il SUD (2011-PDR-13) and the Fondazione Banco di Napoli to M.C.; CLHNS. We thank the Office of Population Studies Foundation research and data collection teams for the Cebu Longitudinal Health and Nutrition Survey. This work was supported by National Institutes of Health grants DK078150, TW05596, HL085144 and TW008288 and pilot funds from RR20649, ES10126 and DK56350.; DIABNORD. We are grateful to the study participants who dedicated their time and samples to these studies. We also thank the VHS, the Swedish Diabetes Registry and the Umea Medical Biobank staff for biomedical data and DNA extraction. We also thank M. Sterner, M. Juhas and P. Storm for their expert technical assistance with genotyping and genotype data preparation. The current study was funded by Novo Nordisk, the Swedish Research Council, Pahlssons Foundation, the Swedish Heart Lung Foundation and the Skane Regional Health Authority (all to P.W.F.).; EGCUT. EGCUT received targeted financing from the Estonian government (SF0180142s08), the Center of Excellence in Genomics (EXCEGEN) and the University of Tartu (SP1GVARENG). We acknowledge EGCUT technical personnel, especially V. Soo and S. Smit. Data analyses were carried out in part at the High-Performance Computing Center of the University of Tartu.; FINCAVAS. This work was supported by Competitive Research Funding from Tampere University Hospital (grants 9M048 and 9N035), the Finnish Cultural Foundation, the Finnish Foundation for Cardiovascular Research, the Emil Aaltonen Foundation, Finland, and the Tampere Tuberculosis Foundation. The authors thank the staff of the Department of Clinical Physiology for collecting the exercise test data.; GEMS. This work was partially supported by US NIH grants R01CA107431 and P42ES10349 to H. Ahsan. We would like to thank the study participants, as well as the staff of UChicago Research Bangladesh.; GeneBank. The Cleveland Clinic GeneBank study is supported by National Heart, Lung, and Blood Institute grants P01HL098055, P01HL076491, R01HL103866, P20HL113452 and R01HL103931. H. Allayee was supported by grant R01ES021801 from the National Institute of Environmental Health Sciences.; GenSalt. The Genetic Epidemiology Network of Salt Sensitivity is supported by research grants (U01HL072507, R01HL087263 and R01HL090682) from the National Heart, Lung, and Blood Institute, US NIH.; GLACIER-exome. We are indebted to the study participants who dedicated their time and samples to these studies. We thank J. Hutiainen and A. Agren (Umea Medical Biobank) for data organization and K. Enquist and T. Johansson (Vasterbottens County Council) for technical assistance with DNA extraction. We also thank M. Sterner, M. Juhas and P. Storm for their expert technical assistance with genotyping and genotype data preparation. The current study was funded by Novo Nordisk, the Swedish Research Council, Pahlssons Foundation, the Swedish Heart Lung Foundation and the Skane Regional Health Authority (all to P.W.F.).; GLACIER Metabochip. We are indebted to the study participants who dedicated their time and samples to these studies. We also thank the VIP and Umea Medical Biobank staff for biomedical data collection and preparation. We specifically thank J. Hutiainen, A. Agren and S. Nilsson (Umea Medical Biobank) for data organization, K. Enquist and T. Johansson (Vasterbottens County Council) for expert technical assistance with DNA preparation, and D. Hunter, P. Soule and H. Ranu (Harvard School of Public Health) for expert assistance with planning and undertaking genotyping of GLACIER samples. The current study was funded by Novo Nordisk, the Swedish Research Council, Pahlssons Foundation, the Swedish Heart Lung Foundation and the Skane Regional Health Authority (all to P.W.F.).; Health2006. The Health2006 study was financially supported by grants from the Velux Foundation; the Danish Medical Research Council, Danish Agency for Science, Technology and Innovation; the Aase and Ejner Danielsens Foundation; and ALK-Abello (Horsholm, Denmark), Timber Merchant Vilhelm Bangs Foundation, MEKOS Laboratories Denmark and Research Centre for Prevention and Health, the Capital Region of Denmark. This project was also funded by the Lundbeck Foundation and produced by the Lundbeck Foundation Centre for Applied Medical Genomics in Personalised Disease Prediction, Prevention and Care (LuCamp; http://www.lucamp.org/). The Novo Nordisk Foundation Centre for Basic Metabolic Research is an independent Research Centre at the University of Copenhagen partially funded by an unrestricted donation from the Novo Nordisk Foundation (http://www.metabol.ku.dk/).; HEXA. This work was supported by grants from the Korean Centers for Disease Control and Prevention (4845-301, 4851-302 and 4851-307) and an intramural grant from the Korean National Institute of Health (2012-N73002-00), Republic of Korea.; HPS. The Heart Protection Study (ISRCTN48489393) was funded by the UK Medical Research Council, the British Heart Foundation, Merck & Co., and Roche Vitamins, Ltd. Genotyping and analysis were supported by a grant to the University of Oxford and the Centre National de Genotypage from Merck & Co. and the Oxford British Heart Foundation Centre of Research Excellence. J.C.H. acknowledges support from the British Heart Foundation (FS/14/55/30806).; GOYA. This study was conducted as part of the activities of the Gene-Diet Interactions in Obesity project (GENDINOB; http://www.gendinob.dk/) and the Medical Research Council Centre for Causal Analyses in Translational Epidemiology (MRC CAiTE). We thank the staff of the Copenhagen City Heart Study for their skillful examination of the study subjects in the collection of baseline and follow-up data. T.S.A. was also funded by the GENDINOB project and acknowledges the same.; GUSTO. The GUSTO study group includes P. Agarwal, A. Biswas, C. Looi Bong, B.F.P. Broekman, S. Cai, J.K.Y. Chan, Y.H. Chan, C.Y.I. Chee, H.Y.H. Chen, Y.B. Cheung, A. Chia, A. Chinnadurai, C.K. Chng, M.F.-F. Chong, S. C. Chong, M.C. Chua, C.M. Ding, E.A. Finkelstein, D. Fok, M. Fortier, A.E.N. Goh, Y.T.D. Goh, J.J. Gooley, W.M. Han, M. Hanson, C.J. Henry, C.-Y. Hsu, H. Inskip, J. Kapur, K. Kwek, I.Y.-M. Lau, B.W. Lee, N. Lek, S. B. Lim, Y.-L. Low, I. Magiati, L. Mary Daniel, C. Ngo, K. Naiduvaje, W.W. Pang, A. Qiu, B.L. Quah, V.S. Rajadurai, M. Rauff, S. A. Rebello, J.L. Richmond, A. Rifkin-Graboi, L.P.-C. Shek, A. Sheppard, B. Shuter, L. Singh, W. Stunkel, L.L. Su, O.H. Teoh, H.P.S. van Bever, R.M. van Dam, I.B.Y. Wong, P.C. Wong and G.S.H. Yeo. This research is supported by the Singapore National Research Foundation under its Translational and Clinical Research (TCR) Flagship Programme and administered by the Singapore Ministry of Health's National Medical Research Council (NMRC), Singapore-NMRC/TCR/012-NUHS/2014. Additional funding is provided by the Singapore Institute for Clinical Sciences, A*STAR, Singapore.; INGI-VB. The research was supported by funds from Compagnia di San Paolo (Torino, Italy); Fondazione Cariplo, Italy, and the Ministry of Health, Ricerca Finalizzata 2008 and CCM 2010, and Telethon, Italy, to D.T. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. We thank the inhabitants of Val Borbera who made this study possible, the local administrations, the Tortona and Genova archdioceses, and the ASL-22, Novi Ligure (Al), for support. We also thank C. Camaschella for the supervision of data collection and organization of the clinical data collection, F. Vigano for technical help, and C. Masciullo and M. Cocca for building the analysis platform.; Inter99. Inter99 was initiated by T.J. (principal investigator), K. Borch-Johnsen (co-principal investigator), H. Ibsen and T.F. Thomsen. The steering committee comprises the first two and C. Pisinger. The study was financially supported by research grants from the Danish Research Council, the Danish Centre for Health Technology Assessment, Novo Nordisk, the Research Foundation of Copenhagen County, the Ministry of Internal Affairs and Health, the Danish Heart Foundation, the Danish Pharmaceutical Association, the Augustinus Foundation, the Ib Henriksen Foundation, the Becket Foundation and the Danish Diabetes Association. This project was also funded by the Lundbeck Foundation and produced by LuCamp (http://www.lucamp.org/). The Novo Nordisk Foundation Centre for Basic Metabolic Research is an independent Research Centre at the University of Copenhagen partially funded by an unrestricted donation from the Novo Nordisk Foundation (http://www.metabol.ku.dk/).; InterAct. We are grateful to all participants who gave their time and effort to the study. We are also extremely grateful to all persons who contributed to the data collection across the study sites. This study was supported by funding from the European Union (integrated project LSHM-CT-2006-037197 in the Sixth Framework Programme of the European Community) and the Medical Research Council, UK.; This work was supported by Grants-in-Aid for Scientific Research (Priority Areas 'Medical Genome Science (Millennium Genome Project)' and 'Applied Genomics'), the Leading Project for Personalized Medicine and Scientific Research (20390185, 21390099, 19659163, 16790336, 12204008, 15790293, 16590433, 17790381, 17790381, 18390192, 18590265, 18590587, 18590811, 19590929, 19650188, 19790423, 17390186, 20390184 and 21390223) from the Ministry of Education, Culture, Sports, Science and Technology of Japan; Grants-in-Aid (H15-Longevity-005, H17-Longevity-003, H16-Kenko-001, H18-Longevity(kokusai), H11-Longevity-020, H17-Kenkou-007, H17-Pharmaco-common-003, H18-Junkankitou[Seishuu]-Ippan-012 and H20-Junkankitou[Seishuu]-Ippan-009, 013) from the Ministry of Health, Labor and Welfare of Japan, Health and Labor Sciences Research Grants, Japan; a Science and Technology Incubation Program in Advanced Regions, the Japanese Science and Technology Agency; Grants-in-Aid from Japanese Society for the Promotion of Science fellows (16.54041, 18.54042, 19.7152, 20.7198, 20.7477 and 20.54043); Health Science Research Grants and Medical Technology Evaluation Research Grants from the Ministry of Health, Labour and Welfare of Japan; the Japanese Atherosclerosis Prevention Fund; the Uehara Memorial Foundation; the Takeda Medical Research Foundation; National Cardiovascular Research Grants; Biomedical Innovation Grants; and the Japanese Research Foundation for Clinical Pharmacology.; KARE. This work was supported by grants from the Korean Centers for Disease Control and Prevention (4845-301, 4851-302 and 4851-307) and an intramural grant from the Korean National Institute of Health (2012-N73002-00), Republic of Korea.; KORA. KORA was initiated and financed by the Helmholtz Zentrum Munchen-German Research Center for Environmental Health and supported by grants from the German Federal Ministry of Education and Research (BMBF), the Federal Ministry of Health and the Munich Center of Health Sciences (MC Health) as part of LMUinnovativ. This research was supported by a grant from the German-Israeli Foundation for Scientific Research and Development, by the European Union's Seventh Framework Programme (FP7-HEALTH-F5-2012) under grant agreement 305280 (MIMOmics), by Helmholtz-Russia Joint Research Group (HRJRG) 310 and by the German Center for Diabetes Research (DZD). We thank all members of the field staff who were involved in the planning and conduct of the MONICA/KORA Augsburg studies. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. C.G. is supported by EU-FP7-HEALTH grant 602936: CARTARDIS-Identification and Validation of Novel Pharmaceutical Drug Targets for Cardiovascular Disease and BMBF e:Med project e:AtheroSysMed-Systems Medicine of Myocardial Infarction and Stroke.; LBC1921. We thank the cohort participants and team members who contributed to these studies. Phenotype collection was supported by the UK Biotechnology and Biological Sciences Research Council (BBSRC), the Royal Society and the Chief Scientist Office of the Scottish government. Genotyping was funded by the BBSRC. The work was undertaken by the University of Edinburgh Centre for Cognitive Ageing and Cognitive Epidemiology, part of the cross-council Lifelong Health and Wellbeing Initiative (MR/K026992/1). Funding from the BBSRC and Medical Research Council, UK, is gratefully acknowledged.; LBC1936. We thank the cohort participants and team members who contributed to these studies. Phenotype collection was supported by Age UK (The Disconnected Mind project). Genotyping was funded by the BBSRC. The work was undertaken by the University of Edinburgh Centre for Cognitive Ageing and Cognitive Epidemiology, part of the cross-council Lifelong Health and Wellbeing Initiative (MR/K026992/1). Funding from the BBSRC and Medical Research Council, UK, is gratefully acknowledged.; LifeLines. The LifeLines Cohort Study and the generation and management of GWAS genotype data for the LifeLines Cohort Study are supported by the Netherlands Organization for Scientific Research (NWO; grant 175.010.2007.006), the Economic Structure-Enhancing Fund (FES) of the Dutch government, the Ministry of Economic Affairs, the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the Northern Netherlands Collaboration of Provinces (SNN), the province of Groningen, University Medical Center Groningen, the University of Groningen, the Dutch Kidney Foundation and the Dutch Diabetes Research Foundation. We thank B. Alizadeh, A. Boesjes, M. Bruinenberg, N. Festen, I. Nolte, L. Franke and M. Valimohammadi for their help in creating the GWAS database and R. Bieringa, J. Keers, R. Oostergo, R. Visser and J. Vonk for their work related to data collection and validation. The authors are grateful to the study participants, the staff of the LifeLines Cohort Study and Medical Biobank Northern Netherlands, and the participating general practitioners and pharmacists. LifeLines Scientific Protocol Preparation: R. de Boer, H. Hillege, M. van der Klauw, G. Navis, H. Ormel, D. Postma, J. Rosmalen, J. Slaets, R. Stolk and B. Wolffenbuttel; LifeLines GWAS Working Group: B. Alizadeh, M. Boezen, M. Bruinenberg, N. Festen, L. Franke, P. van der Harst, G. Navis, D. Postma, H. Snieder, C. Wijmenga and B. Wolffenbuttel.; LOLIPOP. The LOLIPOP study is supported by the NIHR Comprehensive Biomedical Research Centre Imperial College Healthcare NHS Trust, the British Heart Foundation (SP/04/002), the Medical Research Council, UK (G0601966 and G0700931), the Wellcome Trust (084723/Z/08/Z), the NIHR (RP-PG-0407-10371), the European Union's Seventh Framework Programme (EpiMigrant, 279143) and Action on Hearing Loss (G51). We thank the participants and research staff who made the study possible.; LURIC. We extend our appreciation to the participants of the LURIC study; without their collaboration, this report would not have been written. We thank the LURIC study team who were either temporarily or permanently involved in patient recruitment as well as sample and data handling, in addition to the laboratory staff at the Ludwigshafen General Hospital, the University of Freiburg and the University of Ulm, Germany. LURIC has received funding from the Sixth Framework Programme (integrated project Bloodomics, grant LSHM-CT-2004-503485) and from the Seventh Framework Programme (Atheroremo, grant agreement 201668 and RiskyCAD, grant agreement 305739) of the European Union as well as from the INTERREG IV Oberrhein Program (project A28, Genetic Mechanisms of Cardiovascular Diseases) with support from the European Regional Development Fund (ERDF) and the Wissenschaftsoffensive TMO.; NFBC86. We thank P. Rantakallio (launch of NFBC1986 and initial data collection), S. Vaara (data collection), T. Ylitalo (administration), M. Koiranen (data management), and O. Tornwall and M. Jussila (DNA biobanking). Financial support was provided by the Academy of Finland (project grants 104781, 120315, 129269 Center of Excellence in Complex Disease Genetics), University Hospital Oulu, Biocenter, University of Oulu, Finland (75617), the European Commission (EURO-BLCS, Fifth Framework Programme award QLG1-CT-2000-01643), National Heart, Lung, and Blood Institute grant 5R01HL087679-02 through the STAMPEED program (1RL1MH083268-01), the US NIH/National Institute of Mental Health (5R01MH63706:02), the ENGAGE project and grant agreement HEALTH-F4-2007-201413 and the Medical Research Council, UK (grants G0500539, G0600331 nad PrevMetSyn). DNA extraction, sample quality control, biobank upkeep and aliquotting were performed at the National Public Health Institute, Biomedicum Helsinki, Finland, and supported financially by the Academy of Finland and Biocentrum Helsinki. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.; POPGEN. The POPGEN study was supported by the German Ministry of Education and Research (BMBF) through the National Genome Research Network (NGFN) and the Ministry of Science, Commerce and Transportation of the state of Schleswig-Holstein. The project has also received infrastructure support through the DFG excellence cluster 'Inflammation at Interfaces'. The POPGEN 2.0 network is supported by a grant from the German Ministry of Education and Research (01EY1103).; PREVEND. PREVEND genetics is supported by the Dutch Kidney Foundation (grant E033), European Union project grant GENECURE (FP-6 LSHM CT 2006 037697), the US NIH (grant 2R01LM010098), the Netherlands Organization for Health Research and Development (NWO-Groot grant 175.010.2007.006, NWO VENI grant 916.761.70 and ZonMw grant 90.700.441) and the Dutch Interuniversity Cardiology Institute Netherlands (ICIN).; PROMIS. Genotyping in PROMIS was supported by the Wellcome Trust and Pfizer. Some core support to PROMIS was provided by the British Heart Foundation. The Cardiovascular Epidemiology Unit at the University of Cambridge is underpinned by the Medical Research Council, UK (G0800270), the British Heart Foundation (SP/09/002), the British Heart Foundation Cambridge Cardiovascular Centre of Excellence and the NIHR Cambridge Biomedical Research Centre.; PROSPER. The PROSPER study was supported by an investigator-initiated grant obtained from Bristol-Myers-Squibb. J.W.J. is an Established Clinical Investigator of the Netherlands Heart Foundation (grant 2001 D 032). Support for genotyping was provided by the Seventh Framework Programme of the European Commission (grant 223004) and by the Netherlands Genomics Initiative (Netherlands Consortium for Healthy Aging grant 050-060-810).; RHS. RHS was supported by a grant from the National Center for Global Health and Medicine.; Rotterdam Study. The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, the Netherlands Organization for Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission (DG XII) and the municipality of Rotterdam. The authors are grateful to the study participants, the staff from the Rotterdam Study and the participating general practitioners and pharmacists. The generation and management of the Illumina 450K methylation array data (EWAS data) for the Rotterdam Study were executed by the Human Genotyping Facility of the Genetic Laboratory of the Department of Internal Medicine, Erasmus Medical Center, the Netherlands. The EWAS data were funded by the Genetic Laboratory of the Department of Internal Medicine, Erasmus Medical Center, and by the Netherlands Organization for Scientific Research (NWO; project 184021007) and were made available as a Rainbow Project (RP3; BIOS) of BBMRI-NL. We thank M. Verbiest, M. Jhamai, S. Higgins and M. Verkerk for their help in creating the methylation database.; SCES. SCES is funded by the Biomedical Research Council of Singapore (grant 08/1/35/19/550) and the NMRC, Singapore (grants STaR/0003/2008 and CG/SERI/2010). The National University Health System Tissue Repository and the Genome Institute of Singapore (A*STAR, Singapore) provided services for tissue archiving and genotyping, respectively.; SCHS. We would like to thank S.-H. Low of the National University of Singapore for supervising the field work of the Singapore Chinese Health Study and K. Arakawa for development of the cohort study database. The founding, long-standing principal investigator of the Singapore Chinese Health Study is M. C. Yu. Significant contributions to the GWAS substudy of SCHS were made by W.-P. Koh, J.-M. Yuan, R. Wang, Z. Chen, M. Seielstad, A. O. Odegaard, E. S. Tai, Y.-Y. Teo, J. Liu, B. Thyagarajan and R. Koratkar. Funding sources included Genetic and Environmental Determinants of Type 2 Diabetes in Chinese Singaporeans, grant R01DK080720 from the US NIH. Additional support came from the NMRC of Singapore under the individual research grants scheme, from the Genome Institute of Singapore, the NMRC of Singapore under its individual research grants and clinician scientist award scheme, and from A*STAR, Singapore. The Singapore Chinese Health Study primary cohort was supported by US NIH/National Cancer Institute grants RO1CA55069, R35CA53890, R01CA80205 and R01CA144034.; SCHS_MI. SCHS was supported by the US NIH (NCI RO1CA55069, R35CA53890, R01CA80205 and R01CA144034), the NUS-HUJ CREATE Programme of the National Research Foundation, Singapore (project 370062002) and a grant from the NMRC, Singapore (NMRC/1270/2010).; SiMES. SiMES is funded by the NMRC, Singapore (grants 0796/2003, IRG07nov013, IRG09nov014, STaR/0003/2008 and CG/SERI/2010) and the Biomedical Research Council of Singapore (grant 09/1/35/19/616). The Singapore Tissue Network and the Genome Institute of Singapore (A*STAR, Singapore) provided services for tissue archiving and genotyping, respectively. SINDI. SINDI is funded by the Biomedical Research Council of Singapore (A*STAR, Singapore) provided services for tissue archiving and genotyping, respectively.; SINDI. SINDI is funded by the Biomedical Research Council of Singapore (grant 08/1/35/19/550) and the NMRC, Singapore (grants STaR/0003/2008 and CG/SERI/2010). The National University Health System Tissue Repository and the Genome Institute of Singapore (A*STAR, Singapore) provided services for tissue archiving and genotyping, respectively.; SMART. This research was financially supported by BBMRI-NL, a research infrastructure financed by the Dutch government (NWO 184.021.007).; SMHS. The study was supported by grants RO1CA82729 and UM1CA173640 from the US NIH. The authors thank the participants and staff members of the SMHS research team for their important contributions.; SMSS. SMSS was supported by the National Natural Science Foundation of China (grant 81172761) and the Project of the Priority Academic Program Development of Jiangsu Higher Education Institutions.; SMHS. The study was supported by grants RO1CA82729 and UM1CA173640 from the US NIH. The authors thank the participants and staff members of the SMHS research team for their important contributions.; SMSS. SMSS was supported by the National Natural Science Foundation of China (grant 81172761) and the Project of the Priority Academic Program Development of Jiangsu Higher Education Institutions.; SP2. This project acknowledges the support of the Yong Loo Lin School of Medicine, the National University Health System and the Life Sciences Institute of the National University of Singapore. We also acknowledge the support of the National Research Foundation of Singapore (NRF-RF-2010-05), the Biomedical Research Council of Singapore (under the individual research grants scheme) and the NMRC, Singapore, under the individual research grant and the clinician scientist award schemes).; SRS. This work was supported by the Chinese National Key Program for Basic Research (973 grants: 2004CB518603, 2006CB503804 and 2009CB521905), the Chinese National High-Tech Program (863 grants: 2009AA022703 and 2006AA022179) and the Ministry of Science and Technology, National Natural Science Foundation of China (30871361).; SWHS. This research was supported by US NIH research grant R37CA70867. The authors thank the participants and staff members of SWHS for their important contributions.; TWSC. We gratefully acknowledge the members of the Translational Resource Center (TRC) (NSC102-2325-B-001-040) and the National Center for Genome Medicine (NSC102-2319-B-001-001) at Academia Sinica for their support in subject recruitment, genotyping and statistical analysis. The TWSC study was supported by the Academia Sinica Genomic Medicine Multicenter Study, Taiwan (40-05-GMM).; WHII. The WHII study is supported by grants from the Medical Research Council, UK (G0902037), the British Heart Foundation (RG/07/008/23674), the Stroke Association, the National Heart, Lung, and Blood Institute (5RO1HL036310), the National Institute on Aging (5RO1AG13196), the Agency for Health Care Policy Research (HS06516) and the John D. and Catherine T. MacArthur Foundation Research Networks on Successful Midlife Development and Socio-Economic Status and Health.; YFS. The Young Finns Study has been financially supported by the Academy of Finland through grants 286284 (T.L.), 134309 (Eye), 126925, 121584, 124282, 129378 (Salve), 117787 (Gendi) and 41071 (Skidi); the Social Insurance Institution of Finland; Kuopio, Tampere and Turku University Hospital Medical Funds (grant X51001 for T.L.); the Juho Vainio Foundation; the Paavo Nurmi Foundation; the Finnish Foundation of Cardiovascular Research (T.L.); the Finnish Cultural Foundation; the Tampere Tuberculosis Foundation (T.L.); the Emil Aaltonen Foundation (T.L.); and the Yrjo Jahnsson Foundation (T.L.).	Adeyemo, 2009, PLOS GENET, V5; Palli D, 2003, TUMORI, V89, P586; Hong KW, 2010, J HUM HYPERTENS, V24, P367, DOI 10.1038/jhh.2009.86; Ong RTH, 2010, BIOINFORMATICS, V26, P1269, DOI 10.1093/bioinformatics/btq125; Tomaszewski M, 2010, HYPERTENSION, V56, P1069, DOI 10.1161/HYPERTENSIONAHA.110.155721; Teh AL, 2014, GENOME RES, V24, P1064, DOI 10.1101/gr.171439.113; Cheng YF, 2012, DRUG METAB DISPOS, V40, P617, DOI 10.1124/dmd.111.042036; Beca S, 2013, CIRC RES, V112, P289, DOI 10.1161/CIRCRESAHA.111.300003; Jacoby M, 2012, EPIGENETICS-US, V7, P1421, DOI 10.4161/epi.22845; Woo SK, 2002, CLIN PHARMACOL THER, V71, P246, DOI 10.1067/mcp.2002.122474; Akilesh S, 2011, J CLIN INVEST, V121, P4127, DOI 10.1172/JCI46458; McLaren W, 2010, BIOINFORMATICS, V26, P2069, DOI 10.1093/bioinformatics/btq330; Archer SL, 2010, CIRCULATION, V121, P2661, DOI 10.1161/CIRCULATIONAHA.109.916098; Forouhi NG, 2006, DIABETOLOGIA, V49, P2580, DOI 10.1007/s00125-006-0393-2; Levy D, 2009, NAT GENET, V41, P677, DOI 10.1038/ng.384; Ganesh SK, 2013, HUM MOL GENET, V22, P1663, DOI 10.1093/hmg/dds555; Ueshima H, 2008, CIRCULATION, V118, P2702, DOI 10.1161/CIRCULATIONAHA.108.790048; Xu XF, 2011, HYPERTENS RES, V34, P981, DOI 10.1038/hr.2011.79; Zhang Z, 2011, HUM MOL GENET, V20, P4167, DOI 10.1093/hmg/ddr341; Davis CA, 2006, MOL CELL BIOL, V26, P2626, DOI 10.1128/MCB.26.7.2626-2636.2006; Chambers JC, 2010, NAT GENET, V42, P373, DOI 10.1038/ng.566; Flister MJ, 2013, GENOME RES, V23, P1996, DOI 10.1101/gr.160283.113; Imano H, 2009, STROKE, V40, P1571, DOI 10.1161/STROKEAHA.108.538629; Hebels DGAJ, 2013, ENVIRON HEALTH PERSP, V121, P480, DOI 10.1289/ehp.1205657; Morris AP, 2011, GENET EPIDEMIOL, V35, P809, DOI 10.1002/gepi.20630; Johnson T, 2011, AM J HUM GENET, V89, P688, DOI 10.1016/j.ajhg.2011.10.013; Newton-Cheh C, 2009, NAT GENET, V41, P666, DOI 10.1038/ng.361; Lim SS, 2012, LANCET, V380, P2224, DOI 10.1016/S0140-6736(12)61766-8; Sofer T, 2013, BIOINFORMATICS, V29, P2884, DOI 10.1093/bioinformatics/btt498; Slieker RC, 2013, EPIGENET CHROMATIN, V6, DOI 10.1186/1756-8935-6-26; Chambers JC, 2015, LANCET DIABETES ENDO, V3, P526, DOI 10.1016/S2213-8587(15)00127-8; Franceschini N, 2013, AM J HUM GENET, V93, P545, DOI 10.1016/j.ajhg.2013.07.010; Wain LV, 2011, NAT GENET, V43, P1005, DOI 10.1038/ng.922; Bellavia A, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000212; Halachev K, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-10-r96; Hallmans Göran, 2003, Scand J Public Health Suppl, V61, P18; Houseman EA, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-86; Ehret GB, 2011, NATURE, V478, P103, DOI 10.1038/nature10405; Kato N, 2011, NAT GENET, V43, P530, DOI 10.1038/ng.834; Lehne B, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0600-x; Lokk K, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-4-r54; Ma L, 2013, NEW ENGL J MED, V369, P351, DOI 10.1056/NEJMoa1211097; Mohanraj L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055084; Padmanabhan S, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001177; Pan H, 2012, EPIGENETICS-US, V7, P1173, DOI 10.4161/epi.22102; Soh SE, 2014, INT J EPIDEMIOL, V43, P1401, DOI 10.1093/ije/dyt125; Turcot V, 2012, CLIN EPIGENETICS, V4, DOI 10.1186/1868-7083-4-10; Ward LD, 2012, NUCLEIC ACIDS RES, V40, pD930, DOI 10.1093/nar/gkr917; Wellcome Trust Case Control Consortium, 2012, NAT GENET, V44, P1294; Zeller T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010693	50	1	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2015	47	11					1282	+		10.1038/ng.3405		14	Genetics & Heredity	Genetics & Heredity	CV1BN	WOS:000363988200012		
J	Kataoka, K; Nagata, Y; Kitanaka, A; Shiraishi, Y; Shimamura, T; Yasunaga, JI; Totoki, Y; Chiba, K; Sato-Otsubo, A; Nagae, G; Ishii, R; Muto, S; Kotani, S; Watatani, Y; Takeda, J; Sanada, M; Tanaka, H; Suzuki, H; Sato, Y; Shiozawa, Y; Yoshizato, T; Yoshida, K; Makishima, H; Iwanaga, M; Ma, GY; Nosaka, K; Hishizawa, M; Itonaga, H; Imaizumi, Y; Munakata, W; Ogasawara, H; Sato, T; Sasai, K; Muramoto, K; Penova, M; Kawaguchi, T; Nakamura, H; Hama, N; Shide, K; Kubuki, Y; Hidaka, T; Kameda, T; Nakamaki, T; Ishiyama, K; Miyawaki, S; Yoon, SS; Tobinai, K; Miyazaki, Y; Takaori-Kondo, A; Matsuda, F; Takeuchi, K; Nureki, O; Aburatani, H; Watanabe, T; Shibata, T; Matsuoka, M; Miyano, S; Shimoda, K; Ogawa, S				Kataoka, Keisuke; Nagata, Yasunobu; Kitanaka, Akira; Shiraishi, Yuichi; Shimamura, Teppei; Yasunaga, Jun-Ichirou; Totoki, Yasushi; Chiba, Kenichi; Sato-Otsubo, Aiko; Nagae, Genta; Ishii, Ryohei; Muto, Satsuki; Kotani, Shinichi; Watatani, Yosaku; Takeda, June; Sanada, Masashi; Tanaka, Hiroko; Suzuki, Hiromichi; Sato, Yusuke; Shiozawa, Yusuke; Yoshizato, Tetsuichi; Yoshida, Kenichi; Makishima, Hideki; Iwanaga, Masako; Ma, Guangyong; Nosaka, Kisato; Hishizawa, Masakatsu; Itonaga, Hidehiro; Imaizumi, Yoshitaka; Munakata, Wataru; Ogasawara, Hideaki; Sato, Toshitaka; Sasai, Ken; Muramoto, Kenzo; Penova, Marina; Kawaguchi, Takahisa; Nakamura, Hiromi; Hama, Natsuko; Shide, Kotaro; Kubuki, Yoko; Hidaka, Tomonori; Kameda, Takuro; Nakamaki, Tsuyoshi; Ishiyama, Ken; Miyawaki, Shuichi; Yoon, Sung-Soo; Tobinai, Kensei; Miyazaki, Yasushi; Takaori-Kondo, Akifumi; Matsuda, Fumihiko; Takeuchi, Kengo; Nureki, Osamu; Aburatani, Hiroyuki; Watanabe, Toshiki; Shibata, Tatsuhiro; Matsuoka, Masao; Miyano, Satoru; Shimoda, Kazuya; Ogawa, Seishi			Integrated molecular analysis of adult T cell leukemia/lymphoma	NATURE GENETICS			English	Article							KAPPA-B ACTIVATION; VIRUS TYPE-I; PROTEIN-KINASE; LYMPHOBLASTIC-LEUKEMIA; TRANSCRIPTION FACTORS; DNA METHYLATION; HUMAN CANCERS; MUTATIONS; EXPRESSION; HTLV-1	Adult T cell leukemia/lymphoma (ATL) is a peripheral T cell neoplasm of largely unknown genetic basis, associated with human T cell leukemia virus type-1 (HTLV-1) infection. Here we describe an integrated molecular study in which we performed whole-genome, exome, transcriptome and targeted resequencing, as well as array-based copy number and methylation analyses, in a total of 426 ATL cases. The identified alterations overlap significantly with the HTLV-1 Tax interactome and are highly enriched for T cell receptor-NF-kappa B signaling, T cell trafficking and other T cell-related pathways as well as immunosurveillance. Other notable features include a predominance of activating mutations (in PLCG1, PRKCB, CARD11, VAV1, IRF4, FYN, CCR4 and CCR7) and gene fusions (CTLA4-CD28 and ICOS-CD28). We also discovered frequent intragenic deletions involving IKZF2, CARD11 and TP73 and mutations in GATA3, HNRNPA2B1, GPR183, CSNK2A1, CSNK2B and CSNK1A1. Our findings not only provide unique insights into key molecules in T cell signaling but will also guide the development of new diagnostics and therapeutics in this intractable tumor.	[Kataoka, Keisuke; Nagata, Yasunobu; Sato-Otsubo, Aiko; Kotani, Shinichi; Watatani, Yosaku; Takeda, June; Sanada, Masashi; Suzuki, Hiromichi; Sato, Yusuke; Shiozawa, Yusuke; Yoshizato, Tetsuichi; Yoshida, Kenichi; Makishima, Hideki; Ogawa, Seishi] Kyoto Univ, Grad Sch Med, Dept Pathol & Tumor Biol, Kyoto, Japan; [Kitanaka, Akira; Shide, Kotaro; Kubuki, Yoko; Hidaka, Tomonori; Kameda, Takuro; Shimoda, Kazuya] Miyazaki Univ, Fac Med, Dept Gastroenterol & Hematol, Miyazaki, Japan; [Shiraishi, Yuichi; Chiba, Kenichi; Tanaka, Hiroko; Miyano, Satoru] Univ Tokyo, Ctr Human Genome, Lab DNA Informat Anal, Tokyo, Japan; [Shimamura, Teppei] Nagoya Univ, Grad Sch Med, Ctr Neurol Dis & Canc, Div Syst Biol, Nagoya, Aichi 4648601, Japan; [Yasunaga, Jun-Ichirou; Ma, Guangyong; Matsuoka, Masao] Kyoto Univ, Inst Virus Res, Lab Virus Control, Kyoto 606, Japan; [Totoki, Yasushi; Nakamura, Hiromi; Hama, Natsuko; Shibata, Tatsuhiro] Natl Canc Ctr, Res Inst, Div Canc Genom, Tokyo 104, Japan; [Nagae, Genta; Aburatani, Hiroyuki] Univ Tokyo, Res Ctr Adv Sci & Technol, Genome Sci Div, Tokyo, Japan; [Ishii, Ryohei; Nureki, Osamu] Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Tokyo 113, Japan; [Muto, Satsuki; Watanabe, Toshiki] Univ Tokyo, Grad Sch Frontier Sci, Tokyo, Japan; [Sanada, Masashi] Nagoya Med Ctr, Clin Res Ctr, Dept Adv Diag, Nagoya, Aichi, Japan; [Iwanaga, Masako] Nagasaki Univ, Grad Sch Biomed Sci, Dept Frontier Life Sci, Nagasaki 852, Japan; [Nosaka, Kisato] Kumamoto Univ, Sch Med, Dept Hematol, Kumamoto 860, Japan; [Hishizawa, Masakatsu; Takaori-Kondo, Akifumi] Kyoto Univ, Grad Sch Med, Dept Hematol & Oncol, Kyoto, Japan; [Itonaga, Hidehiro] Sasebo City Gen Hosp, Dept Hematol, Sasebo, Japan; [Imaizumi, Yoshitaka; Miyazaki, Yasushi] Nagasaki Univ, Atom Bomb Dis & Hibakusya Med Unit, Dept Hematol, Atom Bomb Dis Inst, Nagasaki 852, Japan; [Munakata, Wataru] Natl Canc Ctr, Dept Hematol, Tokyo, Japan; [Ogasawara, Hideaki; Sato, Toshitaka; Sasai, Ken; Muramoto, Kenzo] KAN Res Inst Inc, Kobe, Hyogo, Japan; [Penova, Marina; Kawaguchi, Takahisa; Matsuda, Fumihiko] Kyoto Univ, Grad Sch Med, Ctr Genom Med, Kyoto, Japan; [Nakamaki, Tsuyoshi] Showa Univ, Sch Med, Dept Med, Div Hematol, Tokyo 142, Japan; [Ishiyama, Ken] Kanazawa Univ Hosp, Dept Hematol & Oncol, Kanazawa, Ishikawa, Japan; [Miyawaki, Shuichi] Tokyo Metropolitan Otsuka Hosp, Dept Internal Med, Div Hematol, Tokyo, Japan; [Yoon, Sung-Soo] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 151, South Korea; [Takeuchi, Kengo] Japanese Fdn Canc Res, Inst Canc, Pathol Project Mol Targets, Tokyo 170, Japan; [Shibata, Tatsuhiro] Univ Tokyo, Inst Med Sci, Ctr Human Genome, Lab Mol Med, Tokyo, Japan	Ogawa, S (reprint author), Kyoto Univ, Grad Sch Med, Dept Pathol & Tumor Biol, Kyoto, Japan.	sogawa-tky@umin.ac.jp			Ministry of Health, Labour and Welfare of Japan; Japanese Agency for Medical Research and Development (Health and Labour Sciences Research Expenses for Commission and Applied Research for Innovative Treatment of Cancer); Japanese Society for the Promotion of Science (JSPS) KAKENHI [22134006]; National Cancer Center Research and Development Funds [26-A-6]; Funding Program for World-Leading Innovative Research and Development on Science and Technology (FIRST); National Cancer Center Research and Development Fund, Japan	We thank S. Sakaguchi for expert opinion and M. Sago, M. Nakamura, H. Higashi, Y. Ogino, Y. Mori and S. Baba for technical assistance. This work was supported by Grants-in-Aid from the Ministry of Health, Labour and Welfare of Japan and the Japanese Agency for Medical Research and Development (Health and Labour Sciences Research Expenses for Commission and Applied Research for Innovative Treatment of Cancer), Japanese Society for the Promotion of Science (JSPS) KAKENHI (22134006), National Cancer Center Research and Development Funds (26-A-6) and the Funding Program for World-Leading Innovative Research and Development on Science and Technology (FIRST). The National Cancer Center Biobank was supported by the National Cancer Center Research and Development Fund, Japan. This research used computational resources of the K computer provided by the RIKEN Advanced Institute for Computational Science through the HPCI System Research project (hp140230). Supercomputing resources were also provided by the Human Genome Center, the Institute of Medical Science, The University of Tokyo.	Accomando WP, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-3-r50; Kaida D, 2012, CANCER SCI, V103, P1611, DOI 10.1111/j.1349-7006.2012.02356.x; Leonard TA, 2011, CELL, V144, P55, DOI 10.1016/j.cell.2010.12.013; Teschendorff AE, 2013, BIOINFORMATICS, V29, P189, DOI 10.1093/bioinformatics/bts680; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; Shaffer AL, 2012, ANNU REV IMMUNOL, V30, P565, DOI 10.1146/annurev-immunol-020711-075027; Zhang Z, 2007, BLOOD, V109, P2190, DOI 10.1182/blood-2005-01-031930; Zhang JH, 2012, NATURE, V481, P157, DOI 10.1038/nature10725; Bidere N, 2009, NATURE, V458, P92, DOI 10.1038/nature07613; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Mackay HJ, 2007, NAT REV CANCER, V7, P554, DOI 10.1038/nrc2168; Nannya Y, 2005, CANCER RES, V65, P6071, DOI 10.1158/0008-5472.CAN-05-0465; Phillips-Mason PJ, 2011, J CELL BIOCHEM, V112, P39, DOI 10.1002/jcb.22710; Feschotte C, 2012, NAT REV GENET, V13, P283, DOI 10.1038/nrg3199; Tsukasaki K, 2009, J CLIN ONCOL, V27, P453, DOI 10.1200/JCO.2008.18.2428; Mallory MJ, 2011, MOL CELL BIOL, V31, P2184, DOI 10.1128/MCB.05170-11; Vallabhapurapu S, 2009, ANNU REV IMMUNOL, V27, P693, DOI 10.1146/annurev.immunol.021908.132641; Griffith JW, 2014, ANNU REV IMMUNOL, V32, P659, DOI 10.1146/annurev-immunol-032713-120145; Sato Y, 2013, NAT GENET, V45, P860, DOI 10.1038/ng.2699; Tong X, 2011, EMBO REP, V12, P428, DOI 10.1038/embor.2011.49; Rudd CE, 2009, IMMUNOL REV, V229, P12, DOI 10.1111/j.1600-065X.2009.00770.x; Yamamoto G, 2007, AM J HUM GENET, V81, P114, DOI 10.1086/518809; Perissi V, 2004, CELL, V116, P511, DOI 10.1016/S0092-8674(04)00133-3; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Childs KS, 2003, NUCLEIC ACIDS RES, V31, P3016, DOI 10.1093/nar/gkg431; Kinpara S, 2015, LEUKEMIA, V29, P1425, DOI 10.1038/leu.2015.1; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Fu J, 2011, BLOOD, V117, P1652, DOI 10.1182/blood-2010-08-303073; Sommer K, 2005, IMMUNITY, V23, P561, DOI 10.1016/j.immuni.2005.09.014; Bangham CRM, 2005, ONCOGENE, V24, P6035, DOI 10.1038/sj.onc.1208970; Paul S, 2013, TRENDS IMMUNOL, V34, P269, DOI 10.1016/j.it.2013.02.002; Bhatia A, 2014, EXPERT REV CLIN IMMU, V10, P41, DOI 10.1586/1744666X.2014.865519; Supek F, 2014, CELL, V156, P1324, DOI 10.1016/j.cell.2014.01.051; Iwanaga M, 2010, BLOOD, V116, P1211, DOI 10.1182/blood-2009-12-257410; Chiu YL, 2008, ANNU REV IMMUNOL, V26, P317, DOI 10.1146/annurev.immunol.26.021607.090350; Orel L, 2010, J CELL MOL MED, V14, P1555, DOI 10.1111/j.1582-4934.2009.00866.x; Yoshida K, 2011, NATURE, V478, P64, DOI 10.1038/nature10496; WALL KA, 1988, P NATL ACAD SCI USA, V85, P5644, DOI 10.1073/pnas.85.15.5644; You JS, 2012, CANCER CELL, V22, P9, DOI 10.1016/j.ccr.2012.06.008; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Hodson DJ, 2010, NAT IMMUNOL, V11, P717, DOI 10.1038/ni.1901; Matsuoka M, 2007, NAT REV CANCER, V7, P270, DOI 10.1038/nrc2111; Haferlach T, 2014, LEUKEMIA, V28, P241, DOI 10.1038/leu.2013.336; Palomero T, 2014, NAT GENET, V46, P166, DOI 10.1038/ng.2873; Asanuma S, 2013, CANCER SCI, V104, P1097, DOI 10.1111/cas.12181; Oeckinghaus A, 2011, NAT IMMUNOL, V12, P695, DOI 10.1038/ni.2065; Najafabadi HS, 2015, NAT BIOTECHNOL, V33, P555, DOI 10.1038/nbt.3128; Ramsay AJ, 2013, NAT GENET, V45, P526, DOI 10.1038/ng.2584; Chen LP, 2013, NAT REV IMMUNOL, V13, P227, DOI 10.1038/nri3405; Van Loo P, 2010, P NATL ACAD SCI USA, V107, P16910, DOI 10.1073/pnas.1009843107; Antal CE, 2015, CELL, V160, P489, DOI 10.1016/j.cell.2015.01.001; Boxus M, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-76; Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689; Ishitsuka K, 2014, LANCET ONCOL, V15, pE517, DOI 10.1016/S1470-2045(14)70202-5; Koss H, 2014, TRENDS BIOCHEM SCI, V39, P603, DOI 10.1016/j.tibs.2014.09.004; Mermel CH, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-4-r41; Nakagawa M, 2014, J EXP MED, V211, P2497, DOI 10.1084/jem.20140987; Shiraishi Y, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt126; Swerdllow SH, 2008, WHO CLASSIFICATION T; Thome M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003004; Yamagishi M, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00334	61	1	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2015	47	11					1304	+		10.1038/ng.3415		15	Genetics & Heredity	Genetics & Heredity	CV1BN	WOS:000363988200014		
J	Kuramochi, E; Notomi, M				Kuramochi, Eiichi; Notomi, Masaya			OPTICAL MEMORY Phase-change memory	NATURE PHOTONICS			English	News Item							SWITCH; CHIP	Integrated nano-optical memories may help overcome the limitations of communication speeds and energy costs in electronic chips. Now, using nanoscale phase-change materials researchers have realized the first multi-bit all-optical non-volatile memories with a very small footprint.	[Kuramochi, Eiichi; Notomi, Masaya] NTT Corp, Nanophoton Ctr, Atsugi, Kanagawa 2430198, Japan; [Kuramochi, Eiichi; Notomi, Masaya] NTT Corp, NTT Basic Res Labs, Atsugi, Kanagawa 2430198, Japan	Kuramochi, E (reprint author), NTT Corp, Nanophoton Ctr, Atsugi, Kanagawa 2430198, Japan.	kuramochi.eiichi@lab.ntt.co.jp; notomi.masaya@lab.ntt.co.jp	Kuramochi, Eiichi/C-7858-2011	Kuramochi, Eiichi/0000-0002-6284-823X			Gholipour B, 2013, ADV MATER, V25, P3050, DOI 10.1002/adma.201300588; Loke D, 2012, SCIENCE, V336, P1566, DOI 10.1126/science.1221561; Yamada N, 2000, J APPL PHYS, V88, P7020, DOI 10.1063/1.1314323; Nozaki K, 2012, NAT PHOTONICS, V6, P248, DOI 10.1038/nphoton.2012.2; Raoux S, 2014, MRS BULL, V39, P703, DOI 10.1557/mrs.2014.139; Pernice WHP, 2012, APPL PHYS LETT, V101, DOI 10.1063/1.4758996; Shacham A, 2008, IEEE T COMPUT, V57, P1246, DOI 10.1109/TC.2008.78; Kuramochi E, 2014, NAT PHOTONICS, V8, P474, DOI 10.1038/nphoton.2014.93; Wuttig M, 2007, NAT MATER, V6, P824, DOI 10.1038/nmat2009; Rios C, 2015, NAT PHOTONICS, V9, P725, DOI 10.1038/NPHOTON.2015.182; Tanaka D, 2012, OPT EXPRESS, V20, DOI 10.1364/OE.20.010283	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1749-4885	1749-4893		NAT PHOTONICS	Nat. Photonics	NOV	2015	9	11					712	714				4	Optics; Physics, Applied	Optics; Physics	CV1TA	WOS:000364039800006		
J	Horiuchi, N				Horiuchi, Noriaki			VIEW FROM... IRMMW-THZ Strength in diversity	NATURE PHOTONICS			English	News Item								Next-generation wireless communication, high-harmonic generation of sub-cycle pulses and ultrafast probing of the excitation dynamics of materials were all topics of discussion at this year's IRMMW-THz conference in Hong Kong.	Nat Photon, Shinjuku Ku, Tokyo 1620843, Japan	Horiuchi, N (reprint author), Nat Photon, Shinjuku Ku, 2-37 Ichigayatamachi, Tokyo 1620843, Japan.	n.horiuchi@nature.com						0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1749-4885	1749-4893		NAT PHOTONICS	Nat. Photonics	NOV	2015	9	11					714	716				4	Optics; Physics, Applied	Optics; Physics	CV1TA	WOS:000364039800007		
J	Karl, NJ; McKinney, RW; Monnai, Y; Mendis, R; Mittleman, DM				Karl, Nicholas J.; McKinney, Robert W.; Monnai, Yasuaki; Mendis, Rajind; Mittleman, Daniel M.			Frequency-division multiplexing in the terahertz range using a leaky-wave antenna	NATURE PHOTONICS			English	Article							GUIDE; THZ; LOSSES; BAND; TE1	The idea of using radiation in the 0.1-1.0 THz range as carrier waves for free-space wireless communications has attracted growing interest in recent years, due to the promise of the large available bandwidth(1,2). Recent research has focused on system demonstrations(3,4), as well as the exploration of new components for modulation(5), beam steering(6) and polarization control(7). However, the multiplexing and demultiplexing of terahertz signals remains an unaddressed challenge, despite the importance of such capabilities for broadband networks. Using a leaky-wave antenna based on a metal parallel-plate waveguide, we demonstrate frequency-division multiplexing and demultiplexing over more than one octave of bandwidth. We show that this device architecture offers a unique method for controlling the spectrum allocation, by variation of the waveguide plate separation. This strategy, which is distinct from those previously employed in either the microwave(8) or optical(9) regimes, enables independent control of both the centre frequency and bandwidth of multiplexed terahertz channels.	[Karl, Nicholas J.; McKinney, Robert W.; Mendis, Rajind; Mittleman, Daniel M.] Rice Univ, Dept Elect & Comp Engn, Houston, TX 77005 USA; [Monnai, Yasuaki] Univ Tokyo, Dept Complex Sci & Engn, Bunkyo Ku, Tokyo 1138656, Japan	Mittleman, DM (reprint author), Rice Univ, Dept Elect & Comp Engn, MS-378,6100 Main St, Houston, TX 77005 USA.	mittleman@brown.edu			US National Science Foundation; W.M. Keck Foundation	The authors thank K. Reichel for contributions. This work was supported by the US National Science Foundation and the W.M. Keck Foundation.	Acampora A. S., 1994, INTRO BROADBAND NETW; CHUANG CW, 1988, IEEE T ANTENN PROPAG, V36, P1227, DOI 10.1109/8.8600; Mendis R, 2001, OPT LETT, V26, P846, DOI 10.1364/OL.26.000846; Mbonye M, 2013, J INFRARED MILLIM TE, V34, P416, DOI 10.1007/s10762-013-9990-6; Mbonye M, 2012, OPT EXPRESS, V20, P27800, DOI 10.1364/OE.20.027800; Monnai Y, 2013, OPT EXPRESS, V21, P2347, DOI 10.1364/OE.21.002347; Koenig S, 2013, NAT PHOTONICS, V7, P977, DOI [10.1038/nphoton.2013.275, 10.1038/NPHOTON.2013.275]; Kleine-Ostmann T, 2011, J INFRARED MILLIM TE, V32, P143, DOI 10.1007/s10762-010-9758-1; Lee CW, 1999, IEEE T ANTENN PROPAG, V47, P171, DOI 10.1109/8.753007; Song HJ, 2012, ELECTRON LETT, V48, P953, DOI 10.1049/el.2012.1708; Sabharwal A, 2007, IEEE ACM T NETWORK, V15, P533, DOI 10.1109/TNET.2007.893230; Mendis R, 2012, APPL PHYS LETT, V101, DOI 10.1063/1.4752241; Lee JI, 1999, IEEE T ANTENN PROPAG, V47, P701; Mendis R, 2010, IEEE T MICROW THEORY, V58, P1993, DOI 10.1109/TMTT.2010.2050386; Su K, 2012, J OPT SOC AM A, V29, P179, DOI 10.1364/JOSAA.29.000179; Chen HT, 2006, NATURE, V444, P597, DOI 10.1038/nature05343; Liu JB, 2013, APPL PHYS LETT, V103, DOI 10.1063/1.4813820; Hon PWC, 2013, J APPL PHYS, V113, DOI 10.1063/1.4776761; Mendis R, 2009, OPT EXPRESS, V17, P14839, DOI 10.1364/OE.17.014839; Piesiewicz R, 2007, IEEE ANTENN PROPAG M, V49, P24, DOI 10.1109/MAP.2007.4455844; KESHAVAMURTHY TL, 1981, IEEE T ANTENN PROPAG, V29, P112, DOI 10.1109/TAP.1981.1142548; Esquius-Morote M, 2014, IEEE T THZ SCI TECHN, V4, P116, DOI 10.1109/TTHZ.2013.2294538; Keiser Gerd, 2011, OPTICAL FIBER COMMUN; Luo LW, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4069; Mendis R., 2009, J OPT SOC AM B, V26, P6; Monnai Y., 2012, APPL PHYS LETT, V101; Oliner A. A., 2007, ANTENNA ENG HDB; Shuvaev A, 2013, PHYS REV LETT, V111, DOI 10.1103/PhysRevLett.111.227201; Suen JY, 2014, IEEE T THZ SCI TECHN, V4, P86, DOI 10.1109/TTHZ.2013.2294018; Yan Y, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5876	30	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1749-4885	1749-4893		NAT PHOTONICS	Nat. Photonics	NOV	2015	9	11					717	+		10.1038/NPHOTON.2015.176		5	Optics; Physics, Applied	Optics; Physics	CV1TA	WOS:000364039800009		
J	Katsuno, K; Burrows, JN; Duncan, K; van Huijsduijnen, RH; Kaneko, T; Kita, K; Mowbray, CE; Schmatz, D; Warner, P; Slingsby, BT				Katsuno, Kei; Burrows, Jeremy N.; Duncan, Ken; van Huijsduijnen, Rob Hooft; Kaneko, Takushi; Kita, Kiyoshi; Mowbray, Charles E.; Schmatz, Dennis; Warner, Peter; Slingsby, B. T.			Hit and lead criteria in drug discovery for infectious diseases of the developing world	NATURE REVIEWS DRUG DISCOVERY			English	Article							NONREPLICATING MYCOBACTERIUM-TUBERCULOSIS; RESISTANT PLASMODIUM-FALCIPARUM; HIGH-THROUGHPUT SCREEN; ARTEMISININ RESISTANCE; NEXT-GENERATION; CHAGAS-DISEASE; MALARIA; ASSAY; INHIBITORS; MODEL	Reducing the burden of infectious diseases that affect people in the developing world requires sustained collaborative drug discovery efforts. The quality of the chemical starting points for such projects is a key factor in improving the likelihood of clinical success, and so it is important to set clear go/no-go criteria for the progression of hit and lead compounds. With this in mind, the Japanese Global Health Innovative Technology (GHIT) Fund convened with experts from the Medicines for Malaria Venture, the Drugs for Neglected Diseases initiative and the TB Alliance, together with representatives from the Bill & Melinda Gates Foundation, to set disease-specific criteria for hits and leads for malaria, tuberculosis, visceral leishnnaniasis and Chagas disease. Here, we present the agreed criteria and discuss the underlying rationale.	[Katsuno, Kei; Slingsby, B. T.] Global Hlth Innovat Technol GHIT Fund, Minato Ku, Tokyo 1060032, Japan; [Burrows, Jeremy N.; van Huijsduijnen, Rob Hooft; Schmatz, Dennis] Med Malaria Venture, CH-1215 Geneva 15, Switzerland; [Duncan, Ken; Warner, Peter] Bill & Melinda Gates Fdn, Seattle, WA 98102 USA; [Kaneko, Takushi] Global Alliance TB Drug Dev, TB Alliance, New York, NY 10005 USA; [Kita, Kiyoshi] Univ Tokyo, Bunkyo Ku, Tokyo 1130033, Japan; [Mowbray, Charles E.] Drugs Neglected Dis Initiat, CH-1202 Geneva, Switzerland	Katsuno, K (reprint author), Global Hlth Innovat Technol GHIT Fund, Minato Ku, Ark Hills,Sengokuyama Mori Tower 25F, Tokyo 1060032, Japan.	kei.katsuno@ghitfund.org	Hooft van Huijsduijnen, Rob/B-3653-2009	Hooft van Huijsduijnen, Rob/0000-0002-2261-9424			Angulo-Barturen I, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002252; Ansari MT, 2013, MINI-REV MED CHEM, V13, P1879; Endo A, 2010, P JPN ACAD B-PHYS, V86, P484, DOI 10.2183/pjab.86.484; Mbengue A, 2015, NATURE, V520, P683, DOI 10.1038/nature14412; Khanna I, 2012, DRUG DISCOV TODAY, V17, P1088, DOI 10.1016/j.drudis.2012.05.007; Nwaka S, 2006, NAT REV DRUG DISCOV, V5, P941, DOI 10.1038/nrd2144; Wayne L G, 2001, Methods Mol Med, V54, P247, DOI 10.1385/1-59259-147-7:247; Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0; Clark RL, 2009, REPROD TOXICOL, V28, P285, DOI 10.1016/j.reprotox.2009.05.002; Tsang CK, 2007, DRUG DISCOV TODAY, V12, P112, DOI 10.1016/j.drudis.2006.12.008; Bosman A, 2007, AM J TROP MED HYG, V77, P193; Molina I, 2014, NEW ENGL J MED, V370, P1899, DOI 10.1056/NEJMoa1313122; Tobert JA, 2003, NAT REV DRUG DISCOV, V2, P517, DOI 10.1038/nrd1112; Leibert E, 2014, THER CLIN RISK MANAG, V10, P597, DOI 10.2147/TCRM.S37743; Baell JB, 2010, J MED CHEM, V53, P2719, DOI 10.1021/jm901137j; De Rycker M, 2013, ANTIMICROB AGENTS CH, V57, P2913, DOI 10.1128/AAC.02398-12; Ashley EA, 2014, NEW ENGL J MED, V371, P411, DOI 10.1056/NEJMoa1314981; Lakshminarayana SB, 2015, J ANTIMICROB CHEMOTH, V70, P857, DOI 10.1093/jac/dku457; Ariey F, 2014, NATURE, V505, P50, DOI 10.1038/nature12876; Hawn TR, 2015, IMMUNOL REV, V264, P344, DOI 10.1111/imr.12255; Isozumi R, 2015, EMERG INFECT DIS, V21, P490, DOI 10.3201/eid2103.140898; Tun KM, 2015, LANCET INFECT DIS, V15, P415, DOI 10.1016/S1473-3099(15)70032-0; Braselmann S, 2006, J PHARMACOL EXP THER, V319, P998, DOI 10.1124/jpet.106.109058; Omura S, 2004, NAT REV MICROBIOL, V2, P984, DOI 10.1038/nrmicro1048; Franzblau SG, 1998, J CLIN MICROBIOL, V36, P362; Guiguemde WA, 2010, NATURE, V465, P311, DOI 10.1038/nature09099; Dhar N, 2007, CURR OPIN MICROBIOL, V10, P30, DOI 10.1016/j.mib.2006.12.007; Datta M, 2015, P NATL ACAD SCI USA, V112, P1827, DOI 10.1073/pnas.1424563112; Franzblau SG, 2012, TUBERCULOSIS, V92, P453, DOI 10.1016/j.tube.2012.07.003; Burrows J, 2015, NATURE, V520, P628, DOI 10.1038/nature14387; Mak PA, 2012, ACS CHEM BIOL, V7, P1190, DOI 10.1021/cb2004884; Russell DG, 2009, NAT IMMUNOL, V10, P943, DOI 10.1038/ni.1781; Oberlies NH, 2004, J NAT PROD, V67, P129, DOI 10.1021/np030498t; Holmes D, 2013, NAT REV DRUG DISCOV, V12, P894, DOI 10.1038/nrd4197; Harper J, 2012, J INFECT DIS, V205, P595, DOI 10.1093/infdis/jir786; Meister S, 2011, SCIENCE, V334, P1372, DOI 10.1126/science.1211936; Borel JF, 2002, WIEN KLIN WOCHENSCHR, V114, P433; Mitchison DA, 2004, FRONT BIOSCI, V9, P1059, DOI 10.2741/1293; Deng XY, 2014, J MED CHEM, V57, P5381, DOI 10.1021/jm500481t; Nilsen A, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005029; Strader CR, 2011, J NAT PROD, V74, P900, DOI 10.1021/np2000528; Payne DJ, 2007, NAT REV DRUG DISCOV, V6, P29, DOI 10.1038/nrd2201; Kita K, 2007, TRENDS PARASITOL, V23, P223, DOI 10.1016/j.pt.2007.03.005; Orme I, 1998, NOVART FDN SYMP, V217, P112, DOI 10.1002/0470846526.ch8; Swinney DC, 2013, CLIN PHARMACOL THER, V93, P299, DOI 10.1038/clpt.2012.236; Wunberg T, 2006, DRUG DISCOV TODAY, V11, P175, DOI 10.1016/S1359-6446(05)03700-1; Baell J, 2014, NATURE, V513, P481, DOI 10.1038/513481a; Toovey S, 2006, CLIN INFECT DIS, V42, P1214, DOI 10.1086/502658; Gamo FJ, 2010, NATURE, V465, P305, DOI 10.1038/nature09107; Silva-Miranda M, 2015, ANTIMICROB AGENTS CH, V59, P693, DOI 10.1128/AAC.03705-14; Crump A, 2011, P JPN ACAD B-PHYS, V87, P13, DOI 10.2183/pjab.87.13; Don R, 2014, PARASITOLOGY, V141, P140, DOI 10.1017/S003118201300142X; Eder J, 2014, NAT REV DRUG DISCOV, V13, P577, DOI 10.1038/nrd4336; Burrows JN, 2011, FUTURE MED CHEM, V3, P1401, DOI [10.4155/fmc.11.91, 10.4155/FMC.11.91]; Gilbert IH, 2013, J MED CHEM, V56, P7719, DOI 10.1021/jm400362b; Cho SH, 2007, ANTIMICROB AGENTS CH, V51, P1380, DOI 10.1128/AAC.00055-06; Pethe K, 2013, NAT MED, V19, P1157, DOI 10.1038/nm.3262; Schuster FL, 2002, CLIN MICROBIOL REV, V15, P355, DOI 10.1128/CMR.15.3.355-364.2002; Priest BT, 2008, CHANNELS, V2, P87; Burrows J. N., 2011, 3 WORLD DIS, P125; Burrows JN, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-187; Chatelain E, 2015, J BIOMOL SCREEN, V20, P22, DOI 10.1177/1087057114550585; Dembele L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018162; Hughes M, 2012, ASSAY GUIDANCE MANUA; Keenan M, 2013, FUTURE MED CHEM, V5, P1733, DOI [10.4155/fmc.13.139, 10.4155/FMC.13.139]; Martis E. A., 2011, J APPL PHARM SCI, V01, P2; McGovern SL, 2002, J MED CHEM, V45, P1712, DOI 10.1021/jm010533y; Moore E M, 2010, J Glob Infect Dis, V2, P151, DOI 10.4103/0974-777X.62883; Mutai BK, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-S3-S6; Nwaka S, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000440; Pena I, 2015, SCI REP-UK, V5, DOI 10.1038/srep08771; Plouffe D, 2008, P NATL ACAD SCI USA, V105, P9059, DOI 10.1073/pnas.0802982105; Riss T. L., ASSAY GUIDANCE MANUA; Ruecker A, 2014, ANTIMICROB AGENTS CH, V58, P7292, DOI 10.1128/AAC.03666-14; Sinden RE, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-70; Slingsby BT, 2013, LANCET GLOB HEALTH, V1, pE184, DOI 10.1016/S2214-109X(13)70055-X; Sundar S., 2014, EXPERT OPIN PHARMACO, V16, P237; Wells T. N. C., 2015, NAT REV DRUG DISCOV, V14, P1; WHO, 2014, GLOB TUB REP 2014, pOrganization WHO; Winzeler EA, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0544-6; World Health Organization, 2014, ANT RES GLOB REP SUR; Xavier Alphienes Stanley, 2014, J Pharmacol Pharmacother, V5, P222, DOI 10.4103/0976-500X.136121	82	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1474-1776	1474-1784		NAT REV DRUG DISCOV	Nat. Rev. Drug Discov.	NOV	2015	14	11					751	758		10.1038/nrd4683		8	Biotechnology & Applied Microbiology; Pharmacology & Pharmacy	Biotechnology & Applied Microbiology; Pharmacology & Pharmacy	CV4YO	WOS:000364272600014		
J	Kanoh, Y; Matsumoto, S; Fukatsu, R; Kakusho, N; Kono, N; Renard-Guillet, C; Masuda, K; Iida, K; Nagasawa, K; Shirahige, K; Masai, H				Kanoh, Yutaka; Matsumoto, Seiji; Fukatsu, Rino; Kakusho, Naoko; Kono, Nobuaki; Renard-Guillet, Claire; Masuda, Koji; Iida, Keisuke; Nagasawa, Kazuo; Shirahige, Katsuhiko; Masai, Hisao			Rif1 binds to G quadruplexes and suppresses replication over long distances	NATURE STRUCTURAL & MOLECULAR BIOLOGY			English	Article							CONTROLS DNA-REPLICATION; PROTEIN PHOSPHATASE 1; FISSION YEAST; TELOMERE FUNCTION; TIMING PROGRAM; END RESECTION; BUDDING-YEAST; REPAIR; 53BP1; CELLS	Rif1 regulates replication timing and repair of double-strand DNA breaks. Using a chromatin immunoprecipitation-sequencing method, we identified 35 high-affinity kill-binding sites in fission yeast chromosomes. Binding sites tended to be located near dormant origins and to contain at least two copies of a conserved motif, CNWWGTGGGGG. Base substitution within these motifs resulted in complete loss of Rif1 binding and in activation of late-firing or dormant origins located up to 50 kb away. We show that Rif1-binding sites adopt G quadruplex-like structures in vitro, in a manner dependent on the conserved sequence and on other G tracts, and that purified Rif1 preferentially binds to this structure. These results suggest that Rif1 recognizes and binds G quadruplex-like structures at selected intergenic regions, thus generating local chromatin structures that may exert long-range suppressive effects on origin firing.	[Kanoh, Yutaka; Matsumoto, Seiji; Fukatsu, Rino; Kakusho, Naoko; Masai, Hisao] Tokyo Metropolitan Inst Med Sci, Dept Genome Med, Tokyo 113, Japan; [Kono, Nobuaki] Keio Univ, Inst Adv Biosci, Yamagata, Japan; [Renard-Guillet, Claire; Masuda, Koji; Shirahige, Katsuhiko] Univ Tokyo, Res Ctr Epigenet Dis, Inst Mol & Cellular Biosci, Lab Genome Struct & Funct, Tokyo, Japan; [Iida, Keisuke; Nagasawa, Kazuo] Tokyo Univ Agr & Technol, Fac Technol, Dept Biotechnol & Life Sci, Tokyo, Japan	Masai, H (reprint author), Tokyo Metropolitan Inst Med Sci, Dept Genome Med, Tokyo 113, Japan.	masai-hs@igakuken.or.jp			Japan Society for the Promotion of Science (JSPS); JSPS KAKENHI [23247031, 26251004, 24114520, 25125724, 24570205, 15H02369, 26870575]; Naito Foundation	We thank J. Horiuchi for critical reading of the manuscript and useful suggestions. We would like to thank K. Ohta and the members of his laboratory for assistance in ChIP-seq analyses, which were supported by Japan Society for the Promotion of Science (JSPS) Grant-in-Aid for Scientific Research on Priority Areas ('non-coding DNA'). This work was supported by JSPS KAKENHI (Grant-in-Aid for Scientific Research (A) (grant nos. 23247031 and 26251004) and Grant-in-Aid for Scientific Research on Priority Areas ('non-coding RNA' and 'Genome Adaptation'; grant nos. 24114520 and 25125724, respectively) to H.M. and Grant-in-Aid for Scientific Research (C) (grant no. 24570205) to S.M., Grant-in-Aid for Scientific Research (A) (grant no. 15H02369) to K.S. and Grant-in-Aid for Young Scientists (B) (grant no. 26870575) to N. Kono) and by the Naito Foundation Continuation Subsidy for Outstanding Projects (to H.M.). We thank members of our laboratory for helpful discussion.	Knott SRV, 2012, CELL, V148, P99, DOI 10.1016/j.cell.2011.12.012; Silverman J, 2004, GENE DEV, V18, P2108, DOI 10.1101/gad.1216004; Sukackaite R, 2014, J BIOL CHEM, V289, P13903, DOI 10.1074/jbc.M114.557843; Uno S, 2012, METHODS, V57, P214, DOI 10.1016/j.ymeth.2012.06.016; Biffi G, 2013, NAT CHEM, V5, P182, DOI [10.1038/nchem.1548, 10.1038/NCHEM.1548]; Hayano M, 2012, GENE DEV, V26, P137, DOI 10.1101/gad.178491.111; Tanizawa H, 2010, NUCLEIC ACIDS RES, V38, P8164, DOI 10.1093/nar/gkq955; Bailey TL, 2009, NUCLEIC ACIDS RES, V37, pW202, DOI 10.1093/nar/gkp335; Aparicio OM, 2013, GENE DEV, V27, P117, DOI 10.1101/gad.209999.112; Kanoh J, 2001, CURR BIOL, V11, P1624, DOI 10.1016/S0960-9822(01)00503-6; Shi T, 2013, CELL, V153, P1340, DOI 10.1016/j.cell.2013.05.007; Chapman JR, 2013, MOL CELL, V49, P858, DOI 10.1016/j.molcel.2013.01.002; Yoshida K, 2013, J MOL BIOL, V425, P4696, DOI 10.1016/j.jmb.2013.09.020; Mattarocci S, 2014, CELL REP, V7, P62, DOI 10.1016/j.celrep.2014.03.010; Bochman ML, 2012, NAT REV GENET, V13, P770, DOI 10.1038/nrg3296; Yamazaki S, 2012, EMBO J, V31, P3667, DOI 10.1038/emboj.2012.180; Hiraga S, 2014, GENE DEV, V28, P372, DOI 10.1101/gad.231258.113; Masai H, 2010, ANNU REV BIOCHEM, V79, P89, DOI 10.1146/annurev.biochem.052308.103205; Dave A, 2014, CELL REP, V7, P53, DOI 10.1016/j.celrep.2014.02.019; Fletcher TM, 1998, BIOCHEMISTRY-US, V37, P5536, DOI 10.1021/bi972681p; Cornacchia D, 2012, EMBO J, V31, P3678, DOI 10.1038/emboj.2012.214; Valton AL, 2014, EMBO J, V33, P732, DOI 10.1002/embj.201387506; Cayrou C, 2012, CELL CYCLE, V11, P658, DOI 10.4161/cc.11.4.19097; Xu DY, 2010, EMBO J, V29, P3140, DOI 10.1038/emboj.2010.186; Callen E, 2013, CELL, V153, P1266, DOI 10.1016/j.cell.2013.05.023; Zimmermann M, 2013, SCIENCE, V339, P700, DOI 10.1126/science.1231573; Mechali M, 2013, CURR OPIN GENET DEV, V23, P124, DOI 10.1016/j.gde.2013.02.010; Burge S, 2006, NUCLEIC ACIDS RES, V34, P5402, DOI 10.1093/nar/gkl655; Escribano-Diaz C, 2013, MOL CELL, V49, P872, DOI 10.1016/j.molcel.2013.01.001; Matsumoto S, 2011, J CELL BIOL, V195, P387, DOI 10.1083/jcb.201107025; Feng L, 2013, J BIOL CHEM, V288, P11135, DOI 10.1074/jbc.M113.457440; Wang JL, 2006, NATURE, V444, P364, DOI 10.1038/nature05284; Dan JM, 2014, DEV CELL, V29, P7, DOI 10.1016/j.devcel.2014.03.004; Iida K, 2013, ANGEW CHEM INT EDIT, V52, P12052, DOI 10.1002/anie.201305366; Di Virgilio M, 2013, SCIENCE, V339, P711, DOI 10.1126/science.1230624; Park S, 2011, P NATL ACAD SCI USA, V108, P14572, DOI 10.1073/pnas.1105262108; Sabouri N, 2014, BMC BIOL, V12, DOI 10.1186/s12915-014-0101-5; Sengar A, 2014, BIOCHEMISTRY-US, V53, P7718, DOI 10.1021/bi500990v	38	1	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1545-9993	1545-9985		NAT STRUCT MOL BIOL	Nat. Struct. Mol. Biol.	NOV	2015	22	11					889	897		10.1038/nsmb.3102		9	Biochemistry & Molecular Biology; Biophysics; Cell Biology	Biochemistry & Molecular Biology; Biophysics; Cell Biology	CV4ZA	WOS:000364273800012		
J	Miyabe, I; Mizuno, K; Keszthelyi, A; Daigaku, Y; Skouteri, M; Mohebi, S; Kunkel, TA; Murray, JM; Carr, AM				Miyabe, Izumi; Mizuno, Ken'Ichi; Keszthelyi, Andrea; Daigaku, Yasukazu; Skouteri, Meliti; Mohebi, Saed; Kunkel, Thomas A.; Murray, Johanne M.; Carr, Antony M.			Polymerase delta replicates both strands after homologous recombination-dependent fork restart	NATURE STRUCTURAL & MOLECULAR BIOLOGY			English	Article							BREAK-INDUCED REPLICATION; GROSS CHROMOSOMAL REARRANGEMENTS; ONCOGENE-INDUCED SENESCENCE; CONSERVATIVE DNA-SYNTHESIS; GENOME INSTABILITY; TEMPLATE EXCHANGE; INVERTED REPEATS; DAMAGE RESPONSE; CNV FORMATION; HUMAN-CELLS	To maintain genetic stability, DNA must be replicated only once per cell cycle, and replication must be completed even when individual replication forks are inactivated. Because fork inactivation is common, passive convergence of an adjacent fork is insufficient to rescue all inactive forks. Thus, eukaryotic cells have evolved homologous recombination-dependent mechanisms to restart persistent inactive forks. Completing DNA synthesis via homologous recombination-restarted replication (HoRReR) ensures cell survival, but at a cost. One such cost is increased mutagenesis because HoRReR is more error prone than canonical replication. This increased error rate implies the HoRReR mechanism is distinct from that of a canonical fork. Here we demonstrate, in Schizosaccharomyces pombe, that a DNA sequence duplicated by HoRReR during S phase is replicated semiconservatively, but both the leading and lagging strands are synthesized by DNA polymerase delta.	[Miyabe, Izumi; Mizuno, Ken'Ichi; Keszthelyi, Andrea; Skouteri, Meliti; Mohebi, Saed; Murray, Johanne M.; Carr, Antony M.] Univ Sussex, Genome Damage & Stabil Ctr, Brighton, E Sussex, England; [Daigaku, Yasukazu] Tohoku Univ, Frontier Res Inst Interdisciplinary Sci, Sendai, Miyagi 980, Japan; [Kunkel, Thomas A.] NIEHS, Genome Integr & Struct Biol Lab, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA	Carr, AM (reprint author), Univ Sussex, Genome Damage & Stabil Ctr, Brighton, E Sussex, England.	a.m.carr@sussex.ac.uk			Division of Intramural Research of the US National Institutes of Health [Z01 ES065070]; Medical Research Council (UK) [G0801078, G1100074]; European Research Council [268788-SMI-DDR]	This work was supported by Project Z01 ES065070 (T.A.K.) from the Division of Intramural Research of the US National Institutes of Health, by Medical Research Council (UK) grants G0801078 and G1100074 (A.M.C.) and by European Research Council grant 268788-SMI-DDR (A.M.C.). We thank H. Masukata (Osaka University) for the cdc20::hphMX6-Pnmtl-cdc2OCTD strain.	Anand RP, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a010397; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Daigaku Y, 2015, NAT STRUCT MOL BIOL, V22, P192, DOI 10.1038/nsmb.2962; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Barlow JH, 2013, CELL, V152, P620, DOI 10.1016/j.cell.2013.01.006; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Lopes M, 2001, NATURE, V412, P557, DOI 10.1038/35087613; Carr AM, 2013, J MOL BIOL, V425, P4733, DOI 10.1016/j.jmb.2013.04.023; Sun Z, 2013, HUM MOL GENET, V22, P749, DOI 10.1093/hmg/dds482; Reijns MAM, 2015, NATURE, V518, P502, DOI 10.1038/nature14183; Lambert S, 2005, CELL, V121, P689, DOI 10.1016/j.cell.2005.03.022; MESELSON M, 1958, P NATL ACAD SCI USA, V44, P671, DOI 10.1073/pnas.44.7.671; Lambert S, 2013, CHROMOSOMA, V122, P33, DOI 10.1007/s00412-013-0398-9; Clausen AR, 2015, NAT STRUCT MOL BIOL, V22, P185, DOI 10.1038/nsmb.2957; Liu PF, 2012, CURR OPIN GENET DEV, V22, P211, DOI 10.1016/j.gde.2012.02.012; Eydmann T, 2008, GENETICS, V180, P27, DOI 10.1534/genetics.108.089243; Malkova A, 2013, CURR OPIN GENET DEV, V23, P271, DOI 10.1016/j.gde.2013.05.007; Jain S, 2009, GENE DEV, V23, P291, DOI 10.1101/gad.1751209; Handa T, 2012, MOL BIOL CELL, V23, P3240, DOI 10.1091/mbc.E12-05-0339; Lambert S, 2010, MOL CELL, V39, P346, DOI 10.1016/j.molcel.2010.07.015; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; Schlacher K, 2012, CANCER CELL, V22, P106, DOI 10.1016/j.ccr.2012.05.015; Dominguez-Sola D, 2007, NATURE, V448, P445, DOI 10.1038/nature05953; Donnianni RA, 2013, P NATL ACAD SCI USA, V110, P13475, DOI 10.1073/pnas.1309800110; Smith CE, 2007, NATURE, V447, P102, DOI 10.1038/nature05723; Georgescu RE, 2014, NAT STRUCT MOL BIOL, V21, P664, DOI 10.1038/nsmb.2851; Mizuno K, 2009, GENE DEV, V23, P2876, DOI 10.1101/gad.1863009; Kesti T, 1999, MOL CELL, V3, P679, DOI 10.1016/S1097-2765(00)80361-5; Lambert S, 2013, CURR OPIN GENET DEV, V23, P132, DOI 10.1016/j.gde.2012.11.009; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Saini N, 2013, NATURE, V502, P389, DOI 10.1038/nature12584; Ge XQ, 2007, GENE DEV, V21, P3331, DOI 10.1101/gad.457807; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Mizuno K, 2013, NATURE, V493, P246, DOI 10.1038/nature11676; Errico A, 2012, CRIT REV BIOCHEM MOL, V47, P222, DOI 10.3109/10409238.2012.655374; Jones RM, 2013, ONCOGENE, V32, P3744, DOI 10.1038/onc.2012.387; Petermann E, 2010, MOL CELL, V37, P492, DOI 10.1016/j.molcel.2010.01.021; Bignell GR, 2007, GENOME RES, V17, P1296, DOI 10.1101/gr.6522707; Carvalho CMB, 2013, NAT GENET, V45, P1319, DOI 10.1038/ng.2768; Neelsen KJ, 2013, J CELL BIOL, V200, P699, DOI 10.1083/jcb.201212058; Higgs MR, 2015, MOL CELL, V59, P462, DOI 10.1016/j.molcel.2015.06.007; Kunkel TA, 2008, TRENDS CELL BIOL, V18, P521, DOI [10.1016/j.tcb.2008.08.005, 10.1016/i.tcb.2008.08.005]; Wilson MA, 2013, NATURE, V502, P393, DOI 10.1038/nature12585; Bester AC, 2011, CELL, V145, P435, DOI 10.1016/j.cell.2011.03.044; Calzada A, 2005, GENE DEV, V19, P1905, DOI 10.1101/gad.337205; Costantino L, 2014, SCIENCE, V343, P88, DOI 10.1126/science.1243211; Deem A, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1000594; Iraqui I, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002976; Kai M, 2003, GENE DEV, V17, P64, DOI 10.1101/gad.1043203; Lujan SA, 2014, GENOME RES, V24, P1751, DOI 10.1101/gr.178335.114; Miyabe I, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002407; Mohebi S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7357; Nguyen M.O., 2015, ELIFE, V4	53	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1545-9993	1545-9985		NAT STRUCT MOL BIOL	Nat. Struct. Mol. Biol.	NOV	2015	22	11					932	938		10.1038/nsmb.3100		7	Biochemistry & Molecular Biology; Biophysics; Cell Biology	Biochemistry & Molecular Biology; Biophysics; Cell Biology	CV4ZA	WOS:000364273800018		
J	Taniguchi, A; Mochizuki, H; Nagamachi, S; Ebihara, Y; Ishii, N; Shiomi, K; Nakazato, M				Taniguchi, Akitoshi; Mochizuki, Hitoshi; Nagamachi, Shigeki; Ebihara, Yuka; Ishii, Nobuyuki; Shiomi, Kazutaka; Nakazato, Masamitsu			Hypometabolism of watershed areas of the brain in HTLV-1-associated myelopathy/tropical spastic paraparesis	NEUROLOGICAL SCIENCES			English	Article						HTLV-1-associated myelopathy; Watershed area; Brain metabolism; PET-CT; Slow blood flow	I-ASSOCIATED MYELOPATHY; CENTRAL-NERVOUS-SYSTEM; WHITE-MATTER LESIONS; HTLV-I; SPINAL-CORD; HAM/TSP; INFECTION; FLOW; HAM	In previous studies of human T-lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), areas of slow blood flow in the spinal cord were related to pathological changes. While the pathological changes in the brain are milder than those in the spinal cord, they are also more significant in sites with slow blood flow. In this study, we investigated brain glucose metabolism in slow blood flow areas using fluorine-18 fluorodeoxyglucose positron emission tomography (F-18-FDG-PET). Clinical features and brain F-18-FDG-PET parameters were analyzed in six patients with HAM/TSP. For comparison of PET data, eight healthy volunteers were enrolled as normal controls (NLs). Glucose metabolism in the watershed areas of the middle and posterior cerebral arteries, as compared with that in the occipital lobes as a control, was significantly lower in HAM/TSP patients than in NLs. This result confirmed the relationship between slow blood flow areas and hypometabolism in HAM/TSP, and is consistent with previous findings that pathological changes are accentuated in sites with slow blood flow.	[Taniguchi, Akitoshi; Mochizuki, Hitoshi; Ebihara, Yuka; Ishii, Nobuyuki; Shiomi, Kazutaka; Nakazato, Masamitsu] Miyazaki Univ, Div Neurol Respirol Endocrinol & Metab, Dept Internal Med, Fac Med, Kiyotake, Miyazaki 8891692, Japan; [Nagamachi, Shigeki] Miyazaki Univ, Fac Med, Dept Radiol, Miyazaki, Japan	Mochizuki, H (reprint author), Miyazaki Univ, Div Neurol Respirol Endocrinol & Metab, Dept Internal Med, Fac Med, 5200 Kihara, Kiyotake, Miyazaki 8891692, Japan.	mochizuki-h@umin.net					Zhang ZA, 1997, NEUROPATHOLOGY, V17, P32, DOI 10.1111/j.1440-1789.1997.tb00008.x; KURTZKE JF, 1983, NEUROLOGY, V33, P1444; YOSHIOKA A, 1993, J NEUROL NEUROSUR PS, V56, P1004, DOI 10.1136/jnnp.56.9.1004; Izumo S, 2010, NEUROPATHOLOGY, V30, P480, DOI 10.1111/j.1440-1789.2010.01135.x; SOKOLOFF L, 1981, FED PROC, V40, P2311; Oh U, 2008, NEUROL CLIN, V26, P781, DOI 10.1016/j.ncl.2008.03.008; Souza A, 2012, REV SOC BRAS MED TRO, V45, P545, DOI 10.1590/S0037-86822012000500002; IWASAKI Y, 1990, J NEUROL SCI, V96, P103, DOI 10.1016/0022-510X(90)90060-Z; Aye MM, 2000, ACTA NEUROPATHOL, V100, P245; Izumo S, 1996, NEUROLOGY, V46, P1016; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Mohan S, 1999, AM J PHYSIOL-CELL PH, V276, pC1100; DETHE G, 1993, AIDS RES HUM RETROV, V9, P381, DOI 10.1089/aid.1993.9.381; Morgan DJ, 2007, AIDS RES HUM RETROV, V23, P1499, DOI 10.1089/aid.2007.0077; Puccioni-Sohler M, 2012, ARQ NEURO-PSIQUIAT, V70, P246, DOI 10.1590/S0004-282X2012000400004; Rafatpanah H, 2013, IRAN J BASIC MED SCI, V16, P235; Shoeibi A, 2013, IRAN J BASIC MED SCI, V16, P202; WHO, 1989, WKLY EPIDEMIOL REC, V64, P382	18	0	0	SPRINGER-VERLAG ITALIA SRL	MILAN	VIA DECEMBRIO, 28, MILAN, 20137, ITALY	1590-1874	1590-3478		NEUROL SCI	Neurol. Sci.	NOV	2015	36	11					2117	2120		10.1007/s10072-015-2323-x		4	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CV1MJ	WOS:000364022100018		
J	Nishijima, H; Suzuki, C; Tomiyama, M				Nishijima, Haruo; Suzuki, Chieko; Tomiyama, Masahiko			Bilateral episcleritis followed by right optic perineuritis with severe visual loss: a case report	NEUROLOGICAL SCIENCES			English	Letter							SCLERITIS		[Nishijima, Haruo; Suzuki, Chieko; Tomiyama, Masahiko] Aomori Prefectural Cent Hosp, Dept Neurol, Aomori, Aomori 0308553, Japan	Nishijima, H (reprint author), Aomori Prefectural Cent Hosp, Dept Neurol, 2-1-1 Higashi Tsukurimichi, Aomori, Aomori 0308553, Japan.	hnishijima-tky@umin.ac.jp		Nishijima, Haruo/0000-0002-1065-664X			Ohtsuka K, 1997, BRIT J OPHTHALMOL, V81, P514; Purvin V, 2001, ARCH OPHTHALMOL-CHIC, V119, P1299; KENNERDELL JS, 1984, SURV OPHTHALMOL, V29, P93, DOI 10.1016/0039-6257(84)90166-8; Okhravi N, 2005, SURV OPHTHALMOL, V50, P351, DOI 10.1016/j.survophthal.2005.04.001; Tatsugawa Maria, 2010, J Med Case Rep, V4, P404, DOI 10.1186/1752-1947-4-404	5	0	0	SPRINGER-VERLAG ITALIA SRL	MILAN	VIA DECEMBRIO, 28, MILAN, 20137, ITALY	1590-1874	1590-3478		NEUROL SCI	Neurol. Sci.	NOV	2015	36	11					2139	2140		10.1007/s10072-015-2310-2		2	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CV1MJ	WOS:000364022100022		
J	Kon, T; Nishijima, H; Kon, H; Watanabe, M; Tomiyama, M				Kon, Tomoya; Nishijima, Haruo; Kon, Hiroyuki; Watanabe, Mika; Tomiyama, Masahiko			Erdheim-Chester disease: yellow-tinge appearance on neuroendoscopic imaging	NEUROLOGICAL SCIENCES			English	Letter							INVOLVEMENT		[Kon, Tomoya; Nishijima, Haruo; Tomiyama, Masahiko] Aomori Prefectural Cent Hosp, Dept Neurol, Aomori 0308553, Japan; [Kon, Hiroyuki] Aomori Prefectural Cent Hosp, Dept Neurosurg, Aomori 0308553, Japan; [Watanabe, Mika] Tohoku Univ Hosp, Dept Pathol, Sendai, Miyagi, Japan	Kon, T (reprint author), Aomori Prefectural Cent Hosp, Dept Neurol, 2-1-1 Higashi Tsukurimichi, Aomori 0308553, Japan.	t-kon@umin.ac.jp		Nishijima, Haruo/0000-0002-1065-664X			Conley A, 2010, NEUROPATHOLOGY, V30, P634, DOI 10.1111/j.1440-1789.2010.01104.x; Oweity T, 2002, J NEUROSURG, V96, P344, DOI 10.3171/jns.2002.96.2.0344; Drier A, 2010, RADIOLOGY, V255, P586, DOI 10.1148/radiol.10090320; TIEN RD, 1989, RADIOLOGY, V172, P791; Thorns V, 2003, CLIN NEUROPATHOL, V22, P246; Haroche J, 2015, J CLIN ONCOL, V33, P411, DOI 10.1200/JCO.2014.57.1950; Haroche J, 2014, CURR RHEUMATOL REP, V16, DOI 10.1007/s11926-014-0412-0	7	0	0	SPRINGER-VERLAG ITALIA SRL	MILAN	VIA DECEMBRIO, 28, MILAN, 20137, ITALY	1590-1874	1590-3478		NEUROL SCI	Neurol. Sci.	NOV	2015	36	11					2159	2160		10.1007/s10072-015-2331-x		2	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CV1MJ	WOS:000364022100028		
J	Noguchi, T; Nishihara, M; Egashira, Y; Azama, S; Hirai, T; Kitano, I; Yakushiji, Y; Kawashima, M; Irie, H				Noguchi, Tomoyuki; Nishihara, Masashi; Egashira, Yoshiaki; Azama, Shinya; Hirai, Tetsuyoshi; Kitano, Isao; Yakushiji, Yusuke; Kawashima, Masatou; Irie, Hiroyuki			Arterial spin-labeling MR imaging of cerebral hemorrhages	NEURORADIOLOGY			English	Article						Arterial spin-labeling; Brain perfusion; Cerebral hemorrhage; Putaminal hemorrhage; Thalamic hemorrhage	CROSSED-CEREBELLAR DIASCHISIS; INTRACEREBRAL HEMORRHAGE; ISCHEMIC-STROKE; PERFUSION MRI; BLOOD-FLOW; DISEASE; TOMOGRAPHY	The purpose of this study is to identify the characteristics of brain perfusion measured by arterial spin-labeling magnetic resonance imaging (ASL-MRI) in cerebral hemorrhages. Brain blood flow values (CBF-ASL values) for cerebral and cerebellar hemispheres and segmented cerebral regions were measured by ASL-MRI in 19 putaminal hemorrhage patients and 20 thalamic hemorrhage patients in acute or subacute stages. We assessed the lateralities of CBF-ASL values and the relationships between CBF-ASL values and other imaging findings and clinical manifestations. Both the 19 putaminal hemorrhage patients and the 20 thalamic hemorrhage patients had significantly low CBF-ASL values of the contralateral cerebellum in subacute stage, suggesting that ASL-MRI might delineate crossed cerebellar diaschisis (CCD). Ipsilateral low CBF-ASL values were observed in frontal lobes and thalami with a putaminal hemorrhage and lentiform nuclei, temporal lobes, and parietal lobes with a thalamic hemorrhage, suggesting that ASL-MRI showed the ipsilateral cerebral diaschisis (ICD). In the putaminal hemorrhage patients, the hematoma volume negatively affected both the bilateral cerebellar and cerebral hemispheric CBF-ASL values. In the thalamic hemorrhage patients, a concomitant intraventricular hemorrhage caused low cerebral hemispheric CBF-ASL values. The use of ASL-MRI is sensitive to the perfusion abnormalities and could thus be helpful to estimate functional abnormalities in cerebral hemorrhage patients.	[Noguchi, Tomoyuki] Natl Ctr Global Hlth & Med, Dept Radiol, Shinjuku Ku, Tokyo 1628655, Japan; [Noguchi, Tomoyuki; Nishihara, Masashi; Egashira, Yoshiaki; Azama, Shinya; Hirai, Tetsuyoshi; Kitano, Isao; Irie, Hiroyuki] Saga Univ, Fac Med, Dept Radiol, Saga 840, Japan; [Noguchi, Tomoyuki; Nishihara, Masashi; Egashira, Yoshiaki; Azama, Shinya; Hirai, Tetsuyoshi; Kitano, Isao; Yakushiji, Yusuke; Kawashima, Masatou; Irie, Hiroyuki] Saga Univ, Grad Sch Med, Saga 840, Japan; [Yakushiji, Yusuke] Saga Univ, Fac Med, Dept Neurol, Saga 840, Japan; [Kawashima, Masatou] Saga Univ, Fac Med, Dept Neurosurg, Saga 840, Japan	Noguchi, T (reprint author), Natl Ctr Global Hlth & Med, Dept Radiol, Shinjuku Ku, 1-21-1 Toyama, Tokyo 1628655, Japan.	tnogucci@radiol.med.kyushu-u.ac.jp			Japan Society for the Promotion of Science	This work was partly supported by Grant-in-Aid for Scientific Research of Japan Society for the Promotion of Science.	Pascual AM, 2007, CEREBROVASC DIS, V23, P6, DOI 10.1159/000095752; DETRE JA, 1992, MAGNET RESON MED, V23, P37, DOI 10.1002/mrm.1910230106; Yoshiura T, 2009, EUR RADIOL, V19, P2819, DOI 10.1007/s00330-009-1511-6; Noguchi T, 2011, EUR J RADIOL, V80, pE557, DOI 10.1016/j.ejrad.2011.01.016; Miyazawa N, 1998, AM J NEURORADIOL, V19, P1741; Wang JJ, 2003, J MAGN RESON IMAGING, V18, P404, DOI 10.1002/jmri.10372; Luh WM, 1999, MAGNET RESON MED, V41, P1246, DOI 10.1002/(SICI)1522-2594(199906)41:6<1246::AID-MRM22>3.0.CO;2-N; Chalela JA, 2000, STROKE, V31, P680; FEENEY DM, 1986, STROKE, V17, P817; BARON JC, 1986, BRAIN, V109, P1243, DOI 10.1093/brain/109.6.1243; Berthezene Y, 1998, J NEUROL SCI, V157, P67, DOI 10.1016/S0022-510X(98)00064-1; METTER EJ, 1983, BRAIN LANG, V19, P33, DOI 10.1016/0093-934X(83)90054-8; Noguchi T, 2010, INTERV NEURORADIOL, V16, P409; Noguchi T, 2013, EUR J RADIOL, V82, pE840, DOI 10.1016/j.ejrad.2013.08.040; O'Gorman RL, 2010, PEDIATR NEUROL, V42, P437, DOI 10.1016/j.pediatrneurol.2010.02.008; Warmuth C, 2003, RADIOLOGY, V228, P523, DOI 10.1148/radiol.2282020409; Ghetti G, 2012, FRONT NEUROL NEUROSC, V30, P141, DOI 10.1159/000333617; Schellinger PD, 2003, STROKE, V34, P1674, DOI 10.1161/01.STR.0000076010.10696.55; Kimura H, 2005, J MAGN RESON IMAGING, V22, P189, DOI 10.1002/jmri.20382; Kidwell CS, 2001, NEUROLOGY, V57, P1611; Araki Y, 2010, J STROKE CEREBROVASC, V19, P450, DOI 10.1016/j.jstrokecerebrovasdis.2009.09.001; Chen S, 2014, J STROKE CEREBROVASC, V23, P2378, DOI 10.1016/j.jstrokecerebrovasdis.2014.05.009; FARRELL B, 1991, J NEUROL NEUROSUR PS, V54, P1044, DOI 10.1136/jnnp.54.12.1044; Olivot Jean-Marc, 2010, Curr Treat Options Cardiovasc Med, V12, P230, DOI 10.1007/s11936-010-0072-y; Torizuka Kanji, 1996, Kaku Igaku, V33, P329	25	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0028-3940	1432-1920		NEURORADIOLOGY	Neuroradiology	NOV	2015	57	11					1135	1144		10.1007/s00234-015-1574-9		10	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	CV1MO	WOS:000364022600007		
J	Takanashi, J; Mizuguchi, M; Terai, M; Barkovich, AJ				Takanashi, Jun-ichi; Mizuguchi, Masashi; Terai, Masaru; Barkovich, A. James			Disrupted glutamate-glutamine cycle in acute encephalopathy with biphasic seizures and late reduced diffusion	NEURORADIOLOGY			English	Article						Encephalopathy; Acute encephalopathy with biphasic seizures and late reduced diffusion (AESD); MR spectroscopy; Glutamine; Glutamate	BRAIN; DISORDERS; INFLUENZA; INJURY	Acute encephalopathy with biphasic seizures and late reduced diffusion (AESD) is the most common subtype of infectious pediatric encephalopathy in Japan. It is sometimes difficult to make an early diagnosis of AESD; excitotoxicity is postulated to be the pathogenesis based on elevated glutamine (Gln) and glutamate (Glu) complex (Glx = Glu + Gln) observed on MR spectroscopy. It is uncertain whether Gln or Glu contributes to the elevated Glx, or whether MR spectroscopy is useful for an early diagnosis. Five Japanese patients with AESD (three boys and two girls, 1 year of age) were enrolled in this study. MR spectroscopy was acquired from the frontal white matter (repetition time (TR) of 5000 ms, echo time (TE) of 30 ms) with a 1.5- or 3.0-T scanner. MR spectroscopy was performed four times for two patients, three times for one patient, and two times for two patients. Quantification of Glu and Gln was performed using LCModel. Glu was elevated in three of four studies on days 1-4 and became normal or low afterward. Gln was normal in three studies on days 1-2, elevated in all seven studies on days 4-12, and became normal or low afterward. These findings suggest that MR spectroscopy may be useful for an early diagnosis. Acute Glu elevation changes to subacute Gln elevation, suggesting that a disrupted Glu-Gln cycle may play an important role.	[Takanashi, Jun-ichi; Terai, Masaru] Tokyo Womens Med Univ, Yachiyo Med Ctr, Dept Pediat, Yachiyo 2768524, Japan; [Mizuguchi, Masashi] Univ Tokyo, Grad Sch Med, Dept Dev Med Sci, Tokyo, Japan; [Barkovich, A. James] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA	Takanashi, J (reprint author), Tokyo Womens Med Univ, Yachiyo Med Ctr, Dept Pediat, 477-96 Owadashinden, Yachiyo 2768524, Japan.	jtaka44@hotmail.co.jp			Japan Society for the Promotion of Science [B24390258, C-24591790]	This study was supported by the Grants-in-Aid for Scientific Research (B24390258 and C-24591790) from the Japan Society for the Promotion of Science. We thank Daisuke Yoshimaru, RT, at Tokyo Women's Medical University Yachiyo Medical Center for his technical support to this study.	Agarwal N, 2012, AM J NEURORADIOL, V33, P595, DOI 10.3174/ajnr.A2587; Kusaka T, 2004, PEDIATR RES, V55, P273, DOI 10.1203/01.PDR.0000102702.39608.82; Kawashima H, 2004, NEUROCHEM RES, V29, P1537, DOI 10.1023/B:NERE.0000029566.22533.c6; Moritani T, 2005, AM J NEURORADIOL, V26, P216; Trendelenburg G, 2005, GLIA, V50, P307, DOI 10.1002/glia.20204; Zhou Y, 2014, J NEURAL TRANSM, V121, P799, DOI 10.1007/s00702-014-1180-8; Petroff OAC, 2002, EPILEPSIA, V43, P703, DOI 10.1046/j.1528-1157.2002.38901.x; DiNuzzo M, 2014, EPILEPSY RES, V108, P995, DOI 10.1016/j.eplepsyres.2014.04.001; Takanashi J, 2009, AM J NEURORADIOL, V30, P132, DOI 10.3174/ajnr.A1247; Takanashi J, 2012, J MAGN RESON IMAGING, V35, P174, DOI 10.1002/jmri.22802; Tanuma N, 2010, BRAIN DEV-JPN, V32, P435, DOI 10.1016/j.braindev.2009.07.004; LAAKE JH, 1995, J NEUROCHEM, V65, P871; Hoshino A, 2012, BRAIN DEV-JPN, V34, P337, DOI 10.1016/j.braindev.2011.07.012; Takanashi J, 2006, NEUROLOGY, V66, P1304, DOI 10.1212/01.wnl.0000210487.36667.a5; Fujikawa DG, 2005, EPILEPSY BEHAV, V7, pS3, DOI 10.1016/j.yebeh.2005.08.003; Mizuguchi M, 2007, ACTA NEUROL SCAND, V115, P45, DOI 10.1111/j.1600-0404.2007.00809.x; Schousboe Arne, 2013, Front Endocrinol (Lausanne), V4, P102, DOI 10.3389/fendo.2013.00102; Shiihara T, 2014, BRAIN DEV-JPN, V36, P489, DOI 10.1016/j.braindev.2013.06.011; Spencer AE, 2014, J CLIN PSYCHIAT, V75, P1226, DOI 10.4088/JCP.13r08767; Takanashi J, 2009, BRAIN DEV-JPN, V31, P521, DOI 10.1016/j.braindev.2009.02.012; Wassink G, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00040	21	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0028-3940	1432-1920		NEURORADIOLOGY	Neuroradiology	NOV	2015	57	11					1163	1168		10.1007/s00234-015-1573-x		6	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	CV1MO	WOS:000364022600010		
J	Fukaya, Y; Goto, M; Nishihara, T				Fukaya, Y.; Goto, M.; Nishihara, T.			Study on erbium loading method to improve reactivity coefficients for low radiotoxic spent fuel HTGR	NUCLEAR ENGINEERING AND DESIGN			English	Article							GAS-COOLED REACTOR	Erbium loading methods are investigated to improve reactivity coefficients of Low Radiotoxic Spent Fuel High Temperature Gas-cooled Reactor (LRSF-HTGR). Highly enriched uranium is used for fuel to reduce the generation of toxicity from uranium-238. The power coefficients are positive without the use of any additive. Then, the erbium is loaded into the core to obtain negative reactivity coefficients owing to the large resonance the peak of neutron capture reaction of erbium-167. The loading methods are attempted to find the suitable method for LRSF-HTGR. The erbium is mixed in a CPF fuel kernel, loaded by binary packing with fuel particles and erbium particles, and embedded into the graphite shaft deployed in the center of the fuel compact. It is found that erbium loading causes negative reactivity as moderator temperature reactivity, and from the viewpoint of heat transfer, it should be loaded into fuel pin elements for pin-in-block type fuel. Moreover, the erbium should be incinerated slowly to obtain negative reactivity coefficients even at the End Of Cycle (EOC). A loading method that effectively causes self-shielding should be selected to avoid incineration with burn-up. The incineration mechanism is elucidated using the Bondarenko approach. As a result, it is concluded that erbium embedded into graphite shaft is preferable for LRSF-HTGR to ensure that the reactivity coefficients remain negative at EOC. (C) 2015 Elsevier B.V. All rights reserved.	[Fukaya, Y.; Goto, M.; Nishihara, T.] Japan Atom Energy Agcy, Nucl Hydrogen & Heat Applicat Res Ctr, Oarai, Ibaraki 3111393, Japan	Fukaya, Y (reprint author), Japan Atom Energy Agcy, Nucl Hydrogen & Heat Applicat Res Ctr, 4002 Narita Cho, Oarai, Ibaraki 3111393, Japan.	fukaya.yuji@jaea.go.jp					Shiratori T, 1999, J NUCL MATER, V274, P40, DOI 10.1016/S0022-3115(99)00061-6; Tak NI, 2008, NUCL ENG DES, V238, P2821, DOI 10.1016/j.nucengdes.2008.05.008; Oigawa Hiroyuki, 2012, Radioisotopes, V61, P571; MacFarlane RE, 2010, NUCL DATA SHEETS, V111, P2739, DOI 10.1016/j.nds.2010.11.001; Yan X, 2003, NUCL ENG DES, V222, P247, DOI 10.1016/S0029-5493(03)00030-X; YAMASHITA K, 1994, J NUCL SCI TECHNOL, V31, P979; Akie H, 2007, J NUCL SCI TECHNOL, V44, P853, DOI 10.3327/jnst.44.853; WIGNER EP, 1955, J APPL PHYS, V26, P260, DOI 10.1063/1.1721975; El-Genk MS, 2004, PROG NUCL ENERG, V44, P215, DOI 10.1016/j.pnucene.2004.01.002; Murata I, 1997, J NUCL SCI TECHNOL, V34, P734, DOI 10.3327/jnst.34.734; AKIE H, 1994, NUCL TECHNOL, V107, P182; Shibata K, 2011, J NUCL SCI TECHNOL, V48, P1, DOI 10.3327/jnst.48.1; Bondarenko I., 1964, GROUP CONSTANTS NUCL; Carlvik I., 1966, THESIS CHALMERS U; Fukaya Y., 2015, J AT ENERGY IN PRESS, V14; Kodochigov N, 2003, NUCL ENG DES, V222, P161, DOI 10.1016/S0029-5493(03)00010-4; Nagaya Y., 2006, Transactions of the American Nuclear Society, V95; Shirasu N., 2001, JAERI RES 2001 018; The Proliferation Resistance and Physical Protection Evaluation Methodology Expert Group of the Generation IV International Forum, 2006, GIFPRPPWG2006005 OEC	19	0	0	ELSEVIER SCIENCE SA	LAUSANNE	PO BOX 564, 1001 LAUSANNE, SWITZERLAND	0029-5493	1872-759X		NUCL ENG DES	Nucl. Eng. Des.	NOV	2015	293						30	37		10.1016/j.nucengdes.2015.07.047		8	Nuclear Science & Technology	Nuclear Science & Technology	CV3LX	WOS:000364161800004		
J	Katano, I; Doi, H; Eriksson, BK; Hillebrand, H				Katano, Izumi; Doi, Hideyuki; Eriksson, Britas Klemens; Hillebrand, Helmut			A cross-system meta-analysis reveals coupled predation effects on prey biomass and diversity	OIKOS			English	Article							FOOD WEBS; TERRESTRIAL ECOSYSTEMS; SPECIES-DIVERSITY; TROPHIC CASCADES; RESOURCE CONTROL; BIODIVERSITY; CONSUMER; COMPETITION; COMMUNITIES; CONSTRAINTS	Predator diversity and abundance are under strong human pressure in all types of ecosystems. Whereas predator potentially control standing biomass and species interactions in food webs, their effects on prey biomass and especially prey biodiversity have not yet been systematically quantified. Here, we test the effects of predation in a cross-system meta-analysis of prey diversity and biomass responses to local manipulation of predator presence. We found 291 predator removal experiments from 87 studies assessing both diversity and biomass responses. Across ecosystem types, predator presence significantly decreased both biomass and diversity of prey across ecosystems. Predation effects were highly similar between ecosystem types, whereas previous studies had shown that herbivory or decomposition effects differed fundamentally between terrestrial and aquatic systems based on different stoichiometry of plant material. Such stoichiometric differences between systems are unlikely for carnivorous predators, where effect sizes on species richness strongly correlated to effect sizes on biomass. However, the negative predation effect on prey biomass was ameliorated significantly with increasing prey richness and increasing species richness of the manipulated predator assemblage. Moreover, with increasing richness of the predator assemblage present, the overall negative effects of predation on prey richness switched to positive effects. Our meta-analysis revealed strong general relationships between predator diversity, prey diversity and the interaction strength between trophic levels in terms of biomass. This study indicates that anthropogenic changes in predator abundance and diversity will potentially have strong effects on trophic interactions across ecosystems.	[Katano, Izumi; Doi, Hideyuki; Hillebrand, Helmut] Carl Von Ossietzky Univ Oldenburg, Inst Chem & Biol Marine Environm, DE-26382 Wilhelmshaven, Germany; [Katano, Izumi] Univ Hyogo, Sch Human Sci & Environm, Himeji, Hyogo 6700092, Japan; [Doi, Hideyuki] Univ Hyogo, Grad Sch Simulat Studies, Chuo Ku, Kobe, Hyogo 6500047, Japan; [Eriksson, Britas Klemens] Univ Groningen, Groningen Inst Evolutionary Life Sci, Dept Marine Benth Ecol & Evolut, NL-9747 AG Groningen, Netherlands	Doi, H (reprint author), Carl Von Ossietzky Univ Oldenburg, Inst Chem & Biol Marine Environm, Schleusenstr 1, DE-26382 Wilhelmshaven, Germany.	hideyuki.doi@icloud.com	Eriksson, Britas Klemens/D-8601-2015		German Science Foundation (DFG) [Hi848/9]; Japanese Society for the Promotion of Science (JSPS)	This work was supported by the German Science Foundation (DFG grant Hi848/9 to HH) and Japanese Society for the Promotion of Science (JSPS to HD). Jon Chase, Jon Shurin, Elizabeth Borer and Eric Seabloom provided very helpful comments on the analysis and the manuscript.	Hillebrand H, 2007, P NATL ACAD SCI USA, V104, P10904, DOI 10.1073/pnas.0701918104; Hillebrand H, 2004, ECOL LETT, V7, P192, DOI 10.1111/j.1461-0248.2004.00570.x; Griffin JN, 2013, ECOLOGY, V94, P2180, DOI 10.1890/13-0179.1; Stachowicz JJ, 2007, ANNU REV ECOL EVOL S, V38, P739, DOI 10.1146/annurev.ecolsys.38.091206.095659; Cardillo M, 2004, PLOS BIOL, V2, P909, DOI 10.1371/journal.pbio.0020197; Cebrian J, 2004, ECOL MONOGR, V74, P237, DOI 10.1890/03-4019; Shurin JB, 2006, P ROY SOC B-BIOL SCI, V273, P1, DOI 10.1098/rspb.2005.3377; Duffy JE, 2003, ECOL LETT, V6, P680, DOI 10.1046/j.1461-0248.2003.00494.x; Pauly D, 1998, SCIENCE, V279, P860, DOI 10.1126/science.279.5352.860; HURLBERT SH, 1971, ECOLOGY, V52, P577, DOI 10.2307/1934145; Hedges LV, 1999, ECOLOGY, V80, P1150, DOI 10.1890/0012-9658(1999)080[1150:TMAORR]2.0.CO;2; Gruner DS, 2008, ECOL LETT, V11, P740, DOI 10.1111/j.1461-0248.2008.01192.x; Amarasekare P, 2002, P ROY SOC B-BIOL SCI, V269, P2541, DOI 10.1098/rspb.2002.2181; Gotelli NJ, 2001, ECOL LETT, V4, P379, DOI 10.1046/j.1461-0248.2001.00230.x; Blackburn TM, 2004, SCIENCE, V305, P1955, DOI 10.1126/science.1101617; Terborgh J, 2001, SCIENCE, V294, P1923, DOI 10.1126/science.1064397; Brose U, 2006, ECOLOGY, V87, P2411, DOI 10.1890/0012-9658(2006)87[2411:CBRINF]2.0.CO;2; Letourneau DK, 2009, ANNU REV ECOL EVOL S, V40, P573, DOI 10.1146/annurev.ecolsys.110308.120320; Jost L, 2006, OIKOS, V113, P363, DOI 10.1111/j.2006.0030-1299.14714.x; Schemske DW, 2009, ANNU REV ECOL EVOL S, V40, P245, DOI 10.1146/annurev.ecolsys.39.110707.173430; DeMott WR, 1998, ECOLOGY, V79, P2463, DOI 10.1890/0012-9658(1998)079[2463:UOACAA]2.0.CO;2; McCann K, 1998, NATURE, V395, P794, DOI 10.1038/27427; Chesson P, 2008, NATURE, V456, P235, DOI 10.1038/nature07248; Finke DL, 2005, ECOL LETT, V8, P1299, DOI 10.1111/j.1461-0248.2005.00832.x; Jackson JBC, 2001, SCIENCE, V293, P629, DOI 10.1126/science.292.5517.629; Chase JM, 2002, ECOL LETT, V5, P302, DOI 10.1046/j.1461-0248.2002.00315.x; Ives AR, 2005, ECOL LETT, V8, P102, DOI 10.1111/j.1461-0248.2004.00698.x; Chase JM, 2013, ECOL LETT, V16, P17, DOI 10.1111/ele.12112; Elser JJ, 2000, NATURE, V408, P578, DOI 10.1038/35046058; Myers RA, 2003, NATURE, V423, P280, DOI 10.1038/nature01610; Whittaker RJ, 2010, ECOLOGY, V91, P2522, DOI 10.1890/08-0968.1; HOLT RD, 1994, AM NAT, V144, P741, DOI 10.1086/285705; Johnson JB, 2004, TRENDS ECOL EVOL, V19, P101, DOI 10.1016/j.tree.2003.10.013; Croll DA, 2005, SCIENCE, V307, P1959, DOI 10.1126/science.1108485; Thebault E, 2003, P NATL ACAD SCI USA, V100, P14949, DOI 10.1073/pnas.2434847100; Halpern BS, 2005, ECOL LETT, V8, P189, DOI 10.1111/j.1461-0248.2004.00712.x; Hillebrand H, 2010, ECOLOGY, V91, P2545, DOI 10.1890/09-0070.1; Edwards KF, 2010, ECOL LETT, V13, P194, DOI 10.1111/j.1461-0248.2009.01417.x; Borer ET, 2005, ECOLOGY, V86, P528, DOI 10.1890/03-0816; Frank KT, 2006, ECOL LETT, V9, P1096, DOI 10.1111/j.1461-0248.2006.00961.x; Shurin JB, 2002, ECOL LETT, V5, P785, DOI 10.1046/j.1461-0248.2002.00381.x; Byrnes JE, 2009, ECOLOGY, V90, P2879, DOI 10.1890/08-1073.1; Borenstein M., 2009, INTRO METAANALYSIS; Bruno J. F., 2008, FRONTIERS ECOLOGY EN, V10, P539; Burnham KP, 2002, MODEL SELECTION MULT; Hillebrand H., 2005, AQUATIC FOOD WEBS EC, P1084; MENGE BA, 1995, ECOL MONOGR, V65, P21, DOI 10.2307/2937158; PAINE RT, 1966, AM NAT, V100, P65, DOI 10.1086/282400; Ripple WJ, 2014, SCIENCE, V343, P151, DOI 10.1126/science.1241484	49	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0030-1299	1600-0706		OIKOS	Oikos	NOV	2015	124	11					1427	1435		10.1111/oik.02430		9	Ecology	Environmental Sciences & Ecology	CU9LV	WOS:000363866900002		
J	Shinozaki, K; Abe, S; Honma, T; Komatsu, T				Shinozaki, K.; Abe, S.; Honma, T.; Komatsu, T.			Self-organized homo-epitaxial growth in nonlinear optical BaAlBO3F2 crystal crossing lines patterned by laser in glass	OPTICAL MATERIALS			English	Article						Laser-induced crystallization; Homo-epitaxial growth; Crystal crossing line; Birefringence imaging; Crystal orientation; Nonlinear optical crystal	BETA-BAB2O4 CRYSTALS; INDUCED CRYSTALLIZATION; BARIUM BORATE; CERAMICS; ORIENTATION; SURFACE; ARCHITECTURES; NANOCRYSTALS; IRRADIATION; MORPHOLOGY	Crystallization processing of glasses is important as a novel technique for the development of new optical materials, and laser-induced crystallization provides a new challenge in science and technology of materials. Nonlinear optical BaAlBO3F2 crystal lines with crossing, bending, and spiral shapes were patterned at the surface of 2NiO-49BaF(2)-24.5Al(2)O(3)-24.5B(2)O(3) (mol%) and 2.9NiO-48.5BaF(2)-24.3Al(2)O(3)-24.3B(2)O(3) (mol%) glasses by laser irradiation (Yb: YVO4 laser with a wavelength of 1080 nm) and the orientation state of BaAlBO3F2 crystals was examined from birefringence image observations. The birefringence images indicate that the growth of highly c-axis oriented BaAlBO3F2 crystals follows along the laser scanning direction even if the laser scanning direction changes, and in particular the direction of the c-axis of BaAlBO3F2 crystals changes gradually at the crossing and bending points. The model of "self-organized homo-epitaxial growth" is proposed for the crystal orientation at the crossing and bending points, as a new crystal growth science and engineering beyond the wise providence of nature. (C) 2015 Elsevier B.V. All rights reserved.	[Shinozaki, K.; Abe, S.; Honma, T.; Komatsu, T.] Nagaoka Univ Technol, Dept Mat Sci & Technol, Nagaoka, Niigata 9402188, Japan	Komatsu, T (reprint author), Nagaoka Univ Technol, Dept Mat Sci & Technol, 1603-1 Kamitomioka Cho, Nagaoka, Niigata 9402188, Japan.	komatsu@mst.nagaokaut.ac.jp			Ministry of Education, Science, Sports, Culture and Technology, Japan [23246114]; Program for High Reliable Materials Design and Manufacturing in Nagaoka University of Technology	This work was supported from the Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports, Culture and Technology, Japan (No. 23246114) and by Program for High Reliable Materials Design and Manufacturing in Nagaoka University of Technology.	Yue YC, 2011, J OPT SOC AM B, V28, P861; HEADLEY TJ, 1984, J AM CERAM SOC, V67, P620, DOI 10.1111/j.1151-2916.1984.tb19606.x; Honma T, 2010, OPT MATER, V32, P443, DOI 10.1016/j.optmat.2009.10.005; Fokin VM, 2006, J NON-CRYST SOLIDS, V352, P2681, DOI 10.1016/j.jnoncrysol.2006.02.074; Honma T, 2003, APPL PHYS LETT, V83, P2796, DOI 10.1063/1.1615833; Suzuki F, 2014, J PHYS CHEM SOLIDS, V75, P954, DOI 10.1016/j.jpcs.2014.04.007; Yamazawa T, 2009, J AM CERAM SOC, V92, P2924, DOI 10.1111/j.1551-2916.2009.03348.x; Komatsu T, 2007, J AM CERAM SOC, V90, P699, DOI 10.1111/j.1551-2916.2006.01441.x; Honma T, 2004, J PHYS CHEM SOLIDS, V65, P1705, DOI 10.1016/j.jpcs.2004.04.010; Burgner LL, 2001, PHYS CHEM GLASSES, V42, P184; Stone A, 2010, J NON-CRYST SOLIDS, V356, P3059, DOI 10.1016/j.jnoncrysol.2010.03.048; Hu ZG, 2004, J CRYST GROWTH, V260, P287, DOI 10.1016/j.crysgro.2003.09.041; Ida H, 2012, J SOLID STATE CHEM, V196, P384, DOI 10.1016/j.jssc.2012.07.006; Hu ZG, 2002, JPN J APPL PHYS 2, V41, pL1131, DOI 10.1143/JJAP.41.L1131; Arai K, 2012, PHYS REV B, V85, DOI 10.1103/PhysRevB.85.104418; Sakamoto A, 2010, INT J APPL GLASS SCI, V1, P237, DOI 10.1111/j.2041-1294.2010.00027.x; Ogawa K, 2013, J SOLID STATE CHEM, V207, P6, DOI 10.1016/j.jssc.2013.08.021; Beall GH, 1999, J AM CERAM SOC, V82, P5; Sakai R, 2000, APPL PHYS LETT, V77, P2118, DOI 10.1063/1.1313805; Teng Y, 2014, J NON-CRYST SOLIDS, V383, P91, DOI 10.1016/j.jnoncrysol.2013.04.015; Honma T, 2010, OPT EXPRESS, V18, P8019, DOI 10.1364/OE.18.008019; Zhou Y, 2009, OPT EXPRESS, V17, P20033, DOI 10.1364/OE.17.020033; Hu ZG, 2011, SOLID STATE SCI, V13, P875, DOI 10.1016/j.solidstatesciences.2011.03.002; Abe M, 2005, J APPL PHYS, V97, DOI 10.1063/1.1938269; Komatsu T, 2013, INT J APPL GLASS SCI, V4, P125, DOI 10.1111/ijag.12023; Suzuki F, 2012, J SOLID STATE CHEM, V185, P130, DOI 10.1016/j.jssc.2011.11.005; Park H, 2000, J SOLID STATE CHEM, V155, P354, DOI 10.1006/jssc.2000.8924; Shinozaki K, 2015, J EUR CERAM SOC, V35, P2541, DOI 10.1016/j.jeurceramsoc.2015.03.020; Nishii A, 2015, J SOLID STATE CHEM, V221, P145, DOI 10.1016/j.jssc.2014.09.031; Shinozaki K, 2014, OPT MATER, V36, P1384, DOI 10.1016/j.optmat.2014.03.037; Komatsu T, 2011, J SOLID STATE CHEM, V184, P411, DOI 10.1016/j.jssc.2010.12.016; Jain H, 2004, FERROELECTRICS, V306, P111, DOI 10.1080/00150190490458446; Schmelzer JWP, 2006, J NON-CRYST SOLIDS, V352, P434, DOI 10.1016/j.jnoncrysol.2006.01.016; EIMERL D, 1987, J APPL PHYS, V62, P1968, DOI 10.1063/1.339536; Honma T., 2009, IOP C SERIES MAT SCI, V1; Inoue T., 2015, FRONTIERS MAT GLASS, V2; Komatsu T., 2012, T GIGAKU, V1; Komatsu T., 2013, J ASIAN CERAM SOC, V1, P9; Shinozaki K., 2012, J APPL PHYS, V112; Tsukada Y., 2009, APPL PHYS LETT, V94	40	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0925-3467	1873-1252		OPT MATER	Opt. Mater.	NOV	2015	49						182	189		10.1016/j.optmat.2015.09.016		8	Materials Science, Multidisciplinary; Optics	Materials Science; Optics	CV4RV	WOS:000364255100029		
J	Abuelwafa, AA; El-Denglawey, A; Dongol, M; El-Nahass, MM; Soga, T				Abuelwafa, A. A.; El-Denglawey, A.; Dongol, M.; El-Nahass, M. M.; Soga, T.			Influence of annealing temperature on structural and optical properties of nanocrystalline Platinum octaethylporphyrin (PtOEP) thin films	OPTICAL MATERIALS			English	Article						PtOEP thin films; Nanostructural; Optical properties; Non-linear optical; Thermal annealing	ELECTRONIC-STRUCTURE; INFRARED-SPECTRA; PORPHYRIN; PHTHALOCYANINE; ABSORPTION; CONSTANTS; ELECTROLUMINESCENCE; CHALCOGENIDES; IR(PPY)(3); FIELD	Thermal evaporation technique was used to prepare the Platinum octaethylporphyrin (PtOEP) thin films at room temperature. The deposited films were studied before and after thermal annealing at 373 and 473 K for 3 h under vacuum (10(-3) Pa). The film structure, surface morphologies and molecular structure were investigated as a function of annealing temperature by X-ray Diffraction (XRD), Field-Emission Scanning Electron Microscopy (FESEM) and Fourier-transform infrared techniques (FT-IR) respectively. The results confirmed that the as-deposited and annealed films have nanostructural features. Optical constants of the as-deposited and annealed films have been obtained in the wavelength range 200-1100 nm by using spectrophotometric measurements. Analysis of the spectra of absorption coefficient showed indirect allowed transition and optical energy gap found to decrease with increase in annealing temperature. The dispersion of refractive index at the normal dispersion (lambda > 600 nm) was discussed in terms of single oscillator model of Wemple-Didomenico. Based on generalized Miller's rule the third order non-linear susceptibility, chi((3)) and nonlinear refractive index, n(2) were estimated and studied at lower photon energy and showing lower value for the annealed film. (C) 2015 Published by Elsevier B.V.	[Abuelwafa, A. A.; El-Denglawey, A.; Dongol, M.] South Valley Univ, Nano & Thin Film Lab, Fac Sci, Dept Phys, Qena 83523, Egypt; [Abuelwafa, A. A.; Soga, T.] Nagoya Inst Technol, Dept Frontier Mat, Showa Ku, Nagoya, Aichi 4668555, Japan; [El-Denglawey, A.] Taif Univ, Fac Appl Med Sci, Dept Phys, Turabah 21995, Saudi Arabia; [El-Nahass, M. M.] Ain Shams Univ, Fac Educ, Dept Phys, Cairo 11757, Egypt	Abuelwafa, AA (reprint author), South Valley Univ, Nano & Thin Film Lab, Fac Sci, Dept Phys, Qena 83523, Egypt.	Amr.abuelwafa@sci.svu.edu.eg					Anderson HL, 1999, CHEM COMMUN, P2323, DOI 10.1039/a904209a; Andreas B., 2005, CHEMPHYSCHEM, V6, P1; KINCAID JR, 1983, J PHYS CHEM-US, V87, P3096, DOI 10.1021/j100239a028; Sharma N, 2014, ELECTRON MATER LETT, V10, P101, DOI 10.1007/s13391-013-3168-1; NALWA HS, 1993, ADV MATER, V5, P341, DOI 10.1002/adma.19930050504; Tsiper EV, 2002, CHEM PHYS LETT, V360, P47, DOI 10.1016/S0009-2614(02)00774-1; COATS AW, 1963, ANALYST, V88, P906, DOI 10.1039/an9638800906; Ticha H, 2002, J OPTOELECTRON ADV M, V4, P381; Scudiero L, 2002, J PHYS CHEM B, V106, P996, DOI 10.1021/jp012436m; Bushroa AR, 2012, VACUUM, V86, P1107, DOI 10.1016/j.vacuum.2011.10.011; Frumar M, 2003, J NON-CRYST SOLIDS, V326, P399, DOI 10.1016/S0022-3093(03)00446-0; Bansal AK, 2006, CHEM PHYS, V330, P118, DOI 10.1016/j.chemphys.2006.08.002; El-Nahass MM, 2011, SOLID STATE SCI, V13, P596, DOI 10.1016/j.solidstatesciences.2010.12.032; ELSHAIR HT, 1992, CZECH J PHYS, V42, P695, DOI 10.1007/BF01598730; Tsuboi T, 2003, THIN SOLID FILMS, V438, P301, DOI 10.1016/S0040-6090(03)00734-X; WEMPLE SH, 1971, PHYS REV B, V3, P1338, DOI 10.1103/PhysRevB.3.1338; NALWA HS, 1993, THIN SOLID FILMS, V235, P175, DOI 10.1016/0040-6090(93)90262-N; Ramana CV, 2003, PHYS STATUS SOLIDI A, V199, pR4, DOI 10.1002/pssa.200309009; Kijima Y, 2000, J MATER SCI, V35, P2193, DOI 10.1023/A:1004714623548; Tsuboi T, 2006, THIN SOLID FILMS, V496, P674, DOI 10.1016/j.tsf.2005.09.078; El-Nahass MM, 2011, MATER CHEM PHYS, V125, P247, DOI 10.1016/j.matchemphys.2010.09.017; SHIRK JS, 1992, J PHYS CHEM-US, V96, P5847, DOI 10.1021/j100193a038; Ziabari AA, 2012, SOL ENERG MAT SOL C, V105, P249, DOI 10.1016/j.solmat.2012.05.014; Dongol M, 2012, CURR APPL PHYS, V12, P1334, DOI 10.1016/j.cap.2012.03.022; Zhang QG, 2014, RSC ADV, V4, P47325, DOI 10.1039/c4ra07601j; El-Nahass MM, 2014, OPT LASER TECHNOL, V64, P28, DOI 10.1016/j.optlastec.2014.04.013; Zhou P, 2005, OPT EXPRESS, V13, P1508, DOI 10.1364/OPEX.13.001508; Chauhan R, 2011, PROG NAT SCI, V21, P205; Shen FZ, 2004, J PHYS CHEM B, V108, P1014, DOI 10.1021/jp036111c; Kim DU, 2008, COLLOID SURFACE A, V313, P444, DOI 10.1016/j.colsurfa.2007.04.135; Wang L, 2005, THIN SOLID FILMS, V491, P323, DOI 10.1016/j.tsf.2005.05.048; Che CM, 2008, CHEM-ASIAN J, V3, P1092, DOI 10.1002/asia.200800011; Stendal A, 1996, J PHYS B-AT MOL OPT, V29, P2589, DOI 10.1088/0953-4075/29/12/020; Al-Hossainy AF, 2015, OPT MATER, V46, P131, DOI 10.1016/j.optmat.2015.04.011; Manjunatha KN, 2015, APPL SURF SCI, V352, P10, DOI 10.1016/j.apsusc.2015.03.092; Tsuboi T, 2006, THIN SOLID FILMS, V499, P306, DOI 10.1016/j.tsf.2005.07.020; Akgul FA, 2014, MATER CHEM PHYS, V147, P987, DOI 10.1016/j.matchemphys.2014.06.047; El-Nahass MM, 2014, OPT COMMUN, V325, P116, DOI 10.1016/j.optcom.2014.03.077; Zhokhavets U, 2003, SYNTHETIC MET, V138, P491, DOI 10.1016/S0379-6779(02)00502-7; El-Nahass MM, 2015, J ALLOY COMPD, V646, P937, DOI 10.1016/j.jallcom.2015.05.217; Bialek B, 2002, SYNTHETIC MET, V129, P151, DOI 10.1016/S0379-6779(02)00042-5; Boyd R, 2001, ENCY MAT SCI TECHNOL, P6237; Briitting W., 2005, PHYS ORGANIC SEMICON; Dongol M., 2015, OPTIK, V126, P1325; El-Nahass M. M., 1992, J MATER SCI, V27, P6592; Dongol M, 2012, CURR APPL PHYS, V12, P1178, DOI 10.1016/j.cap.2012.02.051; El-Nahass MM, 2015, MAT SCI SEMICON PROC, V38, P177, DOI 10.1016/j.mssp.2015.04.014; Fox M., 2001, OXFORD MASTER SER CO, P64; Ha J.-H., 2011, J ANAL SCI TECHNOL, V2, P42; Laugier J., 2000, BP4638042 ENSP LAB M; LI XY, 1990, J PHYS CHEM-US, V94, P31, DOI 10.1021/j100364a007; Lunt RR, 2009, J APPL PHYS, V105, DOI 10.1063/1.3079797; Lutterotti L, 1999, P 12 INT C TEXT MAT, V1, P1599; Milgron L.R., 1988, POLYHEDRON, V7, P5741; Moss T. S., 1973, SEMICONDUCTOR OPTOEL; Noh Y., 2003, ADV MATER, V15, P700; Ogoshi H., 1971, B CHEM SOC JPN, V44, P44; STENZEL O, 1995, J PHYS D APPL PHYS, V28, P2154, DOI 10.1088/0022-3727/28/10/026; Tolansky S., 1948, MULTIPLE BEAM INTERF; WANG CC, 1970, PHYS REV B, V2, P2045, DOI 10.1103/PhysRevB.2.2045	60	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0925-3467	1873-1252		OPT MATER	Opt. Mater.	NOV	2015	49						271	278		10.1016/j.optmat.2015.09.032		8	Materials Science, Multidisciplinary; Optics	Materials Science; Optics	CV4RV	WOS:000364255100043		
J	Hirayama, T; Miyazawa, T; Harai, H				Hirayama, Takahiro; Miyazawa, Takaya; Harai, Hiroaki			Queueing analysis of optical and electronic combined buffer for optical packet switches	OPTICAL SWITCHING AND NETWORKING			English	Article						Optical packet switch; FDL buffer; Analytical model; Queueing theory	VARIABLE-LENGTH PACKETS; DELAY-LINES; MANAGEMENT; NETWORKS	Optical packet switching provides high-speed and energy-efficient packet forwarding. Fiber delay line (FDL)-based buffer is one practical solution to avoid packet contention in optical packet switches. However, the FDL buffer suffers from scalability problems, and thus, cannot accommodate a large volume of network traffic at a time. An optical and electronic combined (OE) buffer architecture alleviates the scalability issues. This architecture uses supplementary electronic RAM buffers when the traffic volume increases. We then propose an analytical model of the OE buffer to estimate the blocking probability and the average delay. We find that complex OE combined model can be simply modeled by combination of an existing analytic model of the FDL buffer and an M/M/1/K queueing system. Comparing analytical results with packet-level simulation results, we demonstrate that our analytical results display characteristics similar to the simulation results. This analysis enables to determine appropriate setting of the OE buffer such as the buffer size and use policy. (C) 2015 Elsevier B.V. All rights reserved.	[Hirayama, Takahiro; Miyazawa, Takaya; Harai, Hiroaki] Natl Inst Informat & Commun Technol NICT, Koganei, Tokyo 1848795, Japan	Hirayama, T (reprint author), Natl Inst Informat & Commun Technol NICT, 4-2-1 Nukui Kitamachi, Koganei, Tokyo 1848795, Japan.	hirayama@nict.go.jp; takaya@nict.go.jp; harai@nict.go.jp					Ge A, 2000, P SOC PHOTO-OPT INS, V4233, P247, DOI 10.1117/12.401824; Hunter DK, 1998, J LIGHTWAVE TECHNOL, V16, P2081, DOI 10.1109/50.736577; Harai H, 2006, IEEE ICC, P2574; Zhu XM, 2003, OPT ENG, V42, P1741, DOI 10.1117/1.1572500; Wada N, 2011, IEICE T COMMUN, VE94B, P868, DOI 10.1587/transcom.E94.B.868; Kankaya HE, 2009, J OPT COMMUN NETW, V1, P530, DOI 10.1364/JOCN.1.000530; Hirayama T, 2015, J OPT COMMUN NETW, V7, P776, DOI 10.1364/JOCN.7.000776; Akar N, 2011, IEEE T COMMUN, V59, P2832, DOI 10.1109/TCOMM.2011.071111.100521; Rogiest W, 2013, PHOTONIC NETW COMMUN, V26, P65, DOI 10.1007/s11107-013-0409-z; Urata R, 2010, OPT EXPRESS, V18, P15283, DOI 10.1364/OE.18.015283; Das G, 2008, OPT EXPRESS, V16, P21849, DOI 10.1364/OE.16.021849; Callegati F, 2001, PHOTONIC NETW COMMUN, V3, P383, DOI 10.1023/A:1011964113336; Harai H, 2006, IEEE ACM T NETWORK, V14, P191, DOI 10.1109/TNET.2005.863450; Zhang T, 2006, IEEE J SEL AREA COMM, V24, P118, DOI [10.1109/JSAC.2006.1613777, 10.1109/JSAC-OCN.2006.04010]; Liu JM, 2009, J LIGHTWAVE TECHNOL, V27, P955, DOI 10.1109/JLT.2008.2004951; HOSONO T, 1981, RADIO SCI, V16, P1015, DOI 10.1029/RS016i006p01015; Callegati F, 2004, PHOTONIC NETW COMMUN, V8, P163, DOI 10.1023/B:PNET.0000033976.33668.65; Develder C., 2002, P ONDM 2002 6 WORK C, P247; Furukawa H., 2014, P OPT FIB COMM C OFC; Hirayama T., 2014, P GLOBECOM 2014 DEC, P2089; Murakami Y., 2012, J LIGHTWAVE TECHNOL, V30, P54; Shinada S., 2013, P OPT FIB COMM C OFC; Uzawa H., 2011, P IEEE GLOBECOM DEC; Yao S, 2000, P SOC PHOTO-OPT INS, V4233, P235, DOI 10.1117/12.401823; Yoo S. J. B., 2003, IEEE Journal on Selected Areas in Communications, V21, DOI 10.1109/JSAC.2003.815684	25	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1573-4277	1872-9770		OPT SWITCH NETW	Opt. Switch. Netw.	NOV	2015	18		3				201	210		10.1016/j.osn.2015.08.003		10	Computer Science, Information Systems; Optics; Telecommunications	Computer Science; Optics; Telecommunications	CV4PV	WOS:000364249900001		
J	Yusup, A; Kaneko, H; Liu, L; Ning, L; Sadatsuki, R; Hada, S; Kamagata, K; Kinoshita, M; Futami, I; Shimura, Y; Tsuchiya, M; Saita, Y; Takazawa, Y; Ikeda, H; Aoki, S; Kaneko, K; Ishijima, M				Yusup, A.; Kaneko, H.; Liu, L.; Ning, L.; Sadatsuki, R.; Hada, S.; Kamagata, K.; Kinoshita, M.; Futami, I.; Shimura, Y.; Tsuchiya, M.; Saita, Y.; Takazawa, Y.; Ikeda, H.; Aoki, S.; Kaneko, K.; Ishijima, M.			Bone marrow lesions, subchondral bone cysts and subchondral bone attrition are associated with histological synovitis in patients with end-stage knee osteoarthritis: a cross-sectional study	OSTEOARTHRITIS AND CARTILAGE			English	Article						Synovitis; Symptom; Bone marrow lesion; Subchondral bone cyst; Subchondral bone attrition; TGF-beta	TISSUE INFLAMMATION; DISEASE SEVERITY; OUTCOME MEASURE; GROWTH-FACTOR; PAIN; JOINT; PROGRESSION; FEATURES; PATHOGENESIS; REPLACEMENT	Objective: The aim of this study was to examine the osteoarthritis (OA)-related structural changes associated with histological synovitis in end-stage knee OA patients. Methods: Forty end-stage knee OA patients (female: 88%, mean age: 71.8 y) were enrolled. All participants underwent 3.0-T MRI. The structural changes, such as cartilage morphology, subchondral bone marrow lesion (BML), subchondral bone cyst (SBC), subchondral bone attrition (SBA), osteophytes, meniscal lesion and synovitis, were scored using the whole-organ MRI scoring (WORMS) method. Synovial samples were obtained from five regions of interest (ROIs) of the knee joint during total joint replacement surgery. The associations between the histological synovitis score (HSS) and WORMS or the synovial expression levels of cyclooxygenase (COX)-2, interleukin (IL)-1 beta, IL-6 and transforming growth factor (TGF)-beta were examined using Spearman's correlation coefficient. Results: Among the seven OA-related structural changes, the BML, SBC, SBA and synovitis were significantly associated with the HSS (r = 0.33, 0.35, 0.48 and 0.36, respectively), while other morphological changes were not. Although synovial COX-2, IL-1 beta or IL-6 expression levels were not associated with the HSS, the synovial TGF-beta expression levels were associated with the HSS. Conclusion: The presence of BML, SBC and SBA was associated with histological synovitis in end-stage knee OA patients. (C) 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.	[Yusup, A.; Kaneko, H.; Liu, L.; Sadatsuki, R.; Hada, S.; Kinoshita, M.; Futami, I.; Saita, Y.; Takazawa, Y.; Ikeda, H.; Kaneko, K.; Ishijima, M.] Juntendo Univ, Grad Sch Med, Dept Med Orthopaed & Motor Organ, Tokyo 1138421, Japan; [Yusup, A.; Ning, L.] Juntendo Univ, Grad Sch Med, Res Inst Dis Old Age, Tokyo 1138421, Japan; [Liu, L.; Kaneko, K.; Ishijima, M.] Juntendo Univ, Grad Sch Med, Sportol Ctr, Tokyo 1138421, Japan; [Kamagata, K.; Aoki, S.] Juntendo Univ, Grad Sch Med, Dept Radiol, Tokyo 1138421, Japan; [Shimura, Y.; Tsuchiya, M.] Juntendo Tokyo Koto Geriatr Med Ctr, Dept Orthoped, Tokyo, Japan; [Kaneko, K.; Ishijima, M.] Juntendo Univ, Grad Sch Med, Dept Pathophysiol Locomot & Neoplast Dis, Tokyo 1138421, Japan	Ishijima, M (reprint author), Juntendo Univ, Grad Sch Med, Dept Med Orthopaed & Motor Organ, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	anwarjan108@yahoo.com; harukago@juntendo.ac.jp; liulizu@juntendo.ac.jp; realnl@juntendo.ac.jp; rsadatsu@juntendo.ac.jp; shada@juntendo.ac.jp; kkamagat@juntendo.ac.jp; mayukok@juntendo.ac.jp; ippei@juntendo.ac.jp; shimura@juntendo.ac.jp; potatointheball_1007@yahoo.co.jp; saita0617@hotmail.com; ytakaza@juntendo.ac.jp; hrikeda@juntendo.ac.jp; saoki@juntendo.ac.jp; k-kaneko@juntendo.ac.jp; ishijima@juntendo.ac.jp			Ministry of Education, Culture, Sports, Science and Technology, Japan [24592281]; MEXT (Ministry of Education, Culture, Sports, Science and Technology)-Supported Program for the Strategic Research Foundation at Private Universities	This work was supported in part by a Grants-in-Aids from the Ministry of Education, Culture, Sports, Science and Technology, Japan (24592281) to MI. This study was also supported by Grants from MEXT (Ministry of Education, Culture, Sports, Science and Technology)-Supported Program for the Strategic Research Foundation at Private Universities (2011-2015) and (2014-2018).	ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/art.1780290816; Menashe L, 2012, OSTEOARTHR CARTILAGE, V20, P13, DOI 10.1016/j.joca.2011.10.003; Scanzello CR, 2011, ARTHRITIS RHEUM-US, V63, P391, DOI 10.1002/art.30137; Crofford LJ, 1999, OSTEOARTHR CARTILAGE, V7, P406, DOI 10.1053/joca.1999.0226; Roemer FW, 2010, OSTEOARTHR CARTILAGE, V18, P47, DOI 10.1016/j.joca.2009.08.018; Saito I, 2002, OSTEOARTHR CARTILAGE, V10, P156, DOI 10.1053/joca.2001.0494; Ning L, 2011, INT ORTHOP, V35, P831, DOI 10.1007/s00264-010-1045-1; Benito MJ, 2005, ANN RHEUM DIS, V64, P1263, DOI 10.1136/ard.2004.025270; KELLGREN JH, 1957, ANN RHEUM DIS, V16, P494, DOI 10.1136/ard.16.4.494; Loeuille D, 2005, ARTHRITIS RHEUM, V52, P3492, DOI 10.1002/art.21373; FERNANDEZMADRID F, 1995, MAGN RESON IMAGING, V13, P177, DOI 10.1016/0730-725X(94)00119-N; SODEN M, 1989, BRIT J RHEUMATOL, V28, P287; Scanzello CR, 2012, BONE, V51, P249, DOI 10.1016/j.bone.2012.02.012; Carr AJ, 2012, LANCET, V379, P1331, DOI 10.1016/S0140-6736(11)60752-6; Ravaud P, 1996, BRIT J RHEUMATOL, V35, P761; Peterfy CG, 2004, OSTEOARTHR CARTILAGE, V12, P177, DOI 10.1016/j.joca.2003.11.003; BUCKLANDWRIGHT JC, 1995, ANN RHEUM DIS, V54, P872, DOI 10.1136/ard.54.11.872; van der Kraan PM, 2007, OSTEOARTHR CARTILAGE, V15, P237, DOI 10.1016/j.joca.2006.11.006; Felson DT, 2005, CURR OPIN RHEUMATOL, V17, P624, DOI 10.1097/01.bor.0000172800.49120.97; Dieppe PA, 2005, LANCET, V365, P965, DOI 10.1016/S0140-6736(05)71086-2; Felson DT, 2007, ARTHRITIS RHEUM, V56, P2986, DOI 10.1002/art.22851; Liu LZ, 2010, CLIN RHEUMATOL, V29, P1185, DOI 10.1007/s10067-010-1522-3; Goldring MB, 2007, J CELL PHYSIOL, V213, P626, DOI 10.1002/jcp.21258; Felson DT, 2012, OSTEOARTHR CARTILAGE, V20, P1514, DOI 10.1016/j.joca.2012.08.020; Shimura Y, 2013, OSTEOARTHR CARTILAGE, V21, P1179, DOI 10.1016/j.joca.2013.05.014; Wenham CYJ, 2009, NAT CLIN PRACT RHEUM, V5, P149, DOI 10.1038/ncprheum1023; Hayashi D, 2012, OSTEOARTHR CARTILAGE, V20, P1227, DOI 10.1016/j.joca.2012.07.020; Felson DT, 2006, NEW ENGL J MED, V354, P841, DOI 10.1056/NEJMcp051726; Felson DT, 2003, ANN INTERN MED, V139, P330; Kubota M, 2010, J ORTHOP SCI, V15, P641, DOI 10.1007/s00776-010-1512-y; Mussener A, 1997, CLIN EXP IMMUNOL, V107, P112, DOI 10.1046/j.1365-2249.1997.d01-896.x; Akai M, 2005, J RHEUMATOL, V32, P1524; Ayral X, 2005, OSTEOARTHR CARTILAGE, V13, P361, DOI 10.1016/j.joca.2005.01.005; de Lange-Brokaar BJE, 2014, OSTEOARTHR CARTILAGE, V22, P1606, DOI 10.1016/j.joca.2013.12.013; Fiocco U, 2012, J RHEUMATOL, V39, P61, DOI 10.3899/jrheum.120246; Hada S, 2014, OSTEOARTHR CARTILAGE, V22, P1583, DOI 10.1016/j.joca.2014.07.021; Ishijima Muneaki, 2014, Ther Adv Musculoskelet Dis, V6, P144, DOI 10.1177/1759720X14541175; Ishijima M, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3246	38	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1063-4584	1522-9653		OSTEOARTHR CARTILAGE	Osteoarthritis Cartilage	NOV	2015	23	11					1858	1864		10.1016/j.joca.2015.05.017		7	Orthopedics; Rheumatology	Orthopedics; Rheumatology	CV0LB	WOS:000363941100006		
J	Takahashi, A; de Andres, MC; Hashimoto, K; Itoi, E; Oreffo, ROC				Takahashi, A.; de Andres, M. C.; Hashimoto, K.; Itoi, E.; Oreffo, R. O. C.			Epigenetic regulation of interleukin-8, an inflammatory chemokine, in osteoarthritis	OSTEOARTHRITIS AND CARTILAGE			English	Article						Interleukin-8; Chemokine; DNA methylation; Epigenetics; Inflammation; Osteoarthritis	NF-KAPPA-B; HUMAN ARTICULAR CHONDROCYTES; MATRIX-METALLOPROTEINASE 13; GENE-EXPRESSION; CPG SITES; IN-VIVO; RHEUMATOID-ARTHRITIS; TRANSCRIPTION; PROMOTER; IL-8	Objective: To determine whether altered IL8 methylation status is associated with increased expression of IL8 in human osteoarthritic (OA) chondrocytes. Methods: IL8 expression levels and the percentage CpG methylation in human chondrocytes were quantified by qRT-PCR and pyrosequencing in OA patients and in non-OA osteoporotic controls. The effect of CpG methylation on IL8 promoter activity was determined using a CpG-free vector; co-transfections with expression vectors encoding nuclear factor-kappa B (NF-kappa B), AP-1 and C/EBP were subsequently undertaken to analyse for IL8 promoter activity in response to changes in methylation status. Results: IL8 expression in OA patients was 37-fold higher than in osteoporotic controls. Three CpG sites in the IL8 promoter were significantly demethylated in OA patients. Multiple regression analysis revealed that the degree of methylation of the CpG site located at -116-bp was the strongest predictor of IL8 expression. In vitro DNA methylation was noted to decrease IL8 promoter basal activity. Furthermore, NF-kappa B, AP-1 and C/EBP strongly enhanced IL8 promoter activity whilst DNA methylation inhibited the effects of these three transcription factors. Conclusions: The present study demonstrates the key role of DNA methylation status on the expression of IL8 in human chondrocytes. We demonstrate a quantitative relationship between percentage methylation and gene expression within clinical samples. These studies provide direct evidence linking the activation of IL8, DNA demethylation and the induction of the OA process with important therapeutic implications therein for patients with this debilitating disease. (C) 2015 The Authors. Published by Elsevier Ltd and Osteoarthritis Research Society International.	[Takahashi, A.; de Andres, M. C.; Oreffo, R. O. C.] Univ Southampton, Ctr Human Dev Stem Cells & Regenerat, Bone & Joint Res Grp, Inst Dev Sci,Med Sch, Southampton SO16 6YD, Hants, England; [Takahashi, A.; Hashimoto, K.; Itoi, E.] Tohoku Univ, Sch Med, Dept Orthopaed Surg, Sendai, Miyagi 980, Japan	Oreffo, ROC (reprint author), Univ Southampton, Inst Dev Sci, Bone & Joint Res Grp, Sch Med, MP 887,Tremona Rd, Southampton SO16 6YD, Hants, England.	roco@soton.ac.uk	Oreffo, Richard/A-4615-2011	Oreffo, Richard/0000-0001-5995-6726	Biotechnology and Biological Sciences Research Council [BB/G010579/1]; Leverhulme Trust	Funding from the Leverhulme Trust and Biotechnology and Biological Sciences Research Council (BB/G010579/1) to RO is gratefully acknowledged. The study sponsors had no direct involvement in the study, in writing of the manuscript or the decision to submit.	Pozgan U, 2010, BIOL CHEM, V391, P571, DOI 10.1515/BC.2010.035; de Andres MC, 2011, BIOCHEM BIOPH RES CO, V407, P54, DOI 10.1016/j.bbrc.2011.02.101; Loeser RF, 2012, ARTHRITIS RHEUM-US, V64, P1697, DOI 10.1002/art.34453; Dequeker J, 1999, ADV EXP MED BIOL, V455, P419; Pierzchala AW, 2011, ARCH IMMUNOL THER EX, V59, P151, DOI 10.1007/s00005-011-0115-4; Borzi RM, 1999, FEBS LETT, V455, P238, DOI 10.1016/S0014-5793(99)00886-8; Borzi RM, 2002, ARTHRITIS RHEUM, V46, P3201, DOI 10.1002/art.10650; Hoffmann E, 2002, J LEUKOCYTE BIOL, V72, P847; da Silva MA, 2009, J ORTHOP RES, V27, P593, DOI 10.1002/jor.20799; de Andres MC, 2013, ARTHRITIS RHEUM-US, V65, P732, DOI 10.1002/art.37806; Khanjani S, 2012, MEDIAT INFLAMM, DOI 10.1155/2012/504952; Olson TS, 2002, AM J PHYSIOL-REG I, V283, pR7, DOI 10.1152/ajpregu.00738.2001; Imagawa K, 2011, BIOCHEM BIOPH RES CO, V405, P362, DOI 10.1016/j.bbrc.2011.01.007; Roach HI, 2005, ARTHRITIS RHEUM, V52, P3110, DOI 10.1002/art.21300; Hashimoto K, 2013, J BIOL CHEM, V288, P10061, DOI 10.1074/jbc.M112.421156; Rosenkilde MM, 2004, APMIS, V112, P481, DOI 10.1111/j.1600-0463.2004.apm11207-0808.x; [Anonymous], 2004, CLIN ORTHOP S, DOI 10.1097/01.blo.0000143805.64755.4f; Hoffmann E, 2005, J BIOL CHEM, V280, P9706, DOI 10.1074/jbc.M407071200; Reik W, 2007, NATURE, V447, P425, DOI 10.1038/nature05918; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Klug M, 2006, EPIGENETICS, V1, P127; Kapoor M, 2011, NAT REV RHEUMATOL, V7, P33, DOI 10.1038/nrrheum.2010.196; MATSUKAWA A, 1995, J IMMUNOL, V154, P5418; Rushton MD, 2014, ARTHRITIS RHEUMATOL, V66, P2450, DOI 10.1002/art.38713; Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915; Marcu KB, 2010, CURR DRUG TARGETS, V11, P599; [Anonymous], 2010, NUCLEIC ACIDS RES, DOI DOI 10.1093/NAR/GKP1005; Bui C, 2012, FASEB J, V26, P3000, DOI 10.1096/fj.12-206367; Hashimoto K, 2009, ARTHRITIS RHEUM-US, V60, P3303, DOI 10.1002/art.24882; Alaaeddine N, 1999, CYTOKINE, V11, P1020, DOI 10.1006/cyto.1999.0505; Ma B, 2013, OSTEOARTHR CARTILAGE, V21, P599, DOI 10.1016/j.joca.2013.01.014; Yuan GH, 2001, ARTHRITIS RHEUM, V44, P1056, DOI 10.1002/1529-0131(200105)44:5<1056::AID-ANR186>3.0.CO;2-U; Pritzker KPH, 2006, OSTEOARTHR CARTILAGE, V14, P13, DOI 10.1016/j.joca.2005.07.014; Murayama A, 2006, EMBO J, V25, P1081, DOI 10.1038/sj.emboj.7601012; Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Hoch RC, 1996, J LAB CLIN MED, V128, P134, DOI 10.1016/S0022-2143(96)90005-0; Edwards MR, 2005, PULM PHARMACOL THER, V18, P337, DOI 10.1016/j.pupt.2004.12.015; Merz D, 2003, J IMMUNOL, V171, P4406; MUKAIDA N, 1994, J LEUKOCYTE BIOL, V56, P554; Ayral X, 2005, OSTEOARTHR CARTILAGE, V13, P361, DOI 10.1016/j.joca.2005.01.005; Chauffier K, 2012, JOINT BONE SPINE, V79, P604, DOI 10.1016/j.jbspin.2011.12.013; Blagojevic M, 2010, OSTEOARTHR CARTILAGE, V18, P24, DOI 10.1016/j.joca.2009.08.010; Elliott CL, 2001, MOL HUM REPROD, V7, P787, DOI 10.1093/molehr/7.8.787; HARADA A, 1994, J LEUKOCYTE BIOL, V56, P559; Imagawa K, 2014, ARTHRITIS RHEUMATOL, V66, P3040, DOI 10.1002/art.38774; Moskowitz Roland W, 2009, Am J Manag Care, V15, pS223; Nourbakhsh M, 2001, J BIOL CHEM, V276, P4501, DOI 10.1074/jbc.M007532200	47	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1063-4584	1522-9653		OSTEOARTHR CARTILAGE	Osteoarthritis Cartilage	NOV	2015	23	11					1946	1954		10.1016/j.joca.2015.02.168		9	Orthopedics; Rheumatology	Orthopedics; Rheumatology	CV0LB	WOS:000363941100017		
J	Kano, H; Okada, K; Morimoto, K; Bao, W; Fukase, K; Ito, A; Okita, Y				Kano, H.; Okada, K.; Morimoto, K.; Bao, W.; Fukase, K.; Ito, A.; Okita, Y.			Prediction of reversibility of intestinal mucosal damage after ischemia-reperfusion injury by plasma intestinal fatty acid-binding protein levels in pigs	PERFUSION-UK			English	Article						intestinal ischemia; intestinal fatty acid-binding protein; cardiovascular surgery; reperfusion injury; E-cadherin	ACUTE MESENTERIC ISCHEMIA; DIAGNOSTIC-ACCURACY; CELIAC-DISEASE; I-FABP; MARKER; SURGERY; GUT; PERMEABILITY; BIOMARKERS; BARRIER	Objective: The aims of this study were to elucidate the association between plasma intestinal fatty acid-binding protein (I-FABP) level and actual pathological damage of intestinal mucosa and its reversibility. Methods: An intestinal ischemia-reperfusion model was created by temporary occlusion of the descending aorta in 9 pigs which were divided into 3 groups according to the duration of visceral ischemic insult: 15-minute ischemia (n=3), 30-minute ischemia (n=3) and 60-minute ischemia (n=3). Blood samples and short segments of the jejunum for pathological examinations, including immunohistochemical staining of I-FABP, Ki-67 and E-cadherin, were taken at the beginning of the operation (T1) and 15 minutes (T2), 30 minutes (T3), 45 minutes (T4) and 60 minutes (T5) after reperfusion. Results: Plasma I-FABP after 15 minutes of ischemia reached a peak of 18591089 pg/ml at T3, while the level after 30 minutes of ischemia achieved a peak level of 5053 +/- 1717 pg/ml at T5. The level after 60 minutes of ischemia demonstrated a rapid increment up to 10734 +/- 93 pg/ml at T3. There was a significant difference in the trend of plasma I-FABP levels between 30 minutes and 60 minutes of ischemia (p=0.01). The strongest immunohistochemical staining of the intestinal epithelium for I-FABP was observed at T4 after 30 minutes of ischemia, with the shedding of injured epithelium followed by re-epithelialisation, with sequential up-regulation of Ki67 and E-cadherin. However, the intestinal epithelium after 60 minutes of ischemia demonstrated the lack of I-FABP expression with irreversible damage. Conclusion: Plasma I-FABP levels may be a crucial marker to recognize the reversibility of damage of the intestinal epithelium after an ischemic insult and the level of 5000 pg/ml is considered to be the critical borderline for irreversibility, which might prevent diagnostic delay in the clinical setting.	[Kano, H.; Okada, K.; Morimoto, K.; Bao, W.; Fukase, K.; Okita, Y.] Kobe Univ, Grad Sch Med, Dept Surg, Div Cardiovasc Surg, Kobe, Hyogo 6500017, Japan; [Ito, A.] Kinki Univ, Fac Med, Dept Pathol, Osaka, Japan	Okada, K (reprint author), Kobe Univ, Grad Sch Med, Dept Surg, Div Cardiovasc Surg,Chuo Ku, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	yutamo@aol.com					D'Ancona G, 2003, TEX HEART I J, V30, P280; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Thuijls G, 2011, ANN SURG, V253, P303, DOI 10.1097/SLA.0b013e318207a767; Doig CJ, 1998, AM J RESP CRIT CARE, V158, P444; Kanda T, 2011, J GASTROENTEROL, V46, P492, DOI 10.1007/s00535-011-0373-2; Swank GM, 1996, WORLD J SURG, V20, P411; Block T, 2008, SCAND J CLIN LAB INV, V68, P242, DOI 10.1080/00365510701646264; Kanda T, 1996, GASTROENTEROLOGY, V110, P339, DOI 10.1053/gast.1996.v110.pm8566578; Adriaanse MPM, 2013, ALIMENT PHARM THER, V37, P482, DOI 10.1111/apt.12194; Chang M, 2012, SHOCK, V37, P297, DOI 10.1097/SHK.0b013e318240b59b; Goto T, 2010, EUR J CARDIO-THORAC, V37, P426, DOI 10.1016/j.ejcts.2009.06.041; Pelsers MMAL, 2003, CLIN BIOCHEM, V36, P529, DOI 10.1016/S0009-9120(03)00096-1; Sonnino R, 2000, TRANSPLANT P, V32, P1280, DOI 10.1016/S0041-1345(00)01225-2; Eltarawy IG, 2009, AM SURGEON, V75, P212; Acosta S, 2012, J THROMB THROMBOLYS, V33, P355, DOI 10.1007/s11239-011-0660-z; Evennett NJ, 2009, WORLD J SURG, V33, P1374, DOI 10.1007/s00268-009-0074-7; Derikx JPM, 2009, J CLIN GASTROENTEROL, V43, P727, DOI 10.1097/MCG.0b013e31819194b0; Windsant ICV, 2012, ANN SURG, V255, P796, DOI 10.1097/SLA.0b013e31824b1e16; Acosta S, 2007, J SURG RES, V143, P320, DOI 10.1016/j.jss.2007.02.003; Fahrner R, 2012, J SURG RES, V178, P879, DOI 10.1016/j.jss.2012.08.011; Kozuch PL, 2005, ALIMENT PHARM THERAP, V21, P201, DOI 10.1111/j.1365-2036.2005.02269.x; Derikx JPM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003954; Derikx JPM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003428	23	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0267-6591	1477-111X		PERFUSION-UK	Perfusion-UK	NOV	2015	30	8					617	625		10.1177/0267659114566063		9	Cardiac & Cardiovascular Systems; Peripheral Vascular Disease	Cardiovascular System & Cardiology	CV0VK	WOS:000363971500003		
J	Mukaida, H; Matsushita, S; Inotani, T; Futaki, S; Takano, A; Watanabe, M; Morita, T; Miida, T; Amano, A				Mukaida, H.; Matsushita, S.; Inotani, T.; Futaki, S.; Takano, A.; Watanabe, M.; Morita, T.; Miida, T.; Amano, A.			Peripheral circulation evaluation with near-infrared spectroscopy in skeletal muscle during cardiopulmonary bypass	PERFUSION-UK			English	Article						near-infrared spectroscopy; adult cardiac surgery; hemodilution; oxyhemoglobin delivery; microcirculation	CARDIAC-SURGERY; HEMATOCRIT; INHIBITION; FAILURE	Background: We designed a non-invasive, observational, real-time study, using near-infrared spectroscopy (NIRS) to assess the in vivo effects of cardiopulmonary bypass (CPB) on patients' skeletal muscle as well as the effects of hemodilution and hypothermia on tissue oxygen delivery during CPB. Methods: The study included 20 consecutive adult patients undergoing open-heart surgery with CPB. Evaluation parameters for peripheral circulation were measured using the NIRO-200NX and recorded every 30 seconds. To assess how hemodilution influences peripheral circulation parameters, we compared data between a group of patients with hematocrit (Hct) values >22% (high Hct group) and those with Hct values 22% (low Hct group). Results: Changes in the concentration of oxygenated hemoglobin (O(2)Hb, mol/L), which flows into the skeletal muscle, was an important factor for deciding the tissue oxygenation index (TOI%), showing the tissue oxygen saturation. The low Hct group showed a significant increase in the normalized tissue hemoglobin index (nTHI), showing the percentage change in the amount of initial hemoglobin and TOI compared to the high Hct group. Changes in the concentration of oxygenated hemoglobin (O(2)Hb, mol/L) and deoxygenated hemoglobin (HHb, mol/L) were significantly less in the low Hct group than in the high Hct group, thus, showing good peripheral circulation despite the low hematocrit levels. Conclusion: Our study indicated the presence of a compensatory mechanism in which increased blood flow of the microcirculation is in compensation for the lack of oxyhemoglobin delivery caused by hemodilution.	[Mukaida, H.; Inotani, T.; Futaki, S.; Takano, A.; Watanabe, M.] Juntendo Univ Hosp, Dept Clin Engn, Tokyo, Japan; [Matsushita, S.; Morita, T.; Amano, A.] Juntendo Univ, Fac Med, Dept Cardiovasc Surg, Tokyo 1138421, Japan; [Miida, T.] Juntendo Univ, Fac Med, Dept Clin Lab Med, Tokyo 1138421, Japan	Matsushita, S (reprint author), Juntendo Univ, Fac Med, Dept Cardiovasc Surg, Bunkyo Ku, Hongo 2-1-1, Tokyo 1138421, Japan.	saty-m@juntendo.ac.jp	Miida, Takashi/A-5589-2012	Miida, Takashi/0000-0002-4294-8030			AI-Rawi PG, 2006, STROKE, V37, P2720; den Uil CA, 2008, J THORAC CARDIOV SUR, V136, P129, DOI 10.1016/j.jtcvs.2007.10.046; HAMPSON NB, 1988, J APPL PHYSIOL, V64, P2449; Wan S, 1997, ANN THORAC SURG, V63, P269; WILSON JR, 1989, CIRCULATION, V80, P1668; Park KW, 1996, ANESTH ANALG, V83, P286, DOI 10.1097/00000539-199608000-00015; De Blasi RA, 2012, INTENS CARE MED, V38, P413, DOI 10.1007/s00134-011-2404-0; GORDON RJ, 1975, J THORAC CARDIOV SUR, V69, P552; Maeda N, 1996, JPN J PHYSIOL, V46, P1, DOI 10.2170/jjphysiol.46.1; Patila T, 2006, ANN THORAC SURG, V82, P2072, DOI 10.1016/j.athoracsur.2006.06.025; Habib RH, 2003, J THORAC CARDIOV SUR, V125, P1438, DOI 10.1016/S0022-5223(02)125:1438-50; GAEHTGENS P, 1984, INT J MICROCIRC, V3, P147; Khan TA, 2003, CIRCULATION, V108, P348, DOI 10.1161/01.cir.0000087652.93751.0e; GUYTON AC, 1961, CIRC RES, V9, P157; Ruel M, 2004, EUR J CARDIO-THORAC, V26, P1002, DOI 10.1016/j.ejcts.2004.07.040; Khan TA, 2003, SURGERY, V134, P247, DOI 10.1067/msy.2003.229; Galletti PM, 1962, HEART LUNG BYPASS PR, P211; Gravlee GP, 2010, CARDIOPULMONARY BYPA, P403; Higuchi T, 2008, JPN J EXTRACORPOREAL, V35, P19; Ito T, 1998, Jpn J Thorac Cardiovasc Surg, V46, P1260; Murase N, 2010, J JPN COLL ANGIOL, V50, P467; Ohnishi Y, 1993, Masui, V42, P1217; PRIES AR, 1992, AM J PHYSIOL, V263, pH1770; Sakamoto T, 2004, PEDIAT CARDIOLOGY CA, V20, P610; Yasukawa T, 2005, J JAPAN SOC CLIN ANE, V25, P42, DOI 10.2199/jjsca.25.42	25	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0267-6591	1477-111X		PERFUSION-UK	Perfusion-UK	NOV	2015	30	8					653	659		10.1177/0267659115575419		7	Cardiac & Cardiovascular Systems; Peripheral Vascular Disease	Cardiovascular System & Cardiology	CV0VK	WOS:000363971500009		
J	Shirai, A; Kajiura, M; Omasa, T				Shirai, Akihiro; Kajiura, Masato; Omasa, Takeshi			Synergistic Photobactericidal Activity Based on Ultraviolet-A Irradiation and Ferulic Acid Derivatives	PHOTOCHEMISTRY AND PHOTOBIOLOGY			English	Article							PHOTOACTIVE YELLOW PROTEIN; P-COUMARIC ACID; PHENOLIC-ACIDS; CINNAMIC ACID; ANTIMICROBIAL ACTIVITY; PHOTODYNAMIC THERAPY; LIGHT; TRANS; CIS; ANTIOXIDANT	Ultraviolet-A (UV-A)-mediated bactericidal activity was enhanced by combined treatment with trans-ferulic acid (trans-FA, compound 1) or its derivatives. Derivative compounds 4 and 10 contain a phenyl group or an l-tyrosine HCl tert-butyl ester, respectively, linked to the carboxyl group of trans-FA. Of the three compounds, 10 exhibited the highest synergistic activity in a photobactericidal assay based on treating Escherichia coli with a derivative compound and UV-A irradiation (wavelength 350-385 nm). Inactivation of viable cells at a 4.9 J cm(-2) UV-A fluence increased from 1.90 to 5.19 logs in the presence of 10 (100 m); a 4.95-log inactivation was achieved with 10 (5 m) and a 7.4 J cm(-2) UV-A fluence. Addition of antioxidants significantly suppressed photosynergistic bactericidal activity, suggesting that reactive oxygen species (ROS) are involved in the combined bactericidal mechanism. Flow cytometry revealed that combined treatment with UV-A and compound 10, which showed the highest photobactericidal activity, generates an excess of oxidative radicals in bacterial cells. The bactericidal activity of compound 10 may be due to electrostatic interaction between the molecule's cationic moiety and the cell surface, followed by amplification of ROS generation in the cells.	[Shirai, Akihiro; Omasa, Takeshi] Univ Tokushima, Inst Sci & Technol, Dept Biol Sci & Technol, Biosyst Engn, Tokushima 770, Japan; [Kajiura, Masato] Univ Tokushima, Fac Engn, Dept Biol Sci & Technol, Tokushima 770, Japan	Shirai, A (reprint author), Univ Tokushima, Inst Sci & Technol, Dept Biol Sci & Technol, Biosyst Engn, Tokushima 770, Japan.	a.shirai@tokushima-u.ac.jp			Japan Society for the Promotion of Science [25870476]	This work was supported by a Grant-in-Aid for Young Scientists (B) from the Japan Society for the Promotion of Science (25870476).	Dovigo LN, 2011, PHOTOCHEM PHOTOBIOL, V87, P895, DOI 10.1111/j.1751-1097.2011.00937.x; Chen YL, 2011, EUR J PHARM SCI, V43, P188, DOI 10.1016/j.ejps.2011.04.012; Shirai A, 2014, J PHOTOCH PHOTOBIO B, V130, P226, DOI 10.1016/j.jphotobiol.2013.11.027; Segalla A, 2002, PHOTOCH PHOTOBIO SCI, V1, P641, DOI 10.1039/b202031a; Shrestha A, 2012, PHOTOCHEM PHOTOBIOL, V88, P577, DOI 10.1111/j.1751-1097.2011.01026.x; HARTLEY RD, 1975, J CHROMATOGR, V107, P213, DOI 10.1016/S0021-9673(00)82768-5; Fan Q, 2012, FOOD CHEM, V134, P1081, DOI 10.1016/j.foodchem.2012.03.021; Kumar V, 2004, PHOTOCHEM PHOTOBIOL, V80, P15, DOI 10.1562/2003-12-23-RA-036.1; Yin R, 2013, CURR OPIN PHARMACOL, V13, P731, DOI 10.1016/j.coph.2013.08.009; Hegge AB, 2012, EUR J PHARM SCI, V47, P65, DOI 10.1016/j.ejps.2012.05.002; Ergun BC, 2011, ARCH PHARM RES, V34, P1251, DOI 10.1007/s12272-011-0803-y; CHIGNELL CF, 1994, PHOTOCHEM PHOTOBIOL, V59, P295, DOI 10.1111/j.1751-1097.1994.tb05037.x; Ryan WL, 2002, J AM CHEM SOC, V124, P6194, DOI 10.1021/ja017505p; Hamamoto A, 2007, J APPL MICROBIOL, V103, P2291, DOI 10.1111/j.1365-2672.2007.03464.x; Narasimhan B, 2004, EUR J MED CHEM, V39, P827, DOI 10.1016/j.ejmech.2004.06.013; MAILLARD MN, 1995, J AGR FOOD CHEM, V43, P1789, DOI 10.1021/jf00055a008; Kort R, 1996, FEBS LETT, V382, P73, DOI 10.1016/0014-5793(96)00149-4; Tsai CM, 2013, EUR J PHARM SCI, V48, P494, DOI 10.1016/j.ejps.2012.11.013; Mattila P, 2007, J FOOD COMPOS ANAL, V20, P152, DOI 10.1016/j.jfca.2006.05.007; GRAF E, 1992, FREE RADICAL BIO MED, V13, P435, DOI 10.1016/0891-5849(92)90184-I; Nakamura K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060053; Nakamura K., 2001, PEPT SCI, V38, P43; Nakamura K, 2014, TETRAHEDRON, V70, P8097, DOI 10.1016/j.tet.2014.08.028; Nakata K., 2010, J APPL MICROBIOL, V110, P568	24	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0031-8655	1751-1097		PHOTOCHEM PHOTOBIOL	Photochem. Photobiol.	NOV-DEC	2015	91	6					1422	1428		10.1111/php.12507		7	Biochemistry & Molecular Biology; Biophysics	Biochemistry & Molecular Biology; Biophysics	CV5MJ	WOS:000364314500019		
J	Yamamoto, T; Ishikawa, E; Miki, S; Sakamoto, N; Zaboronok, A; Matsuda, M; Akutsu, H; Nakai, K; Tsuruta, W; Matsumura, A				Yamamoto, Tetsuya; Ishikawa, Eiichi; Miki, Shunichiro; Sakamoto, Noriaki; Zaboronok, Alexander; Matsuda, Masahide; Akutsu, Hiroyoshi; Nakai, Kei; Tsuruta, Wataro; Matsumura, Akira			Photodynamic Diagnosis Using 5-Aminolevulinic Acid in 41 Biopsies for Primary Central Nervous System Lymphoma	PHOTOCHEMISTRY AND PHOTOBIOLOGY			English	Article							FLUORESCENCE-GUIDED RESECTIONS; MALIGNANT BRAIN-TUMORS; TALAPORFIN SODIUM; TISSUE; GLIOMA; THERAPY; SURGERY	We evaluated the feasibility of 5-aminolevulinic acid (5-ALA)-mediated photodynamic diagnosis (PDD) in the biopsy for primary central nervous system lymphoma (PCNSL). 5-ALA (20 mg kg(-1)) was administered orally 4 hours preoperatively. Forty-one biopsies obtained under PDD in 47 consecutive biopsies (46 patients) that were finally pathologically diagnosed as PCNSL were evaluated. Positive fluorescence was observed in 34 of those 41 biopsies (82.9%). An intraoperative pathological diagnosis (IOD) of suspected PCNSL was made in 21 of the biopsies with positive fluorescence (61.8%). However, the eight IODs in the remaining 13 biopsies (23.5%) were not correct (atypical cell, 4; high-grade glioma, 1; gliosis, 1; unremarkable, 2). In those 8 biopsies, PCNSL was confirmed by the final pathological diagnosis. There was no difference in the mean Mib-1 labeling index between the biopsies with positive fluorescence (86.5%) and those without positive fluorescence (90.0%). IOD was not performed in 6 biopsies; however, 5 of those biopsies (83.3%) showed positive fluorescence and were finally pathologically diagnosed as PCNSL. Use of PDD in biopsies for patients with suspected PCNSL is a reliable way of obtaining specimens of adequate quality for the final pathological diagnosis and may lead to improved diagnostic yield in the biopsy of PCNSL.	[Yamamoto, Tetsuya; Ishikawa, Eiichi; Miki, Shunichiro; Sakamoto, Noriaki; Zaboronok, Alexander; Matsuda, Masahide; Akutsu, Hiroyoshi; Nakai, Kei; Tsuruta, Wataro; Matsumura, Akira] Univ Tsukuba, Fac Med, Dept Neurosurg, Tsukuba, Ibaraki, Japan	Yamamoto, T (reprint author), Univ Tsukuba, Fac Med, Dept Neurosurg, Tsukuba, Ibaraki, Japan.	yamamoto_neurosurg@md.tsukuba.ac.jp			SJFE (Japanese Foundation for Research and Promotion of Endoscopy) grant	We thank Flaminia Miyamasu (ELS, 2012) for the native speaker revision. This study was supported in part by an SJFE (Japanese Foundation for Research and Promotion of Endoscopy) grant.	Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Eljamel MS, 2009, J NEURO-ONCOL, V92, P417, DOI 10.1007/s11060-009-9820-9; Schucht P, 2011, ACTA NEUROCHIR, V153, P1497, DOI 10.1007/s00701-011-0991-8; Desmoulin SK, 2012, CANCER BIOL THER, V13, P1355, DOI 10.4161/cbt.22020; Moriuchi S, 2011, J NEUROSURG, V115, P278, DOI 10.3171/2011.4.JNS102137; Tsuda K, 2011, NEUROL MED-CHIR, V51, P694; Ishihara R, 2007, NEUROL MED-CHIR, V47, P53, DOI 10.2176/nmc.47.53; MOORE GE, 1948, J NEUROSURG, V5, P392, DOI 10.3171/jns.1948.5.4.0392; Utsuki S, 2007, NEUROL MED-CHIR, V47, P210, DOI 10.2176/nmc.47.210; Muragaki Y, 2013, J NEUROSURG, V119, P845, DOI 10.3171/2013.7.JNS13415; Tsurubuchi T, 2009, PHOTODIAGN PHOTODYN, V6, P19, DOI 10.1016/j.pdpdt.2009.03.005; Weller M, 2012, NEURO-ONCOLOGY, V14, P1481, DOI 10.1093/neuonc/nos159; Stummer W, 1998, ACTA NEUROCHIR, V140, P995, DOI 10.1007/s007010050206; Kostron H, 2010, METHODS MOL BIOL, V635, P261, DOI 10.1007/978-1-60761-697-9_17; Colditz MJ, 2012, J CLIN NEUROSCI, V19, P1611, DOI 10.1016/j.jocn.2012.03.013; Stummer W, 2003, ACT NEUR S, V88, P9; Grossman R, 2014, J NEUROSURG, V120, P67, DOI 10.3171/2013.9.JNS131076; Widhalm G, 2012, NEUROSURG REV, V35, P381, DOI 10.1007/s10143-012-0374-5; Stummer W, 2006, LANCET ONCOL, V7, P392, DOI 10.1016/S1470-2045(06)70665-9; Coluccia D, 2010, ACTA NEUROCHIR, V152, P1711, DOI 10.1007/s00701-010-0708-4; Zimmermann A, 2001, PHOTOCHEM PHOTOBIOL, V74, P611, DOI 10.1562/0031-8655(2001)074<0611:MMPDOM>2.0.CO;2; Eljamel M Sam, 2009, Clin Neurosurg, V56, P93; Stummer W, 2014, ACTA NEUROCHIR, V156, P2315, DOI 10.1007/s00701-014-2234-2; Takada T, 2014, J CLIN BIOCHEM NUTR, V54, P26, DOI 10.3164/jcbn.13-87	24	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0031-8655	1751-1097		PHOTOCHEM PHOTOBIOL	Photochem. Photobiol.	NOV-DEC	2015	91	6					1452	1457		10.1111/php.12510		6	Biochemistry & Molecular Biology; Biophysics	Biochemistry & Molecular Biology; Biophysics	CV5MJ	WOS:000364314500023		
J	Ikehata, H; Mori, T; Yamamoto, M				Ikehata, Hironobu; Mori, Toshio; Yamamoto, Masayuki			In Vivo Spectrum of UVC-induced Mutation in Mouse Skin Epidermis May Reflect the Cytosine Deamination Propensity of Cyclobutane Pyrimidine Dimers	PHOTOCHEMISTRY AND PHOTOBIOLOGY			English	Article							INDUCED DNA-DAMAGE; ULTRAVIOLET-RADIATION; DIPYRIMIDINE SITES; SIGNATURE MUTATIONS; INDUCED MUTAGENESIS; LIGHT MUTAGENESIS; ESCHERICHIA-COLI; MAMMALIAN-CELLS; P53 MUTATIONS; SUNLIGHT	Although ultraviolet radiation (UVR) has a genotoxicity for inducing skin cancers, the skin may tolerate UVC component because the epidermal layer prevents this short wavelength range from passing through. Here, UVC genotoxicity for mouse skin was evaluated in terms of DNA damage formation and mutagenicity. UVC induced UVR photolesions and mutations remarkably in the epidermis but poorly in the dermis, confirming the barrier ability of the epidermis against shorter UVR wavelengths. Moreover, the epidermis itself responded to UVC mutagenicity with mutation induction suppression, which suppressed the mutant frequencies to a remarkably low, constant level regardless of UVC dose. The mutation spectrum observed in UVC-exposed epidermis showed a predominance of UV-signature mutation, which occurred frequently in 5-TCG-3, 5-TCA-3 and 5-CCA-3 contexts. Especially, for the former two contexts, the mutations recurred at several sites with more remarkable recurrences at the 5-TCG-3 sites. Comparison of the UVC mutation spectrum with those observed in longer UVR wavelength ranges led us to a mechanism that explains why the sequence context preference of UV-signature mutation changes according to the wavelength, which is based on the difference in the mCpG preference of cyclobutane pyrimidine dimer (CPD) formation among UVR ranges and the sequence context-dependent cytosine deamination propensity of CPD.	[Ikehata, Hironobu; Yamamoto, Masayuki] Tohoku Univ, Grad Sch Med, Dept Med Biochem, Sendai, Miyagi 980, Japan; [Mori, Toshio] Nara Med Univ, Sch Med, Radioisotope Res Ctr, Kashihara, Nara 634, Japan	Ikehata, H (reprint author), Tohoku Univ, Grad Sch Med, Dept Med Biochem, Sendai, Miyagi 980, Japan.	ikehata@med.tohoku.ac.jp			JSPS KAKENHI [15H02815]	We thank K. Takahashi, L.-C. Wang, Y. Hasegawa, Y. Shono and Y. Takahashi for experimental assistance, and B. Bell for help in editing the manuscript. This study was supported by JSPS KAKENHI Grant Number 15H02815 to H. Ikehata.	Jans J, 2005, CURR BIOL, V15, P105, DOI 10.1016/j.cub.2005.01.001; Ikehata H, 2002, MUTAT RES-FUND MOL M, V508, P41, DOI 10.1016/S0027-5107(02)00145-8; Mouret S, 2006, P NATL ACAD SCI USA, V103, P13765, DOI 10.1073/pnas.0604213103; Nakajima S, 2004, J BIOL CHEM, V279, P46674, DOI 10.1074/jbc.M406070200; Tu YQ, 1998, J MOL BIOL, V284, P297, DOI 10.1006/jmbi.1998.2176; GROLLMAN AP, 1993, TRENDS GENET, V9, P246, DOI 10.1016/0168-9525(93)90089-Z; Burger A, 2003, MUTAT RES-FUND MOL M, V522, P145, DOI 10.1016/S0027-5107(02)00310-X; Ikehata H, 2003, MUTAGENESIS, V18, P511, DOI 10.1093/mutage/geg030; GOSSEN JA, 1989, P NATL ACAD SCI USA, V86, P7971, DOI 10.1073/pnas.86.20.7971; Song Q, 2012, J BIOL CHEM, V287, P8021, DOI 10.1074/jbc.M111.333591; Drouin R, 1997, PHOTOCHEM PHOTOBIOL, V66, P719, DOI 10.1111/j.1751-1097.1997.tb03213.x; Lee DH, 2003, J BIOL CHEM, V278, P10314, DOI 10.1074/jbc.M212696200; Rochette PJ, 2009, MUTAT RES-FUND MOL M, V665, P7, DOI 10.1016/j.mrfmmm.2009.02.008; Ikehata H, 2011, J RADIAT RES, V52, P115, DOI 10.1269/jrr.10175; Ikehata H, 2007, DNA REPAIR, V6, P82, DOI 10.1016/j.dnarep.2006.09.003; You YH, 1999, J MOL BIOL, V293, P493, DOI 10.1006/jmbi.1999.3174; Tewari A, 2012, J INVEST DERMATOL, V132, P394, DOI 10.1038/jid.2011.283; Cannistraro VJ, 2009, J MOL BIOL, V392, P1145, DOI 10.1016/j.jmb.2009.07.048; DROBETSKY EA, 1987, P NATL ACAD SCI USA, V84, P9103, DOI 10.1073/pnas.84.24.9103; STERENBORG HJCM, 1988, PHOTOCHEM PHOTOBIOL, V47, P245, DOI 10.1111/j.1751-1097.1988.tb02722.x; Peng W, 1996, BIOCHEMISTRY-US, V35, P10172, DOI 10.1021/bi960001x; MILLER JH, 1985, J MOL BIOL, V182, P45, DOI 10.1016/0022-2836(85)90026-9; You YH, 2001, J MOL BIOL, V305, P389, DOI 10.1006/jmbi.2000.4322; BRULS WAG, 1984, PHOTOCHEM PHOTOBIOL, V40, P485, DOI 10.1111/j.1751-1097.1984.tb04622.x; TESSMAN I, 1994, J MOL BIOL, V235, P807, DOI 10.1006/jmbi.1994.1040; Ikehata H, 2004, MUTAT RES-FUND MOL M, V556, P11, DOI 10.1016/j/mrfmmm.2004.06.038; DEERING RA, 1963, BIOCHIM BIOPHYS ACTA, V68, P526; SCHAAPER RM, 1987, J MOL BIOL, V198, P187, DOI 10.1016/0022-2836(87)90305-6; Cadet J, 2005, MUTAT RES-FUND MOL M, V571, P3, DOI 10.1016/j.mrfmmm.2004.09.012; Ikehata H, 2013, J INVEST DERMATOL, V133, P1850, DOI 10.1038/jid.2012.504; Ikehata H, 2010, MUTAGENESIS, V25, P397, DOI 10.1093/mutage/geq019; Tommasi S, 1997, CANCER RES, V57, P4727; Ikehata H, 2013, PHOTOCH PHOTOBIO SCI, V12, P1319, DOI 10.1039/c3pp25444e; ROMAC S, 1989, J MOL BIOL, V209, P195, DOI 10.1016/0022-2836(89)90272-6; Brash DE, 2015, PHOTOCHEM PHOTOBIOL, V91, P15, DOI 10.1111/php.12377; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; Wang F, 2006, ENVIRON MOL MUTAGEN, V47, P107, DOI 10.1002/em.20173; Perdiz D, 2000, J BIOL CHEM, V275, P26732; CARIELLO NF, 1994, CARCINOGENESIS, V15, P2281, DOI 10.1093/carcin/15.10.2281; Ikehata H, 2007, PHOTOCHEM PHOTOBIOL, V83, P196, DOI 10.1562/2006-02-28-IR-822; Ikehata H, 2008, J INVEST DERMATOL, V128, P2289, DOI 10.1038/jid.2008.61; Kozmin SG, 2003, NUCLEIC ACIDS RES, V31, P4541, DOI 10.1093/nar/gkg489; Besaratinia A, 2011, FASEB J, V25, P3079, DOI 10.1096/fj.11-187336; BARAK Y, 1995, J BIOL CHEM, V270, P24174; Friedberg E. C., 2005, DNA REPAIR MUTAGENES; Grunwald S., 1989, PROG CLIN BIOCH MED, V9, P61; Ikehata H, 2014, DNA REPAIR, V22, P112, DOI 10.1016/j.dnarep.2014.07.012; Ikehata H, 2003, ENVIRON MOL MUTAGEN, V41, P280, DOI 10.1002/em.10153	48	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0031-8655	1751-1097		PHOTOCHEM PHOTOBIOL	Photochem. Photobiol.	NOV-DEC	2015	91	6					1488	1496		10.1111/php.12525		9	Biochemistry & Molecular Biology; Biophysics	Biochemistry & Molecular Biology; Biophysics	CV5MJ	WOS:000364314500027		
J	Fujisawa, Y; Okajima, Y				Fujisawa, Yuhki; Okajima, Yasutomo			Characteristics of Handwriting of People With Cerebellar Ataxia: Three-Dimensional Movement Analysis of the Pen Tip, Finger, and Wrist	PHYSICAL THERAPY			English	Article							SCALE; SYMPTOMS; TABLET; TREMOR	Background. There are several functional tests for evaluating manual performance; however, quantitative manual tests for ataxia, especially those for evaluating handwriting, are limited. Objective. This study aimed to investigate the characteristics of cerebellar ataxia by analyzing handwriting, with a special emphasis on correlation between the movement of the pen tip and the movement of the finger or wrist. Design. This was an observational study. Methods. Eleven people who were right-handed and had cerebellar ataxia and 17 people to serve as controls were recruited. The Scale for the Assessment and Rating of Ataxia was used to grade the severity of ataxia. Handwriting movements of both hands were analyzed. The time required for writing a character, the variability of individual handwriting, and the correlation between the movement of the pen tip and the movement of the finger or wrist were evaluated for participants with ataxia and control participants. Results. The writing time was longer and the velocity profile and shape of the track of movement of the pen tip were more variable in participants with ataxia than in control participants. For participants with ataxia, the direction of movement of the pen tip deviated more from that of the finger or wrist, and the shape of the track of movement of the pen tip differed more from that of the finger or wrist. The severity of upper extremity ataxia measured with the Scale for the Assessment and Rating of Ataxia was mostly correlated with the variability parameters. Furthermore, it was correlated with the directional deviation of the trajectory of movement of the pen tip from that of the finger and with increased dissimilarity of the shapes of the tracks. Limitations. The results may have been influenced by the scale and parameters used to measure movement. Conclusions. Ataxic handwriting with increased movement noise is characterized by irregular pen tip movements unconstrained by the finger or wrist. The severity of ataxia is correlated with these unconstrained movements.	[Fujisawa, Yuhki] Kyorin Univ, Fac Allied Hlth Sci, Dept Phys Therapy, Mitaka, Tokyo 1818611, Japan; [Okajima, Yasutomo] Kyorin Univ, Fac Med, Dept Rehabil Med, Sch Med, Mitaka, Tokyo 1818611, Japan	Fujisawa, Y (reprint author), Kyorin Univ, Fac Allied Hlth Sci, Dept Phys Therapy, Shinkawa 6-20-2, Mitaka, Tokyo 1818611, Japan.	yfujisawa@ks.kyorin-u.ac.jp			Japan Society for the Promotion of Science [23500615]	This study was supported, in part, by a Grant-in-Aid for Scientific Research (23500615) from the Japan Society for the Promotion of Science.	Holmes G, 1917, BRAIN, V40, P461, DOI 10.1093/brain/40.4.461; Harada T, 2010, ARCH PHYS MED REHAB, V91, P1210, DOI 10.1016/j.apmr.2010.01.023; Marini F, 2010, IEEE ENG MED BIO, P6633, DOI 10.1109/IEMBS.2010.5627144; TEULINGS HL, 1993, ACTA PSYCHOL, V82, P69, DOI 10.1016/0001-6918(93)90005-C; Erasmus LP, 2001, J NEUROSCI METH, V108, P25, DOI 10.1016/S0165-0270(01)00373-9; Freeman FN, 1914, PSYCHOL MONOGR, V17, P1; Louis ED, 2012, CEREBELLUM, V11, P872, DOI 10.1007/s12311-011-0352-4; CASTIELLO U, 1993, ACTA PSYCHOL, V82, P53, DOI 10.1016/0001-6918(93)90004-B; Pullman SL, 1998, MOVEMENT DISORD, V13, P85; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Bastian AJ, 1996, J NEUROPHYSIOL, V76, P492; Menegoni F, 2009, EUR J NEUROL, V16, P232, DOI 10.1111/j.1468-1331.2008.02396.x; Schmitz-Hubsch T, 2006, NEUROLOGY, V66, P1717, DOI 10.1212/01.wnl.0000219042.60538.92; Kim KW, 2005, DEMENT GERIATR COGN, V19, P324, DOI 10.1159/000084558; Sato Kazunori, 2009, Brain and Nerve (Tokyo), V61, P591; Maurel N, 2013, CLIN BIOMECH, V28, P386, DOI 10.1016/j.clinbiomech.2013.02.007; [Anonymous], 1975, J PSYCHIATR RES, DOI DOI 10.1016/0022-3956(75)90026-6; Viviani P, 1980, ADV PSYCHOL, V1, P525, DOI DOI 10.1016/S0166-4115(08)61967-6	18	0	0	AMER PHYSICAL THERAPY ASSOC	ALEXANDRIA	1111 N FAIRFAX ST, ALEXANDRIA, VA 22314 USA	0031-9023	1538-6724		PHYS THER	Phys. Ther.	NOV	2015	95	11					1547	1558		10.2522/ptj.20140118		12	Orthopedics; Rehabilitation	Orthopedics; Rehabilitation	CV2UM	WOS:000364112700010		
J	Okamoto, T; Nakamura, AM; Hasegawa, S				Okamoto, Takaya; Nakamura, Akiko M.; Hasegawa, Sunao			Impact experiments on highly porous targets: cavity morphology and disruption thresholds in the strength regime (vol 107, pg 36, 2015)	PLANETARY AND SPACE SCIENCE			English	Correction									[Okamoto, Takaya; Nakamura, Akiko M.] Kobe Univ, Dept Earth & Planetary Sci, Nada Ku, Kobe, Hyogo 6578501, Japan; [Hasegawa, Sunao] JAXA, Inst Space & Astronaut Sci, Tokyo, Japan	Okamoto, T (reprint author), Kobe Univ, Dept Earth & Planetary Sci, Nada Ku, 1-1 Rokkodai, Kobe, Hyogo 6578501, Japan.	tokamoto@stu.kobe-u.ac.jp					Okamoto T, 2015, PLANET SPACE SCI, V107, P36, DOI 10.1016/j.pss.2014.08.008	1	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0032-0633			PLANET SPACE SCI	Planet Space Sci.	NOV	2015	117						485	485		10.1016/j.pss.2015.03.023		1	Astronomy & Astrophysics	Astronomy & Astrophysics	CV4SS	WOS:000364257400042		
J	Limkul, J; Misaki, R; Kato, K; Fujiyama, K				Limkul, Juthamard; Misaki, Ryo; Kato, Ko; Fujiyama, Kazuhito			The combination of plant translational enhancers and terminator increase the expression of human glucocerebrosidase in Nicotiana benthamiana plants	PLANT SCIENCE			English	Article						Human glucocerebrosidase; Gaucher's disease; Nicotiana benthamiana; Plant-made pharmaceuticals	DEHYDROGENASE GENE FUNCTIONS; GAUCHER-DISEASE; 5'-UNTRANSLATED REGION; TRANSGENIC TOBACCO; ANTIBODIES; CELLS; THERAPY; LEVEL; YIELD	Gaucher's disease is a lysosomal storage disorder caused by mutations in the gene encoding glucocerebrosidase (GCase). It is currently treated by enzyme replacement therapy using recombinant GCase expressed in mammalian cells. Plant production systems are among the most attractive alternatives for pharmaceutical protein production due to such advantages as low-cost, high-scalability, and safety from human pathogen contamination. Because of its high biomass yield, Nicotiana benthamiana could be an economical recombinant GCase production system. In this study, a translational enhancer and suitable terminator were utilized to obtain a powerful expression system for GCase production in N. benthamiana plants. Six plasmid constructs were used. The highest activity of 44.5 units/mg protein (after subtraction of endogenous glucosidase activity of the wild-type plant) was observed in transgenic plants transformed with pAt-GC-HSP combined with a 5' untranslated region of the Arabidopsis alcohol dehydrogenase gene with the Arabidopsis heat shock protein terminator. These transgenic plant lines could pave the way to a stable plant-production system for low-cost, high-yield human GCase production. (C) 2015 Elsevier Ireland Ltd. All rights reserved.	[Limkul, Juthamard; Misaki, Ryo; Fujiyama, Kazuhito] Osaka Univ, Int Ctr Biotechnol, Suita, Osaka 5650871, Japan; [Kato, Ko] Nara Inst Sci & Technol NAIST, Grad Sch Biol Sci, Nara 6300192, Japan	Fujiyama, K (reprint author), Osaka Univ, Int Ctr Biotechnol, 2-1 Yamada Oka, Suita, Osaka 5650871, Japan.	fujiyama@icb.osaka-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology (MEXT); Ministry of Economy, Trade and Industry (METI) of Japan project, Development of Fundamental Technologies for Production of High-value Materials using Transgenic Plants	This work was supported in part by Ministry of Economy, Trade and Industry (METI) of Japan project, Development of Fundamental Technologies for Production of High-value Materials using Transgenic Plants (2006-2010) and from the Ministry of Education, Culture, Sports, Science and Technology (MEXT). This research was conducted by Juthamard Limkul in partial fulfillment of the requirements for a Ph.D. We are grateful to Dr. Hiroyuki Kajiura for cloning GCase gene and also Mr. Hirotaka Sasami and Ms. Nhung Ly Hong for preparing pNt-GC-NOS and pAt-GC-NOS used in this research.	Schmitz J, 2007, HAEMATOL-HEMATOL J, V92, P148, DOI 10.3324/haematol.11193; Wood J, 2013, DRUG DISCOV TODAY, V18, P1043, DOI 10.1016/j.drudis.2013.08.006; LIU D, 1994, P NATL ACAD SCI USA, V91, P1888, DOI 10.1073/pnas.91.5.1888; Strasser R, 2008, PLANT BIOTECHNOL J, V6, P392, DOI 10.1111/j.1467-7652.2008.00330.x; Weinreb NJ, 2004, SEMIN HEMATOL, V41, P15, DOI 10.1073/j.seminhematol.2004.07.010; INGELBRECHT ILW, 1989, PLANT CELL, V1, P671, DOI 10.1105/tpc.1.7.671; CARSWELL S, 1989, MOL CELL BIOL, V9, P4248; Jmoudiak M, 2005, BRIT J HAEMATOL, V129, P178, DOI 10.1111/j.1365-2141.2004.05351.x; Fischer R, 2003, VACCINE, V21, P820, DOI 10.1016/S0264-410X(02)00607-2; Buyel JF, 2012, BIOTECHNOL BIOENG, V109, P2575, DOI 10.1002/bit.24523; Stevens LH, 2000, PLANT PHYSIOL, V124, P173, DOI 10.1104/pp.124.1.173; O'Keefe BR, 2009, P NATL ACAD SCI USA, V106, P6099, DOI 10.1073/pnas.0901506106; GINNS EI, 1985, P NATL ACAD SCI USA, V82, P7101, DOI 10.1073/pnas.82.20.7101; BECKER D, 1992, PLANT MOL BIOL, V20, P1195, DOI 10.1007/BF00028908; Shaaltiel Y, 2007, PLANT BIOTECHNOL J, V5, P579, DOI 10.1111/j.1467-7652.2007.00263.x; Sugio T, 2008, J BIOSCI BIOENG, V105, P300, DOI 10.1263/jbb.105.300; Goldstein DA, 2004, QJM-INT J MED, V97, P705, DOI 10.1093/qjmed/hch121; Babajani G, 2012, MOL GENET METAB, V106, P323, DOI 10.1016/j.ymgme.2012.04.018; Mitsuhara I, 1996, PLANT CELL PHYSIOL, V37, P49; JEFFERSON RA, 1987, EMBO J, V6, P3901; Satoh J, 2004, J BIOSCI BIOENG, V98, P1, DOI 10.1016/S1389-1723(04)70234-0; Ramirez N, 2002, TRANSGENIC RES, V11, P61, DOI 10.1023/A:1013967705337; Twyman RM, 2013, CURR PHARM DESIGN, V19, P5486; Whaley KJ, 2011, HUM VACCINES, V7, P349, DOI 10.4161/hv.7.3.14266; Matsui T, 2012, PLANT BIOTECHNOL-NAR, V29, P319, DOI 10.5511/plantbiotechnology.12.0322a; Nagaya S, 2010, PLANT CELL PHYSIOL, V51, P328, DOI 10.1093/pcp/pcp188; He X, 2012, GLYCOBIOLOGY, V22, P492, DOI 10.1093/glycob/cwr157; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999; Ernst O., 2010, J VIS EXP, V38; Klimyuk V, 2014, CURR TOP MICROBIOL, V375, P127, DOI 10.1007/82_2012_212; Ling H., 2012, PLOS ONE; Sasaki K, 2014, PLANT BIOTECHNOL-NAR, V31, P309, DOI 10.5511/plantbiotechnology.14.0907a; Zor T, 1996, ANAL BIOCHEM, V236, P302, DOI 10.1006/abio.1996.0171	33	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0168-9452			PLANT SCI	Plant Sci.	NOV	2015	240						41	49		10.1016/j.plantsci.2015.08.018		9	Biochemistry & Molecular Biology; Plant Sciences	Biochemistry & Molecular Biology; Plant Sciences	CV4OC	WOS:000364245400004		
J	Kira, T; Omokawa, S; Akahane, M; Shimizu, T; Nakano, K; Nakanishi, Y; Onishi, T; Kido, A; Inagaki, Y; Tanaka, Y				Kira, Tsutomu; Omokawa, Shohei; Akahane, Manabu; Shimizu, Takamasa; Nakano, Kenichi; Nakanishi, Yasuaki; Onishi, Tadanobu; Kido, Akira; Inagaki, Yusuke; Tanaka, Yasuhito			Effectiveness of Bone Marrow Stromal Cell Sheets in Maintaining Random-Pattern Skin Flaps in an Experimental Animal Model	PLASTIC AND RECONSTRUCTIVE SURGERY			English	Article							MESENCHYMAL STEM-CELLS; IMPROVES CARDIAC-FUNCTION; GROWTH-FACTORS; RAT MODEL; IN-VIVO; TRANSPLANTATION; SURVIVAL		Nara Med Univ, Dept Orthoped Surg, Kashihara, Nara 6348522, Japan; Nara Med Univ, Dept Publ Hlth Hlth Management & Policy, Kashihara, Nara 6348522, Japan	Omokawa, S (reprint author), Nara Med Univ, Dept Hand Surg, 840 Shijo Cho, Kashihara, Nara 6348522, Japan.	shoheiomokawa@gmail.com			Japan Orthopaedics and Traumatology Research Foundation, Inc. [281]	This work was supported by a grant from the Japan Orthopaedics and Traumatology Research Foundation, Inc. (no. 281). The authors thank Dr. Akinori Okuda (Nara Medical University) and Dr. Fumika Kunda (Nara Medical University) for their technical assistance.	Mylotte LA, 2008, STEM CELLS, V26, P1325, DOI 10.1634/stemcells.2007-1072; Chung HM, 2009, EXPERT OPIN BIOL TH, V9, P1499, DOI 10.1517/14712590903307362; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Nagaya N, 2005, CIRCULATION, V112, P1128, DOI 10.1161/CIRCULATIONAHA.104.500447; Simman R, 2005, ANN PLAS SURG, V54, P546, DOI 10.1097/01.sap.0000158068.86576.73; Nishida K, 2004, NEW ENGL J MED, V351, P1187, DOI 10.1056/NEJMoa040455; Woodfin A, 2007, ARTERIOSCL THROM VAS, V27, P2514, DOI 10.1161/ATVBAHA.107.151456; Ding G, 2010, STEM CELLS, V28, P1829, DOI 10.1002/stem.512; Zheng Y, 2008, PLAST RECONSTR SURG, V121, P59, DOI 10.1097/01.prs.0000293877.84531.5a; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Ohashi K, 2007, NAT MED, V13, P880, DOI 10.1038/nm1576; Wei FL, 2012, J CELL PHYSIOL, V227, P3216, DOI 10.1002/jcp.24012; Ohnishi S, 2007, J MOL CELL CARDIOL, V42, P88, DOI 10.1016/j.yjmcc.2006.10.003; Kagiwada H, 2008, J TISSUE ENG REGEN M, V2, P184, DOI 10.1002/term.79; Fang TL, 2014, J RECONSTR MICROSURG, V30, P1, DOI 10.1055/s-0033-1345429; Crisostomo PR, 2008, AM J PHYSIOL-CELL PH, V294, pC675, DOI 10.1152/ajpcell.00437.2007; Shimizu T, 2006, FASEB J, V20, P708, DOI 10.1096/fj.05-4715fje; Akahane M, 2008, J TISSUE ENG REGEN M, V2, P196, DOI 10.1002/term.81; Inagaki Y, 2013, BIOMED RES INT, DOI 10.1155/2013/842192; Chen L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096161; Hung SC, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000416; Li TS, 2002, AM J PHYSIOL-HEART C, V283, pH468, DOI 10.1152/ajpheart.00261.2002; Nagaya N, 2004, AM J PHYSIOL-HEART C, V287, pH2670, DOI 10.1152/ajpheart.01071.2003; Tsai Chih-Chien, 2012, Am J Blood Res, V2, P148	24	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0032-1052	1529-4242		PLAST RECONSTR SURG	Plast. Reconstr. Surg.	NOV	2015	136	5					624E	632E				9	Surgery	Surgery	CV2OJ	WOS:000364095800001		
J	Seki, Y; Yamamoto, T; Yoshimatsu, H; Hayashi, A; Kurazono, A; Mori, M; Kato, Y; Koshima, I				Seki, Yukio; Yamamoto, Takumi; Yoshimatsu, Hidehiko; Hayashi, Akitatsu; Kurazono, Arito; Mori, Masanori; Kato, Yoichi; Koshima, Isao			The Superior-Edge-of-the-Knee Incision Method in Lymphaticovenular Anastomosis for Lower Extremity Lymphedema	PLASTIC AND RECONSTRUCTIVE SURGERY			English	Article							INDOCYANINE-GREEN-LYMPHOGRAPHY; DERMAL BACKFLOW PATTERNS; SUBCLINICAL LYMPHEDEMA; SUPERMICROSURGERY; VALVULOPLASTY		[Seki, Yukio; Yamamoto, Takumi; Yoshimatsu, Hidehiko; Hayashi, Akitatsu; Kurazono, Arito; Mori, Masanori; Kato, Yoichi; Koshima, Isao] Univ Tokyo, Dept Plast & Reconstruct Surg, Grad Sch Med, Tokyo 1138655, Japan	Seki, Y (reprint author), Univ Tokyo, Dept Plast & Reconstruct Surg, Grad Sch Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	yukioseki.pla@gmail.com					Akita S, 2013, PLAST RECONSTR SURG, V132, P1008, DOI 10.1097/PRS.0b013e31829fe12f; Yamamoto T, 2011, J PLAST RECONSTR AES, V64, P1541, DOI 10.1016/j.bjps.2011.05.025; Yamamoto T, 2011, PLAST RECONSTR SURG, V127, P1987, DOI 10.1097/PRS.0b013e31820cf5c6; Mihara M, 2014, ANN PLAS SURG, V72, P706, DOI 10.1097/SAP.0b013e31826a18b1; Yamamoto T, 2014, J PLAST RECONSTR AES, V67, P587, DOI 10.1016/j.bjps.2013.10.044; Ogata F, 2007, ANN PLAS SURG, V59, P180, DOI 10.1097/01.sap.0000253341.70866.54; Yamamoto T, 2014, ANN PLAS SURG, V72, P67, DOI 10.1097/SAP.0b013e3182605580; Chang DW, 2010, PLAST RECONSTR SURG, V126, P752, DOI 10.1097/PRS.0b013e3181e5f6a9; Yamamoto T, 2014, J PLAST RECONSTR AES, V67, pE142, DOI 10.1016/j.bjps.2013.12.045; Yamamoto T, 2013, MICROSURG, V33, P130, DOI 10.1002/micr.22040; Koshima I, 2003, J RECONSTR MICROSURG, V19, P209; Koshima I, 2000, J RECONSTR MICROSURG, V16, P437; Yamamoto T, 2014, J PLAST RECONSTR AES, V67, P432, DOI 10.1016/j.bjps.2013.09.033; Campisi C, 2007, MICROSURG, V27, P333, DOI 10.1002/micr.20346; Yamamoto T, 2011, PLAST RECONSTR SURG, V128, P941, DOI 10.1097/PRS.0b013e3182268cd9; Yamamoto T, 2014, ANN PLAS SURG, V73, P46, DOI 10.1097/SAP.0b013e31826caff1; Yoshimatsu H, 2012, J PLAST RECONSTR AES, V65, P1438, DOI 10.1016/j.bjps.2012.04.051; Yamamoto T, 2011, J PLAST RECONSTR AES, V64, P812, DOI 10.1016/j.bjps.2010.10.011; Koshima I, 1996, PLAST RECONSTR SURG, V97, P397, DOI 10.1097/00006534-199602000-00018; Yamamoto T, 2014, MICROSURG, V34, P308, DOI 10.1002/micr.22187; Yamamoto T, 2011, PLAST RECONSTR SURG, V127, P1979, DOI 10.1097/PRS.0b013e31820cf5df; International Society of Lymphology, 2009, LYMPHOLOGY, V42, P51; Nagase Takashi, 2005, Int J Clin Oncol, V10, P304, DOI 10.1007/s10147-005-0518-5; Yamaguchi K, 2012, PLAST RECONSTR SURG, V130, p233E, DOI 10.1097/PRS.0b013e3182550274; Yamamoto T, 2013, ANN PLAS SURG, V71, P538, DOI 10.1097/SAP.0b013e318250f0a0; Yamamoto T, 2014, MICROSURG, V34, P23, DOI 10.1002/micr.22115; Yamamoto T, 2011, PLAST RECONSTR SURG, V128, p314E, DOI 10.1097/PRS.0b013e3182268da8; Yamamoto T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059523; Yamamoto T, 2013, ANN PLAS SURG, V71, P591, DOI 10.1097/SAP.0b013e318255168a; Yamamoto T, 2013, J VASC SURG VENOUS L, V1, P400; Yamamoto T, 2014, ANN PLAST SURG; Yamamoto T, 2013, PLAST RECONSTR SURG, V132, p472E, DOI 10.1097/PRS.0b013e31829acdd0	32	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0032-1052	1529-4242		PLAST RECONSTR SURG	Plast. Reconstr. Surg.	NOV	2015	136	5					665E	675E				11	Surgery	Surgery	CV2OU	WOS:000364096900001		
J	Kamakura, T; Kataoka, J; Maeda, K; Teramachi, H; Mihara, H; Miyata, K; Ooi, K; Sasaki, N; Kobayashi, M; Ito, K				Kamakura, Tatsuro; Kataoka, Jiro; Maeda, Kazuhiko; Teramachi, Hideaki; Mihara, Hisayuki; Miyata, Kazuhiro; Ooi, Kouichi; Sasaki, Naomi; Kobayashi, Miyuki; Ito, Kouhei			Platelet-Rich Plasma with Basic Fibroblast Growth Factor for Treatment of Wrinkles and Depressed Areas of the Skin	PLASTIC AND RECONSTRUCTIVE SURGERY			English	Article							HYALURONIC-ACID; TISSUE AUGMENTATION; CLINICAL-TRIAL; INJECTION; REJUVENATION; SURGERY; QUALITY; FILLERS; FACE	Background: There are several treatments for wrinkles and depressed areas of the face, hands, and body. Hyaluronic acid is effective, but only for 6 months to 1 year. Autologous fat grafting may cause damage during tissue harvest. Methods: In this study, patients were injected with platelet-rich plasma plus basic fibroblast growth factor (bFGF). Platelet-rich plasma was prepared by collecting blood and extracting platelets using double centrifugation. Basic fibroblast growth factor diluted with normal saline was added to platelet-rich plasma. There were 2005 patients who received platelet-rich plasma plus bFGF therapy. Results: Of the 2005 patients treated, 1889 were female and 116 were male patients; patients had a mean age of 48.2 years. Treated areas inlcuded 1461 nasolabial folds, 437 marionette lines, 1413 nasojugal grooves, 148 supraorbital grooves, 253 midcheek grooves, 304 foreheads, 49 temples, and 282 glabellae. Results on the Global Aesthetic Improvement Scale indicated that the level of patient satisfaction was 97.3 percent and the level of investigator satisfaction was 98.4 percent. The period for the therapy's effectiveness to become apparent was an average of 65.4 days. Platelet-rich plasma plus bFGF therapy resulted in an improved grade on the Wrinkle Severity Rating Scale. Improvement was 0.55 for a Wrinkle Severity Rating Scale grade of 2, 1.13 for a Wrinkle Severity Rating Scale grade of 3, 1.82 for a Wrinkle Severity Rating Scale grade of 4, and 2.23 for a Wrinkle Severity Rating Scale grade of 5. Conclusions: Platelet-rich plasma plus bFGF is effective in treating wrinkles and depressed areas of the skin of the face and body. The study revealed that platelet-rich plasma plus bFGF is an innovative therapy that causes minimal complications. CLINCAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, IV.	[Kamakura, Tatsuro; Kataoka, Jiro; Maeda, Kazuhiko; Teramachi, Hideaki; Mihara, Hisayuki; Miyata, Kazuhiro; Ooi, Kouichi; Sasaki, Naomi; Kobayashi, Miyuki; Ito, Kouhei] Seishin Plast & Aesthet Surg Clin, Tokyo 1060032, Japan	Kamakura, T (reprint author), Seishin Plast & Aesthet Surg Clin, Minato Ku, Pyramide 2F,6-6-9 Roppongi, Tokyo 1060032, Japan.	tatsu@biyougeka.com					Shin MK, 2012, DERMATOL SURG, V38, P623, DOI 10.1111/j.1524-4725.2011.02280.x; Lim HK, 2014, J COSMET LASER THER, V16, P32, DOI 10.3109/14764172.2013.854620; Coleman SR, 2006, CLIN PLAST SURG, V33, P567, DOI 10.1016/j.cps.2006.09.002; Huang XL, 2013, EUR J DERMATOL, V23, P592, DOI 10.1684/ejd.2013.2151; Sommeling CE, 2013, J PLAST RECONSTR AES, V66, P301, DOI 10.1016/j.bjps.2012.11.009; Meduri A, 2012, J REFRACT SURG, V28, P220, DOI 10.3928/1081597X-20120103-02; Akita S, 2005, BURNS, V31, P855, DOI 10.1016/j.burns.2005.04.008; Morimoto N, 2013, TISSUE ENG PT A, V19, P1931, DOI [10.1089/ten.TEA.2012.0634, 10.1089/ten.tea.2012.0634]; Nakamura S, 2010, ANN PLAS SURG, V65, P101, DOI 10.1097/SAP.0b013e3181b0273c; Kawazoe T, 2012, CELL TRANSPLANT, V21, P601, DOI 10.3727/096368911X605538; Redaelli A, 2010, J DRUGS DERMATOL, V9, P466; Smith SR, 2010, ARCH DERMATOL RES, V302, P757, DOI 10.1007/s00403-010-1086-8; Aggarwal AK, 2014, INT ORTHOP, V38, P387, DOI 10.1007/s00264-013-2136-6; Komura M, 2014, J PEDIATR SURG, V49, P296, DOI 10.1016/j.jpedsurg.2013.11.040; Uebel CO, 2006, PLAST RECONSTR SURG, V118, P1458, DOI 10.1097/01.prs.0000239560.29172.33; Anjayani S, 2014, INT J DERMATOL, V53, P109, DOI 10.1111/ijd.12162; Na JI, 2011, DERMATOL SURG, V37, P463, DOI 10.1111/j.1524-4725.2011.01916.x; Kadouch JA, 2013, DERMATOL SURG, V39, P1474, DOI 10.1111/dsu.12313; Akita S, 2006, J BURN CARE RES, V27, P333, DOI 10.1097/01.BCR.0000216742.23127.7A; Jiang XW, 2013, OR SURG OR MED OR PA, V116, P570, DOI 10.1016/j.oooo.2013.07.003; Coleman SR, 2006, PLAST RECONSTR SURG, V118, P108; Farhi David, 2013, J Drugs Dermatol, V12, pe88	22	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0032-1052	1529-4242		PLAST RECONSTR SURG	Plast. Reconstr. Surg.	NOV	2015	136	5					931	939		10.1097/PRS.0000000000001705		9	Surgery	Surgery	CV2MW	WOS:000364091800001		
J	Rho, NK; Chang, YY; Chao, YYY; Furuyama, N; Huang, PYC; Kerscher, M; Kim, HJ; Park, JY; Peng, HLP; Rummaneethorn, P; Rzany, B; Sundaram, H; Wong, CH; Yang, YL; Prasetyo, AD				Rho, Nark-Kyoung; Chang, Yao-Yuan; Chao, Yates Yen-Yu; Furuyama, Nobutaka; Huang, Peter Y. C.; Kerscher, Martina; Kim, Hee-Jin; Park, Je-Young; Peng, Hsien Li Peter; Rummaneethorn, Paisal; Rzany, Berthold; Sundaram, Hema; Wong, Chin Ho; Yang, Yuli; Prasetyo, Adri Dwi			Consensus Recommendations for Optimal Augmentation of the Asian Face with Hyaluronic Acid and Calcium Hydroxylapatite Fillers	PLASTIC AND RECONSTRUCTIVE SURGERY			English	Article							SOFT-TISSUE LOSS; NASOLABIAL FOLDS; DERMAL FILLER; CLINICAL-IMPLICATIONS; NONANIMAL ORIGIN; HAND REJUVENATION; COSMETIC FILLER; VISUAL-LOSS; SPLIT-FACE; SKIN	Background: Although the use of filling agents for soft-tissue augmentation has increased worldwide, most consensus statements do not distinguish between ethnic populations. There are, however, significant differences between Caucasian and Asian faces, reflecting not only cultural disparities, but also distinctive treatment goals. Unlike aesthetic patients in the West, who usually seek to improve the signs of aging, Asian patients are younger and request a broader range of indications. Methods: Members of the Asia-Pacific Consensus groupcomprising specialists from the fields of dermatology, plastic surgery, anatomy, and clinical epidemiologyconvened to develop consensus recommendations for Asians based on their own experience using cohesive polydensified matrix, hyaluronic acid, and calcium hydroxylapatite fillers. Results: The Asian face demonstrates differences in facial structure and cosmetic ideals. Improving the forward projection of the T zone (i.e., forehead, nose, cheeks, and chin) forms the basis of a safe and effective panfacial approach to the Asian face. Successful augmentation may be achieved with both (1) high- and low-viscosity cohesive polydensified matrix/hyaluronic acid and (2) calcium hydroxylapatite for most indications, although some constraints apply. Conclusion: The Asia-Pacific Consensus recommendations are the first developed specifically for the use of fillers in Asian populations. CLINCIAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, V.	Yonsei Univ, Leaders Clin, Oracle Derm Clin, Seoul 120749, South Korea; Rebecca Cosmet Ctr, L1 Cosmet Surg & Laser Ctr, Lake Mary, FL USA; Jiyugaoka Clin, Obihiro, Hokkaido, Japan; Univ Hamburg, Hamburg, Germany; Rzany & Hund, Berlin, Germany; Pinklao Clin, Bangkok, Thailand; Sundaram Dermatol Cosmet & Laser Surg, Rockville, MD USA; W Aesthet Plast Surg, Singapore, Singapore; Rejuva Skin & Beauty, Brookfield, CT 06804 USA	Rho, NK (reprint author), Leaders Aesthet Laser & Cosmet Surg Ctr, Class 500 Bldg 90,Neungdong Ro, Seoul 143854, South Korea.	rhonark@hanmail.net					Jung W, 2014, DERMATOL SURG, V40, P618, DOI 10.1111/dsu.0000000000000004; Wang F, 2007, ARCH DERMATOL, V143, P155, DOI 10.1001/archderm.143.2.155; Ledon J, 2013, AM J CLIN DERMATOL, V14, P401, DOI 10.1007/s40257-013-0043-7; Rzany B, 2013, HAUTARZT, V64, P163, DOI 10.1007/s00105-012-2485-x; Roberts SAI, 2012, OPHTHAL PLAST RECONS, V28, pE68, DOI 10.1097/IOP.0b013e3182288e4d; Carruthers JDA, 2014, PLAST RECONSTR SURG, V134, P1197, DOI 10.1097/PRS.0000000000000754; Wysong A, 2014, DERMATOL SURG, V40, P786, DOI 10.1111/dsu.0000000000000035; Berlin AL, 2008, DERMATOL SURG, V34, pS64, DOI 10.1111/j.1524-4725.2008.34245.x; Bardazzi F, 2007, J DERMATOL TREAT, V18, P59, DOI 10.1080/09546630601121052; GHERSETICH I, 1994, INT J DERMATOL, V33, P119, DOI 10.1111/j.1365-4362.1994.tb01540.x; Taieb M, 2012, J COSMET DERMATOL-US, V11, P87, DOI 10.1111/j.1473-2165.2012.00608.x; Moulonguet I, 2013, AM J DERMATOPATH, V35, pE37, DOI 10.1097/DAD.0b013e3182732324; Prager W, 2012, DERMATOL SURG, V38, P1143, DOI 10.1111/j.1524-4725.2012.02468.x; Kuhne U, 2012, J DRUGS DERMATOL, V11, P1032; Borrell M, 2011, J COSMET LASER THER, V13, P21, DOI 10.3109/14764172.2011.552609; Tzikas TL, 2008, DERMATOL SURG, V34, pS9, DOI 10.1111/j.1524-4725.2008.34237.x; Marmur E, 2010, DERMATOL SURG, V36, P309, DOI 10.1111/j.1524-4725.2009.01435.x; Yutskovskaya Y, 2014, J DRUGS DERMATOL, V13, P1047; Williams S, 2009, J COSMET DERMATOL-US, V8, P216, DOI 10.1111/j.1473-2165.2009.00447.x; Busso M, 2010, DERMATOL SURG, V36, P790, DOI 10.1111/j.1524-4725.2010.01568.x; Wysong A, 2013, DERMATOL SURG, V39, P1895, DOI 10.1111/dsu.12362; Park SW, 2012, AM J OPHTHALMOL, V154, P653, DOI 10.1016/j.ajo.2012.04.019; Ahn BK, 2013, DERMATOL SURG, V39, P1843, DOI 10.1111/dsu.12317; Alijotas-Reig J, 2013, SEMIN ARTHRITIS RHEU, V43, P241, DOI 10.1016/j.semarthrit.2013.02.001; Lazzeri D, 2012, PLAST RECONSTR SURG, V129, P995, DOI 10.1097/PRS.0b013e3182442363; Prager W, 2010, EUR J DERMATOL, V20, P748, DOI 10.1684/ejd.2010.1085; Narins RS, 2011, DERMATOL SURG, V37, P644, DOI 10.1111/j.1524-4725.2010.01863.x; Kim DW, 2011, J PLAST RECONSTR AES, V64, P1590, DOI 10.1016/j.bjps.2011.07.013; Rohrich RJ, 2007, PLAST RECONSTR SURG, V119, P2219, DOI 10.1097/01.prs.0000265403.66886.54; Lee A, 2010, DERMATOL SURG, V36, P1071, DOI 10.1111/j.1524-4725.2010.01585.x; Sung MS, 2010, OPHTHAL PLAST RECONS, V26, P289, DOI 10.1097/IOP.0b013e3181bd4341; Fabi SG, 2012, DERMATOL SURG, V38, P1112, DOI 10.1111/j.1524-4725.2011.02291.x; Bidic SM, 2010, PLAST RECONSTR SURG, V126, P163, DOI 10.1097/PRS.0b013e3181da86ee; Narins RS, 2010, DERMATOL SURG, V36, P730, DOI 10.1111/j.1524-4725.2010.01553.x; Wong WW, 2010, J PLAST RECONSTR AES, V63, P2032, DOI 10.1016/j.bjps.2009.12.015; Schunemann HJ, 2006, AM J RESP CRIT CARE, V174, P605, DOI 10.1164/rccm.200602-197ST; Yang HM, 2014, PLAST RECONSTR SURG, V133, P1077, DOI 10.1097/PRS.0000000000000099; Sadick NS, 2011, J DRUGS DERMATOL, V10, P47; Hayreh SS, 1997, AM J OPHTHALMOL, V124, P641; Kerscher M, 2008, DERMATOL SURG, V34, P720, DOI 10.1111/j.1524-4725.2008.34176.x; Ozturk CN, 2013, AESTHET SURG J, V33, P862, DOI 10.1177/1090820X13493638; Daley T, 2012, OR SURG OR MED OR PA, V114, P107, DOI 10.1016/j.oooo.2012.03.012; Reuther T, 2010, ARCH DERMATOL RES, V302, P37, DOI 10.1007/s00403-009-0988-9; Weindl G, 2004, SKIN PHARMACOL PHYSI, V17, P207, DOI 10.1159/000080213; Broer PN, 2014, J CRANIOFAC SURG, V25, pE157, DOI 10.1097/SCS.0000000000000406; Haddock NT, 2009, PLAST RECONSTR SURG, V123, P1332, DOI 10.1097/PRS.0b013e31819f2b36; Park TH, 2011, J PLAST RECONSTR AES, V64, P892, DOI 10.1016/j.bjps.2011.01.008; Batniji Rami K, 2010, Facial Plast Surg Clin North Am, V18, P19, DOI 10.1016/j.fsc.2009.11.015; Beer Kenneth, 2012, J Clin Aesthet Dermatol, V5, P44; Busso M, 2008, DERMATOL SURG S1, V34, pS24; Busso M, 2013, SOFT TISSUE AUGMENTA, P81; Busso M, 2008, DERMATOL SURG, V34, pS16, DOI 10.1111/j.1524-4725.2008.34238.x; Cassuto D, 2013, PLAST RECONSTR SURG, V132, p48S, DOI 10.1097/PRS.0b013e31829e52a7; Coleman Sydney R, 2002, Aesthet Surg J, V22, P555, DOI 10.1067/maj.2002.129625; Distante F, 2009, DERMATOL SURG, V35, P389, DOI 10.1111/j.1524-4725.2008.01051.x; Distante F, 2009, DERMATOL SURG S1, V35, P394; Fried Isabella, 2011, J Cutan Pathol, V38, P261, DOI 10.1111/j.1600-0560.2010.01658_2.x; Funt David, 2013, Clin Cosmet Investig Dermatol, V6, P295, DOI 10.2147/CCID.S50546; Glashofer MD, 2013, SOFT TISSUE AUGMENTA, P179; Graivier MH, 2007, PLAST RECONSTR SURG, V120, p55S, DOI 10.1097/01.prs.0000285109.34527.b9; Hilinski JM, 2009, FACIAL REJUVENATION, P77; Hirsch Ranelle J, 2007, J Cosmet Laser Ther, V9, P182, DOI 10.1080/14764170701291674; Kim MM, 2007, FACIAL PLAST SURG CL, V15, pvii; Kim Michael M, 2007, Facial Plast Surg Clin North Am, V15, P381, DOI 10.1016/j.fsc.2007.04.007; Lam SM, 2007, FACIAL PLAST SURG CL, V15, pv; Lam Samuel M, 2007, Facial Plast Surg Clin North Am, V15, P283, DOI 10.1016/j.fsc.2007.04.006; Lee SK, 2011, J KOREAN SOC AESTHET, V3, P17; Marmur Ellen S, 2004, J Cosmet Laser Ther, V6, P223, DOI 10.1080/147641704100003048; Pavicic T, 2013, J DRUGS DERMATOL, V12, P996; Seo KK-II, 2012, SOFT TISSUE AUGMENTA, P112; Streker M, 2013, J DRUGS DERMATOL, V12, P990; Sundaram H, 2013, PLAST RECONSTR SURG, V132, P5; Tsukahara Kazue, 2004, J Cosmet Sci, V55, P351; Waldorf HA, 2013, SOFT TISSUE AUGMENTA, P155	74	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0032-1052	1529-4242		PLAST RECONSTR SURG	Plast. Reconstr. Surg.	NOV	2015	136	5					940	956		10.1097/PRS.0000000000001706		17	Surgery	Surgery	CV2MW	WOS:000364091800002		
J	Fujita, M				Fujita, Masahiro			Toward Unification of Synthesis and Verification in Topologically Constrained Logic Design	PROCEEDINGS OF THE IEEE			English	Article						Automatic test pattern generation; circuit synthesis; formal verification; logic circuits		In logic synthesis, the search space is infinite in the sense that any number of gates can be connected using any topology to come up with the best circuit under performance and other constraints. In formal verification, to achieve full coverage, an n-input circuit must be checked either explicitly or implicitly using the complete set of 2(n) input values. There are, however, situations when the possible circuit topologies are limited. Logic optimization methods, in general, do not change circuit topologies dramatically. Most of them are based on series of local circuit transformations. In this paper, we discuss formal verification of circuits produced by logic synthesis where the search space is limited, and only gates or subcircuits are transformed whereas their interconnections never change. If there are p possible transformations for each gate or subcircuit, and there are m gates or subcircuits in the entire circuit, the number of all possible transformations for the entire circuit is p(m). Logic synthesis with this restriction attempts to find the best circuit among the p(m) alternatives. The logic synthesis problem can be formulated as a sequence of incremental SAT problems and the complete set of test patterns can be computed, which detects all possible errors in the synthesized circuit. As long as the search space is limited to the p(m) alternatives, such complete set of test patterns can be used for formal verification. The number of test patterns needed in this case is experimentally shown to be very small, e.g., a few hundred, even for circuits having several hundred inputs and several thousand gates. With the complete set of test patterns generated for the circuit transformations, logic synthesis and formal verification are unified in the sense that the small number of test patterns allows for logic synthesis with 100% correctness.	Univ Tokyo, Tokyo 1130032, Japan	Fujita, M (reprint author), Univ Tokyo, Tokyo 1130032, Japan.	fujita@ee.t.u-tokyo.ac.jp					LIN CC, 1995, DES AUT CON, P647, DOI 10.1109/DAC.1995.250044; [Anonymous], 2005, THEORY APPL SATISFIA, DOI 10.1007/11499107_37; [Anonymous], 2013, P INT C COMP AID DES; Biere A., 2008, J SATISFIABILITY BOO, V4, P75; Brayton R. K., 2010, P 22 INT C COMP AID, P24; Brayton R. K., 1996, P 8 INT C COMP AID V, P428; Fujita M., 2014, P INT TEST C OCT; Fujita M., 2014, P 22 INT C VER LARG, DOI [10.1109/VLSI-SoC.2014.7004155, DOI 10.1109/VLSI-S0C.2014.7004155]; Janota M., 2012, THEORY APPL SATISFIB, V7317, P114; Jha S., 2010, P 32 ACM IEEE INT C, P215; Jiang Jie-Hong R, 2009, Proceedings of the 2009 IEEE/ACM International Conference on Computer-Aided Design (ICCAD 2009), DOI 10.1145/1687399.1687544; Jo S., 2012, P AS TEST S NOV, P19; Lai C.-F., 2010, P DAC, P499, DOI 10.1145/1837274.1837398; Lin H.-P., 2008, P INT C COMP AID DES, P32; Mishchenko A., 2012, P INT C COMP AID DES, P557; Seshia S. A., 2012, P DES AUT C JUN, P356; Sinha S., 2002, P INT C COMP AID DES, P679, DOI 10.1145/774572.774672; Solar-Lezama A., 2012, P 12 INT C ARCH SUPP, P404	18	0	0	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	0018-9219	1558-2256		P IEEE	Proc. IEEE	NOV	2015	103	11			SI		2052	2060		10.1109/JPROC.2015.2476472		9	Engineering, Electrical & Electronic	Engineering	CV1QE	WOS:000364032300010		
J	Yamada, N; Theerawitaya, C; Kageyama, H; Cha-um, S; Takabe, T				Yamada, Nana; Theerawitaya, Cattarin; Kageyama, Hakuto; Cha-um, Suriyan; Takabe, Teruhiro			Expression of developmentally regulated plasma membrane polypeptide (DREPP2) in rice root tip and interaction with Ca2+/CaM complex and microtubule	PROTOPLASMA			English	Article						Ca2+-binding protein; Calmodulin; Cell elongation; DREPP; Microtubule; Oryza sativa; Salt stress	DESTABILIZING CORTICAL MICROTUBULES; CATION-BINDING PROTEIN; PHOSPHATIDYLINOSITOL PHOSPHATES; ARABIDOPSIS; CALMODULIN; SPECIFICITY; TRANSDUCER; MECHANISM; GROWTH; PCAP2	The cytoplasmic free Ca2+ could play an important role for salt tolerance in rice root (Oryza sativa L.). Here, we compared the expression profiles of two putative developmentally regulated plasma membrane polypeptides (DREPP1 and DREPP2) in rice roots of salt-tolerant cv. Pokkali and salt-sensitive cv. IR29. The messenger RNA (mRNA) for OsDREPP1 could be detected in all parts of root and did not change upon salt stress, whereas the mRNA for OsDREPP2 was detected only in root tips. The transcript level of OsDREPP2 first disappeared upon salt stress, then recovered in Pokkali, but not recovered in IR29. The gene-encoding OsDREPP2 was cloned from cv. Pokkali and expressed in Escherichia coli, and its biochemical properties were studied. It was found that OsDREPP2 is a Ca2+-binding protein and binds also to calmodulin (CaM) as well as microtubules. The mutation of Trp4 and Phe16 in OsDREPP2 to Ala decreased the binding of DREPP2 to Ca2+/CaM complex, indicating the N-terminal basic domain is involved for the binding. The binding of OsDREPP2 to microtubules was inhibited by Ca2+/CaM complex, while the binding of double-mutant OsDREPP2 protein to microtubules was not inhibited by Ca2+/CaM complex. We propose that CaM inhibits the binding of DREPP2 to cortical microtubules, causes the inhibition of microtubule depolymerization, and enhances the cell elongation.	[Yamada, Nana; Theerawitaya, Cattarin; Cha-um, Suriyan] BIOTEC, Plant Physiol & Biochem Lab, Pathum Thani 12120, Thailand; [Kageyama, Hakuto; Takabe, Teruhiro] Meijo Univ, Grad Sch Environm & Human Sci, Nagoya, Aichi 4688502, Japan; [Takabe, Teruhiro] Meijo Univ, Res Inst, Tenpaku Ku, Nagoya, Aichi 4688502, Japan	Takabe, T (reprint author), Meijo Univ, Res Inst, Tenpaku Ku, Nagoya, Aichi 4688502, Japan.	takabe@meijo-u.ac.jp			National Science and Technology Development Agency (NSTDA), Thailand; JSPS Invitation Fellowship Program for Research in Japan; Ministry of Education, Science and Culture of Japan; International Center for Green Biotechnology of Meijo University	This work was supported by postdoctoral program of the National Science and Technology Development Agency (NSTDA), Thailand, to NY and JSPS Invitation Fellowship Program for Research in Japan to SC. This work was also partially granted by Grants-in-Aid for Scientific Research from the Ministry of Education, Science and Culture of Japan and the International Center for Green Biotechnology of Meijo University. The authors declare that they have no conflict of interest.	Pittman JK, 2011, CELL CALCIUM, V50, P139, DOI 10.1016/j.ceca.2011.01.004; Wang X, 2007, PLANT CELL, V19, P877, DOI 10.1105/tpc.106.048579; Ide Y, 2007, J EXP BOT, V58, P1173, DOI 10.1093/jxb/erl284; Kato M, 2013, PLANT J, V74, P690, DOI 10.1111/tpj.12155; Yamada N, 2011, J PLANT PHYSIOL, V168, P1609, DOI 10.1016/j.jplph.2011.03.007; Tidow H, 2012, NATURE, V491, P468, DOI 10.1038/nature11539; Gantet P, 1996, BIOCHEM MOL BIOL INT, V40, P469; Waditee R, 2005, P NATL ACAD SCI USA, V102, P1318, DOI 10.1073/pnas.0409017102; Castoldi M, 2003, PROTEIN EXPRES PURIF, V32, P83, DOI 10.1016/S1046-5928(03)00218-3; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Yamada N, 2014, PROTOPLASMA, V251, P1067, DOI 10.1007/s00709-014-0615-2; Huda KMK, 2013, J EXP BOT, V64, P3099, DOI 10.1093/jxb/ert182; Nagasaki N, 2008, FEBS J, V275, P2267, DOI 10.1111/j.1742-4658.2008.06379.x; Kato M, 2010, PLANT CELL PHYSIOL, V51, P366, DOI 10.1093/pcp/pcq003; Khush GS, 2005, PLANT MOL BIOL, V59, P1, DOI 10.1007/s11103-005-2159-5; Mao TL, 2005, PLANT PHYSIOL, V138, P654, DOI 10.1104/pp.104.052456; Yuasa K, 2001, PLANT MOL BIOL, V47, P633, DOI 10.1023/A:1012355205991; Li JJ, 2011, PLANT CELL, V23, P4411, DOI 10.1105/tpc.111.092684; CAMPBELL KP, 1983, J BIOL CHEM, V258, P1267; Cha-um S., 2012, Australian Journal of Crop Science, V6, P176; Kato Mariko, 2010, Plant Signal Behav, V5, P848, DOI 10.1093/pcp/pcq003.; [Anonymous], 1962, PHYSIOL PLANTARUM, DOI DOI 10.1111/J.1399-3054.1962.TB08052.X; Bose J, 2011, FRONT PLANT SCI, V2, DOI 10.3389/fpls.2011.00085; Tuteja Narendra, 2007, Plant Signal Behav, V2, P79, DOI 10.4161/psb.2.2.4176	24	0	0	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0033-183X	1615-6102		PROTOPLASMA	Protoplasma	NOV	2015	252	6					1519	1527		10.1007/s00709-015-0781-x		9	Plant Sciences; Cell Biology	Plant Sciences; Cell Biology	CV0QV	WOS:000363957200010		
J	Hatta, K				Hatta, Kotaro			Practical pharmacotherapy for acute schizophrenia patients	PSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Review						antipsychotic; augmentation; early response; high dose; switching	ACUTE-PHASE SCHIZOPHRENIA; RANDOMIZED CONTROLLED-TRIALS; OPEN-LABEL TRIAL; ANTIPSYCHOTIC RESPONSE; 1ST-EPISODE SCHIZOPHRENIA; EARLY PREDICTION; DOUBLE-BLIND; EARLY IMPROVEMENT; 2ND-GENERATION ANTIPSYCHOTICS; SCHIZOAFFECTIVE DISORDER	Well-organized clinical guidelines of pharmacotherapy for schizophrenia are not necessarily applicable to emergency and acute-phase situations. Thus, practical pharmacotherapy for acute schizophrenia patients should be based on data from real clinical practice and be independent of pharmaceutical companies. This study investigated the current guidelines being used to determine the initially preferred antipsychotics, durations required before an antipsychotic is viewed as being ineffective, and the strategies utilized for early non-responders that include switching, high dose, and augmentation. In patients who develop side-effects to the preferred antipsychotic drug, continued use may depend on the specific characteristics of the side-effects. For acute-phase patients, antipsychotics with high efficacy and effectiveness may be chosen based on meta-analysis findings for not only double-blinded but also rater-blinded randomized controlled trials. Many previous studies have reported being able to make an early prediction at 2 weeks regarding the later response. These predictions were supported by the findings of a recent meta-analysis of 34 studies that examined 9975 participants. In early non-responders to the initial antipsychotic, the effectiveness of the switching strategy appears to depend on the initial antipsychotic administered and the antipsychotic the patient is subsequently switched to. Furthermore, the effectiveness of the strategy between switching and augmentation might also depend on the initial antipsychotic administered. The current findings might serve as the basis for the use of dosing above the licensed range versus continuing the use of conventional dosing in non-responders, provided there is close monitoring of the side-effects. Further research is required before any modifications of routine practices are undertaken regarding the direction of new potential treatments.	[Hatta, Kotaro] Juntendo Univ, Nerima Hosp, Dept Psychiat, Tokyo 1778521, Japan	Hatta, K (reprint author), Juntendo Univ, Nerima Hosp, Dept Psychiat, Nerima Ku, Takanodai 3-1-10, Tokyo 1778521, Japan.	khatta@juntendo.ac.jp					Molina JD, 2011, PHARMACOPSYCHIATRY, V44, P142, DOI 10.1055/s-0031-1279728; Mitchell M, 2006, CLIN THER, V28, P881, DOI 10.1016/j.clinthera.2006.06.008; Takahashi H, 2006, J CLIN PSYCHIAT, V67, P1577; Stauffer VL, 2011, PSYCHIAT RES, V187, P42, DOI 10.1016/j.psychres.2010.11.017; Lieberman JA, 2005, NEW ENGL J MED, V353, P1209, DOI 10.1056/NEJMoa051688; Gardner DM, 2010, AM J PSYCHIAT, V167, P686, DOI 10.1176/appi.ajp.2009.09060802; Lipscombe LL, 2014, SCHIZOPHR RES, V154, P54, DOI 10.1016/j.schres.2014.01.043; Leucht S, 2013, LANCET, V382, P951, DOI 10.1016/S0140-6736(13)60733-3; Heres S, 2006, AM J PSYCHIAT, V163, P185, DOI 10.1176/appi.ajp.163.2.185; Lindenmayer JP, 2011, J CLIN PSYCHOPHARM, V31, P160, DOI 10.1097/JCP.0b013e31820f4fe0; Derks EM, 2010, J CLIN PSYCHOPHARM, V30, P176, DOI 10.1097/JCP.0b013e3181d2193c; Peng M, 2013, PSYCHOPHARMACOLOGY, V228, P577, DOI 10.1007/s00213-013-3060-6; Findling RL, 2013, J CHILD ADOL PSYCHOP, V23, P490, DOI 10.1089/cap.2012.0092; Hatta K, 2014, SCHIZOPHR RES, V158, P213, DOI 10.1016/j.schres.2014.07.015; Citrome L, 2005, J CLIN PSYCHIAT, V66, P1512; Citrome L, 2009, J CLIN PSYCHIAT, V70, P975; Kinon BJ, 2008, J CLIN PSYCHOPHARM, V28, P392, DOI 10.1097/JCP.0b013e31817e63a5; Correll CU, 2008, J CLIN PSYCHIAT, V69, P860; Kane JM, 2009, J CLIN PSYCHIAT, V70, P1348, DOI 10.4088/JCP.09m05154yel; Hatta K, 2012, PSYCHIAT RES, V198, P194, DOI 10.1016/j.psychres.2012.01.006; Chang YC, 2006, J CLIN PSYCHOPHARM, V26, P554, DOI 10.1097/01.jcp.0000246211.95905.8c; Citrome L, 2007, PSYCHIAT SERV, V58, P11, DOI 10.1176/appi.ps.58.1.11; Kim JH, 2013, J CLIN PSYCHOPHARM, V33, P69, DOI 10.1097/JCP.0b013e31827d14e3; Levine SZ, 2012, SCHIZOPHR RES, V141, P168, DOI 10.1016/j.schres.2012.08.030; Agid O, 2013, EUR NEUROPSYCHOPHARM, V23, P842, DOI 10.1016/j.euroneuro.2012.10.005; Jager M, 2009, EUR PSYCHIAT, V24, P501, DOI 10.1016/j.eurpsy.2009.02.005; Kinon BJ, 2010, NEUROPSYCHOPHARMACOL, V35, P581, DOI 10.1038/npp.2009.164; Schennach R, 2013, ACTA PSYCHIAT SCAND, V127, P474, DOI 10.1111/acps.12006; Lambert M, 2009, PHARMACOPSYCHIATRY, V42, P277, DOI 10.1055/s-0029-1234105; Giegling I, 2012, NEUROPSYCHOBIOLOGY, V66, P100, DOI 10.1159/000337739; Hatta K, 2009, SCHIZOPHR RES, V113, P49, DOI 10.1016/j.schres.2009.05.030; Hatta K, 2013, PSYCHIAT RES, V210, P396, DOI 10.1016/j.psychres.2013.07.005; Agid O, 2013, EUR NEUROPSYCHOPHARM, V23, P1017, DOI 10.1016/j.euroneuro.2013.04.010; Heres S, 2014, PROG NEURO-PSYCHOPH, V48, P207, DOI 10.1016/j.pnpbp.2013.09.015; O'Gorman C, 2011, HUM PSYCHOPHARM CLIN, V26, P282, DOI 10.1002/hup.1200; Park JI, 2014, INT CLIN PSYCHOPHARM, V29, P77, DOI 10.1097/YIC.0000000000000005; Gallego JA, 2011, J CLIN PSYCHIAT, V72, P1691, DOI 10.4088/JCP.10m06349; Schennach-Wolff R, 2010, BRIT J PSYCHIAT, V196, P460, DOI 10.1192/bjp.bp.109.069328; Takahashi H, 2006, PROG NEURO-PSYCHOPH, V30, P1067, DOI 10.1016/j.pnpbp.2006.03.041; Kane JM, 2008, SCHIZOPHRENIA BULL, V34, P302, DOI 10.1093/schbul/sbm143; Mencacci C, 2012, PHARMACOPSYCHIATRY, V45, P236, DOI 10.1055/s-0032-1301884; Zarin DA, 2005, SOC PSYCH PSYCH EPID, V40, P27, DOI 10.1007/s00127-005-0838-9; Correll CU, 2009, SCHIZOPHRENIA BULL, V35, P443, DOI 10.1093/schbul/sbn018; Correll CU, 2013, J AM ACAD CHILD PSY, V52, P689, DOI 10.1016/j.jaac.2013.04.018; Hatta K, 2011, SCHIZOPHR RES, V128, P127, DOI 10.1016/j.schres.2011.02.011; Ascher-Svanum H, 2011, BMC PSYCHIATRY, V11, DOI 10.1186/1471-244X-11-152; Chan HY, 2013, J CLIN PSYCHOPHARM, V33, P747, DOI 10.1097/JCP.0b013e31829e8168; Correll CU, 2003, AM J PSYCHIAT, V160, P2063, DOI 10.1176/appi.ajp.160.11.2063; Essock AJP, 2011, AM J PSYCHIAT, V168, P702; Samara MT, 2015, AM J PSYCHIAT	50	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-1316	1440-1819		PSYCHIAT CLIN NEUROS	Psychiatry Clin. Neurosci.	NOV	2015	69	11					674	685		10.1111/pcn.12325		12	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	CU9UR	WOS:000363891900002		
J	Yoshida, Y; Iwasa, H; Kumagai, S; Suzuki, T; Awata, S; Yoshida, H				Yoshida, Yuko; Iwasa, Hajime; Kumagai, Shu; Suzuki, Takao; Awata, Shuichi; Yoshida, Hideyo			Longitudinal association between habitual physical activity and depressive symptoms in older people	PSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article						community-dwelling older adults; depression symptoms; longitudinal study; physical activity	INFLAMMATORY MARKERS; BODY-COMPOSITION; ADULTS; HEALTH; POPULATION; DISORDERS; TAIWANESE; EXERCISE; DECLINE; ANXIETY	AimsPrevention of depressive symptoms is an essential issue with regard to the promotion of healthy lifestyles in older people. To date, few studies have examined the relation between fluctuations in physical activity and depression among older individuals. We thus conducted a longitudinal survey of older adults to examine the effect of long-term fluctuating physical activity on the incidence of depressive symptoms. MethodsA 3-year prospective cohort study was performed in a community-based environment. A total of 680 individuals (291 men and 389 women) aged 65 years and over at the baseline assessment participated. The 15-item Geriatric Depression Scale was used to assess depressive symptoms, with scores of 6 indicative of depression. Participants were categorized into the following four groups based on change in physical activity status between 2002 and 2003: sedentary, cessation, initiation, and maintenance. ResultsThe incidence of depressive symptoms was 16.9% (16.8% in men and 17.0% in women) at the 3-year follow up (in 2006). Multiple logistic regression analyses showed that physical activity maintenance (odds ratio, 0.50; 95% confidence interval, 0.30-0.83) only reduced the incidence of depressive symptoms at the 3-year follow up after adjusting for confounding variables. ConclusionsContinuous physical activity may be a valuable and simple way to prevent depressive symptoms in community-dwelling older people. Therefore, it is necessary to implement interventions that teach older adults how to integrate physical activity into their daily lives.	[Yoshida, Yuko; Iwasa, Hajime; Awata, Shuichi; Yoshida, Hideyo] Tokyo Metropolitan Inst Gerontol, Tokyo, Japan; [Iwasa, Hajime] Fukushima Med Univ, Sch Med, Dept Publ Hlth, Fukushima 9601295, Japan; [Kumagai, Shu] Univ Human Arts & Sci, Saitama, Japan; [Suzuki, Takao] Natl Ctr Geriatr & Gerontol, Obu, Aichi, Japan	Iwasa, H (reprint author), Fukushima Med Univ, Sch Med, Dept Publ Hlth, 1 Hikarigaoka, Fukushima 9601295, Japan.	hajimei@fmu.ac.jp			Tokyo Metropolitan Institute of Gerontology; International Life Sciences Institute of Japan;  [24590835]	The authors are grateful to the participants and the municipal employees and staff who participated in this study. The authors declare no potential conflicts of interest with respect to the authorship or publication of this paper. This work was supported by grants from the Tokyo Metropolitan Institute of Gerontology and the International Life Sciences Institute of Japan and a Grant-in-Aid for Scientific Research C (24590835).	Jacka FN, 2011, PSYCHOSOM MED, V73, P483, DOI 10.1097/PSY.0b013e318222831a; Isaac V, 2009, AM J GERIAT PSYCHIAT, V17, P688, DOI 10.1097/JGP.0b013e3181a88441; Iwasa H, 2009, INT J GERIATR PSYCH, V24, P1192, DOI 10.1002/gps.2245; Schoevers RA, 2009, INT J GERIATR PSYCH, V24, P169, DOI 10.1002/gps.2088; Strawbridge WJ, 2002, AM J EPIDEMIOL, V156, P328, DOI 10.1093/aje/kwf047; Lindwall M, 2011, HEALTH PSYCHOL, V30, P453, DOI 10.1037/a0023268; Schreiner AS, 2003, INT J GERIATR PSYCH, V18, P498, DOI 10.1002/gps.880; Potvin O, 2011, J AM GERIATR SOC, V59, P1421, DOI 10.1111/j.1532-5415.2011.03521.x; Shiovitz-Ezra S, 2012, SOC SCI MED, V75, P901, DOI 10.1016/j.socscimed.2012.04.031; KOYANO W, 1991, ARCH GERONTOL GERIAT, V13, P103, DOI 10.1016/0167-4943(91)90053-S; Golden J, 2009, INT J GERIATR PSYCH, V24, P694, DOI 10.1002/gps.2181; Penninx BWJH, 1998, JAMA-J AM MED ASSOC, V279, P1720, DOI 10.1001/jama.279.21.1720; Tsai AC, 2013, PREV MED, V57, P92, DOI 10.1016/j.ypmed.2013.04.021; Cordova C, 2011, NEUROIMMUNOMODULAT, V18, P165, DOI 10.1159/000323396; Weyerer S, 2013, AGE AGEING, V42, P173, DOI 10.1093/ageing/afs184; Wilson RS, 2004, J NEUROL NEUROSUR PS, V75, P126; Niu KJ, 2009, AM J CLIN NUTR, V90, P1615, DOI 10.3945/ajcn.2009.28216; Colbert LH, 2004, J AM GERIATR SOC, V52, P1098, DOI 10.1111/j.1532-5415.2004.52307.x; Smith TL, 2010, J AM GERIATR SOC, V58, P1447, DOI 10.1111/j.1532-5415.2010.02981.x; Nicklas BJ, 2008, J AM GERIATR SOC, V56, P2045, DOI 10.1111/j.1532-5415.2008.01994.x; Chen LJ, 2012, INT J BEHAV NUTR PHY, V9, DOI 10.1186/1479-5868-9-28; Garfield LD, 2014, PSYCHOSOM MED, V76, P128, DOI 10.1097/PSY.0000000000000027; Heesch Kristiann C, 2011, J Epidemiol Community Health, V65, P807, DOI 10.1136/jech.2009.103077; Niino N., 1991, CLIN GERONTOL, V10, P85; Penninx BWJH, 2003, BIOL PSYCHIAT, V54, P566, DOI 10.1016/S0006-3223(03)01811-5; Yoshida Y, 2006, JPN J GERONTOL, V28, P348	26	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-1316	1440-1819		PSYCHIAT CLIN NEUROS	Psychiatry Clin. Neurosci.	NOV	2015	69	11					686	692		10.1111/pcn.12324		7	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	CU9UR	WOS:000363891900003		
J	Miyaoka, T; Ieda, M; Hashioka, S; Wake, R; Furuya, M; Liaury, K; Hayashida, M; Tsuchie, K; Arauchi, R; Araki, T; Shioji, I; Ezoe, S; Inoue, K; Yamaguchi, T; Horiguchi, J				Miyaoka, Tsuyoshi; Ieda, Masa; Hashioka, Sadayuki; Wake, Rei; Furuya, Motohide; Liaury, Kristian; Hayashida, Maiko; Tsuchie, Keiko; Arauchi, Ryosuke; Araki, Tomoko; Shioji, Izuru; Ezoe, Satoko; Inoue, Ken; Yamaguchi, Tokio; Horiguchi, Jun			Analysis of oxidative stress expressed by urinary level of biopyrrins and 8-hydroxydeoxyguanosine in patients with chronic schizophrenia	PSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article						8-hydroxydeoxyguanosine; biopyrrins; chronic schizophrenia; oxidative stress markers; reactive oxygen species; urine	BILIRUBIN MONOCLONAL-ANTIBODY; CORONARY-ARTERY-DISEASE; DNA-DAMAGE; HEME OXYGENASE; PSYCHOLOGICAL STRESS; HEART-FAILURE; BILE-PIGMENTS; IN-VIVO; MARKER; RATS	AimsPrevious studies have supported the claim that psychological stress induces the production of reactive oxygen species. Several authors have suggested that patients with psychiatric disorders show high levels of oxidative stress markers. We examined different oxidative stress markers in patients with chronic schizophrenia. MethodsThis study included 29 patients with chronic schizophrenia and 30 healthy volunteers. The concentration of urinary biopyrrins and 8-hydroxydeoxyguanosine (8-OHdG), as measured by enzyme-linked immunosorbent assay, were normalized to the urinary concentration of creatinine. Psychiatric symptoms were assessed by the administration of the Brief Psychiatric Rating Scale (BPRS). ResultsThe concentration of biopyrrins in patients with chronic schizophrenia was significantly higher when compared with healthy volunteers. The correlation between biopyrrin level and the duration of illness was highly significant. There were no significant differences in the levels of urinary 8-OHdG between the two groups. In schizophrenic patients, the level of urinary biopyrrins showed correlations with BPRS scores, while the level of urinary 8-OHdG did not show correlations with BPRS. ConclusionsUrinary biopyrrins are increased in patients with chronic schizophrenia while urinary 8-OHdG is not increased. These findings suggest that patients with chronic schizophrenia are under the condition of certain oxidative stresses.	[Miyaoka, Tsuyoshi; Ieda, Masa; Hashioka, Sadayuki; Wake, Rei; Furuya, Motohide; Liaury, Kristian; Hayashida, Maiko; Tsuchie, Keiko; Arauchi, Ryosuke; Araki, Tomoko; Ezoe, Satoko; Horiguchi, Jun] Shimane Univ, Sch Med, Dept Psychiat, Izumo, Shimane 6938501, Japan; [Inoue, Ken] Shimane Univ, Sch Med, Dept Publ Hlth, Izumo, Shimane 6938501, Japan; [Yamaguchi, Tokio] Tokyo Med & Dent Univ, Med Res Inst, Dept Biochem Genet, Tokyo, Japan	Miyaoka, T (reprint author), Shimane Univ, Sch Med, Dept Psychiat, 89-1 Enyacho, Izumo, Shimane 6938501, Japan.	miyanyan@med.shimane-u.ac.jp			Ministry of Education, Science, Sports and Culture of Japan [13770544, 50284047]; Ministry of Health, Labor, and Welfare of Japan	Part of this project (04T-580) was supported by a Grant-in-Aid for Scientific Research on Priority Areas (13770544 and 50284047) from the Ministry of Education, Science, Sports and Culture of Japan, and Gants-in-Aid from the Ministry of Health, Labor, and Welfare of Japan. The authors would like to thank Dr Akira Nishida (Kaisei Hospital, Izumo, Japan). All authors declare that they have no conflicts of interest.	Cernak I, 2000, MAGNESIUM RES, V13, P29; Wu LL, 2004, CLIN CHIM ACTA, V339, P1, DOI 10.1016/j.cccn.2003.09.010; Yasukawa R, 2007, PSYCHIAT RES, V153, P203, DOI 10.1016/j.psychres.2006.04.009; Yamaguchi T, 2002, BIOCHEM BIOPH RES CO, V293, P517, DOI 10.1016/S0006-291X(02)00233-4; YAMAGUCHI T, 1994, J BIOCHEM-TOKYO, V116, P298; Morita T, 2005, ARTERIOSCL THROM VAS, V25, P1786, DOI 10.1161/01.ATV.0000178169.95781.49; Nagayoshi Y, 2009, FREE RADICAL RES, V43, P1159, DOI 10.3109/10715760903214470; Yanagawa Y, 2010, ENDOCR J, V57, P339, DOI 10.1507/endocrj.K09E-359; Pilger A, 2006, INT ARCH OCC ENV HEA, V80, P1, DOI 10.1007/s00420-006-0106-7; Hopkins PN, 1996, ARTERIOSCL THROM VAS, V16, P250; ADACHI S, 1993, CANCER RES, V53, P4153; Irie M, 2003, BIOCHEM BIOPH RES CO, V311, P1014, DOI 10.1016/j.bbrc.2003.10.105; Yamaguchi T, 1996, BBA-GEN SUBJECTS, V1289, P110, DOI 10.1016/0304-4165(95)00128-X; SHIGENAGA MK, 1989, P NATL ACAD SCI USA, V86, P9697, DOI 10.1073/pnas.86.24.9697; Novio S, 2012, BASIC CLIN PHARMACOL, V111, P206, DOI 10.1111/j.1742-7843.2012.00888.x; Yamaguchi T, 1996, BIOCHEM BIOPH RES CO, V223, P129, DOI 10.1006/bbrc.1996.0857; Yager S, 2010, PSYCHONEUROENDOCRINO, V35, P1356, DOI 10.1016/j.psyneuen.2010.03.010; Maes M, 2009, NEUROENDOCRINOL LETT, V30, P715; Kropp S, 2005, J NEUROPSYCH CLIN N, V17, P227, DOI 10.1176/appi.neuropsych.17.2.227; Inoue A, 2009, J PSYCHOSOM RES, V66, P329, DOI 10.1016/j.jpsychores.2008.09.016; Otani K, 2001, J SURG RES, V96, P44, DOI 10.1006/jsre.2000.6036; LOFT S, 1993, J TOXICOL ENV HEALTH, V40, P391; Otani K, 2000, DIGEST DIS SCI, V45, P2313, DOI 10.1023/A:1005626622203; Wei YC, 2009, INT J NEUROPSYCHOPH, V12, P1089, DOI 10.1017/S1461145709000091; DENNERY PA, 1995, FREE RADICAL BIO MED, V19, P395, DOI 10.1016/0891-5849(95)00032-S; Miyaoka T, 2005, EUR NEUROPSYCHOPHARM, V15, P249, DOI 10.1016/j.euroneuro.2004.11.002; Pilger A, 2001, FREE RADICAL RES, V35, P273, DOI 10.1080/10715760100300811; SHIMIZU S, 1988, BIOCHIM BIOPHYS ACTA, V967, P255, DOI 10.1016/0304-4165(88)90017-7; Irie M, 2000, NEUROSCI LETT, V288, P13, DOI 10.1016/S0304-3940(00)01194-0; Irie M, 2001, INT ARCH OCC ENV HEA, V74, P153, DOI 10.1007/s004200000209; Braunwald E, 2008, NEW ENGL J MED, V358, P2148, DOI 10.1056/NEJMra0800239; Kupper N, 2009, PSYCHOSOM MED, V71, P973, DOI 10.1097/PSY.0b013e3181bee6dc; SUZUKI N, 1988, J BIOL CHEM, V263, P5037; Cooke MS, 2000, FREE RADICAL RES, V32, P381, DOI 10.1080/10715760000300391; Stocker R, 2004, ANTIOXID REDOX SIGN, V6, P841, DOI 10.1089/ars.2004.6.841; STOCKER R, 1990, FREE RADICAL RES COM, V9, P101, DOI 10.3109/10715769009148577	36	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-1316	1440-1819		PSYCHIAT CLIN NEUROS	Psychiatry Clin. Neurosci.	NOV	2015	69	11					693	698		10.1111/pcn.12319		6	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	CU9UR	WOS:000363891900004		
J	Meilinger, T; Frankenstein, J; Watanabe, K; Bulthoff, HH; Holscher, C				Meilinger, Tobias; Frankenstein, Julia; Watanabe, Katsumi; Buelthoff, Heinrich H.; Hoelscher, Christoph			Reference frames in learning from maps and navigation	PSYCHOLOGICAL RESEARCH-PSYCHOLOGISCHE FORSCHUNG			English	Article							COGNITIVE MAPS; KNOWLEDGE; MEMORY; REAL; REPRESENTATIONS; ENVIRONMENTS; ACQUISITION; PERSPECTIVE; ORIENTATION; ROUTE	In everyday life, navigators often consult a map before they navigate to a destination (e.g., a hotel, a room, etc.). However, not much is known about how humans gain spatial knowledge from seeing a map and direct navigation together. In the present experiments, participants learned a simple multiple corridor space either from a map only, only from walking through the virtual environment, first from the map and then from navigation, or first from navigation and then from the map. Afterwards, they conducted a pointing task from multiple body orientations to infer the underlying reference frames. We constructed the learning experiences in a way such that map-only learning and navigation-only learning triggered spatial memory organized along different reference frame orientations. When learning from maps before and during navigation, participants employed a map- rather than a navigation-based reference frame in the subsequent pointing task. Consequently, maps caused the employment of a map-oriented reference frame found in memory for highly familiar urban environments ruling out explanations from environmental structure or north preference. When learning from navigation first and then from the map, the pattern of results reversed and participants employed a navigation-based reference frame. The priority of learning order suggests that despite considerable difference between map and navigation learning participants did not use the more salient or in general more useful information, but relied on the reference frame established first.	[Meilinger, Tobias; Buelthoff, Heinrich H.] Max Planck Inst Biol Cybernet, D-72076 Tubingen, Germany; [Meilinger, Tobias; Watanabe, Katsumi] Univ Tokyo, Res Ctr Adv Sci & Technol, Meguro Ku, Tokyo 1538904, Japan; [Frankenstein, Julia; Hoelscher, Christoph] Univ Freiburg, Ctr Cognit Sci, D-79098 Freiburg, Germany; [Frankenstein, Julia; Hoelscher, Christoph] ETH, Swiss Fed Inst Technol, CH-8092 Zurich, Switzerland; [Buelthoff, Heinrich H.] Korea Univ, Dept Brain & Cognit Engn, Seoul 136713, South Korea	Meilinger, T (reprint author), Max Planck Inst Biol Cybernet, Spemannstr 38, D-72076 Tubingen, Germany.	tobias.meilinger@tuebingen.mpg.de; heinrich.buelthoff@tuebingen.mpg.de	Bulthoff, Heinrich/J-6579-2012	Bulthoff, Heinrich/0000-0003-2568-0607	DFG [ME 3476/2-2]; DFG in the SFB/TR8 Spatial Cognition project [I6NavTalk]; Japanese Society for the Promotion of Science, Japan KAKENHI grant [23240034]; Humboldt Foundation; Brain Korea 21 PLUS Program through the National Research Foundation of Korea - Ministry of Education	This work was supported by the DFG grants ME 3476/2-2 and in the SFB/TR8 Spatial Cognition project I6NavTalk, by the Japanese Society for the Promotion of Science, Japan KAKENHI grant (23240034), the Humboldt Foundation, and by the Brain Korea 21 PLUS Program through the National Research Foundation of Korea funded by the Ministry of Education. We would like to thank Chantal Horeis and Nikola Bubalo for their help in data collection and analysis.	Carrubba S, 2007, NEUROSCIENCE, V144, P356, DOI 10.1016/j.neuroscience.2006.08.068; Latini-Corazzini L, 2010, PSYCHOL RES-PSYCH FO, V74, P545, DOI 10.1007/s00426-010-0276-5; Marchette SA, 2011, MEM COGNITION, V39, P1401, DOI 10.3758/s13421-011-0108-x; Shelton AL, 2001, COGNITIVE PSYCHOL, V43, P274, DOI 10.1006/cogp.2001.0758; Taylor HA, 1999, MEM COGNITION, V27, P309, DOI 10.3758/BF03211414; Kelly JW, 2010, COGNITION, V116, P409, DOI 10.1016/j.cognition.2010.06.002; Shelton AL, 2004, J EXP PSYCHOL LEARN, V30, P158, DOI 10.1037/0278-7393.30.1.158; Iachini T, 2009, J ENVIRON PSYCHOL, V29, P227, DOI 10.1016/j.jenvp.2008.07.001; Wilson PN, 2007, MEM COGNITION, V35, P1432, DOI 10.3758/BF03193613; Meilinger T, 2014, Q J EXP PSYCHOL, V67, P542, DOI 10.1080/17470218.2013.821145; Rossano MJ, 1999, J ENVIRON PSYCHOL, V19, P101, DOI 10.1006/jevp.1998.0115; Meilinger T, 2013, COGNITION, V129, P24, DOI 10.1016/j.cognition.2013.05.013; McNamara TP, 2003, PSYCHON B REV, V10, P589, DOI 10.3758/BF03196519; Tlauka M, 2011, Q J EXP PSYCHOL, V64, P2236, DOI 10.1080/17470218.2011.586710; Sun HJ, 2004, MEM COGNITION, V32, P51, DOI 10.3758/BF03195820; Frankenstein J, 2012, PSYCHOL SCI, V23, P120, DOI 10.1177/0956797611429467; Richardson AE, 1999, MEM COGNITION, V27, P741, DOI 10.3758/BF03211566; Borella E., 2014, PSYCHOL RES, P1; Hinzman D. L., 1981, COGNITIVE PSYCHOL, V13, P149; LLOYD R, 1989, ANN ASSOC AM GEOGR, V79, P101, DOI 10.1111/j.1467-8306.1989.tb00253.x; McNamara T. P., 2008, LEARNING MEMORY COMP, V2, P157; MOESER SD, 1988, ENVIRON BEHAV, V20, P21, DOI 10.1177/0013916588201002; Piaget J., 1969, PSYCHOL CHILD; SHOLL MJ, 1987, J EXP PSYCHOL LEARN, V13, P615, DOI 10.1037//0278-7393.13.4.615; Snijders T., 1999, MULTILEVEL ANAL; THORNDYKE PW, 1982, COGNITIVE PSYCHOL, V14, P560, DOI 10.1016/0010-0285(82)90019-6; Tlauka M., 2004, SPAT COGN COMPUT, V4, P359, DOI [10.1207/s15427633scc0404_4, DOI 10.1207/S15427633SCC0404_4]; Werner S., 1999, SPAT COGN COMPUT, V1, P447, DOI DOI 10.1023/A:1010095831166	28	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0340-0727	1430-2772		PSYCHOL RES-PSYCH FO	Psychol. Res.-Psychol. Forsch.	NOV	2015	79	6					1000	1008		10.1007/s00426-014-0629-6		9	Psychology, Experimental	Psychology	CV1NW	WOS:000364026000009		
J	Teramoto, C; Nagata, S; Okamoto, R; Suzuki, R; Kishi, E; Nomura, M; Jojima, N; Nishida, M; Koide, K; Kusano, E; Iwamoto, S; Murashima, S				Teramoto, Chie; Nagata, Satoko; Okamoto, Reiko; Suzuki, Ruriko; Kishi, Emiko; Nomura, Michie; Jojima, Noriko; Nishida, Masumi; Koide, Keiko; Kusano, Emiko; Iwamoto, Saori; Murashima, Sachiyo			Identifying Residents' Health Issues SixWeeks after the Great East Japan Earthquake	PUBLIC HEALTH NURSING			English	Article						disasters; earthquakes; prevention and control; public health nurses; symptom assessment; tsunamis	NIIGATA-CHUETSU EARTHQUAKE; QUALITY-OF-LIFE; WENCHUAN EARTHQUAKE; MENTAL-HEALTH; SURVIVORS	ObjectiveThe aim of this study was to identify the characteristics and health issues of residents in need of assistance in a town affected by the Great East Japan Earthquake, sixweeks after the disaster, through an outreach initiative. Design and SampleA cross-sectional qualitative design was used. Public health nurses conducted comprehensive semi-structured interviews during home visits with residents. A total of 5,082 residents from the affected town. MeasuresThese included demographic information, public records of the extent of the damages, and qualitative interview data to determine the urgency of the necessary interventions. ResultsA total of 281 residents needed some kind of assistance and were identified as requiring early intervention (within twoweeks) or requiring assistance (within 12weeks). The most common health issue requiring early intervention was interruption of treatment (25.0%), followed by need for mental care. The most frequent health issue requiring assistance within 12weeks was the need for mental health care (39.7%), followed by interruption of treatment, and need for nursing care. ConclusionsDuring a disaster, it is imperative to identify cases requiring early intervention. Home-visit interviews were necessary to identify existing health concerns to prevent the development of more serious health problems.	[Teramoto, Chie; Nagata, Satoko] Univ Tokyo, Grad Sch Med, Tokyo 1130033, Japan; [Okamoto, Reiko; Nishida, Masumi; Koide, Keiko] Okayama Univ, Grad Sch Hlth Sci, Okayama 7008530, Japan; [Suzuki, Ruriko] Iwate Coll Nursing, Iwate, Japan; [Kishi, Emiko] Toho Univ, Grad Sch Nursing, Tokyo, Japan; [Nomura, Michie] Ehime Prefectural Univ Hlth Sci, Ehime, Japan; [Jojima, Noriko] Nara Med Univ, Nara, Japan; [Kusano, Emiko] Osaka Med Coll, Fac Nursing, Osaka, Japan; [Iwamoto, Saori] Univ Tokushima, Inst Biomed Sci, Tokushima 770, Japan; [Murashima, Sachiyo] Oita Univ Nursing & Hlth Sci, Oita, Japan	Teramoto, C (reprint author), Univ Tokyo, Grad Sch Med, Dept Community Hlth Nursing, Div Hlth Sci & Nursing,Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	cteramoto-tky@umin.ac.jp			Ministry of Health, Labour and Welfare	We extend our gratitude to all of the participating PHNs. This study was conducted as a part of the project "Structuring the Process of Assistance for Rebuilding the Livelihood of Aged Households Affected by the Tsunami following the Earthquake," financed by the Ministry of Health, Labour and Welfare.	Heir T, 2009, BRIT J PSYCHIAT, V194, P510, DOI 10.1192/bjp.bp.108.056580; Xu JP, 2011, COMPR PSYCHIAT, V52, P431, DOI 10.1016/j.comppsych.2010.08.002; Tsai KY, 2007, J PSYCHIAT RES, V41, P90, DOI 10.1016/j.jpsychires.2005.10.004; Wang XD, 2000, PSYCHIAT CLIN NEUROS, V54, P427, DOI 10.1046/j.1440-1819.2000.00732.x; Oyama Mari, 2012, Environmental Health and Preventive Medicine, V17, P118, DOI 10.1007/s12199-011-0225-y; Hirano M, 2011, J COMMUN HEALTH, V36, P765, DOI 10.1007/s10900-011-9373-7; Frankenberg E, 2008, AM J PUBLIC HEALTH, V98, P1671, DOI 10.2105/AJPH.2007.120915; Zhang Z, 2011, PUBLIC HEALTH, V125, P293, DOI 10.1016/j.puhe.2010.12.008; Architects Regional Planners & Associates Kyoto [ARPAK], 2015, IN AR MAP TSUN IW PR; Disaster Prevention Iwate, 2015, DAM SIT; Geospatial Information Authority of Japan, 2015, IN AR MAP IW PREF; Kuki K., 2001, MED J KOBE U, V62, P33; Ministry of Internal Affairs and Communications Japan, 2011, 2010 POP CENS JAP PO; Nagao T., 1996, B FACULTY HLTH SCI K, V12, P95; National Police Agency, 2015, DAM SIT POL COUNT AS; Setoh N., 1996, B ALLIED MED SCI KOB, V12, P171; Shimizu M., 1998, B FACULTY HLTH SCI K, V14, P11; Toyabe S, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-230; U. S. Department of Health and Human Services Substance Abuse and Mental Health Services Administration, 2000, TRAIN MAN MENT HLTH; vansGriensven F., 2006, JAMA-J AM MED ASSOC, V296, P537	20	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0737-1209	1525-1446		PUBLIC HEALTH NURS	Public Health Nurs.	NOV-DEC	2015	32	6					654	661		10.1111/phn.12201		8	Public, Environmental & Occupational Health; Nursing	Public, Environmental & Occupational Health; Nursing	CV4EC	WOS:000364217900008		
J	Li, CK; Nakahara, M; Poon, YT; Sze, NS				Li, Chi-Kwong; Nakahara, Mikio; Poon, Yiu-Tung; Sze, Nung-Sing			Maximal noiseless code rates for collective rotation channels on qudits	QUANTUM INFORMATION PROCESSING			English	Article						Quantum error correction; Special unitary groups; Irreducible representations; Qudits	QUANTUM ERROR-CORRECTION; GENERAL NOISE; INFORMATION; DECOHERENCE; SUBSYSTEMS	We study noiseless subsystems on collective rotation channels of qudits, i.e., quantum channels with operators in the set epsilon(d, n) = {U-circle times n : U is an element of SU(d)}. This is done by analyzing the decomposition of the algebra A(d, n) generated by epsilon(d, n). We summarize the results for the channels on qubits (d = 2) and obtain the maximum dimension of the noiseless subsystem that can be used as the quantum error correction code for the channel. Then we extend our results to general d. In particular, it is shown that the code rate, i.e., the number of protected qudits over the number of physical qudits, always approaches 1 for a suitable noiseless subsystem. Moreover, one can determine the maximum dimension of the noiseless subsystem by solving a non-trivial discrete optimization problem. The maximum dimension of the noiseless subsystem for d = 3 (qutrits) is explicitly determined by a combination of mathematical analysis and the symbolic software Mathematica.	[Li, Chi-Kwong] Coll William & Mary, Dept Math, Williamsburg, VA 23187 USA; [Nakahara, Mikio] Kinki Univ, Grad Sch Sci & Engn, Res Ctr Quantum Comp, Higashiosaka, Osaka 5778502, Japan; [Nakahara, Mikio] Kinki Univ, Dept Phys, Higashiosaka, Osaka 5778502, Japan; [Nakahara, Mikio] Shanghai Univ, Dept Math, Shanghai 200444, Peoples R China; [Nakahara, Mikio] Shanghai Univ, Dept Phys, Shanghai 200444, Peoples R China; [Poon, Yiu-Tung] Iowa State Univ, Dept Math, Ames, IA 50011 USA; [Sze, Nung-Sing] Hong Kong Polytech Univ, Dept Appl Math, Hong Kong, Hong Kong, Peoples R China	Nakahara, M (reprint author), Kinki Univ, Grad Sch Sci & Engn, Res Ctr Quantum Comp, 3-4-1 Kowakae, Higashiosaka, Osaka 5778502, Japan.	nakahara@math.kindai.ac.jp			USA NSF grant; Japan Society for the Promotion of Science [23540470, 24320008, 26400422]; HK RGC [PolyU 502512]; HK RGC grant	The research of Li was supported by a USA NSF grant, a HK RGC grant. He is an affiliate member of the Institute for Quantum Computing, University of Waterloo; an honorary professor of the Shanghai University and the University of Hong Kong. The research of Nakahara was supported by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (Grant Nos. 23540470, 24320008 and 26400422). He is grateful to Qing-Wen Wang and Xi Chen for warm hospitality extended to him while he was staying at Shanghai University, where a part of this work was done. The research of Poon was supported by a USA NSF grant and a HK RGC grant. The research of Sze was supported by a HK RGC grant PolyU 502512. The authors want to thank Utkan Gungordu for some helpful discussion concerning the decomposition in (4). We would like to thank Paolo Zanardi for drawing our attention to Refs. [30-32] and useful comments that improved our manuscript.	Yang CP, 2001, PHYS REV A, V63, DOI 10.1103/PhysRevA.63.022311; Zanardi P, 1998, PHYS REV A, V57, P3276, DOI 10.1103/PhysRevA.57.3276; Barrett SD, 2010, PHYS REV LETT, V105, DOI 10.1103/PhysRevLett.105.200502; Stace TM, 2010, PHYS REV A, V81, DOI 10.1103/PhysRevA.81.022317; Knill E, 2000, PHYS REV LETT, V84, P2525, DOI 10.1103/PhysRevLett.84.2525; Bishop CA, 2009, J PHYS A-MATH THEOR, V42, DOI 10.1088/1751-8113/42/5/055301; Byrd MS, 2006, PHYS REV A, V73, DOI 10.1103/PhysRevA.73.032330; Li CK, 2012, QUANTUM INF COMPUT, V12, P149; Bartlett SD, 2007, REV MOD PHYS, V79, P555, DOI 10.1103/RevModPhys.79.555; Li CK, 2011, PHYS REV A, V84, DOI 10.1103/PhysRevA.84.044301; Bishop CA, 2008, PHYS REV A, V77, DOI 10.1103/PhysRevA.77.012314; Kempe J, 2001, PHYS REV A, V63, DOI 10.1103/PhysRevA.63.042307; Varnava M, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.120501; Zanardi P, 1997, PHYS REV LETT, V79, P3306, DOI 10.1103/PhysRevLett.79.3306; Holbrook JA, 2005, INTEGR EQUAT OPER TH, V51, P215, DOI 10.1007/s00020-004-1345-1; Migdal P, 2011, PHYS REV A, V84, DOI 10.1103/PhysRevA.84.052318; Cleve R, 1999, PHYS REV LETT, V83, P648, DOI 10.1103/PhysRevLett.83.648; Viola L, 2001, SCIENCE, V293, P2059, DOI 10.1126/science.1064460; Wesslen MSM, 2008, J MATH PHYS, V49, DOI 10.1063/1.2949249; Zanardi P, 1997, MOD PHYS LETT B, V11, P1085, DOI 10.1142/S0217984997001304; Lidar DA, 1998, PHYS REV LETT, V81, P2594, DOI 10.1103/PhysRevLett.81.2594; Bishop CA, 2011, PHYS REV A, V83, DOI 10.1103/PhysRevA.83.062327; Bartlett SD, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.027901; Chen J.Q., 2002, GROUP REPRESENTATION; Fulton W., 2004, REPRESENTATION THEOR; Gungordu U, 2014, PHYS REV A, V89, DOI 10.1103/PhysRevA.89.042301; Kribs DW, 2006, QUANTUM INFORM COMPU, V6, P382; Lider D.A., 2014, ADV CHEM PHYS, V154, P295; Muralidharan S., 2015, ARXIV150408054QUANTP; Nakahara M., 2008, QUANTUM COMPUTING LI; Nielsen M A, 2000, QUANTUM COMPUTATION	31	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1570-0755	1573-1332		QUANTUM INF PROCESS	Quantum Inf. Process.	NOV	2015	14	11					4039	4055		10.1007/s11128-015-1101-2		17	Physics, Multidisciplinary; Physics, Mathematical	Physics	CV1OI	WOS:000364027300003		
J	Ban, M				Ban, Masashi			Quantum Fisher information of a qubit initially correlated with a non-Markovian environment	QUANTUM INFORMATION PROCESSING			English	Article						Quantum Fisher information; Initial correlation; Non-Markovian time evolution	DYNAMICS; STATES	The quantum Fisher information in phase estimation is investigated for a qubit which is placed under the influence of a non-Markovian environment. The multi-mode Jaynes-Cummings model which has at least one excitation is used as a qubit-environment model. It is examined how initial correlation between the qubit and the environment affects time evolution of the quantum Fisher information. Although information on the phase parameter is included only in off-diagonal elements of the reduced density matrix of the qubit in the absence of the initial correlation, it is included not only in off-diagonal elements but also in diagonal elements in the presence of the initial correlation. This implies that the quantum Fisher information is greatly affected by the initial correlation. In particular, when the time evolution of the reduced density operator of the qubit is non-Markovian, the quantum Fisher information can take values greater than its initial value due to the initial correlation.	Ochanomizu Univ, Grad Sch Humanities & Sci, Bunkyo Ku, Tokyo 1128610, Japan	Ban, M (reprint author), Ochanomizu Univ, Grad Sch Humanities & Sci, Bunkyo Ku, 2-1-1 Ohtsuka, Tokyo 1128610, Japan.	ban.masashi@ocha.ac.jp					Alicki R, 2007, QUANTUM DYNAMICAL SE; Ban M, 2012, INT J THEOR PHYS, V51, P2419, DOI 10.1007/s10773-012-1121-y; Bellomo B, 2008, PHYS REV A, V77, DOI 10.1103/PhysRevA.77.032342; Lu XM, 2010, PHYS REV A, V82, DOI 10.1103/PhysRevA.82.042103; Hall MJW, 2014, PHYS REV A, V89, DOI 10.1103/PhysRevA.89.042120; Ma J, 2011, PHYS REV A, V84, DOI 10.1103/PhysRevA.84.022302; Sarovar M, 2006, J PHYS A-MATH GEN, V39, P8487, DOI 10.1088/0305-4470/39/26/015; Zhong W, 2013, PHYS REV A, V87, DOI 10.1103/PhysRevA.87.022337; Micadei K, 2015, NEW J PHYS, V17, DOI 10.1088/1367-2630/17/2/023057; Ban M, 2011, PHYS LETT A, V375, P2283, DOI 10.1016/j.physleta.2011.04.049; Escher BM, 2011, NAT PHYS, V7, P406, DOI [10.1038/nphys1958, 10.1038/NPHYS1958]; PECHUKAS P, 1994, PHYS REV LETT, V73, P1060, DOI 10.1103/PhysRevLett.73.1060; RUSKAI MB, 1994, REV MATH PHYS, V6, P1147, DOI 10.1142/S0129055X94000407; Monras A, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.160401; Dajka J, 2011, PHYS REV A, V84, DOI 10.1103/PhysRevA.84.032120; Alipour S, 2014, PHYS REV LETT, V112, DOI 10.1103/PhysRevLett.112.120405; Smirne A, 2010, PHYS REV A, V82, DOI 10.1103/PhysRevA.82.062114; BRAUNSTEIN SL, 1994, PHYS REV LETT, V72, P3439, DOI 10.1103/PhysRevLett.72.3439; Watanabe Y, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.020401; Jordan TF, 2004, PHYS REV A, V70, DOI 10.1103/PhysRevA.70.052110; Chin AW, 2012, PHYS REV LETT, V109, DOI 10.1103/PhysRevLett.109.233601; Vacchini B, 2011, NEW J PHYS, V13, DOI 10.1088/1367-2630/13/9/093004; Dajka J, 2010, PHYS REV A, V82, DOI 10.1103/PhysRevA.82.012341; Bellomo B, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.160502; Chruscinski D, 2011, PHYS REV A, V83, DOI 10.1103/PhysRevA.83.052128; Berrada K, 2012, PHYS LETT A, V376, P1412, DOI 10.1016/j.physleta.2012.03.023; Bellomo B, 2008, PHYS REV A, V78, DOI 10.1103/PhysRevA.78.060302; Mazzola L, 2010, PHYS REV A, V81, DOI 10.1103/PhysRevA.81.052116; Berrada K, 2013, PHYS REV A, V88, DOI 10.1103/PhysRevA.88.035806; Breuer HP, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.210401; Breuer H.-P., 2006, THEORY OPEN QUANTUM; Devi Usha, 2011, PHYS REV A, V83; Helstrom C. W., 1976, QUANTUM DETECTION ES; Holevo A., 1982, PROBABILISTIC STAT A; Hu ZD, 2014, J PHYS SOC JPN, V83, DOI 10.7566/JPSJ.83.114004; Jaeger G, 2009, FRONT COLLECT, P1, DOI 10.1007/978-3-540-92128-8; Jaeger G., 2007, QUANTUM INFORM; Kraus K., 1983, STATES EFFECTS OPERA; Laine EM, 2010, EPL-EUROPHYS LETT, V92, DOI 10.1209/0295-5075/92/60010; Nielsen M A, 2000, QUANTUM COMPUTATION; Ozaydin F, 2014, PHYS LETT A, V378, P3161, DOI 10.1016/j.physleta.2014.08.035; Paris M.G.A., 2010, LECT NOTES PHYS, V649; Pezze L., 2014, ARXIV14115164 LANL; Rivas A, 2014, REP PROG PHYS, V77, DOI 10.1088/0034-4885/77/9/094001; Rivas A., 2011, OPEN QUANTUM SYSTEMS; Rodoriguez-Rosario C.A., 2008, J PHYS A, V41; van Kampen NG, 1981, STOCHASTIC PROCESSES; Weiss U., 1993, QUANTUM DISSIPATIVE; Wiseman H. M., 2009, QUANTUM MEASUREMENT	49	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1570-0755	1573-1332		QUANTUM INF PROCESS	Quantum Inf. Process.	NOV	2015	14	11					4163	4177		10.1007/s11128-015-1097-7		15	Physics, Multidisciplinary; Physics, Mathematical	Physics	CV1OI	WOS:000364027300012		
J	Ruhm, W; Woloschak, GE; Shore, RE; Azizova, TV; Grosche, B; Niwa, O; Akiba, S; Ono, T; Suzuki, K; Iwasaki, T; Ban, N; Kai, M; Clement, CH; Bouffler, S; Toma, H; Hamada, N				Ruehm, Werner; Woloschak, Gayle E.; Shore, Roy E.; Azizova, Tamara V.; Grosche, Bernd; Niwa, Ohtsura; Akiba, Suminori; Ono, Tetsuya; Suzuki, Keiji; Iwasaki, Toshiyasu; Ban, Nobuhiko; Kai, Michiaki; Clement, Christopher H.; Bouffler, Simon; Toma, Hideki; Hamada, Nobuyuki			Dose and dose-rate effects of ionizing radiation: a discussion in the light of radiological protection	RADIATION AND ENVIRONMENTAL BIOPHYSICS			English	Article						Radiation risk; LNT model; DDREF; LDEF; DREF; ICRP	ATOMIC-BOMB SURVIVORS; MAYAK-PRODUCTION-ASSOCIATION; HIGH BACKGROUND-RADIATION; TECHA RIVER COHORT; RATE GAMMA-RAYS; LONG-TERM IRRADIATION; CHROMOSOME-ABERRATIONS; NUCLEAR INDUSTRY; CANCER INCIDENCE; HUMAN-CELLS	The biological effects on humans of low-dose and low-dose-rate exposures to ionizing radiation have always been of major interest. The most recent concept as suggested by the International Commission on Radiological Protection (ICRP) is to extrapolate existing epidemiological data at high doses and dose rates down to low doses and low dose rates relevant to radiological protection, using the so-called dose and dose-rate effectiveness factor (DDREF). The present paper summarizes what was presented and discussed by experts from ICRP and Japan at a dedicated workshop on this topic held in May 2015 in Kyoto, Japan. This paper describes the historical development of the DDREF concept in light of emerging scientific evidence on dose and dose-rate effects, summarizes the conclusions recently drawn by a number of international organizations (e.g., BEIR VII, ICRP, SSK, UNSCEAR, and WHO), mentions current scientific efforts to obtain more data on low-dose and low-dose-rate effects at molecular, cellular, animal and human levels, and discusses future options that could be useful to improve and optimize the DDREF concept for the purpose of radiological protection.	[Ruehm, Werner] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Radiat Protect, D-85764 Neuherberg, Germany; [Woloschak, Gayle E.] Northwestern Univ, Feinberg Sch Med, Dept Radiat Oncol, Chicago, IL 60611 USA; [Shore, Roy E.] Radiat Effects Res Fdn, Minami Ku, Hiroshima 7320815, Japan; [Azizova, Tamara V.] Southern Urals Biophys Inst, Ozyorsk, Chelyabinsk Reg, Russia; [Grosche, Bernd] Fed Off Radiat Protect, D-85764 Oberschleissheim, Germany; [Niwa, Ohtsura] Fukushima Med Univ, Fukushima 9601295, Japan; [Akiba, Suminori] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Epidemiol & Prevent Med, Kagoshima 890, Japan; [Ono, Tetsuya] Inst Environm Sci, Aomori 0393212, Japan; [Suzuki, Keiji] Nagasaki Univ, Atom Bomb Dis Inst, Dept Radiat Med Sci, Nagasaki 852, Japan; [Iwasaki, Toshiyasu] Cent Res Inst Elect Power Ind, Radiat Safety Res Ctr, Nucl Technol Res Lab, Tokyo 2018511, Japan; [Ban, Nobuhiko] Tokyo Healthcare Univ, Fac Nursing, Meguro Ku, Tokyo 1528558, Japan; [Kai, Michiaki] Oita Univ Nursing & Hlth Sci, Dept Environm Hlth Sci, Oita 8401201, Japan; [Clement, Christopher H.; Hamada, Nobuyuki] Int Commiss Radiol Protect, Ottawa, ON K1P 5S9, Canada; [Bouffler, Simon] Publ Hlth England, Ctr Radiat Chem & Environm Hazards, Didcot OX11 0RQ, Oxon, England; [Toma, Hideki] JAPAN NUS Co Ltd JANUS, Shinjuku Ku, Tokyo 1600023, Japan	Hamada, N (reprint author), Int Commiss Radiol Protect, POB 1046,Stn B,280 Slater St, Ottawa, ON K1P 5S9, Canada.	hamada@icrp.org			Japanese Ministry of Health, Labour and Welfare (MHLW); US Department of Energy (USDOE); USDOE award [DE-HS0000031]	The present paper is based on presentations held at and discussions stimulated during a one-day workshop on DDREF jointly organized by ICRP and JANUS, on May 22, 2015, in Kyoto, Japan. RS and WR acknowledge the contribution of Dr. Linda Walsh (Bundesamt fur Strahlenschutz, Germany) toward the planned meta-analysis of epidemiological studies. RERF, Hiroshima and Nagasaki, Japan, is a public interest foundation funded by the Japanese Ministry of Health, Labour and Welfare (MHLW) and the US Department of Energy (USDOE). RERF research is also funded in part through USDOE award DE-HS0000031 to the NAS. This publication is associated with RERF Research Protocol 1-75. The views of the authors do not necessarily reflect those of the two governments. The study at IES is performed under contract with the Aomori Prefectural Government, Japan.	Tanaka K, 2009, RADIAT RES, V171, P290, DOI 10.1667/RR1238.1; Degteva MO, 2012, HEALTH PHYS, V102, P25, DOI 10.1097/HP.0b013e318228159a; Otsuka K, 2013, RADIAT RES, V179, P637, DOI 10.1667/RR3253.1; Vrijheid M, 2007, RADIAT RES, V167, P361, DOI 10.1667/RR0554.1; Tao ZF, 2012, HEALTH PHYS, V102, P173, DOI 10.1097/HP.0b013e31822c7f1e; Cologne JB, 2001, HEALTH PHYS, V80, P491, DOI 10.1097/00004032-200105000-00010; RUSSELL WL, 1982, P NATL ACAD SCI-BIOL, V79, P542, DOI 10.1073/pnas.79.2.542; Tanaka S, 2003, RADIAT RES, V160, P376, DOI 10.1667/RR3042; Lobrich M, 2007, NAT REV CANCER, V7, P861, DOI 10.1038/nrc2248; Khokhryakov VV, 2013, HEALTH PHYS, V104, P366, DOI 10.1097/HP.0b013e31827dbf60; Degteva MO, 2006, RADIAT RES, V166, P255, DOI 10.1667/RR3438.1; Ojima M, 2011, RADIAT RES, V175, P90, DOI 10.1667/RR2223.1; Wang QO, 2010, RADIAT ENVIRON BIOPH, V49, P317, DOI 10.1007/s00411-010-0270-8; Darby S, 2005, BRIT MED J, V330, P223, DOI 10.1136/bmj.38308.477650.63; Ozasa K, 2012, RADIAT RES, V177, P229, DOI 10.1667/RR2629.1; Leuraud K, 2015, LANCET HAEMATOL, V2, pE276, DOI 10.1016/S2352-3026(15)00094-0; Vrijheid M, 2007, INT J EPIDEMIOL, V36, P1126, DOI 10.1093/ije/dym138; Hayata I, 2004, CYTOGENET GENOME RES, V104, P237, DOI 10.1159/000077496; Loucas BD, 2004, RADIAT RES, V162, P339, DOI 10.1667/RR3245; Verbiest T, 2015, CARCINOGENESIS, V36, P413, DOI 10.1093/carcin/bgv016; Kajita M, 2015, J BIOCHEM, V158, P15, DOI 10.1093/jb/mvv050; Vasilenko EK, 2007, HEALTH PHYS, V93, P190, DOI 10.1097/01.HP.0000266071.43137.0e; Jacob P, 2009, OCCUP ENVIRON MED, V66, P789, DOI 10.1136/oem.2008.043265; Daniels RD, 2013, OCCUP ENVIRON MED, V70, P41, DOI 10.1136/oemed-2012-100906; Nakajima T, 2008, J RADIAT RES, V49, P661, DOI 10.1269/jrr.08074; Shagina NB, 2012, RADIAT ENVIRON BIOPH, V51, P349, DOI 10.1007/s00411-012-0414-0; Ostroumova E, 2008, BRIT J CANCER, V99, P1940, DOI 10.1038/sj.bjc.6604775; Krestinina LY, 2013, BRIT J CANCER, V109, P2886, DOI 10.1038/bjc.2013.614; Manning G, 2013, INT J RADIAT BIOL, V89, P512, DOI 10.3109/09553002.2013.769694; Taki K, 2009, J RADIAT RES, V50, P241, DOI 10.1269/jrr.09011; CARNES BA, 1991, RADIAT RES, V128, P125, DOI 10.2307/3578129; Preston DL, 2007, RADIAT RES, V168, P1, DOI 10.1667/RR0763.1; Birschwilks M, 2011, RADIAT RES, V175, P526, DOI 10.1667/RR2471.1; Rothkamm K, 2003, P NATL ACAD SCI USA, V100, P5057, DOI 10.1073/pnas.0830918100; Beels L, 2009, CIRCULATION, V120, P1903, DOI 10.1161/CIRCULATIONAHA.109.880385; Takai D, 2011, INT J RADIAT BIOL, V87, P729, DOI 10.3109/09553002.2010.545861; Akiba S, 2012, J RADIOL PROT, V32, P73, DOI 10.1088/0952-4746/32/1/73; Spycher BD, 2015, ENVIRON HEALTH PERSP, V123, P622, DOI 10.1289/ehp.1408548; Nair RRK, 2009, HEALTH PHYS, V96, P55, DOI 10.1097/01.HP.0000327646.54923.11; Okudaira N, 2010, RADIAT RES, V173, P138, DOI 10.1667/RR1932.1; Haley B, 2011, HEALTH PHYS, V100, P613, DOI 10.1097/HP.0b013e3181febad3; Uehara Y, 2010, RADIAT RES, V174, P611, DOI 10.1667/RR2195.1; CARNES BA, 1993, RADIAT RES, V136, P103, DOI 10.2307/3578646; Tolstykh EI, 2011, HEALTH PHYS, V101, P28, DOI 10.1097/HP.0b013e318206d0ff; Cardis E, 2005, BRIT MED J, V331, P77, DOI 10.1136/bmj.38499.599861.E0; Cardis E, 2007, RADIAT RES, V167, P396, DOI 10.1667/RR0553.1; Tapio S, 2008, INT J RADIAT BIOL, V84, P930, DOI 10.1080/09553000802460214; Grudzenski S, 2010, P NATL ACAD SCI USA, V107, P14205, DOI 10.1073/pnas.1002213107; Beels L, 2010, INT J RADIAT BIOL, V86, P760, DOI 10.3109/09553002.2010.484479; Neumaier T, 2012, P NATL ACAD SCI USA, V109, P443, DOI 10.1073/pnas.1117849108; Degteva MO, 2000, HEALTH PHYS, V79, P24, DOI 10.1097/00004032-200007000-00007; Otsuka K, 2015, J RADIAT RES, V56, P615, DOI 10.1093/jrr/rrv012; WANG ZY, 1990, J NATL CANCER I, V82, P478, DOI 10.1093/jnci/82.6.478; Kendall GM, 2013, LEUKEMIA, V27, P3, DOI 10.1038/leu.2012.151; Degteva MO, 2009, INDIVIDUAL DOSE CALC; Gerber G, 1996, INT RADIOLBIOLOGY AR; Ghandhi SA, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0097-x; Haley B, 2015, PLOS ONE; Hamada Nobuyuki, 2011, Curr Mol Pharmacol, V4, P79; LUXIN W, 1980, SCIENCE, V209, P877; Hoel DG, 2015, HEALTH PHYS, V108, P351, DOI 10.1097/HP.0000000000000189; Hosoda M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124433; Hsu WL, 2013, RADIAT RES, V179, P361, DOI 10.1667/RR2892.1; ICRP, 2005, ANN ICRP, V35; ICRP, 2015, ANN ICRP, V44; ICRP, 1991, ANN ICRP, V21; ICRP, 2007, ANN ICRP, V7; ICRP, 2013, TASK GROUP 91 RAD RI; ICRP, 2013, ICRP MAIN COMM M APR; Jayalekshmi P, 2007, CANC INCIDENCE 5 CON, VIX; KELLERER A M, 1972, Current Topics in Radiation Research Quarterly, V8, P85; Kudo H, 2015, Radiat Prot Dosimetry, V167, P155, DOI 10.1093/rpd/ncv235; Kuznetsova IS, 2015, PLOS ONE; Manning G, 2014, MUTAT RES-FUND MOL M, V770, P29, DOI 10.1016/j.mrfmmm.2014.09.002; Morgan WF, 2015, CANCER LETT, V356, P17, DOI 10.1016/j.canlet.2013.09.009; Nair MK, 1997, CANC INCIDENCE 5 CON, VVII, P350; Nair MK, 2002, CANC INCIDENCE 5 CON, VVIII, P240; NAS, 2006, HLTH RISKS EXP LOW L; NCRP, 1980, 64 NCRP; NEARY GJ, 1965, INT J RADIAT BIOL RE, V9, P477, DOI 10.1080/09553006514550551; Schonfeld SJ, 2013, RADIAT RES, V179, P183, DOI 10.1667/RR2932.1; Searle AG, 1974, ADV RADIAT BIOL, V4, P131; Shagina N, 2012, HEALTH PHYS, V103, pS96; Sokolnikov M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117784; Tanaka IB, 2007, RADIAT RES, V167, P417, DOI 10.1667/RR0728.1; Tolstykh EI, 2006, RAD SAFETY PROB, V1, P68; UNSCEAR, 1958, 13 SESS S; UNSCEAR, 1964, 19 SESS S; UNSCEAR, 1969, REP UN SCI COMM EFF; UNSCEAR, 1977, SOURC EFF ION RAD; UNSCEAR, 2013, SOURC EFF RISKS ION; UNSCEAR, 1993, SOURC EFF ION RAD; UNSCEAR, 1986, GEN SOM EFF ION RAD; UNSCEAR, 2000, SOURC EFF ION RAD; UNSCEAR, 2006, EFF ION RAD; UNSCEAR, 1994, SOURC EFF ION RAD; UNSCEAR 2010, 2010, SUMM LOW DOS RAD EFF; UNSCEAR (United Nations Scientific Committee on the Effects of Atomic Radiation), 1962, REP UN SCI COMM EFF; UNSCEAR (United Nations Scientific Committee on the Effects of Atomic Radiation), 1988, SOURC EFF RISKS ION; WHO, 2013, HLTH RISK ASS NUCL A	100	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0301-634X	1432-2099		RADIAT ENVIRON BIOPH	Radiat. Environ. Biophys.	NOV	2015	54	4					379	401		10.1007/s00411-015-0613-6		23	Biology; Biophysics; Environmental Sciences; Radiology, Nuclear Medicine & Medical Imaging	Life Sciences & Biomedicine - Other Topics; Biophysics; Environmental Sciences & Ecology; Radiology, Nuclear Medicine & Medical Imaging	CV1OT	WOS:000364028400001		
J	Matsuda, S; Furuya, K; Ikura, M; Matsuda, T; Ikura, T				Matsuda, Shun; Furuya, Kanji; Ikura, Masae; Matsuda, Tomonari; Ikura, Tsuyoshi			Absolute quantification of acetylation and phosphorylation of the histone variant H2AX upon ionizing radiation reveals distinct cellular responses in two cancer cell lines	RADIATION AND ENVIRONMENTAL BIOPHYSICS			English	Article						gamma H2AX; Multiple reaction monitoring/selected reaction monitoring (MRM/SRM); Absolute quantification; DNA damage; Acetylation; Phosphorylation	DOUBLE-STRAND BREAKS; HEPG2 CELLS; DEPHOSPHORYLATES GAMMA-H2AX; IN-VIVO; DNA; GENOTOXICITY; CHROMATIN; REPAIR; ASSAY; WIP1	Histone modifications change upon the cellular response to ionizing radiation, and their cellular amounts could reflect the DNA damage response activity. We previously reported a sensitive and reliable method for the absolute quantification of gamma H2AX within cells, using liquid chromatography-tandem mass spectrometry (LC/MS/MS). The technique has broad adaptability to a variety of biological systems and can quantitate different modifications of histones. In this study, we applied it to quantitate the levels of gamma H2AX and K5-acetylated H2AX, and to compare the radiation responses between two cancer cell lines: HeLa and U-2 OS. The two cell lines have distinct properties in terms of their H2AX modifications. HeLa cells have relatively high gamma H2AX (3.1 %) against the total H2AX even in un-irradiated cells, while U-2 OS cells have an essentially undetectable level (nearly 0 %) of gamma H2AX. In contrast, the amounts of acetylated histones are lower in HeLa cells (9.3 %) and higher in U-2 OS cells (24.2 %) under un-irradiated conditions. Furthermore, after ionizing radiation exposure, the time-dependent increases and decreases in the amounts of histone modifications differed between the two cell lines, especially at the early time points. These results suggest that each biological system has distinct kinase/phosphatase and/or acetylase/deacetylase activities. In conclusion, for the first time, we have succeeded in simultaneously monitoring the absolute amounts of phosphorylated and acetylated cellular H2AX after ionizing radiation exposure. This multi-criteria assessment enables precise comparisons of the effects of radiation between any biological systems.	[Matsuda, Shun; Matsuda, Tomonari] Kyoto Univ, Res Ctr Environm Qual Management, Lab Environm Qual Management, Otsu, Shiga 5200811, Japan; [Furuya, Kanji] Kyoto Univ, Dept Mutagenesis, Ctr Radiat Biol, Lab Cell Cycle Response,Kyoto Sakyo Ku, Kyoto 6068501, Japan; [Ikura, Masae; Ikura, Tsuyoshi] Kyoto Univ, Ctr Radiat Biol, Dept Mutagenesis, Lab Chromatin Regulatory Network,Kyoto Sakyo Ku, Kyoto 6068501, Japan	Ikura, T (reprint author), Kyoto Univ, Ctr Radiat Biol, Dept Mutagenesis, Lab Chromatin Regulatory Network,Kyoto Sakyo Ku, Kyoto 6068501, Japan.	ikurat@house.rbc.kyoto-u.ac.jp			KAKENHI from the Japan Society for the Promotion of Science [23221006];  [22131001]	This study was supported by KAKENHI (23221006) from the Japan Society for the Promotion of Science (S.M. and T.M.) and Grants-in-Aid for Scientific Research on Innovative Areas (22131001) (K.F. and T.I.).	Ando M, 2014, J BIOMOL SCREEN, V19, P1246, DOI 10.1177/1087057114541147; Macurek L, 2010, ONCOGENE, V29, P2281, DOI 10.1038/onc.2009.501; Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008-5472.CAN-03-3207; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Ikura T, 2007, MOL CELL BIOL, V27, P7028, DOI 10.1128/MCB.00579-07; Redon CE, 2010, CLIN CANCER RES, V16, P4532, DOI 10.1158/1078-0432.CCR-10-0523; Wu J, 2013, CLIN CANCER RES, V19, P721, DOI 10.1158/1078-0432.CCR-12-2529; Tsamou M, 2012, MUTAGENESIS, V27, P645, DOI 10.1093/mutage/ges030; Matsuda S, 2015, ANAL BIOANAL CHEM, V407, P5521, DOI 10.1007/s00216-015-8725-z; Cha H, 2010, CANCER RES, V70, P4112, DOI 10.1158/0008-5472.CAN-09-4244; Watters GP, 2009, MUTAT RES-GEN TOX EN, V679, P50, DOI 10.1016/j.mrgentox.2009.07.007; Douglas P, 2010, MOL CELL BIOL, V30, P1368, DOI 10.1128/MCB.00741-09; Taneja N, 2004, J BIOL CHEM, V279, P2273, DOI 10.1074/jbc.M310030200; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Chowdhury D, 2005, MOL CELL, V20, P801, DOI 10.1016/j.molcel.2005.10.003; Sanchez-Flores M, 2015, TOXICOL SCI, V144, P406, DOI 10.1093/toxsci/kfv011; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Kao J, 2006, CURR CANCER DRUG TAR, V6, P197, DOI 10.2174/156800906776842957; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/bjc.C100569200; Sedelnikova OA, 2006, CELL CYCLE, V5, P2909, DOI 10.4161/cc.5.24.3569; Moon SH, 2010, CELL CYCLE, V9, P2092; Khoury L, 2013, ENVIRON MOL MUTAGEN, V54, P737, DOI 10.1002/em.21817; PADOVANI L, 1993, MUTAT RES, V319, P55, DOI 10.1016/0165-1218(93)90030-H; Smart DJ, 2011, MUTAT RES-FUND MOL M, V715, P25, DOI 10.1016/j.mrfmmm.2011.07.001; Hunt CR, 2013, RADIAT RES, V179, P383, DOI 10.1667/RR3308.2; Podhorecka M, 2010, J NUCL ACIDS, DOI [10.4061/2010/920161, DOI 10.4061/2010/920161]	26	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0301-634X	1432-2099		RADIAT ENVIRON BIOPH	Radiat. Environ. Biophys.	NOV	2015	54	4					403	411		10.1007/s00411-015-0608-3		9	Biology; Biophysics; Environmental Sciences; Radiology, Nuclear Medicine & Medical Imaging	Life Sciences & Biomedicine - Other Topics; Biophysics; Environmental Sciences & Ecology; Radiology, Nuclear Medicine & Medical Imaging	CV1OT	WOS:000364028400002		
J	Seo, SJ; Han, SM; Cho, JH; Hyodo, K; Zaboronok, A; You, H; Peach, K; Hill, MA; Kim, JK				Seo, Seung-Jun; Han, Sung-Mi; Cho, Jae-Hoon; Hyodo, Kazuyuki; Zaboronok, Alexander; You, He; Peach, Ken; Hill, Mark A.; Kim, Jong-Ki			Enhanced production of reactive oxygen species by gadolinium oxide nanoparticles under core-inner-shell excitation by proton or monochromatic X-ray irradiation: implication of the contribution from the interatomic de-excitation-mediated nanoradiator effect to dose enhancement	RADIATION AND ENVIRONMENTAL BIOPHYSICS			English	Article						Interatomic de-excitation; Reactive oxygen species; Nanoparticle atomic clusters; Inner-shell ionization; Nanoradiator effect; Low-energy electrons; Radiosensitization	GOLD NANOPARTICLES; COULOMBIC DECAY; ENERGY; CELLS; RADIOTHERAPY	Core-inner-valence ionization of high-Z nanoparticle atomic clusters can de-excite electrons through various interatomic de-excitation processes, thereby leading to the ionization of both directly exposed atoms and adjacent neutral atoms within the nanoparticles, and to an enhancement in photon-electron emission, which is termed the nanoradiator effect. To investigate the nanoradiator-mediated dose enhancement in the radio-sensitizing of high-Z nanoparticles, the production of reactive oxygen species (ROS) was measured in a gadolinium oxide nanoparticle (Gd-oxide NP) solution under core-inner-valence excitation of Gd with either 50 keV monochromatic synchrotron X-rays or 45 MeV protons. This measurement was compared with either a radiation-only control or a gadolinium-chelate magnetic resonance imaging contrast agent solution containing equal amounts of gadolinium as the separate atomic species in which Gd-Gd interatomic de-excitations are absent. Ionization excitations followed by ROS measurements were performed on nanoparticle-loaded cells or aqueous solutions. Both photoexcitation and proton impact produced a dose-dependent enhancement in the production of ROS by a range of factors from 1.6 to 1.94 compared with the radiation-only control. Enhanced production of ROS, by a factor of 1.83, was observed from Gd-oxide NP atomic clusters compared with the Gd-chelate molecule, with a Gd concentration of 48 mu g/mL in the core-level photon excitation, or by a factor of 1.82 under a Gd concentration of 12 mu g/mL for the proton impact at 10 Gy (p < 0.02). The enhanced production of ROS in the irradiated nanoparticles suggests the potential for additional therapeutic dose enhancements in radiation treatment via the potent Gd-Gd interatomic de-excitation-driven nanoradiator effect.	[Seo, Seung-Jun; Kim, Jong-Ki] Catholic Univ Daegu, Sch Med, Biomed Engn & Radiol, Taegu, South Korea; [Han, Sung-Mi] Catholic Univ Daegu, Sch Med, Anat, Taegu, South Korea; [Cho, Jae-Hoon] Catholic Univ Daegu, Sch Med, Neurosurg, Taegu, South Korea; [Hyodo, Kazuyuki] Natl Lab High Energy Phys, KEK, High Energy Accelerator Res Org, Photon Factory, Tsukuba, Ibaraki 305, Japan; [Zaboronok, Alexander] Univ Tsukuba, Dept Neurosurg, Tsukuba, Ibaraki, Japan; [You, He] Shanghai Synchrotron Radiat Facil, Shanghai, Peoples R China; [Peach, Ken] Univ Oxford, Particle Therapy Canc Res Inst, Oxford, England; [Hill, Mark A.] Univ Oxford, Gray Inst Radiat Oncol & Biol, Oxford, England	Kim, JK (reprint author), Catholic Univ Daegu, Sch Med, Biomed Engn & Radiol, Taegu, South Korea.	jkkim@cu.ac.kr			Basic Science Research Program through the National Research Foundation of Korea - Ministry of Education, Science and Technology [20090088454, 2012M2A7A1026636, 2013M2B2B1075774]; International Corporation Foundation Establishment Program through the National Research Foundation of Korea - Ministry of Education, Science and Technology [20090088454, 2012M2A7A1026636, 2013M2B2B1075774]; Atomic energy research expansion program through the National Research Foundation of Korea - Ministry of Education, Science and Technology [20090088454, 2012M2A7A1026636, 2013M2B2B1075774]; Catholic University of Daegu [20115004]	The authors greatly thank Prof. Reinhard Dorner at Goethe University, Germany, for the discussion about interatomic Coulomb decay in ionized nanoparticles and its potential relevance to the nanoradiator effect. This work was performed with financial support from the Basic Science Research Program, International Corporation Foundation Establishment Program and Atomic energy research expansion program through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (20090088454, 2012M2A7A1026636, 2013M2B2B1075774). This work was also partially supported by research Grants (20115004) from the Catholic University of Daegu in 2012.	Baluchamy S, 2010, J BIOL CHEM, V285, P24769, DOI 10.1074/jbc.M110.138099; Lechtman E, 2011, PHYS MED BIOL, V56, P4631, DOI 10.1088/0031-9155/56/15/001; Carter JD, 2007, J PHYS CHEM B, V111, P11622, DOI 10.1021/jp075253u; Qin Y, 2008, CELL BIOL INT, V32, P224, DOI 10.1016/j.cellbi.2007.08.028; Sisourat N, 2010, NAT PHYS, V6, P508, DOI 10.1038/NPHYS1685; Kim JK, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/42/425102; Hergenhahn U, 2012, INT J RADIAT BIOL, V88, P871, DOI 10.3109/09553002.2012.698031; MATTHEW JAD, 1975, SURF SCI, V53, P716, DOI 10.1016/0039-6028(75)90166-1; Averbukh V, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.263002; Jahnke T, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.163401; Kalyanaraman B, 2012, FREE RADICAL BIO MED, V52, P1, DOI 10.1016/j.freeradbiomed.2011.09.030; Pradhan AK, 2009, J PHYS CHEM A, V113, P12356, DOI 10.1021/jp904977z; Le Duc G, 2011, ACS NANO, V5, P9566, DOI 10.1021/nn202797h; Polf JC, 2011, APPL PHYS LETT, V98, DOI 10.1063/1.3589914; Schatz T, 1999, J PHYS CHEM B, V103, P10209, DOI 10.1021/jp992269e; Belkic D, 2010, J MATH CHEM, V47, P1366, DOI 10.1007/s10910-010-9662-x; Misawa M, 2011, NANOMED-NANOTECHNOL, V7, P604, DOI 10.1016/j.nano.2011.01.014; Hainfeld JF, 2008, J PHARM PHARMACOL, V60, P977, DOI 10.1211/jpp.60.8.0005; Cho SH, 2005, PHYS MED BIOL, V50, P163; Choi GH, 2012, RADIAT ONCOL, V7, DOI 10.1186/1748-717X-7-184; Dunford RW, 2012, PHYS REV A, V86, DOI 10.1103/PhysRevA.86.033401; Hainfeld JF, 2004, PHYS MED BIOL, V49, pN309, DOI 10.1088/0031-9155/49/18/N03; Hergenhahn U, 2011, J ELECTRON SPECTROSC, V184, P78, DOI 10.1016/j.elspec.2010.12.020; Jahnke T, 2015, J PHYS B ATOM MOL PH, V48; Kim JK, 2012, PHYS MED BIOL, V57, DOI 10.1088/0031-9155/57/24/8309; Kreidi K, 2008, PHYS REV A, V78, DOI 10.1103/PhysRevA.78.043422; Leung MKK, 2011, MED PHYS, V38, P1; Luchette M, 2014, NANOMED-NANOTECHNOL, V10, P1751, DOI 10.1016/j.nano.2014.06.004; Miladi I, 2015, NANOMED-NANOTECHNOL, V11, P247, DOI 10.1016/j.nano.2014.06.013; Mohan S, 2007, AM J PHYSIOL-CELL PH, V292, pC362, DOI 10.1152/ajpcell.00535.2005; Porcel E, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/8/085103; Porcel E, 2014, NANOMED-NANOTECHNOL, V10, P1601, DOI 10.1016/j.nano.2014.05.005; Stolterfoht N, 1988, LECTURE NOTES PHYSIC, V294, P3	33	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0301-634X	1432-2099		RADIAT ENVIRON BIOPH	Radiat. Environ. Biophys.	NOV	2015	54	4					423	431		10.1007/s00411-015-0612-7		9	Biology; Biophysics; Environmental Sciences; Radiology, Nuclear Medicine & Medical Imaging	Life Sciences & Biomedicine - Other Topics; Biophysics; Environmental Sciences & Ecology; Radiology, Nuclear Medicine & Medical Imaging	CV1OT	WOS:000364028400004		
J	Damiani, A; Cordero, RR; Carrasco, J; Watanabe, S; Kawamiya, M; Lagun, VE				Damiani, A.; Cordero, R. R.; Carrasco, J.; Watanabe, S.; Kawamiya, M.; Lagun, V. E.			Changes in the UV Lambertian equivalent reflectivity in the Southern Ocean: Influence of sea ice and cloudiness	REMOTE SENSING OF ENVIRONMENT			English	Article						Lambertian equivalent reflectivity; Albedo; Sea ice; Southern Ocean; Total cloud fraction	SURFACE ALBEDO; CLIMATE MODELS; TRENDS; RADIATION; CLOUDS; FEEDBACK; COVER; SNOW; ULTRAVIOLET; VARIABILITY	Existing Lambertian equivalent reflectivity (LER) ultraviolet (UV) data for the west region of the Southern Ocean indicate a decreasing trend. Since the area surrounding Antarctica is largely unpolluted, LER changes can only be due to variations in the cloud cover and/or in the sea ice extension. In order to evaluate their influence on LER and assess the trend of the UV reflectivity under ice-free and various sea ice concentration (SIC) levels, we compared a multi-satellite-based LER dataset with different satellite observations of cloud cover and SIC for October to March from 1979 to 2012. Despite the high cloud fraction for most of this period, sea ice was found to be the main driver of LER variability and had a greater influence on LER variability than cloud cover. The cloud cover was lower in spring than in summer for all datasets, and this difference appears to be primarily associated with the sea ice extent. While an increment of the cloud fraction of 20% has been found to cause an increase in LER of up to 13 reflectivity units (RU) under ice-free conditions, this increase is halved under low SIC. In contrast, no significant changes in LER data were found under high SIC levels. The correlation between LER and SIC is evident when the latter is higher than approximately 30%. The best correlations (r) between LER and SIC were found for the Weddell Sea (r = 0.87), the Ross Sea (r = 0.85), and the Indian Ocean (r = 0.90) for November, and for the Bellingshausen/Amundsen Seas (r = 0.86) and the Pacific Ocean (r = 0.83) for February and October, respectively. In contrast, no correlation was found in the proximity of the coastlines of west Antarctica in October. Overall, an enhancement of SIC from 0% to 100% results in a LER increase of 44 RU. This value is larger than the corresponding sea ice-induced increase computed for the observed and modeled shortwave albedos at the top of the atmosphere (21 and 13 RU, respectively). The LER data distributions for different regions and months show a marked seasonal double peak in reflectivity. The highest relative frequency is driven by the sea ice and peaks at approximately 90 RU, whereas the secondary peak of approximately 50 RU is dominated by cloudiness. Negative trends in the UV reflectivity of the grid cells characterized by a SIC greater than 30% were found for the Bellingshausen/Amundsen Seas (up to -3.6 +/- 1.0 per decade in March). Trends computed over the entire Southern Ocean for mid/high SIC bins are mostly negative, although are often not statistically significant. However, the trend in the reflectivity of the ice-free grid cells was generally positive, probably due to changes in the cloud amount/opacity. (C) 2015 Elsevier Inc All rights reserved.	[Damiani, A.; Watanabe, S.; Kawamiya, M.] Japan Agcy Marine Earth Sci & Technol, Kanazawa Ku, Yokohama, Kanagawa 2360001, Japan; [Cordero, R. R.] Univ Santiago Chile, Dept Phys, Santiago 8370966, Chile; [Carrasco, J.] Univ Magallanes, Punta Arenas 6200000, Chile; [Lagun, V. E.] Arctic & Antarctic Res Inst, Lab Antarctic Climate & Ocean Res, St Petersburg 199226, Russia	Damiani, A (reprint author), Japan Agcy Marine Earth Sci & Technol, Kanazawa Ku, 3173-25 Showa Machi, Yokohama, Kanagawa 2360001, Japan.	alecarlo.damiani@gmail.com			SOUSEI program, MEXT, Japan; CORFO [Preis 14BPC4-28651]; CONICYT-BMBF [Preis PCCI20130041]; FONDEF [Preis IT13I10034]; FONDECYF [Preis 1151034, Preis 1140239]; USACH-DICYT ASOCIATIVO	We would like to thank the three anonymous reviewers for providing constructive comments that improved the quality of our paper. The present study was supported by the SOUSEI program, MEXT, Japan. The Chilean team gratefully acknowledges the support of CORFO (Preis 14BPC4-28651), CONICYT-BMBF (Preis PCCI20130041), FONDEF (Preis IT13I10034), FONDECYF (Preis 1151034, and Preis 1140239), and USACH-DICYT ASOCIATIVO. VEL acknowledges the AARI Antarctic Science Program Subprogram "Study and Research of the Antarctic" of the Federal Target Program "World Ocean". Thanks are due to the Principal Investigators of the different experiments from which data were taken as well as to the corresponding data centers and services. LER data are available at the Goddard Earth Sciences Data and Information Services Center. The GEWEX Cloud Assessment data were obtained from the ClimServ Data Center of IPSL/CNRS. Sea ice concentration data are available at the NASA National Snow and Ice Data Center.	Ackerman S., 2006, DISCRIMINATING CLEAR; Herman JR, 2009, J GEOPHYS RES-ATMOS, V114, DOI [10.1029/2007JD009508.2009, 10.1029/2007JD009508]; Riihela A, 2013, ATMOS CHEM PHYS, V13, P3743, DOI 10.5194/acp-13-3743-2013; Pistone K, 2014, P NATL ACAD SCI USA, V111, P3322, DOI 10.1073/pnas.1318201111; Verlinden KL, 2011, J CLIMATE, V24, P5799, DOI 10.1175/2011JCLI3922.1; Weiss AI, 2012, CRYOSPHERE, V6, P479, DOI 10.5194/tc-6-479-2012; Holland PR, 2012, NAT GEOSCI, V5, P872, DOI [10.1038/ngeo1627, 10.1038/NGEO1627]; Loeb NG, 2012, NAT GEOSCI, V5, P110, DOI [10.1038/ngeo1375, 10.1038/NGEO1375]; Liu YH, 2010, J CLIMATE, V23, P1894, DOI 10.1175/2009JCLI3386.1; Cavalieri DJ, 2008, J GEOPHYS RES-OCEANS, V113, DOI 10.1029/2007JC004564; Heidinger AK, 2012, J APPL METEOROL CLIM, V51, P1129, DOI 10.1175/JAMC-D-11-02.1; Kleipool QL, 2008, J GEOPHYS RES-ATMOS, V113, DOI 10.1029/2008JD010290; Watanabe S, 2011, GEOSCI MODEL DEV, V4, P845, DOI 10.5194/gmd-4-845-2011; Mahlstein I, 2013, J GEOPHYS RES-ATMOS, V118, P5105, DOI 10.1002/jgrd.50443; Brandt RE, 2005, J CLIMATE, V18, P3606, DOI 10.1175/JCLI3489.1; Eisenman I, 2014, CRYOSPHERE, V8, P1289, DOI 10.5194/tc-8-1289-2014; Wuttke S, 2006, ANN GEOPHYS-GERMANY, V24, P7; Hartmann DL, 2014, J CLIMATE, V27, P2444, DOI 10.1175/JCLI-D-13-00411.1; Flanner MG, 2011, NAT GEOSCI, V4, P151, DOI [10.1038/ngeo1062, 10.1038/NGEO1062]; Rossow WB, 1999, B AM METEOROL SOC, V80, P2261, DOI 10.1175/1520-0477(1999)080<2261:AIUCFI>2.0.CO;2; Stammerjohn S, 2012, GEOPHYS RES LETT, V39, DOI 10.1029/2012GL050874; Winton M, 2006, J CLIMATE, V19, P359, DOI 10.1175/JCLI3624.1; den Outer PN, 2012, ATMOS MEAS TECH, V5, P3041, DOI 10.5194/amt-5-3041-2012; Cavalieri DJ, 2012, CRYOSPHERE, V6, P881, DOI 10.5194/tc-6-881-2012; Liu JP, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL019858; Comiso JC, 2008, GEOPHYS RES LETT, V35, DOI 10.1029/2007GL031972; Li XC, 2014, NATURE, V505, P538, DOI 10.1038/nature12945; Wylie D, 2005, J CLIMATE, V18, P3021, DOI 10.1175/JCLI3461.1; Palm SP, 2010, J GEOPHYS RES-ATMOS, V115, DOI 10.1029/2010JD013900; Damiani A, 2013, INT J REMOTE SENS, V34, P5812, DOI 10.1080/01431161.2013.796101; Gorodetskaya IV, 2006, ATMOS OCEAN, V44, P195, DOI 10.3137/ao.440206; CURRY JA, 1995, J CLIMATE, V8, P240, DOI 10.1175/1520-0442(1995)008<0240:SIACFM>2.0.CO;2; Wang XJ, 2012, ADV METEOROL, DOI 10.1155/2012/505613; Cavalieri DJ, 1999, J GEOPHYS RES-OCEANS, V104, P15803, DOI 10.1029/1999JC900081; Menzel WP, 2008, J APPL METEOROL CLIM, V47, P1175, DOI 10.1175/2007JAMC1705.1; Town MS, 2007, J CLIMATE, V20, P544, DOI 10.1175/JCLI4005.1; Sigmond M, 2010, GEOPHYS RES LETT, V37, DOI 10.1029/2010GL044301; Chan MA, 2013, J CLIMATE, V26, P3285, DOI 10.1175/JCLI-D-12-00204.1; Loeb NG, 2012, SURV GEOPHYS, V33, P359, DOI 10.1007/s10712-012-9175-1; Riihela A, 2013, NAT CLIM CHANGE, V3, P895, DOI [10.1038/nclimate1963, 10.1038/NCLIMATE1963]; Bender FAM, 2006, TELLUS A, V58, P320, DOI 10.1111/j.1600-0870.2006.00181.x; Damiani A, 2012, REMOTE SENS ENVIRON, V127, P162, DOI 10.1016/j.rse.2012.08.023; Herman J, 2013, ATMOS CHEM PHYS, V13, P8505, DOI 10.5194/acp-13-8505-2013; Adhikari L, 2012, J GEOPHYS RES-ATMOS, V117, DOI 10.1029/2011JD016719; Pirazzini R, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2004JD004617; Comiso JC, 2011, J GEOPHYS RES-OCEANS, V116, DOI 10.1029/2010JC006391; Vasilkov AP, 2010, ATMOS MEAS TECH, V3, P619, DOI 10.5194/amt-3-619-2010; Bromwich DH, 2012, REV GEOPHYS, V50, DOI 10.1029/2011RG000363; Herman JR, 2001, J GEOPHYS RES-ATMOS, V106, P5353, DOI 10.1029/2000JD900435; Winker DM, 2009, J ATMOS OCEAN TECH, V26, P2310, DOI 10.1175/2009JTECHA1281.1; Cordero RR, 2013, APPL OPTICS, V52, P6287, DOI 10.1364/AO.52.006287; CAVALIERI DJ, 1995, J GLACIOL, V41, P455; Lubin D, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD002702; Bodas-Salcedo A, 2014, J CLIMATE, V27, P41, DOI 10.1175/JCLI-D-13-00169.1; Turner J, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2009GL037524; Evan AT, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2006GL028083; Parkinson CL, 2012, CRYOSPHERE, V6, P871, DOI 10.5194/tc-6-871-2012; Labow GJ, 2011, J GEOPHYS RES-ATMOS, V116, DOI 10.1029/2010JD014980; Cavalieri D., 1996, SEA ICE CONCENTRATIO; Cordero R. R., 2014, PLOS ONE, V9; Damiani A., 2014, ATMOSPHERIC RES, V138, P2014; Grenfell T. C., 1994, J GEOPHYS RES; Herman JR, 1997, J GEOPHYS RES-ATMOS, V102, P28003, DOI 10.1029/97JD02074; Holland P. R., 2014, J CLIMATE; Ivanova N., 2015, CRYOSPHERE DISCUSSIO, V9, P1269, DOI DOI 10.5194/TCD-9-1269-2015; Laine V, 2014, REMOTE SENS ENVIRON, V140, P604, DOI 10.1016/j.rse.2013.10.001; Laine V, 2008, REMOTE SENS ENVIRON, V112, P646, DOI 10.1016/j.rse.2007.06.005; Lubin D., 2001, J GEOPHYS RES, V106, P33; Stubenrauch C. J., 2012, BULLETIN OF THE AMER; Trenberth K. E., 2010, J CLIMATE, V23; Vaughan D, 2013, CLIMATE CHANGE 2013; Watanabe S., 2008, J EARTH SIMULATOR, V9, P2008	72	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0034-4257	1879-0704		REMOTE SENS ENVIRON	Remote Sens. Environ.	NOV	2015	169						75	92		10.1016/j.rse.2015.07.030		18	Environmental Sciences; Remote Sensing; Imaging Science & Photographic Technology	Environmental Sciences & Ecology; Remote Sensing; Imaging Science & Photographic Technology	CU8TB	WOS:000363815900005		
J	Widlowski, JL; Mio, C; Disney, M; Adams, J; Andredakis, I; Atzberger, C; Brennan, J; Busetto, L; Chelle, M; Ceccherini, G; Colombo, R; Cote, JF; Eenmae, A; Essery, R; Gastellu-Etchegorry, JP; Gobron, N; Grau, E; Haverd, V; Homolova, L; Huang, H; Hunt, L; Kobayashi, H; Koetz, B; Kuusk, A; Kuusk, J; Lang, M; Lewis, PE; Lovell, JL; Malenovsky, Z; Meroni, M; Morsdorf, F; Mottus, M; Ni-Meister, W; Pinty, B; Rautiainen, M; Schlerf, M; Somers, B; Stuckens, J; Verstraete, MM; Yang, WZ; Zhao, F; Zenone, T				Widlowski, Jean-Luc; Mio, Corrado; Disney, Mathias; Adams, Jennifer; Andredakis, Ioannis; Atzberger, Clement; Brennan, James; Busetto, Lorenzo; Chelle, Michael; Ceccherini, Guido; Colombo, Roberto; Cote, Jean-Francois; Eenmaee, Alo; Essery, Richard; Gastellu-Etchegorry, Jean-Philippe; Gobron, Nadine; Grau, Eloi; Haverd, Vanessa; Homolova, Lucie; Huang, Huaguo; Hunt, Linda; Kobayashi, Hideki; Koetz, Benjamin; Kuusk, Andres; Kuusk, Joel; Lang, Mait; Lewis, Philip E.; Lovell, Jennifer L.; Malenovsky, Zbynek; Meroni, Michele; Morsdorf, Felix; Mottus, Matti; Ni-Meister, Wenge; Pinty, Bernard; Rautiainen, Miina; Schlerf, Martin; Somers, Ben; Stuckens, Jan; Verstraete, Michel M.; Yang, Wenze; Zhao, Feng; Zenone, Terenzio			The fourth phase of the radiative transfer model intercomparison (RAMI) exercise: Actual canopy scenarios and conformity testing	REMOTE SENSING OF ENVIRONMENT			English	Article						Conformity testing; Radiative transfer; Model benchmarking; 3D virtual plant canopy; Digital hemispherical photography; Optical remote sensing; Shared risk; Guarded acceptance; GCOS; ISO-13528	FOREST REFLECTANCE MODEL; ABSOLUTE RADIOMETRIC CALIBRATION; REMOTE-SENSING DATA; BIDIRECTIONAL SCATTERING; GAP FRACTION; CSAR MODEL; VALIDATION; LIGHT; SIMULATION; ATMOSPHERE	The RAdiative transfer Model Intercomparison (RAMI) activity focuses on the benchmarking of canopy radiative transfer (RT) models. For the current fourth phase of RAMI, six highly realistic virtual plant environments were constructed on the basis of intensive field data collected from (both deciduous and coniferous) forest stands as well as test sites in Europe and South Africa. Twelve RT modelling groups provided simulations of canopy scale (directional and hemispherically integrated) radiative quantities, as well as a series of binary hemispherical photographs acquired from different locations within the virtual canopies. The simulation results showed much greater variance than those recently analysed for the abstract canopy scenarios of RAMI-IV. Canopy complexity is among the most likely drivers behind operator induced errors that gave rise to the discrepancies. Conformity testing was introduced to separate the simulation results into acceptable and non-acceptable contributions. More specifically, a shared risk approach is used to evaluate the compliance of RI model simulations on the basis of reference data generated with the weighted ensemble averaging technique from ISO-13528. However, using concepts from legal metrology, the uncertainty of this reference solution will be shown to prevent a confident assessment of model performance with respect to the selected tolerance intervals. As an alternative, guarded risk decision rules will be presented to account explicitly for the uncertainty associated with the reference and candidate methods. Both guarded acceptance and guarded rejection approaches are used to make confident statements about the acceptance and/or rejection of RT model simulations with respect to the predefined tolerance intervals. (C) 2015 The Authors. Published by Elsevier Inc.	[Widlowski, Jean-Luc; Mio, Corrado; Adams, Jennifer; Gobron, Nadine; Pinty, Bernard] Commiss European Communities, Joint Res Ctr, Inst Environm & Sustainabil, Land Resources Management Unit, I-21027 Ispra, VA, Italy; [Disney, Mathias; Adams, Jennifer; Brennan, James; Lewis, Philip E.] UCL, Dept Geog, London WC1E 6BT, England; [Disney, Mathias; Brennan, James; Lewis, Philip E.] NERC, NCEO, Sheffield, S Yorkshire, England; [Andredakis, Ioannis] Commiss European Communities, Joint Res Ctr, Inst Protect & Secur Citizen, Global Secur & Crisis Management Unit, I-21027 Ispra, VA, Italy; [Atzberger, Clement] Univ Nat Resources & Life Sci, Inst Surveying Remote Sensing & Land Informat, Vienna, Austria; [Busetto, Lorenzo] Natl Res Council CNR IREA, Inst Remote Sensing Environm, I-20133 Milan, Italy; [Chelle, Michael] INRA, Ecosys UMR1402, F-78850 Thiverval Grignon, France; [Ceccherini, Guido] Commiss European Communities, Joint Res Ctr, Inst Environm & Sustainabil, Water Resources Unit, I-21027 Ispra, VA, Italy; [Colombo, Roberto] Univ Milano Bicocca, Dept Earth & Environm Sci DISAT, Remote Sensing Environm Dynam Lab, I-20126 Milan, Italy; [Cote, Jean-Francois] Nat Resources Canada, Canadian Wood Fibre Ctr, Ste Foy, PQ G1V 4C7, Canada; [Eenmaee, Alo; Lang, Mait] Estonian Univ Life Sci, Inst Forestry & Rural Engn, EE-51014 Tartu, Estonia; [Eenmaee, Alo; Kuusk, Andres; Kuusk, Joel; Lang, Mait] Tartu Observ, EE-61602 Toravere, Tartumaa, Estonia; [Essery, Richard] Univ Edinburgh, Sch Geosci, Edinburgh, Midlothian, Scotland; [Gastellu-Etchegorry, Jean-Philippe; Grau, Eloi] Ctr Natl Etud Spatiales, F-31055 Toulouse, France; [Haverd, Vanessa] CSIRO Oceans & Atmosphere Flagship, Canberra, ACT 2601, Australia; [Homolova, Lucie] Acad Sci Czech Republic, Global Change Res Ctr, Vvi, Brno 60300, Czech Republic; [Huang, Huaguo] Beijing Forestry Univ, Beijing, Peoples R China; [Hunt, Linda] Sci Syst & Applicat Inc, Hampton, VA 23666 USA; [Kobayashi, Hideki] Japan Agcy Marine Earth Sci & Technol, Yokohama, Kanagawa, Japan; [Koetz, Benjamin] European Space Agcy, ESRIN D EOP SEP, I-00044 Frascati, Italy; [Lovell, Jennifer L.] CSIRO Oceans & Atmosphere Flagship, Hobart, Tas 7001, Australia; [Malenovsky, Zbynek] Univ Wollongong, Sch Biol Sci, Inst Conservat Biol, Wollongong, NSW 2522, Australia; [Meroni, Michele] Commiss European Communities, Joint Res Ctr, Inst Environm & Sustainabil, Monitoring Agr Resources Unit, I-21027 Ispra, VA, Italy; [Morsdorf, Felix] Univ Zurich, Dept Geog, Remote Sensing Labs, CH-8057 Zurich, Switzerland; [Mottus, Matti] Univ Helsinki, Dept Geosci & Geog, FI-00014 Helsinki, Finland; [Ni-Meister, Wenge] CUNY Hunter Coll, Dept Geog, New York, NY 10021 USA; [Rautiainen, Miina] Aalto Univ, Dept Real Estate Planning & Geoinformat, Espoo 00076, Finland; [Rautiainen, Miina] Aalto Univ, Dept Radiosci & Engn, Espoo 00076, Finland; [Schlerf, Martin] Luxembourg Inst Sci & Technol, Dept Environm Res & Innovat, Belvaux, Luxembourg; [Somers, Ben] Katholieke Univ Leuven, Div Forest Nat & Landscape, Heverlee, Belgium; [Stuckens, Jan] Merkator Nv, B-1731 Zellik, Belgium; [Verstraete, Michel M.] South Africa Natl Space Agcy, SANSA Earth Observat, ZA-0087 Pretoria, South Africa; [Verstraete, Michel M.] Univ Witwatersrand, GCSRI, Johannesburg, South Africa; [Yang, Wenze] Univ Maryland, Earth Syst Sci Interdisciplinary Ctr, Cooperat Inst Climate & Satellites, College Pk, MD 20740 USA; [Zhao, Feng] Beijing Univ Aeronaut & Astronaut, Sch Instrument Sci & Optoelect Engn, Beijing 100191, Peoples R China; [Zenone, Terenzio] Univ Antwerp, Res Grp Plant & Vegetat Ecol, Dept Biol, B-2610 Antwerp, Belgium	Gobron, N (reprint author), Commiss European Communities, Joint Res Ctr, Inst Environm & Sustainabil, Land Resources Management Unit, Via E Fermi 2749, I-21027 Ispra, VA, Italy.		Homolova, Lucie/A-8436-2011; Yang, Wenze/B-8356-2012; Busetto, Lorenzo/M-1600-2014	Chelle, Michael/0000-0001-8151-1555; Busetto, Lorenzo/0000-0001-9634-6038	Estonian Ministry of Education and Research; Estonian Science Foundation	This study would not have been possible without the continuing support of A. Belward, head of the Land Resources Monitoring unit, at the Institute for Environment and Sustainability of the European Commission's Joint Research Centre in Ispra, Italy. A special thank you must also go to M. Buzica and M. Gerboles who clarified the first authors' understanding of both equivalence and compliance testing in the context of European ambient air quality directives. The technical support of M. Robustelli, as well as the contributions of J. Pisek and T. Lukk for the test site characterizations, are also greatly appreciated. The field work at Jarvselja was funded by the Estonian Ministry of Education and Research (target financing) as well as by Estonian Science Foundation grants.	Lavergne T, 2007, REMOTE SENS ENVIRON, V107, P362, DOI 10.1016/j.rse.2006.05.021; Pisek J, 2011, AGR FOREST METEOROL, V151, P365, DOI 10.1016/j.agrformet.2010.11.009; Bousquet L, 2005, REMOTE SENS ENVIRON, V98, P201, DOI 10.1016/j.rse.2005.07.005; [Anonymous], 1994, 5725 ISO; Kuusk A, 2008, REMOTE SENS ENVIRON, V112, P51, DOI 10.1016/j.rse.2006.06.025; Bruegge CJ, 2002, IEEE T GEOSCI REMOTE, V40, P1477, DOI 10.1109/TGRS.2002.801583; Yang WZ, 2010, AGR FOREST METEOROL, V150, P895, DOI 10.1016/j.agrformet.2010.02.008; Morsdorf F, 2006, REMOTE SENS ENVIRON, V104, P50, DOI 10.1016/j.rse.2006.04.019; [Anonymous], 2012, JCGM106; Pinty B, 2001, J GEOPHYS RES-ATMOS, V106, P11937, DOI 10.1029/2000JD900493; Widlowski JL, 2010, AGR FOREST METEOROL, V150, P1501, DOI 10.1016/j.agrformet.2010.07.011; Chelle M, 2006, ECOL MODEL, V198, P219, DOI 10.1016/j.ecolmodel.2006.04.010; Huang HG, 2009, INT J REMOTE SENS, V30, P5421, DOI 10.1080/01431160903130911; Pinty B, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2004JD005214; Liu QH, 2007, IEEE T GEOSCI REMOTE, V45, P2900, DOI 10.1109/TGRS.2007.902272; BRAKKE TW, 1989, REMOTE SENS ENVIRON, V29, P175, DOI 10.1016/0034-4257(89)90025-4; Lovell JL, 2012, AGR FOREST METEOROL, V158, P1, DOI 10.1016/j.agrformet.2012.01.020; Thome KJ, 2008, IEEE T GEOSCI REMOTE, V46, P3285, DOI 10.1109/TGRS.2008.928730; Kuusk A, 2009, REMOTE SENS ENVIRON, V113, P889, DOI 10.1016/j.rse.2009.01.005; Widlowski JL, 2013, J GEOPHYS RES-ATMOS, V118, P6869, DOI 10.1002/jgrd.50497; Smolander S, 2003, REMOTE SENS ENVIRON, V88, P363, DOI 10.1016/j.rse.2003.06.003; Somers B, 2009, PHOTOGRAMM ENG REM S, V75, P57; Ni-Meister W, 2010, AGR FOREST METEOROL, V150, P881, DOI 10.1016/j.agrformet.2010.02.009; Wang Y, 2011, REMOTE SENS ENVIRON, V115, P2710, DOI 10.1016/j.rse.2011.06.011; Sandmeier SR, 2000, REMOTE SENS ENVIRON, V73, P257, DOI 10.1016/S0034-4257(00)00102-4; McCorkel J, 2013, IEEE T GEOSCI REMOTE, V51, P1309, DOI 10.1109/TGRS.2012.2219874; Morsdorf F, 2004, REMOTE SENS ENVIRON, V92, P353, DOI 10.1016/j.rse.2004.05.013; Schlerf M, 2006, REMOTE SENS ENVIRON, V100, P281, DOI 10.1016/j.rse.2005.10.006; Stenberg P, 2001, TREE PHYSIOL, V21, P805; Kuusk A, 2014, REMOTE SENS ENVIRON, V149, P196, DOI 10.1016/j.rse.2014.03.035; Zhao F, 2010, REMOTE SENS ENVIRON, V114, P265, DOI 10.1016/j.rse.2009.09.018; [Anonymous], 2008, JCGM101; Schneider FD, 2014, REMOTE SENS ENVIRON, V152, P235, DOI 10.1016/j.rse.2014.06.015; Haverd V, 2012, AGR FOREST METEOROL, V160, P14, DOI 10.1016/j.agrformet.2012.01.018; Kaasalainen S, 2007, APPL OPTICS, V46, P4916, DOI 10.1364/AO.46.004916; Disney MI, 2009, IEEE T GEOSCI REMOTE, V47, P3262, DOI 10.1109/TGRS.2009.2019268; Jonckheere I, 2006, ECOL MODEL, V197, P179, DOI 10.1016/j.ecolmodel.2006.02.036; Holben BN, 1998, REMOTE SENS ENVIRON, V66, P1, DOI 10.1016/S0034-4257(98)00031-5; Kobayashi H, 2008, REMOTE SENS ENVIRON, V112, P173, DOI 10.1016/j.rse.2007.04.0l; Lewis P, 1999, AGRONOMIE, V19, P185, DOI 10.1051/agro:19990302; Jonckheere I, 2005, AGR FOREST METEOROL, V132, P96, DOI 10.1016/j.agrformet.2005.06.003; Kuusk A, 2010, REMOTE SENS ENVIRON, V114, P2962, DOI 10.1016/j.rse.2010.07.014; [Anonymous], 1998, ISO142531; Mottus M, 2006, ECOL MODEL, V198, P506, DOI 10.1016/j.ecolmodel.2006.05.033; Kuusk A, 2000, REMOTE SENS ENVIRON, V72, P244, DOI 10.1016/S0034-4257(99)00111-X; Govaerts YM, 2004, IEEE T GEOSCI REMOTE, V42, P1900, DOI 10.1109/TGRS.2004.831882; [Anonymous], 2008, 100 JCGM; Kotz B, 2004, REMOTE SENS ENVIRON, V92, P332, DOI 10.1016/j.rse.2004.05.015; Claverie M, 2013, REMOTE SENS ENVIRON, V139, P216, DOI 10.1016/j.rse.2013.07.027; [Anonymous], 2003, ISO105761; BREECE HT, 1971, APPL OPTICS, V10, P119, DOI 10.1364/AO.10.000119; Atzberger C., 2000, DECADE TRANSEUROPEAN, P39; Biliouris D., 2007, SENSORS, V7, P1846; Bojinski S., 2014, B AM METEOROLOGICAL, P95; Cote J.-F., 2015, HEMISPHERIC IN PRESS; Essery R, 2008, J HYDROMETEOROL, V9, P228, DOI 10.1175/2007JHM870.1; GastelluEtchegorry JP, 1996, REMOTE SENS ENVIRON, V58, P131, DOI 10.1016/0034-4257(95)00253-7; Gastellu-Etchegorry JP, 2004, INT J REMOTE SENS, V25, P73, DOI 10.1080/0143116031000115166; Gastellu-Etchegorry JP, 2015, REMOTE SENS-BASEL, V7, P1667, DOI 10.3390/rs70201667; GCOS, 2011, GCOS154 WORLD MET OR; Govaerts Y., 1995, THESIS U CATHOLIQUE; Helder D, 2013, IEEE T GEOSCI REMOTE, V51, P1360, DOI 10.1109/TGRS.2013.2243738; International Organization for Standardization, 2005, 13528 ISO; Kuusk A., 2013, LIGHT SCATTERING REV, V7, P109; Lintermann B., 1999, IEEE COMPUT GRAPH, V19, P2; Lolli L., 2014, METROLOGIA, V51, P309; Milton E.J., 2007, REMOTE SENS ENVIRON, V113, P92; Pendrill L. R., 2014, METROLOGIA, V51, P206; Penn J., 1995, SIGGRAPH 95, P119, DOI DOI 10.1145/218380.218427; Pharr M, 2010, PHYSICALLY BASED RENDERING: FROM THEORY TO IMPLEMENTATION, 2ND EDITION, P1; Pinty B., 2004, J GEOPHYS RES-ATMOSP, V109, DOI DOI 10.1029/2003JD004252; RAHMAN H, 1993, J GEOPHYS RES-ATMOS, V98, P20791, DOI 10.1029/93JD02072; RAHMAN H, 1993, J GEOPHYS RES-ATMOS, V98, P20779, DOI 10.1029/93JD02071; Sommer K.D., 2002, OIML B, VXLIII, P19; Stuckens J., 2009, J QUANTITATIVE SPECT; Widlowski JL, 2011, J GEOPHYS RES-BIOGEO, V116, DOI 10.1029/2010JG001511; Widlowski J.-L., 2007, REMOTE SENS ENVIRON, V112, P1144; Widlowski J.-L., 2006, LECT NOTES COMPUTATI, V48, P122; Widlowski J.-L., 2007, J GEOPHYS RES, V112, pD0911; Widlowski JL, 2015, ENVIRON SCI POLICY, V51, P149, DOI 10.1016/j.envsci.2015.03.018; Zenone T., 2008, P SHORT ROT CROPS IN	81	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0034-4257	1879-0704		REMOTE SENS ENVIRON	Remote Sens. Environ.	NOV	2015	169						418	437		10.1016/j.rse.2015.08.016		20	Environmental Sciences; Remote Sensing; Imaging Science & Photographic Technology	Environmental Sciences & Ecology; Remote Sensing; Imaging Science & Photographic Technology	CU8TB	WOS:000363815900032		
J	Inoue, M; Balaratnasingam, C; Freund, KB				Inoue, Maiko; Balaratnasingam, Chandrakumar; Freund, K. Bailey			OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY OF POLYPOIDAL CHOROIDAL VASCULOPATHY AND POLYPOIDAL CHOROIDAL NEOVASCULARIZATION	RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES			English	Article						optical coherence tomography angiography; polypoidal choroidal vasculopathy; polypoidal choroidal neovascuralization; indocyanine green angiography; multimodal imaging; pachychoroid neovasculopathy; branching vascular network	INDOCYANINE GREEN ANGIOGRAPHY; MACULAR DEGENERATION; CHORIORETINOPATHY; CLASSIFICATION; THICKNESS; EYES	Purpose: To describe the use of optical coherence tomography angiography (OCT-A) for evaluating the spectrum of polypoidal vascular diseases. Methods: Retrospective observational case series of seven patients with polypoidal choroidal vasculopathy (three cases) or polypoidal choroidal neovascularization (four cases). Optical coherence tomography angiography information was acquired using two different OCT-A devices (the Optovue RTVue XR Avanti SD-OCT and the Spectralis OCT angiography). Flow signals within branching vascular networks, type 1 neovascularization and polyps were evaluated. Comparisons were made between en face and cross-sectional OCT-A images. Vascular information from OCT-A was also compared with indocyanine green angiography. Results: En face images from OCT-A provided anatomical information about branching vascular networks that were comparable to indocyanine green angiography. Polyps were poorly resolved on en face OCT-A images but were clearly defined on cross-sectional OCT-A images. Cross-sectional OCT-A revealed flow signals within focal regions of the polyps with a significant portion of the polyp lumen being devoid of flow signal. Flow signals from cross-sectional OCT-A images also showed that branching vascular networks, type 1 neovascularization, and polyps were confined to the anatomic compartment between the retinal pigment epithelium and Bruch's membrane. It was not possible to detect leakage on en face or cross-sectional OCT-A. Conclusion: The combination of en face and cross-sectional OCT-A images provides anatomical information about polypoidal structures that is comparable to indocyanine green angiography. OCT-A may be a useful modality for the management of polypoidal diseases. However, the limitations of OCT-A identified in this study suggest that it is not a replacement for indocyanine green angiography.	[Inoue, Maiko; Balaratnasingam, Chandrakumar; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY 10022 USA; [Inoue, Maiko; Balaratnasingam, Chandrakumar; Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY USA; [Inoue, Maiko] Yokohama City Univ, Med Ctr, Dept Ophthalmol, Yokohama, Kanagawa 232, Japan; [Balaratnasingam, Chandrakumar] Univ Western Australia, Dept Physiol & Pharmacol, Ctr Ophthalmol & Visual Sci, Lions Eye Inst, Perth, WA 6009, Australia; [Freund, K. Bailey] NYU, Sch Med, Dept Ophthalmol, New York, NY USA	Freund, KB (reprint author), Vitreous Retina Macula Consultants New York, 460 Pk Ave,5th Floor, New York, NY 10022 USA.	kbfnyf@aol.com			LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear and Throat Hospital, New York, NY; Macular Foundation, Inc, New York, NY	Supported by the LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear and Throat Hospital, New York, NY, and the Macular Foundation, Inc, New York, NY. The funding organization had no role in the design or execution of this research.	Alshahrani Saeed T, 2014, Clin Ophthalmol, V8, P1689, DOI 10.2147/OPTH.S68471; Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018; Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502; Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1; Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010; Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b; HOPEROSS M, 1994, OPHTHALMOLOGY, V101, P529; Ross RD, 1996, RETINA-J RET VIT DIS, V16, P105; Kim JH, 2013, AM J OPHTHALMOL, V156, P974, DOI 10.1016/j.ajo.2013.06.013; Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5; Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14; Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134; Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007; Goldman DR, 2013, RETINA-J RET VIT DIS, V33, P48, DOI 10.1097/IAE.0b013e31825df12a; Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004; Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4; Lim TH, 2010, EYE, V24, P483, DOI 10.1038/eye.2009.323; Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05; Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035; Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321; Yuzawa Mitsuko, 2012, Nippon Ganka Gakkai Zasshi, V116, P200; Stanga PE, 2003, OPHTHALMOLOGY, V110, P15, DOI 10.1016/S0161-6420(02)01563-4; Yang LH, 2013, RETINA-J RET VIT DIS, V33, P1584, DOI 10.1097/IAE.0b013e318285cbb3; Miura M, 2015, INVEST OPHTH VIS SCI, V56, P3179, DOI 10.1167/iovs.14-16252; Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616; Bartlett HM, 2001, RETINA-J RET VIT DIS, V21, P396; Balaratnasingam C, RETINA IN PRESS; Dansingani KK, 2015, RETINA; Mashayekhi Arman, 2013, J Ophthalmic Vis Res, V8, P264; Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331; Peiretti Enrico, 2009, Retin Cases Brief Rep, V3, P12, DOI 10.1097/ICB.0b013e318166bd70; Stanga PE, 2003, OPHTHALMOLOGY, V110, P22; Tan CSH, 2014, BRIT J OPHTHALMOL, V98, P1528, DOI 10.1136/bjophthalmol-2014-305059; Tateiwa S, 2002, GRAEFES ARCH CLIN EX, V240, P354	34	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0275-004X	1539-2864		RETINA-J RET VIT DIS	Retin.-J. Retin. Vitr. Dis.	NOV	2015	35	11					2265	2274				10	Ophthalmology	Ophthalmology	CV5LD	WOS:000364311100014		
J	Takase, N; Nozaki, M; Kato, A; Ozeki, H; Yoshida, M; Ogura, Y				Takase, Noriaki; Nozaki, Miho; Kato, Aki; Ozeki, Hironori; Yoshida, Munenori; Ogura, Yuichiro			ENLARGEMENT OF FOVEAL AVASCULAR ZONE IN DIABETIC EYES EVALUATED BY EN FACE OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY	RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES			English	Article						deep capillary plexus layer; diabetic retinopathy; en face OCT angiography; foveal avascular zone (FAZ); microaneurysms; superficial capillary plexus layer	FLUORESCEIN ANGIOGRAPHY; ADHESION MOLECULE-1; VISUAL IMPAIRMENT; CAPILLARY NETWORK; RETINOPATHY; PREVALENCE; MELLITUS; PREVENTION; JAPAN	Purpose: To evaluate the area of the foveal avascular zone (FAZ) detected by en face OCTA (AngioVue, Avanti OCT; Optovue) in healthy and diabetic eyes. Methods: Retrospective chart review of patients who underwent fundus examination including en face OCTA. Eyes with proliferative diabetic retinopathy and history of laser photocoagulation were excluded. The FAZ area in the superficial and deep plexus layers were measured and evaluated using ImageJ software. Results: The FAZ area in the superficial layer was 0.25 0.06 mm(2) in healthy eyes (n = 19), whereas it was 0.37 +/- 0.07 mm(2) in diabetic eyes without retinopathy (n = 24) and 0.38 +/- 0.11 mm(2) in eyes with diabetic retinopathy (n = 20). Diabetic eyes showed statistically significant FAZ enlargement compared with healthy eyes, regardless of the presence of retinopathy (P < 0.01). The FAZ area in the deep plexus layer was also significantly larger in diabetic eyes than in healthy eyes (P < 0.01). Conclusion: Our data suggest that diabetic eyes show retinal microcirculation impairment in the macula even before retinopathy develops. En face OCTA is a useful noninvasive screening tool for detecting early microcirculatory disturbance in patients with diabetes.	[Takase, Noriaki; Nozaki, Miho; Kato, Aki; Yoshida, Munenori; Ogura, Yuichiro] Nagoya City Univ, Grad Sch Med Sci, Dept Ophthalmol & Visual Sci, Nagoya, Aichi 4678601, Japan; [Ozeki, Hironori] Ozeki Eye Clin, Kanie, Japan	Nozaki, M (reprint author), Nagoya City Univ, Grad Sch Med Sci, Dept Ophthalmol & Visual Sci, Mizuho Ku, 1 Kawasumi, Nagoya, Aichi 4678601, Japan.	nozakim@med.nagoya-cu.ac.jp					Jia YL, 2014, OPHTHALMOLOGY, V121, P1322, DOI 10.1016/j.ophtha.2014.01.021; Kim DY, 2012, INVEST OPHTH VIS SCI, V53, P85, DOI 10.1167/iovs.11-8249; Davis MD, 1998, INVEST OPHTH VIS SCI, V39, P233; Nittala MG, 2012, RETINA-J RET VIT DIS, V32, P1302, DOI 10.1097/IAE.0b013e3182365a24; AREND O, 1991, BRIT J OPHTHALMOL, V75, P514, DOI 10.1136/bjo.75.9.514; Kim SY, 2005, DIABETES, V54, P1534, DOI 10.2337/diabetes.54.5.1534; Nagaoka T, 2013, CURR EYE RES, V38, P1148, DOI 10.3109/02713683.2013.805232; Wako Rina, 2014, Nippon Ganka Gakkai Zasshi, V118, P495; Kawasaki R, 2011, DIABETOLOGIA, V54, P2288, DOI 10.1007/s00125-011-2199-0; Lecleire-Collet A, 2011, INVEST OPHTH VIS SCI, V52, P2861, DOI 10.1167/iovs.10-5960; MANSOUR AM, 1993, RETINA-J RET VIT DIS, V13, P125; Zhang XZ, 2010, JAMA-J AM MED ASSOC, V304, P649, DOI 10.1001/jama.2010.1111; Miyamoto K, 1999, P NATL ACAD SCI USA, V96, P10836, DOI 10.1073/pnas.96.19.10836; Stefansson E, 2000, ACTA OPHTHALMOL SCAN, V78, P374, DOI 10.1034/j.1600-0420.2000.078004374.x; Tam J, 2011, INVEST OPHTH VIS SCI, V52, P9257, DOI 10.1167/iovs.11-8481; Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710; Conrath J, 2005, EYE, V19, P322, DOI 10.1038/sj.eye.6701456; BRESNICK GH, 1984, ARCH OPHTHALMOL-CHIC, V102, P1286; MCLEOD DS, 1995, AM J PATHOL, V147, P642; Yamada M, 2010, OPHTHAL EPIDEMIOL, V17, P50, DOI 10.3109/09286580903450346; Schoenfeld ER, 2001, OPHTHALMOLOGY, V108, P563, DOI 10.1016/S0161-6420(00)00600-X; Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616; KLEIN R, 1987, INT OPHTHALMOL CLIN, V27, P230, DOI 10.1097/00004397-198702740-00003; Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034; YAMANA Y, 1988, BRIT J OPHTHALMOL, V72, P660, DOI 10.1136/bjo.72.9.660; Chibber Rakesh, 2007, Curr Diabetes Rev, V3, P3, DOI 10.2174/157339907779802139; De Benedetto U, 2014, RETINA-J RET VIT DIS, V34, P2171, DOI 10.1097/IAE.0000000000000205; Kawasaki R, 2015, OPHTHAL EPIDEMIOL, V22, P4, DOI 10.3109/09286586.2014.988876; Miyamoto K, 1999, Semin Ophthalmol, V14, P233, DOI 10.3109/08820539909069542; Nelson Darin A, 2011, Clin Ophthalmol, V5, P1095, DOI 10.2147/OPTH.S20103; Tam J, 2012, OPTOMETRY VISION SCI, V89, pE692, DOI 10.1097/OPX.0b013e3182548b07	31	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0275-004X	1539-2864		RETINA-J RET VIT DIS	Retin.-J. Retin. Vitr. Dis.	NOV	2015	35	11					2377	2383				7	Ophthalmology	Ophthalmology	CV5LD	WOS:000364311100027		
J	Totsuka, K; Inui, H; Roggia, MF; Hirasawa, K; Noda, Y; Ueta, T				Totsuka, Kiyohito; Inui, Hiroko; Roggia, Murilo F.; Hirasawa, Kazunori; Noda, Yasuo; Ueta, Takashi			SUPPLEMENTAL SCLERAL BUCKLE IN VITRECTOMY FOR THE REPAIR OF RHEGMATOGENOUS RETINAL DETACHMENT A Systematic Review of Literature and Meta-Analysis	RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES			English	Review						retinal detachment; vitrectomy; scleral buckle; meta-analysis	PARS-PLANA VITRECTOMY; SURGICAL-MANAGEMENT; SURGERY	Purpose: To evaluate the effect of supplemental scleral buckle (SB) in pars plana vitrectomy (PPV) for rhegmatogenous retinal detachment. Methods: MEDLINE, EMBASE, and CENTRAL were searched to identify studies comparing PPV with supplemental SB (PPV + SB) to PPV alone for the repair of rhegmatogenous retinal detachment. The outcome measures were primary and final reattachment rates, and postoperative complications. Odds ratio with 95% confidence interval in random effects for the comparison of outcomes between PPV + SB and PPV alone was calculated. Results: Ten studies consisting of 1,704 patients were included. Meta-analysis showed that the overall primary reattachment rate was significantly higher in PPV + SB than PPV alone (odds ratio, 1.70; 95% confidence interval, 1.21-2.39; P = 0.002). The final reattachment rate was equally high in both groups. Postoperative development of epiretinal membrane was more frequent in PPV + SB than in PPV alone (odds ratio, 1.89; 95% confidence interval, 1.30-2.76; P = 0.001), whereas no significant difference in postoperative development of macular edema, proliferative vitreoretinopathy, or elevation of intraocular pressure was found. Conclusion: Supplemental SB increases the primary reattachment rate in PPV for rhegmatogenous retinal detachment, although final reattachment rate was equally high with or without SB.	[Totsuka, Kiyohito; Inui, Hiroko; Roggia, Murilo F.; Hirasawa, Kazunori; Noda, Yasuo; Ueta, Takashi] Univ Tokyo, Dept Ophthalmol, Grad Sch Med, Tokyo 1138655, Japan; [Totsuka, Kiyohito; Inui, Hiroko; Roggia, Murilo F.; Hirasawa, Kazunori; Noda, Yasuo; Ueta, Takashi] Univ Tokyo, Fac Med, Tokyo 113, Japan; [Hirasawa, Kazunori] Kitasato Univ, Sch Allied Hlth Sci, Dept Rehabil, Orthopt & Visual Sci, Sagamihara, Kanagawa, Japan	Ueta, T (reprint author), Univ Tokyo, Dept Ophthalmol, Grad Sch Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	ueta-tky@umin.ac.jp					Mehta S, 2011, CAN J OPHTHALMOL, V46, P237, DOI 10.1016/j.jcjo.2011.05.003; Li TJ, 2013, OPHTHALMOLOGY, V120, P1113, DOI 10.1016/j.ophtha.2012.11.038; Hayashi H, 1997, OPHTHALMOLOGY, V104, P831; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Pournaras CJ, 2003, EUR J OPHTHALMOL, V13, P298; Stangos AN, 2004, AM J OPHTHALMOL, V138, P952, DOI 10.1016/j.ajo.2004.06.086; Soni C, 2013, OPHTHALMOLOGY, V120, P1440, DOI 10.1016/j.ophtha.2012.12.033; KWARTZ J, 1994, BRIT J OPHTHALMOL, V78, P409, DOI 10.1136/bjo.78.5.409; FISON PN, 1987, BRIT J OPHTHALMOL, V71, P521, DOI 10.1136/bjo.71.7.521; Weichel ED, 2006, OPHTHALMOLOGY, V113, P2033, DOI 10.1016/j.ophtha.2006.05.038; Kinori M, 2011, AM J OPHTHALMOL, V152, P291, DOI 10.1016/j.ajo.2011.01.049; YOSHIDA A, 1983, AM J OPHTHALMOL, V95, P182, DOI 10.1016/0002-9394(83)90012-0; Arya AV, 2006, OPHTHALMOLOGY, V113, P1724, DOI 10.1016/j.ophtha.2006.05.044; Romano MR, 2011, RETINA-J RET VIT DIS, V31, P686, DOI 10.1097/IAE.0b013e3181f0d249; Schaal S, 2011, RETINA-J RET VIT DIS, V31, P1500, DOI 10.1097/IAE.0b013e31820d3f55; Orlin A, 2014, RETINA-J RET VIT DIS, V34, P1069, DOI 10.1097/IAE.0000000000000050; Heimann H, 2007, OPHTHALMOLOGY, V114, P2142, DOI 10.1016/j.ophtha.2007.09.013; Higgins JP, 2011, COCHRANE COLLABORATI, DOI DOI 10.1136/BMJ.D5928; Siqueira Rubens Camargo, 2007, Arq Bras Oftalmol, V70, P298, DOI 10.1590/S0004-27492007000200020; Storey P, 2014, RETINA-J RET VIT DIS, V34, P1945, DOI 10.1097/IAE.0000000000000216	20	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0275-004X	1539-2864		RETINA-J RET VIT DIS	Retin.-J. Retin. Vitr. Dis.	NOV	2015	35	11					2423	2431				9	Ophthalmology	Ophthalmology	CV5LD	WOS:000364311100035		
J	Kikuchi, H; Inoue, S; Odagiri, Y; Inoue, M; Sawada, N; Tsugane, S				Kikuchi, Hiroyuki; Inoue, Shigeru; Odagiri, Yuko; Inoue, Manami; Sawada, Norie; Tsugane, Shoichiro		JPHC Study Grp	Occupational sitting time and risk of all-cause mortality among Japanese workers	SCANDINAVIAN JOURNAL OF WORK ENVIRONMENT & HEALTH			English	Article						Japan; occupational health; occupational injury; occupational illness; sedentary lifestyle	TELEVISION VIEWING TIME; ISCHEMIC-HEART-DISEASE; PHYSICAL-ACTIVITY; LEISURE-TIME; CARDIOVASCULAR-DISEASE; SEDENTARY BEHAVIOR; METABOLIC RISK; LIFE-STYLE; FINNISH SUBJECTS; OBESITY	Objectives Prolonged sitting is a health risk for cardiovascular diseases and all-cause mortality, independent of moderate-to-vigorous physical activity. Epidemiological evaluation of occupational sitting has received little attention, even though it may have a potential impact on workers' health. We prospectively examined the association between occupational sitting time and all-cause mortality. Methods Community-dwelling, Japanese workers aged 50-74 years who responded to a questionnaire in 2000-2003 were followed for all-cause mortality through 2011. Cox proportional hazard models were employed to calculate hazard ratios (BR) of all-cause mortality among middle (1-<3 hours/day) or longer (>= 3 hours/day) occupationally sedentary subjects by gender or types of engaging industry ("primary industry" and "secondary or tertiary industry"). Results During 368 120 person-years of follow-up (average follow-up period, 10.1 years) for the 36 516 subjects, 2209 deaths were identified. Among workers in primary industry, longer duration of occupational sitting was significantly or marginally associated with higher mortality [HR 1.23, 95% confidence interval (95% CI) 1.00-1.51 among men; HR 1.34, 95% CI 0.97-1.84 among women]. No associations were found among secondary or tertiary industry workers (men: HR 0.87, 95% CI 0.75-1.01; women: HR 1.03, 95% CI 0.77-1.39). Conclusions Occupational sitting time increased all-cause mortality among primary industry workers, however similar relationships were not observed for secondary-tertiary workers. Future studies are needed to confirm detailed dose response relationships by using objective measures. In addition, studies using cause-specific mortality data would be important to clarify the physiological underlying mechanism.	[Kikuchi, Hiroyuki; Inoue, Shigeru; Odagiri, Yuko] Tokyo Med Univ, Dept Prevent Med & Publ Hlth, Tokyo 1608402, Japan; [Inoue, Manami; Sawada, Norie; Tsugane, Shoichiro] Univ Tokyo, Grad Sch Med, Tokyo, Japan; [Inoue, Manami; Sawada, Norie; Tsugane, Shoichiro] Natl Canc Ctr, Res Ctr Canc Prevent & Screening, Epidemiol & Prevent Grp, Tokyo 104, Japan	Inoue, S (reprint author), Tokyo Med Univ, Shinjuku Ku, 6-1-1 Shinjuku, Tokyo 1608402, Japan.	inoue@tokyo-med.ac.jp			National Cancer Centre Research and Development Fund [23-A-31, 26-A-2]; Cancer Research from the Ministry of Health, Labor and Welfare of Japan; Japan Ministry of Education, Culture, Sports, Science and Technology [25282209]	This study was supported by National Cancer Centre Research and Development Fund (23-A-31[toku] and 26-A-2) (since 2011) and a Grant-in-Aid for Cancer Research from the Ministry of Health, Labor and Welfare of Japan (1989-2010). Shigeru Inoue was supported by the Grant-in-Aid for Scientific Research (B): 25282209 from the Japan Ministry of Education, Culture, Sports, Science and Technology.	Grontved A, 2011, JAMA-J AM MED ASSOC, V305, P2448, DOI 10.1001/jama.2011.812; Tremblay MS, 2010, APPL PHYSIOL NUTR ME, V35, P725, DOI 10.1139/H10-079; Wijndaele K, 2011, INT J EPIDEMIOL, V40, P150, DOI 10.1093/ije/dyq105; Holtermann A, 2010, SCAND J WORK ENV HEA, V36, P366; Hu FB, 2003, JAMA-J AM MED ASSOC, V289, P1785, DOI 10.1001/jama.289.14.1785; Hu G, 2004, CIRCULATION, V110, P666, DOI 10.1161/01.CIR.0000138102.23783.94; Haskell WL, 2007, CIRCULATION, V116, P1081, DOI 10.1161/CIRCULATIONAHA.107.185649; Owen N, 2011, AM J PREV MED, V41, P189, DOI 10.1016/j.amepre.2011.05.013; Ford ES, 2012, INT J EPIDEMIOL, V41, P1338, DOI 10.1093/ije/dys078; Owen N, 2010, EXERC SPORT SCI REV, V38, P105, DOI 10.1097/JES.0b013e3181e373a2; Healy GN, 2008, MED SCI SPORT EXER, V40, P639, DOI 10.1249/MSS.0b013e3181607421; Hamilton MT, 2007, DIABETES, V56, P2655, DOI 10.2337/db07-0882; Dunstan DW, 2010, CIRCULATION, V121, P384, DOI 10.1161/CIRCULATIONAHA.109.894824; SALONEN JT, 1988, AM J EPIDEMIOL, V127, P87; Lagersted-Olsen J, 2014, INT J SPORTS MED, V35, P534, DOI 10.1055/s-0033-1358467; Brown WJ, 2003, INT J OBESITY, V27, P1340, DOI 10.1038/sj.ijo.0802426; Katzmarzyk PT, 2009, MED SCI SPORT EXER, V41, P998, DOI 10.1249/MSS.0b013e3181930355; Andersen LB, 2000, ARCH INTERN MED, V160, P1621, DOI 10.1001/archinte.160.11.1621; Biddle SJH, 2004, J R SOC PROMO HEALTH, V124, P29, DOI 10.1177/146642400312400110; Evenson KR, 2002, AM J EPIDEMIOL, V155, P692, DOI 10.1093/aje/155.8.692; Wilmot EG, 2012, DIABETOLOGIA, V55, P2895, DOI 10.1007/s00125-012-2677-z; Krause N, 2000, SCAND J WORK ENV HEA, V26, P227; Healy GN, 2008, DIABETES CARE, V31, P661, DOI 10.2337/dc07-2046; van Uffelen JGZ, 2010, AM J PREV MED, V39, P379, DOI 10.1016/j.amepre.2010.05.024; Hamilton MT, 2004, EXERC SPORT SCI REV, V32, P161; Bey L, 2003, J PHYSIOL-LONDON, V551, P673, DOI 10.1113/jphysiol.2003.045591; Davis-Lameloise N, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1090; Ekelund U, 2006, PLOS MED, V3, P2449, DOI 10.1371/journal.pmed.0030488; Hamilton MT, 2008, CURR CARDIOVASC RISK, V2, P292, DOI DOI 10.1007/S12170-008-0054-8; Hu G, 2007, AM J HYPERTENS, V20, P1242, DOI 10.1016/j.amjhyper.2007.07.015; Matsuzawa Y, 2000, J JAPAN SOC STUDY OB, V6, P18; Messing K, 2015, J OCCUP ENVIRON HYG, V12, pD11, DOI 10.1080/15459624.2014.987388; Sedentary Behaviour Research Network, 2012, APPL PHYSIOL NUTR ME, V37, P540, DOI DOI 10.1139/H2012-024; Stamatakis E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073753; Touvier M, 2010, INT J BEHAV NUTR PHY, V7, DOI 10.1186/1479-5868-7-14; Tsugane S, 2014, JPN J CLIN ONCOL, V44, P777, DOI 10.1093/jjco/hyu096; Wong SL, 2009, PREV CHRONIC DIS, V6; World Health Organization, 1990, INT CLASS DIS HLTH R	38	0	0	SCANDINAVIAN JOURNAL WORK ENVIRONMENT & HEALTH	HELSINKI	TOPELIUKSENKATU 41A, SF-00250 HELSINKI, FINLAND	0355-3140	1795-990X		SCAND J WORK ENV HEA	Scand. J. Work Environ. Health	NOV	2015	41	6					519	528		10.5271/sjweh.3526		10	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	CV1EY	WOS:000363997700003		
J	Polischuk, OV; Popov, VV; Otsuji, T				Polischuk, O. V.; Popov, V. V.; Otsuji, T.			Superradiant amplification of terahertz radiation by plasmons in inverted graphene with a planar distributed Bragg resonator	SEMICONDUCTORS			English	Article								It is shown theoretically that stimulated generation of terahertz radiation by plasmons in graphene with a planar distributed Bragg resonator is possible at two different frequencies for each plasmon mode. This behavior may be attributed to the superradiance of the collective plasmon mode, which is associated with superlinear increase in the radiative damping of the plasmons with increase in pumping power. As a result, the curves of the radiative damping and the plasmon gain as a function of the pumping power intersect at two points corresponding to different generation conditions.	[Polischuk, O. V.; Popov, V. V.] Russian Acad Sci, Kotelnikov Inst Radioengn & Elect, Saratov Branch, Saratov 410019, Russia; [Otsuji, T.] Tohoku Univ, Elect Commun Res Inst, Sendai, Miyagi 9808577, Japan	Polischuk, OV (reprint author), Russian Acad Sci, Kotelnikov Inst Radioengn & Elect, Saratov Branch, Saratov 410019, Russia.	polischuk.sfire@mail.ru; popov_slava@yahoo.co.uk			Russian Foundation for Basic Research [13-02-12070, 14-02-92102]	Financial support was provided by the Russian Foundation for Basic Research (grants nos. 13-02-12070 and 14-02-92102).	Sprinkle M, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.226803; Novoselov KS, 2005, NATURE, V438, P197, DOI 10.1038/nature04233; Hanson GW, 2008, J APPL PHYS, V103, DOI 10.1063/1.2891452; Popov VV, 2010, PHYS REV B, V81, DOI 10.1103/PhysRevB.81.073404; Fei Z, 2012, NATURE, V487, P82, DOI 10.1038/nature11253; Popov VV, 2003, J APPL PHYS, V94, P3556, DOI 10.1063/1.1599051; Rana F, 2007, PHYS REV B, V76, DOI 10.1103/PhysRevB.76.155431; Dubinov AA, 2011, J PHYS-CONDENS MAT, V23, DOI 10.1088/0953-8984/23/14/145302; Dawlaty JM, 2008, APPL PHYS LETT, V92, DOI 10.1063/1.2837539; Popov VV, 2012, PHYS REV B, V86, DOI 10.1103/PhysRevB.86.195437; Ryzhii V, 2009, J APPL PHYS, V106, DOI 10.1063/1.3247541; George PA, 2008, NANO LETT, V8, P4248, DOI 10.1021/nl8019399; Chen JN, 2012, NATURE, V487, P77, DOI 10.1038/nature11254; Popov VV, 2013, J OPTICS-UK, V15, DOI 10.1088/2040-8978/15/11/114009; Otsuji T, 2012, J PHYS D APPL PHYS, V45, DOI 10.1088/0022-3727/45/30/303001; Boubanga-Tombet S, 2012, PHYS REV B, V85, DOI 10.1103/PhysRevB.85.035443; Peres NMR, 2010, REV MOD PHYS, V82, P2673, DOI 10.1103/RevModPhys.82.2673; Orlita M, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.267601; Falkovsky LA, 2007, PHYS REV B, V76, DOI 10.1103/PhysRevB.76.153410; Neto H. C., 2009, REV MOD PHYS, V81, P109; Ryzhii V., 2001, JPN J APPL PHYS, V50; Tan YW, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.246803; Winzer T, 2012, PHYS REV B, V85, DOI 10.1103/PhysRevB.85.241404	23	0	0	MAIK NAUKA/INTERPERIODICA/SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013-1578 USA	1063-7826	1090-6479		SEMICONDUCTORS+	Semiconductors	NOV	2015	49	11					1468	1472		10.1134/S1063782615110172		5	Physics, Condensed Matter	Physics	CV4HM	WOS:000364227800015		
J	Valentini-Botinhao, C; Toman, M; Pucher, M; Schabus, D; Yamagishi, J				Valentini-Botinhao, Cassia; Toman, Markus; Pucher, Michael; Schabus, Dietmar; Yamagishi, Junichi			Intelligibility of time-compressed synthetic speech: Compression method and speaking style	SPEECH COMMUNICATION			English	Article						Fast speech; Time-compression; HMM-based speech synthesis; Blind individuals	PERCEPTION; ALGORITHMS	We present a series of intelligibility experiments performed on natural and synthetic speech time-compressed at a range of rates and analyze the effect of speech corpus and compression method on the intelligibility scores of sighted and blind individuals. Particularly we are interested in comparing linear and non-linear compression methods applied to normal and fast speech of different speakers. We recorded English and German language voice talents reading prompts at a normal and a fast rate. To create synthetic voices we trained a statistical parametric speech synthesis system based on the normal and the fast data of each speaker. We compared three compression methods: scaling the variance of the state duration model, interpolating the duration models of the fast and the normal voices, and applying a linear compression method to the generated speech waveform. Word recognition results for the English voices show that generating speech at a normal speaking rate and then applying linear compression resulted in the most intelligible speech at all tested rates. A similar result was found when evaluating the intelligibility of the natural speech corpus. For the German voices, interpolation was found to be better at moderate speaking rates but the linear method was again more successful at very high rates, particularly when applied to the fast data. Phonemic level annotation of the normal and fast databases showed that the German speaker was able to reproduce speech at a fast rate with fewer deletion and substitution errors compared to the English speaker, supporting the intelligibility benefits observed when compressing his fast speech. This shows that the use of fast speech data to create faster synthetic voices does not necessarily lead to more intelligible voices as results are highly dependent on how successful the speaker was at speaking fast while maintaining intelligibility. Linear compression applied to normal rate speech can more reliably provide higher intelligibility, particularly at ultra fast rates. (C) 2015 Elsevier B.V. All rights reserved.	[Valentini-Botinhao, Cassia; Yamagishi, Junichi] Univ Edinburgh, Ctr Speech Technol Res, Edinburgh, Midlothian, Scotland; [Toman, Markus; Pucher, Michael; Schabus, Dietmar] Telecommun Res Ctr Vienna FTW, Vienna, Austria; [Yamagishi, Junichi] Natl Inst Informat, Tokyo, Japan	Valentini-Botinhao, C (reprint author), Univ Edinburgh, Ctr Speech Technol Res, Edinburgh, Midlothian, Scotland.	cvbotinh@inf.ed.ac.uk			Austrian Federal Ministry of Science and Research (BMWF) - Sparkling Science project Sprachsynthese von Auditiven Lehrbuchern fur Blinde SchulerInnen (SALB); BMVIT; BMWA; City of Vienna	This work was supported by the Austrian Federal Ministry of Science and Research (BMWF) - Sparkling Science project Sprachsynthese von Auditiven Lehrbuchern fur Blinde SchulerInnen (SALB). The Competence Center FTW Forschungszentrum Telekommunikation Wien GmbH is funded within the program COMET - Competence Centers for Excellent Technologies by BMVIT, BMWA, and the City of Vienna. The COMET program is managed by the FFG.	MAXEMCHUK NF, 1980, AT&T TECH J, V59, P1383; PORT RF, 1981, J ACOUST SOC AM, V69, P262, DOI 10.1121/1.385347; Sanderman AA, 1997, LANG SPEECH, V40, P391; Nygaard LC, 1998, PERCEPT PSYCHOPHYS, V60, P355, DOI 10.3758/BF03206860; Janse E, 2003, SPEECH COMMUN, V41, P287, DOI 10.1016/S0167-6393(02)00130-9; Yamagishi J, 2009, IEEE T AUDIO SPEECH, V17, P66, DOI 10.1109/TASL.2008.2006647; Tokuda K, 2000, INT CONF ACOUST SPEE, P1315, DOI 10.1109/ICASSP.2000.861820; Neubarth F, 2008, INTERSPEECH 2008: 9TH ANNUAL CONFERENCE OF THE INTERNATIONAL SPEECH COMMUNICATION ASSOCIATION 2008, VOLS 1-5, P1877; GAY T, 1978, J ACOUST SOC AM, V63, P223, DOI 10.1121/1.381717; Tachibana M, 2005, IEICE T INF SYST, VE88D, P2484, DOI 10.1093/ietisy/e88-d.11.2484; Pucher M, 2010, 11TH ANNUAL CONFERENCE OF THE INTERNATIONAL SPEECH COMMUNICATION ASSOCIATION 2010 (INTERSPEECH 2010), VOLS 3 AND 4, P2186; Cooke M, 2013, SPEECH COMMUN, V55, P572, DOI 10.1016/j.specom.2013.01.001; Hazan V, 2011, J ACOUST SOC AM, V130, P2139, DOI 10.1121/1.3623753; GREISBACH R, 1992, SPEECH COMMUN, V11, P469, DOI 10.1016/0167-6393(92)90053-A; Stent A, 2011, ASSETS 11: PROCEEDINGS OF THE 13TH INTERNATIONAL ACM SIGACCESS CONFERENCE ON COMPUTERS AND ACCESSIBILITY, P211; Janse E, 2004, SPEECH COMMUN, V42, P155, DOI 10.1016/j.specom.2003.07.001; Zen H, 2007, IEICE T INF SYST, VE90D, P825, DOI 10.1093/ietisy/e90-d.5.825; Kawahara H, 1999, SPEECH COMMUN, V27, P187, DOI 10.1016/S0167-6393(98)00085-5; [Anonymous], 1998, ACOUST SPEECH SIG PR; Richmond K, 2010, 11TH ANNUAL CONFERENCE OF THE INTERNATIONAL SPEECH COMMUNICATION ASSOCIATION 2010 (INTERSPEECH 2010), VOLS 3 AND 4, P1974; Arons B., 1994, THESIS MIT; Arons B., 1992, P 1992 C AM VOIC I O, P169; Boersma P., PRAAT DOINT PHONETIC; Fukada T., 1992, P ICASSP 92, V1, P137; Goldman-Eisler Frieda, 1968, PSYCHOLINGUISTICS EX; He L., 2001, P C MULT OTT, P382; IEEE, 1969, IEEE T AUDIO ELECTRO, V17, P225, DOI DOI 10.1109/TAU.1969.1162058; Moers D., 2010, P 6 ISCA TUT RES WOR; Moers D., 2010, P SPEECH PROS CHIC U; Moos A., 2007, P 16 INT C PHON SCI, V1, P677; Pucher M., 2015, P INTERSPEECH; Rabiner L. R., 2010, THEORY APPL DIGITAL; Saunders S., 2010, WORKING PAPERS LINGU, V20, P63; Sticht T.G., 1969, PSYCHOL BULL, V72, P50; Syrdal A.K., 2012, P INTERSPEECH; Trouvain J., 2007, SAARLAND WORKING PAP, V1, P5; Valentini-Botinhao C., 2014, P INTERSPEECH; Verhelst W., 1993, IEEE INT C AC SPEECH, V2, P554, DOI 10.1109/ICASSP.1993.319366; Yoshimura T., 1998, P ICSLP, P29; Yoshimura T., 2000, Journal of the Acoustical Society of Japan (E), V21, DOI 10.1250/ast.21.199	40	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0167-6393	1872-7182		SPEECH COMMUN	Speech Commun.	NOV	2015	74						52	64		10.1016/j.specom.2015.09.002		13	Acoustics; Computer Science, Interdisciplinary Applications	Acoustics; Computer Science	CV4RY	WOS:000364255400004		
J	Masuda, M; Ueta, T; Shiba, K; Iwamoto, Y				Masuda, Muneaki; Ueta, Takayoshi; Shiba, Keiichiro; Iwamoto, Yukihide			D-dimer screening for deep venous thrombosis in traumatic cervical spinal injuries	SPINE JOURNAL			English	Article						Deep venous thrombosis; Cervical spinal injuries; D-dimer; Ultrasonography; Screening test; Pulmonary embolism; Comorbidity	CORD-INJURY; VEIN THROMBOSIS; DUPLEX ULTRASOUND; HETEROTOPIC OSSIFICATION; PULMONARY-EMBOLISM; REHABILITATION; DIAGNOSIS; ADMISSION; RISK	BACKGROUND CONTEXT: Deep venous thrombosis (DVT) in spinal cord injury (SCI) patients is a life-threatening comorbidity. Despite its seriousness, prophylaxis and screening for DVT in SCI patients are still not sophisticated. PURPOSE: This study aimed to define the epidemiology and incidence of DVT in acute traumatic cervical SCI in a Japanese population, determine the best timing for DVT screening, and determine the optimal D-dimer threshold level for use as an easy and minimally invasive screening tool. STUDY DESIGN: This is a prospective clinical study. PATIENT SAMPLE: The patient sample included acute traumatic cervical SCI patients who were admitted to our facility within 2 weeks after injury. OUTCOME MEASURE: Multivariate logistic regression was performed for outcome measure. METHODS: We enrolled 268 patients (223 men and 45 women), from April 2007 to December 2012. After excluding early drop-out patients, 211 patients remained. Assessment for neurological status and blood chemistry, especially blood coagulation levels (prothrombin time, prothrombin time-international normalized ratio, activated partial thromboplastin time, and serumD-dimer), was performed every week until 1 month after injury. Ultrasonography was performed for DVT detection every 2 weeks. RESULTS: Deep venous thromboses were detected in 22 patients (10.4% of patients studied). All DVT-positive patients demonstrated severe paralysis classified as C or greater on the American Spinal Injury Association (ASIA) Impairment Scale. Multivariate logistic regression of clinical and laboratory parameters revealed that only the D-dimer level at 2 weeks after injury was an accurate predictor of DVT formation. The optimal threshold of D-dimer for prediction was determined to be 16 mg/dL. The sensitivity and specificity for detecting DVT were 77.3% and 69.2%, respectively. CONCLUSIONS: D-dimer levels may be used to predict the likelihood of DVT development in patients with acute cervical SCI. Furthermore, the optimal timing for screening test by D-dimer is 2 weeks after injury, and optimal threshold level for D-dimer for diagnosing DVT is 16 mg/dL. Such a screening test would be cost-efficient and simple to administer and could then be followed with additional investigations, such as ultrasonography or venography. (C) 2015 Elsevier Inc. All rights reserved.	[Masuda, Muneaki; Ueta, Takayoshi; Shiba, Keiichiro] Japan Labour Hearth & Welf Org Spinal Injuries Ct, Dept Orthopaed Surg, Iizuka, Fukuoka 8200053, Japan; [Iwamoto, Yukihide] Kyushu Univ, Grad Sch Med Sci, Dept Orthopaed Surg, Higashi Ku, Fukuoka 8128582, Japan	Masuda, M (reprint author), Japan Labour Hearth & Welf Org Spinal Injuries Ct, Dept Orthopaed Surg, 550-4 Igisu, Iizuka, Fukuoka 8200053, Japan.	sudarax@mac.com			General Insurance Association of Japan; Japan Labour Health and Welfare Organization; Japan Orthopedics and Traumatology Foundation [237]	This study was funded by The General Insurance Association of Japan, The Japan Labour Health and Welfare Organization, and The Japan Orthopedics and Traumatology Foundation (grant no. 237) (each amount was 1 million JPY, equal to 8,300 USD). These three organizations are nonprofit institutions, and there were no interest-associated biases in this study by these fundings. No conflicts of interest were reported.	Linkins LA, 2013, ANN INTERN MED, V158, P93, DOI 10.7326/0003-4819-158-2-201301150-00003; Roussi J, 1999, SPINAL CORD, V37, P548, DOI 10.1038/sj.sc.3100891; MYLLYNEN P, 1985, J TRAUMA, V25, P541, DOI 10.1097/00005373-198506000-00013; Maxwell RA, 2002, J TRAUMA, V52, P902, DOI 10.1097/00005373-200205000-00013; Sugimoto Y, 2009, J ORTHOP SCI, V14, P374, DOI 10.1007/s00776-009-1342-y; Kadyan V, 2003, J SPINAL CORD MED, V26, P231; Powell M, 1999, ARCH PHYS MED REHAB, V80, P1044, DOI 10.1016/S0003-9993(99)90058-8; Iversen PO, 2002, BRIT J HAEMATOL, V119, P1011, DOI 10.1046/j.1365-2141.2002.03953.x; Audibert G, 2005, ANN FR ANESTH, V24, P928, DOI 10.1016/j.annfar.2005.05.010; Akman MN, 2004, ARCH PHYS MED REHAB, V85, P1091, DOI 10.1016/j.apmr.2003.10.023; Wells PS, 2003, NEW ENGL J MED, V349, P1227, DOI 10.1056/NEJMoa023153; COLACHIS SC, 1993, PARAPLEGIA, V31, P507; Germing A, 2010, J CLIN ULTRASOUND, V38, P17, DOI 10.1002/jcu.20634; Furlan JC, 2007, SPINE, V32, P1908, DOI 10.1097/BRS.0b013e31811ec26a; Riklin C, 2003, SPINAL CORD, V41, P192, DOI 10.1038/sj.sc.3101421; Haut ER, 2011, J TRAUMA, V70, P27, DOI 10.1097/TA.0b013e3182077d55; Aito S, 2007, SPINAL CORD, V45, P627, DOI 10.1038/sj.sc.3102018; Boudaoud L, 1997, SPINAL CORD, V35, P151, DOI 10.1038/sj.sc.3100373; Aito S, 2002, SPINAL CORD, V40, P300, DOI 10.1038/sj.sc.3101298; Rathore MFA, 2008, SPINAL CORD, V46, P523, DOI 10.1038/sj.sc.3102170; Chung SB, 2011, J TRAUMA, V71, P867, DOI 10.1097/TA.0b013e31822dd3be; Chung SB, 2011, J TRAUMA, V71, P70; Geerts WH, 2008, CHEST, V133, p381S, DOI 10.1378/chest.08-0656; Sakai H, 2010, J SPINE RES, V1, P41; Saraf Shyam K, 2007, Indian J Orthop, V41, P194, DOI 10.4103/0019-5413.33681; Virchow R, 1856, GESAMMELTE ABHANDLUN	26	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1529-9430	1878-1632		SPINE J	Spine Journal	NOV 1	2015	15	11					2338	2344		10.1016/j.spinee.2015.06.060		7	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	CV3QO	WOS:000364173900027		
J	Sacramento-Dominguez, C; Yagi, M; Ayamga, J; Nemani, VM; Akoto, H; Mahmud, R; Wulff, IA; Gupta, M; Papadopoulos, EC; Pellise, F; Sanchez-Perez-Grueso, F; Hess, WF; Kim, HJ; Hodes, R; Boachie-Adjei, O				Sacramento-Dominguez, Cristina; Yagi, Mitsuru; Ayamga, Jennifer; Nemani, Venu M.; Akoto, Harry; Mahmud, Rufai; Wulff, Irene A.; Gupta, Munish; Papadopoulos, Elias C.; Pellise, Ferran; Sanchez-Perez-Grueso, Francisco; Hess, William F.; Kim, Han Jo; Hodes, Richard; Boachie-Adjei, Oheneba		FOCOS Spine Res Grp	Apex of deformity for three-column osteotomy. Does it matter in the occurrence of complications?	SPINE JOURNAL			English	Article						Kyphosis; Kyphoscoliosis; Vertebral column resection osteotomy; Pediatric deformity; Neurologic complications	VERTEBRAL COLUMN RESECTION; SPINAL DEFORMITIES; KYPHOSIS; KYPHOSCOLIOSIS; SCOLIOSIS	BACKGROUND: Posterior vertebral column resection (PVCR) is a challenging but effective technique for the correction of complex spinal deformity. However, it has a high complication rate and carries a substantial risk for neurologic injury. PURPOSE: The aim was to test whether the apex of the deformity influences the clinical outcomes and complications in patients undergoing PVCR. STUDY DESIGN: A historical cohort was recruited from a single center and evaluated preoperatively, postoperatively, and at final follow-up. PATIENT SAMPLE: Ninety-eight hyperkyphotic patients undergoing PVCR were included. Inclusion criteria consisted of kyphoscoliosis and hyperkyphosis surgically treated with PVCR as a primary or revision procedure. OUTCOME MEASURES: The outcome measures included a number of neurologic complications. METHODS: Receiver operator characteristic (ROC) curve analysis and Youden index (J) were used to estimate the optimum cut-off to predict neurologic complications for each potential risk factor. In three ROC analyses, we included separately body mass index (BMI), kyphosis degree, and age as independent variables and neurologic complications as the dependent variable. Logistic regression was used to estimate the odds ratios (ORs) and construct 95% confidence intervals (CIs). RESULTS: Among the 98 patients, the etiologies were: post infectious (50), congenital (31), and others (17). The averages were: age 14 +/- 6.5 years, BMI 20 +/- 10 kg/m(2), American Society of Anesthesiologists 3 +/- 0.7, forced vital capacity 76 +/- 23%, fusion levels 10 +/- 3, estimated blood loss 1,319 +/- 720 mL, surgical time 375 +/- 101 minutes, and preoperative localized kyphosis 104 +/- 30 degrees. Thirty-three patients had abnormal preoperative neurologic status. Major complications occurred in 46 patients (neurologic in 25). The apex of kyphosis was proximal thoracic T1-T5 (five patients), thoracic (TH) T6-T9 (17 patients), thoracolumbar T10-L2 (55 patients), and lumbar L3-S1 (nine patients). The level of apex and BMI were independent risk factors for neurologic complications: TH apex (OR: 101.30, 95% CI: 1.420-infinite; p=.037); BMI (OR: 1.92, 95% CI: 1.110-infinite; p=.026). CONCLUSIONS: Posterior vertebral column resection for severe spine deformity is technically demanding and carries a substantial risk. The apex is a variable that influences the occurrence of neurologic complications, and the presence of a TH apex in particular could be a preoperative risk factor for neurologic complications. (C) 2015 Elsevier Inc. All rights reserved.	[Sacramento-Dominguez, Cristina] Hosp Ruber Int, Unidad Patol Vertebral, Madrid 28034, Spain; [Yagi, Mitsuru] Natl Hosp Org Murayama Med Ctr, Dept Orthopaed Surg, Tokyo, Japan; [Ayamga, Jennifer; Akoto, Harry; Mahmud, Rufai; Wulff, Irene A.; Boachie-Adjei, Oheneba; FOCOS Spine Res Grp] FOCOS Orthoped Hosp, Pantang, Accra, Ghana; [Nemani, Venu M.; Kim, Han Jo] Hosp Special Surg, Scoliosis Serv, New York, NY 10021 USA; [Gupta, Munish] UC Davis Med Ctr, Dept Orthopaed Surg, Sacramento, CA USA; [Papadopoulos, Elias C.] Univ Athens, Orthopaed Clin, Athens, Greece; [Pellise, Ferran] Hosp Valle De Hebron, Serv COT, Spine Unit, Barcelona, Spain; [Sanchez-Perez-Grueso, Francisco] Hosp La Paz, Dept Orthoped Surg, Spine Unit, Madrid, Spain; [Hess, William F.] Geisinger Med Ctr, Dept Orthopaed, Danville, PA 17822 USA; [Hodes, Richard] Amer Jewish Joint Distribut Comm Inc, Addis Ababa, Ethiopia	Sacramento-Dominguez, C (reprint author), Hosp Ruber Int, Unidad Patol Vertebral, 38 Mirasierra, Madrid 28034, Spain.	cristisacra@yahoo.es			Depuy Synthes; Medicrea; Medtronic; DePuySynthes; K2M; FOCOS Orthopedic Hospital	CS-D: Nothing to disclose. MY: Nothing to disclose. JA: Nothing to disclose. VMN: Nothing to disclose. HA: Nothing to disclose. RM: Nothing to disclose. IAW: Nothing to disclose. MG: Other: FOSA/SRS (Treasurer/Board Member); Personal Fees/Other: Depuy Synthes (F, Consultant/Royalties); Personal Fees: Medicrea (D), Medtronic (B, Consultant); Other: Proctor and Gamble (C), Johnson and Johnson (D), Pfizer (B), Pioneer (B, Stock). ECP: Nothing to disclose. FP: Grant: DePuySynthes (F), K2M (D); Personal Fees: DePuySynthes (C). FS-P-G: Grant: Depuy Synthes (A). WFH: Other: K2M (C, Research Support). HJK: Medtronic (B), Biomet (B), Depuy (B), Stryker (B), K2M (B, Speaker Bureau, Honorarium, or Consulting Fees). RH: Nothing to disclose. OB-A: Other: Depuy Spine (D, Consulting Agreement); Personal Fees/Non-Financial Support/Other: K2M (D, Consulting Agreement); Non-Financial Support: Medtronic (D); Personal Fees/Other: FOCOS Orthopedic Hospital (D, Board Member and CEO); Pending/Royalties: K2M Mesa deformity system (D). FSRG: Nothing to disclose.	Boachie-Adjei O, 2013, EUR SPINE J, V22, P641, DOI 10.1007/s00586-012-2338-4; Shimode M, 2002, SPINE, V27, P2260, DOI 10.1097/01.BRS.0000029258.87142.E0; Suk SI, 2005, SPINE, V30, P1682, DOI 10.1097/01.brs.0000170590.21071.c1; Bradford DS, 1997, SPINE, V22, P1590, DOI 10.1097/00007632-199707150-00013; Lenke LG, 2009, SPINE, V34, P2213, DOI 10.1097/BRS.0b013e3181b53cba; Ozturk C, 2012, SPINE, V37, P1054, DOI 10.1097/BRS.0b013e31823b4142; Lenke LG, 2010, CLIN ORTHOP RELAT R, V468, P687, DOI 10.1007/s11999-009-1037-x; BOACHIEADJEI O, 1991, J SPINAL DISORD, V4, P193, DOI 10.1097/00002517-199106000-00010; Lenke LG, 2013, SPINE, V38, P119, DOI 10.1097/BRS.0b013e318269fab1; Suk S, 2002, SPINE, V27, P2374, DOI 10.1097/01.BRS.0000032026.72156.1D; Papadopoulos EC, 2015, SPINE J, V15, P983, DOI 10.1016/j.spinee.2013.03.023; Bradford DS, 1987, ORTHOP T, V11, P502	12	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1529-9430	1878-1632		SPINE J	Spine Journal	NOV 1	2015	15	11					2351	2359		10.1016/j.spinee.2015.07.010		9	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	CV3QO	WOS:000364173900029		
J	Mori, K; Nishizawa, K; Nakamura, A; Ishida, M; Imai, S				Mori, Kanji; Nishizawa, Kazuya; Nakamura, Akira; Ishida, Mitsuaki; Imai, Shinji			Sudden paraplegia because of dumbbell-shaped metastatic neuroendocrine tumor (carcinoid tumor)	SPINE JOURNAL			English	Editorial Material									[Mori, Kanji; Nishizawa, Kazuya; Nakamura, Akira; Imai, Shinji] Shiga Univ Med Sci, Dept Orthopaed Surg, Otsu, Shiga 5202192, Japan; [Ishida, Mitsuaki] Shiga Univ Med Sci, Dept Clin Lab Med, Otsu, Shiga 5202192, Japan	Mori, K (reprint author), Shiga Univ Med Sci, Dept Orthopaed Surg, Tsukinowa Cho, Otsu, Shiga 5202192, Japan.						Tanabe M, 2008, SPINE J, V8, P841, DOI 10.1016/j.spinee.2007.06.015	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1529-9430	1878-1632		SPINE J	Spine Journal	NOV 1	2015	15	11					E1	E3		10.1016/j.spinee.2015.06.037		3	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	CV3QO	WOS:000364173900001		
J	Fukuda, H; Hayashi, K; Handa, A; Kurosaki, Y; Lo, B; Yamagata, S				Fukuda, Hitoshi; Hayashi, Kosuke; Handa, Akira; Kurosaki, Yoshitaka; Lo, Benjamin; Yamagata, Sen			Reflux of Anterior Spinal Artery Predicts Recurrent Posterior Circulation Stroke in Bilateral Vertebral Artery Disease	STROKE			English	Article							ANATOMY		[Fukuda, Hitoshi; Hayashi, Kosuke; Handa, Akira; Kurosaki, Yoshitaka; Yamagata, Sen] Kurashiki Cent Hosp, Dept Neurosurg, Kurashiki, Okayama 7100052, Japan; [Lo, Benjamin] McGill Univ, Dept Neurol & Neurosurg, Montreal Neurol Inst & Hosp, Ctr Hlth, Montreal, PQ, Canada	Fukuda, H (reprint author), Kurashiki Cent Hosp, Dept Neurosurg, 1-1-1 Miwa, Kurashiki, Okayama 7100052, Japan.	fukudaharpseal@gmail.com					Alvernia JE, 2006, J NEUROSURG, V58, DOI [10.1227/ 01. NEU. 0000193519.00443.34., DOI 10.1227/01.NEU.0000193519.00443.34]; AKAR ZC, 1995, J NEUROSURG, V82, P97, DOI 10.3171/jns.1995.82.1.0097; Chimowitz MI, 2011, NEW ENGL J MED, V365, P993, DOI 10.1056/NEJMoa1105335; Shin HK, 1999, ARCH NEUROL-CHICAGO, V56, P1353, DOI 10.1001/archneur.56.11.1353; GIBO H, 1981, J NEUROSURG, V55, P560, DOI 10.3171/jns.1981.55.4.0560; Takahashi M, 1974, ATLAS VERTEBRAL ANGI, P316	6	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	NOV	2015	46	11					3263	3265				3	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	CV0WN	WOS:000363974500036		
J	Tsuda, K				Tsuda, Kazushi			Letter by Tsuda Regarding Article, "Proteinuria, but Not eGFR, Predicts Stroke Risk in Chronic Kidney Disease: Chronic Renal Insufficiency Cohort Study"	STROKE			English	Letter									Kansai Univ Hlth Sci, Dept Cardiovasc Med, Cardiovasc & Metab Res Ctr, Osaka, Japan	Tsuda, K (reprint author), Kansai Univ Hlth Sci, Dept Cardiovasc Med, Cardiovasc & Metab Res Ctr, Osaka, Japan.						Tsuda K, 2013, INT HEART J, V54, P154; Dounousi E, 2006, AM J KIDNEY DIS, V48, P752, DOI 10.1053/j.ajkd.2006.08.015; TAKAHASHI K, 1992, J CLIN INVEST, V90, P136, DOI 10.1172/JCI115826; Sandsmark DK, 2015, STROKE, V46, P2075, DOI 10.1161/STROKEAHA.115.009861; Tsuda K, 2014, NEPHROLOGY S2, V19, P187	5	1	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	NOV	2015	46	11					E239	E239		10.1161/STROKEAHA.115.011018		1	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	CV0WP	WOS:000363974700007		
J	Abraham, E; Fukunaga, K				Abraham, Emmanuel; Fukunaga, Kaori			Terahertz imaging applied to the examination of artistic objects	STUDIES IN CONSERVATION			English	Review						Terahertz; Imaging; Spectroscopy; Tomography; Non-destructive; Painting; Sculpture	TIME-DOMAIN SPECTROSCOPY; X-RAY; COMPUTED-TOMOGRAPHY; RAMAN MICROSCOPY; PAINTINGS; BONE	Terahertz (THz) radiation can be employed onsite for the analysis of museum artifacts related to art conservation science. This review presents two complementary portable THz imaging devices which have been employed at the Tokyo National Museum (Japan) and at the Museum of Aquitaine (France). A Japanese panel screen, African fetish figures, and a nearly 3500-year-old sealed Egyptian jar were imaged with THz waves, revealing their internal structures.	[Abraham, Emmanuel] Univ Bordeaux, LOMA, Talence, France; [Fukunaga, Kaori] Natl Inst Informat & Commun Technol, Appl Electromagnet Res, Koganei, Tokyo 1848795, Japan	Fukunaga, K (reprint author), Natl Inst Informat & Commun Technol, Appl Electromagnet Res, 4-2-1 Nukuikitamachi, Koganei, Tokyo 1848795, Japan.	kaori@nict.go.jp			Action Interdisciplinaire de Recherche Archeometrie (CNRS, France)	This work was supported by the Action Interdisciplinaire de Recherche Archeometrie (CNRS, France). The authors gratefully acknowledge Francois Hubert, Director of the Museum of Aquitaine, the city of Bordeaux and private collectors for the authorization to perform the measurements at the museum, and to use photographs of artworks in academic publications. They also thank the Optical and Lasers Technological Center ALPhANOV for the development of the millimeter wave imaging system, Maryelle Bessou (PACEA, Univeristy Bordeaux) for X-radiography, and Alain Dautant for fruitful discussions. The authors also thank Nobuyuki Kamba of Tokyo National Museum, Yohsei Kohdzuma of Nara Institute for Cultural Properties, and Xiaoli Du of the Inner Mongolia Museum in Hohhot for fruitful discussions and measurement of artworks during conservation, and to use photographs of artworks in academic publications.	Aitken M. J., 1985, THERMOLUMINESCENCE D; Manceau JM, 2008, APPL PHYS B-LASERS O, V90, P365, DOI 10.1007/s00340-008-2933-6; Fukunaga K, 2010, APPL PHYS A-MATER, V100, P591, DOI 10.1007/s00339-010-5643-y; Caumes JP, 2011, APPL OPTICS, V50, P3604, DOI 10.1364/AO.50.003604; Calza C, 2007, NUCL INSTRUM METH B, V263, P249, DOI 10.1016/j.nimb.2007.04.100; Casadio F, 2001, J CULT HERIT, V2, P71, DOI 10.1016/S1296-2074(01)01107-4; Abraham E, 2010, APPL PHYS A-MATER, V100, P585, DOI 10.1007/s00339-010-5642-z; Labaune J, 2010, APPL PHYS A-MATER, V100, P607, DOI 10.1007/s00339-010-5693-1; Stringer MR, 2005, PHYS MED BIOL, V50, P3211, DOI 10.1088/0031-9155/50/14/001; Bessou M, 2012, OPT COMMUN, V285, P4175, DOI 10.1016/j.optcom.2012.07.007; KARR C, 1969, APPL SPECTROSC, V23, P219, DOI 10.1366/000370269774380932; Ferguson B, 2002, OPT LETT, V27, P1312, DOI 10.1364/OL.27.001312; Hahn O, 2005, STUD CONSERV, V50, P23; Burgio L, 2001, SPECTROCHIM ACTA B, V56, P905, DOI 10.1016/S0584-8547(01)00215-4; Recur B, 2011, OPT EXPRESS, V19, P5105, DOI 10.1364/OE.19.005105; Clark RJH, 2007, APPL PHYS A-MATER, V89, P833, DOI 10.1007/s00339-007-4212-5; Ferrer N, 2005, RESTAURATOR, V26, P105; Adam AJL, 2009, OPT EXPRESS, V17, P3407, DOI 10.1364/OE.17.003407; Jackson JB, 2009, MEAS SCI TECHNOL, V20, DOI 10.1088/0957-0233/20/7/075502; Ohrstrom L, 2010, AM J PHYS ANTHROPOL, V142, P497, DOI 10.1002/ajpa.21292; Fukunaga K, 2007, IEICE ELECTRON EXPR, V4, P258, DOI 10.1587/elex.4.258; Bonnemaison J., 1996, ARTS OF VANUATU; Dupre M. C., 1998, BATEKE PEINTRES SCUL; Fraser J. A., 1988, AICCM B, V14, P33; Fukunaga K., 2011, J EUROPEAN OPTICAL S, V6; Fukunaga K., 2010, J EUROPEAN OPTICAL S, V5; Fukunaga K., 2012, TERAHERTZ SPECTROSCO, P521; Fukunagaa K, 2008, IEICE ELECTRON EXPR, V5, P223, DOI 10.1587/elex.5.223; Gwete L., 1995, TRESORS AFRIQUE MUSE; Kamba N., 2011, P 10 INT C NOND INV; Kjellgren E., 2000, METROPOLITAN MUSEUM, V59, P73; Kohler W., 2006, P EUR C NOND TEST BE; Jackson JB, 2008, OPT COMMUN, V281, P527, DOI 10.1016/j.optcom.2007.10.049; Radon J., 1917, SITZUNGSBERICHT SACH, V69, P262; Saragoza F., 2008, REV ARCHEOLOGIQUE BO, V90, P131; Targowski P., 2006, LASER CHEM, V2006, P93658; Toishi K., 1974, SCI CONSERVATION TOK, V12, P71; Verswijver G., 1999, MASTERPIECES CENTRAL; Yamamoto K., 2010, EL P 35 INT C INFR M	39	0	0	MANEY PUBLISHING	LEEDS	STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND	0039-3630	2047-0584		STUD CONSERV	Stud. Conserv.	NOV	2015	60	6					343	352		10.1179/2047058414Y.0000000146		10	Archaeology; Art; Chemistry, Applied; Chemistry, Analytical; Spectroscopy	Archaeology; Art; Chemistry; Spectroscopy	CV4GI	WOS:000364224600002		
J	Vasu, D; Yorimitsu, H; Osuka, A				Vasu, Dhananjayan; Yorimitsu, Hideki; Osuka, Atsuhiro			Base-Free Palladium-Catalyzed Cross-Coupling of Arylsulfonium Salts with Sodium Tetraarylborates	SYNTHESIS-STUTTGART			English	Article						C-S cleavage; C-C bond formation; cross-coupling; sulfonium salts; sodium tetraarylborates; palladium	BOND-FORMING REACTIONS; ARYLBORONIC ACIDS; ARYL SULFIDES; ORGANOBORON COMPOUNDS; EFFICIENT CATALYST; GRIGNARD-REAGENTS; SULFONIUM SALTS; MILD CONDITIONS; CARBON-SULFUR; LIGAND-FREE	Palladium-catalyzed cross-coupling reactions of arylsulfonium salts with sodium tetraarylborates were found to proceed smoothly without recourse to an additional base, providing a new, reliable route to biaryls from organosulfur compounds.	[Vasu, Dhananjayan; Yorimitsu, Hideki; Osuka, Atsuhiro] Kyoto Univ, Grad Sch Sci, Dept Chem, Sakyo Ku, Kyoto 6068502, Japan; [Yorimitsu, Hideki] JST, ACT C, Sakyo Ku, Kyoto 6068502, Japan	Vasu, D (reprint author), Kyoto Univ, Grad Sch Sci, Dept Chem, Sakyo Ku, Kyoto 6068502, Japan.	yori@kuchem.kyoto-u.ac.jp			MEXT [25107002]; JSPS [24685007, 26620081]; JSPS; Japan Association for Chemical Innovation	This work was supported by Grants-in-Aid from MEXT (No. 25107002 'Science of Atomic Layers') and from the JSPS [Nos. 24685007 (Young Scientists (A)) and 26620081 (Exploratory Research)]. D.V. acknowledges a JSPS Postdoctoral Fellowship. H.Y. acknowledges the Japan Association for Chemical Innovation for financial support.	Abou A, 2007, ARKIVOC, P191; ACHESON RM, 1970, J CHEM SOC C, P1764, DOI 10.1039/j39700001764; Hornillos V, 2013, ORG LETT, V15, P5114, DOI 10.1021/ol402408v; Littke AF, 2000, J AM CHEM SOC, V122, P4020, DOI 10.1021/ja0002058; MIYAURA N, 1995, CHEM REV, V95, P2457, DOI 10.1021/cr00039a007; OKI M, 1988, B CHEM SOC JPN, V61, P707, DOI 10.1246/bcsj.61.707; Pan F, 2014, ACS CATAL, V4, P280, DOI 10.1021/cs400985m; Yan J, 2006, SYNTHETIC COMMUN, V36, P1495, DOI 10.1080/00397910600588454; Miyaura N, 2002, J ORGANOMET CHEM, V653, P54, DOI 10.1016/S0022-328X(02)01264-0; KUROSAWA H, 1990, J AM CHEM SOC, V112, P2813, DOI 10.1021/ja00163a060; Nicolaou KC, 2005, ANGEW CHEM INT EDIT, V44, P4442, DOI 10.1002/anie.200500368; Dubbaka SR, 2005, ANGEW CHEM INT EDIT, V44, P7674, DOI 10.1002/anie.200463007; Ma XW, 2013, APPL ORGANOMET CHEM, V27, P707, DOI 10.1002/aoc.3045; Gartia Y, 2014, J MOL CATAL A-CHEM, V392, P253, DOI 10.1016/j.molcata.2014.05.013; Pattanayak P, 2015, INORG CHIM ACTA, V429, P122, DOI 10.1016/j.ica.2015.02.002; Ghosh K, 2015, CATAL SCI TECHNOL, V5, P1606, DOI 10.1039/c4cy01278j; Nishide K, 2002, TETRAHEDRON LETT, V43, P5177, DOI 10.1016/S0040-4039(02)00968-1; Wu YN, 2014, ORG BIOMOL CHEM, V12, P6820, DOI 10.1039/c4ob01211a; Yamada YMA, 2010, CHEM-EUR J, V16, P11311, DOI 10.1002/chem.201000511; Laali KK, 2007, J ORG CHEM, V72, P8383, DOI 10.1021/jo701502y; Fodor A, 2015, CATAL LETT, V145, P834, DOI 10.1007/s10562-015-1490-y; Kabalka GW, 2006, TETRAHEDRON LETT, V47, P6887, DOI 10.1016/j.tetlet.2006.07.042; Yan J, 2005, TETRAHEDRON LETT, V46, P8173, DOI 10.1016/j.tetlet.2005.09.141; Nadri S, 2015, SYNLETT, V26, P619, DOI 10.1055/s-0034-1379954; Otsuka S, 2014, CHEM-EUR J, V20, P13146, DOI 10.1002/chem.201404380; Zhang SJ, 1999, J ORG CHEM, V64, P2796, DOI 10.1021/jo982250s; Zhou WJ, 2010, TETRAHEDRON, V66, P7633, DOI 10.1016/j.tet.2010.07.022; Mo FY, 2011, TETRAHEDRON LETT, V52, P518, DOI 10.1016/j.tetlet.2010.11.099; Dai CY, 2001, J AM CHEM SOC, V123, P2719, DOI 10.1021/ja003954y; Bjerglund KM, 2014, ORG LETT, V16, P1888, DOI 10.1021/ol5003362; Yasuike S, 2007, TETRAHEDRON LETT, V48, P721, DOI 10.1016/j.tetlet.2006.10.163; Ohmura T, 2013, ORGANOMETALLICS, V32, P2870, DOI 10.1021/om400138u; Srogl J, 1997, J AM CHEM SOC, V119, P12376, DOI 10.1021/ja9726926; OHARA Y, 1983, B CHEM SOC JPN, V56, P1508, DOI 10.1246/bcsj.56.1508; Wang LD, 2013, CHEM SOC REV, V42, P599, DOI 10.1039/c2cs35323g; Ookubo Y, 2012, CHEM-EUR J, V18, P12690, DOI 10.1002/chem.201201261; Suzuki A, 1999, J ORGANOMET CHEM, V576, P147, DOI 10.1016/S0022-328X(98)01055-9; CIATTINI PG, 1992, TETRAHEDRON LETT, V33, P4815, DOI 10.1016/S0040-4039(00)61293-5; Barder TE, 2004, ORG LETT, V6, P2649, DOI 10.1021/ol0491686; Braga AAC, 2005, J AM CHEM SOC, V127, P9298, DOI 10.1021/ja050583l; TORII S, 1973, B CHEM SOC JPN, V46, P2912, DOI 10.1246/bcsj.46.2912; Nishide K, 2004, MONATSH CHEM, V135, P189, DOI 10.1007/s00706-003-0122-1; CATELLANI M, 1990, GAZZ CHIM ITAL, V120, P779; Modha SG, 2013, CHEM SOC REV, V42, P5042, DOI 10.1039/c3cs60041f; Murakami K, 2014, ANGEW CHEM INT EDIT, V53, P7510, DOI 10.1002/anie.201403288; Sugahara T, 2014, ANGEW CHEM INT EDIT, V53, P9329, DOI 10.1002/anie.201404355; Ohsugi S, 2003, TETRAHEDRON, V59, P8393, DOI 10.1016/j.tet.2003.08.055; Vasu D, 2015, ANGEW CHEM INT EDIT, V54, P7162, DOI 10.1002/anie.201501992; Chemler SR, 2001, ANGEW CHEM INT EDIT, V40, P4544, DOI 10.1002/1521-3773(20011217)40:24<4544::AID-ANIE4544>3.0.CO;2-N; Suzuki A, 2011, CHEM LETT, V40, P894, DOI 10.1246/cl.2011.894; Prokopcova H, 2008, ANGEW CHEM INT EDIT, V47, P3674, DOI 10.1002/anie.200800449; Baralle A, 2015, SYNLETT, V26, P327, DOI 10.1055/s-0034-1378914; Basu B, 2008, SYNLETT, P255, DOI 10.1055/s-2008-1000874; Chen LY, 2015, CATAL TODAY, V245, P122, DOI 10.1016/j.cattod.2014.03.074; Emmanuvel L, 2007, ARKIVOC, P126; Garnier-Amblard E. C., 2011, BORONIC ACIDS; Lennox AJJ, 2013, ANGEW CHEM INT EDIT, V52, P7362, DOI 10.1002/anie.201301737; Lin H, 2012, EUR J ORG CHEM, P4675, DOI 10.1002/ejoc.201200758; MATSUMOT.M, 1974, J AM CHEM SOC, V96, P3322, DOI 10.1021/ja00817a055; Murakami K, 2014, B CHEM SOC JPN, V87, P1349, DOI 10.1246/bcsj.20140241; Nishide K, 2004, J SYN ORG CHEM JPN, V62, P895; Ohashi M, 2013, EUR J ORG CHEM, P443, DOI 10.1002/ejoc.201201405; OKAMURA H, 1979, TETRAHEDRON LETT, P43; Suzuki A., 2011, ANGEW CHEM INT EDIT, V50, P6723; WENKERT E, 1979, J CHEM SOC CHEM COMM, P637, DOI 10.1039/c39790000637; Yan J, 2006, EUR J ORG CHEM, P2060, DOI 10.1002/ejoc.200500915; Zapf A, 2003, ANGEW CHEM INT EDIT, V42, P5394, DOI 10.1002/anie.200301681	67	0	0	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0039-7881	1437-210X		SYNTHESIS-STUTTGART	Synthesis	NOV	2015	47	21					3286	3291		10.1055/s-0035-1560476		6	Chemistry, Organic	Chemistry	CV4GJ	WOS:000364224700007		
J	Ozeki, M; Egawa, H; Kuse, A; Takano, T; Yasuda, N; Mizutani, H; Izumiya, S; Nakashima, D; Arimitsu, K; Miura, T; Kajimoto, T; Hosoi, S; Iwasaki, H; Kojima, N; Node, M; Yamashita, M				Ozeki, Minoru; Egawa, Honoka; Kuse, Akiko; Takano, Toshiki; Yasuda, Narumi; Mizutani, Hideki; Izumiya, Sumire; Nakashima, Daichi; Arimitsu, Kenji; Miura, Takuya; Kajimoto, Tetsuya; Hosoi, Shinzo; Iwasaki, Hiroki; Kojima, Naoto; Node, Manabu; Yamashita, Masayuki			Practical and Highly Stereoselective Synthesis of Trisubstituted (E)-alpha,beta-Unsaturated Esters	SYNTHESIS-STUTTGART			English	Article						stereoselective synthesis; enoates; aldol reactions; acylations; elimination reactions	BAYLIS-HILLMAN ADDUCTS; SERINE-PROTEASE INHIBITORS; WADSWORTH-EMMONS REACTION; BETA-AMINO ACIDS; CONJUGATE ADDITION; UNSATURATED ESTERS; INSECT PHEROMONES; SIMPLE ACCESS; EFFICIENT; OLEFINS	Trisubstituted (E)-alpha,beta-unsaturated esters bearing various substituents were synthesized with high geometrical selectivity by using three reactions: an aldol reaction, acetylation of the hydroxy group at the beta-position, and an E1cB reaction induced by 1,8-diazabicyclo[5.4.0]undec-7-ene. The method does not require separation of the diastereoisomeric mixture of beta-hydroxy ester intermediates before the E1cB reaction, and is usable for gram-scale syntheses of trisubstituted (E)-alpha,beta-unsaturated esters.	[Ozeki, Minoru; Egawa, Honoka; Kuse, Akiko; Takano, Toshiki; Yasuda, Narumi; Mizutani, Hideki; Izumiya, Sumire; Nakashima, Daichi; Arimitsu, Kenji; Miura, Takuya; Kajimoto, Tetsuya; Hosoi, Shinzo; Iwasaki, Hiroki; Kojima, Naoto; Node, Manabu; Yamashita, Masayuki] Kyoto Pharmaceut Univ, Dept Pharmaceut Mfg Chem, Yamashina Ku, Kyoto 6078414, Japan; [Kajimoto, Tetsuya] Ritsumeikan Univ, Res Ctr Drug Discovery & Pharmaceut Dev Sci, Res Org Sci & Technol, Kusatsu, Shiga 5258577, Japan	Ozeki, M (reprint author), Kyoto Pharmaceut Univ, Dept Pharmaceut Mfg Chem, Yamashina Ku, 1 Shichono Cho, Kyoto 6078414, Japan.	ozekim@mb.kyoto-phu.ac.jp			MEXT; Japan Society for the Promotion of Science (JSPS) [22590024]	This research was financially supported in part by the MEXT-Supported Program for the Strategic Research Foundation at Private Universities, a Grant-in-Aid for Scientific Research (C) (22590024) from the Japan Society for the Promotion of Science (JSPS).	Feuillet FJP, 2005, ORG BIOMOL CHEM, V3, P2976, DOI 10.1039/b503633j; Langenhan JM, 2003, J ORG CHEM, V68, P6440, DOI 10.1021/jo034583h; Lerebours R, 2007, ORG LETT, V9, P2737, DOI 10.1021/ol071067v; Guindon Y, 1998, J ORG CHEM, V63, P6554, DOI 10.1021/jo980636x; Basavaiah D, 1999, J ORG CHEM, V64, P1197, DOI 10.1021/jo981761b; Das B, 2006, TETRAHEDRON LETT, V47, P6615, DOI 10.1016/j.tetlet.2006.07.014; Das B, 2006, CHEM PHARM BULL, V54, P1725, DOI 10.1248/cpb.54.1725; KOWALSKI CJ, 1990, J ORG CHEM, V55, P1977, DOI 10.1021/jo00294a003; MOULOUNGUI Z, 1992, TETRAHEDRON, V48, P1219, DOI 10.1016/S0040-4020(01)90785-9; Fernandes L, 2004, TETRAHEDRON, V60, P9983, DOI 10.1016/j.tet.2004.08.018; Sai H, 1999, TETRAHEDRON LETT, V40, P5019, DOI 10.1016/S0040-4039(99)00923-5; Sturm T, 2003, ADV SYNTH CATAL, V345, P160, DOI 10.1002/adsc.200390003; Tsoi YT, 2010, ORG LETT, V12, P4506, DOI 10.1021/ol101796t; Ando K, 1997, J ORG CHEM, V62, P1934, DOI 10.1021/jo970057c; SENOKUCHI K, 1995, J MED CHEM, V38, P4508, DOI 10.1021/jm00022a017; HEISSLER D, 1991, TETRAHEDRON LETT, V32, P7587, DOI 10.1016/0040-4039(91)80541-D; MARFAT A, 1979, J ORG CHEM, V44, P3888, DOI 10.1021/jo01336a029; Shindo M, 1998, TETRAHEDRON LETT, V39, P4857, DOI 10.1016/S0040-4039(98)00921-6; McNulty J, 2012, BIOORG MED CHEM LETT, V22, P718, DOI 10.1016/j.bmcl.2011.10.039; Li SH, 2011, ANGEW CHEM INT EDIT, V50, P2578, DOI 10.1002/anie.201007128; SENOKUCHI K, 1995, J MED CHEM, V38, P2521, DOI 10.1021/jm00014a003; WATANABE T, 1980, J MED CHEM, V23, P50, DOI 10.1021/jm00175a010; Kisanga P, 2001, TETRAHEDRON, V57, P8047, DOI 10.1016/S0040-4020(01)00782-7; TANIGUCHI M, 1993, TETRAHEDRON, V49, P11169, DOI 10.1016/S0040-4020(01)81804-4; Bartoli G, 2000, ORG LETT, V2, P1791, DOI 10.1021/ol005766i; Kojima S, 1997, J AM CHEM SOC, V119, P5970, DOI 10.1021/ja964122w; BASAVAIAH D, 1994, J CHEM SOC CHEM COMM, P1091, DOI 10.1039/c39940001091; Concellon JM, 2000, ANGEW CHEM INT EDIT, V39, P2773, DOI 10.1002/1521-3773(20000804)39:15<2773::AID-ANIE2773>3.0.CO;2-W; DAVIES SG, 1994, J CHEM SOC PERK T 1, P1141, DOI 10.1039/p19940001141; Franklin AS, 1999, J CHEM SOC PERK T 1, P3537, DOI 10.1039/a808136k; Huang J., 2003, J ORG LETT, V5, P3455; Ravichandran S, 2001, SYNTHETIC COMMUN, V31, P2055, DOI 10.1081/SCC-100104425; Sano S, 1997, CHEM COMMUN, P559, DOI 10.1039/a608495h; VILLA MJ, 1994, J CHEM SOC PERK T 1, P1569, DOI 10.1039/p19940001569	34	0	0	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0039-7881	1437-210X		SYNTHESIS-STUTTGART	Synthesis	NOV	2015	47	21					3392	3402		10.1055/s-0034-1378786		11	Chemistry, Organic	Chemistry	CV4GJ	WOS:000364224700020		
J	El Jaouhari, A; Laabd, M; Bazzaoui, EA; Albourine, A; Martins, JI; Wang, R; Nagy, G; Bazzaoui, M				El Jaouhari, A.; Laabd, M.; Bazzaoui, E. A.; Albourine, A.; Martins, J. I.; Wang, R.; Nagy, G.; Bazzaoui, M.			Electrochemical and spectroscopical studies of polypyrrole synthesized on carbon steel from aqueous medium	SYNTHETIC METALS			English	Article						Carbon steel; Polypyrrole; Electrochemistry; Aqueous media; Corrosion	NEUTRAL ORGANIC MEDIA; CORROSION PROTECTION; MILD-STEEL; PHOTOELECTRON-SPECTROSCOPY; CONDUCTING POLYMERS; STRONGLY ADHERENT; NONFERROUS METALS; IRON ELECTRODES; FILMS; COATINGS	Polypyrrole films were deposited electrochemically on carbon steel from sodium saccharinate aqueous medium using cyclic voltammetry, potentiostatic and galvanostatic techniques. X-ray photoelectron spectroscopy (XPS), scanning electron microscopy (SEM) and normalized tape test show that the polypyrrole coating is homogeneous and adherent to carbon steel surface with globular structure. The adherence rate depends closely on the applied current densities. The corrosion protection performance of the coating was investigated by potentiodynamic polarization technique, open circuit potential over time, and electrochemical impedance spectroscopy (EIS) in 3% sodium chloride solution. (c) 2015 Elsevier B.V. All rights reserved.	[El Jaouhari, A.; Laabd, M.; Albourine, A.; Bazzaoui, M.] Univ Ibn Zohr, Dept Chim, Fac Sci, Lab Mat & Environm,Equipe Chim Coordinat, Agadir, Morocco; [Bazzaoui, E. A.] Univ Mohammed 1, Dept Chim, Fac Sci, Oujda 60000, Morocco; [Martins, J. I.; Bazzaoui, M.] Univ Porto, Dept Engn Quim, Fac Engn, P-4200465 Oporto, Portugal; [Wang, R.] Hiroshima Inst Technol, Fac Engn, Dept Mech Syst Engn, Saeki Ku, Hiroshima 7315193, Japan; [Nagy, G.] Univ Pecs, Fac Sci, H-7622 Pecs, Hungary; [Nagy, G.] Univ Pecs, Gen & Phys Chem Dept, H-7622 Pecs, Hungary	Bazzaoui, M (reprint author), Univ Ibn Zohr, Dept Chim, Fac Sci, Lab Mat & Environm,Equipe Chim Coordinat, BP 8106, Agadir, Morocco.	m.bazzaoui@uiz.ac.ma			CNRST [PPR/30/2015]; Hungary (CNRST/NIH) [1091/2014/CNR]; Portugal (CNRST/FCT) [1006/2013/CNR]	This work was supported by the CNRST under grant no. PPR/30/2015 and the cooperation agreements with Hungary (CNRST/NIH) 1091/2014/CNR and with Portugal (CNRST/FCT) 1006/2013/CNR.	BRION D, 1980, APPL SURF SC, V5, P133, DOI 10.1016/0378-5963(80)90148-8; Kinlen PJ, 2002, CORROSION, V58, P490; Herrasti P, 2001, APPL SURF SCI, V172, P276, DOI 10.1016/S0169-4332(00)00866-7; Zeybek B, 2011, ELECTROCHIM ACTA, V56, P9277, DOI 10.1016/j.electacta.2011.08.003; Dominis AJ, 2003, PROG ORG COAT, V48, P43, DOI 10.1016/S0300-9440(03)00111-5; Guernion N, 2002, SYNTHETIC MET, V126, P301, DOI 10.1016/S0379-6779(01)00572-0; del Amo B, 1998, PROG ORG COAT, V33, P28, DOI 10.1016/S0300-9440(97)00124-0; Martins JI, 2009, PROG ORG COAT, V65, P62, DOI 10.1016/j.porgcoat.2008.09.011; Hien NTL, 2005, ELECTROCHIM ACTA, V50, P1747, DOI 10.1016/j.electacta.2004.10.072; Wessling B, 1999, ELECTROCHIM ACTA, V44, P2139, DOI 10.1016/S0013-4686(98)00322-3; Martins JI, 2002, SYNTHETIC MET, V129, P221, DOI 10.1016/S0379-6779(02)00057-7; Martins JI, 2004, CORROS SCI, V46, P2361, DOI 10.1016/j.corsci.2004.02.006; Jiang Q, 2014, T NONFERR METAL SOC, V24, P2713, DOI 10.1016/S1003-6326(14)63402-6; Kinlen PJ, 1997, SYNTHETIC MET, V85, P1327, DOI 10.1016/S0379-6779(97)80257-3; Bazzaoui M, 2005, THIN SOLID FILMS, V485, P155, DOI 10.1016/j.tsf.2005.04.001; Charlier J, 1997, J VAC SCI TECHNOL A, V15, P353, DOI 10.1116/1.580491; Bazzaoui M, 2006, ELECTROCHIM ACTA, V51, P2417, DOI 10.1016/j.electacta.2005.07.020; Aeiyach S, 1999, ELECTROCHIM ACTA, V44, P2889, DOI 10.1016/S0013-4686(98)00404-6; BECK F, 1992, J COATING TECHNOL, V64, P59; Bethencourt M, 1998, CORROS SCI, V40, P1803, DOI 10.1016/S0010-938X(98)00077-8; Bazzaoui M, 2002, SYNTHETIC MET, V128, P103, DOI 10.1016/S0379-6779(01)00666-X; Osaka T, 1999, J ELECTROCHEM SOC, V146, P3295, DOI 10.1149/1.1392470; Gonzalez MB, 2012, PROG ORG COAT, V75, P178, DOI 10.1016/j.porgcoat.2012.04.015; Hasik M, 2002, SURF SCI, V507, P916, DOI 10.1016/S0039-6028(02)01372-9; Lim SL, 1998, SYNTHETIC MET, V92, P213, DOI 10.1016/S0379-6779(98)80089-1; Kowalski D, 2010, J MATER CHEM, V20, P7630, DOI 10.1039/c0jm00866d; Maurice V, 1998, J ELECTROCHEM SOC, V145, P909, DOI 10.1149/1.1838366; Bazzaoui M, 2014, MATER CORROS, V65, P67, DOI 10.1002/maco.201206502; Bazzaoui M, 2002, SYNTHETIC MET, V130, P73, DOI 10.1016/S0379-6779(02)00101-7; Bazzaoui M, 2002, ELECTROCHIM ACTA, V47, P2953, DOI 10.1016/S0013-4686(02)00188-3; Martins JI, 2012, J BRAZIL CHEM SOC, V23, P377, DOI 10.1590/S0103-50532012000300002; Aeiyach S, 1997, J ELECTROANAL CHEM, V434, P153, DOI 10.1016/S0022-0728(97)00044-2; [Anonymous], 1986, HDB CONDUCTING POLYM; FERREIRA CA, 1990, J ELECTROANAL CHEM, V284, P351, DOI 10.1016/0022-0728(90)85044-6; Ivanova V, 2003, J ELECTROANAL CHEM, V552, P45, DOI 10.1016/S0022-0728(03)00211-0; BARR TL, 1978, J PHYS CHEM-US, V82, P1801, DOI 10.1021/j100505a006; Bazzaoui M, 2006, ELECTROCHIM ACTA, V51, P4516, DOI 10.1016/j.electacta.2006.01.002; BRIGGS D, 1990, PRACTICAL SURFACE AN, V1; Inzelt G, 2000, ELECTROCHIM ACTA, V45, P2403, DOI 10.1016/S0013-4686(00)00329-7; Mobin M, 2011, Port. Electrochim. Acta, V29, P139; NguyenThi Le H., 2001, ELECTROCHIM ACTA, V46, P4259; Oh E.J., 2002, SYNTHETIC MET, V125, P267, DOI DOI 10.1016/S0379-6779(01)00384-8	42	1	1	ELSEVIER SCIENCE SA	LAUSANNE	PO BOX 564, 1001 LAUSANNE, SWITZERLAND	0379-6779			SYNTHETIC MET	Synth. Met.	NOV	2015	209						11	18		10.1016/j.synthmet.2015.06.017		8	Materials Science, Multidisciplinary; Physics, Condensed Matter; Polymer Science	Materials Science; Physics; Polymer Science	CV4OH	WOS:000364245900002		
J	Lopez, JR; Akutsu, H; Martin, L				Lopez, Jordan R.; Akutsu, Hiroki; Martin, Lee			Radical-cation salt with novel BEDT-TTF packing motif containing tris (oxalato)germanate(IV)	SYNTHETIC METALS			English	Article						BEDT-TTF; Semiconductor; Conductivity; tris(Oxalato)germanate	CHARGE-TRANSFER SALTS; TRIS(OXALATO) FERRATE(III) ANIONS; MOLECULAR CONDUCTORS; CRYSTAL-STRUCTURE; GUEST MOLECULES; SUPERCONDUCTIVITY; CONDUCTIVITY; SERIES	The synthesis, crystal structure and resistivity of a new semiconducting BEDT-TTF radical-cation salt containing the tris(oxalato)germanate(IV) anion is reported. BEDT-TTF4[Ge(C2O4)(3)].0.5dichloromethane crystallizes in the space group P2(1)/c, a =18.322(7), b = 11.919(4), c= 32.746(11)angstrom, beta = 105.797(5)degrees, V= 6881 (4) angstrom(3),T= 295(1) K, Z=4. Electrical resistivity measurements show that BEDT-TTF4[Ge(C2O4)(3)].0.5dichloromethane is a semiconductor with an activation energy of 0.224 eV and room temperature resistivity of 212 Omega cm. (c) 2015 Elsevier B.V. All rights reserved.	[Lopez, Jordan R.; Martin, Lee] Nottingham Trent Univ, Sch Sci & Technol, Nottingham NG11 8NS, England; [Akutsu, Hiroki] Osaka Univ, Grad Sch Sci, Dept Chem, Toyonaka, Osaka 5600043, Japan	Martin, L (reprint author), Nottingham Trent Univ, Sch Sci & Technol, Clifton Lane, Nottingham NG11 8NS, England.	lee.martin@ntu.ac.uk			Royal Society of Chemistry; Royal Society [RG100853, >RG081209, IE130367, JP0869972]	LM thanks the Royal Society of Chemistry for a journals Grant for International Authors. This work has been supported by the Royal Society [Research Grants (RG100853 and >RG081209), International Exchange Scheme (IE130367), and International Joint Project (JP0869972)].	Akutsu H, 2004, CHEM COMMUN, P18, DOI 10.1039/b310683g; Martin L, 1999, J MATER CHEM, V9, P2731, DOI 10.1039/a905723d; Coronado E, 2004, CHEM REV, V104, P5419, DOI 10.1021/cr030641n; Martin L, 2008, CRYSTENGCOMM, V10, P192, DOI 10.1039/b711325k; Akutsu-Sato A, 2007, J MATER CHEM, V17, P2497, DOI 10.1039/b618832j; Akutsu H, 2002, J AM CHEM SOC, V124, P12430, DOI 10.1021/ja0273849; Martin L, 2001, INORG CHEM, V40, P1363, DOI 10.1021/ic001193u; Martin L, 2010, CRYSTENGCOMM, V12, P1369, DOI 10.1039/b916136h; Zorina LV, 2011, CRYSTENGCOMM, V13, P2430, DOI 10.1039/c0ce00804d; Coronado E, 2000, NATURE, V408, P447, DOI 10.1038/35044035; Coronado E, 2012, INORG CHEM, V51, P1111, DOI 10.1021/ic202269x; Martin L, 2010, B CHEM SOC JPN, V83, P419, DOI 10.1246/bcsj.20090273; Coronado E, 2005, J MATER CHEM, V15, P1429, DOI 10.1039/b500107m; Martin L, 2010, J MATER CHEM, V20, P2738, DOI 10.1039/b920224b; Guionneau P, 1997, SYNTHETIC MET, V86, P1973, DOI 10.1016/S0379-6779(97)80983-6; Martin L, 1999, SYNTHETIC MET, V102, P1638, DOI 10.1016/S0379-6779(98)00240-9; Prokhorova TG, 2013, CRYSTENGCOMM, V15, P7048, DOI 10.1039/c3ce40919h; Arvedson P., 1966, INORG SYNTH, V8, P35; Kurmoo M., 1995, J AM CHEM SOC, V117, P209; Martin H., 2015, EUR J INORG CHEM; Martin H., 2015, DALTON T, V44, P6219; Martin L., 1997, J CHEM SOC CHEM COMM, P1367; Martin L, 2015, CRYSTENGCOMM, V17, P2783, DOI 10.1039/c5ce00121h; Martin L., 2007, J MATER CHEM, V31, P3324; Martin L, 1999, J CHEM SOC CHEM COMM, P513; Martin L, 2008, CRYSTENGCOMM, V2, P192; Prokhorova T., 2014, EUR J INORG CHEM, V24, P3933	27	0	0	ELSEVIER SCIENCE SA	LAUSANNE	PO BOX 564, 1001 LAUSANNE, SWITZERLAND	0379-6779			SYNTHETIC MET	Synth. Met.	NOV	2015	209						188	191		10.1016/j.synthmet.2015.07.019		4	Materials Science, Multidisciplinary; Physics, Condensed Matter; Polymer Science	Materials Science; Physics; Polymer Science	CV4OH	WOS:000364245900028		
J	Itoh, T; Aomori, S; Oh-e, M				Itoh, Tetsuji; Aomori, Shigeru; Oh-e, Masahito			Synthesis, properties and FET characteristics of oxygen-based heterocycle dimers 9,9 '-bi(benzo[b]naphtha[2,1-d]furan)	SYNTHETIC METALS			English	Article						Organic semiconductor; Organic field-effect transistor; Organic thin film; Transistor; pi-Conjugated system; Heteroacene	FIELD-EFFECT TRANSISTORS; THIN-FILM TRANSISTORS; CONJUGATED POLYMERS; ELECTROLUMINESCENT DEVICES; PHYSICAL-PROPERTIES; SOLAR-CELLS; PENTACENE; SEMICONDUCTORS; OLIGOMERS; LIGHT	We have successfully synthesized and characterized newly synthesized oxygen-heterocyclic and pi-conjugated dimers, 9,9'-bi(benzo[b]naphtha[2,1-d]furan) (9-BBR), as a potential semiconductor material with good environmental stability for organic field-effect transistor (OFET) devices. As expected from DFT calculations, spectroscopic analyses allow us to confirm the compound has lower highest occupied molecular orbital (HOMO) energy level and larger HOMO-lowest unoccupied molecular orbital (LUMO) gap than those of pentacene. Absorption spectra of 9-BBR in an air-saturated solution remain unchanged, indicating substantial environmental stability; in fact, the mobility values of 9-BBR-based OFET devices are stable even in the presence of air. Maximum field-effect mobilities up to 10(-2) cm(2) V-1 s(-1) are obtained by 9-BBR-based OFETs with hexamethyldisilazane (HMDS)-treated substrates at T-sub = 100 degrees C. X-ray diffraction and atomic force microscopy allow us to conclude that better characteristics of 9-BBR-based OFETs prepared at high T-sub are attributed to good crystallinity and large-sized grain morphology in the thin films. (C) 2015 Elsevier B.V. All rights reserved.	[Itoh, Tetsuji; Aomori, Shigeru; Oh-e, Masahito] Sharp Co, Mat & Energy Technol Labs, Kashiwa, Chiba 2770005, Japan; [Itoh, Tetsuji; Aomori, Shigeru; Oh-e, Masahito] Univ Tokyo, Inst Nano Quantum Informat Elect NanoQuine, Meguro Ku, Tokyo 1538505, Japan	Oh-e, M (reprint author), Sharp Co, Mat & Energy Technol Labs, 273-1 Kashiwa, Kashiwa, Chiba 2770005, Japan.	ohe.masahito@sharp.co.jp			Project for Developing Innovation Systems of the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan	This work was supported by Project for Developing Innovation Systems of the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan. The authors appreciate Prof. Yasuhiko Arakawa in the University of Tokyo for his valuable discussion and encouragement. They also thank M. Urayama (Sharp Co.) for the preparation of OFET devices and discussion.	Yamamoto T, 2007, J AM CHEM SOC, V129, P2224, DOI 10.1021/ja068429z; Sun YM, 2005, J MATER CHEM, V15, P53, DOI 10.1039/b411245h; Holmes D, 1999, CHEM-EUR J, V5, P3399, DOI 10.1002/(SICI)1521-3765(19991105)5:11<3399::AID-CHEM3399>3.0.CO;2-V; Murphy AR, 2007, CHEM REV, V107, P1066, DOI 10.1021/cr0501386; Mitschke U, 2000, J MATER CHEM, V10, P1471, DOI 10.1039/a908713c; Suzue Y, 2005, JPN J APPL PHYS 1, V44, P561, DOI 10.1143/JJAP.44.561; Zaumseil J, 2007, CHEM REV, V107, P1296, DOI 10.1021/cr0501543; Grimsdale AC, 2009, CHEM REV, V109, P897, DOI 10.1021/cr000013v; Siegrist T, 2001, ANGEW CHEM INT EDIT, V40, P1732, DOI 10.1002/1521-3773(20010504)40:9<1732::AID-ANIE17320>3.0.CO;2-7; [Anonymous], 2000, CRYSTALSTRUCTURE 4 0; Satoh T, 1998, B CHEM SOC JPN, V71, P2239, DOI 10.1246/bcsj.71.2239; Boudreault PLT, 2007, J AM CHEM SOC, V129, P9125, DOI 10.1021/ja071923y; Burla MC, 2005, J APPL CRYSTALLOGR, V38, P381, DOI 10.1107/S002188980403225X; CAMPBELL RB, 1962, ACTA CRYSTALLOGR, V15, P289, DOI 10.1107/S0365110X62000699; Takimiya K, 2006, J AM CHEM SOC, V128, P12604, DOI 10.1021/ja064052l; Locklin J, 2006, ADV MATER, V18, P2989, DOI 10.1002/adma.200601608; Di CA, 2007, J PHYS CHEM B, V111, P14083, DOI 10.1021/jp071753b; Kobayashi N, 2009, CHEM MATER, V21, P552, DOI 10.1021/cm802826m; Gunes S, 2007, CHEM REV, V107, P1324, DOI 10.1021/cr050149z; Kelley TW, 2003, J PHYS CHEM B, V107, P5877, DOI 10.1021/jp034352e; TANG CW, 1987, APPL PHYS LETT, V51, P913, DOI 10.1063/1.98799; Thompson BC, 2008, ANGEW CHEM INT EDIT, V47, P58, DOI 10.1002/anie.200702506; Friend RH, 1999, NATURE, V397, P121, DOI 10.1038/16393; Klauk H, 2003, APPL PHYS LETT, V82, P4175, DOI 10.1063/1.1579870; Frisch MJ, 2009, GAUSSIAN 09 REVISION; Kraft A, 1998, ANGEW CHEM INT EDIT, V37, P402, DOI 10.1002/(SICI)1521-3773(19980302)37:4<402::AID-ANIE402>3.0.CO;2-9; Maliakal A, 2004, CHEM MATER, V16, P4980, DOI 10.1021/cm049060k; Mattheus CC, 2001, ACTA CRYSTALLOGR C, V57, P939, DOI 10.1107/S010827010100703X; Nakano K., 2011, MOL ELECT BIO ELECT, V22, P9; Sano T, 1998, IEEE J SEL TOP QUANT, V4, P34, DOI 10.1109/2944.669462	30	0	0	ELSEVIER SCIENCE SA	LAUSANNE	PO BOX 564, 1001 LAUSANNE, SWITZERLAND	0379-6779			SYNTHETIC MET	Synth. Met.	NOV	2015	209						355	360		10.1016/j.synthmet.2015.08.008		6	Materials Science, Multidisciplinary; Physics, Condensed Matter; Polymer Science	Materials Science; Physics; Polymer Science	CV4OH	WOS:000364245900051		
J	Melvin, GJH; Ni, QQ; Natsuki, T; Wang, ZP; Morimoto, S; Fujishige, M; Takeuchi, K; Hashimoto, Y; Endo, M				Melvin, Gan Jet Hong; Ni, Qing-Qing; Natsuki, Toshiaki; Wang, Zhipeng; Morimoto, Shingo; Fujishige, Masatsugu; Takeuchi, Kenji; Hashimoto, Yoshio; Endo, Morinobu			Ag/CNT nanocomposites and their single- and double-layer electromagnetic wave absorption properties	SYNTHETIC METALS			English	Article						Carbon nanotube; Silver nanoparticle; Nanocomposite; Electromagnetic wave absorber; Reflection loss	MICROWAVE-ABSORBING PROPERTIES; CARBON NANOTUBE COMPOSITES; SILVER NANOPARTICLES; HYBRID NANOCOMPOSITES; SURFACE; OXIDES; MEDIA; FILMS	The electromagnetic wave absorption properties of single- and double-layer silver nanoparticle/carbon nanotube (Ag/CNT) nanocomposites were evaluated. The reflection loss (R.L.) of the samples was calculated based on the measured complex permittivity and permeability. The double-layer composites constructed from CNT 30 wt.% and Ag/CNT 30 wt.% with total thickness of 3.3 mm showed a minimum R.L. of similar to-52.9 dB (over 99.999% absorption) at 63 GHz. The bandwidth of reflection loss less than 10 dB was observed at 3 regions, with wideness of 3.5, 0.8, and 1.5 GHz. Thin absorber with large RI. and wide response bandwidth at low and high frequency regions can be obtained with double-layer composites. The capability to modulate the absorption and bandwidth of these samples to suit various applications in different frequency bands indicates that these nanocomposites could be an excellent electromagnetic wave absorber. (C) 2015 Elsevier B.V. All rights reserved.	[Melvin, Gan Jet Hong; Natsuki, Toshiaki; Wang, Zhipeng; Morimoto, Shingo; Fujishige, Masatsugu; Takeuchi, Kenji; Hashimoto, Yoshio; Endo, Morinobu] Shinshu Univ, Inst Carbon Sci & Technol, Nagano 3808553, Japan; [Ni, Qing-Qing; Natsuki, Toshiaki] Shinshu Univ, Dept Funct Machinery & Mech, Ueda, Nagano 3868576, Japan; [Ni, Qing-Qing] Zhejiang Sci Tech Univ, Minist Educ, Key Lab Adv Text Mat & Mfg Technol, Hangzhou, Zhejiang, Peoples R China	Melvin, GJH (reprint author), Shinshu Univ, Inst Carbon Sci & Technol, 4-17-1 Wakasato, Nagano 3808553, Japan.	melvin@shinshu-u.ac.jp					Melvin GJH, 2014, J MATER SCI, V49, P5199, DOI 10.1007/s10853-014-8229-9; Qin F, 2012, J APPL PHYS, V111, DOI 10.1063/1.3688435; Yusoff AN, 2002, J APPL PHYS, V92, P876, DOI 10.1063/1.1489092; Liu Y, 2011, APPL SURF SCI, V257, P7678, DOI 10.1016/j.apsusc.2011.04.007; Yi LX, 2015, COMPOS PART A-APPL S, V76, P233, DOI 10.1016/j.compositesa.2015.05.009; Zhang L, 2009, MATER LETT, V63, P272, DOI 10.1016/j.matlet.2008.10.015; Nam IW, 2011, COMPOS PART A-APPL S, V42, P1110, DOI 10.1016/j.compositesa.2011.04.016; Hou CL, 2012, MATER DESIGN, V33, P413, DOI 10.1016/j.matdes.2011.04.042; Wu FC, 2015, J MATER SCI-MATER EL, V26, P6781, DOI 10.1007/s10854-015-3289-4; Chen LY, 2011, MATER DESIGN, V32, P570, DOI 10.1016/j.matdes.2010.08.021; Yang GW, 2008, CARBON, V46, P747, DOI 10.1016/j.carbon.2008.01.026; Ni QQ, 2015, CERAM INT, V41, P9885, DOI 10.1016/j.ceramint.2015.04.065; Zhang WW, 2010, FIBER POLYM, V11, P1132, DOI 10.1007/s12221-010-1132-3; Lee SH, 2011, J COLLOID INTERF SCI, V364, P1, DOI 10.1016/j.jcis.2011.08.029; Huo J, 2009, J MATER SCI, V44, P3917, DOI 10.1007/s10853-009-3561-1; Zhao DL, 2008, MATER SCI ENG B-ADV, V150, P105, DOI 10.1016/j.mseb.2008.04.004; Wu HJ, 2012, APPL PHYS A-MATER, V108, P439, DOI 10.1007/s00339-012-6906-6; Makeiff DA, 2006, SYNTHETIC MET, V156, P497, DOI 10.1016/j.synthmet.2005.05.019; Melvin GJH, 2014, J ALLOY COMPD, V615, P84, DOI 10.1016/j.jallcom.2014.06.191; Wang WT, 2011, SYNTHETIC MET, V161, P44, DOI 10.1016/j.synthmet.2010.10.032; Yang YQ, 2012, MATER LETT, V66, P229, DOI 10.1016/j.matlet.2011.08.027; Ting TH, 2012, APPL SURF SCI, V258, P3184, DOI 10.1016/j.apsusc.2011.11.061; Park KY, 2011, COMPOS PART A-APPL S, V42, P573, DOI 10.1016/j.compositesa.2011.01.020; Micheli D, 2014, CARBON, V77, P756, DOI 10.1016/j.carbon.2014.05.080; Natsuki J, 2011, J COLLOID INTERF SCI, V359, P19, DOI 10.1016/j.jcis.2011.03.079; Zhu H, 2010, MATER LETT, V64, P227, DOI 10.1016/j.matlet.2009.07.023; Dong RX, 2012, ACS APPL MATER INTER, V4, P1449, DOI 10.1021/am2016969; Wei CY, 2012, MATER DESIGN, V35, P363, DOI 10.1016/j.matdes.2011.09.018	28	0	0	ELSEVIER SCIENCE SA	LAUSANNE	PO BOX 564, 1001 LAUSANNE, SWITZERLAND	0379-6779			SYNTHETIC MET	Synth. Met.	NOV	2015	209						383	388		10.1016/j.synthmet.2015.08.017		6	Materials Science, Multidisciplinary; Physics, Condensed Matter; Polymer Science	Materials Science; Physics; Polymer Science	CV4OH	WOS:000364245900055		
J	Sasaki, Y; Hamalainen, RP; Saarinen, E				Sasaki, Yasuo; Hamalainen, Raimo P.; Saarinen, Esa			Modeling Systems of Holding Back as Hypergames and their Connections with Systems Intelligence	SYSTEMS RESEARCH AND BEHAVIORAL SCIENCE			English	Article						hypergames; systems intelligence; systems of holding back; subjective games; cognitive dissonance	GAMES; UNAWARENESS; BEHAVIOR	We discuss linkages between hypergame theory and systems intelligence and examine how both perspectives can benefit one another. We argue that hypergame theory can provide a formal foundation for key premises of systems intelligence, whereas the philosophy of systems intelligence can present a new way to illustrate hypergame theory as a perspective in order for an agent acting inside a system to become systems intelligent. The integrated perspective elaborated here is particularly relevant in the context of certain kinds of paradoxical but ubiquitous human interactive situations called systems of holding back. Copyright (c) 2014 John Wiley & Sons, Ltd.	[Sasaki, Yasuo] Value Management Inst Inc, Tokyo 1000004, Japan; [Hamalainen, Raimo P.] Aalto Univ, Dept Math & Syst Anal, Syst Anal Lab, Sch Sci, Espoo, Finland; [Saarinen, Esa] Aalto Univ, Dept Ind Engn & Management, Sch Sci, Espoo, Finland	Sasaki, Y (reprint author), Value Management Inst Inc, Chiyoda Ku, 2-2-1 Ootemachi, Tokyo 1000004, Japan.	ysasaki1011@gmail.com	Saarinen, Esa/G-2407-2013				BENNETT PG, 1977, OMEGA-INT J MANAGE S, V5, P749, DOI 10.1016/0305-0483(77)90056-1; Li J, 2009, J ECON THEORY, V144, P977, DOI 10.1016/j.jet.2008.10.001; BENNETT PG, 1980, FUTURES, V12, P489, DOI 10.1016/0016-3287(80)90005-1; WANG MH, 1989, APPL MATH COMPUT, V34, P147, DOI 10.1016/0096-3003(89)90102-1; Sasaki Y, 2012, J SYST SCI COMPLEX, V25, P720, DOI 10.1007/s11424-012-1074-5; Spohrer J, 2008, PROD OPER MANAG, V17, P238, DOI 10.3401/poms.1080.0027; WANG M, 1988, BEHAV SCI, V33, P207, DOI 10.1002/bs.3830330305; Dekel E, 1998, ECONOMETRICA, V66, P159, DOI 10.2307/2998545; Jones R, 2012, SYST RES BEHAV SCI, V29, P30, DOI 10.1002/sres.1090; Heifetz A, 2013, GAME ECON BEHAV, V81, P50, DOI 10.1016/j.geb.2013.04.003; Feinberg Y., 2012, GRADUATE SCH BUSINES; Festinger L., 1957, THEORY COGNITIVE DIS; Gardenfors P., 1992, BELIEF REVISION; Gardner H., 1993, FRAMES MIND THEORY M; Gentner D., 1983, MENTAL MODELS; Gilboa I, 2001, THEORY CASE BASED DE; GILBOA I, 1995, Q J ECON, V110, P605, DOI 10.2307/2946694; Gintis H, 2010, ECON J, V120, P162; Goleman D., 1995, EMOTIONAL INTELLIGEN; Goleman D., 2006, SOCIAL INTELLIGENCE; Hamalainen R., 2006, REFLECTIONS SOL J KN, V7, P17; Hamalainen RP, 2004, SYSTEMS INTELLIGENCE; Harsanyi J., 1967, MANAGE SCI, P159, DOI DOI 10.1287/MNSC.14.3.159; Harsanyi JC., 1967, MANAGE SCI, V14, P320; Harsanyi JC., 1967, MANAGE SCI, V14, P486; Jackson M. C., 2003, SYSTEMS THINKING CRE; Kaneko M., 1999, J PUBLIC ECON THEORY, V1, P101, DOI 10.1111/1097-3923.00005; Kijima K., 1996, Information & Systems Engineering, V2; Matsumura R, 2005, P 1 WORLD C IFSR KOB; MYERSON R.B., 1991, GAME THEORY; PEARCE DG, 1984, ECONOMETRICA, V52, P1029, DOI 10.2307/1911197; Popper K., 1959, LOGIC SCI DISCOVERY; Sasaki Y, 2008, P 52 ANN M ISSS MAD; Sasaki Y, 2010, P 7 INT C SERV SYST; Senge P., 1990, 5 DISCIPLINE ART PRA	35	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1092-7026	1099-1743		SYST RES BEHAV SCI	Syst. Res. Behav. Sci.	NOV-DEC	2015	32	6					593	602		10.1002/sres.2276		10	Management; Social Sciences, Interdisciplinary	Business & Economics; Social Sciences - Other Topics	CV5MM	WOS:000364314800004		
J	Hamajima, R; Kobayashi, M; Ikeda, M				Hamajima, Rina; Kobayashi, Michihiro; Ikeda, Motoko			Identification of amino acid residues of AcMNPV P143 protein involved in rRNA degradation and restricted viral replication in BM-N cells from the silkworm Bombyx mori	VIROLOGY			English	Article						Baculovirus; AcMNPV; BmNPV; Bombyx mori cells; P143; rRNA degradation; Translation arrest	NUCLEAR POLYHEDROSIS-VIRUS; AUTOGRAPHA-CALIFORNICA NUCLEOPOLYHEDROVIRUS; HOST-RANGE EXPANSION; DNA HELICASE; INSECT CELLS; GENE; SEQUENCE; LINES; NPV; LEPIDOPTERA	We previously demonstrated that rRNA undergoes rapid and extensive degradation in Bombyx mori BM-N cells upon infection with AcMNPV, which is triggered by AcMNPV P143 (Ac-P143) protein. Here, we showed that six amino acid residues of Ac-P143 protein, distributing between positions 514 and 599, are involved in rRNA degradation in BM-N cells. The six residues are highly conserved among P143 proteins from AcMNPV, HycuMNPV, SeMNPV and SpItMNPV, which trigger rRNA degradation in BM-N cells upon infection, but are only partially conserved in Bm-P143 protein, which does not induce rRNA degradation in BM-N cells. We also demonstrated that substitution of only two selected residues (N565S/L578F) of Bm-P143 protein with the corresponding Ac-P143 protein residues generates a mutant Bm-P143 protein that is capable of triggering rRNA degradation in BM-N cells. These results indicate that BmNPV evolved a unique P143 protein to evade the antiviral response and allow replication in B. mori cells. (C) 2015 Elsevier Inc. All rights reserved.	[Hamajima, Rina; Kobayashi, Michihiro; Ikeda, Motoko] Nagoya Univ, Grad Sch Bioagr Sci, Lab Sericulture & Entomoresources, Nagoya, Aichi 4648601, Japan	Ikeda, M (reprint author), Nagoya Univ, Grad Sch Bioagr Sci, Lab Sericulture & Entomoresources, Nagoya, Aichi 4648601, Japan.	q2u_q1@yahoo.co.jp; michihir@agr.nagoya-u.ac.jp; mochiko@agr.nagoya-u.ac.jp			Japan Society for the Promotion of Science (JSPS) [23380033, 23380034, 26292173, 15J02649]; JSPS; Program for Leading Graduate Schools "Integrative Graduate Education and Research in Green Sciences" of the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan	We thank Dr. T. Yaginuma and Dr. T. Niimi of the Laboratory of Sericulture and Entomoresources, Nagoya University, Japan, for their helpful discussions during this study. This work was supported in part by Grants-in-Aid (23380033, 23380034, 26292173, and 15J02649) from the Japan Society for the Promotion of Science (JSPS). RH was supported by the Research Fellowship for Young Scientist from the JSPS and the Program for Leading Graduate Schools "Integrative Graduate Education and Research in Green Sciences" of the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan.	MORRIS TD, 1993, VIROLOGY, V197, P339, DOI 10.1006/viro.1993.1595; Kamita SG, 1997, GENE, V190, P173, DOI 10.1016/S0378-1119(96)00671-3; NAGAMINE T, 1989, APPL ENTOMOL ZOOL, V24, P235; Laufs S, 1997, VIROLOGY, V228, P98, DOI 10.1006/viro.1996.8361; Thiem SM, 1997, CURR OPIN BIOTECH, V8, P317, DOI 10.1016/S0958-1669(97)80010-9; CROIZIER G, 1994, P NATL ACAD SCI USA, V91, P48, DOI 10.1073/pnas.91.1.48; Grasela James J., 2000, In Vitro Cellular and Developmental Biology Animal, V36, P205, DOI 10.1290/1071-2690(2000)036<0205:EOTGFP>2.3.CO;2; Liu G, 1999, VIROLOGY, V253, P125, DOI 10.1006/viro.1998.9485; Ikeda M, 2015, ENTOMOL SCI, V18, P1, DOI 10.1111/ens.12105; Hamajima R, 2013, J GEN VIROL, V94, P2102, DOI 10.1099/vir.0.053645-0; LU A, 1991, VIROLOGY, V181, P336, DOI 10.1016/0042-6822(91)90500-B; Ikeda M, 2004, VIROLOGY, V321, P359, DOI 10.1016/j.virol.2004.01.002; Thiem Suzanne M., 2009, Virologica Sinica, V24, P436, DOI 10.1007/s12250-009-3058-8; Ikeda M, 2013, VIROLOGY, V435, P1, DOI 10.1016/j.virol.2012.10.016; Iwanaga M, 2009, J INVERTEBR PATHOL, V101, P124, DOI 10.1016/j.jip.2009.05.004; Shirata N, 1999, APPL ENTOMOL ZOOL, V34, P507; VOLKMAN LE, 1982, APPL ENVIRON MICROB, V44, P227; Gomi S, 1999, J GEN VIROL, V80, P1323; Suganuma I, 2011, INSECT BIOCHEM MOLEC, V41, P909, DOI 10.1016/j.ibmb.2011.08.005; MAEDA S, 1993, J VIROL, V67, P6234; GORDON JD, 1984, VIROLOGY, V138, P69, DOI 10.1016/0042-6822(84)90148-X; Ikeda M, 2011, J GEN VIROL, V92, P2654, DOI 10.1099/vir.0.033332-0; Argaud O, 1998, J GEN VIROL, V79, P931; Shirata N, 2010, VIROLOGY, V398, P149, DOI 10.1016/j.virol.2009.11.049; KAMITA SG, 1993, J VIROL, V67, P6239; McDougal VV, 2000, J VIROL, V74, P5273, DOI 10.1128/JVI.74.11.5273-5279.2000; Cohen David P. A., 2009, Virologica Sinica, V24, P359, DOI 10.1007/s12250-009-3059-7; AYRES MD, 1994, VIROLOGY, V202, P586, DOI 10.1006/viro.1994.1380; Fujita Ryousuke, 2005, Journal of Insect Biotechnology and Sericology, V74, P125; Granados R. R., 1986, BIOL BACULOVIRUSES, VI, P89; Hamajima R., 2014, Journal of Insect Biotechnology and Sericology, V83, P19; Herniou E.A., 2012, FAMILY BACULOVIRIDAE, P167; Miller L.K., 1997, MOL BASIS BACULOVIRU, P217; Shirata Noriko, 2004, Journal of Insect Biotechnology and Sericology, V73, P23	34	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0042-6822			VIROLOGY	Virology	NOV	2015	485						244	251		10.1016/j.virol.2015.08.008		8	Virology	Virology	CV1DH	WOS:000363993100025		
J	Lu, L; An, YL; Zou, J; Gu, L; Zhao, ZX; Zhang, XH; Li, CH; Kurihara, C; Hokari, R; Itakura, J; Kurosaki, M; Izumi, N; Fu, YS; Nakano, T; Kato, T; Negro, F; Chen, GH				Lu, Ling; An, Yuling; Zou, Ji; Gu, Lin; Zhao, Zhixin; Zhang, Xiaohong; Li, Chunhua; Kurihara, Chie; Hokari, Ryota; Itakura, Jun; Kurosaki, Masayuki; Izumi, Namiki; Fu, Yongshui; Nakano, Tatsunori; Kato, Takanobu; Negro, Francesco; Chen, Guihua			The evolutionary patterns of hepatitis C virus subtype 2a and 6a isolates linked to an outbreak in China in 2012	VIROLOGY			English	Article						Outbreak; Evolution; HCV; Genetic sequence	VOLUNTEER BLOOD-DONORS; MOLECULAR EPIDEMIOLOGY; GENOTYPE DISTRIBUTION; GLOBAL EPIDEMIOLOGY; SEQUENCE-ANALYSIS; INFECTION; TRANSMISSION; VARIANTS; PREVALENCE; POPULATION	An HCV outbreak occurred in 2012 in China, affecting hundreds of patients. We characterized HCV subtype 2a and 6a sequences from 60 and 102 patients, respectively, and co-analyzed them with 82 local controls and 103 calibrating references. The close grouping of the patients' sequences contrasted sharply with the diversity of local controls. Scaled by the calibrating references, the emergence of patients' isolates was estimated at 2-5 years before sampling. In contrast, the controls intermingled with the calibrating references that were much older. For both subtypes, the major and minor clusters could be defined, with the closeness to indicate linked transmission. Conclusion: HCV sequences from the study patients grouped into three subtype 2a and two subtype 6a clusters, in addition to three 6a solitary branches, representing descendants of eight earlier strains that were distinct and otherwise sporadic. Due to iatrogenic transmission through reusing needles, five strains were highly selected and preferentially spread. (C) 2015 Published by Elsevier Inc.	[Lu, Ling; Zou, Ji; Gu, Lin; Zhao, Zhixin; Zhang, Xiaohong] Sun Yat Sen Univ, Affiliated Hosp 3, Lab Hepatol, Guangzhou 510630, Guangdong, Peoples R China; [Lu, Ling; Li, Chunhua] Univ Kansas, Med Ctr, Ctr Viral Oncol, Dept Pathol & Lab Med, Kansas City, KS 66103 USA; [An, Yuling; Chen, Guihua] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Liver Transplantat, Guangzhou 510630, Guangdong, Peoples R China; [Kurihara, Chie; Hokari, Ryota] Natl Def Med Coll, Dept Internal Med, Tokorozawa, Saitama 359, Japan; [Itakura, Jun; Kurosaki, Masayuki; Izumi, Namiki] Musashino Red Cross Hosp, Dept Gastroenterol & Hepatol, Musashino, Tokyo, Japan; [Fu, Yongshui] Guangzhou Blood Ctr, Guangzhou, Guangdong, Peoples R China; [Nakano, Tatsunori] Fujita Hlth Univ, Dept Internal Med, Nanakuri Sanatorium, Tsu, Mie, Japan; [Kato, Takanobu] Natl Inst Infect Dis, Dept Virol 2, Shinjyuku Ku, Tokyo 1628640, Japan; [Negro, Francesco] Univ Hosp Geneva, Div Gastroenterol & Hepatol, Geneva, Switzerland; [Negro, Francesco] Univ Hosp Geneva, Div Clin Pathol, Geneva, Switzerland	Lu, L (reprint author), Sun Yat Sen Univ, Affiliated Hosp 3, Lab Hepatol, Guangzhou 510630, Guangdong, Peoples R China.	llu@kumc.edu; chgh1955@263.net			National Institute of Allergy and Infectious Diseases [5 R01 AI080734]	The study described was financially supported by a Grant from the National Institute of Allergy and Infectious Diseases (5 R01 AI080734). The funding agencies had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alter MJ, 2002, HEPATOLOGY, V36, pS93, DOI 10.1053/jhep.2002.36389; Dal Molin G, 2002, J MED VIROL, V68, P352, DOI 10.1002/jmv.10210; Gu L, 2013, J CLIN VIROL, V57, P311, DOI 10.1016/j.jcv.2013.04.013; Xiao JP, 2012, INT J INFECT DIS, V16, pE692, DOI 10.1016/j.ijid.2012.05.1027; Lu L, 2005, J MED VIROL, V75, P538, DOI 10.1002/jmv.20307; KIYOSAWA K, 1994, GASTROENTEROLOGY, V106, P1596; Okayama A, 2002, J VIRAL HEPATITIS, V9, P43, DOI 10.1046/j.1365-2893.2002.00331.x; Kurihara C, 2001, J MED VIROL, V64, P466, DOI 10.1002/jmv.1073; Simmonds P, 2005, HEPATOLOGY, V42, P962, DOI 10.1002/hep.20819; Esteban JI, 1996, NEW ENGL J MED, V334, P555, DOI 10.1056/NEJM199602293340902; Penin F, 2004, HEPATOLOGY, V39, P5, DOI 10.1002/hep.20032; Garten RJ, 2004, INT J EPIDEMIOL, V33, P182, DOI 10.1093/ije/dyh019; Re V, 2003, MEDICINA-BUENOS AIRE, V63, P205; Shepard CW, 2005, LANCET INFECT DIS, V5, P558, DOI 10.1016/S1473-3099(05)70216-4; Posada D, 2008, MOL BIOL EVOL, V25, P1253, DOI 10.1093/molbev/msn083; Yerly S, 2001, J INFECT DIS, V184, P369, DOI 10.1086/322036; Hauri AM, 2004, INT J STD AIDS, V15, P7, DOI 10.1258/095646204322637182; Kato T, 2001, J MED VIROL, V64, P334, DOI 10.1002/jmv.1055; Murphy DG, 2007, J CLIN MICROBIOL, V45, P1102, DOI 10.1128/JCM.02366-06; Metzker ML, 2002, P NATL ACAD SCI USA, V99, P14292, DOI 10.1073/pnas.222522599; He J, 2005, NEW ENGL J MED, V353, P1124, DOI 10.1056/NEJMsa050467; Fu Y, 2011, J VIRAL HEPATITIS, V18, P42, DOI 10.1111/j.1365-2893.2010.01280.x; Wasley A, 2000, SEMIN LIVER DIS, V20, P1, DOI 10.1055/s-2000-9506; Ansaldi F, 2005, J MED VIROL, V76, P327, DOI 10.1002/jmv.20376; Dore GJ, 2003, J CLIN VIROL, V26, P171, DOI 10.1016/S1386-6532(02)00116-6; Lu L, 2008, HEPATOL RES, V38, P704, DOI 10.1111/j.1872-034X.2008.00320.x; Guadagnino V, 1997, HEPATOLOGY, V26, P1006, DOI 10.1002/hep.510260431; Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520; Lu L, 2014, J VIROL, V88, P7120, DOI 10.1128/JVI.00414-14; Saksena NK, 2005, CELL RES, V15, P953, DOI 10.1038/sj.cr.7290373; OKAMOTO H, 1992, VIROLOGY, V188, P331, DOI 10.1016/0042-6822(92)90762-E; An YL, 2014, VIROLOGY, V464, P21, DOI 10.1016/j.virol.2014.06.011; OKAMOTO H, 1991, J GEN VIROL, V72, P2697, DOI 10.1099/0022-1317-72-11-2697; Birch CJ, 2000, J INFECT DIS, V182, P941, DOI 10.1086/315751; Gower E, 2014, J HEPATOL, V61, pS45, DOI 10.1016/j.jhep.2014.07.027; OU CY, 1992, SCIENCE, V256, P1165, DOI 10.1126/science.256.5060.1165; Bracho MA, 2005, J CLIN MICROBIOL, V43, P2750, DOI 10.1128/JCM.43.6.2750-2755.2005; Li CH, 2014, VIROLOGY, V468, P197, DOI 10.1016/j.virol.2014.07.026; TOKITA H, 1994, J GEN VIROL, V75, P931, DOI 10.1099/0022-1317-75-4-931; Lu L, 2013, J VIROL, V87, P12041, DOI 10.1128/JVI.01773-13; Di Lello FA, 2015, ARCH VIROL, V160, P909, DOI 10.1007/s00705-015-2390-6; Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214; Fu YS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0028006; Gonzalez-Candelas F, 2013, BMC BIOL, V11, DOI 10.1186/1741-7007-11-76; Noppornpath S, 2008, J GEN VIROL, V89, P1276, DOI 10.1099/vir.0.83593-0; Re VE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019471; World Health Organization, 2011, SEXUALLY TRANSMITTED; Zhou XM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024889	48	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0042-6822			VIROLOGY	Virology	NOV	2015	485						431	438		10.1016/j.virol.2015.08.012		8	Virology	Virology	CV1DH	WOS:000363993100045		
J	Wakae, K; Aoyama, S; Wang, Z; Kitamura, K; Liu, GY; Monjurul, AM; Koura, M; Imayasu, M; Sakamoto, N; Nakamura, M; Kyo, S; Kondo, S; Fujiwara, H; Yoshizaki, T; Kukimoto, I; Yamaguchi, K; Shigenobu, S; Nishiyama, T; Muramatsu, M				Wakae, Kousho; Aoyama, Satoru; Wang, Zhe; Kitamura, Kouichi; Liu, Guangyan; Monjurul, Ahasan Md.; Koura, Miki; Imayasu, Mieko; Sakamoto, Naoya; Nakamura, Mitsuhiro; Kyo, Satoru; Kondo, Satoru; Fujiwara, Hiroshi; Yoshizaki, Tomokazu; Kukimoto, Iwao; Yamaguchi, Katsushi; Shigenobu, Shuji; Nishiyama, Tomoaki; Muramatsu, Masamichi			Detection of hypermutated human papillomavirus type 16 genome by Next-Generation Sequencing	VIROLOGY			English	Article						HPV16; Hypermutation; APOBEC3; Cervical cancer; Next-Generation Sequencing	INDUCED CYTIDINE DEAMINASE; HEPATITIS-B-VIRUS; APOBEC PROTEINS; HUMAN CANCERS; DNA; ACTIVATION; HIV-1; GENE; MUTAGENESIS; MECHANISMS	Human papillomavirus type 16(HPV16) is a major cause of cervical cancer. We previously demonstrated that C-to-T and G-to-A hypermutations accumulated in the HPV16 genome by APOBEC3 expression in vitro. To investigate in vivo characteristics of hypermutation, differential DNA denaturation-PCR (3D-PCR) was performed using three clinical specimens obtained from HPV16-positive cervical dysplasia, and detected hypermutation from two out of three specimens. One sample accumulating hypermutations in both E2 and the long control region (LCR) was further subjected to Next-Generation Sequencing, revealing that hypermutations spread across the LCR and all early genes. Notably, hypermutation was more frequently observed in the LCR, which contains a viral replication origin and the early promoter. APOBEC3 expressed abundantly in an HPV16-positive cervix, suggesting that single-stranded DNA exposed during viral replication and transcription may be efficient targets for deamination. The results further strengthen a role of APOBEC3 in introducing HPV16 hypermutation in vivo. (C) 2015 Elsevier Inc. All rights reserved.	[Wakae, Kousho; Aoyama, Satoru; Wang, Zhe; Kitamura, Kouichi; Liu, Guangyan; Monjurul, Ahasan Md.; Koura, Miki; Imayasu, Mieko; Sakamoto, Naoya; Muramatsu, Masamichi] Kanazawa Univ, Grad Sch Med Sci, Dept Mol Genet, Kanazawa, Ishikawa 9208640, Japan; [Aoyama, Satoru] Tokyo Med & Dent Univ Hosp, Fac Med, Tokyo 1138510, Japan; [Wang, Zhe] Dalian Univ, Affiliated Zhongshan Hosp, Div Med Oncol, Dalian 116001, Peoples R China; [Nakamura, Mitsuhiro; Kyo, Satoru; Fujiwara, Hiroshi] Kanazawa Univ, Grad Sch Med Sci, Dept Obstet & Gynecol, Kanazawa, Ishikawa 9208640, Japan; [Kyo, Satoru] Shimane Univ, Fac Med, Dept Obstet & Gynecol, Izumo, Shimane 6938501, Japan; [Kondo, Satoru; Yoshizaki, Tomokazu] Kanazawa Univ, Grad Sch Med Sci, Div Otorhinolaryngol & Head & Neck Surg, Kanazawa, Ishikawa 9208640, Japan; [Kukimoto, Iwao] Natl Inst Infect Dis, Pathogen Genom Ctr, Tokyo 2080011, Japan; [Yamaguchi, Katsushi; Shigenobu, Shuji] Natl Inst Basic Biol, Funct Genom Facil, Okazaki, Aichi 4448585, Japan; [Nishiyama, Tomoaki] Kanazawa Univ, Adv Sci Res Ctr, Kanazawa, Ishikawa 9208640, Japan	Nishiyama, T (reprint author), Kanazawa Univ, Adv Sci Res Ctr, Kanazawa, Ishikawa 9208640, Japan.	tomoakin@staff.kanazawa-u.ac.jp; muramatu@med.kanazawa-u.ac.jp	Nishiyama, Tomoaki/J-8897-2015	Nishiyama, Tomoaki/0000-0003-1279-7806	Japan Society for the Promotion of Science [26861318]; Founding Program for Next Generation World-Leading Researchers [LS051]; YASUDA Medical Foundation; Takeda Science Foundation; Association for Research on Lactic Acid Bacteria	We thank Professor Peter Howley for providing p1203 PML2d HPV-16 (obtained from Addgene, 10869 (Romanczuk and Howley, 1992)). We also thank Ms. Shimadzu for technical support. This study was supported by the Founding Program for Next Generation World-Leading Researchers (LS051) and a Grant-in-Aid for Young Scientists (B) (26861318) from the Japan Society for the Promotion of Science, the YASUDA Medical Foundation, Takeda Science Foundation, and the Association for Research on Lactic Acid Bacteria.	Kreimer AR, 2011, CANCER PREV RES, V4, P1346, DOI 10.1158/1940-6207.CAPR-11-0379; Harris RS, 2004, NAT REV IMMUNOL, V4, P868, DOI 10.1038/nri1489; Stanley MA, 2007, BIOCHEM SOC T, V35, P1456, DOI 10.1042/BST0351456; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707; Wang Z, 2014, J VIROL, V88, P1308, DOI 10.1128/JVI.03091-13; Roberts SA, 2013, NAT GENET, V45, P970, DOI 10.1038/ng.2702; Vartanian JP, 2008, SCIENCE, V320, P230, DOI 10.1126/science.1153201; Henderson S, 2014, CELL REP, V7, P1833, DOI 10.1016/j.celrep.2014.05.012; Liang GX, 2013, P NATL ACAD SCI USA, V110, P2246, DOI 10.1073/pnas.1221921110; Kitamura K, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003361; Roberts SA, 2014, NAT REV CANCER, V14, P786, DOI 10.1038/nrc3816; Chowdhury S, 2013, FEBS LETT, V587, P3148, DOI 10.1016/j.febslet.2013.07.055; Mori S, 2015, BIOCHEM BIOPH RES CO, V460, P555, DOI 10.1016/j.bbrc.2015.03.068; ROMANCZUK H, 1992, P NATL ACAD SCI USA, V89, P3159, DOI 10.1073/pnas.89.7.3159; Zan H, 2013, AUTOIMMUNITY, V46, P83, DOI 10.3109/08916934.2012.749244; Knoepfel SA, 2011, J VIROL METHODS, V171, P329, DOI 10.1016/j.jviromet.2010.11.016; Hultquist JF, 2011, J VIROL, V85, P11220, DOI 10.1128/JVI.05238-11; Ganesh K, 2011, FASEB J, V25, P1123, DOI 10.1096/fj.11-0402ufm; Stenglein MD, 2010, NAT STRUCT MOL BIOL, V17, P222, DOI 10.1038/nsmb.1744; Bodily J, 2011, TRENDS MICROBIOL, V19, P33, DOI 10.1016/j.tim.2010.10.002; Herdman MT, 2006, CARCINOGENESIS, V27, P2341, DOI 10.1093/carcin/bg1172; Vieira VC, 2013, BIOMED RES INT, DOI 10.1155/2013/683095; Burns MB, 2013, NAT GENET, V45, P977, DOI 10.1038/ng.2701; Kukimoto I, 2015, J MED VIROL, V87, P1754, DOI 10.1002/jmv.24215; Malim MH, 2009, PHILOS T R SOC B, V364, P675, DOI 10.1098/rstb.2008.0185; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Goila-Gaur R, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-51; Henry M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004277; Ohba K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097787; Vieira VC, 2014, MBIO, V5, DOI 10.1128/mBio.02234-14; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	31	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0042-6822			VIROLOGY	Virology	NOV	2015	485						460	466		10.1016/j.virol.2015.08.017		7	Virology	Virology	CV1DH	WOS:000363993100048		
J	Bohaty, L; Becker, P; Haussuhl, E; Nemec, I; Lux, O; Eichler, HJ; Yoneda, H; Shirakawa, A; Kaminskii, AA				Bohaty, Ladislav; Becker, Petra; Haussuehl, Eiken; Nemec, Ivan; Lux, Oliver; Eichler, Hans Joachim; Yoneda, Hitoki; Shirakawa, Akira; Kaminskii, Alexander A.			Single crystals of guanidinium zinc sulfate, [C(NH2)(3)](2)Zn(SO4)(2) - growth, structure, vibrational spectroscopy and stimulated Raman scattering	ZEITSCHRIFT FUR KRISTALLOGRAPHIE-CRYSTALLINE MATERIALS			English	Article						[C(NH2)(3)](2)Zn(SO4)(2); guanidinium zinc sulfate; refractive indices; stimulated Raman scattering; vibrational spectroscopy	NONLINEAR-OPTICAL-PROPERTIES; LASER CONVERTERS	Large single crystals of the tetragonal (space group I (4) over bar 2d) guanidinium zinc sulfate, [C(NH2)(3)](2)Zn(SO4)(2), were grown and the crystal structure was redetermined. Vibrational spectra obtained by Raman and IR investigations are presented, together with an assignment of the observed vibration modes. Precise refractive index data in the wavelength range from 0.365 to 1.083 mu m are given. [C(NH2)(3)](2)Zn(SO4)(2) is introduced as a new stimulated Raman scattering (SRS)-active crystal with three SRS-active vibration modes with omega(SRS1) approximate to 985 cm(-1), omega(SRS2) approximate to 3390 cm(-1) and omega(SRS3) approximate to 1015 cm(-1). They allow for the generation of broadband nonlinear emission via chi((3))-(SRS and Raman-induced four wave mixing, RFWM) as well as cascaded chi((2))<->chi((3))-processes.	[Bohaty, Ladislav; Becker, Petra] Univ Cologne, Inst Kristallog, D-50939 Cologne, Germany; [Haussuehl, Eiken] Goethe Univ Frankfurt, Inst Geowissensch, D-60438 Frankfurt, Germany; [Nemec, Ivan] Charles Univ Prague, Dept Inorgan Chem, Prague 12843 2, Czech Republic; [Lux, Oliver; Eichler, Hans Joachim] Tech Univ Berlin, Inst Opt & Atom Phys, D-10623 Berlin, Germany; [Yoneda, Hitoki; Shirakawa, Akira] Univ Electrocommun, Inst Laser Sci, Tokyo 1828585, Japan; [Kaminskii, Alexander A.] Russian Acad Sci, Inst Crystallog, Moscow 119333, Russia	Bohaty, L (reprint author), Univ Cologne, Inst Kristallog, Greinstr 6, D-50939 Cologne, Germany.	Ladislav.Bohaty@Uni-Koeln.de			Deutsche Forschungsgemeinschaft (DFG) [HA 5137/3]; Czech Science Foundation [14-05506S]	Financial support from the Deutsche Forschungsgemeinschaft (DFG) under project number HA 5137/3 and the Czech Science Foundation (grant No. 14-05506S) is gratefully acknowledged. The authors wish to note that this study was considerably enhanced through mutual scientific help within the "Joint Open Laboratory for Laser Crystal and Precise Laser Systems." One of us (A.A.K.) is grateful to the Russian Foundation for Basic Research, the Program "Extreme light field and their applications" of the Presidium of the Russian Academy of Sciences, as well as the Alexander von Humboldt Foundation.	Kaminskii AA, 2011, PHYS STATUS SOLIDI A, V208, P695, DOI 10.1002/pssa.201026512; Bohaty L, 1999, CRYST RES TECHNOL, V34, P533, DOI 10.1002/(SICI)1521-4079(199904)34:4<533::AID-CRAT533>3.0.CO;2-Q; Czapla Z, 2011, SOLID STATE IONICS, V196, P25, DOI 10.1016/j.ssi.2011.05.021; Kaminskii AA, 2010, LASER PHYS LETT, V7, P743, DOI 10.1002/lapl.201010052; Franz P, 1998, PHYS STATUS SOLIDI B, V210, pR7, DOI 10.1002/(SICI)1521-3951(199812)210:2<R7::AID-PSSB99997>3.0.CO;2-E; Drozd M, 2013, SPECTROCHIM ACTA A, V115, P345, DOI 10.1016/j.saa.2013.06.023; Cho M, 1998, J CHEM PHYS, V108, P7114, DOI 10.1063/1.476128; HAUSSUHL S, 1984, Z KRISTALLOGR, V167, P307, DOI 10.1524/zkri.1984.167.3-4.307; Kaminskii AA, 2002, PHYS STATUS SOLIDI A, V193, P167, DOI 10.1002/1521-396X(200209)193:1<167::AID-PSSA167>3.0.CO;2-9; Bohaty L, 2005, LASER PHYS, V15, P1509; Kaminskii AA, 2001, OPT COMMUN, V194, P201, DOI 10.1016/S0030-4018(01)01274-3; Kaminskii AA, 2012, LASER PHYS LETT, V9, P879, DOI 10.7452/lapl.201210103; Gruszka K, 2013, NUKLEONIKA, V58, P387; Kaminskii AA, 2011, APPL PHYS B-LASERS O, V105, P363, DOI 10.1007/s00340-011-4388-4; Becker P, 2009, CRYST RES TECHNOL, V44, P603, DOI 10.1002/crat.200900179; Fleck M, 2004, SOLID STATE SCI, V6, P469, DOI 10.1016/j.solidstatesciences.2004.02.008; ROUSSEAU DL, 1981, J RAMAN SPECTROSC, V10, P253, DOI 10.1002/jrs.1250100152; BIRCH KP, 1994, METROLOGIA, V31, P315, DOI 10.1088/0026-1394/31/4/006; Kaminskii AA, 2004, LASER PHYS LETT, V1, P205, DOI 10.1002/lapl.200310050; Kaminskii AA, 2013, LASER PHYS LETT, V10, DOI 10.1088/1612-2011/10/7/073001; Hulliger J, 2001, ADV FUNCT MATER, V11, P243, DOI 10.1002/1616-3028(200108)11:4<243::AID-ADFM243>3.0.CO;2-U; Antonya CJ, 2009, SPECTROCHIM ACTA A, V73, P942, DOI 10.1016/j.saa.2009.04.024; Bohaty L., 2005, Z KRISTALLOGR, V22, P57; Canneri G., 1925, GAZZ CHIM ITAL, V55, P611; Drozd M, 2007, MAT SCI ENG B-SOLID, V136, P20, DOI 10.1016/j.mseb.2006.08.063; Kaiser W., 1972, LASER HDB, V2, P1077; Machackova Z., 2002, THESIS CHARLES U PRA; MORIMOTO CN, 1970, ACTA CRYSTALL B-STRU, VB 26, P335, DOI 10.1107/S0567740870002364; Ochrombel R., 2007, THESIS U COLOGNE; Sheldrick G. M., 1997, SHELXS97 PROGRAM SOL; Sheldrick GM, 2008, ACTA CRYSTALLOGR A, V64, P112, DOI 10.1107/S0108767307043930; Sheldrick G.M., 1997, SHELXL97 PROGRAM REF; Shen Y R, 1984, PRINCIPLES NONLINEAR; Sivashankar V., 2009, J CRYST GROWTH, V311, P2709	34	0	0	WALTER DE GRUYTER GMBH	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	2194-4946	2196-7105		Z KRIST-CRYST MATER	Z. Krist.-Cryst. Mater.	NOV	2015	230	11			SI		639	649		10.1515/zkri-2015-1839		11	Crystallography	Crystallography	CV5NJ	WOS:000364317300003		
J	Kakeda, S; Futatsuya, K; Ide, S; Watanabe, K; Miyata, M; Moriya, J; Ogasawara, A; Sato, T; Narimatsu, H; Okada, K; Uozumi, T; Liu, T; Wang, Y; Korogi, Y				Kakeda, Shingo; Futatsuya, Koichiro; Ide, Satoru; Watanabe, Keita; Miyata, Mari; Moriya, Junji; Ogasawara, Atsushi; Sato, Toru; Narimatsu, Hidekuni; Okada, Kazumasa; Uozumi, Takenori; Liu, Tian; Wang, Yi; Korogi, Yukunori			Improved Detection of Cortical Gray Matter Involvement in Multiple Sclerosis with Quantitative Susceptibility Mapping	ACADEMIC RADIOLOGY			English	Article						MRI; quantitative susceptibility mapping; multiple sclerosis; cortical lesion; lesion detection	NORMAL APPEARING WHITE; MAGNETIC-RESONANCE; DIAGNOSTIC-CRITERIA; GREY-MATTER; LESIONS; BRAIN; IRON; INVERSION; DISEASE; PLAQUES	Rationale and Objectives: Quantitative susceptibility mapping (QSM) is a novel technique which allows determining the bulk magnetic susceptibility distribution of tissue in vivo from gradient echo magnetic resonance (MR) phase images. Our purpose was to evaluate if there is additional diagnostic value of QSM images in detecting the cortical gray matter involvement in multiple sclerosis (MS) patients. Materials and Methods: Our institutional review board approved this study. Conventional MR imaging, including T2-weighted imaging and two- or three-dimensional fluid-attenuated inversion recovery images, and QSM imaging examinations were performed in 27 patients (19 male and eight female) with MS. Two radiologists (radiologists 1 and 2) assessed the MS lesions in the following 3 anatomic regions: intracortical, mixed white matter-gray matter (WM-GM), and juxtacortical regions. The numbers of lesions per region category were compared between conventional MR images with and without QSM images. Results: For radiologists 1 and 2, QSM images identified 6(50.0%) and 7(50.0%) additional lesions that were not seen in the conventional MR images, respectively. In a lesion-by-lesion analysis, the substantial fraction (20 [25.3%] of 79 at radiologist 1, 22 [29.7%] of 74 at radiologist 2) of juxtacortical white matter lesions on the conventional MR images were scored as mixed WM-GM lesions with QSM images. Conclusions: Our preliminary results suggest that the MR imaging with QSM may increase the sensitivity in cortical lesion detection in the MS brain and improved distinction between juxtacortical and mixed WM-GM lesions.	[Kakeda, Shingo; Futatsuya, Koichiro; Ide, Satoru; Watanabe, Keita; Miyata, Mari; Moriya, Junji; Ogasawara, Atsushi; Sato, Toru; Narimatsu, Hidekuni; Korogi, Yukunori] Univ Occupat & Environm Hlth, Sch Med, Dept Radiol, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan; [Okada, Kazumasa; Uozumi, Takenori] Univ Occupat & Environm Hlth, Sch Med, Dept Neurol, Kitakyushu, Fukuoka 8078555, Japan; [Liu, Tian; Wang, Yi] Cornell Univ, Dept Biomed Engn, Ithaca, NY USA	Kakeda, S (reprint author), Univ Occupat & Environm Hlth, Sch Med, Dept Radiol, Yahatanishi Ku, 1-1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan.	kakeda@med.uoeh-u.ac.jp					Schweser F, 2011, NEUROIMAGE, V54, P2789, DOI 10.1016/j.neuroimage.2010.10.070; Zivadinov R, 2012, NEUROIMAGE, V59, P331, DOI 10.1016/j.neuroimage.2011.07.045; Polman CH, 2005, ANN NEUROL, V58, P840, DOI 10.1002/ana.206703; Peterson JW, 2001, ANN NEUROL, V50, P389, DOI 10.1002/ana.1123; Bilgic B, 2012, NEUROIMAGE, V59, P2625, DOI 10.1016/j.neuroimage.2011.08.077; Cercignani M, 2001, J NEUROL NEUROSUR PS, V70, P311, DOI 10.1136/jnnp.70.3.311; Langkammer C, 2012, NEUROIMAGE, V59, P1413, DOI 10.1016/j.neuroimage.2011.08.045; Barkhof F, 1997, BRAIN, V120, P2059, DOI 10.1093/brain/120.11.2059; Liu J, 2012, NEUROIMAGE, V59, P2560, DOI 10.1016/j.neuroimage.2011.08.082; McDonald WI, 2001, ANN NEUROL, V50, P121, DOI 10.1002/ana.1032; Miki Y, 1998, NEUROLOGY, V50, P1301; CRAELIUS W, 1982, ARCH PATHOL LAB MED, V106, P397; BROWNELL B, 1962, J NEUROL NEUROSUR PS, V25, P315, DOI 10.1136/jnnp.25.4.315; Geurts JJG, 2005, RADIOLOGY, V236, P254, DOI 10.1148/radiol.2361040450; HALLGREN B, 1960, J NEUROCHEM, V5, P307, DOI 10.1111/j.1471-4159.1960.tb13369.x; de Rochefort L, 2010, MAGN RESON MED, V63, P194, DOI 10.1002/mrm.22187; Schweser F, 2010, MED PHYS, V37, P5165, DOI 10.1118/1.3481505; Barkhof F, 2015, BRAIN, V138, P828, DOI 10.1093/brain/awv031; Kidd D, 1999, BRAIN, V122, P17, DOI 10.1093/brain/122.1.17; Pitt D, 2010, ARCH NEUROL-CHICAGO, V67, P812, DOI 10.1001/archneurol.2010.148; Kakeda S, 2012, ACAD RADIOL, V19, P1225, DOI 10.1016/j.acra.2012.04.017; Hammond KE, 2008, ANN NEUROL, V64, P707, DOI 10.1002/ana.21582; Liu T, 2012, RADIOLOGY, V262, P269, DOI 10.1148/radiol.11110251; Filippi M, 2011, RADIOLOGY, V259, P659, DOI 10.1148/radiol.11101362; Miller DH, 2003, J NEUROL, V250, P1407, DOI 10.1007/s00415-003-0243-9; Ide S, 2015, EUR RADIOL, V25, P710, DOI 10.1007/s00330-014-3472-7; Murakami Y, 2015, AM J NEURORADIOLOGY	27	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1076-6332	1878-4046		ACAD RADIOL	Acad. Radiol.	NOV	2015	22	11					1427	1432		10.1016/j.acra.2015.08.003		6	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CU5WG	WOS:000363602100012		
J	Huang, JW; Mori, T; Takashima, K; Hashi, S; Kitamura, Y				Huang, Jiawei; Mori, Tsuyoshi; Takashima, Kazuki; Hashi, Shuichiro; Kitamura, Yoshifumi			IM6D: Magnetic Tracking System with 6-DOF Passive Markers for Dexterous 3D Interaction and Motion	ACM TRANSACTIONS ON GRAPHICS			English	Article; Proceedings Paper	ACM SIGGRAPH Asia Conference	NOV 02-05, 2015	Kobe, JAPAN	Assoc Comp Machinery SIGGRAPH		motion capture; sensor; virtual reality; augmented reality; 3D user interface	CAPTURE SYSTEM; ACCURACY	We propose IM6D, a novel real-time magnetic motion-tracking system using multiple identifiable, tiny, lightweight, wireless and occlusion-free markers. It provides reasonable accuracy and update rates and an appropriate working space for dexterous 3D interaction. Our system follows a novel electromagnetic induction principle to externally excite wireless LC coils and uses an externally located pickup coil array to track each of the LC coils with 5-DOF. We apply this principle to design a practical motion-tracking system using multiple markers with 6-DOF and to achieve reliable tracking with reasonable speed. We also solved the principle's inherent dead-angle problem. Based on this method, we simulated the configuration of parameters for designing a system with scalability for dexterous 3D motion. We implemented an actual system and applied a parallel computation structure to increase the tracking speed. We also built some examples to show how well our system works for actual situations.	[Huang, Jiawei; Mori, Tsuyoshi; Takashima, Kazuki; Hashi, Shuichiro; Kitamura, Yoshifumi] Tohoku Univ, Res Inst Elect Commun, Sendai, Miyagi 980, Japan	Huang, JW (reprint author), Tohoku Univ, Res Inst Elect Commun, Sendai, Miyagi 980, Japan.						Harrison C, 2009, UIST 2009: PROCEEDINGS OF THE 22ND ANNUAL ACM SYMPOSIUM ON USER INTERFACE SOFTWARE AND TECHNOLOGY, P121; RAAB FH, 1979, IEEE T AERO ELEC SYS, V15, P709, DOI 10.1109/TAES.1979.308860; Tang DH, 2013, IEEE I CONF COMP VIS, P3224, DOI 10.1109/ICCV.2013.400; Ribo M, 2001, IEEE IMTC P, P1932, DOI 10.1109/IMTC.2001.929537; Shotton J, 2011, PROC CVPR IEEE, P1297, DOI 10.1109/CVPR.2011.5995316; Tompson J, 2014, ACM T GRAPHIC, V33, DOI 10.1145/2629500; Paradiso JA, 2003, J NEW MUSIC RES, V32, P395, DOI 10.1076/jnmr.32.4.395.18858; Hashi S, 2009, IEEE T MAGN, V45, P2736, DOI 10.1109/TMAG.2009.2020541; Hashi S, 2008, SENSOR ACTUAT A-PHYS, V142, P520, DOI 10.1016/j.sna.2007.09.011; CHAN L., 2013, P S US INT SOFTW TEC, P255; CHEN K.-Y., 2013, P S US INT SOFTW TEC, P237; FOXLIN E., 1994, P VIRT REAL SOFTW TE, P159; FOXLIN E., 1998, P 25 ANN C COMP GRAP, P371, DOI 10.1145/280814.280937; GROSSMAN T., 2004, P 17 ANN ACM S US IN, P61, DOI DOI 10.1145/1029632.1029644; Hilliges O., 2012, P 2012 ACM ANN C HUM, P2421; HUANG J., 2014, SIGGRAPH EMERGING TE, V12, P1; Nakagawa T., 1982, EXPT DATA ANAL LEAST; Sandilands P., 2012, LECT NOTES COMPUTER, V7660, P220; SHARP T., 2015, P C HUM FACT COMP SY, P3633; SHIRATORI T., 2011, ACM T GRAPHIC, V30, P31; SONG P., 2008, P ACM SIGGRAPH INT C, P7; SUTHERLAND I., 1968, P FALL JOINT COMP C, V1, P757; VLASIC DANIEL, 2007, P SIGGRAPH; Wang RY, 2009, ACM T GRAPHIC, V28, DOI 10.1145/1531326.1531369; Wang YG, 2013, KEY ENG MATER, V567, P15, DOI 10.4028/www.scientific.net/KEM.567.15; Wang Y, 2013, J EXP CLIN CANC RES, V32, P1, DOI DOI 10.1186/1756-9966-32-8; Yabukami S., 2007, Journal of the Magnetics Society of Japan, V31, DOI 10.3379/jmsjmag.31.439; Yabukami S., 2004, Journal of the Magnetics Society of Japan, V28, DOI 10.3379/jmsjmag.28.877; ZHANG P., 2014, ACM T GRAPHIC, V33, P221; ZHAO W., 2012, P ACM SIGGRAPH EUR S, P33; ZIMMERMAN T. G., 1987, P HUM FACT COMP SYST, P189, DOI 10.1145/29933.275628	31	0	0	ASSOC COMPUTING MACHINERY	NEW YORK	2 PENN PLAZA, STE 701, NEW YORK, NY 10121-0701 USA	0730-0301	1557-7368		ACM T GRAPHIC	ACM Trans. Graph.	NOV	2015	34	6							217	10.1145/2816795.2818135		10	Computer Science, Software Engineering	Computer Science	CU6UZ	WOS:000363671200054		
J	Koyama, Y; Sueda, S; Steinhardt, E; Igarashi, T; Shamir, A; Matusile, W				Koyama, Yuki; Sueda, Shinjiro; Steinhardt, Emma; Igarashi, Takeo; Shamir, Ariel; Matusile, Wojciech			AutoConnect: Computational Design of 3D-Printable Connectors	ACM TRANSACTIONS ON GRAPHICS			English	Article; Proceedings Paper	ACM SIGGRAPH Asia Conference	NOV 02-05, 2015	Kobe, JAPAN	Assoc Comp Machinery SIGGRAPH		3D printing; fabrication; functional design		We present AutoConnect, an automatic method that creates customized, 3D-printable connectors attaching two physical objects together. Users simply position and orient virtual models of the two objects that they want to connect and indicate some auxiliary information such as weight and dimensions. Then, AutoConnect creates several alternative designs that users can choose from for 3D printing. The design of the connector is created by combining two holders, one for each object. We categorize the holders into two types. The first type holds standard objects such as pipes and planes. We utilize a database of parameterized mechanical holders and optimize the holder shape based on the grip strength and material consumption. The second type holds free-form objects. These are procedurally generated shell-gripper designs created based on geometric analysis of the object. We illustrate the use of our method by demonstrating many examples of connectors and practical use cases.	[Koyama, Yuki; Sueda, Shinjiro; Steinhardt, Emma; Shamir, Ariel] Disney Res Boston, Boston, MA USA; [Koyama, Yuki; Igarashi, Takeo] Univ Tokyo, Tokyo 1138654, Japan; [Shamir, Ariel] IDC Herzliya, Herzliyya, Israel; [Matusile, Wojciech] MIT, Cambridge, MA 02139 USA	Koyama, Y (reprint author), Disney Res Boston, Boston, MA USA.						ANJYO K., 2014, ACM SIGGRAPH 2014 CO, P27; HIRUKAWA H, 1994, IEEE T ROBOTIC AUTOM, V10, P309, DOI 10.1109/70.294206; von Luxburg U, 2007, STAT COMPUT, V17, P395, DOI 10.1007/s11222-007-9033-z; Shi JB, 2000, IEEE T PATTERN ANAL, V22, P888; Mitra NJ, 2006, ACM T GRAPHIC, V25, P560, DOI 10.1145/1141911.1141924; Vanek J, 2014, COMPUT GRAPH FORUM, V33, P117, DOI 10.1111/cgf.12437; Podolak J, 2006, ACM T GRAPHIC, V25, P549, DOI 10.1145/1141911.1141923; Saul G, 2011, TEI 2011: PROCEEDINGS OF THE FIFTH INTERNATIONAL CONFERENCE ON TANGIBLE EMBEDDED AND EMBODIED INTERACTION, P73; Agrawala M, 2003, ACM T GRAPHIC, V22, P828, DOI 10.1145/882262.882352; Bacher M, 2012, ACM T GRAPHIC, V31, DOI 10.1145/2185520.2185543; Bacher M, 2014, ACM T GRAPHIC, V33, DOI 10.1145/2601097.2601157; Bicchi A, 2000, P IEEE INT C ROB AUT, P348; Bickel B., 2010, ACM T GRAPHIC, V29, P4, DOI DOI 10.1145/1778765.1778800.63; Cali J., 2012, ACM T GRAPHIC, V31, P130; Ceylan D., 2013, ACM T GRAPHIC, V32, P6; Chen X, 2014, ACM T GRAPHIC, V33, DOI 10.1145/2601097.2601189; Coros S., 2013, ACM T GRAPHIC, V32, P4, DOI DOI 10.1145/2461912.2461953.83; Fish N., 2014, ACM T GRAPHIC, V33, P4; GAL R., 2009, ACM T GRAPHIC, V28, P3; GELFAND N., 2004, P S GEOM PROC, P214, DOI 10.1145/1057432.1057461; GELFAND N., 2003, INT C 3 D DIG IM MOD, P260; Hu RZ, 2014, ACM T GRAPHIC, V33, DOI 10.1145/2661229.2661244; Koo BJ, 2014, ACM T GRAPHIC, V33, DOI 10.1145/2661229.2661289; Li HH, 2012, ACM T GRAPHIC, V31, DOI 10.1145/2366145.2366177; Lu L, 2014, ACM T GRAPHIC, V33, DOI 10.1145/2601097.2601168; Powell M. J. D., 1998, Acta Numerica, V7, DOI 10.1017/S0962492900002841; Prevost R., 2013, ACM T GRAPHIC, V32, P81; Schulz A, 2014, ACM T GRAPHIC, V33, DOI 10.1145/2601097.2601127; Stava O., 2012, ACM T GRAPHIC, V31, P4; Thomaszewski B, 2014, ACM T GRAPHIC, V33, DOI 10.1145/2601097.2601143; UMETANI N., 2013, SIGGRAPH ASIA 2013 T, V13, P5; Umetani N, 2014, ACM T GRAPHIC, V33, DOI 10.1145/2601097.2601129; Umetani N., 2012, ACM T GRAPHIC, V31, P4, DOI DOI 10.1145/2185520.2185582.86; WANG W., 2013, ACM T GRAPHIC, V6, P1; WILSON R. H., 1992, THESIS STANFORD; Xu WW, 2009, ACM T GRAPHIC, V28, DOI 10.1145/1531326.1531341; Zhou YH, 2014, ACM T GRAPHIC, V33, DOI 10.1145/2601097.2601173; Zhu L., 2012, ACM T GRAPHIC, V31, P6, DOI DOI 10.1145/2366145.2366146.127	38	0	0	ASSOC COMPUTING MACHINERY	NEW YORK	2 PENN PLAZA, STE 701, NEW YORK, NY 10121-0701 USA	0730-0301	1557-7368		ACM T GRAPHIC	ACM Trans. Graph.	NOV	2015	34	6							231	10.1145/2816795.2818060		11	Computer Science, Software Engineering	Computer Science	CU6UZ	WOS:000363671200067		
J	Luo, SJ; Yue, YH; Huang, CK; Chung, YH; Imai, S; Nishita, T; Chen, BY				Luo, Sheng-Jie; Yue, Yonghao; Huang, Chun-Kai; Chung, Yu-Huan; Imai, Sei; Nishita, Tomoyuki; Chen, Bing-Yu			Legolization: Optimizing LEGO Designs	ACM TRANSACTIONS ON GRAPHICS			English	Article; Proceedings Paper	ACM SIGGRAPH Asia Conference	NOV 02-05, 2015	Kobe, JAPAN	Assoc Comp Machinery SIGGRAPH		LEGO; stability-aware design; fabrication	RIGID BODIES; DYNAMICS	Building LEGO sculptures requires accounting for the target object's shape, colors, and stability. In particular, finding a good layout of LEGO bricks that prevents the sculpture from collapsing ( due to its own weight) is usually challenging, and it becomes increasingly difficult as the target object becomes larger or more complex. We devise a force-based analysis for estimating physical stability of a given sculpture. Unlike previous techniques for Legolization, which typically use heuristic-based metrics for stability estimation, our force-based metric gives 1) an ordering in the strength so that we know which structure is more stable, and 2) a threshold for stability so that we know which one is stable enough. In addition, our stability analysis tells us the weak portion of the sculpture. Building atop our stability analysis, we present a layout refinement algorithm that iteratively improves the structure around the weak portion, allowing for automatic generation of a LEGO brick layout from a given 3D model, accounting for color information, required workload (in terms of the number of bricks) and physical stability. We demonstrate the success of our method with real LEGO sculptures built up from a wide variety of 3D models, and compare against previous methods.	[Luo, Sheng-Jie; Huang, Chun-Kai; Chung, Yu-Huan; Chen, Bing-Yu] Natl Taiwan Univ, Taipei, Taiwan; [Yue, Yonghao] Columbia Univ, New York, NY 10027 USA; [Imai, Sei] Univ Tokyo, Tokyo 1138654, Japan; [Nishita, Tomoyuki] Hiroshima Shudo Univ, Hiroshima, Japan	Luo, SJ (reprint author), HTC Corp, Taoyuan, Taiwan.						Guendelman E, 2003, ACM T GRAPHIC, V22, P871, DOI 10.1145/882262.882358; Tachi T, 2010, IEEE T VIS COMPUT GR, V16, P298, DOI 10.1109/TVCG.2009.67; Mitani J, 2004, ACM T GRAPHIC, V23, P259, DOI 10.1145/1015706.1015711; Silva LFMS, 2009, SIBGRAPI, P17, DOI 10.1109/SIBGRAPI.2009.18; Kaufman DM, 2005, ACM T GRAPHIC, V24, P946, DOI 10.1145/1073204.1073295; HOPCROFT J, 1973, COMMUN ACM, V16, P372, DOI 10.1145/362248.362272; Yue YH, 2012, COMPUT GRAPH FORUM, V31, P575, DOI 10.1111/j.1467-8659.2012.03036.x; Baraff D., 1994, P SIGGRAPH 94, P23, DOI 10.1145/192161.192168; CHEN H., 1998, J GRAPHICS TOOLS, V3, P33; CLAGUE K., 2002, LEGO SOFTWARE POWER; COURTNEY T., 2003, VIRTUAL LEGO OFFICIA; Erleben K, 2007, ACM T GRAPHIC, V26, DOI 10.1145/1243980.1243986; Garg A., 2014, ACM T GRAPHIC, V33, P66; GASCON J., 2010, P SCA 2010, P39; GOWER R., 1998, P 32 EUR STUD GROUP, P81; HILDEBRAND K., 2012, COMPUT GRAPH FORUM, V31, P2; Jakob Wenzel, 2010, MITSUBA RENDERER; JESSIMAN J., 1995, LDRAW LEGO CAD SOFTW; KAUFMAN D.M., 2008, ACM T GRAPHIC, V27, P5; Kilian M., 2008, ACM T GRAPHIC, V27, P3; KIM J.-W., 2014, P 2014 IEEE WORLD FO, P89; Li X.-Y, 2011, ACM T GRAPHIC, V30, P4, DOI DOI 10.1145/2010324.1964993; Li XY, 2010, ACM T GRAPHIC, V29, DOI 10.1145/1778765.1778848; Mitra N. J., 2009, ACM T GRAPHIC, V28, P5; Mori Y., 2007, ACM T GRAPHIC, V26, P3, DOI DOI 10.1145/1276377.1276433; MUELLER S., 2014, P 32 ANN ACM C HUM F, P3827; Panozzo D., 2013, ACM T GRAPHIC, V32, P4; PETROVIC P., 2001, P NIK 2001; Prevost R., 2013, ACM T GRAPHIC, V32, P81; Schulz A, 2014, ACM T GRAPHIC, V33, DOI 10.1145/2601097.2601127; Schwartzburg Y, 2014, ACM T GRAPHIC, V33, DOI 10.1145/2601097.2601200; SHIGEO T., 2011, COMPUT GRAPH FORUM, V30, P2077; Skouras M, 2014, ACM T GRAPHIC, V33, DOI 10.1145/2601097.2601166; Smith B, 2012, ACM T GRAPHIC, V31, DOI 10.1145/2185520.2185602; Song P, 2012, ACM T GRAPHIC, V31, DOI 10.1145/2366145.2366147; Stava O., 2012, ACM T GRAPHIC, V31, P4; TESTUZ R., 2013, EUROGRAPHICS 2013 SH, P81; THE LEGO GROUP, 2012, LEGO DIG DES; THE LEGO GROUP, 2010, CO PROF INTR LEGO GR; Thomaszewski B, 2014, ACM T GRAPHIC, V33, DOI 10.1145/2601097.2601143; Umetani N., 2012, ACM T GRAPHIC, V31, P4, DOI DOI 10.1145/2185520.2185582.86; VAN ZIJL L., 2008, P AUT 2008 WORKSH, P425; VIDIMCE K., 2013, ACM T GRAPHIC, V32, P136; VOUGA E, 2012, ACM T GRAPHIC, V31, P4; WASSMANN M., 2012, P 20 ANN EUR C ALG, P813; Weyrich T, 2007, ACM T GRAPHIC, V26, DOI 10.1145/1239451.1239483; Whiting E., 2009, ACM T GRAPHIC, V28, P5; Whiting E., 2012, ACM T GRAPHIC, V31, P6; YUE Y., 2014, ACM T GRAPHIC, V33, P31	49	0	0	ASSOC COMPUTING MACHINERY	NEW YORK	2 PENN PLAZA, STE 701, NEW YORK, NY 10121-0701 USA	0730-0301	1557-7368		ACM T GRAPHIC	ACM Trans. Graph.	NOV	2015	34	6							222	10.1145/2816795.2818091		12	Computer Science, Software Engineering	Computer Science	CU6UZ	WOS:000363671200059		
J	Miyashita, L; Yonezawa, R; Watanabe, Y; Ishikawa, M				Miyashita, Leo; Yonezawa, Ryota; Watanabe, Yoshihiro; Ishikawa, Masatoshi			3D Motion Sensing of any Object without Prior Knowledge	ACM TRANSACTIONS ON GRAPHICS			English	Article; Proceedings Paper	ACM SIGGRAPH Asia Conference	NOV 02-05, 2015	Kobe, JAPAN	Assoc Comp Machinery SIGGRAPH		6-axis; rotation; translation; motion capture; velocity; TOF; LDV		We propose a novel three-dimensional motion sensing method using lasers. Recently, object motion information is being used in various applications, and the types of targets that can be sensed continue to diversify. Nevertheless, conventional motion sensing systems have low universality because they require some devices to be mounted on the target, such as accelerometers and gyro sensors, or because they are based on cameras, which limits the types of targets that can be detected. Our method solves this problem and enables noncontact, high-speed, deterministic measurement of the velocity of a moving target without any prior knowledge about the target shape and texture, and can be applied to any unconstrained, unspecified target. These distinctive features are achieved by using a system consisting of a laser range finder, a laser Doppler velocimeter, and a beam controller, in addition to a robust 3D motion calculation method. The motion of the target is recovered from fragmentary physical information, such as the distance and speed of the target at the laser irradiation points. From the acquired laser information, our method can provide a numerically stable solution based on the generalized weighted Tikhonov regularization. Using this technique and a prototype system that we developed, we also demonstrated a number of applications, including motion capture, video game control, and 3D shape integration with everyday objects.	[Miyashita, Leo; Yonezawa, Ryota; Watanabe, Yoshihiro; Ishikawa, Masatoshi] Univ Tokyo, Tokyo 1138654, Japan	Miyashita, L (reprint author), Univ Tokyo, Tokyo 1138654, Japan.	Leo_Miyashita@ipc.i.u-tokyo.ac.jp					ALCANTARILLA P.F., 2013, P BRIT MACH VIS C BM, P131; [Anonymous], 2011, P IEEE INT C COMP VI; Watanabe Y, 2007, IEEE INT CONF ROBOT, P3192, DOI 10.1109/ROBOT.2007.363965; Calonder M., 2010, P EUR C COMP VIS, P778; Curless B., 1996, Computer Graphics Proceedings. SIGGRAPH '96; ENGELHARD N., 2011, P RGB D WORKSH 3D PE; GRANGER S., 2002, P EUR C COMP VIS, P418; HARRISON C., 2009, P UIST 09, P121, DOI 10.1145/1622176.1622199; IZADI S., 2011, P 24 ANN ACM S US IN, P559; Kato H., 1999, Proceedings 2nd IEEE and ACM International Workshop on Augmented Reality (IWAR'99), DOI 10.1109/IWAR.1999.803809; KEHL R., 2006, COMPUTER VISION IMAG, V104; KETABDAR H., 2010, P 14 INT C INT US IN, P413; Klein G., 2007, P 6 IEEE ACM INT S M; LEGOC M., 2014, P 32 ANN ACM C HUM F, P3167; LEPETIT V., 2009, INT J COMPUT VISION; LIU Y., 2006, IMAGE VISION COMPUT, V24, P7; MITOBE K., 2006, P 33 ACM INT C EXH C; Newcombe R. A., 2011, P 10 IEEE INT S MIX, P127, DOI DOI 10.1109/ISMAR.2011.6092378; NISHITANI A., 2005, P IEEE SENS 2005; NOGUCHI S., 2013, P 20 IEEE INT C IM P, P2140; RASKAR R., 2007, ACM T GRAPHIC, V26, P3; ROTHBERG S., 1989, J SOUND VIBRATION, V135, P3; SHIRATORI T., 2011, ACM T GRAPHIC, V30, P4; SHOTTON J., 2011, P IEEE INT C COMP VI, P119; VLASIC D., 2007, ACM T GRAPHIC, V26, P3; WANG Y., 2012, COMPUTATIONAL METHOD; WATANABE Y., 2009, P 12 IEEE INT C COMP; ZERROUG A., 2011, P VIRT REALINT C VRI, P31	28	0	0	ASSOC COMPUTING MACHINERY	NEW YORK	2 PENN PLAZA, STE 701, NEW YORK, NY 10121-0701 USA	0730-0301	1557-7368		ACM T GRAPHIC	ACM Trans. Graph.	NOV	2015	34	6							218	10.1145/2816795.2818133		11	Computer Science, Software Engineering	Computer Science	CU6UZ	WOS:000363671200055		
J	Xing, J; Wei, LY; Shiratori, T; Yatani, K				Xing, Jun; Wei, Li-Yi; Shiratori, Takaaki; Yatani, Koji			Autocomplete Hand-drawn Animations	ACM TRANSACTIONS ON GRAPHICS			English	Article; Proceedings Paper	ACM SIGGRAPH Asia Conference	NOV 02-05, 2015	Kobe, JAPAN	Assoc Comp Machinery SIGGRAPH		animation; drawing; auto-complete; analysis; synthesis; beautification; workflow; user interface; deformation		Hand-drawn animation is a major art form and communication medium, but can be challenging to produce. We present a system to help people create frame-by-frame animations through manual sketches. We design our interface to be minimalistic: it contains only a canvas and a few controls. When users draw on the canvas, our system silently analyzes all past sketches and predicts what might be drawn in the future across spatial locations and temporal frames. The interface also offers suggestions to beautify existing drawings. Our system can reduce manual workload and improve output quality without compromising natural drawing flow and control: users can accept, ignore, or modify such predictions visualized on the canvas by simple gestures. Our key idea is to extend the local similarity method in [Xing et al. 2014], which handles only low-level spatial repetitions such as hatches within a single frame, to a global similarity that can capture high-level structures across multiple frames such as dynamic objects. We evaluate our system through a preliminary user study and confirm that it can enhance both users' objective performance and subjective satisfaction.	[Xing, Jun; Wei, Li-Yi] Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China; [Yatani, Koji] Univ Tokyo, Tokyo 1138654, Japan	Xing, J (reprint author), Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China.						Belongie S, 2002, IEEE T PATTERN ANAL, V24, P509, DOI 10.1109/34.993558; Jones B, 2015, COMPUT ANIMAT VIRT W, V26, P97, DOI 10.1002/cav.1608; Whited B, 2010, COMPUT GRAPH FORUM, V29, P605, DOI 10.1111/j.1467-8659.2009.01630.x; Chu NSH, 2005, ACM T GRAPHIC, V24, P504, DOI 10.1145/1073204.1073221; Lindemeier T, 2015, COMPUT GRAPH FORUM, V34, P311, DOI 10.1111/cgf.12562; Igarashi T, 2005, ACM T GRAPHIC, V24, P1134, DOI 10.1145/1073204.1073323; Baxter W, 2006, COMPUT GRAPH FORUM, V25, P477, DOI 10.1111/j.1467-8659.2006.00967.x; CHEN H.-T., 2014, CHI 14, P2027; COLE F., 2013, ACM T GRAPHIC, V32, P119; DAVIS J., 2003, SCA 03, P320; Lu JW, 2013, ACM T GRAPHIC, V32, DOI 10.1145/2461912.2461998; Grabler F, 2009, ACM T GRAPHIC, V28, DOI 10.1145/1531326.1531372; GRAVES A., 2013, ABS13080850 CORR; GUAY M., 2015, ACM T GRAPHIC, V34, P118; HUANG Q.-X., 2008, SGP 08 P 6 S GEOM PR, P1449; IARUSSI E., 2013, UIST 13, P183; KAZI R. H., 2014, CHI 14, P351; KAZI R. H., 2014, UIST 14, P395; KIM V., 2012, ACM T GRAPHIC, V31, P4; Lee YJ, 2011, ACM T GRAPHIC, V30, DOI 10.1145/1964921.1964922; LI H., 2008, SGP 08, P1421; LIMPAECHER A., 2013, ACM T GRAPHIC, V32, P54; LUKAC M., 2013, ACM T GRAPHIC, V32, P116; Ma CY, 2011, ACM T GRAPHIC, V30, DOI 10.1145/1964921.1964957; MILLIEZ A., 2014, NPAR 14, P71; MYERS B. A., 2015, CHI 15, P4227; NANCEL M., 2014, CHI 14, P1777; NORIS G., 2011, NPAR 11, P93; Sumner R. W., 2007, ACM T GRAPHIC, V26, P3; SYKORA D., 2009, NPAR 09, P25; Thorne M, 2004, ACM T GRAPHIC, V23, P424, DOI 10.1145/1015706.1015740; WEBER O., 2009, COMPUT GRAPH FORUM, V28, P2; Xing J, 2014, ACM T GRAPHIC, V33, DOI 10.1145/2661229.2661247; ZITNICK C. L., 2013, ACM T GRAPHIC, V32, P53	34	0	0	ASSOC COMPUTING MACHINERY	NEW YORK	2 PENN PLAZA, STE 701, NEW YORK, NY 10121-0701 USA	0730-0301	1557-7368		ACM T GRAPHIC	ACM Trans. Graph.	NOV	2015	34	6							169	10.1145/2816795.2818079		11	Computer Science, Software Engineering	Computer Science	CU6UZ	WOS:000363671200006		
J	Ohira, A; Hara, K; Johannesson, G; Tanito, M; Asgrimsdottir, GM; Lund, SH; Loftsson, T; Stefansson, E				Ohira, Akihiro; Hara, Katsunori; Johannesson, Gauti; Tanito, Masaki; Asgrimsdottir, Gudrun Marta; Lund, Sigrun H.; Loftsson, Thorsteinn; Stefansson, Einar			Topical dexamethasone -cyclodextrin nanoparticle eye drops increase visual acuity and decrease macular thickness in diabetic macular oedema	ACTA OPHTHALMOLOGICA			English	Article						cyclodextrin; dexamethasone; diabetes macular edema; nanoparticle; topical treatment; triamcinolone	INTRAVITREAL TRIAMCINOLONE ACETONIDE; RANIBIZUMAB PLUS PROMPT; POSTERIOR SEGMENT; DEFERRED LASER; DRUG-DELIVERY; IMPLANT	PurposeTo compare in a randomized, controlled trial topical 1.5% dexamethasone -cyclodextrin nanoparticle eye drops (DexNP) with posterior subtenon injection of triamcinolone acetonide in diabetic macular oedema (DME). MethodsIn this prospective, randomized, controlled trial, 22 eyes of 22 consecutive patients with DME were randomized to (i) topical treatment with DexNP x3/day (4weeks), x2/day (4weeks) and x1/day (4weeks) or (ii) one posterior subtenon injection of 20mg triamcinolone acetonide. Study visits were at baseline and 4, 8, 12 and 16weeks. ResultsThe logMAR (Snellen) visual acuity (meanSD) improved significantly with DexNP from 0.41 +/- 0.3 (Snellen 0.39) to 0.32 +/- 0.25 (0.48) and 0.30 +/- 0.26 (0.50) at 4 and 8weeks, respectively. One-third of the DexNP group improved more than 0.3 logMAR units. For triamcinolone, logMAR changed significantly from 0.42 +/- 0.28 (0.38) at baseline to 0.32 +/- 0.29 (0.48) at 4w and 0.33 +/- 0.37 (0.47) at 12w. The central macular thickness (CMT) decreased significantly with DexNP from 483 +/- 141m to 384 +/- 142m at 4w and 342 +/- 114m at 8w. For triamcinolone, CMT decreased significantly at all time-points: 494 +/- 94m, 388 +/- 120, 388 +/- 145, 390 +/- 136 and 411 +/- 104m at 0, 4, 8, 12 and 16weeks, respectively. There was a modest increase in intraocular pressure (IOP) at all time-points with DexNP while no increase was seen with triamcinolone. Serum cortisol was affected by both treatments. ConclusionTopical DexNP significantly improve visual acuity and decrease macular thickness in patients with DME. The effect is similar to that from subtenon triamcinolone. A modest increase in IOP was seen with the nanoparticle eye drops, but IOP normalized after the discontinuation of treatment.	[Ohira, Akihiro; Hara, Katsunori; Tanito, Masaki] Shimane Univ, Fac Med, Dept Ophthalmol, Izumo, Shimane, Japan; [Johannesson, Gauti] Umea Univ, Dept Clin Sci Ophthalmol, SE-90185 Umea, Sweden; [Asgrimsdottir, Gudrun Marta] Oculis Ehf, Reykjavik, Iceland; [Lund, Sigrun H.] Univ Iceland, Fac Med, Ctr Publ Hlth Sci, Reykjavik, Iceland; [Loftsson, Thorsteinn] Univ Iceland, Fac Pharmaceut Sci, Reykjavik, Iceland; [Stefansson, Einar] Univ Iceland, Natl Univ Hosp, Fac Med, Dept Ophthalmol, Reykjavik, Iceland	Johannesson, G (reprint author), Umea Univ, Dept Clin Sci Ophthalmol, SE-90185 Umea, Sweden.	gauti.johannesson@umu.se			Technology Development Fund; Icelandic research council; Swedish Medical Society; Kempe Fund; Oculis ehf	This study was supported by unrestricted grants from Technology Development Fund, Icelandic research council, Swedish Medical Society, Kempe Fund and Oculis ehf.	Fasce F, 2014, ACTA OPHTHALMOL, V92, pe330, DOI 10.1111/aos.12332; Kriechbaum K, 2014, EYE, V28, P9, DOI 10.1038/eye.2013.242; Elman MJ, 2011, OPHTHALMOLOGY, V118, P609, DOI 10.1016/j.ophtha.2010.12.033; Boyer DS, 2011, RETINA-J RET VIT DIS, V31, P915, DOI 10.1097/IAE.0b013e318206d18c; Medeiros MD, 2014, OPHTHALMOLOGICA, V231, P141, DOI 10.1159/000356413; Elman MJ, 2010, OPHTHALMOLOGY, V117, P1064, DOI 10.1016/j.ophtha.2010.02.031; Sigurdsson HH, 2007, ACTA OPHTHALMOL SCAN, V85, P598, DOI 10.1111/j.1600-0420.2007.00885.x; Zucchiatti I, 2012, OPHTHALMOLOGICA, V228, P117, DOI 10.1159/000336225; Tanito M, 2011, INVEST OPHTH VIS SCI, V52, P7944, DOI 10.1167/iovs.11-8178; [Anonymous], 2014, HIGHLIGHT PRESCRIBIN, P1; Simo R, 2014, DIABETES CARE, V37, P893, DOI 10.2337/dc13-2002; Loftsson T, 2008, PHARMAZIE, V63, P171, DOI 10.1691/ph.2008.7322; Loftsson T, 2007, J PHARM PHARMACOL, V59, P629, DOI 10.1211/jpp.59.5.0002; Jansook P, 2010, J PHARM PHARM SCI, V13, P336; Campochiaro PA, 2012, OPHTHALMOLOGY, V119, P2125, DOI 10.1016/j.ophtha.2012.04.030; Callanan DG, 2013, OPHTHALMOLOGY, V120, P1843, DOI 10.1016/j.ophtha.2013.02.018; Bandello F, 2014, OPHTHALMIC RES, V51, P88, DOI 10.1159/000356693; Ozdek S, 2006, J DIABETES COMPLICAT, V20, P246, DOI 10.1016/jjdiacomp.2005.06.015; Nakano S, 2010, GRAEF ARCH CLIN EXP, V248, P805, DOI 10.1007/s00417-010-1316-y; Ciulla TA, 2014, EXPERT OPIN PHARMACO, V15, P953, DOI 10.1517/14656566.2014.896899; Cho Hee Yoon, 2012, Korean J Ophthalmol, V26, P362, DOI 10.3341/kjo.2012.26.5.362; Johannesson G, 2013, ACTA OPHTHALMOL, V92, P550; Pacella Elena, 2013, Clin Ophthalmol, V7, P1423, DOI 10.2147/OPTH.S48364; Sarao V, 2014, SCI WORLD J, V2014	24	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1755-375X	1755-3768		ACTA OPHTHALMOL	Acta Ophthalmol.	NOV	2015	93	7					610	615		10.1111/aos.12803		6	Ophthalmology	Ophthalmology	CU9UG	WOS:000363890500024		
J	Shiraya, T; Kato, S; Araki, F; Yamaguchi, T; Kaiya, T				Shiraya, Tomoyasu; Kato, Satoshi; Araki, Fumiaki; Yamaguchi, Takuhiro; Kaiya, Tadayoshi			Comparison of burn sizes resulting from photocoagulation using a transpupillary laser and an endolaser	ACTA OPHTHALMOLOGICA			English	Letter							DIABETIC-RETINOPATHY		[Shiraya, Tomoyasu; Kato, Satoshi; Araki, Fumiaki] Univ Tokyo, Grad Sch Med, Dept Ophthalmol, Tokyo 1138655, Japan; Univ Tokyo, Grad Sch Med, Dept Clin Trial Data Management, Tokyo 1138655, Japan; [Kaiya, Tadayoshi] Kaiya Eye Clin, Hamamatsu, Shizuoka, Japan	Kato, S (reprint author), Univ Tokyo, Grad Sch Med, Dept Ophthalmol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	katou-s@ka2.so-net.ne.jp					Maeshima K, 2004, RETINA-J RET VIT DIS, V24, P507, DOI 10.1097/00006982-200408000-00002; Fong DS, 2007, RETINA-J RET VIT DIS, V27, P816	2	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1755-375X	1755-3768		ACTA OPHTHALMOL	Acta Ophthalmol.	NOV	2015	93	7					E595	+		10.1111/aos.12656		2	Ophthalmology	Ophthalmology	CU9UG	WOS:000363890500014		
J	Sugihara, K; Tanito, M; Takai, Y; Ohira, A				Sugihara, Kazunobu; Tanito, Masaki; Takai, Yasuyuki; Ohira, Akihiro			Case series of pseudoexfoliation material on intra-ocular lenses	ACTA OPHTHALMOLOGICA			English	Letter									[Sugihara, Kazunobu; Tanito, Masaki; Takai, Yasuyuki; Ohira, Akihiro] Shimane Univ, Fac Med, Dept Ophthalmol, Izumo, Shimane, Japan; [Tanito, Masaki] Matsue Red Cross Hosp, Div Ophthalmol, Matsue, Shimane 6908506, Japan	Tanito, M (reprint author), Matsue Red Cross Hosp, Div Ophthalmol, 200 Horo Machi, Matsue, Shimane 6908506, Japan.	tanito-oph@umin.ac.jp					Bahadur GG, 2007, J CATARACT REFR SURG, V33, P1827, DOI 10.1016/j.jcrs.2007.06.032; Park KA, 2007, J CATARACT REFR SURG, V33, P1815, DOI 10.1016/j.jcrs.2007.05.045; STEWART JFG, 1995, BRIT J OPHTHALMOL, V79, P1050, DOI 10.1136/bjo.79.11.1050-a; Roberts MA, 2009, EUR J OPHTHALMOL, V19, P1082; Kaliaperumal S, 2013, INDIAN J OPHTHALMOL, V61, P359, DOI 10.4103/0301-4738.109514; Park Hae-Young Lopilly, 2012, Korean J Ophthalmol, V26, P402, DOI 10.3341/kjo.2012.26.5.402; Sato M, 2005, IOL RS, V19, P339	7	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1755-375X	1755-3768		ACTA OPHTHALMOL	Acta Ophthalmol.	NOV	2015	93	7					E596	E597		10.1111/aos.12637		2	Ophthalmology	Ophthalmology	CU9UG	WOS:000363890500016		
J	Gottardi, P; Kajii, A; Nakajima, T				Gottardi, Piero; Kajii, Atsushi; Nakajima, Tomoyuki			Optimal Taxation and Debt with Uninsurable Risks to Human Capital Accumulation	AMERICAN ECONOMIC REVIEW			English	Article							OPTIMAL FISCAL-POLICY; INCOME TAXATION; GROWTH-MODEL; EQUILIBRIUM; DYNAMICS	We consider an economy where individuals face uninsurable risks to their human capital accumulation and analyze the optimal level of linear taxes on capital and labor income together with the optimal path of government debt. We show that in the presence of such risks, it is beneficial to tax both labor and capital and to issue public debt. We also assess the quantitative importance of these findings, and show that the benefits of government debt and capital taxes both increase with the magnitude of idiosyncratic risks and the degree of relative risk aversion.	[Gottardi, Piero] European Univ Inst, Dept Econ, I-50133 Florence, Italy; [Kajii, Atsushi; Nakajima, Tomoyuki] Kyoto Univ, Inst Econ Res, Kyoto 6068501, Japan; [Kajii, Atsushi] Singapore Management Univ, Singapore 178902, Singapore; [Nakajima, Tomoyuki] Canon Inst Global Studies, Tokyo, Japan	Gottardi, P (reprint author), European Univ Inst, Dept Econ, Via Piazzola 43, I-50133 Florence, Italy.	Piero.Gottardi@eui.eu; kajii@kier.kyoto-u.ac.jp; nakajima@kier.kyoto-u.ac.jp	KAJII, Atsushi/H-6818-2013		EUI Research Council; MIUR PRIN [2010NE9L9Z-004]; JSPS [26245024, 23530218, 24223003, 15H01939]	Gottardi: Department of Economics, European University Institute, Via della Piazzola 43, 50133 Firenze, Italy, and University of Venice (e-mail: Piero. Gottardi@eui.eu); Kajii: Institute of Economic Research, Kyoto University, Kyoto, Japan 606-8501, and Singapore Management University (e-mail: kajii@kier.kyoto-u.ac.jp); Nakajima: Institute of Economic Research, Kyoto University, Kyoto, Japan 606-8501, and Canon Institute for Global Studies (e-mail: nakajima@kier.kyoto-u.ac.jp). We are grateful to three anonymous referees for very useful comments and suggestions. We also thank Arpad Abraham, Mark Aguiar, Toni Braun, Seung Mo Choi, Hugo Hopenhayn, Selo Imrohoroglu, Young Sik Kim, Robert Lucas, John Quah, Richard Rogerson, Nancy Stokey, Jaume Ventura, Gianluca Violante, Xiaodong Zhu, and seminar participants at the CIGS, Federal Reserve Bank of Atlanta, GRIPS, Otaru University of Commerce, Seoul National University, the World Congress of the Econometric Society in Shanghai, and the Society for Economic Dynamics in Ghent for helpful comments and discussions. An earlier version of the paper was circulated under the title "Optimal Taxation and Constrained Inefficiency in an Infinite Horizon Economy with Incomplete Markets." Gottardi gratefully acknowledges support from the EUI Research Council and MIUR PRIN prot. 2010NE9L9Z-004; Kajii acknowledges support from the JSPS KAKENHI Grant Number 26245024; and Nakajima acknowledges support from the JSPS KAKENHI Grant Numbers 23530218, 24223003, and 15H01939. Nakajima thanks the hospitality of the Federal Reserve Bank of Atlanta, where a part of this research was carried out. The authors declare that they have no relevant or material financial interests that relate to the research described in this paper.	Acikgoz Omer T, 2013, 50160 MUN PERS REPEC; AIYAGARI SR, 1994, Q J ECON, V109, P659, DOI 10.2307/2118417; Anastasios G, 2013, 201307 FED RES BANK; TROSTEL PA, 1993, J POLIT ECON, V101, P327, DOI 10.1086/261878; Imrohoroglu S, 1998, INT ECON REV, V39, P307, DOI 10.2307/2527295; BARSKY RB, 1986, AM ECON REV, V76, P676; Card D, 2001, ECONOMETRICA, V69, P1127, DOI 10.1111/1468-0262.00237; Palacios-Huerta I, 2003, AM ECON REV, V93, P948, DOI 10.1257/000282803322157197; Davila J, 2012, ECONOMETRICA, V80, P2431, DOI 10.3982/ECTA5989; ATKINSON AB, 1976, J PUBLIC ECON, V6, P55, DOI 10.1016/0047-2727(76)90041-4; CHAMLEY C, 1986, ECONOMETRICA, V54, P607, DOI 10.2307/1911310; Krueger D, 2013, AM ECON REV, V103, P496, DOI 10.1257/aer.103.3.496; Domeij D, 2004, INT ECON REV, V45, P523, DOI 10.1111/j.1468-2354.2004.00135.x; CHARI VV, 1994, J POLIT ECON, V102, P617, DOI 10.1086/261949; Aiyagari SR, 1998, J MONETARY ECON, V42, P447, DOI 10.1016/S0304-3932(98)00031-2; AIYAGARI SR, 1995, J POLIT ECON, V103, P1158; Meghir C, 2004, ECONOMETRICA, V72, P1, DOI 10.1111/j.1468-0262.2004.00476.x; Conesa JC, 2009, AM ECON REV, V99, P25, DOI 10.1257/aer.99.1.25; Storesletten K, 2004, J POLIT ECON, V112, P695, DOI 10.1086/383105; Jones LE, 1997, J ECON THEORY, V73, P93, DOI 10.1006/jeth.1996.2238; JONES LE, 1990, J POLIT ECON, V98, P1008, DOI 10.1086/261717; JONES LE, 1993, J POLIT ECON, V101, P485, DOI 10.1086/261884; EATON J, 1980, AM ECON REV, V70, P705; Gottardi Piero, 2011, OPTIMAL TAXATION CON; JUDD KL, 1985, J PUBLIC ECON, V28, P59, DOI 10.1016/0047-2727(85)90020-9; Kajii Atsushi, 2014, J PUBLIC EC THEORY; Krebs T, 2003, Q J ECON, V118, P709, DOI 10.1162/003355303321675491; Werning Ivan, 2014, UNPUB; ZHU XD, 1992, J ECON THEORY, V58, P250, DOI 10.1016/0022-0531(92)90055-M	29	0	0	AMER ECONOMIC ASSOC	NASHVILLE	2014 BROADWAY, STE 305, NASHVILLE, TN 37203 USA	0002-8282	1944-7981		AM ECON REV	Am. Econ. Rev.	NOV	2015	105	11					3443	3470		10.1257/aer.20110576		28	Economics	Business & Economics	CU9SP	WOS:000363885700007		
J	Sato, S; Yamamoto, K; Matsushita, T; Isobe, N; Kawano, Y; Iinuma, K; Niino, M; Fukazawa, T; Nakamura, Y; Watanabe, M; Yonekawa, T; Masaki, K; Yoshimura, S; Murai, H; Yamasaki, R; Kira, J				Sato, Shinya; Yamamoto, Ken; Matsushita, Takuya; Isobe, Noriko; Kawano, Yuji; Iinuma, Kyoko; Niino, Masaaki; Fukazawa, Toshiyuki; Nakamura, Yuri; Watanabe, Mitsuru; Yonekawa, Tomomi; Masaki, Katsuhisa; Yoshimura, Satoshi; Murai, Hiroyuki; Yamasaki, Ryo; Kira, Jun-ichi		Japan Multiple Sclerosis Genet Con	Copy number variations in multiple sclerosis and neuromyelitis optica	ANNALS OF NEUROLOGY			English	Article							CELL-RECEPTOR REPERTOIRE; GENOME-WIDE ASSOCIATION; DELTA T-CELLS; ANTI-AQUAPORIN-4 ANTIBODY; PROTEOLIPID PROTEIN; BRAIN-LESIONS; JAPANESE; GAMMA; AQUAPORIN-4; HETEROGENEITY	ObjectiveTo clarify the potential association of copy number variations (CNVs) with multiple sclerosis (MS) and neuromyelitis optica (NMO) in Japanese cases. MethodsGenome-wide association analyses of CNVs among 277 MS patients, 135 NMO/NMO spectrum disorder (NMOSD) patients, and 288 healthy individuals as a discovery cohort, and among 296 MS patients, 76 NMO/NMOSD patients, and 790 healthy individuals as a replication cohort were performed using high-density single nucleotide polymorphism microarrays. ResultsA series of discovery and replication studies revealed that most identified CNVs were 5 to 50kb deletions at particular T cell receptor (TCR) gamma and alpha loci regions. Among these CNVs, a TCR gamma locus deletion was found in 16.40% of MS patients (p=2.44E-40, odds ratio [OR]=52.6), and deletion at the TCR alpha locus was found in 17.28% of MS patients (p=1.70E-31, OR=13.0) and 13.27% of NMO/NMOSD patients (p=5.79E-20, OR=54.6). These CNVs were observed in peripheral blood T-cell subsets only, suggesting the CNVs were somatically acquired. NMO/NMOSD patients carrying the CNV tended to be seronegative for anti-aquaporin-4 antibody or had significantly lower titers than those without CNV. InterpretationDeletion-type CNVs at specific TCR loci regions contribute to MS and NMO susceptibility. Ann Neurol 2015;78:Ann Neurol 2015;78:679-696	[Sato, Shinya; Isobe, Noriko; Kawano, Yuji; Iinuma, Kyoko; Nakamura, Yuri; Watanabe, Mitsuru; Yonekawa, Tomomi; Masaki, Katsuhisa; Yoshimura, Satoshi; Murai, Hiroyuki; Kira, Jun-ichi] Kyushu Univ, Grad Sch Med Sci, Neurol Inst, Dept Neurol, Fukuoka 8128582, Japan; [Yamamoto, Ken] Kurume Univ, Sch Med, Dept Med Chem, Kurume, Fukuoka 830, Japan; [Matsushita, Takuya; Yamasaki, Ryo] Kyushu Univ, Grad Sch Med Sci, Neurol Inst, Dept Neurol Therapeut, Fukuoka 8128582, Japan; [Niino, Masaaki] Hokkaido Med Ctr, Dept Clin Res, Sapporo, Hokkaido, Japan; [Fukazawa, Toshiyuki] Sapporo Neurol Clin, Sapporo, Hokkaido, Japan	Kira, J (reprint author), Kyushu Univ, Grad Sch Med Sci, Neurol Inst, Dept Neurol,Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	kira@neuro.med.kyushu-u.ac.jp			Japan Agency for Medical Research and Development (AMED), Japan	This study was supported by a research grant for Practical Research Project for Rare/Intractable Diseases from Japan Agency for Medical Research and Development (AMED), Japan (recipient: J.K.).	Alonso A, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-264; Matsuoka T, 2008, J NEUROL SCI, V266, P115, DOI 10.1016/j.jns.2007.09.010; Sawcer S, 2011, NATURE, V476, P214, DOI 10.1038/nature10251; WUCHERPFENNIG KW, 1992, P NATL ACAD SCI USA, V89, P4588, DOI 10.1073/pnas.89.10.4588; Blink SE, 2009, CURR MOL MED, V9, P15; OKSENBERG JR, 1993, NATURE, V362, P68, DOI 10.1038/362068a0; Pohl M, 2011, ACTA NEUROPATHOL, V122, P21, DOI 10.1007/s00401-011-0824-0; Wingerchuk DM, 2007, LANCET NEUROL, V6, P805, DOI 10.1016/S1474-4422(07)70216-8; Craddock N, 2010, NATURE, V464, P713, DOI 10.1038/nature08979; SOBEL RA, 1992, J IMMUNOL, V149, P1444; Li Y, 2011, J NEUROIMMUNOL, V234, P155, DOI 10.1016/j.jneuroim.2011.03.009; Nishiyama S, 2009, NEUROLOGY, V72, P1960, DOI 10.1212/WNL.0b013e3181a82621; Ishizu T, 2009, J NEUROL SCI, V280, P22, DOI 10.1016/j.jns.2009.01.008; Diskin SJ, 2009, NATURE, V459, P987, DOI 10.1038/nature08035; Lassmann H, 2007, BRAIN PATHOL, V17, P210, DOI 10.1111/j.1750-3639.2007.00064.x; Isobe N, 2012, MULT SCLER J, V18, P1541, DOI 10.1177/1352458512443917; Beecham AH, 2013, NAT GENET, V45, P1353, DOI 10.1038/ng.2770; McElroy JP, 2013, MULT SCLER J, V19, P1014, DOI 10.1177/1352458512469696; Kira J, 2003, LANCET NEUROL, V2, P117, DOI 10.1016/S1474-4422(03)00308-9; Walsh KM, 2010, MUTAT RES-FUND MOL M, V690, P89, DOI 10.1016/j.mrfmmm.2010.05.005; Varrin-Doyer M, 2012, ANN NEUROL, V72, P53, DOI 10.1002/ana.23651; Yoshimura S, 2013, J NEUROL NEUROSUR PS, V84, P29, DOI 10.1136/jnnp-2012-302925; Alkan C, 2011, NAT REV GENET, V12, P363, DOI 10.1038/nrg2958; Ionita-Laza I, 2009, GENOMICS, V93, P22, DOI 10.1016/j.ygeno.2008.08.012; Ionita-Laza I, 2008, GENET EPIDEMIOL, V32, P273, DOI 10.1002/gepi.20302; HVAS J, 1993, J NEUROIMMUNOL, V46, P225, DOI 10.1016/0165-5728(93)90253-U; Matsushita T, 2009, MULT SCLER, V15, P834, DOI 10.1177/1352458509104595; Warabi Y, 2006, J NEUROL SCI, V249, P145, DOI 10.1016/j.jns.2006.06.011; Junker A, 2007, BRAIN, V130, P2789, DOI 10.1093/brain/awm214; Schwienbacher C, 2010, IMMUNOGENETICS, V62, P561, DOI 10.1007/s00251-010-0459-7; Stranger BE, 2007, SCIENCE, V315, P848, DOI 10.1126/science.1136678; Blink SE, 2014, CELL IMMUNOL, V290, P39, DOI 10.1016/j.cellimm.2014.04.013; Matsuoka T, 2007, BRAIN, V130, P1206, DOI 10.1093/brain/awm027; Matsuya N, 2011, INT IMMUNOL, V23, P565, DOI 10.1093/intimm/dxr056; Ferlini A, 2010, BMC MED GENET, V11, DOI 10.1186/1471-2350-11-64; Hohlfeid R, 2004, P NATL ACAD SCI USA, V101, P14599, DOI 10.1073/pnas.0404874101; Iafrate AJ, 2004, NAT GENET, V36, P949, DOI 10.1038/ng1416; Hafler DA, 2007, NEW ENGL J MED, V357, P851, DOI 10.1056/NEJMoa073493; Isobe N, 2014, CLIN EXP NEUROIMMUNO, V5, P61; Jager A, 2009, J IMMUNOL, V183, P7169, DOI 10.4049/jimmunol.0901906; Kira J, 2013, CLIN EXP NEUROIMMUNO, V4, P261; Kira J, 2011, J NEUROL SCI, V311, P69, DOI 10.1016/j.jns.2011.08.043; Kyat-Atamer A, 2013, EUR J NEUROL, V20, P781; Lennon VA, 2004, LANCET, V326, P2106; Matsushita T, 2013, PLOS ONE, V8; Oksenberg JR, 1991, NATURE, V353, P344; Paul S, 2015, J LEUKOCYTE BIOL, V97, P259, DOI 10.1189/jlb.3RU0914-443R; Pohl Maria, 2013, Acta Neuropathol Commun, V1, P85, DOI 10.1186/2051-5960-1-85; Sawcer S, 2014, LANCET NEUROL, V14, P70041; Yoshimura S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048592	50	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	NOV	2015	78	5					762	774		10.1002/ana.24511		13	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CU7NP	WOS:000363727900011		
J	Yatsuga, S; Fujita, Y; Ishii, A; Fukumoto, Y; Arahata, H; Kakuma, T; Kojima, T; Ito, M; Tanaka, M; Saiki, R; Koga, Y				Yatsuga, Shuichi; Fujita, Yasunori; Ishii, Akiko; Fukumoto, Yoshihiro; Arahata, Hajime; Kakuma, Tatsuyuki; Kojima, Toshio; Ito, Masafumi; Tanaka, Masashi; Saiki, Reo; Koga, Yasutoshi			Growth differentiation factor 15 as a useful biomarker for mitochondrial disorders	ANNALS OF NEUROLOGY			English	Article							SQUAMOUS-CELL CARCINOMA; DISEASE; STRESS; METABOLISM; ACTIVATION; PATHWAY; MARKER; FGF21	ObjectiveThe diagnosis of mitochondrial disorders (MDs) is occasionally difficult because patients often present with solitary, or a combination of, symptoms caused by each organ insufficiency, which may be the result of respiratory chain enzyme deficiency. Growth differentiation factor 15 (GDF-15) has been reported to be elevated in serum of patients with MDs. In this study, we investigated whether GDF-15 is a more useful biomarker for MDs than several conventional biomarkers. MethodsWe measured the serum levels of GDF-15 and fibroblast growth factor 21 (FGF-21), as well as other biomarkers, in 48 MD patients and in 146 healthy controls in Japan. GDF-15 and FGF-21 concentrations were measured by enzyme-linked immunosorbant assay and compared with lactate, pyruvate, creatine kinase, and the lactate-to-pyruvate ratio. We calculated sensitivity and specificity and also evaluated the correlation based on two rating scales, including the Newcastle Mitochondrial Disease Rating Scale (NMDAS). ResultsMean GDF-15 concentration was 6-fold higher in MD patients compared to healthy controls (2,711 2,459 pg/ml vs 462.5 +/- 141.0 pg/mL; p < 0.001). Using a receiver operating characteristic curve, the area under the curve was significantly higher for GDF-15 than FGF-21 and other conventional biomarkers. Our date suggest that GDF-15 is the most useful biomarker for MDs of the biomarkers examined, and it is associated with MD severity. InterpretationOur results suggest that measurement of GDF-15 is the most useful first-line test to indicate the patients who have the mitochondrial respiratory chain deficiency. Ann Neurol 2015;78:Ann Neurol 2015;78:679-696	[Yatsuga, Shuichi; Saiki, Reo; Koga, Yasutoshi] Kurume Univ, Sch Med, Dept Pediat & Child Hlth, Kurume, Fukuoka 8300011, Japan; [Fujita, Yasunori; Ito, Masafumi] Tokyo Metropolitan Inst Gerontol, Res Team Mechanism Aging, Tokyo, Japan; [Ishii, Akiko] Univ Tsukuba, Fac Med, Dept Neurol, Ibaraki, Japan; [Fukumoto, Yoshihiro] Kurume Univ, Sch Med, Dept Internal Med, Div Cardiovasc Med, Fukuoka, Japan; [Arahata, Hajime] Natl Omuta Hosp, Neuromuscular Ctr, Dept Neurol, Fukuoka, Japan; [Kakuma, Tatsuyuki] Kurume Univ, Grad Sch Med, Dept Biostat, Kurume, Fukuoka 8300011, Japan; [Kojima, Toshio] Toyohashi Univ Technol, Hlth Care Ctr, Toyohashi, Aichi, Japan; [Tanaka, Masashi] Tokyo Metropolitan Inst Gerontol, Dept Genom Longev & Hlth, Tokyo, Japan	Koga, Y (reprint author), Kurume Univ, Sch Med, Dept Pediat & Child Hlth, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan.	yasukoga@med.kurume-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology (MEXT) [25461571, 25860891, 25242062]; Ministry of Health, Labor and Welfare of Japan; Japan Agency for Medical Research and development, AMED [15ek0109088h0001]	This work was supported, in part, by grant nos. 25461571 (to Y.K.), 25860891 (to S.Y.), and 25242062 (to M.T.) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) and by Grant-in-Aid no. 24-Nanchi-Ippan-005 (to Y.K.) for Research on Intractable Diseases from the Ministry of Health, Labor and Welfare of Japan. This research is (partially) supported by the intractable/rare disorders no. 15ek0109088h0001 (to Y.K.) from Japan Agency for Medical Research and development, AMED.	Schiegnitz E, 2012, ORAL ONCOL, V48, P608, DOI 10.1016/j.oraloncology.2012.01.020; Shalev H, 2013, EUR J HAEMATOL, V90, P31, DOI 10.1111/ejh.12027; Davis RL, 2013, NEUROLOGY, V81, P1819, DOI 10.1212/01.wnl.0000436068.43384.ef; Suomalainen A, 2011, LANCET NEUROL, V10, P806, DOI [10.1016/S1474-4422(11)70155-7, 10.1016/S1474-4422(11)70155-2]; Jousse C, 2007, J BIOL CHEM, V282, P15851, DOI 10.1074/jbc.M611723200; Lambrecht S, 2014, ARTHRITIS RHEUMATOL, V66, P418, DOI 10.1002/art.38241; Cui R, 2014, LEUKEMIA RES, V38, P545, DOI 10.1016/j.leukres.2014.01.016; Tarkun P, 2013, EUR J HAEMATOL, V91, P228, DOI 10.1111/ejh.12150; Schaefer AM, 2006, NEUROLOGY, V66, P1932, DOI 10.1212/01.wnl.0000219759.72195.41; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Haas RH, 2007, PEDIATRICS, V120, P1326, DOI 10.1542/peds.2007-0391; Lindahl B, 2013, CLIN CHEM, V59, P1550, DOI 10.1373/clinchem.2013.212811; Yatsuga S, 2012, BBA-GEN SUBJECTS, V1820, P619, DOI 10.1016/j.bbagen.2011.03.015; Canto C, 2012, SCIENCE, V336, P675, DOI 10.1126/science.1222646; Kim KH, 2013, BIOCHEM BIOPH RES CO, V440, P76, DOI 10.1016/j.bbrc.2013.09.026; Jiang S, 2014, J BIOL CHEM, V289, P29751, DOI 10.1074/jbc.M114.565960; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Munnich A, 1996, J INHERIT METAB DIS, V19, P521, DOI 10.1007/BF01799112; Liang C, 2014, BBA-GEN SUBJECTS, V1840, P1360, DOI 10.1016/j.bbagen.2013.10.040; DesSousa-Coelho AL, 2012, BIOCHEM J, V443, P165; Fujita Y, 2014, MITOCHONDRION C, V20C, P34; Kalko SG, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-91; Santhanakrishnan R, 2012, EUR J HEART FAIL, V14, P1338, DOI 10.1093/eurjhf/hfs130; Yang CZ, 2014, J ORAL PATHOL MED, V43, P28, DOI 10.1111/jop.12091	24	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	NOV	2015	78	5					814	823		10.1002/ana.24506		10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CU7NP	WOS:000363727900015		
J	Igari, K; Kudo, T; Toyofuku, T; Inoue, Y				Igari, Kimihiro; Kudo, Toshifumi; Toyofuku, Takahiro; Inoue, Yoshinori			Bilateral Axillary Artery Aneurysms Presenting as Upper Limb Ischemia	ANNALS OF VASCULAR SURGERY			English	Article							ENDOVASCULAR TREATMENT; SUBCLAVIAN ARTERY; MARFAN-SYNDROME; MANAGEMENT	An axillary artery aneurysm (AxAA) is a rare entity. Although some cases with AxAA are asymptomatic, complications including local pain, neurogenic symptoms, upper limb ischemia, and rupture may occur. Therefore, an early diagnosis and treatment are necessary. We herein report a case of bilateral AxAAs, in which the right AxAA showed acute upper limb ischemia and the left AxAA were asymptomatic. Both AxAAs were successfully treated by aneurysmectomy and interposition grafting. In the endovascular era, open surgical treatment for AxAAs remains a promising procedure.	[Igari, Kimihiro; Kudo, Toshifumi; Toyofuku, Takahiro; Inoue, Yoshinori] Tokyo Med & Dent Univ, Dept Surg, Div Vasc & Endovasc Surg, Tokyo, Japan	Igari, K (reprint author), 1-5-45 Yushima,Bunkyo Ku, Tokyo 1138519, Japan.	igari.srg1@tmd.ac.jp					Lawrence PF, 1999, J VASC SURG, V30, P632, DOI 10.1016/S0741-5214(99)70102-3; Matsuno Y, 2012, J VASC SURG, V56, P219, DOI 10.1016/j.jvs.2012.01.012; Jhirad R, 1998, J VASC SURG, V28, P708, DOI 10.1016/S0741-5214(98)70098-9; Nawa S, 2003, ANN VASC SURG, V17, P562, DOI 10.1007/s10016-003-0045-7; NEUMAYER LA, 1992, J CARDIOVASC SURG, V33, P172; Rose JF, 2011, J VASC SURG, V53, P478, DOI 10.1016/j.jvs.2010.08.076; Malik MK, 2012, VASCULAR, V20, P46, DOI 10.1258/vasc.2011.cr0293; Troutman DA, 2010, VASC ENDOVASC SURG, V44, P708, DOI 10.1177/1538574410377239; Bowman JN, 2010, ANN VASC SURG, V24; Gray RJ, 1998, J VASC SURG, V28, P606, DOI 10.1016/S0741-5214(98)70083-7; Moriaski K, 2012, ANN VASC SURG, V26; Ortiz-Pomales Y, 2014, ANN VASC SURG, V28; Park SK, 2015, INTERACT CARDIOV TH, V20, P140, DOI 10.1093/icvts/ivu308; Saito Y, 2014, ANN VASC SURG, V28; Vasic Dragan, 2011, Am Surg, V77, pE19	15	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0890-5096	1615-5947		ANN VASC SURG	Ann. Vasc. Surg.	NOV	2015	29	8								10.1016/j.avsg.2015.05.031		4	Surgery; Peripheral Vascular Disease	Surgery; Cardiovascular System & Cardiology	CU4CY	WOS:000363475300037		
J	Terai, Y; Mitsuoka, H; Nakai, M; Goto, S; Miyano, Y; Tsuchiya, H; Yamazaki, F				Terai, Yasuhiko; Mitsuoka, Hiroshi; Nakai, Masanao; Goto, Shinnosuke; Miyano, Yuta; Tsuchiya, Hirokazu; Yamazaki, Fumio			Endovascular Aneurysm Repair of Acute Occlusion of Abdominal Aortic Aneurysm with Intra-Aneurysmal Dissection	ANNALS OF VASCULAR SURGERY			English	Article							ACUTE THROMBOSIS; MANAGEMENT	Background: To report a rare case of acute abdominal aortic aneurysm (AAA) occlusion successfully treated by endovascular aneurysm repair (EVAR). Case Report: An 89-year-old man complained of severe back pain and weakness in the bilateral lower extremities. Although there were neither acute ischemic signs on the brain computed tomography (CT) nor critical leg ischemia, the patient presented progressing weakness in the bilateral lower extremities and decreased sensation in the perianal and saddle area. Contrast-enhanced CT demonstrated an infrarenal AAA, the formation of an ulcer-like lesion in the aneurysmal wall, and the complete occlusion of distal AAA because of the caudal extension of intramural hematoma. Both common iliac arteries were patent because of the development of collateral vessels. The neurologic symptoms were considered to be caused by the occlusion of lumbar radicular arteries. EVAR seemed anatomically feasible, if the occlusion could be crossed by guidewires from both side of the common femoral artery. Wires easily traversed the occlusion, and the stent graft could be smoothly unwrapped and opened. The patient could recover decent iliac arterial flow. The neurovascular deficits recovered within 4 days after the procedure. Conclusions: Although our experience may not be reproduced in all case of AAA occlusion, EVAR warrants consideration to reduce the high mortality rate associated with the classical treatments.	[Terai, Yasuhiko; Mitsuoka, Hiroshi; Nakai, Masanao; Goto, Shinnosuke; Miyano, Yuta; Tsuchiya, Hirokazu; Yamazaki, Fumio] Shizuoka Hosp, Dept Cardiovasc Surg, Shizuoka, Japan	Terai, Y (reprint author), 10-93 Ote Machi,Aoi Ward, Shizuoka 4208630, Japan.	yasuhiko_t@mac.com					JOHNSON JM, 1974, ARCH SURG-CHICAGO, V108, P792; Kumar V, 2005, J ENDOVASC THER, V12, P70, DOI 10.1583/04-1367.1; DRAGER SB, 1979, AM J SURG, V138, P293, DOI 10.1016/0002-9610(79)90389-1; Surowiec SM, 1998, AM J SURG, V176, P193, DOI 10.1016/S0002-9610(98)00129-9; Wong SSN, 2013, J VASC SURG, V57, P218, DOI 10.1016/j.jvs.2012.06.092; CORSON JD, 1982, SURG GYNECOL OBSTET, V155, P369; PATEL H, 1994, AM SURGEON, V60, P801; Bogie R, 2008, EUR J VASC ENDOVASC, V35, P590, DOI 10.1016/j.ejvs.2007.11.023; Eugster T, 2005, ANN VASC SURG, V19, P411, DOI 10.1007/s10016-005-0016-2; CERVANTES J, 1985, J CARDIOVASC SURG, V26, P598; Handa N, 2010, ANN VASC SURG, V24; Hirose H, 2000, ANGIOLOGY, V51, P515, DOI 10.1177/000331970005100611; Schnmacker HB., 1959, POSTGRAD MED, V25, P535; Sevcíková Hana, 2010, Acta Medica (Hradec Kralove), V53, P119	14	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0890-5096	1615-5947		ANN VASC SURG	Ann. Vasc. Surg.	NOV	2015	29	8								10.1016/j.avsg.2015.06.078		4	Surgery; Peripheral Vascular Disease	Surgery; Cardiovascular System & Cardiology	CU4CY	WOS:000363475300032		
J	Yuji, D; Katayama, I; Tanaka, M				Yuji, Daisuke; Katayama, Ikuo; Tanaka, Masashi			A Patient with Aortic Arch Aneurysm Perforating the Left Pulmonary Artery	ANNALS OF VASCULAR SURGERY			English	Article							AORTOPULMONARY FISTULA	An aortic arch aneurysm rarely perforates the pulmonary artery, but once this occurs symptoms of heart failure may develop rapidly and result in a serious course. Here, we report such a case that was treated with life-saving emergency surgery. The patient was an 86-year-old man in whom aortic arch aneurysm had been pointed out 8 years earlier, but left untreated. In January 2014, dyspnea developed and he visited the emergency unit of our hospital. Continuous murmur was heard on auscultation, and aorta-pulmonary artery shunt was noted on transthoracic echo-cardiography. Chest computed tomography revealed a giant aortic arch aneurysm of size 106 mm that had perforated the left pulmonary artery (LPA). Emergency surgery was performed for a diagnosis of acute heart failure associated with perforation of the LPA by a giant aortic arch aneurysm. The postoperative course was favorable, and the patient was discharged with independent walking on postoperative day 28.	[Yuji, Daisuke; Katayama, Ikuo; Tanaka, Masashi] Shonan Fujisawa Tokushukai Hosp, Dept Cardiovasc Surg, Fujisawa, Kanagawa, Japan	Yuji, D (reprint author), Shonan Fujisawa Tokushukai Hosp, Dept Cardiovasc Surg, Fujisawa, Kanagawa, Japan.	yujidaisuke0216@yahoo.co.jp					Piciche M, 1999, ANN THORAC SURG, V68, P1833, DOI 10.1016/S0003-4975(99)00754-7; Nishimura Y, 2009, EUR J CARDIO-THORAC, V36, P212, DOI 10.1016/j.ejcts.2009.03.007; Adhyapak SM, 2009, ANN THORAC SURG, V88, P1672, DOI 10.1016/j.athoracsur.2009.03.018; GIACOBINE JW, 1960, J THORAC CARDIOV SUR, V39, P130; Dixit MD, 2009, TEX HEART I J, V36, P483; Boyd LJ, 1924, AM J MED SCI, V168, P654, DOI 10.1097/00000441-192411000-00006; Daidoji H, 2011, J CARDIOL, P90; Fujimori S, 1988, SHINZOU, V20, P1007; Iwahashi K, 2007, Kyobu Geka, V60, P853; Jinnouchi K, 2012, J VASC SURG, V21, P687; Kaki N, 2005, J VASC SURG, V14, P105; Kakio T, 1992, Kokyu To Junkan, V40, P603; Kameyama T, 1992, Nihon Kyobu Geka Gakkai Zasshi, V40, P432; Messetti M, 1995, ANN THORAC SURG, V59, P1563; Nara I., 2012, MED J AKITA CITY HOS, V21, P15; OKA Y, 1980, Journal of the Japanese Association for Thoracic Surgery, V28, P147; Okada T, 2012, J CARDIOVASC SURG, V41, P195; Pessotto R, 1995, Cardiovasc Surg, V3, P707, DOI 10.1016/0967-2109(96)82874-2; Shirai J, 2012, J JPN SURG ASS, V73, P3086; Suzuki K, 2003, J CARDIOVASC SURG, V32, P137; Takahashi Ai, 2013, Kyobu Geka, V66, P532; Yoshida M, 2004, J CARDIOVASC SURG, V33, P403	22	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0890-5096	1615-5947		ANN VASC SURG	Ann. Vasc. Surg.	NOV	2015	29	8								10.1016/j.avsg.2015.05.027		4	Surgery; Peripheral Vascular Disease	Surgery; Cardiovascular System & Cardiology	CU4CY	WOS:000363475300031		
J	Nishibe, T; Maruno, K; Iwahori, A; Fujiyoshi, T; Suzuki, S; Takahashi, S; Ogino, H; Nishibe, M				Nishibe, Toshiya; Maruno, Keita; Iwahori, Akinari; Fujiyoshi, Toshiki; Suzuki, Shun; Takahashi, Satoshi; Ogino, Hitoshi; Nishibe, Masayasu			The Role of Common Femoral Artery Endarterectomy in the Endovascular Era	ANNALS OF VASCULAR SURGERY			English	Article							OCCLUSIVE DISEASE; STENT PLACEMENT; THERAPY; LESIONS	Background: The purpose of this study was to review our experiences treating peripheral artery disease (PAD) by common femoral artery endarterectomy (CFE) with and without endovascular therapy (EVT), and to describe the role of CFE in the endovascular era. Methods: We retrospectively reviewed a contemporary series of 38 limbs from January 2010 to September 2014. Clinical outcomes of primary patency, assisted primary patency, limb salvage, and survival were analyzed with the Kaplan-Meier method. Multivariable perioperative predictors of primary patency were identified using the stepwise Cox proportional hazards regression model. Results: Hemodynamic success was achieved in 36 of the 38 limbs (95%). The mean ankle brachial pressure index improved significantly, rising from 0.56 +/- 0.04 preoperatively to 0.89 +/- 0.04 postoperatively (P = 0.0001). Overall primary and assisted primary patency rates, respectively, were 90% and 100% at 12 months and 85% and 94% at 24 months. There was no significant difference in primary patency rate between isolated CFE and hybrid CFE plus EVT. Both limb salvage and survival rates were 97% at 12 months and 97% at 24 months. Multivariate Cox regression analysis revealed that no clinical or perioperative risk factors were predictive of decreased primary patency. Conclusions: CFE is a safe, effective, and durable procedure for common femoral artery disease, and hybrid CFE plus EVT can be a valid alternative to open surgical bypass for multilevel occlusive artery disease. These observations stress that CFE plays a vital role in the management of PAD even in the endovascular era.	[Nishibe, Toshiya; Maruno, Keita; Iwahori, Akinari; Fujiyoshi, Toshiki; Suzuki, Shun; Takahashi, Satoshi; Ogino, Hitoshi] Tokyo Med Univ, Dept Cardiovasc Surg, Tokyo 1600023, Japan; [Nishibe, Toshiya; Nishibe, Masayasu] Eniwa Midorino Clin, Dept Surg, Eniwa, Japan	Nishibe, T (reprint author), Tokyo Med Univ, Dept Cardiovasc Surg, Shinjuku Ku, 6-7-1 Nishishinjuku, Tokyo 1600023, Japan.	toshiyanishibe@yahoo.co.jp					Chang RW, 2008, J VASC SURG, V48, P362, DOI 10.1016/j.jvs.2008.03.042; Siracuse JJ, 2014, VASC ENDOVASC SURG, V48, P27, DOI 10.1177/1538574413508827; Nishibe T, 2009, J CARDIOVASC SURG, V50, P493; Bonvini RF, 2011, J AM COLL CARDIOL, V58, P792, DOI 10.1016/j.jacc.2011.01.070; Kechagias A, 2008, WORLD J SURG, V32, P51, DOI 10.1007/s00268-007-9309-7; Cotroneo AR, 2007, CARDIOVASC INTER RAD, V30, P355, DOI 10.1007/s00270-005-0296-5; Ballotta E, 2010, SURGERY, V147, P268, DOI 10.1016/j.surg.2009.08.004; Nelson PR, 2002, J VASC SURG, V35, P1107, DOI 10.1067/mva.2002.124374; White CJ, 2007, CIRCULATION, V116, P2203, DOI 10.1161/CIRCULATIONAHA.106.621391; Murphy TP, 2004, RADIOLOGY, V231, P243, DOI 10.1148/radiol.2311030408; Kondo Y, 2010, SURG TODAY, V40, P433, DOI 10.1007/s00595-009-4102-x; Nishibe T, 2009, SURG TODAY, V39, P21, DOI 10.1007/s00595-008-3812-9; Kang JL, 2008, J VASC SURG, V48, P872, DOI 10.1016/j.jvs.2008.05.025; Davies MG, 2005, J AM COLL SURGEONS, V201, P275, DOI 10.1016/j.jamcollsurg.2005.03.007; Cordon A, 2001, ANN CHIR, V126, P777; MUKHERJEE D, 1989, AM J SURG, V157, P498, DOI 10.1016/0002-9610(89)90644-2; Soga Yoshimitsu, 2013, Cardiovasc Interv Ther, V28, P250, DOI 10.1007/s12928-013-0164-1; Springhorn M E, 1991, Ann Vasc Surg, V5, P234, DOI 10.1007/BF02329379	18	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0890-5096	1615-5947		ANN VASC SURG	Ann. Vasc. Surg.	NOV	2015	29	8					1501	1507		10.1016/j.avsg.2015.05.005		7	Surgery; Peripheral Vascular Disease	Surgery; Cardiovascular System & Cardiology	CU4CY	WOS:000363475300004		
J	Onohara, T; Inoue, K; Furuyama, T; Ohno, T				Onohara, Toshihiro; Inoue, Kentaro; Furuyama, Tadashi; Ohno, Tomokazu			Preoperative Cardiovascular Assessment and Late Cardiovascular Events after Elective Abdominal Aortic Aneurysm Repair	ANNALS OF VASCULAR SURGERY			English	Article							CORONARY-ARTERY REVASCULARIZATION; VASCULAR-SURGERY; TRIAL; SURVIVAL; OUTCOMES; DISEASE; RISK	Background: Cardiovascular evaluation is performed before elective repair of abdominal aortic aneurysm (AAA) because of the high prevalence of cardiovascular disease. We investigated the association between preoperative cardiovascular evaluation and the incidence of late cardiovascular events after AAA repair. Methods: We retrospectively analyzed 438 patients who underwent elective repair of AAA. Echocardiography, serial coronary assessment using functional myocardial scanning or coronary angiography, and carotid ultrasound scanning were performed preoperatively. Coronary revascularization after serial coronary assessment was performed preoperatively or simultaneously in 21 patients, and 54 patients had a remote history of coronary revascularization. Results: The 5-year survival rate, incidence rate of cardiovascular events (myocardial infarction or stroke), and incidence rate of major adverse cardiovascular events (MACE; cardiovascular death or cardiovascular events) were 86.0%, 5.7%, and 11.5%, respectively. Carotid stenosis was associated with these long-term outcomes, and hypokinesis, determined by echocardiography, increased the incidence of cardiovascular events and MACE. Serial coronary assessment findings and history of previous or preoperative coronary revascularization were not associated with these long-term outcomes. Conclusions: Preoperative cardiovascular evaluation and treatment are beneficial for reducing not only perioperative risk but also late cardiovascular events.	[Onohara, Toshihiro; Inoue, Kentaro; Furuyama, Tadashi; Ohno, Tomokazu] Kyushu Med Ctr, Dept Vasc Surg, Fukuoka 8108563, Japan	Onohara, T (reprint author), Kyushu Med Ctr, Dept Vasc Surg, Chuou Ku, Jigyohama 1-8-1, Fukuoka 8108563, Japan.	onohara@kyumed.jp					Garcia S, 2011, CATHETER CARDIO INTE, V77, P134, DOI 10.1002/ccd.22699; Liapis CD, 2003, J VASC SURG, V38, P1220, DOI 10.1016/S0741-5214(03)00716-X; Parmar GM, 2013, J VASC SURG, V58, P355, DOI 10.1016/j.jvs.2013.01.036; Hertzer NR, 2002, J VASC SURG, V35, P1145, DOI 10.1067/mva.2002.123686; Brown LC, 2011, BRIT J SURG, V98, P935, DOI 10.1002/bjs.7485; Onohara T, 2000, J AM COLL SURGEONS, V191, P619, DOI 10.1016/S1072-7515(00)00759-6; McFalls EO, 2007, J VASC SURG, V46, P694, DOI 10.1016/j.jvs.2007.05.060; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; Johnsen SH, 2010, ARTERIOSCL THROM VAS, V30, P1263, DOI 10.1161/ATVBAHA.110.203588; McFalls EO, 2004, NEW ENGL J MED, V351, P2795, DOI 10.1056/NEJMoa041905	10	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0890-5096	1615-5947		ANN VASC SURG	Ann. Vasc. Surg.	NOV	2015	29	8					1533	1542		10.1016/j.avsg.2015.05.026		10	Surgery; Peripheral Vascular Disease	Surgery; Cardiovascular System & Cardiology	CU4CY	WOS:000363475300008		
J	Wang, FZ; Tanaka, R; Cai, ZG; Nakayama, Y; Shiono, T				Wang, Fuzhou; Tanaka, Ryo; Cai, Zhengguo; Nakayama, Yuushou; Shiono, Takeshi			Room-temperature Suzuki-Miyaura cross-coupling reaction with alpha-diimine Pd(II) catalysts	APPLIED ORGANOMETALLIC CHEMISTRY			English	Article						alpha-diimine Pd(II) complexes; Suzuki-Miyaura cross-coupling reaction; room temperature; aniline bromides	SEC-PHENETHYL GROUPS; ETHYLENE POLYMERIZATION; PALLADIUM COMPLEXES; HECK REACTIONS; ARYL HALIDES; LIGAND; NICKEL(II); EFFICIENT; WATER; SONOGASHIRA	An -diimine Pd(II) complex containing chiral sec-phenethyl groups, {bis[N,N-(4-methyl-2-sec-phenethylphenyl)imino]-2,3-butadiene}dichloropalladium (rac-C1), was synthesized and characterized. rac-C1 was applied as an efficient catalyst for the Suzuki-Miyaura cross-coupling reaction between various aniline halides and arylboronic acid in PEG-400-H2O at room temperature. Among a series of aniline halides, rac-C1 did not catalyze the cross-coupling of aniline chlorides and fluorides but efficiently catalyzed the cross-coupling of aniline bromides and iodides with phenylboronic acid. The catalytic activity reduced slightly with increasing steric hindrance of the aniline bromides. The complexes {bis[N,N-(4-fluoro-2,6-diphenylphenyl)imino]-2,3-butadiene}dichloropalladium and {bis[N,N-(4-fluoro-2,6-diphenylphenyl)imino]acenaphthene}dichloropalladium were also found to be efficient catalysts for the reaction. Copyright (c) 2015 John Wiley & Sons, Ltd.	[Wang, Fuzhou; Tanaka, Ryo; Nakayama, Yuushou; Shiono, Takeshi] Hiroshima Univ, Grad Sch Engn, Higashihiroshima 7398527, Japan; [Cai, Zhengguo] Donghua Univ, Coll Mat Sci & Engn, State Key Lab Chem Fibers & Polymer Mat, Shanghai 201620, Peoples R China	Shiono, T (reprint author), Hiroshima Univ, Grad Sch Engn, Kagamiyama 1-4-1, Higashihiroshima 7398527, Japan.	tshiono@hiroshima-u.ac.jp	Tanaka, Ryo/K-8254-2014	Tanaka, Ryo/0000-0002-6085-074X			Kantchev EAB, 2007, ANGEW CHEM INT EDIT, V46, P2768, DOI 10.1002/anie.200601663; Hanhan ME, 2008, APPL ORGANOMET CHEM, V22, P270, DOI 10.1002/aoc.1389; Qureshi ZS, 2012, CATAL TODAY, V198, P148, DOI 10.1016/j.cattod.2012.03.039; Durgun G, 2007, J MOL CATAL A-CHEM, V278, P189, DOI 10.1016/j.molcata.2007.09.010; Das P, 2011, TETRAHEDRON LETT, V52, P1176, DOI 10.1016/j.tetlet.2011.01.009; Guha NR, 2012, ADV SYNTH CATAL, V354, P2911, DOI 10.1002/adsc.201200418; Anderson KW, 2005, ANGEW CHEM INT EDIT, V44, P6173, DOI 10.1002/anie.200502017; Grasa GA, 2001, ORG LETT, V3, P1077, DOI 10.1021/ol015676t; Kumar A, 2013, DALTON T, V42, P5200, DOI 10.1039/c2dt32432f; Wang FZ, 2013, APPL ORGANOMET CHEM, V27, P319, DOI 10.1002/aoc.2962; Gholinejad M, 2014, APPL ORGANOMET CHEM, V28, P221, DOI 10.1002/aoc.3110; Susanto W, 2012, J ORG CHEM, V77, P2729, DOI 10.1021/jo202482h; Martin R, 2008, ACCOUNTS CHEM RES, V41, P1461, DOI 10.1021/ar800036s; Schmid M, 2001, ORGANOMETALLICS, V20, P2321, DOI 10.1021/om010001f; Alonso F, 2008, TETRAHEDRON, V64, P3047, DOI 10.1016/j.tet.2007.12.036; Peng YY, 2010, GREEN CHEM, V12, P1072, DOI 10.1039/c000739k; Yuan JC, 2013, ORGANOMETALLICS, V32, P3960, DOI 10.1021/om400433t; Lamblin M, 2010, ADV SYNTH CATAL, V352, P33, DOI 10.1002/adsc.200900765; Bermejo A, 2008, J AM CHEM SOC, V130, P15798, DOI [10.1021/ja8074693, 10.1021/Ja8074693]; Wang FZ, 2014, APPL ORGANOMET CHEM, V28, P477, DOI 10.1002/aoc.3151; Yuan JC, 2013, J MOL CATAL A-CHEM, V370, P132, DOI 10.1016/j.molcata.2013.01.016; Valente C, 2012, ANGEW CHEM INT EDIT, V51, P3314, DOI 10.1002/anie.201106131; Jana R, 2011, CHEM REV, V111, P1417, DOI 10.1021/cr100327p; Allen KE, 2015, ACS CATAL, V5, P456, DOI 10.1021/cs5016029; Amatore C, 2007, CHEM-EUR J, V13, P2002, DOI 10.1002/chem.200600153; Suzuki K, 2008, ADV SYNTH CATAL, V350, P652, DOI 10.1002/adsc.200700543; Barder TE, 2005, J AM CHEM SOC, V127, P4685, DOI 10.1021/ja042491j; Liu FL, 2009, ORGANOMETALLICS, V28, P3941, DOI 10.1021/om900305u; Costa NJS, 2010, J CATAL, V276, P382, DOI 10.1016/j.jcat.2010.09.028; Nair D, 2001, TETRAHEDRON LETT, V42, P8219, DOI 10.1016/S0040-4039(01)01734-8; Wang FZ, 2015, J MOL CATAL A-CHEM, V398, P231, DOI 10.1016/j.molcata.2014.11.004; Bakherad M, 2010, APPL CATAL A-GEN, V390, P135, DOI 10.1016/j.apcata.2010.10.003; desMeijere A., 2004, METAL CATALYZED CROS, V2; Molnar A., 2013, PALLADIUM CATALYZED; Zhang GF, 2012, EUR J ORG CHEM, P669, DOI 10.1002/ejoc.201101400	35	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0268-2605	1099-0739		APPL ORGANOMET CHEM	Appl. Organomet. Chem.	NOV	2015	29	11					771	776		10.1002/aoc.3365		6	Chemistry, Applied; Chemistry, Inorganic & Nuclear	Chemistry	CU9RN	WOS:000363882700009		
J	Chu, JP; Hsiung, GY; Huang, WX; Luo, MF; Chiu, YP; Horng, RH; Hasegawa, S; Chang, CC				Chu, Jinn P.; Hsiung, Gao-Yu; Huang, Weixin; Luo, Meng-Fan; Chiu, Ya-Ping; Horng, Ray-Hua; Hasegawa, Shuji; Chang, Chia-Ching			Preface: 7th Vacuum and Surface Sciences Conference of Asia and Australia (VASSCAA-7)	APPLIED SURFACE SCIENCE			English	Editorial Material									[Chu, Jinn P.] Natl Taiwan Univ Sci & Technol, Taipei, Taiwan; [Hsiung, Gao-Yu] Natl Synchrotron Radiat Res Ctr, Taipei, Taiwan; [Huang, Weixin] Univ Sci & Technol, Sch Chem & Mat Sci, Beijing, Peoples R China; [Luo, Meng-Fan; Chiu, Ya-Ping] Natl Taiwan Normal Univ, Dept Phys, Taipei, Taiwan; [Horng, Ray-Hua] Natl Chung Hsing Univ, Grad Inst Precis Engn, Taipei, Taiwan; [Hasegawa, Shuji] Univ Tokyo, Sch Sci, Dept Phys, Tokyo 1138654, Japan; [Chang, Chia-Ching] Natl Chiao Tung Univ, Dept Biol Sci & Technol, Taipei, Taiwan	Chu, JP (reprint author), Natl Taiwan Univ Sci & Technol, Taipei, Taiwan.	jpchu@mail.ntust.edu.tw						0	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0169-4332	1873-5584		APPL SURF SCI	Appl. Surf. Sci.	NOV 1	2015	354		A				1	1		10.1016/j.apsusc.2015.09.046		1	Chemistry, Physical; Materials Science, Coatings & Films; Physics, Applied; Physics, Condensed Matter	Chemistry; Materials Science; Physics	CU6VH	WOS:000363672100001		
J	Itoh, M; Iida, H; Uhara, Y; Saito, S				Itoh, Masatoshi; Iida, Hiroyuki; Uhara, Yoshio; Saito, Shigeru			Cu filling into trenches with Co (00.2) layer by using high-vacuum magnetron sputtering in N-2-addded Ar gas	APPLIED SURFACE SCIENCE			English	Article						ULSI; Cu interconnect; Cu filling; Magnetron sputtering; Co layer; Nitrogen	THIN-FILMS; DEPOSITION; COPPER; RU	We have investigated the relationship between the presence or absence of Co (00.2) layer orientation and the characteristics of Cu filling into trenches. High-vacuum planar magnetron sputtering systems were used in the deposition of Co and Cu. Co-coated substrates with different Co (00.2) layer orientations were used in experiments on Cu filling into trenches of a width of 40 nm and aspect ratio 10. From the results of the Cu filling experiments, Cu filling into trenches was observed in substrates with Co (00.2) layer orientation. Similar Cu filling was also observed in trenches of a width of 20 nm and aspect ratio 4.5. We concentrated on lattice misfit between the Co (00.2) layer and the Cu (1 1 1) layer as the reason why Cu filling occurred in substrates with Co (00.2) layer orientation, and conducted a study from the capillary theory. (C) 2015 Elsevier B.V. All rights reserved.	[Itoh, Masatoshi; Iida, Hiroyuki; Uhara, Yoshio; Saito, Shigeru] Tokyo Univ Sci, Dept Elect Engn, Fac Engn, Tokyo, Japan	Itoh, M (reprint author), Tokyo Univ Sci, Dept Elect Engn, Fac Engn, 6-3-1 Niijyuku, Tokyo, Japan.	itoh@ee.kagu.tus.ac.jp					Akolkar R., 2011, P INT INTERCONNECT T, V10, P2; Wojcik H, 2012, J ELECTROCHEM SOC, V159, pH166, DOI 10.1149/2.066202jes; Ito F, 2012, MICROELECTRON ENG, V92, P62, DOI 10.1016/j.mee.2011.01.077; Ishizaka T, 2012, MICROELECTRON ENG, V92, P76, DOI 10.1016/j.mee.2011.04.048; Itoh M, 2012, JPN J APPL PHYS, V51, DOI 10.1143/JJAP.51.025701; Dulkin A, 2011, J VAC SCI TECHNOL A, V29, DOI 10.1116/1.3602079; Kim H, 2005, J ELECTROCHEM SOC, V152, pG594, DOI 10.1149/1.1939353; GALLOIS B, 1981, METALL TRANS B, V12, P549, DOI 10.1007/BF02654326; Itoh M, 2013, J PHYS CONF SER, V417, DOI 10.1088/1742-6596/417/1/012016; Kim H, 2007, J ELECTROCHEM SOC, V154, pG13, DOI 10.1149/1.2392984; Xu WZ, 2013, J ELECTROCHEM SOC, V160, pD3075, DOI 10.1149/2.013312jes; Antonelli GA, 2012, MICROELECTRON ENG, V92, P9, DOI 10.1016/j.mee.2011.04.035; Ooka M, 2006, JPN J APPL PHYS 1, V45, P9058, DOI 10.1143/JJAP.45.9058; ASAMAKI T, 1994, JPN J APPL PHYS 1, V33, P4566, DOI 10.1143/JJAP.33.4566; Radzimski ZJ, 1998, J VAC SCI TECHNOL B, V16, P1102, DOI 10.1116/1.590016; Armini S, 2013, J ELECTROCHEM SOC, V160, pD89, DOI 10.1149/2.032303jes; Carbonell L, 2009, PROCEEDINGS OF THE 2009 IEEE INTERNATIONAL INTERCONNECT TECHNOLOGY CONFERENCE, P200; Edelstein D, 1997, INTERNATIONAL ELECTRON DEVICES MEETING - 1997, TECHNICAL DIGEST, P773, DOI 10.1109/IEDM.1997.650496; He M, 2013, J ELECTROCHEM SOC, V160, pD3040, DOI 10.1149/2.009312jes; Itoh M., 2012, J VAC SOC JPN, V55, P445; Itoh M, 2014, JPN J APPL PHYS, V53, DOI 10.7567/JJAP.53.05GA04; Kim K, 2007, J ELECTROCHEM SOC, V154, pH177, DOI 10.1149/1.2429035; Kokaze Y, 2013, JPN J APPL PHYS, V52, DOI 10.7567/JJAP.52.05FA01; Kwon OK, 2004, J ELECTROCHEM SOC, V151, pG109, DOI 10.1149/1.1640633; Nogami T., 2010, P INT INTERCONNECT T, V3, P1; Ohring M., 1992, MAT SCI THIN FILMS, V40, P198; Sakamoto Y, 2011, JPN J APPL PHYS, V50, DOI 10.1143/JJAP.50.05EA03; Tyagi S, 2000, INTERNATIONAL ELECTRON DEVICES MEETING 2000, TECHNICAL DIGEST, P567, DOI 10.1109/IEDM.2000.904383; Wang X., 2013, J SOLID STATE SCI TE, V2, pN41	29	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0169-4332	1873-5584		APPL SURF SCI	Appl. Surf. Sci.	NOV 1	2015	354		A				124	128		10.1016/j.apsusc.2015.05.023		5	Chemistry, Physical; Materials Science, Coatings & Films; Physics, Applied; Physics, Condensed Matter	Chemistry; Materials Science; Physics	CU6VH	WOS:000363672100024		
J	Hirano, M; Yamane, M; Ohtsu, N				Hirano, Mitsuhiro; Yamane, Misao; Ohtsu, Naofumi			Surface characteristics and cell-adhesion performance of titanium treated with direct-current gas plasma comprising nitrogen and oxygen	APPLIED SURFACE SCIENCE			English	Article						Titanium; Oxynitride layer; DC plasma treatment; Surface characteristics; Cell adhesion	HUMAN PRIMARY OSTEOBLASTS; IMPLANT MATERIAL; TINOX COATINGS; NITRIDE; OSSEOINTEGRATION; PROLIFERATION; OXIDATION; FILMS	In this study, we attempted to form titanium oxynitride (TiOxNy) layers on titanium (Ti) surfaces using direct-current (DC) plasmas generated from gas mixture comprising hydrogen, nitrogen, and oxygen. Additionally, the effect of gas mixture ratio on the surface characteristics and cell-adhesion performance was investigated. Scanning probe microscopy (SPM) images showed that the plasma-treated surfaces were slightly rougher than untreated Ti surfaces, owing to the formation of new layers. Chemical state analysis using X-ray photoelectron spectroscopy (XPS) revealed that the layers were comprised TiOxNy, titanium nitride (TiN), and titanium dioxide (TiO2); the concentrations of TiOxNy and TiN decreased and that of TiO2 increased with an increase in the amount of oxygen in the gas. An increase in the amount of oxygen gas did not affect the layer thickness, which was approximately 25 nm. Furthermore, no differences in cell morphology and cell-adhesion performance were found between the specimens treated with various plasma gases. This is probably because the treatment insufficiently improved the hydrophilicity. Layers composed of TiOxNy, TiN, and TiO2 were formed using the DC plasma treatment; however, the layers did not improve the cell-adhesion at an initial stage after the seeding. (C) 2015 Elsevier B.V. All rights reserved.	[Hirano, Mitsuhiro; Yamane, Misao; Ohtsu, Naofumi] Kitami Inst Technol, Instrument Anal Ctr, Kitami, Hokkaido 0908507, Japan	Ohtsu, N (reprint author), Kitami Inst Technol, Instrument Anal Ctr, 165 Koen Cho, Kitami, Hokkaido 0908507, Japan.	nohtsu@mail.kitami-it.ac.jp			Ministry of Education, Science, Sports, and Culture (MEXT) of Japan [24560841]	We gratefully acknowledge Dr. Furuse from the Kitami Institute of Technology for help with measuring optical spectra. We also wish to thank Mr. Kozuka in our laboratory for help with the experiment involving cells. This work was supported by the Grants-in-aid for Scientific Research (C) (No. 24560841) from the Ministry of Education, Science, Sports, and Culture (MEXT) of Japan.	de Souza GB, 2005, SURF COAT TECH, V191, P76, DOI 10.1016/j.surfcoat.2004.08.207; Durual S, 2011, CLIN ORAL IMPLAN RES, V22, P552, DOI 10.1111/j.1600-0501.2010.02033.x; Akahori T, 1998, MAT SCI ENG A-STRUCT, V243, P237, DOI 10.1016/S0921-5093(97)00807-1; Lee YH, 2001, SURF COAT TECH, V146, P474, DOI 10.1016/S0257-8972(01)01459-1; Long M, 1998, BIOMATERIALS, V19, P1621, DOI 10.1016/S0142-9612(97)00146-4; Ohtsu N, 2011, SURF COAT TECH, V205, P3785, DOI 10.1016/j.surfcoat.2011.01.035; Kiyono H, 2011, CERAM INT, V37, P1813, DOI 10.1016/j.ceramint.2011.03.003; Jeong BY, 2001, SURF COAT TECH, V141, P182, DOI 10.1016/S0257-8972(01)01232-4; VANNOORT R, 1987, J MATER SCI, V22, P3801; Tsyganov I, 2013, RSC ADV, V3, P11205, DOI 10.1039/c3ra23351k; Mavrogenis AF, 2009, J MUSCULOSKEL NEURON, V9, P61; Ohtsu N, 2009, LANGMUIR, V25, P11586, DOI 10.1021/la901505m; Glaser A, 2007, SURF SCI, V601, P1153, DOI 10.1016/j.susc.2006.12.010; Rieder P, 2012, BIO-MED MATER ENG, V22, P277, DOI 10.3233/BME-2012-0717; Newport A, 2002, J MATER CHEM, V12, P1906, DOI 10.1039/b201974b; Esaka F, 1997, J VAC SCI TECHNOL A, V15, P2521, DOI 10.1116/1.580764; Banakh O, 2014, APPL SURF SCI, V317, P986, DOI 10.1016/j.apsusc.2014.09.009; Durual S, 2013, BONE, V52, P230, DOI 10.1016/j.bone.2012.09.014; Wei JH, 2009, BIOMED MATER, V4, DOI 10.1088/1748-6041/4/4/045002; Yoshinri M., 2009, WASET, V58, P171	20	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0169-4332	1873-5584		APPL SURF SCI	Appl. Surf. Sci.	NOV 1	2015	354		A				161	167		10.1016/j.apsusc.2015.02.153		7	Chemistry, Physical; Materials Science, Coatings & Films; Physics, Applied; Physics, Condensed Matter	Chemistry; Materials Science; Physics	CU6VH	WOS:000363672100031		
J	Fujii, S; Kaneko, S; Liu, CY; Kiguchi, M				Fujii, Shintaro; Kaneko, Satoshi; Liu Chenyang; Kiguchi, Manabu			Single naphthalene and anthracene molecular junctions using Ag and Cu electrodes in ultra high vacuum	APPLIED SURFACE SCIENCE			English	Article						Single molecular junction; Charge transport; Mechanically controllable break junction; Acene	CONDUCTANCE; TRANSISTOR; CONTACTS; DIODE	We present a charge transport study on single naphthalene and anthracene molecular junctions wired into Ag and Cu electrodes using mechanically controllable break junction technique at 100 K under ultra-high vacuum condition. In particular we focus on effect of metal-pi interaction on the formation probability of the molecular junctions. We found that the single molecular junctions of the acene molecules (e.g. naphthalene and anthracene) exhibit highly conductive character below 0.2 G(0) (G(0) = 2e(2)/h). The acene molecular junctions displayed formation probability of ca. 20% for Ag system and >40% for Cu system. The high formation probability of the molecular junctions with respect to benzene/Au junctions can be qualitatively explained by size effect, in which larger molecules of the naphthalene and anthracene can effectively bridge the gap between metal electrodes compared with small molecule such as benzene. The acene/Cu junctions displayed higher formation probability than the acene/Ag junctions. This result demonstrated that not only the size effect but the degree of the metal-pi interaction have to be taken into account to quantitatively evaluate the formation probability of the molecular junctions for Ag and Cu system. (C) 2015 Elsevier B.V. All rights reserved.	[Fujii, Shintaro; Kaneko, Satoshi; Liu Chenyang; Kiguchi, Manabu] Tokyo Inst Technol, Dept Chem, Meguro Ku, Tokyo 1528551, Japan	Fujii, S (reprint author), Tokyo Inst Technol, Dept Chem, Meguro Ku, 2-12-1 Ookayama, Tokyo 1528551, Japan.	fujii.s.af@m.titech.ac.jp; kiguti@chem.titech.ac.jp	Kiguchi, Manabu/F-2856-2013		Ministry of Education, Culture, Sports, Science and Technology [26102013, 21340074]; Asahi Glass Foundation; MEXT [26102013, 24245027]	This work was financially supported by Grants-in-Aid for Scientific Research in Innovative Areas (26102013) and a Grant-in-Aid for Scientific Research (A) (No. 21340074) from the Ministry of Education, Culture, Sports, Science and Technology and Asahi Glass Foundation.; This work was supported by a Grant-in-Aid for Scientific Research (Nos. 24245027, 26102013) from MEXT, and Asahi Glass foundation. The authors would like to express their sincere gratitude to Mr. Hiroshi Tanaka in Shinkukougaku Co. Ltd.	Elbing M, 2005, P NATL ACAD SCI USA, V102, P8815, DOI 10.1073/pnas.0408888102; Li CZ, 2000, APPL PHYS LETT, V76, P1333, DOI 10.1063/1.126025; vanRuitenbeek JM, 1996, REV SCI INSTRUM, V67, P108, DOI 10.1063/1.1146558; Lortscher E, 2012, ACS NANO, V6, P4931, DOI 10.1021/nn300438h; Xu BQ, 2005, J AM CHEM SOC, V127, P2386, DOI 10.1021/ja042385h; Lindstrom CD, 2007, J PHYS CHEM B, V111, P6913, DOI 10.1021/jp0662505; Reed MA, 1997, SCIENCE, V278, P252, DOI 10.1126/science.278.5336.252; Diez-Perez I, 2009, NAT CHEM, V1, P635, DOI [10.1038/nchem.392, 10.1038/NCHEM.392]; Xu BQ, 2003, SCIENCE, V301, P1221, DOI 10.1126/science.1087481; Agrait N, 2003, PHYS REP, V377, P81, DOI 10.1016/S0370-1573(02)00633-6; Nakazumi T, 2012, J PHYS CHEM C, V116, P18250, DOI 10.1021/jp304733u; Park H, 2000, NATURE, V407, P57; Zhao JW, 2008, J PHYS CHEM C, V112, P20088, DOI 10.1021/jp8055448; Dhungana KB, 2012, J PHYS CHEM C, V116, P17268, DOI 10.1021/jp3043335; Murai D, 2014, PHYS CHEM CHEM PHYS, V16, P15662, DOI 10.1039/c4cp01950d; Kiguchi M, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.046801; Yelin T, 2013, NANO LETT, V13, P1956, DOI 10.1021/nl304702z; Chen F, 2005, NANO LETT, V5, P503, DOI 10.1021/nl0478474; He HX, 2002, J ELECTROANAL CHEM, V522, P26, DOI 10.1016/S0022-0728(01)00714-8; Song H, 2009, NATURE, V462, P1039, DOI 10.1038/nature08639; Bohler T, 2007, PHYS REV B, V76, DOI 10.1103/PhysRevB.76.125432; Kiguchi M, 2009, APPL PHYS LETT, V95, DOI 10.1063/1.3204466; Kiguchi M, 2008, PHYS REV B, V77, DOI 10.1103/PhysRevB.77.245421; Liu CY, 2014, APPL PHYS EXPRESS, V7, DOI 10.7567/APEX.7.105201; Ulman A, 1996, CHEM REV, V96, P1533, DOI 10.1021/cr9502357	25	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0169-4332	1873-5584		APPL SURF SCI	Appl. Surf. Sci.	NOV 1	2015	354		B				362	366		10.1016/j.apsusc.2015.05.071		5	Chemistry, Physical; Materials Science, Coatings & Films; Physics, Applied; Physics, Condensed Matter	Chemistry; Materials Science; Physics	CU6VS	WOS:000363673500018		
J	Mizutani, T; Ogawa, S; Murai, T; Nameki, H; Yoshida, T; Yagi, S				Mizutani, Tsuyoshi; Ogawa, Satoshi; Murai, Takaaki; Nameki, Hirofumi; Yoshida, Tomoko; Yagi, Shinya			In situ UV-vis investigation of growth of gold nanoparticles prepared by solution plasma sputtering in NaCl solution	APPLIED SURFACE SCIENCE			English	Article						Gold nanoparticle; Solution plasma; Ostwald ripening; In situ UV-vis	SIZE	Gold nanoparticles are prepared in various concentrations of NaCl solutions by solution plasma sputtering. The absorption spectra of these solutions during and after the plasma process are measured by in situ ultraviolet-visible (UV-vis) spectroscopy to estimate the particle diameters and concentrations of gold. The distributions of particle diameters are obtained by transmission electron microscope (TEM) observations. These experiments indicate the gold nanoparticles with about 2.2 nm are directly formed by plasma phase and the diameters are increasing over time. These increases of particle diameters are caused by Ostwald ripening of gold nanoparticles in NaCl solution. We estimate the equilibrium diameter at which the gold nanoparticles are not solved in NaCl solution using in situ UV-vis spectroscopy. These diameters are about 5, 7 and 10 nm in 3, 5 and 10 mM NaCl solution, respectively. We make it possible to control the diameter of gold nanoparticles prepared by solution plasma sputtering in NaCl solution. (C) 2015 Elsevier B.V. All rights reserved.	[Mizutani, Tsuyoshi; Ogawa, Satoshi] Nagoya Univ, Dept Mat Phys & Energy Engn, Sch Engn, Dept Mat Phys & Energy Engn,Chikusa Ku, Nagoya, Aichi 4648603, Japan; [Murai, Takaaki; Nameki, Hirofumi] Aichi Ctr Ind & Sci Technol, Kariya, Aichi 4480013, Japan; [Yoshida, Tomoko; Yagi, Shinya] Nagoya Univ, EcoTopia Sci Inst, Chikusa Ku, Nagoya, Aichi 4648603, Japan	Mizutani, T (reprint author), Nagoya Univ, Dept Mat Phys & Energy Engn, Sch Engn, Dept Mat Phys & Energy Engn,Chikusa Ku, Furo Cho, Nagoya, Aichi 4648603, Japan.	mizutani.tsuyoshi@g.mbox.nagoya-u.ac.jp			JSPS [253892]; Japan Society for the Promotion of Science (JSPS) [24360332, 26289225]	The authors are grateful for the financial support of JSPS Research Fellowship for Young Scientists (No. 253892) and Grant-in-Aids for Scientific Research (B) (Nos. 24360332 and 26289225) from the Japan Society for the Promotion of Science (JSPS).	Kowalska E, 2010, PHYS CHEM CHEM PHYS, V12, P2344, DOI 10.1039/b917399d; Saito G, 2011, MATER CHEM PHYS, V130, P79, DOI 10.1016/j.matchemphys.2011.05.084; Haiss W, 2007, ANAL CHEM, V79, P4215, DOI 10.1021/ac0702084; Liu GL, 2007, NAT METHODS, V4, P1015, DOI 10.1038/nmeth1133; Sylvestre JP, 2004, J PHYS CHEM B, V108, P16864, DOI 10.1021/jp047134+; Hu XL, 2012, CRYST GROWTH DES, V12, P119, DOI 10.1021/cg2008528; Compton OC, 2007, J AM CHEM SOC, V129, P7793, DOI 10.1021/ja069033q; BRUST M, 1994, J CHEM SOC CHEM COMM, P801, DOI 10.1039/c39940000801; Hu X.L., 2013, J PHYS C SER, V417; Mie G, 1908, ANN PHYS-BERLIN, V25, P377; Mizutani T., 2015, NUCL INSTRUM B UNPUB; Mizutani T., 2014, JPN J APPL PHYS, V53; Ostwald W., 1901, Z PHYS CHEM, V37, P385; Voorhees W., 1985, J STAT PHYS, V38, P231	14	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0169-4332	1873-5584		APPL SURF SCI	Appl. Surf. Sci.	NOV 1	2015	354		B				397	400		10.1016/j.apsusc.2015.04.139		4	Chemistry, Physical; Materials Science, Coatings & Films; Physics, Applied; Physics, Condensed Matter	Chemistry; Materials Science; Physics	CU6VS	WOS:000363673500023		
J	Tanaka, Y; Azuma, S; Sugie, T				Tanaka, Yosuke; Azuma, Shun-ichi; Sugie, Toshiharu			Simultaneous Perturbation Stochastic Approximation with Norm-Limited Update Vector	ASIAN JOURNAL OF CONTROL			English	Article						Simultaneous perturbation stochastic approximation; system identification	OPTIMIZATION; REGISTRATION; CONTROLLER; GRADIENT; SYSTEMS	This paper addresses the convergence of simultaneous perturbation stochastic approximation (SPSA) with a norm-limited update vector. We first illustrate an unstable solution of the standard SPSA algorithm which motivates the consideration of a modified version, where the norm of the update vector is limited to a certain value. Next, a result on the almost-sure convergence is presented by reducing the modified algorithm into the standard SPSA algorithm and restricting the probability distribution for the perturbation to a Bernoulli distribution. Finally, we apply the modified algorithm to a system identification problem to demonstrate its performance.	[Tanaka, Yosuke; Azuma, Shun-ichi; Sugie, Toshiharu] Kyoto Univ, Grad Sch Informat, Sakyo Ku, Kyoto 6068501, Japan	Azuma, S (reprint author), Kyoto Univ, Grad Sch Informat, Sakyo Ku, Kyoto 6068501, Japan.	sazuma@i.kyoto-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan [25249058, 24686051]	This work was partly supported by Grant-in-Aid for Scientific Research (A) 25249058 and Grant-in-Aid for Young Scientists (A) 24686051 from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	Ahmad Mohd Ashraf, 2014, SICE Journal of Control, Measurement, and System Integration, V7; Spall JC, 2000, IEEE T AUTOMAT CONTR, V45, P1839, DOI 10.1109/TAC.2000.880982; Li Q, 2006, INT GEOSCI REMOTE SE, P184, DOI 10.1109/IGARSS.2006.52; Antal C, 2010, IEEE DECIS CONTR P, P3656, DOI 10.1109/CDC.2010.5717903; Azuma S, 2012, IEEE T AUTOMAT CONTR, V57, P2308, DOI 10.1109/TAC.2012.2186927; SPALL JC, 1994, PROCEEDINGS OF THE 1994 AMERICAN CONTROL CONFERENCE, VOLS 1-3, P2560; Spall JC, 1997, AUTOMATICA, V33, P109, DOI 10.1016/S0005-1098(96)00149-5; Cole-Rhodes AA, 2003, IEEE T IMAGE PROCESS, V12, P1495, DOI 10.1109/TIP.2003.819237; MAEDA Y, 1995, NEURAL NETWORKS, V8, P251, DOI 10.1016/0893-6080(94)00084-Y; Song Q, 2008, IEEE T NEURAL NETWOR, V19, P817, DOI 10.1109/TNN.2007.912315; REZAYAT F, 1995, AUTOMATICA, V31, P913, DOI 10.1016/0005-1098(95)00002-E; Azuma S, 2013, AUTOMATICA, V49, P2307, DOI 10.1016/j.automatica.2013.04.022; Martin S, 2004, ELECTRON LETT, V40, P595, DOI 10.1049/el:20040375; Spall JC, 1998, IEEE T AUTOMAT CONTR, V43, P1198, DOI 10.1109/9.718605; Vakhitov A, 2010, P AMER CONTR CONF, P4004; Maryak JL, 2008, IEEE T AUTOMAT CONTR, V53, P780, DOI 10.1109/TAC.2008.917738; Baba Ichiro, 2013, Transactions of the Society of Instrument and Control Engineers, V49; Borkar V. S., 2008, STOCHASTIC APPROXIMA; Hahn B., 2012, IEEE T CONTR SYST T, V20, P194; Kushner H. J., 1978, STOCHASTIC APPROXIMA; Martinez J. I. M., 2009, P ICCAS SICE C FUK J, P4567; Prashanth L. A., 2013, LECT NOTES CONTROL I, V434; SPALL JC, 1992, IEEE T AUTOMAT CONTR, V37, P332, DOI 10.1109/9.119632	23	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1561-8625	1934-6093		ASIAN J CONTROL	Asian J. Control	NOV	2015	17	6					2083	2090		10.1002/asjc.1153		8	Automation & Control Systems	Automation & Control Systems	CU8ME	WOS:000363796100004		
J	Ishikawa, M; Naka, A; Ohshita, J				Ishikawa, Mitsuo; Naka, Akinobu; Ohshita, Joji			The Chemistry of Silacyclopropenes	ASIAN JOURNAL OF ORGANIC CHEMISTRY			English	Review						photochemistry; silacyclopropenes; silylenes; thermolysis; transition-metal catalysis	CARBON UNSATURATED-COMPOUNDS; INTRAMOLECULAR STERIC INTERACTIONS; NICKEL-CATALYZED REACTIONS; SILICON-COMPOUNDS; PHOTOCHEMICAL BEHAVIOR; MOLECULAR-STRUCTURE; DISILENE ADDITIONS; SILYLENE REACTIONS; THERMAL-BEHAVIOR; STABLE SILYLENE	The synthesis and reactions of silacyclopropenes are summarized. Addition of silylenes to acetylenes and photochemical isomerization of alkynyldisilanes are known as two major routes for the synthesis of silacyclopropenes. Silacyclopropenes had been thought to be highly reactive and difficult to handle until the first crystal structure of a stable one was reported in 1980. Currently, however, it is commonly accepted that those molecules are stable under ambient conditions when sufficiently bulky substituents are introduced onto the strained three-membered ring system to stabilize it kinetically. The reactivity of silacyclopropenes is interesting and depends on the nature of substituents. They, indeed, undergo a variety of reactions, such as photolysis, thermolysis, and transition-metal-catalyzed reactions, leading to the formation of reactive intermediates including silylenes and silapropadienes, and their transition-metal complexes, through which numerous transformations into silicon-containing cyclic and acyclic compounds are possible.	[Ishikawa, Mitsuo; Naka, Akinobu] Kurashiki Univ Sci & Arts, Dept Life Sci, Kurashiki, Okayama 7128505, Japan; [Ohshita, Joji] Hiroshima Univ, Grad Sch Engn, Dept Appl Chem, Higashihiroshima 7398527, Japan	Ishikawa, M (reprint author), Kurashiki Univ Sci & Arts, Dept Life Sci, Kurashiki, Okayama 7128505, Japan.	ishikawa-m@zeus.eonet.ne.jp; anaka@chem.kusa.ac.jp; jo@hiroshima-u.ac.jp	Ohshita, Joji/C-7576-2011				ATWELL WH, 1967, J ORG CHEM, V32, P885, DOI 10.1021/jo01279a007; ATWELL WH, 1968, J AM CHEM SOC, V90, P3438, DOI 10.1021/ja01015a028; Rekken BD, 2012, J AM CHEM SOC, V134, P6504, DOI 10.1021/ja301091v; ISHIKAWA M, 1986, J AM CHEM SOC, V108, P7417, DOI 10.1021/ja00283a052; Kira M, 1999, J AM CHEM SOC, V121, P9722, DOI 10.1021/ja9925305; Sekiguchi A, 2003, J AM CHEM SOC, V125, P4962, DOI 10.1021/ja020929e; ISHIKAWA M, 1984, ORGANOMETALLICS, V3, P1930, DOI 10.1021/om00090a032; WEST R, 1981, SCIENCE, V214, P1343, DOI 10.1126/science.214.4527.1343; Gehrhus B, 2001, J ORGANOMET CHEM, V617, P209, DOI 10.1016/S0022-328X(00)00729-4; ISHIKAWA M, 1983, ORGANOMETALLICS, V2, P974, DOI 10.1021/om50002a006; SEYFERTH D, 1977, J ORGANOMET CHEM, V125, pC11, DOI 10.1016/S0022-328X(00)93713-6; ISHIKAWA M, 1975, J ORGANOMET CHEM, V86, pC23, DOI 10.1016/S0022-328X(00)89622-9; Kawachi A, 2004, ORGANOMETALLICS, V23, P2949, DOI 10.1021/om04001u; SAKURAI H, 1977, J AM CHEM SOC, V99, P3879, DOI 10.1021/ja00453a078; ISHIKAWA M, 1982, ORGANOMETALLICS, V1, P1473, DOI 10.1021/om00071a013; Ostendorf D, 2000, ORGANOMETALLICS, V19, P4938, DOI 10.1021/om000714i; ISHIKAWA M, 1973, J ORGANOMET CHEM, V49, pC71, DOI 10.1016/S0022-328X(00)84211-4; Zhao J, 2014, COORDIN CHEM REV, V270, P2, DOI 10.1016/j.ccr.2013.08.032; Tanaka H, 2011, ORGANOMETALLICS, V30, P3160, DOI 10.1021/om2002393; Ohshita J, 2006, ORGANOMETALLICS, V25, P3955, DOI 10.1021/om060458v; SEYFERTH D, 1976, J AM CHEM SOC, V98, P6382, DOI 10.1021/ja00436a053; ISHIKAWA M, 1980, J ORGANOMET CHEM, V194, P147, DOI 10.1016/S0022-328X(00)86663-2; BARTON TJ, 1976, J AM CHEM SOC, V98, P7746, DOI 10.1021/ja00440a049; ISHIKAWA M, 1979, J ORGANOMET CHEM, V179, P377, DOI 10.1016/S0022-328X(00)91854-0; [Anonymous], 1981, ADV ORGANOMETALLIC C, DOI 10.1016/S0065-3055(08)60363-9; Kunai A, 1997, J ORGANOMET CHEM, V545, P611, DOI 10.1016/S0022-328X(97)00355-0; SEYFERTH D, 1984, J ORGANOMET CHEM, V272, P123, DOI 10.1016/0022-328X(84)80461-1; Lips F, 2014, J AM CHEM SOC, V136, P634, DOI 10.1021/ja411951y; ISHIKAWA M, 1982, J AM CHEM SOC, V104, P2872, DOI 10.1021/ja00374a029; ISHIKAWA M, 1986, ORGANOMETALLICS, V5, P1518, DOI 10.1021/om00138a045; ISHIKAWA M, 1992, ORGANOMETALLICS, V11, P597, DOI 10.1021/om00038a016; Hatano K, 2000, J AM CHEM SOC, V122, P4829, DOI 10.1021/ja000501k; Yao SL, 2011, ORGANOMETALLICS, V30, P1748, DOI 10.1021/om200017h; DENK M, 1994, J AM CHEM SOC, V116, P2691, DOI 10.1021/ja00085a088; Han JS, 2012, CHEM-ASIAN J, V7, P298, DOI 10.1002/asia.201100833; Ghadwal RS, 2013, CHEM COMMUN, V49, P5987, DOI 10.1039/c3cc43199a; ISHIKAWA M, 1981, J ORGANOMET CHEM, V217, P43, DOI 10.1016/S0022-328X(00)86021-0; ISHIKAWA M, 1991, J ORGANOMET CHEM, V402, pC20, DOI 10.1016/0022-328X(91)83073-D; VOLPIN ME, 1962, TETRAHEDRON, V18, P107, DOI 10.1016/0040-4020(62)80030-1; Protchenko AV, 2012, J AM CHEM SOC, V134, P6500, DOI 10.1021/ja301042u; Ohshita J, 2003, ORGANOMETALLICS, V22, P2436, DOI 10.1021/om020996h; Suzuki K, 2011, J AM CHEM SOC, V133, P19710, DOI 10.1021/ja209736d; Ishida S, 2011, HETEROATOM CHEM, V22, P432, DOI 10.1002/hc.20705; OHSHITA J, 1991, J ORGANOMET CHEM, V407, P157, DOI 10.1016/0022-328X(91)86113-5; Tajima T, 2003, J ORGANOMET CHEM, V686, P118, DOI 10.1016/S0022-328X(03)00446-7; ISHIKAWA M, 1985, ORGANOMETALLICS, V4, P2040, DOI 10.1021/om00130a019; ISHIKAWA M, 1977, J ORGANOMET CHEM, V135, pC45, DOI 10.1016/S0022-328X(00)80869-4; Ando W, 1997, J AM CHEM SOC, V119, P3629, DOI 10.1021/ja9637412; SUZUKI H, 1995, B CHEM SOC JPN, V68, P2471, DOI 10.1246/bcsj.68.2471; ISHIKAWA M, 1977, J ORGANOMET CHEM, V131, pC15, DOI 10.1016/S0022-328X(00)93417-X; ATWELL WH, 1969, ANGEW CHEM INT EDIT, V8, P469, DOI 10.1002/anie.196904691; Zhang WX, 2011, ACCOUNTS CHEM RES, V44, P541, DOI 10.1021/ar200078e; ATWELL WH, 1966, J ORGANOMET CHEM, V5, P594, DOI 10.1016/S0022-328X(00)85171-2; SEYFERTH D, 1985, ORGANOMETALLICS, V4, P57, DOI 10.1021/om00120a011; ISHIKAWA M, 1980, J ORGANOMET CHEM, V190, P117, DOI 10.1016/S0022-328X(00)85910-0; Ostendorf D, 2001, J ORGANOMET CHEM, V636, P7, DOI 10.1016/S0022-328X(01)00672-6; Lee VY, 2009, ORGANOMETALLICS, V28, P4262, DOI 10.1021/om900310u; Anderson LL, 2009, ORG LETT, V11, P425, DOI 10.1021/ol802412b; LAMBERT RL, 1972, J AM CHEM SOC, V94, P9246, DOI 10.1021/ja00781a055; Yao SL, 2008, ANGEW CHEM INT EDIT, V47, P3250, DOI 10.1002/anie.200704939; ISHIKAWA M, 1978, J ORGANOMET CHEM, V152, P155, DOI 10.1016/S0022-328X(00)91918-1; Sekiguchi A, 1999, J AM CHEM SOC, V121, P10231, DOI 10.1021/ja991694i; Palmer WS, 1997, ORGANOMETALLICS, V16, P4824, DOI 10.1021/om9704861; ISHIKAWA M, 1977, J ORGANOMET CHEM, V142, pC45, DOI 10.1016/S0022-328X(00)88357-6; Naka A, 2000, ORGANOMETALLICS, V19, P4921, DOI 10.1021/om000584d; OHSHITA J, 1989, ORGANOMETALLICS, V8, P2050, DOI 10.1021/om00110a036; KUNAI A, 1995, ORGANOMETALLICS, V14, P1204, DOI 10.1021/om00003a022; ISHIKAWA M, 1977, J AM CHEM SOC, V99, P245, DOI 10.1021/ja00443a045; Belzner J, 2001, TETRAHEDRON, V57, P511, DOI 10.1016/S0040-4020(00)01020-6; ISHIKAWA M, 1981, J AM CHEM SOC, V103, P4170, DOI 10.1021/ja00404a032; CONLIN RT, 1976, J AM CHEM SOC, V98, P3715, DOI 10.1021/ja00428a059; ATWELL WH, 1973, J ORGANOMET CHEM, V52, pC21, DOI 10.1016/S0022-328X(00)95127-1; SEYFERTH D, 1977, J ORGANOMET CHEM, V125, pC5, DOI 10.1016/S0022-328X(00)93712-4; Haaf M, 2000, ACCOUNTS CHEM RES, V33, P704, DOI 10.1021/ar950192g; Clark TB, 2006, ORG LETT, V8, P4109, DOI 10.1021/ol061652g; Lee VY, 2014, J AM CHEM SOC, V136, P6243, DOI 10.1021/ja5026084; Kirmaier L, 1998, ORGANOMETALLICS, V17, P1237, DOI 10.1021/om970791m; Atwell W. H., 1969, ANGEW CHEM, V81, P485, DOI 10.1002/ange.19690811303; Gaspar P. P., 1978, REACTIVE INTERMEDIAT, V1, P229; Gasper P. P., 1999, CHEM ORGANIC SILICON, V2, P2463; Hirotsu K., 1983, J CHEM SOC CHEM COMM, P726; Ishikawa M., 1985, J AM CHEM SOC, V107, P7706; ISHIKAWA M, 1988, J CHEM SOC CHEM COMM, P804, DOI 10.1039/c39880000804; ISHIKAWA M, 1971, J CHEM SOC CHEM COMM, P489, DOI 10.1039/c29710000489; ISHIKAWA M, 1975, TETRAHEDRON LETT, P645; Ishikawa M., 1970, J CHEM SOC CHEM COMM, p612a, DOI 10.1039/c2970000612a; Ishikawa M., 1977, J CHEM SOC CHEM COMM, p352a, DOI 10.1039/c3977000352a; NEFEDOV OM, 1966, ANGEW CHEM INT EDIT, V5, P1021, DOI 10.1002/anie.196610211; Nefedow O. M., 1966, ANGEW CHEM, V78, P1039, DOI 10.1002/ange.19660782303; OKINOSHI.H, 1972, J AM CHEM SOC, V94, P9263, DOI 10.1021/ja00781a066; Ostendorf D, 1999, EUR J INORG CHEM, P2301; Rekken A. D., 2013, J AM CHEM SOC, V135, P10134; Weyenberg D. R., 1969, PURE APPL CHEM, V19, P343, DOI 10.1351/pac196919030343; Yao S, 2008, ANGEW CHEM, V120, P3294, DOI 10.1002/ange.200704939	94	0	0	WILEY-V C H VERLAG GMBH	WEINHEIM	POSTFACH 101161, 69451 WEINHEIM, GERMANY	2193-5807	2193-5815		ASIAN J ORG CHEM	Asian J. Org. Chem.	NOV	2015	4	11					1192	1209		10.1002/ajoc.201500271		18	Chemistry, Organic	Chemistry	CU9RE	WOS:000363881600001		
J	Nambu, H; Noda, N; Niu, WQ; Fujiwara, T; Yakura, T				Nambu, Hisanori; Noda, Narumi; Niu, Wenqi; Fujiwara, Tomoya; Yakura, Takayuki			Stereoselective Total Synthesis of Myriocin Using Rhodium(II)-Catalyzed C-H Amination Followed by Alkylation	ASIAN JOURNAL OF ORGANIC CHEMISTRY			English	Article						alkylation; C-H amination; myriocin; rhodium; total synthesis	RH-CATALYZED AMINATION; ALPHA-AZIDO ALDEHYDES; SERINE PALMITOYLTRANSFERASE; POTENT IMMUNOSUPPRESSANTS; IMMUNOMODULATOR (+)-CONAGENIN; ENANTIOSELECTIVE SYNTHESIS; SUBSTITUTED 1,2-DIAMINES; BIOLOGICAL-ACTIVITY; FUNGAL METABOLITES; AMINE DERIVATIVES	The stereoselective total synthesis of myriocin was achieved by using the Du Bois Rh-II-catalyzed C-H amination of sulfamate 6, derived from diethyl l-tartrate, and a subsequent alkylation. The reaction of sulfamate 6 with PhI(OAc)(2) and MgO in the presence of Rh-2(OAc)(4) gave an oxathiazinane N,O-acetal as the sole product in high yield. Alkylation of the N,O-acetal with vinylmagnesium bromide in the presence of ZnCl2 proceeded stereoselectively to provide an oxathiazinane bearing a quaternary chiral center in high yield. This route includes the first application of the Du Bois procedure for the construction of a quaternary chiral center.	[Nambu, Hisanori; Noda, Narumi; Niu, Wenqi; Fujiwara, Tomoya; Yakura, Takayuki] Toyama Univ, Grad Sch Med & Pharmaceut Sci, Sugitani, Toyama 9300194, Japan	Yakura, T (reprint author), Toyama Univ, Grad Sch Med & Pharmaceut Sci, Sugitani, Toyama 9300194, Japan.	yakura@pha.u-toyama.ac.jp					Kim M, 2006, ORG LETT, V8, P1073, DOI 10.1021/ol052920y; Wehn PM, 2009, ANGEW CHEM INT EDIT, V48, P3802, DOI 10.1002/anie.200806292; Bess EN, 2014, J AM CHEM SOC, V136, P5783, DOI 10.1021/ja5015508; Olson DE, 2012, ORG LETT, V14, P6174, DOI 10.1021/ol302895f; Wadsworth JM, 2013, J AM CHEM SOC, V135, P14276, DOI 10.1021/ja4059876; Fujita T, 1996, J MED CHEM, V39, P4451, DOI 10.1021/jm960391l; Fleming JJ, 2007, J AM CHEM SOC, V129, P9964, DOI 10.1021/ja071501o; Fujita T, 1996, J ANTIBIOT, V49, P846; Yang JH, 2008, ORG LETT, V10, P2525, DOI 10.1021/ol8008057; Oishi T, 2002, B CHEM SOC JPN, V75, P1927, DOI 10.1246/bcsj.75.1927; KIM E, 1993, J ORG CHEM, V58, P5500, DOI 10.1021/jo00072a038; Fleming JJ, 2003, J AM CHEM SOC, V125, P2028, DOI 10.1021/ja028916o; Conrad RM, 2007, ORG LETT, V9, P5465, DOI 10.1021/ol702375r; KLUEPFEL D, 1972, J ANTIBIOT, V25, P109; Hayes CJ, 2006, J ORG CHEM, V71, P2661, DOI 10.1021/jo052408q; Chan TH, 1999, J AM CHEM SOC, V121, P3228, DOI 10.1021/ja984359n; Fiori KW, 2004, ANGEW CHEM INT EDIT, V43, P4349, DOI 10.1002/anie.200460791; Hatakeyama S, 1997, TETRAHEDRON LETT, V38, P7887, DOI 10.1016/S0040-4039(97)10077-6; Espino CG, 2004, J AM CHEM SOC, V126, P15378, DOI 10.1021/ja0446294; Paquette LA, 1996, J AM CHEM SOC, V118, P1931, DOI 10.1021/ja953682c; VANMIDDLESWORTH F, 1992, J ANTIBIOT, V45, P861; Fiori KW, 2009, TETRAHEDRON, V65, P3042, DOI 10.1016/j.tet.2008.11.073; Olson DE, 2008, J AM CHEM SOC, V130, P11248, DOI 10.1021/ja803344v; Inai M, 2008, TETRAHEDRON-ASYMMETR, V19, P2771, DOI 10.1016/j.tetasy.2008.12.020; Yakura T, 2007, TETRAHEDRON, V63, P4429, DOI 10.1016/j.tet.2007.03.079; Thornton AR, 2009, J AM CHEM SOC, V131, P2434, DOI 10.1021/ja809078d; Wehn PM, 2003, ORG LETT, V5, P4823, DOI 10.1021/ol035776u; Roizen JL, 2013, ANGEW CHEM INT EDIT, V52, P11343, DOI 10.1002/anie.201304238; ZWEERINK MM, 1992, J BIOL CHEM, V267, P25032; YOSHIKAWA M, 1995, TETRAHEDRON, V51, P6209, DOI 10.1016/0040-4020(95)00279-H; Fleming JJ, 2006, J AM CHEM SOC, V128, P3926, DOI 10.1021/ja0608545; RAO AVR, 1993, TETRAHEDRON LETT, V34, P1653, DOI 10.1016/0040-4039(93)85033-S; Chen JK, 1999, CHEM BIOL, V6, P221, DOI 10.1016/S1074-5521(99)80038-6; Espino CG, 2001, J AM CHEM SOC, V123, P6935, DOI 10.1021/ja011033x; DELOISY S, 1994, TETRAHEDRON LETT, V35, P4783, DOI 10.1016/S0040-4039(00)76967-X; Du Bois J, 2011, ORG PROCESS RES DEV, V15, P758, DOI 10.1021/op200046v; Zalatan DN, 2008, J AM CHEM SOC, V130, P9220, DOI 10.1021/ja8031955; Deloisy S, 1996, B SOC CHIM FR, V133, P581; Espino CG, 2001, ANGEW CHEM INT EDIT, V40, P598, DOI 10.1002/1521-3773(20010202)40:3<598::AID-ANIE598>3.0.CO;2-9; SASAKI S, 1994, J ANTIBIOT, V47, P420; Lee KY, 2002, TETRAHEDRON LETT, V43, P9361, DOI 10.1016/S0040-4039(02)02371-7; BAGLI JF, 1973, J ORG CHEM, V38, P1253, DOI 10.1021/jo00947a001; Yakura T, 2007, CHEM PHARM BULL, V55, P1284, DOI 10.1248/cpb.55.1284; HORN WS, 1992, J ANTIBIOT, V45, P1692; MIYAKE Y, 1995, BIOCHEM BIOPH RES CO, V211, P396, DOI 10.1006/bbrc.1995.1827; ARAGOZZI.F, 1972, TETRAHEDRON, V28, P5493, DOI 10.1016/S0040-4020(01)93872-4; Araki S., 1988, J ORG CHEM, V53, P1833; BANFI L, 1982, J CHEM SOC CHEM COMM, P488, DOI 10.1039/c39820000488; BANFI L, 1983, J CHEM SOC PERK T 1, P1613, DOI 10.1039/p19830001613; David O., 2008, BIOCONJUGATE CHEM, V19, P1855; Espino C.G., 2001, ANGEW CHEM, V113, P618, DOI 10.1002/1521-3757(20010202)113:3<618::AID-ANGE618>3.0.CO;2-F; FUJITA T, 1994, J ANTIBIOT, V47, P208; Jones M. C., 2008, ORG LETT, V10, P4125; Oishi T, 2001, CHEM COMMUN, P1932, DOI 10.1039/b104864n; Roizen J. L., 2013, ANGEW CHEM, V125, P11553; Sano S., 1995, TETRAHEDRON LETT, V36, P2097; Torrente S., 2001, ORG LETT, V3, P1985; Uchida K, 1999, SYNTHESIS-STUTTGART, P1678; Wehn P. M., 2009, ANGEW CHEM, V121, P3860; Williams Fiori K., 2004, ANGEW CHEM, V116, P4449; Yakura T, 2006, SYNLETT, P930, DOI 10.1055/s-2006-933145; Yoshikawa M., 1994, CHEM PHARM BULL, V42, P994	62	0	0	WILEY-V C H VERLAG GMBH	WEINHEIM	POSTFACH 101161, 69451 WEINHEIM, GERMANY	2193-5807	2193-5815		ASIAN J ORG CHEM	Asian J. Org. Chem.	NOV	2015	4	11					1246	1249		10.1002/ajoc.201500318		4	Chemistry, Organic	Chemistry	CU9RE	WOS:000363881600003		
J	Nakagawa, T; Katsuno, T; Noguchi, Y; Mandai, Y; Yoshihama, S; Saito, K; Maruoka, D; Matsumura, T; Arai, M; Yokosuka, O				Nakagawa, Tomoo; Katsuno, Tatsuro; Noguchi, Yoshiko; Mandai, Yasushi; Yoshihama, Sayuri; Saito, Keiko; Maruoka, Daisuke; Matsumura, Tomoaki; Arai, Makoto; Yokosuka, Osamu			Irsogladine Maleate Prevents Colitis in Interleukin-10 Gene-Deficient Mice by Reducing Interleukin-12 and-23 Production	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Article						irsogladine; interleukin (IL)-10 gene-deficient mouse; T-helper (Th)1; Th17; IL-12p40; interferon (IFN)-gamma	INFLAMMATORY-BOWEL-DISEASE; PROINFLAMMATORY CYTOKINE; CROHNS-DISEASE; PATHOGENESIS; EXPRESSION; BACTERIA; ENTEROCOLITIS; MACROPHAGES; ACTIVATION; RESPONSES	Irsogladine maleate (2,4-diamino-6[2,5-dichlorophenyl]-s-triazine maleate; IM), an anti-peptic ulcer drug, may have a protective effect on the gastrointestinal mucosa. This study investigated the effects of IM on spontaneous colitis in interleukin-10 gene-deficient (IL-10(-/-)) mice. Five-week-old IL-10(-/-) mice were fed a control diet or one containing 100 ppm of IM for 10 weeks. Colonic tissues were evaluated morphologically and histologically. J774A.1 murine monocyte/macrophage cells were incubated with IM after lipopolysaccharide stimulation. mRNA expression was assessed by quantitative polymerase chain reaction (PCR) and protein concentration by enzyme-linked immunosorbent assay (ELISA). Colonic length, weight, and histological scores clearly demonstrated that spontaneous colitis was prevented in IL-10(-/-)' mice fed a diet containing IM compared with those fed control diet. Levels of tumor necrosis factor-alpha (TNF-alpha) (-2.5-fold), IL-1 beta (-5.4), interferon-gamma (IFN-gamma) (-4.5), IL-17 (-113.0), IL-12p35 (-21.0), IL-12p40 (-3.4), and IL-23p19 (-4.2) mRNA expression were significantly decreased in the colonic tissues of IM-treated animals, suggesting that oral treatment with IM suppressed the T-helper (Th)1/Th17 immune response in the colonic mucosa. An in vitro study using monocyte/macrophage cells to clarify the pharmacological action of IM indicated that IL-12p40 and IL-23p19 mRNA expression levels were dose-dependently decreased by IM treatment. ELISA showed that IL-12p40 and IL-23 protein secretion were significantly decreased by IM in a dose-dependent manner. Oral treatment with IM prevented spontaneous colitis in IL-10(-/-) mice by suppressing the colonic mucosal Thl/Th17 immune response through inhibition of IL-12 and -23 production in monocyte/macrophage cells.	[Nakagawa, Tomoo; Katsuno, Tatsuro; Noguchi, Yoshiko; Mandai, Yasushi; Yoshihama, Sayuri; Saito, Keiko; Maruoka, Daisuke; Matsumura, Tomoaki; Arai, Makoto; Yokosuka, Osamu] Chiba Univ, Grad Sch Med, Dept Gastroenterol & Nephrol K1, Chuo Ku, Chiba 2608670, Japan	Nakagawa, T (reprint author), Chiba Univ, Grad Sch Med, Dept Gastroenterol & Nephrol K1, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	tom20852@yahoo.co.jp			Nippon-Shinyaku Co., Ltd. (Kyoto, Japan)	This study was supported in part by a Grant from Nippon-Shinyaku Co., Ltd. (Kyoto, Japan).	NAKASHIMA M, 1984, ARZNEIMITTEL-FORSCH, V34-1, P492; Rath HC, 1996, J CLIN INVEST, V98, P945, DOI 10.1172/JCI118878; Montufar-Solis D, 2008, INT IMMUNOL, V20, P141, DOI 10.1093/intimm/dxm126; Sellon RK, 1998, INFECT IMMUN, V66, P5224; Saito S, 2006, CLIN VACCINE IMMUNOL, V13, P876, DOI 10.1128/CVI.00075-06; Akagi M, 2013, CURR PHARM DESIGN, V19, P106; Strober W, 2011, GASTROENTEROLOGY, V140, P1756, DOI 10.1053/j.gastro.2011.02.016; Geremia A, 2012, EXPERT REV GASTROENT, V6, P223, DOI [10.1586/egh.11.107, 10.1586/EGH.11.107]; Raza A, 2012, EXPERT REV CLIN IMMU, V8, P161, DOI [10.1586/eci.11.96, 10.1586/ECI.11.96]; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251; Liu B, 2011, GASTROENTEROLOGY, V141, P653, DOI 10.1053/j.gastro.2011.04.053; Kamei K, 2008, DIGEST DIS SCI, V53, P2657, DOI 10.1007/s10620-008-0199-9; McGeachy MJ, 2009, NAT IMMUNOL, V10, P314, DOI 10.1038/ni.1698; Popoff I, 2002, J PHARMACOL EXP THER, V303, P1145, DOI 10.1124/jpet.102.039768; Yen D, 2006, J CLIN INVEST, V116, P1310, DOI 10.1172/JCI21404; Andou A, 2009, GASTROENTEROLOGY, V136, P564, DOI 10.1053/j.gastro.2008.09.062; Watanabe N, 2003, DIGEST DIS SCI, V48, P408, DOI 10.1023/A:1021960401290; Di Sabatino A, 2012, INFLAMM BOWEL DIS, V18, P368, DOI 10.1002/ibd.21735; Hansen JJ, 2009, INFLAMM BOWEL DIS, V15, P890, DOI 10.1002/ibd.20850; Kamada N, 2005, J IMMUNOL, V175, P6900; Hiraishi H, 2010, ALIMENT PHARM THER, V31, P824, DOI 10.1111/j.1365-2036.2010.04250.x; Sandborn WJ, 2012, NEW ENGL J MED, V367, P1519, DOI 10.1056/NEJMoa1203572; Lee JW, 2007, GASTROENTEROLOGY, V133, P108, DOI 10.1053/j.gastro.2007.03.113; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Yamaguchi H, 2012, MED MOL MORPHOL, V45, P140, DOI 10.1007/s00795-011-0550-7; Sartor RB, 2008, GASTROENTEROLOGY, V134, P577, DOI 10.1053/j.gastro.2007.11.059; Khor B, 2011, NATURE, V474, P307, DOI 10.1038/nature10209; Murakami K, 2011, SCAND J GASTROENTERO, V46, P287, DOI 10.3109/00365521.2010.531485; Kobayashi T, 2012, J IMMUNOL, V189, P1792, DOI 10.4049/jimmunol.1200042; Kobayashi T, 2008, GUT, V57, P1682, DOI 10.1136/gut.2007.135053; Xavier RJ, 2007, NATURE, V448, P427, DOI 10.1038/nature06005; Berg DJ, 1996, J CLIN INVEST, V98, P1010, DOI 10.1172/JCI118861; Murphy Stephen F, 2012, Curr Gastroenterol Rep, V14, P146, DOI 10.1007/s11894-012-0250-z; Rennick DM, 2000, AM J PHYSIOL-GASTR L, V278, pG829	34	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	NOV	2015	38	11					1681	1688				8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CV0AA	WOS:000363907600001		
J	Umetsu, R; Abe, J; Ueda, N; Kato, Y; Matsui, T; Nakayama, Y; Kinosada, Y; Nakamura, M				Umetsu, Ryogo; Abe, Junko; Ueda, Natsumi; Kato, Yamato; Matsui, Toshinobu; Nakayama, Yoko; Kinosada, Yasutomi; Nakamura, Mitsuhiro			Association between Selective Serotonin Reuptake Inhibitor Therapy and Suicidality: Analysis of US Food and Drug Administration Adverse Event Reporting System Data	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Article						selective serotonin reuptake inhibitor (SSRI); suicidality; adverse event; reporting odds ratio (ROR)	SELF-HARM; RISK; ANTIDEPRESSANTS; DISPROPORTIONALITY; PHARMACOVIGILANCE; PRESCRIPTION; DEPRESSION; DISCOVERY; BENEFITS; TRIALS	Selective serotonin reuptake inhibitors (SSRIs) are prescribed for the treatment of depression worldwide. SSRIs are suspected to increase the risk of suicidal ideation and behavior (suicidality) in children, adolescents, and young adults. We examined the association between SSRI therapy and suicidality by applying a logistic regression model to age-stratified data from the Food and Drug Administration (FDA) Adverse Event Reporting System database. We attempted to mitigate the effect of patient-related factors by data subsetting. We selected case reports for SSRIs as referred to in the World Health Organization Anatomical Therapeutic Chemical classification code NO6AB. The association between SSRIs and "suicidal events" or "self-harm events" was calculated as a reporting odds ratio (ROR) and adjusted for covariates by logistic regression. For subjects <18 years old (y.o.) the adjusted RORs (95% confidence interval) of SSRI therapy with suicidal events were 9.58 (8.97-10.23) in the whole data analysis and 4.64 (4.15-5.19) in the subset analysis; those with self-harm events were 31.40 (27.71-35.58) and 16.31 (13.12-20.29), respectively. Although the adjusted RORs were lower in the subset analyses than in the whole data analyses, both analyses indicated associations between SSRI treatment and suicidal and self-harm events. In both analyses these associations were stronger in the <18 y.o. group than other age groups. Children and adolescents should be closely monitored for the occurrence of suicidality when they are prescribed SSRIs. In addition, we found that data subsetting might mitigate the effect of an intrinsic risk among patients taking the suspected drug.	[Umetsu, Ryogo; Abe, Junko; Ueda, Natsumi; Kato, Yamato; Matsui, Toshinobu; Nakayama, Yoko; Nakamura, Mitsuhiro] Gifu Pharmaceut Univ, Lab Drug Informat, Gifu 5011196, Japan; [Abe, Junko] Med Database Co Ltd, Shibuya Ku, Tokyo 1500011, Japan; [Kinosada, Yasutomi] Gifu Univ, United Grad Sch Drug Discovery & Med Informat Sci, Gifu 5011194, Japan	Nakamura, M (reprint author), Gifu Pharmaceut Univ, Lab Drug Informat, 1-25-4 Daigaku Nishi, Gifu 5011196, Japan.	mnakamura@gifu-pu.ac.jp			JSPS KAKENHI [24390126]	This research was partially supported by JSPS KAKENHI Great Number, 24390126.	Hammad TA, 2006, ARCH GEN PSYCHIAT, V63, P332, DOI 10.1001/archpsyc.63.3.332; Healy D, 2003, J PSYCHIATR NEUROSCI, V28, P331; Olfson M, 2006, ARCH GEN PSYCHIAT, V63, P865, DOI 10.1001/archpsyc.63.8.865; Mann JJ, 2005, JAMA-J AM MED ASSOC, V294, P2064, DOI 10.1001/jama.294.16.2064; Toprak S, 2011, PSYCHIAT RES, V187, P140, DOI 10.1016/j.psychres.2010.09.009; Wishart DS, 2006, NUCLEIC ACIDS RES, V34, pD668, DOI 10.1093/nar/gkj067; Gibbons RD, 2012, ARCH GEN PSYCHIAT, V69, P572, DOI 10.1001/archgenpsychiatry.2011.2044; van Puijenbroek EP, 2000, EUR J CLIN PHARMACOL, V56, P733, DOI 10.1007/s002280000215; Harpaz R, 2012, CLIN PHARMACOL THER, V91, P1010, DOI 10.1038/clpt.2012.50; Suzuki Y, 2015, BIOL PHARM BULL, V38, P680, DOI 10.1248/bpb.b14-00191; Didham RC, 2005, BRIT J CLIN PHARMACO, V60, P519, DOI 10.1111/j.1365-2125.2005.02480.x; March J, 2004, JAMA-J AM MED ASSOC, V292, P807; Almenoff JS, 2007, CLIN PHARMACOL THER, V82, P157, DOI 10.1038/sj.clpt.2007.6100258; Hazell L, 2006, DRUG SAFETY, V29, P385, DOI 10.2165/00002018-200629050-00003; Pacher P, 1999, CURR MED CHEM, V6, P469; Barbui C, 2009, CAN MED ASSOC J, V180, P291, DOI 10.1503/cmaj.081514; Raschi E, 2013, ACTA DIABETOL, V50, P569, DOI 10.1007/s00592-011-0340-7; Wishart DS, 2008, NUCLEIC ACIDS RES, V36, pD901, DOI 10.1093/nar/gkm958; Baldessarini RJ, 2006, ARCH GEN PSYCHIAT, V63, P246, DOI 10.1001/archpsyc.63.3.246; Knox C, 2011, NUCLEIC ACIDS RES, V39, pD1035, DOI 10.1093/nar/gkq1126; Sakaeda T, 2013, INT J MED SCI, V10, P796, DOI 10.7150/ijms.6048; Gregoire F, 2008, BRIT J CLIN PHARMACO, V66, P142, DOI 10.1111/j.1365-2125.2008.03176.x; Gibbons RD, 2006, AM J PSYCHIAT, V163, P1898, DOI 10.1176/appi.ajp.163.11.1898; Montastruc JL, 2011, BRIT J CLIN PHARMACO, V72, P905, DOI 10.1111/j.1365-2125.2011.04037.x; Martinez C, 2005, BRIT MED J, V330, P389, DOI 10.1136/bmj.330.7488.389; van Puijenbroek EP, 2002, PHARMACOEPIDEM DR S, V11, P3, DOI 10.1002/pds.668; Egberts ACG, 2002, DRUG SAFETY, V25, P453, DOI 10.2165/00002018-200225060-00010; Arroll B, 2009, COCHRANE DB SYST REV, V3; Coupland C, 2015, BMJ-BRIT MED J, V350, DOI [10.1136/bmj.h517, 10.1136/BMJ.h517]; FDA, QUEST ANSW ANT US CH; FDA, REV PROD LAB; Fergusson D, 2005, BRIT MED J, V330, P396, DOI 10.1136/bmj.330.7488.396; Law V, 2014, NUCLEIC ACIDS RES, V42, pD1091, DOI 10.1093/nar/gkt1068; Lockhart Pauline, 2011, Br J Gen Pract, V61, pe565, DOI 10.3399/bjgp11X593848; Poluzzi E, 2012, DATA MINING TECHNIQU, P255; Qian YF, 2010, BRIT J CLIN PHARMACO, V69, P67, DOI 10.1111/j.1365-2125.2009.03557.x; van Puijenbroek EP, 1999, BRIT J CLIN PHARMACO, V47, P689, DOI 10.1046/j.1365-2125.1999.00957.x; Wijlaars LPMM, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003247	38	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	NOV	2015	38	11					1689	1699				11	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CV0AA	WOS:000363907600002		
J	Miyashita, N; Tanaka, M; Gotoda, R				Miyashita, Noe; Tanaka, Makoto; Gotoda, Ryusuke			New Approach for Setting a Management Criterion in Microbiological Monitoring Using Rapid Microbiological Methods	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Article						rapid microbiological method; bacterial monitoring; management criterion value; probability distribution model		The application of rapid microbiological methods (RMM) to bacterial monitoring in pharmaceutical manufacturing processes is now a key topic, since timely microbiological data are critical for product release, continuous process improvement and quality control. An automated, highly sensitive detection system has been developed which can measure the amount of ATP in a sample in 2h with one hundredfold more sensitive than the conventional ATP method. One of the major subjects for adoption and implementation of RMM is how to set the criterion value for practical microbial control. This value was conventionally been set by experimental rule and indicated as the number of colonies counted after incubation in a particular medium. We have adopted a new approach to set a criterion value which enables assessment in whether the status of the object is normal or not. By setting this criterion value, it is possible to conduct the microbiological control with the intended probability of false-positive and false-negative. In this approach the probability distribution model of the measurement value of each object in a normal status has been established by performing repetitive measurement of each object. We have suggested and verified the probability distribution form of the ATP measurement value using measurement data of the standard bacterial solution of Staphylococcus aureus. The theoretical value of the model was in good agreement with the actual measured value. The results suggest it is possible to set an applicable management criterion value using this model and to conduct new microbiological monitoring using RMM.	[Miyashita, Noe; Tanaka, Makoto; Gotoda, Ryusuke] Infrastruct Syst Co, Hitachi Ltd, Matsudo Res Ctr, Air Conditioning & Plant Engn Syst Dept, Matsudo, Chiba 2710064, Japan	Miyashita, N (reprint author), Infrastruct Syst Co, Hitachi Ltd, Matsudo Res Ctr, Air Conditioning & Plant Engn Syst Dept, 537 Kami Hongo, Matsudo, Chiba 2710064, Japan.	noe.miyashita.gx@hitachi.com					Alternative methods for control of microbiological quality, 2009, EUROPEAN PHARMACOPOE; Jimenez L, 2001, PDA J PHARM SCI TECH, V55, P278; STANLEY PE, 1989, J BIOLUM CHEMILUM, V4, P375, DOI 10.1002/bio.1170040151; [Anonymous], 2008, EU GUIDELINES GOOD M; [Anonymous], 2012, JAPANESE PHARMACOPOE; [Anonymous], 2014, JAPANESE PHARMACOPOE, V23; Hattori N, 2003, ANAL BIOCHEM, V319, P287, DOI 10.1016/S0003-2697(03)00322-1; KARL DM, 1980, MICROBIOL REV, V44, P739; Evaluation Validation and Implementation of Alternative and Rapid Microbiological Methods. PDA, 2013, 33 PDA; Hitachi Plant Services Ltd. product information, NEXT GEN TYP MECR AI; Kimura R, 2015, 4 MICR S PDA JAP TOK, P39; MCELROY WD, 1947, P NATL ACAD SCI USA, V33, P342, DOI 10.1073/pnas.33.11.342; Microbiological Control and Monitoring of Aseptic Processing Environments, 2013, US PHARMACOPOEIA, V36; Miller MJ, 2012, EUROPEAN PHARMACEUTI, V17, P14; Miller MJ, 2010, EUROPEAN PHARMACEUTI, V15, P27; Miller MJ, 2010, EUROPEAN PHARMACEUTI, V15, P39; Miller MJ, 2010, EUROPEAN PHARMACEUTI, V15, P9; Nyuumon T, 1991, INTRO STAT, P126; Riley BS, 2004, AM PHARM REV, V7, P28; Validation of alternative microbiological methods, 2009, US PHARMACOPOEIA, V32	20	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	NOV	2015	38	11					1714	1721				8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CV0AA	WOS:000363907600005		
J	Jin, ZH; Furukawa, T; Kumata, K; Xie, L; Yui, JJ; Wakizaka, H; Fujibayashi, Y; Zhang, MR; Saga, T				Jin, Zhao-Hui; Furukawa, Takako; Kumata, Katsushi; Xie, Lin; Yui, Joji; Wakizaka, Hidekatsu; Fujibayashi, Yasuhisa; Zhang, Ming-Rong; Saga, Tsuneo			Development of the Fibronectin Mimetic Peptide KSSPHSRN(SG)(5)RGDSP as a Novel Radioprobe for Molecular Imaging of the Cancer Biomarker alpha(5)beta(1) Integrin	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Article						positron emission tomography; alpha(5)beta(1) integrin; fibronectin-mimetic peptide; radioprobe; fluorine-18	ALPHA-5-BETA-1 INTEGRIN; PROGNOSTIC-SIGNIFICANCE; PEGYLATED LIPOSOMES; CELL-ADHESION; AMINO-ACID; IN-VIVO; PR-B; EXPRESSION; DESIGN; ALPHA-V-BETA-3	alpha(5)beta(1) Integrin, a fibronectin receptor, is becoming a pertinent therapeutic target and a promising prognostic biomarker for cancer patients. The aim of this study was to functionalize an alpha(5)beta(1)-specific fibronectinmimetic peptide sequence KSSPHSRN(SG)(5)RGDSP (called PR_b) as a positron emission tomography (PET) probe. PR_b was modified by addition of a beta-alanine residue, conjugated with 2-S-(4-isothiocyanatobenzy1)1,4,7-triazacyclononane-1,4,7-triacetic acid (p-SCN-Bn-NOTA), and radiolabeled with 18F based on the chelation of 18F-aluminum fluoride. A control probe was produced by glycine to alanine substitution in the RGD motif of PR_b. Cell binding and blocking assays, autoradiographic evaluation of tissue binding and blocking, dynamic PET scans, and a biodistribution study were conducted using cell lines and murine tumor models with determined expression levels of oc,fli and other related integrins. F-18-PR_b was produced with a labeling yield of 22.3 1.9% based on F-18-F-, a radiochemical purity of >99%, and a specific activity of 30-70 GBq/mmol; it exhibited alpha(5)beta(1)-binding activity and specificity in vitro, ex vivo, and in vivo, and had a rapid blood clearance and a predominant renal excretion pathway. In vivo alpha(5)beta(1)-positive tumors could be clearly visualized by F-18-PR_b PET imaging. Both imaging and biodistribution studies suggested higher uptake of F-18-PR_b in alpha(5)beta(1)-positive tumors than in alpha(5)beta(1)-negative tumors and higher alpha(5)beta(1)-positive tumor uptake of F-18-PR_b than the control probe. In contrast, there was no significant difference seen in the contralateral muscle uptake. A PET radioprobe, F-18-PR_b, was developed de novo and potentially can be used for noninvasive detection of alpha(5)beta(1) expression in tumors.	[Jin, Zhao-Hui; Furukawa, Takako; Kumata, Katsushi; Xie, Lin; Yui, Joji; Wakizaka, Hidekatsu; Fujibayashi, Yasuhisa; Zhang, Ming-Rong; Saga, Tsuneo] Natl Inst Radiol Sci, Mol Imaging Ctr, Inage Ku, Chiba 2638555, Japan	Jin, ZH (reprint author), Natl Inst Radiol Sci, Mol Imaging Ctr, Inage Ku, 4-9-1 Anagawa, Chiba 2638555, Japan.	zhaohui@nirs.go.jp; zhang@nirs.go.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan [24591827]	This work was supported, in part, by a Grant-in-Aid for Scientific Research (C) 24591827 from the Ministry of Education, Culture, Sports, Science and Technology of Japan. We would like to thank the Molecular Probe Program for supplying the <SUP>18</SUP>F produced for this study; the Cyclotron Operation Section for cyclotron operation; and all other members of Molecular Imaging Center, NIRS, for kindly assisting with the animal experiments.	Feng YZ, 2004, BIOCHEMISTRY-US, V43, P15811, DOI 10.1021/bi049174+; Garg A, 2009, INT J PHARM, V366, P201, DOI 10.1016/j.ijpharm.2008.09.016; Veine DM, 2014, CLIN EXP METASTAS, V31, P379, DOI 10.1007/s10585-013-9634-1; Mardilovich A, 2006, LANGMUIR, V22, P3259, DOI 10.1021/la052756n; Liu SL, 2011, EUR J NUCL MED MOL I, V38, P1732, DOI 10.1007/s00259-011-1847-4; Neubauer S, 2013, ANGEW CHEM INT EDIT, V52, P11656, DOI 10.1002/anie.201306376; Jin ZH, 2014, EUR J PHARM BIOPHARM, V86, P478, DOI 10.1016/j.ejpb.2013.11.006; Craig JA, 2008, LANGMUIR, V24, P10282, DOI 10.1021/la702434p; Wang HY, 2013, ASIAN PAC J CANCER P, V14, P3891, DOI 10.7314/APJCP.2013.14.6.3891; Shroff K, 2012, LANGMUIR, V28, P4729, DOI 10.1021/la204466g; Xie L, 2014, INT J CANCER, V135, P1852, DOI 10.1002/ijc.28842; Qian F, 2005, BIOCHEM BIOPH RES CO, V333, P1269, DOI 10.1016/j.bbrc.2005.03.039; KOIVUNEN E, 1994, J CELL BIOL, V124, P373, DOI 10.1083/jcb.124.3.373; Nam JM, 2010, CANCER RES, V70, P5238, DOI 10.1158/0008-5472.CAN-09-2319; AOTA S, 1994, J BIOL CHEM, V269, P24756; Redick SD, 2000, J CELL BIOL, V149, P521, DOI 10.1083/jcb.149.2.521; Ren J, 2014, CLIN TRANSL ONCOL, V16, P668, DOI 10.1007/s12094-013-1133-y; Demirgoz D, 2008, LANGMUIR, V24, P13518, DOI 10.1021/la801961r; Shroff K, 2012, LANGMUIR, V28, P1858, DOI 10.1021/la203322t; Heckmann D, 2008, CHEMBIOCHEM, V9, P1397, DOI 10.1002/cbic.200800045; Laverman P, 2014, J LABELLED COMPD RAD, V57, P219, DOI 10.1002/jlcr.3161; Haubner R, 2001, J NUCL MED, V42, P326; Garcia AJ, 1998, J BIOL CHEM, V273, P34710, DOI 10.1074/jbc.273.52.34710; Jin ZH, 2010, BIOL PHARM BULL, V33, P370; Mardilovich A, 2004, BIOMACROMOLECULES, V5, P950, DOI 10.1021/bm0344351; McBride WJ, 2009, J NUCL MED, V50, P991, DOI 10.2967/jnumed.108.060418; Mierke CT, 2011, J CELL SCI, V124, P369, DOI 10.1242/jcs.071985; Haubner R, 2014, BIOMED RES INT, DOI 10.1155/2014/871609; Yang B, 2013, NEOPLASMA, V60, P254, DOI 10.4149/neo_2013_034; Pangburn TO, 2012, SOFT MATTER, V8, P4449, DOI 10.1039/c2sm06922a; PFAFF M, 1994, J BIOL CHEM, V269, P20233; Liu ZF, 2014, J NUCL MED, V55, P989, DOI 10.2967/jnumed.113.132969; Martinkova E, 2010, INT J CANCER, V127, P1240, DOI 10.1002/ijc.25187; Campbell ID, 2011, COLD SPRING HARB PER, V3, DOI DOI 10.1101/CSHPERSPECT.A004994; Dingemans AMC, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-152; Guo YY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058290; Jin ZH, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-41; Mateo J, 2014, CANCER CHEMOTH PHARM, V74, P1039, DOI 10.1007/s00280-014-2576-8; Schaffner Florence, 2013, Cancers (Basel), V5, P27, DOI 10.3390/cancers5010027; Takada Y., 2007, BIOL, V8, P215, DOI DOI 10.1186/GB-2007-8-5-215	40	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	NOV	2015	38	11					1722	1731				10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CV0AA	WOS:000363907600006		
J	Miyagi, K; Harada, S; Tokuyama, S				Miyagi, Kei; Harada, Shinichi; Tokuyama, Shogo			Pancreatic Changes in Nerve Growth Factor/TrkA Associated with Insulin Secretion in Cerebral Ischemia	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Article						cerebral ischemia; insulin; pancreas; nerve growth factor; tropomyosin-related kinase A	BETA-CELLS; GLUCOSE-METABOLISM; BLOOD-GLUCOSE; STROKE; NGF; ACTIVATION; APOPTOSIS; P75(NTR); DAMAGE; RATS	Regulation of blood glucose levels as a therapeutic strategy for cerebral ischemia plays an important role in suppressing neuronal damage. In particular, suppression of post-ischemic glucose intolerance improves cerebral ischemia. We have reported that cerebral ischemia induces glucose intolerance and an increase in plasma insulin levels. However, the mechanism of insulin secretion after cerebral ischemia is unclear. Nerve growth factor (NGF), a member of the neurotrophin family, has high affinity for tropomyosin-related kinase A (TrkA). NGF/TrkA signaling is associated with neuronal survival, differentiation, and function. Recently, NGF/TrkA signaling has been reported to be associated with insulin synthesis and secretion. In the present study, we evaluated the insulin content and expression of NGF/TrkA by immunofluorescence and Western blotting after middle cerebral artery occlusion (MCAO) as a cerebral ischemia model. At 6, 12, and 24 h after MCAO, insulin contents were increased in MCAO mice. The expression of NGF was increased at 6, 12, and 24h, whereas the expression of TrkA tended to decrease in pancreas after MCAO. These results suggest that NGF/TrkA signaling is an important factor in cerebral ischemia-induced insulin synthesis and secretion in the pancreas.	[Miyagi, Kei; Harada, Shinichi; Tokuyama, Shogo] Kobe Gakuin Univ, Sch Pharmaceut Sci, Dept Clin Pharm, Chuo Ku, Kobe, Hyogo 6508586, Japan	Tokuyama, S (reprint author), Kobe Gakuin Univ, Sch Pharmaceut Sci, Dept Clin Pharm, Chuo Ku, 1-1-3 Minatojima, Kobe, Hyogo 6508586, Japan.	stoku@pharm.Kobegalcuin.ac.jp			Kobe Gakuin University Joint Research	This study was supported in part by Grants-in-Aid and Special Coordination Funds from Kobe Gakuin University Joint Research (C).	Matz K, 2006, DIABETES CARE, V29, P792, DOI 10.2337/diacare.29.04.06.dc05-1818; Rosenbaum T, 1998, P NATL ACAD SCI USA, V95, P7784, DOI 10.1073/pnas.95.13.7784; Harada S, 2012, J PHARMACOL SCI, V118, P109, DOI 10.1254/jphs.11164FP; Irmady K, 2014, J NEUROSCI, V34, P3419, DOI 10.1523/JNEUROSCI.1982-13.2014; Rosenbaum T, 2001, DIABETES, V50, P1755, DOI 10.2337/diabetes.50.8.1755; Gentile NT, 2006, ACAD EMERG MED, V13, P174, DOI 10.1197/j.aem.2005.08.009; Leibiger B, 2000, J BIOL CHEM, V275, P30153, DOI 10.1074/jbc.M005216200; Harada S, 2009, BRAIN RES, V1279, P174, DOI 10.1016/j.brainres.2009.05.014; Saleh TM, 2005, BRAIN RES, V1066, P187, DOI 10.1016/j.brainres.2005.10.062; Harms H, 2011, CEREBROVASC DIS, V32, P552, DOI 10.1159/000331922; Harada S, 2009, BIOL PHARM BULL, V32, P405, DOI 10.1248/bpb.32.405; Auer RN, 1998, NEUROLOGY, V51, pS39; Rizk NN, 2007, ENDOCRINE, V31, P66, DOI 10.1007/s12020-007-0012-0; Guo K, 2013, MOL CANCER THER, V12, P264, DOI 10.1158/1535-7163.MCT-12-0809; Chaldakov GN, 2009, RIV PSICHIATR, V44, P79; Raile K, 2006, REGUL PEPTIDES, V135, P30, DOI 10.1016/j.regpep.2006.03.004; Navarro-Tableros V, 2004, DIABETES, V53, P2018, DOI 10.2337/diabetes.53.8.2018; Gezginci-Oktayoglu S, 2012, DIABETES-METAB RES, V28, P654, DOI 10.1002/dmrr.2339; Go AS, 2014, CIRCULATION, V129, pE28, DOI 10.1161/01.cir.0000441139.02102.80; Gonzalez-Moreno EI, 2014, TRANSL STROKE RES, V5, P638, DOI 10.1007/s12975-014-0365-7; Harada S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095433; Reichardt LF, 2006, PHILOS T R SOC B, V361, P1545, DOI 10.1098/rstb.2006.1894	22	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	NOV	2015	38	11					1747	1751				5	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CV0AA	WOS:000363907600009		
J	Sakurada, T; Kakiuchi, S; Tajima, S; Horinouchi, Y; Konaka, K; Okada, N; Nishisako, H; Nakamura, T; Teraoka, K; Kawazoe, K; Yanagawa, H; Nishioka, Y; Ishizawa, K				Sakurada, Takumi; Kakiuchi, Soji; Tajima, Soichiro; Horinouchi, Yuya; Konaka, Ken; Okada, Naoto; Nishisako, Hirotaka; Nakamura, Toshimi; Teraoka, Kazuhiko; Kawazoe, Kazuyoshi; Yanagawa, Hiroaki; Nishioka, Yasuhiko; Ishizawa, Keisuke			Pemetrexed-Induced Rash May Be Prevented by Supplementary Corticosteroids	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Article						pemetrexed; rash; dexamethasone; corticosteroid; risk factor	CELL LUNG-CANCER; MULTITARGETED ANTIFOLATE LY231514; MALIGNANT PLEURAL MESOTHELIOMA; PHASE-II; FOLIC-ACID; JAPANESE PATIENTS; BREAST-CANCER; SOLID TUMORS; DISODIUM; CHEMOTHERAPY	Pemetrexed, a chemotherapeutic drug, is highly active in non-small cell lung cancer and malignant pleural mesothelioma. Unfortunately, rashes are more commonly associated with pemetrexed than other chemotherapies, and it is recommended that patients receive corticosteroids (8 mg/d of dexamethasone) for 3 d, including the day of pemetrexed administration (day 1). However, the efficacy of corticosteroids in this context has not been fully verified. In this retrospective study, we evaluated the medical records of 78 patients who received pemetrexed between April 2009 and March 2014, to confirm whether supplementary corticosteroids prevented rash development. The incidence of rash was lower in the 47 patients who received supplementary corticosteroids (after day 1) compared with the incidence among the 31 patients who did not receive supplementary corticosteroids (19.1% vs. 38.7%). The average cutoff dosage of supplementary corticosteroids on day 2 and day 3 was 1.5 mg/d of dexamethasone, as calculated using the receiver operating characteristic curve, and the odds ratio was 0.33 (95% confidence interval: 0.12-0.94). Administration of >= 1.5 mg of corticosteroids on day 2 and day 3 significantly reduced the severity of the rash compared to no supplementary treatment (grades 2/3, 13.3% vs. 33.3%, p<0.05). However, increasing the dose of corticosteroids had no additional effect on rash development. These results suggest that >= 1.5 mg of supplementary dexamethasone on day 2 and day 3 (in addition to day 1) may be necessary for preventing pemetrexed-induced rash, but high doses of dexamethasone (e.g., 8 mg/d) are unnecessary.	[Sakurada, Takumi; Horinouchi, Yuya; Konaka, Ken; Okada, Naoto; Nishisako, Hirotaka; Nakamura, Toshimi; Teraoka, Kazuhiko; Kawazoe, Kazuyoshi; Ishizawa, Keisuke] Tokushima Univ Hosp, Dept Pharm, Tokushima 7708503, Japan; [Kakiuchi, Soji] Univ Tokushima, Grad Sch, Inst Biomed Sci, Dept Med Oncol, Tokushima 7708503, Japan; [Kakiuchi, Soji; Nishioka, Yasuhiko] Univ Tokushima, Grad Sch, Inst Biomed Sci, Dept Resp Med & Rheumatol, Tokushima 7708503, Japan; [Tajima, Soichiro] Kyushu Univ Hosp, Dept Pharm, Higashi Ku, Fukuoka 8128582, Japan; [Kawazoe, Kazuyoshi; Ishizawa, Keisuke] Univ Tokushima, Grad Sch, Inst Biomed Sci, Dept Clin Pharm, Tokushima 7708503, Japan; [Yanagawa, Hiroaki] Tokushima Univ Hosp, Clin Trial Ctr Dev Therapeut, Tokushima 7708503, Japan	Sakurada, T (reprint author), Tokushima Univ Hosp, Dept Pharm, 2-50-1 Kuramoto Cho, Tokushima 7708503, Japan.	sakurada@tokushima-u.ac.jp					Bajetta E, 2003, ANN ONCOL, V14, P1543, DOI 10.1093/annonc/mdg406; Mita AC, 2006, J CLIN ONCOL, V24, P552, DOI 10.1200/JCO.2004.00.9720; Nakagawa K, 2006, BRIT J CANCER, V95, P677, DOI 10.1038/sj.bjc.6603321; Goedhals L, 2006, INT J GYNECOL CANCER, V16, P1172, DOI 10.1111/j.1525-1438.2006.00451.x; Hanauske AR, 2001, ONCOLOGIST, V6, P363, DOI 10.1634/theoncologist.6-4-363; Pivot X, 2001, BRIT J CANCER, V85, P649, DOI 10.1054/bjoc.2001.2010; Bracke A, 2009, CLIN EXP DERMATOL, V34, P337, DOI 10.1111/j.1365-2230.2008.02902.x; Nakagawa K, 2008, JPN J CLIN ONCOL, V38, P339, DOI 10.1093/jjco/hyn024; Miller KD, 2000, ANN ONCOL, V11, P101, DOI 10.1023/A:1008305205159; Tummino C, 2007, REV MAL RESPIR, V24, P635, DOI 10.1019/200720030; Martin M, 2003, ANN ONCOL, V14, P1246, DOI 10.1093/annonc/mdg339; Niyikiza C, 2002, MOL CANCER THER, V1, P545; Vogelzang NJ, 2003, J CLIN ONCOL, V21, P2636, DOI 10.1200/JCO.2003.11.136; Shih C, 1998, ADV ENZYME REGUL, V38, P135; Hanna N, 2004, J CLIN ONCOL, V22, P1589, DOI 10.1200/JCO.2004.08.163; Rinaldi DA, 1999, CANCER CHEMOTH PHARM, V44, P372, DOI 10.1007/s002800050992; Scagliotti GV, 2008, J CLIN ONCOL, V26, P3543, DOI 10.1200/JCO.2007.15.0375; Cripps C, 1999, ANN ONCOL, V10, P1175, DOI 10.1023/A:1008372529239; Bosch-Barrera J, 2009, ONKOLOGIE, V32, P580, DOI 10.1159/000232315; Rusthoven JJ, 1999, J CLIN ONCOL, V17, P1194; TAYLOR EC, 1992, TETRAHEDRON, V48, P8089, DOI 10.1016/S0040-4020(01)80479-8; Miles DW, 2001, EUR J CANCER, V37, P1366, DOI 10.1016/S0959-8049(01)00117-4; Ohe Y, 2008, CLIN CANCER RES, V14, P4206, DOI [10.1158/1078-0432.CCR-07-5143, 10.1168/1078-0432.CCR-07-5143]; John W, 2000, CANCER, V88, P1807, DOI 10.1002/(SICI)1097-0142(20000415)88:8<1807::AID-CNCR8>3.0.CO;2-L; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Hayashi A, 2012, J JPN SOC HOSP PHARM, V48, P4; Ishikawa Hiroshi, 2013, Gan To Kagaku Ryoho, V40, P75; Spielmann M, 2001, Clin Breast Cancer, V2, P47, DOI 10.3816/CBC.2001.n.010	28	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	NOV	2015	38	11					1752	1756				5	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CV0AA	WOS:000363907600010		
J	Yokomizo, A; Takatori, S; Hashikawa-Hobara, N; Goda, M; Kawasaki, H				Yokomizo, Ayako; Takatori, Shingo; Hashikawa-Hobara, Narumi; Goda, Mitsuhiro; Kawasaki, Hiromu			Characterization of Perivascular Nerve Distribution in Rat Mesenteric Small Arteries	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Article						adrenergic nerve; nonadrenergic noncholinergic nerve; nerve distribution; rat mesenteric small artery	SPONTANEOUSLY HYPERTENSIVE-RATS; NEUROPEPTIDE-Y; ADRENERGIC NEUROTRANSMISSION; NOREPINEPHRINE RELEASE; RESISTANCE ARTERIES; INNERVATION; VESSELS; FIBERS; INHIBITION; NEURONS	The distribution pattern of perivascular nerves in some branches of rat mesenteric arteries was studied. Mesenteric arteries isolated from 8-week-old Wistar rats were divided into the 1st-, 2nd-, and 3rd-order branches. The distribution of perivascular nerves in each branch was immunohistochemically evaluated using antibodies against neuropeptide Y (NPY), tyrosine hydroxylase (TH), calcitonin gene-related peptide (CGRP), substance P (SP), and neuronal nitric oxide synthase (nNOS). The density of NPY-, TH-, CGRP-, and SP-like immunoreactive (LI) nerves in the 2nd and 3rd branches was significantly greater than that in the 1st branch, and a negative relationship was found between nerve density and arterial diameter, except for TH-LI nerves. The density of NPY- and TH-LI nerves in all branches, which was similar, was greater than that of CGRP- (except for NPY-LI nerves in the 1st branch), SP-, or nNOS-LI nerves. Double immunostaining revealed that TH-LI nerves made contact with nNOS-LI, CGRP-LI, and SP-LI nerves and that CGRP-LI nerves made contact with TH-, NPY-, or nNOS-LI nerves, while TH-LI and CGRP-LI nerves nearly merged with NPY-LI and SP-LI nerves, respectively. These results suggest that the each branch of mesenteric arteries is densely innervated by vasoconstrictor nerves containing NPY, TH, and vasodilator CGRP nerves. They also suggest that the intense density of perivascular nerves in the 2nd and 3rd branches may contribute to maintaining vascular tone.	[Yokomizo, Ayako; Takatori, Shingo; Goda, Mitsuhiro; Kawasaki, Hiromu] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Clin Pharmaceut Sci, Okayama 7008530, Japan; [Takatori, Shingo; Kawasaki, Hiromu] Matsuyama Univ, Coll Pharmaceut Sci, Dept Clin Pharm, Matsuyama, Ehime 7908578, Japan; [Hashikawa-Hobara, Narumi] Okayama Univ Sci, Dept Life Sci, Okayama 7000005, Japan	Takatori, S (reprint author), Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Clin Pharmaceut Sci, 1-1-1 Tsushima Naka, Okayama 7008530, Japan.	stakator@cc.matsuyama-u.ac.jp					Sequeira IM, 2005, ANN ANAT, V187, P345, DOI 10.1016/j.aanat.2005.05.003; TSUDA K, 1991, AM J HYPERTENS, V4, P327; Birch D, 2008, NEUROGASTROENT MOTIL, V20, P660, DOI 10.1111/j.1365-2982.2008.01082.x; TORRES G, 1992, NEUROSCI LETT, V148, P39, DOI 10.1016/0304-3940(92)90799-D; Jew JY, 1996, J AUTONOM NERV SYST, V58, P35, DOI 10.1016/0165-1838(95)00106-9; KAWASAKI H, 1990, J PHARMACOL EXP THER, V252, P403; Haddock RE, 2011, J PHYSIOL-LONDON, V589, P3289, DOI 10.1113/jphysiol.2011.207944; McDermott BJ, 2007, CURR TOP MED CHEM, V7, P1692, DOI 10.2174/156802607782340939; Lambert E, 2010, HYPERTENSION, V56, P351, DOI 10.1161/HYPERTENSIONAHA.110.155663; Henderson J, 2006, J PLAST RECONSTR AES, V59, P942, DOI 10.1016/j.bjps.2005.11.038; Hobara N, 2006, NEUROSCIENCE, V141, P1087, DOI 10.1016/j.neuroscience.2006.04.001; Grassi G, 2010, OBESITY, V18, P92, DOI 10.1038/oby.2009.195; KAWASAKI H, 1988, NATURE, V335, P164, DOI 10.1038/335164a0; YOSHIDA K, 1993, BRAIN RES, V629, P67, DOI 10.1016/0006-8993(93)90482-3; Hobara N, 2005, HYPERTENS RES, V28, P465, DOI 10.1291/hypres.28.465; Takatori S, 2014, HYPERTENS RES, V37, P398, DOI 10.1038/hr.2013.151; PERNOW J, 1987, REGUL PEPTIDES, V19, P313, DOI 10.1016/0167-0115(87)90173-X; KAWAMURA K, 1989, HYPERTENSION, V14, P660; Zamami Y, 2011, HYPERTENS RES, V34, P1190, DOI 10.1038/hr.2011.97; Hatanaka Y, 2006, J PHARMACOL EXP THER, V316, P490, DOI 10.1124/jpet.105.094656; SCHWARZ P, 1995, CIRC RES, V77, P841	21	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	NOV	2015	38	11					1757	1764				8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CV0AA	WOS:000363907600011		
J	Hayashi, I; Aoki, Y; Asano, D; Ushikubo, H; Mori, A; Sakamoto, K; Nakahara, T; Ishii, K				Hayashi, Ikumi; Aoki, Yuto; Asano, Daiki; Ushikubo, Hiroko; Mori, Asami; Sakamoto, Kenji; Nakahara, Tsutomu; Ishii, Kunio			Protective Effects of Everolimus against N-Methyl-D-aspartic Acid-Induced Retinal Damage in Rats	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Article						excitotoxicity; extracellular signal-regulated kinase (ERK); Muller cell; mammalian target of rapamycin (mTOR); glutamate	CELL-DEATH; CAPILLARY DEGENERATION; REPERFUSION INJURY; MULLER CELLS; IN-VIVO; RAPAMYCIN; ISCHEMIA; EXCITOTOXICITY; INHIBITION; ACTIVATION	We previously demonstrated that rapamycin, an inhibitor of the mammalian target of rapamycin (mTOR), protects against N-methyl-D-aspartic acid (NMDA)-induced retinal neurotoxicity, but the mechanism underlying this protection is not fully understood. The present study aimed to examine the effects of everolimus, another inhibitor of mTOR, on neuronal cell loss and inflammation in a rat model of NMDA-induced retinal neurotoxicity, and to determine whether the extracellular signal-regulated kinase (ERK) pathway contributes to the protective effect of everolimus. Intravitreal injection of NMDA (200 nmol) resulted in (1) cell loss in the ganglion cell layer, (2) increase in the numbers of CD45-positive leukocytes and Iba1-positive microglia, and (3) phosphorylation of ribosomal protein S6 (pS6), a downstream indicator of mTOR activity. Simultaneous injection of everolimus with NMDA significantly attenuated these NMDA-induced responses. The neuroprotective effect of everolimus was almost completely prevented by the mitogen-activated protein kinase/ERK kinase inhibitor U0126 (1 nmol). NMDA increased the level of phosphorylated ERK (pERK) in Muller cells, and increase in pERK levels was also observed after co-injection of NMDA and everolimus. These results suggest that everolimus has a neuroprotective effect against NMDA-induced retinal neurotoxicity, an effect that seems to be mediated partly by activation of the ERK pathway in Muller cells.	[Hayashi, Ikumi; Aoki, Yuto; Asano, Daiki; Ushikubo, Hiroko; Mori, Asami; Sakamoto, Kenji; Nakahara, Tsutomu; Ishii, Kunio] Kitasato Univ, Sch Pharmaceut Sci, Dept Mol Pharmacol, Minato Ku, Tokyo 1088641, Japan	Nakahara, T (reprint author), Kitasato Univ, Sch Pharmaceut Sci, Dept Mol Pharmacol, Minato Ku, 5-9-1 Shirokane, Tokyo 1088641, Japan.	nakaharat@pharm.kitasato-u.ac.jp			JSPS KAKENHI [23590112, 26460103]	This study was supported by JSPS KAKENHI Grant Numbers 23590112 and 26460103 (T.N.).	Al-Gayyar MMH, 2011, BRIT J PHARMACOL, V164, P170, DOI 10.1111/j.1476-5381.2011.01336.x; Raught B, 2001, P NATL ACAD SCI USA, V98, P7037, DOI 10.1073/pnas.121145898; Sakamoto K, 2010, EUR J PHARMACOL, V635, P56, DOI 10.1016/j.ejphar.2010.03.001; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Ichikawa A, 2014, J NEUROSCI RES, V92, P692, DOI 10.1002/jnr.23358; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Casson RJ, 2006, CLIN EXP OPHTHALMOL, V34, P54, DOI 10.1111/j.1442-9071.2006.1146.x; Vorwerk CK, 1997, INVEST OPHTH VIS SCI, V38, P2038; SZABO ME, 1991, INVEST OPHTH VIS SCI, V32, P1471; Ravikumar B, 2010, PHYSIOL REV, V90, P1383, DOI 10.1152/physrev.00030.2009; Carracedo A, 2008, J CLIN INVEST, V118, P3065, DOI [10.1172/JCI34739, 10.1172/jCI34739]; Ueda K, 2013, EUR J PHARMACOL, V699, P188, DOI 10.1016/j.ejphar.2012.11.054; Shimazawa M, 2010, J PHARMACOL EXP THER, V332, P380, DOI 10.1124/jpet.109.156612; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Nakazawa T, 2007, J NEUROCHEM, V100, P1018, DOI 10.1111/j.1471-4159.2006.04274.x; Chiu K, 2005, BRAIN RES, V1046, P207, DOI 10.1016/j.brainres.2005.04.016; Naruoka T, 2013, EUR J PHARMACOL, V718, P138, DOI 10.1016/j.ejphar.2013.08.041; Morizane C, 1997, EUR J PHARMACOL, V328, P45, DOI 10.1016/S0014-2999(97)83026-9; Melemedjian OK, 2013, PAIN, V154, P1080, DOI 10.1016/j.pain.2013.03.021; Hernandez C, 2012, CURR DIABETES REP, V12, P329, DOI 10.1007/s11892-012-0284-5; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Russo R, 2013, CURR OPIN PHARMACOL, V13, P72, DOI 10.1016/j.coph.2012.09.004; Taylor S, 2003, MOL BRAIN RES, V111, P189, DOI 10.1016/S0169-328X(03)00030-5; Rodriguez-Muela N, 2012, CELL DEATH DIFFER, V19, P162, DOI 10.1038/cdd.2011.88; Tsujikawa A, 1999, INVEST OPHTH VIS SCI, V40, P1183; Zhang C, 2005, EXP EYE RES, V81, P700, DOI 10.1016/j.exer.2005.04.008; Walter L, 2009, SEMIN IMMUNOPATHOL, V31, P513, DOI 10.1007/s00281-009-0180-5; Honjo M, 2000, INVEST OPHTH VIS SCI, V41, P552; Tsuda Y, 2012, BIOL PHARM BULL, V35, P2209; Solberg Y, 1997, INVEST OPHTH VIS SCI, V38, P1380; Lam TT, 1997, J OCUL PHARMACOL TH, V13, P129, DOI 10.1089/jop.1997.13.129; Aoki Y, 2015, BIOL PHARM BULL, V38, P321, DOI 10.1248/bpb.b14-00631; Piras A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022514	33	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	NOV	2015	38	11					1765	1771				7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CV0AA	WOS:000363907600012		
J	Saita, T; Yamamoto, Y; Noda, S; Shioya, M; Hira, D; Andoh, A; Morita, S; Terada, T; Shin, M				Saita, Tetsuya; Yamamoto, Yuta; Noda, Satoshi; Shioya, Makoto; Hira, Daiki; Andoh, Akira; Morita, Shin-ya; Terada, Tomohiro; Shin, Masashi			Quantification of Sorafenib in Human Serum by Competitive Enzyme-Linked Immunosorbent Assay	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Article						sorafenib; enzyme-linked immunosorbent assay; sorafenib N-oxide; multikinase inhibitor	HPLC-UV METHOD; HEPATOCELLULAR-CARCINOMA; MULTIKINASE INHIBITOR; CANCER; VARIABILITY; IMMUNOASSAY; PATIENT; PLASMA; MODEL	The multikinase inhibitor sorafenib has been used in the treatment of hepatocellular carcinoma, renal cell carcinoma, and differentiated thyroid carcinoma. Here we have demonstrated the production of the first specific antibody against sorafenib. Anti-sorafenib serum was obtained by immunizing mice with an antigen conjugated with bovine serum albumin and carboxylic modified 4-(4-aminophenoxy)-N-methyl-2-pyridine-carboxamide (AMPC) using the N-succinimidyl ester method. Enzyme labeling of sorafenib with horseradish peroxidase was similarly performed using carboxylic modified AMPC. A simple competitive enzyme-linked immunosorbent assay (ELISA) for sorafenib was developed using the principle of direct competition between sorafenib and the enzyme marker for anti-sorafenib antibody, which had been adsorbed by the plastic surface of a microtiter plate. Serum sorafenib concentrations lower than 0.04 mu g/mL were reproducibly measurable using the ELISA. This ELISA was specific to sorafenib and showed very slight cross-reactivity (2.5%) with a major metabolite, sorafenib N-oxide. The values of serum sorafenib levels from 32 patients measured by this ELISA were comparable with those measured by HPLC, and there was a strong correlation between the values determined by the two methods (Y=1.016X-0.137, r=0.979). The specificity and sensitivity of the ELISA for sorafenib should provide a valuable new tool for use in therapeutic drug monitoring and pharmacokinetic studies of sorafenib.	[Saita, Tetsuya; Yamamoto, Yuta; Shin, Masashi] Sojo Univ, Fac Biotechnol & Life Sci, Appl Life Sci Dept, Kumamoto 8600082, Japan; [Noda, Satoshi; Hira, Daiki; Morita, Shin-ya; Terada, Tomohiro] Shiga Univ, Med Sci Hosp, Dept Pharm, Otsu, Shiga 5202192, Japan; [Shioya, Makoto; Andoh, Akira] Shiga Univ, Med Sci Hosp, Dept Gastroenterol, Otsu, Shiga 5202192, Japan	Saita, T (reprint author), Sojo Univ, Fac Biotechnol & Life Sci, Appl Life Sci Dept, 4-22-1 Ikeda, Kumamoto 8600082, Japan.	sait1102@life.sojo-u.ac.jp					Lathia C, 2006, CANCER CHEMOTH PHARM, V57, P685, DOI 10.1007/s00280-005-0068-6; Noda S, 2013, CANCER CHEMOTH PHARM, V72, P269, DOI 10.1007/s00280-013-2187-9; Wang Z, 2008, CLIN CANCER RES, V14, P5124, DOI 10.1158/1078-0432.CCR-07-4774; Minami H, 2008, CANCER SCI, V99, P1492, DOI 10.1111/j.1349-7006.2008.00837.x; Terada T, 2015, PHARMACOL THERAPEUT, V152, P125, DOI 10.1016/j.pharmthera.2015.05.009; Shimada M, 2014, TOHOKU J EXP MED, V233, P103, DOI 10.1620/tjem.233.103; Gomo C, 2011, INVEST NEW DRUG, V29, P1511, DOI 10.1007/s10637-010-9514-3; Saita T, 2013, BIOL PHARM BULL, V36, P1964; Ogasawara S, 2011, HEPATOL INT, V5, P850, DOI 10.1007/s12072-010-9249-4; Boudou-Rouquette P, 2012, ONCOLOGIST, V17, P1204, DOI 10.1634/theoncologist.2011-0439; FUJIWARA K, 1982, CANCER RES, V42, P1487; Bobin-Dubigeon C, 2011, THER DRUG MONIT, V33, P705, DOI 10.1097/FTD.0b013e3182357891; Wilhelm S, 2006, NAT REV DRUG DISCOV, V5, P835, DOI 10.1038/nrd2130; Keating GM, 2009, DRUGS, V69, P223, DOI 10.2165/00003495-200969020-00006; HOSODA H, 1981, CHEM PHARM BULL, V29, P170; Liu L, 2006, CANCER RES, V66, P11851, DOI 10.1158/0008-5472.CAN-06-1377; Saita T, 2005, BIOL PHARM BULL, V28, P1833, DOI 10.1248/bpb.28.1833; Blanchet B, 2009, J PHARMACEUT BIOMED, V49, P1109, DOI 10.1016/j.jpba.2009.02.008; Boudou-Rouquette P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042875; HABEEB AFS, 1966, ANAL BIOCHEM, V14, P328, DOI 10.1016/0003-2697(66)90275-2; Lee HJ, 2015, LANCET, V385, P228, DOI 10.1016/S0140-6736(15)60055-1; VANWEEMEN BK, 1975, IMMUNOCHEMISTRY, V12, P667, DOI 10.1016/0019-2791(75)90213-X	22	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	NOV	2015	38	11					1788	1793				6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CV0AA	WOS:000363907600015		
J	Nishina, A; Ukiya, M; Fukatsu, M; Koketsu, M; Ninomiya, M; Sato, D; Yamamoto, J; Kobayashi-Hattori, K; Okubo, T; Tokuoka, H; Kimura, H				Nishina, Atsuyoshi; Ukiya, Motohiko; Fukatsu, Makoto; Koketsu, Mamoru; Ninomiya, Masayuki; Sato, Daisuke; Yamamoto, Junpei; Kobayashi-Hattori, Kazuo; Okubo, Takeshi; Tokuoka, Hideyo; Kimura, Hirokazu			Effects of Various 5,7-Dihydroxyflavone Analogs on Adipogenesis in 3T3-L1 Cells	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Article						flavonoid; adipogenesis; lipolysis; lipogenesis; glucose transporter type 4 (GLUT4)	GLUT4-MEDIATED GLUCOSE-UPTAKE; AMPK SIGNALING PATHWAY; DIETARY FLAVONOIDS; INSULIN; ADIPOCYTES; ACTIVATION; INHIBITION; MECHANISM; ACCUMULATION; ADIPONECTIN	We studied the effects of twelve 5,7-dihydroxyflavone analogs on adipogenesis in 3T3-L1 cells. Among the compounds, luteolin, diosmetin, and chrysoeriol partly inhibited adipogenesis by blocking the accumulation of triacylglycerol in the cells. Conversely, tricetin facilitated triacylglycerol accumulation in the cells. The induction of lipogenesis or lipolysis may depend on the number and bonding position of hydroxyl or methoxy groups on the B ring of 5,7-dihydroxyflavone. The mRNA expression levels of adipogenic and lipogenic genes were suppressed by luteolin treatment in the cells, while the mRNA levels of lipolytic genes were not affected. However, the expression levels of the adipogenic, lipogenic, and lipolytic genes, except for adipocyte protein 2 (aP2), were not affected by the addition of tricetin. Moreover, luteolin suppressed glucose transporter type 4 (GLUT4) gene and protein levels. These results indicate that luteolin decreased triacylglycerol levels in 3T3-L1 cells during adipogenesis through the suppression of adipogenic/lipogenic and GLUT4 genes and GLUT4 protein.	[Nishina, Atsuyoshi; Ukiya, Motohiko; Fukatsu, Makoto] Nihon Univ, Coll Sci & Technol, Chiyoda Ku, Tokyo 1010062, Japan; [Koketsu, Mamoru; Ninomiya, Masayuki] Gifu Univ, Fac Engn, Dept Chem & Biomol Sci, Gifu 5011193, Japan; [Sato, Daisuke] Yamagata Univ, Grad Sch Med Sci, Dept Biomed Informat Engn, Yamagata 9909585, Japan; [Yamamoto, Junpei; Kobayashi-Hattori, Kazuo] Tokyo Univ Agr, Fac Appl Biosci, Dept Nutr Sci, Tokyo 1568502, Japan; [Okubo, Takeshi; Tokuoka, Hideyo] Meiji Pharmaceut Univ, Dept Biochem, Tokyo 2040004, Japan; [Kimura, Hirokazu] Natl Inst Infect Dis, Tokyo 2080011, Japan	Nishina, A (reprint author), Nihon Univ, Coll Sci & Technol, Chiyoda Ku, Tokyo 1010062, Japan.	nishina.atsuyoshi@nihon-u.ac.jp					ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; Ninomiya M, 2011, J MED CHEM, V54, P1529, DOI 10.1021/jm1015457; Nomura M, 2008, BIOL PHARM BULL, V31, P1403, DOI 10.1248/bpb.31.1403; SARGEANT RJ, 1993, BIOCHEM J, V290, P913; Hollman PCH, 1997, BIOMED PHARMACOTHER, V51, P305, DOI 10.1016/S0753-3322(97)88045-6; Wu CH, 2010, J AGR FOOD CHEM, V58, P7075, DOI 10.1021/jf101415v; Brusq JM, 2006, J LIPID RES, V47, P1281, DOI 10.1194/jlr.M600020-JLR200; Lagace DC, 2004, J BIOL CHEM, V279, P18851, DOI 10.1074/jbc.M312795200; Nishida M, 2007, MED MOL MORPHOL, V40, P55, DOI 10.1007/s00795-007-0366-7; Bazuine M, 2005, BIOCHEM BIOPH RES CO, V326, P511, DOI 10.1016/j.bbrc.2004.11.055; Fujimori K, 2014, MOL CELL ENDOCRINOL, V384, P12, DOI 10.1016/j.mce.2013.12.014; Mourad AAF, 2013, BIOORG MED CHEM LETT, V23, P4813, DOI 10.1016/j.bmcl.2013.06.101; Fujimori K, 2013, J AGR FOOD CHEM, V61, P5139, DOI 10.1021/jf401154c; Zechner R, 2009, J LIPID RES, V50, P3, DOI 10.1194/jlr.R800031-JLR200; Nishina A, 2006, J LIPID RES, V47, P1434, DOI 10.1194/jlr.M600045-JLR200; OKADA Y, 1995, CHEM PHARM BULL, V43, P1385; Cazarolli LH, 2008, MINI-REV MED CHEM, V8, P1032, DOI 10.2174/138955708785740580; Hosogai N, 2007, DIABETES, V56, P901, DOI 10.2337/db06-0911; Yamaguchi M, 2013, CELL TISSUE RES, V354, P743, DOI 10.1007/s00441-013-1707-6; Hwang JT, 2007, BIOCHEM BIOPH RES CO, V364, P1002, DOI 10.1016/j.bbrc.2007.10.125; PILCH PF, 1981, J BIOL CHEM, V256, P1570; Havel PJ, 2002, CURR OPIN LIPIDOL, V13, P51, DOI 10.1097/00041433-200202000-00008; Koch CE, 2013, BRIT J NUTR, V109, P1040, DOI 10.1017/S0007114512003005; de Groot H, 1998, FUND CLIN PHARMACOL, V12, P249; Kettmann V, 2004, PHARMAZIE, V59, P548; Lan H, 2011, J LIPID RES, V52, P646, DOI 10.1194/jlr.M012757; Wang P, 2007, DIABETOLOGIA, V50, P654, DOI 10.1007/s00125-006-0565-0; Christianson JL, 2010, J LIPID RES, V51, P3455, DOI 10.1194/jlr.M009498; Ouadda ABD, 2009, BIOSCIENCE REP, V29, P283, DOI 10.1042/BSR20080141; Dave S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030831; Formica JV, 1995, FOOD CHEM TOXICOL, V33, P1061, DOI 10.1016/0278-6915(95)00077-1; Harmon AW, 2003, BIOCHEM BIOPH RES CO, V305, P229, DOI 10.1016/S0006-291X(03)00720-4; Middleton E, 1998, ADV EXP MED BIOL, V439, P175; Ninomiya M, 2013, J NAT MED-TOKYO, V67, P460, DOI 10.1007/s11418-012-0697-0; Robak Jadwiga, 1996, Polish Journal of Pharmacology, V48, P555	35	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	NOV	2015	38	11					1794	1800				7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CV0AA	WOS:000363907600016		
J	Matsumoto, T; Watanabe, S; Yamada, K; Ando, M; Iguchi, M; Taguchi, K; Kobayashi, T				Matsumoto, Takayuki; Watanabe, Shun; Yamada, Kosuke; Ando, Makoto; Iguchi, Maika; Taguchi, Kumiko; Kobayashi, Tsuneo			Relaxation Induced by Atrial Natriuretic Peptide Is Impaired in Carotid but Not Renal Arteries from Spontaneously Hypertensive Rats Due to Reduced BKCa Channel Activity	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Article						atrial natriuretic peptide (ANP); carotid artery; potassium channel; relaxation; spontaneously hypertensive rat (SHR)	ACTIVATED POTASSIUM CHANNELS; VASCULAR SMOOTH-MUSCLE; GOTO-KAKIZAKI RATS; NITRIC-OXIDE; ENDOTHELIAL DYSFUNCTION; CARDIOVASCULAR-DISEASES; INDUCED CONTRACTION; PROTEIN-KINASES; MECHANISMS; EXPRESSION	Atrial natriuretic peptide (ANP) plays an important role in vascular functions such as blood pressure regulation and relaxant activity. Individual vascular beds exhibit differences in vascular reactivity to various ligands, however, the difference in responsiveness to ANP between carotid and renal arteries and the molecular mechanisms of its vasorelaxant activity in a pathophysiological state, including hypertension, remain unclear. We therefore investigated this issue by exposing carotid and renal artery rings obtained from spontaneously hypertensive rats (SHR) to ANP. In the SHR artery (vs. control WKY artery), the ANP-induced relaxations were reduced in carotid artery but not renal artery. Acetylcholine-induced relaxations were reduced in both arteries in SHR (vs. WKY). Sodium nitroprusside-induced relaxation was similar in both arteries between the groups. In carotid arteries, the ANP-induced relaxation was not affected by endothelial denudation or by treatment with inhibitors of nitric oxide synthase, cyclooxygenase, the voltage-dependent potassium channel, or ATP-sensitive potassium channel in arteries from both SHR and WKY. In the carotid artery from WKY but not SHR, the ANP-induced relaxation was significantly reduced by inhibition of the large-conductance calcium-activated potassium channel (BKCa). The BKCa activator-induced relaxation was reduced in the SHR artery (vs. WKY). These results suggest that ANP-induced relaxation is impaired in the carotid artery from SHR and this impairment may be at least in part due to the reduction of BICca activity rather than endothelial components.	[Matsumoto, Takayuki; Watanabe, Shun; Yamada, Kosuke; Ando, Makoto; Iguchi, Maika; Taguchi, Kumiko; Kobayashi, Tsuneo] Hoshi Univ, Inst Med Chem, Dept Physiol & Morphol, Shinagawa Ku, Tokyo 1428501, Japan	Kobayashi, T (reprint author), Hoshi Univ, Inst Med Chem, Dept Physiol & Morphol, Shinagawa Ku, Tokyo 1428501, Japan.	tkoba@hoshi.ac.jp			JSPS KAKENHI [26460107, 15K21419, 15K07975]; Science Research Promotion Fund from the Promotion and Mutual Aid Corporation for Private Schools of Japan	We thank R. Arai, C. Uehara, C. Kanazu, N. Sagawa, M. Toba, T. Adachi, M. Oda, K. Matsubara, Y. Noishiki, J. Takagi, Y. Kimoto, H. Higa, and M. Nagata for technical assistance. This study was supported in part by JSPS KAKENHI Grant Numbers 26460107, 15K21419, and 15K07975 and by the Science Research Promotion Fund from the Promotion and Mutual Aid Corporation for Private Schools of Japan.	DeMarco VG, 2014, NAT REV ENDOCRINOL, V10, P364, DOI 10.1038/nrendo.2014.44; Ross B, 2010, AM J PHYSIOL-REG I, V298, pR1156, DOI 10.1152/ajpregu.00706.2009; Volpe M, 2014, INT J CARDIOL, V176, P630, DOI 10.1016/j.ijcard.2014.08.032; Tanaka Y, 2004, J PHARMACOL SCI, V94, P339, DOI 10.1254/jphs.94.339; Kishimoto I, 2011, FEBS J, V278, P1830, DOI 10.1111/j.1742-4658.2011.08116.x; Francis SH, 2010, PHARMACOL REV, V62, P525, DOI 10.1124/pr.110.002907; Khaleghi M, 2009, AM J CARDIOL, V103, P1255, DOI 10.1016/j.amjcard.2009.01.012; Muller MD, 2013, J APPL PHYSIOL, V115, P1219, DOI 10.1152/japplphysiol.00885.2013; Del Ry S, 2013, PHARMACOL RES, V76, P190, DOI 10.1016/j.phrs.2013.08.006; Liang CF, 2010, J PHARMACOL EXP THER, V334, P223, DOI 10.1124/jpet.110.166652; Pontes LB, 2012, FUND CLIN PHARMACOL, V26, P690, DOI 10.1111/j.1472-8206.2011.00999.x; Hu XQ, 2012, DRUG DISCOV TODAY, V17, P974, DOI 10.1016/j.drudis.2012.04.002; De Vito P, 2010, PEPTIDES, V31, P1412, DOI 10.1016/j.peptides.2010.04.001; Woodard GE, 2008, INT REV CEL MOL BIO, V268, P59, DOI 10.1016/S1937-6448(08)00803-4; Tostes RC, 2008, CLIN SCI, V114, P85, DOI 10.1042/CS20070169; Spitler KM, 2013, AM J PHYSIOL-HEART C, V305, pH344, DOI 10.1152/ajpheart.00952.2012; ANANDSRIVASTAVA MB, 1993, PHARMACOL REV, V45, P455; Kohan DE, 2011, PHYSIOL REV, V91, P1, DOI 10.1152/physrev.00060.2009; Schubert R, 2001, TRENDS PHARMACOL SCI, V22, P505, DOI 10.1016/S0165-6147(00)01775-2; Goulopoulou S, 2014, AM J PHYSIOL-HEART C, V306, pH610, DOI 10.1152/ajpheart.00588.2013; Zois NE, 2014, NAT REV CARDIOL, V11, P403, DOI 10.1038/nrcardio.2014.64; Marrachelli VG, 2011, PHARMACOL RES, V63, P190, DOI 10.1016/j.phrs.2010.10.015; Rubattu S, 2008, AM J HYPERTENS, V21, P733, DOI 10.1038/ajh.2008.174; Sergeeva IA, 2013, BBA-MOL BASIS DIS, V1832, P2403, DOI 10.1016/j.bbadis.2013.07.003; Tanaka Y, 2006, J PHARMACOL EXP THER, V317, P341, DOI 10.1124/jpet.105.096115; Nilius B, 2001, PHYSIOL REV, V81, P1415; Nishikimi T, 2006, CARDIOVASC RES, V69, P318, DOI 10.1016/j.cardiores.2005.10.001; Tanaka Y, 1998, N-S ARCH PHARMACOL, V357, P705, DOI 10.1007/PL00005228; Matsumoto T, 2014, PFLUG ARCH EUR J PHY, V466, P331, DOI 10.1007/s00424-013-1330-0; Matsumoto T, 2014, PHARMACOL RES, V87, P123, DOI 10.1016/j.phrs.2014.07.001; Feletou M, 2009, BRIT J PHARMACOL, V156, P545, DOI 10.1111/j.1476-5381.2009.00052.x; Nishikimi T, 2011, J CARDIOL, V57, P131, DOI 10.1016/j.jjcc.2011.01.002; Sellak H, 2013, CARDIOVASC RES, V97, P200, DOI 10.1093/cvr/cvs327; Volpe M, 2014, EUR HEART J, V35, P419, DOI 10.1093/eurheartj/eht466; Kobayashi T, 2012, CLIN SCI, V123, P375, DOI [10.1042/CS20110621, 10.1041/CS20110621]; WEI CM, 1994, HYPERTENSION, V23, P903; Feletou M, 2011, BRIT J PHARMACOL, V164, P894, DOI 10.1111/j.1476-5381.2011.01276.x; Marrachelli VG, 2012, PHARMACOL RES, V66, P392, DOI 10.1016/j.phrs.2012.07.008; Pereira SL, 2014, FUND CLIN PHARMACOL, V28, P29, DOI 10.1111/j.1472-8206.2012.01076.x; MORITOKI H, 1992, EUR J PHARMACOL, V210, P61, DOI 10.1016/0014-2999(92)90652-K; TRIPPODO NC, 1981, CIRC RES, V48, P309; Coffman TM, 2011, NAT MED, V17, P1402, DOI 10.1038/nm.2541; Mukohda M, 2012, J PHARMACOL SCI, V120, P26, DOI 10.1254/jphs.12088FP; Kuhn M, 2003, CIRC RES, V93, P700, DOI 10.1161/01.RES.0000094745.28948.4D; Schiffrin EL, 2005, VASC PHARMACOL, V43, P19, DOI 10.1016/j.vph.2005.03.004; Blacher J, 2014, FUND CLIN PHARMACOL, V28, P1, DOI 10.1111/fcp.12044; Carrillo-Sepulveda MA, 2014, ACTA PHYSIOL, V211, P20, DOI 10.1111/apha.12281; Cockrill BA, 2013, HANDB EXP PHARMACOL, V218, P229, DOI 10.1007/978-3-642-38664-0_10; Feletou M, 2006, AM J PHYSIOL-HEART C, V291, pH985, DOI 10.1152/ajpheart.00292.2006; Ishida K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102310; Liu YP, 1997, HYPERTENSION, V30, P1403; Marangoni RA, 2014, PEPTIDES, V61, P69, DOI 10.1016/j.peptides.2014.08.016; Matsumoto T, 2011, ADV PHARM SCI, V2011; Matsumoto T, 2014, LIFE SCI, V118, P200, DOI 10.1016/j.lfs.2013.11.016; Otsuka Kazuoki, 2002, Journal of Smooth Muscle Research, V38, P117, DOI 10.1540/jsmr.38.117; Stott JB, 2015, HYPERTENSION, V65, P676, DOI 10.1161/HYPERTENSIONAHA.114.04373	56	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	NOV	2015	38	11					1801	1808				8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CV0AA	WOS:000363907600017		
J	Ito, K; Matsuzaki, M; Sasahara, T; Shin, M; Yayama, K				Ito, Kazuya; Matsuzaki, Mai; Sasahara, Tomoya; Shin, Mariko; Yayama, Katsutoshi			Orthovanadate-Induced Vasoconstriction of Rat Mesenteric Arteries Is Mediated by Rho Kinase-Dependent Inhibition of Myosin Light Chain Phosphatase	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Article						myosin light chain phosphatase; orthovanadate; mesenteric artery	VASCULAR SMOOTH-MUSCLE; ACTIVATED PROTEIN-KINASE; VANADATE-INDUCED CONTRACTION; GROWTH-FACTOR RECEPTOR; TYROSINE PHOSPHORYLATION; CA2+ SENSITIVITY; CELL-MIGRATION; GUINEA-PIG; MECHANISM; PROLIFERATION	Orthovanadate (OVA), a protein tyrosine phosphatase inhibitor, induces vasoconstriction in a Rho kinase-dependent manner. The aim of this study was to determine the mechanism underlying OVA-induced vasoconstriction of rat mesenteric arteries. OVA-induced constriction of mesenteric arterial rings treated with N-G-nitro-L-arginine methyl ester (L-NAME, 0.1 mm), a nitric oxide synthase inhibitor, was significantly blocked by the Rho kinase inhibitor Y-27632 (R-(+)-trans-N-(4-pyridyl)-4-(1-aminoethyl)-cyclohexanecarboxamide, 10 mu m), extracellular signal-regulated kinase 1 and 2 (Erk1/2) inhibitor FR180204 (5-(2-phenyl-pyrazolo[1,5-a]pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridazin-3-ylamine, 10 mu m), Erk1/2 kinase (MEK) inhibitor PD98059 (2'-amino-3'-methoxyfiavone, 10 mu m), epidermal growth factor receptor (EGFR) inhibitor AG1478 (4-(3-chloroanilino)-6,7-dimethoxyquinazoline, 10 mu m), and Src inhibitor PP2 (4-amino-3-(4-chloropheny1)-1-(t-buty1)-1H-pyrazolo[3,4-d]pyrimidine, 3 mu m). However, the myosin light chain kinase inhibitor ML-7 (1-(5-iodonaphthalene-1-sulfony1)-homopiperazine, 10 mu m) did not affect OVA-induced constriction. Phosphorylation of myosin phosphatase target subunit 1 (MYPT1, an index of Rho kinase activity) was abrogated by inhibitors of Src, EGFR MEK, Erk1/2, and Rho kinase. OVA-stimulated Erk1/2 phosphorylation was blocked by inhibitors of EGFR, Src, MEK, and Erk1/2 but not affected by an inhibitor of Rho kinase. OVA-induced Src phosphorylation was abrogated by an Src inhibitor but not affected by inhibitors of EGFR, MEK, Erk1/2, and Rho kinase. In addition, the metalloproteinase inhibitor TAPI-0 (N-(R)-[2-(hydroxyaminocarbonyl)methyl]-4-methylpentanoyl-L-naphthylalanyl-L-alanine amide, 10 mu m) and an inhibitor of heparin/epidermal growth factor binding (CRM 197, 10,ug/mL) did not affect OVA-induced contraction of rat mesenteric arterial rings. These results suggest that OVA induces vasoconstriction in rat mesenteric arteries via Src, EGFR, MEK, and Erk1/2 activation, leading to the inactivation of myosin light chain phosphatase through phosphorylation of MYPT1.	[Ito, Kazuya; Matsuzaki, Mai; Sasahara, Tomoya; Shin, Mariko; Yayama, Katsutoshi] Kobe Gakuin Univ, Dept Biopharmaceut Sci, Lab Cardiovasc Pharmacol, Chuo Ku, Kobe, Hyogo 6508586, Japan	Yayama, K (reprint author), Kobe Gakuin Univ, Dept Biopharmaceut Sci, Lab Cardiovasc Pharmacol, Chuo Ku, 1-1-3 Minatojima, Kobe, Hyogo 6508586, Japan.	yayama@pharm.kobegakuin.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan [15K07984]	This study was partially supported by a Grant-in-Aid for Scientific Research (C) (No. 15K07984) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	SATO KI, 1995, BIOCHEM BIOPH RES CO, V215, P1078, DOI 10.1006/bbrc.1995.2574; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; Papapetropoulos A, 2004, MOL PHARMACOL, V65, P407, DOI 10.1124/mol.65.2.407; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Wozniak K, 2004, ARCH TOXICOL, V78, P7, DOI 10.1007/s00204-003-0506-3; FOX AAL, 1983, J CARDIOVASC PHARM, V5, P309, DOI 10.1097/00005344-198303000-00024; Spurrell BE, 2000, AM J PHYSIOL-HEART C, V278, pH373; SABBIONI E, 1991, CARCINOGENESIS, V12, P47, DOI 10.1093/carcin/12.1.47; Murphy TV, 2002, EUR J PHARMACOL, V442, P107, DOI 10.1016/S0014-2999(02)01498-X; Chen QH, 2003, J VASC SURG, V37, P660, DOI 10.1067/mva.2003.95; SANCHEZFERRER CF, 1988, BRIT J PHARMACOL, V93, P53; LANIYONU A, 1994, BRIT J PHARMACOL, V113, P403; Mori M, 2004, J PHARMACOL SCI, V95, P443, DOI 10.1254/jphs.FP0030576; Nelson PR, 1998, J VASC SURG, V27, P117, DOI 10.1016/S0741-5214(98)70298-8; NAYLER RA, 1983, BRIT J PHARMACOL, V80, P163; CHEN YX, 1993, ARCH BIOCHEM BIOPHYS, V305, P9, DOI 10.1006/abbi.1993.1387; Yue P, 2012, ONCOGENE, V31, P2309, DOI 10.1038/onc.2011.409; Sasahara T, 2015, EUR J PHARMACOL, V762, P89, DOI 10.1016/j.ejphar.2015.05.042; Sasahara T, 2013, BIOL PHARM BULL, V36, P1849; SHIMADA T, 1986, BLOOD VESSELS, V23, P113; Alcon S, 2000, BIOCHEM PHARMACOL, V59, P1077, DOI 10.1016/S0006-2952(00)00237-9; Somlyo AP, 2003, PHYSIOL REV, V83, P1325, DOI 10.1152/physrev.00023.2003; Hellermann GR, 2000, ARTERIOSCL THROM VAS, V20, P2045; Masui H, 2000, LIFE SCI, V68, P363, DOI 10.1016/S0024-3205(00)00942-5; Mehdi MZ, 2006, CELL BIOCHEM BIOPHYS, V44, P73, DOI 10.1385/CBB:44:1:073; CANTLEY LC, 1977, J BIOL CHEM, V252, P7421; DISALVO J, 1993, ARCH BIOCHEM BIOPHYS, V304, P386, DOI 10.1006/abbi.1993.1366; Sakurada S, 2003, CIRC RES, V93, P548, DOI 10.1161/01.RES.0000090998.08629.60; Huang C, 2003, NATURE, V424, P219, DOI 10.1038/nature01745; Korbecki J, 2012, ACTA BIOCHIM POL, V59, P195; Chitaley K, 2002, HYPERTENSION, V39, P438, DOI 10.1161/hy02t2.102960; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; Morita A, 2010, CANCER RES, V70, P257, DOI 10.1158/0008-5472.CAN-08-3771; Ohtsu H, 2005, ARTERIOSCL THROM VAS, V25, P1831, DOI 10.1161/01.ATV.0000175749.41799.9b; Nakaike R, 1996, AM J PHYSIOL-HEART C, V271, pH296; Rapp JP, 1981, HYPERTENSION, V3, P1168; Yayama K, 2014, PHARM RES PERSPECT, V2	38	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	NOV	2015	38	11					1809	1816				8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CV0AA	WOS:000363907600018		
J	Yokoyama, Y; Matsumoto, K; Ikawa, K; Watanabe, E; Yamamoto, H; Imoto, Y; Morikawa, N; Takeda, Y				Yokoyama, Yuta; Matsumoto, Kazuaki; Ikawa, Kazuro; Watanabe, Erika; Yamamoto, Hiroyuki; Imoto, Yutaka; Morikawa, Norifumi; Takeda, Yasuo			Pharmacokinetics of Prophylactic Ampicillin Sulbactam and Dosing Optimization in Patients Undergoing Cardiovascular Surgery with Cardiopulmonary Bypass	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Article						ampicillin; sulbactam; cardiovascular surgery; prophylaxis; cardiopulmonary bypass	SURGICAL-SITE INFECTIONS; CARDIAC-SURGERY; ANTIBIOTIC-PROPHYLAXIS; RENAL-FUNCTION; PREVENTION; GUIDELINE; EFFICACY; TISSUES; PLASMA	Antibiotic concentrations must be maintained at an adequate level throughout cardiovascular surgery to prevent surgical site infection. This study aimed to determine the most appropriate timing for intraoperative repeated dosing of ampicillin-sulbactam, a commonly used antibiotic prophylaxis regimen, to maintain adequate concentrations throughout the course of cardiovascular surgery with cardiopulmonary bypass (CPB). The total plasma concentrations of ampicillin were monitored in 8 patients after ampicillin (1 g)-sulbactam (0.5g) administration via initial intravenous infusion and subsequent CPB priming. Pharmacokinetic parameters were estimated and used to predict the free plasma concentrations of ampicillin. The mean values for the volume of distribution, elimination rate constant, elimination half-life, and total clearance of ampicillin were 15.8 +/- 4.1L, 0.505 +/- 0.186 h(-1), 1.52+/-0.47 h, and 7.72 +/- 2.72L/h, respectively. When ampicillin (1 g)-sulbactam (0.5g) was intravenously administered every 3, 4, 6, and 12h after the start of CPB, the predicted free trough plasma concentrations of ampicillin were 15.20, 8.25, 2.74, and 0.13 mu g/mL, respectively. Therefore, an every-6-h regimen was needed to maintain the free ampicillin concentration at more than 2 mu g/mL during cardiovascular surgery with CPB. We suggest that the dose and dosing interval for ampicillin-sulbactam should be adjusted to optimize the efficacy and safety of treatment, according to the minimum inhibitory concentrations for methicillin-sensitive Staphylococcus aureus isolates at each institution. Registration number: UMIN000007356.	[Yokoyama, Yuta; Matsumoto, Kazuaki; Watanabe, Erika; Takeda, Yasuo] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Clin Pharm & Pharmacol, Kagoshima 8908520, Japan; [Yokoyama, Yuta; Ikawa, Kazuro; Morikawa, Norifumi] Hiroshima Univ, Dept Clin Pharmacotherapy, Hiroshima 7348551, Japan; [Yamamoto, Hiroyuki; Imoto, Yutaka] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Thorac Cardiovasc & Hepatobiliary Pancreat S, Kagoshima 8908520, Japan	Takeda, Y (reprint author), Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Clin Pharm & Pharmacol, 8-35-1 Sakuragaoka, Kagoshima 8908520, Japan.	takeda@m.kufm.kagoshima-u.ac.jp					Gardlund B, 2007, APMIS, V115, P989, DOI 10.1111/j.1600-0463.2007.00845.x; Martin C, 1998, ANTIMICROB AGENTS CH, V42, P1093; Mand'ak J, 2007, PERFUSION-UK, V22, P129, DOI 10.1177/0264659107080116; BLUM RA, 1989, ANTIMICROB AGENTS CH, V33, P1470; Kara I, 2013, ANN THORAC CARDIOVAS, V19, P435, DOI 10.5761/atcs.oa.12.02043; Takesue Y, 2012, J INFECT CHEMOTHER, V18, P816, DOI 10.1007/s10156-012-0509-1; KRETER B, 1992, J THORAC CARDIOV SUR, V104, P590; KERNODLE DS, 1993, ANTIMICROB AGENTS CH, V37, P702; BUYLAERT WA, 1989, CLIN PHARMACOKINET, V17, P10, DOI 10.2165/00003088-198917010-00002; Menges T, 1997, J CARDIOTHOR VASC AN, V11, P565, DOI 10.1016/S1053-0770(97)90005-7; Zhu XL, 2001, CLIN THER, V23, P1281, DOI 10.1016/S0149-2918(01)80107-7; Gulluoglu BM, 2013, ANN SURG, V257, P37, DOI 10.1097/SLA.0b013e31826d832d; Yokoyama Y, 2012, J INFECT CHEMOTHER, V18, P878, DOI 10.1007/s10156-012-0431-6; Gardlund B, 2002, EUR J CARDIO-THORAC, V21, P825, DOI 10.1016/S1010-7940(02)00084-2; Engelman R, 2007, ANN THORAC SURG, V83, P1569, DOI 10.1016/j.athoracsur.2006.09.046; Mangram AJ, 1999, INFECT CONT HOSP EP, V20, P250, DOI 10.1086/501620; Ministry of Health. Labour and Welfare (Tokyo Japan), JAPAN NOSOCOMIAL INF; Saadatian-Elahi Mitra, 2008, Int J Surg, V6, P238, DOI 10.1016/j.ijsu.2007.05.001; Shimizu T, 1974, Jpn J Antibiot, V27, P296; YAMAOKA K, 1981, J PHARMACOBIO-DYNAM, V4, P879	20	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	NOV	2015	38	11					1817	1821				5	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CV0AA	WOS:000363907600019		
J	Murai, R; Nogi, T; Tateoka, K; Sato, A				Murai, Ryuichi; Nogi, Taiki; Tateoka, Komei; Sato, Atsushi			Affinity Selection of Peptide Binders with Magnetic Beads via Organic Phase Separation (MOPS)	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Article						biopanning; organic phase separation; magnetic bead; phage display	PHAGE DISPLAY LIBRARIES; BINDING	We describe a new method for affinity selection of peptide binders for soluble protein targets using magnetic beads via organic phase separation (MOPS) from a phage display library. As a model target molecule, a mouse monoclonal antibody against human integrin alpha 9 beta 1 (Y9A2) immobilized onto protein G magnetic beads was incubated with a 15-mer or 20-mer random peptide phage-display library. The suspensions containing the phage-magnetic beads conjugates were then transferred onto the organic phase and centrifuged in order to recover the Y9A2 bound phage immobilized on the protein G magnetic beads in the lower organic phase. After three rounds of biopanning, we were able to isolate specific phage clones that could not be obtained by the conventional approach. Furthermore, this new approach was found to be highly effective for isolating phage-binders for Fc-fusion constructs; indeed, enrichment of specific phage-binders was observed after only the first panning cycle. Thus, MOPS can improve the selection of specific phage-binders for soluble protein targets mainly due to the removal of non-specific binders.	[Murai, Ryuichi; Nogi, Taiki; Tateoka, Komei; Sato, Atsushi] Tokyo Univ Technol, Sch Biosci & Biotechnol, Hachioji, Tokyo 1920982, Japan	Sato, A (reprint author), Tokyo Univ Technol, Sch Biosci & Biotechnol, 1404-1 Katakura, Hachioji, Tokyo 1920982, Japan.	atsato@stf.teu.ac.jp					Kurosawa G, 2008, P NATL ACAD SCI USA, V105, P7287, DOI 10.1073/pnas.0712202105; Sato A, 1996, BIOCHEMISTRY-US, V35, P10441, DOI 10.1021/bi960132y; Wang A, 1996, AM J RESP CELL MOL, V15, P664; Konthur Z, 2010, ANTIBODY ENGINEERING, VOL 1, SECOND EDITION, P267, DOI 10.1007/978-3-642-01144-3_18; Vodnik M, 2011, MOLECULES, V16, P790, DOI 10.3390/molecules16010790; Mine S, 2004, BIOCHEMISTRY-US, V43, P2458, DOI 10.1021/bi0356855; Smith GP, 1997, CHEM REV, V97, P391, DOI 10.1021/cr960065d; McConnell SJ, 1999, BIOTECHNIQUES, V26, P208; Thomas WD, 2010, ANAL BIOCHEM, V407, P237, DOI 10.1016/j.ab.2010.07.037; Sato A, 2003, BIOCHEM J, V371, P603, DOI 10.1042/BJ20020993; Akahori Y, 2009, BIOCHEM BIOPH RES CO, V378, P832, DOI 10.1016/j.bbrc.2008.11.129; Giordano RJ, 2001, NAT MED, V7, P1249, DOI 10.1038/nm1101-1249	12	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	NOV	2015	38	11					1822	1826				5	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CV0AA	WOS:000363907600020		
J	Kobayashi, C; Kurohane, K; Imai, Y				Kobayashi, Chie; Kurohane, Kohta; Imai, Yasuyuki			Lack of Impact of High Dietary Vitamin A on T Helper 2-Dependent Contact Hypersensitivity to Fluorescein Isothiocyanate in Mice	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Article						vitamin A; dietary supplement; overuse; contact hypersensitivity; mouse	MOUSE MODEL; CELLS; SENSITIZATION; SUPPLEMENTS; DECREASES	Overuse of vitamin A as a dietary supplement is a concern in industrialized countries. High-level dietary vitamin A is thought to shift immunity to a T helper 2 (Th2)-dominant one, resulting in the promotion of allergies. We have been studying a fluorescein isothiocyanate (FITC)-induced contact hypersensitivity (CHS) mouse model that involves Th2-type immunity. We fed a diet with a high retinyl palmitate content (250 international units (IU)/g diet) or a control diet (4IU/g diet) to BALB/c mice for three weeks. No augmentation of FITC-induced CHS was found in mice fed the diet with a high vitamin A content, although accumulation of the vitamin was confirmed in the livers of these animals. The results indicated that relatively short-term feeding of the high-level vitamin A diet did not influence the Th2-driven response at a stage with significant retinol accumulation in the liver. The results were in contrast to the high-dose pyridoxine diets that produced a reduced response in FITC-induced CHS.	[Kobayashi, Chie; Kurohane, Kohta; Imai, Yasuyuki] Univ Shizuoka, Sch Pharmaceut Sci, Lab Microbiol & Immunol, Suruga Ku, Shizuoka 4228526, Japan	Imai, Y (reprint author), Univ Shizuoka, Sch Pharmaceut Sci, Lab Microbiol & Immunol, Suruga Ku, 52-1 Yada, Shizuoka 4228526, Japan.	imai@u-shizuoka-ken.ac.jp			Japan Society for the Promotion of Science [23390031, 15K14990]	This work was supported partly by a Grant-in-Aid for Scientific Research (B) (Grant No. 23390031) and Grant-in-Aid for Challenging Exploratory Research (Grant No. 15K14990) of the Japan Society for the Promotion of Science. We thank Mr. NJ Halewood for providing an English editing service as a native English speaker.	Imai Y, 2006, CLIN EXP ALLERGY, V36, P1462, DOI 10.1111/j.1365-2222.2006.02574.x; Schuster GU, 2008, J IMMUNOL, V180, P1834; Shiba T, 2012, TOXICOL APPL PHARM, V264, P370, DOI 10.1016/j.taap.2012.08.012; Iwata M, 2004, IMMUNITY, V21, P527, DOI 10.1016/j.immuni.2004.08.011; Dearman RJ, 2000, IMMUNOLOGY, V101, P442, DOI 10.1046/j.1365-2567.2000.00126.x; Al-Suhaimi EA, 2012, INT J VITAM NUTR RES, V82, P288, DOI 10.1024/0300-9831/a000121; van de Pavert SA, 2014, NATURE, V508, P123, DOI 10.1038/nature13158; Cui DM, 2000, J NUTR, V130, P1132; Stickel F, 2011, LIVER INT, V31, P595, DOI 10.1111/j.1478-3231.2010.02439.x; Takeshita K, 2004, INT IMMUNOL, V16, P685, DOI 10.1093/intimm/dxh073; Kobayashi C, 2012, BIOL PHARM BULL, V35, P532, DOI 10.1248/bpb.35.532; Mayo-Wilson E, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d5094	12	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	NOV	2015	38	11					1827	1830				4	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CV0AA	WOS:000363907600021		
J	Kanazawa, T; Kadota, K; Mitsudo, K				Kanazawa, Takenori; Kadota, Kazushige; Mitsudo, Kazuaki			Successful rescue of stuck rotablator burr entrapment using a Kiwami straight catheter	CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS			English	Article						angiography; coronary; percutaneous coronary intervention; carotid artery disease; intervention	ROTATIONAL ATHERECTOMY; SUCCESSFUL RETRIEVAL	Rotational atherectomy is an indispensable modality for percutaneous coronary intervention of severely calcified lesions. An entrapped rotablator burr is a rare but life-threatening complication because retrieval is difficult. Although emergent surgical removal is a reliable option for this complication, it is invasive. There are various methods to retrieve an entrapped burr by bailout endovascular approaches. We present two cases of successful rescue of stuck rotablator burr entrapment using a Kiwami straight catheter (4 Fr, Heartrail II, Terumo, Tokyo, Japan). (c) 2015 Wiley Periodicals, Inc.	[Kanazawa, Takenori; Kadota, Kazushige; Mitsudo, Kazuaki] Kurashiki Cent Hosp, Dept Cardiovasc Med, Kurashiki, Okayama 7108602, Japan	Kanazawa, T (reprint author), Kurashiki Cent Hosp, Dept Cardiovasc Med, 1-1-1 Miwa, Kurashiki, Okayama 7108602, Japan.	tk13857@kchnet.or.jp					Grise MA, 2002, CATHETER CARDIO INTE, V57, P31, DOI 10.1002/ccd.10263; Nobuyoshi M, 2000, CATHETER CARDIO INTE, V49, P85, DOI 10.1002/(SICI)1522-726X(200001)49:1<85::AID-CCD19>3.0.CO;2-R; Cunnington M, 2012, CATHETER CARDIO INTE, V79, P271, DOI 10.1002/ccd.23032; Sulimov DS, 2013, EUROINTERVENTION, V9, P251, DOI 10.4244/EIJV9I2A41; Kimura M, 2011, CATHETER CARDIO INTE, V78, P558, DOI 10.1002/ccd.22995	5	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1522-1946	1522-726X		CATHETER CARDIO INTE	Catheter. Cardiovasc. Interv.	NOV 1	2015	86	5					942	945		10.1002/ccd.25903		4	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CU3WM	WOS:000363456700029		
J	Ashikaga, T; Yoshikawa, S; Isobe, M				Ashikaga, Takashi; Yoshikawa, Shunji; Isobe, Mitsuaki			The effectiveness of excimer laser coronary atherectomy with contrast medium for underexpanded stent: The findings of optical frequency domain imaging	CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS			English	Article						coronary artery disease; percutaneous coronary intervention; optical frequency domain imaging	ANGIOPLASTY; REMOVAL; ENERGY	Stent underexpansion is a risk factor for in-stent restenosis (ISR) and stent thrombosis. Although excimer laser coronary atherectomy (ELCA) with contrast medium was shown to be effective to improve stent underexpansion in undilatable lesions, precise mechanism of this technique was not well understood. We report a case of ISR with stent underoptimal implantation within a circumferential-calcified atherosclerotic plaque beneath the stent strut that could not be dilated by repeated high-pressure balloon inflations. After rotational atherectomy, the mechanism of the underexpanded lesion could be obtained by optical frequency domain imaging (OFDI). High-pressure balloon could not dilate the underexpanded stent. Since ELCA with saline flush only gave intimal erosions and minor dissections, additional high-pressure balloon was also ineffective. Finally, ELCA with contrast medium could disrupt the calcific lesion beneath the underexpanded stent. The angiographic and OFDI findings confirmed the full stent expansion could be accomplished by further balloon dilatation with an ordinary pressure. ELCA with contrast medium is feasible to improve stent underexpansion by disrupting the calcified plaque behind the stent strut. (c) 2015 Wiley Periodicals, Inc.	[Ashikaga, Takashi; Yoshikawa, Shunji; Isobe, Mitsuaki] Tokyo Med & Dent Univ, Dept Cardiovasc Med, Tokyo, Japan	Ashikaga, T (reprint author), 1-5-45 Yushima,Bunkyo Ku, Tokyo 1138519, Japan.	ashikaga.cvm@tmd.ac.jp					Egred M, 2012, J INVASIVE CARDIOL, V24, pE161; Topaz O, 1996, CARDIOLOGY, V87, P384, DOI 10.1159/000177125; Noble S, 2008, CATHETER CARDIO INTE, V71, P803, DOI 10.1002/ccd.21490; DECKELBAUM LI, 1995, J AM COLL CARDIOL, V26, P1264, DOI 10.1016/0735-1097(95)00330-4; TCHENG JE, 1995, CATHETER CARDIO DIAG, V34, P15, DOI 10.1002/ccd.1810340306; Viceconte N, 2011, INT J CARDIOL, V149, P395, DOI 10.1016/j.ijcard.2011.03.021; Balan Octavia, 2002, J Invasive Cardiol, V14, P697; Herzum M, 2005, HEART, V91, DOI 10.1136/hrt.2004.056648; Lam SCC, 2013, CATHETER CARDIOVASC, V83, pE64; Latib Azeem, 2014, Cardiovasc Revasc Med, V15, P8, DOI 10.1016/j.carrev.2013.10.005; Van sLeeuwen TG, 1993, CIRCULATION, V87, P1258	11	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1522-1946	1522-726X		CATHETER CARDIO INTE	Catheter. Cardiovasc. Interv.	NOV 1	2015	86	5					946	949		10.1002/ccd.25915		4	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CU3WM	WOS:000363456700030		
J	Schluter, M; Bothe, D; Terasaka, K				Schlueter, Michael; Bothe, Dieter; Terasaka, Koichi			Multiscale Multiphase Process Engineering	CHEMICAL ENGINEERING & TECHNOLOGY			English	Editorial Material									[Schlueter, Michael] Hamburg Univ Technol, Hamburg, Germany; [Bothe, Dieter] Tech Univ Darmstadt, Ctr Smart Interfaces, Darmstadt, Germany; [Terasaka, Koichi] Keio Univ, Tokyo 108, Japan	Schluter, M (reprint author), Hamburg Univ Technol, Hamburg, Germany.							0	0	0	WILEY-V C H VERLAG GMBH	WEINHEIM	POSTFACH 101161, 69451 WEINHEIM, GERMANY	0930-7516	1521-4125		CHEM ENG TECHNOL	Chem. Eng. Technol.	NOV	2015	38	11			SI		1918	1918		10.1002/ceat.201590063		1	Engineering, Chemical	Engineering	CU9UO	WOS:000363891500001		
J	Kastens, S; Hosoda, S; Schluter, M; Tomiyama, A				Kastens, Sven; Hosoda, Shogo; Schlueter, Michael; Tomiyama, Akio			Mass Transfer from Single Taylor Bubbles in Minichannels	CHEMICAL ENGINEERING & TECHNOLOGY			English	Article						Carbon dioxide; Channel geometry; Mass transfer; Sherwood number correlation; Taylor bubble	AIR-BUBBLES; GAS-BUBBLES; LIQUIDS; RISE; CAPILLARIES; VELOCITIES; TUBES; WALL	Mass transfer from single CO2 Taylor bubbles in vertical minichannels was measured for various channel hydraulic diameters D-h. The effects of channel geometries on the mass transfer were also investigated by using square ducts and circular pipes. Bubble rising velocities, v(B), in the ducts were much faster than those in the pipes due to large liquid flow areas in the corners of the ducts. The values of mass transfer coefficients in the pipes were almost the same as those in the ducts, in spite of a large difference in v(B). Sherwood numbers, Sh(D), using D-h as a characteristic length, are well-correlated in terms of the Eotvos number. The proposed Sh(D) correlation can well predict a long-term dissolution process of a Taylor bubble.	[Kastens, Sven; Schlueter, Michael] Hamburg Univ Technol, Inst Multiphase Flows, Hamburg, Germany; [Hosoda, Shogo; Tomiyama, Akio] Kobe Univ, Grad Sch Engn, Kobe, Hyogo 6578501, Japan	Tomiyama, A (reprint author), Kobe Univ, Grad Sch Engn, Dept Mech Engn, 1 1 Rokkodai, Kobe, Hyogo 6578501, Japan.	tomiyama@mech.kobe-u.ac.jp			German Research Foundation (DFG), priority program "Transport processes at fluidic interfaces", SPP 1506; Graduate School of Engineering, Kobe-University	This work has been supported by the German Research Foundation (DFG), priority program "Transport processes at fluidic interfaces", SPP 1506, and the Premium Program of Graduate School of Engineering, Kobe-University. The authors gratefully acknowledge the financial supports.	Abe S., 2008, J SCI TECHNOL, V3, P667, DOI 10.1299/jfst.3.667; van Baten JM, 2004, CHEM ENG SCI, V59, P2535, DOI 10.1016/j.ces.2004.03.010; Kurimoto R, 2013, INT J MULTIPHAS FLOW, V49, P8, DOI 10.1016/j.ijmultiphaseflow.2012.08.001; Gibson AH, 1913, PHILOS MAG, V26, P952, DOI 10.1080/14786441308635043; ESTEVES MTS, 1993, CHEM ENG SCI, V48, P3497; Vandu CO, 2005, CHEM ENG SCI, V60, P6430, DOI 10.1016/j.ces.2005.01.037; Alves SS, 2005, CHEM ENG SCI, V60, P1, DOI 10.1016/j.ces.2004.07.053; Hosoda S, 2014, INT J HEAT MASS TRAN, V69, P215, DOI 10.1016/j.ijheatmasstransfer.2013.10.031; TAYLOR GI, 1961, J FLUID MECH, V10, P161, DOI 10.1017/S0022112061000159; Llewellin EW, 2012, P ROY SOC A-MATH PHY, V468, P1041, DOI 10.1098/rspa.2011.0476; WHITE ET, 1962, CHEM ENG SCI, V17, P351, DOI 10.1016/0009-2509(62)80036-0; Krishna R, 1999, INT COMMUN HEAT MASS, V26, P781, DOI 10.1016/S0735-1933(99)00066-4; BROWN RAS, 1965, CAN J CHEM ENG, V43, P217; HIMMELBLAU DM, 1964, CHEM REV, V64, P527, DOI 10.1021/cr60231a002; Boden S, 2014, EXP FLUIDS, V55, DOI 10.1007/s00348-014-1768-7; Clift R., 1978, BUBBLES DROPS PARTIC; FILLA M, 1981, CHEM ENG J BIOCH ENG, V22, P213, DOI 10.1016/0300-9467(81)80016-0; Meyer C, 2014, INT J MULTIPHAS FLOW, V67, P140, DOI 10.1016/j.ijmultiphaseflow.2014.07.004	18	0	0	WILEY-V C H VERLAG GMBH	WEINHEIM	POSTFACH 101161, 69451 WEINHEIM, GERMANY	0930-7516	1521-4125		CHEM ENG TECHNOL	Chem. Eng. Technol.	NOV	2015	38	11			SI		1925	1932		10.1002/ceat.201500065		8	Engineering, Chemical	Engineering	CU9UO	WOS:000363891500003		
J	Ueyama, K				Ueyama, Korekazu			Virtual Force Term Based on the Velocity Distribution Surrounding a Spherical Particle Settling in a Simple Shear Flow	CHEMICAL ENGINEERING & TECHNOLOGY			English	Article						Interaction term; Simple shear flow; Two-fluid model equation; Virtual force term	POROUS MEDIA	Recently, the inside-out property of the interaction term in the two-fluid model equation was revealed, and the mathematical expression for the virtual force term, which compensates the gap between the correct interaction term and the conventional interaction term, was given. In this work, analytical solutions are given for the velocity field surrounding a spherical solid particle settling in a simple shear flow. The convection term in the Navier-Stokes equation was neglected. The virtual force term is calculated on the basis of the analytical solutions. The horizontal and vertical components of the virtual force term are 2.5 times the product of the viscosity, the velocity gradient, and the holdup gradient. These terms should be considered in the two-fluid model equation to simulate the dispersed multiphase flow with spatial distributions of velocity and holdup.	[Ueyama, Korekazu] Osaka Univ, Kawasaki, Kanagawa 2150021, Japan	Ueyama, K (reprint author), Osaka Univ, Asao Ku, 4-26-2 Kamiasao, Kawasaki, Kanagawa 2150021, Japan.	ueyama@cc.kogakuin.ac.jp					ANDERSON TB, 1967, IND ENG CHEM FUND, V6, P527, DOI 10.1021/i160024a007; Ueyama K, 2012, J FLUID MECH, V690, P474, DOI 10.1017/jfm.2011.452; SLATTERY JC, 1967, AICHE J, V13, P1066, DOI 10.1002/aic.690130606; WHITAKER S, 1967, AICHE J, V13, P420, DOI 10.1002/aic.690130308; Ishii M., 2006, THERMOFLUID DYNAMICS; Ishii M., 1975, COLLECTION DIRECTION, V22; Kolev N. I., 2007, MULTIPHASE FLOW DYNA; Ueyama K., 1976, KAGAKU KOGAKU RONBUN, V2, P595	8	0	0	WILEY-V C H VERLAG GMBH	WEINHEIM	POSTFACH 101161, 69451 WEINHEIM, GERMANY	0930-7516	1521-4125		CHEM ENG TECHNOL	Chem. Eng. Technol.	NOV	2015	38	11			SI		1933	1939		10.1002/ceat.201500030		7	Engineering, Chemical	Engineering	CU9UO	WOS:000363891500004		
J	Huang, J; Saito, T				Huang, Jie; Saito, Takayuki			Influence of Bubble-Surface Contamination on Instantaneous Mass Transfer	CHEMICAL ENGINEERING & TECHNOLOGY			English	Article						Bubble-surface contamination; CO2 bubble; Mass transfer; Surfactant; Zigzag motion	LIQUID; DYNAMICS; BEHAVIOR; SHAPE	The relationship between instantaneous mass transfer, bubble motions, and bubble-induced surrounding liquid motions is discussed on the basis of precise measurements in time and space. The influence of bubble-surface contamination on the above is considered quantitatively through comparison with those in a purified system. The bubble's surface motion, centroid motion, volume, and surface area were acquired precisely from moment to moment using two high-speed cameras and an own innovative image processing method. The dissolution process of CO2 was visualized via the laser-induced fluorescence/8-hydroxypyrene-1,3,6-trisulfonic acid (LIF/HPTS) method. Combining these experimental results carefully, the effects of the surfactant on the mass transfer, bubble motions, and vortex mechanism are discussed.	[Huang, Jie] Shizuoka Univ, Grad Sch Engn, Shizuoka, Japan; [Saito, Takayuki] Shizuoka Univ, Res Inst Green Sci & Technol, Hamamatsu, Shizuoka 4328561, Japan	Saito, T (reprint author), Shizuoka Univ, Res Inst Green Sci & Technol, Naka Ku, 351 Johoku, Hamamatsu, Shizuoka 4328561, Japan.	ttsaito@ipc.shizuoka.ac.jp			Japan Society for the Promotion of Science (JSPS)	The present study was promoted and financially supported by Category A of the Grants-in-Aid for Scientific Research, Japan Society for the Promotion of Science (JSPS) which is gratefully acknowledged.	Brucker C, 1999, PHYS FLUIDS, V11, P1781, DOI 10.1063/1.870043; Coppeta J, 1998, EXP FLUIDS, V25, P1, DOI 10.1007/s003480050202; Saito T, 2010, CHEM ENG J, V158, P39, DOI 10.1016/j.cej.2008.07.021; Khinast JG, 2003, CHEM ENG SCI, V58, P3961, DOI 10.1016/S0009-2509(03)00311-7; Yamada M, 2012, FLOW MEAS INSTRUM, V27, P8, DOI 10.1016/j.flowmeasinst.2012.04.004; Terasaka K, 2004, J CHEM ENG JPN, V37, P921, DOI 10.1252/jcej.37.921; Saito T, 2000, ENVIRON SCI TECHNOL, V34, P4140, DOI 10.1021/es990155a; Takemura F, 2000, CHEM ENG SCI, V55, P3907, DOI 10.1016/S0009-2509(00)00022-1; BEARD KV, 1991, J ATMOS SCI, V48, P2245, DOI 10.1175/1520-0469(1991)048<2245:LMOSRD>2.0.CO;2; Saito T, 2015, CHEM ENG J, V265, P164, DOI 10.1016/j.cej.2014.12.039; MOTARJEMI M, 1978, CHEM ENG SCI, V33, P1415, DOI 10.1016/0009-2509(78)85190-2; Lunde K, 1998, APPL SCI RES, V58, P387; Aoki J, 2015, CHEM ENG TECHNOL, V38, P1955, DOI 10.1002/ceat.201500063; Metz B, 2005, IPCC SPECIAL REPORT; Miyamoto Y., 2005, T JAPAN SOC MECH E B, V71, P1307	15	0	0	WILEY-V C H VERLAG GMBH	WEINHEIM	POSTFACH 101161, 69451 WEINHEIM, GERMANY	0930-7516	1521-4125		CHEM ENG TECHNOL	Chem. Eng. Technol.	NOV	2015	38	11			SI		1947	1954		10.1002/ceat.201500056		8	Engineering, Chemical	Engineering	CU9UO	WOS:000363891500006		
J	Aoki, J; Hayashi, K; Hosokawa, S; Tomiyama, A				Aoki, Jiro; Hayashi, Kosuke; Hosokawa, Shigeo; Tomiyama, Akio			Effects of Surfactants on Mass Transfer from Single Carbon Dioxide Bubbles in Vertical Pipes	CHEMICAL ENGINEERING & TECHNOLOGY			English	Article						Mass transfer; Sherwood number; Surfactant; Taylor bubble; Wall effect	GAS; LIQUID; DISSOLUTION; ABSORPTION; DIFFUSION	Mass transfer from single fully contaminated carbon dioxide bubbles rising through vertical pipes was measured to investigate the effects of surfactants. The diameter ratio of the bubble diameter to the pipe diameter was varied to cover various bubble shapes from ellipsoidal to Taylor bubbles. Triton X-100 and 1-octanol served as surfactants. The mass transfer rates, k(L), of contaminated bubbles in the ellipsoidal regime were smaller than those of clean bubbles due to the interface immobilization. The k(L) of Taylor bubbles contaminated with Triton X-100 and 1-octanol showed varying trends because of the difference in the surfactant distributions at the bubble interfaces which strongly depend on the Hatta number. The Sherwood numbers of contaminated bubbles were well correlated by introducing the bubble diameter, at which the bubble shape transits from ellipsoidal to Taylor bubbles.	[Aoki, Jiro; Hayashi, Kosuke; Hosokawa, Shigeo; Tomiyama, Akio] Kobe Univ, Grad Sch Engn, Kobe, Hyogo 6578501, Japan	Tomiyama, A (reprint author), Kobe Univ, Grad Sch Engn, Nada Ku, Kobe, Hyogo 6578501, Japan.	tomiyama@mech.kobe-u.ac.jp			Japan Society for Promotion Science (JSPS) [24360070]	The authors would like to express their thanks to Mr. Shogo Hosoda and Mr. Yohei Hori for their assistance in this work and the financial support by the Japan Society for Promotion Science (JSPS) (grants-in-aid for scientific research (B), No. 24360070).	Hayashi K, 2012, INT J MULTIPHAS FLOW, V39, P78, DOI 10.1016/j.ijmultiphaseflow.2011.11.001; FRUMKIN A, 1947, ZH FIZ KHIM+, V21, P1183; Sardeing R, 2006, CHEM ENG SCI, V61, P6249, DOI 10.1016/j.ces.2006.05.051; Aoki J, 2015, INT J HEAT MASS TRAN, V83, P652, DOI 10.1016/j.ijheatmasstransfer.2014.12.062; Takemura F, 1998, CHEM ENG SCI, V53, P2691, DOI 10.1016/S0009-2509(98)00094-3; CHANG CH, 1994, CHEM ENG SCI, V49, P313, DOI 10.1016/0009-2509(94)87003-9; Hosoda S, 2015, J CHEM ENG JPN, V48, P418, DOI 10.1252/jcej.14we241; LIN SY, 1990, AICHE J, V36, P1785, DOI 10.1002/aic.690361202; JOHNSON AI, 1969, CAN J CHEM ENG, V47, P559; Hosoda S, 2014, INT J HEAT MASS TRAN, V69, P215, DOI 10.1016/j.ijheatmasstransfer.2013.10.031; LOCHIEL AC, 1964, CHEM ENG SCI, V19, P471, DOI 10.1016/0009-2509(64)85074-0; SUSSMAN M, 1994, J COMPUT PHYS, V114, P146, DOI 10.1006/jcph.1994.1155; HIMMELBLAU DM, 1964, CHEM REV, V64, P527, DOI 10.1021/cr60231a002; Beek W. J., 1962, CHEM ENG SCI, V16, P909, DOI 10.1016/0009-2509(62)87023-7; Boussinesq J., 1905, J MATH, V1, P285; Clift R., 1978, BUBBLES DROPS PARTIC; FILLA M, 1981, CHEM ENG J BIOCH ENG, V22, P213, DOI 10.1016/0300-9467(81)80016-0; Frossling N., 1938, Gerlands Beitrage zur Geophysik, V52; Higbie R, 1935, T AM INST CHEM ENG, V31, P365; Hosokawa S., 2005, P 6 WORLD C EXP HEAT; Koide K., 1976, CHEM ENG SCI, V31, P471, DOI 10.1016/0009-2509(76)87048-0; Landau L. D., 1987, FLUID MECH; Levich V. G., 1962, PHYSICOCHEMICAL HYDR; Liberzon D, 2006, PHYS FLUIDS, V18, DOI 10.1063/1.2192781; McClure D.D., 2015, CHEM ENG TECHNOL, V38, P1	25	1	1	WILEY-V C H VERLAG GMBH	WEINHEIM	POSTFACH 101161, 69451 WEINHEIM, GERMANY	0930-7516	1521-4125		CHEM ENG TECHNOL	Chem. Eng. Technol.	NOV	2015	38	11			SI		1955	1964		10.1002/ceat.201500063		10	Engineering, Chemical	Engineering	CU9UO	WOS:000363891500007		
J	Uchiyama, H; Kariyasaki, A; Kagawa, M; Yamasaki, Y; Matsukuma, Y; Morooka, S				Uchiyama, Hiroki; Kariyasaki, Akira; Kagawa, Masazumi; Yamasaki, Yoshikazu; Matsukuma, Yosuke; Morooka, Shigeharu			Bubble Mobilization Pressure in a Small-Diameter Tube	CHEMICAL ENGINEERING & TECHNOLOGY			English	Article						Capillary tube; Fringe method; Liquid film; Two-phase flow	POROUS MEMBRANE; 2-PHASE FLOW; GAS; MICROCHANNELS; PERFORMANCE; MECHANISMS; REMOVAL; DMFC	The mobilization pressure was measured for a train of bubbles in a capillary tube when the liquid film forming between the bubble surface and the inner surface of the duct does (CaseB) and does not cover the bubble surface (CaseA). In CaseA, the measured bubble mobilization pressure mostly agreed with the estimated capillary pressure for different numbers of bubbles in the duct. In CaseB, the bubble mobilization pressure was lower, with a larger scatter than in CaseA. Increasing the number of bubbles caused the mobilization pressure to converge to the CaseB results. Factors that affect the mobilization pressure were considered.	[Uchiyama, Hiroki; Kariyasaki, Akira; Kagawa, Masazumi; Yamasaki, Yoshikazu; Matsukuma, Yosuke; Morooka, Shigeharu] Fukuoka Univ, Dept Chem Engn, Fukuoka 81401, Japan	Uchiyama, H (reprint author), Fukuoka Univ, Dept Chem Engn, 8-19-1 Nanakuma Jonan Ku, Fukuoka 81401, Japan.	kagakuko@fukuoka-u.ac.jp					Venkatesan M, 2010, CAN J CHEM ENG, V88, P936, DOI 10.1002/cjce.20410; Skelley AM, 2008, LAB CHIP, V8, P1733, DOI 10.1039/b807037g; Chen TL, 2012, J HEAT TRANS-T ASME, V134, DOI 10.1115/1.4004715; Kariyasaki A, 2009, HEAT TRANSFER ENG, V30, P28, DOI 10.1080/01457630802290122; Khirani S, 2012, IND ENG CHEM RES, V51, P1997, DOI 10.1021/ie200604g; FUKANO T, 1993, NUCL ENG DES, V141, P59, DOI 10.1016/0029-5493(93)90092-N; PRAKASH A, 1990, CAN J CHEM ENG, V68, P204; Shao N, 2009, CHEM ENG SCI, V64, P2749, DOI 10.1016/j.ces.2009.01.067; Metz T, 2010, MICROFLUID NANOFLUID, V9, P341, DOI 10.1007/s10404-009-0551-1; Blackmore B, 2001, J COLLOID INTERF SCI, V241, P514, DOI 10.1006/jcis.2001.7755; Campolo M, 2011, CHEM ENGINEER TRANS, V24, P913, DOI 10.3303/CET1124153; Wong CW, 2005, J ELECTROCHEM SOC, V152, pA1600, DOI 10.1149/1.1949067; Litterst C, 2006, J MICROMECH MICROENG, V16, pS248, DOI 10.1088/0960-1317/16/9/S12; LENORMAND R, 1983, J FLUID MECH, V135, P337, DOI 10.1017/S0022112083003110; Sobieszuk P, 2012, CHEM ENG TECHNOL, V35, P1346, DOI 10.1002/ceat.201100643; Xu J, 2010, MICROFLUID NANOFLUID, V9, P765, DOI 10.1007/s10404-010-0592-5; de Gennes P. G., 2004, CAPILLARITY WETTING; Fukano T., 1991, P ASME JSME THERM EN, P127; Kenny T. W., 2006, INT J HIGH SPEED ELE, V16, P301, DOI [10.1142/S0129156406003655, DOI 10.1142/S0129156406003655]; Kockman N., 2005, P 6 HXFC, VRP2, P191; Mohammadi M, 2015, J FLUID ENG-T ASME, V137, DOI 10.1115/1.4029033; ROSSEN WR, 1990, J COLLOID INTERF SCI, V136, P1, DOI 10.1016/0021-9797(90)90074-X; KONG VWT, 1991, CAN J CHEM ENG, V69, P259	23	0	0	WILEY-V C H VERLAG GMBH	WEINHEIM	POSTFACH 101161, 69451 WEINHEIM, GERMANY	0930-7516	1521-4125		CHEM ENG TECHNOL	Chem. Eng. Technol.	NOV	2015	38	11			SI		1965	1971		10.1002/ceat.201500012		7	Engineering, Chemical	Engineering	CU9UO	WOS:000363891500008		
J	Murai, H; Suzuki, Y; Kiyosawa, M; Tokumaru, AM; Ishiwata, K; Ishii, K				Murai, Hideki; Suzuki, Yukihisa; Kiyosawa, Motohiro; Tokumaru, Aya M.; Ishiwata, Kiichi; Ishii, Kenji			Cerebral glucose metabolism in the striate cortex positively correlates with fractional anisotropy values of the optic radiation in patients with glaucoma	CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY			English	Article						cerebral glucose metabolism; diffusion-tensor magnetic resonance imaging; glaucoma; optic radiation	POSITRON-EMISSION-TOMOGRAPHY; PRIMARY VISUAL-CORTEX; OPEN-ANGLE GLAUCOMA; RETINOTOPIC ORGANIZATION; FIELD; PATHWAY; ACUITY; MOTION; NERVE	BackgroundIt has recently become clear that glaucoma is not only an ocular disease, but involves central visual pathways as well. The purpose of this study was to examine functional and structural alterations in the brains of glaucoma patients. DesignCase-control study in a hospital. ParticipantsA total of 32 glaucoma patients and 19 healthy controls. MethodsAll participants underwent positron emission tomography with F-18-fluorodeoxyglucose, diffusion-tensor magnetic resonance imaging, and the 30-2 program of the Humphrey Visual Field Analyzer. Main Outcome MeasuresFractional anisotropy values of the optic radiation were compared between the two groups by defining regions of interests. Cerebral glucose metabolism was compared using statistical parametric mapping software. The correlation coefficients were calculated between the average of the total deviation of hemivisual fields of both eyes, fractional anisotropy values of the contralateral optic radiation and glucose metabolism in the contralateral striate cortex. ResultsFractional anisotropy values in the bilateral optic radiations were significantly lower in patients with glaucoma. A significant glucose hypometabolism in the bilateral striate cortex was also observed in the glaucoma group. Regression analyses for glaucoma patients demonstrated that the average of the total deviation of hemivisual fields significantly correlated with both fractional anisotropy value of the contralateral optic radiation and glucose metabolism in the contralateral striate cortex. Moreover, there were significant correlations between fractional anisotropy values of the optic radiation and ipsilateral striatal glucose metabolism. ConclusionWe observed structural alterations in the bilateral optic radiations and glucose hypometabolism in the bilateral striate cortex of glaucoma patients.	[Murai, Hideki; Suzuki, Yukihisa; Kiyosawa, Motohiro] Tokyo Med & Dent Univ, Grad Sch, Dept Ophthalmol & Visual Sci, Tokyo, Japan; [Murai, Hideki; Suzuki, Yukihisa; Ishiwata, Kiichi; Ishii, Kenji] Tokyo Metropolitan Inst Gerontol, Res Team Neuroimaging, Itabashi Ku, Tokyo 1730015, Japan; [Kiyosawa, Motohiro] Kiyosawa Eye Clin, Tokyo, Japan; [Tokumaru, Aya M.] Tokyo Metropolitan Geriatr Hosp, Dept Diagnost Radiol, Tokyo 173, Japan; [Tokumaru, Aya M.] Inst Gerontol, Tokyo, Japan	Ishii, K (reprint author), Tokyo Metropolitan Inst Gerontol, Res Team Neuroimaging, Itabashi Ku, 35-2 Sakaecho, Tokyo 1730015, Japan.	ishii@pet.tmig.or.jp			Japan Society for the Promotion of Science [21791725, 20591038]	This research was supported by Grants-in-Aid for Scientific Research (B) 21791725 (Y.S.) and (C) 20591038 (Ke.I.) from the Japan Society for the Promotion of Science.	Anderson DR, 1999, AUTOMATED STATIC PER, P121; KIYOSAWA M, 1989, AM J OPHTHALMOL, V108, P147; McKeefry DJ, 1997, NEUROIMAGE, V5, P1, DOI 10.1006/nimg.1996.0246; Boucard CC, 2009, BRAIN, V132, P1898, DOI 10.1093/brain/awp119; Yucel Y, 2008, PROG BRAIN RES, V173, P465, DOI 10.1016/S0079-6123(08)01132-1; Endo S, 1997, IEEE T MED IMAGING, V16, P252, DOI 10.1109/42.585759; Gupta N, 2009, BRIT J OPHTHALMOL, V93, P56, DOI 10.1136/bjo.2008.138172; Horton JC, 2006, CAN J OPHTHALMOL, V41, P584; Hernowo AT, 2011, INVEST OPHTH VIS SCI, V52, P2758, DOI 10.1167/iovs.10-5682; Engelhorn T, 2011, ACAD RADIOL, V18, P764, DOI 10.1016/j.acra.2011.01.014; Suzuki Y, 2007, J NEUROL, V254, P890, DOI 10.1007/s00415-006-0468-5; Quigley HA, 1999, PROG RETIN EYE RES, V18, P39, DOI 10.1016/S1350-9462(98)00014-7; Much JW, 2008, OPHTHALMOLOGY, V115, P1162, DOI 10.1016/j.ophtha.2007.09.004; Ito Y, 2009, EXP EYE RES, V89, P246, DOI 10.1016/j.exer.2009.03.013; McKendrick AM, 2005, INVEST OPHTH VIS SCI, V46, P3693, DOI 10.1167/iovs.04-1406; Duncan RO, 2007, PROG RETIN EYE RES, V26, P38, DOI 10.1016/j.preteyeres.2006.10.001; Foster PJ, 2002, BRIT J OPHTHALMOL, V86, P238, DOI 10.1136/bjo.86.2.238; Qing GP, 2010, INVEST OPHTH VIS SCI, V51, P4627, DOI 10.1167/iovs.09-4834; Suzuki Y, 2004, JPN J OPHTHALMOL, V48, P128, DOI 10.1007/s10384-003-0040-0; Suzuki Y, 2011, NEUROIMAGE, V56, P1, DOI 10.1016/j.neuroimage.2011.01.081; Garaci FG, 2009, RADIOLOGY, V252, P496, DOI 10.1148/radiol.2522081240; Murai H, 2013, JPN J OPHTHALMOL, V57, P257, DOI 10.1007/s10384-013-0233-0; Hawkins AS, 2003, J GLAUCOMA, V12, P134, DOI 10.1097/00061198-200304000-00008; Engelhorn T, 2012, THESCIENTIFICWORLDJO, V2012, DOI [10.1100/2012/849632, DOI 10.1100/2012/849632]; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690; FRISTON KJ, 1990, J CEREBR BLOOD F MET, V10, P458; Holladay JT, 1997, J REFRACT SURG, V13, P388; Papaconstantinou Dimitris, 2009, Clin Ophthalmol, V3, P251; ZEKI S, 1991, J NEUROSCI, V11, P641	29	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1442-6404	1442-9071		CLIN EXP OPHTHALMOL	Clin. Exp. Ophthalmol.	NOV	2015	43	8					711	719		10.1111/ceo.12543		9	Ophthalmology	Ophthalmology	CU7OM	WOS:000363731200002		
J	Ohki, T; Sato, K; Yamagami, M; Ito, D; Yamada, T; Kawanishi, K; Kojima, K; Seki, M; Toda, N; Tagawa, K				Ohki, Takamasa; Sato, Koki; Yamagami, Mari; Ito, Daisaku; Yamada, Tomoharu; Kawanishi, Koki; Kojima, Kentaro; Seki, Michiharu; Toda, Nobuo; Tagawa, Kazumi			Efficacy of Transcatheter Arterial Chemoembolization Followed by Sorafenib for Intermediate/Advanced Hepatocellular Carcinoma in Patients in Japan: A Retrospective Analysis	CLINICAL DRUG INVESTIGATION			English	Article							TRANSARTERIAL CHEMOEMBOLIZATION; CONSENSUS RECOMMENDATIONS; INFUSION CHEMOTHERAPY; PLUS SORAFENIB; PHASE-III; TRIAL; EPIDEMIOLOGY; GUIDELINES; TACE; ANGIOGENESIS	Background Sorafenib might prevent hepatocellular carcinoma (HCC) recurrence caused by the promotion of neoangiogenesis after transarterial chemoembolization (TACE). Objectives To evaluate the efficacy and safety of TACE followed by sorafenib for treating advanced HCC. Patients and Methods We retrospectively analyzed 95 advanced HCC patients treated with TACE between July 2008 and December 2012 at our institution. Twenty-four patients received TACE followed by sorafenib within 14 days (S-TACE) and 71 received TACE alone. Progression-free survival (PFS) and cumulative survival from the time of non-responsiveness to TACE were compared between groups and predictive factors for PFS were analyzed. Results The median patient age was 72.2 years and 74 patients were male (77.9 %). Although median tumor size was similar between groups, the mean tumor number was significantly higher in the S-TACE versus TACE-alone group (16 vs. 8, P = 0.04). The number of prior treatments was significantly higher in the S-TACE group. Other baseline variables were similar. There were two severe adverse events in the S-TACE group and none in the TACE-alone group. Median PFS (189 vs. 106 days, P = 0.02) and median overall survival time (861 vs. 467 days, P = 0.01) from the time of non-responsiveness to TACE were significantly longer with S-TACE than TACE alone. Adjusting for significant factors in univariate analysis, multivariate analysis indicated that sorafenib administration, tumor size, and alanine transaminase were independent predictors of PFS. Conclusion TACE followed by sorafenib significantly improved PFS and survival in patients with advanced HCC unresponsive to TACE.	[Ohki, Takamasa; Sato, Koki; Yamagami, Mari; Ito, Daisaku; Yamada, Tomoharu; Kawanishi, Koki; Kojima, Kentaro; Seki, Michiharu; Toda, Nobuo; Tagawa, Kazumi] Mitsui Mem Hosp, Dept Gastroenterol, Chiyoda Ku, Tokyo 1018643, Japan	Ohki, T (reprint author), Mitsui Mem Hosp, Dept Gastroenterol, Chiyoda Ku, Kanda Izumi Cho 1, Tokyo 1018643, Japan.	anb72547@nifty.com					Yuen MF, 2009, J GASTROEN HEPATOL, V24, P346, DOI 10.1111/j.1440-1746.2009.05784.x; Lai CL, 2003, LANCET, V362, P2089, DOI 10.1016/S0140-6736(03)15108-2; Ikeda M, 2014, J GASTROENTEROL, V49, P932, DOI 10.1007/s00535-013-0853-7; Fattovich G, 2004, GASTROENTEROLOGY, V127, pS35, DOI 10.1053/j.gast.2004.09.014; Umemura T, 2007, HEPATOL RES, V37, pS95, DOI 10.1111/j.1872-034X.2007.00169.x; Kudo M, 2011, EUR J CANCER, V47, P2117, DOI 10.1016/j.ejca.2011.05.007; Wilhelm SM, 2008, MOL CANCER THER, V7, P3129, DOI 10.1158/1535-7163.MCT-08-0013; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Bruix J, 2012, J HEPATOL, V57, P821, DOI 10.1016/j.jhep.2012.06.014; El-Serag HB, 2007, HEPATOL RES, V37, pS88, DOI 10.1111/j.1872-034X.2007.00168.x; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Nagaoki Y, 2012, HEPATOL RES, V42, P368, DOI 10.1111/j.1872-034X.2011.00929.x; Kudo M, 2011, DIGEST DIS, V29, P339, DOI 10.1159/000327577; Omata M, 2010, HEPATOL INT, V4, P439, DOI 10.1007/s12072-010-9165-7; Llovet JM, 2002, LANCET, V359, P1734, DOI 10.1016/S0140-6736(02)08649-X; Yang M, 2014, MOL BIOL REP, V41, P6575, DOI 10.1007/s11033-014-3541-7; Nishikawa H, 2013, INT J ONCOL, V43, P1333, DOI 10.3892/ijo.2013.2061; Shim JH, 2008, CANCER SCI, V99, P2037, DOI 10.1111/j.1349-7006.2008.00909.x; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1; Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7; Sergio A, 2008, AM J GASTROENTEROL, V103, P914, DOI 10.1111/j.1572-0241.2007.01712.x; Cheng AL, 2014, LIVER INT, V34, P174, DOI 10.1111/liv.12314; Raoul JL, 2011, CANCER TREAT REV, V37, P212, DOI 10.1016/j.ctrv.2010.07.006; Sansonno D, 2012, ONCOLOGIST, V17, P359, DOI 10.1634/theoncologist.2011-0313; Pawlik TM, 2011, J CLIN ONCOL, V29, P3960, DOI 10.1200/JCO.2011.37.1021; Nishikawa H, 2012, EXP THER MED, V4, P381, DOI 10.3892/etm.2012.611; Umemura T, 2009, J GASTROENTEROL, V44, P102, DOI 10.1007/s00535-008-2251-0; Makuuchi M, 2008, HEPATOL RES, V38, P37, DOI 10.1111/j.1872-034X.2007.00216.x; Ikai I, 2007, HEPATOL RES, V37, P676, DOI 10.1111/j.1872-034X.2007.00119.x; Cabrera R, 2011, ALIMENT PHARM THER, V34, P205, DOI 10.1111/j.1365-2036.2011.04697.x; Bruix J, 2011, HEPATOLOGY, V53, P1020, DOI 10.1002/hep.24199; Nishikawa H, 2014, ANTICANCER RES, V34, P6877; Cheng HY, 2005, WORLD J GASTROENTERO, V11, P3644; Arizumi T, 2014, ONCOLOGY-BASEL, V87, P32, DOI 10.1159/000368143; Chao Y, 2015, INT J CANCER, V136, P1458, DOI 10.1002/ijc.29126; CM Lo, 2002, HEPATOLOGY, V35, P1164, DOI [10.1053/jhep.2002.33156, DOI 10.1053/JHEP.2002.33156]; Erhardt A, 2014, CANCER CHEMOTH PHARM, V74, P947, DOI 10.1007/s00280-014-2568-8; Llovet JM, 2012, J HEPATOL, V56, P908; Firouznia K, 2014, HEPAT MON, V14, DOI 10.5812/hepatmon.25792; Kondo M, 2015, J DIGEST DIS, V16, P143, DOI 10.1111/1751-2980.12221; Kudo M, 2014, ONCOLOGY-BASEL, V87, P22, DOI 10.1159/000368142; Liu L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091124; Mittal S, 2013, J CLIN GASTROENTEROL, V47, pS2, DOI 10.1097/MCG.0b013e3182872f29; Ogasawara S, 2014, ONCOLOGY-BASEL, V87, P330, DOI 10.1159/000365993; Qiu LD, 2001, GANDAN WAIKE ZAZHI, V9, P6; Qu XD, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-263; Raoul Jean-Luc, 2014, Liver Cancer, V3, P119, DOI 10.1159/000343867; Shao WB, 2014, ONCOL LETT, V8, P2263, DOI 10.3892/ol.2014.2512; Tang ZY, 1999, ZHONGHUA GANDAN WAIK, V5, P3; Terashima T, 2014, HEPATOL RES, V44, P1179, DOI 10.1111/hepr.12266	51	0	0	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	1173-2563	1179-1918		CLIN DRUG INVEST	Clin. Drug Invest.	NOV	2015	35	11					751	759		10.1007/s40261-015-0333-3		9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CU7MI	WOS:000363723500008		
J	Kondo, T; Kitano-Amahori, Y; Nagai, H; Mino, M; Takeshita, A; Kusakabe, KT; Okada, T				Kondo, Tomohiro; Kitano-Amahori, Yoko; Nagai, Hiroaki; Mino, Masaki; Takeshita, Ai; Kusakabe, Ken Takeshi; Okada, Toshiya			Effects of maternal subtotal nephrectomy on the development of the fetal kidney: A morphometric study	CONGENITAL ANOMALIES			English	Article						fetal rat kidney; glomerulus; maternal subtotal nephrectomy; morphometry; proximal tubules	EPIDERMAL-GROWTH-FACTOR; LOW-PROTEIN INTAKE; RAT-KIDNEY; REMAINING KIDNEY; IMMATURE RATS; EXPRESSION	The present study was designed to explore if maternal subtotal (5/6) nephrectomy affects the development of fetal rat kidneys using morphometric methods and examining whether there are any apoptotic changes in the fetal kidney. To generate 5/6 nephrectomized model rats, animals underwent 2/3 left nephrectomy on gestation day (GD) 5 and total right nephrectomy on GD 12. The fetal kidneys were examined on GDs 16 and 22. A significant decrease in fetal body weight resulting from maternal 5/6 nephrectomy was observed on GD 16, and a significant decrease in fetal renal weight and fetal body weight caused by maternal nephrectomy was observed on GD 22. Maternal 5/6 nephrectomy induced a significant increase in glomerular number, proximal tubular length, and total proximal tubular volume of fetuses on GD 22. Maternal 5/6 nephrectomy resulted in an increase in the number of apoptotic cells in the metanephric mesenchyme of the kidney on GD 16, and in the collecting tubules on GD 22. These findings suggest that maternal 5/6 nephrectomy stimulates the development of the fetal kidney while suppressing fetal growth.	[Kondo, Tomohiro; Kitano-Amahori, Yoko; Nagai, Hiroaki; Mino, Masaki; Takeshita, Ai; Okada, Toshiya] Osaka Prefecture Univ, Grad Sch Life & Environm Biosci, Div Vet Sci, Dept Integrated Struct Biosci, Izumi, Osaka 5988531, Japan; [Kusakabe, Ken Takeshi] Yamaguchi Univ, Fac Common Vet Med, Dept Vet Anat, Yoshida, Japan	Okada, T (reprint author), Osaka Prefecture Univ, Grad Sch Life & Environm Biosci, Div Vet Sci, Dept Integrated Struct Biosci, 1-58 Rinku Ourai Kita, Izumi, Osaka 5988531, Japan.	okada@vet.osakafu-u.ac.jp					Carev D, 2006, PEDIATR NEPHROL, V21, P627, DOI 10.1007/s00467-006-0057-y; Meyer TN, 2004, DEV BIOL, V275, P44, DOI 10.1016/j.ydbio.2004.07.022; Mino M, 2010, MED MOL MORPHOL, V43, P116, DOI 10.1007/s00795-009-0485-4; Dressler GR, 2006, ANNU REV CELL DEV BI, V22, P509, DOI 10.1146/annurev.cellbio.22.010305.104340; MUGRAUER G, 1988, J CELL BIOL, V107, P1325, DOI 10.1083/jcb.107.4.1325; Okada T, 1998, J MORPHOL, V238, P337, DOI 10.1002/(SICI)1097-4687(199812)238:3<337::AID-JMOR5>3.0.CO;2-D; MATSUO M, 1986, EXP PATHOL-JENA, V30, P203; Mino M, 2007, J VET MED SCI, V69, P247, DOI 10.1292/jvms.69.247; SEYERHANSEN K, 1985, ACTA PATH MICRO IM A, V93, P9; Costantini F, 2006, DIFFERENTIATION, V74, P402, DOI 10.1111/j.1432-0436.2006.00106.x; Lee SH, 2004, AM J NEPHROL, V24, P212, DOI 10.1159/000077275; OKADA T, 1993, ANN ANAT, V175, P89; Benz K, 2010, BBA-MOL BASIS DIS, V1802, P1309, DOI 10.1016/j.bbadis.2010.03.002; OKADA T, 1988, JPN J VET SCI, V50, P985; BAKALA H, 1985, CONNECT TISSUE RES, V13, P283, DOI 10.3109/03008208509152409; Elias H, 1967, QUANTITATIVE METHODS; FETTERMA.GH, 1965, PEDIATRICS, V35, P601; Kim J, 1996, AM J PHYSIOL-RENAL, V270, pF575; Liggins GC, 1972, REPRODUCTION MAMMALS, V2, P77; Okada T, 2012, RENAL FAILURE, P81	20	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0914-3505	1741-4520		CONGENIT ANOM	Congenit. Anom.	NOV	2015	55	4					178	182		10.1111/cga.12116		5	Pediatrics	Pediatrics	CU9US	WOS:000363892000002		
J	Shigeta, N; Kanagawa, T; Mimura, K; Kimura, T				Shigeta, Naoya; Kanagawa, Takeshi; Mimura, Kazuya; Kimura, Tadashi			Severe micrognathia with 21 trisomy assessed prenatally by performing three-dimensional computed tomography	CONGENITAL ANOMALIES			English	Article						prenatal; severe micrognathia; three-dimensional computed tomography	DYSGNATHIA COMPLEX; DIAGNOSIS; FETUS; EXIT; AIRWAY	Severe micrognathia can lead to death shortly after birth without a proper resuscitation. However, it is difficult to develop an effective resuscitation strategy without a prenatal diagnosis of the severity of micrognathia. In the present case, we used fetal three-dimensional computed tomography (3D-CT) to assess the severity of micrognathia. Its images clearly demonstrated bony framework of mandible and suggested that mandibular hypoplasia was too severe to allow for oral intubation. We therefore decided that the ex utero intrapartum treatment (EXIT) procedure would be more appropriate to establish the airway at birth. The prenatal 3D-CT is useful to evaluate the mandibular anatomy in utero if the severity of the micrognathia is not confirmed by the ultrasound or magnetic resonance imaging (MRI).	[Shigeta, Naoya; Kanagawa, Takeshi; Mimura, Kazuya; Kimura, Tadashi] Osaka Univ, Grad Sch Med, Dept Obstet & Gynecol, Suita, Osaka 5650871, Japan	Kanagawa, T (reprint author), Osaka Univ, Grad Sch Med, Dept Obstet & Gynecol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	kanagawa@gyne.med.osaka-u.ac.jp			JSPS [2646248]	This work was supported by JSPS KAKENHI Grant Number 2646248.	Erlich MS, 2000, AM J MED GENET, V95, P269, DOI 10.1002/1096-8628(20001127)95:3<269::AID-AJMG14>3.0.CO;2-P; Morris LM, 2009, FETAL DIAGN THER, V26, P162, DOI 10.1159/000240162; Rajan PV, 2007, PRENATAL DIAG, V27, P130, DOI 10.1002/pd.1626; Victoria T, 2013, AM J ROENTGENOL, V200, P989, DOI 10.2214/AJR.12.9722; Baker PA, 2004, PEDIATR ANESTH, V14, P781, DOI 10.1111/j.1460-9592.2004.01284.x; Gekas J, 2010, EUR J MED GENET, V53, P358, DOI 10.1016/j.ejmg.2010.09.002; Ebina Y, 2001, PRENATAL DIAG, V21, P68, DOI 10.1002/1097-0223(200101)21:1<68::AID-PD994>3.0.CO;2-3; Paladini D, 1999, OBSTET GYNECOL, V93, P382, DOI 10.1016/S0029-7844(98)00414-1; Umekawa T, 2007, PRENATAL DIAG, V27, P679, DOI 10.1002/pd.1754; Pugash D, 2008, EUR J RADIOL, V68, P214, DOI 10.1016/j.ejrad.2008.06.031; Shibata Takashi, 2006, Congenital Anomalies, V46, P10, DOI 10.1111/j.1741-4520.2006.00095.x	11	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0914-3505	1741-4520		CONGENIT ANOM	Congenit. Anom.	NOV	2015	55	4					183	185		10.1111/cga.12110		3	Pediatrics	Pediatrics	CU9US	WOS:000363892000003		
J	Morita, Y; Morishige, N; Yamada, N; Ohta, M; Sonoda, KH; Nishida, T				Morita, Yukiko; Morishige, Naoyuki; Yamada, Naoyuki; Ohta, Manami; Sonoda, Koh-Hei; Nishida, Teruo			Recovery of the Corneal Stroma Associated With Rapid Reepithelialization Induced by the Fibronectin-Derived Peptide PHSRN in 2 Cases of Corneal Perforation Due to a Persistent Epithelial Defect	CORNEA			English	Article						fibronectin; peptide; corneal perforation; persistent epithelial defect	CELL-BINDING SITE; COMPLICATIONS; MIGRATION	Purpose:To report 2 cases of corneal perforation associated with a persistent epithelial defect (PED), which were treated with eye drops containing the fibronectin-derived peptide PHSRN (Pro-His-Ser-Arg-Asn).Methods:A 67-year-old man and a 58-year-old man presented with corneal perforation associated with a PED caused by lagophthalmos. PHSRN eye drops were administered 4 times a day to both patients.Results:Both patients experienced healing of the epithelial defect and closure of corneal perforation within 3 or 4 days after the onset of PHSRN treatment. Anterior segment optical coherence tomography also revealed recovery of corneal stromal thickness at the lesion site.Conclusions:PHSRN eye drops were effective for the treatment of corneal perforation due to the PED, with rapid reepithelialization being followed by full restoration of stromal thickness.	[Morita, Yukiko; Morishige, Naoyuki; Yamada, Naoyuki; Ohta, Manami; Sonoda, Koh-Hei; Nishida, Teruo] Yamaguchi Univ, Dept Ophthalmol, Grad Sch Med, Ube, Yamaguchi 7558505, Japan	Morishige, N (reprint author), Yamaguchi Univ, Dept Ophthalmol, Grad Sch Med, 1-1-1 Minami Kogushi, Ube, Yamaguchi 7558505, Japan.	morishig@yamaguchi-u.ac.jp					Kimura K, 2007, INVEST OPHTH VIS SCI, V48, P1110, DOI 10.1167/iovs.06-0704; Hara M, 2003, CORNEA, V22, P512, DOI 10.1097/00003226-200308000-00005; Yanai R, 2009, INVEST OPHTH VIS SCI, V50, P2757, DOI 10.1167/iovs.08-2341; FOULKS GN, 1979, ARCH OPHTHALMOL-CHIC, V97, P1076; Radhakrishnan S, 2001, ARCH OPHTHALMOL-CHIC, V119, P1179; Yamada N, 2012, CORNEA, V31, P1408, DOI 10.1097/ICO.0b013e31824afd6c; Hattori A, 2009, BIOCHEM BIOPH RES CO, V379, P346, DOI 10.1016/j.bbrc.2008.12.057; LIESEGANG TJ, 1985, OPHTHALMOLOGY, V92, P316; Nishida T, 2009, CURR OPIN OPHTHALMOL, V20, P276, DOI 10.1097/ICU.0b013e32832b758f; Bradley JC, 2011, CORNEA, P1385; Honig MA, 2011, CORNEA, P1571	11	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0277-3740	1536-4798		CORNEA	Cornea	NOV	2015	34	11					1504	1507		10.1097/ICO.0000000000000592		4	Ophthalmology	Ophthalmology	CU6HK	WOS:000363632500030		
J	Jongkhajornpong, P; Nakamura, T; Sotozono, C; Inatomi, T; Kinoshita, S				Jongkhajornpong, Passara; Nakamura, Takahiro; Sotozono, Chie; Inatomi, Tsutomu; Kinoshita, Shigeru			Phenotypic Investigation of Regenerated Epithelial Cells After Gonococcal Corneal Perforation: A Clinical, Histological, and Immunohistochemical Study	CORNEA			English	Article						phenotype; epithelial cell; corneal perforation; gonococcal infection	AMNIOTIC MEMBRANE; EXPRESSION; KERATIN	Purpose:To determine the characteristics of regenerated epithelial cells after severe gonococcal infection after corneal perforation.Methods:Pathological tissue was obtained from the cornea at the time of surgery. Hematoxylin and eosin staining and immunohistochemical analysis were performed for cytoskeletal keratins (K12, K13, and K15), basement membrane and junctional markers (laminin 5, ZO-1 and Desmoplakin), and proliferative and mesenchymal markers (Ki67, -SMA, and vimentin).Results:A 42-year-old patient with severe gonococcal keratoconjunctivitis rapidly progressed to corneal perforation during administration of intensive topical and systemic antibiotics. After conservative treatment, the perforation healed and 5- x 3-mm corneal ectasia occurred with localized iris attachment. Complete closure of the cornea was confirmed by a negative Seidel test. After lamellar keratoplasty to improve corneal integrity and to prevent secondary glaucoma, the pathological tissue revealed a poorly organized epithelial layer at the regenerated ectatic area. The regenerated epithelial cells clearly expressed K12, ZO-1, and Desmoplakin with underlying laminin 5 (+) basement membrane. K15 and Ki67 expressions were observed predominantly at the limbal area but not in the regenerated area. -SMA and vimentin were sporadically expressed in the underlying connective tissue.Conclusions:We speculate that the process of epithelial wound healing at the site of corneal perforation was responsible for migration of the surrounding epithelial cells. Although the regenerated cells expressed several cytokeratins and junctional markers, they remained disorganized and fragile.	[Jongkhajornpong, Passara; Nakamura, Takahiro; Sotozono, Chie; Inatomi, Tsutomu; Kinoshita, Shigeru] Kyoto Prefectural Univ Med, Dept Ophthalmol, Kyoto 6020841, Japan; [Jongkhajornpong, Passara] Mahidol Univ, Ramathibodi Hosp, Dept Ophthalmol, Bangkok 10700, Thailand; [Nakamura, Takahiro; Kinoshita, Shigeru] Kyoto Prefectural Univ Med, Dept Frontier Med Sci & Technol Ophthalmol, Kyoto 6020841, Japan	Nakamura, T (reprint author), Kyoto Prefectural Univ Med, Dept Frontier Med Sci & Technol Ophthalmol, Kamigyo Ku, 465 Kajii Cho, Kyoto 6020841, Japan.	tnakamur@koto.kpu-m.ac.jp					WANG Y, 1993, EXP EYE RES, V57, P283, DOI 10.1006/exer.1993.1126; Ramirez-Miranda A, 2011, MOL VIS, V17, P1652; CHEN WYW, 1994, CURR EYE RES, V13, P765, DOI 10.3109/02713689409047012; Prajna NV, 2013, JAMA OPHTHALMOL, V131, P1088, DOI 10.1001/jamaophthalmol.2013.1612; Ban Y, 2003, EXP EYE RES, V76, P735, DOI 10.1016/S0014-4835(03)00033-2; Kawashima M, 2009, EYE, V23, P339, DOI 10.1038/sj.eye.6703051; Nakamura T, 2014, J CLIN INVEST, V124, P385, DOI 10.1172/JCI71488; Fukuda K, 1999, CORNEA, V18, P73, DOI 10.1097/00003226-199901000-00013; Yoshida S, 2006, INVEST OPHTH VIS SCI, V47, P4780, DOI 10.1167/iovs.06-0574; Suzuki K, 2003, PROG RETIN EYE RES, V22, P113, DOI 10.1016/S1350-9462(02)00042-3; McElnea E, 2014, INT OPHTHALMOL; Nishida T, 2005, CORNEA, P3	12	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0277-3740	1536-4798		CORNEA	Cornea	NOV	2015	34	11					1508	1512		10.1097/ICO.0000000000000551		5	Ophthalmology	Ophthalmology	CU6HK	WOS:000363632500031		
J	Tanida, M; Gotoh, H; Yamamoto, N; Wang, M; Kuda, Y; Kurata, Y; Mori, M; Shibamoto, T				Tanida, Mamoru; Gotoh, Hitoshi; Yamamoto, Naoki; Wang, Mofei; Kuda, Yuhichi; Kurata, Yasutaka; Mori, Masatomo; Shibamoto, Toshishige			Hypothalamic Nesfatin-1 Stimulates Sympathetic Nerve Activity via Hypothalamic ERK Signaling	DIABETES			English	Article							CORTICOTROPIN-RELEASING HORMONE; ACTIVATED PROTEIN-KINASE; FOOD-INTAKE; PARAVENTRICULAR NUCLEUS; SPINAL-CORD; RAT; LEPTIN; NEURONS; PATHWAY; BRAIN	Nesfatin-1 acts on the hypothalamus and regulates the autonomic nervous system. However, the hypothalamic mechanisms of nesfatin-1 on the autonomic nervous system are not well understood. In this study, we found that intracerebroventricular (ICV) administration of nesfatin-1 increased the extracellular signal-regulated kinase (ERK) activity in rats. Furthermore, the activity of sympathetic nerves, in the kidneys, liver, and white adipose tissue (WAT), and blood pressure was stimulated by the ICV injection of nesfatin-1, and these effects were abolished owing to pharmacological inhibition of ERK. Renal sympathoexcitatory and hypertensive effects were also observed with nesfatin-1 microinjection into the paraventricular hypothalamic nucleus (PVN). Moreover, nesfatin-1 increased the number of phospho (p)-ERK1/2-positive neurons in the PVN and coexpression of the protein in neurons expressing corticotropin-releasing hormone (CRH). Pharmacological blockade of CRH signaling inhibited renal sympathetic and hypertensive responses to nesfatin-1. Finally, sympathetic stimulation of WAT and increased p-ERK1/2 levels in response to nesfatin-1 were preserved in obese animals such as rats that were fed a high-fat diet and leptin receptor-deficient Zucker fatty rats. These findings indicate that nesfatin-1 regulates the autonomic nervous system through ERK signaling in PVN-CRH neurons to maintain cardiovascular function and that the antiobesity effect of nesfatin-1 is mediated by hypothalamic ERK-dependent sympathoexcitation in obese animals.	[Tanida, Mamoru; Wang, Mofei; Kuda, Yuhichi; Kurata, Yasutaka; Shibamoto, Toshishige] Kanazawa Med Univ, Dept Physiol 2, Uchinada, Ishikawa 92002, Japan; [Gotoh, Hitoshi] Kyoto Prefectural Univ Med, Dept Biol, Kyoto, Japan; [Yamamoto, Naoki] Hokuriku Univ, Coll Pharm, Kanazawa, Ishikawa, Japan; [Mori, Masatomo] Kitakanto Mol Novel Res Inst Obes & Metab, Midori City, Gunma, Japan	Tanida, M (reprint author), Kanazawa Med Univ, Dept Physiol 2, Uchinada, Ishikawa 92002, Japan.	mtanida@kanazawa-med.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan [21689008, 26870672]; Promoted Research from Kanazawa Medical University [S2014-2]; Takeda Science Foundation	This study was supported by grants (to M.T.) from the Ministry of Education, Culture, Sports, Science and Technology of Japan (Grant-in-Aid for Young Scientists 21689008 and 26870672), the Promoted Research from Kanazawa Medical University (S2014-2), and the Takeda Science Foundation.	Adler ES, 2012, J NEUROSCI, V32, P15913, DOI 10.1523/JNEUROSCI.2591-12.2012; Cao J, 2006, MOL PHARMACOL, V69, P998, DOI 10.1124/mol.105.019539; SCHRAMM LP, 1993, BRAIN RES, V616, P251, DOI 10.1016/0006-8993(93)90216-A; Yosten GLC, 2014, AM J PHYSIOL-REG I, V306, pR722, DOI 10.1152/ajpregu.00396.2013; Yosten GLC, 2010, AM J PHYSIOL-REG I, V298, pR1642, DOI 10.1152/ajpregu.00804.2009; Foo KS, 2008, NEUROSCIENCE, V156, P563, DOI 10.1016/j.neuroscience.2008.07.054; Xu Y, 2010, CELL METAB, V12, P88, DOI 10.1016/j.cmet.2010.05.002; Harlan SM, 2013, CELL METAB, V17, P599, DOI 10.1016/j.cmet.2013.02.017; Konczol K, 2012, INT J OBESITY, V36, P1514, DOI 10.1038/ijo.2012.2; Gotoh K, 2013, J NEUROCHEM, V124, P90, DOI 10.1111/jnc.12066; Goebel M, 2009, NEUROSCI LETT, V452, P241, DOI 10.1016/j.neulet.2009.01.064; Yang ML, 2012, DIABETES, V61, P1959, DOI 10.2337/db11-1755; Maejima Y, 2009, CELL METAB, V10, P355, DOI 10.1016/j.cmet.2009.09.002; SAWCHENKO PE, 1982, J COMP NEUROL, V205, P260, DOI 10.1002/cne.902050306; Huang JH, 1999, BRAIN RES, V845, P77, DOI 10.1016/S0006-8993(99)01937-X; Tanida M, 2015, J NEUROSCI, V35, P474, DOI 10.1523/JNEUROSCI.1828-14.2015; DEGREEF WJ, 1992, ACTA MED AUST, V19, P77; Buijs RM, 2003, J COMP NEUROL, V464, P36, DOI 10.1002/cne.10765; Dagon Y, 2012, CELL METAB, V16, P104, DOI 10.1016/j.cmet.2012.05.010; Tanida M, 2011, NEUROREPORT, V22, P309, DOI 10.1097/WNR.0b013e328346107f; SAWCHENKO PE, 1987, BRAIN RES, V437, P253, DOI 10.1016/0006-8993(87)91641-6; Wernecke K, 2014, OBESITY, V22, P1662, DOI 10.1002/oby.20736; Stengel A, 2009, ENDOCRINOLOGY, V150, P4911, DOI 10.1210/en.2009-0578; Minokoshi Y, 2004, NATURE, V428, P569, DOI 10.1038/nature02440; Oh-I S, 2006, NATURE, V443, P709, DOI 10.1038/nature05162; Rahmouni K, 2009, DIABETES, V58, P536, DOI 10.2337/db08-0822; Tagaya Y, 2012, ENDOCRINOLOGY, V153, P3308, DOI 10.1210/en.2011-2154; Mimee A, 2012, AM J PHYSIOL-REG I, V302, pR1297, DOI 10.1152/ajpregu.00266.2011; Ishida E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050918; Paxinos G, 2007, RAT BRAIN STEREOTAXI; Stengel A, 2013, OBES REV, V14, P859, DOI 10.1111/obr.12063; Tanida M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056660	32	0	0	AMER DIABETES ASSOC	ALEXANDRIA	1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA	0012-1797	1939-327X		DIABETES	Diabetes	NOV	2015	64	11					3725	3736		10.2337/db15-0282		12	Endocrinology & Metabolism	Endocrinology & Metabolism	CU8ZL	WOS:000363832500013		
J	Yoshida, R; Noguchi, K; Shigemura, N; Jyotaki, M; Takahashi, I; Margolskee, RF; Ninomiya, Y				Yoshida, Ryusuke; Noguchi, Kenshi; Shigemura, Noriatsu; Jyotaki, Masafumi; Takahashi, Ichiro; Margolskee, Robert F.; Ninomiya, Yuzo			Leptin Suppresses Mouse Taste Cell Responses to Sweet Compounds	DIABETES			English	Article							PANCREATIC BETA-CELLS; CHORDA TYMPANI NERVE; DIABETIC DB/DB MOUSE; SENSITIVE POTASSIUM CHANNELS; DIET-INDUCED OBESITY; RECEPTOR-CELLS; SIGNALING PATHWAYS; PLASMA LEPTIN; WEIGHT-LOSS; MICE	Leptin is known to selectively suppress neural and behavioral responses to sweet-tasting compounds. However, the molecular basis for the effect of leptin on sweet taste is not known. Here, we report that leptin suppresses sweet taste via leptin receptors (Ob-Rb) and K-ATP channels expressed selectively in sweet-sensitive taste cells. Ob-Rb was more often expressed in taste cells that expressed T1R3 (a sweet receptor component) than in those that expressed glutamate-aspartate transporter (a marker for Type I taste cells) or GAD67 (a marker for Type III taste cells). Systemically administered leptin suppressed taste cell responses to sweet but not to bitter or sour compounds. This effect was blocked by a leptin antagonist and was absent in leptin receptor deficient db/db mice and mice with diet-induced obesity. Blocking the K-ATP channel subunit sulfonylurea receptor 1, which was frequently coexpressed with Ob-Rb in T1R3-expressing taste cells, eliminated the effect of leptin on sweet taste. In contrast, activating the K-ATP channel with diazoxide mimicked the sweet-suppressing effect of leptin. These results indicate that leptin acts via Ob-Rb and K-ATP channels that are present in T1R3-expressing taste cells to selectively suppress their responses to sweet compounds.	[Yoshida, Ryusuke; Noguchi, Kenshi; Shigemura, Noriatsu; Jyotaki, Masafumi; Ninomiya, Yuzo] Kyushu Univ, Grad Sch Dent Sci, Sect Oral Neurosci, Fukuoka 812, Japan; [Noguchi, Kenshi; Takahashi, Ichiro] Kyushu Univ, Grad Sch Dent Sci, Sect Orthodont & Dentofacial Orthoped, Fukuoka 812, Japan; [Margolskee, Robert F.] Monell Chem Senses Ctr, Philadelphia, PA 19104 USA; [Ninomiya, Yuzo] Kyushu Univ, Res & Dev Ctr Taste & Odor Sensing, Div Sensory Physiol, Fukuoka 812, Japan	Yoshida, R (reprint author), Kyushu Univ, Grad Sch Dent Sci, Sect Oral Neurosci, Fukuoka 812, Japan.	yoshida.ryusuke.319@m.kyushu-u.ac.jp; ninomiya.yuzo.285@m.kyushu-u.ac.jp			MEW [18109013, 18077004, 23249081, 26670810, 15H02571]; Japan Society for the Promotion of Science [23689076, 26462815]	This work was supported by MEW Grants-in-Aid for Scientific Research 18109013, 18077004, 23249081, 26670810, and 15H02571 (to Y.N.) and 23689076 and 26462815 (to R.Y.) from the Japan Society for the Promotion of Science.	Park SH, 2013, P NATL ACAD SCI USA, V110, P12673, DOI 10.1073/pnas.1216351110; Yoshida R, 2010, P NATL ACAD SCI USA, V107, P935, DOI 10.1073/pnas.0912048107; Harvey J, 2000, J BIOL CHEM, V275, P4660, DOI 10.1074/jbc.275.7.4660; Ninomiya Y, 1998, AM J PHYSIOL-REG I, V274, pR1324; Max M, 2001, NAT GENET, V28, P58, DOI 10.1038/ng0501-58; Spanswick D, 1997, NATURE, V390, P521; Shigemura N, 2013, J NEUROSCI, V33, P6267, DOI 10.1523/JNEUROSCI.5599-12.2013; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Niki M, 2011, CELL MOL NEUROBIOL, V31, P1033, DOI 10.1007/s10571-011-9702-5; Donaldson LF, 2009, AM J CLIN NUTR, V90, p800S, DOI 10.3945/ajcn.2009.27462Q; NINOMIYA Y, 1995, AM J PHYSIOL-REG I, V269, pR930; Chen CY, 2009, J NEUROSCI, V29, P2754, DOI 10.1523/JNEUROSCI.4413-08.2009; Shigemura N, 2003, ARCH HISTOL CYTOL, V66, P253, DOI 10.1679/aohc.66.253; Kawai K, 2000, P NATL ACAD SCI USA, V97, P11044, DOI 10.1073/pnas.190066697; Bartoshuk LM, 2006, PHILOS T R SOC B, V361, P1137, DOI 10.1098/rstb.2006.1853; Huang YA, 2008, J PHYSIOL-LONDON, V586, P2903, DOI 10.1113/jphysiol.2008.151233; Yoshida R, 2006, J NEUROPHYSIOL, V96, P3088, DOI 10.1152/jn.00409.2006; Tamamaki N, 2003, J COMP NEUROL, V467, P60, DOI 10.1002/cne.10905; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Salomon G, 2006, PROTEIN EXPRES PURIF, V47, P128, DOI 10.1016/j.pep.2005.09.016; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; Zhang XJ, 2013, PEPTIDES, V47, P115, DOI 10.1016/j.peptides.2013.07.015; Domingos AI, 2011, NAT NEUROSCI, V14, P1562, DOI 10.1038/nn.2977; Ning K, 2006, EMBO J, V25, P2377, DOI 10.1038/sj.emboj.7601118; Sako N, 1996, CHEM SENSES, V21, P59, DOI 10.1093/chemse/21.1.59; Harvey J, 1997, J PHYSIOL-LONDON, V504, P527, DOI 10.1111/j.1469-7793.1997.527bd.x; Kusuhara Y, 2013, J PHYSIOL-LONDON, V591, P1967, DOI 10.1113/jphysiol.2012.236604; Martin B, 2010, DIABETES, V59, P1143, DOI 10.2337/db09-0807; Shigemura N, 2004, ENDOCRINOLOGY, V145, P839, DOI 10.1210/en.2003-0602; Yoshida R, 2009, J PHYSIOL-LONDON, V587, P4425, DOI 10.1113/jphysiol.2009.175075; Lu B, 2012, PHYSIOL BEHAV, V107, P533, DOI 10.1016/j.physbeh.2012.04.018; DeFazio RA, 2006, J NEUROSCI, V26, P3971, DOI 10.1523/JNEUROSCI.0515-06.2006; Nakamura Y, 2008, DIABETES, V57, P2661, DOI 10.2337/db07-1103; Zhang YF, 2003, CELL, V112, P293, DOI 10.1016/S0092-8674(03)00071-0; Mirshamsi S, 2004, BMC NEUROSCI, V5, DOI 10.1186/1471-2202-5-54; Umabiki M, 2010, TOHOKU J EXP MED, V220, P267, DOI 10.1620/tjem.220.267; Yasumatsu K, 2012, J PHYSIOL-LONDON, V590, P1155, DOI 10.1113/jphysiol.2011.211920; Chen PC, 2013, J BIOL CHEM, V288, P34098, DOI 10.1074/jbc.M113.516880; Yee KK, 2011, P NATL ACAD SCI USA, V108, P5431, DOI 10.1073/pnas.1100495108; Friedman JM, 2004, NAT MED, V10, P563, DOI 10.1038/nm0604-563; Wong GT, 1999, J NEUROSCI, V19, P5802; Nichols CG, 2006, NATURE, V440, P470, DOI 10.1038/nature04711; VanHeek M, 1997, J CLIN INVEST, V99, P385, DOI 10.1172/JCI119171; Lawton DM, 2000, EUR J NEUROSCI, V12, P3163, DOI 10.1046/j.1460-9568.2000.00207.x; Damak S, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-96; de Lartigue G, 2011, AM J PHYSIOL-ENDOC M, V301, pE187, DOI 10.1152/ajpendo.00056.2011; Domingos AI, 2013, ELIFE, V2, DOI 10.7554/eLife.01462; Domingos Ana I, 2014, Mol Metab, V3, P73, DOI 10.1016/j.molmet.2013.10.007; Maliphol AB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079403; Murray RG, 1971, HDB SENSORY PHYSIO 2, V4, P31; Niki M, 2015, J PHYSIOL-LONDON, V593, P2527, DOI 10.1113/JP270295; Shin AC, 2011, AM J PHYSIOL-REG I, V301, pR1267, DOI 10.1152/ajpregu.00314.2011	53	1	1	AMER DIABETES ASSOC	ALEXANDRIA	1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA	0012-1797	1939-327X		DIABETES	Diabetes	NOV	2015	64	11					3751	3762		10.2337/db14-1462		12	Endocrinology & Metabolism	Endocrinology & Metabolism	CU8ZL	WOS:000363832500015		
J	Takeyama, H; Mizushima, T; Iijima, H; Shinichiro, S; Uemura, M; Nishimura, J; Hata, T; Takemasa, I; Yamamoto, H; Doki, Y; Mori, M				Takeyama, Hiroshi; Mizushima, Tsunekazu; Iijima, Hideki; Shinichiro, Shinzaki; Uemura, Mamoru; Nishimura, Junichi; Hata, Taishi; Takemasa, Ichiro; Yamamoto, Hirofumi; Doki, Yuichiro; Mori, Masaki			Platelet Activation Markers Are Associated with Crohn's Disease Activity in Patients with Low C-Reactive Protein	DIGESTIVE DISEASES AND SCIENCES			English	Article						Platelet factor 4 (PF-4); Beta-thromboglobulin (beta-TG); Inflammatory bowel diseases (IBD); Crohn's disease (CD)	INFLAMMATORY-BOWEL-DISEASE; ULCERATIVE-COLITIS; THROMBOEMBOLISM; DEFENSE; INDEX; LEVEL; SERUM	In assessing Crohn's disease (CD) activity, C-reactive protein (CRP) is an important indicator of inflammation; however, it is not necessarily associated with the Crohn's Disease Activity Index (CDAI), particularly in patients with low CRP. Recently, platelet activation factors have been recognized due to their importance in the inflammatory response. In this study, we examined associations between the CDAI and platelet factor 4 (PF-4), beta-thromboglobulin (beta-TG), and other coagulation and fibrinolysis factors. We aimed to find a new marker for evaluating disease activity in patients with CD and low CRP. Nine markers, including CRP, platelet count, white blood cell count, fibrin and fibrinogen degradation product, fibrinogen, thrombin-antithrombin complex, prothrombin fragments 1 + 2, PF-4, and beta-TG were evaluated in 47 patients with CD and low CRP (< 1.0 mg/dl). Patients were assigned to high or low disease activity groups, CDAI-H (CDAI a parts per thousand yen 150) and CDAI-L (CDAI < 150), respectively. CDAI-H exhibited significantly higher PF-4 and beta-TG levels than CDAI-L (P < 0.01). Other markers were not significantly different between groups. CDAI was positively correlated with the levels of PF-4 and beta-TG (P = 0.0033 and 0.0024; r = 0.4202 and 0.4321, respectively). Receiver operating characteristic curve analyses of PF-4 and beta-TG showed high sensitivity (61.9 and 81 %, respectively) and specificity (84.7 and 69.2 %, respectively) for diagnosing active CD. Among eight potential markers, PF-4 and beta-TG were the most highly correlated with CDAI in patients with CD and low CRP. PF-4 and beta-TG levels showed promise as new markers for assessing CD in patients with low CRP.	[Takeyama, Hiroshi; Mizushima, Tsunekazu; Uemura, Mamoru; Nishimura, Junichi; Hata, Taishi; Takemasa, Ichiro; Yamamoto, Hirofumi; Doki, Yuichiro; Mori, Masaki] Osaka Univ, Grad Sch Med, Dept Surg, Gastroenterol Surg, Suita, Osaka 5650871, Japan; [Iijima, Hideki; Shinichiro, Shinzaki] Osaka Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Suita, Osaka 5650871, Japan	Mizushima, T (reprint author), Osaka Univ, Grad Sch Med, Dept Surg, Gastroenterol Surg, 2-2 Yamada Oka, Suita, Osaka 5650871, Japan.	tmizushima@gesurg.med.osaka-u.ac.jp	Nishimura, Junichi/K-8390-2015	Nishimura, Junichi/0000-0001-8220-3423			Gear ARL, 2003, MICROCIRCULATION, V10, P335, DOI 10.1038/sj.mn.7800198; Jones J, 2008, CLIN GASTROENTEROL H, V6, P1218, DOI 10.1016/j.cgh.2008.06.010; BEST WR, 1979, GASTROENTEROLOGY, V77, P843; Husain N, 2013, J CLIN GASTROENTEROL, V47, P246, DOI 10.1097/MCG.0b013e3182582cdb; Miehsler W, 2004, GUT, V53, P542, DOI 10.1136/gut.2003.025411; Chamouard P, 2006, CLIN GASTROENTEROL H, V4, P882, DOI 10.1016/j.cgh.2006.02.003; Bernhard H, 2011, INFLAMM BOWEL DIS, V17, P2333, DOI 10.1002/ibd.21631; Filik L, 2006, ADV THER, V23, P655, DOI 10.1007/BF02850054; Diaz-Jimenez D, 2011, WORLD J GASTROENTERO, V17, P2181, DOI 10.3748/wjg.v17.i17.2181; Florin THJ, 2006, SCAND J GASTROENTERO, V41, P306, DOI 10.1080/00365520500217118; Vrij AA, 2000, EUR J CLIN INVEST, V30, P188; Desai D, 2007, ALIMENT PHARM THERAP, V25, P247, DOI 10.1111/j.1365-2036.2006.03184.x; Thornton M, 2002, INT J COLORECTAL DIS, V17, P287, DOI 10.1007/s00384-002-0408-5; Sandborn WJ, 2002, GASTROENTEROLOGY, V122, P512, DOI 10.1053/gast.2002.31072; SIMI M, 1987, GUT, V28, P336, DOI 10.1136/gut.28.3.336; Danese S, 2004, AM J GASTROENTEROL, V99, P938, DOI 10.1111/j.1572-0241.2004.04129.x; Hayat M, 2002, EUR J GASTROEN HEPAT, V14, P249, DOI 10.1097/00042737-200203000-00008; Grainge MJ, 2010, LANCET, V375, P657, DOI 10.1016/S0140-6736(09)61963-2; Irving PM, 2005, CLIN GASTROENTEROL H, V3, P617, DOI 10.1053/S1542-3565(05)00154-0; Rosenberg L, 2013, CLIN GASTROENTEROL H, V11, P991, DOI 10.1016/j.cgh.2013.02.030; Rodgers AD, 2007, DIGEST DIS SCI, V52, P2063, DOI 10.1007/s10620-006-9691-2; WEBBERLEY MJ, 1993, GUT, V34, P247, DOI 10.1136/gut.34.2.247; Denis MA, 2007, INFLAMM BOWEL DIS, V13, P1100, DOI 10.1002/ibd.20178; Kasperska-Zajac A, 2007, INFLAMMATION, V30, P161, DOI 10.1007/s10753-007-9033-3; Kasperska-Zajac A, 2006, J INVEST ALLERG CLIN, V16, P1; Kiss LS, 2011, ALIMENT PHARM THER, V34, P911, DOI 10.1111/j.1365-2036.2011.04827.x; COLLINS CE, 1995, GUT, V36, P5, DOI 10.1136/gut.36.1.5	27	1	1	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0163-2116	1573-2568		DIGEST DIS SCI	Dig. Dis. Sci.	NOV	2015	60	11					3418	3423		10.1007/s10620-015-3745-2		6	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU5AC	WOS:000363542700034		
J	Yamada, A; Niikura, R; Yoshida, S; Hirata, Y; Koike, K				Yamada, Atsuo; Niikura, Ryota; Yoshida, Shuntaro; Hirata, Yoshihiro; Koike, Kazuhiko			Endoscopic management of colonic diverticular bleeding	DIGESTIVE ENDOSCOPY			English	Review						colon diverticulum; endoscopic hemostasis; gastrointestinal bleeding	LOWER GASTROINTESTINAL HEMORRHAGE; BAND LIGATION; URGENT COLONOSCOPY; RISK-FACTORS; HEMOSTASIS; DIAGNOSIS; PREDICTORS; OUTCOMES; DEVICES; TRIAL	Colonic diverticular bleeding is the most common cause of lower gastrointestinal bleeding. Colonoscopy can be used for both diagnosis and treatment of colonic diverticular bleeding. Identification of the stigmata of recent hemorrhage allows for various endoscopic hemostasis methods. Clipping, endoscopic band ligation, injection therapy, and thermal contact are available methods for endoscopic hemostasis. However, the optimal technique remains to be determined. Herein, we review the techniques and clinical outcomes of endoscopic hemostasis for colonic diverticular bleeding.	[Yamada, Atsuo; Niikura, Ryota; Yoshida, Shuntaro; Hirata, Yoshihiro; Koike, Kazuhiko] Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Tokyo 1138655, Japan; [Yoshida, Shuntaro] Tokyo Univ Hosp, Dept Endoscopy & Endoscop Surg, Tokyo 113, Japan	Yamada, A (reprint author), Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	yamada-a@umin.ac.jp					Strate LL, 2010, CLIN GASTROENTEROL H, V8, P333, DOI 10.1016/j.cgh.2009.12.017; Green BT, 2005, AM J GASTROENTEROL, V100, P2395, DOI 10.1111/j.1572-0241.2005.00306.x; Kaltenbach T, 2012, CLIN GASTROENTEROL H, V10, P131, DOI 10.1016/j.cgh.2011.10.029; Tanaka Y, 2012, GUT LIVER, V6, P334, DOI 10.5009/gnl.2012.6.3.334; Fujino Y, 2013, COLORECTAL DIS, V15, P982, DOI 10.1111/codi.12232; BERTONI G, 1990, ENDOSCOPY, V22, P154, DOI 10.1055/s-2007-1012827; Song LMWK, 2008, AM J GASTROENTEROL, V103, P1881, DOI 10.1111/j.1572-0241.2008.02075.x; Ishii N, 2012, GASTROINTEST ENDOSC, V75, P382, DOI 10.1016/j.gie.2011.07.030; Ishii N, 2010, DIGEST ENDOSC, V22, P232, DOI 10.1111/j.1443-1661.2010.00993.x; Prakash C, 1999, ENDOSCOPY, V31, P460, DOI 10.1055/s-1999-124; TADA M, 1991, GASTROENTEROL JPN, V26, P121; Foutch PG, 1996, AM J GASTROENTEROL, V91, P2589; Conway JD, 2009, GASTROINTEST ENDOSC, V69, P987, DOI 10.1016/j.gie.2008.12.251; Setoyama T, 2011, SURG ENDOSC, V25, P3574, DOI 10.1007/s00464-011-1760-8; Ohyama T, 2000, DIGESTION, V61, P189, DOI 10.1159/000007756; Laine L, 2010, AM J GASTROENTEROL, V105, P2636, DOI 10.1038/ajg.2010.277; Strate LL, 2005, GASTROINTEST ENDOSC, V61, P46, DOI 10.1016/S0016-5107(04)02227-8; Bloomfeld RS, 2001, AM J GASTROENTEROL, V96, P2367, DOI 10.1111/j.1572-0241.2001.04048.x; Yamada A, 2008, DIS COLON RECTUM, V51, P116, DOI 10.1007/s10350-007-9137-8; Witte JT, 2000, GASTROINTEST ENDOSC, V52, P762, DOI 10.1067/mge.2000.109872; Yen EF, 2008, DIGEST DIS SCI, V53, P2480, DOI 10.1007/s10620-007-0151-4; Obana T, 2013, DIGEST DIS SCI, V58, P1985, DOI 10.1007/s10620-013-2629-6; WARA P, 1984, ENDOSCOPY, V16, P43, DOI 10.1055/s-2007-1018530; Strate LL, 2003, AM J GASTROENTEROL, V98, P317, DOI 10.1016/S0002-9270(02)05900-2; Farrell JJ, 2003, ENDOSCOPY, V35, P823; Pasha SF, 2014, GASTROINTEST ENDOSC, V79, P875, DOI 10.1016/j.gie.2013.10.039; Chaudhry V, 1998, AM SURGEON, V64, P723; Ishii N, 2012, GASTROINTEST ENDOSC, V76, P1175, DOI 10.1016/j.gie.2012.07.040; Jensen DM, 2000, NEW ENGL J MED, V342, P78, DOI 10.1056/NEJM200001133420202; Aytac E, 2014, INT J COLORECTAL DIS, V29, P373, DOI 10.1007/s00384-013-1804-8; Longstreth GF, 1997, AM J GASTROENTEROL, V92, P419; MCGUIRE HH, 1994, ANN SURG, V220, P653, DOI 10.1097/00000658-199411000-00008; Mizuki A., 2013, JAPANESE J GASTROENT, V110, P1927; Nagata N, 2015, J GASTROENTEROL, V50, P1162, DOI 10.1007/s00535-015-1069-9; Navaneethan U, 2014, GASTROINTEST ENDOSC, V79, P297, DOI 10.1016/j.gie.2013.08.001; Niikura R, 2015, J CLIN GASTROENTEROL, V49, pE24, DOI 10.1097/MCG.0000000000000140; Rustagi T, 2014, GASTROENT RES PRACT, DOI 10.1155/2014/353508	37	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0915-5635	1443-1661		DIGEST ENDOSC	Dig. Endosc.	NOV	2015	27	7					720	725		10.1111/den.12534		6	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	CU7UH	WOS:000363746700001		
J	Saka, A; Yagi, K; Nimura, S				Saka, Akiko; Yagi, Kazuyoshi; Nimura, Satoshi			OLGA- and OLGIM-based staging of gastritis using narrow-band imaging magnifying endoscopy	DIGESTIVE ENDOSCOPY			English	Article						gastritis; magnifying endoscopy; narrow-band imaging; operative link for gastric intestinal metaplasia assessment (OLGIM); operative link for gastritis assessment (OLGA)	SYSTEM; CORPUS	Background and AimAs atrophic gastritis and intestinal metaplasia as a result of Helicobacter pylori are considered risk factors for gastric cancer, it is important to assess their severity. In the West, the operative link for gastritis assessment (OLGA) and operative link for gastric intestinal metaplasia assessment (OLGIM) staging systems based on biopsy have been widely adopted. In Japan, however, narrow-band imaging (NBI)-magnifying endoscopic diagnosis of gastric mucosal inflammation, atrophy, and intestinal metaplasia has been reported to be fairly accurate. Therefore, we investigated the practicality of NBI-magnifying endoscopy (NBI-ME) for gastritis staging. MethodsWe enrolled 55 patients, in whom NBI-ME was used to score the lesser curvature of the antrum (antrum) and the lesser curvature of the lower body (corpus). The NBI-ME score classification was established from images obtained beforehand, and then biopsy specimens taken from the observed areas were scored according to histological findings. The NBI-ME and histology scores were then compared. Furthermore, we assessed the NBI-ME and histology stages using a combination of scores for the antrum and corpus, and divided the stages into two risk groups: low and high. The degree to which the stage assessed by NBI-ME approximated that assessed by histology was then ascertained. ResultsDegree of correspondence between the NBI-ME and histology scores was 69.1% for the antrum and 72.7% for the corpus, and that between the high- and low-risk groups was 89.1%. ConclusionStaging of gastritis using NBI-ME approximates that based on histology, and would be a practical alternative to the latter.	[Saka, Akiko; Yagi, Kazuyoshi] Niigata Prefectural Yoshida Hosp, Dept Gastroenterol, Tsubame, Niigata 9590242, Japan; [Nimura, Satoshi] Fukuoka Univ, Fac Med, Dept Pathol, Fukuoka 81401, Japan	Yagi, K (reprint author), Niigata Prefectural Yoshida Hosp, Dept Gastroenterol, 32-14 Daibo Cho, Tsubame, Niigata 9590242, Japan.	yagikazu@pop12.odn.ne.jp					Rugge M, 2008, DIGEST LIVER DIS, V40, P650, DOI 10.1016/j.dld.2008.02.030; Rugge M, 2005, HUM PATHOL, V36, P228, DOI 10.1016/j.humpath.2004.12.008; Uedo N, 2006, ENDOSCOPY, V38, P819, DOI 10.1055/s-2006-944632; Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999; Satoh K, 2008, HELICOBACTER, V13, P225, DOI 10.1111/j.1523-5378.2008.00599.x; Yagi K, 2002, ENDOSCOPY, V34, P376, DOI 10.1055/s-2002-25281; Kawamura M, 2011, J GASTROEN HEPATOL, V26, P477, DOI 10.1111/j.1440-1746.2010.06527.x; Capelle LG, 2010, GASTROINTEST ENDOSC, V71, P1150, DOI 10.1016/j.gie.2009.12.029; Yagi K, 2005, ENDOSCOPY, V37, P660, DOI 10.1055/s-861423; Rugge M, 2007, GUT, V56, P631, DOI 10.1136/gut.2006.106666; Yagi K, 2005, J GASTROENTEROL, V40, P443, DOI 10.1007/s00535-005-1605-0; Yao KS, 2012, DIGEST ENDOSC, V24, P419, DOI 10.1111/j.1443-1661.2012.01314.x; CORREA P, 1992, CANCER RES, V52, P6735; Dixon MF, 1996, AM J SURG PATHOL, V20, P1161, DOI 10.1097/00000478-199610000-00001; Yagi K, STOM INTEST, V44, P1446; Yao K., 2014, ZOOM GASTROSCOPY, P73	16	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0915-5635	1443-1661		DIGEST ENDOSC	Dig. Endosc.	NOV	2015	27	7					734	741		10.1111/den.12483		8	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	CU7UH	WOS:000363746700004		
J	Miyagi, M; Yoshio, T; Hirasawa, T; Ishiyama, A; Yamamoto, Y; Tsuchida, T; Fujisaki, J; Igarashi, M				Miyagi, Motoshi; Yoshio, Toshiyuki; Hirasawa, Toshiaki; Ishiyama, Akiyoshi; Yamamoto, Yorimasa; Tsuchida, Tomohiro; Fujisaki, Junko; Igarashi, Masahiro			Precordial skin burns after endoscopic submucosal dissection for gastric tube cancer	DIGESTIVE ENDOSCOPY			English	Article						endoscopic submucosal dissection; gastric tube cancer; presternal route reconstruction; skin burn; thermal injury	ESOPHAGECTOMY; RESECTION	Background and AimEndoscopic submucosal dissection (ESD) is useful as a minimally invasive treatment option for early gastric cancer. ESD is also used in the management of postoperative remnant gastric cancers in the stomach and gastric tube cancers. Perforation and delayed bleeding have been the main complications of ESD reported in the management of gastric tube cancer. However, in the current literature, there is no description of precordial skin burns caused by electrical coagulation. MethodsWhile we treated 22 patients with gastric tube cancers by ESD from 2005 to 2014, we experienced five skin burns in four patients after ESD. We retrospectively analyzed clinical characteristics of precordial skin burn as a complication of ESD. ResultsAll skin burns occurred in patients reconstructed using a presternal route, whose incidence of precordial skin burn was 55.6%. In all cases, lesions were located in the upper or middle third of gastric tubes irrespective of their direction. Skin burn developed on postoperative day (POD) 1 or POD 2, taking 4-7 days to heal and was accompanied by high fever in 60% of cases. ConclusionThe present study suggests that when carrying out ESD for gastric tube cancer using the presternal route, it is necessary to consider the occurrence of a precordial skin burn as a possible complication.	[Miyagi, Motoshi; Yoshio, Toshiyuki; Hirasawa, Toshiaki; Ishiyama, Akiyoshi; Yamamoto, Yorimasa; Tsuchida, Tomohiro; Fujisaki, Junko; Igarashi, Masahiro] Canc Inst Hosp, Japanese Fdn Canc Res, Dept Gastroenterol, Tokyo 1358550, Japan	Miyagi, M (reprint author), Canc Inst Hosp, Japanese Fdn Canc Res, Dept Gastroenterol, Koto Ku, 3-8-31 Ariake, Tokyo 1358550, Japan.	toshiyuki.yoshio@jfcr.or.jp					Allum WH, 2009, J CLIN ONCOL, V27, P5062, DOI 10.1200/JCO.2009.22.2083; Sugiura T, 2002, J AM COLL SURGEONS, V194, P578, DOI 10.1016/S1072-7515(02)01135-3; HEIMBACH D, 1992, WORLD J SURG, V16, P10; Tsujimoto H, 2012, ONCOL REP, V28, P2205, DOI 10.3892/or.2012.2046; Ando N, 2003, J CLIN ONCOL, V21, P4592, DOI 10.1200/JCO.2003.12.095; Lee H, 2012, GASTRIC CANCER, V15, P83, DOI 10.1007/s10120-011-0073-x; Osumi W, 2009, ENDOSCOPY, V41, P777, DOI 10.1055/s-0029-1215024; Japan Esophageal Society, 2012, GUID DIAGN TREATM ES; Japanese Gastric Canc Assoc, 2011, GASTRIC CANCER, V14, P101, DOI 10.1007/s10120-011-0041-5; Nonaka S, 2014, GASTROINTEST ENDOSC, V79, P260, DOI 10.1016/j.gie.2013.07.059	10	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0915-5635	1443-1661		DIGEST ENDOSC	Dig. Endosc.	NOV	2015	27	7					742	746		10.1111/den.12494		5	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	CU7UH	WOS:000363746700005		
J	Horikawa, Y; Mimori, N; Mizutamari, H; Kato, Y; Shimazu, K; Sawaguchi, M; Tawaraya, S; Igarashi, K; Okubo, S				Horikawa, Yohei; Mimori, Nobuya; Mizutamari, Hiroya; Kato, Yuhei; Shimazu, Kazuhiro; Sawaguchi, Masayuki; Tawaraya, Shin; Igarashi, Kimihiro; Okubo, Syunji			Proper muscle layer damage affects ulcer healing after gastric endoscopic submucosal dissection	DIGESTIVE ENDOSCOPY			English	Article						endoscopic submucosal dissection (ESD); pharmacotherapy; proper muscle layer injury; ulcer healing; ulcer reduction ratio	PROTON PUMP INHIBITORS; MUCOSAL RESECTION; COMBINATION THERAPY; FIBROSIS; CANCER; TUMORS; ESD	Background and Aim: Endoscopic submucosal dissection (ESD) is the established therapy for superficial gastrointestinal neoplasms. However, management of the artificial ulcers associated with ESD has become important and the relationship between ulcer healing factors and treatment is still unclear. We aimed to evaluate ESD-related artificial ulcer reduction ratio at 4 weeks to assess factors associating with ulcer healing after ESD that may lead to optimal treatment. Methods: Between January 2009 and December 2013, a total of 375 lesions fulfilled the expanded criteria for ESD. We defined ulcer reduction rate <90% as (A) poor-healing group; and rate 90% as (B) well-healing group. After exclusion, 328 lesions were divided into two groups and analyzed. These two groups were compared based on clinicopathological/endoscopic features, concomitant drugs, and treatment. Results: Ulcer reduction rate was significantly correlated with factors related to the ESD procedure (i.e. procedure time, submucosal fibrosis, and injury of the proper muscle layer, in univariate analysis. Multivariate logistic regression analysis showed that submucosal fibrosis (F2) (P = 0.03; OR, 16.46; 95% CI, 1.31-206.73) and injury of the proper muscle layer (P=0.01; OR, 4.27; 95% CI, 2.04-8.92) were statistically significant predictors of delayed healing. Conclusion: This single-center retrospective study indicated that ESD-induced artificial ulcer healing was affected by submucosal fibrosis and injury of the proper muscle layer, which induced damage to the muscle layer. Therefore, the preferable pharmacotherapy can be determined on completion of the ESD procedure.	[Horikawa, Yohei; Mimori, Nobuya; Mizutamari, Hiroya; Kato, Yuhei; Shimazu, Kazuhiro; Okubo, Syunji] Hiraka Gen Hosp, Dept Gastroenterol, Yokote City, Akita 0130013, Japan; [Sawaguchi, Masayuki; Tawaraya, Shin] Akita Univ, Grad Sch Med, Dept Gastroenterol, Akita 010, Japan; [Igarashi, Kimihiro] Shizuoka Canc Ctr, Div Endoscopy, Shizuoka, Japan	Horikawa, Y (reprint author), Hiraka Gen Hosp, Dept Gastroenterol, 3-1 Yatukuchi, Yokote City, Akita 0130013, Japan.	horikawa_01@me.com					Fujiwara S, 2011, J GASTROENTEROL, V46, P595, DOI 10.1007/s00535-011-0372-3; Kakushima N, 2006, J GASTROEN HEPATOL, V21, P1586, DOI 10.1111/j.1440-1746.2006.04321.x; Jeong JY, 2012, GASTROINTEST ENDOSC, V76, P59, DOI 10.1016/j.gie.2012.03.172; LAINE L, 1994, NEW ENGL J MED, V331, P717, DOI 10.1056/NEJM199409153311107; Ono S, 2009, DIGEST LIVER DIS, V41, P725, DOI 10.1016/j.dld.2009.01.007; Shin WG, 2012, GASTROINTEST ENDOSC, V75, P739, DOI 10.1016/j.gie.2011.11.004; Inaba T, 2010, HEPATO-GASTROENTEROL, V57, P678; Asakuma Y, 2009, HEPATO-GASTROENTEROL, V56, P1270; Niimi K, 2012, DIGEST ENDOSC, V24, P110, DOI 10.1111/j.1443-1661.2011.01178.x; Matsumoto A, 2010, SCAND J GASTROENTERO, V45, P1329, DOI 10.3109/00365521.2010.495416; Yang ZP, 2011, DIGESTION, V84, P315, DOI 10.1159/000331138; Kobayashi M, 2012, DIGEST DIS SCI, V57, P119, DOI 10.1007/s10620-011-1850-4; Fu K, 2005, DIGEST DIS SCI, V50, P1324, DOI 10.1007/s10620-005-2781-8; Oh TH, 2009, DIGEST DIS SCI, V54, P1494, DOI 10.1007/s10620-008-0506-5; FORREST JAH, 1974, LANCET, V2, P394; Ono H, 2001, GUT, V48, P225, DOI 10.1136/gut.48.2.225; Goto O, 2011, GUT LIVER, V5, P293, DOI 10.5009/gnl.2011.5.3.293; Kato T, 2010, J GASTROENTEROL, V45, P285, DOI 10.1007/s00535-009-0157-0; Kakushima N, 2006, ENDOSCOPY, V38, P412, DOI 10.1055/s-2006-925166; Gotoda T, 2000, GASTRIC CANCER, V3, P219, DOI 10.1007/PL00011720; Japanese Gastric Cancer Association, 2011, GASTRIC CANCER, V14, P113, DOI [10.1007/s10120-011-0042-4, DOI 10.1007/S10120-011-0042-4]]; Japanese Gastric Canc Assoc, 2011, GASTRIC CANCER, V14, P101, DOI 10.1007/s10120-011-0041-5; Lee SH, 2012, DIGEST DIS SCI, V57, P429, DOI 10.1007/s10620-011-1941-2; Lim EJ, 2015, SURG ENDOSC, V5; Oyama Tsuneo, 2005, Clin Gastroenterol Hepatol, V3, pS67, DOI 10.1016/S1542-3565(05)00291-0; Park J, 2010, KOREAN J GASTROIN S1, V40, P256; Takeuchi K, 1983, JPN J GASTROENTEROL, V80, P9; Tarnawski AS, 2014, J GASTROEN HEPATOL, V29, P112, DOI 10.1111/jgh.12734; Toyonaga T, 2005, DIGEST ENDOSC, V17, P246, DOI 10.1111/j.1443-1661.2005.00534.x; Yahagi Naohisa, 2004, Stomach and Intestine (Tokyo), V39, P39	30	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0915-5635	1443-1661		DIGEST ENDOSC	Dig. Endosc.	NOV	2015	27	7					747	753		10.1111/den.12501		7	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	CU7UH	WOS:000363746700006		
J	Kudo, T; Kudo, S; Wakamura, K; Mori, Y; Misawa, M; Hayashi, T; Kutsukawa, M; Ichimasa, K; Miyachi, H; Ishida, F; Inoue, H				Kudo, Toyoki; Kudo, Shin-ei; Wakamura, Kunihiko; Mori, Yuichi; Misawa, Masashi; Hayashi, Takemasa; Kutsukawa, Makoto; Ichimasa, Katsuro; Miyachi, Hideyuki; Ishida, Fumio; Inoue, Haruhiro			Diagnostic performance of endocytoscopy for evaluating the invasion depth of different morphological types of colorectal tumors	DIGESTIVE ENDOSCOPY			English	Article						colorectal cancer; endocytoscopic classification; endocytoscopy; morphological type; pit pattern classification	LYMPH-NODE METASTASIS; LONG-TERM OUTCOMES; IN-VIVO; ENDOSCOPIC RESECTION; LESIONS; CARCINOMA; CANCER; CLASSIFICATION; NEOPLASMS; ABILITY	Background and Aim: Endocytoscopy (EC) is a next-generation endoscopic technique that enables diagnostic imaging at 450x magnification. In the present study, we retrospectively evaluated the diagnostic performance of EC and magnifying chromoendoscopy (MCE) for diagnosing the invasion depth of colorectal tumors. Methods: We investigated 330 lesions with a >= 10-mm tumor diameter that could be diagnosed by both MCE and EC. The lesions were classified according to morphological type as follows: laterally spreading type-granular (LST-G), laterally spreading type-non-granular (LST-NG), protruding, or depressed. After all lesions had been classified by both pit pattern and EC, qualitative and quantitative (invasion depth) diagnoses were made. The diagnostic accuracy was then compared between pit pattern classification and EC classification. Results: Diagnostic accuracy of EC classification was significantly higher for LST-NG lesions (90.5%) than for protruding lesions (80.6%) (P<0.05). Diagnostic accuracy for LST-NG lesions was significantly higher with EC classification (90.5%) than with pit pattern classification (79.3%) (P<0.001). Comparison of the diagnostic performance of EC3a findings using EC classification between LST-NG and protruding lesions revealed a sensitivity of 92.9% versus 11.3% (P<0.001), positive predictive value of 78.0% versus 27.3% (P<0.001), negative predictive value of 95.5% versus 56.1% (P<0.001), and diagnostic accuracy of 87.9% versus 51.2% (P<0.001), respectively. Conclusion: EC is a very useful method for evaluating the invasion depth of LST-NG lesions.	[Kudo, Toyoki; Kudo, Shin-ei; Wakamura, Kunihiko; Mori, Yuichi; Misawa, Masashi; Hayashi, Takemasa; Kutsukawa, Makoto; Ichimasa, Katsuro; Miyachi, Hideyuki; Ishida, Fumio] Showa Univ, Yokohama Northern Hosp, Ctr Digest Dis, Yokohama, Kanagawa 2248503, Japan; [Inoue, Haruhiro] Showa Univ, Koto Toyosu Hosp, Ctr Digest Dis, Tokyo, Japan	Kudo, T (reprint author), Showa Univ, Yokohama Northern Hosp, Ctr Digest Dis, 35-1 Chigasaki Chuo, Yokohama, Kanagawa 2248503, Japan.	kudos@med.showa-u.ac.jp					Sasajima K, 2006, GASTROINTEST ENDOSC, V63, P1010, DOI 10.1016/j.gie.2006.01.021; Yoshii S, 2014, CLIN GASTROENTEROL H, V12, P292, DOI 10.1016/j.cgh.2013.08.008; KUDO S, 1994, J CLIN PATHOL, V47, P880, DOI 10.1136/jcp.47.10.880; Yoda Y, 2013, ENDOSCOPY, V45, P718, DOI 10.1055/s-0033-1344234; Ikematsu H, 2013, GASTROENTEROLOGY, V144, P551, DOI 10.1053/j.gastro.2012.12.003; Kudo SE, 2008, GASTROINTEST ENDOSC, V68, pS3, DOI 10.1016/j.gie.2008.07.052; Inoue H, 2006, ENDOSCOPY, V38, P891, DOI 10.1055/s-2006-944667; Kiesslich R, 2004, GASTROENTEROLOGY, V127, P706, DOI 10.1053/j.gastro.2004.06.050; Polglase AL, 2005, GASTROINTEST ENDOSC, V62, P686, DOI 10.1016/j.gie.2005.05.021; Minami H, 2012, DIS ESOPHAGUS, V25, P235, DOI 10.1111/j.1442-2050.2011.01241.x; Kitajima K, 2004, J GASTROENTEROL, V39, P534, DOI 10.1007/s00535-004-1339-4; Tsuruta O, 1997, INT J ONCOL, V10, P1003; Kudo SE, 2011, ENDOSCOPY, V43, P869, DOI 10.1055/s-0030-1256663; Kudo S, 2014, J GASTROEN HEPATOL, V29, P83, DOI 10.1111/jgh.12374; Kudo SE, 1996, GASTROINTEST ENDOSC, V44, P8, DOI 10.1016/S0016-5107(96)70222-5; Rotondano G, 2010, INT J COLORECTAL DIS, V25, P1111, DOI 10.1007/s00384-010-0969-7; Ueno H, 2004, GASTROENTEROLOGY, V127, P385, DOI 10.1053/S0016-5085(04)00717-6; Mori Y, 2013, ENDOSCOPY, V45, P98, DOI 10.1055/s-0032-1325932; Ichimasa K, 2014, DIGEST ENDOSC, V26, P403, DOI 10.1111/den.12164; Cipolletta L, 2009, ENDOSCOPY, V41, P129, DOI 10.1055/s-0028-1103452; Kobayashi Y, 2011, INT J COLORECTAL DIS, V26, P1531, DOI 10.1007/s00384-011-1246-0; Wada Y, 2009, GASTROINTEST ENDOSC, V70, P522, DOI 10.1016/j.gie.2009.01.040; Hamilton S, 1999, WHO CLASSIFICATION T; Inoue Haruhiro, 2004, Gastrointest Endosc Clin N Am, V14, P589, DOI 10.1016/j.giec.2004.03.013; Japanese Society for Cancer of the Colon and Rectum, 2013, JAP CLASS COL CARC; Kudo S, 2001, Gastrointest Endosc Clin N Am, V11, P519; Kutsukawa M, 2014, GASTROINTEST ENDOSC, V79, P648, DOI 10.1016/j.gie.2013.08.029; Neumann Helmut, 2013, Gastrointest Endosc Clin N Am, V23, P695, DOI 10.1016/j.giec.2013.03.006	28	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0915-5635	1443-1661		DIGEST ENDOSC	Dig. Endosc.	NOV	2015	27	7					754	761		10.1111/den.12469		8	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	CU7UH	WOS:000363746700007		
J	Sahara, K; Yamada, R; Fujiwara, T; Koizumi, K; Horiguchi, S; Hishima, T; Yamaguchi, T				Sahara, Kota; Yamada, Rin; Fujiwara, Takashi; Koizumi, Koichi; Horiguchi, Shin-ichiro; Hishima, Tsunekazu; Yamaguchi, Tatsuro			Idiopathic myointimal hyperplasia of mesenteric veins: Rare case of ischemic colitis mimicking inflammatory bowel disease	DIGESTIVE ENDOSCOPY			English	Article						colon; idiopathic myointimal hyperplasia of mesenteric veins; inflammatory bowel disease; ischemia; mesenteric veins		Idiopathic myointimal hyperplasia of mesenteric veins (IMHMV) is a rare and poorly understood ischemic colitis that occurs in the rectosigmoid colon of predominantly young, previously healthy, male patients. A 76-year-old Japanese man presented to our hospital with a 1-year history of worsening diarrhea, lower abdominal pain, and weight loss (-6 kg). Laboratory evaluation revealed white blood cell count of 13200/mu L, C-reactive protein level of 2.0 mg/dL (normal range, 0.0-0.3), and negative results for stool culture (including Clostridium difficile). Colonoscopy showed circumferential and edematous narrowing of the sigmoid colon with deep longitude ulceration. Biopsy was done and examination of the specimen demonstrated no specific ischemia. The patient was treated with bowel rest, antibiotics, and i.v. fluids; however, his symptoms worsened. Finally, sigmoidectomy was carried out. Histological examination demonstrated significant myointimal hyperplasia of mesenteric veins leading to thickening and stenosis of the venous lumen. Therefore, the final diagnosis was IMHMV. Three months following sigmoidectomy, he was asymptomatic.	[Sahara, Kota; Yamaguchi, Tatsuro] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Surg, Tokyo 1138677, Japan; [Yamada, Rin; Horiguchi, Shin-ichiro; Hishima, Tsunekazu] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Pathol, Tokyo 1138677, Japan; [Fujiwara, Takashi; Koizumi, Koichi] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Gastroenterol Med, Tokyo 1138677, Japan	Yamaguchi, T (reprint author), Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Surg, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138677, Japan.	tatsuro@yamaguchi.email.ne.jp					FLAHERTY MJ, 1994, AM J SURG PATHOL, V18, P779, DOI 10.1097/00000478-199408000-00003; Feo L, 2013, INT J COLORECTAL DIS, V28, P433, DOI 10.1007/s00384-012-1480-0; AbuAlfa AK, 1996, AM J SURG PATHOL, V20, P1271, DOI 10.1097/00000478-199610000-00014; Kao PC, 2005, J CLIN GASTROENTEROL, V39, P704, DOI 10.1097/00004836-200509000-00011; Lavu K, 2003, GASTROENTEROLOGY, V125, P236, DOI 10.1016/S0016-5085(03)00663-2; Savoie LM, 1999, DIS COLON RECTUM, V42, P1093, DOI 10.1007/BF02236711; GENTA RM, 1991, GASTROENTEROLOGY, V101, P533; Chiang CK, 2014, ENDOSCOPY, V44, pe54; Garcia-Castellanos R, 2011, J CROHNS COLITIS, V5, P239, DOI 10.1016/j.crohns.2010.12.003	9	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0915-5635	1443-1661		DIGEST ENDOSC	Dig. Endosc.	NOV	2015	27	7					767	770		10.1111/den.12470		4	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	CU7UH	WOS:000363746700009		
J	Tomoda, T; Tsutsumi, K; Okada, H				Tomoda, Takeshi; Tsutsumi, Koichiro; Okada, Hiroyuki			Comparison between Roux-en-Y patients with and without gastrectomy during endoscopic retrograde cholangiopancreatography using a short double-balloon enteroscope	DIGESTIVE ENDOSCOPY			English	Letter							ERCP		[Tomoda, Takeshi; Tsutsumi, Koichiro; Okada, Hiroyuki] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol & Hepatol, Okayama, Japan	Tomoda, T (reprint author), Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol & Hepatol, Okayama, Japan.						Shimatani M, 2009, ENDOSCOPY, V41, P849, DOI 10.1055/s-0029-1215108; Tsutsumi K, 2015, SURG ENDOSC, V29, P1944, DOI 10.1007/s00464-014-3889-8; Sakakihara I, 2015, DIGEST ENDOSC, V27, P146, DOI 10.1111/den.12332; Skinner M, 2014, ENDOSCOPY, V46, P560, DOI 10.1055/s-0034-1365698	4	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0915-5635	1443-1661		DIGEST ENDOSC	Dig. Endosc.	NOV	2015	27	7					775	775		10.1111/den.12509		1	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	CU7UH	WOS:000363746700011		
J	Kudo, Y; Kurita, A; Yazumi, S				Kudo, Yasushi; Kurita, Akira; Yazumi, Shujiro			Endoscopic retrieval of a proximally migrated pancreatic stent	DIGESTIVE ENDOSCOPY			English	Letter									[Kudo, Yasushi; Kurita, Akira; Yazumi, Shujiro] Kitano Hosp, Tazuke Kofukai Med Res Inst, Ctr Digest Dis, Osaka, Japan	Kudo, Y (reprint author), Kitano Hosp, Tazuke Kofukai Med Res Inst, Ctr Digest Dis, Osaka, Japan.						JOHANSON JF, 1992, GASTROINTEST ENDOSC, V38, P341, DOI 10.1016/S0016-5107(92)70429-5	1	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0915-5635	1443-1661		DIGEST ENDOSC	Dig. Endosc.	NOV	2015	27	7					777	777		10.1111/den.12513		1	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	CU7UH	WOS:000363746700013		
J	Kumagai, Y; Watanabe, Y; Ishida, H				Kumagai, Youichi; Watanabe, Yuichiro; Ishida, Hideyuki			Endocytoscopic observation of duodenal polyps associated with familial adenomatous polyposis: Report of four cases	DIGESTIVE ENDOSCOPY			English	Letter							UPPER GASTROINTESTINAL CANCER; CHROMOENDOSCOPY		[Kumagai, Youichi; Watanabe, Yuichiro; Ishida, Hideyuki] Saitama Med Univ, Saitama Med Ctr, Dept Digest Tract & Gen Surg, Saitama, Japan	Kumagai, Y (reprint author), Saitama Med Univ, Saitama Med Ctr, Dept Digest Tract & Gen Surg, Saitama, Japan.						Kumagai Y, 2004, ENDOSCOPY, V36, P590, DOI 10.1055/s-2004-814533; SPIGELMAN AD, 1989, LANCET, V2, P783; Kumagai Y, 2010, DIGEST ENDOSC, V22, P10, DOI 10.1111/j.1443-1661.2009.00931.x; JAGELMAN DG, 1988, LANCET, V1, P1149; Dekker E, 2009, ENDOSCOPY, V41, P666, DOI 10.1055/s-0029-1214980	5	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0915-5635	1443-1661		DIGEST ENDOSC	Dig. Endosc.	NOV	2015	27	7					778	778		10.1111/den.12516		1	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	CU7UH	WOS:000363746700014		
J	Ito, T; Inokuma, T				Ito, Takahiko; Inokuma, Tetsurou			Gastric metastasis of pancreatic neuroendocrine tumor 5 years after surgical resection of the primary lesion	DIGESTIVE ENDOSCOPY			English	Letter							STOMACH		[Ito, Takahiko; Inokuma, Tetsurou] Kobe City Med Ctr Gen Hosp, Dept Gastroenterol, Kobe, Hyogo, Japan	Ito, T (reprint author), Kobe City Med Ctr Gen Hosp, Dept Gastroenterol, Kobe, Hyogo, Japan.						Oda I, 2001, ENDOSCOPY, V33, P507, DOI 10.1055/s-2001-14960; MENUCK LS, 1975, AM J DIG DIS, V20, P903, DOI 10.1007/BF01070875	2	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0915-5635	1443-1661		DIGEST ENDOSC	Dig. Endosc.	NOV	2015	27	7					781	781		10.1111/den.12531		1	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	CU7UH	WOS:000363746700017		
J	Hamada, Y; Maeshiro, K; Nakayama, Y				Hamada, Yoshihiro; Maeshiro, Kensei; Nakayama, Yoshifuku			Spherical protein plug in the dilated branch duct of the pancreas	DIGESTIVE ENDOSCOPY			English	Letter									[Hamada, Yoshihiro] Fukuoka Univ, Fac Med, Dept Pathol, Fukuoka 81401, Japan; [Maeshiro, Kensei] St Maria Hosp, Dept Surg, Kurume, Fukuoka, Japan; [Nakayama, Yoshifuku] Murakami Mem Hosp, Dept Pathol, Nakatsu, Japan	Hamada, Y (reprint author), Fukuoka Univ, Fac Med, Dept Pathol, Fukuoka 81401, Japan.						Kaneko K, 2007, DIGEST DIS SCI, V52, P1979, DOI 10.1007/s10620-006-9398-4; Inoue K, 2013, PROG DIS ENDOSCOPY, V83, P204; Noda A, 2013, PANCREAS, V15, P209; Yamamoto M, 2002, J AICHI MED U ASS, V30, P209	4	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0915-5635	1443-1661		DIGEST ENDOSC	Dig. Endosc.	NOV	2015	27	7					782	782		10.1111/den.12530		1	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	CU7UH	WOS:000363746700018		
J	Han, Z; Chen, GQ; Li, YG; He, Y				Han, Zheng; Chen, Guangqi; Li, Yange; He, Yi			Assessing entrainment of bed material in a debris-flow event: a theoretical approach incorporating Monte Carlo method	EARTH SURFACE PROCESSES AND LANDFORMS			English	Article						debris flow; bed-sediment entrainment; critical line; Monte Carlo method; the 2010 Yohutagawa debris-flow event	3-DIMENSIONAL TERRAIN; VELOCITY DISTRIBUTION; NUMERICAL-SIMULATION; CROSS-SECTIONS; LANDSLIDE; MODEL; FIELD; GIS; AVALANCHES; DISCHARGE	Entrainment of underlying bed sediment by a debris flow can significantly increase the debris-flow magnitude. To study this phenomenon, a theoretical approach to assessing bed-sediment entrainment is presented. The approach is based on a static approximation that bed-sediment entrainment occurs when the shearing stress of the flow is sufficiently high to overcome the basal resistance of the bed sediment. In order to delineate erodible zones in a channel, we analyze the critical condition of this static equilibrium model, and subsequently propose a new concept of a critical line to detect the entrainment reaches in a channel. Considering the spatial and temporal uncertainties of the input parameter, the approach is further incorporated within a Monte Carlo method, and the distribution of entrainment zones and post-entrainment volumes can be analyzed. This approach is illustrated by back-analysis of the 2010 Yohutagawa debris-flow event, Japan. Results from 10 000 trials of Monte Carlo simulation are compared with the in situ surveys. It is shown that the present approach can be satisfactorily used to delineate erodible zones and estimate possible entrainment volume of the event. Discussion regarding the sensitivities and limitations of the approach concludes the paper. Copyright (c) 2015 John Wiley & Sons, Ltd.	[Han, Zheng; Chen, Guangqi; He, Yi] Kyushu Univ, Dept Civil & Struct Engn, Nishi Ku, Fukuoka 8190395, Japan; [Han, Zheng; Li, Yange] Cent S Univ, Sch Civil Engn, Changsha, Hunan, Peoples R China; [Li, Yange] Chengdu Univ Technol, State Key Lab Geohazard Prevent & Geoenvironm Pro, Chengdu, Peoples R China	Han, Z (reprint author), Kyushu Univ, Dept Civil & Struct Engn, Nishi Ku, West 2-1110,744 Motooka, Fukuoka 8190395, Japan.	hankzzz@163.com			Japan Society for the Promotion of Science [15K12483]; Kyushu University Interdisciplinary Programs in Education and Projects in Research Development; Foundation of State Key Laboratory of Geohazard Prevention and Geoenvironment Protection [SKLGP2015K008]	This study was financially supported by Grant-in-Aid for challenging Exploratory Research (15K12483, G. Chen) from Japan Society for the Promotion of Science, and Kyushu University Interdisciplinary Programs in Education and Projects in Research Development. Besides, the financial support from Foundation of State Key Laboratory of Geohazard Prevention and Geoenvironment Protection (SKLGP2015K008, Y. Li) is gratefully acknowledged. The authors extend their gratitude to editor-in-chief Prof. Lane, assistant editor Fiona Kirkby, Prof. Dr Fritz Schlunegger, and an anonymous reviewer for their insightful comments.	Abele G, 1997, Z GEOMORPHOL, V41, P1; Papa M, 2004, NAT HAZARD EARTH SYS, V4, P469; Iverson RM, 2001, J GEOPHYS RES-SOL EA, V106, P537, DOI 10.1029/2000JB900329; McCoy SW, 2012, J GEOPHYS RES-EARTH, V117, DOI 10.1029/2011JF002278; Bovis MJ, 1999, EARTH SURF PROC LAND, V24, P1039, DOI 10.1002/(SICI)1096-9837(199910)24:11<1039::AID-ESP29>3.0.CO;2-U; Abanco C, 2014, NAT HAZARDS, V71, P363, DOI 10.1007/s11069-013-0930-5; Mangeney A, 2011, NAT GEOSCI, V4, P77, DOI 10.1038/ngeo1077; Jakob M, 2005, EARTH SURF PROC LAND, V30, P755, DOI 10.1002/esp.1188; Dowling CA, 2014, NAT HAZARDS, V71, P203, DOI 10.1007/s11069-013-0907-4; Iverson RM, 2011, NAT GEOSCI, V4, P116, DOI [10.1038/ngeo1040, 10.1038/NGEO1040]; Scheidl C, 2010, EARTH SURF PROC LAND, V35, P157, DOI 10.1002/esp.1897; HUNGR O, 1984, CAN GEOTECH J, V21, P663, DOI 10.1139/t84-073; Crosta GB, 2009, J GEOPHYS RES-EARTH, V114, DOI 10.1029/2008JF001186; Chen JC, 2014, NAT HAZARD EARTH SYS, V14, P1719, DOI 10.5194/nhess-14-1719-2014; Michalowski RL, 2005, J GEOTECH GEOENVIRON, V131, P1429, DOI 10.1061/(ASCE)1090-0241(2005)131:11(1429); Wu J, 2013, J MT SCI-ENGL, V10, P522, DOI 10.1007/s11629-013-2486-y; McCoy SW, 2013, J GEOPHYS RES-EARTH, V118, P589, DOI 10.1002/jgrf.20041; Sovilla B, 2006, J GEOPHYS RES-EARTH, V111, DOI 10.1029/2005JF000391; Tang C, 2012, QUATERN INT, V250, P63, DOI 10.1016/j.quaint.2010.11.020; Stock JD, 2006, GEOL SOC AM BULL, V118, P1125, DOI 10.1130/B25902.1; Hungr O, 2009, COMPUT GEOSCI-UK, V35, P978, DOI 10.1016/j.cageo.2007.12.003; Egashira S, 2001, PHYS CHEM EARTH PT C, V26, P645, DOI 10.1016/S1464-1917(01)00062-9; Chen NS, 2007, GEOMORPHOLOGY, V84, P44, DOI 10.1016/j.geomorph.2006.07.007; Imran J, 2001, J HYDRAUL ENG-ASCE, V127, P959, DOI 10.1061/(ASCE)0733-9429(2001)127:11(959); Han Z, 2015, ENG GEOL, V190, P52, DOI 10.1016/j.enggeo.2015.02.009; Bouchut F, 2008, ACTA MECH, V199, P181, DOI 10.1007/s00707-007-0534-9; Iverson RM, 1997, REV GEOPHYS, V35, P245, DOI 10.1029/97RG00426; Mangeney A, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2007GL031348; Lin DG, 2009, NAT HAZARDS, V50, P623, DOI 10.1007/s11069-009-9371-6; HUTCHINS.JN, 1971, GEOTECHNIQUE, V21, P353; Blijenberg HM, 2007, ENG GEOL, V91, P25, DOI 10.1016/j.enggeo.2006.12.010; Cui P, 2013, GEOMORPHOLOGY, V182, P173, DOI 10.1016/j.geomorph.2012.11.009; Hungr O, 2005, S-P BKS GEOPHYS SCI, P135; Liu JF, 2013, LANDSLIDES, V10, P161, DOI 10.1007/s10346-012-0316-x; Godt JW, 2007, GEOMORPHOLOGY, V84, P80, DOI 10.1016/j.geomorph.2006.07.009; Breien H, 2008, LANDSLIDES, V5, P271, DOI 10.1007/s10346-008-0118-3; Brayshaw D, 2009, GEOMORPHOLOGY, V109, P122, DOI 10.1016/j.geomorph.2009.02.021; Han Z, 2015, GEOMORPHOLOGY, V241, P72, DOI 10.1016/j.geomorph.2015.03.043; Guthrie RH, 2008, LANDSLIDES, V5, P151, DOI 10.1007/s10346-007-0104-1; Chen JC, 2008, J HYDRAUL RES, V46, P835, DOI 10.3826/jhr.2008.3173; Osozawa S, 2009, GEOL SOC AM BULL, V121, P1190, DOI 10.1130/B26038.1; RICKENMANN D, 1993, GEOMORPHOLOGY, V8, P175, DOI 10.1016/0169-555X(93)90036-2; Hergarten S, 2014, EARTH SURF DYNAM, V2, P97, DOI 10.5194/esurf-2-97-2014; Wang C, 2008, NAT HAZARD EARTH SYS, V8, P47; Iverson RM, 2012, J GEOPHYS RES-EARTH, V117, DOI 10.1029/2011JF002189; Berti M, 1999, GEOMORPHOLOGY, V29, P265, DOI 10.1016/S0169-555X(99)00018-5; Iverson RM, 2001, GEOLOGY, V29, P115, DOI 10.1130/0091-7613(2001)029<0115:NVOGMF>2.0.CO;2; Glade T, 2005, GEOMORPHOLOGY, V66, P189, DOI 10.1016/j.geomorph.2004.09.023; Mangeney A, 2010, J GEOPHYS RES-EARTH, V115, DOI 10.1029/2009JF001462; Christen M, 2010, COLD REG SCI TECHNOL, V63, P1, DOI 10.1016/j.coldregions.2010.04.005; Wang CX, 2006, ENVIRON GEOL, V51, P91, DOI 10.1007/s00254-006-0307-0; Luna BQ, 2012, ENG GEOL, V128, P63, DOI 10.1016/j.enggeo.2011.04.007; Sovilla B, 2010, J GEOPHYS RES-EARTH, V115, DOI 10.1029/2009JF001390; Armanini A, 2005, J FLUID MECH, V532, P269, DOI 10.1017/S0022112005004283; Chen H, 2006, GEOTECHNIQUE, V56, P305, DOI 10.1680/geot.2006.56.5.305; VANDINE DF, 1985, CAN GEOTECH J, V22, P44, DOI 10.1139/t85-006; Calvo B, 2009, COMPUT GEOSCI-UK, V35, P967, DOI 10.1016/j.cageo.2008.04.002; McDougall S, 2005, CAN GEOTECH J, V42, P1437, DOI 10.1139/T05-064; Farin M, 2014, J GEOPHYS RES-EARTH, V119, P504, DOI 10.1002/2013JF002750; Iverson RM, 2015, REV GEOPHYS, V53, P27, DOI 10.1002/2013RG000447; Brufau P, 2000, J HYDRAUL RES, V38, P435; Medina V, 2008, LANDSLIDES, V5, P127, DOI 10.1007/s10346-007-0102-3; Crosta GB, 2009, ENG GEOL, V109, P135, DOI 10.1016/j.enggeo.2008.10.004; Berger C, 2011, GEOMORPHOLOGY, V125, P421, DOI 10.1016/j.geomorph.2010.10.019; Rickenmann D, 1999, NAT HAZARDS, V19, P47, DOI 10.1023/A:1008064220727; Begueria S, 2009, NAT HAZARD EARTH SYS, V9, P1897; Costa J. E., 1988, FLOOD GEOMORPHOLOGY, P439; desBlasio FV, 2011, EARTH SURF PROCESSES, V36, P753; Han Z, 2014, GEOMAT NAT HAZ RISK, DOI [10.1080/19475705.2014.966868, DOI 10.1080/19475705.2014.966868]; Han Z, 2014, NAT HAZARDS, V74, P2053, DOI 10.1007/s11069-014-1276-3; Jitousono T., 1996, J JAPAN SOC EROSION, V48, P109; King J, 1996, 696 SPR HONG KONG GO; Medina V, 2010, LATEST TRENDS ENG ME, P38; Mizuyama T., 1992, P INT S INT BERN SWI, V4, P99; O'Connor JE, 2001, 1606 USGS; Ouyang C, 2015, ENG GEOLOGY IN PRESS; Pirulli M., 2012, Geotechnique, V62, DOI 10.1680/geot.10.P.074; Rickenmann D, 2003, EROSION DEBRIS FLOWS, P883; Sassa K, 1988, P 5 INT S LANDSL LAU, V1, P37; Soil and Water Conservation Bureau (SWCB), 2005, TECHN HDB SOIL WAT C; TAKAHASHI T, 1978, J HYDR ENG DIV-ASCE, V104, P1153; Takahashi T, 1991, INT ASS HYDRAULIC RE; Tropeano D, 1996, QUADERNI STUDI DOCUM, V20, P5; Wang GH, 2003, ENG GEOL, V69, P30; Wise MP, 1997, THESIS U BRIT COLUMB; Wrachien D., 2011, AGR SCI, V2, P9, DOI 10.4236/as.2011.21002	86	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0197-9337	1096-9837		EARTH SURF PROC LAND	Earth Surf. Process. Landf.	NOV	2015	40	14					1877	1890		10.1002/esp.3766		14	Geography, Physical; Geosciences, Multidisciplinary	Physical Geography; Geology	CU7FN	WOS:000363702200003		
J	Itabashi, Y; Shibayama, K; Mihara, H; Utsunomiya, H; Berdejo, J; Arsanjani, R; Siegel, R; Chakravarty, T; Jilaihawi, H; Makkar, RR; Shiota, T				Itabashi, Yuji; Shibayama, Kentaro; Mihara, Hirotsugu; Utsunomiya, Hiroto; Berdejo, Javier; Arsanjani, Reza; Siegel, Robert; Chakravarty, Tarun; Jilaihawi, Hasan; Makkar, Raj R.; Shiota, Takahiro			Significant Reduction in Mitral Regurgitation Volume Is the Main Contributor for Increase in Systolic Forward Flow in Patients with Functional Mitral Regurgitation after Transcatheter Aortic Valve Replacement: Hemodynamic Analysis Using Echocardiography	ECHOCARDIOGRAPHY-A JOURNAL OF CARDIOVASCULAR ULTRASOUND AND ALLIED TECHNIQUES			English	Article						cardiac output; mitral regurgitation; stroke volume; transcatheter aortic valve replacement	DOPPLER-ECHOCARDIOGRAPHY; TASK-FORCE; IMPLANTATION; STENOSIS; QUANTIFICATION; RECOMMENDATIONS; OUTCOMES; IMPACT; TRIAL; AREA	Background: Reduction in mitral regurgitation (MR) after transcatheter aortic valve replacement (TAVR) has previously been reported. However, the hemodynamic effects of TAVR in patients with MR have not been previously evaluated. Methods: We analyzed 571 patients who underwent TAVR from December 2010 to December 2013. We studied 20 patients with moderate or severe preprocedural functional mitral regurgitation (FMR) who also had a follow-up transthoracic echocardiography (TTE) examination between 90 and 360 days (median 213 days) after TAVR (Significant FMR Group). We also studied age- and gender-matched 20 patients with mild or lesser MR (Nonsignificant MR Group). Left ventricular functional measurements were assessed using echocardiography before and after TAVR. Left ventricular outflow tract stroke volume measurements using pulsed-wave Doppler (SVLVOT) were calculated as a representative of systolic forward flow, and stroke volume by the Simpson's method (SVSimpson) was calculated as a parameter of degree of LV contraction. Results: MR grade improved in 22 of 40 patients after TAVR. In both groups, BNP level decreased, left ventricular ejection fraction increased, and SVLVOT increased after TAVR. SVSimpson increased in the Nonsignificant MR Group and remained unchanged in the Significant FMR Group. Vena contracta width of MR (MRVC) decreased in the Significant FMR Group. Using multivariable analysis in the Significant FMR Group, the increase in SVLVOT significantly correlated with the decrease in MRVC (P < 0.05). Conclusions: SVLVOT increased significantly after TAVR in patients with FMR. In these patients, increase in SVLVOT after TAVR was associated with decrease in severity of MR.	[Itabashi, Yuji; Mihara, Hirotsugu; Utsunomiya, Hiroto; Berdejo, Javier; Arsanjani, Reza; Siegel, Robert; Chakravarty, Tarun; Jilaihawi, Hasan; Makkar, Raj R.; Shiota, Takahiro] Cedars Sinai Heart Inst, Noninvas Cardiac Lab, Los Angeles, CA 90048 USA; [Shibayama, Kentaro] Tokyo Bay Urayasu Ichikawa Med Ctr, Ctr Heart, Chiba, Japan	Shiota, T (reprint author), Cedars Sinai Heart Inst, Noninvas Cardiac Lab, 127 S San Vicente Blvd Suite A3411, Los Angeles, CA 90048 USA.	ShiotaT@cshs.org					Zoghbi WA, 2003, J AM SOC ECHOCARDIOG, V16, P777, DOI 10.1016/S0894-7317(03)00335-3; Lauten A, 2012, JACC-CARDIOVASC INTE, V5, P552, DOI 10.1016/j.jcin.2012.04.001; Nishimura RA, 2014, CIRCULATION, V129, pE521, DOI 10.1161/CIR.0000000000000031; Fairbairn TA, 2013, HEART, V99, P1185, DOI 10.1136/heartjnl-2013-303927; Douglas PS, 2013, J AM SOC ECHOCARDIOG, V26, P348, DOI 10.1016/j.echo.2013.01.013; D'Andrea A, 2015, ECHOCARDIOGR-J CARD, V32, P928, DOI 10.1111/echo.12808; Herrmann HC, 2013, CIRCULATION, V127, P2316, DOI 10.1161/CIRCULATIONAHA.112.001290; Kempny A, 2013, INT J CARDIOL, V167, P2239, DOI 10.1016/j.ijcard.2012.06.012; Giordana F, 2013, ECHOCARDIOGR-J CARD, V30, P250, DOI 10.1111/echo.12050; Gotzmann M, 2012, CATHETER CARDIO INTE, V79, P693, DOI 10.1002/ccd.23240; Toggweiler S, 2012, J AM COLL CARDIOL, V59, P2068, DOI 10.1016/j.jacc.2012.02.020; BLUMLEIN S, 1986, CIRCULATION, V74, P306; Rifkin RD, 2010, JACC-CARDIOVASC IMAG, V3, P1091, DOI 10.1016/j.jcmg.2010.08.013; Barbanti M, 2013, CIRCULATION, V128, P2776, DOI 10.1161/CIRCULATIONAHA.113.003885; Park SJ, 2013, JACC-CARDIOVASC IMAG, V6, P137, DOI 10.1016/j.jcmg.2012.10.013; Zeng X, 2011, CIRC-CARDIOVASC IMAG, V4, P506, DOI 10.1161/CIRCIMAGING.110.961649; Hutter A, 2013, ANN THORAC SURG, V95, P77, DOI 10.1016/j.athoracsur.2012.08.030; Bedogni F, 2013, CIRCULATION, V128, P2145, DOI 10.1161/CIRCULATIONAHA.113.001822; Quinones MA, 2002, J AM SOC ECHOCARDIOG, V15, P167, DOI 10.1067/mje.2002.120202; Hekimian G, 2012, J AM SOC ECHOCARDIOG, V25, P160, DOI 10.1016/j.echo.2011.10.001; D'Onofrio A, 2012, EUR J CARDIO-THORAC, V41, P1276, DOI DOI 10.1093/EJCTS/EZR236; DesChiara B, 2011, CATHETER CARDIOVASC, V78, P638; D'Onofrio A, 2012, EUR J CARDIO-THORAC, V41, P1271, DOI 10.1093/ejcts/ezr236; Goncalves A, 2013, CIRCULATION, V18, P2101; Lang RM, 2015, J AM SOC ECHOCARDIOG, V28, P1, DOI 10.1016/j.echo.2014.10.003; LesVen F, 2013, J AM COLL CARDIOL, V62, P782; Baumgartner H, 2009, J AM SOC ECHOCARDIOG, V22, P1, DOI 10.1016/j.echo.2008.11.029; Quinones M, 2009, J AM SOC ECHOCARDIOG, V22, P101, DOI DOI 10.1016/J.ECHO.2008.11.029; Ramineni R, 2015, ECHOCARDIOGR-J CARD, V32, P677, DOI 10.1111/echo.12854; Thavendiranathan P, 2013, CIRC-CARDIOVASC IMAG, V6, P125, DOI 10.1161/CIRCIMAGING.112.980383; Wang WG, 2014, J AM SOC ECHOCARDIOG, V27, P268, DOI 10.1016/j.echo.2013.11.015	31	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0742-2822	1540-8175		ECHOCARDIOGR-J CARD	Echocardiography-J. Cardiovasc. Ultrasound Allied Tech.	NOV	2015	32	11					1621	1627		10.1111/echo.12936		7	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CU7SA	WOS:000363740600003		
J	Kojima, MS; Noda, A; Miyata, S; Kojima, J; Hara, Y; Minoshima, M; Murohara, T				Kojima, Mari Sugiura; Noda, Akiko; Miyata, Seiko; Kojima, Jun; Hara, Yuki; Minoshima, Makoto; Murohara, Toyoaki			The Effect of Habitual Physical Training on Left Ventricular Function During Exercise Assessed by Three-Dimensional Echocardiography	ECHOCARDIOGRAPHY-A JOURNAL OF CARDIOVASCULAR ULTRASOUND AND ALLIED TECHNIQUES			English	Article						cardiac output; physical training; stroke volume; three-dimensional echocardiography; tissue Doppler imaging	MAXIMAL UPRIGHT EXERCISE; STROKE VOLUME RESPONSE; HYPERTROPHIC CARDIOMYOPATHY; MYOCARDIAL-INFARCTION; FREQUENCY RELATIONS; EJECTION FRACTION; FORCE-FREQUENCY; BLOOD-VOLUME; INDEXES; HEART	BackgroundStroke volume (SV) in trained athletes continuously increases with progressive exercise intensity. We studied whether physical training affected left ventricle (LV) function response to exercise using 3D echocardiography and tissue Doppler imaging (TDI). MethodsEleven male university athletes and 12 male university nonathletes were enrolled in this study. After baseline data were collected, subjects performed a symptom-limited supine bicycle ergometer exercise test. Initial workload was 25Watts (W) and increased 25W every 3minutes. At rest and every exercise stage, LV end-systolic and diastolic volume index (LVEDVI and LVESVI), SV index (SVI), cardiac index (CI), LV ejection fraction (LVEF), and early lateral mitral flow velocity (Ea) were evaluated. Heart rate (HR), and systolic and diastolic blood pressure (SBP and DBP) were continuously recorded. ResultsNonathletes showed a slow increase in CI, and SVI reached a plateau value at a HR of 90beats per minute (bpm). In contrast, CI and SVI increased progressively and continuously in athletes. Both CI and SVI were significantly higher in athletes than in nonathletes at HRs of 100, 110, and 120bpm. LVEDVI kept increasing in athletes while it plateaued in nonathletes. In contrast, LVESV decreased continuously during exercise in both groups. There was no significant difference in LVEF, Ea, SBP, or DBP at rest and during exercise between the two groups. ConclusionLV responses to exercise in athletes were different from those of in nonathletes; thus, habitual physical training may play an important role in the increase in both SVI and CI in young individuals.	[Kojima, Mari Sugiura; Kojima, Jun; Hara, Yuki; Minoshima, Makoto] Nagoya Univ, Sch Hlth Sci, Nagoya, Aichi 4648601, Japan; [Noda, Akiko; Miyata, Seiko] Chubu Univ, Dept Biomed Sci, Kasugai, Aichi 4878501, Japan; [Murohara, Toyoaki] Nagoya Univ, Grad Sch Med, Nagoya, Aichi 4648601, Japan	Noda, A (reprint author), Chubu Univ, Dept Biomed Sci, 1200 Matsumoto Cho, Kasugai, Aichi 4878501, Japan.	anoda@isc.chubu.ac.jp	Murohara, Toyoaki/M-4958-2014				American College of Sports Medicine, 2013, ACSMS GUID EX TEST P; Sundstedt M, 2004, ACTA PHYSIOL SCAND, V182, P45, DOI 10.1111/j.1365-201X.2004.01304.x; Zhou B, 2001, MED SCI SPORT EXER, V33, P1849, DOI 10.1097/00005768-200111000-00008; Sohn DW, 1997, J AM COLL CARDIOL, V30, P474, DOI 10.1016/S0735-1097(97)88335-0; King DL, 2002, J AM SOC ECHOCARDIOG, V15, P1503, DOI 10.1067/mje.2002.126418; Jenkins C, 2007, AM J CARDIOL, V99, P300, DOI 10.1016/j.amjcard.2006.08.026; Stringer WW, 1997, J APPL PHYSIOL, V82, P908; Pagourelias ED, 2013, ECHOCARDIOGR-J CARD, V30, P131, DOI 10.1111/echo.12014; Rowland T, 2009, SPORTS MED, V39, P687, DOI 10.2165/00007256-200939080-00005; Martino M, 2002, MED SCI SPORT EXER, V34, P966, DOI 10.1097/00005768-200206000-00010; CHENG CP, 1992, CIRC RES, V70, P9; Izawa H, 1997, CIRCULATION, V96, P2959; Rowland T, 2008, SPORTS MED, V38, P541, DOI 10.2165/00007256-200838070-00002; HIGGINBOTHAM MB, 1986, CIRC RES, V58, P281; Vella CA, 2005, BRIT J SPORT MED, V39, P190, DOI 10.1136/bjsm.2004.013037; Yamani H, 2012, ECHOCARDIOGR-J CARD, V29, P66, DOI 10.1111/j.1540-8175.2011.01526.x; Kilner PJ, 1997, HEART VESSELS, V12, P103, DOI 10.1007/BF02767127; Takeichi Y, 2001, J AM COLL CARDIOL, V38, P335, DOI 10.1016/S0735-1097(01)01384-5; Arai K, 2004, AM J CARDIOL, V94, P552, DOI 10.1016/j.amjcard.2004.05.015; Krip B, 1997, MED SCI SPORT EXER, V29, P1469, DOI 10.1097/00005768-199711000-00013; GINZTON LE, 1989, J AM COLL CARDIOL, V14, P364, DOI 10.1016/0735-1097(89)90187-3; HOROWITZ RS, 1982, CIRCULATION, V65, P323; Ruddox V, 2013, INT J CARDIOL, V168, P1306, DOI 10.1016/j.ijcard.2012.12.002; Borlaug BA, 2014, CIRC J, V78, P20, DOI 10.1253/circj.CJ-13-1103; Malm S, 2005, J AM SOC ECHOCARDIOG, V18, P1044, DOI 10.1016/j.echo.2005.03.002; Inagaki M, 1999, CIRCULATION, V99, P1822; Caselli S, 2014, AM J CARDIOL, V114, P1383, DOI 10.1016/j.amjcard.2014.07.070; Sugiura M, 2008, CHOONPA IGAKU, V35, P409, DOI 10.3179/jjmu.35.409	28	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0742-2822	1540-8175		ECHOCARDIOGR-J CARD	Echocardiography-J. Cardiovasc. Ultrasound Allied Tech.	NOV	2015	32	11					1670	1675		10.1111/echo.12934		6	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CU7SA	WOS:000363740600009		
J	Sawa, T; Tanaka, H; Motoji, Y; Hiraishi, M; Mochizuki, Y; Ryo, K; Matsumoto, K; Otake, H; Shinke, T; Hirata, K				Sawa, Takuma; Tanaka, Hidekazu; Motoji, Yoshiki; Hiraishi, Mana; Mochizuki, Yasuhide; Ryo, Keiko; Matsumoto, Kensuke; Otake, Hiromasa; Shinke, Toshiro; Hirata, Ken-ichi			Utility of Isovolumic Contraction Peak Velocity for Evaluation of Adult Patient Status after Transcatheter Closure of Atrial Septal Defect Reply	ECHOCARDIOGRAPHY-A JOURNAL OF CARDIOVASCULAR ULTRASOUND AND ALLIED TECHNIQUES			English	Letter									[Sawa, Takuma; Tanaka, Hidekazu; Motoji, Yoshiki; Hiraishi, Mana; Mochizuki, Yasuhide; Ryo, Keiko; Matsumoto, Kensuke; Otake, Hiromasa; Shinke, Toshiro; Hirata, Ken-ichi] Kobe Univ, Grad Sch Med, Dept Internal Med, Div Cardiovasc Med, Kobe, Hyogo 657, Japan	Sawa, T (reprint author), Kobe Univ, Grad Sch Med, Dept Internal Med, Div Cardiovasc Med, Kobe, Hyogo 657, Japan.						Rudski LG, 2010, J AM SOC ECHOCARDIOG, V23, P685, DOI 10.1016/j.echo.2010.05.010; Lang RM, 2015, J AM SOC ECHOCARDIOG, V28, P1, DOI 10.1016/j.echo.2014.10.003; Rudski LG, 2010, J AM SOC ECHOCARDIOG, V23, p:, DOI DOI 10.1016/J.ECH0.2010.05.010; Sawa T, 2015, ECHOCARDIOGR-J CARD, DOI [10.1111/echo.12982, DOI 10.1111/ECHO.12982]	4	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0742-2822	1540-8175		ECHOCARDIOGR-J CARD	Echocardiography-J. Cardiovasc. Ultrasound Allied Tech.	NOV	2015	32	11					1743	1743		10.1111/echo.13038		1	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CU7SA	WOS:000363740600022		
J	Kato, T; Uehara, K; Ishigaki, S; Nihashi, T; Arimoto, A; Nakamura, H; Kamiya, T; Oshiro, T; Ebata, T; Nagino, M				Kato, T.; Uehara, K.; Ishigaki, S.; Nihashi, T.; Arimoto, A.; Nakamura, H.; Kamiya, T.; Oshiro, T.; Ebata, T.; Nagino, M.			Clinical significance of dual-energy CT-derived iodine quantification in the diagnosis of metastatic LN in colorectal cancer	EJSO			English	Article						Colorectal cancer; Lymph node metastasis; Dual-energy CT; Iodine content	CERVICAL LYMPH-NODES; RECTAL-CANCER; SPECTRAL CT; COMPUTED-TOMOGRAPHY; INITIAL-EXPERIENCE; PREOPERATIVE DIAGNOSIS; RENAL MASSES; COLON-CANCER; DIFFERENTIATION; CARCINOMA	Background: The purpose of this study was to evaluate the diagnostic value of dual-energy computed tomography (DECT) in detecting lymph node (LN) metastasis in patients with colorectal cancer. Methods: Data from 81 LNs from 28 patients with colorectal adenocarcinoma were retrospectively analyzed. All patients received DECT before surgery without any neoadjuvant therapy. The diagnostic value was assessed using the iodine concentration (IC). Results: In the pathological findings, 35 (43.2%) LNs from 13 patients were metastatic and 46 (56.8%) LNs from 17 patients were non-metastatic. The mean IC of metastatic LNs in the portal venous phase (PP) was 1.60 mg/ml, which was significantly lower compared with non-metastatic LNs (3.25 mg/ml, p < 0.001). Receiver operating characteristic (ROC) analysis revealed that the IC in PP had the highest ability to discriminate LN metastasis (area under the ROC curve [AUC] 0.932). The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of IC in PP (cutoff 2.1 mg/ml) were 87.0%, 88.6%, 85.3%, 90.0%, and 87.9%, respectively. When clinically obvious metastatic LNs in conventional CT findings were excluded, 50 LNs remained (5 metastatic and 45 non-metastatic LNs). In this subgroup analysis, the IC in PP remained the most powerful predictor of metastatic LNs (cutoff: 2.1 mg/ml, AUC 0.933). Conclusions: The evaluation of IC in DECT may improve the diagnostic capabilities of discriminating metastatic LNs. This method may be particularly useful when conventional CT findings lead to equivocal results. (C) 2015 Elsevier Ltd. All rights reserved.	[Kato, T.; Uehara, K.; Arimoto, A.; Nakamura, H.; Kamiya, T.; Oshiro, T.; Ebata, T.; Nagino, M.] Nagoya Univ, Grad Sch Med, Dept Surg, Div Surg Oncol, Nagoya, Aichi 4648601, Japan; [Ishigaki, S.; Nihashi, T.] Nagoya Univ, Grad Sch Med, Dept Radiol, Nagoya, Aichi 4648601, Japan	Uehara, K (reprint author), Nagoya Univ, Grad Sch Med, Dept Surg, Div Surg Oncol, Nagoya, Aichi 4648601, Japan.	kuehara@med.nagoya-u.ac.jp					Chandarana H, 2011, AM J ROENTGENOL, V196, pW693, DOI 10.2214/AJR.10.5541; Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4; Smith NJ, 2007, BRIT J CANCER, V96, P1030, DOI 10.1038/sj.bjc.6603646; Filippone A, 2004, RADIOLOGY, V231, P83, DOI 10.1148/radiol.2311021152; Dighe S, 2010, BRIT J SURG, V97, P1407, DOI 10.1002/bjs.7096; Kim JH, 2004, EUR J RADIOL, V52, P78, DOI 10.1016/j.ejrad.2003.12.005; Al-Sukhni E, 2012, ANN SURG ONCOL, V19, P2212, DOI 10.1245/s10434-011-2210-5; Johnson TRC, 2007, EUR RADIOL, V17, P1510, DOI 10.1007/s00330-006-0517-6; Ascenti G, 2013, EUR RADIOL, V23, P2288, DOI 10.1007/s00330-013-2811-4; Liu XW, 2015, RADIOLOGY, V275, P167, DOI 10.1148/radiol.14140481; Taylor A, 2007, ABDOM IMAGING, V32, P323, DOI 10.1007/s00261-006-9081-4; Yu YX, 2013, EUR RADIOL, V23, P1660, DOI 10.1007/s00330-012-2747-0; Dighe S, 2010, CLIN RADIOL, V65, P708, DOI 10.1016/j.crad.2010.01.024; Cho EY, 2013, EUR J RADIOL, V82, pE662, DOI 10.1016/j.ejrad.2013.08.007; Zenk J, 2005, ANN OTO RHINOL LARYN, V114, P43; Zhang XF, 2013, ACAD RADIOL, V20, P947, DOI 10.1016/j.acra.2013.02.011; Tsunoda Y, 2008, JPN J CLIN ONCOL, V38, P347, DOI 10.1093/jjco/hyn032; Tawfik AM, 2014, EUR RADIOL, V24, P574, DOI 10.1007/s00330-013-3035-3; Chau Ian, 2003, Clin Colorectal Cancer, V3, P19, DOI 10.3816/CCC.2003.n.009; de Vries FEE, 2014, EJSO-EUR J SURG ONC, V40, P1777, DOI 10.1016/j.ejso.2014.08.483; Fornaro J., 2011, INSIGHTS IMAGING, V2, P149, DOI 10.1007/s13244-010-0057-0; Hou WS, 2015, ACAD RADIOL, V22, P337, DOI 10.1016/j.acra.2014.10.004; Kawabata-Shoda E, 2015, CANCER EPIDEMIOL, V39, P97, DOI 10.1016/j.canep.2014.11.008; Li XT, 2015, COLORECTAL DIS, V17, P129; Liu HH, 2015, EUR J RADIOL, V84, P228, DOI 10.1016/j.ejrad.2014.11.016; Shihab OC, 2011, BRIT J SURG, V98, P1798, DOI 10.1002/bjs.7662; Pan ZL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053651; Silva AC, 2011, RADIOGRAPHICS, V31, P1031, DOI 10.1148/rg.314105159; Silva AC, 2011, RADIOGRAPHICS, V31, P1047, DOI DOI 10.1148/RG.314105159; Watanabe T, 2015, INT J CLIN ONCOL, V20, P207, DOI 10.1007/s10147-015-0801-z	30	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0748-7983	1532-2157		EJSO-EUR J SURG ONC	EJSO	NOV	2015	41	11					1464	1470		10.1016/j.ejso.2015.08.154		7	Oncology; Surgery	Oncology; Surgery	CU8WO	WOS:000363825000003		
J	Abe, T; Amano, H; Shimamoto, F; Hattori, M; Kuroda, S; Kobayashi, T; Tashiro, H; Ohdan, H				Abe, T.; Amano, H.; Shimamoto, F.; Hattori, M.; Kuroda, S.; Kobayashi, T.; Tashiro, H.; Ohdan, H.			Prognostic evaluation of mucin-5AC expression in intrahepatic cholangiocarcinoma, mass-forming type, following hepatectomy	EJSO			English	Article						Intrahepatic cholangiocarcinoma; Mass-forming type; Mucin core protein	BILIARY-TRACT CANCER; RESECTION; MUC5AC; RECURRENCE; SURVIVAL; MUC2; OUTCOMES; SURGERY	Aim: This study aimed to investigate the clinicopathological predictors of survival in patients with intrahepatic cholangiocarcinoma, mass-forming type (ICC-MF), following curative intent hepatectomy. Methods: Clinical characteristics and outcomes were analyzed in a series of 42 patients who underwent curative hepatectomy for ICC-MF between February 1987 and December 2012. The relationship between immunohistochemical expression profiles of mucin (MUC) core proteins (MUC2, MUC5AC, and MUC6) and surgical outcomes was examined Results: The overall median follow-up period was 2.6 years (0.2-17.9). Bile duct reconstruction (p = 0.017), lymph node metastasis (p = 0.049), maximal mass diameter >= 5.0 cm (p = 0.002), and MUC5AC expression (p = 0.003) were identified as significant adverse predictors of overall survival by univariate analysis. Bile duct reconstruction (p = 0.048), maximal mass diameter >= 5.0 cm (p = 0.002), and MUC5AC expression (p = 0.005) were found to be independent predictors of poor prognosis by multivariate analysis. Maximal mass diameter >= 5.0 cm (p = 0.011) was found to be an independent predictor for the tumor recurrence. There was a strong correlation between MUC5AC expression and lymph node metastasis (p = 0.021). MUC6 expression was more frequent in patients with concurrent MUC5AC expression (p = 0.019). Conclusions: MUC5AC expression was significantly related to long-term prognosis and aggressive tumor development, and may be a useful prognostic marker. (C) 2015 Elsevier Ltd. All rights reserved.	[Abe, T.; Amano, H.; Kuroda, S.; Kobayashi, T.; Tashiro, H.; Ohdan, H.] Hiroshima Univ, Inst Biomed & Hlth Sci, Appl Life Sci, Dept Gastroenterol & Transplant Surg, Hiroshima, Japan; [Shimamoto, F.] Prefectural Univ Hiroshima Human Life & Environm, Div Pathol, Hiroshima, Japan; [Hattori, M.] Hiroshima Univ, Inst Biomed & Hlth Sci, Adv Med Skill Training Ctr, Hiroshima, Japan	Tashiro, H (reprint author), Hiroshima Univ, Inst Biomed & Hlth Sci, Appl Life Sci, Dept Gastroenterol & Transplant Surg, Hiroshima, Japan.	htashiro@hiroshima-u.ac.jp			Japan Society for the Promotion of Science [22591505]	This work was supported in part by a Grant-in-Aid for Scientific Research (22591505) from the Japan Society for the Promotion of Science.	Tamandl D, 2008, ANN SURG ONCOL, V15, P2787, DOI 10.1245/s10434-008-0081-1; Tuncel H, 2012, ONCOL LETT, V3, P1109, DOI 10.3892/ol.2012.633; Rakha EA, 2005, MODERN PATHOL, V18, P1295, DOI 10.1038/modpathol.3800445; [Anonymous], 1989, JPN J SURG, V19, P98; Shibahara H, 2004, HEPATOLOGY, V39, P220, DOI 10.1002/hep.20031; Ruzzenente A, 2014, SURGERY, V155, P633, DOI 10.1016/j.surg.2013.12.003; Adachi T, 2014, J HEPATO-BIL-PAN SCI, V21, P162, DOI 10.1002/jhbp.30; Tashiro H, 2011, J SURG ONCOL, V104, P3, DOI 10.1002/jso.21745; McGuckin MA, 2011, NAT REV MICROBIOL, V9, P265, DOI 10.1038/nrmicro2538; Aishima S, 2006, HISTOPATHOLOGY, V49, P35, DOI 10.1111/j.1365-2559.2006.02414.x; Matsumura N, 2002, CANCER, V94, P1770, DOI 10.1002/cncr.10397; Nathan H, 2009, ANN SURG ONCOL, V16, P14, DOI 10.1245/s10434-008-0180-z; Yonezawa S, 1997, PATHOL INT, V47, P813, DOI 10.1111/j.1440-1827.1997.tb03713.x; Ercolani G, 2010, ANN SURG, V252, P107, DOI 10.1097/SLA.0b013e3181e462e6; Sasaki M, 1996, HEPATOLOGY, V24, P1074; Uenishi T, 2014, J SURG ONCOL, V110, P176, DOI 10.1002/jso.23611; Hollingsworth MA, 2004, NAT REV CANCER, V4, P45, DOI 10.1038/nrc1251; Park SY, 2009, ONCOL REP, V22, P649, DOI 10.3892/or_00000485; Shirabe K, 2010, ANN SURG ONCOL, V17, P1816, DOI 10.1245/s10434-010-0929-z; Matull WR, 2008, BRIT J CANCER, V98, P1675, DOI 10.1038/sj.bjc.6604364; Guglielmi A, 2011, HPB, V13, P240, DOI 10.1111/j.1477-2574.2010.00277.x; Shaib YH, 2004, J HEPATOL, V40, P472, DOI 10.1016/j.jhep.2003.11.030; Guglielmi A, 2009, WORLD J SURG, V33, P1247, DOI 10.1007/s00268-009-9970-0; Babu SD, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-10; Luo XW, 2014, J GASTROINTEST SURG, V18, P562, DOI 10.1007/s11605-013-2447-3; Schiffman SC, 2014, J SURG ONCOL, V109, P98, DOI 10.1002/jso.23459; Yamamoto M, 2001, J Hepatobiliary Pancreat Surg, V8, P154, DOI 10.1007/s005340170039	27	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0748-7983	1532-2157		EJSO-EUR J SURG ONC	EJSO	NOV	2015	41	11					1515	1521		10.1016/j.ejso.2015.07.006		7	Oncology; Surgery	Oncology; Surgery	CU8WO	WOS:000363825000010		
J	Ubukata, K; Chiba, N; Hanada, S; Morozumi, M; Wajima, T; Shouji, M; Iwata, S				Ubukata, Kimiko; Chiba, Naoko; Hanada, Shigeo; Morozumi, Miyuki; Wajima, Takeaki; Shouji, Michi; Iwata, Satoshi		Invasive Pneumococcal Dis Surveill	Serotype Changes and Drug Resistance in Invasive Pneumococcal Diseases in Adults after Vaccinations in Children, Japan, 2010-2013	EMERGING INFECTIOUS DISEASES			English	Article							13-VALENT CONJUGATE VACCINE; IMMUNIZATION PRACTICES ACIP; STREPTOCOCCUS-PNEUMONIAE; UNITED-STATES; POLYSACCHARIDE VACCINE; ADVISORY-COMMITTEE; OTITIS-MEDIA; RECOMMENDATIONS; IMPACT; EPIDEMIOLOGY	After 7-valent pneumococcal conjugate vaccine (PCV) for children was introduced in Japan in November 2010, we examined changes in Streptococcus pneumoniae serotypes and in genetic antimicrobial drug resistance of isolates from adults with invasive pneumococcal diseases. During April 2010 March 2013, a total of, 715 isolates were collected from adults with invasive pneunnococcal diseases. Seven-valent PCV serotypes in adults decreased from 43.3% to 23.8%, most noticeably for serotype 6B. Concomitantly, 23-valent pneumococcal polysaccharide vaccine (PPSV23) serotypes decreased from 82.2% to 72.2%; non-PPSV23 serotypes increased from 13.8% to 25.1%. Parallel with serotype changes, genotypic penicillin-resistant S. pneumoniae decreased from 32.4% to 21.1%, and 6 non-PPSV23 serotypes emerged (6D, 15A, 15C, 16F, 23A, and 35B). Respective vaccine coverage rates for 13-valent PCV and PPSV23 differed by disease: 73.9% and 84.3% for patients with pneumonia, 56.4% and 69.2% for patients with bacteremia and sepsis, and 45.7% and 69.3% for patients with meningitis.	[Ubukata, Kimiko; Chiba, Naoko; Morozumi, Miyuki; Iwata, Satoshi] Keio Univ, Sch Med, Tokyo 1608582, Japan; [Hanada, Shigeo] Toranomon Gen Hosp, Tokyo, Japan; [Wajima, Takeaki] Tokyo Univ Pharm & Life Sci, Tokyo, Japan; [Shouji, Michi] Natl Canc Ctr, Tokyo, Japan	Ubukata, K (reprint author), Keio Univ, Sch Med, Dept Infect Dis, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	ubukatak@a6.keio.jp			Japanese Ministry of Health, Labour and Welfare [H22-013]	This study was funded in part by a grant (Research on Emerging and Re-emerging Infectious Diseases H22-013) from the Japanese Ministry of Health, Labour and Welfare to K. U.	Rosen JB, 2011, CLIN INFECT DIS, V53, P137, DOI 10.1093/cid/cir326; Pai R, 2005, J CLIN MICROBIOL, V43, P5440, DOI 10.1128/JCM.43.11.5440-5444.2005; Shea KM, 2011, VACCINE, V29, P8042, DOI 10.1016/j.vaccine.2011.08.057; Moore MR, 2008, J INFECT DIS, V197, P1016, DOI 10.1086/528996; Sakai F, 2011, J INFECT CHEMOTHER, V17, P334, DOI 10.1007/s10156-010-0180-3; Angoulvant F, 2014, CLIN INFECT DIS, V58, P918, DOI 10.1093/cid/ciu006; Pan XS, 1996, ANTIMICROB AGENTS CH, V40, P2321; Steens A, 2013, VACCINE, V31, P6232, DOI 10.1016/j.vaccine.2013.10.032; Kyaw MH, 2006, NEW ENGL J MED, V354, P1455, DOI 10.1056/NEJMoa051642; Ko KS, 2012, J CLIN MICROBIOL, V50, P818, DOI 10.1128/JCM.05895-11; Chiba N, 2012, MICROB DRUG RESIST, V18, P149, DOI 10.1089/mdr.2011.0102; Richter SS, 2013, EMERG INFECT DIS, V19, P1074, DOI 10.3201/eid1907.121830; Beall B, 2002, J INFECT DIS, V186, P118, DOI 10.1086/341072; Taylor S, 2012, CLIN INFECT DIS, V54, P1765, DOI 10.1093/cid/cis292; Song JH, 2011, J CLIN MICROBIOL, V49, P1758, DOI 10.1128/JCM.02628-10; Hsu HE, 2009, NEW ENGL J MED, V360, P244, DOI 10.1056/NEJMoa0800836; Grabenstein JD, 2014, CLIN INFECT DIS, V58, P854, DOI 10.1093/cid/cit800; Miller E, 2011, LANCET INFECT DIS, V11, P760, DOI 10.1016/S1473-3099(11)70090-1; Griffin MR, 2013, NEW ENGL J MED, V369, P155, DOI 10.1056/NEJMoa1209165; Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B; Gertz RE, 2010, J INFECT DIS, V201, P770, DOI 10.1086/650496; Alanee SRJ, 2007, CLIN INFECT DIS, V45, P46, DOI 10.1086/518538; Whitney CG, 2003, NEW ENGL J MED, V348, P1737, DOI 10.1056/NEJMoa022823; Lexau CA, 2005, JAMA-J AM MED ASSOC, V294, P2043, DOI 10.1001/jama.294.16.2043; Hampton LM, 2012, J INFECT DIS, V205, P401, DOI 10.1093/infdis/jir755; Brueggemann AB, 2007, PLOS PATHOG, V3, P1628, DOI 10.1371/journal.ppat.0030168; Bennett Nancy M., 2012, Morbidity and Mortality Weekly Report, V61, P816; Centers for Disease Control and Prevention, 2005, MMWR-MORBID MORTAL W, V54, P893; Centers for Disease Control and Prevention (CDC), 2010, MMWR-MORBID MORTAL W, V59, P258; Nuorti J. P., 2010, Morbidity and Mortality Weekly Report, V59, P1102; Chiba N, 2014, EMERG INFECT DIS, V20, P1132, DOI 10.3201/eid2007.131485; Clinical and Laboratory Standards Institute, 2011, M100S21 CLIN LAB STA, V31; Harboe ZB, 2014, CLIN INFECT DIS, V59, P1066, DOI 10.1093/cid/ciu524; Lee Lucia H, 2014, Vaccines (Basel), V2, P112, DOI 10.3390/vaccines2010112; Moore CE, 2014, J INFECT DIS, V210, P1001, DOI 10.1093/infdis/jiu213; Muhammad Riyadh D, 2013, Clin Infect Dis, V56, pe59, DOI 10.1093/cid/cis971; Pilishvili T, 2010, J INFECT DIS, V201, P32, DOI 10.1086/648593; Richter SS, 2014, ANTIMICROB AGENTS CH, V58, P6484, DOI 10.1128/AAC.03344-14; Tomczyk S, 2014, MMWR-MORBID MORTAL W, V63, P822	39	0	0	CENTERS  DISEASE CONTROL	ATLANTA	1600 CLIFTON RD, ATLANTA, GA 30333 USA	1080-6040	1080-6059		EMERG INFECT DIS	Emerg. Infect. Dis	NOV	2015	21	11					1956	1965		10.3201/eid2111.142029		10	Immunology; Infectious Diseases	Immunology; Infectious Diseases	CU5WA	WOS:000363601500009		
J	Aizawa, Y; Watanabe, K; Oishi, T; Hirano, H; Hasegawa, I; Saitoh, A				Aizawa, Yuta; Watanabe, Kanako; Oishi, Tomohiro; Hirano, Harunobu; Hasegawa, Isao; Saitoh, Akihiko			Role of Maternal Antibodies in Infants with Severe Diseases Related to Human Parechovirus Type 3	EMERGING INFECTIOUS DISEASES			English	Article							YOUNG-CHILDREN; CLINICAL-SAMPLES; INFECTIONS; ASSOCIATION; PCR; STOOL	Human parechovirus type 3 (HPeV3) is an emerging pathogen that causes sepsis and meningoencephalitis in young infants. To test the hypothesis that maternal antibodies can protect this population, we measured neutralizing antibody titers (NATs) to HPeV3 and other genotypes (HPeV1 and HPeV6) in 175 cord blood samples in Japan. The seropositivity rate (>= 1:32) for HPeV3 was 61%, similar to that for the other genotypes, but decreased significantly as maternal age increased (p<0.001). Furthermore, during the 2014 HPeV3 epidemic, prospective measurement of NATs to HPeV3 in 45 patients with severe diseases caused by HPeV3 infection showed low NATs (<= 1:16) at onset and persistently high NATs (>= 1:512) until age 6 months. All intravenous immunoglobulin samples tested elicited high NATs to HPeV3. Our findings indicate that maternal antibodies to HPeV3 may help protect young infants from severe diseases related to HPeV3 and that antibody supplementation may benefit these patients.	[Aizawa, Yuta; Oishi, Tomohiro; Saitoh, Akihiko] Niigata Univ, Grad Sch Med & Dent Sci, Niigata 9518510, Japan; [Watanabe, Kanako] Niigata Univ, Grad Sch Hlth Sci, Niigata 9518510, Japan; [Hirano, Harunobu; Hasegawa, Isao] Saiseikai Niigata Daini Hosp, Niigata, Japan; [Saitoh, Akihiko] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA	Saitoh, A (reprint author), Niigata Univ, Grad Sch Med & Dent Sci, Dept Pediat, Chuo Ku, 1-757 Asahimachi Dori, Niigata 9518510, Japan.	asaitoh@med.niigata-u.ac.jp			Japan Society for Promotion of Science [26461569]; Morinaga Foundation for Health Nutrition [AN601269]	This work was supported by the Japan Society for Promotion of Science (Grants-in-Aid for Scientific Research 26461569) to A.S., and by the Morinaga Foundation for Health & Nutrition (AN601269) to Y.A.	Pajkrt D, 2009, PEDIATR INFECT DIS J, V28, P1008, DOI 10.1097/INF.0b013e3181a7ab5f; Wildenbeest JG, 2013, PEDIATRICS, V132, pE243, DOI 10.1542/peds.2012-1136; Benschop KSM, 2006, CLIN INFECT DIS, V42, P204, DOI 10.1086/498905; Mohamed N, 2004, J CLIN VIROL, V30, P150, DOI 10.1016/j.jcv.2003.08.016; ABZUG MJ, 1995, CLIN INFECT DIS, V20, P1201; Chhabra P, 2013, J INFECT DIS, V208, P790, DOI 10.1093/infdis/jit254; Foo DGW, 2007, MICROBES INFECT, V9, P1299, DOI 10.1016/j.micinf.2007.06.002; Selvarangan R, 2011, PEDIATR INFECT DIS J, V30, P238, DOI 10.1097/INF.0b013e3181fbefc8; HYYPIA T, 1992, P NATL ACAD SCI USA, V89, P8847, DOI 10.1073/pnas.89.18.8847; Ito M, 2010, J CLIN MICROBIOL, V48, P2683, DOI 10.1128/JCM.00086-10; Corey L, 2005, J MED VIROL, V76, P350, DOI 10.1002/jmv.20365; Tauriainen S, 2007, J MED VIROL, V79, P457, DOI 10.1002/jmv.20831; Wildenbeest JG, 2010, EXPERT REV ANTI-INFE, V8, P1417, DOI [10.1586/eri.10.130, 10.1586/ERI.10.130]; Wolthers KC, 2008, CLIN INFECT DIS, V47, P358, DOI 10.1086/589752; Schuffenecker I, 2012, J CLIN VIROL, V54, P337, DOI 10.1016/j.jcv.2012.04.016; Harvala H, 2009, J INFECT DIS, V199, P1753, DOI 10.1086/599094; Westerhuis BM, 2012, J GEN VIROL, V93, P2363, DOI 10.1099/vir.0.043323-0; Ito M, 2004, J GEN VIROL, V85, P391, DOI 10.1099/vir.0.19456-0; Esposito S, 2014, J CLIN VIROL, V60, P84, DOI 10.1016/j.jcv.2014.03.003; Sedmak G, 2010, CLIN INFECT DIS, V50, P357, DOI 10.1086/649863; Nix WA, 2008, J CLIN MICROBIOL, V46, P2519, DOI 10.1128/JCM.00277-08; Westerhuis B, 2013, J CLIN VIROL, V58, P211, DOI 10.1016/j.jcv.2013.06.036; Kolehmainen P, 2012, J CLIN VIROL, V54, P156, DOI 10.1016/j.jcv.2012.02.006; Watanabe K, 2007, EMERG INFECT DIS, V13, P889; Yang CF, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-306; Verboon-Maciolek MA, 2008, ANN NEUROL, V64, P266, DOI 10.1002/ana.21445; Condit RC, 2013, FIELDS VIROLOGY, V1, P21; Japan National Institute of Infectious Diseases, 2005, MONTHL REP PAR IS DE; Pallansch MA, 2013, 29 CLIN VIR S APR 28; Racaniello VR, 2013, FIELDS VIROLOGY, V1, P610; Stoll Barbara J., 2011, NELSON TXB PEDIAT, P629	31	0	0	CENTERS  DISEASE CONTROL	ATLANTA	1600 CLIFTON RD, ATLANTA, GA 30333 USA	1080-6040	1080-6059		EMERG INFECT DIS	Emerg. Infect. Dis	NOV	2015	21	11					1966	1972		10.3201/eid2111.150267		7	Immunology; Infectious Diseases	Immunology; Infectious Diseases	CU5WA	WOS:000363601500010		
J	Hashimoto, Y; Tanaka, M; Kimura, T; Kitagawa, N; Hamaguchi, M; Asano, M; Yamazaki, M; Oda, Y; Toda, H; Nakamura, N; Fukui, M				Hashimoto, Yoshitaka; Tanaka, Muhei; Kimura, Toshihiro; Kitagawa, Noriyuki; Hamaguchi, Masahide; Asano, Mai; Yamazaki, Masahiro; Oda, Yohei; Toda, Hitoshi; Nakamura, Naoto; Fukui, Michiaki			Hemoglobin concentration and incident metabolic syndrome: a population-based large-scale cohort study	ENDOCRINE			English	Article						Epidemiology; Metabolic syndrome; Hematological parameters; Hemoglobin	COMMUNITY-DWELLING PERSONS; GAMMA-GLUTAMYL-TRANSFERASE; TYPE-2 DIABETES-MELLITUS; NONALCOHOLIC FATTY LIVER; SERUM URIC-ACID; INSULIN-RESISTANCE; RISK-FACTORS; HEMATOLOGICAL PARAMETERS; HEART-DISEASE; CARDIOVASCULAR-DISEASE	Previous cross-sectional studies revealed an association between hemoglobin concentration and a prevalence of metabolic syndrome (MetS). However, the association between hemoglobin concentration and incident MetS remains to be elucidated. Thus, the aim of this study was to investigate the association between hemoglobin concentration and incident MetS. We enrolled 2695 subjects (1454 men and 1241 women) and performed 8-year follow-up cohort study. MetS was diagnosed, according to the joint interim statement, when a subject had three or more of the following components: hypertension; hyperglycemia; hypertriglyceridemia; low high-density lipoprotein cholesterol; and abdominal obesity. Logistic regression analyses were performed to assess the impact of hemoglobin concentration on incident MetS by adjusting for age, body mass index, lifestyle factors, including smoking status, habit of alcohol and habit of exercise, systolic blood pressure, fasting plasma glucose, triglycerides, high-density lipoprotein cholesterol, creatinine, and uric acid. The highest (a parts per thousand yen157 g/L) and third (151-156 g/L) hemoglobin concentration quartiles were associated with the increased risk of incident MetS compared to the lowest (< 145 g/L) hemoglobin concentration quartile after adjusting for covariates in men (multivariate odds ratio (OR) 2.24, 95 % CI 1.34-3.85, P = 0.0021 and multivariate OR 2.03, 95 % CI 1.21-3.45, P = 0.0070). On the other hand, there was no association between hemoglobin concentration and incident MetS in women. Hemoglobin concentration was a novel risk marker for incident MetS in men.	[Hashimoto, Yoshitaka; Tanaka, Muhei; Kimura, Toshihiro; Kitagawa, Noriyuki; Hamaguchi, Masahide; Asano, Mai; Yamazaki, Masahiro; Oda, Yohei; Nakamura, Naoto; Fukui, Michiaki] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Endocrinol & Metab, Kamigyo Ku, Kyoto 6028566, Japan; [Toda, Hitoshi] Oike Clin, Dept Internal Med, Kyoto, Japan	Fukui, M (reprint author), Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Endocrinol & Metab, Kamigyo Ku, 465 Kajii Cho, Kyoto 6028566, Japan.	sayarinapm@hotmail.com		Hamaguchi, Masahide/0000-0002-8651-4445; Hashimoto, Yoshitaka/0000-0002-8794-0550			Matsuo S, 2009, AM J KIDNEY DIS, V53, P982, DOI 10.1053/j.ajkd.2008.12.034; Choi KM, 2003, DIABETES RES CLIN PR, V60, P205, DOI 10.1016/S0168-8227(03)00059-7; Tulloch-Reid MK, 2004, DIABETES CARE, V27, P2245, DOI 10.2337/diacare.27.9.2245; Xu Y, 2011, ENDOCRINE, V39, P175, DOI 10.1007/s12020-010-9425-2; Ozdemir A, 2007, ANN SAUDI MED, V27, P356, DOI 10.4103/0256-4947.51476; Hamaguchi M, 2005, ANN INTERN MED, V143, P722; MOAN A, 1994, METABOLISM, V43, P423, DOI 10.1016/0026-0495(94)90070-1; Ota T, 2002, DIABETES CARE, V25, P1252, DOI 10.2337/diacare.25.7.1252; Carnethon MR, 2004, DIABETES CARE, V27, P2707, DOI 10.2337/diacare.27.11.2707; Wang TG, 2011, ENDOCRINE, V40, P109, DOI 10.1007/s12020-011-9449-2; Wannamethee SG, 1996, DIABETES, V45, P576, DOI 10.2337/diabetes.45.5.576; Sone H, 2009, J ATHEROSCLER THROMB, V16, P380; Li Y, 2014, EUR J GASTROEN HEPAT, V26, P332, DOI 10.1097/MEG.0000000000000015; Jiang YZ, 2014, J GASTROEN HEPATOL, V29, P1508, DOI 10.1111/jgh.12580; Nakamura T, 2001, JPN CIRC J, V65, P11, DOI 10.1253/jcj.65.11; Xu Y, 2011, J DIABETES, V3, P38, DOI 10.1111/j.1753-0407.2010.00111.x; Nakanishi N, 2004, DIABETIC MED, V21, P476, DOI 10.1111/j.1464-5491.2004.01152.x; Facchini FS, 1998, METABOLISM, V47, P831, DOI 10.1016/S0026-0495(98)90121-4; Brown DW, 2001, AM HEART J, V142, P657, DOI 10.1067/mhj.2001.118467; Kawamoto R, 2013, ENDOCRINE, V43, P334, DOI 10.1007/s12020-012-9662-7; Xu Y, 2011, ENDOCRINE, V40, P265, DOI 10.1007/s12020-011-9468-z; Wang YY, 2004, J DIABETES COMPLICAT, V18, P322, DOI 10.1016/S1056-8727(04)00003-0; Kawamoto R, 2013, ENDOCRINE, V44, P132, DOI 10.1007/s12020-013-9912-3; GAGNON DR, 1994, AM HEART J, V127, P674, DOI 10.1016/0002-8703(94)90679-3; Kunnas T, 2009, PREV MED, V49, P45, DOI 10.1016/j.ypmed.2009.04.015; Kawamoto R, 2011, J ATHEROSCLER THROMB, V18, P182; Goncalves JP, 2012, ENDOCRINE, V41, P450, DOI 10.1007/s12020-012-9629-8; Miyatake N, 2006, INTERNAL MED, V45, P107, DOI 10.2169/internalmedicine.45.1509; Alberti KGMM, 2009, CIRCULATION, V120, P1640, DOI 10.1161/CIRCULATIONAHA.109.192644; DESIMONE G, 1990, CIRCULATION, V81, P107; Sonmez A, 2010, CLIN J AM SOC NEPHRO, V5, P45, DOI 10.2215/CJN.05080709; Martinez-Garcia MA, 2009, DIABETES CARE, V32, P1525, DOI 10.2337/dc09-0420; Tamariz LJ, 2008, AM J EPIDEMIOL, V168, P1153, DOI 10.1093/aje/kwn243; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Hsueh WA, 2003, AM J CARDIOL, V92, P10, DOI 10.1016/S0002-9149(03)00611-8; Lohsoonthorn V., 2007, DIABETES METAB SYNDR, V1, P143, DOI 10.1016/j.dsx.2007.05.002; Miller E.M., 2014, PLOS ONE, DOI [10.1371/journal.pone.0112216, DOI 10.1371/J0URNAL.P0NE.0112216]; Nagahama S., 2014, BMJ OPEN, DOI [10.1136/bmjopen-2014-005241, DOI 10.1136/BMJ0PEN-2014-005241]; Nebeck Kelsey, 2012, Diabetes Metab Syndr, V6, P22, DOI 10.1016/j.dsx.2012.05.009; Schultz T.A., 1997, AM J PHYSIOL, V233, pE514; Matsuzawa Y, 2002, CIRC J, V66, P987	41	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1355-008X	1559-0100		ENDOCRINE	Endocrine	NOV	2015	50	2					390	396		10.1007/s12020-015-0587-9		7	Endocrinology & Metabolism	Endocrinology & Metabolism	CU4HP	WOS:000363488800017		
J	Mi-ichi, F; Nozawa, A; Yoshida, H; Tozawa, Y; Nozaki, T				Mi-ichi, Fumika; Nozawa, Akira; Yoshida, Hiroki; Tozawa, Yuzuru; Nozaki, Tomoyoshi			Evidence that the Entamoeba histolytica Mitochondrial Carrier Family Links Mitosomal and Cytosolic Pathways through Exchange of 3 '-Phosphoadenosine 5 '-Phosphosulfate and ATP	EUKARYOTIC CELL			English	Article							SULFATE ACTIVATION; EVOLUTION; EXPRESSION; IDENTIFICATION; NUCLEOTIDASE; ARABIDOPSIS; EUKARYOTES	Entamoeba histolytica, a microaerophilic protozoan parasite, possesses mitosomes. Mitosomes are mitochondrion-related organelles that have largely lost typical mitochondrial functions, such as those involved in the tricarboxylic acid cycle and oxidative phosphorylation. The biological roles of Entamoeba mitosomes have been a long-standing enigma. We previously demonstrated that sulfate activation, which is not generally compartmentalized to mitochondria, is a major function of E. histolytica mitosomes. Sulfate activation cooperates with cytosolic enzymes, i. e., sulfotransferases (SULTs), for the synthesis of sulfolipids, one of which is cholesteryl sulfate. Notably, cholesteryl sulfate plays an important role in encystation, an essential process in the Entamoeba life cycle. These findings identified a biological role for Entamoeba mitosomes; however, they simultaneously raised a new issue concerning how the reactions of the pathway, separated by the mitosomal membranes, cooperate. Here, we demonstrated that the E. histolytica mitochondrial carrier family (EhMCF) has the capacity to exchange 3'-phosphoadenosine 5'-phosphosulfate (PAPS) with ATP. We also confirmed the cytosolic localization of all the E. histolytica SULTs, suggesting that in Entamoeba, PAPS, which is produced through mitosomal sulfate activation, is translocated to the cytosol and becomes a substrate for SULTs. In contrast, ATP, which is produced through cytosolic pathways, is translocated into the mitosomes and is a necessary substrate for sulfate activation. Taking our findings collectively, we suggest that EhMCF functions as a PAPS/ATP antiporter and plays a crucial role in linking the mitosomal sulfate activation pathway to cytosolic SULTs for the production of sulfolipids.	[Mi-ichi, Fumika; Yoshida, Hiroki] Saga Univ, Fac Med, Dept Biomol Sci, Div Mol & Cellular Immunosci, Saga 840, Japan; [Nozawa, Akira] Ehime Univ, Proteosci Ctr, Matsuyama, Ehime, Japan; [Tozawa, Yuzuru] Saitama Univ, Grad Sch Sci & Engn, Saitama 3388570, Japan; [Nozaki, Tomoyoshi] Natl Inst Infect Dis, Dept Parasitol, Shinjuku Ku, Tokyo, Japan; [Nozaki, Tomoyoshi] Univ Tsukuba, Grad Sch Life & Environm Sci, Tsukuba, Ibaraki, Japan	Tozawa, Y (reprint author), Saitama Univ, Grad Sch Sci & Engn, Saitama 3388570, Japan.	tozawa@mail.saitama-u.ac.jp; nozaki@nih.go.jp			Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan [22890136, 24117517, 26117719, 24580094, 24589511, 15K07006, 25460594, 24117516, 26117717, 23117001, 23117005, 26293093]; Research Program on Emerging and Re-emerging Infectious Diseases from Japan Agency for Medical Research and Development (AMED)	This work was supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan to F.M. (22890136, 24117517, and 26117719), to A.N. (24580094, 24589511, and 15K07006), to H.Y. (25460594), to Y.T. (24117516 and 26117717), and to T.N. (23117001, 23117005, and 26293093) and from the Research Program on Emerging and Re-emerging Infectious Diseases from Japan Agency for Medical Research and Development (AMED) to T.N. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.	Nozawa A, 2014, METHODS MOL BIOL, V1072, P259, DOI 10.1007/978-1-62703-631-3_19; Gigolashvili T, 2012, PLANT CELL, V24, P4187, DOI 10.1105/tpc.112.101964; Van Der Giezen M, 2009, J EUKARYOT MICROBIOL, V56, P221, DOI 10.1111/j.1550-7408.2009.00407.x; Palmieri F, 2011, PLANT J, V66, P161, DOI 10.1111/j.1365-313X.2011.04516.x; Makiuchi T, 2014, BIOCHIMIE, V100, P3, DOI 10.1016/j.biochi.2013.11.018; Monne M, 2014, CURR TOP MEMBR, V73, P289, DOI 10.1016/B978-0-12-800223-0.00008-6; Bernhard F, 2013, CURR OPIN STRUC BIOL, V23, P374, DOI 10.1016/j.sbi.2013.03.012; Thuswaldner S, 2007, J BIOL CHEM, V282, P8848, DOI 10.1074/jbc.M609130200; Chan KW, 2005, CURR BIOL, V15, P737, DOI 10.1016/j.cub.2005.02.068; Toledano E, 2012, BIOCHEM J, V443, P485, DOI 10.1042/BJ20111057; Mai ZM, 1999, MOL CELL BIOL, V19, P2198; Mi-ichi F, 2015, P NATL ACAD SCI USA, V112, pE2884, DOI 10.1073/pnas.1423718112; Muller M, 2012, MICROBIOL MOL BIOL R, V76, P444, DOI 10.1128/MMBR.05024-11; RAMASWAMY SG, 1987, J BIOL CHEM, V262, P10044; Nozawa A, 2011, BIOCHEM BIOPH RES CO, V414, P612, DOI 10.1016/j.bbrc.2011.09.130; Hjort K, 2010, PHILOS T R SOC B, V365, P713, DOI 10.1098/rstb.2009.0224; Mi-ichi F, 2009, P NATL ACAD SCI USA, V106, P21731, DOI 10.1073/pnas.0907106106; Dolezal P, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000812; Tarique KF, 2014, ACTA CRYSTALLOGR D, V70, P3023, DOI 10.1107/S1399004714021245; Tarique KF, 2014, ACTA CRYSTALLOGR D, V70, P2019, DOI 10.1107/S1399004714010268; Husain A, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-275; Mi-ichi F, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001263; MURGUIA JR, 1995, SCIENCE, V267, P232; Ralston KS, 2011, TRENDS PARASITOL, V27, P253, DOI 10.1016/j.pt.2011.02.006	24	0	0	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	1535-9778	1535-9786		EUKARYOT CELL	Eukaryot. Cell	NOV	2015	14	11					1144	1150		10.1128/EC.00130-15		7	Microbiology; Mycology	Microbiology; Mycology	CU8SQ	WOS:000363814000011		
J	Barrios, CH; Blackstein, ME; Blay, JY; Casali, PG; Chacon, M; Gu, J; Kang, YK; Nishida, T; Purkayastha, D; Woodman, RC; Reichardt, P				Barrios, Carlos H.; Blackstein, Martin E.; Blay, Jean-Yves; Casali, Paolo G.; Chacon, Matias; Gu, Jin; Kang, Yoon-Koo; Nishida, Toshirou; Purkayastha, Das; Woodman, Richard C.; Reichardt, Peter			The GOLD ReGISTry: a Global, Prospective, Observational Registry Collecting Longitudinal Data on Patients with Advanced and Localised Gastrointestinal Stromal Tumours	EUROPEAN JOURNAL OF CANCER			English	Article						CD117 (c-KIT)-positive gastrointestinal stromal tumour (GIST); Global cancer registry; Imatinib; Tyrosine kinase inhibitor; Long-term outcomes; Patient management; Mutational analysis; Localised; Advanced; Adjuvant	ESMO CLINICAL RECOMMENDATIONS; POPULATION-BASED INCIDENCE; IMATINIB MESYLATE; FOLLOW-UP; ADJUVANT IMATINIB; RANDOMIZED-TRIAL; DOSE IMATINIB; PHASE-III; DIAGNOSIS; GIST	Background: Gastrointestinal stromal tumours (GISTs) are the most common gastrointestinal sarcomas. This global, prospective registry followed patients with advanced or localised GIST (2007-2011). Methods: Current and evolving diagnostics, treatments and outcome measures in patients with GIST were assessed. Eligible patients were diagnosed with advanced or localised GIST within 15 months of registry entry. No treatment plan was prescribed, and no visit schedule was mandated. Treating physicians recorded patient information, including tumour response, diagnostic methods, medications, surgeries performed, mutation status and adverse events leading to dose/medication changes. Survival outcomes were estimated using the Kaplan-Meier method. Other data were analysed using descriptive statistics. Results: The registry included 1663 patients (advanced GIST, n = 1095; localised GIST, n = 537). Medications (e.g. tyrosine kinase inhibitor use and dosing), disease progression or recurrence and physician assessment of response to treatment in registry patients were consistent with controlled trials and prevailing clinical recommendations. In advanced GIST, estimated 30-month progression-free survival (PFS) (59.8%) and overall survival (OS) (82.7%) were higher than results from previously reported trials (approximate to 40% and approximate to 70%, respectively). Consistent with treatment guidelines, the most common initial treatments were imatinib for advanced GIST, and complete surgical resection for localised GIST. Computed tomography scans were the most common imaging technique used at diagnosis and follow-up. Mutation analysis was performed at diagnosis in only 15.3% and 14.5% of patients with advanced and localised GIST, respectively. Conclusions: In this real-world GIST registry, patients with advanced GIST were treated with imatinib and patients with localised GIST received surgical resection, in accordance with prevailing clinical recommendations. (C) 2015 The Authors. Published by Elsevier Ltd.	[Barrios, Carlos H.] PUCRS Sch Med, Porto Alegre, RS, Brazil; [Blackstein, Martin E.] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada; [Blay, Jean-Yves] Univ Lyon 1, F-69365 Lyon, France; [Casali, Paolo G.] Ist Nazl Tumori, I-20133 Milan, Italy; [Chacon, Matias] Alexander Fleming Inst, Dept Med Oncol, Buenos Aires, DF, Argentina; [Gu, Jin] Peking Univ, Canc Hosp, Beijing 100871, Peoples R China; [Kang, Yoon-Koo] Univ Ulsan, Coll Med, Seoul, South Korea; [Nishida, Toshirou] Natl Canc Ctr Hosp East, Kashiwa, Chiba 2778577, Japan; [Purkayastha, Das; Woodman, Richard C.] Novartis Pharmaceut, E Hanover, NJ USA; [Reichardt, Peter] HELIOS Klinikum Berlin Buch, D-13125 Berlin, Germany	Reichardt, P (reprint author), HELIOS Klinikum Berlin Buch, Schwanebecker Chaussee 50, D-13125 Berlin, Germany.	chbe@via-rs.net; martin.blackstein@utoronto.ca; jean-yves.blay@lyon.unicancer.fr; paolo.casali@istitutotumori.mi.it; matiemi@yahoo.com; zlgujin@126.com; ykkang@amc.seoul.kr; tnishida@east.ncc.go.jp; das.purkayastha@novartis.com; richard.woodman@novartis.com; peter.reichardt@helios-kliniken.de					Casali PG, 2010, ANN ONCOL, V21, pv98, DOI 10.1093/annonc/mdq208; Sircar K, 1999, AM J SURG PATHOL, V23, P377, DOI 10.1097/00000478-199904000-00002; DeMatteo RP, 2009, LANCET, V373, P1097, DOI 10.1016/S0140-6736(09)60500-6; Demetri GD, 2006, LANCET, V368, P1329, DOI 10.1016/S0140-6736(06)69446-4; [Anonymous], 2012, GLEEVEC; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Corless CL, 2004, J CLIN ONCOL, V22, P3813, DOI 10.1200/JCO.2004.05.140; Blay JY, 2007, ANN ONCOL, V18, P27, DOI 10.1093/annonc/mdm024; Miettinen M, 2006, ARCH PATHOL LAB MED, V130, P1466; Blay JY, 2007, J CLIN ONCOL, V25, P1107, DOI 10.1200/JCO.2006.09.0183; Heinrich MC, 2008, J CLIN ONCOL, V26, P5352, DOI 10.1200/JCO.2007.15.7461; Blay JY, 2005, ANN ONCOL, V16, P566, DOI 10.1093/annonc/mdi127; Nilsson B, 2005, CANCER, V103, P821, DOI 10.1002/cncr.20862; Blanke CD, 2008, J CLIN ONCOL, V26, P626, DOI 10.1200/JCO.2007.13.4452; Verweij J, 2004, LANCET, V364, P1127, DOI 10.1016/S0140-6736(04)17098-0; Mazzola P, 2008, HISTOL HISTOPATHOL, V23, P1379; Corless CL, 2008, ANNU REV PATHOL-MECH, V3, P557, DOI 10.1146/annurev.pathol.3.121806.151538; Wozniak A, 2012, ANN ONCOL, V23, P353, DOI 10.1093/annonc/mdr127; Casali PG, 2009, ANN ONCOL, V20, P64, DOI 10.1093/annonc/mdp131; Rubio J, 2007, EUR J CANCER, V43, P144, DOI 10.1016/j.ejca.2006.07.015; Casali PG, 2008, ANN ONCOL, V19, P35, DOI 10.1093/annonc/mdn080; Joensuu H, 2012, JAMA-J AM MED ASSOC, V307, P1265, DOI 10.1001/jama.2012.347; Tryggvason G, 2005, INT J CANCER, V117, P289, DOI 10.1002/ijc.21167; Demetri GD, 2013, LANCET, V381, P295, DOI 10.1016/S0140-6736(12)61857-1; Blanke CD, 2008, J CLIN ONCOL, V26, P620, DOI 10.1200/JCO.2007.13.4403; Miettinen M, 2006, SEMIN DIAGN PATHOL, V23, P70, DOI 10.1053/j.semdp.2006.09.001; Pisters PWT, 2011, ANN ONCOL, V22, P2523, DOI 10.1093/annonc/mdq773; Blay Jean-Yves, 2012, Discov Med, V13, P357; Blesius A, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-72; Bulusu VR, 2013, P ASCO; Call J, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-90; Chiang NJ, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-102; DeMatteo R, 2007, P ASCO; Rutkowski P, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0765-7; Blay JY, 2012, ANN ONCOL, V23, P49, DOI 10.1093/annonc/mds252	35	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-8049	1879-0852		EUR J CANCER	Eur. J. Cancer	NOV	2015	51	16					2423	2433		10.1016/j.ejca.2015.07.010		11	Oncology	Oncology	CU3ZY	WOS:000363466800018		
J	Tokunaga, Y; Liu, DG; Nakano, J; Zhang, X; Nii, K; Go, T; Huang, CL; Yokomise, H				Tokunaga, Yoshimasa; Liu, Dage; Nakano, Jun; Zhang, Xia; Nii, Kazuhito; Go, Tetsuhiko; Huang, Cheng-Long; Yokomise, Hiroyasu			Potent effect of adenoviral vector expressing short hairpin RNA targeting ribonucleotide reductase large subunit M1 on cell viability and chemotherapeutic sensitivity to gemcitabine in non-small cell lung cancer cells	EUROPEAN JOURNAL OF CANCER			English	Article						RRM1; shRNA; Adenovirus; Gene therapy; Gemcitabine; Chemotherapeutic sensitivity	RANDOMIZED-TRIAL; MAMMALIAN-CELLS; GENE-THERAPY; RESISTANCE; SURVIVAL; INHIBITION; METABOLISM; INDUCTION; GEFITINIB; MECHANISM	Background: Ribonucleotide reductase large subunit (RRM1) is the main enzyme responsible for synthesis of the deoxyribonucleotides used during DNA synthesis. It is also a cellular target for gemcitabine (GEM). Overexpression of RRM1 is reportedly associated with resistance to GEM and the poor prognosis for many types of malignant tumours. Aim of the present study is to establish gene therapy against RRM1-overexpressing tumours. Method: An adenoviral vector that encoded a short hairpin siRNA targeting the RRM1 gene (Ad-shRRM1) was constructed. Two RRM1-overexpressing non-small cell lung cancer (NSCLC) lines, MAC10 and RERF-LC-MA, were used. Finally, a human tumour xenograft model in nude mice was prepared by subcutaneously implanting tumours derived from RERF-LC-MA cells. Results: Ad-shRRM1 effectively downregulated RRM1 mRNA and protein in both types of NSCLC cells and significantly reduced the percentage of viable cells as detected by 3-(4,5-dime thylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (p < 0.005). Caspase 3/7 analysis revealed that transfection with Ad-RRM1 increased the percentage of apoptotic cells in culture containing either type of RRM1-overexpressing cell (p < 0.001). Treatment with Ad-shRRM1 exerted a potent antitumour effect against the RRM1-overexpressing RERF-LC-MA xenografts (p < 0.05). Furthermore, Ad-shRRM1-mediated inhibition of RRM1 specifically increased sensitivity to gemcitabine of each type of RRM1-overexpressing tumour cell. Combination treatment with Ad-shRRM1 and GEM exerted significantly greater inhibition on cell proliferation than Ad-shRRM1 or GEM treatment alone. Conclusion: RRM1 appeared to be a promising target for gene therapy, and Ad-shRRM1 had strong antitumour effects, specifically anti-proliferative and pro-apoptotic effects, against NSCLC cells that overexpressed RRM1. Combination therapy with Ad-shRRM1 and GEM may become a new treatment option for patients with NSCLC. (C) 2015 Elsevier Ltd. All rights reserved.	[Tokunaga, Yoshimasa; Liu, Dage; Nakano, Jun; Nii, Kazuhito; Go, Tetsuhiko; Yokomise, Hiroyasu] Kagawa Univ, Dept Gen Thorac Surg, Fac Med, Miki, Kagawa 7610793, Japan; [Zhang, Xia] Kagawa Univ, Dept Urol, Fac Med, Miki, Kagawa 7610793, Japan; [Huang, Cheng-Long] Kitano Hosp, Med Res Inst, Kita Ku, Osaka 5308480, Japan	Liu, DG (reprint author), Kagawa Univ, Dept Gen Thorac Surg, Fac Med, Miki, Kagawa 7610793, Japan.	dgliu@kms.ac.jp					Rao DD, 2009, ADV DRUG DELIVER REV, V61, P746, DOI 10.1016/j.addr.2009.04.004; Ceppi P, 2006, ANN ONCOL, V17, P1818, DOI 10.1093/annonc/mdl300; Vile R, 2000, J GENE MED, V2, P141; ELLEDGE SJ, 1992, TRENDS BIOCHEM SCI, V17, P119, DOI 10.1016/0968-0004(92)90249-9; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Scherer L, 2004, BIOTECHNIQUES, V36, P557; PARKER WB, 1991, CANCER RES, V51, P2386; Rosell R, 2004, CLIN CANCER RES, V10, P1318, DOI 10.1158/1078-0432.CCR-03-0156; Davidson JD, 2004, CANCER RES, V64, P3761, DOI 10.1158/0008-5472.CAN-03-3363; Bergman AM, 2005, CANCER RES, V65, P9510, DOI 10.1158/0008-5472.CAN-05-0989; Gong WY, 2012, LUNG CANCER, V75, P374, DOI 10.1016/j.lungcan.2011.08.003; Wong A, 2009, DRUG METAB REV, V41, P77, DOI 10.1080/03602530902741828; Huang C, 2008, EXPERT OPIN THER TAR, V12, P637, DOI [10.1517/14728222.12.5.637 , 10.1517/14728220802075157]; Wonganan P, 2012, CANCER BIOL THER, V13, P908, DOI 10.4161/cbt.20843; Bepler G, 2006, J CLIN ONCOL, V24, P4731, DOI 10.1200/JCO.2006.06.1101; Nakano Y, 2007, BRIT J CANCER, V96, P457, DOI 10.1038/sj.bjc.6603559; Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753; Jackman DM, 2009, CLIN CANCER RES, V15, P5267, DOI 10.1158/1078-0432.CCR-09-0888; Jordheim LP, 2005, MOL CANCER THER, V4, P1268, DOI 10.1158/1535-7163.MCT-05-0121; Rosell R, 2003, ONCOGENE, V22, P3548, DOI 10.1038/sj.onc.1206419; Pereira S, 2004, J COMPUT CHEM, V25, P1286, DOI 10.1002/jcc.20054; Yokomise H, 2013, ANTICANCER RES, V33, P1107; Thatcher N, 2005, LANCET, V366, P1527, DOI 10.1016/S0140-6736(05)67625-8; Miller VA, 2012, LANCET ONCOL, V13, P528, DOI 10.1016/S1470-2045(12)70087-6; HEINEMANN V, 1990, MOL PHARMACOL, V38, P567; Anderson WF, 1998, NATURE, V392, P25; KANEGAE Y, 1994, JPN J MED SCI BIOL, V47, P157; Lee JJ, 2010, LUNG CANCER, V70, P205, DOI 10.1016/j.lungcan.2010.02.005; Nordlund Pär, 2006, Annu Rev Biochem, V75, P681, DOI 10.1146/annurev.biochem.75.103004.142443; Reid Glen, 2009, J RNAi Gene Silencing, V5, P321; Rosell R, 2004, CLIN CANCER RES, V10, p4215s; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Taricani L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111714; Wang QC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070191	34	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-8049	1879-0852		EUR J CANCER	Eur. J. Cancer	NOV	2015	51	16					2480	2489		10.1016/j.ejca.2015.05.013		10	Oncology	Oncology	CU3ZY	WOS:000363466800024		
J	Yoshikawa, T; Nakajima, Y; Yamada, Y; Enoki, R; Watanabe, K; Yamazaki, M; Sakimura, K; Honma, S; Honma, K				Yoshikawa, Tomoko; Nakajima, Yoshihiro; Yamada, Yoshiko; Enoki, Ryosuke; Watanabe, Kazuto; Yamazaki, Maya; Sakimura, Kenji; Honma, Sato; Honma, Ken-ichi			Spatiotemporal profiles of arginine vasopressin transcription in cultured suprachiasmatic nucleus	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						arginine vasopressin-Emerald-luciferase; bioluminescence; circadian rhythm; mouse; suprachiasmatic nucleus	VASOACTIVE INTESTINAL POLYPEPTIDE; CIRCADIAN-RHYTHMS; MESSENGER-RNA; IMMUNOREACTIVE NEURONS; PERIPHERAL-TISSUES; CELLULAR CLOCKS; RAT; EXPRESSION; INNERVATION; PATTERNS	Arginine vasopressin (AVP), a major neuropeptide in the suprachiasmatic nucleus (SCN), is postulated to mediate the output of the circadian oscillation. Mice carrying a reporter gene of AVP transcription (AVP(ELuc)) were produced by knocking-in a cDNA of Emerald-luciferase (ELuc) in the translational initiation site. Homozygous mice did not survive beyond postnatal day 7. Using the heterozygous (AVP(ELuc/+)) mice, a bioluminescence reporter system was developed that enabled to monitor AVP transcription through AVP-ELuc measurement in real time for more than 10 cycles in the cultured brain slice. AVP(ELuc/+) mice showed circadian behaviour rhythms and light responsiveness indistinguishable from those of the wild-type. Robust circadian rhythms in AVP-ELuc were detected in the cultured SCN slice at a single cell as well as tissue levels. The circadian rhythm of the whole SCN slice was stable, with the peak at the mid-light phase of a light-dark cycle, while that of a single cell was more variable. By comparison, rhythmicity in the paraventricular nucleus and supraoptic nucleus in the hypothalamus was unstable and damped rapidly. Spatiotemporal profiles of AVP expression at the pixel level revealed significant circadian rhythms in the entire area of AVP-positive cells in the SCN, and at least two clusters that showed different circadian oscillations. Contour analysis of bioluminescence intensity in a cell-like region demonstrated the radiation area was almost identical to the cell size. This newly developed reporter system for AVP gene expression is a useful tool for the study of circadian rhythms.	[Yoshikawa, Tomoko; Yamada, Yoshiko; Enoki, Ryosuke] Hokkaido Univ, Grad Sch Med, Photon Bioimaging Sect, Sapporo, Hokkaido 0608638, Japan; [Yoshikawa, Tomoko; Yamada, Yoshiko; Enoki, Ryosuke; Honma, Sato; Honma, Ken-ichi] Hokkaido Univ, Grad Sch Med, Dept Chronomed, Sapporo, Hokkaido 0608638, Japan; [Nakajima, Yoshihiro] Natl Inst Adv Ind Sci & Technol, Hlth Res Inst, Takamatsu, Kagawa 7610395, Japan; [Enoki, Ryosuke] Japan Sci & Technol Agcy JST, Precursory Res Embryon Sci & Technol PRESTO, Saitama 3320012, Japan; [Watanabe, Kazuto] Dokkyo Med Univ, Sch Med, Dept Regulatory Physiol, Mibu, Tochigi 3210293, Japan; [Yamazaki, Maya; Sakimura, Kenji] Niigata Univ, Brain Res Inst, Dept Cellular Neurobiol, Niigata 9518585, Japan	Honma, K (reprint author), Hokkaido Univ, Grad Sch Med, Dept Chronomed, Sapporo, Hokkaido 0608638, Japan.	kenhonma@med.hokudai.ac.jp			Japan Society for the Promotion of Science (JSPS) [24390055, 20249010]; Cooperative Research Project for Advanced Photonic Bioimaging from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT); Project for Creation of Innovation Centers for Advanced Interdisciplinary Research Areas Program from JSPS; MEXT [200119002]	The authors thank Dr Y. Ueta (University of Occupational and Environmental Health) for his valuable suggestions, which enabled them to generate AVP<SUP>ELuc</SUP> knock-in mice. The authors also thank Dr A. Wirz-Justice for her critical reading of the manuscript, Dr H. Gainer (National Institutes of Health) for the generous donation of AVP antibody for immunohistochemistry, and Drs G.J. Boer and J.J. van Heerikhuize (the Netherlands Institute for Brain Research) for the donation of AVP antiserum for radioimmunoassay. The authors thank the Genetically-Encoded Neuronal Indicator and Effector (GENIE) Project and the Janelia Farm Research Campus of the Howard Hughes Medical Institute for sharing GCaMP6 constructs. The authors appreciate the technical assistance of Ms M. Shudo, Y. Suzuki and M. Fukiya. This work was supported in part by Grant-in-Aid for Scientific Research (B) (No. 24390055 to S.H.) from Japan Society for the Promotion of Science (JSPS), Grant-in-Aid for Scientific Research (A) (No. 20249010 to K.H.) from JSPS, Cooperative Research Project for Advanced Photonic Bioimaging from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT), Project for Creation of Innovation Centers for Advanced Interdisciplinary Research Areas Program from JSPS, and Grant-in-Aid for Scientific Research on Priority Areas-Integrative Brain Research (No. 200119002) from MEXT.	SHINOHARA K, 1995, P NATL ACAD SCI USA, V92, P7396, DOI 10.1073/pnas.92.16.7396; Maruyama T, 2010, PEPTIDES, V31, P2089, DOI 10.1016/j.peptides.2010.08.010; Yasunaga M, 2015, J BIOTECHNOL, V194, P115, DOI 10.1016/j.jbiotec.2014.12.004; Iovino M, 2012, CURR PHARM DESIGN, V18, P4714; Baba K, 2008, EUR J NEUROSCI, V27, P909, DOI 10.1111/j.1460-9568.2008.06053.x; BURBACH JPH, 1988, MOL BRAIN RES, V4, P157, DOI 10.1016/0169-328X(88)90007-1; Nagano M, 2003, J NEUROSCI, V23, P6141; NOTO T, 1983, PEPTIDES, V4, P875, DOI 10.1016/0196-9781(83)90084-0; Nishide S, 2006, GENES CELLS, V11, P1173, DOI 10.1111/j.1365-2443.2006.01015.x; Yamaguchi S, 2003, SCIENCE, V302, P1408, DOI 10.1126/science.1089287; Hamada T, 2004, EUR J NEUROSCI, V19, P1741, DOI 10.1111/j.1460.9568.2004.03275.x; Rood BD, 2011, J COMP NEUROL, V519, P2434, DOI 10.1002/cne.22635; Yizhar O, 2011, NEURON, V71, P9, DOI 10.1016/j.neuron.2011.06.004; Yoshikawa T, 2013, EUR J NEUROSCI, V37, P491, DOI 10.1111/ejn.12052; Dardente H, 2004, MOL BRAIN RES, V124, P143, DOI 10.1016/j.molbrainres.2004.01.010; NELSON W, 1979, CHRONOBIOLOGIA, V6, P305; SHINOHARA K, 1993, J NEUROSCI, V13, P793; Mishina M, 2007, NEUROSCI RES, V58, P105, DOI 10.1016/j.neures.2007.01.004; SCHWARTZ WJ, 1985, J NEUROSCI, V5, P2771; SOFRONIEW MV, 1985, NEUROSCIENCE, V15, P347, DOI 10.1016/0306-4522(85)90217-9; SODERSTEN P, 1985, NEUROSCI LETT, V58, P37, DOI 10.1016/0304-3940(85)90325-8; YAMASE K, 1991, NEUROSCI LETT, V130, P255, DOI 10.1016/0304-3940(91)90409-M; Francl JM, 2010, NEUROREPORT, V21, P1055, DOI 10.1097/WNR.0b013e32833fcba4; ROBINSON BG, 1988, SCIENCE, V241, P342, DOI 10.1126/science.3388044; Enoki R, 2012, P NATL ACAD SCI USA, V109, P21498, DOI 10.1073/pnas.1214415110; MILLAR AJ, 1992, PLANT CELL, V4, P1075; Yamaguchi Y, 2013, SCIENCE, V342, P85, DOI 10.1126/science.1238599; Ueta Y, 2005, ENDOCRINOLOGY, V146, P406, DOI 10.1210/en.2004-0830; WELSH DK, 1995, NEURON, V14, P697, DOI 10.1016/0896-6273(95)90214-7; Romijn HJ, 1997, EUR J NEUROSCI, V9, P2613, DOI 10.1111/j.1460-9568.1997.tb01691.x; Fukaya M, 2006, EUR J NEUROSCI, V24, P2177, DOI 10.1111/j.1460-9568.2006.05081.x; Ban Y, 1997, J NEUROSCI, V17, P3920; Kalsbeek A, 2010, J NEUROENDOCRINOL, V22, P362, DOI 10.1111/j.1365-2826.2010.01956.x; Dzirbikova Z, 2011, CELL MOL NEUROBIOL, V31, P225, DOI 10.1007/s10571-010-9612-y; Moore RY, 2002, CELL TISSUE RES, V309, P89, DOI 10.1007/s00441-002-0575-2; Inagaki N, 2007, P NATL ACAD SCI USA, V104, P7664, DOI 10.1073/pnas.0607713104; TOMINAGA K, 1992, NEUROREPORT, V3, P809, DOI 10.1097/00001756-199209000-00022; Yoo SH, 2004, P NATL ACAD SCI USA, V101, P5339, DOI 10.1073/pnas.0308709101; CAGAMPANG FRA, 1994, MOL BRAIN RES, V24, P179, DOI 10.1016/0169-328X(94)90130-9; Honma S, 2004, NEUROSCI LETT, V358, P173, DOI 10.1016/j.neulet.2004.01.022; Herzog ED, 2004, J BIOL RHYTHM, V19, P35, DOI 10.1177/0748730403260776; Foley NC, 2011, EUR J NEUROSCI, V33, P1851, DOI 10.1111/j.1460-9568.2011.07682.x; Garbarino-Pico E, 2007, COLD SPRING HARB SYM, V72, P145, DOI 10.1101/sqb.2007.72.022; Evans JA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015869; Mieda M, 2015, NEURON, V85, P1103, DOI 10.1016/j.neuron.2015.02.005; Nakajima Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010011; van densPol A., 1991, SUPRACHIASMATIC NUCL, P17	47	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	NOV	2015	42	9					2678	2689		10.1111/ejn.13061		12	Neurosciences	Neurosciences & Neurology	CU9SD	WOS:000363884500007		
J	Masi, A; Narducci, R; Resta, F; Carbone, C; Kobayashi, K; Mannaioni, G				Masi, Alessio; Narducci, Roberto; Resta, Francesco; Carbone, Carmen; Kobayashi, Kazuto; Mannaioni, Guido			Differential contribution of Ih to the integration of excitatory synaptic inputs in substantia nigra pars compacta and ventral tegmental area dopaminergic neurons	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						dopaminergic neurons; hcn channels; Parkinson's disease; patch clamp; th-gfp mice	K-ATP CHANNELS; PARKINSONS-DISEASE; MIDBRAIN NEURONS; SUBTHALAMIC NUCLEUS; H CHANNELS; EXPRESSION; SYSTEM; VULNERABILITY; CALCIUM; MODEL	The selective vulnerability of substantia nigra pars compacta (SNc) dopaminergic (DA) neurons is an enigmatic trait of Parkinson's disease (PD), especially if compared to the remarkable resistance of closely related DA neurons in the neighboring ventral tegmental area (VTA). Overall evidence indicates that specific electrophysiological, metabolic and molecular factors underlie SNc vulnerability, although many pieces of the puzzle are still missing. In this respect, we recently demonstrated that 1-methyl-4-phenylpyridinium (MPP+), the active metabolite of the parkinsonizing toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), alters the electrophysiological properties of SNc DA neurons invitro by inhibiting the hyperpolarization-activated current (Ih). Here, we present an electrophysiological investigation of the functional role of Ih in the integration of synaptic inputs in identified SNc and VTA DA neurons, comparatively, in acute midbrain slices from TH-GFP mice. We show that pharmacological suppression of Ih increases the amplitude and decay time of excitatory postsynaptic potentials, leading to temporal summation of multiple excitatory potentials at somatic level. Importantly, these effects are quantitatively more evident in SNc DA neurons. We conclude that Ih regulates the responsiveness to excitatory synaptic transmission in SNc and VTA DA neurons differentially. Finally, we present the hypothesis that Ih loss of function may be linked to PD trigger mechanisms, such as mitochondrial failure and ATP depletion, and act in concert with SNc-specific synaptic connectivity to promote selective vulnerability.	[Masi, Alessio; Narducci, Roberto; Resta, Francesco; Carbone, Carmen; Mannaioni, Guido] Univ Florence, Sect Pharmacol & Toxicol, Dept Neurosci Psychol Drug Res & Child Hlth NEURO, I-50139 Florence, Italy; [Masi, Alessio; Mannaioni, Guido] Azienda Osped Univ Careggi, Toxicol Unit, Florence, Italy; [Kobayashi, Kazuto] Fukushima Med Univ, Sch Med, Inst Biomed Sci, Dept Mol Genet, Fukushima, Japan	Masi, A (reprint author), Univ Florence, Sect Pharmacol & Toxicol, Dept Neurosci Psychol Drug Res & Child Hlth NEURO, Viale G Pieraccini 6, I-50139 Florence, Italy.	alessio.masi@unifi.it			Regione Toscana Bando Salute; Fondazione Ente Cassa di Risparmio di Firenze; Michael J Fox Foundation for Parkinson's Research, RRIA; Fondazione Umberto Veronesi; Ministero della Salute Bando Ricerca Finalizzata	This work was supported by Regione Toscana Bando Salute 2009 (A.M.), Fondazione Ente Cassa di Risparmio di Firenze (G.M.), The Michael J Fox Foundation for Parkinson's Research, RRIA 2011 (A.M., G.M.), Fondazione Umberto Veronesi (A.M.) and Ministero della Salute Bando Ricerca Finalizzata 2011-2012 (A.M.).	Neuhoff H, 2002, J NEUROSCI, V22, P1290; Grace AA, 2007, TRENDS NEUROSCI, V30, P220, DOI 10.1016/j.tins.2007.03.003; Wallace BA, 2007, BRAIN, V130, P2129, DOI 10.1093/brain/awm137; Guzman JN, 2009, J NEUROSCI, V29, P11011, DOI 10.1523/JNEUROSCI.2519-09.2009; Dufour MA, 2014, J NEUROSCI RES, V92, P981, DOI 10.1002/jnr.23382; Surmeier DJ, 2010, CELL CALCIUM, V47, P175, DOI 10.1016/j.ceca.2009.12.003; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; MERCURI NB, 1995, EUR J NEUROSCI, V7, P462, DOI 10.1111/j.1460-9568.1995.tb00342.x; Ambrosi G, 2014, J NEURAL TRANSM, V121, P849, DOI 10.1007/s00702-013-1149-z; Inyushin MU, 2010, NEUROSCIENCE, V167, P287, DOI 10.1016/j.neuroscience.2010.01.052; D'Ardenne K, 2012, P NATL ACAD SCI USA, V109, P19900, DOI 10.1073/pnas.1116727109; Franz O, 2000, EUR J NEUROSCI, V12, P2685, DOI 10.1046/j.1460-9568.2000.00151.x; Masi A, 2013, BRIT J PHARMACOL, V169, P130, DOI 10.1111/bph.12104; Piallat B, 1999, J NEURAL TRANSM-SUPP, P71; Klar M, 2003, N-S ARCH PHARMACOL, V367, P422, DOI 10.1007/s00210-003-0707-6; Wahl-Schott C, 2009, CELL MOL LIFE SCI, V66, P470, DOI 10.1007/s00018-008-8525-0; Ilijic E, 2011, NEUROBIOL DIS, V43, P364, DOI 10.1016/j.nbd.2011.04.007; Arencibia-Albite F, 2007, NEUROSCIENCE, V149, P303, DOI 10.1016/j.neuroscience.2007.08.009; Liss B, 2005, NAT NEUROSCI, V8, P1742, DOI 10.1038/nn1570; Tsay D, 2007, NEURON, V56, P1076, DOI 10.1016/j.neuron.2007.11.015; Del Tredici K, 2013, J NEUROL NEUROSUR PS, V84, P774, DOI 10.1136/jnnp-2011-301817; Redgrave P, 2010, NAT REV NEUROSCI, V11, P760, DOI 10.1038/nrn2915; Good CH, 2011, FASEB J, V25, P1333, DOI 10.1096/fj.10-173625; Liss B, 1999, EMBO J, V18, P833, DOI 10.1093/emboj/18.4.833; Greene JG, 2005, NEUROBIOL DIS, V18, P19, DOI 10.1016/j.nbd.2004.10.003; Chan CS, 2011, NAT NEUROSCI, V14, P85, DOI 10.1038/nn.2692; Ekstrand MI, 2007, P NATL ACAD SCI USA, V104, P1325, DOI 10.1073/pnas.0605208103; Matsushita N, 2002, J NEUROCHEM, V82, P295, DOI 10.1046/j.1471-4159.2002.00972.x; Blesa J, 2014, FRONT NEUROANAT, V8, DOI 10.3389/fnana.2014.00155; Brichta L, 2014, FRONT NEUROANAT, V8, DOI 10.3389/fnana.2014.00152; Dragicevic E, 2015, NEUROSCIENCE, V284, P798, DOI 10.1016/j.neuroscience.2014.10.037; GRACE AA, 1989, J NEUROSCI, V9, P3463; Huang H, 2014, NEURON, V84, P340, DOI 10.1016/j.neuron.2014.08.046; Lammel S, 2014, NEUROPHARMACOLOGY, V76, P351, DOI 10.1016/j.neuropharm.2013.03.019; Lammel S., 2015, EUR J NEUROSCI, V85, P429; Margolis EB, 2006, J PHYSIOL-LONDON, V577, P907, DOI 10.1113/jphysiol.2006.117069; Pavlov I, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1202; Paxinos G., 2007, MOUSE BRAIN ATLAS ST	38	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	NOV	2015	42	9					2699	2706		10.1111/ejn.13066		8	Neurosciences	Neurosciences & Neurology	CU9SD	WOS:000363884500009		
J	Fujimoto, H; Ohgomori, T; Abe, K; Uchimura, K; Kadomatsu, K; Jinno, S				Fujimoto, Hisataka; Ohgomori, Tomohiro; Abe, Kentaro; Uchimura, Kenji; Kadomatsu, Kenji; Jinno, Shozo			Time-dependent localization of high- and low-sulfated keratan sulfates in the song nuclei of developing zebra finches	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						glycosaminoglycan; phosphacan; sensory motor period; sensory period	CENTRAL-NERVOUS-SYSTEM; SPINAL-CORD-INJURY; CHONDROITIN SULFATE; MONOCLONAL-ANTIBODIES; DEVELOPMENTAL EXPRESSION; LEARNED VOCALIZATIONS; FOREBRAIN CIRCUIT; PERINEURONAL NETS; DEVELOPING BRAIN; CELL-ADHESION	Keratan sulfate proteoglycans (KSPGs) and chondroitin sulfate proteoglycans (CSPGs) consist of a protein core with covalently attached glycosaminoglycan side chain. Although CSPGs are known to regulate the end of the critical period, the role of KSPGs in brain development remains unclear. Young male zebra finches memorise song templates during development. The brain regions that are responsible for song learning, known as song nuclei, are recognized as a suitable model for the study of brain development. To understand the potential role of KSPGs, here we examined the localization of KSs with different degrees of sulfation in the brain of developing male zebra finches. Exclusively in the song nuclei, an increase in expression of 5-D-4-positive (5-D-4(+)) high-sulfated KS started after hatching, and reached a plateau at the end of the sensory period, during which the young bird listens to and memorises the song of an adult tutor. By contrast, weak and ubiquitous expression of BCD-4(+) low-sulfated KS remained unchanged until the end of the sensory period, and first increased in the song nuclei at the end of the sensorimotor period, during which the young bird produces plastic songs. Immunoblot analysis showed that phosphacan was a common core protein of 5-D-4(+) KS and BCD-4(+) KS. Finally, we confirmed that the sulfotransferase responsible for the synthesis of high-sulfated KS was exclusively localised in the song nuclei. Our observations suggest that time-dependent localization of KSPGs with different sulfation patterns in the song nuclei may underlie song learning in developing male zebra finches.	[Fujimoto, Hisataka; Ohgomori, Tomohiro; Jinno, Shozo] Kyushu Univ, Grad Sch Med Sci, Dept Anat & Neurosci, Higashi Ku, Fukuoka 8128582, Japan; [Abe, Kentaro] Kyoto Univ, Dept Biol Sci, Grad Sch Med, Kyoto, Japan; [Uchimura, Kenji; Kadomatsu, Kenji] Nagoya Univ, Grad Sch Med, Dept Biochem, Nagoya, Aichi 4648601, Japan	Jinno, S (reprint author), Kyushu Univ, Grad Sch Med Sci, Dept Anat & Neurosci, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	sjnno@med.kyushu-u.ac.jp	Kadomatsu, Kenji/G-8083-2012		JSPS [25861630, 24110510, 26110714, 15H04267]; MEXT of Japan	This work was supported in part by JSPS KAKENHI grants 25861630 (to H.F.), 24110510 (to S.J.), 26110714 (to S.J.) and 15H04267 (to S.J.), and the Grant-in-Aid for Scientific Research on Innovative Areas 'Comprehensive Brain Science Network' from MEXT of Japan. We thank Mmes. Yoshie Ide and Machiko Endoh for technical and secretarial assistances, Editage (www.editage.jp) for English language editing, and Research Support Center, Graduate School of Medical Sciences, Kyushu University for technical support.	Mikami T, 2009, J BIOL CHEM, V284, P4494, DOI 10.1074/jbc.M809227200; Hensch TK, 2005, NAT REV NEUROSCI, V6, P877, DOI 10.1038/nrn1787; Kiani C, 2002, CELL RES, V12, P19, DOI 10.1038/sj.cr.7290106; Brainard MS, 2002, NATURE, V417, P351, DOI 10.1038/417351a; Funderburgh JL, 2000, GLYCOBIOLOGY, V10, P951, DOI 10.1093/glycob/10.10.951; Miyata S, 2012, NAT NEUROSCI, V15, P414, DOI 10.1038/nn.3023; SCHARFF C, 1991, J NEUROSCI, V11, P2896; Tanaka M, 2003, J NEUROSCI, V23, P2804; Fox K, 2002, SCIENCE, V298, P1187, DOI 10.1126/science.1079224; Morise J, 2014, GLYCOBIOLOGY, V24, P314, DOI 10.1093/glycob/cwt116; Miller B, 1997, J COMP NEUROL, V380, P533, DOI 10.1002/(SICI)1096-9861(19970421)380:4<533::AID-CNE9>3.0.CO;2-2; Reigada D, 2003, P NATL ACAD SCI USA, V100, P3485, DOI 10.1073/pnas.0336914100; NOTTEBOHM F, 1976, SCIENCE, V194, P211, DOI 10.1126/science.959852; Patnode ML, 2013, J BIOL CHEM, V288, P26533, DOI 10.1074/jbc.M113.485409; Imagama S, 2011, J NEUROSCI, V31, P17091, DOI 10.1523/JNEUROSCI.5120-10.2011; Margolis RK, 1996, PERSPECT DEV NEUROBI, V3, P273; Yaji S, 2015, GLYCOBIOLOGY, V25, P376, DOI 10.1093/glycob/cwu118; BOTTJER SW, 1984, SCIENCE, V224, P901, DOI 10.1126/science.6719123; Ito Z, 2010, J NEUROSCI, V30, P5937, DOI 10.1523/JNEUROSCI.2570-09.2010; MOONEY R, 1991, P NATL ACAD SCI USA, V88, P4075, DOI 10.1073/pnas.88.10.4075; Yu AC, 1996, SCIENCE, V273, P1871, DOI 10.1126/science.273.5283.1871; Zhang HQ, 2006, GLYCOBIOLOGY, V16, P702, DOI 10.1093/glycob/cwj115; GLANT TT, 1986, BIOCHEM J, V234, P31; COLE GJ, 1991, NEURON, V7, P1007, DOI 10.1016/0896-6273(91)90345-Z; Dick G, 2013, J BIOL CHEM, V288, P27384, DOI 10.1074/jbc.M111.310029; Hahnloser RHR, 2002, NATURE, V419, P65, DOI 10.1038/nature00974; Wada K, 2006, P NATL ACAD SCI USA, V103, P15212, DOI 10.1073/pnas.0607098103; Doupe AJ, 1999, ANNU REV NEUROSCI, V22, P567, DOI 10.1146/annurev.neuro.22.1.567; Engel M, 1996, J COMP NEUROL, V366, P34; MEYERPUTTLITZ B, 1995, J NEUROCHEM, V65, P2327; Pizzorusso T, 2002, SCIENCE, V298, P1248, DOI 10.1126/science.1072699; Aronov D, 2008, SCIENCE, V320, P630, DOI 10.1126/science.1155140; BRAUN K, 1991, NEUROSCIENCE, V40, P853, DOI 10.1016/0306-4522(91)90017-I; Grunwell JR, 2002, BIOCHEMISTRY-US, V41, P13117, DOI 10.1021/bi020507h; Brainard MS, 2000, NATURE, V404, P762, DOI 10.1038/35008083; Maul KK, 2010, DEV NEUROBIOL, V70, P28, DOI 10.1002/dneu.20751; Dityatev A, 2003, NAT REV NEUROSCI, V4, P456, DOI 10.1038/nrn1115; MAEDA N, 1995, NEUROSCIENCE, V67, P23, DOI 10.1016/0306-4522(94)00069-H; GRUMET M, 1994, J BIOL CHEM, V269, P12142; CATERSON B, 1983, J BIOL CHEM, V258, P8848; NOTTEBOHM F, 1976, J COMP NEUROL, V165, P457, DOI 10.1002/cne.901650405; KONISHI M, 1985, NATURE, V315, P145, DOI 10.1038/315145a0; Balmer TS, 2009, J NEUROSCI, V29, P12878, DOI 10.1523/JNEUROSCI.2974-09.2009; Bandtlow CE, 2000, PHYSIOL REV, V80, P1267; Sugahara K, 2007, CURR OPIN STRUC BIOL, V17, P536, DOI 10.1016/j.sbi.2007.08.015; Fujimoto H, 2011, J NEUROSCI, V31, P10023, DOI 10.1523/JNEUROSCI.1606-11.2011; Hoshino H, 2014, J HISTOCHEM CYTOCHEM, V62, P145, DOI 10.1369/0022155413511619; Konishi M., 1965, Zeitschrift fuer Tierpsychologie, V22, P770; MEHMET H, 1986, EUR J BIOCHEM, V157, P385, DOI 10.1111/j.1432-1033.1986.tb09680.x	49	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	NOV	2015	42	9					2716	2725		10.1111/ejn.13073		10	Neurosciences	Neurosciences & Neurology	CU9SD	WOS:000363884500011		
J	Korai, H; Watanabe, K; Nakao, K; Matsui, T; Hayashi, T				Korai, Hideaki; Watanabe, Ken; Nakao, Katsuhiro; Matsui, Tetsuya; Hayashi, Tomoyuki			Mapping of strength reduction of particleboard subjected to various climatic conditions using a climate deterioration index	EUROPEAN JOURNAL OF WOOD AND WOOD PRODUCTS			English	Article							WOOD-BASED PANELS; OUTDOOR EXPOSURE; BOARD PROPERTIES; DURABILITY; DENSITY	The relationship between climatic factors and strength reduction of particleboard subjected to various climatic conditions at eight sites in Japan was investigated. Climatic factors such as mean temperature, sunshine duration, and precipitation were analyzed by principal component analysis. The first principal component score was introduced as a climate deterioration index (CDI). The particleboard strength reduced in high-CDI area. In this useful index for mapping deterioration zones, the CDI distribution was mapped. The strength reduction was predicted with multiple regression analysis using the CDI and exposure time, and the distribution of strength reduction after the outdoor exposure test was mapped as well. Strength reduced significantly in the southern area, particularly along the Pacific Ocean coast. The high-CDI area had high temperature and long sunshine duration. High temperature led to large strength reduction, and long sunshine duration accelerated the strength reduction process. Conversely, strength reduction in the northern area was smaller than that in the south. The mapping of CDI and strength reduction aided the understanding of the deterioration zone.	[Korai, Hideaki; Watanabe, Ken; Nakao, Katsuhiro; Matsui, Tetsuya] Forestry & Forest Prod Res Inst, Tsukuba, Ibaraki 3058687, Japan; [Hayashi, Tomoyuki] Akita Prefectural Univ, Inst Wood Technol, Noshiro, Akita 0160876, Japan	Korai, H (reprint author), Forestry & Forest Prod Res Inst, Tsukuba, Ibaraki 3058687, Japan.	korai@ffpri.affrc.go.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan [21380108]	This study was supported by a Grant-in-Aid for Scientific Research (21380108) from the Ministry of Education, Culture, Sports, Science and Technology of Japan. The authors are grateful for the grant received. The outdoor exposure test was conducted as part of a project organized by the Research Working Group on Wood-based Panels from the Japan Wood Research Society. The authors express their thanks to all participants of this project. The authors gratefully acknowledge support for the mapping provided by Dr. Dai Koide and Dr. Haruka Ohashi of Forestry and Forest Products Research Institute.	RIVER BH, 1994, FOREST PROD J, V44, P55; Kojima Y, 2012, J WOOD SCI, V58, P525, DOI 10.1007/s10086-012-1287-1; Sekino N, 2014, J WOOD SCI, V60, P141, DOI 10.1007/s10086-013-1384-9; Korai H, 2012, MOKUZAI GAKKAISHI, V58, P347; Korai H, 2014, J WOOD SCI, V60, P127, DOI 10.1007/s10086-013-1374-y; Wong ED, 1998, J WOOD SCI, V44, P287, DOI 10.1007/BF00581309; Kojima Y, 2011, J WOOD SCI, V57, P7, DOI 10.1007/s10086-010-1131-4; Kojima Y, 2009, FOREST PROD J, V59, P35; Korai H, 2013, J WOOD SCI, V59, P24, DOI 10.1007/s10086-012-1291-5; Watanabe K, 2015, J WOOD SCI, V61, P151, DOI 10.1007/s10086-014-1446-7; Korai H, 2014, J WOOD SCI, V60, P134, DOI 10.1007/s10086-013-1375-x; Korai H, 2013, MOKUZAI GAKKAISHI, V59, P361; Korai H, 2012, FOREST PROD J, V62, P184; KAWAI S, 1987, MOKUZAI GAKKAISHI, V33, P385; Kojima Y, 2011, J WOOD SCI, V57, P126, DOI 10.1007/s10086-010-1146-x; Gatchell C. J., 1966, Forest Products Journal, V16, P46; Geographical Survey Institute, 1992, US GUID DIG MAP; Hann R. A., 1962, Forest Products Journal, V12, P577; Hasegawa M, 1996, WOOD PRESERVATION, V22, P246; Japan Meteorological Business Support Center, 2002, MESH CLIM DAT 2000; Japanese Industrial Standards, 2003, A5908 JIS JAP STAND; Korai H, 2014, J ADHES SOC JPN, V50, P260; Korai H, 2015, J WOOD SCI, V61, P35, DOI 10.1007/s10086-014-1433-z; Scheffer T. C., 1971, Forest Products Journal, V21, P25; Suzuki S, 2001, WOOD IND, V56, P7	25	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0018-3768	1436-736X		EUR J WOOD WOOD PROD	Eur. J. Wood Wood Prod.	NOV	2015	73	6					807	817		10.1007/s00107-015-0952-7		11	Forestry; Materials Science, Paper & Wood	Forestry; Materials Science	CU7KZ	WOS:000363718300012		
J	Taniguchi, S; Mizuno, H; Kuwahara, M; Ito, K				Taniguchi, Sakiko; Mizuno, Hisato; Kuwahara, Masayoshi; Ito, Koichi			Early attenuation of long-term potentiation in senescence-accelerated mouse prone 8	EXPERIMENTAL BRAIN RESEARCH			English	Article						Senescence-accelerated mouse; Long-term potentiation; Learning and memory; Aging	AGE-RELATED-CHANGES; MEMORY-DEFICIENT RATS; HIPPOCAMPAL SLICES; ALZHEIMERS-DISEASE; PYRAMIDAL NEURONS; FISCHER-344 RATS; CEREBRAL-CORTEX; IN-VITRO; AREA CA1; MODEL	Senescence-accelerated mouse (SAM) is an experimental model animal showing a short lifespan and rapid advancement of senescence. Especially, SAM prone 8 (SAMP8) shows age-related impairment of learning and memory, and thus, it is a good model for age-related cognitive function. However, the synaptic characteristics related to cognitive function of SAMP8 have been poorly understood. In this study, we quantitatively evaluated the synaptic transmission and synaptic plasticity using hippocampal slices obtained from SAMP8 with electrophysiological methods to elucidate the synaptic features of SAMP8. We used the field recordings to measure some synaptic parameters. The slope of field excitatory postsynaptic potentials decreased with age in both SAMP8 and SAM resistant 1 (SAMR1), the control strain of SAMP8. The paired-pulse ratio (PPR), a representative of short-term synaptic plasticity, also decreased in both strains with age. On the other hand, although both SAMR1 and SAMP8 exhibited age-dependent decrease in long-term potentiation (LTP), a representative of long-term synaptic plasticity, the decrease in LTP in SAMP8 started at 6 months of age, while in SAMR1, it was observed at 14 months but not at 6 months of age. The PPRs after high-frequency stimulation for LTP induction were smaller than those before the stimulation. These results indicate that synaptic plasticity in SAMP8 deteriorates at an earlier age compared to SAMR1, and are consistent with behavioral tests showing early impairment of learning and memory of SAMP8. Our study is the first report on quantitative analysis of synaptic function at SAMP8 hippocampus and corroborates the behavioral studies showing cognitive dysfunction with age; therefore, it will be helpful for future studies on aging.	[Taniguchi, Sakiko; Mizuno, Hisato; Kuwahara, Masayoshi; Ito, Koichi] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Vet Pathophysiol & Anim Hlth, Bunkyo Ku, Tokyo 1138657, Japan	Ito, K (reprint author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Vet Pathophysiol & Anim Hlth, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.	akoito@mail.ecc.u-tokyo.ac.jp			Advanced Research for Medical Products Mining Program of the National Institute of Biomedical Innovation (NIBIO) in Japan [09-1]	This work was supported in part by the Advanced Research for Medical Products Mining Program of the National Institute of Biomedical Innovation (NIBIO) in Japan (09-1).	Rosenzweig ES, 2003, PROG NEUROBIOL, V69, P143, DOI 10.1016/S0301-0082(02)00126-0; MANABE T, 1993, J NEUROPHYSIOL, V70, P1451; Bach ME, 1999, P NATL ACAD SCI USA, V96, P5280, DOI 10.1073/pnas.96.9.5280; Shankar S, 1998, J NEUROPHYSIOL, V79, P334; del Valle J, 2012, J ALZHEIMERS DIS, V32, P233, DOI 10.3233/JAD-2012-120718; Ito K, 2004, J NEUROSCI, V24, P6228, DOI 10.1523/JNEUROSCI.1302-04.2004; KATSUKI H, 1990, ARCH GERONTOL GERIAT, V11, P77, DOI 10.1016/0167-4943(90)90058-E; DEUPREE DL, 1991, BRAIN RES, V554, P1, DOI 10.1016/0006-8993(91)90164-Q; KUBANIS P, 1981, BEHAV NEURAL BIOL, V31, P115, DOI 10.1016/S0163-1047(81)91195-X; Li GM, 2013, NEUROL SCI, V34, P963, DOI 10.1007/s10072-012-1173-z; Chen GH, 2004, PHYSIOL BEHAV, V82, P883, DOI 10.1016/j.physbeh.2004.07.008; Armbrecht HJ, 1999, BRAIN RES, V842, P287, DOI 10.1016/S0006-8993(99)01802-8; TAKEDA T, 1991, J AM GERIATR SOC, V39, P911; YAGI H, 1988, BRAIN RES, V474, P86, DOI 10.1016/0006-8993(88)90671-3; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Lynch MA, 2004, PHYSIOL REV, V84, P87, DOI 10.1152/physrev.00014.2003; Wang F, 2009, NEUROSCI LETT, V454, P212, DOI 10.1016/j.neulet.2009.03.030; Zhang GR, 2009, NEUROSCIENCE, V159, P308, DOI 10.1016/j.neuroscience.2008.06.068; LANDFIELD PW, 1977, J GERONTOL, V32, P523; Craik F I, 1990, Adv Neurol, V51, P201; MIYAMOTO M, 1986, PHYSIOL BEHAV, V38, P399, DOI 10.1016/0031-9384(86)90112-5; Yang S, 2005, NEUROSCI LETT, V379, P7, DOI 10.1016/j.neulet.2004.12.033; DETOLEDOMORRELL L, 1988, NEUROBIOL AGING, V9, P581, DOI 10.1016/S0197-4580(88)80117-9; HARRIS EW, 1984, BRAIN RES, V323, P132, DOI 10.1016/0006-8993(84)90275-0; FLOOD JF, 1993, NEUROBIOL AGING, V14, P153, DOI 10.1016/0197-4580(93)90091-O; Markowska AL, 1998, PHYSIOL BEHAV, V64, P15, DOI 10.1016/S0031-9384(98)00011-0; MOORE CI, 1993, HIPPOCAMPUS, V3, P57, DOI 10.1002/hipo.450030106; LANDFIELD PW, 1978, BRAIN RES, V150, P85, DOI 10.1016/0006-8993(78)90655-8; KITAMURA Y, 1992, NEUROSCI LETT, V137, P169, DOI 10.1016/0304-3940(92)90396-O; WINOCUR G, 1988, NEUROBIOL AGING, V9, P487, DOI 10.1016/S0197-4580(88)80102-7; Ito K, 2013, EXP ANIM TOKYO, V62, P275; YAGI H, 1989, J NEUROPATH EXP NEUR, V48, P577, DOI 10.1097/00005072-198909000-00008; KITAMURA Y, 1989, NEUROSCI LETT, V106, P334, DOI 10.1016/0304-3940(89)90186-9; LIGHT LL, 1991, ANNU REV PSYCHOL, V42, P333, DOI 10.1146/annurev.ps.42.020191.002001	34	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0014-4819	1432-1106		EXP BRAIN RES	Exp. Brain Res.	NOV	2015	233	11					3145	3152		10.1007/s00221-015-4383-9		8	Neurosciences	Neurosciences & Neurology	CU8MF	WOS:000363796200009		
J	Akutsu, J; Zhang, ZL; Morita, R; Kawarabayasi, Y				Akutsu, Jun-ichi; Zhang, Zilian; Morita, Rihito; Kawarabayasi, Yutaka			Identification and characterization of a thermostable bifunctional enzyme with phosphomannose isomerase and sugar-1-phosphate nucleotidylyltransferase activities from a hyperthermophilic archaeon, Pyrococcus horikoshii OT3	EXTREMOPHILES			English	Article						Hyperthermophilic archaea; Sugar-1-phosphate nucleotidylyltransferase; Genomic information; Phosphohexose isomerase; Thermostable enzyme	ALGINATE BIOSYNTHETIC-PATHWAY; D-MANNOSE PYROPHOSPHORYLASE; PSEUDOMONAS-AERUGINOSA; PROTEINS	Mannosylglycerate is known as a compatible solute, and plays important roles for salinity adaptation and high temperature stability of microorganisms. In the gene cluster for the mannosylglycerate biosynthetic pathway predicted from the genomic data of Pyrococcus horikoshii OT3, the PH0925 protein was found as a putative bifunctional enzyme with phosphomannose isomerase (PMI) and mannose-1-phosphate guanylyltransferase (Man-1-P GTase) activities, which can synthesize GDP-mannose when accompanied by a phosphomannomutase/phosphoglucomutase (PMM/PGM) enzyme (PH0923). The recombinant PH0925 protein, expressed in E. coli, exhibited both expected PMI and Man-1-P GTase activities, as well as absolute thermostability; 95 A degrees C was the optimum reaction temperature. According to the guanylyltransferase activity (GTase) of the PH0925 protein, it was found that the protein can catalyze glucose-1-phosphate (Glc-1-P) and glucosamine-1-phosphate (GlcN-1-P) in addition to Man-1-P. The analyses of C-terminus-truncated forms of the PH0925 protein indicated that sugar-1-phosphate nucleotidylyltransferase (Sugar-1-P NTase) activity was located in the region from the N-terminus to the 345th residue, and that the C-terminal 114 residue region of the PH0925 protein inhibited the Man-1-P GTase activity. Conversely, the PMI activity was abolished by deletion of the C-terminal 14 residues. This is the first report of a thermostable enzyme with both PMI and multiple Sugar-1-P NTase activities.	[Akutsu, Jun-ichi; Kawarabayasi, Yutaka] Natl Inst Adv Ind Sci & Technol, Amagasaki, Hyogo 6610974, Japan; [Zhang, Zilian] Xiamen Univ, Inst Marine Microbes & Ecospheres, State Key Lab Marine Environm Sci, Xiamen 361005, Peoples R China; [Morita, Rihito; Kawarabayasi, Yutaka] Kyushu Univ, Fac Agr, Lab Funct Genom Extremophiles, Higashi Ku, Fukuoka, Fukuoka 8128581, Japan	Kawarabayasi, Y (reprint author), Natl Inst Adv Ind Sci & Technol, Nakoji 3-11-46, Amagasaki, Hyogo 6610974, Japan.	kawarabayasi.yutaka@nifty.com			Ministry of Education, Culture, Sports, Science and Technology; Institute for Fermentation, Osaka (IFO)	We thank Mrs. Yuki Machida for her excellent technical assistance. This work was partly supported by a special grant from the Protein 3000 projects of the Ministry of Education, Culture, Sports, Science and Technology, and partly by the Institute for Fermentation, Osaka (IFO).	Costa J, 2007, J BACTERIOL, V189, P1648, DOI 10.1128/JB.00841-06; Empadinhas N, 2011, ENVIRON MICROBIOL, V13, P2056, DOI 10.1111/j.1462-2920.2010.02390.x; Hansen T, 2004, J BIOL CHEM, V279, P2262, DOI 10.1074/jbc.M309849200; Akutsu J, 2005, J BIOCHEM, V138, P159, DOI 10.1093/jb/mvi115; Zhang ZL, 2005, J BIOL CHEM, V280, P9698, DOI 10.1074/jbc.M411211200; Empadinhas N, 2001, J BIOL CHEM, V276, P43580, DOI 10.1074/jbc.M108054200; Wu BY, 2002, FEBS LETT, V519, P87, DOI 10.1016/S0014-5793(02)02717-5; SHINABARGER D, 1991, J BIOL CHEM, V266, P2080; MAY TB, 1994, J BIOL CHEM, V269, P4872; Gonzalez JM, 1998, EXTREMOPHILES, V2, P123, DOI 10.1007/s007920050051; Ning BT, 2000, EUR J BIOCHEM, V267, P6866, DOI 10.1046/j.1432-1327.2000.01781.x; Kawarabayasi Y, 1998, DNA Res, V5, P55, DOI 10.1093/dnares/5.2.55	12	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1431-0651	1433-4909		EXTREMOPHILES	Extremophiles	NOV	2015	19	6					1077	1085		10.1007/s00792-015-0779-5		9	Biochemistry & Molecular Biology; Microbiology	Biochemistry & Molecular Biology; Microbiology	CU9NF	WOS:000363870500003		
J	Fujita, A; Sato, T; Koyama, Y; Misumi, Y				Fujita, Atsushi; Sato, Takaaki; Koyama, Yoshinori; Misumi, Yoshio			A reporter gene system for the precise measurement of promoter activity in Thermus thermophilus HB27	EXTREMOPHILES			English	Article						Thermophile; Thermus thermophilus; beta-Galactosidase; Reporter gene system; Carotenoid	ESCHERICHIA-COLI; EXTREME THERMOPHILE; BETA-GALACTOSIDASE; DIRECTED EVOLUTION; SELECTION MARKER; EXPRESSION; CLONING; KANAMYCIN; VECTORS; MUTAGENESIS	We developed a reporter gene system that enables precise analysis of promoter activity in Thermus thermophilus HB27. The reporter vector employs a promoterless beta-galactosidase gene of Thermus spp. strain T2. However, T. thermophilus HB27 strain has three genes (TTP0042, TTP0220 and TTP0222) whose products have beta-galactosidase activity, which would interfere with correct measurements of promoter activities. Thus, to eliminate this background activity, we disrupted all three of these genes to generate a host strain for measuring promoter expression as beta-galactosidase activity. In addition, T. thermophilus strains also produce carotenoids called thermoxanthins that are yellow pigments. To avoid the influence of these carotenoids on the beta-galactosidase assay, we also disrupted the phytoene synthase gene (crtB). The reporter gene system developed here is a powerful tool for studying transcriptional activity and the mechanisms that regulate gene expression in T. thermophilus HB27. We also showed that the crtB gene cassette could be used in repeated gene-disruption experiments to screen transformants by colony colour, thus eliminating the need for antibiotic resistance markers.	[Fujita, Atsushi; Sato, Takaaki] Natl Inst Adv Ind Sci & Technol, Hlth Res Inst, Biomed Res Inst, Ikeda, Osaka 5638577, Japan; [Koyama, Yoshinori] Natl Inst Adv Ind Sci & Technol, Bioprod Res Inst, Tsukuba, Ibaraki 3058566, Japan; [Misumi, Yoshio] Fukuoka Univ, Sch Med, Dept Cell Biol, Jonan Ku, Fukuoka 8140180, Japan	Fujita, A (reprint author), Natl Inst Adv Ind Sci & Technol, Hlth Res Inst, Biomed Res Inst, 1-8-31 Midorigaoka, Ikeda, Osaka 5638577, Japan.	a-fujita@aist.go.jp					Ooga T, 2009, J BIOL CHEM, V284, P15549, DOI 10.1074/jbc.M900582200; ULRICH JT, 1972, J BACTERIOL, V110, P691; Hoseki J, 1999, J BIOCHEM-TOKYO, V126, P951; Ohta T, 2006, MUTAGENESIS, V21, P255, DOI 10.1093/mutage/gel025; Aoki K, 2007, BIOCHEM BIOPH RES CO, V353, P1028, DOI 10.1016/j.bbrc.2006.12.150; Angelov A, 2013, SYST APPL MICROBIOL, V36, P585, DOI 10.1016/j.syapm.2013.06.001; Henne A, 2004, NAT BIOTECHNOL, V22, P547, DOI 10.1038/nbt956; Fujita A, 2013, GENE, V527, P655, DOI 10.1016/j.gene.2013.06.069; MASEDA H, 1995, FEMS MICROBIOL LETT, V128, P127, DOI 10.1016/0378-1097(95)00094-L; Brouns SJJ, 2005, J BIOL CHEM, V280, P11422, DOI 10.1074/jbc.M413623200; CASADABAN MJ, 1980, J BACTERIOL, V143, P971; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; KOYAMA Y, 1986, J BACTERIOL, V166, P338; Taylor MP, 2011, MICROB BIOTECHNOL, V4, P438, DOI 10.1111/j.1751-7915.2010.00246.x; KOYAMA Y, 1990, APPL ENVIRON MICROB, V56, P2251; Nakamura A, 2005, J BIOSCI BIOENG, V100, P158, DOI 10.1263/jbb.100.158; Hashimoto Y, 2001, FEBS LETT, V506, P231, DOI 10.1016/S0014-5793(01)02926-X; Park HS, 2004, LETT APPL MICROBIOL, V38, P415, DOI 10.1111/j.1472-765X.2004.01512.x; Vian A, 1998, APPL ENVIRON MICROB, V64, P2187; Fujita A, 2012, PLASMID, V67, P272, DOI 10.1016/j.plasmid.2011.12.013; Cava F, 2009, EXTREMOPHILES, V13, P213, DOI 10.1007/s00792-009-0226-6; Carr JF, 2015, EXTREMOPHILES, V19, P221, DOI 10.1007/s00792-014-0663-8; Goffeau A, 1996, SCIENCE, V274, P563; Maniatis T, 1982, MOL CLONING LAB MANU; Miller J. H., 1972, EXPT MOL GENETICS; Moreno R, 2002, PLASMID, V49, P2; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4	27	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1431-0651	1433-4909		EXTREMOPHILES	Extremophiles	NOV	2015	19	6					1193	1201		10.1007/s00792-015-0789-3		9	Biochemistry & Molecular Biology; Microbiology	Biochemistry & Molecular Biology; Microbiology	CU9NF	WOS:000363870500013		
J	Takenaka, T; Ito, T; Miyahara, I; Hemmi, H; Yoshimura, T				Takenaka, Takashi; Ito, Tomokazu; Miyahara, Ikuko; Hemmi, Hisashi; Yoshimura, Tohru			A new member of MocR/GabR-type PLP-binding regulator of d-alanyl-d-alanine ligase in Brevibacillusbrevis	FEBS JOURNAL			English	Article						aminotransferase; d-alanyl-d-alanine; glycylglycine; MocR; GabR family transcriptional regulator; pyridoxal 5-phosphate	BACILLUS-SUBTILIS GABR; DIALKYLGLYCINE DECARBOXYLASE; TRANSCRIPTIONAL REGULATOR; DEPENDENT ENZYMES; AMINOTRANSFERASE; BIOSYNTHESIS; MECHANISM; PROTEIN; PDXR; SPECIFICITY	The Brevibacillusbrevis BBR47_28440 gene (referred to as ddlR) encodes an MocR/GabR family transcriptional regulator consisting of an N-terminal helix-turn-helix DNA binding domain and a C-terminal aminotransferase-like domain. The ddlR gene is located just upstream of the d-alanyl-d-alanine ligase gene (ddl) in the B.brevis genome, and these two genes form an operon. Gel-shift assays indicated that purified DdlR binds specifically to the DNA region that includes putative -35 and -10 regions of the ddlR promoter. A 6-bp inverted repeat that overlaps the -10 region of the ddlR promoter was found to be important for the binding. Invivo reporter assays confirmed that DdlR is an activator of the ddlR-ddl operon. Spectroscopic analyses indicated that purified DdlR is a pyridoxal 5-phosphate binding transcriptional regulator that has dipeptide binding ability for d-alanyl-d-alanine, the enzymatic product of Ddl, and glycylglycine. DdlR is capable of forming a dipeptide-pyridoxal 5-phosphate external aldimine, but it lacks aminotransferase activity. Bioinformatic analyses suggest that DdlR-mediated transcriptional regulation of ddlR and ddl may occur in multiple bacterial systems such as Actinobacteria and Bacillus species.	[Takenaka, Takashi; Ito, Tomokazu; Hemmi, Hisashi; Yoshimura, Tohru] Nagoya Univ, Dept Appl Mol Biosci, Grad Sch Bioagr Sci, Nagoya, Aichi 4648601, Japan; [Miyahara, Ikuko] Osaka City Univ, Grad Sch Sci, Dept Chem, Osaka, Japan	Ito, T (reprint author), Nagoya Univ, Dept Appl Mol Biosci, Grad Sch Bioagr Sci, Chikusa Ku, Nagoya, Aichi 4648601, Japan.	ito-t@agr.nagoya-u.ac.jp			JSPS KAKENHI [25292059, 24780098]	This work was supported by JSPS KAKENHI Grant Numbers 25292059 (to T. Y.) and 24780098 (to T. I.).	Wiethaus J, 2008, J BACTERIOL, V190, P487, DOI 10.1128/JB.01510-07; Ikushiro H, 1998, BIOCHEMISTRY-US, V37, P3043, DOI 10.1021/bi971995+; Toney MD, 2005, ARCH BIOCHEM BIOPHYS, V433, P279, DOI 10.1016/j.abb.2004.09.037; Narayana N, 2006, J MOL BIOL, V362, P414, DOI 10.1016/j.jmb.2006.06.086; Okuda K, 2015, MOL MICROBIOL, V95, P245, DOI 10.1111/mmi.12861; PHILLIPS RS, 1990, BIOCHEMISTRY-US, V29, P8608, DOI 10.1021/bi00489a016; Evers S, 1996, J MOL EVOL, V42, P706, DOI 10.1007/BF02338803; Karsten WE, 2009, BBA-GEN SUBJECTS, V1790, P575, DOI 10.1016/j.bbagen.2009.02.012; Chernobrovkin MG, 2004, J ANAL CHEM+, V59, P55, DOI 10.1023/B:JANC.0000011669.08932.d8; Zhou XZ, 1999, BIOCHEMISTRY-US, V38, P311, DOI 10.1021/bi981455s; Tomita T, 2009, PROTEINS, V75, P348, DOI 10.1002/prot.22245; Ikushiro H, 2004, BIOCHEMISTRY-US, V43, P1082, DOI 10.1021/bi035706v; Belitsky BR, 2014, MOL MICROBIOL, V92, P1113, DOI 10.1111/mmi.12618; Bramucci E, 2011, BIOCHEM BIOPH RES CO, V415, P88, DOI 10.1016/j.bbrc.2011.10.017; Betley JN, 2002, CURR BIOL, V12, P1756, DOI 10.1016/S0960-9822(02)01220-4; Schneider G, 2000, STRUCT FOLD DES, V8, pR1, DOI 10.1016/S0969-2126(00)00085-X; Magarvey N, 2001, MICROBIOL-SGM, V147, P2103; Jochmann N, 2011, MICROBIOL-SGM, V157, P77, DOI 10.1099/mic.0.044818-0; Belitsky BR, 2004, J MOL BIOL, V340, P655, DOI 10.1016/j.jmb.2004.05.020; Sun SX, 1998, BIOCHEMISTRY-US, V37, P3876, DOI 10.1021/bi972056k; Hellman LM, 2007, NAT PROTOC, V2, P1849, DOI 10.1038/nprot.2007.249; Kurtz S, 2001, NUCLEIC ACIDS RES, V29, P4633, DOI 10.1093/nar/29.22.4633; Tramonti A, 2015, FEBS J, V282, P2966, DOI 10.1111/febs.13338; Belitsky BR, 2002, MOL MICROBIOL, V45, P569, DOI 10.1046/j.1365-2958.2002.03036.x; Edayathumangalam R, 2013, P NATL ACAD SCI USA, V110, P17820, DOI 10.1073/pnas.1315887110; ElsQaidi S, 2013, J BACTERIOL, V195, P2187; Hoskisson Paul A, 2009, Adv Appl Microbiol, V69, P1, DOI 10.1016/S0065-2164(09)69001-8	27	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1742-464X	1742-4658		FEBS J	FEBS J.	NOV	2015	282	21					4201	4217		10.1111/febs.13415		17	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	CU5RG	WOS:000363589100011		
J	Iizaka, S; Kaitani, T; Nakagami, G; Sugama, J; Sanada, H				Iizaka, Shinji; Kaitani, Toshiko; Nakagami, Gojiro; Sugama, Junko; Sanada, Hiromi			Clinical validity of the estimated energy requirement and the average protein requirement for nutritional status change and wound healing in older patients with pressure ulcers: A multicenter prospective cohort study	GERIATRICS & GERONTOLOGY INTERNATIONAL			English	Article						dermatology; energy; nursing; nutrition; wound	RANDOMIZED CONTROLLED-TRIAL; DIETARY-PROTEIN; BODY-COMPOSITION; DESIGN-R; ADULTS; METAANALYSIS; SUPPORT; BALANCE; WOMEN; SCORE	AimAdequate nutritional intake is essential for pressure ulcer healing. Recently, the estimated energy requirement (30kcal/kg) and the average protein requirement (0.95g/kg) necessary to maintain metabolic balance have been reported. The purpose was to evaluate the clinical validity of these requirements in older hospitalized patients with pressure ulcers by assessing nutritional status and wound healing. MethodsThis multicenter prospective study carried out as a secondary analysis of a clinical trial included 194 patients with pressure ulcers aged 65years from 29 institutions. Nutritional status including anthropometry and biochemical tests, and wound status by a structured severity tool, were evaluated over 3weeks. Energy and protein intake were determined from medical records on a typical day and dichotomized by meeting the estimated average requirement. Longitudinal data were analyzed with a multivariate mixed-effects model. ResultsMeeting the energy requirement was associated with changes in weight (P<0.001), arm muscle circumference (P=0.003) and serum albumin level (P=0.016). Meeting the protein requirement was associated with changes in weight (P<0.001) and serum albumin level (P=0.043). These markers decreased in patients who did not meet the requirement, but were stable or increased in those who did. Energy and protein intake were associated with wound healing for deep ulcers (P=0.013 for both), improving exudates and necrotic tissue, but not for superficial ulcers. ConclusionsEstimated energy requirement and average protein requirement were clinically validated for prevention of nutritional decline and of impaired healing of deep pressure ulcers. Geriatr Gerontol Int 2015; 15: 1201-1209.	[Iizaka, Shinji; Nakagami, Gojiro; Sanada, Hiromi] Univ Tokyo, Dept Gerontol Nursing Wound Care Management, Grad Sch Med, Div Hlth Sci & Nursing, Tokyo 1130033, Japan; [Kaitani, Toshiko] Sapporo City Univ, Sch Nursing, Sapporo, Hokkaido, Japan; [Sugama, Junko] Kanazawa Univ, Div Hlth Sci, Grad Sch Med Sci, Kanazawa, Ishikawa 9201192, Japan	Iizaka, S (reprint author), Univ Tokyo, Dept Gerontol Nursing Wound Care Management, Grad Sch Med, Bunkyo Ku, Fac Med Bldg 5-308,7-3-1 Hongo, Tokyo 1130033, Japan.	iizaka-tky@umin.ac.jp			Health Labor Sciences Research Grant	This study was funded by a Health Labor Sciences Research Grant (2008-2009). We greatly appreciate the help of wound, ostomy and continence nurses at each hospital in data collection. All authors were involved in research design, recruitment, data collection, data analysis and the editorial process, and all approved the final version of the manuscript.	Matsui Y, 2011, WOUND REPAIR REGEN, V19, P309, DOI 10.1111/j.1524-475X.2011.00674.x; Houston DK, 2008, AM J CLIN NUTR, V87, P150; Iizaka S, 2012, J AM GERIATR SOC, V60, P2027, DOI 10.1111/j.1532-5415.2012.04202.x; Pompeo M, 2007, OSTOMY WOUND MANAG, V53, P30; Sanada H, 2011, WOUND REPAIR REGEN, V19, P559, DOI 10.1111/j.1524-475X.2011.00719.x; Iizaka S, 2010, NUTRITION, V26, P890, DOI 10.1016/j.nut.2009.09.008; Lim Y, 2006, J NUTR BIOCHEM, V17, P328, DOI 10.1016/j.jnutbio.2005.08.004; Bergstrom N, 2008, J AM GERIATR SOC, V56, P1252, DOI 10.1111/j.1532-5415.2008.01765.x; BRESLOW RA, 1993, J AM GERIATR SOC, V41, P357; Ohura T, 2011, WOUND REPAIR REGEN, V19, P330, DOI 10.1111/j.1524-475X.2011.00691.x; Hudgens J, 2004, JPEN-PARENTER ENTER, V28, P416, DOI 10.1177/0148607104028006416; Sergi G, 2007, J GERONTOL A-BIOL, V62, P317; Knight EL, 2003, ANN INTERN MED, V138, P460; [Anonymous], 2002, JPN J NUTR ASSESSMEN, V19, P1; Sugama J, 2007, J CLIN NURS, V16, P1265, DOI 10.1111/j.1365-2702.2006.01790.x; Cereda E, 2009, J AM GERIATR SOC, V57, P1395, DOI 10.1111/j.1532-5415.2009.02351.x; Stratton RJ, 2005, AGEING RES REV, V4, P422, DOI 10.1016/j.arr.2005.03.005; Dambach B, 2005, J AM GERIATR SOC, V53, P478, DOI 10.1111/j.1532-5415.2005.53168.x; Sherman AR, 2011, J WOUND CARE, V20, P357; Cereda E, 2011, J AM DIET ASSOC, V111, P1868, DOI 10.1016/j.jada.2011.09.005; Bauer J, 2013, J AM MED DIR ASSOC, V14, P542, DOI 10.1016/j.jamda.2013.05.021; Bergstrom N, 2005, J AM GERIATR SOC, V53, P1721, DOI 10.1111/j.1532-5415.2005.53506.x; Association for the Advancement of Wound Care (AAWC), 2010, ASS ADV WOUND CAR AA; BERGSTROM N, 1987, NURS RES, V36, P205; Broughton G, 2006, PLAST RECONSTR SURG, V117, P12; Desneves KJ, 2005, CLIN NUTR, V24, P979, DOI 10.1016/j.clnu.2005.06.011; European Pressure Ulcer Advisory Panel, 2009, TREATM PRESS ULC QUI; Expert Committee for Dietary Reference Intakes for Japanese, 2009, DIET REF INT JAP 201; FAO/WHO/UNU Committee, 1985, WHO TECHN REP SER, V724; Japanese Society of Nephrology, 2009, CLIN EXP NEPHROL, V13, P537, DOI 10.1007/s10157-009-0237-8; Kaitani T, 2013, J WOUND TECHNOL, V21, P6; Takeda Toshiaki, 1992, Journal of Dermatology (Tokyo), V19, P602; The Japanese Society of Pressure Ulcers Guideline Revision Committee, 2014, JPN J PU, V16, P12	33	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1444-1586	1447-0594		GERIATR GERONTOL INT	Geriatr. Gerontol. Int.	NOV	2015	15	11					1201	1209		10.1111/ggi.12420		9	Geriatrics & Gerontology; Gerontology	Geriatrics & Gerontology	CU9TD	WOS:000363887200002		
J	Sasiwongsaroj, K; Wada, T; Okumiya, K; Imai, H; Ishimoto, Y; Sakamoto, R; Fujisawa, M; Kimura, Y; Chen, WL; Fukutomi, E; Matsubayashi, K				Sasiwongsaroj, Kwanchit; Wada, Taizo; Okumiya, Kiyohito; Imai, Hissei; Ishimoto, Yasuko; Sakamoto, Ryota; Fujisawa, Michiko; Kimura, Yumi; Chen, Wen-ling; Fukutomi, Eriko; Matsubayashi, Kozo			Buddhist social networks and health in old age: A study in central Thailand	GERIATRICS & GERONTOLOGY INTERNATIONAL			English	Article						Buddhism; community-dwelling elderly; quality of life; social network; Thailand	RELIGIOUS INVOLVEMENT; INFORMAL SUPPORT; MENTAL-HEALTH; DISABILITY; ADULTS; LIFE; COMMUNITY; MACARTHUR; OUTCOMES; DISEASE	AimReligious social networks are well known for their capacity to improve individual health, yet the effects of friendship networks within the Buddhist context remain largely unknown. The present study aimed to compare health status and social support in community-dwelling older adults according to their level of Buddhist social network (BSN) involvement, and to examine the association between BSN involvement and functional health among older adults. MethodsA cross-sectional survey was carried out among 427 Buddhist community-dwelling older adults aged 60 years in Nakhon Pathom, Thailand. Data were collected from home-based personal interviews using a structured questionnaire. Health status was defined according to the measures of basic and advanced activities of daily living (ADL), the 15-item Geriatric Depression Scale and subjective quality of life. Perceived social support was assessed across the four dimensions of tangible, belonging, emotional and information support. Multiple logistic regression was used for analysis. ResultsOlder adults with BSN involvement reported better functional, mental and social health status, and perceived greater social support than those without BSN involvement. In addition, BSN involvement was positively associated with independence in basic and advanced ADL. After adjusting for age, sex, education, income, morbidity and depressive symptoms, BSN showed a strong association with advanced ADL and a weak association with basic ADL. ConclusionThe results show that involvement in BSN could contribute positively to functional health, particularly with regard to advanced ADL. Addressing the need for involvement in these networks by older adults might help delay functional decline and save on healthcare costs. Geriatr Gerontol Int 2015; 15: 1193-1200.	[Sasiwongsaroj, Kwanchit; Wada, Taizo; Okumiya, Kiyohito; Ishimoto, Yasuko; Sakamoto, Ryota; Fujisawa, Michiko; Kimura, Yumi; Matsubayashi, Kozo] Kyoto Univ, Ctr Southeast Asian Studies, Kyoto, Japan; [Imai, Hissei; Chen, Wen-ling; Fukutomi, Eriko] Kyoto Univ, Grad Sch Med, Field Med, Sch Publ Hlth, Kyoto, Japan; [Sakamoto, Ryota] Kyoto Univ, Hakubi Ctr, Kyoto, Japan; [Sasiwongsaroj, Kwanchit] Mahidol Univ, Res Inst Languages & Cultures Asia, Phuttamonton 73170, Nakhon Pathom, Thailand	Sasiwongsaroj, K (reprint author), Mahidol Univ, Res Inst Languages & Cultures Asia, 999 Salaya, Phuttamonton 73170, Nakhon Pathom, Thailand.	kwan7chit@yahoo.com			JSPS [25-26.03008]	The authors thank Phra Ajarn Wichit Paunil, Associate Professor Saowapa Pronsiripong (Mahidol University), Assistant Professor Yongyut Burasith (Mahidol University), Associate Professor Khemika Yamarat (Chulalongkorn University), and Assistant Professor Kanvee Viwatpanich (Thammasat University), for their helpful comments and suggestions on questionnaire development. This study was partly supported by a Grant-in-Aid for JSPS fellows and a JSPS Postdoctoral Fellowship for Foreign Researchers (25-26.03008). Kwanchit Sasiwongsaroj contributed to research conception and design, collection of data, analysis and interpretation of data, and writing the article. Taizo Wada, Kiyohito Okumiya, Hissei Imai and Ryota Sakamoto contributed to research conception and design, interpretation of data, drafting the article, and revising it. Yasuko Ishimoto, Yumi Kimura, Michiko Fujisawa, Wen-ling Chen and Eriko Fukutomi contributed to research conception and design, analysis, and interpretation of data. Kozo Matsubayashi contributed to research conception and design, interpretation of data, critical revision of the article, and final approval of the version to be published.	Litwin H, 2000, J AGING STUD, V14, P213, DOI 10.1016/S0890-4065(00)80012-2; Taylor RJ, 2000, SOC WORK, V45, P73; TAYLOR RJ, 1986, GERONTOLOGIST, V26, P637; Fitchett G, 2013, J GERONTOL B-PSYCHOL, V68, P235, DOI 10.1093/geronb/gbs165; Hayward RD, 2013, J BEHAV MED, V36, P354, DOI 10.1007/s10865-012-9430-4; Unger JB, 1999, J GERONTOL B-PSYCHOL, V54, pS245; Krause N, 2006, J GERONTOL B-PSYCHOL, V61, pS35; Chatters LM, 2002, J BLACK STUD, V33, P66; KOYANO W, 1991, ARCH GERONTOL GERIAT, V13, P103, DOI 10.1016/0167-4943(91)90053-S; Michaud CM, 2001, JAMA-J AM MED ASSOC, V285, P535, DOI 10.1001/jama.285.5.535; SARASON IG, 1983, J PERS SOC PSYCHOL, V44, P127, DOI 10.1037/0022-3514.44.1.127; Johansson L, 2011, J AGING SOC POLICY, V23, P335, DOI 10.1080/08959420.2011.605630; Matsubayashi K, 1999, LANCET, V353, P1445, DOI 10.1016/S0140-6736(05)75972-9; Cohen S, 2007, HEALTH PSYCHOL, V26, P410, DOI 10.1037/0278-6133.26.4.410; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; MASSON PR, 1990, INT MONET FUND S PAP, V37, P453; Seeman TE, 1996, J GERONTOL B-PSYCHOL, V51, pS191; Wongpakaran N, 2012, PSYCHOGERIATRICS, V12, P11, DOI 10.1111/j.1479-8301.2011.00383.x; Park NS, 2008, RES AGING, V30, P279, DOI 10.1177/0164027507313001; VERBRUGGE LM, 1994, SOC SCI MED, V38, P1, DOI 10.1016/0277-9536(94)90294-1; Koenig HG, 1998, J GERONTOL A-BIOL, V53, pM426; Koenig HG, 1998, INT J PSYCHIAT MED, V28, P189; Pickard L, 2000, AGEING SOC, V20, P745, DOI 10.1017/S0144686X01007978; ZIMET GD, 1988, J PERS ASSESS, V52, P30, DOI 10.1207/s15327752jpa5201_2; Lim C, 2010, AM SOCIOL REV, V75, P914, DOI 10.1177/0003122410386686; Benjamins MR, 2004, J AGING HEALTH, V16, P355, DOI 10.1177/0898264304264204; Kawachi I, 2001, J URBAN HEALTH, V78, P458, DOI 10.1093/jurban/78.3.458; Yeager DM, 2006, SOC SCI MED, V63, P2228, DOI 10.1016/j.socscimed.2006.05.007; Apinunmahakul A., 2012, RELIG NONRELIGIOUS G; Aukst-Margetic B, 2005, COLLEGIUM ANTROPOL, V29, P365; COHEN S, 1983, J APPL SOC PSYCHOL, V13, P99, DOI 10.1111/j.1559-1816.1983.tb02325.x; ELLISON CG, 1994, J SCI STUD RELIG, V33, P46, DOI 10.2307/1386636; Faiola A, 2006, FACE POVERTY AGES RA; Fiori K. L., 2006, J GERONTOL B-PSYCHOL, V61, P25, DOI DOI 10.1093/GER0NB/61.1.P25; Ho HK, 2002, GERIATR GERONTOL INT, V2, P80, DOI 10.1046/j.1444-1586.2002.00026.x; Johnson Todd M., 2013, WORLDS RELIG FIGURES; Krause N., 2008, AGING CHURCH SOCIAL; Krause N, 2014, J RELIG HEALTH, V53, P267, DOI 10.1007/s10943-013-9707-0; Krause N, 2001, J SCI STUD RELIG, V40, P637, DOI 10.1111/0021-8294.00082; Krause N., 2005, INT J PSYCHOL RELIG, V15, P73, DOI DOI 10.1207/S15327582IJPR1501_6; Krause Neal, 2009, REV RELIG RES, V51, P181; Kresevic DM., 1999, EVIDENCE BASED GERIA; Matsubayashi Kozo, 1994, Japanese Journal of Geriatrics, V31, P790; McCall N., 2001, WHO WILL PAY LONG TE; Menon J, 2009, WORKING PAPER SERIES, V25, P1; Narksakul K, 2007, SOURCE KNOWLEDGE YOD; National Statistical Office, 2013, STAT YB THAIL 2013; Payutto PA, 1990, HELP YOURSELF HELP O; Reinhardt UE., 2002, EC POLICY AGING SOC, P235; Rovinelli RJ, 1977, DUTCH J ED RES, V2, P49; The United Nations, 2006, WORLD POP PROSP 2006; Wongpakaran Nahathai, 2013, J Clin Med Res, V5, P101, DOI 10.4021/jocmr1239w	52	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1444-1586	1447-0594		GERIATR GERONTOL INT	Geriatr. Gerontol. Int.	NOV	2015	15	11					1210	1218		10.1111/ggi.12421		9	Geriatrics & Gerontology; Gerontology	Geriatrics & Gerontology	CU9TD	WOS:000363887200003		
J	Inagaki, Y; Tanaka, Y; Taniguchi, A; Hara, R; Tomiwa, K; Nogami, K; Shima, M				Inagaki, Y.; Tanaka, Y.; Taniguchi, A.; Hara, R.; Tomiwa, K.; Nogami, K.; Shima, M.			Usefulness of Musculoskeletal Ultrasonography for Early Diagnosis of Heamophilic Synovitis - The Results From the Comprehensive Health Check for Heamophilic Patients	HAEMOPHILIA			English	Meeting Abstract									[Inagaki, Y.; Tanaka, Y.; Taniguchi, A.; Hara, R.; Tomiwa, K.] Nara Med Univ, Dept Orthopaed Surg, Nara, Japan; [Nogami, K.; Shima, M.] Nara Med Univ, Dept Pediat, Nara, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1351-8216	1365-2516		HAEMOPHILIA	Haemophilia	NOV	2015	21	6				FP01.04	E536	E536				1	Hematology	Hematology	CU4OJ	WOS:000363508900065		
J	Kinai, E; Gatanaga, H; Teruya, K; Tsukada, K; Kikuchi, Y; Oka, S				Kinai, E.; Gatanaga, H.; Teruya, K.; Tsukada, K.; Kikuchi, Y.; Oka, S.			Prevalence and Risk Factors of Bone Mineral Density Abnormalities in Japanese HIV-Infected Haemophiliacs	HAEMOPHILIA			English	Meeting Abstract									[Kinai, E.; Gatanaga, H.; Teruya, K.; Tsukada, K.; Kikuchi, Y.; Oka, S.] Natl Ctr Global Hlth & Med, AIDS Clin Ctr, Tokyo, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1351-8216	1365-2516		HAEMOPHILIA	Haemophilia	NOV	2015	21	6				P-217	E550	E550				1	Hematology	Hematology	CU4OJ	WOS:000363508900125		
J	Nakagawa, Y; Shimada, Y; Kinai, E; Kawasaki, Y; Maruoka, Y; Yamamoto, K; Oka, S				Nakagawa, Y.; Shimada, Y.; Kinai, E.; Kawasaki, Y.; Maruoka, Y.; Yamamoto, K.; Oka, S.			Long-handle toothbrush for haemophiliacs with severe elbow arthropathy	HAEMOPHILIA			English	Letter									[Nakagawa, Y.; Kinai, E.; Oka, S.] Natl Ctr Global Hlth & Med, AIDS Clin Ctr, Tokyo 1628655, Japan; [Nakagawa, Y.; Yamamoto, K.] Natl Ctr Global Hlth & Med, Tokyo, Japan; [Shimada, Y.; Maruoka, Y.] Natl Ctr Global Hlth & Med Hosp, Dept Oral & Maxillofacial Surg, Tokyo, Japan; [Kawasaki, Y.] Univ Shizuoka, Sch Pharmaceut Sci, Dept Drug Evaluat & Informat, Shizuoka 4228526, Japan	Nakagawa, Y (reprint author), Natl Ctr Global Hlth & Med, AIDS Clin Ctr, Shinjuku Ku, 1-21-1 Toyama, Tokyo 1628655, Japan.	ynakagaw@acc.ncgm.go.jp					Berntorp E, 2012, LANCET, V379, P1447, DOI 10.1016/S0140-6736(11)61139-2; OLEARY TJ, 1972, J PERIODONTOL, V43, P38, DOI 10.1902/jop.1972.43.1.38; GILBERT MS, 1977, MT SINAI J MED, V44, P389; ARNOLD WD, 1977, J BONE JOINT SURG AM, V59, P287; Pihlstrom BL, 2005, LANCET, V366, P1809, DOI 10.1016/S0140-6736(05)67728-8; [Anonymous], 1996, CLIN ORTHOPAEDICS, DOI 10.1097/00003086-199607000-00017; LOE H, 1965, J PERIODONTOL, V36, P177, DOI 10.1902/jop.1965.36.3.177; Clark WA, 1920, J ORTHOP SURG, V2, P687; Kanamaru N, 2007, B JSSD, V54, P47; Kono J, 1995, JAPANESE SOC DENT HL, V45, P43	10	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1351-8216	1365-2516		HAEMOPHILIA	Haemophilia	NOV	2015	21	6					E481	E483		10.1111/hae.12751		3	Hematology	Hematology	CU4OJ	WOS:000363508900005		
J	Yasuda, H; Mukai, H				Yasuda, Hiroki; Mukai, Hideyuki			Turning off of GluN2B subunits and turning on of CICR in hippocampal LTD induction after developmental GluN2 subunit switch	HIPPOCAMPUS			English	Article						development of synapses; NMDA receptor; ryanodine receptor; synaptic plasticity; electrophysiology	LONG-TERM DEPRESSION; NMDA RECEPTOR; VISUAL-CORTEX; RAT HIPPOCAMPUS; SYNAPTIC PLASTICITY; CA2+ CHANNELS; MUTANT MICE; CA1 REGION; IN-VITRO; ACTIVATION	NMDA receptors (NMDARs) are essential for the induction of synaptic plasticity that mediates activity-dependent refinement of neural circuits during development. GluN2B subunits of NMDARs are abundant at synapses in the immature hippocampus and begin to be replaced by GluN2A subunits with the help of casein kinase 2 activity in the second postnatal week, the critical period for the GluN2 subunit switch (Sanz-Clemente et al. (2000) Neuron 67:984-996). However, the physiological role of GluN2B subunits in the hippocampus during this critical period has not been elucidated. Here, we report that GluN2B subunits mediate the induction of long-term depression (LTD) in the CA1 region of the hippocampus only until this period. Ifenprodil and Ro25-6981, selective inhibitors of NMDARs containing GluN2B subunits, blocked LTD in postnatal Day 11-14 (P11-14) rat hippocampal slices but not in P18-22 hippocampus. Just a few days after P14, synaptic NMDAR currents became narrower than those at P11-14, and calcium influx through NMDARs must be reduced. We found that calcium-induced calcium release (CICR) through ryanodine receptors starts to support the induction of NMDAR-dependent LTD at P18-22. Intracellular application of thapsigargin and ryanodine, inhibitors of Ca2+-ATP pumps on internal stores and ryanodine receptors, respectively, did not at all affect LTD in the hippocampus at P11-14 but completely blocked LTD in the P18-22 hippocampus. Therefore, calcium influx through NMDAR with GluN2B subunits is sufficient to induce LTD at P11-14, after which CICR compensates for the decrease in calcium influx during LTD induction. (c) 2015 Wiley Periodicals, Inc.	[Yasuda, Hiroki] Gunma Univ, Grad Sch Med, Educ & Res Support Ctr, Maebashi, Gumma 3718511, Japan; [Mukai, Hideyuki] Kobe Univ, Biosignal Res Ctr, Kobe, Hyogo 657, Japan	Yasuda, H (reprint author), Gunma Univ, Grad Sch Med, Educ & Res Support Ctr, 3-39-22 Showa Machi, Maebashi, Gumma 3718511, Japan.	yasuda@gunma-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology (MEXT) [20500354, 21200016, 23500461]; Takeda Science Foundation	Grant sponsor: Ministry of Education, Culture, Sports, Science and Technology (MEXT); Grant numbers: 20500354, 21200016, 23500461; Grant sponsor: Takeda Science Foundation.	ALFORD S, 1993, J PHYSIOL-LONDON, V469, P693; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; Yasuda H, 2003, NAT NEUROSCI, V6, P15, DOI 10.1038/nn985; Nishiyama M, 2000, NATURE, V408, P584; Mori F, 2000, NEUROSCI LETT, V285, P57, DOI 10.1016/S0304-3940(00)01046-6; Reyes-Harde M, 1998, NEUROSCI LETT, V252, P155, DOI 10.1016/S0304-3940(98)00496-0; Fitzjohn SM, 2001, J PHYSIOL-LONDON, V537, P421, DOI 10.1111/j.1469-7793.2001.00421.x; Normann C, 2000, J NEUROSCI, V20, P8290; Barth AL, 2001, NAT NEUROSCI, V4, P235, DOI 10.1038/85070; Snyder SH, 1998, NEURON, V21, P283, DOI 10.1016/S0896-6273(00)80538-3; KELLY PT, 1982, BRAIN RES, V247, P85, DOI 10.1016/0006-8993(82)91030-7; Christie BR, 1996, HIPPOCAMPUS, V6, P17, DOI 10.1002/(SICI)1098-1063(1996)6:1<17::AID-HIPO4>3.3.CO;2-B; Emptage N, 1999, NEURON, V22, P115, DOI 10.1016/S0896-6273(00)80683-2; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; Futatsugi A, 1999, NEURON, V24, P701, DOI 10.1016/S0896-6273(00)81123-X; Miwa H, 2008, J PHYSIOL-LONDON, V586, P2539, DOI 10.1113/jphysiol.2007.147652; Barria A, 2002, NEURON, V35, P345, DOI 10.1016/S0896-6273(02)00776-6; Rumbaugh G, 1999, J NEUROSCI, V19, P10603; Kumar A, 2005, BRAIN RES, V1031, P125, DOI 10.1016/j.brainres.2004.10.023; Kutsuwada T, 1996, NEURON, V16, P333, DOI 10.1016/S0896-6273(00)80051-3; Yoshimura Y, 2003, J NEUROSCI, V23, P6557; Otani S, 1998, J PHYSIOL-LONDON, V511, P761, DOI 10.1111/j.1469-7793.1998.761bg.x; CARMIGNOTO G, 1992, SCIENCE, V258, P1007, DOI 10.1126/science.1279803; Sanz-Clemente A, 2010, NEURON, V67, P984, DOI 10.1016/j.neuron.2010.08.011; Philpot BD, 2001, NEURON, V29, P157, DOI 10.1016/S0896-6273(01)00187-8; Schneggenburger R, 1996, BIOPHYS J, V70, P2165; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; KELLY PT, 1987, J NEUROCHEM, V49, P1927, DOI 10.1111/j.1471-4159.1987.tb02456.x; Morishita W, 2007, NEUROPHARMACOLOGY, V52, P71, DOI 10.1016/j.neuropharm.2006.07.005; Kumar A, 2007, J NEUROPHYSIOL, V98, P2729, DOI 10.1152/jn.00514.2007; Choi SY, 2005, J NEUROSCI, V25, P11433, DOI 10.1523/JNEUROSCI.4084-05.2005; Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244; Thomases DR, 2014, J NEUROSCI, V34, P9059, DOI 10.1523/JNEUROSCI.1395-14.2014; DUDEK SM, 1993, J NEUROSCI, V13, P2910; Wang Y, 1997, J NEUROPHYSIOL, V77, P812; Ku HY, 2008, NEUROPSYCHOPHARMACOL, V33, P2847, DOI 10.1038/npp.2008.36; Bear Mark F., 1994, Current Opinion in Neurobiology, V4, P389, DOI 10.1016/0959-4388(94)90101-5; Oliet SHR, 1997, NEURON, V18, P969, DOI 10.1016/S0896-6273(00)80336-0; Jiang B, 2007, J NEUROSCI, V27, P9648, DOI 10.1523/JNEUROSCI.2655-07.2007; Gladding CM, 2009, PHARMACOL REV, V61, P395, DOI 10.1124/pr.109.001735; Kemp N, 2000, EUR J NEUROSCI, V12, P360, DOI 10.1046/j.1460-9568.2000.00903.x; Malenka RC, 2004, NEURON, V44, P5, DOI 10.1016/j.neuron.2004.09.012; Caroni P, 2014, TRENDS NEUROSCI, V37, P604, DOI 10.1016/j.tins.2014.08.011; Cui ZZ, 2013, SCI REP-UK, V3, DOI 10.1038/srep01036; Liu LD, 2004, SCIENCE, V304, P1021, DOI 10.1126/science.1096615	45	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1050-9631	1098-1063		HIPPOCAMPUS	Hippocampus	NOV	2015	25	11					1274	1284		10.1002/hipo.22435		11	Neurosciences	Neurosciences & Neurology	CU6YW	WOS:000363682300010		
J	Cao, JG; Wu, YB; Li, JY; Zhang, QJ				Cao, Jianguo; Wu, Yongbo; Li, Jianyong; Zhang, Qinjian			A grinding force model for ultrasonic assisted internal grinding (UAIG) of SiC ceramics	INTERNATIONAL JOURNAL OF ADVANCED MANUFACTURING TECHNOLOGY			English	Article						Grinding force; Ultrasonic vibration; Internal grinding; SiC ceramics; UAIG		As grinding force plays an influential role in work-surface finish in grinding process, a model is necessary for optimizing input variables to achieve high product quality and productivity. However, to the best of our knowledge, there are few reports on modeling grinding force in ultrasonic assisted internal grinding (UAIG). In this study, a theoretical model is presented to predict the grinding force in UAIG of SiC ceramics. This model stems from undeformed chip length resulting from the relative motion between the grinding wheel and the workpiece. After analyzing the cutting action of an active individual grain, normal and tangential force models for the UAIG of SiC ceramics are developed. Using the developed model, the influence of many principal input variables, namely the workpiece rotational speed n (w) , the wheel infeed rate V (c) , the wheel rotational speed n (g) , the UV amplitude A (u) , and the oscillation frequency f (o) , on grinding force is predicted. Comparing the predicted forces with the experimental ones, it is shown that the predicted forces agree reasonably well with the experimental ones. The obtained results show that (1) the grinding forces are reduced in the UAIG compared to conventional internal grinding, which is attributed to the formation of the longer undeformed chip length in the UAIG; (2) the influence of n (g) , n (w) , and V (c) on grinding force are much pronounced, whereas that of A (u) and f (o) are not very noticeable; and (3) the force reduction of UV can be enhanced either by decreasing n (g) , n (w) , and V (c) or increasing A (u) and f (o) .	[Cao, Jianguo; Li, Jianyong; Zhang, Qinjian] Beijing Jiaotong Univ, Sch Mech Elect & Control Engn, Beijing 100044, Peoples R China; [Wu, Yongbo] Akita Prefectural Univ, Dept Machine Intelligence & Syst Engn, Yurihonjo, Akita 0150055, Japan	Wu, YB (reprint author), Akita Prefectural Univ, Dept Machine Intelligence & Syst Engn, Yurihonjo, Akita 0150055, Japan.	wuyb@akita-pu.ac.jp			Fundamental Research Funds for the Central Universities	The present work was supported by the Fundamental Research Funds for the Central Universities. Authors thank Kimura Co., Ltd. for providing the SiC specimen used in experiments.	Cao JG, 2014, INT J MACH TOOL MANU, V79, P49, DOI 10.1016/j.ijmachtools.2014.02.002; Cao JG, 2014, MATER MANUF PROCESS, V29, P557, DOI 10.1080/10426914.2014.892615; Peng Y, 2011, INT J ADV MANUF TECH, V54, P941, DOI 10.1007/s00170-010-2991-x; Peng Y, 2012, INT J ADV MANUF TECH, V59, P67, DOI 10.1007/s00170-011-3473-5; Peng Y, 2012, INT J ADV MANUF TECH, V62, P563, DOI 10.1007/s00170-011-3839-8; Arfken G, 1984, U PHYS; Fujimoto M, 2011, P 6 INT C LEAD EDG M; Junichiro K, 1961, T JPN SOC MECH ENG, V27, P1412; Keita S, 2009, J JPN SOC ABRAS TECH, V53, P45; Kun L, 1997, J MATER PROCESS TECH, V65, P1; Nomura M, 2007, THESIS TOHOKU U; Nomura Mitsuyoshi W, 2005, J JPN SOC ABRAS TECH, V49, P691; Qin N, 2009, J MANUF SCI E-T ASME, V131; Sanjay A, 2013, INT J MACH TOOL MANU, V65, P68; Syoji K, 2004, GRINDING MANUFACTURI; Wu Y, 2003, P INT C LEAD EDG MAN, V2003, P145; Yan Wang, 2014, International Journal of Advanced Manufacturing Technology, V70, DOI 10.1007/s00170-013-5269-2	17	0	0	SPRINGER LONDON LTD	LONDON	236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND	0268-3768	1433-3015		INT J ADV MANUF TECH	Int. J. Adv. Manuf. Technol.	NOV	2015	81	5-8					875	885		10.1007/s00170-015-7282-0		11	Automation & Control Systems; Engineering, Manufacturing	Automation & Control Systems; Engineering	CU7LB	WOS:000363718600014		
J	Arata, J; Kogiso, S; Sakaguchi, M; Nakadate, R; Oguri, S; Uemura, M; Byunghyun, C; Akahoshi, T; Ikeda, T; Hashizume, M				Arata, Jumpei; Kogiso, Shinya; Sakaguchi, Masamichi; Nakadate, Ryu; Oguri, Susumu; Uemura, Munenori; Byunghyun, Cho; Akahoshi, Tomohiko; Ikeda, Tetsuo; Hashizume, Makoto			Articulated minimally invasive surgical instrument based on compliant mechanism	INTERNATIONAL JOURNAL OF COMPUTER ASSISTED RADIOLOGY AND SURGERY			English	Article						Minimally invasive surgery; Articulated surgical instrument; Compliant mechanism; Robotic surgery	SURGERY	In minimally invasive surgery, instruments are inserted from the exterior of the patient's body into the surgical field inside the body through the minimum incision, resulting in limited visibility, accessibility, and dexterity. To address this problem, surgical instruments with articulated joints and multiple degrees of freedom have been developed. The articulations in currently available surgical instruments use mainly wire or link mechanisms. These mechanisms are generally robust and reliable, but the miniaturization of the mechanical parts required often results in problems with size, weight, durability, mechanical play, sterilization, and assembly costs. We thus introduced a compliant mechanism to a laparoscopic surgical instrument with multiple degrees of freedom at the tip. To show the feasibility of the concept, we developed a prototype with two degrees of freedom articulated surgical instruments that can perform the grasping and bending movements. The developed prototype is roughly the same size of the conventional laparoscopic instrument, within the diameter of 4 mm. The elastic parts were fabricated by Ni-Ti alloy and SK-85M, rigid parts ware fabricated by stainless steel, covered by 3D- printed ABS resin. The prototype was designed using iterative finite element method analysis, and has a minimal number of mechanical parts. The prototype showed hysteresis in grasping movement presumably due to the friction; however, the prototype showed promising mechanical characteristics and was fully functional in two degrees of freedom. In addition, the prototype was capable to exert over 15 N grasping that is sufficient for the general laparoscopic procedure. The evaluation tests thus positively showed the concept of the proposed mechanism. The prototype showed promising characteristics in the given mechanical evaluation experiments. Use of a compliant mechanism such as in our prototype may contribute to the advancement of surgical instruments in terms of simplicity, size, weight, dexterity, and affordability.	[Arata, Jumpei] Kyushu Univ, Dept Mech Engn, Fac Engn, Nishi Ku, Fukuoka 8190395, Japan; [Nakadate, Ryu; Hashizume, Makoto] Kyushu Univ, Ctr Adv Med Innovat, Fukuoka 8190395, Japan; [Kogiso, Shinya; Sakaguchi, Masamichi] Nagoya Inst Technol, Dept Engn Phys Elect & Mech, Nagoya, Aichi, Japan; [Oguri, Susumu; Uemura, Munenori; Byunghyun, Cho; Akahoshi, Tomohiko; Ikeda, Tetsuo] Kyushu Univ, Fac Med Sci, Dept Adv Med Initiat, Fukuoka 812, Japan	Arata, J (reprint author), Kyushu Univ, Dept Mech Engn, Fac Engn, Nishi Ku, 744 Motooka, Fukuoka 8190395, Japan.	jumpei@mech.kyushu-u.ac.jp					Kozuka H, 2012, IEEE INT C INT ROBOT, P2519, DOI 10.1109/IROS.2012.6386108; Romanelli JR, 2009, SURG ENDOSC, V23, P1419, DOI 10.1007/s00464-009-0463-x; Tacchino R, 2009, SURG ENDOSC, V23, P896, DOI 10.1007/s00464-008-0147-y; Arata J, 2010, IEEE INT CONF ROBOT, P1041, DOI 10.1109/ROBOT.2010.5509705; Lim JJB, 2003, MECH MACH THEORY, V38, P1133, DOI 10.1016/S0094-114X(03)00063-6; STAMMBERGER H, 1990, EUR ARCH OTO-RHINO-L, V247, P63; Arata J, 2013, INT J CARS S1, V1, pS369; Arata J, 2014, INT J CARS S1, V9, pS183; Howell L L, 2001, COMPLIANT MECH; Jho H D, 1999, Pituitary, V2, P139, DOI 10.1023/A:1009991631761; Lange D, 2008, P ASME 2008 INT DES, P293; Lobontiu N, 2002, COMPLIANT MECH; Miniati R, 2014, IFMBE P, V41, P1144; Sato R, 2011, J JSCAS, V13, P300; Smith S. T., 2000, FLEXURES ELEMENTS EL; Tolou N, 2008, INT DES ENG TECHN C, P1	16	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1861-6410	1861-6429		INT J COMPUT ASS RAD	Int. J. Comput. Assist. Radiol. Surg.	NOV	2015	10	11					1837	1843		10.1007/s11548-015-1159-4		7	Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging; Surgery	Engineering; Radiology, Nuclear Medicine & Medical Imaging; Surgery	CU7LQ	WOS:000363720700011		
J	Zhang, D; Sessa, S; Kong, WS; Cosentino, S; Magistro, D; Ishii, H; Zecca, M; Takanishi, A				Zhang, Di; Sessa, Salvatore; Kong, Weisheng; Cosentino, Sarah; Magistro, Daniele; Ishii, Hiroyuki; Zecca, Massimiliano; Takanishi, Atsuo			Development of subliminal persuasion system to improve the upper limb posture in laparoscopic training: a preliminary study	INTERNATIONAL JOURNAL OF COMPUTER ASSISTED RADIOLOGY AND SURGERY			English	Article						Laparoscopy; Subliminal persuasion; Workload; Subliminal visual stimuli; Supraliminal visual stimuli	SURGERY; PERFORMANCE; DISCOMFORT; COLECTOMY; SKILLS; TRIAL	Current training for laparoscopy focuses only on the enhancement of manual skill and does not give advice on improving trainees' posture. However, a poor posture can result in increased static muscle loading, faster fatigue, and impaired psychomotor task performance. In this paper, the authors propose a method, named subliminal persuasion, which gives the trainee real-time advice for correcting the upper limb posture during laparoscopic training like the expert but leads to a lower increment in the workload. A 9-axis inertial measurement unit was used to compute the upper limb posture, and a Detection Reaction Time device was developed and used to measure the workload. A monitor displayed not only images from laparoscope, but also a visual stimulus, a transparent red cross superimposed to the laparoscopic images, when the trainee had incorrect upper limb posture. One group was exposed, when their posture was not correct during training, to a short (about 33 ms) subliminal visual stimulus. The control group instead was exposed to longer (about 660 ms) supraliminal visual stimuli. We found that subliminal visual stimulation is a valid method to improve trainees' upper limb posture during laparoscopic training. Moreover, the additional workload required for subconscious processing of subliminal visual stimuli is less than the one required for supraliminal visual stimuli, which is processed instead at the conscious level. We propose subliminal persuasion as a method to give subconscious real-time stimuli to improve upper limb posture during laparoscopic training. Its effectiveness and efficiency were confirmed against supraliminal stimuli transmitted at the conscious level: Subliminal persuasion improved upper limb posture of trainees, with a smaller increase on the overall workload.	[Zhang, Di; Sessa, Salvatore; Kong, Weisheng; Cosentino, Sarah; Ishii, Hiroyuki] Waseda Univ, Fac Sci & Engn, Tokyo, Japan; [Magistro, Daniele] Univ Turin, Dept Psychol, Turin, Italy; [Zecca, Massimiliano] Univ Loughborough, Loughborough LE11 3TU, Leics, England; [Zecca, Massimiliano] Natl Ctr Sports & Exercise Med East Midlands NCSE, Loughborough, Leics, England; [Zecca, Massimiliano] NIHR Leicester Loughborough Diet Lifestyle & Phys, Loughborough, Leics, England; [Takanishi, Atsuo] Waseda Univ, Dept Modern Mech Engn, Tokyo, Japan; [Takanishi, Atsuo] Waseda Univ, Humanoid Robot Inst, Tokyo, Japan	Sessa, S (reprint author), Waseda Univ, Fac Sci & Engn, Tokyo, Japan.	contact@takanishi.mech.waseda.ac.jp		Sessa, Salvatore/0000-0003-3540-8121; Zecca, Massimiliano/0000-0003-4741-4334; Magistro, Daniele/0000-0002-2554-3701	research institute of science and engineering, Waseda University; JSPS [24500616, 25750259]; Waseda University [2014S-091]; MEXT, Japan; Consolidated Research Institute for Advanced Science and Medical Care, Waseda University (ASMeW); STMicroelectronics; Life Performance Research; Italian Ministry of Foreign Affairs, General Directorate for Cultural Promotion and Cooperation	This study was partially supported by the research institute of science and engineering, Waseda University. This research has been supported by the JSPS Scientific Research-C Grant [24500616], the JSPS Grant-in-Aid for Young Scientists (Wakate B) [25750259], the Waseda University Grant for Special Research Projects (for new full-time faculty) [2014S-091], the Global COE Program "Global Robot Academia", MEXT, Japan, and the Consolidated Research Institute for Advanced Science and Medical Care, Waseda University (ASMeW). It was also partially supported by a Grant by STMicroelectronics, which also provided the core sensors and the microcontroller. The authors would like to express their thanks to the Italian Ministry of Foreign Affairs, General Directorate for Cultural Promotion and Cooperation, for its support to RoboCasa. The authors would also like to express their gratitude to Life Performance Research for their support to the research.	Novitsky YW, 2004, SURG ENDOSC, V18, P1411, DOI 10.1007/s00464-003-8275-x; Riener A, 2012, IEEE T INTELL TRANSP, V13, P71, DOI 10.1109/TITS.2011.2178838; CORLETT EN, 1976, ERGONOMICS, V19, P175, DOI 10.1080/00140137608931530; BHATNAGER V, 1985, HUM FACTORS, V27, P189; Derossis AM, 1998, AM J SURG, V175, P482, DOI 10.1016/S0002-9610(98)00080-4; Ritter EM, 2007, SURG INNOV, V14, P107, DOI 10.1177/1553350607302329; Johnson A, 1997, LANCET, V349, P631, DOI 10.1016/S0140-6736(96)10032-5; Tanoue K, 2008, SURG ENDOSC, V22, P985, DOI 10.1007/s00464-007-9554-8; Golub R, 1998, J AM COLL SURGEONS, V186, P545, DOI 10.1016/S1072-7515(98)00080-5; Lacy AM, 2002, LANCET, V359, P2224, DOI 10.1016/S0140-6736(02)09290-5; Cohen MA, 2012, TRENDS COGN SCI, V16, P411, DOI 10.1016/j.tics.2012.06.013; Berguer R, 1997, MINIM INVASIV THER, V6, P36, DOI 10.3109/13645709709152824; Lin ZH, 2011, IEEE ENG MED BIO, P6927; Berguer R, 2001, SURG ENDOSC-ULTRAS, V15, P1204, DOI 10.1007/s004640080030; Kennedy GD, 2009, ANN SURG, V249, P596, DOI 10.1097/SLA.0b013e31819ec903; KANFER R, 1989, J APPL PSYCHOL, V74, P657, DOI 10.1037/0021-9010.74.4.657; Egermann H, 2006, J ARTICLES SUPPORT N, V4, P29; Kantowitz B. H., 1988, MENTAL STATE ESTIMAT, P179; Lin Z, 2010, 2010 IEEE SICE INT S, P420, DOI 10.1109/SII.2010.5708362; Lin Z, 2011, IEEE ICRA, P5737; Lysaught RJ, 1989, 851 AN; Perrin M, 2004, CONTIN ED ANAESTH CR, V4, P107, DOI 10.1093/bjaceaccp/mkh032; Rosen DL, 1992, PSYCHOL MARKET, V9, P157, DOI 10.1002/mar.4220090206; Strayer DL, 2013, MONOGRAPH AAA FDN TR	24	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1861-6410	1861-6429		INT J COMPUT ASS RAD	Int. J. Comput. Assist. Radiol. Surg.	NOV	2015	10	11					1863	1871		10.1007/s11548-015-1198-x		9	Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging; Surgery	Engineering; Radiology, Nuclear Medicine & Medical Imaging; Surgery	CU7LQ	WOS:000363720700014		
J	Bamba, K; Momeni, D; Myrzakulov, R				Bamba, Kazuharu; Momeni, Davood; Myrzakulov, Ratbay			Kaluza-Klein reduction and Bergmann-Wagoner bi-scalar general action of scalar-tensor gravity	INTERNATIONAL JOURNAL OF GEOMETRIC METHODS IN MODERN PHYSICS			English	Article						Compactification and four-dimensional models; particle-theory and field-theory models of the early universe; Kaluza-Klein theories; modified theories of gravity	MULTIDIMENSIONAL MODELS; QUANTUM BILLIARDS	We examine the Kaluza-Klein (KK) dimensional reduction from higher dimensional space-time and the properties of the resultant Bergmann-Wagoner general action of scalar-tensor theories. With the analysis of the perturbations, we also investigate the stability of the anti-de Sitter (AdS) space-time in the (D is an element of N)-dimensional Einstein gravity with the negative cosmological constant. Furthermore, we derive the conditions for the dimensional reduction to successfully be executed and present the KK compactification mechanism.	[Bamba, Kazuharu] Fukushima Univ, Fac Symbiot Syst Sci, Div Human Support Syst, Fukushima 9601296, Japan; [Bamba, Kazuharu] Ochanomizu Univ, Leading Grad Sch Promot Ctr, Tokyo 1128610, Japan; [Bamba, Kazuharu] Ochanomizu Univ, Grad Sch Humanities & Sci, Dept Phys, Tokyo 1128610, Japan; [Momeni, Davood; Myrzakulov, Ratbay] Eurasian Natl Univ, Eurasian Int Ctr Theoret Phys, Astana 010008, Kazakhstan	Bamba, K (reprint author), Fukushima Univ, Fac Symbiot Syst Sci, Div Human Support Syst, Fukushima 9601296, Japan.	bamba@sss.fukushima-u.ac.jp	Myrzakulov, Ratbay/O-7973-2014	Myrzakulov, Ratbay/0000-0002-5274-0815	JSPS [25800136]	The work has been supported in part by the JSPS Grant-in-Aid for Young Scientists (B) # 25800136 (K. Bamba).	Anninos D., ARXIV11085735HEPTH; BRANS C, 1961, PHYS REV, V124, P925, DOI 10.1103/PhysRev.124.925; DUFF MJ, 1986, PHYS REP, V130, P1, DOI 10.1016/0370-1573(86)90163-8; Bamba K, 2012, ASTROPHYS SPACE SCI, V342, P155, DOI 10.1007/s10509-012-1181-8; Klemm D, 2002, NUCL PHYS B, V625, P295, DOI 10.1016/S0550-3213(02)00007-X; Caldarelli MM, 2013, PHYS REV D, V87, DOI 10.1103/PhysRevD.87.061502; Nishio SGJ, 2014, MOD PHYS LETT A, V29, DOI 10.1142/S0217732314502010; Capozziello S, 2011, PHYS REP, V509, P167, DOI 10.1016/j.physrep.2011.09.003; Nojiri S, 2011, PHYS REP, V505, P59, DOI 10.1016/j.physrep.2011.04.001; Overduin JM, 1997, PHYS REP, V283, P303, DOI 10.1016/S0370-1573(96)00046-4; WAGONER RV, 1970, PHYS REV D, V1, P3209, DOI 10.1103/PhysRevD.1.3209; Bamba K, 2006, PROG THEOR PHYS, V115, P269, DOI 10.1143/PTP.115.269; Appelquist T., 1987, MODERN KALUZA KLEIN; Bamba K., ARXIV14027114HEPTH; Bergmann P G, 1968, INT J THEOR PHYS, V1, P25, DOI DOI 10.1007/BF00668828; Bizon P, 2014, GEN RELAT GRAVIT, V46, DOI 10.1007/s10714-014-1724-0; Blagojevic M., 2002, GRAVITATION GAUGE SY, P522; Bronnikov KA, 2013, BLACK HOLES, COSMOLOGY AND EXTRA DIMENSIONS, P1; Capozziello S, 2010, EINSTEIN GRAVITY; Cho Y. M., IASSNSHEP9386; Fernandes K., ARXIV14052172GRQC; Fierz M., 1956, Helvetica Physica Acta, V29; Frob M. B., ARXIV14042785HEPTH; Fujii Y, 2003, SCALAR TENSOR THEORY; Gao C. J., ARXIVGRQC0604083; Ghezelbash A. M., 2002, JHEP, V0201, P005; Ivashchuk VD, 2013, GRAVIT COSMOL-RUSSIA, V19, P171, DOI 10.1134/S0202289313030055; Ivashchuk VD, 2014, EUR PHYS J C, V74, DOI 10.1140/epjc/s10052-014-2805-7; Landau L. D., 1975, CLASSICAL THEORY FIE; Maldacena J., ARXIV11055632HEPTH; Nojiri S., 2006, ECONF C, V0602061, P06; Nojiri S, 2001, PHYS LETT B, V519, P145, DOI 10.1016/S0370-2693(01)00869-3; Nojiri S., 2007, INT J GEOM METHODS M, V4, P115; Papantonopoulos E, 2011, LECT NOTES PHYS, V828, P1, DOI 10.1007/978-3-642-04864-7; Pope C. N., 2000, LECT KALUZA KLEIN TH; Rasouli S. M. M., ARXIV14050229GRQC; Spradlin M, 2002, PHYS REV D, V65, DOI 10.1103/PhysRevD.65.104037; Strominger A., 2001, ARXIVHEPTH0110087, V0111, P049; Strominger A., 2001, JHEP, V0110, P034; Vladimirov Yu. S., 1999, Gravitation & Cosmology, V5	40	0	0	WORLD SCIENTIFIC PUBL CO PTE LTD	SINGAPORE	5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE	0219-8878	1793-6977		INT J GEOM METHODS M	Int. J. Geom. Methods Mod. Phys.	NOV	2015	12	10							1550106	10.1142/S0219887815501066		15	Physics, Mathematical	Physics	CU8HT	WOS:000363783300007		
J	Ueki, K; Moroi, A; Iguchi, R; Kosaka, A; Ikawa, H; Yoshizawa, K				Ueki, K.; Moroi, A.; Iguchi, R.; Kosaka, A.; Ikawa, H.; Yoshizawa, K.			Changes in the computed tomography (pixel) value of mandibular ramus bone and fixation screws after sagittal split ramus osteotomy	INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY			English	Article						Sagittal split ramus osteotomy; Computed tomography (CT) value; Absorbable plate and screws; Bone healing	ALPHA-TRICALCIUM PHOSPHATE; HYDROXYAPATITE HA PARTICLES; BENT PLATE FIXATION; FORT-I OSTEOTOMY; L-LACTIDE PLLA; FORGED COMPOSITES; BIORESORBABLE DEVICES; CORTICAL BONE; CEMENT; STABILITY	The purpose of this retrospective study was to evaluate the changes in computed tomography (CT) values of ramus bone and screws after sagittal split ramus osteotomy (SSRO) setback surgery. The subjects were 64 patients (128 sides) who underwent bilateral SSRO setback surgery. They were divided into six groups according to the fixation plate type used and the use or not of self-setting alpha-tricalcium phosphate (Biopex): group 1: titanium plate and screws; group 2: titanium plate and screws with Biopex; group 3: poly-L-lactic acid (PLLA) plate and screws; group 4: PLLA plate and screws with Biopex; group 5: uncalcined and unsintered hydroxyapatite particles and poly-L-lactic acid (uHA/PLLA) plate and screws; group 6: PLLA/uHA plate and screws with Biopex. CT values (pixel values) of the lateral cortex, medial cortex, osteotomy site, and screws were measured preoperatively, immediately after surgery, and 1 year postoperatively using horizontal CT images at the mandibular foramen taken parallel to the Frankfort horizontal plane. There were significant differences in the time-course change of pixel values for the lateral cortex (P < 0.0001) and the osteotomy site (P < 0.0001) among the six groups. This study suggests that the fixation plate type and use of bone alternative material may affect bone quality during the process of bone healing after SSRO.	[Ueki, K.; Moroi, A.; Iguchi, R.; Kosaka, A.; Ikawa, H.; Yoshizawa, K.] Univ Yamanashi, Interdisciplinary Grad Sch Med & Engn, Dept Oral & Maxillofacial Surg, Div Med, Chuo, Yamanashi, Japan	Ueki, K (reprint author), Univ Yamanashi, Interdisciplinary Grad Sch Med & Engn, Dept Oral & Maxillofacial Surg, Div Med, 1110 Shimokato, Chuo, Yamanashi, Japan.	kueki@yamanashi.ac.jp					Lettry S, 2003, BONE, V32, P35, DOI 10.1016/S8756-3282(02)00921-3; Ueki K, 2005, INT J ORAL MAX SURG, V34, P627, DOI 10.1016/j.ijom.2005.02.013; Yuan HP, 2000, BIOMATERIALS, V21, P1283, DOI 10.1016/S0142-9612(00)00016-8; Ueki K, 2013, J CRANIO MAXILL SURG, V41, P129, DOI 10.1016/j.jcms.2012.06.004; Ueki K, 2008, ORAL SURG ORAL MED O, V106, P656, DOI 10.1016/j.tripleo.2008.03.016; Ueki K, 2006, J ORAL MAXIL SURG, V64, P74, DOI 10.1016/j.joms.2005.09.015; HOFFMAN EJ, 1979, J COMPUT ASSIST TOMO, V3, P299; Yamamoto H, 1998, BIOMATERIALS, V19, P1587, DOI 10.1016/S0142-9612(97)00121-X; Hao H, 2004, BIOMATERIALS, V25, P431, DOI 10.1016/S0142-9612(03)00550-7; Ueki K, 2009, J ORAL MAXIL SURG, V67, P1062, DOI 10.1016/j.joms.2008.11.016; Ueki K, 2011, J ORAL MAXIL SURG, V69, P1464, DOI 10.1016/j.joms.2010.06.187; Shikinami Y, 2005, BIOMATERIALS, V26, P5542, DOI 10.1016/j.biomaterials.2005.02.016; Shikinami Y, 2001, BIOMATERIALS, V22, P3197, DOI 10.1016/S0142-9612(01)00072-2; Yoshioka I, 2011, BRIT J ORAL MAX SURG, V49, P552, DOI 10.1016/j.bjoms.2010.09.014; Ueki K, 2001, INT J ORAL MAX SURG, V30, P490, DOI 10.1054/ijom.2001.0171; Kurashina K, 1997, BIOMATERIALS, V18, P539, DOI 10.1016/S0142-9612(96)00162-7; Shikinami Y, 1999, BIOMATERIALS, V20, P859, DOI 10.1016/S0142-9612(98)00241-5; Arimoto S, 2013, J ORAL MAXIL SURG, V71, DOI 10.1016/j.joms.2013.02.021; Monma H, 1988, FC REP, V6, P475; Ueki K, 2012, J CRANIOMAXILLOFAC S, V40, P119; Ueki K, 2014, J CRANIO MAXILL SURG, V42, pE210, DOI 10.1016/j.jcms.2013.08.009; Yoshioka I, 2012, J CRANIO MAXILL SURG, V40, pE178, DOI 10.1016/j.jcms.2011.09.003	22	0	0	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0901-5027	1399-0020		INT J ORAL MAX SURG	Int. J. Oral Maxillofac. Surg.	NOV	2015	44	11					1337	1345		10.1016/j.ijom.2015.06.010		9	Dentistry, Oral Surgery & Medicine; Surgery	Dentistry, Oral Surgery & Medicine; Surgery	CU8WY	WOS:000363826000003		
J	Ogawa, T; Imamura, T; Nakazawa, M; Hiragata, S; Nagai, T; Minagawa, T; Yokoyama, H; Ishikawa, M; Domen, T; Ishizuka, O				Ogawa, Teruyuki; Imamura, Tetsuya; Nakazawa, Masaki; Hiragata, Shiro; Nagai, Takashi; Minagawa, Tomonori; Yokoyama, Hitoshi; Ishikawa, Masakuni; Domen, Takahisa; Ishizuka, Osamu			Transient receptor potential channel superfamily: Role in lower urinary tract function	INTERNATIONAL JOURNAL OF UROLOGY			English	Review						bladder; lower urinary tract; transient receptor potential	SPINAL-CORD-INJURY; CATION CHANNEL; VANILLOID RECEPTOR; CONSCIOUS RATS; CAPSAICIN RECEPTOR; HUMAN BLADDER; INTRAVESICAL RESINIFERATOXIN; DETRUSOR OVERACTIVITY; INTERSTITIAL CYSTITIS; SENSITIVE NERVES	Lower urinary tract symptoms associated with neurogenic bladder and overactive bladder syndrome are mediated in part by members of the transient receptor potential channel superfamily. The best studied member of this superfamily is the vanilloid receptor. Other transient receptor potential channels, such as the melastatin receptor and the ankyrin receptor, are also active in the pathogenesis of lower urinary tract dysfunction. However, the detailed mechanisms by which the transient receptor potential channels contribute to lower urinary tract symptoms are still not clear, and the therapeutic benefits of modulating transient receptor potential channel activity have not been proved in the clinical setting. In the present review, to better understand the pathophysiology and therapeutic potential for lower urinary tract symptoms, we summarize the presence and role of different members of the transient receptor potential channel superfamily in the lower urinary tract.	[Ogawa, Teruyuki; Imamura, Tetsuya; Nakazawa, Masaki; Hiragata, Shiro; Nagai, Takashi; Minagawa, Tomonori; Yokoyama, Hitoshi; Ishikawa, Masakuni; Domen, Takahisa; Ishizuka, Osamu] Shinshu Univ, Sch Med, Dept Urol, Matsumoto, Nagano 3908621, Japan	Ogawa, T (reprint author), Shinshu Univ, Sch Med, Dept Urol, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	ogawat@shinshu-u.ac.jp					Yamamoto S, 2008, NAT MED, V14, P738, DOI 10.1038/nm1758; Janssen DAW, 2011, J UROLOGY, V186, P1121, DOI 10.1016/j.juro.2011.04.107; Yamada T, 2009, J HISTOCHEM CYTOCHEM, V57, P277, DOI 10.1369/jhc.2008.951962; Nilius B, 2007, PHYSIOL REV, V87, P165, DOI 10.1152/physrev.00021.2006; Geppetti P, 2008, BJU INT, V101, P2, DOI 10.1111/j.1464-410X.2008.07493.x; CHENG CL, 1995, BRAIN RES, V678, P40, DOI 10.1016/0006-8993(95)00212-9; Stokes AJ, 2004, J EXP MED, V200, P137, DOI 10.1084/jem.20032082; Gevaert T, 2007, J CLIN INVEST, V117, P3453, DOI 10.1172/JC131766; Daly D, 2007, J PHYSIOL-LONDON, V583, P663, DOI 10.1113/jphysiol.2007.139147; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; Peier AM, 2002, CELL, V108, P705, DOI 10.1016/S0092-8674(02)00652-9; Birder L, 2007, J PHARMACOL EXP THER, V323, P227, DOI 10.1124/jpet.107.125435; Strotmann R, 2000, NAT CELL BIOL, V2, P695; Cavanaugh DJ, 2011, J NEUROSCI, V31, P5067, DOI 10.1523/JNEUROSCI.6451-10.2011; Stein RJ, 2004, J UROLOGY, V172, P1175, DOI 10.1097/01.ju.0000134880.55119.cf; Lei Z, 2013, NEUROUROL URODYNAM, V32, P500, DOI 10.1002/nau.22325; Imamura T, 2008, NEUROUROL URODYNAM, V27, P348, DOI 10.1002/nau.20497; Vriens J, 2004, P NATL ACAD SCI USA, V101, P396, DOI 10.1073/pnas.0303329101; Seki S, 2005, AM J PHYSIOL-RENAL, V288, pF466, DOI 10.1152/ajprenal.00274.2004; Avelino A, 2002, NEUROSCIENCE, V109, P787, DOI 10.1016/S0306-4522(01)00496-1; Minagawa T, 2014, NEUROUROL URODYNAM, V33, P544, DOI 10.1002/nau.22449; Bautista DM, 2005, P NATL ACAD SCI USA, V102, P12248, DOI 10.1073/pnas.0505356102; McKemy DD, 2002, NATURE, V416, P52, DOI 10.1038/nature719; Andrade EL, 2006, BIOCHEM PHARMACOL, V72, P104, DOI 10.1016/j.bcp.2006.04.003; Nilius B, 2012, PFLUG ARCH EUR J PHY, V464, P425, DOI 10.1007/s00424-012-1158-z; Homma Y, 2013, J UROLOGY, V190, P1925, DOI 10.1016/j.juro.2013.05.049; Smith AC, 2013, AM J PHYSIOL-RENAL, V304, pF918, DOI 10.1152/ajprenal.00417.2012; HARDIE RC, 1992, NEURON, V8, P643, DOI 10.1016/0896-6273(92)90086-S; Caprodossi S, 2008, EUR UROL, V54, P612, DOI 10.1016/j.eururo.2007.10.016; Yoshimura N, 1999, PROG NEUROBIOL, V57, P583, DOI 10.1016/S0301-0082(98)00070-7; Gratzke C, 2010, EUR UROL, V57, P902, DOI 10.1016/j.eururo.2009.08.019; Parajuli SP, 2013, CHANNELS, V7, P537, DOI 10.4161/chan.26289; Everaerts W, 2010, AM J PHYSIOL-RENAL, V298, pF692, DOI 10.1152/ajprenal.00599.2009; Winchester WJ, 2014, J PHARMACOL EXP THER, V351, P259, DOI 10.1124/jpet.114.216010; Mochizuki T, 2009, J BIOL CHEM, V284, P21257, DOI 10.1074/jbc.M109.020206; Apostolidis A, 2005, UROLOGY, V65, P400, DOI 10.1016/j.urology.2004.10.007; Tsavaler L, 2001, CANCER RES, V61, P3760; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; Tominaga M, 2004, J NEUROBIOL, V61, P3, DOI 10.1002/neu.20079; Caterina MJ, 1997, NATURE, V389, P816; Avelino A, 2006, N-S ARCH PHARMACOL, V373, P287, DOI 10.1007/s00210-006-0073-2; Andersson KE, 2010, BJU INT, V106, P1114, DOI 10.1111/j.1464-410X.2010.09650.x; Du SQ, 2008, UROLOGY, V72, P450, DOI 10.1016/j.urology.2007.11.127; Yu WQ, 2011, AM J PHYSIOL-RENAL, V300, pF49, DOI 10.1152/ajprenal.00349.2010; Togashi K, 2006, EMBO J, V25, P1804, DOI 10.1038/sj.emboj.7601083; Du S, 2007, UROLOGY, V70, P826, DOI 10.1016/j.urology.2007.06.1110; Shabir S, 2013, AM J PHYSIOL-RENAL, V305, pF396, DOI 10.1152/ajprenal.00127.2013; Birder LA, 2001, P NATL ACAD SCI USA, V98, P13396, DOI 10.1073/pnas.231243698; FOWLER CJ, 1992, LANCET, V339, P1239, DOI 10.1016/0140-6736(92)91186-C; Qin N, 2008, J NEUROSCI, V28, P6231, DOI 10.1523/JNEUROSCI.0504-08.2008; Yoshimura N, 2002, J UROLOGY, V168, P1897, DOI 10.1097/01.ju.0000031061.70559.40; Birder LA, 2002, NAT NEUROSCI, V5, P856, DOI 10.1038/nn902; Payne CK, 2005, J UROLOGY, V173, P1590, DOI 10.1097/01.ju.0000154631.92150.ef; Ost D, 2002, J UROLOGY, V168, P293, DOI 10.1016/S0022-5347(05)64910-5; MAGGI CA, 1989, J UROLOGY, V142, P150; Komiyama I, 1999, J UROLOGY, V161, P314, DOI 10.1016/S0022-5347(01)62138-4; HABLER HJ, 1990, J PHYSIOL-LONDON, V425, P545; Everaerts W, 2010, P NATL ACAD SCI USA, V107, P19084, DOI 10.1073/pnas.1005333107; Jaquemar D, 1999, J BIOL CHEM, V274, P7325, DOI 10.1074/jbc.274.11.7325; ISHIZUKA O, 1994, J UROLOGY, V152, P525; desGroat WC, 1993, NERVOUS CONTROL UROG, V3, P227; desGroat WC., 2004, UROLOGY, V64, P7; desGroat WC, 2001, ANN REV PHARM TOXICO, V41, P691; Guo CC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082591; Mukerji Gaurav, 2006, BMC Urol, V6, P6, DOI 10.1186/1471-2490-6-6; Nilius B, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-3-218	66	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0919-8172	1442-2042		INT J UROL	Int. J. Urol.	NOV	2015	22	11					994	999		10.1111/iju.12861		6	Urology & Nephrology	Urology & Nephrology	CU9OE	WOS:000363873100005		
J	Osaka, K; Makiyama, K; Nakaigawa, N; Yao, M				Osaka, Kimito; Makiyama, Kazuhide; Nakaigawa, Noboru; Yao, Masahiro			Predictors of trifecta outcomes in laparoscopic partial nephrectomy for clinical T1a renal masses	INTERNATIONAL JOURNAL OF UROLOGY			English	Article						laparoscopy; partial nephrectomy; single surgeon; T1a renal masses; trifecta	ROBOTIC PARTIAL NEPHRECTOMY; WARM ISCHEMIA; EXPERIENCE; COMPLICATIONS; QUALITY; KIDNEY; TUMORS	ObjectivesTo assess trifecta outcomes for laparoscopic partial nephrectomy for clinical T1a renal masses. MethodsA total of 63 patients who underwent laparoscopic partial nephrectomy for clinical T1a renal masses by a single surgeon between January 2007 and December 2012 were evaluated. Demographic and perioperative data were collected and statistically analyzed. We retrospectively evaluated trifecta outcomes. Multivariable logistic regression models were used to analyze predictors of trifecta outcomes. Trifecta outcomes were defined as the combination of total ischemia time <25min, negative surgical margins and no surgical complications. ResultsOf the 63 patients, 39 (62%) achieved trifecta. A total of 21 patients had total ischemia time 25min, four patients had positive surgical margins and two patients had surgical complications. Tumor size (P<0.001), distance from the urine collecting system or sinus (P<0.001) and surgeon's learning curve (P<0.01) were significantly different between the trifecta and no-trifecta group. Multivariate analysis showed tumor size and surgeon's learning curve to be independent predictors of trifecta outcomes. ConclusionsTumor size and surgeon's learning curve seems to be strong predictors of trifecta outcomes after laparoscopic partial nephrectomy in T1a renal masses.	[Osaka, Kimito; Makiyama, Kazuhide; Nakaigawa, Noboru; Yao, Masahiro] Yokohama City Univ, Grad Sch Med, Dept Urol, Yokohama, Kanagawa 2360004, Japan	Osaka, K (reprint author), Yokohama City Univ, Grad Sch Med, Dept Urol, Kanazawa Ku, 3-9 Fukuura, Yokohama, Kanagawa 2360004, Japan.	ousaka@yokohama-cu.ac.jp					Matsuo S, 2009, AM J KIDNEY DIS, V53, P982, DOI 10.1053/j.ajkd.2008.12.034; Dindo D, 2004, ANN SURG, V240, P205, DOI 10.1097/01.sla.0000133083.54934.ae; Makiyama K, 2008, INT J UROL, V15, P854, DOI 10.1111/j.1442-2042.2008.02101.x; Yossepowitch O, 2008, J UROLOGY, V179, P2158, DOI 10.1016/j.juro.2008.01.100; Lane BR, 2008, J UROLOGY, V180, P2363, DOI 10.1016/j.juro.2008.08.036; Bernhard JC, 2010, EUR UROL, V57, P1080, DOI 10.1016/j.eururo.2010.02.019; Mir MC, 2013, UROLOGY, V82, P263, DOI 10.1016/j.urology.2013.03.068; Komninos C, 2014, EUR UROL, V66, P512, DOI 10.1016/j.eururo.2013.10.058; Bensalah K, 2010, EUR UROL, V57, P466, DOI 10.1016/j.eururo.2009.03.048; MARBERGER M, 1978, J UROLOGY, V119, P463; Gorin MA, 2013, J UROLOGY, V190, P1907, DOI 10.1016/j.juro.2013.06.014; Springer C, 2013, BJU INT, V111, P281, DOI 10.1111/j.1464-410X.2012.11280.x; Frank I, 2006, J UROLOGY, V175, P849, DOI 10.1016/S0022-5347(05)00346-0; Venkatesh R, 2006, UROLOGY, V67, P1169, DOI 10.1016/j.urology.2006.01.089; Campbell SC, 2009, J UROLOGY, V182, P1271, DOI 10.1016/j.juro.2009.07.004; Porpiglia F, 2012, WORLD J UROL, V30, P257, DOI 10.1007/s00345-011-0729-5; Hung AJ, 2013, J UROLOGY, V189, P36, DOI 10.1016/j.juro.2012.09.042; Khalifeh A, 2013, J UROLOGY, V189, P1236, DOI 10.1016/j.juro.2012.10.021; Gill IS, 2003, J UROLOGY, V170, P52, DOI 10.1097/01.ju.0000072332.02529.10; Ploussard G, 2013, CUAJ-CAN UROL ASSOC, V7, P348, DOI 10.5489/cuaj.753; Funahashi Y, 2012, UROLOGY, V79, P160, DOI 10.1016/j.urology.2011.08.071; Riggs SB, 2008, CANCER J, V14, P302, DOI 10.1097/PPO.0b013e31818675ae; Arai Y, 2011, UROLOGY, V77, P814, DOI 10.1016/j.urology.2010.12.007; Thompson RH, 2012, UROLOGY, V79, P356, DOI 10.1016/j.urology.2011.10.031; Becker A, 2015, WORLD J UROL, V33, P421, DOI 10.1007/s00345-014-1318-1; Gill OS, 2010, NEW ENGL J MED, V362, P624; Kutuzov A, 2009, J UROLOGY, V182, P844; Minervini A, 2014, WORLD J UROL, V32, P257, DOI 10.1007/s00345-013-1155-7; Propiglia F, 2005, J UROLOGY, V173, P1098; Zargar H, 2015, BJU INT, V116, P407, DOI 10.1111/bju.12933	30	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0919-8172	1442-2042		INT J UROL	Int. J. Urol.	NOV	2015	22	11					1000	1005		10.1111/iju.12893		6	Urology & Nephrology	Urology & Nephrology	CU9OE	WOS:000363873100006		
J	Fujita, K; Inamoto, T; Yamamoto, Y; Tanigawa, G; Nakayama, M; Mori, N; Tsujihata, M; Azuma, H; Nonomura, N; Uemura, M				Fujita, Kazutoshi; Inamoto, Teruo; Yamamoto, Yoshiyuki; Tanigawa, Go; Nakayama, Masashi; Mori, Naoki; Tsujihata, Masao; Azuma, Haruhito; Nonomura, Norio; Uemura, Motohide			Role of adjuvant chemotherapy for lymph node-positive upper tract urothelial carcinoma and the prognostic significance of C-reactive protein: A multi-institutional, retrospective study	INTERNATIONAL JOURNAL OF UROLOGY			English	Article						adjuvant chemotherapy; C-reactive protein; lymph nodes; survival; upper tract urothelial carcinoma	UPPER URINARY-TRACT; TRANSITIONAL-CELL CARCINOMA; RADICAL NEPHROURETERECTOMY; SYSTEMIC CHEMOTHERAPY; CANCER; SURVIVAL; IMPACT; OUTCOMES	ObjectiveTo analyze the role of adjuvant chemotherapy in lymph node-positive patients with upper tract urothelial carcinoma undergoing radical nephroureterectomy, and identified the prognostic adjuvant chemotherapy parameters. MethodsThe clinicopathological records of 74 lymph node-positive upper tract urothelial carcinoma patients who underwent radical nephroureterectomy at multiple institutions were retrospectively reviewed. A total of 45 patients (60.8%) received adjuvant chemotherapy, and 29 (39.2%) underwent radical nephroureterectomy only. Kaplan-Meier analyses and Cox proportional hazard modeling were used to study the association between adjuvant chemotherapy status and both recurrence-free survival and cancer-specific survival. ResultsEstimated 5-year recurrence-free survival was 33.6% in patients undergoing radical nephroureterectomy plus adjuvant chemotherapy compared with 13.5% in patients undergoing radical nephroureterectomy only (hazard ratio 0.52; P=0.014, log-rank test). Estimated 5-year cancer-specific survival was 42.5% in patients undergoing radical nephroureterectomy plus adjuvant chemotherapy, compared with 12.0% in patients undergoing radical nephroureterectomy only (hazard ratio 0.36; P=0.0003, log-rank test). Multivariate analysis showed that adjuvant chemotherapy was a significant prognostic factor for cancer-specific survival (P=0.001), but not for recurrence-free survival (P=0.076). When patients undergoing radical nephroureterectomy plus adjuvant chemotherapy were dichotomized, based on preoperative C-reactive protein levels above or below the normal value, higher C-reactive protein levels were significantly associated with poor survival (P=0.012). ConclusionAdjuvant chemotherapy seems to improve cancer-specific survival in lymph node-positive patients with upper tract urothelial carcinoma. Preoperative C-reactive protein levels could carry a prognostic value in this setting, and lymph node-positive patients with low preoperative CRP values should be considered for adjuvant chemotherapy. Further studies are necessary to validate these observations.	[Fujita, Kazutoshi; Nonomura, Norio; Uemura, Motohide] Osaka Univ, Grad Sch Med, Dept Urol, Suita, Osaka 5650871, Japan; [Inamoto, Teruo; Azuma, Haruhito] Osaka Med Coll, Dept Urol, Takatsuki, Osaka 569, Japan; [Yamamoto, Yoshiyuki] Osaka Police Hosp, Dept Urol, Osaka, Japan; [Tanigawa, Go] Osaka Gen Med Ctr, Dept Urol, Osaka, Japan; [Nakayama, Masashi] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Urol, Osaka, Japan; [Mori, Naoki] Sumitomo Hosp, Dept Urol, Osaka, Japan; [Tsujihata, Masao] Osaka Rosai Hosp, Dept Urol, Sakai, Osaka, Japan	Fujita, K (reprint author), Osaka Univ, Grad Sch Med, Dept Urol, 2-2 Yamada Oka, Suita, Osaka 5650871, Japan.	kazufujita2@gmail.com					Vassilakopoulou M, 2011, CANCER-AM CANCER SOC, V117, P5500, DOI 10.1002/cncr.26172; Kwak C, 2006, UROLOGY, V68, P53, DOI 10.1016/j.urology.2006.01.053; Gandaglia G, 2014, INT J UROL, V21, P249, DOI 10.1111/iju.12267; Roscigno M, 2009, J UROLOGY, V181, P2482, DOI 10.1016/j.juro.2009.02.021; Kaag MG, 2010, EUR UROL, V58, P581, DOI 10.1016/j.eururo.2010.06.029; Leow JJ, 2014, EUR UROL, V66, P529, DOI 10.1016/j.eururo.2014.03.003; Obata J, 2013, UROL ONCOL-SEMIN ORI, V31, P1725, DOI 10.1016/j.urolonc.2012.05.008; Cha EK, 2012, EUR UROL, V61, P818, DOI 10.1016/j.eururo.2012.01.021; Lehrer S, 2005, BJU INT, V95, P961, DOI 10.1111/j.1464-410X.2005.05447.x; Kawashima A, 2012, WORLD J UROL, V30, P701, DOI 10.1007/s00345-011-0775-z; Roupret M, 2013, EUR UROL, V63, P1059, DOI 10.1016/j.eururo.2013.03.032; Fujita K, 2013, INT J UROL, V20, P594, DOI 10.1111/j.1442-2042.2012.03228.x; Guthrie GJK, 2013, CANCER TREAT REV, V39, P89, DOI 10.1016/j.ctrv.2012.07.003; Soga N, 2008, INT J UROL, V15, P800, DOI 10.1111/j.1442-2042.2008.02114.x; Bamias A, 2004, J CLIN ONCOL, V22, P2150, DOI 10.1200/JCO.2004.09.043; Suzuki S, 2004, INT J UROL, V11, P456, DOI 10.1111/j.1442-2042.2004.00841.x; Lucca I, 2015, BJU INT, V116, P72, DOI 10.1111/bju.12801; Saito K, 2007, BJU INT, V100, P269, DOI 10.1111/j.1464-410X.2007.06934.x; Komai Y, 2007, BJU INT, V99, P77, DOI 10.1111/j.1464-410X.2006.06497.x; Tanaka N, 2014, EUR UROL, V65, P227, DOI 10.1016/j.eururo.2012.11.050; Kim TS, 2013, J CANCER, V4, P686, DOI 10.7150/jca.7326; Hellenthal NJ, 2009, J UROLOGY, V182, P900, DOI 10.1016/j.juro.2009.05.011; Oya M, 2015, INT J UROL, V22, P3, DOI 10.1111/iju.12630; Sejima T, 2014, INT J UROL, V21, P52, DOI 10.1111/iju.12161; Stein B, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-101; Yafi FA, 2014, UROL ONCOL, V32, pe17	26	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0919-8172	1442-2042		INT J UROL	Int. J. Urol.	NOV	2015	22	11					1006	1012		10.1111/iju.12868		7	Urology & Nephrology	Urology & Nephrology	CU9OE	WOS:000363873100007		
J	Hara, T; Fujimoto, H; Sakura, M; Inokuchi, J; Nishiyama, H; Miyazaki, J; Ohyama, C; Koie, T; Kikuchi, E; Hinotsu, S				Hara, Tomohiko; Fujimoto, Hiroyuki; Sakura, Mizuaki; Inokuchi, Junichi; Nishiyama, Hiroyuki; Miyazaki, Jun; Ohyama, Chikara; Koie, Takuya; Kikuchi, Eiji; Hinotsu, Shiro		Canc Registration Comm Japanese	Prognostic factors of recurrent disease in upper urinary tract urothelial cancer after radical nephroureterectomy: Subanalysis of the multi-institutional national database of the Japanese Urological Association	INTERNATIONAL JOURNAL OF UROLOGY			English	Article						disease recurrence; disease-free survival; nephroureterectomy; prognostic factors; renal pelvic cancer; ureteral cancer	TRANSITIONAL-CELL CARCINOMA; ONCOLOGIC OUTCOMES; TUMOR LOCATION; SURVIVAL; IMPACT; BLADDER; CLASSIFICATION; GRADE	ObjectivesTo explore predictive factors of disease recurrence after radical nephroureterectomy in patients with upper urinary tract urothelial cancer. MethodsA multi-institutional national database promoted by the Japanese Urological Association including 293 institutions and 1172 patients was used for the present study. Patient with non-metastatic upper urinary tract urothelial cancer who underwent primary radical nephroureterectomy with curative intent were analyzed. Univariate analysis using the Kaplan-Meier method and multivariate Cox regression models with stepwise selection was used to evaluate time to recurrence after surgery. ResultsThe median duration of follow up was 55.8months, and disease recurred in 325 (27.7%) patients at a median of 11.4months after radical nephroureterectomy. According to a Cox proportional hazards model, the Union International Contre le Cancer 2002 pathological stage of the primary tumor, lymph node status, presence of lymphatic and/or vascular invasion, infiltrative growth pattern, and age were independent predictors (P<0.05) of recurrence-free survival. ConclusionsDespite several limitations, our analysis suggests that pathological tumor stage, lymph node status, lymphovascular invasion, infiltrative growth pattern and age represent important prognostic variables after radical nephroureterectomy in Japanese patients with upper urinary tract urothelial cancer. This information could be potentially used to select patients for adjuvant systemic therapy.	[Hara, Tomohiko; Fujimoto, Hiroyuki; Sakura, Mizuaki; Inokuchi, Junichi; Nishiyama, Hiroyuki; Miyazaki, Jun; Ohyama, Chikara; Koie, Takuya; Kikuchi, Eiji; Hinotsu, Shiro] Japanese Urol Assoc, Canc Registrat Comm, Working Grp Renal Pelv & Ureteral Canc, Tokyo, Japan; [Hara, Tomohiko; Fujimoto, Hiroyuki] Natl Canc Ctr, Tokyo 1040045, Japan; [Sakura, Mizuaki] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Urol, Tokyo, Japan; [Inokuchi, Junichi] Kyushu Univ, Grad Sch Med Sci, Dept Urol, Fukuoka 812, Japan; [Nishiyama, Hiroyuki; Miyazaki, Jun] Univ Tsukuba, Fac Med, Dept Urol, Ibaraki, Japan; [Ohyama, Chikara; Koie, Takuya] Hirosaki Univ, Grad Sch Med, Dept Urol, Hirosaki, Aomori, Japan; [Kikuchi, Eiji] Keio Univ, Sch Med, Dept Urol, Tokyo, Japan; [Hinotsu, Shiro] Okayama Univ Hosp, Ctr Innovat Clin Med, Okayama, Japan	Hara, T (reprint author), Natl Canc Ctr, Div Urol, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	tomohara-jua@umin.ac.jp					Ehdaie B, 2011, J UROLOGY, V186, P66, DOI 10.1016/j.juro.2011.03.031; Cha EK, 2012, EUR UROL, V61, P818, DOI 10.1016/j.eururo.2012.01.021; Lughezzani G, 2012, EUR UROL, V62, P100, DOI 10.1016/j.eururo.2012.02.030; Chromecki TF, 2012, EUR UROL, V61, P245, DOI 10.1016/j.eururo.2011.09.017; Roupret M, 2013, EUR UROL, V63, P1059, DOI 10.1016/j.eururo.2013.03.032; Roscigno M, 2008, EUR UROL, V53, P794, DOI 10.1016/j.eururo.2008.01.008; Mullerad M, 2004, J UROLOGY, V172, P2177, DOI 10.1097/01.ju.0000144505.40915.98; Rink M, 2012, EUR UROL, V62, P677, DOI 10.1016/j.eururo.2012.02.018; Simsir A, 2011, INT UROL NEPHROL, V43, P1039, DOI 10.1007/s11255-011-9915-z; Capitanio U, 2009, EUR UROL, V56, P1, DOI 10.1016/j.eururo.2009.03.072; Pieras E, 2010, BJU INT, V106, P1319, DOI 10.1111/j.1464-410X.2010.09341.x; Hashimoto T, 2014, INT J CLIN ONCOL, V19, P373, DOI 10.1007/s10147-013-0548-3; Langner C, 2006, MODERN PATHOL, V19, P272, DOI 10.1038/modpathol.3800529; Raman JD, 2011, UROL ONCOL-SEMIN ORI, V29, P716, DOI 10.1016/j.urolonc.2009.11.007; Li WM, 2010, EUR UROL, V57, P963, DOI 10.1016/j.eururo.2009.12.032; Colin P, 2012, ANN SURG ONCOL, V19, P3613, DOI 10.1245/s10434-012-2453-9; Simone G, 2009, BJU INT, V103, P1052, DOI 10.1111/j.1464-410X.2008.08134.x; Brien JC, 2010, J UROLOGY, V184, P69, DOI 10.1016/j.juro.2010.03.030; Jeldres C, 2010, CANCER-AM CANCER SOC, V116, P3774, DOI 10.1002/cncr.25122; Raman JD, 2011, BJU INT, V107, P1059, DOI 10.1111/j.1464-410X.2010.09675.x; Lee JN, 2014, J SURG ONCOL, V110, P468, DOI 10.1002/jso.23589; Otto W, 2011, WORLD J UROL, V29, P487, DOI 10.1007/s00345-011-0645-8; Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244; Epstein JI, 1998, AM J SURG PATHOL, V22, P1435, DOI 10.1097/00000478-199812000-00001; Raman JD, 2010, EUR UROL, V57, P1072, DOI 10.1016/j.eururo.2009.07.002; Roupret M, 2013, J UROLOGY, V189, P1662, DOI 10.1016/j.juro.2012.10.057; Margulis V, 2009, CANCER, V115, P1224, DOI 10.1002/cncr.24135; Fujimoto H, 2014, INT J UROL, V21, P527, DOI 10.1111/iju.12367; Martinez-Salamanca JI, 2012, BJU INT, V109, P1155, DOI 10.1111/j.1464-410X.2011.10479.x	29	2	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0919-8172	1442-2042		INT J UROL	Int. J. Urol.	NOV	2015	22	11					1013	1020		10.1111/iju.12884		8	Urology & Nephrology	Urology & Nephrology	CU9OE	WOS:000363873100008		
J	Miyazaki, J; Nishiyama, H; Fujimoto, H; Ohyama, C; Koie, T; Hinotsu, S; Kikuchi, E; Sakura, M; Inokuchi, J; Hara, T				Miyazaki, Jun; Nishiyama, Hiroyuki; Fujimoto, Hiroyuki; Ohyama, Chikara; Koie, Takuya; Hinotsu, Shiro; Kikuchi, Eiji; Sakura, Mizuaki; Inokuchi, Junichi; Hara, Tomohiko		Canc Registration Comm Japanese	Impact of smoking on the age at diagnosis of upper tract urothelial carcinoma: Subanalysis of the Japanese Urological Association multi-institutional national database	INTERNATIONAL JOURNAL OF UROLOGY			English	Article						age at diagnosis; Japanese; smoking; upper tract urothelial carcinoma	CANCER REGISTRATION COMMITTEE; UPPER URINARY-TRACT; RADICAL NEPHROURETERECTOMY; BLADDER-CANCER; CELL-CARCINOMA; OUTCOMES; RECURRENCE; DISEASE	ObjectivesTo examine the influence of smoking history on the diagnosis and other tumor characteristics of upper tract urothelial carcinoma in Japan. MethodsA total of 1509 patients with upper tract urothelial carcinoma who were diagnosed in 2005 from 348 Japanese institutions were registered using the multi-institutional national database of the Japanese Urological Association and included in this analysis. Clinical data of the patients were collected in 2011. The associations between the patients' self-reported smoking history and their age at the diagnosis of upper tract urothelial carcinoma, sex, pathological Tstage and tumor grade were analyzed. ResultsThe mean age at the diagnosis of upper tract urothelial carcinoma was approximately 5years earlier for the 238 current smokers than for the 618 current non-smokers (P<0.0001). Similar associations between smoking and the early diagnosis of upper tract urothelial carcinoma were shown in the sex subgroups and in subgroups stratified by pathological Tstages. Among the current smokers, the age at diagnosis for the smoking 20 cigarettes per day group was 6.5years lower than that of the <20 cigarettes per day group, which was significantly different (P<0.0001). ConclusionCurrent smoking is a significant risk factor for the earlier diagnosis of upper tract urothelial carcinoma. The finding is important from the perspective of both healthcare and medical economies.	[Miyazaki, Jun; Nishiyama, Hiroyuki; Fujimoto, Hiroyuki; Ohyama, Chikara; Koie, Takuya; Hinotsu, Shiro; Kikuchi, Eiji; Sakura, Mizuaki; Inokuchi, Junichi; Hara, Tomohiko] Japanese Urol Assoc, Working Grp UTUC Registrat Comm, Tokyo, Japan; [Miyazaki, Jun; Nishiyama, Hiroyuki] Univ Tsukuba, Fac Med, Dept Urol, Ibaraki, Japan; [Fujimoto, Hiroyuki; Hara, Tomohiko] Natl Canc Ctr, Urol Div, Tokyo, Japan; [Ohyama, Chikara; Koie, Takuya] Hirosaki Univ, Grad Sch Med, Dept Urol, Hirosaki, Aomori, Japan; [Hinotsu, Shiro] Okayama Univ Hosp, Ctr Innovat Clin Med, Okayama, Japan; [Kikuchi, Eiji] Keio Univ, Sch Med, Dept Urol, Tokyo, Japan; [Sakura, Mizuaki] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Urol, Tokyo, Japan; [Inokuchi, Junichi] Kyushu Univ, Grad Sch Med Sci, Dept Urol, Fukuoka 812, Japan	Nishiyama, H (reprint author), Univ Tsukuba, Fac Med, Dept Urol, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.	nishiuro@md.tsukuba.ac.jp					Ehdaie B, 2013, BJU INT, V111, P589, DOI 10.1111/j.1464-410X.2012.11260.x; Fleshner N, 1999, CANCER, V86, P2337, DOI 10.1002/(SICI)1097-0142(19991201)86:11<2337::AID-CNCR23>3.0.CO;2-6; Pommer W, 1999, NEPHROL DIAL TRANSPL, V14, P2892, DOI 10.1093/ndt/14.12.2892; Wallerand H, 2005, CARCINOGENESIS, V26, P177, DOI 10.1093/carcin/bgh275; Rink M, 2013, EUR UROL, V63, P1082, DOI 10.1016/j.eururo.2012.06.029; STURGEON SR, 1994, EPIDEMIOLOGY, V5, P218, DOI 10.1097/00001648-199403000-00012; Stefanovic V, 2011, PATHOL BIOL, V59, P286, DOI 10.1016/j.patbio.2009.05.002; Xylinas E, 2014, BJU INT, V114, P56, DOI 10.1111/bju.12400; Jiang XJ, 2012, INT J CANCER, V130, P896, DOI 10.1002/ijc.26068; Hinotsu S, 2009, INT J UROL, V16, P64, DOI 10.1111/j.1442-2042.2008.02194.x; Colin P, 2009, BJU INT, V104, P1436, DOI 10.1111/j.1464-410X.2009.08838.x; Hagiwara M, 2013, J UROLOGY, V189, P2062, DOI 10.1016/j.juro.2013.01.024; Rink M, 2013, BJU INT, V112, P623, DOI 10.1111/bju.12014; Fujimoto H, 2014, INT J UROL, V21, P527, DOI 10.1111/iju.12367; Lee JY, 2015, UROL INT, V94, P50, DOI 10.1159/000360227; Patel N, 2014, UROL ONCOL, V32, pe11; vansRoekel EH, 2013, INT J CANCER, V133, P446	17	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0919-8172	1442-2042		INT J UROL	Int. J. Urol.	NOV	2015	22	11					1023	1027		10.1111/iju.12886		5	Urology & Nephrology	Urology & Nephrology	CU9OE	WOS:000363873100011		
J	Kondo, T				Kondo, Tsunenori			Editorial Comment to Impact of smoking on the age at diagnosis of upper tract urothelial carcinoma: Subanalysis of the Japanese Urological Association multi-institutional national database	INTERNATIONAL JOURNAL OF UROLOGY			English	Editorial Material									Tokyo Womens Med Univ, Dept Urol, Tokyo, Japan	Kondo, T (reprint author), Tokyo Womens Med Univ, Dept Urol, Tokyo, Japan.	tkondo@kc.twmu.ac.jp					Rink M, 2013, EUR UROL, V63, P1082, DOI 10.1016/j.eururo.2012.06.029; Hinotsu S, 2009, INT J UROL, V16, P64, DOI 10.1111/j.1442-2042.2008.02194.x; Colin P, 2009, BJU INT, V104, P1436, DOI 10.1111/j.1464-410X.2009.08838.x; Miyazaki J, 2015, INT J UROL, V22, P1023, DOI 10.1111/iju.12886; vansRoekel EH, 2013, INT J CANCER, V133, P446	5	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0919-8172	1442-2042		INT J UROL	Int. J. Urol.	NOV	2015	22	11					1027	1028		10.1111/iju.12896		2	Urology & Nephrology	Urology & Nephrology	CU9OE	WOS:000363873100012		
J	Narita, S; Mitsuzuka, K; Tsuchiya, N; Koie, T; Kawamura, S; Ohyama, C; Tochigi, T; Yamaguchi, T; Arai, Y; Habuchi, T				Narita, Shintaro; Mitsuzuka, Koji; Tsuchiya, Norihiko; Koie, Takuya; Kawamura, Sadafumi; Ohyama, Chikara; Tochigi, Tatsuo; Yamaguchi, Takuhiro; Arai, Yoichi; Habuchi, Tomonori		Michinoku Japan Urological Canc	Reassessment of the risk factors for biochemical recurrence in D'Amico intermediate-risk prostate cancer treated using radical prostatectomy	INTERNATIONAL JOURNAL OF UROLOGY			English	Article						biochemical recurrence; D'Amico risk classification; intermediate; prostate cancer; prostate specific antigen	BEAM RADIATION-THERAPY; BODY-MASS INDEX; ANTIGEN DENSITY; CLASSIFICATION-SYSTEM; GLEASON SCORE; MEN; DISEASE; IMPACT; MANAGEMENT; MORTALITY	ObjectivesTo assess the risk factors for biochemical recurrence in D'Amico intermediate-risk prostate cancer patients treated using radical prostatectomy. MethodsWe retrospectively reviewed the medical records of 1268 men with prostate cancer treated using radical prostatectomy without neoadjuvant therapy. The association between various risk factors and biochemical recurrence was then statistically evaluated. The Kaplan-Meier method, log-rank tests and Cox proportional hazards models were used for statistical analysis. ResultsIn the intermediate-risk group, 96 patients (14.5%) experienced biochemical recurrence during a median follow up of 41months. In the intermediate-risk group, preoperative prostate-specific antigen level, prostate volume and prostate-specific antigen density were significant preoperative risk factors for biochemical recurrence, whereas other factors including age, primary Gleason4, clinical stage >T2 and percentage of positive biopsies were not. In multivariate analysis, higher preoperative prostate-specific antigen level and density, and a smaller prostate volume were independent risk factors for biochemical recurrence in the intermediate-risk group. Biochemical recurrence-free survival of patients in the intermediate-risk group with a higher prostate-specific antigen level and density (15ng/mL, 0.6ng/mL/cm(3), respectively), and lower prostate volume (10mL) was comparable with that of high-risk group individuals (P=0.632, 0.494 and 0.961, respectively). ConclusionsPreoperative prostate-specific antigen, prostate volume and prostate-specific antigen density are significant risk factors for biochemical recurrence in D'Amico intermediate-risk prostate cancer patients treated using radical prostatectomy. Using these variables, a subset of the intermediate-risk patients can be identified as having equivalent outcomes to high-risk patients.	[Narita, Shintaro; Tsuchiya, Norihiko; Habuchi, Tomonori] Akita Univ, Grad Sch Med, Dept Urol, Akita 0108543, Japan; [Mitsuzuka, Koji; Arai, Yoichi] Tohoku Univ, Grad Sch Med, Dept Urol, Sendai, Miyagi 980, Japan; [Koie, Takuya; Ohyama, Chikara] Hirosaki Univ, Grad Sch Med, Dept Urol, Hirosaki, Aomori, Japan; [Kawamura, Sadafumi; Tochigi, Tatsuo] Miyagi Canc Ctr, Dept Urol, Natori, Miyagi 9811293, Japan; [Yamaguchi, Takuhiro] Tohoku Univ, Grad Sch Med, Dept Med Sci & Biostat, Sendai, Miyagi 980, Japan	Habuchi, T (reprint author), Akita Univ, Grad Sch Med, Dept Urol, 1-1-1 Hondo, Akita 0108543, Japan.	thabuchi@gmail.com					Bastian PJ, 2012, EUR UROL, V61, P1096, DOI 10.1016/j.eururo.2012.02.031; Magheli A, 2008, J UROLOGY, V179, P1780, DOI [10.1016/j.juro.2008.01.032, 10.1016/jjuro.2008.01.032]; Hussain M, 2003, UROLOGY, V61, P774, DOI 10.1016/S0090-4295(02)02519-0; Prayer-Galetti T, 2007, BJU INT, V100, P274, DOI 10.1111/j.1464-410X.2007.06760.x; Freedland SJ, 2002, J UROLOGY, V168, P110, DOI 10.1016/S0022-5347(05)64841-0; Mitchell JA, 2005, J UROLOGY, V173, P1126, DOI 10.1097/01.ju.0000155535.25971.de; Greenberg DC, 2013, BRIT J CANCER, V109, P2115, DOI 10.1038/bjc.2013.589; Mitsuzuka K, 2013, INT J UROL, V20, P1092, DOI 10.1111/iju.12112; Keane FK, 2014, CANCER-AM CANCER SOC, V120, P1787, DOI 10.1002/cncr.28609; BENSON MC, 1992, J UROLOGY, V147, P815; Cho IC, 2011, J KOREAN MED SCI, V26, P807, DOI 10.3346/jkms.2011.26.6.807; Nguyen PL, 2009, INT J RADIAT ONCOL, V73, P659, DOI 10.1016/j.ijrobp.2008.05.009; O'Brien MF, 2009, J CLIN ONCOL, V27, P3591, DOI 10.1200/JCO.2008.19.9794; Magheli A, 2008, UROLOGY, V72, P1246, DOI 10.1016/j.urology.2008.01.052; Narita S, 2013, PROSTATE CANCER P D, V16, P271, DOI 10.1038/pcan.2013.16; Chang AJ, 2014, NAT REV CLIN ONCOL, V11, P308, DOI 10.1038/nrclinonc.2014.68; D'Amico AV, 2013, EUR UROL, V64, P903, DOI 10.1016/j.eururo.2013.03.038; Hong SK, 2007, UROLOGY, V70, P91, DOI 10.1016/j.urology.2007.03.006; D'Amico AC, 2004, J CLIN ONCOL, V22, P3726, DOI 10.1200/JCO.2004.01.164; Zumsteg ZS, 2013, EUR UROL, V64, P895, DOI 10.1016/j.eururo.2013.03.033; Mitsuzuka K, 2013, JPN J CLIN ONCOL, V43, P821, DOI 10.1093/jjco/hyt072; D'Amico AV, 1998, JAMA-J AM MED ASSOC, V280, P969, DOI 10.1001/jama.280.11.969; Kwon T, 2010, BJU INT, V106, P633, DOI 10.1111/j.1464-410X.2009.09182.x; Stark JR, 2009, J CLIN ONCOL, V27, P3459, DOI 10.1200/JCO.2008.20.4669; Mitsuzuka K, 2013, BJU INT, V111, P914, DOI 10.1111/j.1464-410X.2012.11658.x; Corcoran NM, 2012, BJU INT, V110, P821, DOI 10.1111/j.1464-410X.2011.10868.x; Busch J, 2012, J UROLOGY, V188, P2165, DOI 10.1016/j.juro.2012.07.106; Reese AC, 2012, UROLOGY, V80, P1075, DOI 10.1016/j.urology.2012.07.040; Jung JW, 2014, BJU INT, V115, P907; Koie T, 2015, INT J CLIN ONCOL, V20, P176, DOI 10.1007/s10147-014-0696-0	30	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0919-8172	1442-2042		INT J UROL	Int. J. Urol.	NOV	2015	22	11					1029	1035		10.1111/iju.12898		7	Urology & Nephrology	Urology & Nephrology	CU9OE	WOS:000363873100013		
J	Shoji, S; Nakano, M; Fujikawa, H; Endo, K; Hashimoto, A; Tomonaga, T; Terachi, T; Uchida, T				Shoji, Sunao; Nakano, Mayura; Fujikawa, Hiroshi; Endo, Kazuyuki; Hashimoto, Akio; Tomonaga, Tetsuro; Terachi, Toshiro; Uchida, Toyoaki			y Urethra-sparing high-intensity focused ultrasound for localized prostate cancer: Functional and oncological outcomes	INTERNATIONAL JOURNAL OF UROLOGY			English	Article						high-intensity focused ultrasound; localized prostate cancer; tailor-made treatment; urethra-sparing; urinary function	BLADDER OUTLET OBSTRUCTION; RADICAL PROSTATECTOMY; TRANSRECTAL HIFU; FOCAL THERAPY; EXPERIENCE; CONSENSUS; ABLATION	ObjectivesTo evaluate longitudinal changes in urinary function and quality of life, and the oncological outcomes of patients treated with urethra-sparing high-intensity focused ultrasound for localized prostate cancer. MethodsPatients with negative findings in the urethra and the anterior urethral zone using transrectal ultrasound-guided targeted biopsies, and magnetic resonance imaging, received urethra-sparing or whole-gland high-intensity focused ultrasound as the primary therapy for localized prostate cancer without transurethral resection of the prostate. Longitudinal changes in urinary function and quality of life, and the oncological outcomes of the patients were analyzed retrospectively. ResultsThe median follow-up times for urethra-sparing and whole-gland high-intensity focused ultrasound were 36 and 30months, respectively. Comparing the patients treated with urethra-sparing high-intensity focused ultrasound (n=45) with those treated with whole-gland high-intensity focused ultrasound (n=65), there were significant differences in the International Prostate Symptom Score (P=0.014) at 3months, International Prostate Symptom Score quality of life (P=0.033) at 3months, maximum urinary flow rate (mL/s; at 3months, P=0.010; at 6months, P=0.038) and residual urine volume (mL; at 3months, P<0.0001; at 6months, P=0.016; at 12months, P=0.028). For quality of life, there were significant differences in Functional Assessment of Cancer Therapy - General (at 3months, P=0.022) and Functional Assessment of Cancer Therapy - Prostate (at 3months, P=0.028; at 6months, P=0.034). There were no significant differences in oncological outcomes regarding negative biopsy rates on follow up (91% vs 92%; P=0.8) or biochemical disease-free survival rates (86.7% vs 89.2%; P=0.7). ConclusionsUrethra-sparing high-intensity focused ultrasound might prevent prolonged bladder outlet obstruction, and could be a treatment option for localized prostate cancer.	[Shoji, Sunao; Nakano, Mayura; Tomonaga, Tetsuro; Uchida, Toyoaki] Tokai Univ, Hachioji Hosp, Dept Urol, Hachioji, Tokyo 1920032, Japan; [Fujikawa, Hiroshi; Endo, Kazuyuki; Hashimoto, Akio] Tokai Univ, Hachioji Hosp, Dept Radiol, Hachioji, Tokyo 1920032, Japan; [Terachi, Toshiro] Tokai Univ, Sch Med, Dept Urol, Isehara, Kanagawa 25911, Japan	Shoji, S (reprint author), Tokai Univ, Hachioji Hosp, Dept Urol, 1838 Ishikawa Machi, Hachioji, Tokyo 1920032, Japan.	sunashoj@mail.goo.ne.jp					Chaussy Christian, 2003, Curr Urol Rep, V4, P248, DOI 10.1007/s11934-003-0077-0; MADERSBACHER S, 1995, CANCER RES, V55, P3346; Kordan Y, 2009, J UROLOGY, V182, P2291, DOI 10.1016/j.juro.2009.07.020; Thuroff S, 2013, J UROLOGY, V190, P702, DOI 10.1016/j.juro.2013.02.010; Rocco B, 2009, BJU INT, V104, P991, DOI 10.1111/j.1464-410X.2009.08532.x; Shoji S, 2013, J UROLOGY, V190, P1224, DOI 10.1016/j.juro.2013.03.116; Ahmed HU, 2011, J UROLOGY, V185, P1246, DOI 10.1016/j.juro.2010.11.079; Rouviere O, 2001, EUR UROL, V40, P265, DOI 10.1159/000049786; Geraerts I, 2013, BJU INT, V112, P936, DOI 10.1111/bju.12258; Shoji S, 2014, INT J UROL, V21, P942, DOI 10.1111/iju.12515; Herschorn S, 2014, UROLOGY, V83, pS59, DOI 10.1016/j.urology.2013.08.036; FRY WJ, 1955, SCIENCE, V122, P517, DOI 10.1126/science.122.3168.517; Lee HM, 2006, PROSTATE CANCER P D, V9, P439, DOI 10.1038/sj.pcan.4500901; van den Bos W, 2014, EUR UROL, V65, P1078, DOI 10.1016/j.eururo.2014.01.001; Krambeck AE, 2009, BJU INT, V103, P448, DOI 10.1111/j.1464-410X.2008.08012.x; Roach M, 2006, INT J RADIAT ONCOL, V65, P965, DOI 10.1016/j.ijrobp.2006.04.029; Netsch C, 2010, J ENDOUROL, V24, P1399, DOI 10.1089/end.2009.0607; Ahmed HU, 2012, LANCET ONCOL, V13, P622, DOI 10.1016/S1470-2045(12)70121-3; Ahmed HU, 2011, J UROLOGY, V186, P458, DOI 10.1016/j.juro.2011.03.147; Crouzet S, 2014, EUR UROL, V65, P907, DOI 10.1016/j.eururo.2013.04.039; Uchida T, 2009, INT J UROL, V16, P881, DOI 10.1111/j.1442-2042.2009.02389.x; Blana A, 2008, EUR UROL, V53, P1194, DOI 10.1016/j.eururo.2007.10.062; Mearini L, 2009, J UROLOGY, V181, P105, DOI 10.1016/j.juro.2008.09.024; Blana A, 2008, UROLOGY, V71, P863, DOI 10.1016/j.urology.2007.12.076; Chapelon J Y, 1999, Eur J Ultrasound, V9, P31, DOI 10.1016/S0929-8266(99)00005-1; DisPierro GB, 2011, EUR UROL, V59, P1; ElsFegoun AB, 2011, INT BRAZ J UROL, V37, P213; Shoji S, 2014, INT J UROL, V22, P173; STAMEY TA, 1993, CANCER, V71, P933, DOI 10.1002/1097-0142(19930201)71:3+<933::AID-CNCR2820711408>3.0.CO;2-L; Uchida T, 2015, J UROLOGY, V193, P103, DOI 10.1016/j.juro.2014.07.096	30	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0919-8172	1442-2042		INT J UROL	Int. J. Urol.	NOV	2015	22	11					1043	1049		10.1111/iju.12876		7	Urology & Nephrology	Urology & Nephrology	CU9OE	WOS:000363873100016		
J	Inamoto, T; Azuma, H				Inamoto, Teruo; Azuma, Haruhito			Editorial Comment to Urethra-sparing high-intensity focused ultrasound for localized prostate cancer: Functional and oncological outcomes	INTERNATIONAL JOURNAL OF UROLOGY			English	Editorial Material									[Inamoto, Teruo; Azuma, Haruhito] Osaka Med Coll, Dept Urol, Takatsuki, Osaka 569, Japan	Inamoto, T (reprint author), Osaka Med Coll, Dept Urol, Takatsuki, Osaka 569, Japan.	tinamoto@poh.osaka-med.ac.jp					Ahmed S, 2005, BJU INT, V96, P1230, DOI 10.1111/j.1464-410X.2005.05742.x; Komura K, 2011, UROL INT, V87, P276, DOI 10.1159/000330909; Kazi A, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-472; Shoji S, 2015, INT J UROL, V22, P1043, DOI 10.1111/iju.12876	4	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0919-8172	1442-2042		INT J UROL	Int. J. Urol.	NOV	2015	22	11					1050	1050		10.1111/iju.12894		1	Urology & Nephrology	Urology & Nephrology	CU9OE	WOS:000363873100017		
J	Furuya, S; Hisasue, S; Kato, H; Shimamura, S				Furuya, Seiji; Hisasue, Shin-ichi; Kato, Haruaki; Shimamura, Shogo			Novel insight for midline cyst formation in prostate: The involvement of decreased prenatal testosterone suggested by second-to-fourth digit ratio study	INTERNATIONAL JOURNAL OF UROLOGY			English	Article						2D:4D; digit ratio; midline cyst; prostate; testosterone	MULLERIAN DUCT; FINGER-LENGTH; GUIDED OPACIFICATION; SEXUAL-DIMORPHISM; PATTERNS; UTRICLE; 2ND; CLASSIFICATION; MANAGEMENT; PREDICTOR	ObjectivesTo clarify the relationship between midline cyst formation and second to fourth finger length ratio. MethodsThe present study included 95 benign prostatic hyperplasia patients and 61 healthy male college students. All midline cysts were identified by transrectal ultrasonography. In the benign prostatic hyperplasia group, 45 midline cyst (+) men (M-age=67.2years) and age-matched 50 midline cyst (-) men (M-age=67.1years) were included. In the university student group, 12 midline cyst (+) men (M-age=21.7years) and age-matched 49 midline cyst (-) men (M-age=21.1years) were included. We took photocopies of the participants' bilateral hands, and measured the second and fourth finger length was measured by one examiner in a blind manner. ResultsSecond to fourth finger length ratios in the benign prostatic hyperplasia group (right/left meanSD) were higher bilaterally in midline cyst (+) (0.95 +/- 0.03/0.95 +/- 0.03) than those in midline cyst (-) (0.92 +/- 0.03/0.92 +/- 0.03; P<0.0001/P=0.0010). Second to fourth finger length ratios in students were higher only in the right hand in midline cyst (+) (0.96 +/- 0.03/0.94 +/- 0.03) than those in midline cyst (-) (0.93 +/- 0.03/0.94 +/- 0.03; P=0.0018/P=0.9968). The second to fourth finger length ratio of midline cyst (+) men was significantly higher than that in midline cyst (-) men. ConclusionsThe second to fourth finger length ratio is higher in subjects with midline cyst of the prostate. It can be speculated that the prostatic utricle dilates in cases less exposed to male hormones during fetal development.	[Furuya, Seiji] Furuya Hosp, Kitami, Hokkaido, Japan; [Hisasue, Shin-ichi] Juntendo Univ, Grad Sch Med, Dept Urol, Tokyo 1130033, Japan; [Kato, Haruaki] Shinshu Univ, Sch Med, Dept Urol, Matsumoto, Nagano 390, Japan; [Shimamura, Shogo] Sapporo Jieitai Hosp, Dept Urol, Sapporo, Hokkaido, Japan	Hisasue, S (reprint author), Juntendo Univ, Grad Sch Med, Dept Urol, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1130033, Japan.	shisasue@juntendo.ac.jp			Japan Society for the Promotion of Science [20591883]	We acknowledge the Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (no. 20591883). We express our special gratitude to Professor Peter M Olley for help in preparing the manuscript.	Voracek M, 2003, UROLOGY, V62, P201, DOI 10.1016/S0090-4295(02)02598-0; Brosnan MJ, 2006, BRIT J PSYCHOL, V97, P455, DOI 10.1348/000712605X85808; Galosi AB, 2009, J UROLOGY, V181, P647, DOI 10.1016/j.juro.2008.10.006; GLENISTER TW, 1962, J ANAT, V96, P443; Peters M, 2002, AM J PHYS ANTHROPOL, V117, P209, DOI 10.1002/ajpa.10029; Ishikawa M, 2003, AM J ROENTGENOL, V181, P1669; Gillam L, 2008, J ANAT, V213, P325, DOI 10.1111/j.1469-7580.2008.00940.x; Okten A, 2002, EARLY HUM DEV, V70, P47, DOI 10.1016/S0378-3782(02)00073-7; Coppens L, 2002, J UROLOGY, V167, P1740, DOI 10.1016/S0022-5347(05)65190-7; Zheng ZG, 2011, P NATL ACAD SCI USA, V108, P16289, DOI 10.1073/pnas.1108312108; GARAT JM, 1992, UROLOGY, V40, P265; Manning JT, 1998, HUM REPROD, V13, P3000, DOI 10.1093/humrep/13.11.3000; DEVINE CJ, 1980, J UROLOGY, V123, P407; Jung H, 2011, BJU INT, V107, P591, DOI 10.1111/j.1464-410X.2010.09490.x; Kim SH, 1998, EUR UROL, V34, P57, DOI 10.1159/000019680; RITCHEY ML, 1988, J UROLOGY, V140, P795; Manning JT, 2002, MED HYPOTHESES, V59, P334, DOI 10.1016/S0306-9877(02)00181-0; Malas MA, 2006, EARLY HUM DEV, V82, P469, DOI 10.1016/j.earlhumdev.2005.12.002; Shapiro E, 2004, J UROLOGY, V172, P1753, DOI 10.1097/01.ju.0000140267.46772.7d; McIntyre MH, 2006, REPROD BIOL ENDOCRIN, V4, DOI 10.1186/1477-7827-4-10; Brown WM, 2002, HORM BEHAV, V42, P380, DOI 10.1006/hbeh.2002.1830; Furuya R, 2008, BJU INT, V102, P475, DOI 10.1111/j.1464-410X.2008.07472.x; Williams TJ, 2000, NATURE, V404, P455, DOI 10.1038/35006555; NGHIEM HT, 1990, RADIOGRAPHICS, V10, P635; Manning JT, 2000, EVOL HUM BEHAV, V21, P163, DOI 10.1016/S1090-5138(00)00029-5; WILSON JD, 1993, ENDOCR REV, V14, P577, DOI 10.1210/er.14.5.577; Juarez Soto A, 2004, ARCH ITAL UROL ANDRO, V76, P75; Kim E. E., 1997, International Urology and Nephrology, V29, P647, DOI 10.1007/BF02552181	28	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0919-8172	1442-2042		INT J UROL	Int. J. Urol.	NOV	2015	22	11					1063	1067		10.1111/iju.12892		5	Urology & Nephrology	Urology & Nephrology	CU9OE	WOS:000363873100020		
J	Yoshida, K; Kinoshita, H; Hayami, Y; Nakamoto, T; Takayasu, K; Sugi, M; Matsuda, T				Yoshida, Kenji; Kinoshita, Hidefumi; Hayami, Yutaro; Nakamoto, Takahiro; Takayasu, Kenta; Sugi, Motohiko; Matsuda, Tadashi			Laparoscopic upper-pole heminephrectomy for duplicated renal collecting system with superselective artery clamping using virtual partial nephrectomy analysis of Synapse Vincent: A case report	INTERNATIONAL JOURNAL OF UROLOGY			English	Article						duplicated renal collecting systems; Synapse Vincent; three-dimensional image analysis system; upper-pole nephrectomy	ADULT PATIENTS; SIMULATION	A 22-year-old woman was diagnosed with a duplicated renal collecting system with hydronephrosis and parenchymal loss in the upper pole of the left kidney. She underwent laparoscopic left upper-pole nephrectomy. Although a complex hilar vascular anatomy was identified during the operation, preoperative three-dimensional computed tomographic reconstruction using a three-dimensional image analysis device (Synapse Vincent; Fuji Medical Systems, Tokyo, Japan) greatly helped to accurately identify the anatomical renal hilum. For further detail, virtual partial nephrectomy analysis using a Voronoi decomposition was used to visualize the area supplied by a selected arterial branch including the atrophic cleavage line. We controlled the bleeding with selective clamping and safely carried out upper-pole heminephrectomy according to the preoperative plan.	[Yoshida, Kenji; Kinoshita, Hidefumi; Hayami, Yutaro; Nakamoto, Takahiro; Takayasu, Kenta; Sugi, Motohiko; Matsuda, Tadashi] Kansai Med Univ, Dept Urol & Androl, Hirakata, Osaka 5731010, Japan	Matsuda, T (reprint author), Kansai Med Univ, Dept Urol & Androl, 2-5-1 Shinmachi, Hirakata, Osaka 5731010, Japan.	matsudat@takii.kmu.ac.jp					Acka O, 2015, INT J MED ROBOT COMP, V11, P126; Hughes-Hallett A, 2014, UROLOGY, V84, P237, DOI 10.1016/j.urology.2014.02.051; Patel MN, 2010, J ENDOUROL, V24, P567, DOI 10.1089/end.2009.0313; Abouassaly R, 2007, UROLOGY, V69, P1202, DOI 10.1016/j.urology.2007.03.011; Komai Y, 2014, UROLOGY, V83, P500, DOI 10.1016/j.urology.2013.09.053; Isotani S, 2015, INT J UROL, V22, P439, DOI 10.1111/iju.12714; Mason MD, 2012, J ENDOUROL, V26, P838, DOI 10.1089/end.2011.0377; Takamoto T, 2013, AM J SURG, V206, P530, DOI 10.1016/j.amjsurg.2013.01.041; Shao PF, 2014, UROLOGY, V84, P1361, DOI 10.1016/j.urology.2014.07.056	9	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0919-8172	1442-2042		INT J UROL	Int. J. Urol.	NOV	2015	22	11					1075	1077		10.1111/iju.12897		3	Urology & Nephrology	Urology & Nephrology	CU9OE	WOS:000363873100022		
J	Spies, HF				Spies, Hans-Friedrich			The Hospital Structures Act (KHSG) and the Federal Council	INTERNIST			German	Editorial Material									BDI eV, Kyoto, Japan	Spies, HF (reprint author), BDI eV, Kyoto, Japan.							0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0020-9554	1432-1289		INTERNIST	Internist	NOV	2015	56	11					1289	1290				2	Medicine, General & Internal	General & Internal Medicine	CU8LX	WOS:000363795300009		
J	Wang, X; Zakaria, O; Madi, M; Hao, J; Chou, J; Kasugai, S				Wang, Xin; Zakaria, Osama; Madi, Marwa; Hao, Jia; Chou, Joshua; Kasugai, Shohei			Vertical bone augmentation induced by ultrathin hydroxyapatite sputtered coated mini titanium implants in a rabbit calvaria model	JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B-APPLIED BIOMATERIALS			English	Article						Vertical bone augmentation; sputtered coating; hydroxyapatite coating; collagen membrane; dental implants	TEMPERATURE HYDROTHERMAL TREATMENT; MORPHOGENETIC PROTEIN-2; DENTAL IMPLANTS; RAPID OSSEOINTEGRATION; PERI-IMPLANTITIS; CELL-ADHESION; GROWTH-FACTOR; FILM SUBJECT; ANIMAL-MODEL; SURFACE	BackgroundThe purpose of this study was to evaluate the vertical new bone formation induced by sputtered HA-coated titanium implants (HA-coated) compared with sandblasted acid-etched titanium implants (noncoated) in a rabbit calvarial model. Materials and methodTwenty HA-coated and 20 noncoated titanium implants were divided equally into four groups as HA-coated implant (HA); noncoated implant (NC); HA-coated implant with membrane (HA/M); noncoated implant with membrane (NC/M). All implants were placed 5 mm above the original bone (OB). Collagen membranes were placed over the implants in HA/M and NC/M groups. The animals were sacrificed at 4 weeks (n=5) and 8 weeks (n=5). Vertical bone height above OB (VBH, mm) and augmented bone area (ABA, mm(2)) were analyzed histologically and radiographically. ResultsAt 4 weeks, VBH reached significantly higher level in HA/M group compared with other three groups (p<0.05). At 8 weeks, significant difference was detected between HA/M and NC groups (p<0.05). At 4 and 8 weeks, ABA in HA/M group was significantly larger compared with other three groups (p<0.05). ConclusionThe present results indicated that sputtered HA-coated titanium implant together with collagen membrane could be a novel and effective approach for vertical bone augmentation. (c) 2014 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 103B: 1700-1708, 2015.	[Wang, Xin; Zakaria, Osama; Hao, Jia; Kasugai, Shohei] Tokyo Med & Dent Univ, Dept Oral Implantol & Regenerat Dent Med, Tokyo, Japan; [Zakaria, Osama] Pharos Univ Alexandria, Dept Oral & Maxillofacial Surg, Alexandria, Egypt; [Madi, Marwa] Univ Alexandria, Fac Dent, Dept Oral Med Periodontol Oral Diag & Radiol, Alexandria, Egypt; [Chou, Joshua] Univ Technol Sydney, Adv Tissue Engn & Drug Delivery Grp, Sydney, NSW 2007, Australia	Wang, X (reprint author), Tokyo Med & Dent Univ, Dept Oral Implantol & Regenerat Dent Med, Tokyo, Japan.	wangirm@tmd.ac.jp					Evans CH, 2007, TISSUE ENG, V13, P1987, DOI 10.1089/ten.2006.0302; Ozeki K, 2011, BIO-MED MATER ENG, V21, P179, DOI 10.3233/BME-2011-0667; Greenstein G, 2009, J PERIODONTOL, V80, P175, DOI 10.1902/jop.2009.080309 ; Esenwein SA, 2001, CHIRURG, V72, P1360; Madi M, 2013, INT J ORAL MAX IMPL, V28, P701, DOI 10.11607/jomi.2891; Klein MO, 2013, CLIN IMPLANT DENT R, V15, P166, DOI 10.1111/j.1708-8208.2011.00339.x; Schiegnitz E, 2014, CLIN IMPLANT DENT R, V16, P194, DOI 10.1111/j.1708-8208.2012.00469.x; Manfro R, 2008, IMPLANT DENT, V17, P408, DOI 10.1097/ID.0b013e31818c6ba5; Wikesjo UME, 2008, J CLIN PERIODONTOL, V35, P1001, DOI 10.1111/j.1600-051X.2008.01321.x; Ozeki K, 2006, J BIOMED MATER RES A, V76A, P605, DOI 10.1002/jbm.a.30574; Wen B, 2011, J BIOMED MATER RES B, V97B, P315, DOI 10.1002/jbm.b.31817; Ozeki K, 2003, BIO-MED MATER ENG, V13, P451; Bose S, 2012, ACTA BIOMATER, V8, P1401, DOI 10.1016/j.actbio.2011.11.017; Kammerer PW, 2011, EUR CELLS MATER, V21, P364; Garrett MP, 2010, NEUROSURGERY, V66, P1044, DOI 10.1227/01.NEU.0000369517.21018.F2; Verdugo F, 2012, CLIN IMPLANT DENT R, V14, P112, DOI 10.1111/j.1708-8208.2009.00235.x; Discher DE, 2005, SCIENCE, V310, P1139, DOI 10.1126/science.1116995; Abe Y, 2009, MOD RHEUMATOL, V19, P316, DOI 10.1007/s10165-009-0166-0; Schwarz F, 2008, CLIN ORAL IMPLAN RES, V19, P402, DOI 10.1111/j.1600-0501.2007.01486.x; Zhu XL, 2003, J MATER SCI-MATER M, V14, P629, DOI 10.1023/A:1024079109073; Ripamonti U, 2012, BIOMATERIALS, V33, P3813, DOI 10.1016/j.biomaterials.2012.01.050; Le B, 2010, J ORAL MAXIL SURG, V68, P428, DOI 10.1016/j.joms.2009.04.059; Ozeki K, 2006, BIO-MED MATER ENG, V16, P243; Kuwabara A, 2012, DENT MATER J, V31, P368, DOI 10.4012/dmj.2011-220; Kim JE, 2013, OR SURG OR MED OR PA, V115, pE24, DOI 10.1016/j.oooo.2011.10.040; Narayanan R, 2008, J BIOMED MATER RES B, V85B, P279, DOI 10.1002/jbm.b.30932; Kammerer PW, 2013, CLIN ORAL IMPLAN RES, V24, P1222, DOI 10.1111/j.1600-0501.2012.02534.x; Zakaria O, 2012, J ORAL MAXIL SURG, V70, pE225, DOI 10.1016/j.joms.2011.10.032; Buxboim A, 2010, NAT METHODS, V7, P695, DOI 10.1038/nmeth0910-695; Al-Nawas B, 2006, INT J ORAL MAX IMPL, V21, P726; Le Guehennec L, 2007, DENT MATER, V23, P844, DOI 10.1016/j.dental.2006.06.025; Chiapasco M, 2006, CLIN ORAL IMPLAN RES, V17, P136, DOI 10.1111/j.1600-0501.2006.01357.x; Uezono M, 2013, J BIOMED MATER RES B, V101B, P1031, DOI 10.1002/jbm.b.32913; Massaro C, 2001, J BIOMED MATER RES, V58, P651, DOI 10.1002/jbm.1065; Kim I, 2013, INT J ORAL MAX IMPL, V28, P1194, DOI 10.11607/jomi.2685; Kammerer PW, 2014, CLIN ORAL IMPLAN RES, V25, P774, DOI 10.1111/clr.12175; Hao J, 2011, J MATER SCI-MATER M, V22, P1489, DOI 10.1007/s10856-011-4329-0; Carstens MH, 2005, J CRANIOFAC SURG, V16, P1033, DOI 10.1097/01.scs.0000186307.09171.20; Shah MM, 2008, J NEUROS-PEDIATR, V1, P255, DOI 10.3171/PED/2008/1/3/255; Yokota S, 2014, IMPLANT DENT, V23, P343, DOI 10.1097/ID.0000000000000098; Daculsi G, 2003, J MATER SCI-MATER M, V14, P195, DOI 10.1023/A:1022842404495; Draenert FG, 2012, CLIN IMPLANT DENT R, V14, pe169, DOI 10.1111/j.1708-8208.2011.00401.x; Bernstein Simon, 2006, Implant Dent, V15, P219, DOI 10.1097/01.id.0000226824.39526.71; Davies John E, 2003, J Dent Educ, V67, P932; Madi M, 2014, J ORAL IMPLANTOL, V40, P661, DOI 10.1563/AAID-JOI-D-12-00089; Mohammadi Shams, 2003, Clin Implant Dent Relat Res, V5, P241, DOI 10.1111/j.1708-8208.2003.tb00207.x; Ozeki K., 2003, FUNDAMENTAL STUDY AP, P12; Zakaria O, 2012, J TISSUE ENG, V3	48	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1552-4973	1552-4981		J BIOMED MATER RES B	J. Biomed. Mater. Res. Part B	NOV	2015	103	8					1700	1708		10.1002/jbm.b.33347		9	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	CU7CF	WOS:000363692300018		
J	Chimura, M; Kiuchi, K; Okajima, K; Shimane, A; Sawada, T; Onishi, T; Yamada, S; Taniguchi, Y; Yasaka, Y; Kawai, H				Chimura, Misato; Kiuchi, Kunihiko; Okajima, Katsunori; Shimane, Akira; Sawada, Takahiro; Onishi, Tetsuari; Yamada, Shinichiro; Taniguchi, Yasuyo; Yasaka, Yoshinori; Kawai, Hiroya			Distribution of Ventricular Fibrosis Associated With Life-Threatening Ventricular Tachyarrhythmias in Patients With Nonischemic Dilated Cardiomyopathy	JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY			English	Article						cardiac magnetic resonance imaging; implantable cardioverter defibrillator; late gadolinium enhancement; nonischemic cardiomyopathy; ventricular tachycardia	IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; CARDIOVASCULAR MAGNETIC-RESONANCE; CHRONIC HEART-FAILURE; SUDDEN CARDIAC DEATH; CATHETER ABLATION; TACHYCARDIA; SUBSTRATE; THERAPY; QUANTIFICATION; GUIDELINES	Ventricular Fibrosis in Patients With NICM BackgroundCurrent guidelines recommend the implantation of an implantable cardioverter-defibrillator (ICD) for primary prevention of sudden cardiac death (SCD) in a subgroup of patients with nonischemic cardiomyopathy (NICM) who have a left ventricular ejection fraction (LVEF) 30-35%, and are NYHA functional class II or III. However, the majority of patients with an ICD implantation for primary prevention did not receive appropriate ICD therapy. The purpose of this study was to evaluate the association between myocardial fibrosis detected by cardiovascular magnetic resonance (CMR) imaging and life-threatening ventricular arrhythmic events in NICM patients. MethodsOne hundred and seventy-five NICM patients with an LVEF 35 % and NYHA functional class II or III, (60 15 years, LVEF 29 5.4%) were studied. Myocardial fibrosis was identified with a late gadolinium enhancement (LGE) on CMR. Clinical events were defined as SCD or life-threatening ventricular arrhythmic events and were followed up for 5.1 +/- 3.3 years. ResultsThe presence of an LGE was detected in 122 patients (70%). No life-threatening ventricular arrhythmia events occurred in patients with the absence of an LGE. A total of 18 ventricular tachycardia and 8 ventricular fibrillation events were found in patients with the presence of an LGE (P < 0.01). Sensitivity, specificity, and positive and negative predictive value of LGE in predicting life-threatening ventricular arrhythmia events were 100%, 34%, and 15% and 100%, respectively. Multivariate analysis showed that the presence of both septal and lateral mid-wall LGE was associated with life-threatening ventricular arrhythmic events (hazard ratio 23.1 CI; 2.88-184.9, P = 0.003). ConclusionsThe absence of an LGE predicts a low potential risk of SCD and life-threatening ventricular arrhythmia events in the near future. CMR may be a useful tool for selecting suitable patients for primary ICD implantations in NICM patients.	[Chimura, Misato; Kiuchi, Kunihiko; Okajima, Katsunori; Shimane, Akira; Sawada, Takahiro; Onishi, Tetsuari; Yamada, Shinichiro; Taniguchi, Yasuyo; Yasaka, Yoshinori; Kawai, Hiroya] Himeji Cardiovasc Ctr, Dept Cardiol, Himeji, Hyogo, Japan	Kiuchi, K (reprint author), Himeji Cardiovasc Ctr, Dept Cardiol, 520 Kou Saishou, Himeji, Hyogo, Japan.	kunihikokiuchi@yahoo.co.jp					Bardy GH, 2005, NEW ENGL J MED, V352, P225, DOI 10.1056/NEJMoa043399; Lang RM, 2006, EUR J ECHOCARDIOGR, V7, P79, DOI 10.1016/j.euje.2005.12.014; Maceira AM, 2006, J CARDIOV MAGN RESON, V8, P417, DOI 10.1080/10976640600572889; Poole JE, 2008, NEW ENGL J MED, V359, P1009, DOI 10.1056/NEJMoa071098; Gulati A, 2013, JAMA-J AM MED ASSOC, V309, P896, DOI 10.1001/jama.2013.1363; Soejima K, 2004, J AM COLL CARDIOL, V43, P1834, DOI 10.1016/j.jacc.2004.01.029; Kadish A, 2004, NEW ENGL J MED, V350, P2151, DOI 10.1056/NEJMoa033088; Ezekowitz JA, 2007, ANN INTERN MED, V147, P251; Scott PA, 2013, J CARDIOVASC ELECTR, V24, P430, DOI 10.1111/jce.12035; Sanders GD, 2005, NEW ENGL J MED, V353, P1471, DOI 10.1056/NEJMsa051989; Hsia HH, 2003, CIRCULATION, V108, P704, DOI 10.1161/01.CIR.0000083725.72693.EA; Tung R, 2008, J AM COLL CARDIOL, V52, P1111, DOI 10.1016/j.jacc.2008.05.058; Assomull RG, 2006, J AM COLL CARDIOL, V48, P1977, DOI 10.1016/j.jacc.2006.07.049; Dickstein K, 2008, EUR HEART J, V29, P2388, DOI 10.1093/eurheartj/ehn309; Gao P, 2012, CIRC-CARDIOVASC IMAG, V5, P448, DOI 10.1161/CIRCIMAGING.111.971549; Oloriz T, 2014, CIRC-ARRHYTHMIA ELEC, V7, P414, DOI 10.1161/CIRCEP.114.001568; Bristow MR, 2004, NEW ENGL J MED, V350, P2140, DOI 10.1056/NEJMoa032423; Prudente LA, 2003, AM J CRIT CARE, V12, P144; Nakahara S, 2010, J AM COLL CARDIOL, V55, P2355, DOI 10.1016/j.jacc.2010.01.041; ENRIQUEZSARANO M, 1993, CIRCULATION, V87, P841; Mishkin JD, 2009, J AM COLL CARDIOL, V54, P1993, DOI 10.1016/j.jacc.2009.07.039; Epstein AE, 2013, CIRCULATION, V127, pE283, DOI 10.1161/CIR.0b013e318276ce9b; Cano O, 2009, J AM COLL CARDIOL, V54, P799, DOI 10.1016/j.jacc.2009.05.032; Schron EB, 2002, CIRCULATION, V105, P589, DOI 10.1161/hc0502.103330; Bogun FM, 2009, J AM COLL CARDIOL, V53, P1138, DOI 10.1016/j.jacc.2008.11.052; Nazarian S, 2005, CIRCULATION, V112, P2821, DOI 10.1161/CIRCULATIONAHA.105.549659; Thom T, 2006, CIRCULATION, V113, pE85, DOI 10.1161/CIRCULATIONAHA.105.171600; Muller KAL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057077; Yokota H, 2008, J CARDIOVASC MAGN R, V10, DOI 10.1186/1532-429X-10-17	29	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1045-3873	1540-8167		J CARDIOVASC ELECTR	J. Cardiovasc. Electrophysiol.	NOV	2015	26	11					1239	1246		10.1111/jce.12767		8	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CU6ZA	WOS:000363682700010		
J	Nakagawa, A; Hori, Y; Nakahara, S; Taguchi, I				Nakagawa, Ayako; Hori, Yuichi; Nakahara, Shiro; Taguchi, Isao			Massive Air Trapped in the Left Atrial Appendage During Catheter Ablation of Atrial Fibrillation Without a Symptomatic Air Embolism	JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY			English	Article						air embolism; catheter ablation; left atrial appendage			[Nakagawa, Ayako; Hori, Yuichi; Nakahara, Shiro; Taguchi, Isao] Dokkyo Med Univ, Koshigaya Hosp, Dept Cardiol, Saitama, Japan	Hori, Y (reprint author), 2-1-50 Minami Koshigaya, Koshigaya, Saitama 3438555, Japan.	hhkxn763@yahoo.co.jp						0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1045-3873	1540-8167		J CARDIOVASC ELECTR	J. Cardiovasc. Electrophysiol.	NOV	2015	26	11					1278	1278		10.1111/jce.12717		1	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CU6ZA	WOS:000363682700018		
J	Hayashi, T; Mitsuhashi, T; Fujita, H; Momomura, S				Hayashi, Takekuni; Mitsuhashi, Takeshi; Fujita, Hideo; Momomura, Shin-Ichi			Disruption of the Purkinje Network Causing Polymorphic Ventricular Tachycardia	JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY			English	Article						polymorphic ventricular tachycardia; Purkinje potential; ventricular fibrillation; ventricular premature contraction	FIBRILLATION; ABLATION		[Hayashi, Takekuni; Mitsuhashi, Takeshi; Fujita, Hideo; Momomura, Shin-Ichi] Jichi Med Univ, Saitama Med Ctr, Div Cardiovasc Med, Saitama 3308503, Japan	Hayashi, T (reprint author), Jichi Med Univ, Saitama Med Ctr, Div Cardiovasc Med, Oomiya Ku, 1-847 Amanuma, Saitama 3308503, Japan.	hayahsi1979@yahoo.co.jp					Nogami A, 2005, HEART RHYTHM, V2, P646, DOI 10.1016/j.hrthm.2005.02.006; Nogami A, 2015, J CARDIOVASC ELECTR, V26, P110, DOI 10.1111/jce.12547; Haissaguerre M, 2002, CIRCULATION, V106, P962, DOI 10.1161/01.CIR.0000027564.55739.B1	3	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1045-3873	1540-8167		J CARDIOVASC ELECTR	J. Cardiovasc. Electrophysiol.	NOV	2015	26	11					1279	1281		10.1111/jce.12735		3	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CU6ZA	WOS:000363682700019		
J	Yotsu, RR; Murase, C; Sugawara, M; Suzuki, K; Nakanaga, K; Ishii, N; Asiedu, K				Yotsu, Rie R.; Murase, Chiaki; Sugawara, Mariko; Suzuki, Koichi; Nakanaga, Kazue; Ishii, Norihisa; Asiedu, Kingsley			Revisiting Buruli ulcer	JOURNAL OF DERMATOLOGY			English	Review						Buruli ulcer; Mycobacterium ulcerans; mycolactone; neglected tropical diseases; non-tuberculous mycobacteria	MYCOBACTERIUM-BOVIS BCG; MYCOLACTONE-PRODUCING MYCOBACTERIA; RISK-FACTORS; SOUTHEASTERN AUSTRALIA; ENVIRONMENTAL-SAMPLES; TISSUE SPECIMENS; CAUSATIVE AGENT; COTE-DIVOIRE; DISEASE; INFECTION	Buruli ulcer (BU), or Mycobacterium ulcerans infection, is a new emerging infectious disease which has been reported in over 33 countries worldwide. It has been noted not only in tropical areas, such as West Africa where it is most endemic, but also in moderate non-tropical climate areas, including Australia and Japan. Clinical presentation starts with a papule, nodule, plaque or edematous form which eventually leads to extensive skin ulceration. It can affect all age groups, but especially children aged between 5 and 15years in West Africa. Multiple-antibiotic treatment has proven effective, and with surgical intervention at times of severity, it is curable. However, if diagnosis and treatment is delayed, those affected may be left with life-long disabilities. The disease is not yet fully understood, including its route of transmission and pathogenesis. However, due to recent research, several important features of the disease are now being elucidated. Notably, there may be undiagnosed cases in other parts of the world where BU has not yet been reported. Japan exemplifies the finding that awareness among dermatologists plays a key role in BU case detection. So, what about in other countries where a case of BU has never been diagnosed and there is no awareness of the disease among the population or, more importantly, among health professionals? This article will revisit BU, reviewing clinical features as well as the most recent epidemiological and scientific findings of the disease, to raise awareness of BU among dermatologists worldwide.	[Yotsu, Rie R.] Natl Suruga Sanat, Dept Dermatol, Gotemba, Shizuoka 4120033, Japan; [Yotsu, Rie R.] Natl Ctr Global Hlth & Med, Dept Dermatol, Tokyo, Japan; [Murase, Chiaki] Nagoya Univ, Grad Sch Med, Dept Dermatol, Nagoya, Aichi 4648601, Japan; [Sugawara, Mariko] West Yokohama Sugawara Dermatol Clin, Yokohama, Kanagawa, Japan; [Suzuki, Koichi] Teikyo Univ, Fac Med Technol, Dept Clin Lab Sci, Tokyo 173, Japan; [Suzuki, Koichi; Nakanaga, Kazue; Ishii, Norihisa] Natl Inst Infect Dis, Leprosy Res Ctr, Tokyo, Japan; [Asiedu, Kingsley] World Hlth Org, Dept Control Neglected Trop Dis, Geneva, Switzerland	Yotsu, RR (reprint author), Natl Suruga Sanat, 1915 Kouyama, Gotemba, Shizuoka 4120033, Japan.	yotsurie@hotmail.com			Japan Agency for Medical Research and Development (AMED) under the Ministry of Health, Labor and Welfare of Japan; Ministry of Education, Culture, Sports, Science and Technology of Japan	This work was partially supported by the Grant-in-Aid for the Research Program on Emerging and Reemerging Infectious Diseases from the Japan Agency for Medical Research and Development (AMED) under the Ministry of Health, Labor and Welfare of Japan to N. I. and the Grant-in-Aid for Scientific Research (C) from the Ministry of Education, Culture, Sports, Science and Technology of Japan to N. I. The authors thank Dr Deirdre P. Walshe (Liverpool School of Tropical Medicine, UK) for editing and Ms Kayo Shinozaki (Leprosy Research Center, Japan) for logistical support in completing this manuscript.	Ablordey A, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001590; George KM, 1999, SCIENCE, V283, P854, DOI 10.1126/science.283.5403.854; Portaels F, 2004, INFECT IMMUN, V72, P62, DOI 10.1128/IAI.72.1.62-65.2004; SMITH PG, 1976, T ROY SOC TROP MED H, V70, P449, DOI 10.1016/0035-9203(76)90128-0; Tanghe A, 2007, INFECT IMMUN, V75, P2642, DOI 10.1128/IAI.01622-06; MEYERS WM, 1974, AM J TROP MED HYG, V23, P919; Takahashi T, 2014, JAMA DERMATOL, V150, P669, DOI 10.1001/jamadermatol.2013.7497; Fyfe JAM, 2007, APPL ENVIRON MICROB, V73, P4733, DOI 10.1128/AEM.02971-06; Eddyani M, 2009, J CLIN MICROBIOL, V47, P1700, DOI 10.1128/JCM.00197-09; Raghunathan PL, 2005, CLIN INFECT DIS, V40, P1445, DOI 10.1086/429623; Elsner L, 2008, J FELINE MED SURG, V10, P407, DOI [10.1016/j.jfms.2008.03.003, 10.1616/j.jfms.2008.03.003]; [Anonymous], 1969, LANCET, V1, P111; Debacker M, 2006, EMERG INFECT DIS, V12, P1325; Aiga H, 2004, AM J TROP MED HYG, V71, P387; Ortiz RH, 2009, CLIN EXP IMMUNOL, V157, P271, DOI 10.1111/j.1365-2249.2009.03941.x; Boulkroun S, 2010, J IMMUNOL, V184, P1436, DOI 10.4049/jimmunol.0902854; Hall B, 2014, BIOCHEM SOC T, V42, P177, DOI 10.1042/BST20130133; Debacker M, 2004, TROP MED INT HEALTH, V9, P1297, DOI 10.1111/j.1365-3156.2004.01339.x; Stragier P, 2006, EMERG INFECT DIS, V12, P844; Coutanceau E, 2007, J EXP MED, V204, P1395, DOI 10.1084/jem.20070234; MARSTON BJ, 1995, AM J TROP MED HYG, V52, P219; Stinear T, 2000, APPL ENVIRON MICROB, V66, P3206, DOI 10.1128/AEM.66.8.3206-3213.2000; Wallace JR, 2010, APPL ENVIRON MICROB, V76, P6215, DOI 10.1128/AEM.00340-10; [Anonymous], 2004, PROV GUID ROL SPEC A; Ross BC, 1997, J CLIN MICROBIOL, V35, P1696; Portaels F, 2002, CLIN DIAGN LAB IMMUN, V9, P1389, DOI 10.1128/CDLI.9.6.1389-1391.2002; Nakanaga K, 2013, JPN J INFECT DIS, V66, P83; Phillips RO, 2009, J CLIN MICROBIOL, V47, P924, DOI 10.1128/JCM.01842-08; Nackers F, 2006, AM J TROP MED HYG, V75, P768; Eddyani M, 2004, APPL ENVIRON MICROB, V70, P5679, DOI 10.1128/AEM.70.9.5679-5681.2004; Stinear T, 1999, J CLIN MICROBIOL, V37, P1018; Suzuki K, 2012, J DERMATOL, V39, P121, DOI 10.1111/j.1346-8138.2011.01370.x; Kotlowski R, 2004, J MED MICROBIOL, V53, P927, DOI 10.1099/jmm.0.45593-0; Nienhuis WA, 2012, CLIN INFECT DIS, V54, P519, DOI 10.1093/cid/cir856; Njiru ZK, 2012, J CLIN MICROBIOL, V50, P1737, DOI 10.1128/JCM.06460-11; Stinear TP, 2004, P NATL ACAD SCI USA, V101, P1345, DOI 10.1073/pnas.0305877101; Nakanaga K, 2011, J CLIN MICROBIOL, V49, P3829, DOI 10.1128/JCM.00783-11; Ross BC, 1997, APPL ENVIRON MICROB, V63, P4135; Quek TYJ, 2007, EMERG INFECT DIS, V13, P1661, DOI 10.3201/eid1311.061206; MACCALLUM P, 1948, J PATHOL BACTERIOL, V60, P93, DOI 10.1002/path.1700600111; Affolabi D, 2008, TROP MED INT HEALTH, V13, P187, DOI 10.1111/j.1365-3156.2007.01989.x; Herbinger KH, 2009, CLIN INFECT DIS, V48, P1055, DOI 10.1086/597398; Eddyani M, 2008, J CLIN MICROBIOL, V46, P69, DOI 10.1128/JCM.00301-07; Stinear TP, 2005, MICROBIOL-SGM, V151, P683, DOI 10.1099/mic.0.27674-0; Marsollier L, 2004, APPL ENVIRON MICROB, V70, P6296, DOI 10.1128/AEM.70.10.6296-6298.2004; Yotsu RR, 2012, J DERMATOL, V39, P587, DOI 10.1111/j.1346-8138.2012.01543.x; O'Brien DP, 2014, MED J AUSTRALIA, V200, P267, DOI 10.5694/mja13.11331; Simmonds RE, 2009, J IMMUNOL, V182, P2194, DOI 10.4049/jimmunol.0802294; Marsollier L, 2007, CELL MICROBIOL, V9, P347, DOI 10.1111/j.1462-5822.2006.00790.x; Stinear TP, 2008, GENOME RES, V18, P729, DOI 10.1101/gr.075069.107; Stinear TP, 2007, GENOME RES, V17, P192, DOI 10.1101/gr.5942807; Sakaguchi K, 2011, J VET MED SCI, V73, P1217, DOI 10.1292/jvms.10-0386; ALSOP DG, 1972, AUST NZ J SURG, V41, P317; Luo YQ, 2015, FUTURE MICROBIOL, V10, P461, DOI [10.2217/fmb.14.152, 10.2217/FMB.14.152]; MITCHELL PJ, 1984, PATHOLOGY, V16, P256; Marion E, 2014, CELL, V157, P1565, DOI 10.1016/j.cell.2014.04.040; Roltgen K, 2012, INFECT GENET EVOL, V12, P522, DOI 10.1016/j.meegid.2012.01.018; Yip MJ, 2007, J BACTERIOL, V189, P2021, DOI 10.1128/JB.01442-06; Mosi L, 2008, APPL ENVIRON MICROB, V74, P7036, DOI 10.1128/AEM.01234-08; George KM, 2000, INFECT IMMUN, V68, P877, DOI 10.1128/IAI.68.2.877-883.2000; Bratschi MW, 2014, BMC INFECT DIS, V14, DOI 10.1186/s12879-014-0636-7; Brou T, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000271; Converse PJ, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002618; Doig KD, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-258; FENNER F, 1950, Med J Aust, V2, P813; Fyfe JAM, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000791; Kaser M, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-177; Klis S, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002739; Lavender Caroline J, 2013, Methods Mol Biol, V943, P201, DOI 10.1007/978-1-60327-353-4_13; Lavender CJ, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001305; Marion E, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000731; Portaels F, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000178; Portaels F, 2014, LAB DIAGNOSIS BURULI; Pouillot R, 2007, PLOS NEGLECT TROP D, V1, DOI 10.1371/journal.pntd.0000101; Qi WH, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000580; Ruf MT, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001252; Scherr N, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002143; Sugawara M, 2015, J DERMATOL, V42, P581; VANDERWERF TS, 1989, T ROY SOC TROP MED H, V83, P410, DOI 10.1016/0035-9203(89)90521-X; vansZyl A, 2010, AUST VET J, V88, P101; WHO, 2012, TREATM MYC ULC DIS B; Williamson HR, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000205; World Health Organization, 2015, GLOB HLTH OBS GHO DA	83	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0385-2407	1346-8138		J DERMATOL	J. Dermatol.	NOV	2015	42	11					1033	1041		10.1111/1346-8138.13049		9	Dermatology	Dermatology	CU5ML	WOS:000363576200001		
J	Asahina, A; Ohtsuki, M; Etoh, T; Gu, Y; Okun, MM; Teixeira, HD; Yamaguchi, Y; Nakagawa, H				Asahina, Akihiko; Ohtsuki, Mamitaro; Etoh, Takafumi; Gu, Yihua; Okun, Martin M.; Teixeira, Henrique D.; Yamaguchi, Yuji; Nakagawa, Hidemi			Adalimumab treatment optimization for psoriasis: Results of a long-term phase 2/3 Japanese study	JOURNAL OF DERMATOLOGY			English	Article						80mg; adalimumab; Japanese patients; long-term treatment; psoriasis	INTERLEUKIN-12/23 MONOCLONAL-ANTIBODY; RANDOMIZED CONTROLLED-TRIALS; CHRONIC PLAQUE PSORIASIS; RHEUMATOID-ARTHRITIS; DOUBLE-BLIND; OPEN-LABEL; EFFICACY; SAFETY; MODERATE; METAANALYSIS	The tumor necrosis factor- inhibitor, adalimumab, is approved to treat moderate-to-severe plaque psoriasis (40mg every-other-week or 80mg every-other-week following inadequate response at 40mg in Japan). This open-label extension (OLE) trial evaluated the optimal adalimumab dose for long-term efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis following a prior 24-week, phase 2/3, randomized, double-blind study. Of the 169 patients from the phase 2/3 trial, 147 entered the OLE on 40mg (n=89) or 80mg (n=58) adalimumab every-other-week. Patients on 40mg with Psoriasis Area and Severity Index (PASI) of less than 50 could escalate to 80mg. At week 52 (28 of OLE), patients entering the OLE on 80mg were reduced to 40mg, with the option to re-escalate. For patients entering the OLE on 40mg, final PASI 50/75/90 response rates were 85.1%/73.3%/60.4%, respectively, including effects of dose escalation. Among patients whose dose was escalated, final PASI 50/75/90 response rates were 70.0%/53.3%/36.7%, respectively. For patients entering the OLE on 80mg, final PASI 50/75/90 response rates were 92.5%/84.9%/73.6%, respectively, including effects of dose re-escalation. Overall incidence rates of adverse events (AE) and injection-site reaction AE declined over time; rates for serious AE and infections were generally stable. Clinically meaningful efficacy of adalimumab was sustained to 4years. Dose escalation to 80mg every-other-week for patients with suboptimal response to 40mg every-other-week, and dose reduction to 40mg every-other-week for patients satisfactorily controlled on 80mg every-other-week, are viable strategies for adalimumab optimization.	[Asahina, Akihiko; Nakagawa, Hidemi] Jikei Univ, Sch Med, Dept Dermatol, Tokyo 1058461, Japan; [Ohtsuki, Mamitaro] Jichi Med Univ, Dept Dermatol, Shimotsuke, Tochigi, Japan; [Etoh, Takafumi] Tokyo Teishin Postal Serv Agcy Hosp, Div Dermatol, Tokyo, Japan; [Gu, Yihua; Okun, Martin M.; Teixeira, Henrique D.; Yamaguchi, Yuji] AbbVie, Global Pharmaceut Res & Dev, N Chicago, IL USA	Asahina, A (reprint author), Jikei Univ, Sch Med, Dept Dermatol, Minato Ku, 3-25-8 Nishishinbashi, Tokyo 1058461, Japan.	asahina-tky@umin.ac.jp			AbbVie; AbbVie Japan; Mitsubishi Tanabe Pharma; Janssen Pharmaceuticals; Eisai; Eli Lilly; Leo Pharma; Maruho; Kyouwahakkou-Kirin; MSD	AbbVie funded this study and participated in the study design, data collection, data management, data analysis and preparation of the manuscript. A. A. has received consultant and speaker fees from AbbVie Japan and Mitsubishi Tanabe Pharma, and speaker fees from Janssen Pharmaceuticals. M. O. has received consultant and speaker fees from AbbVie Japan, Mitsubishi Tanabe Pharma and Janssen Pharmaceuticals. T. E. has received consultant and speaker fees from AbbVie Japan, Mitsubishi Tanabe Pharma and Janssen Pharmaceuticals. H. N. has received consultant and speaker fees from AbbVie Japan, Mitsubishi Tanabe Pharma, Eisai, Janssen Pharmaceuticals, Eli Lilly, Leo Pharma, Maruho, Kyouwahakkou-Kirin and MSD. Y. Y., Y. G., M. M. O. and H. T. received a salary as employees of AbbVie and also received AbbVie stock and stock options.	Naldi L, 2005, J INVEST DERMATOL, V125, P61, DOI 10.1111/j.0022-202X.2005.23681.x; Weinblatt ME, 2003, ARTHRITIS RHEUM, V48, P35, DOI 10.1002/art.10697; Leonardi C, 2012, BRIT J DERMATOL, V167, P658, DOI 10.1111/j.1365-2133.2012.11041.x; Leonardi CL, 2008, LANCET, V371, P1665, DOI 10.1016/S0140-6736(08)60725-4; Papp KA, 2008, LANCET, V371, P1675, DOI 10.1016/S0140-6736(08)60726-6; Gordon K, 2012, J AM ACAD DERMATOL, V66, P241, DOI 10.1016/j.jaad.2010.12.005; Asahina A, 2010, J DERMATOL, V37, P299, DOI 10.1111/j.1346-8138.2009.00748.x; Neimann AL, 2006, J AM ACAD DERMATOL, V55, P829, DOI 10.1016/j.jaad.2006.08.040; Sterry W, 2007, BRIT J DERMATOL, V157, P649, DOI 10.1111/j.1365-2133.2007.08068.x; Clark L, 2008, J AM ACAD DERMATOL, V58, P443, DOI 10.1016/j.jaad.2007.11.011; Menter A, 2010, J AM ACAD DERMATOL, V63, P448, DOI 10.1016/j.jaad.2009.09.040; Leonardi C, 2011, AM J CLIN DERMATOL, V12, P321, DOI 10.2165/11587890-000000000-00000; Ryan C, 2011, JAMA-J AM MED ASSOC, V306, P864, DOI 10.1001/jama.2011.1211; Bongartz T, 2006, JAMA-J AM MED ASSOC, V295, P2275, DOI 10.1001/jama.295.19.2275; van de Putte L B A, 2004, Ann Rheum Dis, V63, P508, DOI 10.1136/ard.2003.013052	15	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0385-2407	1346-8138		J DERMATOL	J. Dermatol.	NOV	2015	42	11					1042	1052		10.1111/1346-8138.13001		11	Dermatology	Dermatology	CU5ML	WOS:000363576200002		
J	Kondo, M; Akachi, S; Kawano, M; Yamanaka, K; Yamagiwa, A; Gabazza, EC; Ando, K; Mizutani, H				Kondo, Makoto; Akachi, Shigehiro; Kawano, Mitsuo; Yamanaka, Keiichi; Yamagiwa, Akisa; Gabazza, Esteban C.; Ando, Katsuhiko; Mizutani, Hitoshi			Improvement in early diagnosis of Japanese spotted fever by using a novel Rick PCR system	JOURNAL OF DERMATOLOGY			English	Article						diagnosis; infection; Japanese spotted fever; Rick PCR; Rickettsia japonica	RICKETTSIA; SPECIMENS	Rickettsia diseases, including Japanese spotted fever (JSF), are serious infections. Delayed diagnosis occasionally results in life-threatening liver disorders and disseminated intravascular coagulation (DIC). Because of the shortness of the latent period, serological diagnosis is not preferable for early diagnosis of JSF. Until now, a polymerase chain reaction (PCR)-based diagnosis method has been used for early diagnosis, and the sensitivity reaches as high as 90% using skin biopsy samples as we previously reported. On the other hand, the sensitivity of the same PCR method using blood samples is limited at less than 50%. In the present study, using peripheral blood samples, we developed a novel diagnostic method for JSF using a Rick PCR system with original PCR primers, showing improved sensitivity compared with the conventional nested PCR. It may constitute a preferable diagnostic tool for early and sensitive diagnosis of Rickettsia infection.	[Kondo, Makoto; Yamanaka, Keiichi; Yamagiwa, Akisa; Mizutani, Hitoshi] Mie Univ, Grad Sch Med, Dept Dermatol, Tsu, Mie 5148507, Japan; [Akachi, Shigehiro] Mie Univ, Grad Sch Med, Mie Prefecture Hlth & Environm Res Inst, Tsu, Mie 5148507, Japan; [Kawano, Mitsuo] Mie Univ, Grad Sch Med, Dept Mol Genet & Microbiol, Tsu, Mie 5148507, Japan; [Gabazza, Esteban C.] Mie Univ, Grad Sch Med, Dept Immunol, Tsu, Mie 5148507, Japan; [Ando, Katsuhiko] Mie Univ, Grad Sch Med, Dept Med Zool, Tsu, Mie 5148507, Japan	Yamanaka, K (reprint author), Mie Univ, Grad Sch Med, Dept Dermatol, 2-174 Edobashi, Tsu, Mie 5148507, Japan.	yamake@clin.medic.mie-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology, Japan [23591643, 24591647]	K. Y. (no. 23591643) and H. M. (no. 24591647) received grants for scientific research from the Ministry of Education, Culture, Sports, Science and Technology, Japan. The other authors did not receive any financial support.	Mahara F, 1997, EMERG INFECT DIS, V3, P105; Satoh H, 2001, MICROBIOL IMMUNOL, V45, P85; Seki M, 2006, INTERNAL MED, V45, P1323, DOI 10.2169/internalmedicine.45.1831; Kondo M, 2010, INT J DERMATOL, V49, P430, DOI 10.1111/j.1365-4632.2010.04359.x; Tamakuma K, 2012, CLIN MICROBIOL INFEC, V18, P260, DOI 10.1111/j.1469-0691.2011.03569.x; Kurokawa I, 2013, J INFECT CHEMOTHER, V19, P628, DOI 10.1007/s10156-012-0529-x; Nomura T, 2007, JPN J INFECT DIS, V60, P241; Radulovic S, 2002, INFECT IMMUN, V70, P2576, DOI 10.1128/IAI.70.5.2576-2582.2002; Mahara F, 2006, ANN NY ACAD SCI, V1078, P60, DOI 10.1196/annals.1374.007; FURUYA Y, 1995, J CLIN MICROBIOL, V33, P487; Hanaoka N, 2009, EMERG INFECT DIS, V15, P1994, DOI 10.3201/eid1512.090252; Imaoka Kaoru, 2011, Case Rep Dermatol, V3, P68, DOI 10.1159/000326941; Ishimaru M, 1975, Zhonghua Min Guo Wei Sheng Wu Xue Za Zhi, V8, P133; Katayama T, 1996, Kansenshogaku Zasshi, V70, P561; Kodama Kazuya, 2003, Journal of Infection and Chemotherapy, V9, P83, DOI 10.1007/s10156-002-0223-5; Kodama Kazuya, 2002, Journal of Infection and Chemotherapy, V8, P266, DOI 10.1007/s10156-002-0185-7; Mahara F., 1984, J ANAN MED ASS, V68, P4	17	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0385-2407	1346-8138		J DERMATOL	J. Dermatol.	NOV	2015	42	11					1066	1071		10.1111/1346-8138.13015		6	Dermatology	Dermatology	CU5ML	WOS:000363576200005		
J	Motegi, S; Uchiyama, A; Yamada, K; Toki, S; Amano, H; Ishikawa, O				Motegi, Sei-ichiro; Uchiyama, Akihiko; Yamada, Kazuya; Toki, Sayaka; Amano, Hiroo; Ishikawa, Osamu			Lichen planus complicated with thymoma: Report of three Japanese cases and review of the published work	JOURNAL OF DERMATOLOGY			English	Article						Good's syndrome; hypogammaglobulinemia; lichen planus; thymectomy; thymoma	ALOPECIA-AREATA; MYASTHENIA-GRAVIS; GOODS-SYNDROME; HYPOGAMMAGLOBULINEMIA; ASSOCIATION; INFECTIONS; DISORDERS; DISEASES; PATIENT	Thymoma is recognized to be complicated with autoimmune diseases, such as myasthenia gravis, pemphigus vulgaris and bullous pemphigoid. Abnormal regulation of autoreactive lymphocytes may be involved in the pathogenesis of the autoimmune diseases. The association of thymoma and lichen planus (LP) is relatively rare. Among 50 patients with LP, we identified three patients with LP accompanied by thymoma (6%; 3/50) in our department from 2004 to 2014. This is the first report identifying the frequency of thymoma accompanied by LP among patients with LP. We herein report three cases of LP accompanied by thymoma along with clinical and histological features. In addition, we summarize 29 LP patients accompanied by thymoma previously reported in the English-language published works. Regarding the complications, hypogammaglobulinemia accompanied 58.6% (17/29) of patients diagnosed with Good's syndrome. Alopecia was present in 13.8% (4/29) of patients, and myasthenia gravis was present in 17.2% (5/29) of patients with LP and thymoma. Among the 27 patients with thymectomy, only 25.9% (7/27) experienced the improvement of LP, suggesting that thymectomy may not be effective for the lesions of LP. Treatment-resistant LP was reported in 54.2% (13/24) of patients. In all our cases, oral lesions were intractable to treatment with oral predonisone and topical steroids and/or tacrolimus. It is important for dermatologists to recognize the clinical characteristics of the patients with both LP and thymoma.	[Motegi, Sei-ichiro; Uchiyama, Akihiko; Yamada, Kazuya; Toki, Sayaka; Amano, Hiroo; Ishikawa, Osamu] Gunma Univ, Grad Sch Med, Dept Dermatol, Maebashi, Gumma 3718511, Japan	Motegi, S (reprint author), Gunma Univ, Grad Sch Med, Dept Dermatol, 3-39-22 Showa, Maebashi, Gumma 3718511, Japan.	smotegi@gunma-u.ac.jp					ROTHBERG MS, 1989, ORAL SURG ORAL MED O, V68, P411, DOI 10.1016/0030-4220(89)90138-2; Santoro A, 2004, AM J CLIN PATHOL, V121, P758, DOI 10.1309/GHY8AL2D45P2R234; TAN RSH, 1974, P ROY SOC MED, V67, P196; Moutasim KA, 2008, ORAL SURG ORAL MED O, V105, pE57, DOI 10.1016/j.tripleo.2007.09.029; HELM TN, 1994, J AM ACAD DERMATOL, V30, P219; Olivier V, 2002, ARCH DERMATOL, V138, P1335, DOI 10.1001/archderm.138.10.1335; FLAMENBAUM HS, 1982, J AM ACAD DERMATOL, V6, P918, DOI 10.1016/S0190-9622(82)70081-7; Bobbio A, 2007, ANN THORAC SURG, V83, P1197, DOI 10.1016/j.athoracsur.2006.08.024; Suzuki S, 2005, EUR J NEUROL, V12, P566, DOI 10.1111/j.1468-1331.2005.01002.x; Qiao JJ, 2011, J NEUROL SCI, V308, P177, DOI 10.1016/j.jns.2011.05.038; MCMANUS KG, 1994, ANN THORAC SURG, V58, P1534; Kaku Y, 2011, EUR J DERMATOL, V21, P124, DOI 10.1684/ejd.2010.1183; Wright CD, 2008, CRIT REV ONCOL HEMAT, V65, P109, DOI 10.1016/j.critrevonc.2007.04.005; Hon C, 2006, J CLIN ONCOL, V24, P2960, DOI 10.1200/JCO.2005.043133; Hanafusa T, 2010, J DERMATOL, V37, P171, DOI 10.1111/j.1346-8138.2009.00781.x; Sugerman PB, 2002, CRIT REV ORAL BIOL M, V13, P350; Perez E, 1998, DERMATOLOGY, V197, P264, DOI 10.1159/000018010; Hoffacker V, 2000, BLOOD, V96, P3872; Calista D, 2001, INT J DERMATOL, V40, P762, DOI 10.1046/j.1365-4362.2001.01344.x; [Anonymous], 1991, ARCH DERMATOL, V127, P688; Miyagaki T, 2013, AUSTRALAS J DERMATOL, V54, pE25, DOI 10.1111/j.1440-0960.2011.00818.x; ROSENOW EC, 1984, ARCH INTERN MED, V144, P763, DOI 10.1001/archinte.144.4.763; Arnold SJ, 2015, BRIT J DERMATOL, V172, P774, DOI 10.1111/bjd.13293; Ng PPL, 1998, CLIN EXP DERMATOL, V23, P181; Seneschal J, 2008, J EUR ACAD DERMATOL, V22, P506, DOI 10.1111/j.1468-3083.2007.02370.x; Mineo TC, 1996, J THORAC CARDIOV SUR, V111, P486, DOI 10.1016/S0022-5223(96)70461-0; ARONSON IK, 1978, ARCH DERMATOL, V114, P255, DOI 10.1001/archderm.114.2.255; GIBSON LE, 1987, ACTA DERM-VENEREOL, V67, P351; Good RA, 1954, B U MINN HOSP, V26, P1; Hassan J A, 2000, Malays J Med Sci, V7, P38; Hayashi A, 2008, CARDIOVASC THORAC SU, V7, P347; Khan Sujoy, 2009, Interact Cardiovasc Thorac Surg, V9, P345, DOI 10.1510/icvts.2009.207308; Lolis Margarita, 2006, Dermatol Online J, V12, P28; Macdonald JB, 2014, J EUR ACAD DERMATOL, V28, P1828, DOI 10.1111/jdv.12378	34	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0385-2407	1346-8138		J DERMATOL	J. Dermatol.	NOV	2015	42	11					1072	1077		10.1111/1346-8138.12987		6	Dermatology	Dermatology	CU5ML	WOS:000363576200006		
J	Kaneko, S; Masuda, K; Hiragun, T; Inomata, N; Furue, M; Onozuka, D; Takeuchi, S; Murota, H; Sugaya, M; Saeki, H; Shintani, Y; Tsunemi, Y; Abe, S; Kobayashi, M; Kitami, Y; Tanioka, M; Imafuku, S; Abe, M; Hagihara, A; Morisky, DE; Katoh, N				Kaneko, Sakae; Masuda, Koji; Hiragun, Takaaki; Inomata, Naoko; Furue, Masutaka; Onozuka, Daisuke; Takeuchi, Satoshi; Murota, Hiroyuki; Sugaya, Makoto; Saeki, Hidehisa; Shintani, Yoichi; Tsunemi, Yuichiro; Abe, Shinya; Kobayashi, Miwa; Kitami, Yuki; Tanioka, Miki; Imafuku, Shinichi; Abe, Masatoshi; Hagihara, Akihito; Morisky, Donald E.; Katoh, Norito			Transient improvement of urticaria induces poor adherence as assessed by Morisky Medication Adherence Scale-8	JOURNAL OF DERMATOLOGY			English	Article						adherence; oral; topical; transient improvement; urticaria	EPIDEMIOLOGY; GUIDELINES; DIAGNOSIS	Poor adherence to medication is a major public health challenge. Here, we aimed to determine the adherence to oral and topical medications and to analyze underlying associated factors using the translated Japanese version of Morisky Medication Adherence Scale-8 regarding urticaria treatment. Web-based questionnaires were performed for 3096 registered dermatological patients, along with a subanalysis of 751 registered urticaria patients in this study. The adherence to oral medication was significantly associated with the frequency of hospital visits. Variables that affected the adherence to topical medication included age and experience of drug effectiveness. The rate of responses that It felt like the symptoms had improved varied significantly among the dermatological diseases treated with oral medications. Dermatologists should be aware that adherence to the treatment of urticaria is quite low. Regular visits and active education for patients with urticaria are mandatory in order to achieve a good therapeutic outcome by increasing the adherence.	[Kaneko, Sakae] Shimane Univ, Fac Med, Dept Dermatol, Izumo, Shimane 6938501, Japan; [Masuda, Koji; Katoh, Norito] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Dermatol, Kyoto, Japan; [Hiragun, Takaaki] Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Dermatol Integrated Hlth Sci, Hiroshima, Japan; [Inomata, Naoko] Yokohama City Univ, Grad Sch Med, Dept Environm Immunodermatol, Kanagawa, Japan; [Furue, Masutaka] Kyushu Univ, Sch Med Sci, Dept Dermatol, Fukuoka 812, Japan; [Onozuka, Daisuke; Hagihara, Akihito] Kyushu Univ, Sch Med Sci, Dept Hlth Care Adm & Management, Fukuoka 812, Japan; [Takeuchi, Satoshi] Hamanomachi Hosp, Federat Natl Publ Serv Personnel Mutual Aid Assoc, Dept Dermatol, Fukuoka, Japan; [Murota, Hiroyuki] Osaka Univ, Grad Sch Med, Dept Dermatol, Osaka, Japan; [Sugaya, Makoto] Univ Tokyo, Fac Med, Dept Dermatol, Tokyo 113, Japan; [Saeki, Hidehisa] Nippon Med Sch, Dept Dermatol, Tokyo 113, Japan; [Shintani, Yoichi] Nagoya City Univ, Grad Sch Med Sci, Dept Geriatr & Environm Dermatol, Nagoya, Aichi, Japan; [Tsunemi, Yuichiro] Tokyo Womens Med Univ, Dept Dermatol, Tokyo, Japan; [Abe, Shinya] Kanazawa Med Univ, Dept Dermatol, Uchinada, Ishikawa, Japan; [Kobayashi, Miwa] Univ Occupat & Environm Hlth, Dept Dermatol, Fukuoka, Japan; [Kitami, Yuki] Showa Univ, Sch Med, Dept Dermatol, Tokyo 142, Japan; [Tanioka, Miki] Tanioka Dermatol Clin, Kyoto, Japan; [Imafuku, Shinichi] Fukuoka Univ, Fac Med, Dept Dermatol, Fukuoka 81401, Japan; [Abe, Masatoshi] Sapporo Skin Clin, Sapporo, Hokkaido, Japan; [Morisky, Donald E.] UCLA, Dept Community Hlth Sci, Fielding Sch Publ Hlth, Los Angeles, CA USA	Kaneko, S (reprint author), Shimane Univ, Fac Med, Dept Dermatol, 89-1 Enya Cho, Izumo, Shimane 6938501, Japan.	kanekos2@med.shimane-u.ac.jp	Onozuka, Daisuke/F-5067-2014	Onozuka, Daisuke/0000-0001-9596-9188	Mitsubishi Tanabe Pharma	We asked MPR to run the administrative office for the present study, and would like to thank this company for carrying out the questionnaire survey and collecting data. This study was financially supported by Mitsubishi Tanabe Pharma.	Al-Qazaz HK, 2010, DIABETES RES CLIN PR, V90, P216, DOI 10.1016/j.diabres.2010.08.012; Morisky DE, 2008, J CLIN HYPERTENS, V10, P348, DOI 10.1111/j.1751-7176.2008.07572.x; Zuberbier T, 2010, CLIN EXP DERMATOL, V35, P869, DOI 10.1111/j.1365-2230.2010.03840.x; Richmond NA, 2014, J AM ACAD DERMATOL, V70, P201, DOI 10.1016/j.jaad.2013.09.053; Conlon NP, 2014, EUR J DERMATOL, V24, P385, DOI 10.1684/ejd.2014.2323; Zuberbier T, 2009, ALLERGY, V64, P1417, DOI 10.1111/j.1398-9995.2009.02179.x; CORTINA JM, 1993, J APPL PSYCHOL, V78, P98, DOI 10.1037//0021-9010.78.1.98; Nettis E, 2003, BRIT J DERMATOL, V148, P501, DOI 10.1046/j.1365-2133.2003.05169.x; Staubach P, 2006, BRIT J DERMATOL, V154, P294, DOI 10.1111/j.1365-2133.2005.06976.x; Hide M, 2012, ALLERGOL INT, V61, P517, DOI 10.2332/allergolint.12-RAI-0497; Gaig P, 2004, J INVEST ALLERG CLIN, V14, P214; CHAMPION RH, 1988, BRIT J DERMATOL, V119, P427, DOI 10.1111/j.1365-2133.1988.tb03246.x; Furue M, 2015, BRIT J DERMATOL, V172, P272, DOI 10.1111/bjd.13377; Saeki H, 2015, J DERMATOL, V42, P367, DOI 10.1111/1346-8138.12804; World Health Organization, 2003, ADH LONG TERM THER E, P107	15	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0385-2407	1346-8138		J DERMATOL	J. Dermatol.	NOV	2015	42	11					1078	1082		10.1111/1346-8138.12971		5	Dermatology	Dermatology	CU5ML	WOS:000363576200007		
J	Nakajima, R; Komine, M; Miyamoto, Y; Fusumae, T; Fujita, Y; Maekawa, T; Murata, S; Fukushima, N; Ohtsuki, M				Nakajima, Rina; Komine, Mayumi; Miyamoto, Yukiko; Fusumae, Takayuki; Fujita, Yurika; Maekawa, Takeo; Murata, Satoru; Fukushima, Noriyoshi; Ohtsuki, Mamitaro			Sarcomatoid carcinoma arising in the congenital pigmented nevus after treatment with carbon dioxide snow freezing method	JOURNAL OF DERMATOLOGY			English	Article						carbon dioxide now freezing method; congenital pigmented nevus; multiple basal cell carcinoma; p53; sarcomatoid carcinoma	BASAL-CELL CARCINOMA; OF-THE-LITERATURE; CARCINOSARCOMA; SKIN	We report a case of sarcomatoid carcinoma of the skin in a 63-year-old man who was treated with the carbon dioxide snow freezing method for a huge congenital pigmented nevus that extended from the right upper extremity to the right trunk during childhood. He had an exophytic red tumor on the nevus in the right upper extremity that grew slowly for 4years and rapidly recently. Histological and immunohistochemical studies revealed both epithelial and mesenchymal malignancy in the same tumor. The epithelial component was composed of basaloid cells forming multiple nests with peripheral palisading, positive for keratins and BerEP4, implying basal cell carcinoma. The mesenchymal component was composed of spindle-shaped cells negative for keratins and positive for vimentin, suggesting sarcoma. This is, to our knowledge, the first report of sarcomatoid carcinoma arising in the primary pigmented nevus that had been treated by the carbon dioxide snow freezing method.	[Nakajima, Rina; Komine, Mayumi; Miyamoto, Yukiko; Fusumae, Takayuki; Fujita, Yurika; Maekawa, Takeo; Murata, Satoru; Ohtsuki, Mamitaro] Jichi Med Univ, Dept Dermatol, Shimotsuke, Tochigi 3290498, Japan; [Fukushima, Noriyoshi] Jichi Med Univ, Dept Pathol, Shimotsuke, Tochigi 3290498, Japan	Komine, M (reprint author), Jichi Med Univ, Dept Dermatol, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290498, Japan.	mkomine12@jichi.ac.jp					Chittari K, 2012, CLIN EXP DERMATOL, V37, P505, DOI 10.1111/j.1365-2230.2011.04277.x; Rose RF, 2008, J AM ACAD DERMATOL, V59, P627, DOI 10.1016/j.jaad.2008.05.035; Pusey WA, 1907, J AMER MED ASSOC, V49, P1354; IZAKI S, 1993, J CUTAN PATHOL, V20, P272, DOI 10.1111/j.1600-0560.1993.tb00655.x; Tran TA, 2005, J CUTAN PATHOL, V32, P2, DOI 10.1111/j.0303-6987.2005.00260.x; COSMAN B, 1989, ANN PLAS SURG, V22, P36, DOI 10.1097/00000637-198901000-00007; Bagazgoitia L, 2009, J EUR ACAD DERMATOL, V23, P459, DOI 10.1111/j.1468-3083.2008.02904.x; Grando SA, 1996, ARCH DERMATOL, V132, P1185, DOI 10.1001/archderm.132.10.1185; Patel NK, 1997, AM J DERMATOPATH, V19, P363, DOI 10.1097/00000372-199708000-00008; Carlson JA, 2002, J CUTAN PATHOL, V29, P268, DOI 10.1034/j.1600-0560.2002.290502.x; Syme-Grant J, 2006, J PLAST RECONSTR AES, V59, P1402, DOI 10.1016/j.bjps.2005.12.057; Bito M, 2012, RINSHO DERMA, V66, P979	12	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0385-2407	1346-8138		J DERMATOL	J. Dermatol.	NOV	2015	42	11					1083	1086		10.1111/1346-8138.12962		4	Dermatology	Dermatology	CU5ML	WOS:000363576200008		
J	Hatta, N; Takata, A; Ishizawa, S; Niida, Y				Hatta, Naohito; Takata, Akiko; Ishizawa, Shin; Niida, Yo			Family with MSH2 mutation presenting with keratoacanthoma and precancerous skin lesions	JOURNAL OF DERMATOLOGY			English	Article						hereditary non-polyposis colorectal cancer; mismatch repair genes; MLH1; MSH6; Muir-Torre syndrome	MUIR-TORRE-SYNDROME; MICROSATELLITE INSTABILITY; COLORECTAL-CANCER; TUMORS; IMMUNOHISTOCHEMISTRY; FREQUENCY; PROTEINS	Muir-Torre syndrome (MTS) is a familial cancer syndrome characterized by a predisposition to keratoacanthoma (KA) and sebaceous tumors. Although MTS and hereditary non-polyposis colorectal cancer (HNPCC) sharethe same genetic alterations in mismatch repair (MMR) genes, the other skin lesions in MTS or HNPCChave been only rarely reported. We report a family with an MSH2 mutation c.1126_1127delTT (p.Leu376Thrfs*12). A 46-year-old male proband developed KA with sebaceous differentiation, colon cancer and gastric cancer, and fulfilled the diagnostic criteria for MTS. His 80-year-old mother, diagnosed with HNPCC, presented with multiple gastrointestinal tract cancers, Bowen's disease and actinic keratosis. Immunostaining revealed attenuated MSH2 protein expression in KA, as well as in Bowen's disease and actinic keratosis lesions. These findings suggest that MMR gene abnormality is also critical in the development of benign or malignant cutaneous tumors such as actinic keratosis and Bowen's disease in MTS/HNPCC patients.	[Hatta, Naohito; Takata, Akiko] Toyama Prefectural Cent Hosp, Dept Dermatol, Toyama 9308550, Japan; [Ishizawa, Shin] Toyama Prefectural Cent Hosp, Dept Pathol, Toyama 9308550, Japan; [Niida, Yo] Kanazawa Med Univ, Med Res Inst, Div Genom Med, Kanazawa, Ishikawa, Japan	Hatta, N (reprint author), Toyama Prefectural Cent Hosp, Dept Dermatol, 2-2-78 Nishinagae, Toyama 9308550, Japan.	hattanao@tch.pref.toyama.jp			National Cancer Center Research and Development Fund [26-A-4]	This work was partly supported by the National Cancer Center Research and Development Fund (26-A-4).	Takata M, 2000, BRIT J DERMATOL, V143, P851, DOI 10.1046/j.1365-2133.2000.03789.x; Nishizawa A, 2006, AM J DERMATOPATH, V28, P56, DOI 10.1097/01.dad.0000185146.83799.24; Vasen HFA, 1999, GASTROENTEROLOGY, V116, P1453, DOI 10.1016/S0016-5085(99)70510-X; Mathiak M, 2002, AM J SURG PATHOL, V26, P338, DOI 10.1097/00000478-200203000-00007; Kruse R, 2003, J INVEST DERMATOL, V120, P858, DOI 10.1046/j.1523-1747.2003.12125.x; Yamamoto T, 1996, ACTA DERM-VENEREOL, V76, P75; Fernandez-Flores A, 2012, AM J DERMATOPATH, V34, P416, DOI 10.1097/DAD.0b013e3182226a28; Ponti G, 2005, BRIT J DERMATOL, V152, P1335, DOI 10.1111/j.1365-2133.2005.06506.x; Lynch HT, 2003, NEW ENGL J MED, V348, P919; Swale VJ, 1999, J INVEST DERMATOL, V113, P901, DOI 10.1046/j.1523-1747.1999.00788.x; Ponti G, 2005, CANCER, V103, P1018, DOI 10.1002/cncr.20873; Stoebner PE, 2009, DERMATOLOGY, V219, P174, DOI 10.1159/000228830; South CD, 2008, J NATL CANCER I, V100, P277, DOI 10.1093/jnci/djm291; SCHWARTZ RA, 1995, J AM ACAD DERMATOL, V33, P90, DOI 10.1016/0190-9622(95)90017-9	14	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0385-2407	1346-8138		J DERMATOL	J. Dermatol.	NOV	2015	42	11					1087	1090		10.1111/1346-8138.12949		4	Dermatology	Dermatology	CU5ML	WOS:000363576200009		
J	Fujii, M; Takahashi, I; Honma, M; Ishida-Yamamoto, A				Fujii, Mizue; Takahashi, Ichiro; Honma, Masaru; Ishida-Yamamoto, Akemi			Close correlation of herpes zoster-induced voiding dysfunction with severity of zoster-related pain: A single faculty retrospective study	JOURNAL OF DERMATOLOGY			English	Article						cystitis; herpes zoster; pain relief; zoster-associated voiding dysfunction; zoster-related pain	URINARY RETENTION	Herpes zoster (HZ), a common vesiculo-erythematous skin disease associated with reactivation of varicella zoster virus in the cranial nerve, dorsal root, and autonomic ganglia, is accompanied by several related symptoms represented by postherpetic neuralgia. Among them, involvement of vesicorectal dysfunction is relatively rare. The vesicorectal symptom can usually be recovered in transient course, but is quite important in terms of impaired quality of life. Male individuals affected with HZ and skin lesions on sacral dermatome have been reported as independent risk factors of zoster-related voiding dysfunction. In this study, urinary symptoms were focused upon and six patients with zoster-related voiding dysfunction at a single faculty of dermatology in Japan from 2009 to 2014 were retrospectively analyzed. All patients showed HZ lesions on the sacral area and the urinary symptom recovered in approximately 2months (14days to 7months). The term of treatment for zoster-associated urinary dysfunction was positively correlated with that for zoster-related pain without significance (r=0.661, P=0.153). Average treatment term for pain relief of sacral HZ accompanied by voiding dysfunction (91.3 +/- 76.44days) was significantly longer than that of sacral HZ without urinary symptom (18.9 +/- 20.42days) (P=0.032). These results suggested that zoster-related voiding dysfunction would mainly be involved in sacral HZ and closely associated with severity of zoster-related pain. Dermatologists should be aware that severe zoster-related pain accompanied by sacral HZ, which is related to prolonged treatment of pain relief, can be a predictive factor of voiding dysfunction.	[Fujii, Mizue; Takahashi, Ichiro] Kitami Red Cross Hosp, Dermatol Branch, Kitami, Hokkaido 0908666, Japan; [Fujii, Mizue; Honma, Masaru; Ishida-Yamamoto, Akemi] Asahikawa Med Univ, Dept Dermatol, Asahikawa, Hokkaido, Japan	Fujii, M (reprint author), Kitami Red Cross Hosp, Dermatol Branch, Kita 6-Jo Higashi 2-Chome, Kitami, Hokkaido 0908666, Japan.	ma0dj@asahikawa-med.ac.jp					Nagasako EM, 2002, J AM ACAD DERMATOL, V46, P834, DOI 10.1067/mjd.2002.120924; LIESEGANG TJ, 1984, J AM ACAD DERMATOL, V11, P165, DOI 10.1016/S0190-9622(84)70148-4; Chen PH, 2002, ARCH PHYS MED REHAB, V83, P1624, DOI 10.1053/apmr.2002.34602; Imafuku S, 2008, INT J DERMATOL, V47, P36, DOI 10.1111/j.1365-4632.2007.03548.x; Erol B, 2009, UROL INT, V82, P238, DOI 10.1159/000200807; Julia JJ, 2007, INT UROGYNECOL J, V18, P103, DOI 10.1007/s00192-006-0066-1; Ginsberg Phillip C., 1998, Journal of the American Osteopathic Association, V98, P508; PETTERSS.S, 1974, SCAND J UROL NEPHROL, V8, P96, DOI 10.3109/00365597409132112	8	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0385-2407	1346-8138		J DERMATOL	J. Dermatol.	NOV	2015	42	11					1091	1093		10.1111/1346-8138.12957		3	Dermatology	Dermatology	CU5ML	WOS:000363576200010		
J	Nagai, H; Fujiwara, S; Takahashi, Y; Nishigori, C				Nagai, Hiroshi; Fujiwara, Susumu; Takahashi, Yutaka; Nishigori, Chikako			Ameliorating effect of the novel dipeptidyl peptidase-4 inhibitor teneligliptin on psoriasis: A report of two cases	JOURNAL OF DERMATOLOGY			English	Article						CD26; diabetic mellitus; dipeptidyl peptidase-4 inhibitor; psoriasis; teneligliptin	METABOLIC SYNDROME; SITAGLIPTIN; PREVALENCE; CELLS	Dipeptidyl peptidase-4 inhibitors are a new class of antidiabetic agents also shown to possess immunomodulatory functions. Although various dipeptidyl peptidase-4 inhibitors have been widely used and assumed to be administrated in many patients with psoriasis accompanied by type 2 diabetic mellitus, only two studies have shown that sitagliptin, a dipeptidyl peptidase-4 inhibitor, improved the cutaneous symptom of psoriasis independently of its antihyperglycemic effect. We report two cases of psoriatic skin lesions that obviously ameliorated after initiation of therapy with teneligliptin, a novel dipeptidyl peptidase-4 inhibitor. This report strengthens the notion that dipeptidyl peptidase-4 inhibitors clinically exert an ameliorating effect on psoriatic lesions. Considering the pharmacokinetic data that indicate the high penetrative ability of teneligliptin into skin tissue, teneligliptin may be considered an effective agent for improving skin lesions of psoriasis.	[Nagai, Hiroshi; Fujiwara, Susumu; Nishigori, Chikako] Kobe Univ, Grad Sch Med, Div Dermatol, Dept Internal Related, Kobe, Hyogo 6500017, Japan; [Takahashi, Yutaka] Kobe Univ, Grad Sch Med, Div Diabet & Endocrinol, Dept Internal Med, Kobe, Hyogo 6500017, Japan	Nagai, H (reprint author), Kobe Univ, Grad Sch Med, Div Dermatol, Dept Internal Related,Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	hnagai@med.kobe-u.ac.jp					Kim SJ, 2010, DIABETES, V59, P1739, DOI 10.2337/db09-1618; Takahashi H, 2012, J DERMATOL, V39, P212, DOI 10.1111/j.1346-8138.2011.01408.x; Raychaudhuri SP, 2013, CLIN REV ALLERG IMMU, V44, P183, DOI 10.1007/s12016-012-8307-1; Nishioka T, 2012, DERMATOLOGY, V224, P20, DOI 10.1159/000333358; RAYNAUD F, 1992, J CELL PHYSIOL, V151, P378, DOI 10.1002/jcp.1041510219; Deacon CF, 2011, DIABETES OBES METAB, V13, P7, DOI 10.1111/j.1463-1326.2010.01306.x; Bengsch B, 2012, J IMMUNOL, V188, P5438, DOI 10.4049/jimmunol.1103801; Langan SM, 2012, J INVEST DERMATOL, V132, P556, DOI 10.1038/jid.2011.365; Lee SA, 2013, J CLIN ENDOCR METAB, V98, P2553, DOI 10.1210/jc.2012-4288; Ikeda T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066520; Kokpol C, 2014, J DERMATOL, V41, P898, DOI 10.1111/1346-8138.12614; Lynch M, 2014, CLIN EXP DERMATOL, V39, P841, DOI 10.1111/ced.12408; vansLingen RG, 2008, ARCH DERMATOL RES, V300, P561; vansLingen RG, 2008, BRIT J DERMATOL, V158, P1264; Zhao YJ, 2014, DIABETES-METAB RES, V30, P646, DOI 10.1002/dmrr.2530	15	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0385-2407	1346-8138		J DERMATOL	J. Dermatol.	NOV	2015	42	11					1094	1097		10.1111/1346-8138.12955		4	Dermatology	Dermatology	CU5ML	WOS:000363576200011		
J	Lazic-Mosler, E; Jukic, IL; Murat-Susic, S; Husar, K; Skerlev, M; Bukvic Mokos, Z; Ishii, N; Hashimoto, T; Marinovic, B				Lazic-Mosler, Elvira; Jukic, Ines Lakos; Murat-Susic, Slobodna; Husar, Karmela; Skerlev, Mihael; Bukvic Mokos, Zrinka; Ishii, Norito; Hashimoto, Takashi; Marinovic, Branka			Inflammatory epidermolysis bullosa acquisita in a 4-year-old girl	JOURNAL OF DERMATOLOGY			English	Article						acquired epidermolysis bullosa; bullous skin disease; childhood blistering; epidermolysis bullosa aquisita antigen; inflammatory epidermolysis bullosa aquisita	VII COLLAGEN; CHILDHOOD; AUTOANTIBODIES; ANTIGEN; DOMAINS	This study presents a case of linear immunoglobulin A dermatosis-like epidermolysis bullosa acquisita in a 4-year-old girl showing rapid, widespread and inflammatory skin lesions. The diagnosis was confirmed by histopathology, direct and indirect immunofluorescence, various immunoblotting analyses and enzyme-linked immunosorbent assays. Despite the severe clinical manifestations, the disease was successfully controlled by combination therapy of oral prednisolone and dapsone.	[Lazic-Mosler, Elvira] Gen Hosp Dr Ivo Pedis, Dept Dermatol & Venereol, Sisak, Croatia; [Lazic-Mosler, Elvira] Univ Zagreb, Sch Med, Dept Anat, Zagreb 41001, Croatia; [Jukic, Ines Lakos; Murat-Susic, Slobodna; Husar, Karmela; Skerlev, Mihael; Bukvic Mokos, Zrinka; Marinovic, Branka] Univ Hosp Ctr Zagreb, Univ Dept Dermatol & Venereol, Zagreb 10000, Croatia; [Jukic, Ines Lakos; Murat-Susic, Slobodna; Husar, Karmela; Skerlev, Mihael; Bukvic Mokos, Zrinka; Marinovic, Branka] Univ Zagreb, Sch Med, Zagreb 41001, Croatia; [Ishii, Norito; Hashimoto, Takashi] Kurume Univ, Sch Med, Dept Dermatol, Kurume, Fukuoka 830, Japan; [Ishii, Norito; Hashimoto, Takashi] Kurume Univ, Inst Cutaneous Cell Biol, Kurume, Fukuoka 830, Japan	Marinovic, B (reprint author), Univ Hosp Ctr Zagreb, Univ Dept Dermatol & Venereol, Salata 4, Zagreb 10000, Croatia.	branka.marinovic@kbc-zagreb.hr					Yang BQ, 2012, PEDIATR DERMATOL, V29, P614, DOI 10.1111/j.1525-1470.2011.01509.x; CallotMellot C, 1997, ARCH DERMATOL, V133, P1122, DOI 10.1001/archderm.133.9.1122; Fairley JA, 2004, J AM ACAD DERMATOL, V51, P118, DOI 10.1016/j.jaad.2003.12.033; YAOITA H, 1981, J INVEST DERMATOL, V76, P288, DOI 10.1111/1523-1747.ep12526124; Edwards S, 1998, PEDIATR DERMATOL, V15, P184, DOI 10.1046/j.1525-1470.1998.1998015184.x; Saleh MA, 2011, J DERMATOL SCI, V62, P169, DOI 10.1016/j.jdermsci.2011.03.003; Jonkman MF, 2000, ARCH DERMATOL, V136, P227, DOI 10.1001/archderm.136.2.227; Furukawa H, 2004, DERMATOLOGY, V209, P145, DOI 10.1159/000079601; Baican A, 2013, J DERMATOL, V40, P410, DOI 10.1111/1346-8138.12107; Pastar Z, 2007, INT J DERMATOL, V46, P295, DOI 10.1111/j.1365-4632.2006.02969.x; Ishii N, 2010, J DERMATOL, V37, P220, DOI 10.1111/j.1346-8138.2009.00799.x; GAMMON WR, 1984, J AM ACAD DERMATOL, V11, P820, DOI 10.1016/S0190-9622(84)80459-4; Yamada T, 2006, DERMATOLOGY, V212, P381, DOI 10.1159/000092292; Ludwig RJ, 2013, ISRN DERMATOL, V2013; Mayuzumi M, 2006, BRIT J DERMATOL, V155, P1048, DOI 10.1111/j.1365-2133.2006.07443.x	15	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0385-2407	1346-8138		J DERMATOL	J. Dermatol.	NOV	2015	42	11					1098	1100		10.1111/1346-8138.12958		3	Dermatology	Dermatology	CU5ML	WOS:000363576200012		
J	Matsuoka, Y; Ansai, S; Ogita, A; Shinohara, R; Nako, T; Matsuda, H; Tanaka, M				Matsuoka, Yasuko; Ansai, Shin-ichi; Ogita, Azusa; Shinohara, Rie; Nako, Toshie; Matsuda, Hidenori; Tanaka, Masaru			Case of basosquamous carcinoma: Dermoscopic and immunohistochemical findings	JOURNAL OF DERMATOLOGY			English	Letter							CELL-CARCINOMA; SQUAMOUS-CELL; BASAL-CELL		[Matsuoka, Yasuko; Ansai, Shin-ichi; Ogita, Azusa; Shinohara, Rie; Nako, Toshie; Matsuda, Hidenori] Musashi Kosugi Hosp, Nippon Med Sch, Div Dermatol, Kawasaki, Kanagawa 2118533, Japan; [Tanaka, Masaru] Univ Med Ctr East, Tokyo Womens Med, Dept Dermatol, Tokyo, Japan	Ansai, S (reprint author), Musashi Kosugi Hosp, Nippon Med Sch, Div Dermatol, Nakahara Ku, 1-396 Kosugi Cho, Kawasaki, Kanagawa 2118533, Japan.	shin8113@nms.ac.jp					Giacomel J, 2013, BRIT J DERMATOL, V169, P358, DOI 10.1111/bjd.12394; Beer TW, 2000, HISTOPATHOLOGY, V37, P218, DOI 10.1046/j.1365-2559.2000.00999.x; Swanson PE, 1998, J CUTAN PATHOL, V25, P153, DOI 10.1111/j.1600-0560.1998.tb01708.x; Jones MS, 1997, DERMATOL SURG, V23, P181; Kossard S, 2006, WHO CLASSIFICATION T, P13	5	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0385-2407	1346-8138		J DERMATOL	J. Dermatol.	NOV	2015	42	11					1102	1103		10.1111/1346-8138.13032		2	Dermatology	Dermatology	CU5ML	WOS:000363576200014		
J	Ogata, D; Tsuchida, T				Ogata, Dai; Tsuchida, Tetsuya			Characteristic dermoscopic features of verruciform xanthoma: Report of three cases	JOURNAL OF DERMATOLOGY			English	Letter									[Ogata, Dai; Tsuchida, Tetsuya] Saitama Med Univ, Dept Dermatol, Saitama 3500495, Japan	Ogata, D (reprint author), Saitama Med Univ, Dept Dermatol, 38 Morohongo, Saitama 3500495, Japan.	d_ogata@saitama-med.ac.jp					Ferrari A, 2009, ACTA DERM-VENEREOL, V89, P160, DOI 10.2340/00015555-0608; SHAFER WG, 1971, ORAL SURG ORAL MED O, V31, P784, DOI 10.1016/0030-4220(71)90134-4; Song M, 2011, J EUR ACAD DERMATOL, V25, P259, DOI 10.1111/j.1468-3083.2010.03819.x; Ohnishi T, 2015, CLIN EXP DERMATOL, V40, P156, DOI 10.1111/ced.12503	4	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0385-2407	1346-8138		J DERMATOL	J. Dermatol.	NOV	2015	42	11					1103	1104		10.1111/1346-8138.13034		2	Dermatology	Dermatology	CU5ML	WOS:000363576200015		
J	Iikawa, M; Namiki, T; Arima, Y; Kato, K; Arai, M; Ueno, M; Tokoro, S; Miura, K; Yokozeki, H				Iikawa, Madoka; Namiki, Takeshi; Arima, Yumi; Kato, Kohei; Arai, Madoka; Ueno, Makiko; Tokoro, Shown; Miura, Keiko; Yokozeki, Hiroo			Extraocular sebaceous carcinoma in association with a clonal seborrheic keratosis: Dermoscopic features	JOURNAL OF DERMATOLOGY			English	Letter							DIAGNOSIS		[Iikawa, Madoka; Namiki, Takeshi; Arima, Yumi; Kato, Kohei; Arai, Madoka; Ueno, Makiko; Tokoro, Shown; Yokozeki, Hiroo] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Dermatol, Tokyo, Japan; [Miura, Keiko] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Pathol, Tokyo, Japan	Namiki, T (reprint author), Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Dermatol, Bunkyo Ku, I-5-45 Yushima, Tokyo 1138510, Japan.	tnamderm@tmd.ac.jp					Kim NH, 2008, ARCH DERMATOL, V144, P962, DOI 10.1001/archderm.144.7.962; Tsai TM, 2010, J CUTAN MED SURG, V14, P240, DOI 10.2310/7750.2010.09059; Coates D, 2011, AUSTRALAS J DERMATOL, V52, P212, DOI 10.1111/j.1440-0960.2010.00699.x; Coppola R, 2015, J AM ACAD DERMATOL, V72, pE143, DOI 10.1016/j.jaad.2014.12.004; Longo C, 2014, J EUR ACAD DERMATOL, V28, P1397, DOI 10.1111/jdv.12261	5	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0385-2407	1346-8138		J DERMATOL	J. Dermatol.	NOV	2015	42	11					1105	1106		10.1111/1346-8138.13043		2	Dermatology	Dermatology	CU5ML	WOS:000363576200016		
J	Namiki, T; Miura, K; Yokozeki, H				Namiki, Takeshi; Miura, Keiko; Yokozeki, Hiroo			Multiple CD163(+) adult xanthogranuloma associated with myelodysplastic syndrome	JOURNAL OF DERMATOLOGY			English	Letter									[Namiki, Takeshi; Yokozeki, Hiroo] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Dermatol, Tokyo, Japan; [Miura, Keiko] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Pathol, Tokyo, Japan	Namiki, T (reprint author), Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Dermatol, Bunkyo Ku, I-5-45 Yushima, Tokyo 1138510, Japan.	tnamderm@tmd.ac.jp					Shoo BA, 2008, J AM ACAD DERMATOL, V59, P488, DOI 10.1016/j.jaad.2008.03.046; Hagiwara A, 2014, ACTA DERM-VENEREOL, V94, P223, DOI 10.2340/00015555-1656; Chiou CC, 2007, J EUR ACAD DERMATOL, V21, P532, DOI 10.1111/j.1468-3083.2006.02013.x; Shimada R, 2012, ACTA DERM-VENEREOL, V92, P631, DOI 10.2340/00015555-1356; Sugiura K, 2014, ACTA DERM-VENEREOL, V94, P465, DOI 10.2340/00015555-1712	5	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0385-2407	1346-8138		J DERMATOL	J. Dermatol.	NOV	2015	42	11					1106	1107		10.1111/1346-8138.13052		2	Dermatology	Dermatology	CU5ML	WOS:000363576200017		
J	Matsumoto, N; Hata, Y; Tanese, K				Matsumoto, Naoko; Hata, Yasuki; Tanese, Keiji			Case of primary cutaneous adenoid cystic carcinoma: Expression of c-KIT and activation of its downstream signaling molecules	JOURNAL OF DERMATOLOGY			English	Letter							CANCER		[Matsumoto, Naoko; Hata, Yasuki] Saiseikai Yokohama City Toubu Hosp, Div Dermatol, Kanagawa, Japan; [Matsumoto, Naoko; Hata, Yasuki; Tanese, Keiji] Keio Univ, Sch Med, Dept Dermatol, Tokyo 1608582, Japan	Tanese, K (reprint author), Keio Univ, Sch Med, Dept Dermatol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	tanese@a3.keio.jp					Rocas D, 2014, AM J DERMATOPATH, V36, P223, DOI 10.1097/DAD.0b013e31829ae1e7; Ashman LK, 2013, EXPERT OPIN INV DRUG, V22, P103, DOI 10.1517/13543784.2013.740010; Maia BD, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-150; Ellis GL, 2008, AFIP ATLAS TUMOR PAT, P225; Ramakrishnan R, 2013, AM J SURG PATHOL, V37, P1603, DOI 10.1097/PAS.0b013e318299fcac	5	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0385-2407	1346-8138		J DERMATOL	J. Dermatol.	NOV	2015	42	11					1109	1111		10.1111/1346-8138.13054		3	Dermatology	Dermatology	CU5ML	WOS:000363576200019		
J	Egami, S; Honda, H; Yokoyama, T; Sugiura, M				Egami, Shohei; Honda, Haruki; Yokoyama, Tomoaki; Sugiura, Makoto			Intramuscular myxoma on the forehead: An unusual localization with useful sonographic findings	JOURNAL OF DERMATOLOGY			English	Letter									[Egami, Shohei; Honda, Haruki; Yokoyama, Tomoaki; Sugiura, Makoto] Shizuoka Municipal Shimizu Hosp, Dept Dermatol, Shizuoka, Shizuoka 4240911, Japan	Egami, S (reprint author), Shizuoka Municipal Shimizu Hosp, Dept Dermatol, Shimizu Ku, 1231 Miyakami, Shizuoka, Shizuoka 4240911, Japan.	shoheiegami@a6.keio.jp					MIETTINEN M, 1985, AM J CLIN PATHOL, V84, P265; SHUGAR JMA, 1987, LARYNGOSCOPE, V97, P105; KINDBLOM L, 1974, CANCER, V34, P1737, DOI 10.1002/1097-0142(197411)34:5<1737::AID-CNCR2820340523>3.0.CO;2-U; Girish G, 2006, J ULTRAS MED, V25, P865; ENZINGER FRANZ M., 1965, AMER J CLIN PATHOL, V43, P104	5	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0385-2407	1346-8138		J DERMATOL	J. Dermatol.	NOV	2015	42	11					1111	1112		10.1111/1346-8138.13057		2	Dermatology	Dermatology	CU5ML	WOS:000363576200020		
J	Hanami, Y; Yamamoto, T				Hanami, Yuka; Yamamoto, Toshiyuki			Sarcoid reaction associated with basal cell carcinoma	JOURNAL OF DERMATOLOGY			English	Letter									[Hanami, Yuka; Yamamoto, Toshiyuki] Fukushima Med Univ, Dept Dermatol, Fukushima, Fukushima 9601295, Japan	Hanami, Y (reprint author), Fukushima Med Univ, Dept Dermatol, 1 Hikarigaoka, Fukushima, Fukushima 9601295, Japan.	yuka-66@fmu.ac.jp					Tsunoda K, 2011, J DERMATOL, V38, P939, DOI 10.1111/j.1346-8138.2010.01115.x; Stary G, 2007, J EXP MED, V204, P1441, DOI 10.1084/jem.20070021; Cohen PR, 2007, CLIN DERMATOL, V25, P326, DOI 10.1016/j.clindermatol.2007.03.010; Kurata A, 2005, HUM PATHOL, V36, P540; Ogata M, 2013, PRACT DERMATOL, V35, P87	5	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0385-2407	1346-8138		J DERMATOL	J. Dermatol.	NOV	2015	42	11					1112	1113		10.1111/1346-8138.13055		2	Dermatology	Dermatology	CU5ML	WOS:000363576200021		
J	Tsubouchi, K; Kato, H; Nishida, E; Ohguchi, R; Shintani, Y; Morita, A				Tsubouchi, Kasumi; Kato, Hiroshi; Nishida, Emi; Ohguchi, Ryoko; Shintani, Yoichi; Morita, Akimichi			Successful treatment of subcutaneous granuloma annulare with bath-psoralen plus ultraviolet A therapy	JOURNAL OF DERMATOLOGY			English	Letter							PUVA THERAPY; CELLS		[Tsubouchi, Kasumi; Kato, Hiroshi; Nishida, Emi; Ohguchi, Ryoko; Shintani, Yoichi; Morita, Akimichi] Nagoya City Univ, Grad Sch Med Sci, Dept Geriatr & Environm Dermatol, Nagoya, Aichi 4678601, Japan	Tsubouchi, K (reprint author), Nagoya City Univ, Grad Sch Med Sci, Dept Geriatr & Environm Dermatol, Mizuho Ku, 1 Kawasumi, Nagoya, Aichi 4678601, Japan.	tsubokasu_0323@yahoo.co.jp					Kato H, 2013, CL LYMPH MYELOM LEUK, V13, P273, DOI 10.1016/j.clml.2012.12.002; Studer EM, 1996, DERMATOLOGY, V193, P364; MODLIN RL, 1984, ARCH PATHOL LAB MED, V108, P379; Batchelor R, 2006, PEDIATR DERMATOL, V23, P72, DOI 10.1111/j.1525-1470.2006.00175.x; Furuhashi T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054895	5	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0385-2407	1346-8138		J DERMATOL	J. Dermatol.	NOV	2015	42	11					1114	1115		10.1111/1346-8138.13050		2	Dermatology	Dermatology	CU5ML	WOS:000363576200022		
J	Miura, T; Kato, Y; Ohtsuka, M; Yamamoto, T				Miura, Takako; Kato, Yasunobu; Ohtsuka, Mikio; Yamamoto, Toshiyuki			Granulomatous variant of vegetative pyoderma gangrenosum with sternocostoclavicular hyperostosis	JOURNAL OF DERMATOLOGY			English	Letter									[Miura, Takako; Kato, Yasunobu; Ohtsuka, Mikio; Yamamoto, Toshiyuki] Fukushima Med Univ, Dept Dermatol, Fukushima, Fukushima 9601295, Japan	Miura, T (reprint author), Fukushima Med Univ, Dept Dermatol, 1 Hikarigaoka, Fukushima, Fukushima 9601295, Japan.	m-takako@fmu.ac.jp					Griffin GK, 2012, J IMMUNOL, V188, P6287, DOI 10.4049/jimmunol.1200385; Langan SM, 2005, INT J DERMATOL, V44, P623, DOI 10.1111/j.1365-4632.2005.02591.x; Marzano AV, 2011, INT J IMMUNOPATH PH, V24, P451; Marzano AV, 2014, MEDICINE, V93, DOI 10.1097/MD.0000000000000187; Speeckaert R, 2014, J EUR ACAD DERMATOL, DOI [10.1111/jdv.12699, DOI 10.1111/JDV.12699]	5	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0385-2407	1346-8138		J DERMATOL	J. Dermatol.	NOV	2015	42	11					1115	1116		10.1111/1346-8138.13075		2	Dermatology	Dermatology	CU5ML	WOS:000363576200023		
J	Kurokawa, I				Kurokawa, Ichiro			Case reports of adjuvant combination therapy in severe acne vulgaris with chemical peeling using glycolic acid and iontophoresis	JOURNAL OF DERMATOLOGY			English	Letter									Meiwa Hosp, Acne Clin Res Ctr, Dept Dermatol, Nishinomiya, Hyogo 6638186, Japan	Kurokawa, I (reprint author), Meiwa Hosp, Acne Clin Res Ctr, Dept Dermatol, 4-31 Agenaruo Cho, Nishinomiya, Hyogo 6638186, Japan.	kurokawa.i@meiwa-hospital.com					Takenaka Y, 2012, J DERMATOL, V39, P350, DOI 10.1111/j.1346-8138.2011.01321.x; Yamamoto Y, 2012, J DERMATOL, V39, P321, DOI 10.1111/j.1346-8138.2011.01362.x; Inui S, 2007, J DERMATOL, V34, P221, DOI 10.1111/j.1346-8138.2007.00256.x; Hayashi N., 2008, JPN J DERMATOL, V118, P1893; Sato K, 2012, PEPAS, V62, P39	5	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0385-2407	1346-8138		J DERMATOL	J. Dermatol.	NOV	2015	42	11					1120	1121		10.1111/1346-8138.13044		2	Dermatology	Dermatology	CU5ML	WOS:000363576200026		
J	Nakamura, K; Kamijo, F; Negishi, T; Matsumoto, T; Okuyama, R; Uhara, H				Nakamura, Kenta; Kamijo, Fuminao; Negishi, Tatsuya; Matsumoto, Takehisa; Okuyama, Ryuhei; Uhara, Hisashi			Primary cutaneous nocardiosis caused by Nocardia concava	JOURNAL OF DERMATOLOGY			English	Letter							1ST REPORT; INFECTION		[Nakamura, Kenta; Kamijo, Fuminao; Okuyama, Ryuhei; Uhara, Hisashi] Shinshu Univ, Sch Med, Dept Dermatol, Matsumoto, Nagano 3908621, Japan; [Negishi, Tatsuya; Matsumoto, Takehisa] Shinshu Univ Hosp, Dept Lab Med, Nagano, Japan	Nakamura, K (reprint author), Shinshu Univ, Sch Med, Dept Dermatol, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	kenta1983@shinshu-u.ac.jp					Kobayashi N, 2012, INTERNAL MED, V51, P3281, DOI 10.2169/internalmedicine.51.7733; Kageyama A, 2005, INT J SYST EVOL MICR, V55, P2081, DOI 10.1099/ijs.0.63280-0; Kageyama A, 2004, EUR J EPIDEMIOL, V19, P383, DOI 10.1023/B:EJEP.0000024706.02325.c0; Lee SH, 2012, J INFECT CHEMOTHER, V18, P764, DOI 10.1007/s10156-011-0364-5; Hu YX, 2011, MED MYCOL, V49, P662, DOI 10.3109/13693786.2011.555849	5	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0385-2407	1346-8138		J DERMATOL	J. Dermatol.	NOV	2015	42	11					1121	1122		10.1111/1346-8138.13036		2	Dermatology	Dermatology	CU5ML	WOS:000363576200027		
J	Shizukawa, H; Hiragun, M; Hiragun, T; Sugita, Y; Hide, M				Shizukawa, Hiroko; Hiragun, Makiko; Hiragun, Takaaki; Sugita, Yasushi; Hide, Michihiro			Case of erythrokeratodermia variabilis successfully treated with oral vitamin A	JOURNAL OF DERMATOLOGY			English	Letter									[Shizukawa, Hiroko; Hiragun, Makiko; Hiragun, Takaaki; Hide, Michihiro] Hiroshima Univ, Dept Dermatol, Inst Biomed & Hlth Sci, Integrated Hlth Sci, Hiroshima 7348551, Japan; [Sugita, Yasushi] Sugita Dermatol Clin, Hiroshima, Japan	Hide, M (reprint author), Hiroshima Univ, Dept Dermatol, Inst Biomed & Hlth Sci, Integrated Hlth Sci,Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	ed1h-w1de-road@hiroshima-u.ac.jp					Yuksek J, 2011, J DERMATOL, V38, P725, DOI 10.1111/j.1346-8138.2010.01058.x; FIXLER ZC, 1980, CUTIS, V25, P300; Balci DD, 2008, INDIAN J DERMATOL VE, V74, P649; Richard G, 1998, NAT GENET, V20, P366, DOI 10.1038/3840; WULF K, 1960, Dermatol Wochenschr, V142, P1012	5	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0385-2407	1346-8138		J DERMATOL	J. Dermatol.	NOV	2015	42	11					1124	1125		10.1111/1346-8138.13056		2	Dermatology	Dermatology	CU5ML	WOS:000363576200029		
J	Takahashi, H; Sato, K; Takagi, A; Ikawa, S; Ishii, N; Hashimoto, T; Ishida-Yamamoto, A; Iizuka, H				Takahashi, Hidetoshi; Sato, Katsuhiko; Takagi, Akiyoshi; Ikawa, Satomi; Ishii, Norito; Hashimoto, Takashi; Ishida-Yamamoto, Akemi; Iizuka, Hajime			Subepidermal autoimmune blistering lesion in a case of psoriasis successfully treated with cyclosporin	JOURNAL OF DERMATOLOGY			English	Letter									[Takahashi, Hidetoshi; Sato, Katsuhiko; Takagi, Akiyoshi] Takagi Dermatol Clin, Obihiro, Hokkaido 0800013, Japan; [Ikawa, Satomi; Ishida-Yamamoto, Akemi] Asahikawa Med Univ, Dept Dermatol, Asahikawa, Hokkaido, Japan; [Ishii, Norito; Hashimoto, Takashi] Kurume Univ, Sch Med, Dept Dermatol, Kurume, Fukuoka 830, Japan; [Ishii, Norito; Hashimoto, Takashi] Kurume Univ, Inst Cutaneous Cell Biol, Kurume, Fukuoka 830, Japan; [Iizuka, Hajime] Res Inst Psoriasis, Hosui Gen Med Clin, Sapporo, Hokkaido, Japan	Takahashi, H (reprint author), Takagi Dermatol Clin, Nishi 3,Nishi 4-16, Obihiro, Hokkaido 0800013, Japan.	ht@asahikawa-med.ac.jp					Dainichi T, 2009, P NATL ACAD SCI USA, V106, P2800, DOI 10.1073/pnas.0809230106; LAPIDOTH M, 1994, J AM ACAD DERMATOL, V30, P752; Dainichi T, 2010, J DERMATOL, V37, P231, DOI 10.1111/j.1346-8138.2009.00793.x; Zillikens D, 1996, J INVEST DERMATOL, V106, P465, DOI 10.1111/1523-1747.ep12343631	4	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0385-2407	1346-8138		J DERMATOL	J. Dermatol.	NOV	2015	42	11					1125	1126		10.1111/1346-8138.13069		2	Dermatology	Dermatology	CU5ML	WOS:000363576200030		
J	Murata, S; Sumikawa, Y; Takahashi, H; Ota, M; Kusatake, K; Niihara, H; Kaneko, S; Koga, H; Hashimoto, T; Morita, E				Murata, Susumu; Sumikawa, Yasuyuki; Takahashi, Hitoshi; Ota, Masataka; Kusatake, Kenji; Niihara, Hiroyuki; Kaneko, Sakae; Koga, Hiroshi; Hashimoto, Takashi; Morita, Eishin			Case of mucous membrane pemphigoid with immunoglobulin G antibodies to the beta 3 subunit of laminin-332 showing clinically Stevens-Johnson syndrome-like generalized blistering mucocutaneous lesions	JOURNAL OF DERMATOLOGY			English	Letter							INDUCE SUBEPIDERMAL BLISTERS; AUTOANTIBODIES		[Murata, Susumu; Sumikawa, Yasuyuki; Takahashi, Hitoshi; Ota, Masataka; Kusatake, Kenji; Niihara, Hiroyuki; Kaneko, Sakae; Morita, Eishin] Shimane Univ, Dept Dermatol, Fac Med, Izumo, Shimane 6938501, Japan; [Koga, Hiroshi; Hashimoto, Takashi] Kurume Univ, Dept Dermatol, Sch Med, Inst Cutaneous Cell Biol, Fukuoka, Japan	Murata, S (reprint author), Shimane Univ, Dept Dermatol, Fac Med, 89-1 Enya Cho, Izumo, Shimane 6938501, Japan.	smurata@med.shimane-u.ac.jp					Lazarova Z, 2000, CLIN IMMUNOL, V95, P26, DOI 10.1006/clim.2000.4845; Hayashi I, 2012, BRIT J DERMATOL, V166, P1116, DOI 10.1111/j.1365-2133.2011.10776.x; Mulyowa GK, 2006, J AM ACAD DERMATOL, V54, pS43, DOI 10.1016/j.jaad.2005.03.054; Lazarova Z, 2000, J INVEST DERMATOL, V114, P178, DOI 10.1046/j.1523-1747.2000.00829.x; Inaoki M, 2006, J DERMATOL, V33, P727, DOI 10.1111/j.1346-8138.2006.00170.x	5	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0385-2407	1346-8138		J DERMATOL	J. Dermatol.	NOV	2015	42	11					1126	1128		10.1111/1346-8138.13062		3	Dermatology	Dermatology	CU5ML	WOS:000363576200031		
J	Ivars, M; Hashimoto, T; Ishii, N; Bernad, I; Lecumberri, R; Espana, A				Ivars, Marta; Hashimoto, Takashi; Ishii, Norito; Bernad, Isabel; Lecumberri, Ramon; Espana, Agustin			Atypical bullous pemphigoid with extensive cutaneous and mucosal erosions associated with chronic lymphocytic leukemia	JOURNAL OF DERMATOLOGY			English	Letter							CELLS; TH17		[Ivars, Marta; Bernad, Isabel; Espana, Agustin] Univ Navarra, Dept Dermatol, Univ Navarra Clin, Sch Med, Navarra 31080, Spain; [Hashimoto, Takashi; Ishii, Norito] Kurume Univ, Sch Med, Dept Dermatol, Kurume, Fukuoka 830, Japan; [Hashimoto, Takashi; Ishii, Norito] Kurume Univ, Inst Cutaneous Cell Biol, Kurume, Fukuoka 830, Japan; [Lecumberri, Ramon] Univ Navarra, Dept Hematol, Univ Navarra Clin, Sch Med, Navarra, Spain	Ivars, M (reprint author), Univ Navarra, Dept Dermatol, Univ Navarra Clin, Sch Med, POB 4209, Navarra 31080, Spain.	mivars@unav.es					Arakawa M, 2011, EXP DERMATOL, V20, P1022, DOI 10.1111/j.1600-0625.2011.01378.x; Misery L, 1999, BRIT J DERMATOL, V141, P155; Ameen M, 2000, BRIT J DERMATOL, V143, P421, DOI 10.1046/j.1365-2133.2000.03674.x; Jain P, 2012, HAEMATOL-HEMATOL J, V97, P599, DOI 10.3324/haematol.2011.047316; Otten JV, 2014, CURR MOL MED, V14, P69	5	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0385-2407	1346-8138		J DERMATOL	J. Dermatol.	NOV	2015	42	11					1128	1129		10.1111/1346-8138.13067		2	Dermatology	Dermatology	CU5ML	WOS:000363576200032		
J	Uchiyama, A; Motegi, S; Ishikawa, O				Uchiyama, Akihiko; Motegi, Sei-ichiro; Ishikawa, Osamu			Lymphomatoid papulosis associated with follicular B-cell lymphoma in lymph nodes	JOURNAL OF DERMATOLOGY			English	Letter									[Uchiyama, Akihiko; Motegi, Sei-ichiro; Ishikawa, Osamu] Gunma Univ, Dept Dermatol, Grad Sch Med, Gunma 3718511, Japan	Motegi, S (reprint author), Gunma Univ, Dept Dermatol, Grad Sch Med, 3-39-22 Showa Machi, Gunma 3718511, Japan.	smotegi@gunma-u.ac.jp					Plaza JA, 2013, J CUTAN PATHOL, V40, P236, DOI 10.1111/cup.12047; McCurdy O, 2014, AUSTRALAS J DERMATOL, V55, pE1, DOI 10.1111/ajd.12002; Saggini A, 2010, AM J SURG PATHOL, V34, P1168, DOI 10.1097/PAS.0b013e3181e75356; Swerdlow SH, 2008, WHO CLASSIFICATION T	4	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0385-2407	1346-8138		J DERMATOL	J. Dermatol.	NOV	2015	42	11					1129	1130		10.1111/1346-8138.13074		2	Dermatology	Dermatology	CU5ML	WOS:000363576200033		
J	Kimura, Y; Sugawara, K; Tsuruta, D				Kimura, Yuka; Sugawara, Koji; Tsuruta, Daisuke			Case of alopecia universalis accompanied by minimal change nephrotic syndrome	JOURNAL OF DERMATOLOGY			English	Letter							IMMUNOGLOBULIN-E; CHANGE DISEASE		[Kimura, Yuka; Sugawara, Koji; Tsuruta, Daisuke] Osaka City Univ, Dept Dermatol, Grad Sch Med, Osaka 558, Japan	Sugawara, K (reprint author), Osaka City Univ, Grad Sch Med, Dept Dermatol, Abeno Ku, 1-4-3 Asahimachi, Osaka 5458585, Japan.	sugawara@med.osaka-cu.ac.jp					Shao YN, 2009, AM J MED SCI, V338, P264, DOI 10.1097/MAJ.0b013e3181b471e4; Toyabe S, 2005, CLIN EXP IMMUNOL, V142, P162, DOI 10.1111/j.1365-2249.2005.02890.x; Gilhar A, 2012, NEW ENGL J MED, V366, P1515, DOI 10.1056/NEJMra1103442; Zhou Y, 2010, NEPHROLOGY, V15, P592, DOI 10.1111/j.1440-1797.2010.01211.x; Takei Takashi, 2007, Clin Exp Nephrol, V11, P214, DOI 10.1007/s10157-007-0484-5	5	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0385-2407	1346-8138		J DERMATOL	J. Dermatol.	NOV	2015	42	11					1131	1132		10.1111/1346-8138.13046		2	Dermatology	Dermatology	CU5ML	WOS:000363576200034		
J	Fujii, M; Takahashi, I; Honma, M; Ishida-Yamamoto, A				Fujii, Mizue; Takahashi, Ichiro; Honma, Masaru; Ishida-Yamamoto, Akemi			Toxic erythema with eccrine squamous syringometaplasia induced by nanoparticle albumin-bound paclitaxel	JOURNAL OF DERMATOLOGY			English	Letter							CANCER		[Fujii, Mizue; Takahashi, Ichiro] Kitami Red Cross Hosp, Dept Dermatol, Kitami, Hokkaido 0908666, Japan; [Fujii, Mizue; Honma, Masaru; Ishida-Yamamoto, Akemi] Asahikawa Med Univ, Dept Dermatol, Asahikawa, Hokkaido, Japan	Fujii, M (reprint author), Kitami Red Cross Hosp, Dept Dermatol, North 2 East 6, Kitami, Hokkaido 0908666, Japan.	ma0dj@asahikawa-med.ac.jp					BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Plummer RS, 2011, J AM ACAD DERMATOL, V65, P592, DOI 10.1016/j.jaad.2010.07.033; Sasaki Y, 2014, CANCER SCI, V105, P812, DOI 10.1111/cas.12419; Panno ML, 2006, FEBS LETT, V580, P2371, DOI 10.1016/j.febslet.2006.03.055; Van de Voorde K, 2006, J AM ACAD DERMATOL, V55, pS58, DOI 10.1016/j.jaad.2005.12.011	5	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0385-2407	1346-8138		J DERMATOL	J. Dermatol.	NOV	2015	42	11					1134	1135		10.1111/1346-8138.13076		2	Dermatology	Dermatology	CU5ML	WOS:000363576200036		
J	Kaku, K; Eid, MA				Kaku, Kohei; Eid, Mohamed A.			Safety, efficacy, and early clinical experience of insulin degludec in Japanese people with diabetes mellitus: A first-year report from Japan	JOURNAL OF DIABETES INVESTIGATION			English	Review						Insulin; Degludec; Diabetes mellitus	TO-TARGET TRIAL; BASAL-BOLUS TREATMENT; RANDOMIZED CONTROLLED-TRIAL; NON-INFERIORITY TRIAL; GLYCEMIC CONTROL; OPEN-LABEL; NOCTURNAL HYPOGLYCEMIA; NAIVE PATIENTS; TYPE-2; GLARGINE	In Japan, insulin therapy is recommended for the treatment of type2 diabetes mellitus either directly after diet, exercise and lifestyle improvements, or if the target for glycemic control is not achieved with other hypoglycemic agents. Insulin degludec is an ultra-long-acting insulin that was launched in Japan in 2013, having shown good efficacy and safety in its clinical development program. It has now been used in clinical practice for more than 1year. During this time, clinicians and researchers have identified possible factors that could influence the decision as to which patients might be appropriate for insulin degludec treatment. In the present review, we describe how to initiate and manage insulin degludec therapy in routine clinical practice. We also discuss several important topics related to the use of insulin degludec, including patient selection, dosing, handling of bolus insulin, hypoglycemia and other potential safety considerations.	[Kaku, Kohei] Kawasaki Med Univ, Dept Internal Med, Okayama, Japan; [Eid, Mohamed A.] Novo Nordisk Pharma Ltd, Med & Sci Affairs, Tokyo, Japan	Kaku, K (reprint author), Kawasaki Med Univ, Dept Internal Med, Okayama, Japan.	kka@med.kawasaki-m.ac.jp			Novo Nordisk	Editorial and writing assistance was provided by Six Degree Medical Consulting, a division of Six Degrees Worldwide Inc., and by Drs Nicholas D Smith and Keyra Martinez Dunn with funding support from Novo Nordisk. The authors take full responsibility for the intellectual content of this manuscript.	Ratner RE, 2013, DIABETES OBES METAB, V15, P175, DOI 10.1111/dom.12032; Rodbard HW, 2013, DIABETIC MED, V30, P1298, DOI 10.1111/dme.12303; Kuroe A, 2003, DIABETES RES CLIN PR, V59, P71, DOI 10.1016/S0168-8227(02)00177-8; Bretzel RG, 2008, LANCET, V371, P1073, DOI 10.1016/S0140-6736(08)60485-7; Zinman B, 2012, DIABETES CARE, V35, P2464, DOI 10.2337/dc12-1205; Philis-Tsimikas A, 2013, DIABETES OBES METAB, V15, P760, DOI 10.1111/dom.12115; Koehler G, 2014, DIABETOLOGIA, V57, P40, DOI 10.1007/s00125-013-3056-0; Iwamoto Y, 2013, J DIABETES INVEST, V4, P62, DOI 10.1111/j.2040-1124.2012.00240.x; Heise T, 2012, DIABETES OBES METAB, V14, P944, DOI 10.1111/j.1463-1326.2012.01638.x; Garber AJ, 2012, LANCET, V379, P1498, DOI 10.1016/S0140-6736(12)60205-0; Heller S, 2012, LANCET, V379, P1489, DOI 10.1016/S0140-6736(12)60204-9; Turner RC, 1999, JAMA-J AM MED ASSOC, V281, P2005, DOI 10.1001/jama.281.21.2005; Wright A, 2002, DIABETES CARE, V25, P330, DOI 10.2337/diacare.25.2.330; DeVries JH, 2007, DIABETES-METAB RES, V23, P441, DOI 10.1002/dmrr.762; Meneghini L, 2013, DIABETES CARE, V36, P858, DOI 10.2337/dc12-1668; Mathieu C, 2013, J CLIN ENDOCR METAB, V98, P1154, DOI 10.1210/jc.2012-3249; Mathieu C, 2014, DIABETES OBES METAB, V16, P636, DOI 10.1111/dom.12262; Onishi Y, 2013, J DIABETES INVEST, V4, P605, DOI 10.1111/jdi.12102; Evans M, 2011, DIABETES OBES METAB, V13, P677, DOI 10.1111/j.1463-1326.2011.01395.x; Peyrot M, 2012, DIABETIC MED, V29, P682, DOI 10.1111/j.1464-5491.2012.03605.x; Sorli C, 2013, DRUG AGING, V30, P1009, DOI 10.1007/s40266-013-0128-2; Wright A, 1998, ANN INTERN MED, V128, P165; Philis-Tsimikas A, 2013, ADV THER, V30, P607, DOI 10.1007/s12325-013-0036-1; Biester T, 2014, PEDIATR DIABETES, V15, P27, DOI 10.1111/pedi.12116; Bode BW, 2013, DIABETIC MED, V30, P1293, DOI 10.1111/dme.12243; Davies MJ, 2014, DIABETES OBES METAB, V1, P922; Food and Drug Administration, BRIEFING DOCUMENT ND; Fujii H, 2014, J JPN DIABETES SO S1, V57, pS; Hamasaki H, 2013, J ENDOCRINOL METAB, V3, P138; Harris SB, 2013, CAN J DIABETES S4, V37, pS54; Heise T, 2012, DIABETES S1, V61, pA259; Heller SR, 2013, DIABETES S1, V62; Hollander P, 2015, DIABETES OBES METAB, V17, P202, DOI 10.1111/dom.12411; Japan Diabetes Society, TREATM GUID DIAB 201; Kiss I, 2014, CLIN PHARMACOKINET, V53, P175, DOI 10.1007/s40262-013-0113-2; Kusunoki Yoshiki, 2013, Diabetes Ther, V4, P461, DOI 10.1007/s13300-013-0048-5; Lantus&REG;, 2013, HIGHL PRESCR INF, P3; Lantus&REG;, 2014, SUMMARY PRODUCT CHAR; Levemir&REG;, 2012, SUMMARY PRODUCT CHAR; Ogawa S, 2013, J DIABETES MELLITUS, V3, P244; Simon Airin C R, 2011, Diabetes Technol Ther, V13 Suppl 1, pS103, DOI 10.1089/dia.2010.0251; Kunt T, 2009, INT J CLIN PRACT, V63, P6, DOI 10.1111/j.1742-1241.2009.02176.x; Suzuki J, 2014, USEFULNESS INSULIN D, P904; Takeishi S, 2014, EVALUATION SAFETY IN; Yamada K., 2014, DIABETOLOGY INT, V5, P74	45	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2040-1116	2040-1124		J DIABETES INVEST	J. Diabetes Investig.	NOV	2015	6	6					610	619		10.1111/jdi.12348		10	Endocrinology & Metabolism	Endocrinology & Metabolism	CU7AL	WOS:000363687000003		
J	Yasuda, H				Yasuda, Hitoshi			Pharmacological interventions for painful diabetic neuropathy: Comparative analysis using network meta-analysis	JOURNAL OF DIABETES INVESTIGATION			English	Editorial Material							RECOMMENDATIONS; MANAGEMENT		Shiga Hlth Res Ctr, Yasu, Shiga, Japan	Yasuda, H (reprint author), Shiga Hlth Res Ctr, Yasu, Shiga, Japan.	hyasuda@belle.shiga-med.ac.jp					Mills EJ, 2012, JAMA-J AM MED ASSOC, V308, P1246, DOI 10.1001/2012.jama.11228; Griebeler ML, 2014, ANN INTERN MED, V161, P639, DOI 10.7326/M14-0511; Wong MC, 2007, BRIT MED J, V335, P87, DOI 10.1136/bmj.39213.565972.AE; Dworkin RH, 2007, PAIN, V132, P237, DOI 10.1016/j.pain.2007.08.033; Tesfaye S, 2011, DIABETES-METAB RES, V27, P629, DOI 10.1002/dmrr.1225; Griebeler Marcio L, 2012, Syst Rev, V1, P61, DOI 10.1186/2046-4053-1-61	6	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2040-1116	2040-1124		J DIABETES INVEST	J. Diabetes Investig.	NOV	2015	6	6					620	622		10.1111/jdi.12354		3	Endocrinology & Metabolism	Endocrinology & Metabolism	CU7AL	WOS:000363687000004		
J	Umegaki, H				Umegaki, Hiroyuki			Sarcopenia and diabetes: Hyperglycemia is a risk factor for age-associated muscle mass and functional reduction	JOURNAL OF DIABETES INVESTIGATION			English	Editorial Material							FRAILTY		Nagoya Univ, Grad Sch Med, Dept Community Healthcare & Geriatr, Nagoya, Aichi 4648601, Japan	Umegaki, H (reprint author), Nagoya Univ, Grad Sch Med, Dept Community Healthcare & Geriatr, Nagoya, Aichi 4648601, Japan.	Umegaki@med.nagoya-u.ac.jp					Fried LP, 2001, J GERONTOL A-BIOL, V56, pM146; Kim TN, 2010, DIABETES CARE, V33, P1497, DOI 10.2337/dc09-2310; Cruz-Jentoft AJ, 2010, AGE AGEING, V39, P412, DOI 10.1093/ageing/afq034; Kalyani RR, 2015, DIABETES CARE, V38, P82, DOI 10.2337/dc14-1166; Morley JE, 2014, J AM MED DIR ASSOC, V15, P853, DOI 10.1016/j.jamda.2014.10.001	5	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2040-1116	2040-1124		J DIABETES INVEST	J. Diabetes Investig.	NOV	2015	6	6					623	624		10.1111/jdi.12365		2	Endocrinology & Metabolism	Endocrinology & Metabolism	CU7AL	WOS:000363687000005		
J	Iimura, Y; Matsuura, M; Yao, ZM; Ito, S; Fujiwara, M; Yoshitsugu, M; Miyauchi, A; Hiyoshi, T				Iimura, Yuko; Matsuura, Masaaki; Yao, Zemin; Ito, Satoru; Fujiwara, Mutsunori; Yoshitsugu, Michiyasu; Miyauchi, Akito; Hiyoshi, Toru			Lack of predictive power of plasma lipids or lipoproteins for gestational diabetes mellitus in Japanese women	JOURNAL OF DIABETES INVESTIGATION			English	Article						ApolipoproteinC-III; Gestational diabetes mellitus; Glucose challenge test	BETA-CELL FUNCTION; APOLIPOPROTEIN-E; PREGNANCY; GLUCOSE; HYPERGLYCEMIA; ASSOCIATION; CAPACITY; OBESITY; TIME	Aims/IntroductionTo determine the diagnostic potential of plasma lipids and apolipoproteins in gestational diabetes mellitus (GDM), we carried out a retrospective cohort study of 1,161 Japanese women at 20-28weeks of gestation who underwent a glucose challenge test (GCT). Materials and MethodsA total of 1,161 Japanese women at 20-28weeks of gestation underwent a GCT. Participants with a positive test (GCT[+]) underwent a subsequent oral glucose tolerance test. Clinical and biochemical parameters were determined and quantification of apolipoproteins (Apo), including ApoB, ApoB48, ApoA-I and ApoC-III, was carried out. ResultsThe prevalence of GCT(+; with a 130mg/dL glucose cut-off) and GDM was 20% and 4%, respectively. There was a trend for increased triglycerides and ApoC-III in GDM(+) participants. However, the difference in plasma triglycerides, ApoC-III or ApoB48 did not reach statistical significance between GDM(+) and GDM(-) women. Values of 1-h glucose (P<0.001) and fasting glucose (P=0.002) were significant risk factors for GDM. ConclusionsPrediction of GDM using only the ApoC-III value is not easy, although triglycerides and ApoC-III were higher in the GDM(+) group. The present findings show no significant difference in plasma lipid levels between women diagnosed with GDM and those with normal glucose tolerance.	[Iimura, Yuko; Yoshitsugu, Michiyasu; Hiyoshi, Toru] Japanese Red Cross Med Ctr, Dept Diabetes & Endocrinol, Tokyo, Japan; [Fujiwara, Mutsunori] Japanese Red Cross Med Ctr, Dept Clin Pathol, Tokyo, Japan; [Miyauchi, Akito] Japanese Red Cross Med Ctr, Dept Obstet & Gynecol, Tokyo, Japan; [Matsuura, Masaaki] JFCR, Inst Canc, Dept Canc Genom, Tokyo, Japan; [Ito, Satoru] Fujirebio Inc, Tokyo, Japan; [Yao, Zemin] Univ Ottawa, Ottawa Inst Syst Biol, Dept Biochem Microbiol & Immunol, Ottawa, ON, Canada	Iimura, Y (reprint author), Japanese Red Cross Med Ctr, Dept Diabetes & Endocrinol, Tokyo, Japan.	makiyu@juntendo.ac.jp			Fujirebio, Co., Inc.	Dr Ito is a consultant for Fujirebio, Co., Inc. and receives a consultancy fee from Fujirebio, Co., Inc. The other authors declare no conflict of interest.	Akaike H, 1973, 2 INT S INF THEOR AK; American Diabetes Association, 2008, DIABETES CARE S1, V31, pS55, DOI DOI 10.2337/DC08-S055; Nakatani K, 2011, ATHEROSCLEROSIS, V218, P226, DOI 10.1016/j.atherosclerosis.2011.05.009; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; SERMER M, 1994, AM J OBSTET GYNECOL, V171, P607; Metzger BE, 2010, DIABETES CARE, V33, P676, DOI 10.2337/dc09-1848; POTTER JM, 1979, AM J OBSTET GYNECOL, V133, P165; Su JB, 2013, ENDOCRINE, V43, P370, DOI 10.1007/s12020-012-9753-5; Sakai N, 2003, J LIPID RES, V44, P1256, DOI 10.1194/jlr.M300090-JLR200; Jarvie E, 2010, CLIN SCI, V119, P123, DOI 10.1042/CS20090640; Sakurabayashi I, 2001, CLIN CHIM ACTA, V312, P87, DOI 10.1016/S0009-8981(01)00591-5; Kim SM, 2012, REPROD SCI, V19, P202, DOI 10.1177/1933719111417889; Sacks FM, 2000, CIRCULATION, V102, P1886; Clausen TD, 2008, DIABETES CARE, V31, P340, DOI 10.2337/dc07-1596; Chalas J, 2002, HYPERTENS PREGNANCY, V21, P199, DOI 10.1081/PRG-120015846; Kim C, 2002, DIABETES CARE, V25, P1862, DOI 10.2337/diacare.25.10.1862; CLEMENT K, 1995, NEW ENGL J MED, V333, P352, DOI 10.1056/NEJM199508103330605; McElduff A, 2002, MED J AUSTRALIA, V176, P136; Fukushima M, 2004, DIABETES RES CLIN PR, V66, pS37, DOI 10.1016/j.diabres.2003.11.024; Ihaka R, 1996, J COMPUTATIONAL GRAP, V5, P299, DOI DOI 10.2307/1390807; vansLeeuwen M, 2012, BJOG, V119, P393; Wareham N J, 1995, Diabet Med, V12, P931	22	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2040-1116	2040-1124		J DIABETES INVEST	J. Diabetes Investig.	NOV	2015	6	6					640	646		10.1111/jdi.12363		7	Endocrinology & Metabolism	Endocrinology & Metabolism	CU7AL	WOS:000363687000008		
J	Kuwahara, K; Honda, T; Nakagawa, T; Yamamoto, S; Nanri, A; Kurotani, K; Hayashi, T; Mizoue, T				Kuwahara, Keisuke; Honda, Toru; Nakagawa, Tohru; Yamamoto, Shuichiro; Nanri, Akiko; Kurotani, Kayo; Hayashi, Takeshi; Mizoue, Tetsuya			Strength training and risk of type 2 diabetes in a Japanese working population: A cohort study	JOURNAL OF DIABETES INVESTIGATION			English	Article						Cohort studies; Prevention; Resistance training	INSULIN-RESISTANCE; PHYSICAL-ACTIVITY; NETWORK METAANALYSIS; GLYCEMIC CONTROL; SKELETAL-MUSCLE; SENSITIVITY; MEN; MECHANISMS; PREVENTION; MELLITUS	Aims/IntroductionMuscle strength training has been suggested to improve glucose metabolism; however, epidemiological evidence regarding strength training's effects on diabetes risk is scarce. We prospectively examined the association between strength training and the risk of type2 diabetes in Japanese men and women. Materials and MethodsThe sample included health checkups on 26,630 Japanese male and female workers aged 30-64years without diabetes at baseline. Weekly time spent on strength training was elicited using a self-reported questionnaire. Type2 diabetes was diagnosed based on hemoglobin A1c, fasting glucose, random plasma glucose and self-report in an annual health checkup. Hazard ratio (HR) and its 95% confidence interval (CI) for incident diabetes was estimated using a Cox proportional hazards model. ResultsDuring a mean follow up of 5.2years with 139,748person-years, 1,770 individuals developed diabetes. Age- and sex-adjusted HR for diabetes was 0.58 (95% CI 0.42-0.79) in those who engaged in strength training compared with those who engaged in no strength training. After further adjusting for potential confounders, the corresponding HR was 0.66 (95% CI 0.48-0.90). Additional adjustment for body mass index did not materially change the result; the HR was 0.70 (95% CI 0.51-0.96). The association was more pronounced in individuals aged 50years or older than those aged <50years, although the difference in the association by age was not significant. ConclusionsThese results suggest that engagement in strength training could help to reduce the risk of type 2 diabetes in a Japanese working population.	[Kuwahara, Keisuke; Nanri, Akiko; Kurotani, Kayo; Mizoue, Tetsuya] Teikyo Univ, Natl Ctr Global Hlth & Med, Dept Epidemiol & Prevent, Tokyo 173, Japan; [Kuwahara, Keisuke] Teikyo Univ, Grad Sch Publ Hlth, Tokyo 173, Japan; [Honda, Toru; Nakagawa, Tohru; Yamamoto, Shuichiro; Hayashi, Takeshi] Hitachi Ltd, Hitachi Hlth Care Ctr, Ibaraki, Japan	Kuwahara, K (reprint author), Teikyo Univ, Natl Ctr Global Hlth & Med, Dept Epidemiol & Prevent, Tokyo 173, Japan.	kkuwahara@med.teikyo-u.ac.jp			Industrial Health Foundation; Japan Society for the Promotion of Science [25871166]	The present study was supported by a grant from the Industrial Health Foundation and a Grant-in-Aid for Young Scientists (B; 25871166; to Dr Kuwahara) from the Japan Society for the Promotion of Science. The funding bodies played no role in the study design, data collection, data analysis, data interpretation, writing of the manuscript, decision to publish or content of this paper. The authors thank Toshiteru Okubo (Radiation Effects Research Foundation) for scientific advice on the J-ECOH Study; Maki Konishi (National Center for Global Health and Medicine) for data management; and Rika Osawa (National Center for Global Health and Medicine) for administrative support. T Hayashi, T Nakagawa, S Yamamoto and T Honda are occupational physicians in the participating company.	American Diabetes Association, 2010, DIABETES CARE S1, V33, pS62, DOI DOI 10.2337/DC10-S062; Silva AM, 2010, AM J HUM BIOL, V22, P76, DOI 10.1002/ajhb.20956; Thorp AA, 2011, AM J PREV MED, V41, P207, DOI 10.1016/j.amepre.2011.05.004; Braith RW, 2006, CIRCULATION, V113, P2642, DOI 10.1161/CIRCULATIONAHA.105.584060; Umpierre D, 2013, DIABETOLOGIA, V56, P242, DOI 10.1007/s00125-012-2774-z; Qatanani M, 2007, GENE DEV, V21, P1443, DOI 10.1101/gad.1550907; Kahn SE, 2006, NATURE, V444, P840, DOI 10.1038/nature05482; Burr JF, 2010, PHYSICIAN SPORTSMED, V38, P72, DOI 10.3810/psm.2010.04.1764; Croymans DM, 2013, J APPL PHYSIOL, V115, P1245, DOI 10.1152/japplphysiol.00485.2013; Schwingshackl L, 2014, DIABETOLOGIA, V57, P1789, DOI 10.1007/s00125-014-3303-z; Wozniak SE, 2009, DIGEST DIS SCI, V54, P1847, DOI 10.1007/s10620-008-0585-3; Martel GF, 2006, EXP PHYSIOL, V91, P457, DOI 10.1113/expphysiol.2005.032771; Elliott WJ, 2007, LANCET, V369, P201, DOI 10.1016/S0140-6736(07)60108-1; Ma RCW, 2013, ANN NY ACAD SCI, V1281, P64, DOI 10.1111/nyas.12098; Holten MK, 2004, DIABETES, V53, P294, DOI 10.2337/diabetes.53.2.294; Baker WL, 2010, DIABETES RES CLIN PR, V87, P98, DOI 10.1016/j.diabres.2009.10.008; Srikanthan P, 2011, J CLIN ENDOCR METAB, V96, P2898, DOI 10.1210/jc.2011-0435; Jeon CY, 2007, DIABETES CARE, V30, P744, DOI 10.2337/dc06-1842; Strasser B, 2013, BIOMED RES INT, DOI 10.1155/2013/805217; Sattar N, 2010, LANCET, V375, P735, DOI 10.1016/S0140-6736(09)61965-6; Cheng YJ, 2007, DIABETES CARE, V30, P2264, DOI 10.2337/dc07-0372; Grontved A, 2012, ARCH INTERN MED, V172, P1306, DOI 10.1001/archinternmed.2012.3138; Takagi H, 2014, J AM SOC HYPERTENS, V8, P578, DOI 10.1016/j.jash.2014.05.006; Ainsworth BE, 2011, MED SCI SPORT EXER, V43, P1575, DOI 10.1249/MSS.0b013e31821ece12; WANG J, 1994, AM J CLIN NUTR, V60, P23; Williams PT, 2013, ARTERIOSCL THROM VAS, V33, P1085, DOI 10.1161/ATVBAHA.112.300878; Peters SAE, 2014, LANCET, V383, P1973, DOI 10.1016/S0140-6736(14)60040-4; Poehlman ET, 2000, J CLIN ENDOCR METAB, V85, P2463, DOI 10.1210/jc.85.7.2463; Walts CT, 2008, MED SCI SPORT EXER, V40, P669, DOI 10.1249/MSS.0b013e318161aa82; Colberg Sheri R, 2010, Diabetes Care, V33, pe147, DOI 10.2337/dc10-9990; Grontved A, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001587; Guariguata L, 2014, DIABETES RES CLIN PR, V103, P137, DOI 10.1016/j.diabres.2013.11.002; Howley ET, 2001, MED SCI SPORT EXER, V33, pS364, DOI 10.1097/00005768-200106001-00005; Nathan DM, 2009, DIABETES CARE, V32, P1327, DOI 10.2337/dc09-9033; Kashiwagi A, 2012, DIABETOL INT, V3, P8, DOI DOI 10.1007/S13340-012-0069-8; Mendis S, 2011, GLOBAL ATLAS ON CARD; Nakamura Y, 2008, INT J SPORTS HLTH SC, V6, P66, DOI 10.5432/ijshs.6.66; Strasser B, 2010, SPORTS MED, V40, P397, DOI 10.2165/11531380-000000000-00000; The Emerging Risk Factors Collaboration, 2010, IABETES MELLITUS FAS, V375, P2215	39	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2040-1116	2040-1124		J DIABETES INVEST	J. Diabetes Investig.	NOV	2015	6	6					655	661		10.1111/jdi.12347		7	Endocrinology & Metabolism	Endocrinology & Metabolism	CU7AL	WOS:000363687000010		
J	Ayano-Takahara, S; Ikeda, K; Fujimoto, S; Asai, K; Oguri, Y; Harashima, S; Tsuji, H; Shide, K; Inagaki, N				Ayano-Takahara, Shiho; Ikeda, Kaori; Fujimoto, Shimpei; Asai, Kanae; Oguri, Yasuo; Harashima, Shin-ichi; Tsuji, Hidemi; Shide, Kenichiro; Inagaki, Nobuya			Carbohydrate intake is associated with time spent in the euglycemic range in patients with type 1 diabetes	JOURNAL OF DIABETES INVESTIGATION			English	Article						Dietary carbohydrates; Glycemic control; Type 1 diabetes mellitus	BLOOD-GLUCOSE VARIABILITY; GLYCEMIC CONTROL; GLYCATED HEMOGLOBIN; INSULIN; SOCIETY; ADULTS; DETERMINANTS; HYPOGLYCEMIA; ACCURACY; THERAPY	Aims/IntroductionGreater glycemic variability and lack of predictability are important issues for patients with type 1 diabetes. Dietary factors are one of the contributors to this variability, but how closely diet is linked to glycemic fluctuation on a daily basis has not been investigated. We examined the association between carbohydrate intake and glycemic excursion in outpatients. Materials and MethodsA total of 33 patients with type 1 diabetes were included in the analyses (age 44.514.7years, diabetes duration 15.18.3years, 64% female, 30% using insulin pump, glycated hemoglobin 8.1 +/- 1.3%). Time spent in euglycemia (70-180mg/dL), hyperglycemia (>180mg/dL) and hypoglycemia (<70mg/dL) of consecutive 48-h periods of continuous glucose monitoring data were collected together with simultaneous records of dietary intake, insulin dose and physical activity. Correlation analyses and multiple regression analyses were used to evaluate the contribution of carbohydrate intake to time spent in the target glycemic range. ResultsIn multiple regression analyses, carbohydrate intake (=0.53, P=0.001), basal insulin dose per kg per day (=-0.31, P=0.034) and diabetes duration (=0.30, P=0.042) were independent predictors of time spent in euglycemia. Carbohydrate intake (=-0.51, P=0.001) and insulin pump use (=-0.34, P=0.024) were independent predictors of time spent in hyperglycemia. Insulin pump use (=0.52, P<0.001) and bolus insulin dose per kg per day (=0.46, P=0.001) were independent predictors of time spent in hypoglycemia. ConclusionsCarbohydrate intake is associated with time spent in euglycemia in patients with type 1 diabetes.	[Ayano-Takahara, Shiho; Ikeda, Kaori; Fujimoto, Shimpei; Oguri, Yasuo; Harashima, Shin-ichi; Inagaki, Nobuya] Kyoto Univ, Grad Sch Med, Dept Endocrinol Diabetol & Nutr, Kyoto, Japan; [Asai, Kanae; Tsuji, Hidemi; Shide, Kenichiro] Kyoto Univ Hosp, Dept Metab & Clin Nutr, Kyoto, Japan; [Fujimoto, Shimpei] Kochi Univ, Kochi Med Sch, Dept Endocrinol Metab & Nephrol, Kochi 780, Japan	Inagaki, N (reprint author), Kyoto Univ, Grad Sch Med, Dept Endocrinol Diabetol & Nutr, Kyoto, Japan.	inagaki@metab.kuhp.kyoto-u.ac.jp			Integration research for agriculture and interdisciplinary fields, Japan	The present study was supported by Integration research for agriculture and interdisciplinary fields, Japan.	American Diabetes Association, 2014, DIABETES CARE S1, V37, pS14, DOI [DOI 10.2337/DC14-S014, 10.2337/dc14-S014]; Yoshinari M, 2001, DIABETES CARE, V24, P1783, DOI 10.2337/diacare.24.10.1783; Shibasaki Chieri, 2012, Journal of the Japan Diabetes Society, V55, P6; Delahanty LM, 2009, AM J CLIN NUTR, V89, P518, DOI 10.3945/ajcn.2008.26498; Kumahara H, 2004, BRIT J NUTR, V91, P235, DOI 10.1079/BJN20031033; Brazeau AS, 2013, DIABETES RES CLIN PR, V99, P19, DOI 10.1016/j.diabres.2012.10.024; Williamson DA, 2003, J AM DIET ASSOC, V103, P1139, DOI 10.1053/jada.2003.50567; Scheen AJ, 1996, DIABETES METAB, V22, P397; Garg S, 2006, DIABETES CARE, V29, P2644, DOI 10.2337/dc06-1361; Pickup JC, 2006, DIABETES-METAB RES, V22, P232, DOI 10.1002/dmrr.614; Gentilcore D, 2006, J CLIN ENDOCR METAB, V91, P2062, DOI 10.1210/jc.2005-2644; Hashimoto T, 2012, J DIABETES INVEST, V3, P276, DOI 10.1111/j.2040-1124.2011.00171.x; Rabasa-Lhoret R, 1999, DIABETES CARE, V22, P667, DOI 10.2337/diacare.22.5.667; Wolever TMS, 1999, J AM COLL NUTR, V18, P242; Siegelaar SE, 2010, ENDOCR REV, V31, P171, DOI 10.1210/er.2009-0021; CLARKE WL, 1995, DIABETES CARE, V18, P517, DOI 10.2337/diacare.18.4.517; Maahs DM, 2012, DIABETES TECHNOL THE, V14, P658, DOI 10.1089/dia.2012.0053; Jin SM, 2014, DIABETES RES CLIN PR, V104, P266, DOI 10.1016/j.diabres.2014.02.003; Seaquist ER, 2013, DIABETES CARE, V36, P1384, DOI 10.2337/dc12-2480; Evert AB, 2014, DIABETES CARE, V37, pS120, DOI 10.2337/dc14-S120; Sartore G, 2012, ACTA DIABETOL, V49, pS153, DOI 10.1007/s00592-012-0391-4; Kuenen JC, 2011, DIABETES CARE, V34, P1843, DOI 10.2337/dc10-2217; Kawasaki E, 2014, J DIABETES INVEST, V5, P115, DOI 10.1111/jdi.12119; Rodbard D, 2009, DIABETES TECHNOL THE, V11, pS55, DOI 10.1089/dia.2008.0132; Sassa M, 2008, DIABETES RES CLIN PR, V81, P190, DOI 10.1016/j.diabres.2008.04.009; Ayano-Takahara S, 2015, DIABETES CARE, V38, pE1, DOI 10.2337/dc14-1801; Kashiwagi A, 2012, J DIABETES INVEST, V3, P39, DOI 10.1111/j.2040-1124.2012.00207.x; HAYANO J, 1991, AM J CARDIOL, V67, P199, DOI 10.1016/0002-9149(91)90445-Q; [Health Service Bureau Ministry of Health and Welfare Japan Health Promotion and Nutrition Division], 1994, REC DIET ALL JAP; [Science and Technology Agency Resources Council], 2005, STANDARD TABLES OF F; Takhashi K, 2001, JPN J NUTR DIET, V59, P221; The Japan Diabetes Society, 2013, EV BAS PRACT GUID TR	32	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2040-1116	2040-1124		J DIABETES INVEST	J. Diabetes Investig.	NOV	2015	6	6					678	686		10.1111/jdi.12360		9	Endocrinology & Metabolism	Endocrinology & Metabolism	CU7AL	WOS:000363687000013		
J	Murata, T; Tsuzaki, K; Yoshioka, F; Okada, H; Kishi, J; Yamada, K; Sakane, N				Murata, Takashi; Tsuzaki, Kokoro; Yoshioka, Fumi; Okada, Hiroshi; Kishi, Junichiro; Yamada, Kazunori; Sakane, Naoki			The relationship between the frequency of self-monitoring of blood glucose and glycemic control in patients with type1 diabetes mellitus on continuous subcutaneous insulin infusion or on multiple daily injections	JOURNAL OF DIABETES INVESTIGATION			English	Article						Continuous subcutaneous insulin infusion; Self-monitoring of blood glucose; Type1 diabetes mellitus		Aims/IntroductionWe investigated the relationship between the frequency of self-monitoring of blood glucose (SMBG) and glycemic control in type1 diabetes mellitus patients on continuous subcutaneous insulin infusion (CSII) or on multiple daily injections (MDI) using data management software. Materials and MethodsWe recruited 148 adult type1 diabetes mellitus patients (CSII n=42, MDI n=106) and downloaded their SMBG records to the MEQNET SMBG Viewer software (Arkray Inc., Kyoto, Japan). The association between the SMBG frequency and the patients' hemoglobin A1c (HbA1c) levels was analyzed using the (2)-test and linear regression analysis was carried out to clarify their relationship. ResultsThe odds ratio of achieving a target HbA1c level of <8% (63.9mmol/mol) was significantly higher in subjects with SMBG frequencies of 3.5 times/day compared with those with SMBG frequencies of <3.5 times/day in the CSII group (odds ratio 7.00, 95% confidence interval 1.72-28.54), but not in the MDI group (odds ratio 1.35, 95% CI 0.62-2.93). A significant correlation between SMBG frequency and the HbA1c level was detected in the CSII group (HbA1c [%]=-0.24xSMBG frequency [times/day]+8.60 [HbA1c {mmol/L}=-2.61xSMBG frequency {times/day}+70.5], [r=-0.384, P=0.012]), but not in the MDI group. ConclusionsA SMBG frequency of <3.5 times per day appeared to be a risk factor for poor glycemic control (HbA1c 8%) in type1 diabetes mellitus patients on CSII.	[Murata, Takashi; Kishi, Junichiro; Yamada, Kazunori] Kyoto Med Ctr, Ctr Diabet, Kyoto, Japan; [Tsuzaki, Kokoro; Yoshioka, Fumi; Okada, Hiroshi; Sakane, Naoki] Kyoto Med Ctr, Natl Hosp Org, Clin Res Inst, Div Prevent Med, Kyoto, Japan	Sakane, N (reprint author), Kyoto Med Ctr, Ctr Diabet, Kyoto, Japan.	nsakane@kyotolan.hosp.go.jp			NHO; Arkray Inc., Kyoto, Japan	The present study was supported by a Grant-in-Aid from NHO. TM received a lecture fee, and NS received a lecture fee and a research grant from Arkray Inc., Kyoto, Japan. The other authors declare no conflict of interest.	Schutt M, 2006, EXP CLIN ENDOCR DIAB, V114, P384, DOI 10.1055/s-2006-924152; Ziegler R, 2011, PEDIATR DIABETES, V12, P11, DOI 10.1111/j.1399-5448.2010.00650.x; Miller KM, 2013, DIABETES CARE, V36, P2009, DOI 10.2337/dc12-1770; Karter AJ, 2001, AM J MED, V111, P1, DOI 10.1016/S0002-9343(01)00742-2; [Anonymous], 2012, TREATM GUID DIAB 201; Minder AE, 2013, DIABETES RES CLIN PR, V101, P57, DOI 10.1016/j.diabres.2012.12.024; The Diabetes Control and Complications Trial Research Group, 1993, NEW ENGL J MED, V329, P977, DOI [10.1056/NEJM199309303291401, DOI 10.1056/NEJM199309303291401]	7	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2040-1116	2040-1124		J DIABETES INVEST	J. Diabetes Investig.	NOV	2015	6	6					687	691		10.1111/jdi.12362		5	Endocrinology & Metabolism	Endocrinology & Metabolism	CU7AL	WOS:000363687000014		
J	Chen, YH; Ning, G; Wang, CJ; Gong, Y; Patel, S; Zhang, C; Izumoto, T; Woerle, HJ; Wang, WQ				Chen, Yuhong; Ning, Guang; Wang, Changjiang; Gong, Yan; Patel, Sanjay; Zhang, Candice; Izumoto, Toshiyasu; Woerle, Hans-Juergen; Wang, Weiqing			Efficacy and safety of linagliptin monotherapy in Asian patients with inadequately controlled type2 diabetes mellitus: A multinational, 24-week, randomized, clinical trial	JOURNAL OF DIABETES INVESTIGATION			English	Article						Asians; Linagliptin; Monotherapy	ADD-ON THERAPY; JAPANESE PATIENTS; GLYCEMIC CONTROL; DOUBLE-BLIND; SULFONYLUREA; METFORMIN; PHARMACOKINETICS; PLACEBO	Aims/IntroductionAsian patients represent a large portion of the global population with type2 diabetes mellitus, but are underrepresented in trials of glucose-lowering therapies. The present randomized, phaseIII, placebo-controlled, double-blind, 24-week study evaluated the dipeptidyl peptidase-4 inhibitor, linagliptin, as monotherapy in Asian patients with inadequately controlled type2 diabetes mellitus. Materials and MethodsPatients who were treatment naive or had been treated with one oral antidiabetes drug were randomized to either linagliptin 5mg daily or a placebo after washout. The primary end-point was a change from baseline in glycated hemoglobin after 24weeks. ResultsA total of 300 Asian (87% Chinese) patients with type2 diabetes mellitus were randomized to linagliptin or placebo at a 2:1 ratio. After 24weeks of treatment, adjusted mean (standard error) glycated hemoglobin decreased by a placebo-corrected -0.500.11 (P<0.0001). In patients with baseline glycated hemoglobin 8.5%, the placebo-corrected decrease in glycated hemoglobin was -0.91 +/- 0.20% (P<0.0001). Adverse events occurred in 28.0 and 28.3% of linagliptin and placebo patients, respectively, but few were drug-related (3.0 and 2.0%, respectively). Hypoglycemia was reported by one linagliptin patient and no placebo patients. Treatment with linagliptin was weight neutral. ConclusionsIn Asian patients with inadequately controlled type2 diabetes mellitus, linagliptin 5mg as monotherapy was efficacious and well tolerated over 24weeks.	[Chen, Yuhong; Ning, Guang; Wang, Weiqing] Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Shanghai 200030, Peoples R China; [Zhang, Candice] Boehringer Ingelheim Int Trading Co Ltd, Shanghai, Peoples R China; [Wang, Changjiang] Anhui Med Univ, Affiliated Hosp 1, Hefei, Peoples R China; [Gong, Yan; Woerle, Hans-Juergen] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany; [Patel, Sanjay] Boehringer Ingelheim Ltd, Bracknell, Berks, England; [Izumoto, Toshiyasu] Nippon Boehringer Ingelheim Co Ltd, Tokyo, Japan	Chen, YH (reprint author), Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Shanghai 200030, Peoples R China.	chenyh70@126.com			Boehringer Ingelheim, Pharma GmbH Co. KG; Boehringer Ingelheim	This work was supported by Boehringer Ingelheim, Pharma GmbH & Co. KG. Medical writing assistance, supported financially by Boehringer Ingelheim, was provided by Mark Poirier of Envision Scientific Solutions during the preparation of this manuscript.	Graefe-Mody U, 2012, CLIN PHARMACOKINET, V51, P411, DOI 10.2165/11630900-000000000-00000; Graefe-Mody U, 2012, BRIT J CLIN PHARMACO, V74, P75, DOI 10.1111/j.1365-2125.2012.04173.x; Pan CY, 2012, DIABETES-METAB RES, V28, P268, DOI 10.1002/dmrr.1306; Ma RCW, 2013, ANN NY ACAD SCI, V1281, P64, DOI 10.1111/nyas.12098; Mohan V, 2009, DIABETES RES CLIN PR, V83, P106, DOI 10.1016/j.diabres.2008.10.009; Zeng ZP, 2013, CURR MED RES OPIN, V29, P921, DOI 10.1185/03007995.2013.805123; Del Prato S, 2011, DIABETES OBES METAB, V13, P258, DOI 10.1111/j.1463-1326.2010.01350.x; Taskinen MR, 2011, DIABETES OBES METAB, V13, P65, DOI 10.1111/j.1463-1326.2010.01326.x; Rosenstock J, 2013, DIABETES VASC DIS RE, V10, P289, DOI 10.1177/1479164112475102; Ramachandran A, 2004, DIABETES RES CLIN PR, V65, P189, DOI 10.1016/j.diabres.2004.03.012; Kawamori R, 2012, DIABETES OBES METAB, V14, P348, DOI 10.1111/j.1463-1326.2011.01545.x; [Anonymous], 2012, DIABETES CARE, DOI [DOI 10.2337/DC12-041.3, 10.2337/dc12-0413]; Gomis R, 2011, DIABETES OBES METAB, V13, P653, DOI 10.1111/j.1463-1326.2011.01391.x; Scirica BM, 2013, NEW ENGL J MED, V369, P1317, DOI 10.1056/NEJMoa1307684; Chan JCN, 2009, JAMA-J AM MED ASSOC, V301, P2129, DOI 10.1001/jama.2009.726; Inagaki N, 2013, DIABETES OBES METAB, V15, P833, DOI 10.1111/dom.12110; Owens DR, 2011, DIABETIC MED, V28, P1352, DOI 10.1111/j.1464-5491.2011.03387.x; Boehringer Ingelheim Ltd, 2013, TRAJ SUMM PROD CHAR; [Diabetes Atlas International Diabetes Federation. IDF], 2011, IDF DIABETES ATLAS; International Diabetes Federation, 2012, GLOB GUID TYP 2 DIAB; White W, 2013, COMMUNICATION; Zeng Z, 2012, DIABETES S1, V61	22	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2040-1116	2040-1124		J DIABETES INVEST	J. Diabetes Investig.	NOV	2015	6	6					692	698		10.1111/jdi.12346		7	Endocrinology & Metabolism	Endocrinology & Metabolism	CU7AL	WOS:000363687000015		
J	Yamada, K; Nakayama, H; Yoshinobu, S; Kawano, S; Tsuruta, M; Nohara, M; Hasuo, R; Akasu, S; Tokubuchi, I; Wada, N; Hirao, S; Iwata, S; Kaku, H; Tajiri, Y				Yamada, Kentaro; Nakayama, Hitomi; Yoshinobu, Satoko; Kawano, Seiko; Tsuruta, Munehisa; Nohara, Masayuki; Hasuo, Rika; Akasu, Shoko; Tokubuchi, Ichiro; Wada, Nobuhiko; Hirao, Saori; Iwata, Shinpei; Kaku, Hiroo; Tajiri, Yuji			Effects of a sodium glucose co-transporter2 selective inhibitor, ipragliflozin, on the diurnal profile of plasma glucose in patients with type2 diabetes: A study using continuous glucose monitoring	JOURNAL OF DIABETES INVESTIGATION			English	Article						3-Hydroxybutyrate; Continuous glucose monitoring; Sodium glucose co-transporter inhibitor	COTRANSPORTER 2 INHIBITOR; DOUBLE-BLIND; JAPANESE PATIENTS; INSULIN SENSITIVITY; GLYCEMIC CONTROL; MELLITUS; DAPAGLIFLOZIN; CANAGLIFLOZIN; MONOTHERAPY; EFFICACY	Aims/IntroductionTo assess the effects of sodium glucose co-transporter2 inhibitor therapy on the pathophysiology of type2 diabetes. Materials and MethodsWe administered ipragliflozin to 21 inpatients with type2 diabetes for 7days, and analyzed the diurnal profiles of plasma glucose and 3-hydroxybutyrate. A total of 21 age-, sex- and body mass index-matched diabetic patients served as controls. ResultsContinuous glucose monitoring showed that the 24-h glucose curve was shifted downward without hypoglycemia by the administration of ipragliflozin. The average glucose level was reduced from 18254mg/dL to 141 +/- 33mg/dL (P<0.0001). The magnitude of the reduction was highly correlated with the baseline average glucose level. Homeostasis model assessment of insulin resistance was decreased, and homeostasis model assessment of -cell function was increased during the treatment. Urinary glucose excretion was correlated with the average glucose level both on day0 and on day7, although the regression line was steeper and shifted leftward on day7. The ipragliflozin-treated patients lost more weight than the control patients (1.4 +/- 0.5 vs 0.5 +/- 0.6kg, P<0.0001). Plasma levels of 3-hydroxybutyrate were significantly increased with peaks before breakfast and before dinner. Patient age and bodyweight loss were negatively and positively correlated with the peak levels of 3-hydroxybutyrate on day7, respectively. ConclusionsThe ipragliflozin treatment improved the 24-h glucose curve without causing hypoglycemia. The close correlation between the magnitude of glucose reduction and the baseline plasma glucose concentration suggests that the risk of hypoglycemia is likely low. It might be prudent to monitor ketone body levels in younger patients and in patients with rapid weight loss.	[Yamada, Kentaro; Nakayama, Hitomi; Yoshinobu, Satoko; Kawano, Seiko; Tsuruta, Munehisa; Nohara, Masayuki; Hasuo, Rika; Akasu, Shoko; Tokubuchi, Ichiro; Wada, Nobuhiko; Hirao, Saori; Iwata, Shinpei; Kaku, Hiroo; Tajiri, Yuji] Kurume Univ, Sch Med, Dept Med, Div Endocrinol & Metab, Kurume, Fukuoka 830, Japan	Yamada, K (reprint author), Kurume Univ, Sch Med, Dept Med, Div Endocrinol & Metab, Kurume, Fukuoka 830, Japan.	yamada@med.kurume-u.ac.jp			Astellas Pharma	KY received research funds from Astellas Pharma.	American Diabetes Association, 2010, DIABETES CARE S1, V33, pS11, DOI DOI 10.2337/DC10-S011; Inagaki N, 2013, DIABETES OBES METAB, V15, P1136, DOI 10.1111/dom.12149; MOGENSEN CE, 1971, SCAND J CLIN LAB INV, V28, P101, DOI 10.3109/00365517109090668; Seino Y, 2010, J DIABETES INVEST, V1, P212, DOI 10.1111/j.2040-1124.2010.00074.x; Rosenstock J, 2012, DIABETES CARE, V35, P1232, DOI 10.2337/dc11-1926; Stenlof K, 2013, DIABETES OBES METAB, V15, P372, DOI 10.1111/dom.12054; Bakris GL, 2009, KIDNEY INT, V75, P1272, DOI 10.1038/ki.2009.87; FARBER SJ, 1951, J CLIN INVEST, V30, P125, DOI 10.1172/JCI102424; DeFronzo RA, 2012, DIABETES OBES METAB, V14, P5, DOI 10.1111/j.1463-1326.2011.01511.x; Rave K, 2006, NEPHROL DIAL TRANSPL, V21, P2166, DOI 10.1093/ndt/gfl175; Polidori D, 2014, DIABETOLOGIA, V57, P891, DOI 10.1007/s00125-014-3196-x; Mather A, 2011, KIDNEY INT, V79, pS1, DOI 10.1038/ki.2010.509; Mudaliar S, 2014, DIABETES TECHNOL THE, V16, P137, DOI 10.1089/dia.2013.0167; Nakayama H, 2015, ENDOCR J, V62, P235, DOI 10.1507/endocrj.EJ14-0431; Merovci A, 2014, J CLIN INVEST, V124, P509, DOI 10.1172/JCI70704; QUAMME GA, 1987, AM J PHYSIOL, V253, pF151; Rahmoune H, 2005, DIABETES, V54, P3427, DOI 10.2337/diabetes.54.12.3427; Ferrannini E, 2010, DIABETES CARE, V33, P2217, DOI 10.2337/dc10-0612; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; Ji LN, 2014, CLIN THER, V36, P84, DOI 10.1016/j.clinthera.2013.11.002; DeFronzo RA, 2013, DIABETES CARE, V36, P3169, DOI 10.2337/dc13-0387; Kadokura T, 2014, DIABETES RES CLIN PR, V106, P50, DOI 10.1016/j.diabres.2014.07.020; Kaku K, 2014, CARDIOVASC DIABETOL, V13, DOI 10.1186/1475-2840-13-65; Kashiwagi A, 2014, J DIABETES INVEST, V5, P382, DOI 10.1111/jdi.12156; List J. F., 2011, KIDNEY INT S, V120, P20; Seino Y, 2014, CURR MED RES OPIN, V30, P1231, DOI 10.1185/03007995.2014.909390; Tabatabai Niloofar M, 2009, Diabetes Res Clin Pract, V83, pe27, DOI 10.1016/j.diabres.2008.11.003; TURNER RJ, 1982, AM J PHYSIOL, V242, pF406	28	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2040-1116	2040-1124		J DIABETES INVEST	J. Diabetes Investig.	NOV	2015	6	6					699	707		10.1111/jdi.12370		9	Endocrinology & Metabolism	Endocrinology & Metabolism	CU7AL	WOS:000363687000016		
J	Ishikawa, K; Fukui, T; Nagai, T; Kuroda, T; Hara, N; Yamamoto, T; Inagaki, K; Hirano, T				Ishikawa, Koji; Fukui, Tomoyasu; Nagai, Takashi; Kuroda, Takuma; Hara, Noriko; Yamamoto, Takeshi; Inagaki, Katsunori; Hirano, Tsutomu			Type1 diabetes patients have lower strength in femoral bone determined by quantitative computed tomography: A cross-sectional study	JOURNAL OF DIABETES INVESTIGATION			English	Article						Insulin-like growth factor-1; Quantitative computed tomography; Type 1 diabetes	GROWTH-FACTOR-I; INCIDENT HIP FRACTURE; IGF-BINDING PROTEINS; X-RAY ABSORPTIOMETRY; MINERAL DENSITY; METABOLIC-CONTROL; GLYCEMIC CONTROL; TRANSGENIC MICE; PROXIMAL FEMUR; CLINICAL CT	Aims/IntroductionPrevious studies have reported osteoporosis measured by dual-energy X-ray absorptiometry in younger patients with type1 diabetes. Limitations of 2-D imaging, however, limit the precision of dual-energy X-ray absorptiometry for the measurement of bone mineral density and bone strength. Materials and MethodsThree-dimensional quantitative computed tomography was used to calculate volumetric-bone mineral density (vBMD) and strength in femoral bone subfractions. A total of 17 male type1 diabetes patients and 18 sex-matched healthy controls aged from 18 to 49years were investigated in the present cross-sectional study. Patients with overt nephropathy were excluded. ResultsType1 diabetes patients had significantly lower cortical vBMD in the femoral neck, and significantly lower total vBMD, cortical thickness and cortical cross-sectional area (cortical CSA) in the intertrochanter. Bone strength estimated by the buckling ratio (an index of cortical instability) of the intertrochanter was significantly higher in type1 diabetes patients. The following serum bone markers were comparable between the two groups: bone-specific alkaline phosphatase, N-terminal propeptide of type1 procollagen, osteocalcin, pentosidine and homocysteine. Serum insulin-like growth factor-1 values were significantly lower in the type1 diabetes patients than in controls. Serum insulin-like growth factor-1values were positively correlated with serum bone formation markers, and the total vBMD of the femoral neck and lumbar spine in type1 diabetes patients. ConclusionsThe present study is the first investigation by quantitative computed tomography measurement to show cortical instability and lower vBMD in the intertrochanter of young and middle-aged type1 diabetes patients. Low insulin-like growth factor-1 might be a causative factor for osteoporosis in type1 diabetes.	[Ishikawa, Koji; Nagai, Takashi; Kuroda, Takuma; Inagaki, Katsunori] Showa Univ, Sch Med, Dept Orthopaed Surg, Tokyo 142, Japan; [Fukui, Tomoyasu; Hara, Noriko; Yamamoto, Takeshi; Hirano, Tsutomu] Showa Univ, Sch Med, Div Diabet Metab & Endocrinol, Dept Med, Tokyo 142, Japan	Fukui, T (reprint author), Showa Univ, Sch Med, Div Diabet Metab & Endocrinol, Dept Med, Tokyo 142, Japan.	showauft@med.showa-u.ac.jp					Fowlkes JL, 2013, BONE, V57, P36, DOI 10.1016/j.bone.2013.07.017; Danielson KK, 2009, OSTEOPOROSIS INT, V20, P923, DOI 10.1007/s00198-008-0763-3; Burrows M, 2010, OSTEOPOROSIS INT, V21, P515, DOI 10.1007/s00198-009-0913-2; LETTGEN B, 1995, HORM RES, V43, P173, DOI 10.1159/000184273; Borggrefe J, 2010, J BONE MINER RES, V25, P472, DOI 10.1359/jbmr.090820; Pascual J, 1998, CALCIFIED TISSUE INT, V62, P31, DOI 10.1007/s002239900390; Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975; Ito M, 2011, BONE, V49, P328, DOI 10.1016/j.bone.2011.05.002; Seino Y, 2010, J DIABETES INVEST, V1, P212, DOI 10.1111/j.2040-1124.2010.00074.x; Cheng X, 2007, BONE, V40, P169, DOI 10.1016/j.bone.2006.06.018; Valerio G, 2002, HORM RES, V58, P266, DOI 10.1159/000066441; LEVIN ME, 1976, NEW ENGL J MED, V294, P241, DOI 10.1056/NEJM197601292940502; Kemink SAG, 2000, J ENDOCRINOL INVEST, V23, P295; Blake GM, 1997, SEMIN NUCL MED, V27, P210, DOI 10.1016/S0001-2998(97)80025-6; Hedman CA, 2004, J CLIN ENDOCR METAB, V89, P6305, DOI 10.1210/jc.2004-0572; MUELLER K, 1994, AM J PHYSIOL, V267, pE1; Kaptoge S, 2008, J BONE MINER RES, V23, P1892, DOI [10.1359/jbmr.080802, 10.1359/JBMR.080802]; Eastell R, 2010, OSTEOPOROSIS INT, V21, P1277, DOI 10.1007/s00198-009-1077-9; Jiang J, 2006, BONE, V39, P494, DOI 10.1016/j.bone.2006.02.068; Gnudi S, 2012, BRIT J RADIOL, V85, pE467, DOI 10.1259/bjr/57130600; BOUILLON R, 1995, J CLIN ENDOCR METAB, V80, P1194, DOI 10.1210/jc.80.4.1194; Bousson VD, 2011, J BONE MINER RES, V26, P881, DOI 10.1002/jbmr.270; Amin S, 2011, J BONE MINER RES, V26, P1593, DOI 10.1002/jbmr.347; Heap J, 2004, J PEDIATR-US, V144, P56, DOI 10.1016/j.jpeds.2003.10.066; Yang L, 2014, OSTEOPOROSIS INT, V25, P251, DOI 10.1007/s00198-013-2401-y; Mohan S, 2002, J ENDOCRINOL, V175, P19, DOI 10.1677/joe.0.1750019; Black DM, 2008, J BONE MINER RES, V23, P1326, DOI [10.1359/jbmr.080316, 10.1359/JBMR.080316]; Sjogren K, 2002, J BONE MINER RES, V17, P1977, DOI 10.1359/jbmr.2002.17.11.1977; Ito M, 2014, OSTEOPOROSIS INT, V25, P1163, DOI 10.1007/s00198-013-2596-y; Rivadeneira F, 2007, J BONE MINER RES, V22, P1781, DOI 10.1359/JBMR.070712; Liu EY, 2003, DIABETES CARE, V26, P2365, DOI 10.2337/diacare.26.8.2365; Isojima T, 2012, ENDOCR J, V59, P771; Zhao G, 2000, ENDOCRINOLOGY, V141, P2674, DOI 10.1210/en.141.7.2674; Moyer-Mileur LJ, 2008, J BONE MINER RES, V23, P1884, DOI [10.1359/jbmr.080713, 10.1359/JBMR.080713]; Roggen I, 2013, HORM RES PAEDIAT, V79, P68, DOI 10.1159/000346686; Moyer-Mileur LJ, 2004, J PEDIATR-US, V145, P662, DOI 10.1016/j.jpeds.2004.06.070; HUI SL, 1985, J CLIN ENDOCR METAB, V60, P74; Lang TF, 2002, BONE, V30, P247, DOI 10.1016/S8756-3282(01)00647-0; Wakisaka A, 1998, J BONE MINER RES, V13, P13, DOI 10.1359/jbmr.1998.13.1.13; Ito M, 2010, BONE, V46, P453, DOI 10.1016/j.bone.2009.08.059; Leger J, 2006, J CLIN ENDOCR METAB, V91, P3947, DOI 10.1210/jc.2006-0711	41	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2040-1116	2040-1124		J DIABETES INVEST	J. Diabetes Investig.	NOV	2015	6	6					726	733		10.1111/jdi.12372		8	Endocrinology & Metabolism	Endocrinology & Metabolism	CU7AL	WOS:000363687000019		
J	Takei, M; Ishii, H; Kawai, Y; Kato, K; Sekido, T; Sato, Y; Takeda, T; Komatsu, M				Takei, Masahiro; Ishii, Hiroaki; Kawai, Yuko; Kato, Kosuke; Sekido, Takashi; Sato, Yoshihiko; Takeda, Teiji; Komatsu, Mitsuhisa			Efficacy of oral glucocorticoid and cyclosporine in a case of rituximab-refractory type B insulin resistance syndrome	JOURNAL OF DIABETES INVESTIGATION			English	Article						Cyclosporine; Systemic lupus erythematosus; Type B insulin resistance syndrome	SYSTEMIC-LUPUS-ERYTHEMATOSUS; AUTOANTIBODIES; IMMUNOGLOBULIN; THERAPY	We describe a case of type B insulin resistance syndrome associated with systemic lupus erythematosus (SLE) that was refractory to rituximab and successfully treated with a combination of oral glucocorticoids and cyclosporine. Prior to treatment, insulin resistance was severe, and application of a hyperinsulinemic euglycemic clamp was not possible despite the continuous intravenous infusion of insulin at a maximum rate of 9.0mU/kg/min. The addition of cyclosporine to oral glucocorticoid therapy resulted in remission of insulin resistance. The combination of oral prednisolone and cyclosporine might be effective in treating type B insulin resistance syndrome, particularly in rituximab-resistant cases. However, nephrotoxicity is a particular concern for patients receiving long-term cyclosporine therapy.	[Takei, Masahiro; Ishii, Hiroaki; Kawai, Yuko; Kato, Kosuke; Sekido, Takashi; Sato, Yoshihiko; Takeda, Teiji; Komatsu, Mitsuhisa] Shinshu Univ, Sch Med, Dept Internal Med, Div Diabet Endocrinol & Metab, Matsumoto, Nagano 390, Japan	Takei, M (reprint author), Shinshu Univ, Sch Med, Dept Internal Med, Div Diabet Endocrinol & Metab, Matsumoto, Nagano 390, Japan.	masahiro@shinshu-u.ac.jp					Malek R, 2010, J CLIN ENDOCR METAB, V95, P3641, DOI 10.1210/jc.2010-0167; Arioglu E, 2002, MEDICINE, V81, P87, DOI 10.1097/00005792-200203000-00001; Petri M, 2012, ARTHRITIS RHEUM-US, V64, P2677, DOI 10.1002/art.34473; KAHN CR, 1976, NEW ENGL J MED, V294, P739, DOI 10.1056/NEJM197604012941401; Kawashiri S, 2010, INTERNAL MED, V49, P487, DOI 10.2169/internalmedicine.49.2746; Eriksson JW, 1998, DIABETES CARE, V21, P1217, DOI 10.2337/diacare.21.8.1217; FLIER JS, 1975, SCIENCE, V190, P63, DOI 10.1126/science.170678; Zhang SG, 2013, CLIN RHEUMATOL, V32, P181, DOI 10.1007/s10067-012-2098-x; Coll AP, 2004, NEW ENGL J MED, V350, P310, DOI 10.1056/NEJM200401153500324; Tran HA, 2009, MED J AUSTRALIA, V190, P168	10	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2040-1116	2040-1124		J DIABETES INVEST	J. Diabetes Investig.	NOV	2015	6	6					734	738		10.1111/jdi.12337		5	Endocrinology & Metabolism	Endocrinology & Metabolism	CU7AL	WOS:000363687000020		
J	Kuroda, K; Takeshita, Y; Kaneko, S; Takamura, T				Kuroda, Kaori; Takeshita, Yumie; Kaneko, Shuichi; Takamura, Toshinari			Bending of a vertical cannula without alarm during insulin pump therapy as a cause of unexpected hyperglycemia: A Japanese issue?	JOURNAL OF DIABETES INVESTIGATION			English	Letter									[Kuroda, Kaori; Takeshita, Yumie; Kaneko, Shuichi] Kanazawa Univ, Grad Sch Med Sci, Dept Dis Control & Homeostasis, Kanazawa, Ishikawa, Japan; [Takamura, Toshinari] Kanazawa Univ, Grad Sch Med Sci, Dept Comprehens Metabol, Kanazawa, Ishikawa, Japan	Takamura, T (reprint author), Kanazawa Univ, Grad Sch Med Sci, Dept Comprehens Metabol, Kanazawa, Ishikawa, Japan.	ttakamura@m-kanazawa.jp					Schmid Volkmar, 2010, J Diabetes Sci Technol, V4, P976	1	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2040-1116	2040-1124		J DIABETES INVEST	J. Diabetes Investig.	NOV	2015	6	6					739	740		10.1111/jdi.12357		2	Endocrinology & Metabolism	Endocrinology & Metabolism	CU7AL	WOS:000363687000021		
J	Higo, S; Aikawa, S; Iijima, N; Ozawa, H				Higo, Shimpei; Aikawa, Satoko; Iijima, Norio; Ozawa, Hitoshi			Rapid modulation of hypothalamic Kiss1 levels by the suckling stimulus in the lactating rat	JOURNAL OF ENDOCRINOLOGY			English	Article						lactation; reproduction; gonadotrophin releasing hormone; PRL	LUTEINIZING-HORMONE SECRETION; ESTROGEN POSITIVE FEEDBACK; METASTASIS SUPPRESSOR GENE; ARCUATE NUCLEUS; KISSPEPTIN NEURONS; FEMALE RATS; GNRH NEURONS; DOPAMINERGIC-NEURONS; PROLACTIN-RELEASE; MESSENGER-RNA	In mammals, lactation suppresses GnRH/LH secretion resulting in transient infertility. In rats, GnRH/LH secretion is rescued within 18-48 h after pup separation (PS) and rapidly re-suppressed by subsequent re-exposure of pups. To elucidate the mechanisms underlying these rapid modulations, changes in the expression of kisspeptin, a stimulator of GnRH secretion, in several lactating conditions (normal-lactating; 4-h PS; 18-h PS; 4-h PS C1-h re-exposure of pups; non-lactating) were examined using in situ hybridization. PS for 4 h or 18 h increased Kiss1 expressing neurons in both the anteroventral periventricular nucleus (AVPV) and the arcuate nucleus (ARC), and subsequent exposure of pups re-suppressed Kiss1 in the AVPV. A change in Kiss1 expression was observed prior to the reported time of the change in GnRH/LH, indicating that the change in GnRH/LH results from changes in kisspeptin. We further examined the mechanisms underlying the rapid modulation of Kiss1. We first investigated the possible involvement of ascending sensory input during the suckling stimulus. Injection of the anterograde tracer to the subparafascicular parvocellular nucleus (SPFpc) in the midbrain, which relays the suckling stimulus, revealed direct neuronal connections between the SPFpc and kisspeptin neurons in both the AVPV and ARC. We also examined the possible involvement of prolactin (PRL). Administration of PRL for 1 h suppressed Kiss1 expression in the AVPV but not in the ARC. These results indicate that suckling stimulus rapidly modulates Kiss1 expression directly via neuronal connections and indirectly through serum PRL, resulting in modulation in GnRH/LH secretion.	[Higo, Shimpei; Aikawa, Satoko; Iijima, Norio; Ozawa, Hitoshi] Nippon Med Sch, Grad Sch Med, Dept Anat & Neurobiol, Bunkyo Ku, Tokyo 1138602, Japan	Ozawa, H (reprint author), Nippon Med Sch, Grad Sch Med, Dept Anat & Neurobiol, Bunkyo Ku, Sendagi 1-1-5, Tokyo 1138602, Japan.	hozawa@nms.ac.jp			Japan Society for the Promotion of Science (JSPS) KAKENHI [15K20062, 26460323, 26670115]	This study was supported by the Japan Society for the Promotion of Science (JSPS) KAKENHI (Grants-in-Aid for Scientific Research, grant number 15K20062 to S H, 26460323 to H O and 26670115 to N I). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Kinoshita M, 2005, ENDOCRINOLOGY, V146, P4431, DOI 10.1210/en.2005-0195; Herbison AE, 2008, BRAIN RES REV, V57, P277, DOI 10.1016/j.brainresrev.2007.OS.006; BRIDGES RS, 1990, ENDOCRINOLOGY, V126, P837; Terao Y, 2004, BBA-GENE STRUCT EXPR, V1678, P102, DOI 10.1016/j.bbaexp.2004.02.005; Sonigo C, 2012, J CLIN INVEST, V122, P3791, DOI 10.1172/JCI63937; Araujo-Lopes R, 2014, ENDOCRINOLOGY, V155, P1010, DOI 10.1210/en.2013-1889; de Croft S, 2013, ENDOCRINOLOGY, V154, P2750, DOI 10.1210/en.2013-1231; Williams WP, 2011, ENDOCRINOLOGY, V152, P595, DOI 10.1210/en.2010-0943; GUDELSKY GA, 1981, PSYCHONEUROENDOCRINO, V6, P3, DOI 10.1016/0306-4530(81)90044-5; Smith JT, 2006, J NEUROSCI, V26, P6687, DOI 10.1523/JNEUROSCI.1618-06.2006; Takumi K, 2012, NEUROSCI LETT, V531, P40, DOI 10.1016/j.neulet.2012.10.010; Smith JT, 2006, J NEUROENDOCRINOL, V18, P298, DOI 10.1111/j.1365-2826.2006.01417.x; Kotani M, 2001, J BIOL CHEM, V276, P34631, DOI 10.1074/jbc.M104847200; Fukushima A, 2006, J ENDOCRINOL, V191, P339, DOI 10.1677/joe.1.06728; Berghorn KA, 2001, J COMP NEUROL, V438, P423, DOI 10.1002/cne.1325; Overgaard A, 2013, PEPTIDES, V45, P85, DOI 10.1016/j.peptides.2013.04.013; Li C, 1998, ENDOCRINOLOGY, V139, P1645, DOI 10.1210/en.139.4.1645; Zhang CG, 2013, AM J PHYSIOL-ENDOC M, V305, pE1384, DOI 10.1152/ajpendo.00406.2013; MAEDA K, 1987, ENDOCRINOL JAPON, V34, P709; Sawai N, 2012, NEUROSCI RES, V74, P10, DOI 10.1016/j.neures.2012.05.011; Yamada S, 2007, ENDOCRINOLOGY, V148, P2226, DOI 10.1210/en.2006-1529; Szawka RE, 2010, ENDOCRINOLOGY, V151, P3247, DOI 10.1210/en.2009-1414; Kokay IC, 2011, ENDOCRINOLOGY, V152, P526, DOI 10.1210/en.2010-0668; Smith JT, 2008, BRAIN RES REV, V57, P288, DOI 10.1016/j.brainresrev.2007.04.002; Adachi S, 2007, J REPROD DEVELOP, V53, P367, DOI 10.1262/jrd.18146; Iijima N, 2011, J MOL NEUROSCI, V43, P146, DOI 10.1007/s12031-010-9433-y; FOX SR, 1984, ENDOCRINOLOGY, V115, P2045; Li C, 1999, NEUROSCIENCE, V94, P117, DOI 10.1016/S0306-4522(99)00236-5; Szabo FK, 2010, ENDOCRINE, V37, P62, DOI 10.1007/s12020-009-9266-z; Li Q, 2011, J NEUROENDOCRINOL, V23, P871, DOI 10.1111/j.1365-2826.2011.02195.x; Liu X, 2014, ENDOCRINOLOGY, V155, P193, DOI 10.1210/en.2013-1621; Marina N, 2002, BRAIN RES, V954, P100, DOI 10.1016/S0006-8993(02)03349-8; MATTHEIJ JAM, 1984, HORM RES, V20, P261, DOI 10.1159/000180006; MAEDA KI, 1989, J ENDOCRINOL, V121, P277, DOI 10.1677/joe.0.1210277; McNeilly AS, 2001, REPROD FERT DEVELOP, V13, P583, DOI 10.1071/RD01056; Lonstein JS, 1999, DEV PSYCHOBIOL, V35, P264, DOI 10.1002/(SICI)1098-2302(199912)35:4<264::AID-DEV2>3.0.CO;2-U; True C, 2013, ENDOCRINOLOGY, V154, P2821, DOI 10.1210/en.2013-1156; Yamada S, 2012, J NEUROENDOCRINOL, V24, P1234, DOI 10.1111/j.1365-2826.2012.02330.x; True C, 2011, J NEUROENDOCRINOL, V23, P52, DOI 10.1111/j.1365-2826.2010.02076.x; SMITH MS, 1977, BIOL REPROD, V17, P255, DOI 10.1095/biolreprod17.2.255; DELEAN A, 1978, AM J PHYSIOL, V235, pE97; Brown RSE, 2014, J NEUROENDOCRINOL, V26, P898, DOI 10.1111/jne.12223; Li XF, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008334	43	0	0	BIOSCIENTIFICA LTD	BRISTOL	EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT, ENGLAND	0022-0795	1479-6805		J ENDOCRINOL	J. Endocrinol.	NOV	2015	227	2					105	115		10.1530/JOE-15-0143		11	Endocrinology & Metabolism	Endocrinology & Metabolism	CU5CX	WOS:000363550400007		
J	Kainuma, O; Miura, F; Furukawa, D; Yamamoto, H; Cho, A; Sano, K; Nakagohri, T; Asano, T				Kainuma, Osamu; Miura, Fumihiko; Furukawa, Daisuke; Yamamoto, Hiroshi; Cho, Akihiro; Sano, Keiji; Nakagohri, Toshio; Asano, Takehide			Feasibility and efficacy of gemcitabine plus cisplatin combination therapy after curative resection for biliary tract cancer	JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES			English	Article						Adjuvant chemotherapy; Biliary tract cancer; Cisplatin; Gemcitabine	ADJUVANT CHEMOTHERAPY; HILAR CHOLANGIOCARCINOMA; PROGNOSTIC-FACTORS; RANDOMIZED-TRIAL; PHASE-I; SURVIVAL; OUTCOMES; MULTICENTER; CARCINOMA; IMPACT	BackgroundThe aim of this multi-institutional study was to assess the feasibility and the efficacy of gemcitabine plus cisplatin (CDDP) combination therapy (GC therapy) for biliary tract cancer (BTC) in the adjuvant setting. MethodsEligible patients identified between January 2008 and January 2013 were enrolled. GC therapy at 1,000mg/m(2) of gemcitabine and 25mg/m(2) of CDDP on days 1 and 8 repeated every 3weeks was performed for 6months. The primary endpoint was the feasibility and the adverse events, and the secondary endpoint was recurrence-free survival (RFS) and overall survival (OS). ResultsAmong 29 evaluable patients, the protocol was completed in 21 (72%) patients. Relative dose intensity (RDI) of gemcitabine and CDDP was 77% and 81%, respectively. There was no difference in the completion rate and the RDI between patients who underwent resection with vs. without major hepatectomy. Grade 3-4 toxicities included leukopenia (14%) and neutropenia (27%). Two-year RFS and 2-year OS was 59% and 90%, respectively. ConclusionsStandard dose of GC therapy is tolerable in patients with BTC who underwent curative resection either with or without major hepatectomy. The survival effect of this regimen is promising, but further comparative study is needed.	[Kainuma, Osamu; Yamamoto, Hiroshi; Cho, Akihiro] Chiba Canc Ctr, Dept Surg Gastroenterol, Chuo Ku, Chiba 2608717, Japan; [Miura, Fumihiko; Sano, Keiji] Univ Tokyo, Sch Med, Dept Surg, Tokyo 113, Japan; [Furukawa, Daisuke; Nakagohri, Toshio] Tokai Univ, Sch Med, Dept Surg, Isehara, Kanagawa 25911, Japan; [Asano, Takehide] Natl Hosp Org, Chiba East Hosp, Dept Surg, Chiba, Japan	Kainuma, O (reprint author), Chiba Canc Ctr, Dept Surg Gastroenterol, Chuo Ku, 666-2 Nitona, Chiba 2608717, Japan.	okainuma@chiba-cc.jp					Yoshida T, 2002, ARCH SURG-CHICAGO, V137, P69, DOI 10.1001/archsurg.137.1.69; Oettle H, 2013, JAMA-J AM MED ASSOC, V310, P1473, DOI 10.1001/jama.2013.279201; Takada T, 2002, CANCER, V95, P1685, DOI 10.1002/cncr.10831; Dumitrascu T, 2013, J GASTROINTEST SURG, V17, P913, DOI 10.1007/s11605-013-2144-2; Valle J, 2010, NEW ENGL J MED, V362, P1273, DOI 10.1056/NEJMoa0908721; Horgan AM, 2012, J CLIN ONCOL, V30, P1934, DOI 10.1200/JCO.2011.40.5381; Okusaka T, 2010, BRIT J CANCER, V103, P469, DOI 10.1038/sj.bjc.6605779; Murakami Y, 2009, ANN SURG, V250, P950, DOI 10.1097/SLA.0b013e3181b0fc8b; Toyoda M, 2014, CANCER CHEMOTH PHARM, V73, P1295, DOI 10.1007/s00280-014-2431-y; Murakami Y, 2012, J HEPATO-BIL-PAN SCI, V19, P306, DOI 10.1007/s00534-011-0498-y; Miyakawa S, 2009, J HEPATO-BILIARY-PAN, V16, P1, DOI 10.1007/s00534-008-0015-0; Venook AP, 2000, J CLIN ONCOL, V18, P2780; de Jong MC, 2012, CANCER-AM CANCER SOC, V118, P4737, DOI 10.1002/cncr.27492; Neoptolemos JP, 2012, JAMA-J AM MED ASSOC, V308, P147, DOI 10.1001/jama.2012.7352; Koerkamp BG, 2014, J SURG ONCOL, V110, P585, DOI 10.1002/jso.23762; Klempnauer J, 1997, CANCER, V79, P26, DOI 10.1002/(SICI)1097-0142(19970101)79:1<26::AID-CNCR5>3.0.CO;2-K; Kobayashi S, 2011, J CANC THER, V2, P703; National Comprehensive Cancer Network, 2015, HEP CANC	18	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1868-6974	1868-6982		J HEPATO-BIL-PAN SCI	J. Hepato-Biliary-Pancreat. Sci.	NOV	2015	22	11					789	794		10.1002/jhbp.283		6	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	CU9RW	WOS:000363883800003		
J	Wakasugi, M; Tori, M; Shimizu, J; Kim, YK; Noda, T; Dono, K; Takeda, Y; Yamamoto, T; Oshima, S; Morimoto, Y; Asaoka, T; Eguchi, H; Nagano, H; Mori, M; Doki, Y				Wakasugi, Masaki; Tori, Masayuki; Shimizu, Junzo; Kim, Yong Kook; Noda, Takehiro; Dono, Keizo; Takeda, Yutaka; Yamamoto, Tameyoshi; Oshima, Satoshi; Morimoto, Yoshikazu; Asaoka, Tadafumi; Eguchi, Hidetoshi; Nagano, Hiroaki; Mori, Masaki; Doki, Yuichiro		Hepato-Biliary-Pancreatic Grp; Clinical Study Grp Osaka Univ	Efficacy of preoperative dexamethasone for postoperative nausea and vomiting after laparoscopic cholecystectomy: a large-scale, multicenter, randomized, double-blind, placebo-controlled trial in Japan	JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES			English	Article						Dexamethasone; Laparoscopic cholecystectomy; Postoperative nausea and vomiting	CLINICAL-TRIAL; REDUCES NAUSEA; PREVENTION; METAANALYSIS; ONDANSETRON; ANESTHESIA; PROPOFOL	BackgroundTo assess the efficacy of preoperative dexamethasone for postoperative nausea and vomiting (PONV) after laparoscopic cholecystectomy (LC) in Japan. MethodsA total of 270 patients at eight hospitals were randomized to receive dexamethasone 8mg (n=136) or placebo (n=134) intravenously before LC. The primary endpoint was the degree of PONV and antiemetic requirements within 24h after LC. Secondary endpoints were postoperative complications, postoperative hospital stay, and cost of hospital stay. This study was registered: UMIN-CTR (UMIN000003841). ResultsWithin 6h after LC, 17% (23/136) of patients in the dexamethasone group versus 24% (32/134) in the placebo group reported nausea (P=0.3), and 5% (7/136) versus 7% (10/134) reported vomiting (P=0.2). Metoclopramide 10mg was used 0.090.31 versus 0.14 +/- 0.35 times (P=0.2). From 6 to 24h, 10% (14/136) versus 13% (17/134) reported nausea (P=0.5), and 5% (7/136) versus 5% (7/134) reported vomiting (P=0.8). Metoclopramide was used 0.04 +/- 0.19 versus 0.03 +/- 0.17 times (P=0.8). Postoperative complications and postoperative hospital stay did not differ significantly between the two groups, but the cost of hospital stay was slightly higher in the dexamethasone group (P<0.05). ConclusionsRoutine use of preoperative dexamethasone for PONV after elective LC in Japan was not shown to have a clinical advantage.	[Wakasugi, Masaki; Tori, Masayuki] Osaka Police Hosp, Dept Surg, Osaka 5430035, Japan; [Shimizu, Junzo] Osaka Rosai Hosp, Dept Surg, Sakai, Osaka, Japan; [Kim, Yong Kook] Kaizuka City Hosp, Dept Surg, Kaizuka, Japan; [Noda, Takehiro; Dono, Keizo] Toyonaka City Hosp, Dept Surg, Toyonaka, Osaka, Japan; [Takeda, Yutaka] Kansai Rosai Hosp, Dept Surg, Amagasaki, Hyogo, Japan; [Yamamoto, Tameyoshi] Sakai Municipal Hosp, Dept Surg, Sakai, Osaka, Japan; [Oshima, Satoshi] Minoh City Hosp, Dept Surg, Mino, Japan; [Morimoto, Yoshikazu] Osaka Hosp, Dept Surg, Osaka, Japan; [Asaoka, Tadafumi] Osaka Natl Hosp, Dept Surg, Osaka, Japan; [Eguchi, Hidetoshi; Nagano, Hiroaki; Mori, Masaki; Doki, Yuichiro] Osaka Univ, Dept Surg, Grad Sch Med, Osaka, Japan	Tori, M (reprint author), Osaka Police Hosp, Dept Surg, Tennouji Ku, 10-31 Kitayama Cho, Osaka 5430035, Japan.	massibird@gmail.com					Wang JJ, 1999, BRIT J ANAESTH, V83, P772; Wang JJ, 2002, ANESTH ANALG, V95, P229, DOI 10.1097/00000539-200207000-00042; Bisgaard T, 2003, ANN SURG, V238, P651, DOI 10.1097/01.sla.0000094390.82352.cb; Alghanem SM, 2010, SURG ENDOSC, V24, P353, DOI 10.1007/s00464-009-0567-3; Feo CV, 2006, BRIT J SURG, V93, P295, DOI 10.1002/bjs.5252; AAPRO MS, 1981, NEW ENGL J MED, V305, P520; Fukami Y, 2009, J HEPATO-BILIARY-PAN, V16, P367, DOI 10.1007/s00534-009-0079-5; Karanicolas PJ, 2008, ANN SURG, V248, P751, DOI 10.1097/SLA.0b013e3181856024; Bartlett R, 2013, ANAESTHESIA, V68, P892, DOI 10.1111/anae.12309; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jorgensen LN, 2014, BRIT J SURG, V101, P347, DOI 10.1002/bjs.9393; Apfel CC, 2004, NEW ENGL J MED, V350, P2441, DOI 10.1056/NEJMoa032196; Erhan Y, 2008, SURG ENDOSC, V22, P1487, DOI 10.1007/s00464-007-9656-3; Murphy GS, 2011, ANESTHESIOLOGY, V114, P882, DOI 10.1097/ALN.0b013e3181ec642e; LEWIS DA, 1983, J AFFECT DISORDERS, V5, P319, DOI 10.1016/0165-0327(83)90022-8; De Oliveira GS, 2013, ANESTH ANALG, V116, P58, DOI 10.1213/ANE.0b013e31826f0a0a; Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244; Bianchin A, 2007, MINERVA ANESTESIOL, V73, P343; Sistla S, 2009, SURG LAPARO ENDO PER, V19, P506, DOI 10.1097/SLE.0b013e3181bd9149; British Medical Association and Royal Pharmaceutical Society of Great Britain, 2013, BRIT NATL FORMULARY; Deng XQ, 2014, PAK J MED SCI, V30, P1017, DOI 10.12669/pjms.305.5196; Kashmiri Zia uddin A, 2006, J Coll Physicians Surg Pak, V16, P689; Kim SI, 2000, BRIT J ANAESTH, V85, P898, DOI 10.1093/bja/85.6.898; Mangram A.J., 1999, INFECT CONT HOSP EP, V20, P79; Mangram AJ, 1999, INFECT CONT HOSP EP, V20, P250, DOI 10.1086/501620; Perdval VG, 2010, ANAESTH INTENSIVE CA, V38, P661; Sanchez-Rodriguez PE, 2010, WORLD J SURG, V34, P895, DOI 10.1007/s00268-010-0457-9	27	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1868-6974	1868-6982		J HEPATO-BIL-PAN SCI	J. Hepato-Biliary-Pancreat. Sci.	NOV	2015	22	11					802	809		10.1002/jhbp.285		8	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	CU9RW	WOS:000363883800005		
J	Nagai, M; Sho, M; Akahori, T; Tanaka, T; Kinoshita, S; Nishiofuku, H; Nishiwada, S; Ohbayashi, C; Kichikawa, K; Nakajima, Y				Nagai, Minako; Sho, Masayuki; Akahori, Takahiro; Tanaka, Toshihiro; Kinoshita, Shoichi; Nishiofuku, Hideyuki; Nishiwada, Satoshi; Ohbayashi, Chiho; Kichikawa, Kimihiko; Nakajima, Yoshiyuki			Impact of preoperative asymptomatic renal dysfunction on clinical course after pancreatoduodenectomy	JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES			English	Article						Pancreatoduodenectomy; Postoperative complication; Prognosis; Renal dysfunction; Surgery	GLOMERULAR-FILTRATION-RATE; POSTOPERATIVE OUTCOMES; CREATININE CLEARANCE; PANCREATIC-CANCER; CARDIAC-SURGERY; RESECTION; INSUFFICIENCY; TRIAL; TERM; COMPLICATIONS	BackgroundAlthough recent large-scale clinical studies have shown that preoperative renal insufficiency is associated with increased risk of postoperative complications after pancreatoduodenectomy (PD), it is unknown whether asymptomatic renal dysfunction has an impact on postoperative course after PD. MethodsTwo hundred and fifty-four patients who underwent PD between 2007 and 2013 were enrolled. Renal function was evaluated by the preoperative estimated glomerular filtration rate (eGFR). Patients were divided into two groups according to the cutoff value of 55 of eGFR. ResultsThirty-five patients were classified as the low eGFR group, while 219 were classified as the normal group. There were differences between groups in age, comorbidity and pancreatic texture. The incidence of overall postoperative complication, grade B/C pancreatic fistula and severe complication in the low eGFR group was significantly higher than that in the normal group. Multivariate analysis identified low eGFR as an independent risk factor for severe postoperative complications and grade B/C pancreatic fistula after PD. However, there were no differences in mortality and survival between the low and normal eGFR groups. ConclusionsWe have demonstrated for the first time that preoperative asymptomatic renal dysfunction may be a significant risk factor for severe morbidity and clinically relevant pancreatic fistula after PD.	[Nagai, Minako; Sho, Masayuki; Akahori, Takahiro; Kinoshita, Shoichi; Nishiwada, Satoshi; Nakajima, Yoshiyuki] Nara Med Univ, Dept Surg, Kashihara, Nara 6348522, Japan; [Tanaka, Toshihiro; Nishiofuku, Hideyuki; Kichikawa, Kimihiko] Nara Med Univ, Dept Radiol, Kashihara, Nara 6348522, Japan; [Ohbayashi, Chiho] Nara Med Univ, Dept Diagnost Pathol, Kashihara, Nara 6348522, Japan	Sho, M (reprint author), Nara Med Univ, Dept Surg, 840 Shijo Cho, Kashihara, Nara 6348522, Japan.	m-sho@naramed-u.ac.jp			Nara Medical University	This study was partly supported by Nara Medical University Grant-in-Aid for Collaborative Research Projects.	Grant FM, 2013, J SURG ONCOL, V107, P529, DOI 10.1002/jso.23287; LUCCHI L, 1989, NEPHRON, V51, P44; Matsuo S, 2009, AM J KIDNEY DIS, V53, P982, DOI 10.1053/j.ajkd.2008.12.034; Dindo D, 2004, ANN SURG, V240, P205, DOI 10.1097/01.sla.0000133083.54934.ae; Tani M, 2014, BRIT J SURG, V101, P1084, DOI 10.1002/bjs.9544; Betjes MGH, 2013, NAT REV NEPHROL, V9, P255, DOI 10.1038/nrneph.2013.44; Bassi C, 2005, SURGERY, V138, P8, DOI 10.1016/j.surg.2005.05.001; Fischer M, 2010, ANN SURG, V252, P952, DOI 10.1097/SLA.0b013e3181ff36b1; Wang F, 2003, CHEST, V124, P1852, DOI 10.1378/chest.124.5.1852; Kawai M, 2011, J HEPATO-BIL-PAN SCI, V18, P601, DOI 10.1007/s00534-011-0373-x; Squires MH, 2014, J AM COLL SURGEONS, V219, P914, DOI 10.1016/j.jamcollsurg.2014.05.015; Brown JR, 2008, ANN THORAC SURG, V86, P4, DOI 10.1016/j.athoracsur.2008.03.006; Gajdos C, 2013, JAMA SURG, V148, P137, DOI 10.1001/2013.jamasurg.347; Gooiker GA, 2014, BRIT J SURG, V101, P1000, DOI 10.1002/bjs.9468; AbuRahma AF, 2014, J AM COLL SURGEONS, V218, P797, DOI 10.1016/j.jamcollsurg.2013.12.038; Squires MH, 2014, J AM COLL SURGEONS, V218, P92, DOI 10.1016/j.jamcollsurg.2013.09.012; Viana JL, 2014, J AM SOC NEPHROL, V25, P2121, DOI 10.1681/ASN.2013070702; Greenblatt DY, 2011, ANN SURG ONCOL, V18, P2126, DOI 10.1245/s10434-011-1594-6; Iwasaki Y, 2010, PANCREAS, V39, P20, DOI 10.1097/MPA.0b013e3181bab521; Kimura W, 2014, ANN SURG, V259, P773, DOI 10.1097/SLA.0000000000000263; Sho M, 2013, J HEPATO-BIL-PAN SCI, V20, P197, DOI 10.1007/s00534-012-0532-8; Arkadopoulos N, 2014, WORLD J SURG, V38, P2967, DOI 10.1007/s00268-014-2669-x; Croome KP, 2015, J GASTROINTEST SURG, V19, P189, DOI 10.1007/s11605-014-2644-8; Fernandez-del Castillo C, 2012, SURGERY, V152, pS56, DOI 10.1016/j.surg.2012.05.022; Fong ZV, 2014, J GASTROINTEST SURG, V18, P137, DOI 10.1007/s11605-013-2336-9; Fong ZV, 2014, J GASTROINTEST SURG, V18, P44; Gaber AO, 2013, ANN SURG, V258, P169, DOI 10.1097/SLA.0b013e318288e18e; Lavu H, 2014, ANN SURG, V260, P53; Lavu H, 2014, ANN SURG, V260, P445, DOI 10.1097/SLA.0000000000000872; Lee GC, 2014, J GASTROINTEST SURG, V18, P1760, DOI 10.1007/s11605-014-2604-3; Matsumoto S, 2014, WORLD J SURG, V38, P1453, DOI 10.1007/s00268-013-2436-4; McMaster WG, 2015, CIRC RES, V116, P1022, DOI 10.1161/CIRCRESAHA.116.303697; Nakazato T, 2014, ANN THORAC CARDIOVAS, V20, P390, DOI 10.5761/atcs.oa.13-00187; Ravikumar R, 2014, J AM COLL SURGEONS, V218, P401, DOI 10.1016/j.jamcollsurg.2013.11.017; White William E, 2015, World J Nephrol, V4, P19, DOI 10.5527/wjn.v4.i1.19; Yoshidome H, 2014, J HEPATO-BIL-PAN SCI, V21, P850, DOI 10.1002/jhbp.192	36	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1868-6974	1868-6982		J HEPATO-BIL-PAN SCI	J. Hepato-Biliary-Pancreat. Sci.	NOV	2015	22	11					810	818		10.1002/jhbp.286		9	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	CU9RW	WOS:000363883800006		
J	Oktarianti, R; Senjarini, K; Hayano, T; Fatchiyah, F; Aulanni'am				Oktarianti, Rike; Senjarini, Kartika; Hayano, Toshiya; Fatchiyah, Fatchiyah; Aulanni'am			Proteomic analysis of immunogenic proteins from salivary glands of Aedes aegypti	JOURNAL OF INFECTION AND PUBLIC HEALTH			English	Article						Proteomic analysis; Immunogenic proteins; Salivary gland; Aedes aegypti	ARTHROPOD SALIVA; IMMUNOMODULATORY FACTORS; ANTIBODY-RESPONSE; VIRUS-INFECTION; DENGUE-VIRUS; MOSQUITO; ALBOPICTUS; BLOOD; EXPRESSION; ALLERGEN	Humans develop anti-salivary proteins after arthropod bites or exposure to insect salivary proteins. This reaction indicates that vector bites have a positive effect on the host immune response, which can be used as epidemiological markers of exposure to the vector. Our previous study identified two immunogenic proteins with molecular weights of 31 kDa and 56 kDa from salivary gland extract (SGE) of Aedes aegypti that cross-reacted with serum samples from Dengue Hemorrhagic Fever (DHF) patients and healthy people in an endemic area (Indonesia). Serum samples from individuals living in non-endemic area (sub-tropical country) and infants did not show the immunogenic reactions. The objective of this research was to identify two immunogenic proteins, i.e., 31 and 56 kDa by using proteomic analysis. In this study, proteomic analysis resulted in identification of 13 proteins and 7 proteins from the 31 kDa- and 56 kDa-immunogenic protein bands, respectively. Among those proteins, the D7 protein (Arthropode Odorant-Binding Protein, AOBP) was the most abundant in 31-kDa band, and apyrase was the major protein of the 56-kDa band. (C) 2015 King Saud Bin Abdulaziz University for Health Sciences. Published by Elsevier Limited. All rights reserved.	[Oktarianti, Rike; Hayano, Toshiya] Brawijaya Univ, Fac Math & Nat Sci, Dept Biol, Malang, Indonesia; [Oktarianti, Rike; Senjarini, Kartika] Univ Jember, Fac Math & Nat Sci, Dept Biol, Jember, Indonesia; [Hayano, Toshiya] Ritsumeikan Univ, Coll Life Sci, Dept Biomed Sci, Kyoto, Japan; [Aulanni'am] Brawijaya Univ, Fac Math & Nat Sci, Dept Chem, Biochem Lab, Malang, Indonesia	Senjarini, K (reprint author), Univ Jember, Fac Math & Nat Sci, Dept Biol, Jember, Indonesia.	senjarini@unej.ac.id			Sandwich Like Program Grant; Fundamental Research Grant of Directorate General of Higher Education Indonesia	This study was financially supported by a Sandwich Like Program Grant 2013 and Fundamental Research Grant of Directorate General of Higher Education Indonesia.	Chisenhall DM, 2014, AM J TROP MED HYG, V90, P431, DOI 10.4269/ajtmh.13-0412; Jariyapan N, 2012, PARASITOL RES, V111, P1239, DOI 10.1007/s00436-012-2958-y; Calvo E, 2006, J BIOL CHEM, V281, P1935, DOI 10.1074/jbc.M510359200; Dong F, 2012, PARASITOL RES, V110, P931, DOI 10.1007/s00436-011-2579-x; Raviprakash K, 2008, J VIROL, V82, P6927, DOI 10.1128/JVI.02724-07; Doucoure S, 2013, INSECT MOL BIOL, V22, P411, DOI 10.1111/imb.12032; Peng Z, 2006, ALLERGY, V61, P485, DOI 10.1111/j.1398-9995.2006.00985.x; Francischetti IMB, 2010, TOXICON, V56, P1130, DOI 10.1016/j.toxicon.2009.12.003; Ader DB, 2004, VIRAL IMMUNOL, V17, P252, DOI 10.1089/0882824041310496; Wang HS, 1999, INT ARCH ALLERGY IMM, V120, P135, DOI 10.1159/000024231; Andrade BB, 2005, AN ACAD BRAS CIENC, V77, P665, DOI 10.1590/S0001-37652005000400008; Hayano T, 2003, J BIOL CHEM, V278, P34309, DOI 10.1074/jbc.M304304200; Lima DM, 2011, VACCINE, V29, P831, DOI 10.1016/j.vaccine.2010.10.078; Calvo E, 2007, J BIOL CHEM, V282, P26928, DOI 10.1074/jbc.M705669200; Waitayakul A, 2006, ACTA TROP, V98, P66, DOI 10.1016/j.actatropica.2006.02.004; Titus RG, 2006, PARASITE IMMUNOL, V28, P131, DOI 10.1111/j.1365-3024.2006.00807.x; Valenzuela JG, 2002, INSECT MOL BIOL, V11, P149, DOI 10.1046/j.1365-2583.2002.00319.x; Gillespie RD, 2000, PARASITE IMMUNOL, V22, P319, DOI 10.1046/j.1365-3024.2000.00309.x; Guzman MG, 2002, LANCET INFECT DIS, V2, P33, DOI 10.1016/S1473-3099(01)00171-2; Valenzuela JG, 2003, INSECT BIOCHEM MOLEC, V33, P717, DOI 10.1016/S0965-1748(03)00067-5; Almeras L, 2010, VECTOR-BORNE ZOONOT, V10, P391, DOI 10.1089/vbz.2009.0042; Peng ZK, 2004, INT ARCH ALLERGY IMM, V133, P198, DOI 10.1159/000076787; Ribeiro JMC, 2003, ANNU REV ENTOMOL, V48, P73, DOI 10.1146/annurev.ento.48.060402.102812; Cornelie S, 2007, MALARIA J, V6, P1; Doucoure S, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001487; Fontaine A, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-187; Juhn J, 2011, PARASITE VECTOR, V41, P1; Lormeau VMC, 2009, VIROL J, V63, P1; Oktarianti R, 2014, ADV NAT APPL SCI ANA, V8, P101; Orlandi-Pradines E, 2007, MICROBES INFECT, V9, P1454, DOI 10.1016/j.micinf.2007.07.012; Remoue Franck, 2007, Acta Trop, V104, P108, DOI 10.1016/j.actatropica.2007.07.011; Ribeiro JMC, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-6; Senjarini K, 2013, MICROBIOL INDONES, V7, P186; Smith AW, 2008, EXPERT REV VACCINES, V7, P569; Tangamani S, 2009, PARASITE VECTOR, V2, P34	35	0	0	ELSEVIER SCIENCE LONDON	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1876-0341	1876-035X		J INFECT PUBLIC HEAL	J. Infect. Public Health	NOV-DEC	2015	8	6					575	582		10.1016/j.jiph.2015.04.022		8	Public, Environmental & Occupational Health; Infectious Diseases	Public, Environmental & Occupational Health; Infectious Diseases	CU8XN	WOS:000363827500008		
J	Siriphollakul, P; Kanlayanarat, S; Rittiron, R; Wanitchang, J; Suwonsichon, T; Boonyaritthongchai, P; Nakano, K				Siriphollakul, Pornarree; Kanlayanarat, Sirichai; Rittiron, Ronnarit; Wanitchang, Jaitip; Suwonsichon, Thongchai; Boonyaritthongchai, Panida; Nakano, Kazuhiro			Pasting properties by near-infrared reflectance analysis of whole grain paddy rice samples	JOURNAL OF INNOVATIVE OPTICAL HEALTH SCIENCES			English	Article						Pasting properties; near-infrared spectroscopy; paddy rice	SPECTROSCOPY; STARCH	A rapid predictive method based on near-infrared reflectance spectroscopy (NIRS) of paddy rice was developed to measure the pasting properties of rice. The paddy rice samples were scanned by a near-infrared reflectance spectrometer in the wavelength region of 1400-2400 nm and preprocessed by mathematical pretreatments prior to pasting properties analysis using a rapid visco-analyzer (RVA). The results indicated that the developed models of setback (SB), peak viscosity (PV), breakdown (BD) and consistency (CS) provided good prediction results with relatively high correlation coefficients (0.81-0.96). In addition, the validity of the calibration models was statistically tested. Standard error of prediction (SEP) and bias were small enough without any significance at 95% confidence interval. Nonetheless, this study proved that the use of NIRS for predicting pasting properties was feasible in paddy rice and could be applied in commercial trade and research.	[Siriphollakul, Pornarree; Kanlayanarat, Sirichai; Boonyaritthongchai, Panida] KingMongkuts Univ Technol, Div Postharvest Technol, Bangkok 10140, Thailand; [Rittiron, Ronnarit] Kamphaengsaen Kasetsart Univ, Fac Engn, Dept Food Engn, Nakhon Pathom, Thailand; [Siriphollakul, Pornarree; Wanitchang, Jaitip] Rajamungala Univ Technol, Div Agr Engn & Technol, Sriracha, Chonburi, Thailand; [Suwonsichon, Thongchai] Kasetsart Univ, Dept Prod Dev, Chatuchak Bangkok, Thailand; [Nakano, Kazuhiro] Niigata Univ, Grad Sch Sci & Technol, Nishi Ku, Niigata 9502181, Japan	Rittiron, R (reprint author), Kamphaengsaen Kasetsart Univ, Fac Engn, Dept Food Engn, Nakhon Pathom, Thailand.	fengror@ku.ac.th			King Mongkut's University of Technology Thonburi	The authors would like to thank King Mongkut's University of Technology Thonburi for materials funds, Rajamungla University of Technology Tawan-Ok for the Near Infrared Spectrometer and the NIR Technology laboratory of Kasetsart University for Unscrambler program version 9.8.	AACC International, 2000, APPR METH AM ASS CER; Sowbhagya CM, 2001, J CEREAL SCI, V34, P115, DOI 10.1006/jcrs.2001.0371; Cozzolino D, 2012, J CEREAL SCI, V56, P610, DOI 10.1016/j.jcs.2012.07.004; Bao JS, 2001, J FOOD SCI, V66, P936, DOI 10.1111/j.1365-2621.2001.tb08215.x; Natsuga M, 2006, T ASABE, V49, P1069; Delwiche SR, 1996, CEREAL CHEM, V73, P257; Perdon AA, 1997, CEREAL CHEM, V74, P864, DOI 10.1094/CCHEM.1997.74.6.864; Collado LS, 1999, J AGR FOOD CHEM, V47, P4195, DOI 10.1021/jf990110t; Hasjim J, 2013, CARBOHYD POLYM, V92, P682, DOI 10.1016/j.carbpol.2012.09.023; Osborne BG, 2006, J NEAR INFRARED SPEC, V14, P93; Bhattacharya K. R., 2011, RICE QUALITY GUIDE R, P578; Chitrakorn S., 2003, SCI TECHNOLOGY THAI, P13; Fearn T, 2002, NIR NEWS, V13, P12, DOI DOI 10.1255/NIRN.689; Guoquan Lu, 2006, Food Chemistry, V94, P632, DOI 10.1016/j.foodchem.2005.02.006; International Standards Organization (ISO) 12099, 2010, 12099 ISO, P6; Lin W. M., 1979, ACAD SIN, V26, P13; Shibuya N., 1974, J JPN SOC FOOD SCI, V21, P597	17	0	0	WORLD SCIENTIFIC PUBL CO PTE LTD	SINGAPORE	5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE	1793-5458	1793-7205		J INNOV OPT HEAL SCI	J. Innov. Opt. Health Sci.	NOV	2015	8	6							1550035	10.1142/S1793545815500352		8	Optics; Radiology, Nuclear Medicine & Medical Imaging	Optics; Radiology, Nuclear Medicine & Medical Imaging	CU7PO	WOS:000363734000006		
J	Osada, SI; Minematsu, N; Oda, F; Akimoto, K; Kawana, S; Ohno, S				Osada, Shin-Ichi; Minematsu, Naoko; Oda, Fumino; Akimoto, Kazunori; Kawana, Seiji; Ohno, Shigeo			Atypical Protein Kinase C Isoform, aPKC lambda, Is Essential for Maintaining Hair Follicle Stem Cell Quiescence	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Article							EPITHELIAL TIGHT JUNCTION; EPIDERMAL DIFFERENTIATION; POLARITY PROTEIN; CAENORHABDITIS-ELEGANS; KERATIN EXPRESSION; EMBRYONIC POLARITY; TRANSGENIC MICE; SKIN; PAR-3; HOMEOSTASIS	The atypical protein kinase C (aPKC)-partition-defective (PAR) complex regulates the formation of tight junctions and apico-basal epithelial polarity. To examine the role of this complex in the epidermis, we generated mutant mice harboring epidermal-specific deletion of aPKCX (conditional knock-out (cK0)), a major component of the aPKC-PAR complex. The mutant mice exhibited abnormal hair follicle (HF) cycling, progressive losses of pelage hairs and vibrissae, and altered differentiation into the epidermis and sebaceous gland. We found that in the aPKC lambda cKO mice HF stem cell (HFSC) quiescence was lost, as revealed by the decreased expression level of quiescence-inducing factors (Fgf18 and Bmp6) produced in Keratin 6 positive bulge stem cells. The loss of quiescence dysregulated the HFSC marker expression and led to the increase in Lrig1-positive cells, inducing hyperplasia of the interfollicular epidermis and sebaceous glands, and drove an increase in Lef1-positive matrix cells, causing a prolonged anagen-like phase. Persistent bulge stem cell activation led to a gradual depletion of CD34- and foc6 integrin positive HFSC reservoirs. These results suggest that aPKCX regulates signaling pathways implicated in HFSC quiescence.	[Osada, Shin-Ichi; Minematsu, Naoko; Oda, Fumino; Kawana, Seiji] Nippon Med Sch, Dept Dermatol, Tokyo 113, Japan; [Akimoto, Kazunori; Ohno, Shigeo] Yokohama City Univ, Grad Sch Med Sci, Dept Mol Biol, Yokohama, Kanagawa 2360004, Japan	Osada, SI (reprint author), Akita Univ, Grad Sch Med, Dept Dermatol & Plast Surg, 1-1-1 Hondo, Akita 0108543, Japan.	osada0130@gipc.akita-u.ac.jp; ohnos@med.yokohama-cu.ac.jp			Japan Society for the Promotion of Science (JSPS) [24591669]; Shiseido Research Fellowship	We thank J. Takeda and M. Manabe for providing the K5-cre mice and antibodies, respectively. We also thank E. Nishimura, H. Matsumura, and T. Hirose for technical advice and helpful suggestions. This work was supported by a Grant-in-Aid for Scientific Research (#24591669) from the Japan Society for the Promotion of Science (JSPS) and a Shiseido Research Fellowship to S-IO.	Hsu YC, 2011, CELL, V144, P92, DOI 10.1016/j.cell.2010.11.049; Knoblich JA, 2010, NAT REV MOL CELL BIO, V11, P849, DOI 10.1038/nrm3010; AKIMOTO K, 1994, J BIOL CHEM, V269, P12677; Izumi Y, 1998, J CELL BIOL, V143, P95, DOI 10.1083/jcb.143.1.95; Suzuki A, 2006, J CELL SCI, V119, P979, DOI 10.1242/jcs.02898; Imai F, 2006, DEVELOPMENT, V133, P1735, DOI 10.1242/dev.02330; Kemphues K, 2000, CELL, V101, P345, DOI 10.1016/S0092-8674(00)80844-2; Iden S, 2012, CANCER CELL, V22, P389, DOI 10.1016/j.ccr.2012.08.004; Hirose T, 2002, J CELL SCI, V115, P2485; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; WEISS RA, 1984, J CELL BIOL, V98, P1397, DOI 10.1083/jcb.98.4.1397; Hafner M, 2004, GENESIS, V38, P176, DOI 10.1002/gene.20016; Lin D, 2000, NAT CELL BIOL, V2, P540; Tarutani M, 1997, P NATL ACAD SCI USA, V94, P7400, DOI 10.1073/pnas.94.14.7400; Lechler T, 2005, NATURE, V437, P275, DOI 10.1038/nature03922; Tabuse Y, 1998, DEVELOPMENT, V125, P3607; Kimura-Ueki M, 2012, J INVEST DERMATOL, V132, P1338, DOI 10.1038/jid.2011.490; Jensen KB, 2010, NAT PROTOC, V5, P898, DOI 10.1038/nprot.2010.39; BYRNE C, 1993, MOL CELL BIOL, V13, P3176; STOLER A, 1988, J CELL BIOL, V107, P427, DOI 10.1083/jcb.107.2.427; Vidal VPI, 2005, CURR BIOL, V15, P1340, DOI 10.1016/j.cub.2005.06.064; Blanpain C, 2009, NAT REV MOL CELL BIO, V10, P207, DOI 10.1038/nrm2636; Betschinger J, 2003, NATURE, V422, P326, DOI 10.1038/nature01486; Helfrich I, 2007, J INVEST DERMATOL, V127, P782, DOI 10.1038/sj.jid.5700621; Watt FM, 2009, EMBO MOL MED, V1, P260, DOI 10.1002/emmm.200900033; Adolphe C, 2014, J INVEST DERMATOL, V134, P1981, DOI 10.1038/jid.2014.63; Greco V, 2009, CELL STEM CELL, V4, P155, DOI 10.1016/j.stem.2008.12.009; Watts JL, 1996, DEVELOPMENT, V122, P3133; Deschene ER, 2014, SCIENCE, V343, P1353, DOI 10.1126/science.1248373; Yamanaka T, 2001, GENES CELLS, V6, P721, DOI 10.1046/j.1365-2443.2001.00453.x; Jensen KB, 2009, CELL STEM CELL, V4, P427, DOI 10.1016/j.stem.2009.04.014; Rosse C, 2010, NAT REV MOL CELL BIO, V11, P103, DOI 10.1038/nrm2847; Hsu YC, 2012, NAT REV MOL CELL BIO, V13, P103, DOI 10.1038/nrm3272; Muller-Rover S, 2001, J INVEST DERMATOL, V117, P3, DOI 10.1046/j.0022-202x.2001.01377.x; MANSBRIDGE JN, 1987, J INVEST DERMATOL, V89, P253, DOI 10.1111/1523-1747.ep12471216; Alonso L, 2006, J CELL SCI, V119, P391, DOI 10.1242/jcs02793; Rhee H, 2006, SCIENCE, V312, P1946, DOI 10.1126/science.1128004; Yamanaka T, 2003, CURR BIOL, V13, P734, DOI 10.1016/S0960-9822(03)00244-6; Bilder D, 2003, NAT CELL BIOL, V5, P53, DOI 10.1038/ncb897; Williams SE, 2011, NATURE, V470, P353, DOI 10.1038/nature09793; Jaks V, 2008, NAT GENET, V40, P1291, DOI 10.1038/ng.239; Goldstein B, 2007, DEV CELL, V13, P609, DOI 10.1016/j.devcel.2007.10.007; Niessen MT, 2013, J CELL BIOL, V202, P887, DOI 10.1083/jcb.201307001; FUCHS E, 1980, CELL, V19, P1033, DOI 10.1016/0092-8674(80)90094-X; Moscat J, 2006, MOL CELL, V23, P631, DOI 10.1016/j.molcel.2006.08.002; Hutterer A, 2004, DEV CELL, V6, P845, DOI 10.1016/j.devcel.2004.05.003; Nowak JA, 2008, CELL STEM CELL, V3, P33, DOI 10.1016/j.stem.2008.05.009; Hirose T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004194; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; Tornqvist G, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000904	50	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	NOV	2015	135	11					2584	2592		10.1038/jid.2015.222		9	Dermatology	Dermatology	CV1DM	WOS:000363993600009		
J	Yamaguchi, Y; Watanabe, Y; Watanabe, T; Komitsu, N; Aihara, M				Yamaguchi, Yukie; Watanabe, Yuko; Watanabe, Tomoya; Komitsu, Noriko; Aihara, Michiko			Decreased Expression of Caveolin-1 Contributes to the Pathogenesis of Psoriasiform Dermatitis in Mice	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Article							PROTEIN-KINASE-C; SCAFFOLDING DOMAIN; IN-VIVO; LIPID RAFTS; MOUSE MODEL; INSIGHTS; INFLAMMATION; MECHANISMS; INFECTION; FIBROSIS	Psoriasis is a chronic inflammatory skin disease characterized by excessive proliferation and abnormal keratinocyte development, in which T helper type 17 cells and signal transducer and activator of transcription 3 (STAT3) activation have pivotal roles. Moreover, caveolin-1 (CAV-1) has been implicated in the regulation of signal transduction, and aberrant CAV-1 expression is involved in a variety of diseases. However, whether CAV-1 is involved in psoriasis is unknown. Here we examined CAV-1 expression in the psoriatic epidermis and investigated its role in the pathogenesis of psoriasis. CAV-1 was markedly reduced in lesional epidermis of psoriasis patients. CAV/ silencing in keratinocytes in vitro revealed significant activation of STAT3, leading to increased expression of keratin 16 and several cytokine/chemokines, such as IL-6, C-X-C chemokine ligand 8 (CXCL8), CXCL9, and C-C chemokine ligand 20. In addition, psoriasis-related cytokines, including tumor necrosis factor-a (TNF-a), decreased CAV-1 expression in keratinocytes. Finally, administration of CAV-1 scaffolding domain peptide in a murine model of psoriasis-like skin inflammation induced by imiquimod improved the skin phenotype and reduced epidermal thickness and infiltrating cell counts. Furthermore, expression of TNF-a, IL-17A, and IL-23 was significantly suppressed by this treatment. Collectively, our study indicated that CAV-1 participates in the pathogenesis of psoriasis by regulating the STAT3 pathway and cytokine networks.	[Yamaguchi, Yukie; Watanabe, Yuko; Watanabe, Tomoya; Komitsu, Noriko; Aihara, Michiko] Yokohama City Univ, Grad Sch Med, Dept Environm Immunodermatol, Yokohama, Kanagawa 2360004, Japan	Yamaguchi, Y (reprint author), Yokohama City Univ, Grad Sch Med, Dept Environm Immunodermatol, Kanazawa Ku, 3-9 Fukuura, Yokohama, Kanagawa 2360004, Japan.	yui1783@yokohama-cu.ac.jp			Japanese Ministry of Education, Culture, Sports, Science and Technology	This work was supported by a grant from the Japanese Ministry of Education, Culture, Sports, Science and Technology (to YY).	Lowes MA, 2007, NATURE, V445, P866, DOI 10.1038/nature05663; Razani B, 2001, J BIOL CHEM, V276, P6727, DOI 10.1074/jbc.M008340200; Sano S, 2005, NAT MED, V11, P43, DOI 10.1038/nm1162; Yamaguchi Y, 2011, J CELL MOL MED, V15, P957, DOI 10.1111/j.1582-4934.2010.01063.x; Bucci M, 2000, NAT MED, V6, P1362; Hua H, 2003, AM J PHYSIOL-RENAL, V284, pF303, DOI 10.1152/ajprenal.00127.2002; Nograles KE, 2010, SEMIN CUTAN MED SURG, V29, P3, DOI 10.1016/j.sder.2010.03.001; Medina FA, 2006, INFECT IMMUN, V74, P6665, DOI 10.1128/IAI.00949-06; Fakhrzadeh L, 2008, TOXICOL APPL PHARM, V227, P380, DOI 10.1016/j.taap.2007.11.012; Campbell L, 2002, BRIT J DERMATOL, V147, P701, DOI 10.1046/j.1365-2133.2002.05009.x; YAMADA E, 1955, J BIOPHYS BIOCHEM CY, V1, P445, DOI 10.1083/jcb.1.5.445; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; Tourkina E, 2010, ANN RHEUM DIS, V69, P1220, DOI 10.1136/ard.2009.117580; Tourkina E, 2008, AM J PHYSIOL-LUNG C, V294, pL843, DOI 10.1152/ajplung.00295.2007; Oka N, 1997, J BIOL CHEM, V272, P33416, DOI 10.1074/jbc.272.52.33416; Tourkina E, 2005, J BIOL CHEM, V280, P13879, DOI 10.1074/jbc.M412551200; van der Fits L, 2009, J IMMUNOL, V182, P5836, DOI 10.4049/jimmunol.0802999; Griffiths CEM, 2007, LANCET, V370, P263, DOI 10.1016/S0140-6736(07)61128-3; Zheng Y, 2007, NATURE, V445, P648, DOI 10.1038/nature05505; Engelman JA, 1998, FEBS LETT, V428, P205, DOI 10.1016/S0014-5793(98)00470-0; Yamaguchi Y, 2013, BRIT J DERMATOL, V168, P717, DOI 10.1111/bjd.12117; Stan RV, 2005, BBA-MOL CELL RES, V1746, P334, DOI 10.1016/j.bbamcr.2005.08.008; Stralfors P, 2012, ADV EXP MED BIOL, V729, P111, DOI 10.1007/978-1-4614-1222-9_8; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Nickoloff BJ, 2004, J CLIN INVEST, V113, P1664, DOI 10.1172/JCI200422147; Parton RG, 2003, TRAFFIC, V4, P724, DOI 10.1034/j.1600-0854.2003.00128.x; Nestle FO, 2009, NEW ENGL J MED, V361, P496, DOI 10.1056/NEJMra0804595; Park DS, 2002, MOL BIOL CELL, V13, P3416, DOI 10.1091/mbc.E02-05-0071; Yuan KF, 2011, J BIOL CHEM, V286, P21814, DOI 10.1074/jbc.M111.237628; Flutter B, 2013, EUR J IMMUNOL, V43, P3138, DOI 10.1002/eji.201343801; Wang XM, 2006, J EXP MED, V203, P2895, DOI 10.1084/jem.20061536; Galdo FD, 2008, ARTHRITIS RHEUM, V58, P2854, DOI 10.1002/art.23791; Nunez-Wehinger S, 2014, CURR MOL MED, V14, P255; Schlegel A, 2000, FRONT BIOSCI, V5, pD929, DOI 10.2741/schlegel	34	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	NOV	2015	135	11					2764	2774		10.1038/jid.2015.249		11	Dermatology	Dermatology	CV1DM	WOS:000363993600028		
J	Tanese, K; Hashimoto, Y; Berkova, Z; Wang, YL; Samaniego, F; Lee, JE; Ekmekcioglu, S; Grimm, EA				Tanese, Keiji; Hashimoto, Yuuri; Berkova, Zuzana; Wang, Yuling; Samaniego, Felipe; Lee, Jeffrey E.; Ekmekcioglu, Suhendan; Grimm, Elizabeth A.			Cell Surface CD74-MIF Interactions Drive Melanoma Survival in Response to Interferon-gamma	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Article							INVARIANT CHAIN CD74; METASTATIC MELANOMA; RECEPTOR COMPLEX; IFN-GAMMA; EXPRESSION; CANCER; GROWTH; BRAF; IMMUNOTHERAPY; PROLIFERATION	Melanoma is believed to be a highly immunogenic tumor and recent developments in immunotherapies are promising. IFN-y produced by immune cells has a crucial role in tumor immune surveillance; however, it has also been reported to be pro-tumorigenic. In the current study, we found that IFN-y enhances the expression of CD74, which interacts with its ligand, macrophage migration inhibitory factor (MIF), and thereby activates the PI3K/AKT pathway in melanoma, promoting tumor survival. IFN-y increased phosphorylation of Ala Ser473 and upregulated total cell surface expression of CD74 in human melanoma cell lines tested. CD74 was highly expressed in melanoma tissues. Moreover, the expression of CD74 on tumor cells correlated with plasma IFN-gamma levels in melanoma patient samples. In our analysis of melanoma cell lines, all produced MIF constitutively. Blockade of CD74 MIF interaction reduced Ala phosphorylation and expression of pro-tumorigenic molecules, including IL-6, IL-8, and BCL-2. Inhibition of CD74 MIF interaction significantly suppressed tumor growth in the presence of IFN-gamma in our xenograft mouse model. Thus, we conclude that IFN-y promotes melanoma cell survival by regulating CD74 MIF signaling, suggesting that targeting the CD74 MIF interaction under IFN-y-stimulatory conditions would be an effective therapeutic approach for melanoma.	[Tanese, Keiji; Hashimoto, Yuuri; Ekmekcioglu, Suhendan; Grimm, Elizabeth A.] Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX 77030 USA; [Tanese, Keiji] Keio Univ, Sch Med, Dept Dermatol, Tokyo, Japan; [Berkova, Zuzana; Samaniego, Felipe] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA; [Wang, Yuling; Lee, Jeffrey E.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA	Ekmekcioglu, S (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Unit 362,1515 Holcombe Blvd, Houston, TX 77030 USA.	sekmekcioglu@mdanderson.org; egrimm@mdanderson.org			National Institutes of Health [P50 CA09345]; Melanoma Specialized Programs of Research Excellence grant; National Institutes of Health through MD Anderson's Cancer Center Support [P30-CA016672]; Dr Miriam and Sheldon G. Adelson Medical Research Foundation; Japanese Strategic Young Researcher Overseas Visits Program for Accelerating Brain Circulation; JSPS KAKENHI [26860895]; American Cancer Society Mentored Research Scholar Grant [118447-MSRG-10-052-01-LIB]	We thank the members of the MD Anderson Characterized Cell Line Core for their critical fingerprinting analysis of melanoma cell lines and the members of our Melanoma Informatics, Tissue Resource, and Pathology Core, who provided the de-identified tissue samples for this research project and maintained accurate patient information. The progression tissue microarray was prepared as a SPORE collaborative effort with gracious support provided by Dr Lyn Duncan of MGH Dermatopathology Unit, Boston, MA. We also thank Wendy D. Schober and Nalini Patel for assistance with the flow cytometric analysis, Dr Junna Oba and Ms Ping Liu for helping with the statistical analysis, Dr Hirohito Yamaguchi for assistance with anti-apoptotic protein expression analysis, Ms Sandra A. Kinney for excellent technical help, and Mr Donald Norwood for editorial assistance. This work was supported by grant P50 CA09345 from the National Institutes of Health (S.E. and E.A.G.), the Melanoma Specialized Programs of Research Excellence grant (E.A.G.), the National Institutes of Health through MD Anderson's Cancer Center Support Grant P30-CA016672 (E.A.G.), the Dr Miriam and Sheldon G. Adelson Medical Research Foundation (E.A.G.), the Japanese Strategic Young Researcher Overseas Visits Program for Accelerating Brain Circulation (K.T.), JSPS KAKENHI grant number 26860895 (K.T.), and the American Cancer Society Mentored Research Scholar Grant 118447-MSRG-10-052-01-LIB (Z.B.).	Leng L, 2011, J IMMUNOL, V186, P527, DOI 10.4049/jimmunol.1001767; HENNE C, 1995, IMMUNOLOGY, V84, P177; WRAIGHT CJ, 1990, J BIOL CHEM, V265, P5787; Weeraratna AT, 2004, ONCOGENE, V23, P2264, DOI 10.1038/sj.onc.1207337; Nazarian RM, 2010, J CUTAN PATHOL, V37, P41, DOI 10.1111/j.1600-0560.2010.01505.x; Tibes R, 2006, MOL CANCER THER, V5, P2512, DOI 10.1158/1535-7163.MCT-06-0334; MEYSKENS FL, 1995, J NATL CANCER I, V87, P1710, DOI 10.1093/jnci/87.22.1710; Porter GA, 2001, ANN SURG ONCOL, V8, P116, DOI 10.1245/aso.2001.8.2.116; Gollob JA, 2005, CANCER RES, V65, P8869, DOI 10.1158/008-5472.can-05-1387; Ekmekcioglu S, 2008, CYTOKINE, V43, P34, DOI 10.1016/j.cyto.2008.04.010; Bar-Eli M, 1999, PATHOBIOLOGY, V67, P12, DOI 10.1159/000028045; Ong GL, 1999, IMMUNOLOGY, V98, P296; Eikawa S, 2010, J IMMUNOL, V185, P6734, DOI 10.4049/jimmunol.1000225; Binsky I, 2007, P NATL ACAD SCI USA, V104, P13408, DOI 10.1073/pnas.0701553104; Zaidi MR, 2011, CLIN CANCER RES, V17, P6118, DOI 10.1158/1078-0432.CCR-11-0482; Beswick EJ, 2005, INFECT IMMUN, V73, P2736, DOI 10.1128/IAI.73.5.2736-2743.2005; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Gao JJ, 2013, TRENDS IMMUNOL, V34, P90, DOI 10.1016/j.it.2012.08.004; Bedikian AY, 2006, J CLIN ONCOL, V24, P4738, DOI 10.1200/JCO.2006.06.0483; BROWN TJ, 1987, J IMMUNOL, V139, P2977; Cao ZA, 2000, EUR J IMMUNOL, V30, P2604, DOI 10.1002/1521-4141(200009)30:9<2604::AID-IMMU2604>3.0.CO;2-6; Zikich D, 2013, AM J CLIN DERMATOL, V14, P261, DOI 10.1007/s40257-013-0013-0; Salama AKS, 2013, CLIN CANCER RES, V19, P4326, DOI 10.1158/1078-0432.CCR-13-0779; Qin Y, 2011, MOL CANCER RES, V9, P1537, DOI 10.1158/1541-7786.MCR-11-0279; Azijli K, 2014, ANTICANCER RES, V34, P1493; Ekmekcioglu S, 2006, INT J CANCER, V119, P861, DOI 10.1002/ijc.21767; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Shi XR, 2006, IMMUNITY, V25, P595, DOI 10.1016/j.immuni.2006.08.020; Zaidi MR, 2011, NATURE, V469, P548, DOI 10.1038/nature09666; Dunn GP, 2006, NAT REV IMMUNOL, V6, P836, DOI 10.1038/nri1961; Perna D, 2015, P NATL ACAD SCI USA, V112, pE536, DOI 10.1073/pnas.1418163112; Starlets D, 2006, BLOOD, V107, P4807, DOI 10.1182/blood-2005-11-4334; Gore Y, 2008, J BIOL CHEM, V283, P2784, DOI 10.1074/jbc.M703265200; GARBE C, 1990, J INVEST DERMATOL, V95, pS231, DOI 10.1111/1523-1747.ep12875837; Kushiro Kyoko, 2012, Cancer Microenviron, V5, P73, DOI 10.1007/s12307-011-0087-2; Oliveira CS, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-630; ROCHE PA, 1991, NATURE, V354, P392, DOI 10.1038/354392a0; Spranger S, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006504; TANIGUCHI K, 1987, P NATL ACAD SCI USA, V84, P3405, DOI 10.1073/pnas.84.10.3405	39	1	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	NOV	2015	135	11					2775	2784		10.1038/jid.2015.204		10	Dermatology	Dermatology	CV1DM	WOS:000363993600029		
J	Fujimura, T; Kambayashi, Y; Furudate, S; Asano, M; Kakizaki, A; Aiba, S				Fujimura, Taku; Kambayashi, Yumi; Furudate, Sadanori; Asano, Masayuki; Kakizaki, Aya; Aiba, Setsuya			Receptor Activator of NF-kappa B Ligand Promotes the Production of CCL17 from RANK+M2 Macrophages	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Letter							T-CELLS; DIFFERENTIATION; POLARIZATION		[Fujimura, Taku; Kambayashi, Yumi; Furudate, Sadanori; Asano, Masayuki; Kakizaki, Aya; Aiba, Setsuya] Tohoku Univ, Grad Sch Med, Dept Dermatol, Sendai, Miyagi 980, Japan	Fujimura, T (reprint author), Tohoku Univ, Grad Sch Med, Dept Dermatol, Sendai, Miyagi 980, Japan.	tfujimura1@mac.com					Loser K, 2006, NAT MED, V12, P1372, DOI 10.1038/nm1518; Fujimura T, 2012, ACTA DERM-VENEREOL, V92, P625, DOI 10.2340/00015555-1453; Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075; Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Hao NB, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/948098; Martinez FO, 2006, J IMMUNOL, V177, P7303; Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007; Azim H, 2013, EXPERT REV ANTICANC, V13, P195, DOI [10.1586/era.12.177, 10.1586/ERA.12.177]; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; Fujimura T, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/164982; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Kambayashi Y, 2015, J INVEST DE IN PRESS	12	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	NOV	2015	135	11					2884	2887		10.1038/jid.2015.209		4	Dermatology	Dermatology	CV1DM	WOS:000363993600043		
J	Umehara, Y; Kamata, Y; Tominaga, M; Niyonsaba, F; Ogawa, H; Takamori, K				Umehara, Yoshie; Kamata, Yayoi; Tominaga, Mitsutoshi; Niyonsaba, Francois; Ogawa, Hideoki; Takamori, Kenji			Cathelicidin LL-37 Induces Semaphorin 3A Expression in Human Epidermal Keratinocytes: Implications for Possible Application to Pruritus	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Letter							ATOPIC-DERMATITIS; ANTIMICROBIAL PROTEINS; SCRATCHING BEHAVIOR; NC/NGA MICE; SKIN; PSORIASIS; PEPTIDES; ITCH		[Umehara, Yoshie; Kamata, Yayoi; Tominaga, Mitsutoshi; Ogawa, Hideoki; Takamori, Kenji] Juntendo Univ, Grad Sch Med, Inst Environm & Gender Specif Med, Chiba, Japan; [Niyonsaba, Francois; Ogawa, Hideoki] Juntendo Univ, Grad Sch Med, Atopy Allergy Res Ctr, Tokyo, Japan; [Niyonsaba, Francois] Juntendo Univ, Fac Int Liberal Arts, Tokyo, Japan; [Takamori, Kenji] Juntendo Univ, Urayasu Hosp, Dept Dermatol, Chiba, Japan	Umehara, Y (reprint author), Juntendo Univ, Grad Sch Med, Inst Environm & Gender Specif Med, Chiba, Japan.	ktakamor@juntendo.ac.jp					Niyonsaba F, 2010, J IMMUNOL, V184, P3526, DOI 10.4049/jimmunol.0900712; Negi O, 2012, J DERMATOL SCI, V66, P37, DOI 10.1016/j.jdermsci.2012.01.007; Yamaguchi J, 2008, J INVEST DERMATOL, V128, P2842, DOI 10.1038/jid.2008.150; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Nomura I, 2003, J IMMUNOL, V171, P3262; Yosipovitch G, 2000, BRIT J DERMATOL, V143, P969, DOI 10.1046/j.1365-2133.2000.03829.x; Taneda K, 2011, BRIT J DERMATOL, V165, P277, DOI 10.1111/j.1365-2133.2011.10347.x; Tominaga M, 2008, BRIT J DERMATOL, V158, P842, DOI 10.1111/j.1365-2133.2007.08410.x; Barlow PG, 2014, FUTURE MICROBIOL, V9, P55, DOI 10.2217/fmb.13.135; de Jongh GJ, 2005, J INVEST DERMATOL, V125, P1163, DOI 10.1111/j.0022-202X.2005.23935.x; Schauber J, 2008, J ALLERGY CLIN IMMUN, V122, P261, DOI 10.1016/j.jaci.2008.03.027; Niyonsaba F, 2001, EUR J IMMUNOL, V31, P1066, DOI 10.1002/1521-4141(200104)31:4<1066::AID-IMMU1066>3.0.CO;2-#; Niyonsaba F, 2009, CURR PHARM DESIGN, V15, P2393; Reich A, 2007, MEDIAT INFLAMM, DOI 10.1155/2007/64727; Tominaga M, 2014, J DERMATOL, V41, P205, DOI 10.1111/1346-8138.12317	15	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	NOV	2015	135	11					2887	2890		10.1038/jid.2015.243		4	Dermatology	Dermatology	CV1DM	WOS:000363993600044		
J	Ozawa, T; Osaka, I; Ihozaki, T; Hamada, S; Kuroda, Y; Murakami, T; Miyazato, A; Kawasaki, H; Arakawa, R				Ozawa, Tomoyuki; Osaka, Issey; Ihozaki, Taisuke; Hamada, Satoshi; Kuroda, Yusuke; Murakami, Tatsuya; Miyazato, Akio; Kawasaki, Hideya; Arakawa, Ryuichi			Simultaneous detection of phosphatidylcholines and glycerolipids using matrix-enhanced surface-assisted laser desorption/ionization-mass spectrometry with sputter-deposited platinum film	JOURNAL OF MASS SPECTROMETRY			English	Article						ME-Pt-SALDI; Pt film; MALDI; lipids; imaging mass spectrometry	PROTEIN-KINASE-C; ME-SALDI-MS; SMALL MOLECULES; HGTE NANOSTRUCTURES; BRAIN; CELLS; NANOPARTICLES; ISOZYMES; CANCER; LIPIDS	Matrix-assisted laser desorption/ionisation (MALDI) imaging mass spectrometry (IMS) allows for the simultaneous detection and imaging of several molecules in brain tissue. However, the detection of glycerolipids such as diacylglycerol (DAG) and triacylglycerol (TAG) in brain tissues is hindered in MALDI-IMS because of the ion suppression effect from excessive ion yields of phosphatidylcholine (PC). In this study, we describe an approach that employs a homogeneously deposited metal nanoparticle layer (or film) for the detection of glycerolipids in rat brain tissue sections using IMS. Surface-assisted laser desorption/ionisation IMS with sputter-deposited Pt film (Pt-SALDI-IMS) for lipid analysis was performed as a solvent-free and organic matrix-free method. Pt-SALDI produced a homogenous layer of nanoparticles over the surface of the rat brain tissue section. Highly selective detection of lipids was possible by MALDI-IMS and Pt-SALDI-IMS; MALDI-IMS detected the dominant ion peak of PC in the tissue section, and there were no ion peaks representing glycerolipids such as DAG and TAG. In contrast, Pt-SALDI-IMS allowed the detection of these glycerolipids, but not PC. Therefore, using a hybrid method combining MALDI and Pt-SALDI (i.e., matrix-enhanced [ME]-Pt-SALDI-IMS), we achieved the simultaneous detection of PC, PE and DAG in rat brain tissue sections, and the sensitivity for the detection of these molecules was better than that of MALDI-IMS or Pt-SALDI alone. The present simple ME-Pt-SALDI approach for the simultaneous detection of PC and DAG using two matrices (sputter-deposited Pt film and DHB matrix) would be useful in imaging analyses of biological tissue sections. Copyright (c) 2015 John Wiley & Sons, Ltd.	[Ozawa, Tomoyuki; Ihozaki, Taisuke; Kawasaki, Hideya; Arakawa, Ryuichi] Kansai Univ, Fac Chem Mat & Bioengn, Dept Chem & Mat Engn, Suita, Osaka 5648680, Japan; [Osaka, Issey; Murakami, Tatsuya; Miyazato, Akio] Japan Adv Inst Sci & Technol, Ctr Nano Mat & Technol, Nomi, Ishikawa 9231292, Japan; [Hamada, Satoshi] Nissan Chem Ind Co Ltd, Anal Res Dept, Chem Res Labs, Funabashi, Chiba, Japan; [Kuroda, Yusuke] Nissan Chem Ind Co Ltd, Toxicol & Environm Sci Dept, Biol Res Labs, Funabashi, Chiba, Japan	Osaka, I (reprint author), Japan Adv Inst Sci & Technol, Ctr Nano Mat & Technol, 1-1 Asahidai, Nomi, Ishikawa 9231292, Japan.	o-issey@jaist.ac.jp; arak@kansai-u.ac.jp			Creation of Innovation Centers for Advanced Interdisciplinary Research Area Program in Special Coordination Fund for Promoting Science and Technology; Japan Ministry of Education, Culture, Sports and Technology [24619006, 26505011, 15H03250]; Nanotechnology Platform Program of the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan	The authors acknowledge the support from the Creation of Innovation Centers for Advanced Interdisciplinary Research Area Program in the Special Coordination Fund for Promoting Science and Technology, and the support from the Grant-in-Aid for Scientific Research (C) (24619006) and (26505011) and Scientific Research (B) (15H03250) from the Japan Ministry of Education, Culture, Sports and Technology. This work was partly supported by Nanotechnology Platform Program of the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan.	Abalsamo L, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3151; NITSCH RM, 1992, P NATL ACAD SCI USA, V89, P1671, DOI 10.1073/pnas.89.5.1671; Huang MF, 2012, CHEM SCI, V3, P2147, DOI 10.1039/c2sc01066f; Adibhatla RM, 2007, FUTURE LIPIDOL, V2, P403, DOI 10.2217/17460875.2.4.403; Marvin LF, 2003, CLIN CHIM ACTA, V337, P11, DOI 10.1016/j.cccn.2003.08.008; Schwartz SA, 2004, CLIN CANCER RES, V10, P981, DOI 10.1158/1078-0432.CCR-0927-3; Kawasaki H, 2012, RAPID COMMUN MASS SP, V26, P1849, DOI 10.1002/rcm.6301; Liu Q, 2009, J AM SOC MASS SPECTR, V20, P80, DOI 10.1016/j.jasms.2008.09.011; Hankin JA, 2007, J AM SOC MASS SPECTR, V18, P1646, DOI 10.1016/j.jasms.2007.06.010; Sparvero LJ, 2012, CHEM PHYS LIPIDS, V165, P545, DOI 10.1016/j.chemphyslip.2012.06.001; Su CL, 2007, ANAL CHEM, V79, P1626, DOI 10.1021/ac061747w; SINGER SJ, 1972, SCIENCE, V175, P720, DOI 10.1126/science.175.4023.720; Cerbon J, 2003, BIOCHEM J, V373, P917, DOI 10.1042/BJ20021732; DAVIS MEN, 1990, J NEUROCHEM, V54, P662, DOI 10.1111/j.1471-4159.1990.tb01922.x; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Wang CW, 2014, J AM SOC MASS SPECTR, V25, P1247, DOI 10.1007/s13361-014-0886-z; Coleman RA, 2004, PROG LIPID RES, V43, P134, DOI 10.1016/S0163-7827(03)00051-1; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; Muller L, 2015, KIDNEY INT, V88, P186, DOI 10.1038/ki.2015.3; Fukami K, 2002, J BIOCHEM, V131, P293; Gorter E, 1925, J EXP MED, V41, P439, DOI 10.1084/jem.41.4.439; Brasaemle DL, 2007, J LIPID RES, V48, P2547, DOI 10.1194/jlr.R700014-JLR200; OBEID LM, 1990, J BIOL CHEM, V265, P2370; Mochly-Rosen D, 2012, NAT REV DRUG DISCOV, V11, P937, DOI 10.1038/nrd3871; KARAS M, 1987, INT J MASS SPECTROM, V78, P53, DOI 10.1016/0168-1176(87)87041-6; Garrett TJ, 2007, INT J MASS SPECTROM, V260, P166, DOI 10.1016/j.ijms.2006.09.019; Griner EM, 2007, NAT REV CANCER, V7, P281, DOI 10.1038/nrc2110; Le CH, 2012, ANAL CHEM, V84, P8391, DOI 10.1021/ac301901s; Brown VL, 2015, METHODS MOL BIOL, V1203, P175, DOI 10.1007/978-1-4939-1357-2_17; Passarelli MK, 2011, BBA-MOL CELL BIOL L, V1811, P976, DOI 10.1016/j.bbalip.2011.05.007; Tanaka K, 1988, RAPID COMMUN MASS SP, V2, P151, DOI DOI 10.1002/RCM.1290020802	31	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1076-5174	1096-9888		J MASS SPECTROM	J. Mass Spectrom.	NOV	2015	50	11					1264	1269		10.1002/jms.3700		6	Biochemical Research Methods; Chemistry, Analytical; Spectroscopy	Biochemistry & Molecular Biology; Chemistry; Spectroscopy	CU8DU	WOS:000363772300009		
J	Li, YB; Honda, S; Iwami, K; Ohta, Y; Umeda, N				Li, Yongbo; Honda, Satoshi; Iwami, Kentaro; Ohta, Yoshihiro; Umeda, Norihiro			Analysis of mitochondrial mechanical dynamics using a confocal fluorescence microscope with a bent optical fibre	JOURNAL OF MICROSCOPY			English	Article						Bent optical fibre; CLSM; confocal fluorescence microscope; elastic moduli; flat-ended tip; mitochondria; mitochondrial activity	ATOMIC-FORCE MICROSCOPY; PERMEABILITY TRANSITION PORE; SINGLE MITOCHONDRIA; SPECTRAL-ANALYSIS; CELLS; DEPOLARIZATIONS; SPECTROSCOPY; ELASTICITY; STRESS	The cells in the cardiovascular system are constantly subjected to mechanical forces created by blood flow and the beating heart. The effect of forces on cells has been extensively investigated, but their effect on cellular organelles such as mitochondria remains unclear. We examined the impact of nano-Newton forces on mitochondria using a bent optical fibre (BOF) with a flat-ended tip (diameter exceeding 2 m) and a confocal fluorescence microscope. By indenting a single mitochondrion with the BOF tip, we found that the mitochondrial elastic modulus was proportional to the (-1/2) power of the mitochondrial radius in the 9.6-115 kPa range. We stained the mitochondria with a potential-metric dye (TMRE) and measured the changes in TMRE fluorescence intensity. We confirmed that more active mitochondria exhibit a higher frequency of repetitive transient depolarization. The same trend was observed at forces lower than 50 nN. We further showed that the depolarization frequency of mitochondria decreases under an extremely large force (nearly 100 nN). We conclude that mitochondrial function is affected by physical environmental factors, such as external forces at the nano-Newton level. Lay Description The cells in the heart system are constantly influenced by mechanical forces created by blood flow and the beating heart. The effect of forces on cells has been extensively studied, but their effect on cellular organelles such as mitochondria remains unknown. Mitochondrial function is recognized as important for health, disease, and aging in human or animal cells. Therefore, we examined the impact of nano-Newton forces on mitochondria using a bent optical fibre (BOF) with a flat-ended tip (diameter exceeding 2 m) and a confocal laser scanning microscope. In this method, the flat-ended tip of BOF is utilized to apply forces on a single isolated mitochondrion. Simultaneously, to observe the physiological changes in mitochondria depending on mechanical forces, a membrane potential sensitive dye is used to stain mitochondria. By indenting a single mitochondrion with the BOF tip, we found that the mitochondrial hardness was proportional to the (-1/2) power of the mitochondrial radius in the 9.6-115 kPa range. By observing the physiological changes in mitochondria, we confirmed that more active mitochondria exhibit a higher frequency of repetitive transient depolarization. Interestingly, the same trend was observed when applying forces (lower than 50 nN) on the mitochondrion. We further found that the depolarization frequency of mitochondria decreases under an extremely large force (nearly 100 nN). Finally, we conclude that mitochondrial function is affected by physical environmental factors, such as external forces at the nano-Newton level.	[Li, Yongbo; Honda, Satoshi; Iwami, Kentaro; Umeda, Norihiro] Tokyo Univ Agr & Technol, Dept Mech Syst Engn, Koganei, Tokyo 1848588, Japan; [Ohta, Yoshihiro] Tokyo Univ Agr & Technol, Dept Biotechnol & Life Sci, Koganei, Tokyo 1848588, Japan	Umeda, N (reprint author), Tokyo Univ Agr & Technol, Dept Mech Syst Engn, Koganei, Tokyo 1848588, Japan.	umeda@cc.tuat.ac.jp	Ohta, Yoshihiro/C-8741-2013		Japan Society for the Promotion of Science (JSPS) [25286029]	The authors wish to thank Dr. Atsushi Taguchi, who gave us much valuable advice in the early stages of this work. This work was financially supported by Grant-in-Aid for Scientific Research (B) (Grant No. 25286029) from the Japan Society for the Promotion of Science (JSPS).	Duchen MR, 1998, J CELL BIOL, V142, P975, DOI 10.1083/jcb.142.4.975; Lekka M, 1999, EUR BIOPHYS J BIOPHY, V28, P312, DOI 10.1007/s002490050213; Huser J, 1998, BIOPHYS J, V74, P2129; Shyu KG, 2009, CLIN SCI, V116, P377, DOI 10.1042/CS20080163; Vergun O, 2003, BIOPHYS J, V85, P3358; Lekka M, 2009, NAT NANOTECHNOL, V4, P72, DOI 10.1038/nnano.2009.004; Li YB, 2011, SCI CHINA PHYS MECH, V54, P2225, DOI 10.1007/s11433-011-4533-4; Saxton WM, 2012, J CELL SCI, V125, P2095, DOI 10.1242/jcs.053850; Uechi Y, 2006, BIOCHEM BIOPH RES CO, V344, P1094, DOI 10.1016/j.bbrc.2006.03.233; Muller DJ, 2011, TRENDS CELL BIOL, V21, P461, DOI 10.1016/j.tcb.2011.04.008; Orr AW, 2006, DEV CELL, V10, P11, DOI 10.1016/j.devcel.2005.12.006; Dufrene YF, 2011, NAT METHODS, V8, P123, DOI 10.1038/nmeth0211-123; Torii A, 1996, MEAS SCI TECHNOL, V7, P179, DOI 10.1088/0957-0233/7/2/010; Jacobson J, 2002, J CELL SCI, V115, P1175; Kumar S, 2009, CANCER METAST REV, V28, P113, DOI 10.1007/s10555-008-9173-4; SCARGLE JD, 1982, ASTROPHYS J, V263, P835, DOI 10.1086/160554; Dimitriadis EK, 2002, BIOPHYS J, V82, P2798; Huser J, 1999, BIOCHEM J, V343, P311, DOI 10.1042/0264-6021:3430311; Discher DE, 2005, SCIENCE, V310, P1139, DOI 10.1126/science.1116995; Silberberg YR, 2008, J MOL RECOGNIT, V21, P30, DOI 10.1002/jmr.868; Kuznetsova TG, 2007, MICRON, V38, P824, DOI 10.1016/j.micron.2007.06.011; McKee CT, 2011, TISSUE ENG PART B-RE, V17, P155, DOI [10.1089/ten.TEB.2010.0520, 10.1089/ten.teb.2010.0520]; Hattori T, 2005, BIOPHYS J, V88, P2340, DOI 10.1529/biophysj.104.041483; Collins TJ, 2002, EMBO J, V21, P1616, DOI 10.1093/emboj/21.7.1616; Nakayama S, 2002, BIOCHEM BIOPH RES CO, V290, P23, DOI 10.1006/bbrc.2001.6185; Itabashi T, 2012, P NATL ACAD SCI USA, V109, P7320, DOI 10.1073/pnas.1116749109; Vogel V, 2006, NAT REV MOL CELL BIO, V7, P265, DOI 10.1038/nrm1890; Neuman KC, 2008, NAT METHODS, V5, P491, DOI [10.1038/nmeth.1218, 10.1038/NMETH.1218]; PALMER JW, 1977, J BIOL CHEM, V252, P8731; Bratic A, 2013, J CLIN INVEST, V123, P951, DOI 10.1172/JCI64125; PRESS WH, 1989, ASTROPHYS J, V338, P277, DOI 10.1086/167197; Stockle R, 1999, APPL PHYS LETT, V75, P160, DOI 10.1063/1.124305; Detmer SA, 2007, NAT REV MOL CELL BIO, V8, P870, DOI 10.1038/nrm2275; Boland M. L., 2013, FRONT ONCOL, V3, P1; Cheng G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004632; Engler J. A., 2006, CELL, V126, P677; Gere J. M., 2004, MECH MATER; De Giorgi F, 2000, CELL CALCIUM, V28, P365, DOI 10.1054/ceca.2000.0177; Kwon S., 2011, REV SCI INSTRUM, V82, P1; Li S. Q., 2008, BIOCHEM BIOPH RES CO, V374, P609; Rico F, 2005, J PHYS REV E, V72, P1; Sarid D., 1994, SCANNING FORCE MICRO; Wong P. K., 2002, P SOL STAT SENS ACT, P94	43	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-2720	1365-2818		J MICROSC-OXFORD	J. Microsc..	NOV	2015	260	2					140	151		10.1111/jmi.12277		12	Microscopy	Microscopy	CU4UH	WOS:000363525400004		
J	Snoeren, EMS; Antonio-Cabrera, E; Spiteri, T; Musatov, S; Ogawa, S; Pfaff, DW; Agmo, A				Snoeren, E. M. S.; Antonio-Cabrera, E.; Spiteri, T.; Musatov, S.; Ogawa, S.; Pfaff, D. W.; Agmo, A.			Role of Oestrogen Receptors in Sociosexual Behaviour in Female Rats Housed in a Seminatural Environment	JOURNAL OF NEUROENDOCRINOLOGY			English	Article						sexual behaviour; social behaviour; oestrogen receptor; rats; seminatural environment	MEDIAL PREOPTIC AREA; RATTUS-NORVEGICUS; SEXUAL-BEHAVIOR; ULTRASONIC VOCALIZATIONS; VENTROMEDIAL NUCLEUS; SOCIAL RECOGNITION; NORWAY RATS; PERIPHERAL ANOSMIA; STRIA TERMINALIS; INCENTIVE VALUE	The present study investigated the role of oestrogen receptor (ER) in the ventromedial nucleus of the hypothalamus (VMN), the preoptic area (POA), the medial amygdala (MePD) and the bed nucleus of stria terminalis (BNST) in sociosexual behaviour in female rats. This was conducted in two sets of experiments, with the VMN and POA investigated in the first set, and the MePD and BNST in the second set. The VMN and POA received intense projections from the MePD and BNST. We used a short hairpin RNA encoded within an adeno-associated viral vector directed against the gene for ER to reduce the number of ER in the VMN or POA (first set of experiments) or in the BNST or MePD (second set of experiments) in female rats. The rats were housed in groups of four ovariectomised females and three males in a seminatural environment for 8days. Compared with traditional test set-ups, the seminatural environment provides an arena in which the rats can express their full behavioural repertoire, which allowed us to investigate multiple aspects of social and sexual behaviour in groups of rats. Behavioural observation was performed after oestrogen and progesterone injections. A reduction of ER expression in the VMN or POA diminished the display of paracopulatory behaviours and lordosis responses compared to controls, whereas the lordosis quotient remained unaffected. This suggests that ER in the VMN and POA play an important role in intrinsic sexual motivation. The reduction in ER did not affect the social behaviour of the females, although the males sniffed and pursued the females with reduced ER less than the controls. This suggests that the ER in the VMN and POA is involved in the regulation of sexual attractiveness of females. The ER in the MePD and BNST, on the other hand, plays no role in sociosexual behaviour.	[Snoeren, E. M. S.; Spiteri, T.; Agmo, A.] Univ Tromso, Dept Psychol, N-9037 Tromso, Norway; [Antonio-Cabrera, E.] Univ Autonoma Metropolitana, Dept Reprod Biol, Unidad Iztapalapa, Mexico City, DF, Mexico; [Musatov, S.] Cornell Univ, Lab Mol Neurosurg, Weil Med Coll, New York, NY 10021 USA; [Ogawa, S.] Univ Tsukuba, Lab Behav Neuroendocrinol, Tsukuba, Ibaraki, Japan; [Pfaff, D. W.] Rockefeller Univ, Neurobiol & Behav Lab, New York, NY 10021 USA	Snoeren, EMS (reprint author), Univ Tromso, Dept Psychol, N-9037 Tromso, Norway.	eelke.snoeren@uit.no			Faculty of Health Sciences, University of Tromso; CONACyT [176600]; PAEP-UNAM Fellowships	Financial support was received from the Faculty of Health Sciences, University of Tromso (ES, AA), as well as from CONACyT (176600) and PAEP-UNAM Fellowships (EAC). Knut Olsen and Truls Traasdahl assembled the seminatural environment.	ALBERT DJ, 1992, NEUROSCI BIOBEHAV R, V16, P177, DOI 10.1016/S0149-7634(05)80179-4; Bergheim D, 2015, BEHAV PROCESS, V118, P34, DOI 10.1016/j.beproc.2015.05.011; Guarraci FA, 2006, BRAIN RES, V1076, P163, DOI 10.1016/j.brainres.2005.12.120; Kavaliers M, 2004, GENES BRAIN BEHAV, V3, P189, DOI 10.1111/j.1601-183x.2004.00068.x; MCCLINTOCK MK, 1978, BEHAVIOUR, V67, P67, DOI 10.1163/156853978X00260; Veening JG, 1998, BEHAV BRAIN RES, V92, P181, DOI 10.1016/S0166-4328(97)00190-3; LEMAGNEN J, 1952, ARCH SCI PHYSIOL, V6, P295; Aubele T, 2008, HORM BEHAV, V54, P244, DOI 10.1016/j.yhbeh.2008.04.001; Chu X, 2015, J COMP PSYCHOL, V129, P132, DOI 10.1037/a0038722; GLASER JH, 1983, HORM BEHAV, V17, P18, DOI 10.1016/0018-506X(83)90012-0; Spiteri T, 2009, PHYSIOL BEHAV, V98, P247, DOI 10.1016/j.physbeh.2009.05.001; Tang AC, 2005, HORM BEHAV, V47, P350, DOI 10.1016/j.yhbeh.2004.10.010; Musatov S, 2006, P NATL ACAD SCI USA, V103, P10456, DOI 10.1073/pnas.0603045103; Kato A, 2000, BRAIN RES, V862, P90, DOI 10.1016/S0006-8993(00)02076-X; CANTERAS NS, 1995, J COMP NEUROL, V360, P213, DOI 10.1002/cne.903600203; Mazzucco CA, 2008, BEHAV BRAIN RES, V191, P111, DOI 10.1016/j.bbr.2008.03.016; Snoeren EM, 2014, PHYSIOL BEHAV, V132, P17, DOI 10.1016/j.physbeh.2014.04.048; Spiteri T, 2012, BEHAV BRAIN RES, V230, P11, DOI 10.1016/j.bbr.2012.01.048; Laflamme N, 1998, J NEUROBIOL, V36, P357, DOI 10.1002/(SICI)1097-4695(19980905)36:3<357::AID-NEU5>3.0.CO;2-V; BERGVALL AH, 1991, PHYSIOL BEHAV, V50, P33, DOI 10.1016/0031-9384(91)90494-9; Kondo Y, 2005, JPN J PHYSIOL, V55, P345, DOI 10.2170/jjphysiol.RP001105; MATHEWS D, 1977, HORM BEHAV, V8, P40, DOI 10.1016/0018-506X(77)90019-8; Ogawa S, 1998, ENDOCRINOLOGY, V139, P5070, DOI 10.1210/en.139.12.5070; MASCO DH, 1980, PHYSIOL BEHAV, V24, P1073, DOI 10.1016/0031-9384(80)90050-5; Martinez LA, 2011, HORM BEHAV, V60, P651, DOI 10.1016/j.yhbeh.2011.08.018; MCCLINTOCK MK, 1982, ANIM BEHAV, V30, P410, DOI 10.1016/S0003-3472(82)80052-3; THOR DH, 1977, BEHAV BIOL, V20, P128, DOI 10.1016/S0091-6773(77)90682-4; CARR WJ, 1965, J COMP PHYSIOL PSYCH, V59, P370, DOI 10.1037/h0022036; Spiteri T, 2010, NEUROENDOCRINOLOGY, V91, P142, DOI 10.1159/000255766; Polston EK, 2001, J NEUROENDOCRINOL, V13, P13, DOI 10.1046/j.1365-2826.2001.00596.x; Bialy M, 2000, BEHAV NEUROSCI, V114, P983, DOI 10.1037//0735-7044.114.5.983; HLINAK Z, 1993, HORM BEHAV, V27, P159, DOI 10.1006/hbeh.1993.1012; Yamamuro Y, 2006, ANIM SCI J, V77, P386, DOI 10.1111/j.1740-0929.2006.00363.x; Yamada S, 2009, NEUROSCI LETT, V463, P135, DOI 10.1016/j.neulet.2009.07.074; Spiteri T, 2010, BEHAV BRAIN RES, V210, P211, DOI 10.1016/j.bbr.2010.02.033; PFAFF DW, 1979, J PHYSIOL-LONDON, V288, P189; Garey J, 2002, HORM BEHAV, V42, P294, DOI 10.1006/hbeh.2002.1823; Chu X, 2014, BEHAVIOUR, V151, P1143, DOI 10.1163/1568539X-00003177; Brudzynski SM, 2005, BEHAV GENET, V35, P85, DOI 10.1007/s10519-004-0858-3; KRAMES L, 1973, J COMP PHYSIOL PSYCH, V82, P444, DOI 10.1037/h0034126; ROBITAILLE JA, 1976, BIOL BEHAV, V1, P289; Gu G, 2003, J COMP NEUROL, V460, P542, DOI 10.1002/cne.10677; Pfaff D, 2002, TRENDS NEUROSCI, V25, P45, DOI 10.1016/S0166-2236(00)02084-1; MEISEL RL, 1987, NEUROENDOCRINOLOGY, V45, P201, DOI 10.1159/000124726; MCCLINTOCK MK, 1982, ANIM BEHAV, V30, P398, DOI 10.1016/S0003-3472(82)80051-1; HOSHINA Y, 1994, BEHAV BRAIN RES, V61, P197, DOI 10.1016/0166-4328(94)90160-0; Snoeren EMS, 2013, BEHAV NEUROSCI, V127, P439, DOI 10.1037/a0032027; STERN JJ, 1970, PHYSIOL BEHAV, V5, P519, DOI 10.1016/0031-9384(70)90260-X; BARFIELD RJ, 1986, ANN NY ACAD SCI, V474, P33, DOI 10.1111/j.1749-6632.1986.tb27996.x; Calhoun J.B., 1963, ECOLOGY SOCIOLOGY NO; Ervin KSJ, 2015, HORM BEHAV, V74, P53, DOI 10.1016/j.yhbeh.2015.05.023; gmo A, 2008, GENES BRAIN BEHAV, V7, P70; gmo A, 2003, J COMP PSYCHOL, V117, P3; Hernandez-Gonzalez M, 2008, ANN NY ACAD SCI, V1129, P61, DOI 10.1196/annals.1417.010; McClintock MK, 1984, ADV STUD BEHAV, P1; Ogawa S, 1999, P NATL ACAD SCI USA, V96, P12887, DOI 10.1073/pnas.96.22.12887; Paxinos G., 1998, RAT BRAIN STEREOTAXI; Shimogawa Y, 2015, NEUROSCI RES, V91, P19, DOI 10.1016/j.neures.2014.10.016; Snoeren EMS, 2014, J COMP PSYCHOL, V128, P367, DOI 10.1037/a0036541; Snoeren EMS, 2014, J COMP PSYCHOL, V128, P40, DOI 10.1037/a0033204	60	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-8194	1365-2826		J NEUROENDOCRINOL	J. Neuroendocrinol.	NOV	2015	27	11					803	818		10.1111/jne.12321		16	Endocrinology & Metabolism; Neurosciences	Endocrinology & Metabolism; Neurosciences & Neurology	CU6TD	WOS:000363665600001		
J	Takeda, K; Moriyama, Y				Takeda, Kunio; Moriyama, Yoshiko			Kinetic Aspects of Surfactant-Induced Structural Changes of Proteins - Unsolved Problems of Two-State Model for Protein Denaturation -	JOURNAL OF OLEO SCIENCE			English	Review						surfactant; sodium dodecyl sulfate; protein; denaturation; kinetics	SODIUM DODECYL-SULFATE; BOVINE SERUM-ALBUMIN; FLOW CIRCULAR-DICHROISM; PRESSURE-JUMP METHOD; POLY-L-LYSINE; 130 DEGREES-C; CONFORMATIONAL-CHANGE; GUANIDINE-HYDROCHLORIDE; THERMAL-DENATURATION; RIBONUCLEASE-A	The kinetic mechanism of surfactant-induced protein denaturation is discussed on the basis of not only stopped-flow kinetic data but also the changes of protein helicities caused by the surfactants and the discontinuous mobility changes of surfactant-protein complexes. For example, the a-helical structures of bovine serum albumin (BSA) are partially disrupted due to the addition of sodium dodecyl sulfate (SDS). Formation of SDS-BSA complex can lead to only four complex types with specific mobilities depending on the surfactant concentration. On the other hand, the apparent rate constant of the structural change of BSA increases with an increase of SDS concentration, indicating that the rate of the structural change becomes fast as the degree of the change increases. When a certain amount of surfactant ions bind to proteins, their native structures transform directly to particular structures without passing through intermediate stages that might be induced due to the binding of fewer amounts of the surfactant ions. Furthermore, this review brings up a question about two-state and three-state models, N(sic)D and N(sic)D'(sic)D (N: native state, D: denatured sate, D': intermediate between N and D), which have been often adopted without hesitation in discussion on general denaturations of proteins. First of all, doubtful is whether any equilibrium relationship exists in such denaturation reactions. It cannot be disregarded that the D states in these models differ depending on the changes of intensities of the denaturing factors. The authors emphasize that the denaturations or the structural changes of proteins should be discussed assuming one-way reaction models with no backward processes rather than assuming the reversible two-state reaction models or similar modified reaction models.	[Takeda, Kunio; Moriyama, Yoshiko] Okayama Univ Sci, Fac Engn, Dept Appl Chem & Biotechnol, Kita Ku, Okayama 7000005, Japan	Moriyama, Y (reprint author), Okayama Univ Sci, Fac Engn, Dept Appl Chem & Biotechnol, Kita Ku, 1-1 Ridai Cho, Okayama 7000005, Japan.	moriyama@dac.ous.ac.jp					GREENE RF, 1974, J BIOL CHEM, V249, P5388; TAKEDA K, 1987, J COLLOID INTERF SCI, V117, P120, DOI 10.1016/0021-9797(87)90174-3; ROWE ES, 1973, BIOCHEMISTRY-US, V12, P4822, DOI 10.1021/bi00748a002; OAKES J, 1974, J CHEM SOC FARAD T 1, V70, P2200, DOI 10.1039/f19747002200; PALLANSCH MJ, 1954, J AM CHEM SOC, V76, P1396, DOI 10.1021/ja01634a079; TAKEDA K, 1992, J COLLOID INTERF SCI, V154, P385, DOI 10.1016/0021-9797(92)90153-D; Gonzalez-Jimenez J, 2002, J PROTEIN CHEM, V21, P75, DOI 10.1023/A:1014508610017; Moriyama Y, 2010, J PHYS CHEM B, V114, P2430, DOI 10.1021/jp908700j; GOTO Y, 1990, BIOCHEMISTRY-US, V29, P3480, DOI 10.1021/bi00466a009; LIN LN, 1983, BIOCHEMISTRY-US, V22, P573, DOI 10.1021/bi00272a008; TOWNEND R, 1966, BIOCHEM BIOPH RES CO, V23, P163, DOI 10.1016/0006-291X(66)90522-5; TAKEDA K, 1981, B CHEM SOC JPN, V54, P1793, DOI 10.1246/bcsj.54.1793; SASA K, 1993, J COLLOID INTERF SCI, V157, P516, DOI 10.1006/jcis.1993.1218; TAKEDA K, 1985, ARCH BIOCHEM BIOPHYS, V236, P411, DOI 10.1016/0003-9861(85)90641-1; TAKEDA K, 1983, B CHEM SOC JPN, V56, P1037, DOI 10.1246/bcsj.56.1037; Moriyama Y, 2003, J COLLOID INTERF SCI, V257, P41, DOI 10.1016/S0021-9797(02)00017-6; SCHMID FX, 1979, J MOL BIOL, V135, P199, DOI 10.1016/0022-2836(79)90347-4; KO BPN, 1977, BIOCHEMISTRY-US, V16, P1720, DOI 10.1021/bi00627a031; SUZUKI H, 1988, ANAL BIOCHEM, V172, P259, DOI 10.1016/0003-2697(88)90440-X; SARKAR PK, 1966, P NATL ACAD SCI USA, V55, P981, DOI 10.1073/pnas.55.4.981; Moriyama Y, 2008, J PHYS CHEM B, V112, P16585, DOI 10.1021/jp8067624; SATAKE I, 1973, BIOCHEM BIOPH RES CO, V54, P930, DOI 10.1016/0006-291X(73)90783-3; TAKEDA K, 1985, BIOPOLYMERS, V24, P683, DOI 10.1002/bip.360240408; TAKEDA K, 1991, J COLLOID INTERF SCI, V147, P51, DOI 10.1016/0021-9797(91)90133-S; TANFORD C, 1964, J AM CHEM SOC, V86, P2050, DOI 10.1021/ja01064a028; TAKEDA K, 1982, B CHEM SOC JPN, V55, P2547, DOI 10.1246/bcsj.55.2547; TAKEDA K, 1972, J COLLOID INTERF SCI, V40, P127, DOI 10.1016/0021-9797(72)90182-8; AOKI K, 1958, J AM CHEM SOC, V80, P4904, DOI 10.1021/ja01551a035; TAKEDA K, 1988, BIOCHIM BIOPHYS ACTA, V957, P340, DOI 10.1016/0167-4838(88)90223-3; Moriyama Y, 2012, LANGMUIR, V28, P16268, DOI 10.1021/la3035598; Moriyama Y, 2009, J OLEO SCI, V58, P573, DOI 10.5650/jos.58.573; WEBER K, 1971, J BIOL CHEM, V246, P4504; TAKEDA K, 1982, B CHEM SOC JPN, V55, P1335, DOI 10.1246/bcsj.55.1335; TAKEDA K, 1985, B CHEM SOC JPN, V58, P1210, DOI 10.1246/bcsj.58.1210; DAVIDSON B, 1967, BIOCHEMISTRY-US, V6, P1616, DOI 10.1021/bi00858a008; NITTA K, 1977, BIOCHIM BIOPHYS ACTA, V490, P200, DOI 10.1016/0005-2795(77)90120-9; KHAN MY, 1987, J BIOCHEM-TOKYO, V102, P313; TAKEDA K, 1982, B CHEM SOC JPN, V55, P985, DOI 10.1246/bcsj.55.985; Takeda K, 2007, J PHYS CHEM B, V111, P1244, DOI 10.1021/jp066807g; TAKEDA K, 1991, J AM CHEM SOC, V113, P6700, DOI 10.1021/ja00017a067; MCMEEKIN TL, 1949, J AM CHEM SOC, V71, P3606, DOI 10.1021/ja01179a008; TAKEDA K, 1981, J COLLOID INTERF SCI, V82, P38, DOI 10.1016/0021-9797(81)90121-1; TAKEDA K, 1989, J COLLOID INTERF SCI, V133, P497, DOI 10.1016/S0021-9797(89)80061-X; NOZAKA M, 1978, BIOCHEMISTRY-US, V17, P3753, DOI 10.1021/bi00611a013; TAKEDA K, 1988, J COLLOID INTERF SCI, V125, P307, DOI 10.1016/0021-9797(88)90079-3; HAGERMAN PJ, 1979, BIOCHEMISTRY-US, V18, P293, DOI 10.1021/bi00569a009; AHMAD F, 1978, BIOCHEMISTRY-US, V17, P241, DOI 10.1021/bi00595a008; REYNOLDS JA, 1967, BIOCHEMISTRY-US, V6, P937, DOI 10.1021/bi00855a038; MORIYAMA Y, 1994, ANAL BIOCHEM, V219, P378, DOI 10.1006/abio.1994.1281; TAKEDA K, 1981, AGR BIOL CHEM TOKYO, V45, P777; Putnam FW, 1944, J AM CHEM SOC, V66, P692, DOI 10.1021/ja01233a009; GEKKO K, 1981, BIOCHEMISTRY-US, V20, P4677, DOI 10.1021/bi00519a024; HARTLEY RW, 1975, BIOCHEMISTRY-US, V14, P2367, DOI 10.1021/bi00682a015; HOLZWART.G, 1965, J AM CHEM SOC, V87, P218, DOI 10.1021/ja01080a015; IIO T, 1978, J BIOCHEM-TOKYO, V83, P961; Jones M. N., 1975, PROTEIN SURFACTANT I, P114; Salahuddin A., 1979, BIOCHEMISTRY-US, V9, P1342; Steinhardt J., 1969, BINDING OF ORGANIC I, P234; Takeda K., 2002, ENCY SURFACTANT COLL, P2558; Takeda K., 1978, MICELLIZATION SOLUBI, P305	60	0	0	JAPAN OIL CHEMISTS SOC	TOKYO	YUSHI KOGYO KAIKAN BLDG, 13-11, NIHONBASHI 3-CHOME, CHUO-KU, TOKYO, 103-0027, JAPAN	1345-8957	1347-3352		J OLEO SCI	J. Oleo Sci.	NOV	2015	64	11					1143	1158		10.5650/jos.ess15157		16	Chemistry, Applied; Food Science & Technology	Chemistry; Food Science & Technology	CU8YW	WOS:000363831000001		
J	Beppu, F; Asanuma, M; Kawamura, Y; Nagai, T; Yoshinaga, K; Mizobe, H; Kojima, K; Kasatani, S; Nagao, K; Kubo, A; Kanda, J; Gotoh, N				Beppu, Fumiaki; Asanuma, Masaharu; Kawamura, Yoshinori; Nagai, Toshiharu; Yoshinaga, Kazuaki; Mizobe, Hoyo; Kojima, Koichi; Kasatani, Satoshi; Nagao, Koji; Kubo, Atsushi; Kanda, Jota; Gotoh, Naohiro			Trans-octadecenoic Acid Positional Isomers Have Different Accumulation and Catabolism Properties in Mice	JOURNAL OF OLEO SCIENCE			English	Article						accumulation; catabolism; [C-13]-labeled carbon dioxide; stable isotope label; trans fatty acid isomers	CONJUGATED LINOLEIC-ACID; CORONARY-HEART-DISEASE; DIETARY FATTY-ACIDS; VACCENIC ACID; BETA-OXIDATION; RAT-LIVER; RISK; HUMANS; METABOLISM; HEALTH	Trans fatty acids (TFA) are considered risk factors for cardiovascular disease (CVD), while the details of distribution and metabolism of the individual isomers are not clear. Here we investigated the accumulation and catabolic rate of TFA positional isomers of octadecenoic acid (18:1) in mice. ICR mice were fed deuterium- and [1-C-13] stable isotope-labeled trans-9-18:1 (9t-18:1(star)), trans-10-18:1 (10t-18:1(star)), or trans-11-18:1 (11t-18:1(star)) for 2 or 4 weeks, or a TFA mixture (9t-18:1(star), 10t-18:1(star), and 11t-18:1(star)) for 3 weeks. Analysis of whole-body tissues by gas chromatography-chemical ionization mass spectrometry revealed the highest 9t-18:1(star) levels in the heart. Significant differences in the accumulation of the respective trans-18:1 were observed in the heart and erythrocytes, where 9t- > 11t- > 10t-18:1(star), but no significant difference was observed in the liver or white adipose tissue (WAT). Mice fed on 11t-18:1 demonstrated accumulation of endogenously synthesized conjugated linoleic acid in the liver, WAT, and heart, but any other metabolites were not found in other groups. Furthermore, we analyzed catabolic rates of single-dose-administered trans-18:1(star) isomers into [C-13]-labeled CO2 using isotope-ratio mass spectrometry, and the 10t-18:1*catabolic rate was significantly higher than those of 9t- and 11t-18:1(star). We found that the accumulation and catabolism of trans-18:1 positional isomers varied in these mice. Differential accumulation in tissues suggests that individual TFA positional isomers may play different roles in human health.	[Beppu, Fumiaki; Asanuma, Masaharu; Kawamura, Yoshinori; Gotoh, Naohiro] Tokyo Univ Marine Sci & Technol, Dept Food Sci & Technol, Minato Ku, Tokyo 1088477, Japan; [Nagai, Toshiharu; Yoshinaga, Kazuaki; Mizobe, Hoyo; Kojima, Koichi; Kasatani, Satoshi] Tsukishima Foods Ind Co Ltd, Edogawa Ku, Tokyo 1348520, Japan; [Nagao, Koji] Saga Univ, Dept Appl Biochem & Food Sci, Saga, Saga 8408502, Japan; [Kubo, Atsushi; Kanda, Jota] Tokyo Univ Marine Sci & Technol, Dept Ocean Sci, Minato Ku, Tokyo 1088477, Japan	Gotoh, N (reprint author), Tokyo Univ Marine Sci & Technol, Dept Food Sci & Technol, Minato Ku, 4-5-7 Konan, Tokyo 1088477, Japan.	ngotoh@kaiyodai.ac.jp					Allison D.B., 1999, J AM DIET ASSOC, V99, P175; American Oil Chemists' Society, 1997, OFFICIAL METHODS REC; DeLany JP, 2000, AM J CLIN NUTR, V72, P905; YANG LY, 1990, J LIPID RES, V31, P137; POLLARD MR, 1980, LIPIDS, V15, P306, DOI 10.1007/BF02533545; Teegala SM, 2009, J AOAC INT, V92, P1250; Mozaffarian D, 2008, INT J EPIDEMIOL, V37, P182, DOI 10.1093/ije/dym263; Nagao K, 2005, J BIOSCI BIOENG, V100, P152, DOI 10.1263/jbb.100.152; Gotoh N, 2008, J OLEO SCI, V57, P293, DOI 10.5650/jos.57.293; WILLETT WC, 1993, LANCET, V341, P581, DOI 10.1016/0140-6736(93)90350-P; LANDS WEM, 1965, J AM OIL CHEM SOC, V42, P465, DOI 10.1007/BF02540085; Santora JE, 2000, J NUTR, V130, P208; Du ZY, 2010, LIPIDS, V45, P581, DOI 10.1007/s11745-010-3428-x; ASCHERIO A, 1994, CIRCULATION, V89, P94; Zock PL, 1997, CAN J PHYSIOL PHARM, V75, P211, DOI 10.1139/cjpp-75-3-211; Precht D, 2000, NAHRUNG, V44, P222, DOI 10.1002/1521-3803(20000701)44:4<222::AID-FOOD222>3.0.CO;2-9; FOLCH J, 1957, J BIOL CHEM, V226, P497; Meijer GW, 2001, ATHEROSCLEROSIS, V157, P31, DOI 10.1016/S0021-9150(00)00661-4; Shibata R, 2012, EUR J LIPID SCI TECH, V114, P1340, DOI 10.1002/ejlt.201200164; Yu WF, 2004, J BIOL CHEM, V279, P52160, DOI 10.1074/jbc.M409640200; Allison DB, 1999, J AM DIET ASSOC, V99, P166, DOI 10.1016/S0002-8223(99)00041-3; PARODI PW, 1976, J DAIRY SCI, V59, P1870; LAWSON LD, 1981, BIOCHIM BIOPHYS ACTA, V665, P60, DOI 10.1016/0005-2760(81)90232-0; MAHFOUZ MM, 1980, BIOCHIM BIOPHYS ACTA, V618, P1, DOI 10.1016/0005-2760(80)90047-8; Whigham LD, 2007, AM J CLIN NUTR, V85, P1203; Yoshinaga K, 2014, FOOD CHEM, V160, P39, DOI 10.1016/j.foodchem.2014.03.069; Mozaffarian D, 2006, ATHEROSCLEROSIS SUPP, V7, P29, DOI 10.1016/j.atherosclerosissup.2006.04.007; Salas-Salvado J, 2006, CRIT REV FOOD SCI, V46, P479, DOI 10.1080/10408390600723953; Emken E, 2013, J OLEO SCI, V62, P245, DOI 10.5650/jos.62.245; Oomen CM, 2001, LANCET, V357, P746, DOI 10.1016/S0140-6736(00)04166-0; Turpeinen AM, 2002, AM J CLIN NUTR, V76, P504; JONES PJH, 1985, AM J CLIN NUTR, V42, P769; Ledoux M, 2000, SCI ALIMENT, V20, P393, DOI 10.3166/sda.20.393-411; Bhattacharya A, 2006, J NUTR BIOCHEM, V17, P789, DOI 10.1016/j.jnutbio.2006.02.009; OHLROGGE JB, 1981, J LIPID RES, V22, P955; BATES CJ, 1990, BRIT J NUTR, V63, P553, DOI 10.1079/BJN19900142; Demmelmair H., 1997, EUR J PEDIATR, V156, P70; Gayet-Boyer C, 2014, BRIT J NUTR, V112, P1914, DOI 10.1017/S0007114514002578; Japan Oil Chemists Society, 2013, 244 JOCS; Mozaffarian D, 2006, NEW ENGL J MED, V354, P1601, DOI 10.1056/NEJMra054035; Nakamura Y. K., 2008, NUTR METAB, V21, P5; Tyburcz C, 2009, J NUTR, V139, P257, DOI 10.3945/jn.108.098004; Wolff R. L., 1988, T FATTY ACIDS HUMAN, P1	43	0	0	JAPAN OIL CHEMISTS SOC	TOKYO	YUSHI KOGYO KAIKAN BLDG, 13-11, NIHONBASHI 3-CHOME, CHUO-KU, TOKYO, 103-0027, JAPAN	1345-8957	1347-3352		J OLEO SCI	J. Oleo Sci.	NOV	2015	64	11					1159	1167		10.5650/jos.ess15139		9	Chemistry, Applied; Food Science & Technology	Chemistry; Food Science & Technology	CU8YW	WOS:000363831000002		
J	Miyagawa, Y; Ogawa, T; Nakagawa, K; Adachi, S				Miyagawa, Yayoi; Ogawa, Takenobu; Nakagawa, Kyuya; Adachi, Shuji			Effects of Vegetable Oil Type and Lipophilic Emulsifiers on the Induction Period of Fat Crystallization	JOURNAL OF OLEO SCIENCE			English	Article						crystallization; induction period; low-melting point; rapeseed oil; soybean oil	IN-WATER EMULSIONS; FREEZE-THAW STABILITY; BEHAVIOR; CRYSTALS	The induction period of crystallization, which is defined as the time required for oil to start to crystallize, is useful indicator of the freeze-thaw stability of food emulsions such as mayonnaise. We investigated the induction period of vegetable oils with low melting points, such as rapeseed and soybean oils, which are commonly employed for mayonnaise production. The induction period was measured by monitoring the temperature of a specimen during storage at low temperature. The induction period depended on the type of oil and lipophilic emulsifier, emulsifier concentration, and storage temperature. The effect of the oil type on the induction period depended on the composition of the oil. Differential scanning calorimetry (DSC) analyses of the lipophilic emulsifiers suggested that the melting trend of the emulsifier is strongly related to the induction period.	[Miyagawa, Yayoi; Nakagawa, Kyuya; Adachi, Shuji] Kyoto Univ, Grad Sch Agr, Div Food Sci & Biotechnol, Sakyo Ku, Kyoto 6068502, Japan; [Ogawa, Takenobu] Kyoto Univ, Grad Sch Agr, Div Agron & Hort Sci, Uji, Kyoto 6110011, Japan	Adachi, S (reprint author), Kyoto Univ, Grad Sch Agr, Div Food Sci & Biotechnol, Sakyo Ku, Kyoto 6068502, Japan.	adachi@kais.kyoto-u.ac.jp			Nisshin Seifun Group, Inc.	This study was carried out during the course of the project "The Cereal Science Consortium by Kyoto University, Gifu University, and the Nisshin Seifun Group, Inc.," and was supported financially by the group.	Sato K, 2001, CHEM ENG SCI, V56, P2255, DOI 10.1016/S0009-2509(00)00458-9; Cornacchia L, 2011, FOOD BIOPHYS, V6, P288, DOI 10.1007/s11483-010-9203-y; Rousseau D, 2000, FOOD RES INT, V33, P3, DOI 10.1016/S0963-9969(00)00017-X; BOODE K, 1993, COLLOID SURFACE A, V81, P121, DOI 10.1016/0927-7757(93)80239-B; Ghosh S, 2008, FOOD HYDROCOLLOID, V22, P105, DOI 10.1016/j.foodhyd.2007.04.013; DEMAN JM, 1983, J AM OIL CHEM SOC, V60, P82, DOI 10.1007/BF02540897; Vanapalli SA, 2002, J AGR FOOD CHEM, V50, P5224, DOI 10.1021/jf020319y; Vanapalli SA, 2002, COLLOID SURFACE A, V204, P227, DOI 10.1016/S0927-7757(01)01135-9; Himawan C, 2006, ADV COLLOID INTERFAC, V122, P3, DOI 10.1016/j.cis.2006.06.016; Ma FR, 1999, BIORESOURCE TECHNOL, V70, P1, DOI 10.1016/S0960-8524(99)00025-5; Thanasukarn P, 2004, COLLOID SURFACE A, V246, P49, DOI 10.1016/j.colsurfa.2004.07.018; Sonoda T, 2006, CRYST GROWTH DES, V6, P306, DOI 10.1021/cg050045h; Thanasukarn P, 2004, FOOD HYDROCOLLOID, V18, P1033, DOI 10.1016/j.foodhyd.2004.04.010; Buldo P., 2012, J AM OIL CHEM SOC, V87, P787; Campbell D. S., 2002, FOOD RES INT, V35, P953; Sakamoto M., 2005, Journal of Oleo Science, V54, P211	16	0	0	JAPAN OIL CHEMISTS SOC	TOKYO	YUSHI KOGYO KAIKAN BLDG, 13-11, NIHONBASHI 3-CHOME, CHUO-KU, TOKYO, 103-0027, JAPAN	1345-8957	1347-3352		J OLEO SCI	J. Oleo Sci.	NOV	2015	64	11					1169	1174		10.5650/jos.ess15170		6	Chemistry, Applied; Food Science & Technology	Chemistry; Food Science & Technology	CU8YW	WOS:000363831000003		
J	Oiso, S; Nobe, M; Iwasaki, S; Nii, W; Goto, N; Seki, Y; Nakajimal, K; Nakamura, K; Kariyazono, H				Oiso, Shigeru; Nobe, Miyuki; Iwasaki, Syuhei; Nii, Wakana; Goto, Natsumi; Seki, Yukari; Nakajimal, Kensuke; Nakamura, Kazuo; Kariyazono, Hiroko			Inhibitory Effect of Oleic Acid on Octanoylated Ghrelin Production	JOURNAL OF OLEO SCIENCE			English	Article						AGS-GHRL8 cells; octanoylated ghrelin; oleic acid; linoleic acid; alpha-linolenic acid	GROWTH-HORMONE SECRETAGOGUE; STIMULATES FOOD-INTAKE; DES-ACYL GHRELIN; FATTY-ACIDS; PEPTIDE; ACYLTRANSFERASE; SECRETION; RECEPTOR; SYSTEM; METABOLISM	Ghrelin is a growth hormone-releasing peptide that also displays orexigenic activity. Since serine-3 acylation with octanoylate (octanoylation) is essential for the orexigenic activity of ghrelin, suppression of octanoylation could lead to amelioration or prevention of obesity. To enable the exploration of inhibitors of octanoylated ghrelin production, we developed a cell-based assay system using AGS-GHRL8 cells, in which octanoylated ghrelin concentration increases in the presence of octanoic acid. Using this assay system, we investigated whether fatty acids contained in foods or oils, such as acetic acid, stearic acid, oleic acid, linoleic acid, and alpha-linolenic acid, have inhibitory effects on octanoylated ghrelin production. Acetic acid did not suppress the increase in octanoylated ghrelin production in AGS-GHRL8 cells, which was induced by the addition of octanoic acid. However, stearic acid, oleic acid, linoleic acid, and alpha-linolenic acid significantly suppressed octanoylated ghrelin production, with the effect of oleic acid being the strongest. Additionally, oleic acid decreased the serum concentration of octanoylated ghrelin in mice. The serum concentration of des-acyl ghrelin (without acyl modification) was also decreased, but the decrease was smaller than that of octanoylated ghrelin. Decreased octanoylated ghrelin production likely resulted from post-translational ghrelin processing, as there were no significant differences in gene expression in the stomach between oleic acid-treated mice and controls. These results suggest that oleic acid is a potential inhibitor of octanoylated ghrelin production and that our assay system is a valuable tool for screening compounds with suppressive effects on octanoylated ghrelin production.	[Oiso, Shigeru; Nakajimal, Kensuke; Kariyazono, Hiroko] Nagasaki Int Univ, Grad Sch Pharmaceut Sci, Nagasaki 8593298, Japan; [Oiso, Shigeru; Nobe, Miyuki; Iwasaki, Syuhei; Nii, Wakana; Goto, Natsumi; Seki, Yukari; Nakajimal, Kensuke; Kariyazono, Hiroko] Nagasaki Int Univ, Fac Pharmaceut Sci, Dept Pharm, Nagasaki 8593298, Japan; [Nakamura, Kazuo] Nihon Pharmaceut Univ, Dept Biopharmaceut, Ina, Saitama 3620806, Japan	Kariyazono, H (reprint author), Nagasaki Int Univ, Grad Sch Pharmaceut Sci, 2825-7 Huis Ten Bosch Sasebo, Nagasaki 8593298, Japan.	karihiro@niu.ac.jp			JSPS KAKENHI [25350169]	This work was supported by JSPS KAKENHI Grant Number 25350169.	Druce MR, 2006, INT J OBESITY, V30, P293, DOI 10.1038/sj.ijo.0803158; Yang J, 2008, P NATL ACAD SCI USA, V105, P10750, DOI 10.1073/pnas.0805353105; Razquin C, 2009, EUR J CLIN NUTR, V63, P1387, DOI 10.1038/ejcn.2009.106; Hosoda H, 2000, BIOCHEM BIOPH RES CO, V279, P909, DOI 10.1006/bbrc.2000.4039; Shintani M, 2001, DIABETES, V50, P227, DOI 10.2337/diabetes.50.2.227; Heppner KM, 2011, CURR OPIN ENDOCRINOL, V18, P50, DOI 10.1097/MED.0b013e328341e1d3; Gong Z, 2014, AM J PHYSIOL-ENDOC M, V306, pE28, DOI 10.1152/ajpendo.00306.2013; Akamizu T, 2012, EUR J ENDOCRINOL, V166, P235, DOI 10.1530/EJE-11-0785; Toshinai K, 2006, ENDOCRINOLOGY, V147, P2306, DOI 10.1210/en.2005-1357; Nishi Y, 2005, ENDOCRINOLOGY, V146, P2255, DOI 10.1210/en.2004-0695; Nakazato M, 2001, NATURE, V409, P194, DOI 10.1038/35051587; Oiso S, 2013, J BIOMOL SCREEN, V18, P1035, DOI 10.1177/1087057113489349; Neary NM, 2006, GUT, V55, P135; Takahashi T, 2009, J BIOCHEM, V146, P675, DOI 10.1093/jb/mvp112; Hirasawa A, 2005, NAT MED, V11, P90, DOI 10.1038/nm1168; Chen CY, 2009, PHARMACOL REV, V61, P430, DOI 10.1124/pr.109.001958; Tschop M, 2000, NATURE, V407, P908, DOI 10.1038/35038090; Kojima M, 2005, PHYSIOL REV, V85, P495, DOI 10.1152/physrev.00012.2004; Goodyear S, 2010, MOL BIOL REP, V37, P3697, DOI 10.1007/s11033-010-0022-5; Asakawa A, 2005, GUT, V54, P18, DOI 10.1136/gut.2004.038737; VELASQUEZ OR, 1994, J CLIN INVEST, V93, P479, DOI 10.1172/JCI116996; Yang J, 2008, CELL, V132, P387, DOI 10.1016/j.cell.2008.01.017; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Gutierrez JA, 2008, P NATL ACAD SCI USA, V105, P6320, DOI 10.1073/pnas.0800708105; Romero A, 2010, EUR J ENDOCRINOL, V163, P1, DOI 10.1530/EJE-10-0099; WHELAN J, 1993, J NUTR, V123, P2174; Soupene E, 2008, EXP BIOL MED, V233, P507, DOI 10.3181/0710-MR-287; Wren AM, 2001, J CLIN ENDOCR METAB, V86, P5992, DOI 10.1210/jc.86.12.5992; Wren AM, 2001, DIABETES, V50, P2540, DOI 10.2337/diabetes.50.11.2540; Oiso S, 2012, ONCOL REP, V28, P27, DOI 10.3892/or.2012.1801; Zhu XR, 2006, J BIOL CHEM, V281, P38867, DOI 10.1074/jbc.M607955200; Druce MR, 2005, INT J OBESITY, V29, P1130, DOI 10.1038/sj/ijo.0803001; Wortley KE, 2004, P NATL ACAD SCI USA, V101, P8227, DOI 10.1073/pnas.0402763101; Wren AM, 2000, ENDOCRINOLOGY, V141, P4325, DOI 10.1210/en.141.11.4325; Janssen S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040168; Li Y., 2013, AM J PHYSIOL-ENDOC M, V67, pE651; Yan S, 2015, WORLD J GASTROENTERO, V21, P3492, DOI 10.3748/wjg.v21.i12.3492	37	0	0	JAPAN OIL CHEMISTS SOC	TOKYO	YUSHI KOGYO KAIKAN BLDG, 13-11, NIHONBASHI 3-CHOME, CHUO-KU, TOKYO, 103-0027, JAPAN	1345-8957	1347-3352		J OLEO SCI	J. Oleo Sci.	NOV	2015	64	11					1185	1192		10.5650/jos.ess15137		8	Chemistry, Applied; Food Science & Technology	Chemistry; Food Science & Technology	CU8YW	WOS:000363831000005		
J	Watanabe, Y; Sato, S; Asada, M; Arishima, T; Iida, Y; Imagi, J; Saito, K; Sano, T; Sasaki, A; Sasaki, R; Sato, C; Shibuya, T; Tsukahara, Y; Nagai, T; Fukazawa, T; Hori, R; Homma, R; Miyazaki, Y; Yamashita, A; Yoshinage, K; Watanabe, S				Watanabe, Yomi; Sato, Shinichi; Asada, Mihoko; Arishima, Toshiharu; Iida, Yasuhiro; Imagi, Jun; Saito, Katsuyoshi; Sano, Takashi; Sasaki, Akiko; Sasaki, Ryo; Sato, Chiemi; Shibuya, Tadahisa; Tsukahara, Yuki; Nagai, Toshiharu; Fukazawa, Toru; Hori, Ryuji; Homma, Rika; Miyazaki, Yosuke; Yamashita, Atsushi; Yoshinage, Kazuaki; Watanabe, Shimpei			Enzymatic Analysis of Positional Fatty Acid Distributions in Triacylglycerols by 1(3)-Selective Transesterification with Candida antarctica Lipase B: a Collaborative Study	JOURNAL OF OLEO SCIENCE			English	Article						regiospecific distribution; triacylglycerol; 2-monoacylglycerol; Candida antarctica lipase; collaborative study; transesterification	STEREOSPECIFIC ANALYSIS; TRIGLYCERIDES	The positional distributions of fatty acids (FAs) in fats and oils are principally analyzed by selectively transesterifying the target triacylglycerols (TAGs) at the 1(3) position using Pseudozyma (Candida) antarctica lipase, followed by recovering the resulting 2-monoacylglycerols (MAGs) by chromatography. FA compositions were measured by gas chromatography (GC) after methylating target TAGs and 2-MAGs. The method was collaboratively evaluated by 12 laboratories by analyzing the positional FA distributions in soybean, palm, and sardine oils. The maximum reproducibility relative standard deviations for the major FAs and those at the sn-2 positions of soybean, palm, and sardine oils were 4.41% and 3.92% (18:3n-3), 4.48% and 3.82% (18:0), and 8.93 and 8.24% (14:0), respectively. The values at the sn-2 position were always low. Therefore, these results indicated that the variations were mainly caused by the FA analysis procedure, i.e., the methylation and GC analyses, rather than the enzymatic transesterification and chromatography utilized to prepare 2-MAGs from the target oil.	[Watanabe, Yomi] Osaka Municipal Tech Res Inst, Joto Ku, Osaka 5368553, Japan; [Sato, Shinichi] Japan Food Res Labs, Tama Ku, Tokyo 2060025, Japan; [Asada, Mihoko; Shibuya, Tadahisa; Tsukahara, Yuki] Showa Sangyo Co, Funabashi, Chiba 2730015, Japan; [Arishima, Toshiharu; Watanabe, Shimpei] Fuji Oil Co Ltd, Izumisano, Osaka 5988540, Japan; [Iida, Yasuhiro; Fukazawa, Toru] Japan Assoc Inspect & Invest Foods Including Fats, Chuo Ku, Tokyo 1030007, Japan; [Imagi, Jun; Sano, Takashi; Hori, Ryuji] J Oil Mills Inc, Yokohama, Kanagawa 2300053, Japan; [Saito, Katsuyoshi; Homma, Rika] Kao Co, Sumida Ku, Tokyo 1318501, Japan; [Sasaki, Akiko; Sato, Chiemi] Nisshin OilliO Grp Ltd, Yokosuka, Kanagawa 2390832, Japan; [Sasaki, Ryo] Miyoshi Oil & Fat Co, Katsushika Ku, Tokyo 1248510, Japan; [Miyazaki, Yosuke] NOF Co, Kawasaki Ku, Kawasaki, Kanagawa 2100865, Japan; [Nagai, Toshiharu; Yoshinage, Kazuaki] Tsukishima Foods Ind Co, Edogawa Ku, Tokyo 1348520, Japan; [Yamashita, Atsushi] ADEKA Co, Arakawa Ku, Tokyo 1168553, Japan	Watanabe, Y (reprint author), Osaka Municipal Tech Res Inst, Biomat & Commod Chem Res Div, Joto Ku, 1-6-50 Morinomiya, Osaka 5368553, Japan.	yomi@omtri.or.jp					American Oil Chemists Society (AOCS), 2009, 1B89 AOCS CE; [Anonymous], 2013, JOCS STANDARD METHOD; Watanabe Y, 2014, J AM OIL CHEM SOC, V91, P1323, DOI 10.1007/s11746-014-2481-7; Watanabe Y, 2009, NEW BIOTECHNOL, V26, P23, DOI 10.1016/j.nbt.2009.05.004; LUDDY FE, 1964, J AM OIL CHEM SOC, V41, P693, DOI 10.1007/BF02661412; Irimescu R, 2001, J AM OIL CHEM SOC, V78, P285, DOI 10.1007/s11746-001-0258-3; BROCKERH.H, 1965, J LIPID RES, V6, P10; CHRISTIE WW, 1991, J AM OIL CHEM SOC, V68, P695, DOI 10.1007/BF02662155; Gunstone F. D, C NMR SPECTROSCOPY F; Japan Oil Chemists' Society (JOCS), 2013, STAND METH AN FATS O; JOCS, STAND METH AN FATS O; Kosugi Y., 2002, Journal of Oleo Science, V51, P599; Takagi T, 1991, PROG LIPID RES, V29, P277; Yoshinaga K., 2015, J OLEO SCI, V60, P617	14	0	0	JAPAN OIL CHEMISTS SOC	TOKYO	YUSHI KOGYO KAIKAN BLDG, 13-11, NIHONBASHI 3-CHOME, CHUO-KU, TOKYO, 103-0027, JAPAN	1345-8957	1347-3352		J OLEO SCI	J. Oleo Sci.	NOV	2015	64	11					1193	1205		10.5650/jos.ess15182		13	Chemistry, Applied; Food Science & Technology	Chemistry; Food Science & Technology	CU8YW	WOS:000363831000006		
J	Kotake-Nara, E; Yonekura, L; Nagao, A				Kotake-Nara, Eiichi; Yonekura, Lina; Nagao, Akihiko			Lysoglyceroglycolipids Improve the Intestinal Absorption of Micellar Fucoxanthin by Caco-2 Cells	JOURNAL OF OLEO SCIENCE			English	Article						Caco-2; fucoxanthin; glyceroglycolipid; intestinal absorption; mixed micelles	CAROTENOID UPTAKE; MIXED MICELLES; SECRETION; HUMANS	To improve the intestinal absorption of fucoxanthin, we evaluated the effects of dietary glyceroglycolipids on the uptake and secretion of fucoxanthin solubilized in mixed micelles by human intestinal Caco-2 cells. Although digalactosyldiacylglycerol and sulfoquinovosyldiacylglycerol suppressed fucoxanthin uptake and secretion, their lyso-types, digalactosylmonoacylglycerol and sulfoquinovosylmonoa cylglycerol, remarkably enhanced them. Thus, some dietary glyceroglycolipids may be potential enhancers of fucoxanthin bioavailability in humans.	[Kotake-Nara, Eiichi; Yonekura, Lina; Nagao, Akihiko] Natl Agr & Food Res Org, Natl Food Res Inst, Tsukuba, Ibaraki 3058642, Japan	Kotake-Nara, E (reprint author), Natl Agr & Food Res Org, Natl Food Res Inst, 2-1-12 Kannondai, Tsukuba, Ibaraki 3058642, Japan.	ekotake@affrc.go.jp			JSPS KAKENHI [24500962]	This work was supported in part by JSPS KAKENHI Grant Number 24500962.	Sawai T, 2002, PEDIATR SURG INT, V18, P591, DOI 10.1007/s00383-002-0860-x; Kotake-Nara E, 2005, CANCER LETT, V220, P75, DOI 10.1016/j.canlet.2004.07.048; Asai A, 2008, BRIT J NUTR, V100, P273, DOI 10.1017/S0007114507895468; Kotake-Nara E, 2015, LIPIDS, V50, P847, DOI 10.1007/s11745-015-4033-9; During A, 2002, J LIPID RES, V43, P1086, DOI 10.1194/jlr.M200068-JLR200; Sugawara T, 2002, J NUTR, V132, P946; FIELD FJ, 1994, BIOCHEM J, V304, P35; Yonekura L, 2006, LIPIDS, V41, P629, DOI 10.1007/s11745-006-5013-x; Kotake-Nara E, 2012, BIOSCI BIOTECH BIOCH, V76, P875, DOI 10.1271/bbb.110777; Kotake-Nara E, 2011, MAR DRUGS, V9, P1024, DOI 10.3390/md9061024; Barua AB, 1999, BIOCHEM J, V339, P359, DOI 10.1042/0264-6021:3390359; Hashimoto T, 2012, BRIT J NUTR, V107, P1566, DOI 10.1017/S0007114511004879; Fleet JC, 1996, ARCH BIOCHEM BIOPHYS, V329, P228, DOI 10.1006/abbi.1996.0213; Sugawara T, 2001, J NUTR, V131, P2921	14	0	0	JAPAN OIL CHEMISTS SOC	TOKYO	YUSHI KOGYO KAIKAN BLDG, 13-11, NIHONBASHI 3-CHOME, CHUO-KU, TOKYO, 103-0027, JAPAN	1345-8957	1347-3352		J OLEO SCI	J. Oleo Sci.	NOV	2015	64	11					1207	1211		10.5650/jos.ess15180		5	Chemistry, Applied; Food Science & Technology	Chemistry; Food Science & Technology	CU8YW	WOS:000363831000007		
J	Shimotori, Y; Hashi, M; Okabe, H; Miyakoshi, T				Shimotori, Yasutaka; Hashi, Masayuki; Okabe, Hayato; Miyakoshi, Tetsuo			Preparation of Optically Active delta-Tri- and delta-Tetradecalactones by a Combination of Novozym 435-catalyzed Enantioselective Methanolysis and Amidation	JOURNAL OF OLEO SCIENCE			English	Article						delta-tridecalactone; delta-tetradecalactone; lipase-catalyzed kinetic resolution; methanolysis; amidation	SOLID-PHASE MICROEXTRACTION; CHROMATOGRAPHY-MASS-SPECTROMETRY; STEREOISOMERIC FLAVOR COMPOUNDS; GAS-CHROMATOGRAPHY; VOLATILE COMPOUNDS; ENZYME-ACTIVITY; BAKERS-YEAST; HEATED BEEF; FATTY-ACID; LACTONES	A combination of Novozym 435-catalyzed methanolysis and amidation using racemic N-methyl-5-acetoxytridecan- and tetradecanamides as a substrate proceeded in good enantioselectivity to afford the corresponding (R)-N-methyl-5-acetoxyalkanamides, (S)-N-methyl-S-hydroxyalkanamides, and (S)-N-cyclohexyl-5-hydroxyalkanamides. Both enantiomers of delta-tri- and delta-tetradecalactones were synthesized in over 90% enantiomeric excesses from the corresponding (R)- or (S)-alkanamides. Addition of cyclohexylamine to Novozym 435-catalyzed methanolysis shortened 24-hour reaction time to reach about 50% conversion. Enantiomers of optically active delta-tri- and delta-tetradecalactones had different odors and thresholds.	[Shimotori, Yasutaka; Hashi, Masayuki] Kitami Inst Technol, Dept Biotechnol & Environm Chem, Kitami, Hokkaido 0908507, Japan; [Okabe, Hayato; Miyakoshi, Tetsuo] Meiji Univ, Sch Sci & Technol, Dept Appl Chem, Tama Ku, Kawasaki, Kanagawa 2148571, Japan	Shimotori, Y (reprint author), Kitami Inst Technol, Dept Biotechnol & Environm Chem, 165 Koen Cho, Kitami, Hokkaido 0908507, Japan.	yasu@mail.kitami-it.ac.jp					Shimotori Y, 2012, SYNTHETIC COMMUN, V42, P694, DOI 10.1080/00397911.2010.529230; LEHMANN D, 1995, Z LEBENSM UNTERS FOR, V201, P55, DOI 10.1007/BF01193201; Tamogami S, 2001, FLAVOUR FRAG J, V16, P161, DOI 10.1002/ffj.969; Cho IJ, 2013, INT IMMUNOPHARMACOL, V16, P457, DOI 10.1016/j.intimp.2013.05.008; TAYLOR DL, 1995, J AGR FOOD CHEM, V43, P2369, DOI 10.1021/jf00057a010; Van Hoorde K, 2010, INT J FOOD MICROBIOL, V144, P226, DOI 10.1016/j.ijfoodmicro.2010.05.007; Lesniak A, 2014, J MOL CATAL B-ENZYM, V106, P32, DOI 10.1016/j.molcatb.2014.04.014; Nishida R, 1996, J CHEM ECOL, V22, P949, DOI 10.1007/BF02029947; Bendall JG, 2001, J AGR FOOD CHEM, V49, P4825, DOI 10.1021/jf010334n; Kayser MM, 1998, J ORG CHEM, V63, P7103, DOI 10.1021/jo980737v; Brentnall C, 2012, RES VET SCI, V93, P1387, DOI 10.1016/j.rvsc.2012.05.002; MOSANDL A, 1989, J AGR FOOD CHEM, V37, P413, DOI 10.1021/jf00086a031; Paez BC, 2003, ENZYME MICROB TECH, V33, P845, DOI 10.1016/S0141-0229(03)00219-9; UM KW, 1992, J AGR FOOD CHEM, V40, P1641, DOI 10.1021/jf00021a033; Steingass CB, 2015, FOOD CHEM, V168, P496, DOI 10.1016/j.foodchem.2014.07.071; Lemke K, 1997, J ORG CHEM, V62, P6268, DOI 10.1021/jo970838d; Bourne CR, 2013, BBA-PROTEINS PROTEOM, V1834, P46, DOI 10.1016/j.bbapap.2012.09.001; Watkins PJ, 2012, MEAT SCI, V91, P99, DOI 10.1016/j.meatsci.2011.12.004; Stangeland EL, 2004, J ORG CHEM, V69, P2381, DOI 10.1021/jo0351217; Palval IN, 2011, J MOL LIQ, V158, P33, DOI 10.1016/j.molliq.2010.10.004; JOLLY RC, 1975, J AGR FOOD CHEM, V23, P1175, DOI 10.1021/jf60202a032; Abboud JLM, 1999, PURE APPL CHEM, V71, P645, DOI 10.1351/pac199971040645; SHIRATSUCHI H, 1995, J AGR FOOD CHEM, V43, P2453, DOI 10.1021/jf00057a026; Zhang B, 2011, POSTHARVEST BIOL TEC, V60, P7, DOI 10.1016/j.postharvbio.2010.09.012; Van Leuven I, 2008, INT DAIRY J, V18, P790, DOI 10.1016/j.idairyj.2008.01.001; Schlutt B, 2007, J AGR FOOD CHEM, V55, P9634, DOI 10.1021/jf0721545; IKAN R, 1969, J INSECT PHYSIOL, V15, P1709, DOI 10.1016/0022-1910(69)90003-1; Chidley HG, 2013, FOOD CHEM, V136, P585, DOI 10.1016/j.foodchem.2012.08.029; VANDEWEGHE P, 1990, J AGR FOOD CHEM, V38, P1549, DOI 10.1021/jf00097a026; Yamashita Y, 2014, BIOORGAN MED CHEM, V22, P3488, DOI 10.1016/j.bmc.2014.04.029; George J, 2003, J CHEM THERMODYN, V35, P1837, DOI 10.1016/j.jct.2003.07.003; LAURENCE BR, 1982, J CHEM SOC CHEM COMM, P59, DOI 10.1039/c39820000059; Villeneuve MP, 2013, J DAIRY SCI, V96, P7181, DOI 10.3168/jds.2013-6785; MOSANDL A, 1988, Z LEBENSM UNTERS FOR, V187, P40, DOI 10.1007/BF01454321; Wilkinson KL, 2004, TETRAHEDRON, V60, P6091, DOI 10.1016/j.tet.2004.05.070; Ghosh AK, 2008, TETRAHEDRON-ASYMMETR, V19, P1020, DOI 10.1016/j.tetasy.2008.04.005; Lu ZM, 2011, FOOD CHEM, V127, P662, DOI 10.1016/j.foodchem.2010.12.111; Yamamoto T, 2002, TETRAHEDRON LETT, V43, P9081, DOI 10.1016/S0040-4039(02)02312-2; Tanaka H, 2007, LIFE SCI, V80, P1851, DOI 10.1016/j.lfs.2007.02.028; BERNREUTHER A, 1989, J CHROMATOGR, V481, P363, DOI 10.1016/S0021-9673(01)96780-9; Zoute L, 2011, TETRAHEDRON LETT, V52, P2473, DOI 10.1016/j.tetlet.2011.03.014; Cosse AA, 2001, J CHEM ECOL, V27, P1841, DOI 10.1023/A:1010412826373; Rodrigues RC, 2008, J AM OIL CHEM SOC, V85, P925, DOI 10.1007/s11746-008-1284-0; Shimotori Y, 2015, J OLEO SCI, V64, P561, DOI 10.5650/jos.ess14232; Bryantsev VS, 2012, J PHYS CHEM A, V116, P7128, DOI 10.1021/jp301537w; UTAKA M, 1987, J ORG CHEM, V52, P4363, DOI 10.1021/jo00228a039; Bernreuther A, 1991, PHYTOCHEM ANALYSIS, V2, P43, DOI 10.1002/pca.2800020109; DEGN H, 1992, BIOTECHNOL TECH, V6, P161; Fozard JR, 2001, PULM PHARMACOL THER, V14, P289, DOI 10.1006/pupt.2001.0295; Riddick J. A., 1986, TECHNIQUES CHEM, V2; Shaikh M. M., 2013, J PHARM RES, V6, P21; Shimotori Y, 2015, J OLEO SCI, V64, P75, DOI 10.5650/jos.ess14124; Spinola V, 2015, FOOD RES INT, V67, P409, DOI 10.1016/j.foodres.2014.11.055	53	0	0	JAPAN OIL CHEMISTS SOC	TOKYO	YUSHI KOGYO KAIKAN BLDG, 13-11, NIHONBASHI 3-CHOME, CHUO-KU, TOKYO, 103-0027, JAPAN	1345-8957	1347-3352		J OLEO SCI	J. Oleo Sci.	NOV	2015	64	11					1213	1226		10.5650/jos.ess15120		14	Chemistry, Applied; Food Science & Technology	Chemistry; Food Science & Technology	CU8YW	WOS:000363831000008		
J	Nakahashi, H; Nishino, Y; Nakagawa, H; Hara, N; Usami, A; Miyazawa, M				Nakahashi, Hiroshi; Nishino, Yuka; Nakagawa, Hiroki; Hara, Nobuyuki; Usami, Atsushi; Miyazawa, Mitsuo			Evaluation of the Key Odorants in Volatile Oils from Tubers of Apios americana Medikus	JOURNAL OF OLEO SCIENCE			English	Article						Apios americana; essential oil; hydrodistillation; solvent-assisted flavor evaporation (SAFE); aroma extract dilution analysis (AEDA)	AROMA COMPOUNDS; ACIDS; CROP	This study was investigated the chemical composition of volatile oils and aroma evaluation from the tubers of Apios americana Medikus. Theses volatile oils were obtained by the hydrodistillation (HD) and the solvent-assisted flavor evaporation (SAFE) methods. These oils were analyzed by Gas chromatography (GC), GC-mass spectrometry (GC-MS), GC-olfactometry (GC-O), aroma extract dilution analysis (AEDA) and odor activity values (OAV) for the first time. The major compounds in the HD oil were palmitic acid (36.5%), linoleic acid (10.5%) and nonadecanol (5.7%). Meanwhile, in the SAFE oil, the major compounds were 4-hydroxy-4-methyl-2-pentanone (34.2%), hexanal (11.0%) and hexanol (7.9%). Through aroma evaluation, 20 (HD) and 14 (SAFE) aroma-active compounds were identified by GC-0. As a result, the most intense aroma-active compounds in both extraction methods were 1-octen-3-ol and hexanal, both of which showed high odor activity values (OAV).	[Nakahashi, Hiroshi; Nishino, Yuka; Nakagawa, Hiroki; Hara, Nobuyuki; Usami, Atsushi; Miyazawa, Mitsuo] Kinki Univ, Fac Sci & Engn, Dept Appl Chem, Higashiosaka, Osaka 5778502, Japan	Miyazawa, M (reprint author), Kinki Univ, Fac Sci & Engn, Dept Appl Chem, 3-4-1 Kowakae, Higashiosaka, Osaka 5778502, Japan.	miyazawa@apch.kindai.ac.jp					Adams R. P., 2007, IDENTIFICATION ESSEN; Nara K, 2011, FOOD CHEM, V124, P703, DOI 10.1016/j.foodchem.2010.05.107; OKUBO K, 1994, BIOSCI BIOTECH BIOCH, V58, P2248; WALTER WM, 1986, J AGR FOOD CHEM, V34, P39, DOI 10.1021/jf00067a010; Nejia H, 2013, NAT PROD RES, V27, P1795, DOI 10.1080/14786419.2012.755680; WILSON PW, 1986, J FOOD SCI, V51, P1387, DOI 10.1111/j.1365-2621.1986.tb13136.x; Fang Y, 2005, FLAVOUR FRAG J, V20, P22, DOI 10.1002/ffj.1551; Krishnan HB, 1998, CROP SCI, V38, P1052; Greger V, 2007, J AGR FOOD CHEM, V55, P5221, DOI 10.1021/jf0705015; HOSHIKAWA K, 1995, JPN J CROP SCI, V64, P323; Zeller A, 2006, J AGR FOOD CHEM, V54, P3686, DOI 10.1021/jf052944j; BUTTERY RG, 1969, J AGR FOOD CHEM, V17, P1322, DOI 10.1021/jf60166a061; BUTTERY RG, 1988, J AGR FOOD CHEM, V36, P1006, DOI 10.1021/jf00083a025; Yang C, 2010, J SCI FOOD AGR, V90, P1268, DOI 10.1002/jsfa.3969; PUTNAM DH, 1991, HORTSCIENCE, V26, P853; Grosch Werner, 1994, Flavour and Fragrance Journal, V9, P147, DOI 10.1002/ffj.2730090403; WILSON PW, 1987, J FOOD SCI, V52, P224, DOI 10.1111/j.1365-2621.1987.tb14013.x; Strik BC, 2007, HORTTECHNOLOGY, V17, P205; Engel W, 1999, EUR FOOD RES TECHNOL, V209, P237, DOI 10.1007/s002170050486; BLACKMON WJ, 1986, HORTSCIENCE, V21, P1334; BEARDSLEY GRETCHEN, 1939, PAPERS MICHIGAN ACAD SCI ARTS AND LETT, V25, P507; Gemert L. J., 1999, COMPILATIONS ODOUR T; Gemert L. J., 1977, COMPILATIONS ODOUR T; Gemert L. J., 2003, COMPILATIONS ODOUR T; Hoshikawa J, 1996, JPN J CROP SCI, V65, P98; Juliarni, 1997, JPN J CROP SCI, V66, P466; Kinugasa H., 1992, SONODA WOMENS COLL S, V26, P209; Pino A. J., 2006, FLAVOUR FRAG J, V21, P207; Rychlik M., 1998, COMPILATION ODOR THR; TAMURA H, 1993, ACS SYM SER, V525, P121	30	0	0	JAPAN OIL CHEMISTS SOC	TOKYO	YUSHI KOGYO KAIKAN BLDG, 13-11, NIHONBASHI 3-CHOME, CHUO-KU, TOKYO, 103-0027, JAPAN	1345-8957	1347-3352		J OLEO SCI	J. Oleo Sci.	NOV	2015	64	11					1235	1242		10.5650/jos.ess15132		8	Chemistry, Applied; Food Science & Technology	Chemistry; Food Science & Technology	CU8YW	WOS:000363831000010		
J	Tanaka, M; Tajima, S; Mizuno, K; Ishii, A; Konishi, Y; Miike, T; Watanabe, Y				Tanaka, Masaaki; Tajima, Seiki; Mizuno, Kei; Ishii, Akira; Konishi, Yukuo; Miike, Teruhisa; Watanabe, Yasuyoshi			Frontier studies on fatigue, autonomic nerve dysfunction, and sleep-rhythm disorder	JOURNAL OF PHYSIOLOGICAL SCIENCES			English	Review						Autonomic nervous system; Central nervous system; Circadian rhythm; Fatigue; Sleep	HEART-RATE-VARIABILITY; POSITRON-EMISSION-TOMOGRAPHY; MONOZYGOTIC TWINS DISCORDANT; IMMUNOLOGICALLY INDUCED FATIGUE; ANTERIOR CINGULATE CORTEX; BRAIN INTERFERON-ALPHA; CORE BODY-TEMPERATURE; SLOW-WAVE SLEEP; MENTAL FATIGUE; PHYSICAL FATIGUE	Fatigue is defined as a condition or phenomenon of decreased ability and efficiency of mental and/or physical activities, caused by excessive mental or physical activities, diseases, or syndromes. It is often accompanied by a peculiar sense of discomfort, a desire to rest, and reduced motivation, referred to as fatigue sensation. Acute fatigue is a normal condition or phenomenon that disappears after a period of rest; in contrast, chronic fatigue, lasting at least 6 months, does not disappear after ordinary rest. Chronic fatigue impairs activities and contributes to various medical conditions, such as cardiovascular disease, epileptic seizures, and death. In addition, many people complain of chronic fatigue. For example, in Japan, more than one third of the general adult population complains of chronic fatigue. It would thus be of great value to clarify the mechanisms underlying chronic fatigue and to develop efficient treatment methods to overcome it. Here, we review data primarily from behavioral, electrophysiological, and neuroimaging experiments related to neural dysfunction as well as autonomic nervous system, sleep, and circadian rhythm disorders in fatigue. These data provide new perspectives on the mechanisms underlying chronic fatigue and on overcoming it.	[Tanaka, Masaaki; Ishii, Akira; Watanabe, Yasuyoshi] Osaka City Univ, Grad Sch Med, Dept Physiol, Abeno Ku, Osaka 5458585, Japan; [Tajima, Seiki; Konishi, Yukuo; Miike, Teruhisa] Hyogo Rehabil Ctr, Hyogo Childrens Sleep & Dev Med Res Ctr, Nishi Ku, Kobe, Hyogo 6512181, Japan; [Mizuno, Kei; Watanabe, Yasuyoshi] RIKEN Ctr Life Sci Technol, Chuo Ku, Kobe, Hyogo 6500047, Japan	Watanabe, Y (reprint author), Osaka City Univ, Grad Sch Med, Dept Physiol, Abeno Ku, 1-4-3 Asahimachi, Osaka 5458585, Japan.	masa-t@msic.med.osaka-cu.ac.jp; yywata@riken.jp			Ministry of Health, Labour and Welfare of Japan [H25-Shinkei/Kin-Ippan-006]; Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan [15H02502, 25282211, 26282189, 26282185, 10020007, 24119004, 23700804, 25750351]; MEXT	This work was supported by the Ministry of Health, Labour and Welfare of Japan (Grant number H25-Shinkei/Kin-Ippan-006 to Y.W.). This work was also supported by a Grant-in-Aid for Scientific Research (A) (Grant number 15H02502 to Y.W.) (B) (Grant numbers 25282211 and 26282189 to K.M. and 26282185 to M.T.), Research Activity Start-up (Grant number 10020007 to A.I.), Scientific Research on Innovative Areas "Constructive Developmental Science'' (Grant number 24119004 to S.T.), and for Young Scientists (B) (Grant numbers 23700804 and 25750351 to A.I.) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan. We organized an integrated research project titled "The molecular/neural mechanisms of fatigue and fatigue sensation and the way to overcome chronic fatigue'' under the control of the Ministry of Education, Culture, Sports, Science, and Technology (MEXT), Japanese Government, and carried it out from 1999 to 2005. This research project was followed by the 21st Century COE program "Base to overcome fatigue'', from 2005 to 2009 and the Grant-in-Aid for Scientific Research (A), from 2015 to 2020, supported by MEXT. We would like to thank Forte Science Communications for editorial assistance with the manuscript.	Aerenhouts D, 2014, DISABIL REHABIL, V16, P1; ALEXANDER GE, 1990, TRENDS NEUROSCI, V13, P266, DOI 10.1016/0166-2236(90)90107-L; Boneva RS, 2007, AUTON NEUROSCI-BASIC, V137, P94, DOI 10.1016/j.autneu.2007.08.002; Guilleminault C, 2006, SLEEP MED, V7, P513, DOI 10.1016/j.sleep.2006.03.016; Filippi M, 2002, NEUROIMAGE, V15, P559, DOI 10.1006/nimg.2001.1011; Koyama H, 2010, CLIN J AM SOC NEPHRO, V5, P659, DOI 10.2215/CJN.08151109; Vogt BA, 2006, NEUROIMAGE, V29, P452, DOI 10.1016/j.neuroimage.2005.07.048; Ataka S, 2007, NUTRITION, V23, P419, DOI 10.1016/j.nut.2007.03.002; Katafuchi T, 2003, NEUROSCIENCE, V120, P837, DOI 10.1016/S0306-4522(03)00365-8; Hamilos DL, 2001, CLIN PHYSIOL, V21, P184, DOI 10.1046/j.1365-2281.2001.00321.x; Neu D, 2009, J CLIN NEUROPHYSIOL, V26, P207, DOI 10.1097/WNP.0b013e3181a1841b; Thayer JF, 2006, ANN NY ACAD SCI, V1088, P361, DOI 10.1196/annals.1366.014; Dettmers C, 1996, NEUROREPORT, V7, P2103, DOI 10.1097/00001756-199609020-00008; Ataka S, 2008, NUTRITION, V24, P233, DOI 10.1016/j.nut.2007.12.002; Nakamura T, 2013, CLIN VACCINE IMMUNOL, V20, P1736, DOI 10.1128/CVI.00527-13; Cheng Y, 2008, NEUROIMAGE, V40, P1833, DOI 10.1016/j.neuroimage.2008.01.064; Lim J, 2010, NEUROIMAGE, V49, P3426, DOI 10.1016/j.neuroimage.2009.11.020; Paus T, 2001, EUR J NEUROSCI, V14, P1405, DOI 10.1046/j.0953-816x.2001.01757.x; TANJI J, 1988, J NEUROPHYSIOL, V60, P325; Tanaka M, 2008, NUTRITION, V24, P599, DOI 10.1016/j.nut.2008.03.001; GIBSON H, 1993, J NEUROL NEUROSUR PS, V56, P993, DOI 10.1136/jnnp.56.9.993; Tanaka M, 2012, J NEUROL SCI-TURK, V29, P542; Korotkov A, 2005, EXP BRAIN RES, V163, P65, DOI 10.1007/s00221-004-2141-5; Iwatani N, 1997, CLIN ENDOCRINOL, V47, P273, DOI 10.1046/j.1365-2265.1997.2191095.x; Liu JZ, 2007, NEUROIMAGE, V35, P299, DOI 10.1016/j.neuroimage.2006.09.050; Chaudhuri A, 2000, J NEUROL SCI, V179, P34, DOI 10.1016/S0022-510X(00)00411-1; Tanaka M, 2014, BRAIN RES, V1542, P49, DOI 10.1016/j.brainres.2013.10.018; Botvinick M, 2005, NEUROIMAGE, V25, P312, DOI 10.1016/j.neuroimage.2004.11.043; Chaudhuri A, 2004, LANCET, V363, P978, DOI 10.1016/S0140-6736(04)15794-2; Boksem MAS, 2008, BRAIN RES REV, V59, P125, DOI 10.1016/j.brainresrev.2008.07.001; Johnson SA, 2006, J INT NEUROPSYCH SOC, V12, P668, DOI 10.1017/S1355617706060802; Neu D, 2007, NEUROPSYCHOBIOLOGY, V56, P40, DOI 10.1159/000110727; Taylor JL, 2008, J APPL PHYSIOL, V104, P542, DOI 10.1152/japplphysiol.01053.2007; TOMODA A, 1994, BRAIN DEV-JPN, V16, P71, DOI 10.1016/0387-7604(94)90117-1; Varela F, 2001, NAT REV NEUROSCI, V2, P229, DOI 10.1038/35067550; van Heukelom RO, 2006, EUR J NEUROL, V13, P55; Ohinata J, 2008, BRAIN DEV-JPN, V30, P329, DOI 10.1016/j.braindev.2007.10.004; Sisto SA, 1996, AM J MED, V100, P634, DOI 10.1016/S0002-9343(96)00041-1; Ishii A, 2012, BRAIN RES, V1455, P68, DOI 10.1016/j.brainres.2012.03.031; Pall ML, 2000, MED HYPOTHESES, V54, P115, DOI 10.1054/mehy.1998.0825; Le Bon O, 2012, PSYCHIAT RES, V200, P742, DOI 10.1016/j.psychres.2012.06.027; Fabbri-Destro M, 2008, PHYSIOLOGY, V23, P171, DOI 10.1152/physiol.00004.2008; Watson NF, 2003, SLEEP, V26, P324; Mizuno K, 2012, NEUROPSYCHOLOGIA, V50, P1998, DOI 10.1016/j.neuropsychologia.2012.04.025; de Lange FP, 2008, BRAIN, V131, P2172, DOI 10.1093/brain/awn140; Tanaka M, 2008, PSYCHOL REP, V103, P682, DOI 10.2466/PR0.103.3.682-690; MORRISS R, 1993, BRIT MED J, V306, P1161; Burton AR, 2010, EXP BRAIN RES, V204, P71, DOI 10.1007/s00221-010-2296-1; Stores G, 1998, J PSYCHOSOM RES, V45, P85, DOI 10.1016/S0022-3999(98)00024-5; Johnston J, 2001, CLIN NEUROPHYSIOL, V112, P68, DOI 10.1016/S1388-2457(00)00452-1; Carter CS, 2007, COGN AFFECT BEHAV NE, V7, P367, DOI 10.3758/CABN.7.4.367; Neu D, 2015, CLIN NEUROPHYSIOL, V126, P1926, DOI 10.1016/j.clinph.2014.12.016; Tomoda A, 2000, BRAIN DEV-JPN, V22, P60, DOI 10.1016/S0387-7604(99)00111-4; Arnett SV, 2011, MED HYPOTHESES, V77, P77, DOI 10.1016/j.mehy.2011.03.030; Lipton P, 1999, PHYSIOL REV, V79, P1431; Mizokawa S, 2003, NEUROSCI LETT, V353, P169, DOI 10.1016/j.neulet.2003.09.040; Jabbi M, 2007, NEUROIMAGE, V34, P1744, DOI 10.1016/j.neuroimage.2006.10.032; Tanaka M, 2012, NEUROSCI BIOBEHAV R, V36, P727, DOI 10.1016/j.neubiorev.2011.10.004; Tanaka M, 2003, NEUROSCI LETT, V352, P159, DOI 10.1016/S0304-3940(03)01044-9; Tanaka M, 2009, BEHAV MED, V35, P87, DOI 10.1080/08964280903231979; Kishi A, 2008, AM J PHYSIOL-REG I, V294, pR1980, DOI 10.1152/ajpregu.00925.2007; Mizuno K, 2008, NUTRITION, V24, P293, DOI 10.1016/j.nut.2007.12.007; Kishi A, 2011, SLEEP, V34, P1551, DOI 10.5665/sleep.1396; Logothetis NK, 2008, NATURE, V453, P869, DOI 10.1038/nature06976; Mizuno K, 2011, BRAIN DEV-JPN, V33, P470, DOI 10.1016/j.braindev.2010.08.012; Taylor JL, 1996, J PHYSIOL-LONDON, V490, P519; Tanaka M, 2011, BRAIN RES, V1395, P46, DOI 10.1016/j.brainres.2011.04.041; Bastiaansen JACJ, 2009, PHILOS T R SOC B, V364, P2391, DOI 10.1098/rstb.2009.0058; Ohashi K, 2002, PHYSIOL BEHAV, V77, P39, DOI 10.1016/S0031-9384(02)00808-9; Ishii A, 2013, BRAIN RES, V1529, P105, DOI 10.1016/j.brainres.2013.07.022; Takimoto M, 2005, AM J PHYSIOL-REG I, V289, pR1273, DOI 10.1152/ajpregu.00216.2005; Johnson SC, 2002, BRAIN, V125, P1808, DOI 10.1093/brain/awf181; Mizuma H, 2009, NUTR RES, V29, P145, DOI 10.1016/j.nutres.2009.02.003; Yanagisawa H, 2010, NEUROIMAGE, V50, P1702, DOI 10.1016/j.neuroimage.2009.12.023; Tanaka M, 2010, MED HYPOTHESES, V75, P244, DOI 10.1016/j.mehy.2010.02.032; Katafuchi T, 2005, EUR J NEUROSCI, V22, P2817, DOI 10.1111/j.1460-9568.2005.04478.x; Camm AJ, 1996, CIRCULATION, V93, P1043; Takusagawa M, 1999, HEART, V82, P75; Matthews G, 2002, Q J EXP PSYCHOL-A, V55, P659, DOI 10.1080/02724980143000405; Rinzel J, 1998, SCIENCE, V279, P1351, DOI 10.1126/science.279.5355.1351; Armitage R, 2009, J PSYCHOSOM RES, V66, P51, DOI 10.1016/j.jpsychores.2008.08.004; Tanaka M, 2009, LIFE SCI, V84, P235, DOI 10.1016/j.lfs.2008.12.004; Kop WJ, 2005, ARTHRITIS RHEUM, V52, P296, DOI 10.1002/art.20779; Tomoda A, 2005, PSYCHIAT RES, V134, P101, DOI 10.1016/j.psychres.2005.01.002; Tanaka M, 2013, REV NEUROSCIENCE, V24, P617, DOI 10.1515/revneuro-2013-0035; Liu JZ, 2003, J NEUROPHYSIOL, V90, P300, DOI 10.1152/jn.00821.2002; Morriss RK, 1997, J PSYCHOSOM RES, V42, P597, DOI 10.1016/S0022-3999(97)89895-9; Hossain JL, 2003, J SLEEP RES, V12, P223, DOI 10.1046/j.1365-2869.2003.00354.x; Shibasaki H, 2008, CLIN NEUROPHYSIOL, V119, P731, DOI 10.1016/j.clinph.2007.10.026; Wyller VB, 2007, CLIN PHYSIOL FUNCT I, V27, P231, DOI 10.1111/j.1475-097X.2007.00743.x; Boksem MAS, 2006, BIOL PSYCHOL, V72, P123, DOI 10.1016/j.biopsycho.2005.08.007; Fossey M, 2004, J BEHAV MED, V27, P581, DOI 10.1007/s10865-004-0004-y; Benwell NM, 2006, EXP BRAIN RES, V175, P575, DOI 10.1007/s00221-006-0573-9; VOGT BA, 1987, J COMP NEUROL, V262, P271, DOI 10.1002/cne.902620208; Covanis A, 2004, EPILEPSIA, V45, P40, DOI 10.1111/j.0013-9580.2004.451006.x; Watson NF, 2004, SLEEP, V27, P973; Petrides M, 1999, EUR J NEUROSCI, V11, P1011, DOI 10.1046/j.1460-9568.1999.00518.x; Chaudhuri A, 2003, NEUROREPORT, V14, P225, DOI 10.1097/01.wnr.0000054960.21656.64; Thayer Julian F., 2006, Dose-Response, V4, P2, DOI 10.2203/dose-response.004.01.002.Thayer; Shigihara Y, 2010, BEHAV MED, V36, P109, DOI 10.1080/08964289.2010.489079; Pagani M, 1997, CIRCULATION, V95, P1441; Tanaka M, 2012, INT J PSYCHIAT CLIN, V16, P312, DOI 10.3109/13651501.2011.653378; Ishii A, 2014, NEUROSCIENCE, V261, P60, DOI 10.1016/j.neuroscience.2013.12.049; Tanaka M, 2008, INT J NEUROSCI, V118, P683, DOI 10.1080/00207450701242974; Yamano E, 2013, MED SCI MONITOR, V19, P540, DOI 10.12659/MSM.883971; Wicker B, 2003, NEURON, V40, P655, DOI 10.1016/S0896-6273(03)00679-2; Tanaka M, 2014, BRAIN RES, V1561, P60, DOI 10.1016/j.brainres.2014.03.009; Ball N, 2004, J PSYCHOSOM RES, V56, P207, DOI 10.1016/S0022-3999(03)00598-1; Post M, 2009, HUM BRAIN MAPP, V30, P1014, DOI 10.1002/hbm.20562; Brookes MJ, 2011, NEUROIMAGE, V55, P1804, DOI 10.1016/j.neuroimage.2010.10.074; Singer T, 2004, SCIENCE, V303, P1157, DOI 10.1126/science.1093535; APPEL ML, 1989, J AM COLL CARDIOL, V14, P1139, DOI 10.1016/0735-1097(89)90408-7; Katafuchi T, 2006, ANN NY ACAD SCI, V1088, P230, DOI 10.1196/annals.1366.020; Roelcke U, 1997, NEUROLOGY, V48, P1566; Tomoda A, 1997, BIOL PSYCHIAT, V41, P810, DOI 10.1016/S0006-3223(96)00179-5; Mezzacappa E, 1998, J CHILD PSYCHOL PSYC, V39, P525, DOI 10.1017/S0021963098002273; Shigihara Y, 2010, NEUROSCIENCE, V166, P482, DOI 10.1016/j.neuroscience.2009.12.077; Togo F, 2010, MED SCI SPORT EXER, V42, P16, DOI 10.1249/MSS.0b013e3181b11bc7; Mariman A, 2012, ACTA CLIN BELG, V67, P19, DOI 10.2143/ACB.67.1.2062621; Tanaka M, 2014, MED HYPOTHESES, V82, P567, DOI 10.1016/j.mehy.2014.02.013; Siessmeier T, 2003, J NEUROL NEUROSUR PS, V74, P922, DOI 10.1136/jnnp.74.7.922; Afari N, 2003, AM J PSYCHIAT, V160, P221, DOI 10.1176/appi.ajp.160.2.221; Koski L, 2000, EXP BRAIN RES, V133, P55, DOI 10.1007/s002210000400; Ishii A, 2014, REV NEUROSCIENCE, V25, P469, DOI 10.1515/revneuro-2014-0028; Caseras X, 2008, PSYCHOL MED, V38, P941, DOI 10.1017/S0033291708003450; Richards RS, 2000, REDOX REP, V5, P35; AKSELROD S, 1981, SCIENCE, V213, P220, DOI 10.1126/science.6166045; Ohashi K, 2004, METHOD INFORM MED, V43, P26; Kanaya N, 2003, ANESTHESIOLOGY, V98, P34, DOI 10.1097/00000542-200301000-00009; White AT, 2009, MULT SCLER, V15, P580, DOI 10.1177/1352458508100034; Critchley HD, 2003, BRAIN, V126, P2139, DOI 10.1093/brain/awg216; Williams G, 1996, CLIN PHYSIOL, V16, P327, DOI 10.1111/j.1475-097X.1996.tb00722.x; MALLIANI A, 1991, CIRCULATION, V84, P482; Shigihara Y, 2012, BRAIN RES, V1457, P44, DOI 10.1016/j.brainres.2012.03.056; Sasabe T, 2003, CHEM SENSES, V28, P565, DOI 10.1093/chemse/bjg048; Kuratsune H, 2002, NEUROIMAGE, V17, P1256, DOI 10.1006/nimg.2002.1260; Amat J, 2005, NAT NEUROSCI, V8, P365, DOI 10.1038/nn1399; Rahman K, 2011, SLEEP, V34, P671; Sharpley A, 1997, PSYCHOSOM MED, V59, P592; Benarroch EE, 1997, CLIN AUTONOMIC DISOR; Benwell NM, 2007, EXP BRAIN RES, V18, P93; CHALDER T, 1993, J PSYCHOSOM RES, V37, P147, DOI 10.1016/0022-3999(93)90081-P; Decker MJ, 2009, BEHAV BRAIN FUNCT, V6, P43; Desmond P, 2001, STRESS WORKLOAD FATI; Gotts ZM, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002999; Gotts ZM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117136; Ishii A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095763; Ishii A, 2013, BEHAV BRAIN FUNCT, V9, DOI 10.1186/1744-9081-9-24; Ishii A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109740; Kajimoto O, 2007, FATIGUE SCI HUMAN HL; Katafuchi T., 2004, MOL MED, V41, P1264; Kawabata M, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-281; Kishi A., 2013, PHYSL REP, V1; Kuratsune D, 2012, WORLD J NEUROSCI, V2, P113; LOEWY AD, 1990, CENTRAL REGULATION A; Lopes da Silva F., 1991, ELECTROENCEPHALOGRAP, V79, P81; Mizuno K, 2014, BEHAV BRAIN FUNCT, V10, DOI 10.1186/1744-9081-10-25; Mizuno K, 2011, BEHAV BRAIN FUNCT, V7, DOI 10.1186/1744-9081-7-17; Mizuno K, 2007, FATIGUE SCI HUMAN HL; Okada T, 2004, BMC NEUROL, V4, DOI 10.1186/1471-2377-4-14; Otto T., 2013, SOC COGN AFFECT NEUR, V9, P307; Pomeranz M, 1985, AM J PHYSIOL, V248, P151; Reeves WC, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-41; Shigihara Y, 2013, BEHAV BRAIN FUNCT, V9, DOI 10.1186/1744-9081-9-2; Shigihara Y., 2013, NEUROL PSYCHIAT BR, V19, P5; Smith EE, 1999, SCIENCE, V283, P1657, DOI DOI 10.1126/SCIENCE.283.5408.1657; Tajima K, 2008, ERGON IJE HF, V30, P134; Tajima S, 2009, J CLIN EXP MED, V228, P640; Tajima Seiki, 2007, Nihon Rinsho, V65, P1057; Tajima S, 2010, NEUROL RES INT, V2010; Tajima S., 2013, ADV NEUROIMMUNE BIOL, V4, P281; Tanaka M, 2012, BEHAV BRAIN FUNCT, V8, DOI 10.1186/1744-9081-8-48; Tanaka M, 2015, AUSTIN J CLIN NEUROL, V2, P1020; Tanaka M, 2013, PLOS ONE, V8, P80731; Tanaka M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034774; Tanaka M, 2013, ADV NEUROIMMUNE BIOL, V4, P291; Tanaka M, 2014, AUSTIN J CLIN NEUROL, V1, P4; Tanaka M, 2011, BEHAV BRAIN FUNCT, V7, DOI 10.1186/1744-9081-7-46; Tanaka M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070949; Tanaka Masaaki, 2006, BMC Neurol, V6, P9, DOI 10.1186/1471-2377-6-9; Tirelli U, 1998, AM J MED, V105, P54; Togo F, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2425; Tomoda A, 2007, J PEDIAT NEUROL, V5, P199; TOMODA A, 1995, CURR THER RES CLIN E, V56, P1088, DOI 10.1016/0011-393X(95)85116-X; Uehata Tetsunojo, 2005, Nihon Rinsho, V63, P1249; Unger ER, 2004, BMC NEUROL, V19, P6; Vogt BA, 2005, PROG BRAIN RES, V150, P205, DOI 10.1016/S0079-6123(05)50015-3; Watanabe Y, 2005, CHEM SENSES S, V1, pi268; Yamaguti K, 2008, J THERAPY, V90, P537	189	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1880-6546	1880-6562		J PHYSIOL SCI	J. Physiol. Sci.	NOV	2015	65	6					483	498		10.1007/s12576-015-0399-y		16	Physiology	Physiology	CU7MZ	WOS:000363725600001		
J	Ono, M; Ito, T				Ono, Munenori; Ito, Tetsufumi			Functional organization of the mammalian auditory midbrain	JOURNAL OF PHYSIOLOGICAL SCIENCES			English	Review						Inferior colliculus; Local circuit; GABAergic neuron; Membrane property; Synaptic inputs	DORSAL COCHLEAR NUCLEUS; INFERIOR COLLICULUS NEURONS; WHOLE-CELL RECORDINGS; GABAERGIC TECTOTHALAMIC NEURONS; LATERAL SUPERIOR OLIVE; IN-VIVO; BRAIN-STEM; INTRINSIC-PROPERTIES; SYNAPTIC PROPERTIES; MEMBRANE-PROPERTIES	The inferior colliculus (IC) is a critical nexus between the auditory brainstem and the forebrain. Parallel auditory pathways that emerge from the brainstem are integrated in the IC. In this integration, de-novo auditory information processed as local and ascending inputs converge via the complex neural circuit of the IC. However, it is still unclear how information is processed within the neural circuit. The purpose of this review is to give an anatomical and physiological overview of the IC neural circuit. We address the functional organization of the IC where the excitatory and inhibitory synaptic inputs interact to shape the responses of IC neurons to sound.	[Ono, Munenori] Univ Connecticut, Ctr Hlth, Dept Neurosci, Farmington, CT 06030 USA; [Ono, Munenori] Kanazawa Med Univ, Dept Physiol, Sch Med, Uchinada, Ishikawa 9200293, Japan; [Ito, Tetsufumi] Univ Fukui, Dept Anat, Fac Med Sci, Fukui 9101193, Japan; [Ito, Tetsufumi] Univ Fukui, Res & Educ Program Life Sci, Fukui, Fukui 9108507, Japan	Ono, M (reprint author), Univ Connecticut, Ctr Hlth, Dept Neurosci, Farmington, CT 06030 USA.	onomn@kanazawa-med.ac.jp			NIH [R01 DC000189, R21 DC013822]; UConn Health HCRAC [401139UCHC]; Japan Society for Promotion of Science [22700365, 25430034]; Uehara Memorial Foundation; Ichiro Kanehara Foundation; Novartis Foundation for Promotion of Science; Research and Education Program for Life Science of University of Fukui	This work was supported by grants from NIH R01 DC000189, R21 DC013822, UConn Health HCRAC grant 401139UCHC (to Dr D.L. Oliver), the Japan Society for the Promotion of Science (grants 22700365 and 25430034, T.I.), the Uehara Memorial Foundation (T.I.), the Ichiro Kanehara Foundation (T.I.), the Novartis Foundation for the Promotion of Science (T.I.), and Research and Education Program for Life Science of the University of Fukui (T.I.).	Seshagiri CV, 2007, J NEUROPHYSIOL, V98, P2058, DOI 10.1152/jn.01317.2006; OLIVER DL, 1994, J COMP NEUROL, V340, P27, DOI 10.1002/cne.903400104; Coote EJ, 2008, NEUROSCIENCE, V154, P218, DOI 10.1016/j.neuroscience.2008.02.030; Xie RL, 2013, J NEUROSCI, V33, P1598, DOI 10.1523/JNEUROSCI.2541-12.2013; ITOH K, 1984, BRAIN RES, V308, P166, DOI 10.1016/0006-8993(84)90931-4; Cao XJ, 2011, J NEUROPHYSIOL, V106, P630, DOI 10.1152/jn.00015.2010; Ono M, 2014, J NEUROSCI, V34, P3779, DOI 10.1523/JNEUROSCI.2954-13.2014; Kuo SP, 2012, J NEUROPHYSIOL, V108, P1186, DOI 10.1152/jn.00778.2011; Rodrigues ARA, 2006, J NEUROPHYSIOL, V95, P76, DOI 10.1152/jn.00624.2005; OLIVER DL, 1984, J COMP NEUROL, V224, P155, DOI 10.1002/cne.902240202; Joris PX, 2004, PHYSIOL REV, V84, P541, DOI 10.1152/physrev.00029.2003; Kuo RI, 2012, NEURON, V73, P1016, DOI 10.1016/j.neuron.2011.11.035; Gocho Y, 2013, J PHYSIOL SCI, V63, P147, DOI 10.1007/s12576-012-0250-7; Xie R, 2008, NEUROSCIENCE, V154, P245, DOI 10.1016/j.neuroscience.2008.02.039; Tan ML, 2007, J NEUROPHYSIOL, V98, P443, DOI 10.1152/jn.01273.2006; OLIVER DL, 1984, J COMP NEUROL, V222, P237, DOI 10.1002/cne.902220207; Loftus WC, 2010, J NEUROSCI, V30, P13396, DOI 10.1523/JNEUROSCI.0338-10.2010; Xiong XRR, 2013, NEURON, V79, P738, DOI 10.1016/j.neuron.2013.06.012; Schnupp JWH, 2009, NAT NEUROSCI, V12, P692, DOI 10.1038/nn.2325; Ito T, 2014, J COMP NEUROL, V522, P3539, DOI 10.1002/cne.23623; NELSON PG, 1963, J NEUROPHYSIOL, V26, P908; MALMIERCA MS, 1993, J COMP NEUROL, V333, P1, DOI 10.1002/cne.903330102; Ammer JJ, 2012, J NEUROPHYSIOL, V107, P1172, DOI 10.1152/jn.00585.2011; Kasai M, 2012, NEUROSCI RES, V73, P224, DOI 10.1016/j.neures.2012.04.009; ITAYA SK, 1982, BRAIN RES, V233, P45, DOI 10.1016/0006-8993(82)90928-3; Ito T, 2015, J COMP NEUROL, V523, P2277, DOI 10.1002/cne.23789; Konig P, 1996, TRENDS NEUROSCI, V19, P130, DOI 10.1016/S0166-2236(96)80019-1; Kuwada S, 1997, J NEUROSCI, V17, P7565; Grothe B, 2010, PHYSIOL REV, V90, P983, DOI 10.1152/physrev.00026.2009; Gittelman JX, 2009, J NEUROSCI, V29, P13030, DOI 10.1523/JNEUROSCI.2477-09.2009; Li N, 2013, J NEUROSCI, V33, P6367, DOI 10.1523/JNEUROSCI.5735-12.2013; NAKAGAWA H, 1995, BRAIN RES, V690, P236, DOI 10.1016/0006-8993(95)00593-F; Covey E, 1996, J NEUROSCI, V16, P3009; Golding NL, 2012, J PHYSIOL-LONDON, V590, P5563, DOI 10.1113/jphysiol.2012.229328; Winer JA, 1996, P NATL ACAD SCI USA, V93, P8005, DOI 10.1073/pnas.93.15.8005; Ono M, 2005, NEUROSCI RES, V51, P475, DOI 10.1016/j.neures.2004.12.019; Apostolides PF, 2013, NAT NEUROSCI, V16, P1764, DOI 10.1038/nn.3569; Gittelman JX, 2011, J NEUROSCI, V31, P2576, DOI 10.1523/JNEUROSCI.5112-10.2011; Apostolides PF, 2014, NEURON, V83, P324, DOI 10.1016/j.neuron.2014.06.008; Friedrich RW, 2013, ANNU REV NEUROSCI, V36, P383, DOI 10.1146/annurev-neuro-062111-150504; Walcher J, 2011, J NEUROPHYSIOL, V106, P1443, DOI 10.1152/jn.01087.2010; Bender KJ, 2010, NEURON, V68, P500, DOI 10.1016/j.neuron.2010.09.026; Cant NB, 2006, J COMP NEUROL, V495, P511, DOI 10.1002/cne.20888; Chernock ML, 2004, HEARING RES, V188, P12, DOI 10.1016/S0378-5955(03)00340-X; Oliver DL, 1997, J COMP NEUROL, V382, P215, DOI 10.1002/(SICI)1096-9861(19970602)382:2<215::AID-CNE6>3.0.CO;2-6; Wynne B, 1995, J CHEM NEUROANAT, V9, P289, DOI 10.1016/0891-0618(95)00095-X; Ito T, 2009, J NEUROSCI, V29, P13860, DOI 10.1523/JNEUROSCI.3454-09.2009; YAMAUCHI K, 1982, ACTA ANAT, V114, P355; Ono M, 2014, J PHYSIOL-LONDON, V592, P3647, DOI 10.1113/jphysiol.2014.275446; Pedemonte M, 1997, BRAIN RES, V759, P24, DOI 10.1016/S0006-8993(97)00123-6; Ito T, 2011, J COMP NEUROL, V519, P316, DOI 10.1002/cne.22521; Chen C, 2012, J NEUROSCI, V32, P8454, DOI 10.1523/JNEUROSCI.6506-11.2012; Schreiner CE, 1997, NATURE, V388, P383, DOI 10.1038/41106; Sun HY, 2008, BRAIN RES, V1226, P70, DOI 10.1016/j.brainres.2008.06.010; Peruzzi D, 2000, NEUROSCIENCE, V101, P403, DOI 10.1016/S0306-4522(00)00382-1; Ayala YA, 2015, SCI REP-UK, V5, DOI 10.1038/srep10383; Ayala Y, 2013, FRONT NEURAL CIRCUIT, V6, DOI 10.3389/fncir.2012.00089; Chen C, 2012, FRONT NEURAL CIRCUIT, V6, DOI 10.3389/fncir.2012.00062; Franzen DL, 2015, J NEUROPHYSIOL, V113, P524, DOI 10.1152/jn.00601.2014; Rudiger H, 2013, J COMP NEUROL, V521, P189, DOI 10.1002/cne.23170; Gittelman JX, 2012, FRONT NEURAL CIRCUIT, V6, DOI 10.3389/fncir.2012.00067; Ito T, 2014, BRAIN RES, V1590, P45, DOI 10.1016/j.brainres.2014.09.049; Ito T, 2010, FRONT NEUROANAT, V4, DOI 10.3389/fnana.2010.00135; Magnusson AK, 2005, J PHYSIOL-LONDON, V568, P497, DOI 10.1113/jphysiol.2005.094763; Ohmori H, 2014, FRONT NEURAL CIRCUIT, V8, DOI 10.3389/fncir.2014.00047; Oliver DL, 2005, INFERIOR COLLICULUS, P69, DOI 10.1007/0-387-27083-3_2; Roberts MT, 2014, FRONT NEURAL CIRCUIT, V8, DOI 10.3389/fncir.2014.00049; Saldana E, 2005, INFERIOR COLLICULUS, P155, DOI 10.1007/0-387-27083-3_5; Sivaramakrishnan S, 2001, J NEUROSCI, V21, P2861; Tongjaroenbuangam W, 2006, EUR J NEUROSCI, V24, P1987, DOI 10.1111/j.1460-9568.2006.05098.x; Winer JA, 2005, INFERIOR COLLICULUS, P1, DOI 10.1007/0-387-27083-3_1; Winer JA, 2005, INFERIOR COLLICULUS, P231, DOI 10.1007/0-387-27083-3_8; Young ED, 2004, SYNAPTIC ORG BRAIN, P125	73	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1880-6546	1880-6562		J PHYSIOL SCI	J. Physiol. Sci.	NOV	2015	65	6					499	506		10.1007/s12576-015-0394-3		8	Physiology	Physiology	CU7MZ	WOS:000363725600002		
J	Miwa, N				Miwa, Naofumi			Dicalcin, a zona pellucida protein that regulates fertilization competence of the egg coat in Xenopus laevis	JOURNAL OF PHYSIOLOGICAL SCIENCES			English	Review						Fertilization; Egg-coating envelope; Sperm; ZP protein	CALCIUM-BINDING PROTEIN; FROG OLFACTORY EPITHELIUM; IN-VITRO FERTILIZATION; OVIDUCTAL PARS RECTA; SPERM-BINDING; ACROSOME REACTION; S100 PROTEINS; CORONARY FLOW; ION CHANNELS; P26OLF	Fertilization is a highly coordinated process whereby sperm interact with the egg-coating envelope (called the zona pellucida, ZP) in a taxon-restricted manner, Fertilization triggers the resumption of the cell cycle of the egg, ultimately leading to generation of a new organism that contains hereditary information of the parents. The complete sperm-ZP interaction comprises sperm recognition of the ZP, the acrosome reaction, penetration of the ZP, and fusion with the egg. Recent evidence suggests that these processes involve oligosaccharides associated with a ZP constituent (termed ZP protein), the polypeptide backbone of a ZP protein, and/or the proper three-dimensional filamentous structure of the ZP. However, a detailed description of the molecular mechanisms involved in sperm-ZP interaction remains elusive. Recently, I found that dicalcin, a novel ZP protein-associated protein, suppresses fertilization through its association with gp41, the frog counterpart of the mammalian ZPC protein. This review focuses on molecular aspects of sperm-ZP interaction and describes the fertilization-suppressive function of dicalcin and associated molecular mechanisms. The amount of dicalcin in the ZP significantly correlates with alteration of the lectin-staining pattern within the ZP and the orientation pattern of ZP filaments, which may assist in elucidating the complex molecular mechanisms that underlie sperm-ZP interaction.	Toho Univ, Dept Physiol, Sch Med, Tokyo, Japan	Miwa, N (reprint author), Toho Univ, Dept Physiol, Sch Med, Tokyo, Japan.	nmiwa@med.toho-u.ac.jp			Japan Society for Promotion of Science; Toho University Graduate School of Medicine; Novartis Foundation	This work was supported by grants from the Japan Society for the Promotion of Science, the Research Promotion Grant from Toho University Graduate School of Medicine, and the Novartis Foundation to N.M.	Tian JD, 1999, P NATL ACAD SCI USA, V96, P829, DOI 10.1073/pnas.96.3.829; Sachs F, 2010, PHYSIOLOGY, V25, P50, DOI 10.1152/physiol.00042.2009; Lindsay LL, 1999, BIOL REPROD, V60, P989, DOI 10.1095/biolreprod60.4.989; Miwa N, 1998, BIOCHEM BIOPH RES CO, V251, P860, DOI 10.1006/bbrc.1998.9571; Tanaka T, 1999, PROTEIN ENG, V12, P395, DOI 10.1093/protein/12.5.395; Ueda Y, 2002, DEV BIOL, V243, P55, DOI 10.1006/dbio.2001.0541; INODA T, 1987, COMP BIOCHEM PHYS A, V88, P539, DOI 10.1016/0300-9629(87)90077-6; Donato R, 2013, CURR MOL MED, V13, P24; Kubo H, 1999, DEV GENET, V25, P123, DOI 10.1002/(SICI)1520-6408(1999)25:2<123::AID-DVG6>3.0.CO;2-3; Chachisvilis M, 2006, P NATL ACAD SCI USA, V103, P15463, DOI 10.1073/pnas.0607224103; Visconti PE, 2011, ASIAN J ANDROL, V13, P395, DOI 10.1038/aja.2010.69; Miwa N, 2001, EUR J BIOCHEM, V268, P6029, DOI 10.1046/j.0014-2956.2001.02511.x; Suarez SS, 2006, HUM REPROD UPDATE, V12, P23, DOI 10.1093/humupd/dmi047; Clark GF, 2014, BIOCHEM BIOPH RES CO, V450, P1195, DOI 10.1016/j.bbrc.2014.06.051; Gahlay G, 2010, SCIENCE, V329, P216, DOI 10.1126/science.1188178; Miwa N, 2000, J BIOL CHEM, V275, P27245; Olson JH, 2001, P NATL ACAD SCI USA, V98, P11205, DOI 10.1073/pnas.211316798; Hirohashi N, 2008, DEV GROWTH DIFFER, V50, pS221, DOI 10.1111/j.1440-169X.2008.01017.x; Nickel W, 2011, TRAFFIC, V12, P799, DOI 10.1111/j.1600-0854.2011.01187.x; Wassarman PM, 2001, NAT CELL BIOL, V3, pE59, DOI 10.1038/35055178; Storch U, 2012, AM J PHYSIOL-HEART C, V302, pH1241, DOI 10.1152/ajpheart.00818.2011; Miwa N, 2008, FEBS J, V275, P4945, DOI 10.1111/j.1742-4658.2008.06653.x; Blount P, 1996, P NATL ACAD SCI USA, V93, P11652, DOI 10.1073/pnas.93.21.11652; Talevi R, 1997, HUM REPROD, V12, P2773, DOI 10.1093/humrep/12.12.2773; KIMURA H, 1994, MOL REPROD DEV, V39, P322, DOI 10.1002/mrd.1080390309; Hao YH, 2006, BIOL REPROD, V75, P726, DOI 10.1095/biolreprod.106.052589; Bounoutas A, 2007, PFLUG ARCH EUR J PHY, V454, P691, DOI 10.1007/s00424-006-0187-x; Ueda Y, 2003, DEV BIOL, V264, P289, DOI 10.1016/j.ydbio.2003.08.007; Pries AR, 2000, PFLUG ARCH EUR J PHY, V440, P653, DOI 10.1007/s004240000307; Heizmann CW, 2002, FRONT BIOSCI, V7, pD1356, DOI 10.2741/heizmann; Bailey JL, 2010, SYST BIOL REPROD MED, V56, P334, DOI 10.3109/19396368.2010.512377; Miwa N, 2007, DNA SEQUENCE, V18, P400, DOI 10.1080/10425170701241470; Uebi T, 2007, FEBS J, V274, P4863, DOI 10.1111/j.1742-4658.2007.06007.x; Perez-Aguilar S, 2014, AM J PHYSIOL-HEART C, V306, pH699, DOI 10.1152/ajpheart.00481.2013; Rubio R, 2000, AM J PHYSIOL-HEART C, V278, pH106; Miwa N, 2010, J BIOL CHEM, V285, P15627, DOI 10.1074/jbc.M109.079483; Kung C, 2005, NATURE, V436, P647, DOI 10.1038/nature03896; Wassarman PM, 2005, MOL CELL ENDOCRINOL, V234, P95, DOI 10.1016/j.mce.2004.08.017; Chiu PCN, 2007, J CELL SCI, V120, P33, DOI 10.1242/jcs.03258; Spargo SC, 2003, BIOL REPROD, V68, P358, DOI 10.1097/biolreprod.102.008086; Litscher ES, 2007, HISTOL HISTOPATHOL, V22, P337; Ren DJ, 2001, NATURE, V413, P603, DOI 10.1038/35098027; Topfer-Petersen E, 2008, INT J DEV BIOL, V52, P717, DOI 10.1387/ijdb.072536et; Baibakov B, 2007, DEVELOPMENT, V134, P933, DOI 10.1242/dev.02752; FLORMAN HM, 1985, CELL, V41, P313, DOI 10.1016/0092-8674(85)90084-4; Hanaue M, 2011, J MAMM OVA RES, V28, P110; LARABELL CA, 1988, J CELL BIOL, V107, P731, DOI 10.1083/jcb.107.2.731; Miwa N, 2015, SCI REP-UK, V5, DOI 10.1038/srep12672; Miwa N, 2003, MICROSC RES TECHNIQ, V60, P593, DOI 10.1002/jemt.10301; Yanagimachi R., 1994, P189; Yanagimachi R., 1994, Zygote, V2, P371	51	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1880-6546	1880-6562		J PHYSIOL SCI	J. Physiol. Sci.	NOV	2015	65	6					507	514		10.1007/s12576-015-0402-7		8	Physiology	Physiology	CU7MZ	WOS:000363725600003		
J	Mori, Y; Kitamura, T; Kawamura, G; Sato, K; Sato, R; Araki, Y; Yamada, Y				Mori, Yoshiteru; Kitamura, Takayuki; Kawamura, Gaku; Sato, Kanako; Sato, Rui; Araki, Yuko; Yamada, Yoshitsugu			Effects of preoperative and intraoperative glucose administration on glucose use and fat catabolism during laparotomy under sevoflurane anesthesia in fasted rats	JOURNAL OF PHYSIOLOGICAL SCIENCES			English	Article						Intraoperative glycemic control; Insulin secretion; Insulin sensitivity; beta-Hydroxybutyrate; Adipocytokine	SENSITIVITY CHECK INDEX; NECROSIS-FACTOR-ALPHA; INSULIN SENSITIVITY; RESISTANCE; ADIPONECTIN; MODEL; HOMEOSTASIS; METABOLISM; SECRETION; WEIGHT	Preoperative fasting as well as surgical stress significantly modifies metabolisms. Recent studies reported the possible advantageous effects of glucose administration on perioperative metabolisms; however, the underlying mechanisms have not been fully elucidated. Rats were allocated to three groups. During the fasting period, groups A and B were administered water, but group C was administered glucose. During laparotomy and the insulin tolerance test (ITT) under sevoflurane anesthesia, group A was administered saline, but groups B and C were administered glucose. During laparotomy, group C showed higher glucose levels and lower beta-hydroxybutyrate (beta-OHB) levels than group A, and group B showed more decreases in beta-OHB levels than group A without differences in changes in glucose levels. Insulin levels and insulin sensitivity during laparotomy were similar among the three groups. No significant difference in insulin sensitivity was also confirmed in ITT. In conclusion, perioperative glucose administration suppresses lipolysis without affecting insulin secretion and sensitivity.	[Mori, Yoshiteru; Kawamura, Gaku; Sato, Rui; Araki, Yuko; Yamada, Yoshitsugu] Univ Tokyo, Dept Anesthesiol, Fac Med, Bunkyo Ku, Tokyo 1138655, Japan; [Kitamura, Takayuki; Sato, Kanako] Toho Univ, Dept Anesthesiol, Sakura Med Ctr, Sakura Ku, Chiba 2748510, Japan	Kawamura, G (reprint author), Univ Tokyo, Dept Anesthesiol, Fac Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	gaku-kawa@umin.ac.jp			departmental fund (Department of Anesthesiology, Faculty of Medicine, University of Tokyo)	This work was supported by a departmental fund (Department of Anesthesiology, Faculty of Medicine, The University of Tokyo).	HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; DILTOER M, 1988, ANESTHESIOLOGY, V68, P880, DOI 10.1097/00000542-198806000-00008; Weyer C, 2001, J CLIN ENDOCR METAB, V86, P1930, DOI 10.1210/jc.86.5.1930; Hara K, 2006, DIABETES CARE, V29, P1357, DOI 10.2337/dc05-1801; Hivert MF, 2008, J CLIN ENDOCR METAB, V93, P3165, DOI 10.1210/jc.2008-0425; Pajvani UB, 2004, J BIOL CHEM, V279, P12152, DOI 10.1074/jbc.M311113200; Hagiwara S, 2008, CRIT CARE MED, V36, P2407, DOI 10.1097/CCM.0b013e318180b3ba; Mikura M, 2009, ANESTHESIOLOGY, V110, P81, DOI 10.1097/ALN.0b013e318190b6c1; Lee HW, 2011, ENDOCRINOLOGY, V152, P414, DOI 10.1210/en.2010-1164; Yokoyama H, 2003, DIABETES CARE, V26, P2426, DOI 10.2337/diacare.26.8.2426; Chen H, 2005, DIABETES, V54, P1914, DOI 10.2337/diabetes.54.7.1914; Reichstetter S, 2012, PHARM RES-DORDR, V29, P1033, DOI 10.1007/s11095-011-0646-8; Zuurbier CJ, 2008, ANESTH ANALG, V106, P135, DOI 10.1213/01.ane.0000297299.91527.74; Saho S, 1997, ANESTH ANALG, V84, P1359, DOI 10.1097/00000539-199706000-00034; Hirabara SM, 2013, J NUTR BIOCHEM, V24, P1136, DOI 10.1016/j.jnutbio.2012.08.014; Nygren J, 1998, CLIN NUTR, V17, P65, DOI 10.1016/S0261-5614(98)80307-5; Yamasaki K, 2010, J ANESTH, V24, P426, DOI 10.1007/s00540-010-0926-1; EXTON JH, 1972, J BIOL CHEM, V247, P4996; Katz A, 2000, J CLIN ENDOCR METAB, V85, P2402, DOI 10.1210/jc.85.7.2402; Cacho J, 2008, AM J PHYSIOL-ENDOC M, V295, P1269; Ljungqvist Olle, 2009, Best Pract Res Clin Anaesthesiol, V23, P401; Nygren Jonas, 2006, Best Pract Res Clin Anaesthesiol, V20, P429, DOI 10.1016/j.bpa.2006.02.004; Soop N, 2001, AM J PHYSIOL-ENDOC M, V280, pE576; Tanaka Tadashi, 2005, J Anesth, V19, P277, DOI 10.1007/s00540-005-0341-1; WILLATTS SM, 1986, BRIT J ANAESTH, V58, P201, DOI 10.1093/bja/58.2.201	25	1	1	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1880-6546	1880-6562		J PHYSIOL SCI	J. Physiol. Sci.	NOV	2015	65	6					523	530		10.1007/s12576-015-0390-7		8	Physiology	Physiology	CU7MZ	WOS:000363725600005		
J	Mori, Y; Kitamura, T; Kawamura, G; Sato, K; Sato, R; Araki, Y; Yamada, Y				Mori, Yoshiteru; Kitamura, Takayuki; Kawamura, Gaku; Sato, Kanako; Sato, Rui; Araki, Yuko; Yamada, Yoshitsugu			Effects of preoperative and intraoperative glucose administration on glucose use and fat catabolism during laparotomy under sevoflurane anesthesia in fasted rats (vol 65, pg 523, 2015)	JOURNAL OF PHYSIOLOGICAL SCIENCES			English	Correction									[Mori, Yoshiteru; Kawamura, Gaku; Sato, Rui; Araki, Yuko; Yamada, Yoshitsugu] Univ Tokyo, Dept Anesthesiol, Fac Med, Bunkyo Ku, Tokyo 1138655, Japan; [Kitamura, Takayuki; Sato, Kanako] Toho Univ, Dept Anesthesiol, Sakura Med Ctr, Sakura Ku, Chiba 2748510, Japan	Kawamura, G (reprint author), Univ Tokyo, Dept Anesthesiol, Fac Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	gaku-kawa@umin.ac.jp					Mori Y, 2015, J PHYSIOL SCI, V65, P523, DOI 10.1007/s12576-015-0390-7	1	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1880-6546	1880-6562		J PHYSIOL SCI	J. Physiol. Sci.	NOV	2015	65	6					531	531		10.1007/s12576-015-0406-3		1	Physiology	Physiology	CU7MZ	WOS:000363725600006		
J	Kikusato, M; Toyomizu, M				Kikusato, Motoi; Toyomizu, Masaaki			Moderate dependence of reactive oxygen species production on membrane potential in avian muscle mitochondria oxidizing glycerol 3-phosphate	JOURNAL OF PHYSIOLOGICAL SCIENCES			English	Article						Mitochondrial glycerol 3-phosphate dehydrogenase; Mitochondrial membrane potential; Carbonyl cyanide p-trifluoromethoxyphenyl hydrazine	ACUTE HEAT-STRESS; SKELETAL-MUSCLE; GLYCEROL-3-PHOSPHATE DEHYDROGENASE; OXIDATIVE-PHOSPHORYLATION; ROS PRODUCTION; GENERATION; SUPEROXIDE; TISSUES; SITES; RAT	Mitochondria are a major source of reactive oxygen species production in cells, and the production level is sensitive to the magnitude of the membrane potential (Delta Psi). The present study investigated the level of superoxide production in mitochondria oxidizing glycerol 3-phosphate (GP) and its dependence on Delta Psi in isolated avian muscle mitochondria. The levels of superoxide produced in mitochondria oxidizing GP were lower than those obtained with succinate and were similar to those obtained with NADH-linked substrates (glutamate/malate/pyruvate). The dependence of superoxide production on Delta Psi in mitochondria oxidizing GP was lower than that of mitochondria oxidizing succinate, and a weak dependence of GP-supported superoxide production on Delta Psi was observed in the presence of NADH-linked substrates or succinate. These results suggest that the levels of superoxide generated in response to GP are quantitatively low, but they are unsusceptible to changes in Delta Psi in avian muscle mitochondria.	[Kikusato, Motoi; Toyomizu, Masaaki] Tohoku Univ, Anim Nutr, Life Sci, Grad Sch Agr Sci,Aoba Ku, Sendai, Miyagi 9818555, Japan	Kikusato, M (reprint author), Tohoku Univ, Anim Nutr, Life Sci, Grad Sch Agr Sci,Aoba Ku, 1-1 Tsutsumidori Amamiyamachi, Sendai, Miyagi 9818555, Japan.	kmotoi@bios.tohoku.ac.jp			Japan Society for the Promotion of Science (JSPS) KAKENHI grant [90613042, 24380147]	This work was supported by the Japan Society for the Promotion of Science (JSPS) KAKENHI grant nos. 90613042 (M.K.) and 24380147 (M.T.).	Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Mracek T, 2013, BBA-BIOENERGETICS, V1827, P401, DOI 10.1016/j.bbabio.2012.11.014; Rahman M, 2014, ANTIOXID REDOX SIGN, V20, P443, DOI 10.1089/ars.2013.5410; Adam-Vizi V, 2006, TRENDS PHARMACOL SCI, V27, P639, DOI 10.1016/j.tips.2006.10.005; Miwa S, 2003, FREE RADICAL BIO MED, V35, P938, DOI 10.1016/S0891-5849(03)00464-7; ROLFE DFS, 1994, BBA-BIOENERGETICS, V1188, P405, DOI 10.1016/0005-2728(94)90062-0; Toyomizu M, 2011, COMP BIOCHEM PHYS A, V159, P75, DOI 10.1016/j.cbpa.2011.01.020; Korshunov SS, 1997, FEBS LETT, V416, P15, DOI 10.1016/S0014-5793(97)01159-9; REYNAFARJE B, 1985, ANAL BIOCHEM, V145, P406, DOI 10.1016/0003-2697(85)90381-1; Min K, 2011, J APPL PHYSIOL, V111, P1459, DOI 10.1152/japplphysiol.00591.2011; Mracek T, 2009, ARCH BIOCHEM BIOPHYS, V481, P30, DOI 10.1016/j.abb.2008.10.011; Kikusato M, 2010, FEBS LETT, V584, P3143, DOI 10.1016/j.febslet.2010.05.057; Kikusato M, 2015, BRIT POULTRY SCI, V56, P225, DOI 10.1080/00071668.2014.996529; Tretter L, 2007, J NEUROCHEM, V100, P650, DOI 10.1111/j.1471-4159.2006.04223.x; Mujahid A, 2009, AM J PHYSIOL-REG I, V297, pR690, DOI 10.1152/ajpregu.90974.2008; Gilliam LAA, 2012, AM J PHYSIOL-CELL PH, V302, pC195, DOI 10.1152/ajpcell.00217.2011; Li NY, 2003, J BIOL CHEM, V278, P8516, DOI 10.1074/jbc.M210432200; Brand MD, 2010, EXP GERONTOL, V45, P466, DOI 10.1016/j.exger.2010.01.003; Furukawa K, 2015, J POULT SCI IN PRESS; Kikusato M., 2013, EAAP PUBL, V134, P267; KLINGENB.M, 1970, EUR J BIOCHEM, V13, P247, DOI 10.1111/j.1432-1033.1970.tb00924.x; Mracek T, 2014, BBA-BIOENERGETICS, V1837, P98, DOI 10.1016/j.bbabio.2013.08.007; Quinlan CL, 2013, REDOX BIOL, V1, P304, DOI 10.1016/j.redox.2013.04.005; Ramos D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131766; Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478; Wang ZC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075044; Yada K, 2014, J PHYSIOL SCI, V64, P113, DOI 10.1007/s12576-013-0300-9	27	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1880-6546	1880-6562		J PHYSIOL SCI	J. Physiol. Sci.	NOV	2015	65	6					555	559		10.1007/s12576-015-0395-2		5	Physiology	Physiology	CU7MZ	WOS:000363725600009		
J	Matono, T; Kutsuna, S; Koizumi, N; Fujiya, Y; Takeshita, N; Hayakawa, K; Kanagawa, S; Kato, Y; Ohmagari, N				Matono, Takashi; Kutsuna, Satoshi; Koizumi, Nobuo; Fujiya, Yoshihiro; Takeshita, Nozomi; Hayakawa, Kayoko; Kanagawa, Shuzo; Kato, Yasuyuki; Ohmagari, Norio			Imported Flood-Related Leptospirosis From Palau: Awareness of Risk Factors Leads to Early Treatment	JOURNAL OF TRAVEL MEDICINE			English	Article							OUTBREAK; PARTICIPANTS	We describe two Japanese travelers with leptospirosis who visited Palau. Both travelers swam in Ngardmau Falls, which was flooded for two days after typhoon Phanfone. The diagnoses were confirmed by microscopic agglutination test or polymerase chain reaction. This is the first report of leptospirosis in travelers who returned from Palau. It should be noted that choosing the appropriate test to biologically confirm leptospirosis was highly time-dependent. Awareness of the risk factors for leptospirosis, mainly that of the exposure to contaminated fresh water after a flooding, would lead to an early and appropriate treatment before the confirmed diagnosis.	[Matono, Takashi; Kutsuna, Satoshi; Fujiya, Yoshihiro; Takeshita, Nozomi; Hayakawa, Kayoko; Kanagawa, Shuzo; Kato, Yasuyuki; Ohmagari, Norio] Natl Ctr Global Hlth & Med, Ctr Dis Control & Prevent, Tokyo, Japan; [Koizumi, Nobuo] Natl Inst Infect Dis, Dept Bacteriol 1, Tokyo, Japan	Kutsuna, S (reprint author), Natl Ctr Global Hlth & Med, Ctr Dis Control & Prevent, Shinjuku Ku, 1-21-1 Toyama, Tokyo 1628655, Japan.	sonare.since1192@gmail.com					Koizumi N, 2008, JPN J INFECT DIS, V61, P465; Agampodi SB, 2012, CLIN INFECT DIS, V54, P1249, DOI 10.1093/cid/cis035; Morgan J, 2002, CLIN INFECT DIS, V34, P1593, DOI 10.1086/340615; Amilasan AST, 2012, EMERG INFECT DIS, V18, P91, DOI 10.3201/eid1801.101892; Bharti AR, 2003, LANCET INFECT DIS, V3, P757, DOI 10.1016/S1473-3099(03)00830-2; Koizumi N, 2013, J MED MICROBIOL, V62, P630, DOI 10.1099/jmm.0.050039-0; Berlioz-Arthaud A, 2007, T ROY SOC TROP MED H, V101, P714, DOI 10.1016/j.trstmh.2007.02.022; Stern EJ, 2010, CLIN INFECT DIS, V50, P843, DOI 10.1086/650578; van de Werve C, 2013, J TRAVEL MED, V20, P228, DOI 10.1111/jtm.12035; Katz AR, 2001, CLIN INFECT DIS, V33, P1834, DOI 10.1086/324084; Levett PN, 2001, CLIN MICROBIOL REV, V14, P296, DOI 10.1128/CMR.14.2.296-326.2001; Vanasco NB, 2008, ACTA TROP, V107, P255, DOI 10.1016/j.actatropica.2008.06.007; Hochedez P, 2013, EUROSURVEILLANCE, V18, P14; Limmathurotsakul D, 2012, CLIN INFECT DIS, V55, P322, DOI 10.1093/cid/cis403; Stevens A Michal, 2011, Pac Health Dialog, V17, P129	15	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1195-1982	1708-8305		J TRAVEL MED	J. Travel Med.	NOV-DEC	2015	22	6					422	424		10.1111/jtm.12241		3	Medicine, General & Internal	General & Internal Medicine	CU6PD	WOS:000363653700013		
J	Nakata, N; Ohta, T; Nishioka, M; Takeyama, H; Toriumi, Y; Kato, K; Nogi, H; Kamio, M; Fukuda, K				Nakata, Norio; Ohta, Tomoyuki; Nishioka, Makiko; Takeyama, Hiroshi; Toriumi, Yasuo; Kato, Kumiko; Nogi, Hiroko; Kamio, Makiko; Fukuda, Kunihiko			Optimization of Region of Interest Drawing for Quantitative Analysis Differentiation Between Benign and Malignant Breast Lesions on Contrast-Enhanced Sonography	JOURNAL OF ULTRASOUND IN MEDICINE			English	Article						breast lesions; breast ultrasound; contrast-enhanced sonography; kinetic parameters; quantitative analysis; receiver operating characteristic curve	COLOR DOPPLER US; ULTRASOUND; AGENT; ULTRASONOGRAPHY; EXPERIENCE; THERAPY; TUMORS	Objectives-This study was performed to evaluate the diagnostic utility of quantitative analysis of benign and malignant breast lesions using contrast-enhanced sonography. Methods-Contrast-enhanced sonography using the perflubutane-based contrast agent Sonazoid (Daiichi Sankyo, Tokyo, Japan) was performed in 94 pathologically proven palpable breast mass lesions, which could be depicted with B-mode sonography. Quantitative analyses using the time-intensity curve on contrast-enhanced sonography were performed in 5 region of interest (ROI) types (manually traced ROI and circular ROIs of 5, 10, 15, and 20 mm in diameter). The peak signal intensity, initial slope, time to peak, positive enhancement integral, and wash-out ratio were investigated in each ROI. Results-There were significant differences between benign and malignant lesions in the time to peak (P < .05), initial slope (P < .001), and positive enhancement integral (P < .05) for the manual ROI. Significant differences were found between benign and malignant lesions in the time to peak (P < .05) for the 5-mm ROI; the time to peak (P < .05) and initial slope (P < .05) for the 10-mm ROI; absolute values of the peak signal intensity (P < .05), time to peak (P < .01), and initial slope (P < .005) for the 15-mm ROI; and the time to peak (P < .05) and initial slope (P < .05) for the 20-mm ROI. There were no statistically significant differences in any wash-out ratio values for the 5 ROI types. Conclusions-Kinetic analysis using contrast-enhanced sonography is useful for differentiation between benign and malignant breast lesions.	[Nakata, Norio; Ohta, Tomoyuki; Nishioka, Makiko; Takeyama, Hiroshi; Toriumi, Yasuo; Kato, Kumiko; Nogi, Hiroko; Kamio, Makiko; Fukuda, Kunihiko] Jikei Univ, Sch Med, Dept Radiol, Tokyo 1058461, Japan	Nakata, N (reprint author), Jikei Univ, Sch Med, Dept Radiol, Minato Ku, 3-25-8 Nishishimbashi, Tokyo 1058461, Japan.	nakata@jikei.ac.jp					Hoyt K, 2012, J ULTRAS MED, V31, P1759; Sung JS, 2014, RADIOL CLIN N AM, V52, P519, DOI 10.1016/j.rcl.2014.02.012; Sorace AG, 2012, J ULTRAS MED, V31, P1543; [Anonymous], GLOBOCAN 2012 EST CA; Huber S, 1998, RADIOLOGY, V208, P485; Zhao HJ, 2010, EUR J RADIOL, V73, P288, DOI 10.1016/j.ejrad.2009.05.043; Moon WK, 2000, RADIOLOGY, V217, P240; Saracco A, 2012, ACTA RADIOL, V53, P382, DOI 10.1258/ar.2012.110562; Kedar RP, 1996, RADIOLOGY, V198, P679; Kuhl CK, 1999, RADIOLOGY, V211, P101; Du J, 2012, EUR J RADIOL, V81, P3890, DOI 10.1016/j.ejrad.2012.09.004; Caproni N, 2010, EUR RADIOL, V20, P1384, DOI 10.1007/s00330-009-1690-1; Sing T, 2005, BIOINFORMATICS, V21, P3940, DOI 10.1093/bioinformatics/bti623; Szabo BK, 2003, ACTA RADIOL, V44, P379, DOI 10.1034/j.1600-0455.2003.00084.x; Jansen SA, 2009, AM J ROENTGENOL, V193, P832, DOI 10.2214/AJR.08.2025; Preim U, 2012, EUR J RADIOL, V81, P1532, DOI 10.1016/j.ejrad.2011.04.045; Hooley RJ, 2013, RADIOLOGY, V268, P642, DOI 10.1148/radiol.13121606; Hoyt K, 2012, INVEST RADIOL, V47, P167, DOI 10.1097/RLI.0b013e318234e6bc; Wan CF, 2012, EUR J RADIOL, V81, pE444, DOI 10.1016/j.ejrad.2011.03.094	19	0	0	AMER INST ULTRASOUND MEDICINE	LAUREL	SUBSCRIPTION DEPT, 14750 SWEITZER LANE, STE 100, LAUREL, MD 20707-5906 USA	0278-4297	1550-9613		J ULTRAS MED	J. Ultrasound Med.	NOV	2015	34	11					1969	1976		10.7863/ultra.14.10042		8	Acoustics; Radiology, Nuclear Medicine & Medical Imaging	Acoustics; Radiology, Nuclear Medicine & Medical Imaging	CU8VL	WOS:000363822100006		
J	Ishida, H; Suehiro, T; Kurozumi, C; Ono, K; Watanabe, S				Ishida, Hiroshi; Suehiro, Tadanobu; Kurozumi, Chiharu; Ono, Koji; Watanabe, Susumu			Correlation Between Abdominal Muscle Thickness and Maximal Expiratory Pressure	JOURNAL OF ULTRASOUND IN MEDICINE			English	Article						abdominal muscle thickness; expiration; musculoskeletal ultrasound; sonography	CROSS-SECTIONAL AREA; INTRAABDOMINAL PRESSURE; TRANSVERSUS ABDOMINIS; STRENGTH; HUMANS; MANEUVERS; AGE	Objectives-The activity of abdominal muscles mainly produces high expiratory pressure. These include the rectus abdominis, external oblique, internal oblique, and transverse abdominis muscles. The purpose of this study was to determine whether maximal expiratory pressure is associated with each abdominal muscle thickness at rest. Methods-Thirty-nine healthy male volunteers (mean age +/- SD, 20.7 +/- 2.7 years) participated in the study. The thickness of the right rectus abdominis, external oblique, internal oblique, and transverse abdominis muscles was measured by B-mode sonography in the supine position. The maximal expiratory pressure was obtained with a spirometer in the sitting position. The correlations between each abdominal muscle thickness and maximal expiratory pressure were determined by the Pearson correlation coefficient. Results-The correlation coefficient between the rectus abdominis muscle and maximal expiratory pressure was 0.571 (P < .001). Correlation coefficients between the external oblique, internal oblique, and transverse abdominis muscles and maximal expiratory pressure were 0.297 (P = .066), 0.267 (P = .100), and 0.022 (P = .894), respectively. Conclusions-Our results indicate that the rectus abdominis muscle thickness might be more highly correlated with expiratory pressure production than the external oblique, internal oblique, and transverse abdominis muscle thickness.	[Ishida, Hiroshi; Suehiro, Tadanobu; Kurozumi, Chiharu; Watanabe, Susumu] Kawasaki Univ Med Welf, Dept Rehabil, Kurashiki, Okayama 7010193, Japan; [Ono, Koji] Kawasaki Univ Med Welf, Masters Program Rehabil, Kurashiki, Okayama 7010193, Japan	Ishida, H (reprint author), Kawasaki Univ Med Welf, Dept Rehabil, 288 Matsushima, Kurashiki, Okayama 7010193, Japan.	ishida@mw.kawasaki-m.ac.jp					Ota M, 2012, ARCH GERONTOL GERIAT, V55, pE26, DOI 10.1016/j.archger.2012.03.007; CHEN HI, 1989, J APPL PHYSIOL, V66, P943; DETROYER A, 1988, CLIN CHEST MED, V9, P175; Misuri G, 1997, EUR RESPIR J, V10, P2861, DOI 10.1183/09031936.97.10122861; Kim J, 2005, J REHABIL RES DEV, V42, P211, DOI 10.1682/JRRD.2004.07.0077; Abe T, 1996, J APPL PHYSIOL, V80, P1379; Rankin G, 2006, MUSCLE NERVE, V34, P320, DOI 10.1002/mus.20589; DePalo VA, 2004, J APPL PHYSIOL, V96, P731, DOI 10.1152/japplphysiol.00511.2003; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; McMeeken JM, 2004, CLIN BIOMECH, V19, P337, DOI 10.1016/j.clinbiomech.2004.01.007; Kim J, 2009, ARCH GERONTOL GERIAT, V48, P361, DOI 10.1016/j.archger.2008.03.006; Ishida H, 2012, J ORTHOP SPORT PHYS, V42, P815, DOI 10.2519/jospt.2012.4064; Sapienza Christine M., 2006, Seminars in Speech and Language, V27, P236, DOI 10.1055/s-2006-955114; WAKAI Y, 1992, J APPL PHYSIOL, V72, P881; BEARDSMORE CS, 1987, B EUR PHYSIOPATH RES, V23, P465; CRESSWELL AG, 1994, EUR J APPL PHYSIOL O, V68, P315, DOI 10.1007/BF00571450; SCHANTZ P, 1983, ACTA PHYSIOL SCAND, V117, P219, DOI 10.1111/j.1748-1716.1983.tb07200.x; McCool FD, 1997, AM J RESP CRIT CARE, V155, P1329; MIER A, 1985, J APPL PHYSIOL, V58, P1438; CRESSWELL AG, 1993, EUR J APPL PHYSIOL O, V66, P315, DOI 10.1007/BF00237775; CRESSWELL AG, 1992, ACTA PHYSIOL SCAND, V144, P409, DOI 10.1111/j.1748-1716.1992.tb09314.x; Hodges PW, 2003, MUSCLE NERVE, V27, P682, DOI 10.1002/mus.10375; Hodges PW, 1997, J APPL PHYSIOL, V83, P753; Summerhill EM, 2007, LUNG, V185, P315, DOI 10.1007/s00408-007-9027-9; Hides J, 2006, SPINE, V31, pE175, DOI 10.1097/01.brs.0000202740.86338.df; Axler CT, 1997, MED SCI SPORT EXER, V29, P804, DOI 10.1097/00005768-199706000-00011; Ishida H, 2014, J PHYS THER SCI, V26, P1791, DOI 10.1589/jpts.26.1791; Ishida H., 2014, Kawasaki Journal of Medical Welfare, V19, P32; MAUGHAN RJ, 1983, J PHYSIOL-LONDON, V338, P37; McCool FD., 2006, CHEST, V129, p48S; Suzuki M, 1997, Nihon Kyobu Shikkan Gakkai Zasshi, V35, P1305	31	0	0	AMER INST ULTRASOUND MEDICINE	LAUREL	SUBSCRIPTION DEPT, 14750 SWEITZER LANE, STE 100, LAUREL, MD 20707-5906 USA	0278-4297	1550-9613		J ULTRAS MED	J. Ultrasound Med.	NOV	2015	34	11					2001	2005		10.7863/ultra.14.12006		5	Acoustics; Radiology, Nuclear Medicine & Medical Imaging	Acoustics; Radiology, Nuclear Medicine & Medical Imaging	CU8VL	WOS:000363822100010		
J	Hirakawa, M; Hidaka, N; Kido, S; Fukushima, K; Kato, K				Hirakawa, Mariko; Hidaka, Nobuhiro; Kido, Saki; Fukushima, Kotaro; Kato, Kiyoko			Congenital Chloride Diarrhea: Accurate Prenatal Diagnosis Using Color Doppler Sonography to Show the Passage of Diarrhea	JOURNAL OF ULTRASOUND IN MEDICINE			English	Letter							DIFFERENTIAL-DIAGNOSIS; SIBLINGS; FETUS		[Hirakawa, Mariko; Hidaka, Nobuhiro; Kido, Saki; Fukushima, Kotaro; Kato, Kiyoko] Kyushu Univ, Grad Sch Med Sci, Dept Obstet & Gynecol, Fukuoka 812, Japan	Hirakawa, M (reprint author), Kyushu Univ, Grad Sch Med Sci, Dept Obstet & Gynecol, Fukuoka 812, Japan.						Tsukimori K, 2007, J ULTRAS MED, V26, P1805; PATEL PJ, 1989, J CLIN ULTRASOUND, V17, P115, DOI 10.1002/jcu.1870170209; Kim SH, 2001, J ULTRAS MED, V20, P1133; LANGER JC, 1991, J PEDIATR SURG, V26, P1282, DOI 10.1016/0022-3468(91)90599-O; Colombani M, 2010, ULTRASOUND OBST GYN, V35, P560, DOI 10.1002/uog.7509; Imada S, 2012, J CLIN ULTRASOUND, V40, P239, DOI 10.1002/jcu.21895; Lee DH, 2012, J OBSTET GYNAECOL RE, V38, P957, DOI 10.1111/j.1447-0756.2012.01876.x; HARTIKAINENSORRI AL, 1980, ACTA PAEDIATR SCAND, V69, P807, DOI 10.1111/j.1651-2227.1980.tb07158.x; Khan S N, 1992, J Perinatol, V12, P112; KIRKINEN P, 1984, PRENATAL DIAG, V4, P457, DOI 10.1002/pd.1970040611; Lundkvist K, 1996, ACTA PAEDIATR, V85, P295, DOI 10.1111/j.1651-2227.1996.tb14019.x	11	0	0	AMER INST ULTRASOUND MEDICINE	LAUREL	SUBSCRIPTION DEPT, 14750 SWEITZER LANE, STE 100, LAUREL, MD 20707-5906 USA	0278-4297	1550-9613		J ULTRAS MED	J. Ultrasound Med.	NOV	2015	34	11					2113	2115		10.7863/ultra.15.01011		3	Acoustics; Radiology, Nuclear Medicine & Medical Imaging	Acoustics; Radiology, Nuclear Medicine & Medical Imaging	CU8VL	WOS:000363822100026		
J	Okumura, N; Minamiyama, R; Ho, LTY; Kay, EP; Kawasaki, S; Tourtas, T; Schlotzer-Schrehardt, U; Kruse, FE; Young, RD; Quantock, AJ; Kinoshita, S; Koizumi, N				Okumura, Naoki; Minamiyama, Ryuki; Ho, Leona T. Y.; Kay, EunDuck P.; Kawasaki, Satoshi; Tourtas, Theofilos; Schloetzer-Schrehardt, Ursula; Kruse, Friedrich E.; Young, Robert D.; Quantock, Andrew J.; Kinoshita, Shigeru; Koizumi, Noriko			Involvement of ZEB1 and Snail1 in excessive production of extracellular matrix in Fuchs endothelial corneal dystrophy	LABORATORY INVESTIGATION			English	Article							UNFOLDED PROTEIN RESPONSE; MISSENSE MUTATIONS; DISEASE; CANCER; EXPRESSION; SURVIVAL; GENE; BETA; TCF8; EMT	Fuchs endothelial corneal dystrophy (FECD) due to corneal endothelial cell degeneration is a major cause of corneal transplantation. It is characterized by abnormal deposition of extracellular matrix (ECM), such as corneal guttae, accompanied by a loss of endothelial cells. Although recent studies have revealed several genomic factors, the molecular pathophysiology of FECD has not yet been revealed. In this study, we establish a cellular in vitro model by using immortalized corneal endothelial cells obtained from late-onset FECD and control patients and examined the involvement of epithelial mesenchymal transition (EMT) on excessive ECM production. We demonstrate that the EMT-inducing genes ZEB1 and SNAI1 were highly expressed in corneal endothelial cells in FECD and were involved in excessive production of ECM proteins, such as type I collagen and fibronectin through the transforming growth factor (TGF)-beta signaling pathway. Furthermore, we found that SB431542, a specific inhibitor of TGF-beta type I ALK receptors, suppressed the expression of ZEB1 and Snail1 followed by reduced production of ECM. These findings suggest that increased expression levels of ZEB1 and Snail1 in FECD cells were responsible for an increased responsiveness to TGF-beta present in the aqueous humor and excessive production of ECM. In addition, these results suggest that the regulation of EMT-related genes by blocking the TGF-beta signaling pathway may be a feasible therapeutic strategy for FECD.	[Okumura, Naoki; Minamiyama, Ryuki; Ho, Leona T. Y.; Kay, EunDuck P.; Koizumi, Noriko] Doshisha Univ, Fac Life & Med Sci, Dept Biomed Engn, Kyotanabe 6100321, Japan; [Okumura, Naoki; Kawasaki, Satoshi; Kinoshita, Shigeru] Kyoto Prefectural Univ Med, Dept Ophthalmol, Kyoto, Japan; [Tourtas, Theofilos; Schloetzer-Schrehardt, Ursula; Kruse, Friedrich E.] Univ Erlangen Nurnberg, Dept Ophthalmol, Erlangen, Germany; [Young, Robert D.; Quantock, Andrew J.] Cardiff Univ, Sch Optometry & Vis Sci, Struct Biophys Grp, Cardiff CF10 3AX, S Glam, Wales	Koizumi, N (reprint author), Doshisha Univ, Fac Life & Med Sci, Dept Biomed Engn, Kyotanabe 6100321, Japan.	nkoizumi@mail.doshisha.ac.jp			Funding Program for Next Generation World-Leading Researchers from the Cabinet Office in Japan [LS117]	We are grateful to Dr Matthias Zenkel for the valuable advice and Dr Kenta Yamasaki for providing technical assistance. This work was supported by The Funding Program for Next Generation World-Leading Researchers from the Cabinet Office in Japan (Koizumi N: LS117).	America Eye Bank Association of America, 2012, EYE BANK STAT REP; Kajita M, 2004, MOL CELL BIOL, V24, P7559, DOI 10.1128/MCB.24.17.7559-7566.2004; Song JS, 2010, INVEST OPHTH VIS SCI, V51, P822, DOI 10.1167/iovs.09-4240; KENNEY MC, 1984, EXP EYE RES, V39, P267, DOI 10.1016/0014-4835(84)90015-0; Martinez-Alvarez C, 2004, DEV BIOL, V265, P207, DOI 10.1016/j.ydbio.2003.09.022; Klenkler B, 2004, EXP EYE RES, V79, P677, DOI 10.1016/j.exer.2004.07.008; Okumura N, 2014, INVEST OPHTH VIS SCI, V55, P318, DOI 10.1167/iovs.13-12225; Venables JP, 2013, MOL CELL BIOL, V33, P396, DOI 10.1128/MCB.01174-12; Kalluri R, 2009, J CLIN INVEST, V119, P1417, DOI 10.1172/JCI39675; Riazuddin SA, 2010, HUM MUTAT, V31, P1261, DOI 10.1002/humu.21356; Argast GM, 2011, CLIN EXP METASTAS, V28, P593, DOI 10.1007/s10585-011-9394-8; Weller JM, 2014, INVEST OPHTH VIS SCI, V55, P3700, DOI 10.1167/iovs.14-14154; Baratz KH, 2010, NEW ENGL J MED, V363, P1016, DOI 10.1056/NEJMoa1007064; Naumann GOH, 2000, OPHTHALMOLOGY, V107, P1111, DOI 10.1016/S0161-6420(00)00087-7; Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; Koizumi N, 2008, OPHTHALMOLOGY, V115, P292, DOI 10.1016/j.ophtha.2007.04.053; CHI HH, 1958, AM J OPHTHALMOL, V45, P518; Engler C, 2010, AM J OPHTHALMOL, V149, P194, DOI 10.1016/j.ajo.2009.09.009; Hetz C, 2013, NAT REV DRUG DISCOV, V12, P703, DOI 10.1038/nrd3976; Riazuddin SA, 2010, AM J HUM GENET, V86, P45, DOI 10.1016/j.ajhg.2009.12.001; Vithana EN, 2008, HUM MOL GENET, V17, P656, DOI 10.1093/hmg/ddm337; Kawaguchi R, 2001, CORNEA, V20, P100, DOI 10.1097/00003226-200101000-00019; Du JT, 2015, J BIOL CHEM, V290, P5979, DOI 10.1074/jbc.M114.621607; Acloque H, 2009, J CLIN INVEST, V119, P1438, DOI 10.1172/JCI38019; Gottsch JD, 2005, INVEST OPHTH VIS SCI, V46, P4504, DOI 10.1167/iovs.05-0497; Miyazono K, 2009, P JPN ACAD B-PHYS, V85, P314, DOI 10.2183/pjab.85.314; Mehta JS, 2008, INVEST OPHTH VIS SCI, V49, P184, DOI 10.1167/iovs.07-0847; Tan DTH, 2012, LANCET, V379, P1749, DOI 10.1016/S0140-6736(12)60437-1; Goar E L, 1933, Trans Am Ophthalmol Soc, V31, P48; LeMasters KE, 2012, BMC DEV BIOL, V12, DOI 10.1186/1471-213X-12-22; LORENZET.DW, 1967, AM J OPHTHALMOL, V64, P1155; Mootha W, 2015, INVEST OPHTH VIS SCI, V56, P2003; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; Okumura N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058000; Wieben ED, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049083	35	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0023-6837	1530-0307		LAB INVEST	Lab. Invest.	NOV	2015	95	11					1291	1304		10.1038/labinvest.2015.111		14	Medicine, Research & Experimental; Pathology	Research & Experimental Medicine; Pathology	CU8ZB	WOS:000363831500007		
J	Suzuki, D				Suzuki, Daisuke			Form and function of the modal adverbs: Recent linguistic change and constancy in British English	LINGUISTICS			English	Article						modal adverbs; functional analysis; corpus data; discourse; grammaticalization/pragmaticalization		This study examines the modal adverbs in English including doubtless, indeed, no doubt, and of course from a functional perspective. Although an increasing number of studies have investigated "core" modal adverbs (e. g., certainly, possibly, probably), a comprehensive analysis including these four modal adverbs has not been offered in modal adverb studies. The present study begins to address this research gap by providing descriptions of these adverbs using data from the LOB (1961) and FLOB (1991) corpora. To adopt a more comprehensive view of the set of modal adverbs, I compare the behaviors of the modal adverbs without -ly to those with -ly in terms of their discourse and interpersonal functions in the text, and present the relationship between form and function of the modal adverbs. The results of the analysis demonstrate that the modal adverbs that convey the same degree of probability fulfill different functions at the discourse-pragmatic level. Moreover, the modal adverbs without -ly have increased their pragmatic functions over time, thus signaling a short-term diachronic development. Finally, I provide an explanation of this change in terms of grammaticalization and pragmaticalization.	Kyoto Univ, Sakyo Ku, Kyoto 6068501, Japan	Suzuki, D (reprint author), Kyoto Univ, Sakyo Ku, Kyoto 6068501, Japan.	suzuki0213@gmail.com			Japan Society for the Promotion of Science [25.5013]	This research was supported by the Japan Society for the Promotion of Science Grants-in-Aid for Scientific Research (No. 25.5013).	Aijmer K., 1997, MODALITY GERMANIC LA, P1; Hundt M, 1997, LANG COMPUT, P135; [Anonymous], 1994, MERRIAM WEBSTERS DIC; Erman B, 2001, J PRAGMATICS, V33, P1337, DOI 10.1016/S0378-2166(00)00066-7; Nilsen O, 2004, LINGUA, V114, P809, DOI 10.1016/S0024-3841(03)00052-4; Cinque G, 2004, LINGUA, V114, P683, DOI 10.1016/S0024-3841(03)00048-2; [Anonymous], 2009, OXFORD THESAURUS ENG; Ernst T, 2009, NAT LANG LINGUIST TH, V27, P497, DOI 10.1007/s11049-009-9069-1; Giegerich HJ, 2012, ENGL LANG LINGUIST, V16, P341, DOI 10.1017/S1360674312000147; Diewald G, 2011, LINGUISTICS, V49, P365, DOI 10.1515/LING.2011.011; [Anonymous], 2002, LONGMAN LANGUAGE ACT; Ernst T, 2004, LINGUA, V114, P755, DOI 10.1016/S0024-3841(03)00050-0; Papafragou A, 2006, LINGUA, V116, P1688, DOI 10.1016/j.lingua.2005.05.009; Leech G, 2004, LANG COMPUT, P61; [Anonymous], 2008, OXFORD LEARNERS THES; Arnovick Leslie K., 1999, 7 CASE STUDIES ENGLI; Baker Mark C., 2003, LEXICAL CATEGORIES V; BELLERT I, 1977, LINGUIST INQ, V8, P337; Biber Douglas, 1999, LONGMAN GRAMMAR SPOK; Brinton Laurel, 2005, LEXICALIZATION LANGU; Bybee J., 1985, MORPHOLOGY STUDY REL; Bybee Joan, 1994, EVOLUTION GRAMMAR TE; Cinque Guglielmo, 1999, ADVERBS FUNCTIONAL H; DOHERTY M, 1987, FOLIA LINGUIST, V21, P45, DOI 10.1515/flin.1987.21.1.45; Ernst Thomas, 1984, INTEGRATED THEORY AD; Ernst Thomas, 2002, SYNTAX ADJUNCTS; Ernst Thomas, 2010, P 22 N AM C CHIN LIN, V2, P178; Fischer O., 2007, MORPHOSYNTACTIC CHAN; Fowler H. W., 2004, FOWLERS MODERN ENGLI; Greenbaum Sidney, 1969, STUDIES ENGLISH ADVE; HALLIDAY MA, 1970, FOUND LANG, V6, P322; Halliday Michael A., 2004, INTRO FUNCTIONAL GRA; Haspelmath Martin, 2004, CLINE NATURE GRAMMAT, P17; Hoye L., 1997, ADVERBS MODALITY ENG; Huddleston Rodney, 2002, CAMBRIDGE GRAMMAR EN; Jackendoff Ray, 2002, FDN LANGUAGE BRAIN M; Leech G., 2009, CHANGE CONT ENGLISH; Leech Geoffrey, 2006, CHANGING FACE CORPUS, P186; Leech Geoffrey, 2003, MODALITY CONT ENGLIS, P223; Lehmann Christian, 1995, THOUGHTS GRAMMATICAL; Lyons John, 1977, SEMANTICS, V2; Mair Ch., 2002, INT J CORPUS LINGUIS, V7, P245; Mair C, 1997, LANG COMPUT, P195; Nevalainen Terttu, 1997, GRAMMATICALIZATION W, P145; Nuyts J., 2001, EPISTEMIC MODALITY L; Papafragou A., 2000, MODALITY ISSUES SEMA; Payne J., 2010, WORD STRUCTURE, V3, P31, DOI 10.3366/E1750124510000486; Perkins M., 1983, MODAL EXPRESSIONS EN; Plag I., 2003, WORD FORMATION ENGLI; Quirk Randolph, 1985, COMPREHENSIVE GRAMMA; Simon-Vandenbergen Anne-Marie, 2011, LINGUISTICS, V49, P333, DOI [10.1515/ling.2011.010, DOI 10.1515/LING.2011.010]; Simon-Vandenbergen Anne-Marie, 2007, SEMANTIC FIELD MODAL; Smith Nicholas, 2003, MODALITY CONT ENGLIS, P241; Sugioka Yoko, 1983, CLS, p[19, 293]; Swan Michael, 2005, PRACTICAL ENGLISH US; Swan Toril, 1988, SENTENCE ADVERBIALS; Tancredi Christopher, 2007, MULTIMODEL M 1 UNPUB; WATTS RJ, 1984, ENGL STUD, V65, P129, DOI 10.1080/00138388408598312; Zwicky Arnold M., 1995, 31 REG M CHIC LING 1, V31, P523	59	0	0	DE GRUYTER MOUTON	BERLIN	GENTHINER STRASSE 13, 10785 BERLIN, GERMANY	0024-3949	1613-396X		LINGUISTICS	Linguistics	NOV	2015	53	6					1365	1389		10.1515/ling-2015-0035		25	Linguistics; Language & Linguistics	Linguistics	CU9EY	WOS:000363848000004		
J	Wakiya, T; Sanada, Y; Urahashi, T; Ihara, Y; Yamada, N; Okada, N; Hirata, Y; Hakamada, K; Yasuda, Y; Mizuta, K				Wakiya, Taiichi; Sanada, Yukihiro; Urahashi, Taizen; Ihara, Yoshiyuki; Yamada, Naoya; Okada, Noriki; Hirata, Yuta; Hakamada, Kenichi; Yasuda, Yoshikazu; Mizuta, Koichi			Impact of the serum ferritin concentration in liver transplantation	LIVER TRANSPLANTATION			English	Article							RESPIRATORY-DISTRESS-SYNDROME; ISCHEMIA-REPERFUSION INJURY; CULTURED RAT HEPATOCYTES; OXIDATIVE STRESS; TRANSFERRIN SATURATION; WARM ISCHEMIA; LUNG INJURY; IDOXIFENE; ESTRADIOL; ESTROGEN	The serum ferritin (SF) concentration is a widely available and objective laboratory parameter. SF is also widely recognized as an acute-phase reactant. The purpose of the present study was to identify the chronological changes in the recipient's SF concentration during liver transplantation (LT) and to clarify factors having an effect on the recipient's intraoperative SF level. In addition, the study retrospectively evaluated the usefulness of measuring SF during LT. Ninety-eight pediatric recipients were retrospectively analyzed. The data were analyzed and compared according to the SF level in the recipient. Patients were classified into 2 groups based on the intraoperative peak SF levels of 1000 ng/mL (low-SF group) or >1000 ng/mL (high-SF group). The SF value increased dramatically after reperfusion and fell to normal levels within the early postoperative period. The warm ischemia time (WIT) was significantly longer in the high-SF group (47.0 versus 58.5 minutes; P = 0.003). In addition, a significant positive correlation was observed between the peak SF value and WIT (r = 0.35; P < 0.001). There were significant positive correlations between the peak SF value and the donors' preoperative laboratory data, including transaminases, cholinesterase, hemoglobin, transferrin saturation, and SF, of which SF showed the strongest positive correlation (r = 0.74; P < 0.001). The multivariate analysis revealed that WIT and donor's SF level were a significant risk factor for high SF level in the recipient (P = 0.007 and 0.02, respectively). In conclusion, the SF measurement can suggest the degree of ischemia/reperfusion injury (IRI). A high SF level in the donor is associated with the risk of further acute reactions, such as IRI, in the recipient. Liver Transpl 21:1419-1427, 2015. (c) 2015 AASLD.	[Wakiya, Taiichi; Sanada, Yukihiro; Urahashi, Taizen; Ihara, Yoshiyuki; Yamada, Naoya; Okada, Noriki; Hirata, Yuta; Mizuta, Koichi] Jichi Med Univ, Dept Transplant Surg, Shimotsuke, Tochigi 3290498, Japan; [Yasuda, Yoshikazu] Jichi Med Univ, Dept Surg, Shimotsuke, Tochigi 3290498, Japan; [Wakiya, Taiichi; Hakamada, Kenichi] Hirosaki Univ, Grad Sch Med, Dept Surg Gastroenterol, Hirosaki, Aomori, Japan	Mizuta, K (reprint author), Jichi Med Univ, Dept Transplant Surg, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290498, Japan.	koimizu@jichi.ac.jp					Knovich MA, 2009, BLOOD REV, V23, P95, DOI 10.1016/j.blre.2008.08.001; Zandman-Goddard G, 2007, AUTOIMMUN REV, V6, P457, DOI 10.1016/j.autrev.2007.01.016; Tuomainen TP, 2003, FREE RADICAL BIO MED, V35, P922, DOI 10.1016/S0891-5849(03)00433-7; Kalimeris K, 2010, HEPATOL RES, V40, P841, DOI 10.1111/j.1872-034X.2010.00682.x; Nakano M, 2003, FREE RADICAL BIO MED, V35, P826, DOI 10.1016/S0891-5849(03)00432-5; El-Badry AM, 2007, HEPATOLOGY, V45, P855, DOI 10.1002/hep.21625; Totsuka E, 2004, TRANSPLANT P, V36, P2215, DOI 10.1016/j.transproceed.2004.08.052; Deschenes M, 2013, LIVER TRANSPLANT, V19, pS6, DOI 10.1002/lt.23746; Bresgen N, 2010, FREE RADICAL BIO MED, V48, P1347, DOI 10.1016/j.freeradbiomed.2010.02.019; Weismuller TJ, 2011, HEPATOLOGY, V54, P2114, DOI 10.1002/hep.24635; Imai Y, 2008, CELL, V133, P235, DOI 10.1016/j.cell.2008.02.043; Walker NM, 2010, HEPATOLOGY, V51, P1683, DOI 10.1002/hep.23537; Connelly KG, 1997, AM J RESP CRIT CARE, V155, P21; Nastos C, 2014, OXID MED CELL LONGEV, DOI 10.1155/2014/906965; Leithead JA, 2013, TRANSPL INT, V26, P1116, DOI 10.1111/tri.12175; Inoue H, 2003, DIGEST DIS SCI, V48, P570, DOI 10.1023/A:1022553119715; Sharkey RA, 1999, AM J RESP CRIT CARE, V159, P1506; McCormack L, 2011, J HEPATOL, V54, P1055, DOI 10.1016/j.jhep.2010.11.004; Niu XW, 2014, LIVER TRANSPLANT, V20, P904, DOI 10.1002/lt.23893; Omoya T, 2001, LIVER, V21, P183, DOI 10.1034/j.1600-0676.2001.021003183.x; Broedbaek K, 2011, FREE RADICAL RES, V45, P409, DOI 10.3109/10715762.2010.538391; Moore DE, 2005, ARCH SURG-CHICAGO, V140, P273, DOI 10.1001/archsurg.140.3.273; Kell DB, 2014, METALLOMICS, V6, P748, DOI 10.1039/c3mt00347g; Adams PC, 2011, J HEPATOL, V55, P453, DOI 10.1016/j.jhep.2011.02.010; Totsuka E, 2004, TRANSPLANT P, V36, P1955, DOI 10.1016/j.transproceed.2004.08.068; Wang W, 2010, BBA-GEN SUBJECTS, V1800, P760, DOI 10.1016/j.bbagen.2010.03.011; Reiniers MJ, 2014, ANTIOXID REDOX SIGN, V21, P1119, DOI 10.1089/ars.2013.5486; Shimizu I, 2007, WORLD J GASTROENTERO, V13, P4295; Naugler WE, 2007, SCIENCE, V317, P121, DOI 10.1126/science.1140485; desRougemont O, 2010, CURR OPIN ORGAN TRAN, V15, P183; Lang JD, 2002, CHEST, V122, p314S; Lemasters JJ, 1997, ANNU REV PHARMACOL, V37, P327, DOI 10.1146/annurev.pharmtox.37.1.327; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; Schaefer B, 2014, TRANSPL INT, V27, P1109, DOI 10.1111/tri.12374	34	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1527-6465	1527-6473		LIVER TRANSPLANT	Liver Transplant.	NOV	2015	21	11					1419	1427		10.1002/lt.24222		9	Gastroenterology & Hepatology; Surgery; Transplantation	Gastroenterology & Hepatology; Surgery; Transplantation	CU7CQ	WOS:000363693800012		
J	Hasegawa, U; Tateishi, N; Uyama, H; van der Vlies, AJ				Hasegawa, Urara; Tateishi, Naoya; Uyama, Hiroshi; van der Vlies, Andre J.			Hydrolysis-Sensitive Dithiolethione Prodrug Micelles	MACROMOLECULAR BIOSCIENCE			English	Article						block copolymer; cytotoxicity; dithiolehthiones; micelle; prodrug	HYDROGEN-SULFIDE DONORS; ANETHOLE DITHIOLETHIONE; CANCER; CHEMOPREVENTION; INHIBIT; ACID	Prodrug micelles carrying 5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione (ADT-OH), a compound possessing chemopreventive properties, are prepared from amphiphilic block copolymers linking ADT-OH via an ester bond using glycine (PAM-PGlyADT) and isoleucine linkers (PAM-PIleADT). The release of ADT-OH from the PAM-PIleADT micelles is much slower than the PAM-PGlyADT micelles. The PAM-PGlyADT micelles show comparable toxicity with ADT-OH in different cancer cell lines, whereas the PAM-PIleADT micelles are not toxic up to 400 mu M. This ADT-ester prodrug micelle approach enables to modulate the release rate of ADT-OH and thus might find application in cancer therapy and prevention.	[Hasegawa, Urara] Osaka Univ, Grad Sch Engn, Frontier Res Base Young Researchers, Suita, Osaka 5650871, Japan; [Hasegawa, Urara; Tateishi, Naoya; Uyama, Hiroshi; van der Vlies, Andre J.] Osaka Univ, Grad Sch Engn, Dept Appl Chem, Suita, Osaka 5650871, Japan; [van der Vlies, Andre J.] Osaka Univ, Grad Sch Engn, Frontier Res Ctr, Suita, Osaka 5650871, Japan	Hasegawa, U (reprint author), Osaka Univ, Grad Sch Engn, Frontier Res Base Young Researchers, 2-1 Yamadaoka, Suita, Osaka 5650871, Japan.	urara.hasegawa@chem.eng.osaka-u.ac.jp			Japan Society for the Promotion of Science [26560241]	We thank Dr. E. Mochizuki (Osaka University, Japan) for TEM experiments and Prof. M. Sadakane (Hiroshima University, Japan) for supplying Preyssler-type phosphotungstate staining solution. This work was supported by Grant-in-Aid for Challenging Exploratory Research, No. 26560241, from the Japan Society for the Promotion of Science.	Song ZJ, 2014, MEDCHEMCOMM, V5, P557, DOI 10.1039/c3md00362k; Bhattacharyya S, 2010, BIOORGAN MED CHEM, V18, P5945, DOI 10.1016/j.bmc.2010.06.084; Munday R, 2010, J MED CHEM, V53, P4761, DOI 10.1021/jm100425v; MANSUY D, 1986, BIOCHEM BIOPH RES CO, V135, P1015, DOI 10.1016/0006-291X(86)91029-6; Kwak MK, 2003, J BIOL CHEM, V278, P8135, DOI 10.1074/jbc.M211898200; Szabo C, 2007, NAT REV DRUG DISCOV, V6, P917, DOI 10.1038/nrd2425; Maeda H, 2001, ADV ENZYME REGUL, V41, P189, DOI 10.1016/S0065-2571(00)00013-3; Duncan R, 2006, NAT REV CANCER, V6, P688, DOI 10.1038/nrc1958; Kwak MK, 2001, MUTAT RES-FUND MOL M, V480, P305, DOI 10.1016/S0027-5107(01)00190-7; YOKOYAMA M, 1992, BIOCONJUGATE CHEM, V3, P295, DOI 10.1021/bc00016a007; Lammers T, 2012, J CONTROL RELEASE, V161, P175, DOI 10.1016/j.jconrel.2011.09.063; Li L, 2007, FREE RADICAL BIO MED, V42, P706, DOI 10.1016/j.freeradbiomed.2006.12.011; RAJEWSKI LG, 1992, INT J PHARM, V82, P205, DOI 10.1016/0378-5173(92)90176-3; Drukarch B, 2006, J NEURAL TRANSM, V113, P593, DOI 10.1007/s00702-005-0350-0; Chattopadhyay M, 2012, BIOCHEM PHARMACOL, V83, P715, DOI 10.1016/j.bcp.2011.12.018; Moriyama M, 2015, ADV HEALTHC MATER, V4, P569, DOI 10.1002/adhm.201400249; Switzer CH, 2012, CANCER RES, V72, P2394, DOI 10.1158/0008-5472.CAN-11-3115; REDDY BS, 1993, CANCER RES, V53, P3493; Hasegawa U, 2014, BIOCONJUGATE CHEM, V25, P1290, DOI 10.1021/bc500150s; Hasegawa U, 2015, POLYMER, V66, P1, DOI 10.1016/j.polymer.2015.03.080; Duncan R, 2003, NAT REV DRUG DISCOV, V2, P347, DOI 10.1038/nrd1088; Hasegawa U, 2010, J AM CHEM SOC, V132, P18273, DOI 10.1021/ja1075025; Zhang YS, 2008, MOL CANCER THER, V7, P3470, DOI 10.1158/1535-7163.MCT-08-0625; CHRISTEN MO, 1995, METHOD ENZYMOL, V252, P324; JORGENSEN KE, 1979, AM J PHYSIOL, V236, pF103; Ringsdorf H, 1975, J POLYM SCI POLYM S, V51, P135	26	0	0	WILEY-V C H VERLAG GMBH	WEINHEIM	POSTFACH 101161, 69451 WEINHEIM, GERMANY	1616-5187	1616-5195		MACROMOL BIOSCI	Macromol. Biosci.	NOV	2015	15	11					1512	1522		10.1002/mabi.201500156		11	Biochemistry & Molecular Biology; Materials Science, Biomaterials; Polymer Science	Biochemistry & Molecular Biology; Materials Science; Polymer Science	CU7AY	WOS:000363688300005		
J	Takeuchi, M; Tsuboi, A; Kurata, M; Fukuo, K; Kazumi, T				Takeuchi, Mika; Tsuboi, Ayaka; Kurata, Miki; Fukuo, Keisuke; Kazumi, Tsutomu			Association of Metabolic Syndrome with Serum Adipokines in Community-Living Elderly Japanese Women: Independent Association with Plasminogen Activator-Inhibitor-1	METABOLIC SYNDROME AND RELATED DISORDERS			English	Article							C-REACTIVE PROTEIN; BODY-MASS INDEX; LIPOPROTEIN-LIPASE MASS; INSULIN-RESISTANCE; CARDIOVASCULAR EVENTS; RISK-FACTORS; FAT MASS; ADIPONECTIN; OBESITY; MARKERS	Background: Associations between metabolic syndrome (MetS) with serum adipokines and basal lipoprotein lipase mass (serum LPL) have not been extensively studied in elderly Asians, who in general have lower body mass index than European populations. Methods: A cross-sectional analysis was conducted including 159 community-living elderly Japanese women whose age averaged 77 years. MetS was defined by the modified National Cholesterol Education Program Adult Treatment Panel III criteria, but using a body mass index 25kg/m(2) instead of waist circumference. Serum LPL, leptin, adiponectin, plasminogen activator inhibitor 1 (PAI-1), interleukin-6, tumor necrosis factor-alpha, and high-sensitivity C-reactive protein were measured. Results: Both the presence of MetS and the number of MetS components were associated with higher homeostasis assessment of insulin resistance, serum levels of leptin, PAI-1, and tumor necrosis factor-alpha and with lower serum levels of LPL and adiponectin (all P<0.05), but not with high-sensitivity C-reactive protein and interleukin-6. Among six biomarkers of MetS, PAI-1 remained associated with MetS independent of fat mass index and insulin resistance. Conclusions: Although proinflammatory, prothrombotic, and anti-inflammatory states were associated with MetS, higher PAI-1 was associated with MetS independent of fat mass index and insulin resistance in elderly Japanese women, in whom obesity is rare.	[Takeuchi, Mika; Kurata, Miki; Fukuo, Keisuke] Mukogawa Womens Univ, Sch Human Environm Sci, Dept Food Sci & Nutr, Nishinomiya, Hyogo 6638558, Japan; [Tsuboi, Ayaka; Fukuo, Keisuke; Kazumi, Tsutomu] Mukogawa Womens Univ, Sch Human Environm Sci, Postgrad Sch Food Sci & Nutr, Nishinomiya, Hyogo 6638558, Japan; [Kurata, Miki; Fukuo, Keisuke] Mukogawa Womens Univ, Sch Human Environm Sci, Res Inst Nutr Sci, Nishinomiya, Hyogo 6638558, Japan; [Kazumi, Tsutomu] Sadamitsu Hosp, Diabet Div, Kakogawa, Hyogo, Japan	Kazumi, T (reprint author), Mukogawa Womens Univ, Res Inst Nutr Sci, 6-46 Ikebiraki Cho, Nishinomiya, Hyogo 6638558, Japan.	kazumi@mukogawa-u.ac.jp			Japan Society for the Promotion of Science [21300260]	We are indebted to all the participants for their dedicated and conscientious collaboration. This study was supported by a Grant -in-Aid for Scientific Research [KAKENHI B no. 21300260) from the Japan Society for the Promotion of Science.	Alessi MC, 2006, ARTERIOSCL THROM VAS, V26, P2200, DOI 10.1161/01.ATV.0000242905.41404.68; Merkel M, 2002, J LIPID RES, V43, P1997, DOI 10.1194/jlr.R200015/JLR200; Matsuo S, 2009, AM J KIDNEY DIS, V53, P982, DOI 10.1053/j.ajkd.2008.12.034; Kahn SE, 2006, DIABETES, V55, P2357, DOI 10.2337/db06-0116; SCHERER PE, 1995, J BIOL CHEM, V270, P26746; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Ridker PM, 2003, CIRCULATION, V107, P391, DOI 10.1161/01.CIR.0000055014.62083.05; Xydakis AM, 2004, J CLIN ENDOCR METAB, V89, P2697, DOI 10.1210/jc.2003-031826; Horio M, 2013, AM J KIDNEY DIS, V61, P197, DOI 10.1053/j.ajkd.2012.07.007; Bentley-Lewis R, 2007, NAT CLIN PRACT ENDOC, V3, P696, DOI 10.1038/ncpendmet0616; Yoshiike N, 1998, INT J OBESITY, V22, P684, DOI 10.1038/sj.ijo.0800651; Tsuboi A, 2013, J ATHEROSCLER THROMB, V20, P568; Han TS, 2002, OBES RES, V10, P923, DOI 10.1038/oby.2002.126; Shlipak MG, 2003, CIRCULATION, V107, P87, DOI 10.1161/01.CIR.0000042700.48769.59; KOBAYASHI J, 1993, CLIN CHIM ACTA, V216, P113, DOI 10.1016/0009-8981(93)90144-S; [Anonymous], 2005, CIRCULATION, DOI DOI 10.1161/CIRCULATIONAHA.105.169404; Oda E, 2010, INTERNAL MED, V49, P1477, DOI 10.2169/internalmedicine.49.3363; Kazumi T, 2004, METABOLISM, V53, P589, DOI 10.1016/j.metabol.2003.12.008; Inker LA, 2012, NEW ENGL J MED, V367, P20, DOI 10.1056/NEJMoa1114248; Wang TJ, 2007, HYPERTENSION, V49, P432, DOI 10.1161/01.HYP.0000256956.61872.aa; Rutter MK, 2004, CIRCULATION, V110, P380, DOI 10.1161/01.CIR.0000136581.59584.0E; Festa A, 2002, DIABETES, V51, P1131, DOI 10.2337/diabetes.51.4.1131; Briffa JF, 2013, AM J PHYSIOL-RENAL, V305, pF1629, DOI 10.1152/ajprenal.00263.2013; Reilly MP, 2003, CIRCULATION, V108, P1546, DOI 10.1161/01.CIR.0000088846.10655.E0; Abdullah AR, 2009, METAB SYNDR RELAT D, V7, P17, DOI 10.1089/met.2008.0045; Kelly AS, 2007, J DIABETES COMPLICAT, V21, P326, DOI 10.1016/j.jdiacomp.2006.03.006; Ingelsson E, 2007, CIRCULATION, V116, P984, DOI 10.1161/CIRCULATIONAHA.107.708537; Alberti KGMM, 2009, CIRCULATION, V120, P1640, DOI 10.1161/CIRCULATIONAHA.109.192644; You TJ, 2008, J GERONTOL A-BIOL, V63, P414; Stenholm S, 2010, CLIN ENDOCRINOL, V73, P55, DOI 10.1111/j.1365-2265.2009.03742.x; Eckel RH, 2005, LANCET, V365, P1415, DOI 10.1016/S0140-6736(05)66378-7; Matsushita K, 2006, ARTERIOSCL THROM VAS, V26, P871, DOI 10.1161/01.ATV.0000208363.85388.8f; Mertens I, 2006, INT J OBESITY, V30, P1308, DOI 10.1038/sj.ijo.0803189; Bremer A A, 2013, J OBES, V2013, DOI [DOI 10.1155/2013/393192, 10.1155/2013/393192]; Kim CX, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009065; Liu PJ, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-629; Rasouli N, 2008, J CLIN ENDOCR METAB, V93, pS64, DOI 10.1210/jc.2008-1613; Sakurai Masaru, 2008, Diabetes Care, V31, pe12, DOI 10.2337/dc07-0309; Terazawa-Watanabe M, 2014, METAB SYNDR RELAT D, V12, P416, DOI 10.1089/met.2014.0023; Matsuzawa Y, 2002, CIRC J, V66, P987; ZHANG YY, 1995, NATURE, V374, P479	41	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1540-4196	1557-8518		METAB SYNDR RELAT D	Metab. Syndr. Relat. Disord.	NOV 1	2015	13	9					415	421		10.1089/met.2015.0014		7	Medicine, Research & Experimental	Research & Experimental Medicine	CU9TP	WOS:000363888500008		
J	Loukanov, A; Filipov, C; Lecheva, M; Emin, S				Loukanov, Alexandre; Filipov, Chavdar; Lecheva, Marta; Emin, Saim			Immobilization and stretching of 5-pyrene-terminated DNA on carbon film deposited on electron microscope grid	MICROSCOPY RESEARCH AND TECHNIQUE			English	Article						5-pyrene-terminated DNA; immobilization and stretching of DNA; 2-cyanoethyl pyrenyl N; N-diisopropylphosphoramidite	COVALENT ATTACHMENT; SURFACE; PYRENE; GLASS; MICROARRAYS; GENERATION; NANOTUBES	The immobilization and stretching of randomly coiled DNA molecules on hydrophobic carbon film is a challenging microscopic technique, which possess various applications, especially for genome sequencing. In this report the pyrenyl nucleus is used as an anchor moiety to acquire higher affinity of double stranded DNA to the graphite surface. DNA and pyrene are joined through a linker composed of four aliphatic methylene groups. For the preparation of pyrene-terminated DNA a multifunctional phosphoramidite monomer compound was designed. It contains pyrenylbutoxy group as an anchor moiety for -stacking attachment to the carbon film, 2-cyanoethyloxy, and diisopropylamino as coupling groups for conjugation to activated oligonucleotide chain or DNA molecule. This monomer derivative was suitable for incorporation into automated solid-phase DNA synthesis and was attached to the 5 terminus of the DNA chain through a phosphodiester linkage. The successful immobilization and stretching of pyrene-terminated DNA was demonstrated by conventional 100 kV transmission electron microscope. The microscopic analysis confirmed the stretched shape of the negatively charged nucleic acid pieces on the hydrophobic carbon film. Microsc. Res. Tech. 78:994-1000, 2015. (c) 2015 Wiley Periodicals, Inc.	[Loukanov, Alexandre] Saitama Univ, Grad Sch Sci & Engn, Sakura Ku, Saitama 3388570, Japan; [Loukanov, Alexandre; Lecheva, Marta] Univ Min & Geol St Ivan Rilski, Lab Engn NanoBiotechnol, Dept Engn Geoecol, Sofia, Bulgaria; [Filipov, Chavdar] Univ Forestry, Dept Infect Pathol Hyg Technol & Control Food Stu, Fac Vet Med, Sofia, Bulgaria; [Emin, Saim] Univ Nova Gor, Mat Res Lab, SI-5000 Nova Gorica, Slovenia	Loukanov, A (reprint author), Saitama Univ, Grad Sch Sci & Engn, Sakura Ku, Shimo Ohkubo 255, Saitama 3388570, Japan.	loukanov@mail.saitama-u.ac.jp			Japanese Society of the Promotion Science; Bulgarian Ministry of Education and Science (National Science Fund)	Contract grant sponsor: Japanese Society of the Promotion Science; Bulgarian Ministry of Education and Science (National Science Fund).	Akca S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018442; Heller MJ, 2002, ANNU REV BIOMED ENG, V4, P129, DOI 10.1146/annurev.bioeng.4.020702.153438; BENSIMON A, 1994, SCIENCE, V265, P2096, DOI 10.1126/science.7522347; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Sharma J, 2008, CHEM COMMUN, P2140, DOI 10.1039/b800109j; Michalet X, 1997, SCIENCE, V277, P1518, DOI 10.1126/science.277.5331.1518; Dawson ED, 2005, ANAL BIOCHEM, V341, P352, DOI 10.1016/j.ab.2005.03.029; Kim JH, 2007, NANOSCALE RES LETT, V2, P185, DOI 10.1007/s11671-007-9057-5; KATZ E, 1994, J ELECTROANAL CHEM, V365, P157, DOI 10.1016/0022-0728(93)02975-N; Joos B, 1997, ANAL BIOCHEM, V247, P96, DOI 10.1006/abio.1997.2017; MANN JS, 1992, BIOCONJUGATE CHEM, V3, P554, DOI 10.1021/bc00018a015; MCBRIDE LJ, 1983, TETRAHEDRON LETT, V24, P245, DOI 10.1016/S0040-4039(00)81376-3; Ramsay G, 1998, NAT BIOTECHNOL, V16, P40, DOI 10.1038/nbt0198-40; Jiang ZH, 2010, LANGMUIR, V26, P13773, DOI 10.1021/la102647p; Chen RJ, 2001, J AM CHEM SOC, V123, P3838, DOI 10.1021/ja010172b; Rance GA, 2014, DALTON T, V43, P7400, DOI 10.1039/c3dt53372g; Garaj S, 2010, NATURE, V467, P190, DOI 10.1038/nature09379; Brett AMO, 2003, LANGMUIR, V19, P3830, DOI 10.1021/la027047d; Shendure J, 2008, NAT BIOTECHNOL, V26, P1135, DOI 10.1038/nbt1486; Zhang YH, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/6/065201; Laib S, 2005, CHEM COMMUN, P5566, DOI 10.1039/b511716j; Zammatteo N, 2000, ANAL BIOCHEM, V280, P143, DOI 10.1006/abio.2000.4515; Bock CT, 2006, ELECT MICROSCOPY BIO; Deegan RD, 1997, NATURE, V389, P828; Kodali VK, 2010, LANGMUIR, V27, P863; Wittmann C, 2005, TOP CURR CHEM, V260, P161	26	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1059-910X	1097-0029		MICROSC RES TECHNIQ	Microsc. Res. Tech.	NOV	2015	78	11					994	1000		10.1002/jemt.22564		7	Anatomy & Morphology; Biology; Microscopy	Anatomy & Morphology; Life Sciences & Biomedicine - Other Topics; Microscopy	CU7NE	WOS:000363726100007		
J	Almeida, P; Barbosa, R; Zalar, P; Imanishi, Y; Shimizu, K; Turchetti, B; Legras, JL; Serra, M; Dequin, S; Couloux, A; Guy, J; Bensasson, D; Goncalves, P; Sampaio, JP				Almeida, Pedro; Barbosa, Raquel; Zalar, Polona; Imanishi, Yumi; Shimizu, Kiminori; Turchetti, Benedetta; Legras, Jean-Luc; Serra, Marta; Dequin, Sylvie; Couloux, Arnaud; Guy, Julie; Bensasson, Douda; Goncalves, Paula; Sampaio, Jose Paulo			A population genomics insight into the Mediterranean origins of wine yeast domestication	MOLECULAR ECOLOGY			English	Article						comparative genomics; domestication fingerprints; microbe domestication; microbe population genomics; yeast molecular ecology	SACCHAROMYCES-CEREVISIAE EC1118; MULTILOCUS GENOTYPE DATA; MAXIMUM-LIKELIHOOD; SEQUENCE DIVERSITY; GENETIC-VARIATION; EVOLUTIONARY; WILD; PARADOXUS; BEER; ALGORITHMS	The domestication of the wine yeast Saccharomyces cerevisiae is thought to be contemporary with the development and expansion of viticulture along the Mediterranean basin. Until now, the unavailability of wild lineages prevented the identification of the closest wild relatives of wine yeasts. Here, we enlarge the collection of natural lineages and employ whole-genome data of oak-associated wild isolates to study a balanced number of anthropic and natural S. cerevisiae strains. We identified industrial variants and new geographically delimited populations, including a novel Mediterranean oak population. This population is the closest relative of the wine lineage as shown by a weak population structure and further supported by genomewide population analyses. A coalescent model considering partial isolation with asymmetrical migration, mostly from the wild group into the Wine group, and population growth, was found to be best supported by the data. Importantly, divergence time estimates between the two populations agree with historical evidence for winemaking. We show that three horizontally transmitted regions, previously described to contain genes relevant to wine fermentation, are present in the Wine group but not in the Mediterranean oak group. This represents a major discontinuity between the two populations and is likely to denote a domestication fingerprint in wine yeasts. Taken together, these results indicate that Mediterranean oaks harbour the wild genetic stock of domesticated wine yeasts.	[Almeida, Pedro; Barbosa, Raquel; Serra, Marta; Goncalves, Paula; Sampaio, Jose Paulo] Univ Nova Lisboa, Fac Ciencias & Tecnol, Dept Ciencias Vida, UCIBIO REQUIMTE, P-2829516 Caparica, Portugal; [Zalar, Polona] Univ Ljubljana, Biotech Fac, Dept Biol, SI-1000 Ljubljana, Slovenia; [Imanishi, Yumi] Kanto Gakuin Univ, Coll Engn, Dept Appl Mat & Life Sci, Kanazawa Ku, Yokohama, Kanagawa 2368501, Japan; [Shimizu, Kiminori] Chiba Univ, Med Mycol Res Ctr, Chuo Ku, Chiba 2608673, Japan; [Turchetti, Benedetta] Univ Perugia, Dipartimento Sci Agr Alimentari & Ambientali, I-06121 Perugia, Italy; [Turchetti, Benedetta] Univ Perugia, Ind Yeasts Collect DBVPG, I-06121 Perugia, Italy; [Legras, Jean-Luc; Dequin, Sylvie] INRA, Sci OEnol SPO UMR1083, F-34060 Montpellier, France; [Couloux, Arnaud; Guy, Julie] CEA, Inst Genom, Genoscope, Ctr Natl Sequencage, F-91057 Evry, France; [Bensasson, Douda] Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England	Sampaio, JP (reprint author), Univ Nova Lisboa, Fac Ciencias & Tecnol, Dept Ciencias Vida, UCIBIO REQUIMTE, P-2829516 Caparica, Portugal.	jss@fct.unl.pt			FCT Portugal [PTDC/BIA-EVF/118618/2010, PTDC/AGR-ALI/118590/2010, UID/Multi/04378/2013, SFRH/BD/77390/2011]; Infrastructural Centre Mycosmo; MRIC UL, Slovenia; GIS IBiSA-AO France; Natural Environment Research Council UK [NE/D008824/1]	This work was supported by FCT Portugal grants PTDC/BIA-EVF/118618/2010 (JPS, PA, PG), PTDC/AGR-ALI/118590/2010 (JPS, PA, PG, RB), UID/Multi/04378/2013 (JPS, PG) and SFRH/BD/77390/2011 (PA), Infrastructural Centre Mycosmo, MRIC UL, Slovenia (PZ), GIS IBiSA-AO 2010-2011 France (JLL, SD) and the Natural Environment Research Council UK, NE/D008824/1 (DB). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. For kindly providing strains, we thank Ana Pinharanda, Heather Robinson, Eladio Barrio and Stephanie Diezmann.	Almeida P, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5044; Bergstrom A, 2014, MOL BIOL EVOL, V31, P872, DOI 10.1093/molbev/msu037; McGovern PE, 1996, NATURE, V381, P480, DOI 10.1038/381480a0; Gibbons JG, 2012, CURR BIOL, V22, P1403, DOI 10.1016/j.cub.2012.05.033; Sampaio JP, 2008, APPL ENVIRON MICROB, V74, P2144, DOI 10.1128/AEM.02396-07; Marsit S, 2015, MOL BIOL EVOL, V32, P1695, DOI 10.1093/molbev/msv057; Naumov GI, 1998, CAN J MICROBIOL, V44, P1045, DOI 10.1139/cjm-44-11-1045; Joffe AH, 1998, CURR ANTHROPOL, V39, P297, DOI 10.1086/204736; Douglas GL, 2010, ANNU REV FOOD SCI T, V1, P397, DOI 10.1146/annurev.food.102308.124134; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352; Salzberg SL, 2012, GENOME RES, V22, P557, DOI 10.1101/gr.131383.111; Liti G, 2009, NATURE, V458, P337, DOI 10.1038/nature07743; Pritchard JK, 2000, GENETICS, V155, P945; Libkind D, 2011, P NATL ACAD SCI USA, V108, P14539, DOI 10.1073/pnas.1105430108; Schacherer J, 2009, NATURE, V458, P342, DOI 10.1038/nature07670; Stamatakis A, 2006, BIOINFORMATICS, V22, P2688, DOI 10.1093/bioinformatics/btl446; Evanno G, 2005, MOL ECOL, V14, P2611, DOI 10.1111/j.1365-294X.2005.02553.x; Cavalieri D, 2003, J MOL EVOL, V57, pS226, DOI 10.1007/s00239-003-0031-2; McGovern PE, 2004, P NATL ACAD SCI USA, V101, P17593, DOI 10.1073/pnas.0407921102; Hyma KE, 2013, MOL ECOL, V22, P2917, DOI 10.1111/mec.12155; Valamoti SM, 2007, ANTIQUITY, V81, P54; Zerbino DR, 2008, GENOME RES, V18, P821, DOI 10.1101/gr.074492.107; Liti G, 2006, GENETICS, V174, P839, DOI 10.1534/genetics.106.062166; MICHEL RH, 1992, NATURE, V360, P24, DOI 10.1038/360024b0; Doebley JF, 2006, CELL, V127, P1309, DOI 10.1016/j.cell.2006.12.006; Galeote V, 2010, MICROBIOL-SGM, V156, P3754, DOI 10.1099/mic.0.041673-0; Legras JL, 2007, MOL ECOL, V16, P2091, DOI 10.1111/j.1365-294X.2007.03266.x; Samuel D, 1996, SCIENCE, V273, P488, DOI 10.1126/science.273.5274.488; Cromie GA, 2013, G3-GENES GENOM GENET, V3, P2163, DOI 10.1534/g3.113.007492; Leducq JB, 2014, P ROY SOC B-BIOL SCI, V281, DOI 10.1098/rspb.2013.2472; Bing J, 2014, CURR BIOL, V24, pR380, DOI 10.1016/j.cub.2014.04.031; Wang QM, 2012, MOL ECOL, V21, P5404, DOI 10.1111/j.1365-294X.2012.05732.x; Fay JC, 2005, PLOS GENET, V1, P66, DOI 10.1371/journal.pgen.0010005; Novo M, 2009, P NATL ACAD SCI USA, V106, P16333, DOI 10.1073/pnas.0904673106; Thornton K, 2003, BIOINFORMATICS, V19, P2325, DOI 10.1093/bioinformatics/btg316; Lynch M, 2008, P NATL ACAD SCI USA, V105, P9272, DOI 10.1073/pnas.0803466105; Pretorius IS, 2000, YEAST, V16, P675, DOI 10.1002/1097-0061(20000615)16:8<675::AID-YEA585>3.0.CO;2-B; Huson DH, 2006, MOL BIOL EVOL, V23, P254, DOI 10.1093/molbev/msj030; Strope PK, 2015, GENOME RES, V25, P762, DOI 10.1101/gr.185538.114; Hyma KE, 2011, FEMS YEAST RES, V11, P540, DOI 10.1111/j.1567-1364.2011.00746.x; Johnson LJ, 2004, GENETICS, V166, P43, DOI 10.1534/genetics.166.1.43; Hudson RR, 2002, BIOINFORMATICS, V18, P337, DOI 10.1093/bioinformatics/18.2.337; Falush D, 2003, GENETICS, V164, P1567; Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121; Bradley RK, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000392; Charron G, 2014, FEMS YEAST RES, V14, P281, DOI 10.1111/1567-1364.12100; Cheeseman K, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms3876; Cornille A, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002703; Galeote V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017872; Gutenkunst RN, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000695; Hewitt Godfrey M., 2004, Frontiers in Zoology, V1, P1, DOI 10.1186/1742-9994-1-4; Hornsey I, 2007, CHEMISTRY AND BIOLOGY OF WINEMAKING, P1, DOI 10.1039/9781847557667; Hornsey IS, 2003, HIST BEER BREWING; Hutter S, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-409; Kamvar ZN, 2014, PEERJ, V2, DOI 10.7717/peerj.281; Lawson DJ, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002453; McGovern PE, 2009, UNCORKING THE PAST: THE QUEST FOR WINE, BEER, AND OTHER ALCOHOLIC BEVERAGES, P1; McGovern P.E., 2003, ANCIENT WINE SEARCH; McGovern Patrick E, 2013, Proc Natl Acad Sci U S A, V110, P10147, DOI 10.1073/pnas.1216126110; R Core Team, 2013, R LANG ENV STAT COMP; Samuel D, 2000, ANCIENT EGYPTIAN MAT, P537; Sniegowski Paul D., 2002, FEMS Yeast Research, V1, P299, DOI 10.1111/j.1567-1364.2002.tb00048.x	63	2	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0962-1083	1365-294X		MOL ECOL	Mol. Ecol.	NOV	2015	24	21					5412	5427		10.1111/mec.13341		16	Biochemistry & Molecular Biology; Ecology; Evolutionary Biology	Biochemistry & Molecular Biology; Environmental Sciences & Ecology; Evolutionary Biology	CU5HZ	WOS:000363564200009		
J	Nagumo, N; Fujiyoshi, Y				Nagumo, Nobuhiro; Fujiyoshi, Yasushi			Microphysical Properties of Slow-Falling and Fast-Falling Ice Pellets Formed by Freezing Associated with Evaporative Cooling	MONTHLY WEATHER REVIEW			English	Article						Physical Meteorology and Climatology; Freezing precipitation	SUPERCOOLED WATER; TERMINAL VELOCITY; WINTER STORMS; DRAG COEFFICIENT; PRECIPITATION; RAIN; GRAUPEL; DROPS; HAIL; PARTICLES	This paper describes a numerical and observational study focused on ice-pellet formation and microphysical properties near 0 degrees C from an ice-pellet-dominated storm associated with an unusually warm and dry atmosphere on 10 April 2005, in Sapporo, Japan. A one-dimensional numerical model simulation indicated that precipitation particle temperatures were sensitive to environmental temperature and relative humidity and close to the wet-bulb temperature. The simulation demonstrated that completely melted snowflakes could refreeze by evaporative cooling. Moreover, initial freezing could be explained by contact ice nucleation at the height of the minimum wet-bulb temperature.Observations using a 2D video distrometer (2DVD) indicated that ice pellets exhibited two modes of fall velocities at surface temperatures near 0 degrees C during the same time period: slow falling and fast falling. The slow-falling ice pellets exhibited a velocity similar to the average terminal velocity of hail, whereas the velocities of the fast-falling ice pellets were closer to those of raindrops. Surface roundness and fracturing characteristics of ice pellets suggest that slow-falling ice pellets froze rapidly and uniformly in a relatively cold dry layer with a wet-bulb temperature near -4 degrees C. In contrast, the fast-falling ice pellets exhibited the properties of ice particles with a wet smooth surface, suggesting that they froze slowly in a relatively warm layer by contacting ice crystals or splinters generated by preceding slow-falling ice pellets.	[Nagumo, Nobuhiro] Japan Meteorol Agcy, Meteorol Res Inst, Tsukuba, Ibaraki, Japan; [Fujiyoshi, Yasushi] Hokkaido Univ, Inst Low Temp Sci, Sapporo, Hokkaido 060, Japan	Nagumo, N (reprint author), Meteorol Res Inst, Dept Meteorol Satellite & Observat Syst Res, 1-1 Nagamine, Tsukuba, Ibaraki 3050052, Japan.	nagumo@mri-jma.go.jp			Institute of Low Temperature Science, Hokkaido University, Japan	We thank Dr. Takayo Matsuo and Ms. Kyoko Ikeda for their valuable comments and studies, on which the present study was based. This study was partly supported by the Joint Research Program of the Institute of Low Temperature Science, Hokkaido University, Japan.	Anderson M. E., 2011, ELECT J OPER METEOR, V12, P1; Theriault JM, 2010, J ATMOS SCI, V67, P1492, DOI 10.1175/2009JAS3224.1; Sassen K, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017371; Schmitt CG, 2014, GEOPHYS RES LETT, V41, P1301, DOI 10.1002/2013GL058781; WATTS RG, 1971, J ATMOS SCI, V28, P219, DOI 10.1175/1520-0469(1971)028<0219:RTASER>2.0.CO;2; DYE JE, 1968, J ATMOS SCI, V25, P82, DOI 10.1175/1520-0469(1968)025<0082:TIOEPO>2.0.CO;2; STEWART RE, 1987, MON WEATHER REV, V115, P1270, DOI 10.1175/1520-0493(1987)115<1270:FPIWS>2.0.CO;2; HANESIAK JM, 1995, MON WEATHER REV, V123, P3144, DOI 10.1175/1520-0493(1995)123<3144:TMAMSO>2.0.CO;2; ATLAS D, 1973, REV GEOPHYS, V11, P1, DOI 10.1029/RG011i001p00001; YANG LC, 1966, J GEOPHYS RES, V71, P2465; Mikhailov MD, 2013, POWDER TECHNOL, V237, P432, DOI 10.1016/j.powtec.2012.12.033; MARTINEZ AT, 1994, ATMOSFERA, V7, P179; KNIGHT NC, 1983, J ATMOS SCI, V40, P1510, DOI 10.1175/1520-0469(1983)040<1510:MAIOHD>2.0.CO;2; SELBERG BP, 1968, AIAA J, V6, P401; Gibson SR, 2007, ATMOS RES, V85, P64, DOI 10.1016/j.atmosres.2006.11.004; Cortinas JV, 2004, WEATHER FORECAST, V19, P377, DOI 10.1175/1520-0434(2004)019<0377:AAOFRF>2.0.CO;2; Kumjian MR, 2012, J ATMOS SCI, V69, P3471, DOI 10.1175/JAS-D-12-067.1; Zhang GF, 2011, J APPL METEOROL CLIM, V50, P1558, DOI 10.1175/2011JAMC2343.1; JOHNSON DA, 1968, Q J ROY METEOR SOC, V94, P468, DOI 10.1002/qj.49709440204; BLANCHARD DC, 1951, J METEOROL, V8, P268, DOI 10.1175/1520-0469(1951)008<0268:AVOTBD>2.0.CO;2; Gibson SR, 2009, J GEOPHYS RES-ATMOS, V114, DOI 10.1029/2008JD011260; RASMUSSEN RM, 1987, J ATMOS SCI, V44, P2754, DOI 10.1175/1520-0469(1987)044<2754:MASOGA>2.0.CO;2; CRAWFORD RW, 1995, COLD REG SCI TECHNOL, V23, P215, DOI 10.1016/0165-232X(94)00014-O; Beard KV, 1992, ATMOS RES, V28, P125, DOI 10.1016/0169-8095(92)90024-5; MOSSOP SC, 1968, J ATMOS SCI, V25, P889, DOI 10.1175/1520-0469(1968)025<0889:GOACAA>2.0.CO;2; STEWART RE, 1995, ATMOS RES, V36, P17, DOI 10.1016/0169-8095(94)00004-W; Zerr RJ, 1997, J APPL METEOROL, V36, P1647, DOI 10.1175/1520-0450(1997)036<1647:FRAOAT>2.0.CO;2; LIST R, 1971, J ATMOS SCI, V28, P110, DOI 10.1175/1520-0469(1971)028<0110:FFBOPS>2.0.CO;2; Cortinas J, 2000, MON WEATHER REV, V128, P3574, DOI 10.1175/1520-0493(2001)129<3574:ACOFRI>2.0.CO;2; PRUPPACHER HR, 1975, J GEOPHYS RES, V80, P380, DOI 10.1029/JC080i003p00380; Kumjian MR, 2013, J APPL METEOROL CLIM, V52, P2549, DOI 10.1175/JAMC-D-12-0311.1; PITTER RL, 1973, Q J ROY METEOR SOC, V99, P540, DOI 10.1002/qj.49709942111; Gao Y, 2013, J METEOROL SOC JPN, V91, P101, DOI 10.2151/jmsj.2013-202; Heymsfield A, 2014, J ATMOS SCI, V71, P3392, DOI 10.1175/JAS-D-14-0034.1; EDWARDS GR, 1971, J ATMOS SCI, V28, P1443, DOI 10.1175/1520-0469(1971)028<1443:TMOAOI>2.0.CO;2; Berezinski N. A., 1988, ATMOSPHERIC AEROSOLS, P233; Blanchard D. C., 1957, ARTIFICIAL STIMULATI, P233; Bohren C., 1998, ATMOSPHERIC THERMODY; Bringi V.N., 2001, POLARIMETRIC DOPPLER; Brooks C.F., 1920, Monthly Weather Review, V48, DOI 10.1175/1520-0493(1920)48<69b:TNOSAH>2.0.CO;2; BROWNSCO JL, 1968, NATURE, V220, P687, DOI 10.1038/220687a0; DORSEY N. ERNEST, 1948, TRANS AMER PHILOSOPHICAL SOC, V38, P247, DOI 10.2307/1005602; Gokhale N. R., 1971, J APPL METEOR, V10, P469, DOI 10.1175/1520-0450(1971)0100469:MSOCN2.0.CO;2; Gokhale N. R., 1972, Journal of Applied Meteorology, V11, DOI 10.1175/1520-0450(1972)011<0157:FOFSSW>2.0.CO;2; Kumjian M. R., 2014, J OPER METEOR, V2, P209, DOI 10.15191/nwajom.2014.0217; Matsukawa T., 1923, J METEOR SOC JAPAN, V1, P95; Matsuo T., 1981, J METEOR SOC JAPAN, V59, P1; Matsuo T., 1981, J METEOR SOC JAPAN, V59, P10; Matsushrra H, 2008, J METEOROL SOC JPN, V86, P633, DOI 10.2151/jmsj.86.633; Pruppacher H. R., 1997, MICROPHYSICS CLOUDS; PRUPPACH.HR, 1967, J CHEM PHYS, V47, P1807, DOI 10.1063/1.1712169; Ryzhkov A. V., 2011, PROC 35TH CONF ON RA, P197; Schonhuber M., 2007, ADV GEOSCI, V10, P85, DOI [10.5194/adgeo-10-85-2007., DOI 10.5194/ADGE0-10-85-2007]; Schonhuber M., 2008, 2D VIDEO DISTROMETER, P3; Spengler J. D., 1972, Journal of Applied Meteorology, V11, DOI 10.1175/1520-0450(1972)011<1101:FOFSSW>2.0.CO;2; Straka JM, 2009, CLOUD AND PRECIPITATION MICROPHYSICS: PRINCIPLES AND PARAMETERIZATIONS, P1, DOI 10.1017/CBO9780511581168; Takahashi C., 1969, J METEOR SOC JAPAN, V47, P431; Takahashi C., 1975, J METEOR SOC JAPAN, V53, P402; Takahashi C., 1970, J METEOROL SOC JPN, V48, P373	59	0	0	AMER METEOROLOGICAL SOC	BOSTON	45 BEACON ST, BOSTON, MA 02108-3693 USA	0027-0644	1520-0493		MON WEATHER REV	Mon. Weather Rev.	NOV	2015	143	11					4376	4392		10.1175/MWR-D-15-0054.1		17	Meteorology & Atmospheric Sciences	Meteorology & Atmospheric Sciences	CU7DQ	WOS:000363696800005		
J	Kaul, CM; Teixeira, J; Suzuki, K				Kaul, Colleen M.; Teixeira, Joao; Suzuki, Kentaroh			Sensitivities in Large-Eddy Simulations of Mixed-Phase Arctic Stratocumulus Clouds Using a Simple Microphysics Approach	MONTHLY WEATHER REVIEW			English	Article						Geographic location; entity; Arctic; Atm; Ocean Structure; Phenomena; Clouds; Microscale processes; variability; Stratiform clouds; Models and modeling; Large eddy simulations	BOUNDARY-LAYER; LIQUID WATER; PART I; RESOLVING SIMULATIONS; MIDLATITUDE CYCLONES; MICROSCALE STRUCTURE; EXPLICIT FORECASTS; STRATIFORM CLOUDS; FRONTAL RAINBANDS; SIZE DISTRIBUTION	Arctic mixed-phase stratocumulus clouds are maintained by feedbacks between microphysical and dynamical phenomena, but the details of these interactions are incompletely understood. Although large-eddy simulations are a promising means of elucidating microphysics-turbulence relationships, the use of sophisticated microphysical schemes complicates analysis of their results. Here, the ability of a simplified one-moment scheme to capture basic features of this cloud type is investigated through simulations based on Mixed-Phase Arctic Cloud Experiment (MPACE), SHEBA/FIRE-ACE, and Indirect and Semi-Direct Aerosol Campaign (ISDAC) intercomparison studies. The results of the simple scheme show reasonable agreement with liquid and ice water path predictions reported by models using schemes of similar or greater complexity. Additional tests are performed to evaluate the sensitivity of the results to three main parameters of the scheme: the snow and ice size distribution intercept parameters and the exponent appearing in the temperature-dependent phase-partition function, which is used to diagnose cloud condensate amounts. Sensitivities of the SHEBA and ISDAC cases, both of which have low surface heat fluxes and low precipitation rates, tend to be similar, while the MPACE case, with higher surface fluxes and precipitation rates, shows somewhat different trends. Results of all three cases are found to be sensitive to the snow size distribution intercept parameter, but this quantity can be adequately estimated using a recently developed diagnostic expression based on observations of Arctic clouds.	[Kaul, Colleen M.; Teixeira, Joao] CALTECH, Jet Prop Lab, Pasadena, CA USA; [Kaul, Colleen M.] Swiss Fed Inst Technol, Zurich, Switzerland; [Suzuki, Kentaroh] Univ Tokyo, Atmosphere & Ocean Res Inst, Kashiwa, Chiba, Japan	Kaul, CM (reprint author), Swiss Fed Inst Technol Zurich, Inst Geol, Soneggstr 5, CH-8092 Zurich, Switzerland.	colleen.kaul@erdw.ethz.ch	Suzuki, Kentaroh/C-3624-2011				Matheou G, 2011, MON WEATHER REV, V139, P2918, DOI 10.1175/2011MWR3599.1; Ovchinnikov M, 2011, J GEOPHYS RES-ATMOS, V116, DOI 10.1029/2011JD015888; Shupe MD, 2004, J CLIMATE, V17, P616, DOI 10.1175/1520-0442(2004)017<0616:CRFOTA>2.0.CO;2; Noh YJ, 2013, J APPL METEOROL CLIM, V52, P269, DOI 10.1175/JAMC-D-11-0202.1; Harrington JY, 1999, ATMOS RES, V51, P45, DOI 10.1016/S0169-8095(98)00098-2; Curry JA, 2000, B AM METEOROL SOC, V81, P5, DOI 10.1175/1520-0477(2000)081<0005:FACE>2.3.CO;2; Solomon A, 2014, J ATMOS SCI, V71, P574, DOI 10.1175/JAS-D-13-0179.1; Curry JA, 1996, J CLIMATE, V9, P1731, DOI 10.1175/1520-0442(1996)009<1731:OOACAR>2.0.CO;2; Boville BA, 2006, J CLIMATE, V19, P2184, DOI 10.1175/JCLI3749.1; Cantrell W, 2005, B AM METEOROL SOC, V86, P795, DOI 10.1175/BAMS-86-6-795; Boudala FS, 2004, Q J ROY METEOR SOC, V130, P2919, DOI 10.1256/qj.03.153; Seifert A, 2006, METEOROL ATMOS PHYS, V92, P45, DOI 10.1007/s00703-005-0112-4; LI ZX, 1992, CLIM DYNAM, V7, P133; DEARDORFF JW, 1980, BOUND-LAY METEOROL, V18, P495, DOI 10.1007/BF00119502; Korolev AV, 2003, Q J ROY METEOR SOC, V129, P39, DOI 10.1256/gj.01.204; de Boer G, 2009, J ATMOS SCI, V66, P2874, DOI 10.1175/2009JAS3029.1; MARTIN GM, 1994, J ATMOS SCI, V51, P1823, DOI 10.1175/1520-0469(1994)051<1823:TMAPOE>2.0.CO;2; McFarquhar GM, 2007, J GEOPHYS RES-ATMOS, V112, DOI 10.1029/2007JD008633; Gilmore MS, 2008, J APPL METEOROL CLIM, V47, P375, DOI 10.1175/2007JAMC1573.1; Solomon A, 2009, MON WEATHER REV, V137, P3110, DOI 10.1175/2009MWR2688.1; Solomon A, 2011, ATMOS CHEM PHYS, V11, P10127, DOI 10.5194/acp-11-10127-2011; Abel SJ, 2012, Q J ROY METEOR SOC, V138, P2151, DOI 10.1002/qj.1949; Shupe MD, 2011, J APPL METEOROL CLIM, V50, P645, DOI 10.1175/2010JAMC2468.1; Grabowski WW, 1998, J ATMOS SCI, V55, P3283, DOI 10.1175/1520-0469(1998)055<3283:TCRMOL>2.0.CO;2; Fan JW, 2011, J GEOPHYS RES-ATMOS, V116, DOI 10.1029/2010JD015375; Harrington JY, 1995, J ATMOS SCI, V52, P4344, DOI 10.1175/1520-0469(1995)052<4344:POICCP>2.0.CO;2; Shupe MD, 2008, J ATMOS SCI, V65, P1304, DOI 10.1175/2007JAS2479.1; Ovchinnikov M, 2014, J ADV MODEL EARTH SY, V6, P223, DOI 10.1002/2013MS000282; Yang F, 2013, GEOPHYS RES LETT, V40, P3756, DOI 10.1002/grl.50700; Liu XH, 2011, J GEOPHYS RES-ATMOS, V116, DOI 10.1029/2011JD015889; Stephens GL, 2001, J ATMOS SCI, V58, P3391, DOI 10.1175/1520-0469(2001)058<3391:POARTP>2.0.CO;2; Vavrus S, 2004, J CLIMATE, V17, P603, DOI 10.1175/1520-0442(2004)017<0603:TIOCFO>2.0.CO;2; RAUBER RM, 1991, J ATMOS SCI, V48, P1005, DOI 10.1175/1520-0469(1991)048<1005:AEFTEO>2.0.CO;2; Korolev A, 2003, Q J ROY METEOR SOC, V129, P19, DOI 10.1256/gj.01.203; Avramov A, 2011, J GEOPHYS RES-ATMOS, V116, DOI 10.1029/2011JD015910; TRIPOLI GJ, 1981, MON WEATHER REV, V109, P1094, DOI 10.1175/1520-0493(1981)109<1094:TUOLLW>2.0.CO;2; Korolev AV, 2008, Q J ROY METEOR SOC, V134, P595, DOI 10.1002/qj.230; Devasthale A, 2012, J CLIMATE, V25, P7297, DOI 10.1175/JCLI-D-11-00521.1; Ackerman AS, 2009, MON WEATHER REV, V137, P1083, DOI 10.1175/2008MWR2582.1; Ervens B, 2011, J GEOPHYS RES-ATMOS, V116, DOI 10.1029/2011JD015729; Shupe MD, 2006, J ATMOS SCI, V63, P697, DOI 10.1175/JAS3659.1; Kay JE, 2009, J GEOPHYS RES-ATMOS, V114, DOI 10.1029/2009JD011773; Gregory D, 1996, CLIM DYNAM, V12, P641, DOI 10.1007/BF00216271; SEKHON RS, 1970, J ATMOS SCI, V27, P299, DOI 10.1175/1520-0469(1970)027<0299:SSSARR>2.0.CO;2; Luo YL, 2008, J ATMOS SCI, V65, P1285, DOI 10.1175/2007JAS2467.1; Uttal T, 2002, B AM METEOROL SOC, V83, P255, DOI 10.1175/1520-0477(2002)083<0255:SHBOTA>2.3.CO;2; Jiang HL, 2000, J ATMOS SCI, V57, P2105, DOI 10.1175/1520-0469(2000)057<2105:CRSOMP>2.0.CO;2; van Diedenhoven B, 2009, J GEOPHYS RES-ATMOS, V114, DOI 10.1029/2008JD011198; Stevens B, 2005, MON WEATHER REV, V133, P1443, DOI 10.1175/MWR2930.1; Verlinde J, 2007, B AM METEOROL SOC, V88, P205, DOI 10.1175/BAMS-88-2-205; Reisner J, 1998, Q J ROY METEOR SOC, V124, P1071, DOI 10.1002/qj.49712454804; Jiang GS, 2000, SIAM J SCI COMPUT, V21, P2126, DOI 10.1137/S106482759732455X; GRABOWSKI WW, 1989, Q J ROY METEOR SOC, V115, P633, DOI 10.1002/qj.49711548711; Zuidema P, 2005, J ATMOS SCI, V62, P160, DOI 10.1175/JAS-3368.1; Fridlind AM, 2007, J GEOPHYS RES-ATMOS, V112, DOI 10.1029/2007JD008646; Intrieri JM, 2002, J GEOPHYS RES-OCEANS, V107, DOI 10.1029/2000JC000439; Vavrus SJ, 2011, J CLIMATE, V24, P4817, DOI 10.1175/2011JCLI4029.1; BERRY EX, 1974, J ATMOS SCI, V31, P1825, DOI 10.1175/1520-0469(1974)031<1825:AAOCDG>2.0.CO;2; Heymsfield AJ, 2007, J ATMOS SCI, V64, P1047, DOI 10.1175/JAS3890.1; RUTLEDGE SA, 1983, J ATMOS SCI, V40, P1185, DOI 10.1175/1520-0469(1983)040<1185:TMAMSA>2.0.CO;2; Hill AA, 2014, Q J ROY METEOR SOC, V140, P855, DOI 10.1002/qj.2177; Wood R, 2012, MON WEATHER REV, V140, P2373, DOI 10.1175/MWR-D-11-00121.1; Morrison H, 2011, Q J ROY METEOR SOC, V137, P1589, DOI 10.1002/qj.840; Thompson G, 2004, MON WEATHER REV, V132, P519, DOI 10.1175/1520-0493(2004)132<0519:EFOWPU>2.0.CO;2; Klein SA, 2009, Q J ROY METEOR SOC, V135, P979, DOI 10.1002/qj.416; KLEMP JB, 1978, J ATMOS SCI, V35, P1070, DOI 10.1175/1520-0469(1978)035<1070:TSOTDC>2.0.CO;2; Morrison H, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL023614; Held IM, 2005, B AM METEOROL SOC, V86, P1609, DOI 10.1175/BAMS-86-11-1609; Morrison H, 2008, J ATMOS SCI, V65, P1528, DOI 10.1175/2007JAS2491.1; SPALART PR, 1991, J COMPUT PHYS, V96, P297, DOI 10.1016/0021-9991(91)90238-G; McFarquhar GM, 2011, B AM METEOROL SOC, V92, P183, DOI 10.1175/2010BAMS2935.1; Cober SG, 2001, J APPL METEOROL, V40, P1967, DOI 10.1175/1520-0450(2001)040<1967:ACPC>2.0.CO;2; Beare RJ, 2006, BOUND-LAY METEOROL, V118, P247, DOI 10.1007/s10546-004-2820-6; Thompson G, 2008, MON WEATHER REV, V136, P5095, DOI 10.1175/2008MWR2387.1; Savre J, 2014, J ADV MODEL EARTH SY, V6, P630, DOI 10.1002/2013MS000292; Sulia KJ, 2011, J GEOPHYS RES-ATMOS, V116, DOI 10.1029/2011JD016298; Khairoutdinov MF, 2003, J ATMOS SCI, V60, P607, DOI 10.1175/1520-0469(2003)060<0607:CRMOTA>2.0.CO;2; Avramov A, 2010, J GEOPHYS RES-ATMOS, V115, DOI 10.1029/2009JD012108; Morrison H, 2011, J ADV MODEL EARTH SY, V3, DOI 10.1029/2011MS000066; RUTLEDGE SA, 1984, J ATMOS SCI, V41, P2949, DOI 10.1175/1520-0469(1984)041<2949:TMAMSA>2.0.CO;2; Morrison H, 2012, NAT GEOSCI, V5, P11, DOI [10.1038/ngeo1332, 10.1038/NGEO1332]; Doutriaux-Boucher M, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2003GL019095; Fridlind AM, 2012, J ATMOS SCI, V69, P365, DOI 10.1175/JAS-D-11-052.1; Pruppacher H. R., 1978, MICROPHYSICS CLOUDS	84	0	0	AMER METEOROLOGICAL SOC	BOSTON	45 BEACON ST, BOSTON, MA 02108-3693 USA	0027-0644	1520-0493		MON WEATHER REV	Mon. Weather Rev.	NOV	2015	143	11					4393	4421		10.1175/MWR-D-14-00319.1		29	Meteorology & Atmospheric Sciences	Meteorology & Atmospheric Sciences	CU7DQ	WOS:000363696800006		
J	Imada, Y; Tatebe, H; Ishii, M; Chikamoto, Y; Mori, M; Arai, M; Watanabe, M; Kimoto, M				Imada, Yukiko; Tatebe, Hiroaki; Ishii, Masayoshi; Chikamoto, Yoshimitsu; Mori, Masato; Arai, Miki; Watanabe, Masahiro; Kimoto, Masahide			Predictability of Two Types of El Nino Assessed Using an Extended Seasonal Prediction System by MIROC	MONTHLY WEATHER REVIEW			English	Article						ENSO; Hindcasts; Seasonal forecasting; Coupled models; General circulation models	SEA-SURFACE TEMPERATURE; PACIFIC ENSO EVENTS; DATA ASSIMILATION; SOUTHERN-OSCILLATION; ATMOSPHERIC BRIDGE; BOREAL AUTUMN; NORTH PACIFIC; ANNUAL CYCLE; PART I; MODEL	Predictability of El Nino-Southern Oscillation (ENSO) is examined using ensemble hindcasts made with a seasonal prediction system based on the atmosphere and ocean general circulation model, the Model for Interdisciplinary Research on Climate, version 5 (MIROC5). Particular attention is paid to differences in predictive skill in terms of the prediction error for two prominent types of El Nino: the conventional eastern Pacific (EP) El Nino and the central Pacific (CP) El Nino, the latter having a maximum warming around the date line. Although the system adopts ocean anomaly assimilation for the initialization process, it maintains a significant ability to predict ENSO with a lead time of more than half a year. This is partly due to the fact that the system is little affected by the spring prediction barrier, because increases in the error have little dependence on the thermocline variability. Composite analyses of each type of El Nino reveal that, compared to EP El Ninos, the ability to predict CP El Ninos is limited and has a shorter lead time. This is because CP El Ninos have relatively small amplitudes, and thus they are more affected by atmospheric noise; this prevents development of oceanic signals that can be used for prediction.	[Imada, Yukiko; Ishii, Masayoshi] Japan Meteorol Agcy, Meteorol Res Inst, Tsukuba, Ibaraki 3050052, Japan; [Tatebe, Hiroaki] Japan Agcy Marine Earth Sci & Technol, Kanagawa, Japan; [Chikamoto, Yoshimitsu] Univ Hawaii Manoa, Int Pacific Res Ctr, Honolulu, HI 96822 USA; [Mori, Masato; Arai, Miki; Watanabe, Masahiro; Kimoto, Masahide] Univ Tokyo, Atmosphere & Ocean Res Inst, Chiba, Japan	Imada, Y (reprint author), Japan Meteorol Agcy, Meteorol Res Inst, 1-1 Nagamine, Tsukuba, Ibaraki 3050052, Japan.	yimada@mri-jma.go.jp			Program for Generation of Climate Change Risk Information (SOUSEI project) of the Japanese Ministry of Education, Culture, Sports, Science and Technology; Japan Science and Technology Agency (JST); Japan Society for the Promotion of Science (JSPS) (KAKENHI) [26800243, 26247079]; Data Integration and Analysis System (DIAS)	The authors are grateful to the anonymous reviewers for their encouraging comments. This work was supported by the Program for Generation of Climate Change Risk Information (SOUSEI project) of the Japanese Ministry of Education, Culture, Sports, Science and Technology; the Japan Science and Technology Agency (JST); the Japan Society for the Promotion of Science (JSPS) Grants-in-Aid for Scientific Research (KAKENHI) Grants 26800243 and 26247079; and the Data Integration and Analysis System (DIAS).	Bloom SC, 1996, MON WEATHER REV, V124, P1256, DOI 10.1175/1520-0493(1996)124<1256:DAUIAU>2.0.CO;2; Behringer DW, 1998, MON WEATHER REV, V126, P1013, DOI 10.1175/1520-0493(1998)126<1013:AICMFE>2.0.CO;2; Fedorov AV, 2000, SCIENCE, V288, P1997, DOI 10.1126/science.288.5473.1997; Wang G, 2007, J CLIMATE, V20, P4211, DOI 10.1175/JCLI4228.1; Tatebe H, 2012, J METEOROL SOC JPN, V90A, P275, DOI 10.2151/jmsj.2012-A14; Kim HM, 2009, SCIENCE, V325, P77, DOI 10.1126/science.1174062; WEBSTER PJ, 1995, METEOROL ATMOS PHYS, V56, P33, DOI 10.1007/BF01022520; Lau NC, 1996, J CLIMATE, V9, P2036, DOI 10.1175/1520-0442(1996)009<2036:TROTBI>2.0.CO;2; LATIF M, 1994, CLIM DYNAM, V9, P167, DOI 10.1007/BF00208250; Zhang WJ, 2012, J METEOROL SOC JPN, V90, P535, DOI 10.2151/jmsj.2012-407; Weng HY, 2007, CLIM DYNAM, V29, P113, DOI 10.1007/s00382-007-0234-0; Yang S, 2014, J CLIMATE, V27, P4451, DOI 10.1175/JCLI-D-13-00471.1; Lim EP, 2009, MON WEATHER REV, V137, P3796, DOI 10.1175/2009MWR2904.1; EVENSEN G, 1994, J GEOPHYS RES-OCEANS, V99, P10143, DOI 10.1029/94JC00572; Ishii M, 2005, INT J CLIMATOL, V25, P865, DOI 10.1002/joc.1169; Watanabe M, 2010, J CLIMATE, V23, P6312, DOI 10.1175/2010JCLI3679.1; Guilyardi E, 2006, CLIM DYNAM, V26, P329, DOI 10.1007/s00382-005-0084-6; Torrence C, 1998, Q J ROY METEOR SOC, V124, P1985, DOI 10.1256/smsqj.55009; Yin YH, 2011, MON WEATHER REV, V139, P786, DOI 10.1175/2010MWR3419.1; Burgers G, 2003, J CLIMATE, V16, P2396, DOI 10.1175/2766.1; Zhang WJ, 2011, J METEOROL SOC JPN, V89, P563, DOI 10.2151/jmsj.2011-510; Kang IS, 2001, J METEOROL SOC JPN, V79, P1, DOI 10.2151/jmsj.79.1; Kug JS, 2009, J CLIMATE, V22, P1499, DOI 10.1175/2008JCLI2624.1; Arakawa A, 1996, MON WEATHER REV, V124, P511, DOI 10.1175/1520-0493(1996)124<0511:VDOTPE>2.0.CO;2; BALMASEDA MA, 1995, J CLIMATE, V8, P2705, DOI 10.1175/1520-0442(1995)008<2705:DASDOE>2.0.CO;2; Kao HY, 2009, J CLIMATE, V22, P615, DOI 10.1175/2008JCLI2309.1; Zhu J, 2011, ANN GEOPHYS-GERMANY, V29, P529, DOI 10.5194/angeo-29-529-2011; ZEBIAK SE, 1987, MON WEATHER REV, V115, P2262, DOI 10.1175/1520-0493(1987)115<2262:AMENO>2.0.CO;2; Huang BH, 2002, ADV ATMOS SCI, V19, P965, DOI 10.1007/s00376-002-0059-z; HOFFMAN RN, 1983, TELLUS A, V35, P100; Hirahara S, 2014, J CLIMATE, V27, P57, DOI 10.1175/JCLI-D-12-00837.1; Wang B, 2009, CLIM DYNAM, V33, P93, DOI 10.1007/s00382-008-0460-0; Chikira M, 2010, J ATMOS SCI, V67, P2171, DOI 10.1175/2010JAS3316.1; Ishii M, 2009, J OCEANOGR, V65, P287, DOI 10.1007/s10872-009-0027-7; Watanabe M, 2011, J CLIMATE, V24, P543, DOI 10.1175/2010JCLI3878.1; Yeh SW, 2009, NATURE, V461, P511, DOI 10.1038/nature08316; Jin EK, 2008, CLIM DYNAM, V31, P647, DOI 10.1007/s00382-008-0397-3; Keppenne CL, 2005, NONLINEAR PROC GEOPH, V12, P491; Barnston AG, 2012, B AM METEOROL SOC, V93, P631, DOI 10.1175/BAMS-D-11-00111.1; An SI, 2001, J CLIMATE, V14, P2164, DOI 10.1175/1520-0442(2001)014<2164:MOLOTE>2.0.CO;2; Imada Y, 2006, SOLA, V2, P164, DOI 10.2151/sola.2006-042; BATTISTI DS, 1988, J ATMOS SCI, V45, P2889, DOI 10.1175/1520-0469(1988)045<2889:DATOAW>2.0.CO;2; Zhu JS, 2013, CLIM DYNAM, V41, P2785, DOI 10.1007/s00382-013-1965-8; Alexander MA, 2002, J CLIMATE, V15, P2205, DOI 10.1175/1520-0442(2002)015<2205:TABTIO>2.0.CO;2; Ashok K, 2007, J GEOPHYS RES-OCEANS, V112, DOI 10.1029/2006JC003798; Hasumi H, 2006, 25 CCSR; Hendon HH, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2009GL040100; Ishii M, 2006, J OCEANOGR, V62, P155, DOI 10.1007/s10872-006-0041-y; Jeong HI, 2012, CLIM DYNAM, V39, P475, DOI 10.1007/s00382-012-1359-3; Kalnay E, 1996, B AM METEOROL SOC, V77, P437, DOI 10.1175/1520-0477(1996)077<0437:TNYRP>2.0.CO;2; Keenlyside NS, 2008, NATURE, V453, P84, DOI 10.1038/nature06921; Larkin NK, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL022738; Lee T, 2000, J GEOPHYS RES-OCEANS, V105, P26063, DOI 10.1029/2000JC900118; Magnusson L, 2013, CLIM DYNAM, V41, P2393, DOI 10.1007/s00382-012-1599-2; Neelin J. D, 1998, J GEOPHYS RES, V103, P14, DOI [10.1029/ 97JC03424, DOI 10.1029/97JC03424]; Pohlmann H, 2009, J CLIMATE, V22, P3926, DOI 10.1175/2009JCLI2535.1; Smith DM, 2007, SCIENCE, V317, P796, DOI 10.1126/science.1139540; Zhu JS, 2012, GEOPHYS RES LETT, V39, DOI 10.1029/2012GL051503	58	0	0	AMER METEOROLOGICAL SOC	BOSTON	45 BEACON ST, BOSTON, MA 02108-3693 USA	0027-0644	1520-0493		MON WEATHER REV	Mon. Weather Rev.	NOV	2015	143	11					4597	4617		10.1175/MWR-D-15-0007.1		21	Meteorology & Atmospheric Sciences	Meteorology & Atmospheric Sciences	CU7DQ	WOS:000363696800016		
J	Samuels, BA; Anacker, C; Hu, A; Levinstein, MR; Pickenhagen, A; Tsetsenis, T; Madronal, N; Donaldson, ZR; Drew, LJ; Dranovsky, A; Gross, CT; Tanaka, KF; Hen, R				Samuels, Benjamin Adam; Anacker, Christoph; Hu, Alice; Levinstein, Marjorie R.; Pickenhagen, Anouchka; Tsetsenis, Theodore; Madronal, Noelia; Donaldson, Zoe R.; Drew, Liam John; Dranovsky, Alex; Gross, Cornelius T.; Tanaka, Kenji F.; Hen, Rene			5-HT1A receptors on mature dentate gyrus granule cells are critical for the antidepressant response	NATURE NEUROSCIENCE			English	Article							ADULT HIPPOCAMPAL NEUROGENESIS; ENHANCED SYNAPTIC PLASTICITY; NEUROTROPHIC FACTOR; PATTERN SEPARATION; BEHAVIORAL ACTIONS; MAJOR DEPRESSION; RAT HIPPOCAMPUS; ANIMAL-MODEL; ANXIETY; STRESS	Selective serotonin reuptake inhibitors (SSRIs) are widely used antidepressants, but the mechanisms by which they influence behavior are only partially resolved. Adult hippocampal neurogenesis is necessary for some of the responses to SSR1s, but it is not known whether mature dentate gyrus granule cells (DG GCs) also contribute. We deleted the serotonin 1A receptor (5HT1AR, a receptor required for the SSRI response) specifically from DG GCs and found that the effects of the SSRI fluoxetine on behavior and the hypothalamic-pituitary-adrenal (HPA) axis were abolished. By contrast, mice lacking 5HT1ARs only in young adult-born GCs (abGCs) showed normal fluoxetine responses. Notably, 5HT1AR-deficient mice engineered to express functional 5HT1ARs only in DG GCs responded to fluoxetine, indicating that 5HT1ARs in DG GCs are sufficient to mediate an antidepressant response. Taken together, these data indicate that both mature DG GCs and young abGCs must be engaged for an antidepressant response.	[Samuels, Benjamin Adam; Anacker, Christoph; Hu, Alice; Levinstein, Marjorie R.; Pickenhagen, Anouchka; Donaldson, Zoe R.; Drew, Liam John; Dranovsky, Alex; Hen, Rene] Columbia Univ, Dept Psychiat, Med Ctr, New York, NY 10027 USA; [Samuels, Benjamin Adam; Anacker, Christoph; Hu, Alice; Levinstein, Marjorie R.; Pickenhagen, Anouchka; Donaldson, Zoe R.; Drew, Liam John; Dranovsky, Alex; Hen, Rene] New York State Psychiat Inst & Hosp, Res Fdn Mental Hyg, New York, NY 10032 USA; [Tsetsenis, Theodore; Madronal, Noelia; Gross, Cornelius T.] European Mol Biol Lab, Mouse Biol Unit, Monterotondo, Italy; [Tanaka, Kenji F.] Keio Univ, Sch Med, Dept Neuropsychiat, Tokyo, Japan	Hen, R (reprint author), Columbia Univ, Dept Psychiat, Med Ctr, New York, NY 10027 USA.	rh95@columbia.edu		Levinstein, Marjorie/0000-0003-4360-1503	NIMH [R37MH068542, R01MH083862, K01MH098188, T32MH015144, R01MH01844]; HDRF [MPPN8883]; NYSTEM [C029157]; BBRF NARSAD Young Investigator [19658]; Charles H. Revson fellowship; German Research Foundation (DFG) postdoctoral fellowship; EMBL; EC Marie Curie Fellowship	The authors thank K. Win and D. Tora for technical support, and M. Kheirbek and D. Leonardo for discussions. This work was supported by NIMH R37MH068542 (R.H.), NIMH R01MH083862 (R.H.), HDRF MPPN8883 (R.H.), NYSTEM C029157 (R.H.), NIMH K01MH098188 (B.A.S.), BBRF NARSAD Young Investigator 19658 (B.A.S.), a Charles H. Revson fellowship (B.A.S.), a German Research Foundation (DFG) postdoctoral fellowship (C.A.), NIMH T32MH015144 (Z.R.D.), NIMH R01MH01844 (A.D.), funds from EMBL (C.T.G.), and an EC Marie Curie Fellowship (N.M.).	SLOVITER RS, 1989, SCIENCE, V243, P535, DOI 10.1126/science.2911756; NIBUYA M, 1995, J NEUROSCI, V15, P7539; Mendez-David I, 2014, NEUROPSYCHOPHARMACOL, V39, P1366, DOI 10.1038/npp.2013.332; Malberg JE, 2000, J NEUROSCI, V20, P9104; Jankord R, 2008, ANN NY ACAD SCI, V1148, P64, DOI 10.1196/annals.1410.012; Richardson-Jones JW, 2010, NEURON, V65, P40, DOI 10.1016/j.neuron.2009.12.003; Hajszan T, 2005, EUR J NEUROSCI, V21, P1299, DOI 10.1111/j.1460-9568.2005.03968.x; Kheirbek MA, 2013, NEURON, V77, P955, DOI 10.1016/j.neuron.2012.12.038; Shirayama Y, 2002, J NEUROSCI, V22, P3251; McHugh TJ, 2007, SCIENCE, V317, P94, DOI 10.1126/science.1140263; Waterhouse EG, 2012, J NEUROSCI, V32, P14318, DOI 10.1523/JNEUROSCI.0709-12.2012; Monteggia LM, 2004, P NATL ACAD SCI USA, V101, P10827, DOI 10.1073/pnas.0402141101; Murray CJL, 1996, SCIENCE, V274, P740, DOI 10.1126/science.274.5288.740; Gross C, 2002, NATURE, V416, P396, DOI 10.1038/416396a; Sahay A, 2011, NATURE, V472, P466, DOI 10.1038/nature09817; Schloesser RJ, 2009, NEUROREPORT, V20, P553, DOI 10.1097/WNR.0b013e3283293e59; Snyder JS, 2011, NATURE, V476, P458, DOI 10.1038/nature10287; Li Y, 2008, NEURON, V59, P399, DOI 10.1016/j.neuron.2008.06.023; Burghardt NS, 2012, HIPPOCAMPUS, V22, P1795, DOI 10.1002/hipo.22013; Nestler EJ, 2002, NEURON, V34, P13, DOI 10.1016/S0896-6273(02)00653-0; Fanselow MS, 2010, NEURON, V65, P7, DOI 10.1016/j.neuron.2009.11.031; Boldrini M, 2013, NEUROPSYCHOPHARMACOL, V38, P1068, DOI 10.1038/npp.2013.5; Ge SY, 2007, NEURON, V54, P559, DOI 10.1016/j.neuron.2007.05.002; Fakra E, 2009, ARCH GEN PSYCHIAT, V66, P33, DOI 10.1001/archpsyc.66.1.33; David DJ, 2009, NEURON, V62, P479, DOI 10.1016/j.neuron.2009.04.017; Greene J, 2009, NEUROPSYCHOPHARMACOL, V34, P2459, DOI 10.1038/npp.2009.68; Le Francois B, 2008, NEUROPHARMACOLOGY, V55, P977, DOI 10.1016/j.neuropharm.2008.06.046; Drevets WC, 2001, CURR OPIN NEUROBIOL, V11, P240, DOI 10.1016/S0959-4388(00)00203-8; Dranovsky A, 2011, NEURON, V70, P908, DOI 10.1016/j.neuron.2011.05.022; Tsetsenis T, 2007, NAT NEUROSCI, V10, P896, DOI 10.1038/nn1919; Warner-Schmidt JL, 2007, P NATL ACAD SCI USA, V104, P4647, DOI 10.1073/pnas.0610282104; Richardson-Jones JW, 2011, J NEUROSCI, V31, P6008, DOI 10.1523/JNEUROSCI.5836-10.2011; Hannon J, 2008, BEHAV BRAIN RES, V195, P198, DOI 10.1016/j.bbr.2008.03.020; Kheirbek MA, 2012, J NEUROSCI, V32, P8696, DOI 10.1523/JNEUROSCI.1692-12.2012; Surget A, 2011, MOL PSYCHIATR, V16, P1177, DOI 10.1038/mp.2011.48; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; Ramboz S, 1998, P NATL ACAD SCI USA, V95, P14476, DOI 10.1073/pnas.95.24.14476; Lacefield CO, 2012, HIPPOCAMPUS, V22, P106, DOI 10.1002/hipo.20860; McAskill R, 1998, BRIT J PSYCHIAT, V173, P203, DOI 10.1192/bjp.173.3.203; McEwen BS, 2007, PHYSIOL REV, V87, P873, DOI 10.1152/physrev.00041.2006; Schmidt-Hieber C, 2004, NATURE, V429, P184, DOI 10.1038/nature02553; Lucas G, 2007, NEURON, V55, P712, DOI 10.1016/j.neuron.2007.07.041; Strobel A, 2003, J NEURAL TRANSM, V110, P1445, DOI 10.1007/s00702-003-0072-0; Ulrich-Lai YM, 2009, NAT REV NEUROSCI, V10, P397, DOI 10.1038/nrn2647; Gorman J M, 1996, Depress Anxiety, V4, P160, DOI 10.1002/(SICI)1520-6394(1996)4:4<160::AID-DA2>3.0.CO;2-J; Ikrar T, 2013, FRONT NEURAL CIRCUIT, V7, DOI 10.3389/fncir.2013.00204; Kobayashi K, 2011, MOL BRAIN, V4, DOI 10.1186/1756-6606-4-12; Laplagne DA, 2006, PLOS BIOL, V4, P2349, DOI 10.1371/journal.pbio.0040409; Tanaka KF, 2012, PHILOS T R SOC B, V367, P2395, DOI 10.1098/rstb.2012.0038; Treadway MT, 2015, BIOL PSYCHIAT, V77, P285, DOI 10.1016/j.biopsych.2014.06.018	50	1	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1097-6256	1546-1726		NAT NEUROSCI	Nat. Neurosci.	NOV	2015	18	11					1606	1616		10.1038/nn.4116		11	Neurosciences	Neurosciences & Neurology	CU8YT	WOS:000363830700018		
J	Susaki, EA; Tainaka, K; Perrin, D; Yukinaga, H; Kuno, A; Ueda, HR				Susaki, Etsuo A.; Tainaka, Kazuki; Perrin, Dimitri; Yukinaga, Hiroko; Kuno, Akihiro; Ueda, Hiroki R.			Advanced CUBIC protocols for whole-brain and whole-body clearing and imaging	NATURE PROTOCOLS			English	Article							LIGHT-SHEET MICROSCOPY; SINGLE-CELL RESOLUTION; ILLUMINATION MICROSCOPY; MOUSE-BRAIN; TISSUE; RECONSTRUCTION; VISUALIZATION; FLUORESCENCE; VOLUME; AGENT	Here we describe a protocol for advanced CUCUBIC (Clear, Unobstructed Brain/Body Imaging Cocktails and Computational analysis). The CUCUBIC protocol enables simple and efficient organ clearing, rapid imaging by light-sheet microscopy and quantitative imaging analysis of multiple samples. The organ or body is cleared by immersion for 1-14 d, with the exact time required dependent on the sample type and the experimental purposes. A single imaging set can be completed in 30-60 min. Image processing and analysis can take <1 d, but it is dependent on the number of samples in the data set. The CUCUBIC clearing protocol can process multiple samples simultaneously. We previously used CUCUBIC to image whole-brain neural activities at single-cell resolution using Arc-dVenus transgenic (Tg) mice. CUCUBIC informatics calculated the Venus signal subtraction, comparing different brains at a whole-organ scale. These protocols provide a platform for organism-level systems biology by comprehensively detecting cells in a whole organ or body.	[Susaki, Etsuo A.; Tainaka, Kazuki; Kuno, Akihiro; Ueda, Hiroki R.] Univ Tokyo, Dept Syst Pharmacol, Tokyo, Japan; [Susaki, Etsuo A.; Tainaka, Kazuki; Kuno, Akihiro; Ueda, Hiroki R.] Japan Agcy Med Res & Dev AMED, Core Res Evolutionary Sci & Technol, AMED, Tokyo, Japan; [Susaki, Etsuo A.; Tainaka, Kazuki; Yukinaga, Hiroko; Ueda, Hiroki R.] RIKEN, Quantitat Biol Ctr QBiC, Lab Synthet Biol, Osaka, Japan; [Perrin, Dimitri] Queensland Univ Technol, Sch Elect Engn & Comp Sci, Fac Sci & Engn, Brisbane, Qld 4001, Australia; [Kuno, Akihiro] Univ Tsukuba, Dept Anat & Embryol, Fac Med, Ibaraki, Japan; [Kuno, Akihiro] Univ Tsukuba, Sch Integrat & Global Majors, PhD Program Human Biol, Ibaraki, Japan	Ueda, HR (reprint author), Univ Tokyo, Dept Syst Pharmacol, Tokyo, Japan.	uedah-tky@umin.ac.jp			Program for Innovative Cell Biology by Innovative Technology; Brain Mapping by Integrated Neurotechnologies for Disease Studies (Brain/MINDS) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan; MEXT/Japan Society for the Promotion of Science (JSPS) [25221004, 23115006, 15H05650]; strategic programs for R&D (President's discretionary fund) of RIKEN; RIKEN QBiC; AMED-CREST; RIKEN Special Postdoctoral Research Program; RIKEN Foreign Postdoctoral Researcher Program; Japan Foundation for Applied Enzymology; Brain Sciences Project of the Center for Novel Science Initiatives of the National Institutes of Natural Sciences [BS261004, BS271005]; Tokyo Society of Medical Science; Shimabara Science Promotion Foundation	We thank the lab members at RIKEN QBiC and The University of Tokyo, in particular S.I. Kubota for his kind help in preparing the materials; A. Millius for his critical reading and editing of the manuscript; and T. Mano for his kind contributions and suggestions to discuss image resolution. This work was supported by the Program for Innovative Cell Biology by Innovative Technology and the Brain Mapping by Integrated Neurotechnologies for Disease Studies (Brain/MINDS) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan; a Grant-in-Aid for Scientific Research (S) (grant No. 25221004), for Scientific Research on Innovative Areas (grant no. 23115006) and for Young Scientists (A) (grant no. 15H05650) from MEXT/Japan Society for the Promotion of Science (JSPS); by the strategic programs for R&D (President's discretionary fund) of RIKEN; by an intramural Grant-in-Aid from the RIKEN QBiC; by a grant from AMED-CREST; by the RIKEN Special Postdoctoral Research Program; by the RIKEN Foreign Postdoctoral Researcher Program; by a Grant-in-Aid from the Japan Foundation for Applied Enzymology; by the Brain Sciences Project of the Center for Novel Science Initiatives of the National Institutes of Natural Sciences (grant nos. BS261004 and BS271005); by the Tokyo Society of Medical Science; and by the Shimabara Science Promotion Foundation.	Keller PJ, 2010, NAT METHODS, V7, P637, DOI [10.1038/nmeth.1476, 10.1038/NMETH.1476]; Susaki EA, 2014, CELL, V157, P726, DOI 10.1016/j.cell.2014.03.042; Osten P, 2013, NAT METHODS, V10, P515, DOI [10.1038/nmeth.2477, 10.1038/NMETH.2477]; Eguchi M, 2009, NEUROIMAGE, V44, P1274, DOI 10.1016/j.neuroimage.2008.10.046; Hama H, 2011, NAT NEUROSCI, V14, P1481, DOI 10.1038/nn.2928; Erturk A, 2012, NAT PROTOC, V7, P1983, DOI 10.1038/nprot.2012.119; Hou B, 2015, FRONT NEUROANAT, V9, DOI 10.3389/fnana.2015.00019; Costantini I, 2015, SCI REP-UK, V5, DOI 10.1038/srep09808; Lein ES, 2007, NATURE, V445, P168, DOI 10.1038/nature05453; Tomer R, 2014, NAT PROTOC, V9, P1682, DOI 10.1038/nprot.2014.123; Richards KL, 2013, NEUROLOGY, V80, P1240, DOI 10.1212/WNL.0b013e31828970ec; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Alnuami AA, 2008, INT J BIOL MACROMOL, V43, P182, DOI 10.1016/j.ijbiomac.2008.05.002; Faisal AA, 2005, CURR BIOL, V15, P1143, DOI 10.1016/j.cub.2005.05.056; Chung K, 2013, NATURE, V497, P332, DOI 10.1038/nature12107; Keller PJ, 2008, SCIENCE, V322, P1065, DOI 10.1126/science.1162493; Dodt HU, 2007, NAT METHODS, V4, P331, DOI 10.1038/NMETH1036; Murphy K, 2011, IEEE T MED IMAGING, V30, P1901, DOI 10.1109/TMI.2011.2158349; Ke MT, 2013, NAT NEUROSCI, V16, P1154, DOI 10.1038/nn.3447; Yushkevich PA, 2006, NEUROIMAGE, V31, P1116, DOI 10.1016/j.neuroimage.2006.01.015; Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015; Kuwajima T, 2013, DEVELOPMENT, V140, P1364, DOI 10.1242/dev.091844; Weber TG, 2014, CANCER RES, V74, P1913, DOI 10.1158/0008-5472.CAN-13-3001; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; Ahrens MB, 2013, NAT METHODS, V10, P413, DOI [10.1038/nmeth.2434, 10.1038/NMETH.2434]; Yang B, 2014, CELL, V158, P945, DOI 10.1016/j.cell.2014.07.017; Steinke H, 2001, ANN ANAT, V183, P91, DOI 10.1016/S0940-9602(01)80020-0; Aoyagi Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116280; Becker K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033916; Erturk A, 2012, NAT MED, V18, P166, DOI 10.1038/nm.2600; Keller PJ, 2015, NEURON, V85, P462, DOI 10.1016/j.neuron.2014.12.039; Panier T, 2013, FRONT NEURAL CIRCUIT, V7, DOI 10.3389/fncir.2013.00065; Prewitt J. M. S., 1970, PICTURE PROCESSING P, P75; Renier N, 2014, CELL, V159, P896, DOI 10.1016/j.cell.2014.10.010; Schwarz MK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124650; Soderblom C., 2015, ENEURO, V2, DOI [10.1523/ENEURO.0001-15.2015, DOI 10.1523/ENEURO.0001-15.2015]; Spalteholz W., 1914, DURCHSICHTIGMACHEN M; Tainaka K, 2014, CELL, V159, P911, DOI 10.1016/j.cell.2014.10.034	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1754-2189	1750-2799		NAT PROTOC	Nat. Protoc.	NOV	2015	10	11					1709	1727		10.1038/nprot.2015.085		19	Biochemical Research Methods	Biochemistry & Molecular Biology	CU4CC	WOS:000363472700005		
J	Keszthelyi, A; Daigaku, Y; Ptasinska, K; Miyabe, I; Carr, AM				Keszthelyi, Andrea; Daigaku, Yasukazu; Ptasinska, Katie; Miyabe, Izumi; Carr, Antony M.			Mapping ribonucleotides in genomic DNA and exploring replication dynamics by polymerase usage sequencing (Pu-seq)	NATURE PROTOCOLS			English	Article							MISMATCH REPAIR; SIGNALS	Ribonucleotides are frequently misincorporated into DNANA during replication, and they are rapidly repaired by ribonucleotide excision repair (RERRERRER). Although ribonucleotides in template DNANA perturb replicative polymerases and can be considered as DNANA damage, they also serve positive biological functions, including directing the orientation of mismatch repair. Here we describe a method for ribonucleotide identification by high-throughput sequencing that allows mapping of the location of ribonucleotides across the genome. When combined with specific mutations in the replicative polymerases that incorporate ribonucleotides at elevated frequencies, our ribonucleotide identification method was adapted to map polymerase usage across the genome. Polymerase usage sequencing (Pu-seq) has been used to define, in unprecedented detail, replication dynamics in yeasts. Although other methods that examine replication dynamics provide direct measures of replication timing and indirect estimates of origin efficiency, Pu-seq directly ascertains origin efficiency. The Pu-seq protocol can be completed in 12-14 d.	[Keszthelyi, Andrea; Daigaku, Yasukazu; Ptasinska, Katie; Miyabe, Izumi; Carr, Antony M.] Univ Sussex, Sch Life Sci, Genome Damage & Stabil Ctr, Brighton, E Sussex, England; [Daigaku, Yasukazu] Tohoku Univ, Frontier Res Inst Interdisciplinary Sci, Sendai, Miyagi 980, Japan	Carr, AM (reprint author), Univ Sussex, Sch Life Sci, Genome Damage & Stabil Ctr, Brighton, E Sussex, England.	a.m.carr@sussex.ac.uk			UK Medical Research Council (MRC) [G1100074]; European Research Council (ERC) [268788-SMI-DDR]	A.M.C. acknowledges UK Medical Research Council (MRC) grant no. G1100074 and European Research Council (ERC) grant no. 268788-SMI-DDR.	Sparks JL, 2012, MOL CELL, V47, P980, DOI 10.1016/j.molcel.2012.06.035; Shen Y, 2012, NAT STRUCT MOL BIOL, V19, P98, DOI 10.1038/nsmb.2176; Daigaku Y, 2015, NAT STRUCT MOL BIOL, V22, P192, DOI 10.1038/nsmb.2962; Watson AT, 2008, GENE, V407, P63, DOI 10.1016/j.gene.2007.09.024; McElhinny SAN, 2010, P NATL ACAD SCI USA, V107, P4949, DOI 10.1073/pnas.0914857107; Koh KD, 2015, NAT METHODS, V12, P251, DOI [10.1038/nmeth.3259, 10.1038/NMETH.3259]; Vengrova S, 2006, EMBO REP, V7, P59, DOI 10.1038/sj.embor.7400576; McElhinny SAN, 2010, NAT CHEM BIOL, V6, P774, DOI 10.1038/NCHEMBIO.424; Reijns MAM, 2015, NATURE, V518, P502, DOI 10.1038/nature14183; Brown JA, 2011, BIOCHEMISTRY-US, V50, P1135, DOI 10.1021/bi101915z; Dellino GI, 2013, GENOME RES, V23, P1, DOI 10.1101/gr.142331.112; Ghodgaonkar MM, 2013, MOL CELL, V50, P323, DOI 10.1016/j.molcel.2013.03.019; Clausen AR, 2015, NAT STRUCT MOL BIOL, V22, P185, DOI 10.1038/nsmb.2957; LIPKIN D, 1954, J AM CHEM SOC, V76, P2871, DOI 10.1021/ja01640a004; Lazzaro F, 2012, MOL CELL, V45, P99, DOI 10.1016/j.molcel.2011.12.019; Hawkins M, 2013, CELL REP, V5, P1132, DOI 10.1016/j.celrep.2013.10.014; Lujan SA, 2013, MOL CELL, V50, P437, DOI 10.1016/j.molcel.2013.03.017; Watt DL, 2011, DNA REPAIR, V10, P897, DOI 10.1016/j.dnarep.2011.05.009; [Anonymous], 1991, METHOD ENZYMOL; Koh K. D., 2014, PROTOC EXCHANGE, DOI [10.1038/protex.2015.044, DOI 10.1038/PROTEX.2015.044]; Reijns MAM, 2012, CELL, V149, DOI 10.1016/j.cell.2012.04.011; Retkute R, 2012, PHYS REV E, V86, DOI 10.1103/PhysRevE.86.031916	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1754-2189	1750-2799		NAT PROTOC	Nat. Protoc.	NOV	2015	10	11					1786	1801		10.1038/nprot.2015.116		16	Biochemical Research Methods	Biochemistry & Molecular Biology	CU4CC	WOS:000363472700009		
J	Yuki, M; Ishida, T; Sekine, S				Yuki, Michiko; Ishida, Takashi; Sekine, Satoko			Secondary Exposure of Family Members to Cyclophosphamide After Chemotherapy of Outpatients With Cancer: A Pilot Study	ONCOLOGY NURSING FORUM			English	Article						drug exposure; chemotherapy; cyclophosphamide; family member	ANTINEOPLASTIC DRUGS; OCCUPATIONAL-EXPOSURE; DERMAL EXPOSURE; NURSES; AGENTS; CONTAMINATION; PERSONNEL; URINE; HOSPITALS; PHARMACY	Purpose/Objectives: To measure the total amount of cyclophosphamide (CPA) excreted in the urine of patients with cancer and their cohabitating family members seven days after CPA administration. Design: Biological monitoring. Setting: Home setting with outpatients receiving chemotherapy. Sample: 8 patients administered CPA, 10 cohabitating family members, and 10 control participants. Methods: During the first seven days after CPA administration, urine samples were collected from the participants. The samples were analyzed for the unchanged form of CPA using gas chromatography in tandem with mass spectroscopy. Main Research Variables: CPA levels. Findings: CPA was detected in 112 of 276 patient urine samples. The last sample containing detectable CPA levels was collected after more than 48 hours in 63% of the patients, with a maximum length of five days post-treatment. In addition, 243 urine samples were collected from family members, and CPA was detected in the samples of five family members (17-252 ng per member). CPA was not detected in any control participants. Conclusions: These findings indicate that family members in close contact with patients receiving CPA are at high risk for drug exposure as many as seven days post-treatment. Implications for Nursing: Nurses should educate patients and their family members about preventing exposure to antineoplastic drugs in the home setting.	[Yuki, Michiko] Hokkaido Univ, Hlth Sci, Sapporo, Hokkaido, Japan; [Yuki, Michiko] Fukushima Med Univ, Dept Publ Hlth Nursing, Fukushima, Japan; [Ishida, Takashi] Fukushima Med Univ, Clin Oncol Ctr, Fukushima, Japan; [Ishida, Takashi] Fukushima Med Univ, Dept Pulm Med, Fukushima, Japan; [Sekine, Satoko] Fukushima Med Univ, Pulm Med, Fukushima, Japan	Yuki, M (reprint author), Hokkaido Univ, Hlth Sci, Sapporo, Hokkaido, Japan.	yukimck@hs.hokudai.ac.ip			Secom Science and Technology Foundation	Michiko Yuki, RN, PhD, is a professor in Health Sciences at Hokkaido University in Sapporo, Japan, and the Department of Public Health Nursing at Fukushima Medical University in Japan; Takashi Ishida, MD, is director of the Clinical Oncology Center and an associate professor in the Department of Pulmonary Medicine at Fukushima Medical University; and Satoko Sekine, MD, is a doctor of pulmonary medicine at Fukushima Medical University. The study was funded by a grant from the Secom Science and Technology Foundation. Mention of specific products and opinions related to those products do not indicate or imply endorsement by the Oncology Nursing Forum or the Oncology Nursing Society. Yuki can be reached at yukimck@hs.hokudai.ac.ip, with copy to editor at ONFEditor@ons.org. (Submitted March 2014. Accepted for publication May 8, 2015.)	Althouse R., 1979, IARC MONOGRAPHS S1, V1, P1; American society of hospital pharmacists, 1990, AM J HOSP PHARM, V47, P1033; Pethran A, 2003, INT ARCH OCC ENV HEA, V76, P5, DOI 10.1007/s00420-002-0383-8; Cardonick E, 2004, LANCET ONCOL, V5, P283, DOI 10.1016/S1470-2045(04)01466-4; Wick C, 2003, AM J HEALTH-SYST PH, V60, P2314; SESSINK PJM, 1992, PHARM WEEKBLAD, V14, P16, DOI 10.1007/BF01989220; SESSINK PJM, 1993, J CHROMATOGR-BIOMED, V616, P333, DOI 10.1016/0378-4347(93)80404-R; McDiarmid MA, 2010, J OCCUP ENVIRON MED, V52, P1028, DOI 10.1097/JOM.0b013e3181f73ae6; SESSINK PJM, 1992, INT ARCH OCC ENV HEA, V64, P105, DOI 10.1007/BF00381477; SESSINK PJM, 1995, INT ARCH OCC ENV HEA, V67, P317, DOI 10.1007/BF00385647; Hedmer M, 2008, INT ARCH OCC ENV HEA, V81, P899, DOI 10.1007/s00420-007-0284-y; Walusiak J, 2002, ALLERGY, V57, P461, DOI 10.1034/j.1398-9995.2002.13455.x; Fransman W, 2007, EPIDEMIOLOGY, V18, P112, DOI 10.1097/01.ede.0000246827.44093.c1; SKOV T, 1990, LANCET, V336, P1446, DOI 10.1016/0140-6736(90)93148-I; Meijster T, 2006, ANN OCCUP HYG, V50, P657, DOI [10.1093/annhyg/mel023, 10.1093/annhyg/me1023]; Kusnetz E, 2003, AM J IND MED, V44, P107, DOI 10.1002/ajim.10230; Yuki Michiko, 2013, J Oncol Pharm Pract, V19, P208, DOI 10.1177/1078155212459667; Hon CY, 2014, ANN OCCUP HYG, V58, P761, DOI 10.1093/annhyg/meu019; Fransman W, 2005, INT ARCH OCC ENV HEA, V78, P403, DOI 10.1007/s00420-004-0595-1; Burgaz S, 2002, HUM EXP TOXICOL, V21, P129, DOI 10.1191/0960327102ht230oa; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; HEMMINKI K, 1985, J EPIDEMIOL COMMUN H, V39, P141, DOI 10.1136/jech.39.2.141; Nygren O, 1997, INT ARCH OCC ENV HEA, V70, P209, DOI 10.1007/s004200050209; Mader RM, 1996, ARCH ENVIRON HEALTH, V51, P310; International Agency for Research on Cancer, 2013, IARC MON, V1-109; Meirow D, 2005, J NATL CANC I MONOGR, P21; Occupational Safety and Health Administration, 1995, OSHA TECHN MAN CONTR; Polovich M, 2011, SAFE HANDLING HAZARD	28	1	1	ONCOLOGY NURSING SOC	PITTSBURGH	125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA	0190-535X	1538-0688		ONCOL NURS FORUM	Oncol. Nurs. Forum	NOV	2015	42	6					665	671		10.1188/15.ONF.42-06AP		7	Oncology; Nursing	Oncology; Nursing	CU9VP	WOS:000363894600012		
J	Mallen, EAH; Gilmartin, B; Wolffsohn, JS; Tsujimura, S				Mallen, Edward A. H.; Gilmartin, Bernard; Wolffsohn, James S.; Tsujimura, Sei-ichi			Clinical evaluation of the Shin-Nippon SRW-5000 autorefractor in adults: an update	OPHTHALMIC AND PHYSIOLOGICAL OPTICS			English	Article						accommodation measurement; Grand Seiko; open-view autorefractor; Shin-Nippon SRW-5000	INDUCED TRANSIENT MYOPIA; REFRACTIVE ERROR; CARDIOVASCULAR FUNCTION; PERIPHERAL REFRACTION; OCULAR ACCOMMODATION; TONIC ACCOMMODATION; CONTACT-LENS; NEARWORK; ADAPTATION; REPEATABILITY	PurposeThe Shin-Nippon SRW-5000 is an open view autorefractor that superseded the Canon R-1 autorefractor in the mid-1990s and has been used widely in optometry and vision science laboratories. It has been used to measure refractive error, accommodation responses both statically and dynamically, off-axis refractive error, and adapted to measure pupil size. This paper presents an overview of the original 2001 clinical evaluation of the SRW-5000 in adults (Mallen etal., Ophthal Physiol Opt 2001; 21: 101) and provides an update on the use and modification of the instrument since the original publication. Recent findingsThe SRW-5000 instrument, and the family of devices which followed, have shown excellent validity, repeatability, and utility in clinical and research settings. The instruments have also shown great potential for increased research functionality following a number of modifications. SummaryThe SRW-5000 and its derivatives have been, and continue to be, of significant importance in our drive to understand myopia progression, myopia control techniques, and oculomotor function in human vision.	[Mallen, Edward A. H.] Univ Bradford, Sch Optometry & Vis Sci, Bradford BD7 1DP, W Yorkshire, England; [Gilmartin, Bernard; Wolffsohn, James S.] Aston Univ, Ophthalm Res Grp, Aston Triangle, England; [Tsujimura, Sei-ichi] Kagoshima Univ, Fac Sci & Engn, Kagoshima 890, Japan	Mallen, EAH (reprint author), Univ Bradford, Sch Optometry & Vis Sci, Bradford BD7 1DP, W Yorkshire, England.	e.a.h.mallen@bradford.ac.uk			College of Optometrists; Leverhulme Trust	The original work was supported by a postgraduate Research Scholarship to EAH Mallen from the College of Optometrists. S Tsujimura was supported by the Leverhulme Trust. The authors have no proprietary interest in any of the instruments mentioned in this paper.	Hung GK, 1999, OPHTHAL PHYSL OPT, V19, P151, DOI 10.1046/j.1475-1313.1999.00412.x; Armstrong RA, 2013, OPHTHAL PHYSL OPT, V33, P7, DOI 10.1111/opo.12009; Wolffsohn JS, 2004, OPHTHAL PHYSL OPT, V24, P142, DOI 10.1111/j.1475-1313.2004.00186.x; WINN B, 1992, OPHTHAL PHYSL OPT, V12, P252; Wolffsohn JS, 2006, OPTOMETRY VISION SCI, V83, P306, DOI 10.1097/01.opx.0000216059.54932.3a; ROSENFIELD M, 1994, OPHTHAL PHYSL OPT, V14, P265, DOI 10.1111/j.1475-1313.1994.tb00007.x; Alderson A, 2011, OPHTHAL PHYSL OPT, V31, P100, DOI 10.1111/j.1475-1313.2010.00794.x; Chat SWS, 2001, OPHTHAL PHYSL OPT, V21, P87, DOI 10.1046/j.1475-1313.2001.00584.x; Davies LN, 2005, INVEST OPHTH VIS SCI, V46, P1791, DOI 10.1167/iovs.04-0986; PHILLIPS NJ, 1992, VISION RES, V32, P1775, DOI 10.1016/0042-6989(92)90170-N; STRANG NC, 1994, OPHTHAL PHYSL OPT, V14, P88, DOI 10.1111/j.1475-1313.1994.tb00565.x; Mallen EAH, 2001, OPHTHAL PHYSL OPT, V21, P101, DOI 10.1016/S0275-5408(00)00049-1; Sheppard AL, 2010, OPHTHAL PHYSL OPT, V30, P143, DOI 10.1111/j.1475-1313.2009.00701.x; Wolffsohn JS, 2003, INVEST OPHTH VIS SCI, V44, P2284, DOI 10.1167/iovs.02-0373; Atchison DA, 2003, OPTOMETRY VISION SCI, V80, P655, DOI 10.1097/00006324-200309000-00011; Kang PL, 2011, OPTOMETRY VISION SCI, V88, P476, DOI 10.1097/OPX.0b013e31820f16fb; Paune J, 2015, OPTOMETRY VISION SCI, V92, P596, DOI 10.1097/OPX.0000000000000582; Ehsaei A, 2011, OPHTHAL PHYSL OPT, V31, P413, DOI 10.1111/j.1475-1313.2011.00838.x; BULLIMORE MA, 1986, OPHTHAL PHYSL OPT, V6, P57, DOI 10.1111/j.1475-1313.1986.tb00700.x; MCBRIEN NA, 1986, OPHTHAL PHYSL OPT, V6, P145; LOGAN NS, 1995, OPHTHAL PHYSL OPT, V15, P363, DOI 10.1046/j.1475-1313.1995.9500099y.x; Gilmartin B, 2002, OPHTHAL PHYSL OPT, V22, P366, DOI 10.1046/j.1475-1313.2002.00054.x; Lin Z, 2013, OPHTHAL PHYSL OPT, V33, P311, DOI 10.1111/opo.12049; Mallen EAH, 2005, VISION RES, V45, P1641, DOI 10.1016/j.visres.2004.11.022; Moore KE, 2014, OPTOMETRY VISION SCI, V91, P1106, DOI 10.1097/OPX.0000000000000351; Si JK, 2015, OPTOMETRY VISION SCI, V92, P252, DOI 10.1097/OPX.0000000000000505; Verkicharla PK, 2012, OPHTHAL PHYSL OPT, V32, P184, DOI 10.1111/j.1475-1313.2012.00906.x; Davies LN, 2009, OPHTHAL PHYSL OPT, V29, P427, DOI 10.1111/j.1475-1313.2009.00635.x; Arunthavaraja M, 2010, OPHTHAL PHYSL OPT, V30, P766, DOI 10.1111/j.1475-1313.2010.00787.x; Wolffsohn JS, 2003, CURR EYE RES, V27, P363; ROSENFIELD M, 1988, OPHTHAL PHYSL OPT, V8, P172, DOI 10.1111/j.1475-1313.1988.tb01033.x; Tang WC, 2014, OPHTHAL PHYSL OPT, V34, P89, DOI 10.1111/opo.12098; Wolffsohn JS, 2001, OPHTHAL PHYSL OPT, V21, P108, DOI 10.1016/S0275-5408(00)00050-8; Vasudevan B, 2009, INVEST OPHTH VIS SCI, V50, P114, DOI 10.1167/iovs.08-1762; Davies LN, 2003, OPTOMETRY VISION SCI, V80, P320, DOI 10.1097/00006324-200304000-00011; Li RW, 2011, OPHTHAL PHYSL OPT, V21, P114; BLAND JM, 1986, LANCET, V1, P307; McBrien NA, 1985, AM J OPTOM PHYSL OPT, V62, P782; PUGH JR, 1989, OPHTHAL PHYSL OPT, V9, P451; Santodomingo-Rubido J, 2002, BRIT J OPHTHALMOL, V86, P458, DOI 10.1136/bjo.86.4.458; Smith Earl L 3rd, 2013, Ophthalmic Physiol Opt, V33, P379, DOI 10.1111/opo.12060; Thibos LN, 1997, OPTOMETRY VISION SCI, V74, P367, DOI 10.1097/00006324-199706000-00019; Walline JJ, 2013, OPTOMETRY VISION SCI, V90, P1207, DOI 10.1097/OPX.0000000000000036	43	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0275-5408	1475-1313		OPHTHAL PHYSL OPT	Ophthalmic Physiol. Opt.	NOV	2015	35	6					622	627		10.1111/opo.12254		6	Ophthalmology	Ophthalmology	CU9NZ	WOS:000363872600006		
J	Tanaka, J; Kokuryo, S; Yoshiga, D; Tsurushima, H; Sakaguchi, O; Habu, M; Nishihara, T; Yoshioka, I; Tominaga, K				Tanaka, J.; Kokuryo, S.; Yoshiga, D.; Tsurushima, H.; Sakaguchi, O.; Habu, M.; Nishihara, T.; Yoshioka, I.; Tominaga, K.			An osteonecrosis model induced by oral bisphosphonate in ovariectomised rats	ORAL DISEASES			English	Article						oral bisphosphonate; bisphosphonate-related osteonecrosis of the jaw; rat; alendronate; ovariectomy	RISK-FACTORS; WISTAR RATS; IN-VIVO; JAW; ALENDRONATE; OSTEOPOROSIS; ASSOCIATION; PREVALENCE; PREVENTION; FRACTURES	ObjectiveTo develop a model of osteonecrosis using oral bisphosphonate in ovariectomy-induced osteoporotic rats. Materials and MethodsThirty-six rats were subjected to ovariectomy or sham surgery. After 8weeks, rats received oral alendronate (1.0mgkg(-1)) or saline once weekly for 4weeks; then, serum C-telopeptide cross-linked collagen type I levels were measured to evaluate bone metabolism. Twelve rats from each group were injected with either lipopolysaccharide or saline into the bone marrow of the mandibles and femurs, and the areas of osteonecrosis were evaluated by histomorphometry. ResultsSerum C-telopeptide cross-linked collagen type I levels were significantly increased in the ovariectomy group (105.12.1ngml(-1)) compared with the sham group (78.9 +/- 12.5ngml(-1)); they were significantly reduced following oral alendronate administration in the ovariectomy group (91.0 +/- 4.4ngml(-1)). Following alendronate and lipopolysaccharide administration, extensive osteonecrosis was observed in the mandibles and femurs of ovariectomy (0.45 +/- 0.08mm(2), 1.69 +/- 0.72mm(2), respectively) and sham (1.12 +/- 0.45 mm(2), 1.84 +/- 0.66mm(2), respectively) groups. Significantly wider osteonecrosis occurred in the mandibles of sham-operated rats than ovariectomy rats following alendronate or lipopolysaccharide treatment. ConclusionsWe successfully developed a model of osteonecrosis in ovariectomised rats following oral bisphosphonate administration.	[Tanaka, J.; Kokuryo, S.; Tsurushima, H.; Sakaguchi, O.; Yoshioka, I.] Kyushu Dent Univ, Dept Sci Phys Funct, Div Oral Med, Kitakyushu, Fukuoka, Japan; [Yoshiga, D.; Habu, M.; Tominaga, K.] Kyushu Dent Univ, Dept Sci Phys Funct, Div Maxillofacial Surg, Kitakyushu, Fukuoka, Japan; [Nishihara, T.] Kyushu Dent Univ, Dept Hlth Promot, Div Infect & Mol Biol, Kitakyushu, Fukuoka, Japan	Kokuryo, S (reprint author), Dept Sci Phys Funct, Div Oral Med, Kokurakita Ku, 2-6-1 Manazuru, Kitakyushu, Fukuoka 8038580, Japan.	r08kokuryo@fa.kyu-dent.ac.jp					Abboskhujaeva Lola S, 2014, Drugs R D, V14, P315, DOI 10.1007/s40268-014-0069-1; Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws American Association of Oral and Maxillofacial Surgeons, 2007, J ORAL MAXILLOFAC SU, V65, P369, DOI DOI 10.1016/J.JOMS.2006.11.003; Aapro M, 2008, ANN ONCOL, V19, P420, DOI 10.1093/annonc/mdm442; Yoshimura N, 2009, J BONE MINER METAB, V27, P620, DOI 10.1007/s00774-009-0080-8; GUSTILO RB, 1990, J BONE JOINT SURG AM, V72A, P299; Lelovas PP, 2008, COMPARATIVE MED, V58, P424; Marx RE, 2007, J ORAL MAXIL SURG, V65, P2397, DOI 10.1016/j.joms.2007.08.003; Tsurushima H, 2013, INT J ORAL MAX SURG, V42, P1481, DOI 10.1016/j.ijom.2013.06.011; Kuhl S, 2012, ORAL ONCOL, V48, P938, DOI 10.1016/j.oraloncology.2012.03.028; Yoneda T, 2010, J BONE MINER METAB, V28, P365, DOI 10.1007/s00774-010-0162-7; Lee DG, 2014, MOL NUTR FOOD RES, V58, P1249, DOI 10.1002/mnfr.201300319; Dixon RB, 1997, J DENT RES, V76, P2579; Cauley JA, 2008, J BONE MINER RES, V23, P1458, DOI [10.1359/jbmr.080411, 10.1359/JBMR.080411]; Maahs MP, 2011, HEAD NECK-J SCI SPEC, V33, P199, DOI 10.1002/hed.21422; Kozloff KM, 2010, J BONE MINER RES, V25, P1748, DOI 10.1002/jbmr.66; Lo JC, 2010, J ORAL MAXIL SURG, V68, P243, DOI 10.1016/j.joms.2009.03.050; Porras AG, 1999, CLIN PHARMACOKINET, V36, P315, DOI 10.2165/00003088-199936050-00002; Khamaisi M, 2007, J CLIN ENDOCR METAB, V92, P1172, DOI 10.1210/jc.2006-2036; Berti-Couto SA, 2014, HEAD NECK-J SCI SPEC, V36, P84, DOI 10.1002/hed.23260; Mavrokokki T, 2007, J ORAL MAXIL SURG, V65, P415, DOI 10.1016/j.joms.2006.10.061; Yoshiga D, 2013, OSTEOPOROSIS INT, V24, P2365, DOI 10.1007/s00198-013-2277-x; Wehrhan F, 2011, ORAL SURG ORAL MED O, V112, P216, DOI 10.1016/j.tripleo.2011.02.028; Fliefel R, 2015, INT J ORAL MAX SURG, V44, P568, DOI 10.1016/j.ijom.2015.01.026; Cheung A, 2010, NEW ENGL J MED, V363, P2473, DOI 10.1056/NEJMc1002684; Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278-2391(03)00720-1; Yoshimura N, 2010, INT J EPIDEMIOL, V39, P988, DOI 10.1093/ije/dyp276; Allen MR, 2008, J ORAL MAXIL SURG, V66, P987, DOI 10.1016/j.joms.2008.01.038; Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295; Lansdown D, 2011, OSTEOPOROSIS INT, V22, P2365, DOI 10.1007/s00198-010-1452-6; Sedghizadeh PP, 2009, J AM DENT ASSOC, V140, P61; Abtahi J, 2013, INT J ORAL MAX SURG, V42, P632, DOI 10.1016/j.ijom.2013.02.007; Bitto A, 2008, BRIT J PHARMACOL, V155, P896, DOI 10.1038/bjp.2008.305; Sakaguchi O, 2015, INT J ORAL MAX SURG, V44, P528, DOI 10.1016/j.ijom.2014.08.011; Barrett-Connor E, 2005, J BONE MINER RES, V33, P19; Chen GX, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096181; Jee W. S. S., 2001, Journal of Musculoskeletal & Neuronal Interactions, V1, P193; JOHNSON EE, 1990, CLIN ORTHOP RELAT R, P251; Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031; Wells GA, 2008, COCHRANE DB SYST REV	39	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1354-523X	1601-0825		ORAL DIS	Oral Dis.	NOV	2015	21	8					969	976		10.1111/odi.12368		8	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	CU7SY	WOS:000363743000007		
J	Tanaka, U; Sanui, T; Fukuda, T; Toyoda, K; Taketomi, T; Atomura, R; Yamamichi, K; Maeda, H; Nishimura, F				Tanaka, U.; Sanui, T.; Fukuda, T.; Toyoda, K.; Taketomi, T.; Atomura, R.; Yamamichi, K.; Maeda, H.; Nishimura, F.			Sprouty2 inhibition promotes proliferation and migration of periodontal ligament cells	ORAL DISEASES			English	Article						Spry2; periodontal ligament cells; cell proliferation; cell migration; periodontal tissue regeneration	FIBROBLAST-GROWTH-FACTOR; ENDOTHELIAL-CELLS; SIGNALING PATHWAY; REGENERATION; ACTIVATION; DIFFERENTIATION; ANTAGONIST; AKT; FGF; ANGIOGENESIS	ObjectivesWe previously demonstrated that a dominant-negative Sprouty2 (Spry2) mutation promotes osteoblast proliferation and differentiation after basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF) stimulation, whereas it diminishes proliferation of gingival epithelial cells, thereby inducing favourable conditions for periodontal tissue regeneration. In this study, we investigated how Spry2 inhibition affects the cellular physiology of periodontal ligament (PDL) cells. MethodsA total of 1-17 PDL cells (multipotent clonal human PDL cell line) were stimulated with bFGF and EGF after transfection of Spry2 siRNA. Cell proliferation, migration, ALP staining, real-time PCR, Western blot and immunofluorescence assays were performed. ResultsERK1/2 activation and proliferation of 1-17 PDL cells were significantly upregulated by the addition of Spry2 siRNA in the presence of bFGF and EGF. In addition, Spry2 siRNA reduced transcription of osteogenesis-related genes and ALP staining relative to control cells. Furthermore, it increased AKT/phosphatidylinositol 3-kinase (PI3K) phosphorylation; consequently, Rac1 but not Cdc42 was activated, thereby promoting lamellipodia formation, cell proliferation and migration after stimulation by bFGF and EGF. ConclusionSpry2 combined with bFGF and EGF stimulation reduced PDL cell migration and proliferation with inducing osteoblastic differentiation. These invitro findings may provide a molecular basis for novel therapeutic approaches for establishing periodontal tissue regeneration.	[Tanaka, U.; Sanui, T.; Fukuda, T.; Toyoda, K.; Atomura, R.; Yamamichi, K.; Nishimura, F.] Kyushu Univ, Fac Dent Sci, Dept Periodontol, Div Oral Rehabil, Fukuoka 8128582, Japan; [Taketomi, T.] Kurume Univ, Sch Med, Dental & Oral Med Ctr, Fukuoka, Japan; [Maeda, H.] Kyushu Univ, Fac Dent Sci, Dept Endodontol & Operat Dent, Div Oral Rehabil, Fukuoka 8128582, Japan	Sanui, T (reprint author), Kyushu Univ, Fac Dent Sci, Dept Periodontol, Div Oral Rehabil,Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	sanuteru@dent.kyushu-u.ac.jp; tfukuda@dent.kyushu-u.ac.jp			Japan Society for the Promotion of Science [22792092, 24792334]; Takeda Science Foundation; Kyushu University Interdisciplinary Programs in Education and Projects in Research Development	This work was supported by Grants-in-Aid for Young Scientists B (22792092 and 24792334) from the Japan Society for the Promotion of Science, Takeda Science Foundation, and Kyushu University Interdisciplinary Programs in Education and Projects in Research Development. Technical support was provided from the Research Support Center, Graduate School of Medical Sciences, Kyushu University. The authors declare no potential conflict of interests with respect to the authorship and/or publication of this article.	GOTTLOW J, 1984, J CLIN PERIODONTOL, V11, P494, DOI 10.1111/j.1600-051X.1984.tb00901.x; Barnes GL, 2003, CANCER RES, V63, P2631; Wietecha MS, 2011, AM J PHYSIOL-HEART C, V300, pH459, DOI 10.1152/ajpheart.00244.2010; Yusoff P, 2002, J BIOL CHEM, V277, P3195, DOI 10.1074/jbc.M108368200; Kramer S, 1999, DEVELOPMENT, V126, P2515; Impagnatiello MA, 2001, J CELL BIOL, V152, P1087, DOI 10.1083/jcb.152.5.1087; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Murakami S, 1999, J PERIODONTAL RES, V34, P425, DOI 10.1111/j.1600-0765.1999.tb02277.x; Nakamura T, 2010, CELL STRUCT FUNCT, V35, P53; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Zhou GL, 2003, MOL CELL BIOL, V23, P8058, DOI 10.1128/MCB.23.22.8058-8069.2003; Goodnough LH, 2007, DEV DYNAM, V236, P1918, DOI 10.1002/dvdy.21195; Poppleton HM, 2004, BIOCHEM BIOPH RES CO, V323, P98, DOI 10.1016/j.bbrc.2004.08.070; Takayama S, 2001, J DENT RES, V80, P2075; Kolsch V, 2008, J CELL SCI, V121, P551, DOI 10.1242/jcs.023333; Yigzaw Y, 2003, J BIOL CHEM, V278, P284, DOI 10.1074/jbc.M210359200; Morales-Ruiz M, 2000, CIRC RES, V86, P892; Hausott B, 2009, MOL CELL NEUROSCI, V42, P328, DOI 10.1016/j.mcn.2009.08.005; Gross I, 2001, J BIOL CHEM, V276, P46460, DOI 10.1074/jbc.M108234200; Kim HJ, 2004, NAT REV MOL CELL BIO, V5, P441, DOI 10.1038/nrm1400; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Klein OD, 2006, DEV CELL, V11, P181, DOI 10.1016/j.devcel.2006.05.014; Christofori G, 2003, NAT CELL BIOL, V5, P377, DOI 10.1038/ncb0503-377; Komori T, 2011, J CELL BIOCHEM, V112, P750, DOI 10.1002/jcb.22994; Hanafusa H, 2002, NAT CELL BIOL, V4, P850, DOI 10.1038/ncb867; Shimabukuro Y, 2011, J CELL PHYSIOL, V226, P809, DOI 10.1002/jcp.22406; Guy GR, 2009, J ENDOCRINOL, V203, P191, DOI 10.1677/JOE-09-0110; Fujii S, 2006, CELL TISSUE RES, V324, P117, DOI 10.1007/s00441-005-0101-4; Sanui T, 2015, J CELL BIOCHEM, V116, P628, DOI 10.1002/jcb.25014; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; MCCULLOCH CAG, 1991, J PERIODONTAL RES, V26, P144, DOI 10.1111/j.1600-0765.1991.tb01638.x; Rathmanner N, 2013, FEBS LETT, V587, P2597, DOI 10.1016/j.febslet.2013.06.040; Martelli AM, 2006, LEUKEMIA, V20, P911, DOI 10.1038/sj.leu.2404245; Tomokiyo A, 2012, J CELL PHYSIOL, V227, P2040, DOI 10.1002/jcp.22933; Murakami S, 2003, J PERIODONTAL RES, V38, P97, DOI 10.1034/j.1600-0765.2003.00640.x; Nagoshi T, 2005, J CLIN INVEST, V115, P2128, DOI 10.1172/JCI23073; Chavakis E, 2001, CIRCULATION, V103, P2102; Taniguchi K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005467	38	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1354-523X	1601-0825		ORAL DIS	Oral Dis.	NOV	2015	21	8					977	986		10.1111/odi.12369		10	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	CU7SY	WOS:000363743000008		
J	Yufu, K; Shinohara, T; Ebata, Y; Ayabe, R; Fukui, A; Okada, N; Nakagawa, M; Takahashi, N				Yufu, Kunio; Shinohara, Tetsuji; Ebata, Yuki; Ayabe, Reika; Fukui, Akira; Okada, Norihiro; Nakagawa, Mikiko; Takahashi, Naohiko			Endothelial Function Predicts New Hospitalization due to Heart Failure Following Cardiac Resynchronization Therapy	PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY			English	Article						endothelial function; coronary flow reserve; cardiac resynchronization therapy; long-term outcome	FLOW-MEDIATED DILATION; DESCENDING CORONARY-ARTERY; DOPPLER-ECHOCARDIOGRAPHY; PROGNOSTIC-SIGNIFICANCE; NONINVASIVE ASSESSMENT; VELOCITY RESERVE; NITRIC-OXIDE; DYSFUNCTION; DISEASE; RISK	BackgroundCardiac resynchronization therapy (CRT) has been established as a treatment for patients with chronic heart failure (HF). We tested the hypothesis that assessment of peripheral endothelial function is associated with the long-term outcome of CRT and its linkage to coronary flow reserve (CFR) was also investigated. MethodsFrom 2010, a total of 34 consecutive patients implanted with CRT for the treatment of advanced HF were evaluated at baseline (immediately before CRT) and 6-8 months after CRT. Endothelial function was evaluated by measurement of reactive hyperemia peripheral arterial tonometry (RH-PAT). In 24 of 34 patients, CFR was determined by transthoracic echocardiography. ResultsBased on the receiver-operating characteristic curves, depressed RH-PAT index (RHI) was defined as 1.5. Accurate follow-up information during the mean of 343 120 days was obtained in 20 preserved RHI group (mean age 66 +/- 1.8 years) and 14 depressed RHI group (71 +/- 2.2 years). Kaplan-Meier survival analysis demonstrated that depressed RHI group had higher prevalence of new hospitalization due to HF progression (log-rank 5.40). Cox proportional hazards regression analysis revealed that the baseline log brain natriuretic peptide (hazard ratio 5.95) and the baseline RHI value (hazard ratio 0.066) were independently associated with the incidence of new hospitalization due to HF progression. The baseline RHI values were positively correlated with the 6-8 months change of CFR (R = 0.434, P = 0.0343). ConclusionsOur results suggest that the baseline peripheral endothelial function could predict the long-term outcome of CRT. The results also suggest that improvement of coronary microcirculation might be associated with the better baseline endothelial function.	[Yufu, Kunio; Shinohara, Tetsuji; Ebata, Yuki; Ayabe, Reika; Fukui, Akira; Okada, Norihiro; Nakagawa, Mikiko; Takahashi, Naohiko] Oita Univ, Dept Cardiol & Clin Examinat, Fac Med, Oita 8795593, Japan	Yufu, K (reprint author), Oita Univ, Dept Cardiol & Clin Examinat, Fac Med, 1-1 Idaigaoka, Oita 8795593, Japan.	yufukuni@oita-u.ac.jp					Takishima I, 2012, INT J CARDIOL, V158, P417, DOI 10.1016/j.ijcard.2011.01.059; Xie YW, 1996, CIRC RES, V79, P381; Akiyama E, 2012, J AM COLL CARDIOL, V60, P1778, DOI 10.1016/j.jacc.2012.07.036; Deftereos S, 2010, J CARDIOVASC ELECTR, V21, P1233, DOI 10.1111/j.1540-8167.2010.01827.x; KUBO SH, 1991, CIRCULATION, V84, P1589; Akar JG, 2008, HEART RHYTHM, V5, P1229, DOI 10.1016/j.hrthm.2008.05.027; Chung ES, 2008, CIRCULATION, V117, P2608, DOI 10.1161/CIRCULATIONAHA.107.743120; ALZadjali MA, 2009, J AM COLL CARDIOL, V53, P747, DOI 10.1016/j.jacc.2008.08.081; Bonetti PO, 2003, J AM COLL CARDIOL, V41, P1761, DOI 10.1016/S0735-1097(03)00329-2; Cleland JGF, 2005, NEW ENGL J MED, V352, P1539, DOI 10.1056/NEJMoa050496; Fukuda S, 2012, INT J CARDIOL, V157, P216, DOI 10.1016/j.ijcard.2010.12.052; Hozumi T, 1998, J AM COLL CARDIOL, V32, P1251, DOI 10.1016/S0735-1097(98)00389-1; Hozumi T, 1998, CIRCULATION, V97, P1557; Hijmering ML, 2001, ATHEROSCLEROSIS, V157, P369, DOI 10.1016/S0021-9150(00)00748-6; Targonski PV, 2003, CIRCULATION, V107, P2805, DOI 10.1161/01.CIR.0000072765.93106.EE; Yeboah J, 2007, CIRCULATION, V115, P2390, DOI 10.1161/CIRCULATIONAHA.106.678276; Daimon M, 2001, J AM COLL CARDIOL, V37, P1310, DOI 10.1016/S0735-1097(01)01167-6; Matsuzawa Y, 2010, J AM COLL CARDIOL, V55, P1688, DOI 10.1016/j.jacc.2009.10.073; Santini L, 2013, J CARD FAIL, V19, P419, DOI 10.1016/j.cardfail.2013.05.001; Hambrecht R, 1998, CIRCULATION, V98, P2709; Fischer D, 2005, EUR HEART J, V26, P65, DOI 10.1093/eurheartj/ehi001; Scherrer-Crosbie M, 2001, CIRCULATION, V104, P1286, DOI 10.1161/hc3601.094298; Perticone F, 2001, CIRCULATION, V104, P191; CELERMAJER DS, 1992, LANCET, V340, P1111, DOI 10.1016/0140-6736(92)93147-F; Bristow MR, 2004, NEW ENGL J MED, V350, P2140, DOI 10.1056/NEJMoa032423; Schachinger V, 2000, CIRCULATION, V101, P1899; Kelly AS, 2014, ATHEROSCLEROSIS, V234, P410, DOI 10.1016/j.atherosclerosis.2014.03.031; Abraham WT, 2002, NEW ENGL J MED, V346, P1845, DOI 10.1056/NEJMoa013168; Katz SD, 2005, CIRCULATION, V111, P310, DOI 10.1161/01.CIR.0000153349.77489.CF; Camici PG, 2007, NEW ENGL J MED, V356, P830, DOI 10.1056/NEJMra061889	30	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0147-8389	1540-8159		PACE	PACE-Pacing Clin. Electrophysiol.	NOV	2015	38	11					1260	1266		10.1111/pace.12698		7	Cardiac & Cardiovascular Systems; Engineering, Biomedical	Cardiovascular System & Cardiology; Engineering	CU6XA	WOS:000363677100003		
J	Shimizu, Y; Abiko, C; Ikeda, T; Mizuta, K; Matsuzaki, Y				Shimizu, Yukitoshi; Abiko, Chieko; Ikeda, Tatsuya; Mizuta, Katsumi; Matsuzaki, Yoko			INFLUENZA C VIRUS AND HUMAN METAPNEUMOVIRUS INFECTIONS IN HOSPITALIZED CHILDREN WITH LOWER RESPIRATORY TRACT ILLNESS	PEDIATRIC INFECTIOUS DISEASE JOURNAL			English	Article						influenza C virus; human metapneumovirus; hospitalized children; wheezing; pneumonia	REAL-TIME PCR; JAPAN; OUTBREAK; YAMAGATA; ASSAY	A 6-month prospective study in a hospital setting detected influenza C virus and human metapneumovirus in 10.0% (29/289) and 16.6% (48/289), respectively, of children hospitalized with lower respiratory tract illness. Influenza C virus infection had a similar rate of pneumonia (53.3% vs. 57.1%), significantly lower frequency of wheezing (13.3% vs. 68.6%) and higher values of white blood cell and C-reactive protein than human metapneumovirus infection.	[Shimizu, Yukitoshi] Yamagata City Hosp Saiseikan, Dept Pediat, Yamagata, Japan; [Abiko, Chieko; Ikeda, Tatsuya; Mizuta, Katsumi] Yamagata Prefectural Inst Publ Hlth, Dept Microbiol, Yamagata 9900031, Japan; [Matsuzaki, Yoko] Yamagata Univ, Dept Infect Dis, Yamagata 9909585, Japan	Matsuzaki, Y (reprint author), Yamagata Univ, Fac Med, Dept Infect Dis, Iida Nishi 2-2-2, Yamagata 9909585, Japan.	matuzaki@med.id.yamagata-u.ac.jp			JSPS KAKENHI grant [26461563]	Supported by JSPS KAKENHI grant 26461563. The authors have no conflicts of interest to disclose.	Matsuzaki Y, 2006, J INFECT DIS, V193, P1229, DOI 10.1086/502973; Anton A, 2011, DIAGN MICR INFEC DIS, V69, P419, DOI 10.1016/j.diagmicrobio.2010.11.006; Principi N, 2013, INFLUENZA OTHER RESP, V7, P999, DOI 10.1111/irv.12062; Calvo C, 2013, PEDIATR INFECT DIS J, V32, P916, DOI 10.1097/INF.0b013e31828fca10; Echevarria JE, 1998, J CLIN MICROBIOL, V36, P1388; Pabbaraju K, 2013, INFLUENZA OTHER RESP, V7, P954, DOI 10.1111/irv.12099; HOMMA M, 1982, MICROBIOL IMMUNOL, V26, P639; Abiko C, 2013, JPN J INFECT DIS, V66, P76, DOI 10.7883/yoken.66.76; Matsuzaki Y, 2012, J CLIN VIROL, V54, P130, DOI 10.1016/j.jcv.2012.02.012; Matsuzaki Y, 2009, J CLIN MICROBIOL, V47, P2981, DOI 10.1128/JCM.00321-09; Gouarin S, 2008, J MED VIROL, V80, P1441, DOI 10.1002/jmv.21218; Matsuzaki Y, 2014, J CLIN VIROL, V61, P87, DOI 10.1016/j.jcv.2014.06.017; Mizuta K, 2013, JPN J INFECT DIS, V66, P140; KATAGIRI S, 1983, J INFECT DIS, V148, P51; Matoba Y, 2015, JPN J INFECT DIS, V68, P78, DOI 10.7883/yoken.JJID.2014.487	15	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0891-3668	1532-0987		PEDIATR INFECT DIS J	Pediatr. Infect. Dis. J.	NOV	2015	34	11					1273	1275		10.1097/INF.0000000000000863		3	Immunology; Infectious Diseases; Pediatrics	Immunology; Infectious Diseases; Pediatrics	CU4WF	WOS:000363530500028		
J	Takase, M; Watanabe, T				Takase, Miki; Watanabe, Toru			Reactivation of Immune Thrombocytopenia After Japanese Encephalitis Vaccination	PEDIATRIC INFECTIOUS DISEASE JOURNAL			English	Letter							CHILDREN; DISEASE; PCR		[Takase, Miki; Watanabe, Toru] Niigata City Gen Hosp, Dept Pediat, Chuo Ku, Niigata, Japan	Watanabe, T (reprint author), Niigata City Gen Hosp, Dept Pediat, Chuo Ku, Niigata, Japan.	twata@hosp.niigata.niigata.jp					McAvin JC, 2001, J CLIN MICROBIOL, V39, P3446, DOI 10.1128/JCM.39.10.3446-3451.2001; Bourke TW, 2015, LANCET INFECT DIS, V15, P552, DOI 10.1016/S1473-3099(15)70038-1; Azzari C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009282; NICE, 2010, NICE BACT MEN MEN SE	4	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0891-3668	1532-0987		PEDIATR INFECT DIS J	Pediatr. Infect. Dis. J.	NOV	2015	34	11					1276	1276		10.1097/INF.0000000000000877		1	Immunology; Infectious Diseases; Pediatrics	Immunology; Infectious Diseases; Pediatrics	CU4WF	WOS:000363530500029		
J	Sakata, R; Nagita, A; Kidokoro, M; Kato, A; Ogino, K				Sakata, Rika; Nagita, Akira; Kidokoro, Minoru; Kato, Atsushi; Ogino, Keiki			Virus genotypes and responses of serum-specific antibodies in children with primary mumps and mumps reinfection	PEDIATRIC RESEARCH			English	Article							LINKED-IMMUNOSORBENT-ASSAY; IMMUNOGLOBULIN-M; RAPID DIAGNOSIS; INFECTION; CAPTURE	BACKGROUND: Research on children with mumps reinfection after natural infection is limited; there are currently no studies on virus-specific antibody responses in paired sera or genotyping of isolated viruses. METHODS: This study included 281 children (147 boys and 134 girls, age: 1.2-15.9 y) with primary mumps (240), mumps reinfection after natural infection (9), mumps after previous vaccination (26), and vaccine-associated mumps (6). We measured mumps-specific serum antibodies and analyzed isolated virus genes. RESULTS: During acute illness, series-specific IgM and IgG titers exceeded cutoff values in 240 and 232 children with primary mumps, respectively. During convalescence, IgM antibodies were positive in seven and negative in two of nine children with mumps reinfection occurring after natural infection; among 26 previously vaccinated children, 13 were positive and 13 negative. Mumps viruses were isolated from viral cultures from 42 of the 51 children. Except for 6 vaccine-associated cases, all remaining 36 cases of isolated mumps virus were identified as genotype G. CONCLUSION: These results suggest that measurement of IgM antibody on any day of acute illness may be indicative of primary mumps but may be inconsistent for diagnosing mumps reinfection after natural infection or previous vaccination.	[Sakata, Rika; Ogino, Keiki] Okayama Univ, Grad Sch Med Dent & Pharmacol Sci, Dept Publ Hlth, Okayama 7008530, Japan; [Sakata, Rika; Nagita, Akira] Mizushima Cent Hosp, Dept Pediat, Kurashiki, Okayama, Japan; [Kidokoro, Minoru; Kato, Atsushi] Natl Inst Infect Dis, Dept Virol 3, Tokyo, Japan	Nagita, A (reprint author), Mizushima Cent Hosp, Dept Pediat, Kurashiki, Okayama, Japan.	a.nagita@mch.or.jp					NICOLAISCHOLTEN ME, 1980, MED MICROBIOL IMMUN, V168, P81, DOI 10.1007/BF02121756; UKKONEN P, 1981, J MED VIROL, V8, P131, DOI 10.1002/jmv.1890080307; Jin L, 2007, J MED VIROL, V79, P1761, DOI 10.1002/jmv.20880; BRISS PA, 1994, J INFECT DIS, V169, P77; SAKATA H, 1985, J VIROL METHODS, V12, P303, DOI 10.1016/0166-0934(85)90141-7; Momoki TS, 2013, JPN J INFECT DIS, V66, P226, DOI 10.7883/yoken.66.226; GUT JP, 1995, J MED VIROL, V45, P17, DOI 10.1002/jmv.1890450104; Rota JS, 2009, J MED VIROL, V81, P1819, DOI 10.1002/jmv.21557; GUT JP, 1985, J CLIN MICROBIOL, V21, P346; Ihara T., 2011, PEDIAT INFECT MANUAL, V2011, P304; World Health Organization, 2012, WKLY EPIDEMIOL REC, V87, P217	11	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0031-3998	1530-0447		PEDIATR RES	Pediatr. Res.	NOV	2015	78	5					580	584		10.1038/pr.2015.141		5	Pediatrics	Pediatrics	CU5WC	WOS:000363601700016		
J	Inyai, C; Komaikul, J; Kitisripanya, T; Tanaka, H; Sritularak, B; Putalun, W				Inyai, Chadathorn; Komaikul, Jukrapun; Kitisripanya, Tharita; Tanaka, Hiroyuki; Sritularak, Boonchoo; Putalun, Waraporn			Development of a Rapid Immunochromatographic Strip Test for the Detection of Mulberroside A	PHYTOCHEMICAL ANALYSIS			English	Article						immunochromatographic; mulberroside A; Morus alba L; polyclonal antibody	MORUS-ALBA; ROOT BARK; ASSAY; GLYCOSIDES	IntroductionMulberroside A (MuA) is the major active anti-tyrosinase compound in the root bark extract of Morus alba L. (Moraceae). Typically, MuA is widely employed as an active ingredient in whitening cosmetics. A rapid and simple assay system utilizing a small quantity of test sample is essential for the detection of MuA in large number of samples. An immunoassay using highly specific MuA polyclonal antibodies may be useful for the determination of small quantities of MuA in test samples. ObjectiveTo establish a rapid qualitative MuA test, an immunochromatographic strip test was developed using anti-MuA polyclonal antibodies (anti-MuA PAb). MethodologyThe qualitative assay was based on a competitive immunoassay where the detection reagent consisted of anti-MuA PAb colored with colloidal gold particles. The capture reagent was a MuA-ovalbumin (MuA-OVA) conjugate immobilized on the test strip membrane. ResultsA sample containing MuA and the detection reagent were incubated together with immobilized capture reagent on a nitrocellulose membrane. When MuA was present, it competed with the immobilized conjugates on the strip membrane to bind a limited amount of colored antibodies; thus, a positive sample showed no color on the capture spot zone. The detection limit for the strip test was 2 mu g/mL. The developed immunochromatographic strip test was utilized to determine MuA in plants, medical preparations and cosmetic samples. ConclusionThis immunochromatographic strip test is advantageous as a rapid, simple and sensitive screening method for the detection of MuA in plant extracts, cosmetic samples and pharmaceutical products. Mulberroside A (MuA) is the major active anti-tyrosinase compound in the root bark extract of Morus alba L. (Moraceae). Typically, MuA is widely employed as an active ingredient in whitening cosmetics. To establish a rapid qualitative MuA test, an immunochromatographic strip test was developed using anti-MuA polyclonal antibodies (anti-MuA PAb) colored with colloidal gold particles as the detector reagent. The capture reagent was a MuA-ovalbumin (MuA-OVA) conjugate immobilized on the test strip membrane. When MuA was present, it competed with the immobilized conjugates on the strip membrane to bind a limited amount of colored antibodies; thus, a positive sample showed no color on the capture spot zone. The detection limit for the strip test was 2 mu g/ml. This immunochromatographic strip test is advantageous as a rapid, simple and sensitive screening method for the detection of MuA in plant extracts, cosmetic samples and pharmaceutical products.	[Inyai, Chadathorn; Komaikul, Jukrapun; Kitisripanya, Tharita; Putalun, Waraporn] Khon Kaen Univ, Fac Pharmaceut Sci, Khon Kaen 40002, Thailand; [Inyai, Chadathorn; Komaikul, Jukrapun; Kitisripanya, Tharita; Putalun, Waraporn] Khon Kaen Univ, Natl Res Univ, Res Grp Pharmaceut Act Nat Prod Using Pharmaceut, Khon Kaen 40002, Thailand; [Tanaka, Hiroyuki] Kyushu Univ, Grad Sch Pharmaceut Sci, Fukuoka 8128582, Japan; [Sritularak, Boonchoo] Chulalongkorn Univ, Fac Pharmaceut Sci, Bangkok 10330, Thailand	Putalun, W (reprint author), Khon Kaen Univ, Fac Pharmaceut Sci, Khon Kaen 40002, Thailand.	waraporn@kku.ac.th			faculty of Pharmaceutical Sciences, Khon Kaen University; Graduate School of Khon Kaen University; Center of Excellence on Medical Biotechnology (CEMB), Thailand	This work was supported by a grant from the faculty of Pharmaceutical Sciences, Khon Kaen University, the Graduate School of Khon Kaen University and the Center of Excellence on Medical Biotechnology (CEMB), Thailand.	Butt MS, 2008, TRENDS FOOD SCI TECH, V19, P505, DOI 10.1016/j.tifs.2008.06.002; Piao SJ, 2011, PHYTOCHEM ANALYSIS, V22, P230, DOI 10.1002/pca.1270; Imsungnoen N, 2009, PHYTOCHEM ANALYSIS, V20, P64, DOI 10.1002/pca.1098; Putalun W, 2005, PHYTOCHEM ANALYSIS, V16, P370, DOI 10.1002/pca.862; Ercisli S, 2007, FOOD CHEM, V103, P1380, DOI 10.1016/j.foodchem.2006.10.054; Park KM, 2003, J ETHNOPHARMACOL, V84, P181, DOI 10.1016/S0378-8741(02)00318-5; Mohammadi J, 2008, INDIAN J PHARMACOL, V40, P15, DOI 10.4103/0253-7613.40483; Katayama H, 2013, ENVIRON EXP BOT, V85, P30, DOI 10.1016/j.envexpbot.2012.06.001; Putalun W, 2004, PHYTOCHEM ANALYSIS, V15, P112, DOI 10.1002/pca.752; Kim JK, 2010, J IND MICROBIOL BIOT, V37, P631, DOI 10.1007/s10295-010-0722-9; Wang CP, 2011, PLANTA MED, V77, P786, DOI 10.1055/s-0030-1250599; Komaikul J, 2014, FOOD ANAL METHOD, V7, P58, DOI 10.1007/s12161-013-9598-4; Sritularak B, 2012, J NAT MED-TOKYO, V66, P279, DOI 10.1007/s11418-011-0582-2	13	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0958-0344	1099-1565		PHYTOCHEM ANALYSIS	Phytochem. Anal.	NOV-DEC	2015	26	6					423	427		10.1002/pca.2576		5	Biochemical Research Methods; Plant Sciences; Chemistry, Analytical	Biochemistry & Molecular Biology; Plant Sciences; Chemistry	CU2DH	WOS:000363332400005		
J	Yokotani, K; Tamura, K				Yokotani, Kenji; Tamura, Katsuhiro			Effects of Personalized Feedback Interventions on Drug-Related Reoffending: a Pilot Study	PREVENTION SCIENCE			English	Article						Methamphetamine; Amphetamine; Personalized feedback intervention; Drug-related reoffending; Recidivism	MARIJUANA USE; TRIAL; DEPENDENCE	Addiction is serious problem that requires effective treatment. Previous studies support personalized feedback interventions (PFIs) as an effective treatment for drinking; however, the potential beneficial effects of this treatment on illegal drug use have not been explored. The present study examined the effects of PFIs in a sample of repetitive drug-related offenders. Participants were 50 repetitive drug-related offenders incarcerated in a Japanese prison. They were randomly assigned to the PFIs (n = 20) or control (n = 30) group. The PFIs group received six letters for 3 months, whereas the control group did not undergo any interventions. We defined relapse and recidivism as drug-related reoffending and reentering prison after release, respectively. In the 3.6-year follow-up analysis (range, 0.1-5.8 years), participants' criminal records were examined, and results indicated a decreased risk of relapse and recidivism for the PFIs group relative to the control group, even when controlling for age, educational level, number of prison terms, and sentence length. Thus, our findings suggest that PFIs reduce the likelihood of relapse and recidivism in drug-related offenders.	[Yokotani, Kenji; Tamura, Katsuhiro] Niigata Prison, Niigata, Niigata 9518121, Japan; [Yokotani, Kenji] Niigata Seiryo Univ, Grad Sch Clin Psychol, Chuo Ku, Niigata, Niigata 9518121, Japan	Yokotani, K (reprint author), Niigata Prison, Niigata, Niigata 9518121, Japan.	yokotani@n-seiryo.ac.jp			Nikkoso Foundation for Safe Society [SZ2014A-004]	We thank the prison staff members for their cooperation and assistance. We also thank Dr. Tai Kurosawa and Mr. Matachi Koichiro for their insightful feedback on our draft. The present study was funded by the Nikkoso Foundation for Safe Society (SZ2014A-004). The early draft of the present study was orally presented at the 50th Japanese Correctional Education conference in Tokyo, the 16th International Society of Addiction Medicine Annual meeting in Yokohama, and the 2014 Global Addiction meeting in Rio.	NURCO DN, 1991, BEHAV SCI LAW, V9, P221, DOI 10.1002/bsl.2370090303; White HR, 2008, PSYCHOL ADDICT BEHAV, V22, P107, DOI 10.1037/0893-164X.22.1.107; McKay JR, 2010, J CONSULT CLIN PSYCH, V78, P912, DOI 10.1037/a0020700; Messina NP, 1999, J SUBST ABUSE TREAT, V17, P121, DOI 10.1016/S0740-5472(98)00066-X; Budney AJ, 2011, DRUG ALCOHOL DEPEN, V115, P74, DOI 10.1016/j.drugalcdep.2010.10.014; Lee CM, 2010, PSYCHOL ADDICT BEHAV, V24, P265, DOI 10.1037/a0018859; Walters ST, 2005, ADDICT BEHAV, V30, P1168, DOI 10.1016/j.addbeh.2004.12.005; Neighbors C, 2009, J CONSULT CLIN PSYCH, V77, P51, DOI [10.1037/a0014386, 10.1037/0014386]; Kay-Lambkin FJ, 2008, DRUG ALCOHOL REV, V27, P318, DOI 10.1080/09595230801914768; DUPONT WD, 1990, CONTROL CLIN TRIALS, V11, P116, DOI 10.1016/0197-2456(90)90005-M; Palfai TP, 2014, ADDICT BEHAV, V39, P1346, DOI 10.1016/j.addbeh.2014.04.025; Dimeff L.A., 1999, BRIEF ALCOHOL SCREEN; Gendreau P., 1999, EFFECTS PRISON SENTE; LANGAN PA, 2002, FEDERAL SENTENCING R, V0015; Miller W. R., 2013, MOTIVATIONAL INTERVI; National Police Agency, 2015, DRUG GUN SIT 2014; Research and Training Institute of the Ministry of Justice, 2012, HEIS 24 WHIT PAP CRI; Research and Training Institute of theMinistry of Justice, 2009, WHIT PAP CRIM 2009; Research and Training Institute of theMinistry of Justice, 2006, WHIT PAP CRIM 2006; Schoenfeld D. A., 1982, BIOMETRICS, V163-170; Stevens D. J., 1997, J CORRECTIONAL ED, V48, P106; Towe S. L., 2012, THESIS VIRGINIA POLY; Walters Scott T, 2003, Prev Sci, V4, P287, DOI 10.1023/A:1026024400450; World Health Organization, 2010, ATLAS SUBST US RES P; Yokotani K., 2014, TREATMENT EFFECTS SO	25	0	0	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1389-4986	1573-6695		PREV SCI	Prev. Sci.	NOV	2015	16	8					1169	1176		10.1007/s11121-015-0571-x		8	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	CU5HF	WOS:000363562000016		
J	Nakano, T; Iwazaki, M; Sasao, G; Nagai, A; Ebihara, A; Iwamoto, T; Kuwahira, I				Nakano, Takayuki; Iwazaki, Masayuki; Sasao, Gen; Nagai, Asuka; Ebihara, Akinori; Iwamoto, Tokuzen; Kuwahira, Ichiro			Hypobaric hypoxia is not a direct dyspnogenic factor in healthy individuals at rest	RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY			English	Article						Hypoxia; Hypoxemia; Hypoxic ventilatory response; Dyspnea; High altitude	AIR HUNGER; BREATHLESSNESS; EXERCISE; DYSPNEA; MECHANISMS; REPRODUCIBILITY; VENTILATION; DISEASE; HUMANS	Dyspnea consists of various uncomfortable respiratory sensations. It is believed that hypoxia causes dyspnea, but whether hypoxia is a direct dyspnogenic factor remains uncertain. We investigated whether hypoxia has a direct dyspnogenic effect. We evaluated changes in vital signs, arterial blood gases, SaO(2), CaO2, Borg scale, and Mini-Mental State Examination in seven mountain climbers by using a hypobaric hypoxic chamber in which the barometric pressure was lowered to the simulated altitude of 4500 m. PaO2 and CaO2 both decreased significantly as the simulated altitude increased. On the other hand, Borg scale score which reflects dyspnea showed no significant difference. At the simulated altitude of 4500 m, Borg scale score was 1.5 +/- 1.2 (mean +/- SD), despite the presence of absolute hypoxia (PaO2, 46.8 +/- 8.3 T; CaO2, 16.4 +/- 0.6 mL/dL). These results suggest that hypoxia is not a direct dyspnogenic factor in healthy individuals capable of breathing without restriction at rest. (C) 2015 Elsevier B.V. All rights reserved.	[Nakano, Takayuki; Iwazaki, Masayuki] Tokai Univ, Sch Med, Dept Surg, Div Gen Thorac Surg, Isehara, Kanagawa 2591193, Japan; [Sasao, Gen] Sasao Naika, Hadano, Kanagawa 2570003, Japan; [Nagai, Asuka; Ebihara, Akinori; Iwamoto, Tokuzen; Kuwahira, Ichiro] Tokai Univ, Tokyo Hosp, Dept Pulm Med, Shibuya, Tokyo 1510053, Japan	Kuwahira, I (reprint author), Tokai Univ, Tokyo Hosp, Dept Pulm Med, Shibuya, Tokyo 1510053, Japan.	nakanot11299119@yahoo.co.jp; iwasaki@is.icc.u-tokai.ac.jp; gensasao@m4.dion.ne.jp; asuka_nagai@tok.u-tokai.ac.jp; akinoriebihara@hotmail.com; cypns833@yahoo.co.jp; kuwahira@tok.u-tokai.ac.jp			Ministry of Education, Culture, Sports, Sciences, and Technology of Japan [20659133]	This study was supported in part by Grant-in-Aid for Scientific Research (I. Kuwahira, No. 20659133) from the Ministry of Education, Culture, Sports, Sciences, and Technology of Japan.	WARD SA, 1989, J PHYSIOL-LONDON, V411, P27; Grant S, 1999, CHEST, V116, P1208, DOI 10.1378/chest.116.5.1208; SIMON PM, 1990, AM REV RESPIR DIS, V142, P1009; RAHN H, 1949, AM J PHYSIOL, V157, P445; SCHOENE RB, 1982, J APPL PHYSIOL, V53, P886; Meakins J, 1923, BRIT MED J, V1923, P1043; WILSON RC, 1991, CLIN SCI, V80, P309; CHRONOS N, 1988, CLIN SCI, V74, P531; SWINBURN CR, 1984, CLIN SCI, V67, P515; BANZETT RB, 1989, RESP PHYSIOL, V76, P53, DOI 10.1016/0034-5687(89)90017-0; Parshall MB, 2012, AM J RESP CRIT CARE, V185, P435, DOI 10.1164/rccm.201111-2042ST; BANZETT RB, 1990, RESP PHYSIOL, V81, P1, DOI 10.1016/0034-5687(90)90065-7; SIMON PM, 1989, AM REV RESPIR DIS, V140, P1021; Burki NK, 2010, CHEST, V138, P1196, DOI 10.1378/chest.10-0534; ADAMS L, 1985, CLIN SCI, V69, P663; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; [Anonymous], 1975, J PSYCHIATR RES, DOI DOI 10.1016/0022-3956(75)90026-6; Manning H.L., 1997, LUNG BIOL HLTH DIS D, V111, P63; O'Donnell DE, 2005, DYSPNEA MECH MEASURE, V208, P29; Sasao G., 2011, JPN J CLIN PHYSL, V41, P75	20	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1569-9048	1878-1519		RESP PHYSIOL NEUROBI	Respir. Physiol. Neuro.	NOV	2015	218						28	31		10.1016/j.resp.2015.07.009		4	Physiology; Respiratory System	Physiology; Respiratory System	CU8UC	WOS:000363818600004		
J	de Campos, PS; Hasegawa, K; Kumei, Y; Zeredo, JL				de Campos, P. S.; Hasegawa, K.; Kumei, Y.; Zeredo, J. L.			Cineradiographic analysis of respiratory movements in a mouse model for early Parkinson's disease	RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY			English	Article						Respiration; Diaphragm; Radiography; Disease models; Behavior; Animal	RECEPTOR ACTIVATION; SUBSTANTIA-NIGRA; DOPAMINE NEURONS; DYSFUNCTION; 6-HYDROXYDOPAMINE; LESIONS; BRAIN; PREVALENCE; DEPRESSION; TAUOPATHY	Parkinson's disease (PD) is a progressive degenerative disorder of the central nervous system known to cause a typical pattern of motor symptoms. In its later stages, PD is known to cause respiratory alterations including shortening of operational volumes and reduced velocity of respiratory-muscle contraction. It has been proposed that such changes are secondary to changes in posture and osteoarticular degeneration, leading to an alteration in the spinal axis that in turn could affect breathing mechanics. In this study, we examined respiratory movements by using cineradiography on a murine (C57BL/6J) model of mild hemi-PD. Under surgical anesthesia, PD mice received an injection of 6-OHDA solution to the right striatum, and were compared to control mice, which received an injection of saline solution. Two weeks after surgery, all mice had their respiratory movements recorded by video X-ray without any restraint. Behavioral tests were performed to assess the severity of the 6-OHDA lesion. As a result, behavioral tests confirmed mild motor impairments in PD mice as compared to controls. Parameters of respiratory function showed mild alterations in the PD group, suggestive of a restrictive-type respiratory disorder. These results suggest that respiratory alterations in PD may emerge simultaneously to other motor symptoms, and not as a consequence of the latter. (C) 2015 Elsevier B.V. All rights reserved.	[de Campos, P. S.; Zeredo, J. L.] Univ Brasilia Hlth Sci & Technol, Grad Program, Brasilia, DF, Brazil; [Hasegawa, K.] JAXA Inst Space & Astronaut Sci, Sagamihara, Kanagawa, Japan; [Kumei, Y.; Zeredo, J. L.] Tokyo Med & Dent Univ, Dept Hard Tissue Engn, Tokyo, Japan	Zeredo, JL (reprint author), Univ Brasilia, Grad Program Hlth Sci & Technol, Ctr Metropolitano, Lote 1, BR-72220900 Brasilia, DF, Brazil.	jllzeredo@unb.br			JAXA (Japan); JSPS (Japan) [24300190, 23593021, 23659885]	This work was financially supported by grants from JAXA (Japan) to Y. Kumei (FY2010-2011) and from JSPS (Japan) to Y. Kumei (24300190), J.L. Zeredo (23593021), and K. Hasegawa (23659885). P.S. de Campos presented a preliminary version of this work at the Neuroscience 2014 in Washington, DC with travel support from FINATEC (Brazil).	Abdullah R., 2014, EXP GERONTOL; Lalley PM, 2009, AM J PHYSIOL-REG I, V296, pR1829, DOI 10.1152/ajpregu.00057.2009; Menuet C, 2012, NEUROBIOL DIS, V46, P234, DOI 10.1016/j.nbd.2012.01.012; SAUER H, 1994, NEUROSCIENCE, V59, P401, DOI 10.1016/0306-4522(94)90605-X; SCHWAB RS, 1959, NEUROLOGY, V9, P65; Nogues MA, 2008, NEUROLOGIST, V14, P273, DOI 10.1097/NRL.0b013e318173e830; HOEHN MM, 1967, NEUROLOGY, V17, P427; Mehanna R, 2010, PARKINSONISM RELAT D, V16, P628, DOI 10.1016/j.parkreldis.2010.07.004; Vercueil L, 1999, RESP PHYSIOL, V118, P163, DOI 10.1016/S0034-5687(99)00075-4; Hammer MJ, 2010, EXP BRAIN RES, V201, P401, DOI 10.1007/s00221-009-2048-2; PRZEDBORSKI S, 1995, NEUROSCIENCE, V67, P631, DOI 10.1016/0306-4522(95)00066-R; GIBB WRG, 1991, J NEUROL NEUROSUR PS, V54, P388, DOI 10.1136/jnnp.54.5.388; Tolosa E, 2006, LANCET NEUROL, V5, P75, DOI 10.1016/S1474-4422(05)70285-4; Damier P, 1999, BRAIN, V122, P1437, DOI 10.1093/brain/122.8.1437; Hasegawa Katsuya, 2014, Life-Basel, V4, P174, DOI 10.3390/life4020174; Seccombe LM, 2011, RESP PHYSIOL NEUROBI, V179, P300, DOI 10.1016/j.resp.2011.09.012; Pan B, 2008, J NEUROSCI, V28, P14018, DOI 10.1523/JNEUROSCI.4035-08.2008; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; Canning CG, 1997, ARCH PHYS MED REHAB, V78, P199, DOI 10.1016/S0003-9993(97)90264-1; SMITH ME, 1995, J VOICE, V9, P453, DOI 10.1016/S0892-1997(05)80210-3; Heuer A, 2012, BEHAV BRAIN RES, V228, P30, DOI 10.1016/j.bbr.2011.11.027; PETIT JM, 1961, ARCH INT PHYS BIOCH, V69, P413; Branchi I, 2008, J NEUROSCI RES, V86, P2050, DOI 10.1002/jnr.21642; Lalley PM, 2004, RESP PHYSIOL NEUROBI, V139, P247, DOI 10.1016/j.resp.2003.10.007; Jankovic J, 2010, MOVEMENT DISORD, V25, P527, DOI 10.1002/mds.23139; Lalley PM, 2012, RESP PHYSIOL NEUROBI, V181, P183, DOI 10.1016/j.resp.2012.03.008; Stettner GM, 2008, RESP PHYSIOL NEUROBI, V161, P10, DOI 10.1016/j.resp.2007.11.001; Francardo V, 2011, NEUROBIOL DIS, V42, P327, DOI 10.1016/j.nbd.2011.01.024; MOGHAL S, 1994, NEUROEPIDEMIOLOGY, V13, P175, DOI 10.1159/000110376; Ho AK, 2008, MOVEMENT DISORD, V23, P574, DOI 10.1002/mds.21899; Yamauchi M, 2008, RESP PHYSIOL NEUROBI, V162, P117, DOI 10.1016/j.resp.2008.05.003; Sabate M, 1996, J NEUROL SCI, V138, P114, DOI 10.1016/0022-510X(96)00003-2; Moore MW, 2012, RESP PHYSIOL NEUROBI, V183, P35, DOI 10.1016/j.resp.2012.05.001; Dutschmann M, 2010, J NEUROSCI, V30, P1810, DOI 10.1523/JNEUROSCI.5261-09.2010; Jankovic J, 2001, PARKINSONISM RELAT D, V8, P109, DOI 10.1016/S1353-8020(01)00025-6; Siderowf A, 2008, ANN NEUROL, V64, pS139, DOI 10.1002/ana.21462; Bezard E, 2011, MOVEMENT DISORD, V26, P993, DOI 10.1002/mds.23696; Nicholson G, 2002, BRIT J ANAESTH, V89, P904, DOI 10.1093/bja/aef268; NUGENT CA, 1958, AM REV TUBERC PULM, V78, P682; Errea JM, 1999, MOVEMENT DISORD, V14, P596, DOI 10.1002/1531-8257(199907)14:4<596::AID-MDS1008>3.0.CO;2-U; Lalley PM, 2008, RESP PHYSIOL NEUROBI, V164, P160, DOI 10.1016/j.resp.2008.02.004; Da Conceicao F.S.L., 2010, JOVE-J VIS EXP, P9; Hovestadt A., 1989, J NEUROL NEUROSURG P; Jankovic J, 2014, JAMA NEUROL, V71, P1351, DOI 10.1001/jamaneurol.2014.1717; Kato Bunta, 2007, Rinsho Shinkeigaku, V47, P577; Khatter A S, 1996, Parkinsonism Relat Disord, V2, P205, DOI 10.1016/S1353-8020(96)00027-2; Koster D.P., 2014, APPL NEUROPSYCH-ADUL, P1; lancu R., 2005, BEHAV BRAIN RES, V162, P1; Menuet C., 2011, PLOS ONE, V6; Onoue Hiroyuki, 2003, Rinsho Shinkeigaku, V43, P192; Paxinos G, 2008, MOUSE BRAIN STEREOTA; Saoate M., 1996, ARCH PHYS MED REHAB, V77, P29; Tieu K, 2011, CSH PERSPECT MED, V1, DOI 10.1101/cshperspect.a009316	53	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1569-9048	1878-1519		RESP PHYSIOL NEUROBI	Respir. Physiol. Neuro.	NOV	2015	218						40	45		10.1016/j.resp.2015.07.002		6	Physiology; Respiratory System	Physiology; Respiratory System	CU8UC	WOS:000363818600006		
J	Ben, G; Hirabayashi, A; Sakata, K; Nakamura, K; Hirayama, N				Ben, Goichi; Hirabayashi, Akiko; Sakata, Kazuhiro; Nakamura, Koichi; Hirayama, Norio			Evaluation of new GFRTP and CFRTP using epsilon caprolactam as matrix fabricated with VaRTM	SCIENCE AND ENGINEERING OF COMPOSITE MATERIALS			English	Article						carbon fabric; epsilon-caprolactam; FRTP; GF textile; mechanical properties; VaRTM	REINFORCED POLYPROPYLENE COMPOSITES; THERMOPLASTIC COMPOSITES; CYCLIC OLIGOMERS; FIBER	Thermoplastic resins used as a matrix of fiber reinforced thermoplastics (FRTPs) are composed of high polymers that remain highly viscous even at a higher temperature than their melting points. As a result, they need an even higher temperature, a higher pressure and a longer processing time to allow them to bond with fibers that require large and specialized equipment. In contrast, fiber-reinforced thermoset plastics (FRPs) can be easily molded owing to the use of lower viscosity liquid resin as the matrix using simpler devices. In this paper, a new fabrication method of FRTPs using in situ polymerizable epsilon caprolactam as the matrix is presented. This method uses vacuum-assisted resin transfer molding without the need for large and specialized equipment. The epsilon-caprolactam molecules were converted from their monomer form into a polyamide 6 resin, with ring-opening polymerization of epsilon-caprolactam during the molding process at a lower temperature than its melting temperature. The two kinds of FRTPs obtained using e-caprolactam as the matrix had neither voids nor unfilled parts because epsilon-caprolactam had a very low viscosity before the polymerization. These FRTPs not only exhibit superior bending properties but also are suitable for high-speed molding, namely, within a few minutes of process time.	[Ben, Goichi; Hirabayashi, Akiko; Sakata, Kazuhiro] Nihon Univ, Coll Ind Technol, Dept Mech Engn, Narashino, Chiba 2758575, Japan; [Nakamura, Koichi; Hirayama, Norio] Nitto Boseki Co Ltd, Fukushima Inst, Fukushima 9608581, Japan	Ben, G (reprint author), Nihon Univ, Coll Ind Technol, Dept Mech Engn, 1-2-1 Izumicho, Narashino, Chiba 2758575, Japan.	ben.goichi@nihon-u.ac.jp					DOLE M, 1959, MAKROMOLEKUL CHEM, V34, P29; Parton H, 2005, POLYMER, V46, P9871, DOI 10.1016/j.polymer.2005.07.082; Yan C, 2013, MATER DESIGN, V46, P688, DOI 10.1016/j.matdes.2012.11.034; Rezaei F, 2009, MATER DESIGN, V30, P260, DOI 10.1016/j.matdes.2008.05.005; Parton H, 2005, POLYM COMPOSITE, V26, P60, DOI 10.1002/pc.20074; Fu SY, 2000, COMPOS PART A-APPL S, V31, P1117, DOI 10.1016/S1359-835X(00)00068-3; Yashiro S, 2011, ADV COMPOS MATER, V20, P503, DOI 10.1163/092430411X584423; Ben G, 2013, J JPN SOC COMPOS MAT, V39, P127; Ben G, 2012, P COMP 2012; Nakamura Koichi, 2011, Journal of the Japan Society for Composite Materials, V37, DOI 10.6089/jscm.37.182; Nakamura K, 2011, P ICCM 18 JEJ KOR; Ozeki H, 2012, P US JAP C COMP MAT; Studer F, 1983, MATER DESIGN, V4, P804, DOI 10.1016/0261-3069(83)90179-6	13	1	1	WALTER DE GRUYTER GMBH	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	0792-1233	2191-0359		SCI ENG COMPOS MATER	Sci. Eng. Compos. Mater.	NOV	2015	22	6					633	641		10.1515/secm-2014-0013		9	Materials Science, Composites	Materials Science	CU9ZT	WOS:000363906600006		
J	Komaba, H; Fukagawa, M				Komaba, Hirotaka; Fukagawa, Masafumi			Cinacalcet and Clinical Outcomes in Dialysis	SEMINARS IN DIALYSIS			English	Article							CHRONIC KIDNEY-DISEASE; PATIENTS RECEIVING HEMODIALYSIS; CALCIUM-SENSING RECEPTOR; SEVERE SECONDARY HYPERPARATHYROIDISM; STAGE RENAL-DISEASE; VITAMIN-D-RECEPTOR; INDUCED VASCULAR CALCIFICATION; PARATHYROID-GLAND HYPERPLASIA; EVENTS EVOLVE TRIAL; LONG-TERM TREATMENT	Secondary hyperparathyroidism (SHPT) is a common complication of end-stage renal disease and is one of the most prominent causes of a markedly increased risk of death and cardiovascular disease in this patient population. Cinacalcet hydrochloride is a new option for the treatment of SHPT, and the efficacy and effectiveness to lower parathyroid hormone levels and to improve control of mineral metabolism, even in patients with severe disease, has been well established in many clinical trials and observational studies. Currently, the focus has moved to the impact of cinacalcet on hard clinical outcomes, and two randomized controlled trials, ADVANCE and EVOLVE, have been performed to assess the effects of cinacalcet on cardiovascular calcification and the risk of cardiovascular events and mortality, respectively. Although the primary analysis of both trials did not find significant effects of cinacalcet, the benefit of cinacalcet was suggested in the subanalyses in which the potential problems of the trials were taken into account. These positive results are consistent with experimental studies showing favorable effects of cinacalcet on bone metabolism and vascular calcification, providing plausibility to support the beneficial effects of cinacalcet. Definitive evidence is, however, still lacking, and further efforts should be made to establish the optimal role of cinacalcet in the treatment of SHPT.	[Komaba, Hirotaka; Fukagawa, Masafumi] Tokai Univ, Sch Med, Div Nephrol Endocrinol & Metab, Isehara, Kanagawa 2591193, Japan	Fukagawa, M (reprint author), Tokai Univ, Sch Med, Div Nephrol Endocrinol & Metab, 143 Shimo Kasuya, Isehara, Kanagawa 2591193, Japan.	fukagawa@tokai-u.jp			Bayer Yakuhin; Kyowa Hakko Kirin; Astellas Pharma; Ono Pharmaceutical; Torii Pharmaceutical	H.K. has received honoraria and/or consulting fees from Bayer Yakuhin and Kyowa Hakko Kirin. M.F. has received honoraria, consulting fees, and/or grants/research support from Astellas Pharma, Bayer Yakuhin, Kyowa Hakko Kirin, Ono Pharmaceutical, and Torii Pharmaceutical.	Mizobuchi M, 2004, J AM SOC NEPHROL, V15, P2579, DOI 10.1097/01.ASN.0000141016.20133.33; Gogusev J, 1997, KIDNEY INT, V51, P328, DOI 10.1038/ki.1997.41; Wada M, 1998, KIDNEY INT, V53, P448, DOI 10.1046/j.1523-1755.1998.00782.x; Quarles LD, 2003, J AM SOC NEPHROL, V14, P575, DOI 10.1097/01.ASN.0000050224.03126.AD; Tominaga Y, 2006, THER APHER DIAL, V10, P198, DOI 10.1111/j.1744-9987.2006.00364.x; Kalantar-Zadeh K, 2006, KIDNEY INT, V70, P771, DOI 10.1038/sj.ki.5001514; Mendoza FJ, 2011, CALCIFIED TISSUE INT, V88, P169, DOI 10.1007/s00223-010-9442-4; Sumida K, 2011, J CLIN PATHOL, V64, P756, DOI 10.1136/jclinpath-2011-200100; Fukagawa M, 2008, NEPHROL DIAL TRANSPL, V23, P328, DOI 10.1093/ndt/gfm534; Torres PAU, 2012, KIDNEY INT, V82, P19, DOI 10.1038/ki.2012.69; Messa P, 2008, CLIN J AM SOC NEPHRO, V3, P36, DOI 10.2215/CJN.03591006; Meola M, 2009, NEPHROL DIAL TRANSPL, V24, P982, DOI 10.1093/ndt/gfn654; Shanahan CM, 2011, CIRC RES, V109, P697, DOI 10.1161/CIRCRESAHA.110.234914; Komaba H, 2015, KIDNEY INT, V88, P350, DOI 10.1038/ki.2015.72; FUKUDA N, 1993, J CLIN INVEST, V92, P1436, DOI 10.1172/JCI116720; Komaba H, 2008, NEPHROL DIAL TRANSPL, V23, P1760, DOI 10.1093/ndt/gfm891; Kifor O, 1996, J CLIN ENDOCR METAB, V81, P1598, DOI 10.1210/jc.81.4.1598; Ishii H, 2000, BONE, V26, P175, DOI 10.1016/S8756-3282(99)00263-X; Tatsumi Ryoko, 2013, Nephron Clin Pract, V124, P224, DOI 10.1159/000357951; Moe SM, 2005, KIDNEY INT, V67, P760, DOI 10.1111/j.1523-1755.2005.67139.x; Goodman WG, 2002, J AM SOC NEPHROL, V13; Jimbo R, 2014, KIDNEY INT, V85, P1103, DOI 10.1038/ki.2013.332; Tanaka M, 2004, AM J KIDNEY DIS, V44, P762, DOI 10.1053/j.ajkd.2004.06.023; Malluche HH, 2008, CLIN NEPHROL, V69, P269; Kestenbaum B, 2004, KIDNEY INT, V66, P2010, DOI 10.1111/j.1523-1755.2004.00972.x; Raggi P, 2011, NEPHROL DIAL TRANSPL, V26, P1327, DOI 10.1093/ndt/gfq725; Raggi P, 2002, J AM COLL CARDIOL, V39, P695, DOI 10.1016/S0735-1097(01)01781-8; Lindberg JS, 2005, J AM SOC NEPHROL, V16, P800, DOI 10.1681/ASN.2004060512; Fukagawa M, 2012, CLIN J AM SOC NEPHRO, V7, P1473, DOI 10.2215/CJN.13081211; Goodman WG, 2000, NEW ENGL J MED, V342, P1478, DOI 10.1056/NEJM200005183422003; Ribeiro S, 1998, NEPHROL DIAL TRANSPL, V13, P2037, DOI 10.1093/ndt/13.8.2037; Ivanovski O, 2009, ATHEROSCLEROSIS, V205, P55, DOI 10.1016/j.atherosclerosis.2008.10.043; Komaba H, 2008, THER APHER DIAL, V12, pS44, DOI 10.1111/j.1744-9987.2008.00631.x; Shiizaki K, 2003, KIDNEY INT, V64, P992, DOI 10.1046/j.1523-1755.2003.00154.x; Block GA, 2010, KIDNEY INT, V78, P578, DOI 10.1038/ki.2010.167; Parfrey PS, 2013, J CLIN ENDOCR METAB, V98, P4834, DOI 10.1210/jc.2013-2975; Tentori F, 2008, AM J KIDNEY DIS, V52, P519, DOI 10.1053/j.ajkd.2008.03.020; Komaba H, 2013, NAT REV NEPHROL, V9, P435, DOI 10.1038/nrneph.2013.130; FUKAGAWA M, 1990, NEW ENGL J MED, V323, P421; Akizawa T, 2011, CLIN J AM SOC NEPHRO, V6, P2280, DOI 10.2215/CJN.11501210; Zitt E, 2011, NEPHROL DIAL TRANSPL, V26, P1956, DOI 10.1093/ndt/gfq641; Rutten MJ, 1999, AM J PHYSIOL-GASTR L, V277, pG662; Komaba H, 2009, NEPHROL DIAL TRANSPL, V24, P707, DOI 10.1093/ndt/gfn717; Koizumi M, 2012, NEPHROL DIAL TRANSPL, V27, P784, DOI 10.1093/ndt/gfr384; Tentori F, 2014, KIDNEY INT, V85, P166, DOI 10.1038/ki.2013.279; Goodman WG, 2008, KIDNEY INT, V74, P276, DOI 10.1038/sj.ki.5002287; Cunningham J, 2005, KIDNEY INT, V68, P1793, DOI 10.1111/j.1523-1755.2005.00596.x; Rodriguez ME, 2007, AM J PHYSIOL-RENAL, V292, pF1390, DOI 10.1152/ajprenal.00262.2006; Ganesh SK, 2001, J AM SOC NEPHROL, V12, P2131; Fishbane S, 2008, CLIN J AM SOC NEPHRO, V3, P1718, DOI 10.2215/CJN.01040308; Mizobuchi M, 2007, BIOCHEM BIOPH RES CO, V362, P11, DOI 10.1016/j.bbrc.2007.07.177; Fox J, 1999, J PHARMACOL EXP THER, V290, P473; Floege J, 2015, CLIN J AM SOC NEPHRO, V10, P800, DOI 10.2215/CJN.10221014; Lomonte C, 2008, CLIN J AM SOC NEPHRO, V3, P794, DOI 10.2215/CJN.04150907; Chertow GM, 2006, CLIN J AM SOC NEPHRO, V1, P305, DOI 10.2215/CJN.00870805; Drueke T, 2007, NEPHROL DIAL TRANSPL, V22, P1828, DOI 10.1093/ndt/gfm177; Evenepoel P, 2008, KIDNEY INT, V74, P265, DOI 10.1038/ki.2008.166; Palmer SC, 2007, ANN INTERN MED, V147, P840; Scialla JJ, 2013, KIDNEY INT, V83, P1159, DOI 10.1038/ki.2013.3; Urena-Torres PA, 2013, NEPHROL DIAL TRANSPL, V28, P146, DOI 10.1093/ndt/gfs356; Komaba H, 2012, NAT REV NEPHROL, V8, P484, DOI 10.1038/nrneph.2012.116; Wetmore JB, 2010, CLIN J AM SOC NEPHRO, V5, P110, DOI 10.2215/CJN.03630509; Wada M, 1997, J CLIN INVEST, V100, P2977, DOI 10.1172/JCI119851; QUARLES LD, 1994, KIDNEY INT, V45, P1710, DOI 10.1038/ki.1994.223; Okuno S, 2003, NEPHROL DIAL TRANSPL, V18, P2613, DOI 10.1093/ndt/gfg451; Komaba H, 2012, AM J KIDNEY DIS, V60, P262, DOI 10.1053/j.ajkd.2011.12.034; Fukagawa M, 2014, AM J KIDNEY DIS, V63, P979, DOI 10.1053/j.ajkd.2013.08.011; Ciceri P, 2012, NEPHRON EXP NEPHROL, V122, P75, DOI 10.1159/000349935; Moe SM, 2015, J AM SOC NEPHROL, V26, P1466, DOI 10.1681/ASN.2014040414; Li SY, 2011, AM J KIDNEY DIS, V57, P602, DOI 10.1053/j.ajkd.2010.10.041; Yamamoto M, 2012, CLIN EXP NEPHROL, V16, P292, DOI 10.1007/s10157-011-0547-5; Faul C, 2011, J CLIN INVEST, V121, P4393, DOI 10.1172/JCI46122; Martin KJ, 2004, AM J KIDNEY DIS, V43, P558, DOI 10.1053/j.ajkd.2003.12.003; Miller G, 2012, NEPHROL DIAL TRANSPL, V27, P2198, DOI 10.1093/ndt/gfr589; Parfrey PS, 2015, CLIN J AM SOC NEPHRO, V10, P791, DOI 10.2215/CJN.07730814; Chin J, 2000, J AM SOC NEPHROL, V11, P903; Nemeth EF, 1998, P NATL ACAD SCI USA, V95, P4040, DOI 10.1073/pnas.95.7.4040; Fox J, 1999, ENDOCRINE, V10, P97, DOI 10.1385/ENDO:10:2:97; Komaba H, 2011, CLIN EXP NEPHROL, V15, P797, DOI 10.1007/s10157-011-0502-5; Komaba H, 2010, CLIN J AM SOC NEPHRO, V5, P2305, DOI 10.2215/CJN.02110310; Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2; Hamano T, 2010, J AM SOC NEPHROL, V21, P1998, DOI 10.1681/ASN.2009090944; Ichii M, 2010, NEPHRON CLIN PRACT, V115, pC195, DOI 10.1159/000313035; Urena P, 2009, NEPHROL DIAL TRANSPL, V24, P2852, DOI 10.1093/ndt/gfp144; Block GA, 2004, NEW ENGL J MED, V350, P1516, DOI 10.1056/NEJMoa031633; Kilpatrick RD, 2013, AM J NEPHROL, V37, P389, DOI 10.1159/000350213; Taniguchi M, 2006, KIDNEY INT, V70, P363, DOI 10.1038/sj.ki.5001549; Taniguchi M, 2013, THER APHER DIAL, V17, P221, DOI 10.1111/1744-9987.12030; Moe SM, 2015, CIRCULATION, V132, P27, DOI 10.1161/CIRCULATIONAHA.114.013876; Block GA, 2008, NEPHROL DIAL TRANSPL, V23, P2311, DOI 10.1093/ndt/gfn026; Drueke TB, 2000, J AM SOC NEPHROL, V11, P1141; Behets GJ, 2015, KIDNEY INT, V87, P846, DOI 10.1038/ki.2014.349; Chattopadhyay N, 1998, AM J PHYSIOL-GASTR L, V274, pG122; Fujii N, 2010, J AM SOC NEPHROL, V21, p461A; Henaut L, 2014, CARDIOVASC RES, V101, P256, DOI 10.1093/cvr/cvt249; Lafrance JP, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-100; Lim K, 2012, CIRCULATION, V8, P2243; Lindberg K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060658; Palmer SC, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001436; St Peter Wendy L, 2009, Clin J Am Soc Nephrol, V4, P354, DOI 10.2215/CJN.05241008; Tanaka M, 2008, NDT PLUS, V1, piii49; The EVOLVE study investigators, 2012, N ENGL J MED, V367, P2482; Tominaga Y, 1997, SEMIN SURG ONCOL, V13, P78, DOI 10.1002/(SICI)1098-2388(199703/04)13:2<78::AID-SSU3>3.0.CO;2-Z	103	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-0959	1525-139X		SEMIN DIALYSIS	Semin. Dial.	NOV-DEC	2015	28	6					594	603		10.1111/sdi.12413		10	Urology & Nephrology	Urology & Nephrology	CU8RO	WOS:000363811000008		
J	Janis, D; Karasev, A; Inoue, R; Jonsson, PG				Janis, Diana; Karasev, Andrey; Inoue, Ryo; Jonsson, Par G.			A Study of Cluster Characteristics in Liquid Stainless Steel and in a Clogged Nozzle	STEEL RESEARCH INTERNATIONAL			English	Article						stainless steel; Al-deoxidation; inclusions; clusters; casting; nozzle clogging; electrolytic extraction	ALUMINUM-KILLED STEELS	Clusters of Al2O3 inclusions in a liquid stainless steel (18/8) and in a clogged ZrO2 nozzle after casting were studied during a pilot plant trial. Samples were taken from the melt at different holding times after an addition of 0.1 mass% Al. The characteristics (composition, size, number, and morphology) of clusters and clustered inclusions in the steel samples and in the clogged nozzle were investigated after electrolytic extraction and etching by using SEM. It was found that the Al2O3 inclusions in the clusters are transformed from a spherical into irregular and regular (with sharp edges) shape during the holding time. Most of the inclusions in the clusters (>80%) after a 6 min holding time are regular inclusions, which have sharp edges and flat faces. The size of the inclusions in clusters in the melt increased on average from 1.0 mu m at a 1 min to 5.2 mu m at a 12 min holding time. While the sizes of different types of inclusions in the clogged nozzle correspond to those present in the liquid steel at respective time, the frequency of spherical inclusions in the clogged nozzle is about 2-4 times larger (particularly near the nozzle wall) compared to that in the melt. Growth and transformation of Al2O3 clusters in the liquid steel at different holding times after an addition of Al and during casting were considered based on the obtained results.	[Janis, Diana; Karasev, Andrey; Jonsson, Par G.] KTH Royal Inst Technol, S-10044 Stockholm, Sweden; [Inoue, Ryo] Akita Univ, Fac Int Resource Sci, Akita 0108502, Japan	Janis, D (reprint author), KTH Royal Inst Technol, S-10044 Stockholm, Sweden.	dianav@kth.se			Swedish Governmental Agency for Innovation Systems (VINNOVA), Jernkontoret - The Swedish Steel Producers' Association; Sweden-Japan Foundation	The Swedish Governmental Agency for Innovation Systems (VINNOVA), Jernkontoret - The Swedish Steel Producers' Association and technical area TO45, and Sweden-Japan Foundation are acknowledged for financial support. In addition, Dr. Sven Ekerot and Dr. Niklas Kojola are acknowledged for providing samples and helpful information regarding the trials.	Kojola N, 2011, IRONMAK STEELMAK, V38, P81, DOI 10.1179/030192310X12706364542704; Dekkers R, 2003, METALL MATER TRANS B, V34, P161, DOI 10.1007/s11663-003-0003-3; STEINMETZ E, 1977, STAHL EISEN, V97, P1154; Vermeulen Y, 2002, ISIJ INT, V42, P1234, DOI 10.2355/isijinternational.42.1234; SINGH SN, 1974, METALL TRANS, V5, P2165, DOI 10.1007/BF02643930; Dawson S., 1990, IRON STEELMAKER, V17, P33; Dekkers R, 2003, STEEL RES INT, V74, P351; Fuhr F., 2003, IRON STEELMAKER, V12, P53; Povolotskii D. Ya., 1972, STEEL DEOXIDATION; Rastogi R, 2001, STEEL PROC, V84, P789; Schwerdtfeger K., 1970, 28 EL FURN C P AIME, V28, P95; Zhang L., 2003, 24 NAT STEELM S MOR, V1, P138	12	0	0	WILEY-V C H VERLAG GMBH	WEINHEIM	POSTFACH 101161, 69451 WEINHEIM, GERMANY	1611-3683	1869-344X		STEEL RES INT	Steel Res. Int.	NOV	2015	86	11					1271	1278		10.1002/srin.201400316		8	Metallurgy & Metallurgical Engineering	Metallurgy & Metallurgical Engineering	CU6XW	WOS:000363679600006		
J	Kamiya, A; Ito, K; Yanagida, A; Chikada, H; Iwama, A; Nakauchi, H				Kamiya, Akihide; Ito, Keiichi; Yanagida, Ayaka; Chikada, Hiromi; Iwama, Atsushi; Nakauchi, Hiromitsu			MEK-ERK Activity Regulates the Proliferative Activity of Fetal Hepatoblasts Through Accumulation of p16/19(cdkn2a)	STEM CELLS AND DEVELOPMENT			English	Article							HEPATIC PROGENITOR CELLS; RETROVIRAL VECTOR GCDNSAP; HEMATOPOIETIC STEM-CELLS; ADULT-MOUSE LIVER; RAT-LIVER; EXPANSION; MICE; DIFFERENTIATION; IDENTIFICATION; ENRICHMENT	Hepatoblasts are somatic progenitor cells in the fetal liver, which retain a high proliferative capacity and differentiate into both hepatocytes and cholangiocytes in vivo. Although efficient expansion of hepatoblasts in vitro has been difficult without genetic modification, we have previously demonstrated that the interaction with mesenchymal cells is important for expansion of hepatoblasts in vitro. In this study, we show cell signaling pathways regulating the long-term proliferative ability of hepatoblasts. Individual primary hepatoblasts derived from mouse fetal livers formed large colonies when cocultured with mesenchymal feeder cells; however, secondary colony formation was unsuccessful, indicating that in vitro culture could induce short-term, but not long-term, proliferation. When the MEK inhibitor, PD0325901, was added to these cultures, hepatoblasts formed large colonies containing many Ki-67-positive cells. Expression of p16/19(cdkn2a), a cyclin-dependent kinase inhibitor, was induced after 3-6 days culture of hepatoblasts, whereas PD0325901 significantly suppressed this expression. Consistent with these observations, fetal hepatoblasts derived from p16/19(cdkn2a) knockout mice showed long-term proliferation without PD0325901, suggesting that MEK activity induced cell cycle arrest through accumulation of p16/19(cdkn2a). In transplantation assays, we could demonstrate that in vitro expanded hepatoblasts could proliferate and differentiate into hepatocytic and cholangiocytic cells in injured livers. It should also be noted that ERK in primary hepatoblasts was not highly activated during fetal liver development. Collectively, all these findings suggest that the MEK/ERK-independent pathway in the fetal liver is involved in hepatoblast proliferation to avoid accumulation of cyclin-dependent kinase inhibitor.	[Kamiya, Akihide; Chikada, Hiromi] Tokai Univ, Sch Med, Dept Mol Life Sci, Isehara, Kanagawa 2591193, Japan; [Kamiya, Akihide; Ito, Keiichi; Yanagida, Ayaka; Nakauchi, Hiromitsu] Univ Tokyo, Inst Med Sci, Ctr Stem Cell & Regenerat Med, Div Stem Cell Therapy,Minato Ku, Tokyo, Japan; [Iwama, Atsushi] Chiba Univ, Grad Sch Med, Dept Cellular & Mol Med, Chiba, Japan; [Nakauchi, Hiromitsu] Stanford Univ, Sch Med, Inst Stem Cell Biol & Regenerat Med, Stanford, CA 94305 USA	Kamiya, A (reprint author), Tokai Univ, Sch Med, Dept Mol Life Sci, 143 Shimokasuya, Isehara, Kanagawa 2591193, Japan.	kamiyaa@tokai-u.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan [23689040, 24249056, 25670373, 26293178]; Ministry of Health, Labour and Welfare of Japan	This work was supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (23689040, 24249056, 25670373, and 26293178) and Grants-in-Aid for Scientific Research from the Ministry of Health, Labour and Welfare of Japan.	Koike H, 2014, HEPATOLOGY, V60, P323, DOI 10.1002/hep.27046; Watanabe T, 2002, DEV BIOL, V250, P332, DOI 10.1006/dbio.2002.0781; Overturf K, 1997, AM J PATHOL, V151, P1273; Tsuruya K, 2015, STEM CELLS DEV, V24, P1691, DOI 10.1089/scd.2014.0479; Suzuki A, 2008, HEPATOLOGY, V48, P1964, DOI 10.1002/hep.22558; Hoppo T, 2004, HEPATOLOGY, V39, P1362, DOI 10.1002/hep.20180; Raynaud P, 2011, INT J BIOCHEM CELL B, V43, P245, DOI 10.1016/j.biocel.2009.07.020; Okada K, 2012, STEM CELLS DEV, V21, P1124, DOI 10.1089/scd.2011.0229; Suzuki A, 2000, HEPATOLOGY, V32, P1230, DOI 10.1053/jhep.2000.20349; Yovchev MI, 2008, HEPATOLOGY, V47, P636, DOI 10.1002/hep.22047; Tanimizu N, 2003, J CELL SCI, V116, P1775, DOI 10.1242/jcs.00388; Schmelzer E, 2007, J EXP MED, V204, P1973, DOI 10.1084/jem.20061603; Kakinuma S, 2009, J HEPATOL, V51, P127, DOI 10.1016/j.jhep.2009.02.033; Kamiya A, 1999, EMBO J, V18, P2127, DOI 10.1093/emboj/18.8.2127; Lemaigre F, 2004, CURR OPIN GENET DEV, V14, P582, DOI 10.1016/j.gde.2004.08.004; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Oertel M, 2008, GASTROENTEROLOGY, V134, P823, DOI 10.1053/j.gastro.2008.01.007; Nabekura T, 2006, MOL THER, V13, P301, DOI 10.1016/j.ymthe.2005.09.021; Wang YF, 2010, HEPATOLOGY, V52, P1443, DOI 10.1002/hep.23829; Suzuki A, 2002, J NEUROCHEM, V82, P953, DOI 10.1046/j.1471-4159.2002.01048.x; Qiu Q, 2011, STEM CELLS DEV, V20, P2177, DOI 10.1089/scd.2010.0352; Yamazaki S, 2006, EMBO J, V25, P3515, DOI 10.1038/sj.emboj.7601236; Fremin C, 2012, J CELL PHYSIOL, V227, P59, DOI 10.1002/jcp.22742; Kamiya A, 2008, HEPATOLOGY, V48, P252, DOI 10.1002/hep.22303; Coutant A, 2002, HEPATOLOGY, V36, P1079, DOI 10.1053/jhep.2002.36160; Chiba T, 2010, HEPATOLOGY, V52, P1111, DOI 10.1002/hep.23793; Douarin N M, 1975, Med Biol, V53, P427; HOUSSAINT E, 1980, CELL DIFFER DEV, V9, P269, DOI 10.1016/0045-6039(80)90026-3; Kamiya A, 2009, GASTROENTEROLOGY, V137, P1114, DOI 10.1053/j.gastro.2009.06.001	29	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1547-3287	1557-8534		STEM CELLS DEV	Stem Cells Dev.	NOV 1	2015	24	21					2525	2535		10.1089/scd.2015.0015		11	Cell & Tissue Engineering; Hematology; Medicine, Research & Experimental; Transplantation	Cell Biology; Hematology; Research & Experimental Medicine; Transplantation	CU9UA	WOS:000363889800005		
J	Mori, T; Ohya, J; Masumoto, A; Harumiya, M; Fukase, M; Yoshizawa, K; Hayashi, T; Suzuki, T				Mori, Tomohisa; Ohya, Junpei; Masumoto, Aki; Harumiya, Masato; Fukase, Mika; Yoshizawa, Kazumi; Hayashi, Teruo; Suzuki, Tsutomu			Possible Involvement of the Sigma-1 Receptor Chaperone in Chemotherapeutic-Induced Neuropathic Pain	SYNAPSE			English	Article						sigma-1 receptor chaperone; neuropathic pain; SA4503; chemotherapeutic	PERIPHERAL-NERVE INJURY; SPINAL-CORD; MICE; LIGAND; INHIBITION; ANTAGONISM; ANTINOCICEPTION; HALOPERIDOL; METABOLITES; MECHANISMS	Previous studies have shown that ligands of the sigma-1 receptor chaperone ( Sig-1R) regulate pain-related behaviors. Clinical use of chemotherapeutics is often compromised due to their adverse side effects, particularly those related to neuropathy. Previous studies have shown that repeated administration of oxaliplatin and paclitaxel produces neuropathy in rodents. Therefore, the aim of the present study was to clarify the involvement of the Sig-1R in chemotherapeutic-induced neuropathy by examining the effects of oxaliplatin and paclitaxel on the Sig-1R levels in the spinal cord, and by examining the effects of Sig-1R agonist and antagonist on oxaliplatin-and paclitaxel-induced neuropathy in rats. Chemotherapeutic-induced neuropathic pain was accompanied by a significant reduction of the Sig-1R level in the spinal cord. Furthermore, the administration of paclitaxel to CHO cells that stably overexpressed Sig-1Rs induced the clustering of Sig-1Rs. We also found that the Sig-1R agonist SA4503 potently inhibited the neuropathy induced by oxaliplatin-and paclitaxel, whereas this action was abolished by the Sig-1R antagonist NE-100. These results suggest that the reduction of Sig-1R activity is involved in chemotherapeutic-induced neuropathy, and the Sig-1R agonist SA4503 could serve as a potential candidate for the treatment of chemotherapeutic-induced neuropathy. (C) 2015 Wiley Periodicals, Inc.	[Mori, Tomohisa; Ohya, Junpei; Masumoto, Aki; Harumiya, Masato; Fukase, Mika; Yoshizawa, Kazumi; Suzuki, Tsutomu] Hoshi Univ, Sch Pharm & Pharmaceut Sci, Dept Toxicol, Tokyo 1428501, Japan	Suzuki, T (reprint author), Hoshi Univ, Sch Pharm & Pharmaceut Sci, Dept Toxicol, Shinagawa Ku, 2-4-41 Ebara, Tokyo 1428501, Japan.	t-mori@hoshi.ac.jp; suzuki@hoshi.ac.jp			JSPS KAKENHI [15K07977]; MEXT [S1411019]	Contract grant sponsor: JSPS KAKENHI; Contract grant number: 15K07977; Contract grant sponsor: MEXT-Supported Program for the Strategic Research Foundation at Private Universities, 2014-2018; Contract grant number: S1411019.	Vidal-Torres A, 2013, EUR J PHARMACOL, V711, P63, DOI 10.1016/j.ejphar.2013.04.018; Navarro G, 2010, P NATL ACAD SCI USA, V107, P18676, DOI 10.1073/pnas.1008911107; Hayashi T, 2007, CELL, V131, P596, DOI 10.1016/j.cell.2007.08.036; Oladapo AO, 2012, CLIN THER, V34, P605, DOI 10.1016/j.clinthera.2012.02.007; Roh DH, 2008, ANESTHESIOLOGY, V109, P879, DOI 10.1097/ALN.0b013e3181895a83; Tseng LF, 2011, LIFE SCI, V89, P875, DOI 10.1016/j.lfs.2011.09.018; Cendan CM, 2005, PSYCHOPHARMACOLOGY, V182, P485, DOI 10.1007/s00213-005-0127-z; Flatters SJL, 2004, PAIN, V109, P150, DOI 10.1016/j.pain.2004.01.029; Yao HH, 2010, BLOOD, V115, P4951, DOI 10.1182/blood-2010-01-266221; Cendan CM, 2005, EUR J PHARMACOL, V511, P73, DOI 10.1016/j.ejphar.2005.01.036; Ohsawa M, 2010, EUR J PHARMACOL, V641, P49, DOI 10.1016/j.ejphar.2010.05.005; Moore KA, 2002, J NEUROSCI, V22, P6724; Ono Y, 2014, NEUROSCI LETT, V559, P174, DOI 10.1016/j.neulet.2013.12.005; Zamanillo D, 2013, EUR J PHARMACOL, V716, P78, DOI 10.1016/j.ejphar.2013.01.068; Gharibian D, 2013, CLIN J PAIN, V29, P377, DOI 10.1097/AJP.0b013e31825e45d9; Prezzavento O, 2008, LIFE SCI, V82, P549, DOI 10.1016/j.lfs.2007.11.032; Hayashi T, 2011, EXPERT OPIN THER TAR, V15, P557, DOI 10.1517/14728222.2011.560837; Schulze C, 2011, CLIN COLORECTAL CANC, V10, P126, DOI 10.1016/j.clcc.2011.03.010; CHIEN CC, 1994, J PHARMACOL EXP THER, V271, P1583; MARTIN WR, 1976, J PHARMACOL EXP THER, V197, P517; Kibaly C, 2008, FASEB J, V22, P93, DOI 10.1096/fj.07-8930com; Nieto FR, 2012, J PAIN, V13, P1107, DOI 10.1016/j.jpain.2012.08.006; Su TP, 2010, TRENDS PHARMACOL SCI, V31, P557, DOI 10.1016/j.tips.2010.08.007; Entrena JM, 2009, PSYCHOPHARMACOLOGY, V205, P21, DOI 10.1007/s00213-009-1513-8; Kim FJ, 2010, MOL PHARMACOL, V77, P695, DOI 10.1124/mol.109.057083; Marrazzo A, 2006, LIFE SCI, V78, P2449, DOI 10.1016/lfs.2005.10.005; Cormaci G, 2007, J PHARMACOL EXP THER, V320, P202, DOI 10.1124/jpet.106.108415; Zimmermann M, 2001, EUR J PHARMACOL, V429, P23, DOI 10.1016/S0014-2999(01)01303-6; Tuerxun T, 2010, NEUROSCI LETT, V469, P303, DOI 10.1016/j.neulet.2009.12.013; Kourrich S, 2013, CELL, V152, P236, DOI 10.1016/j.cell.2012.12.004; Griesmaier E, 2012, EXP NEUROL, V237, P388, DOI 10.1016/j.expneurol.2012.06.030; Bangaru ML, 2013, MOL PAIN, V9, DOI 10.1186/1744-8069-9-47; Hyrskyluoto A, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.170; Mori T, 2015, SYNAPSE, V69, P166, DOI 10.1002/syn.21799; Nieto FR, 2014, MOL PAIN, V10, DOI 10.1186/1744-8069-10-11; Romero L, 2012, BRIT J PHARMACOL, V166, P2289, DOI 10.1111/j.1476-5381.2012.01942.x; Sanchez-Fernandez C, 2013, NEUROPHARMACOLOGY, V70, P348, DOI 10.1016/j.neuropharm.2013.03.002; Su TP, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.261pe12; Tofthagen C, 2013, CHEMOTHER RES PRACT, V2013	39	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0887-4476	1098-2396		SYNAPSE	Synapse	NOV	2015	69	11					526	532		10.1002/syn.21844		7	Neurosciences	Neurosciences & Neurology	CU6XR	WOS:000363679100002		
J	Deng, Y; Yi, LL; Lin, XX; Lin, L; Li, HF; Lin, JM				Deng, Yong; Yi, Linglu; Lin, Xuexia; Lin, Ling; Li, Haifang; Lin, Jin-Ming			A non-invasive genomic diagnostic method for bladder cancer using size-based filtration and microchip electrophoresis	TALANTA			English	Article						Cell isolation; Genomic analysis; Microchip electrophoresis; Bladder cancer	CIRCULATING TUMOR-CELLS; INVASIVE UROTHELIAL CARCINOMA; IN-SITU HYBRIDIZATION; PROMOTER MUTATIONS; MICROCAVITY ARRAY; URINE SAMPLES; VOIDED URINE; LUNG-CANCER; BLOOD; SURVEILLANCE	Bladder cancer (BC) cells spontaneously exfoliated in the urine of patients with BC. Detection of exfoliated tumor cells has clinical significance in cancer therapy because it would enable earlier non-invasive screening, diagnosis, or prognosis of BC. In this research, a method for analyzing genetic abnormalities of BC cells collected from urine samples was developed. Target BC cells were isolated by filtration. To find conditions that achieve high cell recovery, we investigated the effects of filter type, concentration of fixative, and flow rate. Cells captured on the filter membrane were completely retrieved within 15 s. Selected genes for genomic analysis, mutated genes (FGFR3, TERT and HRAS) and methylated genes (ALX4, RALL3, MT1A, and RUNX3) were amplified by polymerase chain reaction (PCR), and subsequently, were identified by microchip electrophoresis (MCE). Analysis by MCE reduces the risk of contamination, sample consumption, and analysis time. Our developed approach is economical, effectively isolates cancer cells, and permits flexible molecular characterization, all of which make this approach a promising method for non-invasive BC detection. (C) 2015 Elsevier B.V. All rights reserved.	[Deng, Yong; Lin, Xuexia; Li, Haifang; Lin, Jin-Ming] Tsinghua Univ, Dept Chem, Beijing Key Lab Microanalyt Methods & Instrumenta, Beijing 100084, Peoples R China; [Deng, Yong; Yi, Linglu; Lin, Xuexia; Lin, Ling] Beijing Univ Chem Technol, State Key Lab Chem Resource Engn, Beijing 100029, Peoples R China; [Lin, Ling] Univ Tokyo, Sch Engn, Dept Bioengn, Bunkyo Ku, Tokyo 1138656, Japan	Lin, JM (reprint author), Tsinghua Univ, Dept Chem, Beijing Key Lab Microanalyt Methods & Instrumenta, Beijing 100084, Peoples R China.	jmlin@mail.tsinghua.edu.cn			National Natural Science Foundation of China [91213305, 81373373]	This work was supported by National Natural Science Foundation of China (Nos. 91213305 and 81373373).	Allory Y, 2014, EUR UROL, V65, P360, DOI 10.1016/j.eururo.2013.08.052; Andersson E., 2014, PLOS ONE, V4; Esmaeilsabzali H, 2013, BIOTECHNOL ADV, V31, P1063, DOI 10.1016/j.biotechadv.2013.08.016; Cook AM, 1998, BRIT J HAEMATOL, V102, P952, DOI 10.1046/j.1365-2141.1998.00878.x; van Kessel KEM, 2013, J UROLOGY, V189, P1676, DOI 10.1016/j.juro.2012.11.005; Nuchtavorn N, 2013, J CHROMATOGR A, V1286, P216, DOI 10.1016/j.chroma.2013.02.060; Dulaimi E, 2004, CLIN CANCER RES, V10, P1887, DOI 10.1158/1078-0432.CCR-03-0127; Breadmore MC, 2012, J CHROMATOGR A, V1221, P42, DOI 10.1016/j.chroma.2011.09.062; Tilki D, 2011, EUR UROL, V60, P484, DOI 10.1016/j.eururo.2011.05.053; Hosokawa M, 2010, ANAL CHEM, V82, P6629, DOI 10.1021/ac101222x; Porrata P, 2002, CHEM MATER, V14, P4378, DOI 10.1021/cm0205940; Gakis G, 2013, EUR UROL, V63, P45, DOI 10.1016/j.eururo.2012.08.009; PRINZ M, 1993, INT J LEGAL MED, V106, P75, DOI 10.1007/BF01225044; Rachakonda PS, 2013, P NATL ACAD SCI USA, V110, P17426, DOI 10.1073/pnas.1310522110; Lim LS, 2012, LAB CHIP, V12, P4388, DOI 10.1039/c2lc20750h; Serizawa RR, 2011, INT J CANCER, V129, P78, DOI 10.1002/ijc.25651; Toyang NJ, 2013, J ETHNOPHARMACOL, V150, P724, DOI 10.1016/j.jep.2013.09.028; Hosokawa M, 2013, ANAL CHEM, V85, P5692, DOI 10.1021/ac400167x; Kandimalla R, 2013, NAT REV UROL, V10, P327, DOI 10.1038/nrurol.2013.89; Khoja L, 2012, BRIT J CANCER, V106, P508, DOI 10.1038/bjc.2011.545; Gazzaniga P, 2012, ANN ONCOL, V23, P2352, DOI 10.1093/annonc/mdr619; Herceg Z, 2007, MOL ONCOL, V1, P26, DOI 10.1016/j.molonc.2007.01.004; BRAASCH D, 1971, PHYSIOL REV, V51, P679; Bories PN, 2013, CLIN CHEM, V59, P245, DOI 10.1373/clinchem.2012.192260; Li XT, 2013, J CHROMATOGR A, V1318, P251, DOI 10.1016/j.chroma.2013.10.020; Yu J, 2007, CLIN CANCER RES, V13, P7296, DOI 10.1158/1078-0432.CCR-07-0861; Lin XX, 2013, TALANTA, V114, P131, DOI 10.1016/j.talanta.2013.04.012; Hofman V, 2011, CLIN CANCER RES, V17, P827, DOI 10.1158/1078-0432.CCR-10-0445; Song YL, 2013, ANAL CHEM, V85, P4141, DOI 10.1021/ac400366b; Wu ML, 2015, TALANTA, V131, P624, DOI 10.1016/j.talanta.2014.08.051; Karnes RJ, 2012, MAYO CLIN PROC, V87, P835, DOI 10.1016/j.mayocp.2012.04.013; Reinert T, 2011, CLIN CANCER RES, V17, P5582, DOI 10.1158/1078-0432.CCR-10-2659; Pinzani P, 2006, HUM PATHOL, V37, P711, DOI 10.1016/j.humpath.2006.01.026; Zuiverloon TCM, 2010, CLIN CANCER RES, V16, P3011, DOI 10.1158/1078-0432.CCR-09-3013; Huang T, 2014, BIOSENS BIOELECTRON, V51, P213, DOI 10.1016/j.bios.2013.07.044; Meiers I, 2007, ARCH PATHOL LAB MED, V131, P1574; Xu T, 2010, CANCER RES, V70, P6420, DOI 10.1158/0008-5472.CAN-10-0686; De Giorgi V, 2010, J INVEST DERMATOL, V130, P2440, DOI 10.1038/jid.2010.141; Zheng S, 2007, J CHROMATOGR A, V1162, P154, DOI 10.1016/j.chroma.2007.05.064; Birkhahn M, 2013, EUR J CANCER, V49, P3159, DOI 10.1016/j.ejca.2013.04.033; Babjuk M, 2013, EUR UROL, V64, P639, DOI 10.1016/j.eururo.2013.06.003; Burger R., 2013, EUR UROL, V63, P36; [陈薇 Chen Wei], 2014, [中国现代医学杂志, China Journal of Modern Medicine], V24, P1; Coumans FAW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061770; Grover P.K., 2014, ANN ONCOL, V0, P1; Kompier LC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013821; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Vona G, 2000, AM J PATHOL, V156, P57, DOI 10.1016/S0002-9440(10)64706-2; Yusa A., 2014, PLOS ONE, V2; Zhang HD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054510	50	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0039-9140	1873-3573		TALANTA	Talanta	NOV 1	2015	144						136	144		10.1016/j.talanta.2015.05.065		9	Chemistry, Analytical	Chemistry	CU2IC	WOS:000363346200020		
J	Hagiwara, K; Koike, Y; Aizawa, M; Nakamura, T				Hagiwara, Kenta; Koike, Yuya; Aizawa, Mamoru; Nakamura, Toshihiro			On-site quantitation of arsenic in drinking water by disk solid-phase extraction/mobile X-ray fluorescence spectrometry	TALANTA			English	Article						Arsenic; Solid-phase extraction; Mobile X-ray fluorescence spectrometry; On-site analysis	ENVIRONMENTAL WATER; DIPHENYLARSINIC ACID; COLORIMETRIC METHOD; PHENYLARSONIC ACID; AQUEOUS SAMPLES; CHELATING RESIN; TRACE; PRECONCENTRATION; SPECIATION; AS(V)	A rapid and simple method was developed for As determination in drinking water by solid-phase extraction (SPE)/mobile X-ray fluorescence (XRF) spectrometry. A 50 mL aqueous sample was adjusted to pH 3 with dilute hydrochloric acid, and then passed through a Ti and Zr-loaded carbon disk (TiZr-CD) to pre-concentrate the As. The SPE disk was adhered to an acrylic plate with cellophane tape, and then examined by mobile XRF spectrometry. The TiZr-CD adsorbed inorganic As (as As(III) and As(V)) and organic As (as methyl, phenyl and aromatic arsenic compounds) from water. The As calibration curve had good linearity over the range of 0.5-5 mu g, and the limit of detection was 0.10 mu g (2.0 mu g L-1 in As concentration). The concentrations of As in well water samples were determined using the proposed method were similar to results obtained from atomic absorption spectrometry. The proposed method did not require a power supply or a toxic solution and/or gas in any analytical step, therefore it is suitable for the on-site determination of As in drinking water. (C) 2015 Elsevier B.V. All rights reserved.	[Hagiwara, Kenta; Koike, Yuya; Aizawa, Mamoru; Nakamura, Toshihiro] Meiji Univ, Dept Appl Chem, Tama Ku, Kawasaki, Kanagawa 2148571, Japan	Nakamura, T (reprint author), Meiji Univ, Dept Appl Chem, Tama Ku, 1-1-1 Higashimita, Kawasaki, Kanagawa 2148571, Japan.	toshina@isc.meiji.ac.jp					Velitchkova N, 2004, SPECTROCHIM ACTA B, V59, P871, DOI 10.1016/j.sab.2004.03.004; Hung DQ, 2004, TALANTA, V64, P269, DOI 10.1016/j.talanta.2004.01.027; NYAMAH D, 1986, WATER RES, V20, P1341, DOI 10.1016/0043-1354(86)90131-4; He Y, 2007, MICROCHEM J, V85, P265, DOI 10.1016/j.microc.2006.06.012; Inui T, 2011, X-RAY SPECTROM, V40, P301, DOI 10.1002/xrs.1317; Makris KC, 2008, J ENVIRON QUAL, V37, P1626, DOI 10.2134/jeq2007.0479; Hussam A, 1999, ENVIRON SCI TECHNOL, V33, P3686, DOI 10.1021/es9901462; Abe W, 2006, X-RAY SPECTROM, V35, P184, DOI 10.1002/xrs.892; Matsunaga H, 2005, TALANTA, V66, P1287, DOI 10.1016/j.talanta.2005.01.057; Dasgupta PK, 2002, TALANTA, V58, P153, DOI 10.1016/S0039-9140(02)00264-3; Watts MJ, 2010, ENVIRON GEOCHEM HLTH, V32, P479, DOI 10.1007/s10653-010-9321-y; Margui E, 2012, SPECTROCHIM ACTA B, V67, P17, DOI 10.1016/j.sab.2011.12.004; Kilbride C, 2006, ENVIRON POLLUT, V143, P16, DOI 10.1016/j.envpol.2005.11.013; Vanhoof C, 2013, X-RAY SPECTROM, V42, P224, DOI 10.1002/xrs.2485; Latva S, 1999, ANALYST, V124, P1105, DOI 10.1039/a903091c; Salman M, 2012, ANAL METHODS-UK, V4, P242, DOI 10.1039/c1ay05569k; Vidal-Solano JR, 2013, J IBER GEOL, V39, P121, DOI 10.5209/rev_JIGE.2013.v39.n1.41754; Rasul SB, 2002, TALANTA, V58, P33, DOI 10.1016/S0039-9140(02)00254-0; Hagiwara K, 2013, ANAL SCI, V29, P1153; Balaji T, 2002, ANAL SCI, V18, P1345, DOI 10.2116/analsci.18.1345; Rowe H, 2012, CHEM GEOL, V324, P122, DOI 10.1016/j.chemgeo.2011.12.023; Rahman M, 2004, ANAL SCI, V20, P165, DOI 10.2116/analsci.20.165; Gutierrez-Gines MJ, 2013, ENVIRON SCI-PROC IMP, V15, P1545, DOI 10.1039/c3em00078h; George CM, 2012, ENVIRON SCI TECHNOL, V46, P11213, DOI 10.1021/es300253p; Balaji T, 2005, CHEMOSPHERE, V59, P1169, DOI 10.1016/j.chemosphere.2004.12.007; Ishizaki M, 2005, J HEALTH SCI, V51, P130, DOI 10.1248/jhs.51.130; Ge LQ, 2005, X-RAY SPECTROM, V34, P28, DOI 10.1002/xrs.782; Funayama T, 2013, BUNSEKI KAGAKU, V62, P685; Hagiwara K, 2015, TALANTA, V134, P739, DOI 10.1016/j.talanta.2014.12.027; Hanya T., 1974, SUISITUTYOUSAHOU; Margui E, 2014, TRAC-TREND ANAL CHEM, V53, P73, DOI 10.1016/j.trac.2013.09.009; PERANIEMI S, 1994, FRESEN J ANAL CHEM, V349, P510, DOI 10.1007/BF00323983	32	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0039-9140	1873-3573		TALANTA	Talanta	NOV 1	2015	144						788	792		10.1016/j.talanta.2015.07.002		5	Chemistry, Analytical	Chemistry	CU2IC	WOS:000363346200108		
J	Denda, T; Mizutani, R; Iijima, M; Nakahashi, H; Yamamoto, H; Kanekiyo, Y				Denda, Takuya; Mizutani, Ryo; Iijima, Mizuki; Nakahashi, Hitoshi; Yamamoto, Hiroki; Kanekiyo, Yasumasa			Thin films exhibiting multicolor changes induced by formaldehyde-responsive release of anionic dyes	TALANTA			English	Article						Formaldehyde; Imine; Dye; Thin film; Sensor; Colorimetric	NANOFIBROUS MEMBRANES; GAS SENSORS; INDOOR AIR; CHROMATOGRAPHY; ALDEHYDES	A novel methodology for the sensing of formaldehyde that displays a response using distinct and diverse color changes is reported. Through copolymerization of a primary amine monomer with additional comonomers on a pattern-printed microscope slide, primary amine-containing thin films were obtained. After the absorption of a range of colors of anionic dyes, the thin films were immersed in aqueous formaldehyde solutions. It was demonstrated that the color of the thin films changed depending on the formaldehyde concentration in the solution. As the anionic dyes were released from the thin films at varying formaldehyde concentrations, a set of thin films exhibiting a range of color-change patterns was observed. The response selectivity of the thin films towards carbonyl compounds was examined, and sensitivity in the order of formaldehydeDacetaldehyde > acetone was observed. In addition, the effect of amine structure was examined, and it was found that thin films bearing tertiary amino groups show virtually no formaldehyde response. These observations clearly indicate that the existence of primary amino groups is essential for color changes to be observed, and that the formation of an imine is the crucial step in generating a response against formaldehyde. The formaldehyde-responsive system presented herein is advantageous, as its preparation is relatively simple and does not require complex organic synthesis. In addition, a wide range of anionic dyes is compatible with the system, and can be selected in terms of color, charge, toxicology profile, and cost, for example. (C) 2015 Elsevier B.V. All rights reserved.	[Denda, Takuya; Mizutani, Ryo; Iijima, Mizuki; Nakahashi, Hitoshi; Yamamoto, Hiroki; Kanekiyo, Yasumasa] Kitami Inst Technol, Dept Biotechnol & Environm Chem, Kitami, Hokkaido 0908507, Japan	Kanekiyo, Y (reprint author), Kitami Inst Technol, Dept Biotechnol & Environm Chem, 165 Koen Cho, Kitami, Hokkaido 0908507, Japan.	kanekiyo@mail.kitami-it.ac.jp					Wang XQ, 2013, ANALYST, V138, P5129, DOI 10.1039/c3an00812f; Xie HF, 2012, SENSOR ACTUAT B-CHEM, V168, P34, DOI 10.1016/j.snb.2011.12.112; Li JJ, 2014, SENSOR ACTUAT B-CHEM, V196, P10, DOI 10.1016/j.snb.2014.01.054; LORRAIN JM, 1981, ANAL CHEM, V53, P1302, DOI 10.1021/ac00231a038; Chung PR, 2013, SENSORS-BASEL, V13, P4468, DOI 10.3390/s130404468; Iwami Y, 2013, CHEM LETT, V42, P1214, DOI 10.1246/cl.130599; Wang XQ, 2014, SENSOR ACTUAT B-CHEM, V203, P333, DOI 10.1016/j.snb.2014.06.101; Srinives S, 2014, SENSOR ACTUAT B-CHEM, V194, P255, DOI 10.1016/j.snb.2013.12.079; Descamps MN, 2012, SENSOR ACTUAT B-CHEM, V170, P104, DOI 10.1016/j.snb.2011.02.032; Dirksen JA, 2001, SENSOR ACTUAT B-CHEM, V80, P106, DOI 10.1016/S0925-4005(01)00898-X; Iwami Y, 2011, TALANTA, V85, P829, DOI 10.1016/j.talanta.2011.04.068; Kanekiyo Y, 2008, CHEM LETT, V37, P626, DOI 10.1246/cl.2008.626; Peng L, 2009, SENSOR ACTUAT B-CHEM, V136, P80, DOI 10.1016/j.snb.2008.10.057; Suzuki Y, 2003, ENVIRON SCI TECHNOL, V37, P5695, DOI 10.1021/es0305050; Nageswari A, 2012, CHROMATOGRAPHIA, V75, P275, DOI 10.1007/s10337-012-2186-8; Kawamura K, 2005, SENSOR ACTUAT B-CHEM, V105, P495, DOI 10.1016/j.snb.2004.07.010; Colton MD, 2014, ENVIRON SCI TECHNOL, V48, P7833, DOI 10.1021/es501489u; Achmann S, 2008, TALANTA, V75, P786, DOI 10.1016/j.talanta.2007.12.015; DUMAS T, 1982, J CHROMATOGR, V247, P289, DOI 10.1016/S0021-9673(00)85952-X; MANN B, 1987, J CHROMATOGR, V386, P149; Knake R, 2001, ELECTROANAL, V13, P631, DOI 10.1002/1521-4109(200105)13:8/9<631::AID-ELAN631>3.0.CO;2-Z; Nielsen GD, 2013, ARCH TOXICOL, V87, P73, DOI 10.1007/s00204-012-0975-3; Takigawa T, 2010, INT ARCH OCC ENV HEA, V83, P225, DOI 10.1007/s00420-009-0475-9; Glas B, 2015, INT ARCH OCC ENV HEA, V88, P613, DOI 10.1007/s00420-014-0985-y; McMurry J. E., 2012, ORGANIC CHEM; Mohimann G. R., 1985, APPL SPECTROSC, V39, P98; Rocklin R. D., 1985, ADV CHEM SER, V210, P13; Yamada-Maruo Y., 2008, TALANTA, V74, P1141	28	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0039-9140	1873-3573		TALANTA	Talanta	NOV 1	2015	144						816	822		10.1016/j.talanta.2015.06.012		7	Chemistry, Analytical	Chemistry	CU2IC	WOS:000363346200112		
J	Quezada, AA; Ohara, K; Ratanawimarnwong, N; Nacapricha, D; Murakami, H; Teshima, N; Sakai, T				Quezada, Alejandro Ayala; Ohara, Keisuke; Ratanawimarnwong, Nuanlaor; Nacapricha, Duangjai; Murakami, Hiroya; Teshima, Norio; Sakai, Tadao			Stopped-in-loop flow analysis system for successive determination of trace vanadium and iron in drinking water using their catalytic reactions	TALANTA			English	Article						Stopped-in-loop; Flow analysis; Spectrophotometry; Vanadium; Iron; Catalytic reaction; Drinking water	INJECTION DETERMINATION; SPECTROPHOTOMETRIC DETERMINATION; SEQUENTIAL INJECTION; OXIDATION; GLUCOSE; INSTRUMENTATION; BROMATE; RISK	An automated stopped-in-loop flow analysis (SILFA) system is proposed for the successive catalytic determination of vanadium and iron. The determination of vanadium was based on the p-anisidine oxidation by potassium bromate in the presence of Tiron as an activator to form a reddish dye, which has an absorption maximum at 510 nm. The selectivity of the vanadium determination was greatly improved by adding diphosphate as a masking agent of iron. For the iron determination, an iron-catalyzed oxidative reaction of p-anisidine by hydrogen peroxide with 1,10-phenanthroline as an activator to produce a reddish dye (510 nm) was employed. The SILFA system consisted of two peristaltic pumps, two six-port injection valves, a four-port selection valve, a heater device, a spectrophotometric detector and a data acquisition device. One six-port injection valve was used for the isolation of a mixed solution of standard/sample and reagent to promote each catalytic reaction, and another six-port injection valve was used for switching the reagent for vanadium or iron to achieve selective determination of each analyte. The above mentioned four-port selection valve was used to select standard solutions or sample. These three valves and the two peristaltic pumps were controlled by a built-in programmable logic controller in a touchscreen controller. The obtained results showed that the proposed SILFA monitoring system constituted an effective approach for the selective determination of vanadium and iron. The limits of detection, 0.052 and 0.55 mu g L-1, were obtained for vanadium and iron, respectively. The proposed system was successfully applied to drinking water samples without any preconcentration procedures. (C) 2015 Elsevier B.V. All rights reserved.	[Quezada, Alejandro Ayala; Ohara, Keisuke; Murakami, Hiroya; Teshima, Norio; Sakai, Tadao] Aichi Inst Technol, Dept Appl Chem, Toyota 4700392, Japan; [Ratanawimarnwong, Nuanlaor] Srinakharinwirot Univ, Fac Sci, Dept Chem, Bangkok 10110, Thailand; [Nacapricha, Duangjai] Mahidol Univ, Fac Sci, Dept Chem, Bangkok 10400, Thailand; [Nacapricha, Duangjai] Mahidol Univ, Fac Sci, Ctr Excellence Innovat Chem, Bangkok 10400, Thailand	Teshima, N (reprint author), Aichi Inst Technol, Dept Appl Chem, 1247 Yachigusa,Yakusa Cho, Toyota 4700392, Japan.	teshima@aitech.ac.jp			JSPS KAKENHI [26288072, 25860024]; Ministry of Education, Culture, Sports, Science and Technology, Japan	This work was partly supported by JSPS KAKENHI Grant Nos. 26288072 (Grant-in-Aid for Scientific Research (B) for N.T.) and 25860024 (Grant-in-Aid for Young Scientists (B) for H.M.). A.A.-Q. acknowledges to the Ministry of Education, Culture, Sports, Science and Technology, Japan for the scholarship given to support this work.	Huang X, 2003, MUTAT RES-FUND MOL M, V533, P153, DOI 10.1016/j.mrfmmm.2003.08.023; Teshima N, 2010, ANAL SCI, V26, P143; Fortes PR, 2010, TALANTA, V81, P1409, DOI 10.1016/j.talanta.2010.02.044; TOLMAN EL, 1979, LIFE SCI, V25, P1159, DOI 10.1016/0024-3205(79)90138-3; RUZICKA J, 1990, ANAL CHIM ACTA, V237, P329, DOI 10.1016/S0003-2670(00)83937-9; Ohno S, 2004, ANAL SCI, V20, P171, DOI 10.2116/analsci.20.171; Lunvongsa S, 2006, TALANTA, V68, P969, DOI 10.1016/j.talanta.2005.06.067; Itabashi H, 2001, ANAL SCI, V17, P229, DOI 10.2116/analsci.17.229; Lapa RAS, 2002, ANAL CHIM ACTA, V466, P125, DOI 10.1016/S0003-2670(02)00514-7; RUZICKA J, 1975, ANAL CHIM ACTA, V78, P145, DOI 10.1016/S0003-2670(01)84761-9; Kawakubo S, 1996, ANAL SCI, V12, P237, DOI 10.2116/analsci.12.237; Badmaev V, 1999, J ALTERN COMPLEM MED, V5, P273, DOI 10.1089/acm.1999.5.273; Cerda V, 1999, TALANTA, V50, P695, DOI 10.1016/S0039-9140(99)00196-4; Grudpan K, 2004, TALANTA, V64, P1084, DOI 10.1016/j.talanta.2004.07.046; Kawashima T, 1997, TRAC-TREND ANAL CHEM, V16, P132, DOI 10.1016/S0165-9936(97)00012-5; Shiobara T, 1999, TALANTA, V49, P1083, DOI 10.1016/S0039-9140(99)00020-X; Jiang R, 2004, JAMA-J AM MED ASSOC, V291, P711, DOI 10.1001/jama.291.6.711; PETERSEN K, 1989, TALANTA, V36, P49, DOI 10.1016/0039-9140(89)80081-5; Nakano S, 2003, TALANTA, V61, P203, DOI 10.1016/S0039-9140(03)00241-8; Teshima N, 2007, ANAL SCI, V23, P1, DOI 10.2116/analsci.23.1; REIS BF, 1994, ANAL CHIM ACTA, V293, P129, DOI 10.1016/0003-2670(94)00090-5; HEYLIGER CE, 1985, SCIENCE, V227, P1474, DOI 10.1126/science.3156405; Nakano S, 2004, BUNSEKI KAGAKU, V53, P255, DOI 10.2116/bunsekikagaku.53.255; Satinsky D, 2003, ANAL CHIM ACTA, V499, P205, DOI 10.1016/S0003-2670(03)00625-1; Watla-Iad K, 2007, ANAL CHIM ACTA, V604, P139, DOI 10.1016/j.aca.2007.10.010; Fortes PR, 2006, ANAL CHIM ACTA, V572, P316, DOI 10.1016/j.aca.2006.05.046; Huang YM, 2012, TALANTA, V93, P86, DOI 10.1016/j.talanta.2012.01.050; BONTCHEV PR, 1972, TALANTA, V19, P675, DOI 10.1016/0039-9140(72)80207-8; Kawashima T., 2000, ENCY ANAL CHEM APPL, P11034; Kitta T., 2003, PHARMACOMETRICS, V64, P77; Ratanawimarnwong N., 2014, J FLOW INJECTION ANA, V31, P15; Sakurada K., 1999, NIPPON RINSHO, V750, P273; Teshima N, 2009, TALANTA, V79, P517, DOI 10.1016/j.talanta.2009.04.018; Tsuji A, 2000, TALANTA, V52, P161, DOI 10.1016/S0039-9140(99)00340-9; Watanabe T, 1999, CHEM LETT, P521	35	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0039-9140	1873-3573		TALANTA	Talanta	NOV 1	2015	144						844	850		10.1016/j.talanta.2015.07.006		7	Chemistry, Analytical	Chemistry	CU2IC	WOS:000363346200116		
J	Yuan, MF; Fukuda, K; Dohi, H; Uzawa, H; Nishida, Y				Yuan, Mengfei; Fukuda, Kazuo; Dohi, Hirofumi; Uzawa, Hirotaka; Nishida, Yoshihiro			Comparative analyses of helical properties in asymmetric 1,2-diacyl-sn-glycerols by means of circular dichroism and proton NMR spectroscopies: notable effects of substituting groups at sn-3 position	TETRAHEDRON-ASYMMETRY			English	Article							ABSOLUTE-CONFIGURATION; PREFERRED CONFORMATION; PHOSPHOLIPIDS; GLYCEROLS; PHOSPHATIDYLCHOLINE; STEREOCHEMISTRY; BONDS	The titled 1,2-diacyl-sn-glycerol constitutes a common asymmetric backbone of cell-membrane phospholipids and glycolipids. The acyclic sn-glycerol skeleton allows flexible conformational changes by free rotation along each of the glycerol sn-1,2 and sn-2,3 C-C single bonds in solution. It is generally believed, however, that the sn-1,2 tail position adopts two gauche conformers [gt-(+) and gg-(-)] near exclusively to display an ordered conformation. In the present study, our interest was focused on the fact that the two gauche conformers possess helical signs which are the reverse of each other. We examined (+)- and (-)-chirality arising from the disparity between the two helical conformers using a series of 1,2-dibenzoyl-sn-glycerols 2-8 as model compounds, which possess 1,2-dibenzoate chromophore for circular dichroism analysis, while having variable substituent groups at the sn-3 position. First, the analysis was conducted with the circular dichroism 'dibenzoate exciton coupling methodology' of Nakanishi and Harada followed by H-1 NMR analysis to calculate the time-averaged populations (%) of the three staggered conformers, that is, gt-(+), gg-(-) and tg. The results are discussed in terms of the 'helicity index' which covers information on the sign and intensity, of circular dichroism bands in circular dichroism analysis as well as on the helical disparity (%) and the total volume (%) of the two helical conformers in H-1 NMR analysis. The two independent spectroscopic approaches were well matched in the estimation of the helical index, which in turn allowed us to conclude that the sn-3 substituting groups have diverse effects on the helical properties of 1,2-diacyl-sn-glycerols in solution. (C) 2015 Elsevier Ltd. All rights reserved.	[Yuan, Mengfei; Fukuda, Kazuo; Dohi, Hirofumi; Nishida, Yoshihiro] Chiba Univ, Grad Sch Adv Integrat Sci, Dept Nanobiol, Matsudo, Chiba 2718510, Japan; [Fukuda, Kazuo] Chiba Univ, Ctr Analyt Instrumentat, Chiba 2638522, Japan; [Uzawa, Hirotaka] Natl Inst Adv Ind Sci & Technol, Nanomat Res Inst, Tsukuba, Ibaraki 3058565, Japan	Nishida, Y (reprint author), Chiba Univ, Grad Sch Adv Integrat Sci, Dept Nanobiol, Matsudo, Chiba 2718510, Japan.	YNishida@faculty.chiba-u.jp			Japan Society for the Promotion of Science [KAKENHI 26450146]	This work was supported by the Grant in aid from the Japan Society for the Promotion of Science (KAKENHI 26450146). We thank all staffs at Center for Analytical Instrumentation of Chiba University for their technical supports for NMR and other spectroscopic measurements.	UZAWA H, 1989, AGR BIOL CHEM TOKYO, V53, P2327; HAASNOOT CAG, 1980, TETRAHEDRON, V36, P2783, DOI 10.1016/0040-4020(80)80155-4; [Anonymous], NOM LIP; MARCHESSAULT RH, 1979, BIOPOLYMERS, V18, P2369, DOI 10.1002/bip.1979.360180925; Feller SE, 2000, J PHYS CHEM B, V104, P7510, DOI 10.1021/jp0007843; NISHIDA Y, 1989, AGR BIOL CHEM TOKYO, V53, P2319; HAUSER H, 1981, BIOCHIM BIOPHYS ACTA, V650, P21, DOI 10.1016/0304-4157(81)90007-1; Kirschner KN, 2001, P NATL ACAD SCI USA, V98, P10541, DOI 10.1073/pnas.191362798; HAUSER H, 1988, J AM CHEM SOC, V110, P1054, DOI 10.1021/ja00212a009; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; WIESLER WT, 1989, J AM CHEM SOC, V111, P3446, DOI 10.1021/ja00191a061; HAUSER H, 1988, BIOCHEMISTRY-US, V27, P9166, DOI 10.1021/bi00426a014; Rockwell GD, 1998, J AM CHEM SOC, V120, P10953, DOI 10.1021/ja981958l; Nishida Y, 2001, ORG LETT, V3, P1, DOI 10.1021/ol006590n; Krishnamurty S, 2008, J PHYS CHEM B, V112, P13433, DOI 10.1021/jp804934d; Carrasco S, 2007, TRENDS BIOCHEM SCI, V32, P27, DOI 10.1016/j.tibs.2006.11.004; UZAWA H, 1990, J ORG CHEM, V55, P116, DOI 10.1021/jo00288a024; HAMILTON JA, 1991, J BIOL CHEM, V266, P1177; OHRUI H, 1987, CAN J CHEM, V65, P1145, DOI 10.1139/v87-191; Awai K, 2014, P NATL ACAD SCI USA, V111, P13571, DOI 10.1073/pnas.1403708111; Duin J., 1986, J ORG CHEM, V51, P1298; Harada N., 1983, CIRCULAR DICHROIC SP; Hong M., 1996, BIOCHEMISTRY-US, V35, P8355; Nishida Y, 2012, BEILSTEIN J ORG CHEM, V8, DOI 10.3762/bjoc.8.70; NISHIDA Y, 1988, J CARBOHYD CHEM, V7, P239, DOI 10.1080/07328308808058917; Ohrui H., 1983, AGR BIOL CHEM TOKYO, V47, P1750; Uzawa H., 1989, CHEM COMMUN, P862; WOLFE S, 1972, ACCOUNTS CHEM RES, V5, P102, DOI 10.1021/ar50051a003	28	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0957-4166			TETRAHEDRON-ASYMMETR	Tetrahedron-Asymmetry	NOV 1	2015	26	20					1138	1144		10.1016/j.tetasy.2015.08.012		7	Chemistry, Inorganic & Nuclear; Chemistry, Organic; Chemistry, Physical	Chemistry	CV0AE	WOS:000363908100004		
J	Tomizawa, K; Suda, K; Takemoto, T; Mizuno, T; Kuroda, H; Sakakura, N; Iwasaki, T; Sakaguchi, M; Kuwano, H; Mitsudomi, T; Sakao, Y				Tomizawa, Kenji; Suda, Kenichi; Takemoto, Toshiki; Mizuno, Tetsuya; Kuroda, Hiroaki; Sakakura, Noriaki; Iwasaki, Takuya; Sakaguchi, Masahiro; Kuwano, Hiroyuki; Mitsudomi, Tetsuya; Sakao, Yukinori			Prognosis and segment-specific nodal spread of primary lung cancer in the right lower lobe	THORACIC CANCER			English	Article						Basal segment; primary lung cancer; prognosis; segment-specific nodal spread; superior segment	SUBLOBAR RESECTION; METASTASIS; DISSECTION; LOBECTOMY; TUMORS	BackgroundAlthough lobe-specific nodal spread of primary lung cancer has been recently described, segment-specific nodal spread remains unclear. We investigated the frequency of hailer and mediastinal lymph node involvement and survival in patients with tumors located in the superior segment (SS) and basal segment (BS) in the right lower lobe. MethodsTwo hundred and sixty-three patients with primary lung cancer originating in the right lower lobe underwent lobectomy with systematic mediastinal lymph node dissection. Patients were categorized into two groups: SS (n=114) or BS (n=149). ResultsFrequencies of metastasis to station 11s and 11i were significantly higher in the SS (P<0.0001) and BS groups (P=0.022), respectively. Both the SS and BS groups showed a high frequency of subcarinal mediastinal zone (station 7) metastasis (96.9% and 90.6%, respectively; P=0.271). The frequencies of superior mediastinal zone (station 2R and 4R) metastasis were 37.5% in the SS and 35.8% in the BS group (P=0.878). In patients with pN2 disease, three-year disease-free survival was significantly shorter in the SS (22.6%) than the BS group (42.1%; P=0.020). In the BS group, the independent predictive factors of a poor or good prognosis were metastasis to station 11i or skip metastasis, respectively; however, we did not detect an independent prognostic factor in the SS group. In the right lower lung lobe, there was no segment-specific nodal spread. ConclusionWhen segmentectomy is undertaken, mediastinal lymph node dissection should be performed in proportion to lobectomy.	[Tomizawa, Kenji; Suda, Kenichi; Takemoto, Toshiki; Iwasaki, Takuya; Sakaguchi, Masahiro; Mitsudomi, Tetsuya] Kinki Univ, Fac Med, Dept Surg, Div Thorac Surg, Osaka, Japan; [Tomizawa, Kenji; Mizuno, Tetsuya; Kuroda, Hiroaki; Sakakura, Noriaki; Sakao, Yukinori] Aichi Canc Ctr Hosp, Dept Thorac Surg, Nagoya, Aichi 4648681, Japan; [Tomizawa, Kenji; Kuwano, Hiroyuki] Gunma Univ, Grad Sch Med, Dept Gen Surg Sci, Maebashi, Gumma 371, Japan	Sakao, Y (reprint author), Aichi Canc Ctr Hosp, Dept Thorac Surg, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.	ysakao@aichi-cc.jp					Okada M, 2012, INTERACT CARDIOV TH, V14, P5, DOI 10.1093/icvts/ivr065; CAHAN WG, 1951, J THORAC SURG, V22, P449; Mountain CF, 1997, CHEST, V111, P1710, DOI 10.1378/chest.111.6.1710; Rusch VW, 2009, J THORAC ONCOL, V4, P568, DOI 10.1097/JTO.0b013e3181a0d82e; Ichinose Y, 2001, J THORAC CARDIOV SUR, V122, P803, DOI 10.1067/mtc.2001.116473; Legras A, 2014, ANN THORAC SURG, V97, P1156, DOI 10.1016/j.athoracsur.2013.12.047; Watanabe S, 2008, ANN THORAC SURG, V85, P1026, DOI 10.1016/j.athoracsur.2007.10.076; Yoshikawa K, 2002, ANN THORAC SURG, V73, P1055, DOI 10.1016/S0003-4975(01)03466-X; Asamura H, 1999, J THORAC CARDIOV SUR, V117, P1102, DOI 10.1016/S0022-5223(99)70246-1; Shapiro M, 2013, CHEST, V144, P1615, DOI 10.1378/chest.12-3069; Okada M, 2006, J THORAC CARDIOV SUR, V132, P769, DOI 10.1016/j.jtcvs.2006.02.063; Naruke T, 1999, EUR J CARDIO-THORAC, V16, pS17, DOI 10.1016/S1010-7940(99)00178-5; Okada M, 2005, J THORAC CARDIOV SUR, V129, P825, DOI 10.1016/j.jtcvs.2004.06.016; CAHAN WG, 1960, J THORAC CARDIOV SUR, V39, P555; Prenzel KL, 2003, J SURG ONCOL, V82, P256, DOI 10.1002/jso.10219	15	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1759-7706	1759-7714		THORAC CANCER	Thorac. Cancer	NOV	2015	6	6					672	677		10.1111/1759-7714.12235		6	Oncology; Respiratory System	Oncology; Respiratory System	CU9UK	WOS:000363891000002		
J	Jinno, C; Morimoto, N; Mahara, A; Liem, PH; Sakamoto, M; Ogino, S; Kakudo, N; Inoie, M; Fujisato, T; Kusumoto, K; Suzuki, S; Yamaoka, T				Jinno, Chizuru; Morimoto, Naoki; Mahara, Atsushi; Pham Hieu Liem; Sakamoto, Michiharu; Ogino, Shuichi; Kakudo, Natsuko; Inoie, Masukazu; Fujisato, Toshia; Kusumoto, Kenji; Suzuki, Shigehiko; Yamaoka, Tetsuji			Inactivation of Human Nevus Tissue Using High Hydrostatic Pressure for Autologous Skin Reconstruction: A Novel Treatment for Giant Congenital Melanocytic Nevi	TISSUE ENGINEERING PART C-METHODS			English	Article							ARTIFICIAL DERMIS; MANAGEMENT; CELLS; SUBSTITUTES; RISK; ALLOGRAFTS; MELANOMA; INTEGRA; GRAFTS; BONE	Giant congenital melanocytic nevi are intractable lesions associated with a risk of melanoma. High hydrostatic pressure (HHP) technology is a safe physical method for producing decellularized tissues without chemicals. We have reported that HHP can inactivate cells present in various tissues without damaging the native extracellular matrix (ECM). The objectives of this study were to inactivate human nevus tissue using HHP and to explore the possibility of reconstructing skin using inactivated nevus in combination with cultured epidermis (CE). Human nevus specimens 8mm in diameter were pressurized by HHP at 100, 200, 500, and 1000MPa for 10min. The viability of specimens just after HHP, outgrowth of cells, and viability after cultivation were evaluated to confirm the inactivation by HHP. Histological evaluation using hematoxylin-eosin staining and immunohistochemical staining for type IV collagen was performed to detect damage to the ECM of the nevus. The pressurized nevus was implanted into the subcutis of nude mice for 6 months to evaluate the retention of human cells. Then, human CE was applied on the pressurized nevus and implanted into the subcutis of nude mice. The viability of pressurized nevus was not detected just after HHP and after cultivation, and outgrowth of fibroblasts was not observed in the 200, 500, and 1000MPa groups. Human cells were not observed after 6 months of implantation in these groups. No apparent damage to the ECM was detected in all groups; however, CE took on nevus in the 200 and 500MPa groups, but not in the 1000MPa group. These results indicate that human nevus tissue was inactivated by HHP at more than 200MPa; however, HHP at 1000MPa might cause damage that prevents the take of CE. In conclusion, all cells in nevus specimens were inactivated after HHP at more than 200MPa and this inactivated nevus could be used as autologous dermis for covering full-thickness skin defects after nevus removal. HHP between 200 and 500MPa will be optimal to reconstruct skin in combination with cultured epidermal autograft without damage to the ECM.	[Jinno, Chizuru; Pham Hieu Liem; Sakamoto, Michiharu; Ogino, Shuichi; Suzuki, Shigehiko] Kyoto Univ, Grad Sch Med, Dept Plast & Reconstruct Surg, Kyoto, Japan; [Morimoto, Naoki; Kakudo, Natsuko; Kusumoto, Kenji] Kansai Med Univ, Dept Plast & Reconstruct Surg, Hirakata, Osaka 5731010, Japan; [Mahara, Atsushi; Yamaoka, Tetsuji] Natl Cerebral & Cardiovasc Ctr, Res Inst, Dept Biomed Engn, Suita, Osaka, Japan; [Inoie, Masukazu] Japan Tissue Engn Co Ltd, Gamagori, Japan; [Fujisato, Toshia] Osaka Inst Technol, Dept Biomed Engn, Osaka 535, Japan	Morimoto, N (reprint author), Kansai Med Univ, Dept Plast & Reconstruct Surg, 2-5-1 Shin Machi, Hirakata, Osaka 5731010, Japan.	morimotn@hirakata.kmu.ac.jp			Japan Science and Technology Agency (JST); Health and Labor Sciences Research Grants; Ministry of Education, Culture, Sports, Science and Technology, Japan	This work was supported partially by the Center of Innovation Program from the Japan Science and Technology Agency (JST), by Health and Labor Sciences Research Grants, and by a Grant of Translational Research Network Program from the Ministry of Education, Culture, Sports, Science and Technology, Japan.	Alam M., 2001, DERMATOLOGIC THERAPY, V14, P55, DOI 10.1046/j.1529-8019.2001.014001055.x; Macchiarini P, 2008, LANCET, V372, P2023, DOI 10.1016/S0140-6736(08)61598-6; Tannous ZS, 2005, J AM ACAD DERMATOL, V52, P197, DOI 10.1016/j.jaad.2004.07.020; Hashimoto Y, 2011, BIOMATERIALS, V32, P7060, DOI 10.1016/j.biomaterials.2011.06.008; Rivalain N, 2010, BIOTECHNOL ADV, V28, P659, DOI 10.1016/j.biotechadv.2010.04.001; Zaal LH, 2005, PLAST RECONSTR SURG, V116, P1902, DOI 10.1097/01.prs.0000189205.85968.12; Hashimoto Y, 2010, BIOMATERIALS, V31, P3941, DOI 10.1016/j.biomaterials.2010.01.122; Schauwecker J, 2011, ANTICANCER RES, V31, P1235; Suzuki S, 2013, J PLAST RECONSTR AES, V66, pE229, DOI 10.1016/j.bjps.2013.03.018; Earle SA, 2005, J CRANIOFAC SURG, V16, P904, DOI 10.1097/01.scs.0000180485.20043.d5; Gonfiotti A, 2014, LANCET, V383, P238, DOI 10.1016/S0140-6736(13)62033-4; Funamoto S, 2010, BIOMATERIALS, V31, P3590, DOI 10.1016/j.biomaterials.2010.01.073; Turkmen A, 2010, DERMATOL SURG, V36, P1554, DOI 10.1111/j.1524-4725.2010.01641.x; Liem PH, 2013, J ARTIF ORGANS, V16, P332, DOI 10.1007/s10047-013-0708-2; GREEN H, 1979, P NATL ACAD SCI USA, V76, P5665, DOI 10.1073/pnas.76.11.5665; Fu RH, 2014, CELL TRANSPLANT, V23, P621, DOI 10.3727/096368914X678382; Hermans MHE, 2014, BURNS, V40, P408, DOI 10.1016/j.burns.2013.08.020; Hayashi M, 2014, ANN PLAS SURG, V73, P25, DOI 10.1097/SAP.0000000000000200; Arad E, 2014, PLAST RECONSTR SURG, V133, P367, DOI 10.1097/01.prs.0000436852.32527.8a; Follonier S, 2012, APPL MICROBIOL BIOT, V93, P1805, DOI 10.1007/s00253-011-3854-6; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; Diehl P, 2008, ANTICANCER RES, V28, P3877; Watt AJ, 2004, PLAST RECONSTR SURG, V113, P1968, DOI 10.1097/01.prs.0000122209.10277.2a; Dantzer E, 2001, BRIT J PLAST SURG, V54, P659, DOI 10.1054/bjps.2001.3684; TRAU H, 1986, J DERMATOL SURG ONC, V12, P984; Mahara A, 2015, BIOMATERIALS, V58, P54, DOI 10.1016/j.biomaterials.2015.04.031; Philandrianos C, 2012, BURNS, V38, P820, DOI 10.1016/j.burns.2012.02.008; Crapo PM, 2011, BIOMATERIALS, V32, P3233, DOI 10.1016/j.biomaterials.2011.01.057; Hermans MHE, 2011, BURNS, V37, P873, DOI 10.1016/j.burns.2011.01.007; Kanemura Y, 2002, J NEUROSCI RES, V69, P869, DOI 10.1002/jnr.10377; Abai B, 2004, PLAST RECONSTR SURG, V114, P162, DOI 10.1097/01.PRS.0000129078.41960.92; Arneja Jugpal S, 2009, Plast Reconstr Surg, V124, p1e, DOI 10.1097/PRS.0b013e3181ab11be; Mahara A., 2014, BIOMED RES INT, V2014; Mcheik Jiad N, 2014, Plast Reconstr Surg Glob Open, V2, pe218, DOI 10.1097/GOX.0000000000000176; Morimoto N., 2015, BIOMED RES INT, V2015; Negishi J, 2015, J TISSUE ENG REGEN M, V9, pE144, DOI 10.1002/term.1662; Nicoletti G, 2015, J TISSUE ENG REGEN M, V9, P460, DOI 10.1002/term.1939; Wendt JR, 2004, PLAST RECONSTR SURG, V113, P1347, DOI 10.1097/01.PRS.0000112741.11726.91	38	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1937-3384	1937-3392		TISSUE ENG PART C-ME	Tissue Eng. Part C-Methods	NOV 1	2015	21	11					1178	1187		10.1089/ten.tec.2015.0054		10	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology	Cell Biology; Biotechnology & Applied Microbiology	CU9VC	WOS:000363893100008		
J	Cohen, M; Villegas, J; Barfield, W				Cohen, Michael; Villegas, Julian; Barfield, Woodrow			Special issue on spatial sound in virtual, augmented, and mixed-reality environments	VIRTUAL REALITY			English	Editorial Material									[Cohen, Michael; Villegas, Julian] Univ Aizu, Aizu Wakamatsu, Fukushima, Japan	Cohen, M (reprint author), Univ Aizu, Aizu Wakamatsu, Fukushima, Japan.	mcohen@u-aizu.ac.jp					Barfield W, FUNDAMENTALS WEARABL	1	0	0	SPRINGER LONDON LTD	LONDON	236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND	1359-4338	1434-9957		VIRTUAL REAL-LONDON	Virtual Real.	NOV	2015	19	3-4			SI		147	148		10.1007/s10055-015-0279-z		2	Computer Science, Interdisciplinary Applications; Computer Science, Software Engineering; Imaging Science & Photographic Technology	Computer Science; Imaging Science & Photographic Technology	CU9KG	WOS:000363862800001		
J	Kim, S; King, R; Kamekawa, T				Kim, Sungyoung; King, Richard; Kamekawa, Toru			A cross-cultural comparison of salient perceptual characteristics of height channels for a virtual auditory environment	VIRTUAL REALITY			English	Article						Height-channel perception; Multichannel-reproduced virtual auditory environment; Cross-cultural comparison		Perceptual characteristics of virtual auditory environments from three listener groups were compared. To generate convincing and pleasing virtual auditory environments, acoustic impulse responses were measured in two venues using an innovative microphone array and convolved with two anechoic recordings. Subsequently, the convolved sound sources were assigned to loudspeakers (five horizontal channels and four height channels), and inter-channel level balances were optimized. The authors conducted a controlled listening test with two variables: height-channel configurations (eight conditions) and stimuli (four conditions-two musical selections times and two target venues) to determine the influence of (1) two control variables on the perceived appropriateness of virtual auditory environments and (2) the cultural background of three listener groups composed of participants from Canada (group 1, 11 subjects), the USA (group 2, 12 subjects), and Japan (group 3, 14 subjects). The data analysis revealed that the configuration variable (the height position of the loudspeakers) has a greater influence on perceived appropriateness than the stimulus variable for all three groups. In addition, the results showed that although group 1 data had a similar listening response pattern to group 2, the response of group 3 was different. A subsequent analysis of reported descriptors found that groups 1 and 2 chose height configurations that generated a "frontal" and "narrow" impression as a more appropriate virtual auditory environment, while group 3 chose the same characteristics but as a less appropriate environment. Groups 1 and 2 also described a less appropriate auditory environment with "wide, spacious, and surrounding" images that again were described by group 3 as more appropriate. While room acoustics and loudspeaker size also contributed to the overall modulation of listeners' judgment, the findings support the idea that cultural background affects perceptual responses to spatial sound and is therefore important in rendering a homogeneous experience of a virtual auditory environment for listeners in remote spaces.	[Kim, Sungyoung] Rochester Inst Technol, Rochester, NY 14618 USA; [King, Richard] McGill Univ, Montreal, PQ, Canada; [Kamekawa, Toru] Tokyo Univ Arts, Tokyo, Japan	Kim, S (reprint author), Rochester Inst Technol, Rochester, NY 14618 USA.	sxkiee@rit.edu; richard.king@mcgill.ca; kamekawa@ms.geidai.ac.jp					Anderson L. M., 1984, Journal of Arboriculture, V10, P45; ALWIN DF, 1985, PUBLIC OPIN QUART, V49, P535, DOI 10.1086/268949; OLIVE SE, 1989, J AUDIO ENG SOC, V37, P539; Varnum MEW, 2010, CURR DIR PSYCHOL SCI, V19, P9, DOI 10.1177/0963721409359301; AURO Technologies, 2013, AURO 3D LIST FORM; Blesser B, 2006, SPACES SPEAKS ARE YO; Feys J, 2015, NPINTFACTREP NONPARA; Giragama CNW, 2003, P AUD ENG SOC 115 IN; Hamasaki K, 2005, P AUD ENG SOC 118 IN; Herrington J., 1996, J SERV MARK, V10, P26, DOI DOI 10.1108/08876049610114249; Holman T, 2007, MUSIC TECHNOLOGY SER; ITU-R, 2012, MULT STER PHON SOUND; Iwamiya S., 1997, Journal of the Acoustical Society of Japan (E), V18; Karampourniotis A, 2014, J ACOUST SOC AM, V135, P2282; Kim S, 2013, P AUD ENG SOC 135 IN; Kim S, 2007, P 13 REG CONV AES TO; Kim S, 2006, P AUD ENG SOC 28 INT; Koichiro H, 2002, P AUD ENG SOC 113 IN; Martens WL, 2008, J ACOUST SOC AM, V123, P3690, DOI 10.1121/1.2935071; Martens WL, 2007, P AUD ENG SOC 122 IN; Namba S., 1991, Journal of the Acoustical Society of Japan (E), V12; Olive SE, 2004, P AUD ENG SOC 116 IN; Olive SE, 2004, P AUD ENG SOC 117 IN; Olive SE, 2014, P AUD ENG SOC 135 IN; Rumsey F, 2001, SPATIAL AUDIO MUSIC; Woszczyk W, 2009, P 16 INT C SOUND VIB	26	0	0	SPRINGER LONDON LTD	LONDON	236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND	1359-4338	1434-9957		VIRTUAL REAL-LONDON	Virtual Real.	NOV	2015	19	3-4			SI		149	160		10.1007/s10055-015-0269-1		12	Computer Science, Interdisciplinary Applications; Computer Science, Software Engineering; Imaging Science & Photographic Technology	Computer Science; Imaging Science & Photographic Technology	CU9KG	WOS:000363862800002		
J	Villegas, J				Villegas, Julian			Locating virtual sound sources at arbitrary distances in real-time binaural reproduction	VIRTUAL REALITY			English	Article						Headphone reproduction; Binaural hearing; Localization of virtual sound sources; Pure-data	PERCEPTION; RESOLUTION; DISPLAY; DESIGN	A real-time system for sound spatialization via headphones is presented. Conventional headphone spatialization techniques effectively place sources on the surface of a virtual sphere around the listener. In the new system, sources can be spatialized at different distances from a listener by interpolating head-related impulse responses (HRIRs) measured between 20 and 160 cm. These HRIRs are stored in different databases depending on the audio sampling rate. To ease the real-time constraints, users can choose the number of HRIR taps used in the convolution, and an alternative interpolation technique (simplex interpolation) was implemented instead of trilinear interpolation. Subjective tests showed that such simplifications yield satisfactory spatialization for some angles and distances.	Univ Aizu, Comp Arts Lab, Aizu Wakamatsu, Fukushima 9658580, Japan	Villegas, J (reprint author), Univ Aizu, Comp Arts Lab, Aizu Wakamatsu, Fukushima 9658580, Japan.	julian@u-aizu.ac.jp			University of Aizu [P-14]	This research was funded by the Competitive Research Funds (P-14) of the University of Aizu.	Algazi VR, 2001, PROCEEDINGS OF THE 2001 IEEE WORKSHOP ON THE APPLICATIONS OF SIGNAL PROCESSING TO AUDIO AND ACOUSTICS, P99, DOI 10.1109/ASPAA.2001.969552; SCHROEDER M, 1961, J ACOUST SOC AM, V33, P1061, DOI 10.1121/1.1908892; ASHMEAD DH, 1990, PERCEPT PSYCHOPHYS, V47, P326, DOI 10.3758/BF03210871; BERKHOUT AJ, 1993, J ACOUST SOC AM, V93, P2764, DOI 10.1121/1.405852; Blauert J, 2012, ARCH ACOUST, V37, P5, DOI 10.2478/v10168-012-0002-y; Pei SC, 2006, IEEE T CIRCUITS-II, V53, P1113, DOI 10.1109/TCSII.2006.882193; Bellotti F, 2002, PERS UBIQUIT COMPUT, V6, P155, DOI 10.1007/s007790200016; Qu TS, 2009, IEEE T AUDIO SPEECH, V17, P1124, DOI 10.1109/TASL.2009.2020532; Ikei Y, 2006, P IEEE VIRT REAL ANN, P183, DOI 10.1109/VR.2006.141; Nelson WT, 1998, HUM FACTORS, V40, P452, DOI 10.1518/001872098779591304; Kearney G, 2012, ACTA ACUST UNITED AC, V98, P61, DOI 10.3813/AAA.918492; Peirce JW, 2007, J NEUROSCI METH, V162, P8, DOI 10.1016/j.jneumeth.2006.11.017; Bronkhorst AW, 1999, NATURE, V397, P517, DOI 10.1038/17374; BEGAULT DR, 1994, J AUDIO ENG SOC, V42, P819; Sodnik J, 2005, APPL ACOUST, V66, P1219, DOI 10.1016/j.apacoust.2005.04.003; Spors S, 2013, P IEEE, V101, P1920, DOI 10.1109/JPROC.2013.2264784; Zahorik P, 2005, ACTA ACUST UNITED AC, V91, P409; Kan A, 2009, J ACOUST SOC AM, V125, P2233, DOI 10.1121/1.3081395; GARDNER WG, 1995, J ACOUST SOC AM, V97, P3907, DOI 10.1121/1.412407; Chen L, 2008, ICNC 2008: FOURTH INTERNATIONAL CONFERENCE ON NATURAL COMPUTATION, VOL 6, PROCEEDINGS, P162, DOI 10.1109/ICNC.2008.461; Hawksford MO, 1997, J AUDIO ENG SOC, V45, P37; Pollow M, 2012, ACTA ACUST UNITED AC, V98, P72, DOI 10.3813/AAA.918493; Apple Inc, 2015, ITUNES CONN DEV GUID; Blauert J., 1997, SPATIAL HEARING PSYC; Bruel PV, 1962, 1 BRUEL KJAER; Cohen M, 2015, FUNDAMENTALS WEARABL, P309; Doukhan D, 2009, P 3 PUR DAT INT CONV; Estrella J, 2010, THESIS TU BERLIN; Gamper H, 2014, THESIS AALTO U; Gardner WG, 1995, TECHNICAL REPORT; Gardner WG, 1998, 3D AUDIO USING LOUDS; Geier M, 2012, 27 TONM VDT INT CONV; GERZON MA, 1973, J AUDIO ENG SOC, V21, P2; Grosjean P, 2013, MLEARNING MACHINE LE; Guillot P, 2014, P JOINT ICMC SMC C, P855; Hemingway P, 2002, TECHNICAL REPORT; Hosoe S, 2005, FOR AC 2005, P2539; Jot J-M, 1995, P 98 AUD ENG SOC CON; Kim S, 2009, AUD ENG SOC CONV 127; Majdak P, 2013, P 134 AUD ENG SOC CO; Martens W. L., 2003, Acoustical Science and Technology, V24, DOI 10.1250/ast.24.220; McGee R, 2011, THESIS U MICHIGAN; McKinley RL, 1997, FLIGHT DEMONSTRATION, P683; Murphy D, 2011, SPATIAL SOUND COMPUT, P287; Musil T, 2005, P INT C DIG AUD EFF; Penha R, 2013, P SOUND MUS COMP C; Rothauser E. H., 1969, IEEE T AUDIO ELECTRO, V17, P225, DOI DOI 10.1109/TAU.1969.1162058; Sanuki W, 2014, P 136 AUD ENG SOC CO; Smith J, 2008, COMPUTATIONAL ACOUST; Villegas J., 2010, P 9 INT C VR CONT IT; Villegas J, 2013, P 135 AUD ENG SOC CO; Villegas J, 2010, P 135 AUD ENG SOC IN; Warusfel O, 2003, LISTEN HRTF DATABASE; Wenzel E. M., 1993, P IEEE WORKSH APPL S, P102, DOI 10.1109/ASPAA.1993.379986; Wierstorf H, 2011, P 130 AUD ENG SOC CO; Wright M., 2005, ORG SOUND, V10, P193, DOI 10.1017/S1355771805000932; Xiang P, 2005, P 11 INT C AUT DISPL	57	0	0	SPRINGER LONDON LTD	LONDON	236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND	1359-4338	1434-9957		VIRTUAL REAL-LONDON	Virtual Real.	NOV	2015	19	3-4			SI		201	212		10.1007/s10055-015-0278-0		12	Computer Science, Interdisciplinary Applications; Computer Science, Software Engineering; Imaging Science & Photographic Technology	Computer Science; Imaging Science & Photographic Technology	CU9KG	WOS:000363862800005		
J	Lam, J; Kapralos, B; Kanev, K; Collins, K; Hogue, A; Jenkin, M				Lam, Jonathan; Kapralos, Bill; Kanev, Kamen; Collins, Karen; Hogue, Andrew; Jenkin, Michael			Sound localization on a horizontal surface: virtual and real sound source localization	VIRTUAL REALITY			English	Article						Tabletop computer; Surface computer; Spatial sound; Amplitude panning		As the technology improves and their cost decreases, tabletop computers and their inherent ability to promote collaboration amongst users are gaining in popularity. Their use in virtual reality-based applications including virtual training environments and gaming where multi-user interactions are common is poised to grow. However, before tabletop computers become widely accepted, there are many questions with respect to spatial sound production and reception for these devices that need to be addressed. Previous work (Lam et al. in ACM Comput Entertain 12(2): 4: 1-4: 19, 2014) has seen the development of loudspeaker-based amplitude panning spatial sound techniques to spatialize a sound to a position on a plane just above a tabletop computer's (horizontal) surface. Although it has been established that the localization of these virtual sources is prone to error, there is a lack of ground truth (reference) data with which to compare these earlier results. Here, we present the results of an experiment that measured sound localization of an actual sound source on a horizontal surface, thus providing such ground truth data. This ground truth data were then compared with the results of previous amplitude panning-based spatial sound techniques for tabletop computing displays. Preliminary results reveal that no substantial differences exist between previous amplitude panning results and the ground truth data reported here, indicating that amplitude panning is a viable spatial sound technique for tabletop computing and horizontal displays in general.	[Lam, Jonathan; Kapralos, Bill; Hogue, Andrew] Univ Ontario, Inst Technol, Oshawa, ON, Canada; [Kanev, Kamen] Shizuoka Univ, Hamamatsu, Shizuoka, Japan; [Collins, Karen] Univ Waterloo, Waterloo, ON N2L 3G1, Canada; [Jenkin, Michael] York Univ, Toronto, ON M3J 2R7, Canada	Kapralos, B (reprint author), Univ Ontario, Inst Technol, Oshawa, ON, Canada.	jonathan.lam@uoit.ca; bill.kapralos@uoit.ca; kanev@rie.shizuoka.ac.jp; collinsk@uwaterloo.ca; andrew.hogue@uoit.ca; jenkin@cse.yorku.ca			Research Institute of Electronics, Shizuoka University; Social Science and Humanities Research Council of Canada; Natural Sciences and Engineering Research Council of Canada	Funding to support this work has been provided by the Research Institute of Electronics, Shizuoka University, in the form of a Cooperative Research Projects Grant, the Social Science and Humanities Research Council of Canada, and the Natural Sciences and Engineering Research Council of Canada.	Anatomage Inc, 2015, AN TABL VIRT DISS; Algazi VR, 2011, IEEE SIGNAL PROC MAG, V28, P33, DOI 10.1109/MSP.2010.938756; PERROTT DR, 1990, J ACOUST SOC AM, V87, P1728, DOI 10.1121/1.399421; Alais D, 2004, CURR BIOL, V14, P257, DOI 10.1016/j.cub.2004.01.029; Pulkki V, 2001, J AUDIO ENG SOC, V49, P739; Wallace JR, 2009, PERS UBIQUIT COMPUT, V13, P569, DOI 10.1007/s00779-009-0241-8; Sasamoto Y, 2013, 2013 INTERNATIONAL JOINT CONFERENCE ON AWARENESS SCIENCE AND TECHNOLOGY & UBI-MEDIA COMPUTING (ICAST-UMEDIA), P713, DOI 10.1109/ICAwST.2013.6765530; Zhou ZY, 2007, IEEE T SYST MAN CY A, V37, P262, DOI 10.1109/TSMCA.2006.886376; CHOWNING JM, 1971, J AUDIO ENG SOC, V19, P2; Parise CV, 2014, P NATL ACAD SCI USA, V111, P6104, DOI 10.1073/pnas.1322705111; Antani L, 2012, ACM T GRAPHIC, V31, P1; Blauert J, 1996, PSYCHOPHYSICS HUMAN; Bortolaso C, 2014, P 19 INT COMM CONTR, P37; Cohen M, 1995, VIRTUAL ENV ADV INTE, P291; Cohen M, 2010, P 9 ACM SIGGRAPH C V, P95, DOI 10.1145/1900179.1900199; Dubrowski A, 2015, P 6 INT C INF INT SY; Gardner W, 1998, 3 D AUDIO USING LOUD; Han JY, 2005, P 18 ACM S US INT SO, P235; Kapralos B, 2008, PRESENCE-TELEOP VIRT, V17, P524; Kruger R., 2004, Computer Supported Cooperative Work: The Journal of Collaborative Computing, V13, DOI 10.1007/s10606-004-5062-8; Lam J, 2014, ACM COMPUT ENTERTAIN, V12, P4; Makino H, 1996, P 18 ANN INT C IEEE, P506; Nordahl R, 2014, OXFORD HDB INTERACTI, P213; Ohta Y, 2007, P 123 CONV AUD ENG S; Pulkki V, 1996, P INT COMP MUS C ICM, P93; Pulkki V, 2001, THESIS HELSINKI U TE; Pulkki V, 1997, J AUDIO ENG SOC, V45, P456; Scott SD, 2010, TABLETOPS HORIZONTAL, P375; Sodnik J, 2006, P 2000 INT C AUD DIS, P1; Valjamae A, 2005, R0372005 CHALM U TEC	30	0	0	SPRINGER LONDON LTD	LONDON	236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND	1359-4338	1434-9957		VIRTUAL REAL-LONDON	Virtual Real.	NOV	2015	19	3-4			SI		213	222		10.1007/s10055-015-0268-2		10	Computer Science, Interdisciplinary Applications; Computer Science, Software Engineering; Imaging Science & Photographic Technology	Computer Science; Imaging Science & Photographic Technology	CU9KG	WOS:000363862800006		
J	Sutou, S				Sutou, Shizuyo			Tremendous Human, Human, Social, and Economic Losses Caused by Obstinate Application of the Failed Linear No-threshold Model	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Review						lifespan survivor study; threshold of radiation; black rain; hormesis; dose and dose-rate effectiveness factor; Fukushima nuclear disaster	ATOMIC-BOMB SURVIVORS; MUTATION FREQUENCY; CANCER INCIDENCE; RADIATION; IRRADIATION; DROSOPHILA; MORTALITY	The linear no-threshold model (LNT) was recommended in 1956, with abandonment of the traditional threshold dose-response for genetic risk assessment. Adoption of LNT by the International Commission on Radiological Protection (ICRP) became the standard for radiation regulation worldwide. The ICRP recommends a dose limit of 1 mSv/year for the public, which is too low and which terrorizes innocent people. Indeed, LNT arose mainly from the lifespan survivor study (LSS) of atomic bomb survivors. The LSS, which asserts linear dose-response and no threshold, is challenged mainly on three points. 1) Radiation doses were underestimated by half because of disregard for major residual radiation, resulting in cancer risk overestimation. 2) The dose and dose-rate effectiveness factor (DDREF) of 2 is used, but the actual DDREF is estimated as 16, resulting in cancer risk overestimation by several times. 3) Adaptive response (hormesis) is observed in leukemia and solid cancer cases, consistently contradicting the linearity of LNT. Drastic reduction of cancer risk moves the dose-response curve close to the control line, allowing the setting of a threshold. Living organisms have been evolving for 3.8 billion years under radiation exposure, naturally acquiring various defense mechanisms such as DNA repair mechanisms, apoptosis, and immune response. The failure of LNT lies in the neglect of carcinogenesis and these biological mechanisms. Obstinate application of LNT continues to cause tremendous human, social, and economic losses. The 60-year-old LNT must be rejected to establish a new scientific knowledge-based system.	Shujitsu Univ, Sch Pharm, Lab Funct Genom, Naka Ku, Okayama 7038516, Japan	Sutou, S (reprint author), Shujitsu Univ, Sch Pharm, Lab Funct Genom, Naka Ku, 1-6-1 Nishigawara, Okayama 7038516, Japan.	sutou@shujitsu.jp					Abbott B., 2015, NATURE, V523, P17; Rahu K, 2013, J RADIOL PROT, V33, P395, DOI 10.1088/0952-4746/33/2/395; Karam PA, 1999, HEALTH PHYS, V77, P662, DOI 10.1097/00004032-199912000-00010; Calabrese EJ, 2011, ENVIRON TOXICOL CHEM, V30, P2658, DOI 10.1002/etc.687; COHEN BL, 1995, HEALTH PHYS, V68, P157, DOI 10.1097/00004032-199502000-00002; [Anonymous], 1956, SCIENCE, V123, P1157; Sasaki MS, 2014, J RADIAT RES, V55, P391, DOI 10.1093/jrr/rrt133; Ozasa K, 2012, RADIAT RES, V177, P229, DOI 10.1667/RR2629.1; Leuraud K, 2015, LANCET HAEMATOL, V2, pE276, DOI 10.1016/S2352-3026(15)00094-0; Galvan I, 2014, FUNCT ECOL, V28, P1387, DOI 10.1111/1365-2435.12283; Ogura K, 2009, RADIAT RES, V171, P1, DOI 10.1667/RR1288.1; UPHOFF DE, 1949, SCIENCE, V109, P609, DOI 10.1126/science.109.2842.609; LUCKEY TD, 1986, RADIAT RES, V108, P215, DOI 10.2307/3576827; Preston DL, 2007, RADIAT RES, V168, P1, DOI 10.1667/RR0763.1; Pollycove M, 2003, HUM EXP TOXICOL, V22, P290, DOI 10.1191/0960327103ht365oa; Ina Y, 2005, RADIAT RES, V163, P153, DOI 10.1667/RR3289; Ghiassi-nejad M, 2002, HEALTH PHYS, V82, P87, DOI 10.1097/00004032-200201000-00011; Koana T, 2004, RADIAT RES, V161, P391, DOI 10.1667/RR3152; Auxier J. A., CEX 64 3 ICHIBAN DOS; Berrington de Gonzales A, 2004, LANCET, V363, P345, DOI DOI 10.1016/S0140-6736; Calabrese EJ, 2015, ARCH TOXICOL, V89, P647, DOI 10.1007/s00204-015-1454-4; Cuttler J. M., 2015, FUKUSHIMA NUCL ACCID, P27; Doss M., 2015, FUKUSHIMA NUCL ACCID, P61; Fujita S., 2005, P WORKSH NEW RAD DOS, P142; Glaser A., 2007, EFFECTS NUCL WEAPONS; Imanaka T., 2005, P WORKSH NEW RAD DOS, P124; Kodama Y., 2015, FUKUSHIMA NUCL ACCID, P77; Luckey T. D., 2011, J AM PHYS SURG, V16, P45; Maruyama A., 2015, FUKUSHIMA NUCL ACCID, P115; Maruyama T., 2005, P WORKSH NEW RAD DOS, P184; Muller H. J., NOBEL LECT; Muller H J, 1927, Science, V66, P84, DOI 10.1126/science.66.1699.84; Nomura S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060192; Shimada Y., 1992, RADIOL SCI, V35, P378; Sutou S, 2013, GENES ENV, V35, P1; Sutou S, 2013, SHUJITSU RONSO, V43, P381; Sutou S., 2013, GENES ENV, V35, P73; Sutou S., 2015, FUKUSHIMA NUCL ACCID; Sutou S., 2011, SHUJITSU RONSO, V41, P221; Sutou S., 2014, SHUJITSU RONSO, V44, P381; Sutou S, 2012, SHUJITSU RONSO, V42, P195; Tanooka H., 2015, FUKUSHIMA NUCL ACCID, P101; The International Commission on Radiation Protection (ICRP), 2009, ICRP PUBL, V103; The Radiation Effects Research Foundation, US JAP JOINT REASS A; The Radiation Effects Research Foundation, REASS AT BOMB RAD DO, V2; The Radiation Effects Research Foundation, REASS AT BOMB RAD DO, V1; United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR), 2013, UNSCEAR 2013 REP, V1, P204; UNSCEAR, 1958, REP UN SCI COMM S17, P165	48	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	NOV	2015	135	11					1197	1211				15	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CV0AI	WOS:000363908500001		
J	Furukawa, S				Furukawa, Shoei			Basic Research on Neurotrophic Factors and Its Application to Medical Uses	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Review						nerve growth factor; neurotrophins; neurotrophic factors; 2-decenoic acid derivative; mood disorder; spinal cord injury	NERVE GROWTH-FACTOR; SPINAL-CORD-INJURY; ACID ETHYL-ESTER; MOUSE ASTROGLIAL CELLS; MESSENGER-RNA; FATTY-ACID; SYMPATHETIC INNERVATION; HIPPOCAMPAL-NEURONS; ENZYME-IMMUNOASSAY; ALZHEIMERS-DISEASE	The author has studied nerve growth factor (NGF) and its family of neurotrophic factors (neurotrophins) for over 40 years. During the first 20 years, my laboratory established a highly sensitive enzyme immunoassay for NGF and analyzed the regulatory mechanism of NGF synthesis in cultured primary cells. Fibroblast cells cultured from peripheral organs such as the heart and astrocytes from the brain produced a substantial amount of NGF in a growth-dependent manner. Furthermore, synthesis of NGF in these cells could be upregulated by catechol compounds including catecholamines. This observation might explain a physiological relation between the level of NGF mRNA and the density of innervation in the peripheral sympathetic nervous systems. Over the subsequent 20 years, my laboratory investigated the physiological functions of neurotrophic factors, including neurotrophins, during development or post-injury and found that brain-derived neurotrophic factor (BDNF) plays a role in the formation of the laminar structure of the cerebral cortex. In addition, my laboratory discovered that endogenous glial cell line-derived neurotrophic factor (GDNF) contributes to the amelioration of motor activity after spinal cord injury. Therefore we aimed to develop low-molecular weight compounds that generate neurotrophic factor-like intracellular signals to protect or ameliorate neurological/psychiatric diseases. 2-Decenoic acid derivatives and other similar molecules could protect or ameliorate in animal models of mood disorders such as depression and enhance recovery from spinal cord injury-induced motor paralysis. Compounds that can generate neurotrophin-like signals in neurons are expected to be developed as therapeutic drugs for certain neurological or psychiatric disorders.	Gifu Pharmaceut Univ, Dept Biofunctinal Anal, Mol Biol Lab, Gifu 5011196, Japan	Furukawa, S (reprint author), Gifu Pharmaceut Univ, Dept Biofunctinal Anal, Mol Biol Lab, 1-25-4 Daigaku Nishi, Gifu 5011196, Japan.	furukawa@gifu-pu.ac.jp					BOCCHINI V, 1969, P NATL ACAD SCI USA, V64, P787, DOI 10.1073/pnas.64.2.787; Thoenen H, 2002, NAT NEUROSCI, V5, P1046, DOI 10.1038/nn938; FURUKAWA S, 1986, BIOCHEM BIOPH RES CO, V136, P57, DOI 10.1016/0006-291X(86)90876-4; LEVINE ES, 1995, P NATL ACAD SCI USA, V92, P8074, DOI 10.1073/pnas.92.17.8074; FURUKAWA S, 1983, J NEUROCHEM, V40, P734, DOI 10.1111/j.1471-4159.1983.tb08040.x; VARON S, 1967, BIOCHEMISTRY-US, V6, P2202, DOI 10.1021/bi00859a043; FURUKAWA Y, 1986, J BIOL CHEM, V261, P6039; NIBUYA M, 1995, J NEUROSCI, V15, P7539; SHELTON DL, 1984, P NATL ACAD SCI-BIOL, V81, P7951, DOI 10.1073/pnas.81.24.7951; Matrone C, 2009, P NATL ACAD SCI USA, V106, P11358, DOI 10.1073/pnas.0904998106; KORSCHING S, 1985, EMBO J, V4, P1389; Skaper SD, 2008, CNS NEUROL DISORD-DR, V7, P46, DOI 10.2174/187152708783885174; ISHIKAWA E, 1983, J IMMUNOASSAY, V4, P209, DOI 10.1080/15321818308057011; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; HANAOKA Y, 1994, J NEUROL SCI, V122, P28, DOI 10.1016/0022-510X(94)90048-5; McCall J, 2012, CELL TISSUE RES, V349, P27, DOI 10.1007/s00441-012-1388-6; Schwab ME, 2004, CURR OPIN NEUROBIOL, V14, P118, DOI 10.1016/j.conb.2004.01.004; Hirakawa A, 2010, NEUROSCIENCE, V171, P1377, DOI 10.1016/j.neuroscience.2010.10.004; FURUKAWA Y, 1984, J BIOL CHEM, V259, P1259; Ventriglia M, 2002, MOL PSYCHIATR, V7, P136, DOI 10.1038/sj.mp.4000952; Bregman BS, 2002, PROG BRAIN RES, V137, P257; COHEN S, 1960, P NATL ACAD SCI USA, V46, P302, DOI 10.1073/pnas.46.3.302; HANAOKA Y, 1992, EXP NEUROL, V115, P292, DOI 10.1016/0014-4886(92)90064-W; Makino A, 2010, BIOMED RES-TOKYO, V31, P379, DOI 10.2220/biomedres.31.379; Calissano P, 2010, DEV NEUROBIOL, V70, P372, DOI 10.1002/dneu.20759; THOENEN H, 1987, CIBA F SYMP, V126, P82; Jiang HB, 2003, HUM MOL GENET, V12, P1, DOI 10.1093/hmg/ddg002; NAGGERT J, 1991, BIOCHEM J, V273, P787; KORSCHING S, 1983, P NATL ACAD SCI-BIOL, V80, P3513, DOI 10.1073/pnas.80.11.3513; LEVIMONTALCINI R, 1987, EMBO J, V6, P1145; FURUKAWA S, 1987, BIOCHEM BIOPH RES CO, V147, P1048, DOI 10.1016/S0006-291X(87)80176-6; Watabe M, 2004, J BIOL CHEM, V279, P6017, DOI 10.1074/jbc.M306040200; ZAFRA F, 1990, EMBO J, V9, P3545; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; AYERLELIEVRE C, 1988, SCIENCE, V240, P1339, DOI 10.1126/science.2897715; Kamata Y, 2007, NEUROSCIENCE, V146, P1073, DOI 10.1016/j.neuroscience.2007.03.001; THOENEN H, 1980, PHYSIOL REV, V60, P1284; Chen ZY, 2005, J NEUROSCI, V25, P6156, DOI 10.1523/JNEUROSCI.1017-05-2005; Hashimoto M, 2005, NEUROREPORT, V16, P99, DOI 10.1097/00001756-200502080-00004; FURUKAWA Y, 1986, FEBS LETT, V208, P258, DOI 10.1016/0014-5793(86)81028-6; Dawbarn D, 2003, NEUROPATH APPL NEURO, V29, P211, DOI 10.1046/j.1365-2990.2003.00487.x; Cohen S, 2004, ANN NY ACAD SCI, V1038, P98, DOI 10.1196/annals.1315.017; Sen S, 2003, NEUROPSYCHOPHARMACOL, V28, P397, DOI 10.1038/sj.npp.1300053; Shooter EM, 2001, ANNU REV NEUROSCI, V24, P601, DOI 10.1146/annurev.neuro.24.1.601; Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7; Zhao Y, 2008, EUR J PHARMACOL, V581, P113, DOI 10.1016/j.ejphar.2007.12.005; Saita K, 1996, J PHARMACOL EXP THER, V276, P231; KAECHI K, 1995, J PHARMACOL EXP THER, V272, P1300; KATO K, 1976, J IMMUNOL, V116, P1554; HEUMANN R, 1984, EMBO J, V3, P3183; Kasai M, 2011, BIOMED RES-TOKYO, V32, P1, DOI 10.2220/biomedres.32.1; Tao X, 1998, NEURON, V20, P709, DOI 10.1016/S0896-6273(00)81010-7; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Yamamoto-Sasaki M, 1999, BRAIN RES, V824, P300, DOI 10.1016/S0006-8993(99)01220-2; Ito S, 2012, EVID-BASED COMPL ALT, P1, DOI 10.1155/2012/139140; Makino A, 2013, BIOMED RES-TOKYO, V34, P259; Bankova V, 2005, J ETHNOPHARMACOL, V100, P114, DOI 10.1016/j.jep.2005.05.004; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Boudreau LH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031833; COHEN S, 1956, P NATL ACAD SCI USA, V42, P571, DOI 10.1073/pnas.42.9.571; Furukawa S, 2009, CHEM ENG, V54, P18; Hempstead B L, 2014, Handb Exp Pharmacol, V220, P17, DOI 10.1007/978-3-642-45106-5_2; HENDRY IA, 1974, BRAIN RES, V68, P103, DOI 10.1016/0006-8993(74)90536-8; KAECHI K, 1993, J PHARMACOL EXP THER, V264, P321; Kasai M., 2011, EVID-BASED COMPL ALT, V2011; Kreinin A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127643; LEVI-MONTALCINI R, 1968, Brain Research, V8, P347, DOI 10.1016/0006-8993(68)90054-1; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; Pollack Scott J., 2002, Current Drug Targets - CNS and Neurological Disorders, V1, P59, DOI 10.2174/1568007023339490; Shibata S., 2015, PHARM RES PERSPECT, V3; Zorner B, 2010, ANN NY ACAD SCI, V1198, pE22, DOI 10.1111/j.1749-6632.2010.05566.x	71	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	NOV	2015	135	11					1213	1226				14	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CV0AI	WOS:000363908500002		
J	Kobayashi, M				Kobayashi, Masaki			Role of Monocarboxylate Transporter in Statin-induced Cytotoxicity	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Review						monocarboxylate transporter 4; HMG-CoA reductase inhibitor; cytotoxicity	SKELETAL-MUSCLE; INDUCED APOPTOSIS; LACTIC-ACID; CELLS; EXPRESSION; MECHANISM; ACTIVATION; EXERCISE; MYOPATHY; LACTATE	Although exercise and drug therapy are important to prevent progression of arteriosclerotic disease, exercise leads to an increase in muscular disorder induced by HMG-CoA reductase inhibitors (statins). Elucidation of this mechanism is needed to prevent the occurrence of muscular disorders. Since exercise induces expression of monocarboxylate transporter (MCT) 4, we focused on the association between MCT4 function and statin-induced muscle injury. First, we examined the transport of L-lactate via MCT4 using MCT4 cRNA-injected Xenopus laevis oocytes. L-lactate uptake by MCT4-expressing oocytes was markedly reduced by alkalizing the buffer pH and saturated at higher L-lactate concentrations. On the other hand, AMP-activated protein kinase (AMPK) and protein kinase C (PKC) are activated by exercise. We next examined whether AMPK and PKC activation affects the expression and function of MCT4 in rat skeletal muscle and RD cells as an in vitro skeletal muscle model. AMPK and PKC activation increased MCT4 expression level and lactate efflux by MCT4. Finally, we examined the association between MCT4 function and statin-induced cytotoxicity. Statins inhibited transport of L-lactate via MCT4 in a concentration-dependent manner. Statin-induced cytotoxicity was associated with intracellular acidification and caspase-3/7 activation. On the other hand, bicarbonate suppressed statin-induced pH alteration, caspase activation, and morphological change. The results suggest that statin-induced muscle injury exacerbated by exercise is associated with intracellular acidification and that the effects of statins on L-lactate transport are mediated by MCT4.	Hokkaido Univ, Fac Pharmaceut Sci, Lab Clin Pharmaceut & Therapeut, Kita Ku, Sapporo, Hokkaido 0600812, Japan	Kobayashi, M (reprint author), Hokkaido Univ, Fac Pharmaceut Sci, Lab Clin Pharmaceut & Therapeut, Kita Ku, Kita 12 Jo,Nishi 6 Chome, Sapporo, Hokkaido 0600812, Japan.	masaki@pharm.hokudai.ac.jp					Kobayashi M, 2011, EUR J PHARMACOL, V662, P9, DOI 10.1016/j.ejphar.2011.04.043; Narumi K, 2012, INT J PHARMACEUT, V428, P25, DOI 10.1016/j.ijpharm.2012.02.021; Kobayashi M, 2007, INT J PHARM, V341, P181, DOI 10.1016/j.ijpharm.2007.04.010; Jeong DW, 2001, BIOCHEM BIOPH RES CO, V289, P1141, DOI 10.1006/bbrc.2001.6091; Sirvent P, 2005, BIOCHEM BIOPH RES CO, V338, P1426, DOI 10.1016/j.bbrc.2005.10.108; Dimmer KS, 2000, BIOCHEM J, V350, P219, DOI 10.1042/0264-6021:3500219; Furugen A, 2011, LIFE SCI, V88, P163, DOI 10.1016/j.lfs.2010.11.003; Kobayashi M, 2006, INT J PHARMACEUT, V317, P19, DOI 10.1016/j.ijpharm.2006.02.043; Price NT, 1998, BIOCHEM J, V329, P321; Sinzinger H, 2004, BRIT J CLIN PHARMACO, V57, P525, DOI 10.1111/j.1365-2125.2004.02044.x; Kobayashi M, 2013, INT J PHARMACEUT, V452, P36, DOI 10.1016/j.ijpharm.2013.04.019; Hirpara JL, 2001, J BIOL CHEM, V276, P514; Kobayashi M, 2005, BIOL PHARM BULL, V28, P1197, DOI 10.1248/bpb.28.1197; Steinberg GR, 2009, PHYSIOL REV, V89, P1025, DOI 10.1152/physrev.00011.2008; Perrini S, 2004, DIABETES, V53, P21; Meador BM, 2010, MUSCLE NERVE, V42, P469, DOI 10.1002/mus.21817; Halestrap AP, 1999, BIOCHEM J, V343, P281, DOI 10.1042/0264-6021:3430281; Matsuyama S, 2000, NAT CELL BIOL, V2, P318; Dirks AJ, 2006, AM J PHYSIOL-CELL PH, V291, pC1208, DOI 10.1152/ajpcell.00226.2006; Kobayashi M, 2008, LIFE SCI, V82, P969, DOI 10.1016/j.lfs.2008.02.019; Fox JEM, 2000, J PHYSIOL-LONDON, V529, P285, DOI 10.1111/j.1469-7793.2000.00285.x; Sasaki S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067690	22	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	NOV	2015	135	11					1227	1233				7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CV0AI	WOS:000363908500003		
J	Fukami, T				Fukami, Tatsuki			Role of Human Orphan Esterases in Drug-induced Toxicity	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Review						drug hydrolysis; drug-induced toxicity; arylacetamide deacetylase; alpha/beta hydrolase domain containing 10	HUMAN ARYLACETAMIDE DEACETYLASE; HUMAN LIVER; FLUTAMIDE HYDROLYSIS; ENZYME; GLUCURONIDATION; PHENACETIN; INDIPLON; ABHD10	Esterases hydrolyze compounds containing ester, amide, and thioester bonds, causing prodrug activation or detoxification. Among esterases, carboxylesterases have been studied in depth due to their ability to hydrolyze a variety of drugs. However, there are several drugs for which the involved esterase (s) is unknown. We found that flutamide, phenacetin, rifamycins (rifampicin, rifabutin, and rifapentine), and indiplon are hydrolyzed by arylacetamide deacetylase (AADAC), which is highly expressed in human liver and gastrointestinal tissues. Flutamide hydrolysis is considered associated with hepatotoxicity. Phenacetin, a prodrug of acetaminophen, was withdrawn due to side effects such as methemoglobinemia and renal failure. It was demonstrated in vitro and in vivo using mice that AADAC is responsible for phenacetin hydrolysis, which leads to methemoglobinemia. In addition, it was shown that AADAC-mediated hydrolysis attenuates the cytotoxicity of rifamycins. Thus AADAC plays critical roles in drug-induced toxicity. Another orphan esterase, alpha/beta hydrolase domain containing 10 (ABHD10), was found responsible for deglucuronidation of acylglucuronides including mycophenolic acid acyl-glucuronide and probenecid acyl-glucuronide. Because acyl-glucuronides appear associated with toxicity, ABHD10 would function as a detoxification enzyme. The roles of orphan esterases are becoming increasingly understood. Further studies will facilitate our knowledge of the pharmacologic and toxicological significance of orphan esterases in drug therapy.	Kanazawa Univ, Fac Pharmaceut Sci, Drug Metab & Toxicol, Kanazawa, Ishikawa 9201192, Japan	Fukami, T (reprint author), Kanazawa Univ, Fac Pharmaceut Sci, Drug Metab & Toxicol, Kakuma Machi, Kanazawa, Ishikawa 9201192, Japan.	tatsuki@p.kanazawa-u.ac.jp					Ohbuchi M, 2009, DRUG METAB DISPOS, V37, P97, DOI 10.1124/dmd.108.021964; PROBST MR, 1991, BIOCHEM BIOPH RES CO, V177, P453, DOI 10.1016/0006-291X(91)92005-5; Takai S, 1997, BIOL PHARM BULL, V20, P869; Watanabe A, 2009, DRUG METAB DISPOS, V37, P1513, DOI 10.1124/dmd.109.026567; Watanabe A, 2010, DRUG METAB DISPOS, V38, P1532, DOI 10.1124/dmd.110.033720; Kobayashi Y, 2012, BIOCHEM PHARMACOL, V84, P1196, DOI 10.1016/j.bcp.2012.08.015; Kobayashi Y, 2012, DRUG METAB DISPOS, V40, P671, DOI 10.1124/dmd.111.043067; Fukami T, 2012, DRUG METAB PHARMACOK, V27, P466, DOI 10.2133/dmpk.DMPK-12-RV-042; Tiwari R, 2007, EMBO J, V26, P5109, DOI 10.1038/sj.emboj.7601924; Iwamura A, 2012, J BIOL CHEM, V287, P9240, DOI 10.1074/jbc.M111.271288; Shimizu M, 2012, DRUG METAB DISPOS, V40, P1183, DOI 10.1124/dmd.112.044883; Madan A, 2007, XENOBIOTICA, V37, P736, DOI 10.1080/00498250701433054; Nakajima A, 2011, BIOCHEM PHARMACOL, V82, P1747, DOI 10.1016/j.bcp.2011.08.003; Kobayashi Y, 2012, DRUG METAB DISPOS, V40, P1080, DOI 10.1124/dmd.112.044537; Shimizu M, 2014, DRUG METAB DISPOS, V42, P751, DOI 10.1124/dmd.113.056184; Ito Y, 2014, DRUG METAB DISPOS, V42, P2109, DOI 10.1124/dmd.114.059485; SPAHNLANGGUTH H, 1992, DRUG METAB REV, V24, P5	17	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	NOV	2015	135	11					1235	1244				10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CV0AI	WOS:000363908500004		
J	Tarui, A				Tarui, Atsushi			Stereoselective Synthesis of Multi-substituted Fluoro-beta-lactams and Their Conversion to Fluorinated beta-Amino Acid Core	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Review						fluorine; beta-lactam; beta-amino acid; nickel-catalyzed coupling; chiral ligand	ENANTIOSELECTIVE REFORMATSKY REACTION; CATALYZED ALPHA-ARYLATION; ASYMMETRIC-SYNTHESIS; CROSS-COUPLINGS; DIASTEREOSELECTIVE SYNTHESIS; ETHYL BROMODIFLUOROACETATE; ALDEHYDES; KETONES; REAGENTS; ESTERS	Multi-substituted beta-lactam compounds have not only attracted considerable interest as core structures of pharmaceutical compounds such as antibiotics but also have been used as building blocks for the construction of beta-amino acids. Electrophilic beta-lactams can be used to enhance essential biological activities. Furthermore, the ring-opening reactions of electrophilic beta-lactams can be used to provide facile access to beta-amino acids. The introduction of an electronegative fluorine atom to a beta-lactam ring to give the corresponding fluoro-beta-lactam can be used as an effective strategy for the preparation of electrophilic beta-lactams. In this review, we provide a summary of our recent research towards the direct functionalization of fluoro-beta-lactams. This review has been divided into four topics, including: 1) the alkylation and hydroxyalkylation of alpha-bromo-alpha-fluoro-beta-lactams (1); 2) the nickel-catalyzed cross coupling reaction of 1; 3) the asymmetric synthesis of fluoro-beta-lactams using chiral ligands; and 4) the utilization of fluoro-beta-lactams as highly electrophilic building blocks.	Setsunan Univ, Fac Pharmaceut Sci, Hirakata, Osaka 5730101, Japan	Tarui, A (reprint author), Setsunan Univ, Fac Pharmaceut Sci, 45-1 Nagaotoge Cho, Hirakata, Osaka 5730101, Japan.	tarui-a@pharm.setsunan.ac.jp					Li XG, 2008, TETRAHEDRON-ASYMMETR, V19, P1857, DOI 10.1016/j.tetasy.2008.07.017; Tarui A, 2014, ORG LETT, V16, P2080, DOI 10.1021/ol500631j; Galletti P, 2011, CURR MED CHEM, V18, P4265; Tobisu M, 2009, J AM CHEM SOC, V131, P12070, DOI 10.1021/ja9053509; Lin N, 2010, TETRAHEDRON-ASYMMETR, V21, P2816, DOI 10.1016/j.tetasy.2010.11.004; Tarui A, 2007, HETEROCYCLES, V73, P203; O'Hagan D, 2008, CHEM SOC REV, V37, P308, DOI 10.1039/b711844a; Kaupang A, 2013, BEILSTEIN J ORG CHEM, V9, P1407, DOI 10.3762/bjoc.9.157; Hama T, 2003, J AM CHEM SOC, V125, P11176, DOI 10.1021/ja036792p; Fornalczyk M, 2012, ORG BIOMOL CHEM, V10, P3332, DOI 10.1039/c2ob25081k; Cozzi PG, 2006, ADV SYNTH CATAL, V348, P2075, DOI 10.1002/adsc.200606178; Purser S, 2008, CHEM SOC REV, V37, P320, DOI 10.1039/b610213c; Tarui A, 2014, ORG BIOMOL CHEM, V12, P6484, DOI 10.1039/c4ob01184h; Liu NJ, 2009, TETRAHEDRON LETT, V50, P1982, DOI 10.1016/j.tetlet.2009.02.056; Turos E, 2005, BIOORGAN MED CHEM, V13, P6289, DOI 10.1016/j.bmc.2005.08.011; Lundin PM, 2010, J AM CHEM SOC, V132, P11027, DOI 10.1021/ja105148g; KAWECKI R, 1993, TETRAHEDRON LETT, V34, P3087, DOI 10.1016/S0040-4039(00)93386-0; Molander GA, 2014, J ORG CHEM, V79, P5771, DOI 10.1021/jo500905m; OJIMA I, 1994, J ORG CHEM, V59, P1249, DOI 10.1021/jo00085a008; Tarui A, 2008, TETRAHEDRON LETT, V49, P3839, DOI 10.1016/j.tetlet.2008.04.101; Kvaerno L, 2005, J MED CHEM, V48, P6035, DOI 10.1021/jm050422p; Jeschke P, 2004, CHEMBIOCHEM, V5, P570, DOI 10.1002/cbic.200300833; Cozzi PG, 2006, ANGEW CHEM INT EDIT, V45, P2951, DOI 10.1002/anie.200504239; Terao J, 2002, J AM CHEM SOC, V124, P4222, DOI 10.1021/ja025828v; Tarui A, 2013, TETRAHEDRON, V69, P1559, DOI 10.1016/j.tet.2012.12.002; Tarui A, 2013, J ORG CHEM, V78, P7903, DOI 10.1021/jo401072h; Fischer C, 2005, J AM CHEM SOC, V127, P4594, DOI 10.1021/ja0506509; WELCH JT, 1993, J ORG CHEM, V58, P2454, DOI 10.1021/jo00061a019; Cozzi PG, 2005, ANGEW CHEM INT EDIT, V44, P3600, DOI 10.1002/anie.200462757; March TL, 2012, ORG LETT, V14, P182, DOI 10.1021/ol202969w; Liu C, 2007, ORG LETT, V9, P5601, DOI 10.1021/ol702456z; Fernandez-Ibanez MA, 2008, ANGEW CHEM INT EDIT, V47, P1317, DOI 10.1002/anie.200704841; Marcotte S, 1999, J ORG CHEM, V64, P8461, DOI 10.1021/jo990868b; Fornalczyk M, 2012, CHEM COMMUN, V48, P3500, DOI 10.1039/c2cc17985g; Fontenelle CQ, 2014, J ORG CHEM, V79, P4186, DOI 10.1021/jo500396p; Cozzi PG, 2008, ADV SYNTH CATAL, V350, P975, DOI 10.1002/adsc.200700572; Mames A, 2010, J ORG CHEM, V75, P7580, DOI 10.1021/jo101355h; Colbon P, 2010, ORG LETT, V12, P3670, DOI 10.1021/ol101466g; Molander GA, 2013, J ORG CHEM, V78, P4123, DOI 10.1021/jo400488q; Lou S, 2010, J AM CHEM SOC, V132, P1264, DOI 10.1021/ja909689t; Tarui A, 2010, TETRAHEDRON LETT, V51, P2000, DOI 10.1016/j.tetlet.2010.02.023; Fernandez-Ibanez MA, 2008, CHEM COMMUN, P2571, DOI 10.1039/b801749b; Braun M., 1995, LIEBIGS ANN, V1995, P1447, DOI 10.1002/jlac.1995199508196; Cornella J, 2013, ORG LETT, V15, P6298, DOI 10.1021/ol4031815; Cozzi PG, 2008, CHEM COMMUN, P3317, DOI 10.1039/b805197f; Tanaka T, 2008, CHEM LETT, V37, P1298, DOI 10.1246/cl.2008.1298; Kloetzing RJ, 2006, ORG LETT, V8, P1125, DOI 10.1021/ol0531381; OJIMA I, 1995, ACCOUNTS CHEM RES, V28, P383, DOI 10.1021/ar00057a004; PAGE MI, 1984, ACCOUNTS CHEM RES, V17, P144, DOI 10.1021/ar00100a005; Palomo C, 1999, EUR J ORG CHEM, P3223; Tarui A, 2015, SYNLETT, V26, P55, DOI 10.1055/s-0034-1379637	51	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	NOV	2015	135	11					1245	1253				9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CV0AI	WOS:000363908500005		
J	Yoshioka, E				Yoshioka, Eito			Multi-component Reactions Based on Formal [2+2] Reaction of Benzyne with Formamide	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Review						aryne; benzyne; unstable intermediate; [2+2] reaction; pi-bond insertion; multi-component coupling reaction	ARYNE INSERTION REACTIONS; CARBON SIGMA-BONDS; STRAIGHTFORWARD SYNTHESIS; RADICAL POLYMERIZATION; TRAPPING REACTION; ORGANIC-SYNTHESIS; COUPLING REACTION; VISIBLE-LIGHT; CYCLOADDITION; BENZOFURANS	Arynes, such as benzyne, are highly strained and kinetically unstable intermediates that have been widely employed in organic synthesis. In particular, since the initial report regarding the in situ generation of arynes under neutral conditions from ortho- (trimethylsilyl) aryl triflates and fluoride ions in 1983, numerous nucleophilic additions to arynes have been utilized in the synthesis of carbocycles, heterocycles, and multi-substituted arenes. Recently, we reported the insertion of arynes into the pi-bond in formamides, as well as related cascade reactions. First, we synthesized salicylaldehydes and aminophenols via the insertion of arynes into the C=O bond of sterically less hindered N,N-dimethylformamide (DMF). Notably, computational studies revealed the generation of unstable benzoxetene and ortho-quinone methide as reactive intermediates. We also studied multi-component coupling reactions leading to 2H-chromenes, coumarins, and xanthen-1-ones under mild conditions through the stepwise release of the strain energy in arynes. Furthermore, we studied the synthesis of O-heterocycles such as dihydrobenzofuran, benzofuran, and 4H-chromene as an application of our method. In this review, we will describe these studies in detail.	Hyogo Univ Hlth Sci, Sch Pharm, Chuo Ku, Kobe, Hyogo 6508530, Japan	Yoshioka, E (reprint author), Hyogo Univ Hlth Sci, Sch Pharm, Chuo Ku, 1-3-6 Minatojima, Kobe, Hyogo 6508530, Japan.	e.yoshioka@huhs.ac.jp					Enders D, 2007, CHEM REV, V107, P5606, DOI 10.1021/cr068372z; Ouchi M, 2009, CHEM REV, V109, P4963, DOI 10.1021/cr900234b; Yoshioka E, 2015, TETRAHEDRON, V71, P773, DOI 10.1016/j.tet.2014.12.068; Wenk HH, 2003, ANGEW CHEM INT EDIT, V42, P502, DOI 10.1002/anie.200390151; Yoshida H, 2013, ANGEW CHEM INT EDIT, V52, P8629, DOI 10.1002/anie.201302783; Dubrovskiy AV, 2013, ORG BIOMOL CHEM, V11, P191, DOI 10.1039/c2ob26673c; McAusland D, 2011, ORG LETT, V13, P3667, DOI 10.1021/ol201413r; Tadross PM, 2010, ORG LETT, V12, P1612, DOI 10.1021/ol100335y; Yoshida H, 2005, TETRAHEDRON LETT, V46, P6729, DOI 10.1016/j.tetlet.2005.07.119; Xi YM, 2013, ORG BIOMOL CHEM, V11, P2387, DOI 10.1039/c3ob40137e; Yoshioka E, 2011, ANGEW CHEM INT EDIT, V50, P6638, DOI 10.1002/anie.201102088; Yoshioka E, 2014, TETRAHEDRON LETT, V55, P1402, DOI 10.1016/j.tetlet.2013.12.119; Rao B, 2014, ORG LETT, V16, P314, DOI 10.1021/ol403346x; Sato N, 2008, J MED CHEM, V51, P4765, DOI 10.1021/jm8003587; Tambar UK, 2005, J AM CHEM SOC, V127, P5340, DOI 10.1021/ja050859m; Dyke AM, 2008, ANGEW CHEM INT EDIT, V47, P5067, DOI 10.1002/anie.200800750; Diez-Gonzalez S, 2009, CHEM REV, V109, P3612, DOI 10.1021/cr900074m; Yoshioka E, 2013, SYNLETT, V24, P1578, DOI 10.1055/s-0033-1339182; Narayanam JMR, 2011, CHEM SOC REV, V40, P102, DOI 10.1039/b913880n; Yoshioka E, 2012, J ORG CHEM, V77, P8588, DOI 10.1021/jo3015227; Kamigaito M, 2001, CHEM REV, V101, P3689, DOI 10.1021/cr9901182; Yoshida H, 2004, ORG LETT, V6, P4049, DOI 10.1021/ol048298b; Yoshioka E, 2010, ORG LETT, V12, P1956, DOI 10.1021/ol100387h; Vaidya SD, 2013, ORG LETT, V15, P4006, DOI 10.1021/ol4018062; Feltenberger JB, 2009, ORG LETT, V11, P3666, DOI 10.1021/ol901434g; Hamura T, 2006, J AM CHEM SOC, V128, P3534, DOI 10.1021/ja0602647; BROOKHART M, 1987, CHEM REV, V87, P411, DOI 10.1021/cr00078a008; Yoshioka E, 2012, TETRAHEDRON, V68, P179, DOI 10.1016/j.tet.2011.10.072; Yoshioka E, 2014, MOLECULES, V19, P863, DOI 10.3390/molecules19010863; Yoshida H, 2012, SYNLETT, P1725, DOI 10.1055/s-0031-1290401; Yoshioka E, 2013, ORG LETT, V15, P3938, DOI 10.1021/ol4017063; Pellissier H, 2003, TETRAHEDRON, V59, P701, DOI 10.1016/S0040-4020(02)01563-6; Reissig HU, 2003, CHEM REV, V103, P1151, DOI 10.1021/cr010016n; Tadross PM, 2012, CHEM REV, V112, P3550, DOI 10.1021/cr200478h; Tambar UK, 2006, J AM CHEM SOC, V128, P11752, DOI 10.1021/ja0651815; Doyle MP, 1998, CHEM REV, V98, P911, DOI 10.1021/cr940066a; Hamura T, 2006, ANGEW CHEM INT EDIT, V45, P6842, DOI 10.1002/anie.200602539; HIMESHIMA Y, 1983, CHEM LETT, P1211, DOI 10.1246/cl.1983.1211; NAKAYAMA J, 1973, CHEM LETT, P451, DOI 10.1246/cl.1973.451; Tsarevsky NV, 2007, CHEM REV, V107, P2270, DOI 10.1021/cr050947p; Yoshida H, 2005, CHEM COMMUN, P3292, DOI 10.1039/b505392g; Yoshioka E., 2015, MOLBANK, pM841; Yoshiokaa E, 2015, SYNLETT, V26, P265, DOI 10.1055/s-0034-1379699; Yoshioka E, 2011, SYNLETT, P2085, DOI 10.1055/s-0030-1261167	44	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	NOV	2015	135	11					1255	1264				10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CV0AI	WOS:000363908500006		
J	Yamaguchi, Y				Yamaguchi, Yoshiaki			Molecular and Neural Mechanisms for the Robustness of the Circadian Clock	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Review						circadian rhythm; suprachiasmatic nucleus; clock gene; jet lag; arginine vasopressin	MOUSE SUPRACHIASMATIC NUCLEUS; SYNCHRONY; RHYTHMS; PERIOD; CELLS; MICE; V1B	The endogenous circadian clock drives robust oscillations in physiology and behavior, such as hormone secretions and sleep/wake cycles, with a period of about 24 h. We are rarely aware of this internal clock system because it is usually synchronized with environmental light-dark cycles. However, travelling rapidly across multiple time zones in a jet airplane suddenly makes us aware of the desynchrony between the body clock and external time, causing sleep disturbances and gastrointestinal problems. Although jet lag is recognized as a chronobiological problem, its specific molecular and neural mechanisms are poorly understood. To address this issue, we identified genes highly expressed in the suprachiasmatic nucleus of the anterior hypothalamus (SCN), the mammalian master clock that controls rhythmic behavior, then analyzed the behavior of knock-out mice for these genes under jet lag condition. We found that the circadian rhythms of locomotor activity and clock gene expression rapidly re-entrained to phase-shifted light-dark cycles in mice genetically deficient in V1a and V1b receptors. Real-time imaging of cellular rhythms in the SCN suggested that interneuronal communication through V1a and V1b confers on the SCN an intrinsic resistance to external perturbation, enhancing the robustness of the SCN clockwork. Pharmacological blockade of V1a and V1b in the SCN of wild-type mice accelerated their recovery from jet lag symptoms, suggesting vasopressin signaling as a potential pharmaceutical intervention for the management of circadian rhythm misalignment.	Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Syst Biol, Sakyo Ku, Kyoto 6068501, Japan	Yamaguchi, Y (reprint author), Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Syst Biol, Sakyo Ku, 46-29 Yoshida Shimoadachi Cho, Kyoto 6068501, Japan.	yoshiy@pharm.kyoto-u.ac.jp					An S, 2013, P NATL ACAD SCI USA, V110, pE4355, DOI 10.1073/pnas.1307088110; Brown SA, 2012, DEV CELL, V22, P477, DOI 10.1016/j.devcel.2012.02.007; Rey G, 2013, TRENDS CELL BIOL, V23, P234, DOI 10.1016/j.tcb.2013.01.003; Reppert SM, 2001, ANNU REV PHYSIOL, V63, P647, DOI 10.1146/annurev.physiol.63.1.647; Hirano A, 2013, CELL, V152, P1106, DOI 10.1016/j.cell.2013.01.054; O'Neill JS, 2011, NATURE, V469, P498, DOI 10.1038/nature09702; Yamaguchi S, 2003, SCIENCE, V302, P1408, DOI 10.1126/science.1089287; Mohawk JA, 2011, TRENDS NEUROSCI, V34, P349, DOI 10.1016/j.tins.2011.05.003; Czeisler CA, 1999, SCIENCE, V284, P2177, DOI 10.1126/science.284.5423.2177; Hattar S, 2002, SCIENCE, V295, P1065, DOI 10.1126/science.1069609; CASTEL M, 1990, J COMP NEUROL, V298, P172, DOI 10.1002/cne.902980204; Pan A, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001141; Johnson CH, 2011, ANNU REV BIOPHYS, V40, P143, DOI 10.1146/annurev-biophys-042910-155317; Nakahata Y, 2009, SCIENCE, V324, P654, DOI 10.1126/science.1170803; Yamaguchi Y, 2013, SCIENCE, V342, P85, DOI 10.1126/science.1238599; Yamaguchi S, 2001, NATURE, V409, P684, DOI 10.1038/35055628; An S, 2012, J COMP NEUROL, V520, P2730, DOI 10.1002/cne.23078; Marcheva B, 2010, NATURE, V466, P627, DOI 10.1038/nature09253; Vaccari C, 1998, ENDOCRINOLOGY, V139, P5015, DOI 10.1210/en.139.12.5015; Turek FW, 2005, SCIENCE, V308, P1043, DOI 10.1126/science.1108750; Ramsey KM, 2009, SCIENCE, V324, P651, DOI 10.1126/science.1171641; RALPH MR, 1990, SCIENCE, V247, P975, DOI 10.1126/science.2305266; Romanowski A, 2015, FRONT PLANT SCI, V6, DOI 10.3389/fpls.2015.00437	23	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	NOV	2015	135	11					1265	1272				8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CV0AI	WOS:000363908500007		
J	Sanoh, S				Sanoh, Seigo			In Vitro and in Vivo Assessments of Drug-induced Hepatotoxicity and Drug Metabolism in Humans	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Review						spheroid; hepatotoxicity; chimeric mice; hepatocytes; metabolite; pharmacokinetics	ALDEHYDE OXIDASE; CHIMERIC MICE; HUMAN HEPATOCYTES; PREDICTION; IBUPROFEN; LIVER; PHARMACOKINETICS; TOXICITY; FK3453	Drug-induced hepatotoxicity is of concern in drug discovery and development. Reactive metabolites generated by drug metabolizing enzymes in the liver contribute to the induction of hepatotoxicity. Therefore, drug-induced hepatotoxicity, drug metabolism, and pharmacokinetics were evaluated in vitro and in vivo in this pre-clinical study. First, hepatotoxicity was tested in vitro using three-dimensional hepatocyte cultures. Hepatocyte spheroids formed in the three-dimensional culture systems maintain various liver functions such as the expression of drug metabolizing enzymes. High dose exposure to acetaminophen (APAP) induces hepatotoxicity because of the formation of reactive metabolites by CYP. Using fluorescence imaging, we observed that cell viability and glutathione levels were reduced in hepatocyte spheroids exposed to APAP mediated by the metabolic activation of CYP. On the other hand, there are species differences in the expression of drug metabolizing enzymes and metabolite profiles between animals and humans. Therefore, chimeric mice transfected with human hepatocytes were used for the in vivo assessment of metabolic profiles in humans. We found that drug metabolism and pharmacokinetics mediated by CYP and non-CYP enzymes, such as UDP-glucuronosyltransferase and aldehyde oxidase, in chimeric mice with humanized liver were similar to those in humans. The combination of in vitro and in vivo assessments using spheroids and chimeric mice with humanized liver, respectively, during the screening of drug candidates may help to reveal hepatotoxicity induced by the formation of metabolites.	Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Minami Ku, Hiroshima 7348553, Japan	Sanoh, S (reprint author), Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348553, Japan.	sanoh@hiroshima-u.ac.jp					Sanoh S, 2012, DRUG METAB DISPOS, V40, P76, DOI 10.1124/dmd.111.041954; Chen MJ, 2011, DRUG DISCOV TODAY, V16, P697, DOI 10.1016/j.drudis.2011.05.007; Sanoh S, 2012, DRUG METAB DISPOS, V40, P322, DOI 10.1124/dmd.111.040923; SHIRLEY MA, 1994, J PHARMACOL EXP THER, V269, P1166; Hutzler JM, 2013, EXPERT OPIN DRUG MET, V9, P153, DOI 10.1517/17425255.2013.738668; Akabane T, 2011, XENOBIOTICA, V41, P372, DOI 10.3109/00498254.2010.549970; Dalvie D, 2009, CHEM RES TOXICOL, V22, P357, DOI 10.1021/tx8004357; Kola I, 2004, NAT REV DRUG DISCOV, V3, P711, DOI 10.1038/nrd1470; Smith DA, 2009, CHEM RES TOXICOL, V22, P267, DOI 10.1021/tx800415j; Sanoh S, 2012, DRUG METAB DISPOS, V40, P2267, DOI 10.1124/dmd.112.047555; Sanoh S, 2014, TOXICOL IN VITRO, V28, P1176, DOI 10.1016/j.tiv.2014.05.007; Garattini E, 2012, EXPERT OPIN DRUG MET, V8, P487, DOI 10.1517/17425255.2012.663352; Kepp DR, 1997, J CHROMATOGR B, V696, P235, DOI 10.1016/S0378-4347(97)00239-9; Sanoh S, 2014, BIOPHARM DRUG DISPOS, V35, P71, DOI 10.1002/bdd.1864; Gomez-Lechon MJ, 2014, EXPERT OPIN DRUG MET, V10, P1553, DOI 10.1517/17425255.2014.967680; James LP, 2003, DRUG METAB DISPOS, V31, P1499, DOI 10.1124/dmd.31.12.1499; Sanoh S, 2015, DRUG METAB PHARMACOK, V30, P52, DOI 10.1016/j.dmpk.2014.10.009	17	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	NOV	2015	135	11					1273	1279				7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CV0AI	WOS:000363908500008		
J	Sato, Y				Sato, Yuichiro			Structure and Function of a Novel Class of High Mannose-binding Proteins with Anti-viral or Anti-tumor Activity	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Review						high mannose-binding lectin; virus; cancer; integrin; epidermal growth factor receptor; autophagy	ANTI-HIV ACTIVITY; HEPATITIS-C VIRUS; ENTRY INHIBITOR GRIFFITHSIN; HOMOLOG LECTIN FAMILY; ALGA EUCHEUMA-SERRA; OSCILLATORIA-AGARDHII; CYANOVIRIN-N; IN-VITRO; CARBOHYDRATE SPECIFICITY; CYANOBACTERIAL LECTIN	The recently discovered high mannose (HM)-binding lectin family in lower organisms such as bacteria, cyanobacteria, and marine algae represents a novel class of anti-viral or anti-tumor compounds. This lectin family shows unique carbohydrate binding properties with exclusive high specificity for HM glycans with core trisaccharide comprising Man (1-3)Man alpha(1-6) Man at the D2 arm. At low nanomolar levels, these lectins exhibit potent antiviral activity against HIV and influenza viruses through the recognition of HM glycans on virus spike glycoproteins. In addition, some of these lectins, such as bacterial PFL, show cytotoxicity for various cancer cells at low micromolar levels. Cell surface molecules to which PFL bound were identified as integrin alpha 2 and epidermal growth factor receptor (EGFR) by peptide mass finger printing with MALDI-TOF MS. Upon PFL binding, these molecules were rapidly internalized to cytoplasm. EGFR was time dependently degraded in the presence of PFL, and this process was largely responsible for autophagy. Furthermore, PFL sensitizes cancer cells to the EGFR kinase inhibitor, gefitinib. In vivo experiments showed that intratumoral injection of PFL significantly inhibited the growth of tumors in nude mice. PFL-mediated down regulation of integrin/EGFR ultimately contributed to the inhibition of tumor growth both in vitro and in vivo. Thus, the novel anti-cancer mechanism of PFL suggests that this lectin is potentially useful as an anti-cancer drug or as an adjuvant for other drugs. This class of proteins will likely have beneficial impact as a tool for biochemical and biomedical research because of its unique carbohydrate specificity and various biological activities.	Yasuda Womens Univ, Fac Pharm, Dept Med Pharm, Asaminami Ku, Hiroshima 7310153, Japan	Sato, Y (reprint author), Yasuda Womens Univ, Fac Pharm, Dept Med Pharm, Asaminami Ku, 6-13-1 Yasuhigashi, Hiroshima 7310153, Japan.	sato-y@yasuda-u.ac.jp					Sato Y, 2007, J BIOL CHEM, V282, P11021, DOI 10.1074/jbc.M701252200; Bokesch HR, 2003, BIOCHEMISTRY-US, V42, P2578, DOI 10.1021/bi0205698; Ritchie G, 2010, VIROLOGY, V399, P257, DOI 10.1016/j.virol.2009.12.020; Ning Y, 2007, J BIOL CHEM, V282, P6380, DOI 10.1074/jbc.M610915200; Sato Y, 2000, COMP BIOCHEM PHYS B, V125, P169, DOI 10.1016/S0305-0491(99)00164-9; Sato Y, 2011, BIOCHEM BIOPH RES CO, V405, P291, DOI 10.1016/j.bbrc.2011.01.031; Xue J, 2013, ANTIMICROB AGENTS CH, V57, P3976, DOI 10.1128/AAC.00332-13; Moulaei T, 2010, STRUCTURE, V18, P1104, DOI 10.1016/j.str.2010.05.016; Morello V, 2011, ONCOGENE, V30, P4087, DOI 10.1038/onc.2011.107; Kelley BS, 2002, J AM CHEM SOC, V124, P3210, DOI 10.1021/ja025537m; Helle F, 2006, J BIOL CHEM, V281, P25177, DOI 10.1074/jbc.M602431200; O'Keefe BR, 2010, J VIROL, V84, P2511, DOI 10.1128/JVI.02322-09; Bewley CA, 2004, J MOL BIOL, V339, P901, DOI 10.1016/j.jmb.2004.04.019; Li Y, 2008, J VIROL, V82, P638, DOI 10.1128/JVI.01691-07; Hori K, 2007, GLYCOBIOLOGY, V17, P479, DOI 10.1093/glycob/cwm007; Sato Y, 2011, J BIOL CHEM, V286, P19446, DOI 10.1074/jbc.M110.216655; Koharudin LMI, 2012, J BIOL CHEM, V287, P33796, DOI 10.1074/jbc.M112.388579; Whitley MJ, 2013, FEBS J, V280, P2056, DOI 10.1111/febs.12229; Yu X, 2000, J CELL SCI, V113, P2139; Omokawa Y, 2010, INT J PHARMACEUT, V389, P157, DOI 10.1016/j.ijpharm.2010.01.033; Sato Y, 2015, MAR DRUGS, V13, P3454, DOI 10.3390/md13063454; Hung LD, 2011, PHYTOCHEMISTRY, V72, P855, DOI 10.1016/j.phytochem.2011.03.009; O'Keefe BR, 2009, P NATL ACAD SCI USA, V106, P6099, DOI 10.1073/pnas.0901506106; Balzarini J, 2007, NAT REV MICROBIOL, V5, P583, DOI 10.1038/nrmicro1707; Meuleman P, 2011, ANTIMICROB AGENTS CH, V55, P5159, DOI 10.1128/AAC.00633-11; Koharudin LMI, 2011, J BIOL CHEM, V286, P1588, DOI 10.1074/jbc.M110.173278; Mori K, 2005, J VIROL, V79, P10386, DOI 10.1128/JVI.79.16.10386-10396.2005; Mori T, 2005, J BIOL CHEM, V280, P9345, DOI 10.1074/jbc.M411122200; Fukuda Y, 2006, ANTI-CANCER DRUG, V17, P943, DOI 10.1097/01.cad.0000224458.13651.b4; O'Keefe BR, 2003, ANTIMICROB AGENTS CH, V47, P2518, DOI 10.1128/AAC.47.8.2518-2525.2003; Barrientos LG, 2003, ANTIVIR RES, V58, P47, DOI 10.1016/S0166-3542(02)00183-3; Bewley CA, 1998, NAT STRUCT BIOL, V5, P571, DOI 10.1038/828; MirShekari SY, 1997, J BIOL CHEM, V272, P4027; Duvet S, 1998, J BIOL CHEM, V273, P32088, DOI 10.1074/jbc.273.48.32088; Kuo CC, 1996, J CLIN INVEST, V98, P2813, DOI 10.1172/JCI119109; Barton C, 2014, ANTIMICROB AGENTS CH, V58, P120, DOI 10.1128/AAC.01407-13; Ferir G, 2014, J ANTIMICROB CHEMOTH, V69, P2746, DOI 10.1093/jac/dku220; Garrison AR, 2014, ANTIVIR RES, V112, P1, DOI 10.1016/j.antiviral.2014.09.012; Kouokam JC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022635; Morimoto K., 2014, J YASUDA WOMENS U, V42, P329; Sato Y., 2011, J YASUDA WOMENS U, V39, P295; Sato Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045922	42	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	NOV	2015	135	11					1281	1289				9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CV0AI	WOS:000363908500009		
J	Motoyama, K				Motoyama, Keiichi			Development of Cyclodextrin-based Cancer Treatment	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Review						cyclodextrin; folic acid; folate receptor; autophagy; cancer treatment	METHYL-BETA-CYCLODEXTRIN; LIPID RAFTS; CELL-DEATH; AUTOPHAGY; APOPTOSIS; MITOCHONDRIA; BAFILOMYCIN; INVOLVEMENT; DELIVERY; GD3	Drug delivery techniques to tumor cells have attracted considerable attention. For instance, folic acid (FA) as a tumor-targeting ligand is widely used because of overexpression of folate receptor-alpha (FR-alpha) in various kinds of epithelial tumor cells. On the other hand, methyl-beta-cyclodextrin (M-beta-CyD) is acknowledged to induce cell death through the extraction of cholesterol from lipid rafts. It was recently reported that intraperitoneal administration of M-beta-CyD exerted antitumor activity in human tumor xenografted athymic nude mice. However, the cytotoxic activity of M-beta-CyD is known to lack tumor cell selectivity. Therefore in the present study, in an attempt to confer tumor cell selectivity to M-beta-CyD, we newly synthesized folate-appended M-beta-CyD (FA-M-beta-CyD) and evaluated its potential as a novel antitumor agent. FA-M-beta-CyD showed potent antitumor activity in various FR-alpha-positive cells such as KB cells, Ihara cells, and M213 cells but not in FR-alpha-negative cells, A549 cells. FA-M-beta-CyD induced the formation of autophagic vacuoles in KB cells. In addition, the antitumor activity of FA-M-beta-CyD, but not M-beta-CyD, was inhibited by addition of the autophagy inhibitors chloroquine and bafilomycin A1 in KB cells. A single intravenous injection of FA-M-beta-CyD drastically inhibited tumor growth and significantly improved survival rate in Colon-26 cells-allografted or M213 cells-xenografted mice. In conclusion, FA-M-beta-CyD has potential as a novel tumor-selective anticancer agent due to FR-alpha-mediated cellular uptake. The present results provide useful information for the design and development of novel antitumor drug carriers and antitumor drugs based on CyDs.	Kumamoto Univ, Grad Sch Pharmaceut Sci, Dept Phys Pharmaceut, Chuo Ku, Kumamoto 8620973, Japan	Motoyama, K (reprint author), Kumamoto Univ, Grad Sch Pharmaceut Sci, Dept Phys Pharmaceut, Chuo Ku, 5-1 Oe Honmachi, Kumamoto 8620973, Japan.	motoyama@kumamoto-u.ac.jp					Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33; Ziolkowski W, 2010, FEBS LETT, V584, P4606, DOI 10.1016/j.febslet.2010.10.023; Grosse PY, 1998, BRIT J CANCER, V78, P1165, DOI 10.1038/bjc.1998.648; Martinez-Abundis E, 2007, FEBS J, V274, P6500, DOI 10.1111/j.1742-4658.2007.06166.x; Shacka JJ, 2006, AUTOPHAGY, V2, P228; Ono A, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/539748; Chauhan VP, 2012, NAT NANOTECHNOL, V7, P383, DOI [10.1038/nnano.2012.45, 10.1038/NNANO.2012.45]; Motoyama K, 2009, EUR J PHARM SCI, V38, P249, DOI 10.1016/j.ejps.2009.07.010; Johansen T, 2011, AUTOPHAGY, V7, P279, DOI 10.4161/auto.7.3.14487; Yan J, 2012, ANTI-CANCER DRUG, V23, P22, DOI 10.1097/CAD.0b013e32834a099c; Lu YJ, 2002, ADV DRUG DELIVER REV, V54, P675, DOI 10.1016/S0169-409X(02)00042-X; Ayllon V, 2002, J IMMUNOL, V168, P3387; Garofalo T, 2005, CELL DEATH DIFFER, V12, P1378, DOI 10.1038/sj.cdd.4401672; Nabi IR, 2003, J CELL BIOL, V161, P673, DOI 10.1083/jcb.200302028; Kim I, 2011, AM J PHYSIOL-CELL PH, V300, pC308, DOI 10.1152/ajpcell.00056.2010; Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028; Chen H, 2009, MOL CANCER THER, V8, P1955, DOI 10.1158/1535-7163.MCT-09-0045; Parker N, 2005, ANAL BIOCHEM, V338, P284, DOI 10.1016/j.ab.2004.12.026; Janku F, 2011, NAT REV CLIN ONCOL, V8, P528, DOI 10.1038/nrclinonc.2011.71; Malorni W, 2007, APOPTOSIS, V12, P941, DOI 10.1007/s10495-007-0757-1; Connors KA, 1997, CHEM REV, V97, P1325, DOI 10.1021/cr960371r; Uekama K, 2004, CHEM PHARM BULL, V52, P900, DOI 10.1248/cpb.52.900; Fulop T, 2004, AGING CELL, V3, P217, DOI 10.1111/j.1474-9728.2004.00110.x; Reis-Sobreiro M, 2009, ONCOGENE, V28, P3221, DOI 10.1038/onc.2009.183; Bender M. L., 1978, REACTIVITY STRUCTURE; Chaigne-Delalande B, 2009, CELL DEATH DIFFER, V16, P1654, DOI 10.1038/cdd.2009.111; Garofaloa T, 2007, FEBS LETT, V581, P3899, DOI 10.1016/j.febslet.2007.07.020; Irie T, 1997, J PHARM SCI, V86, P147, DOI 10.1021/js960213f; Motoyama K, 2015, BIOL PHARM BULL, V38, P374, DOI 10.1248/bpb.b14-00531; Onodera R, 2014, SCI REP-UK, V4, DOI 10.1038/srep04417; Onodera R, 2013, SCI REP-UK, V3, DOI 10.1038/srep01104	31	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	NOV	2015	135	11					1291	1298				8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CV0AI	WOS:000363908500010		
J	Yamaguchi, Y				Yamaguchi, Yoshihiro			Structure-Function Analysis and Development of Inhibitors of Metallo-beta-lactamases Conferring Drug Resistance in Bacteria	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Review						antibiotic resistance; beta-lactam antibiotics; enzyme; metallo-beta-lactamase; zinc; inhibitor	PSEUDOMONAS-AERUGINOSA; SERRATIA-MARCESCENS; MERCAPTOCARBOXYLATE INHIBITOR; CRYSTAL-STRUCTURE; CLINICAL ISOLATE; THIOL-GROUPS; IMP-1; HYDROLYSIS; BINDING; SCHEME	Metallo-beta-lactamases (MBLs) are di-Zn (II) metalloenzymes that efficiently hydrolyze most beta-lactam antibiotics used in clinical settings. Bacteria producing MBLs have been isolated from clinical settings and from natural environments such as rivers and soils, and are now recognized as a new potential threat to human health. No effective inhibitors are available for clinical use, making the treatment of infectious diseases caused by bacteria producing MBLs more difficult. IMP-1 is encoded on a plasmid which can be horizontally transferred between bacterial strains. Our studies on MBLs, and especially on IMP-1, focus on understanding the role of Zn (II) ion (s) in the hydrolysis of beta-lactam antibiotics and on the detailed structure of the IMP-1 active site in order to develop efficient inhibitors. We investigated the role of the two Zn (II) ions in IMP-1 by kinetic, spectroscopic and thermodynamic analyses. The results revealed that the first Zn (II) ion is necessary for the hydrolysis of beta-lactam.antibiotics while the second Zn (II) ion enhances enzyme activity and structural stability, thus helping the enzyme achieve maximum activity. The detailed structures of the IMP-1 active site were examined by X-ray crystallography. Thiol compounds for irreversibly inhibiting IMP-1 were developed and the binding mode of these inhibitors was investigated in detail. These findings will aid the design of inhibitors that target MBLs.	Kumamoto Univ, Environm Safety Ctr, Chuo Ku, Kumamoto 8608555, Japan	Yamaguchi, Y (reprint author), Kumamoto Univ, Environm Safety Ctr, Chuo Ku, 40-1 Kurokami 2 Chome, Kumamoto 8608555, Japan.	yyamagu@gpo.kumamoto-u.ac.jp					AMBLER RP, 1980, PHILOS T ROY SOC B, V289, P321, DOI 10.1098/rstb.1980.0049; Concha NO, 1996, STRUCTURE, V4, P823, DOI 10.1016/S0969-2126(96)00089-5; BUSH K, 1995, ANTIMICROB AGENTS CH, V39, P1211; Kurosaki H, 2003, ORG BIOMOL CHEM, V1, P17, DOI 10.1039/b209086d; Galleni M, 2001, ANTIMICROB AGENTS CH, V45, P660, DOI 10.1128/AAC.45.3.660-663.2001; de Seny D, 2001, J BIOL CHEM, V276, P45065, DOI 10.1074/jbc.M106447200; OSANO E, 1994, ANTIMICROB AGENTS CH, V38, P71; Goto M, 2003, BIOL PHARM BULL, V26, P589; ARAKAWA Y, 1995, ANTIMICROB AGENTS CH, V39, P1612; Yamaguchi Y, 2007, J MED CHEM, V50, P6647, DOI 10.1021/jm701031n; Fast W, 2013, BBA-PROTEINS PROTEOM, V1834, P1648, DOI 10.1016/j.bbapap.2013.04.024; Tioni MF, 2008, J AM CHEM SOC, V130, P15852, DOI 10.1021/ja801169j; Kurosaki H, 2006, CHEMMEDCHEM, V1, P969, DOI 10.1002/cmdc.200600115; Llarrull LI, 2007, J BIOL CHEM, V282, P18276, DOI 10.1074/jbc.M700742200; Lauretti L, 1999, ANTIMICROB AGENTS CH, V43, P1584; Siemann S, 2002, BBA-GEN SUBJECTS, V1571, P190, DOI 10.1016/S0304-4165(02)00258-1; Goto M, 1997, BIOL PHARM BULL, V20, P1136; Yamaguchi Y, 2011, CHEMBIOCHEM, V12, P1979, DOI 10.1002/cbic.201100342; Haruta S, 2000, ANTIMICROB AGENTS CH, V44, P2304, DOI 10.1128/AAC.44.9.2304-2309.2000; Kurosaki H, 2005, ANGEW CHEM INT EDIT, V44, P3861, DOI 10.1002/anie.200500835; Concha NO, 2000, BIOCHEMISTRY-US, V39, P4288, DOI 10.1021/bi992569m; Yong D, 2009, ANTIMICROB AGENTS CH, V53, P5046, DOI 10.1128/AAC.00774-09	22	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	NOV	2015	135	11					1299	1305				7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CV0AI	WOS:000363908500011		
J	Kurita, K; Mochizuki, Y; Kokubun, H; Atsuta, K				Kurita, Kaoru; Mochizuki, Yuka; Kokubun, Hideya; Atsuta, Kouichirou			Evaluation of Detachment and Clinical Usability of Transdermal Fentanyl Patches in Healthy Volunteers	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Article						transdermal fentanyl; detachment; clinical usability	MORPHINE	The dose of a transdermal fentanyl patch is proportional to its application site area. Therefore, the absorption of fentanyl may decrease if the patch detaches, leading to insufficient analgesia. Sixteen healthy volunteers were enrolled in a study to investigate the appropriate application sites and clinical utility of three transdermal fentanyl patches available in Japan. Three placebos, Fentanyl 1-day (Fentos; Fen), Fentanyl 3-day (Durotep; Dur), and Generic Fentanyl 3-day (HMT) were administered using a crossover study design. The placebos were applied to 11 different sites, including both sides of the upper arm, abdomen, back, thigh, chest, and the middle of the chest. We determined the patch detachment area and incidence of patch-induced itching every 24 h and evaluated differences between each application site using the Wilcoxon signed-rank test. Significant patch detachment was observed on the abdomen and upper arms with Fen, on the abdomen and chest with Dur, and on the chest with HMT compared with that at other sites (p<0.005). Although no significant difference in itching was observed between regions when administering Fen, itching significantly increased on the chest and back when using Dur and on the abdomen when using HMT as compared with that at other sites (p<0.05). Our results indicate that the three transdermal Fen patches exhibit different adhesive properties and local adverse events, indicating that the application site should be cautiously selected for each patch type.	[Kurita, Kaoru] Kitasato Univ Hosp, Dept Nursing, Minami Ku, Sagamihara, Kanagawa 2520375, Japan; [Mochizuki, Yuka; Atsuta, Kouichirou] Kitasato Univ, Sch Pharm, Minato Ku, Tokyo 1088641, Japan; [Kokubun, Hideya; Atsuta, Kouichirou] Kitasato Univ Hosp, Dept Pharm, Minami Ku, Sagamihara, Kanagawa 2520375, Japan	Kurita, K (reprint author), Kitasato Univ Hosp, Dept Nursing, Minami Ku, 1-15-1 Kitasato, Sagamihara, Kanagawa 2520375, Japan.	k.kurita@kitasato-u.ac.jp					Hunt R, 1999, J PAIN SYMPTOM MANAG, V18, P111, DOI 10.1016/S0885-3924(99)00051-2; [Anonymous], 2012, FENT 3 DAYS TAP HMT; Ashburn MA, 2003, J PAIN, V4, P291, DOI 10.1016/S1526-5900(03)00618-7; Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; GUPTA SK, 1992, J PAIN SYMPTOM MANAG, V7, pS17, DOI 10.1016/0885-3924(92)90049-N; [Anonymous], 2011, FENT TAP INT FORM; [Anonymous], 2011, DUR MT PATCH INT FOR; Hattori S., 2010, J NEW REMEDIES CLIN, V59, P1425; Heiskanen T., 1999, PAIN, V144, P218; Image J, IM ANAL SOFTW; Ooi K., 2008, JPN PHARMACOL THER, V36, P589; Oshima S., 2012, JPN J PHARM PALLIAT, V5, P7; World Health Organization, 1986, CANC PAIN REL; Yoshimaru K., 2010, AUTONOMIC NERVOUS SY, V47, P138	14	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	NOV	2015	135	11					1307	1315				9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CV0AI	WOS:000363908500012		
J	Nakai, K; Kamimori, H; Nagao, A; Nakayama, A				Nakai, Keiko; Kamimori, Hiroshi; Nagao, Akemi; Nakayama, Akira			Discussion on Partial Validation in Small Molecule Regulated Bioanalysis: Change in Analytical Instruments	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Article						partial validation; analytical instrument change; guidance/guideline; bioanalytical method validation; discussion group; Japan Bioanalysis Forum	RECENT ISSUES; WHITE PAPER; CARRYOVER	In recent years, the necessity of a bioanalytical method validation has been discussed and guidance/guidelines have been released from regulatory agencies. However, none of these provides any details for partial validation (PV) in case of a partial change in the validated analytical method. Therefore eleven scientists have launched a discussion group (DG) with the approval of Japan Bioanalysis Forum (JBF), and have been discussing PV for chromatographic methods based on survey results of Japanese bioanalysts. This document reports the results of discussion on PV for a change of analytical instruments such as: 1) full system (limited to same manufacturer and model); 2) pump; 3) autosampler; and 4) mass spectrometer. The DG members agreed on an outline that validation items required for PV are as follows: calibration curve and reproducibility in case 1); calibration curve, reproducibility, and selectivity in case 2); calibration curve, reproducibility, and carryover in case 3); and nearly full validation items without recovery, dilution integrity, and stability in case 4), in consideration of instrument specification and characteristics of each analytical method. Note that this report does not represent a consensus of all the members of JBF, but is a recommendation from the DG members at this stage. Thus further thought is recommended for future discussions.	[Nakai, Keiko] LSI Medience Corp, Adv Technol Ctr, Bioanal Dept, Itabashi Ku, Tokyo 1748555, Japan; [Kamimori, Hiroshi] Shionogi & Co Ltd, Res Lab Dev, Appl Chem & Anal, Toyonaka, Osaka 5610825, Japan; [Nagao, Akemi] Japan Tobacco Inc, Cent Pharmaceut Res Inst, Drug Metab & Pharmacokinet Res Labs, Takatsuki, Osaka 5691125, Japan; [Nakayama, Akira] Ajinomoto Pharmaceut Co Ltd, Res Inst, Kawasaki Ku, Kawasaki, Kanagawa 2108681, Japan	Nakai, K (reprint author), LSI Medience Corp, Adv Technol Ctr, Bioanal Dept, Itabashi Ku, 30-1 Shimura 3 Chome, Tokyo 1748555, Japan.	Nakai.Keiko@mu.medience.co.jp					SHAH VP, 1992, PHARMACEUT RES, V9, P588, DOI 10.1023/A:1015829422034; Clouser-Roche A, 2008, J PHARMACEUT BIOMED, V47, P146, DOI 10.1016/j.jpba.2007.12.019; Zeng W, 2006, RAPID COMMUN MASS SP, V20, P635, DOI 10.1002/rcm.2353; Vallano PT, 2005, J PHARMACEUT BIOMED, V36, P1073, DOI 10.1016/j.jpba.2004.09.010; Nakayama A, 2014, BIOANALYSIS, V6, P915, DOI [10.4155/bio.14.41, 10.4155/BIO.14.41]; Garofolo F, 2011, BIOANALYSIS, V3, P2081, DOI [10.4155/bio.11.192, 10.4155/BIO.11.192]; [Anonymous], GUID BIOAN METH VAL; Briggs RJ, 2014, AAPS J, V16, P1143, DOI 10.1208/s12248-014-9650-3; Fluhler E, 2014, BIOANALYSIS, V6, P3039, DOI 10.4155/bio.14.265; Mikami H., 2011, CHROMATOGRAPHY, V32, P17; Ministry of Health Labour and Welfare, GUID BIOAN METH VAL; US Food and Drug Administration, GUID IND BIOAN METH; Viswanathan CT, 2007, AAPS J, V9, pE30, DOI 10.1208/aapsj0901004; Watanabe K., 2013, B RES I MED SCI NIHO, V1, P115; Yuzuriha Teruaki, 1996, Journal of Toxicological Sciences, V21, P505	15	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	NOV	2015	135	11					1317	1324				8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CV0AI	WOS:000363908500013		
J	Fan, JS; Fukumoto, Y; Nakamura, G; Zhou, Y				Fan, Jishan; Fukumoto, Yasuhide; Nakamura, Gen; Zhou, Yong			Regularity criteria for the incompressible Hall-MHD system	ZAMM-ZEITSCHRIFT FUR ANGEWANDTE MATHEMATIK UND MECHANIK			English	Article						Hall-MHD; regularity criterion; pressure	EQUATIONS; MAGNETOHYDRODYNAMICS	This paper proves some regularity criteria for the Hall-MHD system in terms of the pressure and the magnetic field. (C) 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim	[Fan, Jishan] Nanjing Forestry Univ, Dept Appl Math, Nanjing 210037, Jiangsu, Peoples R China; [Fukumoto, Yasuhide] Kyushu Univ, Inst Math Ind, Nishi Ku, Fukuoka 8190395, Japan; [Nakamura, Gen] Inha Univ, Dept Math, Inchon 402751, South Korea; [Zhou, Yong] Shanghai Univ Finance & Econ, Sch Math, Shanghai 200433, Peoples R China; [Zhou, Yong] King Abdulaziz Univ, Fac Sci, Dept Math, Jeddah 21589, Saudi Arabia	Zhou, Y (reprint author), Shanghai Univ Finance & Econ, Sch Math, Shanghai 200433, Peoples R China.	fanjishan@njfu.com.cn; yasuhide@imi.kyushu-u.ac.jp; nakamuragenn@gmail.com; yzhou@mail.shufe.edu.cn			NSFC [11171154]; Deanship of Scientific Research (DSR), King Abdulaziz University [27-130-35-HiCi]; KAU	Fan is partially supported by NSFC (No. 11171154). This project is funded by the Deanship of Scientific Research (DSR), King Abdulaziz University, under Grant No. 27-130-35-HiCi. The authors, therefore acknowledge technical and financial support of KAU.	Acheritogaray M, 2011, KINET RELAT MOD, V4, P901, DOI 10.3934/krm.2011.4.901; Zhou Y, 2006, INT J NONLINEAR MECH, V41, P1174, DOI 10.1016/j.ijnonlinmec.2006.12.001; Lei Z, 2009, DISCRETE CONT DYN S, V25, P575, DOI 10.3934/dcds.2009.25.575; Zhou Y, 2012, FORUM MATH, V24, P691, DOI 10.1515/FORM.2011.079; Chae D, 2013, J DIFFER EQUATIONS, V255, P3971, DOI 10.1016/j.jde.2013.07.059; FEFFERMA.C, 1972, ACTA MATH-UPPSALA, V129, P137, DOI 10.1007/BF02392215; Fan JS, 2013, APPL MATH LETT, V26, P963, DOI 10.1016/j.aml.2013.04.008; Dreher J, 2005, PHYS SCRIPTA, V72, P451, DOI 10.1088/0031-8949/72/6/004; Fan JS, 2011, J MATH FLUID MECH, V13, P557, DOI 10.1007/s00021-010-0039-5; Fan JS, 2014, CONTEMP MATH, V612, P81, DOI 10.1090/conm/612/12225; Chen QL, 2008, COMMUN MATH PHYS, V284, P919, DOI 10.1007/s00220-008-0545-y; Chae D., 2013, ARXIV13125519V1MATHA; Chae D., ANN I H POI IN PRESS; Fan J., 2014, REGULARITY CRITERIA; Lee J., 2013, ARXIV13054681V2MATHA; Sueur F., COMMUN MATH IN PRESS	16	0	0	WILEY-V C H VERLAG GMBH	WEINHEIM	POSTFACH 101161, 69451 WEINHEIM, GERMANY	0044-2267	1521-4001		ZAMM-Z ANGEW MATH ME	ZAMM-Z. Angew. Math. Mech.	NOV	2015	95	11					1156	1160		10.1002/zamm.201400102		5	Mathematics, Applied; Mechanics	Mathematics; Mechanics	CU9SL	WOS:000363885300004		
J	Wang, JQ; Zheng, Y; Li, XF; Yu, CF; Kodaka, K; Li, KQ				Wang, Jianqiang; Zheng, Yang; Li, Xiaofei; Yu, Chenfei; Kodaka, Kenji; Li, Keqiang			Driving risk assessment using near-crash database through data mining of tree-based model	ACCIDENT ANALYSIS AND PREVENTION			English	Article						Naturalistic driving study; Driving risk; Near-crash; Classification and regression tree (CART); K-mean cluster	DRIVER INJURY SEVERITY; CLASSIFICATION TREES; LOGISTIC-REGRESSION; SAFETY PERFORMANCE; ACCIDENT SEVERITY; DECISION TREES; RULES; FREQUENCY; BRAKING; EVENTS	This paper considers a comprehensive naturalistic driving experiment to collect driving data under potential threats on actual Chinese roads. Using acquired real-world naturalistic driving data, a near-crash database is built, which contains vehicle status, potential crash objects, driving environment and road types, weather condition, and driver information and actions. The aims of this study are summarized into two aspects: (1) to cluster different driving-risk levels involved in near-crashes, and (2) to unveil the factors that greatly influence the driving-risk level. A novel method to quantify the driving-risk level of a near-crash scenario is proposed by clustering the braking process characteristics, namely maximum deceleration, average deceleration, and percentage reduction in vehicle kinetic energy. A classification and regression tree (CART) is employed to unveil the relationship among driving risk, driver/vehicle characteristics, and road environment. The results indicate that the velocity when braking, triggering factors, potential object type, and potential crash type exerted the greatest influence on the driving-risk levels in near-crashes. (C) 2015 Elsevier Ltd. All rights reserved.	[Wang, Jianqiang; Zheng, Yang; Li, Xiaofei; Yu, Chenfei; Li, Keqiang] Tsinghua Univ, State Key Lab Automot Safety & Energy, Beijing 10084, Peoples R China; [Kodaka, Kenji] Honda Res & Dev Co Ltd, Automobile R&D Ctr, Haga, Tochigi 3213393, Japan	Li, KQ (reprint author), Tsinghua Univ, State Key Lab Automot Safety & Energy, Beijing 10084, Peoples R China.	likq@tsinghua.edu.cn			joint project of Tsinghua and Honda; National Natural Science Foundation of China [51175290, 51475254]	This collaborative research was supported by a joint project of Tsinghua and Honda. The authors would like to thank the National Natural Science Foundation of China (No. 51175290 and No. 51475254) for its support. The authors would also like to thank those who participated in the driving experiments.	Montella A, 2015, ACCIDENT ANAL PREV, V74, P133, DOI 10.1016/j.aap.2014.10.019; Abdel-Aty M, 2003, J SAFETY RES, V34, P597, DOI 10.1016/j.jsr.2003.05.009; de Ona J, 2013, ACCIDENT ANAL PREV, V50, P1151, DOI 10.1016/j.aap.2012.09.006; Lord D, 2010, TRANSPORT RES A-POL, V44, P291, DOI 10.1016/j.tra.2010.02.001; Li XG, 2008, ACCIDENT ANAL PREV, V40, P1611, DOI 10.1016/j.aap.2008.04.010; Guo F, 2010, TRANSP RES RECORD, P66, DOI 10.3141/2147-09; Al-Ghamdi AS, 2002, ACCIDENT ANAL PREV, V34, P729, DOI 10.1016/S0001-4575(01)00073-2; Sepulcre M, 2013, TRANSPORT RES C-EMER, V26, P233, DOI 10.1016/j.trc.2012.10.003; Rakha H, 2007, IEEE T INTELL TRANSP, V8, P630, DOI 10.1109/TITS.2007.908146; Wu KF, 2012, ACCIDENT ANAL PREV, V45, P507, DOI 10.1016/j.aap.2011.09.002; Abdelwahab HT, 2001, TRANSPORT RES REC, P6; Chang LY, 2005, J SAFETY RES, V36, P365, DOI 10.1016/j.jsr.2005.06.013; Takeda K, 2011, IEEE T INTELL TRANSP, V12, P1609, DOI 10.1109/TITS.2011.2167680; Malta L, 2009, IEEE T INTELL TRANSP, V10, P201, DOI 10.1109/TITS.2009.2018321; Harb R, 2009, ACCIDENT ANAL PREV, V41, P98, DOI 10.1016/j.aap.2008.09.009; Montella A, 2012, ACCIDENT ANAL PREV, V49, P58, DOI 10.1016/j.aap.2011.04.025; Zheng Y, 2014, 2014 IEEE 17TH INTERNATIONAL CONFERENCE ON INTELLIGENT TRANSPORTATION SYSTEMS (ITSC), P2094; Jarasuniene A, 2007, TRANSPORT, V22, P284; Young W, 2014, ACCIDENT ANAL PREV, V66, P89, DOI 10.1016/j.aap.2014.01.008; Chen HQ, 2012, TRAFFIC INJ PREV, V13, P300, DOI 10.1080/15389588.2011.653841; Guo F, 2013, ACCIDENT ANAL PREV, V61, P3, DOI 10.1016/j.aap.2012.06.014; Aoude GS, 2012, IEEE T INTELL TRANSP, V13, P724, DOI 10.1109/TITS.2011.2179537; Lu GQ, 2012, SAFETY SCI, V50, P1898, DOI 10.1016/j.ssci.2012.05.007; Abellan J, 2013, EXPERT SYST APPL, V40, P6047, DOI 10.1016/j.eswa.2013.05.027; Wu KF, 2013, TRANSPORT RES REC, P137, DOI 10.3141/2386-16; Moreno AT, 2013, ACCIDENT ANAL PREV, V61, P23, DOI 10.1016/j.aap.2012.10.013; Montella A, 2011, TRANSPORT RES REC, P107, DOI 10.3141/2237-12; Pande A, 2006, ACCIDENT ANAL PREV, V38, P936, DOI 10.1016/j.aap.2006.03.004; Chang LY, 2006, ACCIDENT ANAL PREV, V38, P1019, DOI 10.1016/j.aap.2006.04.009; Bagdadi O, 2013, TRANSPORT RES F-TRAF, V16, P117, DOI 10.1016/j.trf.2012.08.006; Breiman L, 1984, CLASSIFICATION REGRE; Charlton SG, 2014, TRANSPORT RES F-TRAF, V25, P50, DOI 10.1016/j.trf.2014.05.003; Dingus T.A., 2006, HS810593; Donmez B., 2009, J TRANSP ENG-ASCE, V136, P403; Elvik R., 2004, 740 TOI, V740, P2004; [GMRDC UMTRI], 2005, AUT COLL AV SYST FIE; Jonasson JK, 2014, ACCIDENT ANAL PREV, V62, P102, DOI 10.1016/j.aap.2013.09.013; Jovanis PP, 2011, TRANSPORT RES REC, P49, DOI 10.3141/2236-06; [Ministry of Public Security Department of Traffic Management DTM-China], 2010, ANN REP ROAD TRAFF A; Montella, 2013, TRANSPORT RES REC, V2386, P128; Rousseeuw P.J., 2009, FINDING GROUPS DATA, V344; Wallen W. H., 2008, TRANSPORT RES F-TRAF, V11, P376, DOI DOI 10.1016/J.TRF.2008.03.002; Wang JQ, 2015, INTEGR COMPUT-AID E, V22, P171, DOI 10.3233/ICA-150486; Wu K.F., 2014, ACCIDENT ANAL PREV, V47, P210	44	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0001-4575	1879-2057		ACCIDENT ANAL PREV	Accid. Anal. Prev.	NOV	2015	84						54	64		10.1016/j.aap.2015.07.007		11	Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation	Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation	CU2IU	WOS:000363348000007		
J	Oda, S; Katahira, K; Utsunomiya, D; Takaoka, H; Honda, K; Noda, K; Oshima, S; Yuki, H; Namimoto, T; Yamashita, Y				Oda, Seitaro; Katahira, Kazuhiro; Utsunomiya, Daisuke; Takaoka, Hiroko; Honda, Keiichi; Noda, Katsuo; Oshima, Shuichi; Yuki, Hideaki; Namimoto, Tomohiro; Yamashita, Yasuyuki			Improved image quality at 256-slice coronary CT angiography in patients with a high heart rate and coronary artery disease: comparison with 64-slice CT imaging	ACTA RADIOLOGICA			English	Article						Coronary CT angiography; image quality; 256-slice CT; rotation speed; heart rate; computed tomography (CT)	CARDIAC COMPUTED-TOMOGRAPHY; METAANALYSIS; ASSOCIATION; CARDIOLOGY; RADIOLOGY; TRIAL; MDCT	Background: The 256-slice computed tomography (CT) scanners with wider detector coverage and faster gantry rotation speed are now available. The performance of scanners that feature a rotation speed of 270 ms at coronary CT angiography (CCTA) has not been evaluated in patients with a higher heart rate. Purpose: To evaluate the image quality of 256-slice CT with faster gantry rotation speed in patients undergoing CCTA. Material and Methods: We enrolled 886 patients; 357(40.3%) underwent study on a 64-slice CT at a rotation speed of 420 ms, the other 529 (59.7%) were examined using a 256-slice CT scanner at 270 ms. Two observers judged the image quality of 2658 imaged coronary arteries on a 4-point scale. Results: The mean image quality score was significantly higher for the 256 - than the 64-slice CT scans (3.94 +/- 0.28 vs. 3.73 +/- 0.61; P < 0.01). There was no significant difference in the image quality scores between 64- and 256-slice scans in patients whose heart rate (HR) was <60 bpm. However, in patients whose HR exceeded 60 bpm these scores were significantly higher for 256-slice CT images (P<0.01). Conclusion: CCTA performed on the 256-slice CT scanner yielded significantly better image quality in patients with an HR exceeding 60 bpm.	[Oda, Seitaro; Utsunomiya, Daisuke; Yuki, Hideaki; Namimoto, Tomohiro; Yamashita, Yasuyuki] Kumamoto Univ, Dept Diagnost Radiol, Fac Life Sci, Kumamoto 8608556, Japan; [Katahira, Kazuhiro; Takaoka, Hiroko; Honda, Keiichi] Kumamoto City Hosp, Dept Diagnost Radiol, Kumamoto, Japan; [Noda, Katsuo; Oshima, Shuichi] Kumamoto City Hosp, Dept Cardiol, Kumamoto, Japan	Oda, S (reprint author), Kumamoto Univ, Dept Diagnost Radiol, Fac Life Sci, Chuou Ku, 1-1-1 Honjo, Kumamoto 8608556, Japan.	seisei0430@nifty.com					Abbara Suhny, 2009, J Cardiovasc Comput Tomogr, V3, P190, DOI 10.1016/j.jcct.2009.03.004; Chen JJ, 2009, RADIOGRAPHICS, V29, P1393, DOI 10.1148/rg.295095002; Bamberg F, 2010, EUR J RADIOL, V74, P182, DOI 10.1016/j.ejrad.2009.03.001; Meijer AB, 2008, AM J ROENTGENOL, V191, P1667, DOI 10.2214/AJR.07.4022; Khan A, 2011, AM J ROENTGENOL, V197, P163, DOI 10.2214/AJR.10.5250; Hou Y, 2012, INT J CARDIOVAS IMAG, V28, P153, DOI 10.1007/s10554-010-9760-7; Klass O, 2010, EUR RADIOL, V20, P1124, DOI 10.1007/s00330-009-1652-7; Dewey M, 2010, AM J ROENTGENOL, V194, P93, DOI 10.2214/AJR.09.2833; Leschka S, 2006, RADIOLOGY, V241, P378, DOI 10.1148/radiol.2412051384; Shuman WP, 2008, RADIOLOGY, V248, P431, DOI 10.1148/radiol.2482072192; Maffei E, 2009, EUR RADIOL, V19, P2931, DOI 10.1007/s00330-009-1509-0; Muenzel D, 2011, EUR RADIOL, V21, P2277, DOI 10.1007/s00330-011-2185-4; Miller JM, 2008, NEW ENGL J MED, V359, P2324, DOI 10.1056/NEJMoa0806576; Seneviratne SK, 2010, CIRC-CARDIOVASC IMAG, V3, P375, DOI 10.1161/CIRCIMAGING.109.892638; Jessen KA, 1999, APPL RADIAT ISOTOPES, V50, P165, DOI 10.1016/S0969-8043(98)00024-4; Cademartiri F, 2004, RADIOLOGY, V233, P817, DOI 10.1148/radiol.2333030668; Hoffmann MHK, 2005, RADIOLOGY, V234, P86, DOI 10.1148/radiol.2341031408; Budoff MJ, 2006, CIRCULATION, V114, P1761, DOI 10.1161/CIRCULATIONAHA.106.178458; Wang M, 2009, EUR J RADIOL, V72, P396, DOI 10.1016/j.ejrad.2008.08.010; Wicky S, 2003, J COMPUT ASSIST TOMO, V27, P392, DOI 10.1097/00004728-200305000-00016; Nagao M, 2009, CIRC J, V73, P905; Mowatt G, 2008, HEART, V94, P1386, DOI 10.1136/hrt.2008.145292; Shim SS, 2005, AM J ROENTGENOL, V184, P649; Halliburton SS, 2003, HERZ, V28, P20, DOI 10.1007/s00059-003-2445-4; Jacobs Jill E, 2006, J Am Coll Radiol, V3, P677, DOI 10.1016/j.jacr.2006.06.006; Taylor AJ, 2010, CIRCULATION, V122, pE525, DOI 10.1161/CIR.0b013e3181fcae66	26	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0284-1851	1600-0455		ACTA RADIOL	Acta Radiol.	NOV	2015	56	11					1308	1314		10.1177/0284185114555152		7	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CU0OZ	WOS:000363218100007		
J	Amano, Y; Kitamura, M; Yamada, F; Aita, K; Takayama, M; Tachi, M; Kumita, S				Amano, Yasuo; Kitamura, Mitsunobu; Yamada, Fumi; Aita, Kumiko; Takayama, Morimasa; Tachi, Masaki; Kumita, Shinichiro			Magnetic resonance imaging of microvascular obstruction in hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation	ACTA RADIOLOGICA			English	Article						Magnetic resonance imaging (MRI); microvascular obstruction; hypertrophic obstructive cardiomyopathy; percutaneous transmural septal myocardial ablation	OUTFLOW TRACT OBSTRUCTION; INFARCTION; MORPHOLOGY; CIBENZOLINE; REDUCTION	Background: The clinical significance of microvascular obstruction (MO) in hypertrophic cardiomyopathy (HOCM) after percutaneous transluminal septal myocardial ablation (PTSMA) remains unknown. Purpose: To assess the relationship between the location of MO and the improvement in symptoms and pressure gradient after PTSMA in patients with HOCM. Material and Methods: Twenty-three patients with HOCM underwent MRI within 24 weeks after PTSMA. The MO was defined visually as the hypointense region adjacent to the left or right ventricular cavity, which was surrounded by myocardial infarction. The location of MO and improvement in clinical symptoms and pressure gradient at 3-6 months follow-up were assessed. Results: MO was observed in 16 patients who underwent MRI within 7 weeks after PTSMA. Left-sided MO was observed in 12 patients, and right-sided MO was observed in four patients. Improvement in clinical symptoms and reduction in the pressure gradient were not sufficient in the patients with right-sided MO, while PTSMA was effective in the patients with the left-sided MO. Conclusion: The location of MO identified by MRI may be related to the effectiveness of PTSMA at the short-term follow-up. The left-sided MO is related to complete improvement in clinical symptoms and pressure gradients.	[Amano, Yasuo; Yamada, Fumi; Aita, Kumiko; Tachi, Masaki; Kumita, Shinichiro] Nippon Med Sch, Dept Radiol, Tokyo 1138603, Japan; [Kitamura, Mitsunobu] Nippon Med Sch, Intens Coronary Care Unit, Tokyo 1138603, Japan; [Takayama, Morimasa] Sakakibara Heart Inst, Dept Cardiol, Tokyo, Japan	Amano, Y (reprint author), Nippon Med Sch, Dept Radiol, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138603, Japan.	yas-amano@nifty.com					SIGWART U, 1995, LANCET, V346, P211, DOI 10.1016/S0140-6736(95)91267-3; Maron MS, 2006, CIRCULATION, V114, P2232, DOI 10.1161/CIRCULATIONAHA.106.644682; Fifer MA, 2011, EUR HEART J, V32, P1059, DOI 10.1093/eurheartj/ehr013; van Dockum WG, 2005, CIRCULATION, V111, P2503, DOI 10.1161/01.CIR.0000165084.28065.01; Mikami Y, 2009, AM J ROENTGENOL, V193, pW321, DOI 10.2214/AJR.09.2335; Amano Y, 2004, AM J ROENTGENOL, V182, P523; Maron MS, 2003, NEW ENGL J MED, V348, P295, DOI 10.1056/NEJMoa021332; Kajimoto K, 2010, AM J CARDIOL, V106, P1307, DOI 10.1016/j.amjcard.2010.06.059; Kwon DH, 2008, HEART, V94, P1295, DOI 10.1136/hrt.2007.118018; van Dockum WG, 2004, J AM COLL CARDIOL, V43, P27, DOI 10.1016/j.jacc.2003.08.031; Adabag AS, 2006, AM J CARDIOL, V98, P1507, DOI 10.1016/j.amjcard.2006.07.029; Angelini P, 2007, TEX HEART I J, V34, P336; Nijveldt R, 2009, RADIOLOGY, V250, P363, DOI 10.1148/radiol.2502080739; Hamada M, 1997, CIRCULATION, V96, P1520; Singh M, 2001, MAYO CLIN PROC, V76, P799; Wu KC, 1998, CIRCULATION, V97, P765; Amano Y, 2007, J COMPUT ASSIST TOMO, V31, P600, DOI 10.1097/rct.0b013e31803151fd; Raute-Kreinsen U, 2003, PATHOL RES PRACT, V199, P121, DOI 10.1078/0344-0338-00364	18	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0284-1851	1600-0455		ACTA RADIOL	Acta Radiol.	NOV	2015	56	11					1323	1328		10.1177/0284185114559871		6	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CU0OZ	WOS:000363218100009		
J	Kosaka, N; Tsuchida, T; Tsuji, K; Shimizu, K; Kimura, H				Kosaka, Nobuyuki; Tsuchida, Tatsuro; Tsuji, Kazunobu; Shimizu, Kazuhiro; Kimura, Hirohiko			Standardized uptake value differences between primary and metastatic lesions in F-18-FDG PET/CT of patients with lung cancer	ACTA RADIOLOGICA			English	Article						Fluorodeoxyglucose (FDG); lung cancer; metastasis; positron emission tomography (PET); standardized uptake value (SUV)	POSITRON-EMISSION-TOMOGRAPHY; TUMOR SIZE; FDG-PET	Background: DG-PET/CT is a robust tool for staging of lung cancer, but the differences in FDG uptake between primary and metastatic lesions have not yet been well described. Purpose: To define the potential range of standardized uptake value (SUV) differences between primary and metastatic lesions in lung cancer patients and to identify the factors responsible for these differences. Material and Methods: FDG-PET/CT images of 75 lung cancers with 296 metastases were analyzed retrospectively. Histological types, primary locations, and metastatic sites were recorded. The average and maximum SUV (SUVavg, SUVmax) of each primary tumor and metastasis were measured, and the ratio of metastatic SUVs to primary SUVs (M/Pavg, M/Pmax), its difference from 100% (diff-M/Pavg, diff-M/Pmax), the ratio of ROI area of metastatic to primary lesions (ROI-M/P), and its difference from 100% (diff-ROI-M/P) were calculated. Results: M/Pavg was in the range of 35.9-224.6% (mean +/- SD: 97.9%+/- 35.9%), while M/Pmax was in the range of 24.8-286.7% (98.1%+/- 45.3%). Furthermore, values were in the range of 50-200% for M/Pavg in 280/296 lesions (94.6%) and for M/Pmax in 255/296 lesions (86.1%). M/Pavg and M/Pmax showed significant linear correlations with ROI-M/P (r=0.62, 0.64, respectively). Multivariate analysis showed that diff-ROI-M/P had the greatest effect on diff-M/Pavg and diff-M/Pmax. Conclusion: The SUVs of most metastatic lesions ranged from half to double those of primaries in lung cancer patients. When the SUV of a suspected metastasis is beyond the range of half to double that of the primary lung cancer, other non-metastatic lesions should be considered, while taking ROI size into account.	[Kosaka, Nobuyuki; Tsuchida, Tatsuro; Tsuji, Kazunobu; Shimizu, Kazuhiro; Kimura, Hirohiko] Univ Fukui, Dept Radiol, Fac Med Sci, Fukui 9101193, Japan	Kosaka, N (reprint author), Univ Fukui, Dept Radiol, Fac Med Sci, 23-3 Matsuoka Shimoaizuki, Fukui 9101193, Japan.	nkosaka@u-fukui.ac.jp					Chopra A, 2012, BRIT J RADIOL, V85, pE229, DOI 10.1259/bjr/60606623; Soret M, 2007, J NUCL MED, V48, P932, DOI 10.2967/jnumed.106.035774; van Tinteren H, 2002, LANCET, V359, P1388, DOI 10.1016/S0140-6736(02)08352-6; Uesaka D, 2008, J NUCL MED, V49, P1606, DOI 10.2967/jnumed.108.051250; Aquino SL, 2007, INT J MOL MED, V19, P495; Sobic-Saranovic D, 2013, SEMIN NUCL MED, V43, P404, DOI 10.1053/j.semnuclmed.2013.06.007; Kawano T, 2011, ANN NUCL MED, V25, P109, DOI 10.1007/s12149-010-0442-2; Suzawa N, 2011, LUNG CANCER, V72, P191, DOI 10.1016/j.lungcan.2010.08.017; Prieto E, 2013, CLIN NUCL MED, V38, P103, DOI 10.1097/RLU.0b013e318279b9df; Stiles BM, 2013, ANN THORAC SURG, V95, P397, DOI 10.1016/j.athoracsur.2012.07.038; Cuaron J., 2013, FRONT CANC IMAGING D, V2, P208; Glaudemans AW, 2013, CLIN DEV IMMUNOL, V2013; Wahl RL, 2009, J NUCL MED, V50, p122S, DOI 10.2967/jnumed.108.057307	13	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0284-1851	1600-0455		ACTA RADIOL	Acta Radiol.	NOV	2015	56	11					1329	1335		10.1177/0284185114556705		7	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CU0OZ	WOS:000363218100010		
J	Inoue, S; Ikeda, O; Nakasone, Y; Beppu, T; Masuda, T; Yokoyama, K; Utsunomiya, D; Baba, H; Yamashita, Y				Inoue, Seijiro; Ikeda, Osamu; Nakasone, Yutaka; Beppu, Toru; Masuda, Toshiro; Yokoyama, Koichi; Utsunomiya, Daisuke; Baba, Hideo; Yamashita, Yasuyuki			Percutaneous transhepatic portal embolization using foam ethanolamine oleate and carbon dioxide (CO2): a pilot study	ACTA RADIOLOGICA			English	Article						Vascular; angiography; embolization; vein; adult	RETROGRADE TRANSVENOUS OBLITERATION; VEIN EMBOLIZATION; LIVER RESECTION; GASTRIC VARICES; SCLEROTHERAPY; POLIDOCANOL	Background: Percutaneous transhepatic portal embolization (PTPE) can induce atrophy of the embolized- and hypertrophy of the residual area. These effects are advantageous in patients scheduled for extended hepatectomy. Purpose: To evaluate the clinical safety and effectiveness of foam sclerotherapy with foam ethanolamine oleate (EO) and carbon dioxide (CO2) for PTPE before hepatectomy. Material and Methods: We performed sclerotherapy for PTPE in 15 patients with: hepatocellular carcinoma (HHC; n=9), bile duct carcinoma (n=5), or metastatic liver tumor from colon cancer (n=1). The foam contained 5% EO iopamidol (EOI) and CO2 at a 1:2 ratio. We compared the percentage of the pre- and post-PTPE future liver remnant (FLR) volumes and calculated the percent FLR volume (%FLR) increase after PTPE. Results: The amount of EOI used (range, 14-20mL; median, 16.8mL) was based on the volume of the target portal vein. Technical success was achieved in 14 of 15 patients (93%); the other patient presented with computed tomography evidence of recanalization 1 week after PTPE. The FLR volume before and after portal vein embolization was 599342 and 691 +/- 318cm(3), respectively (P<0.01); the mean %FLR volume increase was 29.5%. There was no significant difference in the mean platelet count, total bilirubin, total aspartate aminotransferase, and total creatinine before and after PTPE. One patient suffered intra-abdominal bleeding that required transcatheter arterial embolization. No other patients developed major complications higher than grade 3. Conclusion: Sclerotherapy using foam EOI and CO2 is clinically safe and effective for PTPE before hepatectomy.	[Inoue, Seijiro; Ikeda, Osamu; Nakasone, Yutaka; Yokoyama, Koichi; Utsunomiya, Daisuke; Yamashita, Yasuyuki] Kumamoto Univ, Dept Diagnost Radiol, Grad Sch Life Sci, Kumamoto 8608556, Japan; [Beppu, Toru; Masuda, Toshiro; Baba, Hideo] Kumamoto Univ, Dept Surg Gastroenterol, Grad Sch Life Sci, Kumamoto 8608556, Japan	Ikeda, O (reprint author), Kumamoto Univ, Dept Diagnost Radiol, Grad Sch Med & Pharmaceut Sci, 1-1-1 Honjo, Kumamoto 8608556, Japan.	osamu-3643ik@do9.enjoy.ne.jp					Angle FJ, 2010, J VASC INTERV RADIOL, V21, P1479; Yamaki T, 2008, J VASC SURG, V47, P578, DOI 10.1016/j.jvs.2007.11.026; Kiyosue H, 2003, RADIOGRAPHICS, V23, P921, DOI 10.1148/rg.234025135; Koizumi J, 2010, J VASC INTERV RADIOL, V21, P1583, DOI 10.1016/j.jvir.2010.05.029; Imamura H, 1999, HEPATOLOGY, V29, P1099, DOI 10.1002/hep.510290415; Beppu T, 2010, J GASTROENTEROL, V45, P211, DOI 10.1007/s00535-009-0143-6; HASHIZUME M, 1988, LANCET, V2, P340; Abdalla EK, 2001, BRIT J SURG, V88, P165, DOI 10.1046/j.1365-2168.2001.01658.x; Morrison N, 2008, J VASC SURG, V47, P830, DOI 10.1016/j.jvs.2007.11.020; Nagino M, 2006, ANN SURG, V243, P364, DOI 10.1097/01.sla.0000201482.11876.14; Morrison N, 2010, EUR J VASC ENDOVASC, V40, P407, DOI 10.1016/j.ejvs.2010.04.018; van Lienden KP, 2013, CARDIOVASC INTER RAD, V36, P25, DOI 10.1007/s00270-012-0440-y; Breu FX, 2004, DERMATOL SURG, V30, P709, DOI 10.1111/j.1524-4725.2004.30209.x; Choi SY, 2011, EUR RADIOL, V21, P122, DOI 10.1007/s00330-010-1895-3; KITANO S, 1987, HEPATO-GASTROENTEROL, V34, P19; Lindner P, 2006, EJSO, V32, P292, DOI 10.1016/j.ejso.2005.12.007; Hirota S, 1999, RADIOLOGY, V211, P349; Child CG, 1964, LIVER PORTAL HYPERTE, P49; Guex Jean-Jérôme, 2005, Semin Vasc Surg, V18, P25, DOI 10.1053/j.semvascsurg.2004.12.008; Shindoh Junichi, 2012, Liver Cancer, V1, P159, DOI 10.1159/000343829	20	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0284-1851	1600-0455		ACTA RADIOL	Acta Radiol.	NOV	2015	56	11					1361	1367		10.1177/0284185115590285		7	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CU0OZ	WOS:000363218100014		
J	Bousquet, J; Schunemann, HJ; Fonseca, J; Samolinski, B; Bachert, C; Canonica, GW; Casale, T; Cruz, AA; Demoly, P; Hellings, P; Valiulis, A; Wickman, M; Zuberbier, T; Bosnic-Anticevitch, S; Bedbrook, A; Bergmann, KC; Caimmi, D; Dahl, R; Fokkens, WJ; Grisle, I; Lodrup Carlsen, K; Mullol, J; Muraro, A; Palkonen, S; Papadopoulos, N; Passalacqua, G; Ryan, D; Valovirta, E; Yorgancioglu, A; Aberer, W; Agache, I; Adachi, M; Akdis, CA; Akdis, M; Annesi-Maesano, I; Ansotegui, IJ; Anto, JM; Arnavielhe, S; Arshad, H; Baiardini, I; Baigenzhin, AK; Barbara, C; Bateman, ED; Beghe, B; Bel, EH; Ben Kheder, A; Bennoor, KS; Benson, M; Bewick, M; Bieber, T; Bindslev-Jensen, C; Bjermer, L; Blain, H; Boner, AL; Boulet, LP; Bonini, M; Bonini, S; Bosse, I; Bourret, R; Bousquet, PJ; Braido, F; Briggs, AH; Brightling, CE; Brozek, J; Buhl, R; Burney, PG; Bush, A; Caballero-Fonseca, F; Calderon, MA; Camargos, PAM; Camuzat, T; Carlsen, KH; Carr, W; Sarabia, AMC; Chavannes, NH; Chatzi, L; Chen, YZ; Chiron, R; Chkhartishvili, E; Chuchalin, AG; Ciprandi, G; Cirule, I; de Sousa, JC; Cox, L; Crooks, G; Costa, DJ; Custovic, A; Dahlen, SE; Darsow, U; De Carlo, G; De Blay, F; Dedeu, T; Deleanu, D; Denburg, JA; Devillier, P; Didier, A; Dinh-Xuan, AT; Dokic, D; Douagui, H; Dray, G; Dubakiene, R; Durham, SR; Dykewicz, MS; El-Gamal, Y; Emuzyte, R; Wagner, AF; Fletcher, M; Fiocchi, A; Forastiere, F; Gamkrelidze, A; Gemicioglu, B; Gereda, JE; Diaz, SG; Gotua, M; Grouse, L; Guzman, MA; Haahtela, T; Hellquist-Dahl, B; Heinrich, J; Horak, F; Hourihane, JOB; Howarth, P; Humbert, M; Hyland, ME; Ivancevich, JC; Jares, EJ; Johnston, SL; Joos, G; Jonquet, O; Jung, KS; Just, J; Kaidashev, I; Kalayci, O; Kalyoncu, AF; Keil, T; Keith, PK; Khaltaev, N; Klimek, L; N'Goran, BK; Kolek, V; Koppelman, GH; Kowalski, ML; Kull, I; Kuna, P; Kvedariene, V; Lambrecht, B; Lau, S; Larenas-Linnemann, D; Laune, D; Le, LTT; Lieberman, P; Lipworth, B; Li, J; Louis, R; Magard, Y; Magnan, A; Mahboub, B; Majer, I; Makela, MJ; Manning, P; Keenoy, ED; Marshall, GD; Masjedi, MR; Maurer, M; Mavale-Manuel, S; Melen, E; Melo-Gomes, E; Meltzer, EO; Merk, H; Miculinic, N; Mihaltan, F; Milenkovic, B; Mohammad, Y; Molimard, M; Momas, I; Montilla-Santana, A; Morais-Almeida, M; Mosges, R; Namazova-Baranova, L; Naclerio, R; Neou, A; Neffen, H; Nekam, K; Niggemann, B; Nyembue, TD; O'Hehir, RE; Ohta, K; Okamoto, Y; Okubo, K; Ouedraogo, S; Paggiaro, P; Pali-Scholl, I; Palmer, S; Panzner, P; Papi, A; Park, HS; Pavord, I; Pawankar, R; Pfaar, O; Picard, R; Pigearias, B; Pin, I; Plavec, D; Pohl, W; Popov, TA; Portejoie, F; Postma, D; Potter, P; Price, D; Rabe, KF; Raciborski, F; Pontal, FR; Repka-Ramirez, S; Robalo-Cordeiro, C; Rolland, C; Rosado-Pinto, J; Reitamo, S; Rodenas, F; Roman Rodriguez, M; Romano, A; Rosario, N; Rosenwasser, L; Rottem, M; Sanchez-Borges, M; Scadding, GK; Serrano, E; Schmid-Grendelmeier, P; Sheikh, A; Simons, FER; Sisul, JC; Skrindo, I; Smit, HA; Sole, D; Sooronbaev, T; Spranger, O; Stelmach, R; Strandberg, T; Sunyer, J; Thijs, C; Todo-Bom, A; Triggiani, M; Valenta, R; Valero, AL; van Hage, M; Vandenplas, O; Vezzani, G; Vichyanond, P; Viegi, G; Wagenmann, M; Walker, S; Wang, DY; Wahn, U; Williams, DM; Wright, J; Yawn, BP; Yiallouros, PK; Yusuf, OM; Zar, HJ; Zernotti, ME; Zhang, L; Zhong, N; Zidarn, M; Mercier, J				Bousquet, J.; Schunemann, H. J.; Fonseca, J.; Samolinski, B.; Bachert, C.; Canonica, G. W.; Casale, T.; Cruz, A. A.; Demoly, P.; Hellings, P.; Valiulis, A.; Wickman, M.; Zuberbier, T.; Bosnic-Anticevitch, S.; Bedbrook, A.; Bergmann, K. C.; Caimmi, D.; Dahl, R.; Fokkens, W. J.; Grisle, I.; Lodrup Carlsen, K.; Mullol, J.; Muraro, A.; Palkonen, S.; Papadopoulos, N.; Passalacqua, G.; Ryan, D.; Valovirta, E.; Yorgancioglu, A.; Aberer, W.; Agache, I.; Adachi, M.; Akdis, C. A.; Akdis, M.; Annesi-Maesano, I.; Ansotegui, I. J.; Anto, J. M.; Arnavielhe, S.; Arshad, H.; Baiardini, I.; Baigenzhin, A. K.; Barbara, C.; Bateman, E. D.; Beghe, B.; Bel, E. H.; Ben Kheder, A.; Bennoor, K. S.; Benson, M.; Bewick, M.; Bieber, T.; Bindslev-Jensen, C.; Bjermer, L.; Blain, H.; Boner, A. L.; Boulet, L. P.; Bonini, M.; Bonini, S.; Bosse, I.; Bourret, R.; Bousquet, P. J.; Braido, F.; Briggs, A. H.; Brightling, C. E.; Brozek, J.; Buhl, R.; Burney, P. G.; Bush, A.; Caballero-Fonseca, F.; Calderon, M. A.; Camargos, P. A. M.; Camuzat, T.; Carlsen, K. H.; Carr, W.; Sarabia, A. M. Cepeda; Chavannes, N. H.; Chatzi, L.; Chen, Y. Z.; Chiron, R.; Chkhartishvili, E.; Chuchalin, A. G.; Ciprandi, G.; Cirule, I.; Correia de Sousa, J.; Cox, L.; Crooks, G.; Costa, D. J.; Custovic, A.; Dahlen, S. E.; Darsow, U.; De Carlo, G.; De Blay, F.; Dedeu, T.; Deleanu, D.; Denburg, J. A.; Devillier, P.; Didier, A.; Dinh-Xuan, A. T.; Dokic, D.; Douagui, H.; Dray, G.; Dubakiene, R.; Durham, S. R.; Dykewicz, M. S.; El-Gamal, Y.; Emuzyte, R.; Wagner, A. Fink; Fletcher, M.; Fiocchi, A.; Forastiere, F.; Gamkrelidze, A.; Gemicioglu, B.; Gereda, J. E.; Gonzalez Diaz, S.; Gotua, M.; Grouse, L.; Guzman, M. A.; Haahtela, T.; Hellquist-Dahl, B.; Heinrich, J.; Horak, F.; Hourihane, J. O. B.; Howarth, P.; Humbert, M.; Hyland, M. E.; Ivancevich, J. C.; Jares, E. J.; Johnston, S. L.; Joos, G.; Jonquet, O.; Jung, K. S.; Just, J.; Kaidashev, I.; Kalayci, O.; Kalyoncu, A. F.; Keil, T.; Keith, P. K.; Khaltaev, N.; Klimek, L.; N'Goran, B. Koffi; Kolek, V.; Koppelman, G. H.; Kowalski, M. L.; Kull, I.; Kuna, P.; Kvedariene, V.; Lambrecht, B.; Lau, S.; Larenas-Linnemann, D.; Laune, D.; Le, L. T. T.; Lieberman, P.; Lipworth, B.; Li, J.; Louis, R.; Magard, Y.; Magnan, A.; Mahboub, B.; Majer, I.; Makela, M. J.; Manning, P.; De Manuel Keenoy, E.; Marshall, G. D.; Masjedi, M. R.; Maurer, M.; Mavale-Manuel, S.; Melen, E.; Melo-Gomes, E.; Meltzer, E. O.; Merk, H.; Miculinic, N.; Mihaltan, F.; Milenkovic, B.; Mohammad, Y.; Molimard, M.; Momas, I.; Montilla-Santana, A.; Morais-Almeida, M.; Moesges, R.; Namazova-Baranova, L.; Naclerio, R.; Neou, A.; Neffen, H.; Nekam, K.; Niggemann, B.; Nyembue, T. D.; O'Hehir, R. E.; Ohta, K.; Okamoto, Y.; Okubo, K.; Ouedraogo, S.; Paggiaro, P.; Pali-Schoell, I.; Palmer, S.; Panzner, P.; Papi, A.; Park, H. S.; Pavord, I.; Pawankar, R.; Pfaar, O.; Picard, R.; Pigearias, B.; Pin, I.; Plavec, D.; Pohl, W.; Popov, T. A.; Portejoie, F.; Postma, D.; Potter, P.; Price, D.; Rabe, K. F.; Raciborski, F.; Pontal, F. Radier; Repka-Ramirez, S.; Robalo-Cordeiro, C.; Rolland, C.; Rosado-Pinto, J.; Reitamo, S.; Rodenas, F.; Roman Rodriguez, M.; Romano, A.; Rosario, N.; Rosenwasser, L.; Rottem, M.; Sanchez-Borges, M.; Scadding, G. K.; Serrano, E.; Schmid-Grendelmeier, P.; Sheikh, A.; Simons, F. E. R.; Sisul, J. C.; Skrindo, I.; Smit, H. A.; Sole, D.; Sooronbaev, T.; Spranger, O.; Stelmach, R.; Strandberg, T.; Sunyer, J.; Thijs, C.; Todo-Bom, A.; Triggiani, M.; Valenta, R.; Valero, A. L.; van Hage, M.; Vandenplas, O.; Vezzani, G.; Vichyanond, P.; Viegi, G.; Wagenmann, M.; Walker, S.; Wang, D. Y.; Wahn, U.; Williams, D. M.; Wright, J.; Yawn, B. P.; Yiallouros, P. K.; Yusuf, O. M.; Zar, H. J.; Zernotti, M. E.; Zhang, L.; Zhong, N.; Zidarn, M.; Mercier, J.			MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation	ALLERGY			English	Article						allergic rhinitis; ARIA; asthma; Information and communications technology; MACVIA-LR	QUALITY-OF-LIFE; VISUAL ANALOG SCALES; EUROPEAN INNOVATION PARTNERSHIP; CHRONIC RESPIRATORY-DISEASES; RANDOMIZED CONTROLLED-TRIAL; WORLD-HEALTH-ORGANIZATION; INTEGRATED CARE PATHWAYS; DECISION-SUPPORT-SYSTEMS; POLLEN COUNTS; CLIMATE-CHANGE	Several unmet needs have been identified in allergic rhinitis: identification of the time of onset of the pollen season, optimal control of rhinitis and comorbidities, patient stratification, multidisciplinary team for integrated care pathways, innovation in clinical trials and, above all, patient empowerment. MASK-rhinitis (MACVIA-ARIA Sentinel NetworK for allergic rhinitis) is a simple system centred around the patient which was devised to fill many of these gaps using Information and Communications Technology (ICT) tools and a clinical decision support system (CDSS) based on the most widely used guideline in allergic rhinitis and its asthma comorbidity (ARIA 2015 revision). It is one of the implementation systems of Action Plan B3 of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA). Three tools are used for the electronic monitoring of allergic diseases: a cell phone-based daily visual analogue scale (VAS) assessment of disease control, CARAT (Control of Allergic Rhinitis and Asthma Test) and e-Allergy screening (premedical system of early diagnosis of allergy and asthma based on online tools). These tools are combined with a clinical decision support system (CDSS) and are available in many languages. An e-CRF and an e-learning tool complete MASK. MASK is flexible and other tools can be added. It appears to be an advanced, global and integrated ICT answer for many unmet needs in allergic diseases which will improve policies and standards.	[Bousquet, J.] Univ Hosp, Montpellier, France; [Bousquet, J.; Bedbrook, A.; Costa, D. J.; Portejoie, F.] European Innovat Partnership Act & Hlth Ageing Re, MACVIA LR MAlad Chron VIeillissement Actif Langue, Montpellier, France; [Bousquet, J.] INSERM, VIMA Ageing & Chron Dis Epidemiol & Publ Hlth App, Paris, France; [Schunemann, H. J.; Brozek, J.] McMaster Univ, Dept Clin Epidemiol & Biostat & Med, Hamilton, ON, Canada; [Fonseca, J.] Univ Porto, Ctr Res Hlth Technol & Informat Syst CINTESIS, P-4100 Oporto, Portugal; [Samolinski, B.; Raciborski, F.] Med Univ Warsaw, Dept Prevent Environm Hazards & Allergol, Warsaw, Poland; [Bachert, C.] Ghent Univ Hosp, ENT Dept, Upper Airways Res Lab, Ghent, Belgium; [Canonica, G. W.; Passalacqua, G.; Baiardini, I.; Braido, F.] Univ Genoa, DIMI, IRCCS AOU San Martino IST, Allergy & Resp Dis Clin, Genoa, Italy; [Casale, T.] Univ S Florida, Div Allergy Immunol, Tampa, FL USA; [Cruz, A. A.] Univ Fed Bahia, ProAR Nucleo Excelencia Asma, BR-41170290 Salvador, BA, Brazil; [Demoly, P.; Caimmi, D.; Chiron, R.; Costa, D. J.] Montpellier Univ Hosp, Dept Resp Dis, Montpellier, France; [Demoly, P.; Annesi-Maesano, I.; Bousquet, P. J.] INSERM, EPAR U707, Paris, France; [Hellings, P.] Katholieke Univ Leuven, Dept Microbiol & Immunol, Clin Immunol Lab, Leuven, Belgium; [Valiulis, A.] Vilnius Univ, Clin Childrens Dis, Vilnius, Lithuania; [Wickman, M.; Kull, I.] Sachs Childrens Hosp, Stockholm, Sweden; [Zuberbier, T.; Bergmann, K. C.; Neou, A.] Charite, Dept Dermatol & Allergy, D-13353 Berlin, Germany; [Bosnic-Anticevitch, S.] Univ Sydney, Woolcock Inst Med Res, Glebe, NSW, Australia; [Bosnic-Anticevitch, S.] Sydney Local Hlth Dist, Glebe, NSW, Australia; [Dahl, R.; Bindslev-Jensen, C.] Odense Univ Hosp, Dept Dermatol, DK-5000 Odense, Denmark; [Dahl, R.; Bindslev-Jensen, C.] Odense Univ Hosp, Allergy Ctr, DK-5000 Odense, Denmark; [Fokkens, W. J.] Univ Amsterdam, Acad Med Ctr, Dept Otorhinolaryngol, NL-1105 AZ Amsterdam, Netherlands; [Grisle, I.] Latvian Assoc Allergists, Ctr TB & Lung Dis Latvia, Riga, Latvia; [Lodrup Carlsen, K.; Skrindo, I.] Oslo Univ Hosp, Dept Paediat, Oslo, Norway; [Mullol, J.] IDIBAPS, Unitat Rinol Clin Olfacte, Serv ORL, Hosp Clin,Clin & Expt Resp Immunoallergy, Barcelona, Catalonia, Spain; [Muraro, A.] Padua Gen Univ Hosp, Dept Women & Child Hlth, Food Allergy Referral Ctr Veneto Reg, Padua, Italy; [Palkonen, S.; De Carlo, G.] EFA European Federat Allergy & Airways Dis Patien, Brussels, Belgium; [Papadopoulos, N.] Univ Manchester, Royal Manchester Childrens Hosp, Inst Human Dev, Ctr Pediat & Child Hlth, Manchester, Lancs, England; [Ryan, D.] Woodbrook Med Ctr, Loughborough, Leics, England; [Valovirta, E.] Univ Turku, Dept Lung Dis & Clin Allergol, Turku, Finland; [Yorgancioglu, A.] Celal Bayar Univ, Dept Pulmonol, Manisa, Turkey; [Aberer, W.] Med Univ Graz, Dept Dermatol, Graz, Austria; [Agache, I.] Transylvania Univ Brasov, Brasov, Romania; [Adachi, M.] Int Univ Hlth & Welfare, Sanno Hosp, Dept Clin Res Ctr, Tokyo, Japan; [Akdis, C. A.; Akdis, M.] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland; [Ansotegui, I. J.] Hosp Quiron Bizkaia, Dept Allergy & Immunol, Erandio, Spain; [Anto, J. M.; Sunyer, J.] Ctr Res Environm Epidemiol, Barcelona, Spain; [Anto, J. M.; Sunyer, J.] Hosp del Mar, Res Inst, Barcelona, Spain; [Anto, J. M.; Sunyer, J.] CIBER Epidemiol & Salud Publ, Barcelona, Spain; [Anto, J. M.; Sunyer, J.] Univ Pompeu Fabra, Dept Expt & Hlth Sci, Barcelona, Spain; [Arnavielhe, S.; Laune, D.] Digi Hlth, Montpellier, France; [Arshad, H.] David Hide Asthma & Allergy Res Ctr, Isle Of Wight, England; [Baigenzhin, A. K.] EuroAsian Resp Soc, Astana City, Kazakhstan; [Barbara, C.; Melo-Gomes, E.] Fac Med Lisbon, Portuguese Natl Programme Resp Dis, Lisbon, Portugal; [Bateman, E. D.] Univ Cape Town, Dept Med, ZA-7925 Cape Town, South Africa; [Beghe, B.] Univ Modena & Reggio Emilia, Dept Oncol Haematol & Resp Dis, Sect Resp Dis, Modena, Italy; [Bel, E. H.] Univ Amsterdam, Acad Med Ctr, Dept Resp Med, NL-1105 AZ Amsterdam, Netherlands; [Ben Kheder, A.] Hop Abderrahman Mami, Serv Pneumol 4, Ariana, Tunisia; [Bennoor, K. S.] Natl Inst Dis Chest & Hosp, Dept Resp Med, Dhaka, Bangladesh; [Benson, M.] Linkoping Univ, Fac Med, Ctr Individualized Med, Dept Pediat, Linkoping, Sweden; [Bieber, T.] Univ Bonn, Dept Dermatol & Allergy, Bonn, Germany; [Bjermer, L.] Univ Lund Hosp, Dept Resp Med & Allergol, S-22185 Lund, Sweden; [Blain, H.] Univ Montpellier, Montpellier Univ Hosp, Dept Geriatr, Montpellier, France; [Blain, H.] Univ Montpellier, Euromov, EA Movement Hlth 2991, Montpellier, France; [Boner, A. L.] Univ Verona Hosp, Dept Pediat, Verona, Italy; [Boulet, L. P.] Univ Laval, Quebec Heart & Lung Inst, Quebec City, PQ, Canada; [Bonini, M.] Univ Roma La Sapienza, Dept Publ Hlth & Infect Dis, I-00185 Rome, Italy; [Bonini, S.] Univ Naples 2, Naples, Italy; [Bonini, S.] Italian Natl Res Council, Inst Translat Med, Naples, Italy; [Bourret, R.] Montpellier Univ Hosp, Montpellier, France; [Briggs, A. H.] Univ Glasgow, Inst Hlth & Wellbeing, Hlth Econ & Hlth Technol Assessment, Glasgow, Lanark, Scotland; [Brightling, C. E.] Univ Hosp Leicester NHS Trust, Inst Lung Hlth, Resp Biomed Unit, Leicester, Leics, England; [Buhl, R.] Johannes Gutenberg Univ Mainz, Univ Med, Mainz, Germany; [Burney, P. G.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England; [Bush, A.] Univ London Imperial Coll Sci Technol & Med, London, England; [Bush, A.] Royal Brompton Hosp, London SW3 6LY, England; [Caballero-Fonseca, F.] Ctr Med Docente La Trinidad, Caracas, Venezuela; [Calderon, M. A.] Univ London Imperial Coll Sci Technol & Med, Royal Brompton Hosp NHS, Natl Heart & Lung Inst, London, England; [Camargos, P. A. M.] Univ Fed Minas Gerais, Sch Med, Dept Pediat, Belo Horizonte, MG, Brazil; [Carlsen, K. H.] Oslo Univ Hosp, Dept Paediat, Oslo, Norway; [Carlsen, K. H.] Univ Oslo, Oslo, Norway; [Carr, W.] Allergy & Asthma Associates Southern Calif, Mission Viejo, CA USA; [Sarabia, A. M. Cepeda] Univ Simon Bolivar, Metropolitan Univ, Allergy & Immunol Lab, Barranquilla, Colombia; [Chavannes, N. H.] Leiden Univ, Med Ctr, Dept Publ Hlth & Primary Care, Leiden, Netherlands; [Chen, Y. Z.] Capital Inst Pediat, Asthma Clin & Educ Ctr, Natl Cooperat Grp Paediat Res Asthma, Beijing, Peoples R China; [Chen, Y. Z.] Ctr Asthma Res & Educ, Beijing, Peoples R China; [Chkhartishvili, E.] Grigol Robakidze Univ, David Tvildiani Med Univ, AIETI Med Sch, Chachava Clin, Tbilisi, Rep of Georgia; [Chuchalin, A. G.] Pulmonolory Res Inst FMBA, Moscow, Russia; [Ciprandi, G.] Azienda Osped Univ San Martino, IRCCS, Dept Med, Genoa, Italy; [Cirule, I.] Univ Children Hosp Latvia, Latvian Assoc Allergists, Riga, Latvia; [Correia de Sousa, J.] Univ Minho, Sch Hlth Sci, ICVS, Life & Hlth Sci Res Inst, Braga, Portugal; [Cox, L.] Nova SE Univ, Dept Med, Davie, FL USA; [Crooks, G.] NHS Scotland, European Innovat Partnership Act & Hlth Ageing, Reference Site, Glasgow, Lanark, Scotland; [Custovic, A.] Univ Manchester, Inst Inflammat & Repair, Ctr Resp Med & Allergy, Manchester, Lancs, England; [Custovic, A.] Univ S Manchester Hosp, Manchester M20 8LR, Lancs, England; [Dahlen, S. E.] Karolinska Inst, Inst Environm Med, Ctr Allergy Res, S-10401 Stockholm, Sweden; [Darsow, U.] Tech Univ Munich, Dept Dermatol & Allergy, D-80290 Munich, Germany; [De Blay, F.] Univ Hosp Strasbourg, Chest Dis Dept, Div Allergy, Strasbourg, France; [Deleanu, D.] European Reg & Local Hlth Assoc, Brussels, Belgium; [Deleanu, D.] Iuliu Hatieganu Univ Med & Pharm, Allergol & Immunol Discipline, Cluj Napoca, Romania; [Denburg, J. A.] McMaster Univ, Dept Med, Div Clin Immunol & Allergy, Hamilton, ON, Canada; [Devillier, P.] Suresnes Univ Versailles St Quentin, Hop Foch, Lab Pharmacol Resp UPRES EA220, Versailles St Quentin, France; [Didier, A.] Rangueil Larrey Hosp, Dept Resp Dis, Toulouse, France; [Dinh-Xuan, A. T.] Univ Paris 05, Hop Cochin, AP HP, Serv Physiol, Paris, France; [Dokic, D.] Univ Skopje, Univ Clin Pulmol & Allergy, Skopje, Macedonia; [Douagui, H.] Ctr Hosp Univ Beni Messous, Serv Pneumo Allergol, Algiers, Algeria; [Dray, G.] Ecole Mines, Ales, France; [Dubakiene, R.] Vilnius State Univ, Fac Med, Vilnius, Lithuania; [Durham, S. R.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Allergy & Clin Immunol Sect, London, England; [Dykewicz, M. S.] St Louis Univ, Sch Med, Sect Allergy & Immunol, St Louis, MI USA; [El-Gamal, Y.] Ain Shams Univ, Pediat Allergy & Immunol Unit, Cairo, Egypt; [Emuzyte, R.] Vilnius State Univ, Fac Med, Clin Childrens Dis, Vilnius, Lithuania; [Wagner, A. Fink; Spranger, O.] Global Allergy & Asthma Platform GAAPP, Vienna, Austria; [Fletcher, M.] Educ Hlth, Warwick, England; [Fiocchi, A.] Bambino Gesu Childrens Res Hosp Holy See, Dept Allergy, Rome, Italy; [Forastiere, F.] Reg Hlth Serv Lazio Reg, Dept Epidemiol, Rome, Italy; [Gamkrelidze, A.] Natl Ctr Dis Control & Publ Hlth Georgia, Tbilisi, Rep of Georgia; [Gemicioglu, B.] Turkish Thorac Soc, Asthma Allergy Working Grp, Kocaeli, Turkey; [Gereda, J. E.] Clin Ricardo Palma, Allergy & Immunol Div, Lima, Peru; [Gonzalez Diaz, S.] Sociedad Latinoamer Allergia Asma & Immunol, Mexico City, DF, Mexico; [Gotua, M.] Georgian Assoc Allergol & Clin Immunol, Ctr Allergy & Immunol, Tbilisi, Rep of Georgia; [Grouse, L.] Univ Washington, Sch Med, Fac Dept Neurol, Seattle, WA USA; [Guzman, M. A.] Univ Chile, Clin Hosp, Immunol & Allergy Div, Santiago, Chile; [Haahtela, T.; Makela, M. J.; Reitamo, S.] Helsinki Univ Hosp, Skin & Allergy Hosp, Helsinki, Finland; [Hellquist-Dahl, B.] Odense Univ Hosp, Dept Resp Dis, DK-5000 Odense, Denmark; [Heinrich, J.] Helmholtz Zentrum Munchen, German Res Ctr Environm Hlth, Inst Epidemiol 1, Neuherberg, Germany; [Horak, F.] Vienna Challenge Chamber, Vienna, Austria; [Hourihane, J. O. B.] Natl Univ Ireland Univ Coll Cork, Dept Paediat & Child Hlth, Cork, Ireland; [Howarth, P.] Univ Southampton, Southampton Univ Hosp, Fac Med, Southampton, Hants, England; [Humbert, M.] Univ Paris 11, Le Kremlin Bicetre, France; Univ Plymouth, Sch Psychol, Plymouth PL4 8AA, Devon, England; [Ivancevich, J. C.] Clin Santa Isabel, Serv Alergia & Immunol, Buenos Aires, DF, Argentina; [Jares, E. J.] Libra Fdn, Buenos Aires, DF, Argentina; [Johnston, S. L.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Airway Dis Infect Sect, London, England; [Joos, G.] Ghent Univ Hosp, Dept Resp Med, Ghent, Belgium; [Jonquet, O.] Montpellier Univ Hosp, Med Commiss, Montpellier, France; [Jung, K. S.] Hallym Univ, Sacred Heart Hosp, Coll Med, Chuncheon Si, Gyeonggi Do, South Korea; [Just, J.] Hop Enfants Armand Trousseau, Ctr Asthme & Allergies, Dept Allergol, Paris, France; [Kaidashev, I.] Ukrainian Med Stomatol Acad, Poltava, Ukraine; [Kalayci, O.] Hacettepe Univ, Sch Med, Pediat Allergy & Asthma Unit, Ankara, Turkey; [Kalyoncu, A. F.] Hacettepe Univ, Sch Med, Dept Chest Dis, Immunol & Allergy Div, Ankara, Turkey; [Keil, T.] Charite, Inst Social Med Epidemiol & Hlth Econ, D-13353 Berlin, Germany; [Keith, P. K.] McMaster Univ, Dept Med, Hlth Sci Ctr 3V47, Hamilton, ON, Canada; [Khaltaev, N.] GARD, Geneva, Switzerland; [Klimek, L.] Ctr Rhinol & Allergol, Wiesbaden, Germany; [N'Goran, B. Koffi; Pigearias, B.] Soc Pneumol Langue Francaise, Paris, France; [N'Goran, B. Koffi; Pigearias, B.] Espace Francophone Pneumol, Paris, France; [Kolek, V.] Univ Hosp Olomouc, Fac Med & Dent, Dept Resp Med, Olomouc, Czech Republic; [Koppelman, G. H.] Univ Groningen, Univ Med Ctr Groningen, Beatrix Childrens Hosp, GRIAC Res Inst,Dept Pediat Pulmonol & Pediat Alle, Groningen, Netherlands; [Kowalski, M. L.] Med Univ Lodz, Dept Immunol Rheumatol & Allergy, Lodz, Poland; [Kuna, P.] Med Univ Lodz, Barlicki Univ Hosp, KUNA, Div Internal Med Asthma & Allergy, Lodz, Poland; [Kvedariene, V.] Vilnius State Univ, Pulmonol & Allergol Ctr, Vilnius, Lithuania; [Lambrecht, B.] Univ Ghent, VIB Inflammat Res Ctr, B-9000 Ghent, Belgium; [Lau, S.] Charite, Dept Pediat Pneumol & Immunol, D-13353 Berlin, Germany; [Larenas-Linnemann, D.] Hosp Med Sur, Clin Alergia Asma & Pediat, Mexico City, DF, Mexico; [Le, L. T. T.] Univ Med & Pharm, Hochiminh City, Vietnam; [Lieberman, P.] Univ Tennessee, Coll Med, Dept Internal Med, Germantown, TN USA; [Lieberman, P.] Univ Tennessee, Coll Med, Dept Pediat, Div Allergy, Germantown, TN USA; [Lieberman, P.] Univ Tennessee, Coll Med, Dept Pediat, Div Immunol, Germantown, TN USA; [Lipworth, B.] Univ Dundee, Ninewells Hosp, Med Res Inst, Scottish Ctr Resp Res Cardiovasc & Diabet Med, Dundee, Scotland; [Li, J.; Zhong, N.] Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou Inst Resp Dis, State Key Lab Resp Dis, Guangzhou, Guangdong, Peoples R China; [Louis, R.] CHU Sart Tilman, Dept Pulm Med, B-4000 Liege, Belgium; [Magard, Y.] Hop St Joseph, Serv Pneumoallergol, F-75674 Paris, France; [Magnan, A.] Univ Nantes, Inst Thorax, UMR INSERM, Serv Pneumol,UMR1087,CNR 6291, Nantes, France; [Mahboub, B.] Rashid Hosp, Dept Pulm Med, Dubai, U Arab Emirates; Univ Hosp, Dept Resp Med, Bratislava, Slovakia; Bon Secours Hosp, Dept Med RCSI, Dublin, Ireland; [De Manuel Keenoy, E.] Kronikgune, Baracaldo, Basque Region, Spain; [Marshall, G. D.] Univ Mississippi, Med Ctr, Lab Behav Immunol Res, Div Clin Immunol, Jackson, MS 39216 USA; [Masjedi, M. R.] Shahid Beheshti Univ Med Sci, Resp Dis Res, Tehran, Iran; [Maurer, M.] Charite, Allergie Ctr Charite, D-13353 Berlin, Germany; [Maurer, M.] Charite, Dept Dermatol & Allergy, D-13353 Berlin, Germany; [Mavale-Manuel, S.] Maputo Cent Hosp, Dept Paediat, Maputo, Mozambique; [Melen, E.] Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; [Meltzer, E. O.] Allergy & Asthma Med Grp & Res Ctr, San Diego, CA USA; [Merk, H.] Rhein Westfal TH Aachen, Univ Klinikum, Hautklin, Klin Dermatol & Allergol, D-52062 Aachen, Germany; [Miculinic, N.] Croatian Pulm Soc, Zagreb, Croatia; [Mihaltan, F.] Natl Inst Pneumol M Nasta, Bucharest, Romania; [Milenkovic, B.] Univ Belgrade, Fac Med, Belgrade, Serbia; [Mohammad, Y.] Tishreen Univ, Sch Med, Natl Ctr Res Chron Resp Dis, Latakia, Syria; [Molimard, M.] Univ Bordeaux, CHU Bordeaux, INSERM U657, Dept Pharmacol, Bordeaux, France; [Momas, I.] Paris Descartes Univ, Dept Publ Hlth & Biostat, Paris, France; [Momas, I.] Paris Municipal Dept Social Act Childhood & Hlth, Paris, France; [Montilla-Santana, A.] Aura Andalucia, Jaen, Spain; [Morais-Almeida, M.] Hosp CUF Descobertas, Allergy & Clin Immunol Dept, Lisbon, Portugal; [Moesges, R.] Univ Cologne, Fac Med, Inst Med Stat Informat & Epidemiol, D-50931 Cologne, Germany; [Namazova-Baranova, L.] Russian Acad Med Sci, Sci Ctr Childrens Hlth, Moscow, Russia; [Naclerio, R.] Univ Chicago, Med Ctr, Sect Otolaryngol Head & Neck Surg, Chicago, IL 60637 USA; [Naclerio, R.] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA; [Neffen, H.] Hosp Ninos Orlando Alassia, Santa Fe, Santa Fe, Argentina; [Nekam, K.] Hosp Hospitaller Bros Buda, Budapest, Hungary; [Niggemann, B.] Charite, Pediat Pneumol & Immunol, D-13353 Berlin, Germany; [Nyembue, T. D.] Univ Hosp Kinshasa, ENT Dept, Kinshasa, Zaire; [O'Hehir, R. E.] Monash Univ, Alfred Hosp & Cent Clin Sch, Dept Allergy Immunol & Resp Med, Melbourne, Vic 3004, Australia; [Ohta, K.] Tokyo Natl Hosp, Natl Hosp Org, Tokyo, Japan; [Okamoto, Y.] Chiba Univ Hosp, Dept Otorhinolaryngol, Chiba, Japan; [Okubo, K.] Nippon Med Sch, Depatment Otolaryngol, Tokyo 113, Japan; [Ouedraogo, S.] Ctr Hosp Univ Pediat Charles Gaulle, Ouagadougou, Burkina Faso; [Plavec, D.] Univ Hosp Pisa, Cardiothorac & Vasc Dept, Pisa, Italy; [Pali-Schoell, I.] Univ Vienna, Messerli Res Inst, Dept Comparat Med, Vienna, Austria; [Pali-Schoell, I.] Univ Vet Med Vienna, Med Univ, Vienna, Austria; [Panzner, P.] Charles Univ Prague, Fac Med, Dept Immunol & Allergol, Plzen, Czech Republic; [Panzner, P.] Charles Univ Prague, Fac Hosp Pilsen, Plzen, Czech Republic; [Papi, A.] Univ Ferrara, Dept Med Sci, Resp Med, I-44100 Ferrara, Italy; [Park, H. S.] Ajou Univ, Sch Med, Dept Allergy & Clin Immunol, Suwon 441749, South Korea; [Pavord, I.] Univ Oxford, Nuffield Dept Med, Oxford, England; [Pawankar, R.] Nippon Med Sch, Dept Pediat, Tokyo 113, Japan; [Pfaar, O.] Ctr Rhinol & Allergol, Wiesbaden, Germany; [Picard, R.] Conseil Gen Econ, Minist Econ Ind & Numer, Paris, France; [Pin, I.] CHU Grenoble, Dept Pediat, F-38043 Grenoble 9, France; [Plavec, D.] Univ JJ Strossmayer, Childrens Hosp Srebrnjak, Zagreb Sch Med, Osijek, Croatia; [Pohl, W.] Hietzing Hosp, Karl Landsteiner Inst Clin & Expt Pneumol, Vienna, Austria; [Popov, T. A.] Med Univ Sofia, Clin Allergy & Asthma, Sofia, Bulgaria; [Postma, D.] Univ Groningen, Univ Med Ctr Groningen, GRIAC Res Inst, Dept Pulm Med & TB, Groningen, Netherlands; [Potter, P.] Univ Cape Town, Lung Inst, Allergy Diagnost & Clin Res Unit, ZA-7925 Cape Town, South Africa; [Price, D.] Univ Aberdeen, Acad Ctr Primary Care, Aberdeen, Scotland; [Rabe, K. F.] LungenClin Grosshansdorf, Airway Res Ctr North, Grosshansdorf, Germany; [Pontal, F. Radier] Maison Profess Liberales, Conseil Dept Ordre Pharmaciens, Montpellier, France; [Repka-Ramirez, S.] SLAAI, Mexico City, DF, Mexico; [Robalo-Cordeiro, C.] Hosp Univ Coimbra, Allergy & Clin Immunol Dept, Coimbra, Portugal; [Rolland, C.] Assoc Asthme & Allergie, Paris, France; [Roman Rodriguez, M.] Inst Invest Sanitaria Palma IdisPa, Primary Care Resp Res Unit, Palma de Mallorca, Spain; [Romano, A.] Complesso Integrato Columbus, Allergy Unit, Rome, Italy; [Rosario, N.] Univ Fed Parana, Hosp Clin, BR-80060000 Curitiba, Parana, Brazil; [Rosenwasser, L.] Univ Misouri, Kansas City Sch Med, Childrens Mercy Hosp & Clin & Pediat & Med, Dept Allergy Asthma & Immunol, Kansas City, MI USA; [Rottem, M.] Emek Med Ctr, Div Allergy Asthma & Clin Immunol, Afula, Israel; [Sanchez-Borges, M.] Ctr Meddocente La, Allergy & Clin Immunol Dept, Trinidad, Venezuela; [Scadding, G. K.] UCL, Royal Natl TNE Hosp, London, England; [Serrano, E.] CHU Rangueil Larrey, Otolaryngol & Head & Neck Surg, Toulouse, France; [Schmid-Grendelmeier, P.] Univ Zurich Hosp, Dept Dermatol, Allergy Unit, CH-8091 Zurich, Switzerland; [Sheikh, A.] Univ Edinburgh, Sch Med, Ctr Populat Hlth Sci, Allergy & Resp Res Grp, Edinburgh, Midlothian, Scotland; [Simons, F. E. R.] Univ Manitoba, Fac Med, Dept Immunol, Dept Pediat & Child Hlth, Winnipeg, MB R3E 0W3, Canada; [Sisul, J. C.] Soc Paraguaya Alergia Asma & Inmunol, Paraguari, Paraguay; [Smit, H. A.] Univ Utrecht, Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [Sole, D.] Univ Fed Sao Paulo, Dept Pediat, Div Allergy Clin Immunol & Rheumatol, Sao Paulo, Brazil; [Sooronbaev, T.] Euroasian Resp Soc, Kyrgyzstan Natl Ctr Cardiol & Internal Med, Bishkek, Kyrgyzstan; [Stelmach, R.] Univ Sao Paulo, Fac Med, Hosp Clin, Heart Inst InCor,Pulm Div, Sao Paulo, Brazil; [Strandberg, T.] European Union Geriatr Med Soc, Vienna, Austria; [Thijs, C.] Maastricht Univ, CAPHRI Sch Publ Hlth & Primary Care, Dept Epidemiol, Maastricht, Netherlands; [Todo-Bom, A.] Univ Coimbra, Fac Med, Ctr Pneumol, Coimbra, Portugal; [Triggiani, M.] Univ Salerno, Div Allergy & Clin Immunol, I-84100 Salerno, Italy; [Valenta, R.] Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Ctr Pathophysiol, Dept Pathophysiol & Allergy Res,Div Immunopathol, Vienna, Austria; [Valero, A. L.] IDIBAPS, Hosp Clin, Pneumol & Allergy Dept, Clin & Expt Resp Immunoallergy, Barcelona, Spain; [van Hage, M.] Karolinska Inst, Dept Med Solna, Clin Immunol & Allergy Unit, Stockholm, Sweden; [Vandenplas, O.] Catholic Univ Louvain, Ctr Hosp Univ Dinant Godinne, Dept Chest Med, Yvoir, Belgium; [Vezzani, G.] Res Hosp, Arcispedale S Maria Nuova IRCCS, Dept Cardiol Thorac & Vasc Med, Pulm Unit, Reggio Emilia, Italy; [Vichyanond, P.] Mahidol Univ, Siriraj Hosp, Fac Med, Dept Pediat,Div Allergy & Immunol, Bangkok 10700, Thailand; [Viegi, G.] CNR, Inst Clin Physiol, Pulm Environm Epidemiol Unit, I-56100 Pisa, Italy; [Wagenmann, M.] Univ Klinikum Dusseldorf, HNO Klin, Dept Otorhinolaryngol, Dusseldorf, Germany; [Walker, S.] Asthma UK, London, England; [Wang, D. Y.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Otolaryngol, Singapore 117548, Singapore; [Williams, D. M.] Univ N Carolina, Eshelman Sch Pharm, Chapel Hill, NC USA; [Wright, J.] Bradford Royal Infirm, Bradford Inst Hlth Res, Bradford, UJ, England; [Yawn, B. P.] Olmsted Med Ctr, Dept Res, Rochester, MN USA; [Yiallouros, P. K.] Cyprus Univ Technol, Harvard Sch Publ Hlth, Cyprus Int Inst Environm & Publ Hlth, Limassol, Cyprus; [Yusuf, O. M.] Allergy & Asthma Inst, Islamabad, Pakistan; [Zar, H. J.] Univ Cape Town, Red Cross Childrens Hosp, Dept Paediat & Child Hlth, MRC Unit Child & Adolescent Hlth, ZA-7925 Cape Town, South Africa; [Zernotti, M. E.] Univ Catolica Cordoba, Cordoba, Argentina; [Zhang, L.] Capital Med Univ, Beijing Tongren Hosp, Dept Otolaryngol Head & Neck Surg, Beijing, Peoples R China; [Zidarn, M.] Univ Clin Resp & Allerg Dis, Golnik, Slovenia; [Mercier, J.] Univ Montpellier, F-34059 Montpellier, France; [Bousquet, J.] Univ Versailles St Quentin En Yvelines UVSQ, UMR S 1168, Paris, France; [Fonseca, J.] Univ Porto, Inst CUF Porto, Allergy Unit, P-4100 Oporto, Portugal; [Fonseca, J.] Univ Porto, Hosp CUF Porto, P-4100 Oporto, Portugal; [Fonseca, J.] Univ Porto, Fac Med, CIDES, Hlth Informat & Decis Sci Dept, P-4100 Oporto, Portugal; [Fonseca, J.] Univ Porto, Fac Med, P-4100 Oporto, Portugal; [Cruz, A. A.] GARD Execut Comm, Salvador, BA, Brazil; [Demoly, P.; Annesi-Maesano, I.; Bousquet, P. J.] UPMC, EPAR, UMR S, Paris, France; [Wickman, M.; Kull, I.] Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; [Lodrup Carlsen, K.; Skrindo, I.] Univ Oslo, Fac Med, Inst Clin Med, Oslo, Norway; [Papadopoulos, N.] Univ Athens, Athens Gen Childrens Hosp P&A Kyriakou, Dept Allergy, Pediat Clin 2, Athens, Greece; [Ryan, D.] Univ Edinburgh, Allergy & Resp Res Grp, Edinburgh, Midlothian, Scotland; [Brightling, C. E.] Univ Leicester, Dept Infect Immun & Inflammat, Leicester, Leics, England; [Burney, P. G.] Univ London Imperial Coll Sci Technol & Med, Wellcome Ctr Global Hlth, London, England; [Burney, P. G.] Univ London Imperial Coll Sci Technol & Med, MRC PHE Ctr Environm & Hlth, London, England; [Camuzat, T.] Reg Languedoc Roussillon, Roussillon, France; [Sarabia, A. M. Cepeda] SLaai, Barranquilla, Colombia; [Chuchalin, A. G.] GARD Execut Comm, Moscow, Russia; [Darsow, U.] Tech Univ Munich, Helmholtz Ctr Munich, ZAUM Ctr Allergy & Environm, D-80290 Munich, Germany; [Humbert, M.] Hop Bicetre, INSERM, UMR S999, Serv Pneumol, F-94270 Le Kremlin Bicetre, France; [Johnston, S. L.] MRC, London, England; [Johnston, S. L.] Asthma UK Ctr Allerg Mech Asthma, London, England; [Just, J.] Univ Paris 06, Univ Paris 04, Inst Pierre Louis Epidemiol & Sante Publ, Equipe EPAR,UMR S 1136, Paris, France; [Keil, T.] Univ Wurzburg, Inst Clin Epidemiol & Biometry, D-97070 Wurzburg, Germany; [Milenkovic, B.] Serbian Assoc Asthma & COPD, Belgrade, Serbia; [O'Hehir, R. E.] Monash Univ, Dept Immunol, Melbourne, Vic 3004, Australia; [Pali-Schoell, I.] Univ Vet Med Vienna, Med Univ, Messerli Res Inst, Vienna, Austria; [Pali-Schoell, I.] Univ Vienna, Vienna, Austria; [Pfaar, O.] Heidelberg Univ, Univ Med Mannheim, Med Fac Mannheim, Dept Otorhinolaryngol Head & Neck Surg, Mannheim, Germany; [Price, D.] Res Real Life, Cambridge, England; [Rabe, K. F.] Univ Kiel, Airway Res Ctr North, Dept Med, Kiel, Germany; [Sanchez-Borges, M.] Clin El Avila, Caracas, Venezuela; [Vezzani, G.] Reg Agcy Hlth & Social Care, Reggio Emilia, Italy; [Viegi, G.] CNR, Inst Biomed & Mol Immunol A Monroy, Palermo, Italy; [Yiallouros, P. K.] Hosp Archbishop Makarios III, Dept Pediat, Nicosia, Cyprus; [Palmer, S.] Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England	Bousquet, J (reprint author), CHRU Montpellier, F-34295 Montpellier 5, France.	jean.bousquet@orange.fr	Wright, John/H-1624-2012; Correia de Sousa, Jaime/H-5607-2015; Custovic, Adnan/A-2435-2012; 	Correia de Sousa, Jaime/0000-0001-6459-7908; Custovic, Adnan/0000-0001-5218-7071; Bonini, Sergio/0000-0003-0079-3031; Hyland, Michael/0000-0003-3879-0469	Chiesi; GSK; Cipla; Sanofi/Regeneron; Novartis; Circassia; Merck; Stallergenes; Medical Research Council; JP Moulton Charitable Foundation; North West Lung Research Centre Charity; European Union; National Institute of Health Research; Thermo Fisher; AstraZeneca; ALK; GlaxoSmithKline; ALK Abello; Merck USA; Biomay; Leti; Biotech Tools; A. Menarini; Aerocrine; Merck Sharp Dohme; Teva; Boehringer Ingelheim; MSD; OrionPharma; Centocor; Sanofi Pasteur; Grunenthal; Synairgen; Stallergens; ALK Abello (Germany/Denmark); Allergopharma (Germany); Stallergenes (Germany/France); HAL Allergy (Germany/the Netherlands); Artu Biologicals (the Netherlands); Allergy Therapeutics/Bencard (UK/Germany); Hartington (Spain); Lofarma (Italy); Novartis/Leti (Germany/Spain); GlaxoSmithKline (UK/Germany); Essex Pharma (Germany); Cytos (Switzerland); Curalogic (Denmark); Roxall (Germany); Biomay (Austria); Thermo Fisher (Germany); Circassia (UK); Biotech Tools s.a. (Belgium); Meda Pharma GmbH (Germany); HAL Allergy (the Netherlands/Germany); Meda (Germany/Sweden); Dutch Lung Foundation; Ubbo Emmius Foundation; Stichting Astma Bestrijding; Adamed; Allergopharma; Almirall; Celon Pharma; FAES; HAL; Meda; Pfizer; Polfarmex; Polpharma; Stallergen; Lekam; UCB; Sanofi; Carnot; Senosiain; Almirral; Jansen; Pearl; Roche; AZ; Astellas; Genentech; Uriach; Abbott Laboratories; ALK-Abello; Ohropax; Servier; Stada; Menarini; Allergy Therapeutics; Bayer; Johnson+ Johnson; Arthrocare; Bencard; BiotechTools; Lofarma; Ursapharm; Bitop; AIPreven; Optima; Torii Co. Ltd.; Shionogi Co. Ltd.; MSD Co. LtD; Tanabe-Mitsubishi; Ono; Taiho; Torii; Kyowa-Kirin; Guidotti-Malesci; Mundipharma; Takeda; Zambon; Chiesi Farmaceutici; Merck Sharp Dohme; DGAKI; GlaxoSmithKline (Germany); Bencard (Germany); Novartis (Germany); Ministry of Science, Education and Sports of Republic of Croatia; Sandoz; Salveo; Schering-Plough; UK National Health Service; British Lung Foundation; AKL Ltd; Eli Lilly; Napp; Orion; Respiratory Effectiveness Group; Zentiva; Efficacy and Mechanism Evaluation programme; HTA; Novartis Farma; Faes Farma; Bial Aristegui; Boehringer; Biomay AG; Vienna, Austria; Uppsala, Sweden	Elisabeth Bel: reports grants from Chiesi and GSK outside the submitted work, and personal fees from Cipla, Sanofi/Regeneron, GSK, and Novartis, outside the submitted work; Jean Bousquet: has received honoraria for: Scientific and advisory boards - Almirall, Meda, Merck, MSD, Novartis, Sanofi-Aventis, Takeda, Teva, Uriach. Lectures during meetings - Almirall, AstraZeneca, Chiesi, GSK, Meda, Menarini, Merck, MSD, Novartis, Sanofi-Aventis, Takeda, Teva, Uriach. Board of Directors - Stallergenes; Warner Carr: Clinical Research, Merck, Mylan, Regeneron, Genentech, Novartis, Oriel, Afferent, Teva-Consultant, Teva, Meda, AstraZeneca, Alcon, Allergan, Merck, Boehringer Ingelheim - Honorarium and Speakers Bureau, Teva, Meda, AstraZeneca, Mylan, Alcon, Allergan; Thomas Casale: reports personal fees from Circassia, grants from Merck, grants from Stallergenes, outside the submitted work; Adnan Custovic: reports grants from Medical Research Council, grants from The JP Moulton Charitable Foundation, grants from North West Lung Research Centre Charity, grants from European Union 7th Framework Programme, grants from National Institute of Health Research, personal fees from Novartis, personal fees from Thermo Fisher, personal fees from AstraZeneca, personal fees from ALK, personal fees from GlaxoSmithKline, outside the submitted work; Ronald Dahl: Consulting, given lectures for: Boehringer-Ingelheim, Novartis, TEVA, MEDA, Pfizer, ALK-Abello, Vectura, AZ, GSK, CIPLA; Ulf Darsow: has been speaker, investigator and / or been a member of advisory boards for Allergopharma, ALK Abello', Bencard, GSK, Hermal, MEDA, Novartis Pharma, Stallergenes, Stiefel; Pascal Demoly: consultant (and speaker) for Stallergenes, ALK, Circassia and Chiesi and a speaker for Allergopharma, Merck, AstraZeneca, Menarini and GlaxoSmithKline. Investigator for Menarini, Pierre Fabre Medicaments, Stallergenes and ALK; Judah Denburg: is CEO and Scientific Advisor of the Allergy, Genes and Environment Network of Centres of Excellence (AllerGen NCE Inc); Alain Didier: have received honorarium for talks from Astra Zeneca, GSK, MSD, Novartis, Stallergenes and has consulting arrangement with GSK, Novartis, Stallergenes and Allerbio (ALK); Anh Tuan Dinh Xuan: has received honoraria from Aerocrine, Chiesi and Stallergenes for invited lectures during satellite scientific symposia of national and international meetings during the last 3 years; Stephen Durham: consultancy fees from ALK Abello, Circassia, Merck USA, Biomay and Leti, manufacturers of allergy vaccines. Research funding via Imperial College from Merck, ALK Abello and Biotech Tools; Mark Dykewicz: Merck (Consultant) and Novartis (research funding); Joao Fonseca: a member of advisory boards for Boehringer Ingelheim and Novartis, has received payment for lectures and services from A. Menarini, Aerocrine, AstraZeneca, Merck Sharp Dohme, Novartis, Teva; Carlos Ivancevich: Chief Editor of the WAO website, Interasma website and the Latin American Society of Allergy, Asthma and Immunology website. Collaborate with the laboratory Faes Pharma of Spain as scientific advisor on social media and speaker at symposiums of Sanofi-Aventis; Tari Haatela: reports personal fees from Boehringer Ingelheim, MSD and OrionPharma, outside the submitted work; Marc Humbert: has relationships with drug companies including Astrazeneca, Chiesi, GSK, Merck, Novartis, Pfizer, Roche, Sanofi and TEVA.; In addition to being an investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards; Michael Hyland: reports grants and personal fees from Novartis, during the conduct of the study; personal fees from GSK, outside the submitted work; Sebastian Johnston: reports grants and personal fees from Centocor, grants and personal fees from Sanofi Pasteur, grants and personal fees from GSK, grants and personal fees from Chiesi, grants and personal fees from Boehringer Ingelheim, personal fees from Grunenthal, grants and personal fees from Novartis, grants, personal fees and Shareholding from Synairgen, outside the submitted work; In addition, Dr. Johnston has a patent Blair ED, Killington RA, Rowlands DJ, Clarke NJ, Johnston SL. Transgenic animal models of HRV with human ICAM-1 sequences. UK patent application No. 02 167 29.4, 18 July 2002 and International patent application No. PCT/EP2003/007939, 17 July 2003. licensed, a patent Wark PA, Johnston SL, Holgate ST, Davies DE. Anti-virus therapy for respiratory diseases. UK patent application No. GB 0405634.7, 12 March 2004. licensed, a patent Wark PA, Johnston SL, Holgate ST, Davies DE. Interferon-Beta for Anti-Virus Therapy for Respiratory Diseases. International Patent Application No. PCT/GB05/50031, 12 March 2004. licensed, a patent Wark PA, Johnston SL, Holgate ST, Davies DE. The use of Interferon Lambda for the treatment and prevention of virally-induced exacerbation in asthma and chronic pulmonary obstructive disease. UK patent application No. 0518425.4, 9 September 2005. licensed, a patent Wark PA, Johnston SL, Holgate ST, Davies DE. Anti-Virus Therapy for Respiratory Diseases. US Patent Application - 11/517,763, Patent No. 7569216, National Phase of PCT/GB2005/050031, 04 August 2009. licensed, a patent Wark PA, Johnston SL, Holgate ST, Davies DE. Interferon-beta for Anti-Virus Therapy for Respiratory Diseases. European Patent Number 1734987, 5 May 2010. licensed, a patent Wark PA, Johnston SL, Holgate ST, Davies DE. Anti-Virus Therapy for Respiratory Diseases (IFNb therapy) Hong Kong Patent Number 1097181, 31 August 2010. licensed, a patent Wark PA, Johnston SL, Holgate ST, Davies DE. Anti-Virus Therapy for Respiratory Diseases (IFNb therapy). Japanese Patent Number 4807526, 26 August 2011. licensed, a patent Wark PA, Johnston SL, Holgate ST, Davies DE. Interferon-beta for Anti-Virus Therapy for Respiratory Diseases. New Hong Kong -Divisional Patent Application No. 11100187.0, 10 January 2011. licensed, and a patent Burdin N, Almond J, Lecouturieir, V, Girerd-Chambaz Y, Guy, B, Bartlett N, Walton R, McLean G, Glanville N, Johnston SL. Induction of cross-reactive cellular response against rhinovirus antigens European Patent Number 13305152, 4 April 2013. Pending; Jocelyne Just: on the advisory board for Novartis, ALK, and Thermofischer; is a speaker for AstraZeneca, Novartis, ALK, Stallergens, Teva; and has received grants from Novartis and Stallergens; Ludger Klimek: has received research grants for his institution from ALK Abello (Germany/Denmark), Allergopharma (Germany), Stallergenes (Germany/France), HAL Allergy (Germany/the Netherlands), Artu Biologicals (the Netherlands), Allergy Therapeutics/Bencard (UK/Germany), Hartington (Spain), Lofarma (Italy), Novartis/Leti (Germany/Spain), GlaxoSmithKline (UK/Germany), Essex Pharma (Germany), Cytos (Switzerland), Curalogic (Denmark), Roxall (Germany), Biomay (Austria), Thermo Fisher (Germany), Circassia (UK), Biotech Tools s.a.; (Belgium), and Meda Pharma GmbH (Germany); and/or he has served as an advisor and on speakers' bureaus for some of the aforementioned companies. LK has received travel grants from HAL Allergy (the Netherlands/Germany), Meda (Germany/Sweden) and Allergopharma (Germany), and he is a consultant for Bencard Germany), Novartis/Leti (Germany), Meda (Germany), ALK Abello (Germany/Denmark), Allergopharma (Germany) and Boehringer Ingelheim (Germany). LK is Board Member of the ENT Section of the European Academy of Allergy and Clinical Immunology (EAACI), Vice-President of the German Academy of Allergology and Clinical Immunology, Vice-President German Union of Allergologists, Member of the Board of Directors of the German Society for Otorhinolaryngology HNS. He is co-editor and author of different chapters of the textbook 'Allergien bei Kindern und Jugendlichen' (publisher: Schattauer-Verlag, Germany), author of one chapter in 'Allergologie' (publisher: Springer, Germany) and author of different chapters in 'Allergologie' (publisher: Schattauer-Verlag); Gerard Koppelman: grants outside this work from Dutch Lung Foundation, Ubbo Emmius Foundation and Stichting Astma Bestrijding; Piotr Kuna: reports personal fees from Adamed, personal fees from Allergopharma, personal fees from Almirall, personal fees from AstraZeneca, personal fees from Boehringer Ingelheim, personal fees from Celon Pharma, personal fees from Chiesi, personal fees from FAES, personal fees from GSK, personal fees from HAL, personal fees from Meda, personal fees from MSD, personal fees from Novartis, personal fees from Pfizer, personal fees from Polfarmex, personal fees from Polpharma, personal fees from Stallergen, personal fees from Teva, personal fees from Lekam, outside the submitted work; Desiree Larenas: Speaker para: Astrazeneca, Pfizer, MIT, Glenmark, MEDA, MSD, Novartis, UCB. Advisory board: Boerhinger-ingelheim, Novartis, Astrazeneca, MEDA, Mit, Glenmark, MSD, Pfizer. Grants from development of guidelines: TEVA, Pfizer, Novartis, UCB, Sanofi, GSK, Carnot, Senosiain, MEDA, MSD, Astrazeneca; Brian Lipworth: unrestricted grant support from Meda, Teva, Chiesi, Almirral. Multi centre grants from Jansen, Pearl, Roche, AZ, Teva. Consulting for Meda, Chiesi, Neopharma, Cipla, Sandoz. Ad boards for Teva, Meda, Chiesi. Support to attend educational meetings from Boerhinger, Teva, Chiesi; Renaud Louis: research grants from GSK, Novartis, Chiesi over the last 2 years -in national Aboard of GSK, AstraZeneca and Mundipharma; Le Ltt: honorarium for lectures, funding for investigation, support to attend symposium of Astra Zeneca, Boehringer-Ingelheim, Glaxo Smith kline, Novartis, Pfizer and MSD. Consultant of Astra -Zeneca and Boehringer-Ingelheim; Antoine Magnan: Investigator: GSK Novartis Astra Zeneca Roche SANOFI Amgen Boehringer. Consultant: Novartis, MSD, AstraZeneca, ALK, TEVA, Mundipharma, Takeda, GSK, Boehringer. Symposia: ALK, Stallergenes,Novartis, MSD, Chiesi, GSK, Astra-Zeneca, Roche. Research Grants: MSD, Astellas, Sanofi, Novartis, Stallergenes; P Manning: Personal Benefits <$10 000: A. Menarrini, Shares: none, Non-Personal Interests/benefits >$10 000: none; Marcus Maurer: Grant/Research/Clinical Trial Support: Novartis; Genentech; Uriach; Abbott Laboratories; FAES; UCB; Moxie.; Consultant/Advisory Boards: Novartis Genentech; Uriach; Abbott Laboratories; FAES; MSD; Almirall; UCB; Moxie; Sanofi; Ralf Mosges: reports personal fees from ALK-Abello, Ohropax, Meda, Servier, Stada, Menarini, Allergy Therapeutics, Novartis, Leti, Allergopharma, Bayer, Faes, GSK, Johnson+ Johnson, MSD, grants and personal fees from Arthrocare, Bencard, Stallergenes, BiotechTools, Lofarma, grants from Ursapharm, Bitop, HAL, AIPreven, Optima, non-financial support from Greer, Roxall, personal fees and non-financial support from UCB, non-financial support from Atmos, outside the submitted work; member of the guidelines task force of the German Academy of Otorhinolaryngology, chairman of the International Standardisation Committee of the European Rhinologic Society (ERS) and chairman of the ENT-Section of the European Academy of Allergy, Asthma and Clinical Immunology (EAACI); Robert Naclerio: Advisory Board: GSK, Merck, Sanofi, Teva - Speaker: Merck, Teva; Ken Ohta: honoraria for lectures and advisory meetings from Kyorin, GSK, Boehringer Ingelheim, AstraZeneca and Astellas; Yoshitaka Okamoto: Research grant from Torii Co. Ltd., Shionogi Co. Ltd., - Lecture fee from Torii Co. LTD., MSD Co. LtD; Kimihio Okubo: Lecture Fee: GSK, MSD, Tanabe-Mitsubishi, Sanofi, Ono, Torii, Kyowa-Kirin - Consultancy: MSD, Tanabe-Mitsubishi, Sanofi, Ono, Torii, Taiho, Astellas, Teikoku; Pier Luigi Paggiaro: personal support for education and research from: AstraZeneca, Almirall, Boehringer Ingelheim, Chiesi, Guidotti-Malesci, GSK, Menarini, MSD, Mundipharma, Novartis, Takeda, Zambon; Nikos Papadopoulos: grant from GSK, Nestle, Merck - Fees from: Abbvie, Sanofi, Meda, GSK, Novartis, Menarini, ALK-Abello, Allergopharma, Uriach, Stallergenes, MSD; Alberto Papi: has received grants, personal fees, and non-financial support from AstraZeneca, Chiesi Farmaceutici, GlaxoSmithKline, Boehringer Ingelheim, Merck Sharp & Dohme, Menarini, Novartis, Zambon, TEVA, Pfizer, Takeda, and Mundipharma; O Pfaar: has received research grants for his institution from ALK Abello (Germany/Denmark), Allergopharma (Germany), Stallergenes (Germany/France), HAL Allergy (Germany/the Netherlands), Artu Biologicals (the Netherlands), Allergy Therapeutics/Bencard (UK/Germany), Hartington (Spain), Lofarma (Italy), Novartis/Leti (Germany/Spain), GlaxoSmithKline (UK/Germany), Essex Pharma (Germany), Cytos (Switzerland), Curalogic (Denmark), Roxall (Germany), Biomay (Austria), Thermo Fisher (Germany), Circassia (UK), European Union (FP-7 Health-2013 Innovation 1), Biotech Tools s.a. (Belgium), and Meda Pharma GmbH (Germany); and/or he has served as an advisor and on speakers' bureaus for some of the aforementioned companies. OP has received travel grants from HAL Allergy (the Netherlands/Germany) and Allergopharma (Germany), and he is a consultant for Bencard (Germany), HAL Allergy (the Netherlands), Novartis/Leti (Germany), Meda (Germany), ALK Abello (Germany/Denmark), Allergopharma (Germany), Biotech Tools s. a. (Belgium), GfK Bridgehead (UK), Navigant Consulting (USA), Sanofi (USA), Guidepoint Global Advisors (USA), Thermo Fisher (Germany) and Stallergenes (Germany/France); he is Scientific Board Member of Mobile Chamber Experts (MCX), a GA2LEN Partner. OP is the current chairman of the Immunotherapy Interest Group (IT IG) of the European Academy of Allergy and Clinical Immunology (EAACI) and is the secretary of the ENT section of the German Society for Allergology and Clinical Immunology (DGAKI).; He has received grants for the 'Spezifische Immuntherapie'-award 2014 and the 'Nachwuchsforderpreis'-award 2010 of the DGAKI. He is co-editor and an author of the textbook 'Allergien bei Kindern und Jugendlichen' (publisher: Schattauer-Verlag, Germany), 'Allergologie' (publisher: Schattauer-Verlag) and author of different chapters of 'Allergologie-Handbuch' (publisher: Schattauer-Verlag, Germany) and has received payment for development of educational presentations from GlaxoSmithKline (Germany), Bencard (Germany), and Novartis (Germany); Davor Plavek: reports grants from Ministry of Science, Education and Sports of Republic of Croatia, grants and personal fees from GlaxoSmithKline, grants and personal fees from MSD, personal fees from Sandoz, personal fees from Salveo, grants from Schering-Plough, outside the submitted work; Dirkje Postma: The University of Groningen has received money for Professor Postma regarding an unrestricted educational grant for research from Astra Zeneca. Travel to ERS and/or ATS has been partially funded by Astra Zeneca, Chiesi, GSK, Takeda. Fees for consultancies were given to the University of Groningen by Astra Zeneca, Boehringer Ingelheim, Chiesi, GSK, Takeda and TEVA. Travel and lectures in China paid by Chiesi; David Price: Board Membership with Aerocrine, Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Meda, Mundipharma, Napp, Novartis, and Teva. Consultancy: A Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Meda, Mundipharma, Napp, Novartis, Pfizer, and Teva; Grants and unrestricted funding for investigator-initiated studies from UK National Health Service, British Lung Foundation, Aerocrine, AKL Ltd, Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Eli Lilly, GlaxoSmithKline, Meda, Merck, Mundipharma, Napp, Novartis, Orion, Pfizer, Respiratory Effectiveness Group, Takeda, Teva, and Zentiva; Payments for lectures/speaking: Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Meda, Merck, Mundipharma, Novartis, Pfizer, SkyePharma, Takeda, and Teva; Payment for manuscript preparation: Mundipharma and Teva; Patents (planned, pending or issued): AKL Ltd.; Payment for the development of educational materials: GlaxoSmithKline, Novartis; Stock/Stock options: Shares in AKL Ltd which produces phytopharmaceuticals and owns 80% of Research in Real Life Ltd and its subsidiary social enterprise Optimum Patient Care; received Payment for travel/accommodations/meeting expenses from Aerocrine, Boehringer Ingelheim, Mundipharma, Napp, Novartis, and Teva; Funding for patient enrolment or completion of research: Almirral, Chiesi, Teva, and Zentiva; and Peer reviewer for grant committees: Medical Research Council (2014), Efficacy and Mechanism Evaluation programme (2012), HTA (2014); Dermot Ryan: Board member URIACH and Stllargenes. received payments from GSK and MEDA to deliver lectures on their behalf. Chair of the Primary Care Interest Group of EAACI; Miguel Roman-Rodriguez: has provided consultancy to or lectured on behalf of AstraZeneca, GlaxoSmithKline, Novartis, Almirall, Chiesi, Mundipharma, Boehringer-Ingelheim, Rovi and Teva; Glenis Scadding: Research grants from GSK, ALK. Honoraria for articles, consulting, lectures/chairing and/or advisory boards: ALK, Astra Zeneca, Brittania Pharmaceuticals, Capnia, Church & Dwight, Circassia, GSK, Groupo Uriach, Meda, Merck, MSD, Ono Pharmaceuticals, Oxford Therapeutics, Sanofi-Aventis, Shionogi, UCB.; Travel funding from Bayer, GSK; Estelle Simons: Uriach Medical Advisory Board, UpToDate, The Medical Letter; Rafael Stelmach: AstraZeneca; Boehringer Ingelheim; Bayer; Chiesi; Eurofarma; Glaxo Smith Kline; Mantecorp-Farmasa; Novartis; MSD; Nycomed; Reckitt Bekinser, related to sponsorship for achievement/participation of clinical trials, conferences or consultancy activities; Ana Todo Bom: Fee for speaking, reimbursement for attending or organising a symposium) from Novartis Farma, Faes Farma, Astrazeneca, Bial Aristegui, Thermo Fisher, Boehringer; Rudolf Valenta: has received research grants from Biomay AG, Vienna, Austria, Thermo Fisher, Uppsala, Sweden. He serves as a consultant for Biomay AG, Vienna, austria, Thermofisher, Uppsala, Sweden and Fresenius Medical Care, Bad Homburg, Germany; Ulrich Wahn: received fees for lectures and consultation within the last 5 years from: Stallergenes, Allergopharma, ALK, Novartis, Merck, and MEDA; All the other authors declare that they have no conflicts of interest.	Lourenco O, 2014, J MANAGE CARE PHARM, V20, P513; Shiffman S, 2008, ANNU REV CLIN PSYCHO, V4, P1, DOI 10.1146/annurev.clinpsy.3.022806.091415; Campbell H, 1998, BRIT MED J, V316, P133; Bousquet J, 2009, ALLERGY, V64, P1516, DOI 10.1111/j.1398-9995.2009.02115.x; Auffray C, 2010, CHEST, V137, P1410, DOI 10.1378/chest.09-1850; [Anonymous], 2007, EXPERT PANEEL REPORT; Shao J, 2014, AM J RHINOL ALLERGY, V28, P131, DOI 10.2500/ajra.2014.28.4006; Demoly P, 2013, CLIN EXP ALLERGY, V43, P881, DOI 10.1111/cea.12121; Lahdensuo A, 1998, BRIT MED J, V316, P1138; Braido F, 2012, ALLERGY, V67, P1443, DOI 10.1111/all.12014; Grant S, 1999, CHEST, V116, P1208, DOI 10.1378/chest.116.5.1208; AGARWAL MK, 1983, J ALLERGY CLIN IMMUN, V72, P40, DOI 10.1016/0091-6749(83)90050-7; Frenz DA, 2000, ANN ALLERG ASTHMA IM, V84, P481; Bousquet J, 2009, INT ARCH ALLERGY IMM, V150, P75, DOI 10.1159/000210383; von Hertzen LC, 2009, ALLERGY, V64, P678, DOI 10.1111/j.1398-9995.2009.02024.x; Montoro J, 2012, ALLERGY, V67, P1437, DOI 10.1111/all.12011; Walker S, 2007, J ALLERGY CLIN IMMUN, V120, P381, DOI 10.1016/j.jaci.2007.03.034; Bousquet PJ, 2013, INT ARCH ALLERGY IMM, V160, P393, DOI 10.1159/000342991; Bousquet PJ, 2007, INT ARCH ALLERGY IMM, V143, P163, DOI 10.1159/000099307; Ragab SM, 2006, ALLERGY, V61, P717, DOI 10.1111/j.1398-9995.2005.01044.x; Shea KM, 2008, J ALLERGY CLIN IMMUN, V122, P443, DOI 10.1016/j.jaci.2008.06.032; Bousquet J, 2009, J ALLERGY CLIN IMMUN, V124, P428, DOI 10.1016/j.jaci.2009.06.027; Samolinski B, 2012, ALLERGY, V67, P726, DOI 10.1111/j.1398-9995.2012.02822.x; Smith M, 2007, ANN AGR ENV MED, V14, P123; Vestbo J, 2010, AM J RESP CRIT CARE, V182, P863, DOI 10.1164/rccm.201004-0602ED; Estrella N, 2006, INT J BIOMETEOROL, V51, P49, DOI 10.1007/s00484-006-0038-7; NewsonSmith G, 1997, EUR ARCH OTO-RHINO-L, V254, P236, DOI 10.1007/BF00874095; Di Lorenzo G, 2011, INT ARCH ALLERGY IMM, V155, P263, DOI 10.1159/000320050; AGARWAL MK, 1984, J ALLERGY CLIN IMMUN, V74, P687, DOI 10.1016/0091-6749(84)90231-8; Ohta K, 2011, ALLERGY, V66, P1287, DOI 10.1111/j.1398-9995.2011.02676.x; Bousquet J, 2010, INT ARCH ALLERGY IMM, V153, P395, DOI 10.1159/000316351; Valero A, 2010, ALLERGY, V65, P1609, DOI 10.1111/j.1398-9995.2010.02410.x; Ziska LH, 2003, J ALLERGY CLIN IMMUN, V111, P290, DOI 10.1067/mai.2003.53; Buters JTM, 2010, ALLERGY, V65, P850, DOI 10.1111/j.1398-9995.2009.02286.x; Ayres JG, 2009, EUR RESPIR J, V34, P295, DOI 10.1183/09031936.00003409; del Cuvillo A, 2010, RHINOLOGY, V48, P201, DOI 10.4193/Rhin09.099; D'Amato G, 2002, ALLERGY, V57, P30, DOI 10.1034/j.1398-9995.57.s72.5.x; de Weger LA, 2014, INT J BIOMETEOROL, V58, P1047, DOI 10.1007/s00484-013-0692-5; Demoly P, 2011, CLIN EXP ALLERGY, V41, P860, DOI 10.1111/j.1365-2222.2011.03734.x; Bousquet J, 2013, PRESSE MED, V42, P1558, DOI 10.1016/j.lpm.2013.11.002; Wei HQ, 2013, INT J MED SCI, V10, P1914, DOI 10.7150/ijms.7117; [Anonymous], 2012, 3206 EMPL SOC POL EH; Laaidi K, 2001, INT J BIOMETEOROL, V45, P124, DOI 10.1007/s004840100096; Garcia-Mozo H, 2006, ANN AGR ENV MED, V13, P209; Ryan D, 2008, ALLERGY, V63, P981, DOI 10.1111/j.1398-9995.2008.01653.x; Bousquet J, 2014, J ALLERGY CLIN IMMUN, V133, P1535, DOI 10.1016/j.jaci.2014.01.018; Fonseca JA, 2010, ALLERGY, V65, P1042, DOI 10.1111/j.1398-9995.2009.02310.x; Baiardini I, 2010, ALLERGY, V65, P290, DOI 10.1111/j.1398-9995.2009.02263.x; Schatz M, 2010, ANN ALLERG ASTHMA IM, V104, P118, DOI 10.1016/j.anai.2009.11.063; HENAUER S, 1987, J INT MED RES, V15, P212; Annesi-Maesano I, 2012, INT ARCH ALLERGY IMM, V158, P397, DOI 10.1159/000332964; Bousquet J, 2003, ALLERGY, V58, P733, DOI 10.1034/j.1398-9995.2003.00076.x; Skrindo I, 2015, PEDIAT ALLERG IMM-UK, V26, P239, DOI 10.1111/pai.12366; Haahtela T, 2008, ALLERGY, V63, P634, DOI 10.1111/j.1398-9995.2008.01712.x; Pfaar O, 2014, ALLERGY, V69, P854, DOI 10.1111/all.12383; Berger U, 2014, CURR OPIN ALLERGY CL, V14, P200, DOI 10.1097/ACI.0000000000000060; Haahtela T, 2009, ALLERGY, V64, P1799, DOI 10.1111/j.1398-9995.2009.02246.x; Ciprandi G, 2009, J BIOL REG HOMEOS AG, V23, P31; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Azevedo P, 2013, PRIM CARE RESP J, V22, P112, DOI 10.4104/pcrj.2013.00012; Mosges R, 2011, ALLERGY, V66, P707, DOI 10.1111/j.1398-9995.2010.02529.x; Kmenta M, 2014, INT J BIOMETEOROL, V58, P1721, DOI 10.1007/s00484-013-0776-2; Baiardini I, 2008, ALLERGY, V63, P1015, DOI 10.1111/j.1398-9995.2008.01823.x; Wayne P, 2002, ANN ALLERG ASTHMA IM, V88, P279; Fitter AH, 2002, SCIENCE, V296, P1689, DOI 10.1126/science.1071617; Frenguelli G, 2010, ANN ALLERG ASTHMA IM, V105, P223, DOI 10.1016/j.anai.2010.06.016; Lu D, 2011, AM J OTOLARYNG, V32, P494, DOI 10.1016/j.amjoto.2010.09.014; Tatar EC, 2012, AM J RHINOL ALLERGY, V26, pE37, DOI 10.2500/ajra.2012.26.3750; Rouve S, 2010, RHINOLOGY, V48, P285, DOI [10.4193/Rhin09.208, 10.4193/Rhino09.208]; Bousquet J, 2010, J ALLERGY CLIN IMMUN, V126, P926, DOI 10.1016/j.jaci.2010.07.019; Bousquet J, 2013, ALLERGY, V68, P555, DOI 10.1111/all.12115; Lubitz S, 2010, ENVIRON TOXICOL, V25, P188, DOI 10.1002/tox.20490; Bright TJ, 2012, ANN INTERN MED, V157, P29, DOI 10.7326/0003-4819-157-1-201207030-00450; Valero A, 2007, J ALLERGY CLIN IMMUN, V120, P359, DOI 10.1016/j.jaci.2007.04.006; D'Amato G, 2007, ALLERGY, V62, P976, DOI 10.1111/j.1398-9995.2007.01393.x; Haahtela T, 2006, THORAX, V61, P663, DOI 10.1136/thx.2005.055699; Bousquet J, 2012, INT ARCH ALLERGY IMM, V158, P216, DOI 10.1159/000332924; Hollins PD, 2004, INT J BIOMETEOROL, V48, P137, DOI 10.1007/s00484-003-0188-9; Emberlin J, 2002, INT J BIOMETEOROL, V46, P159, DOI 10.1007/s00484-002-0139-x; Bousquet J, 2012, J ALLERGY CLIN IMMUN, V130, P1049, DOI 10.1016/j.jaci.2012.07.053; Jaspers MWM, 2011, J AM MED INFORM ASSN, V18, P327, DOI 10.1136/amiajnl-2011-000094; Ahlholm JU, 1998, CLIN EXP ALLERGY, V28, P1384; Reips UD, 2008, BEHAV RES METHODS, V40, P699, DOI 10.3758/BRM.40.3.699; Bousquet J, 2011, ALLERGY, V66, P596, DOI 10.1111/j.1398-9995.2010.02534.x; Bousquet J, 2015, THORAX, V70, P595, DOI 10.1136/thoraxjnl-2014-206304; Brozek JL, 2010, J ALLERGY CLIN IMMUN, V126, P466, DOI 10.1016/j.jaci.2010.06.047; Longhi S, 2009, ANN ALLERG ASTHMA IM, V103, P508, DOI 10.1016/S1081-1206(10)60268-2; Morais-Almeida M, 2013, ALLERGY, V68, P1150, DOI 10.1111/all.12207; Bousquet PJ, 2009, J ALLERGY CLIN IMMUN, V123, P1349, DOI 10.1016/j.jaci.2009.02.033; Beggs PJ, 2005, ENVIRON HEALTH PERSP, V113, P915, DOI 10.1289/ehp.7724; PFENNINGS L, 1995, PSYCHOL REP, V77, P475; Morais-Almeida M, 2013, ALLERGY, V68, P1278, DOI 10.1111/all.12221; Caillaud DM, 2012, J ALLERGY CLIN IMMUN, V130, P812, DOI 10.1016/j.jaci.2012.04.034; Anto JM, 2012, J ALLERGY CLIN IMMUN, V129, P943, DOI 10.1016/j.jaci.2012.01.047; Lupinek C, 2014, METHODS, V66, P106, DOI 10.1016/j.ymeth.2013.10.008; Stach A, 2008, INT J BIOMETEOROL, V52, P311, DOI 10.1007/s00484-007-0127-2; MOLFINO NA, 1992, CLIN EXP ALLERGY, V22, P667, DOI 10.1111/j.1365-2222.1992.tb00189.x; Bousquet PJ, 2010, J ALLERGY CLIN IMMUN, V126, P666, DOI 10.1016/j.jaci.2010.06.034; Emberlin J, 1999, CLIN EXP ALLERGY, V29, P347; Hellings PW, 2013, ALLERGY, V68, P1, DOI 10.1111/all.12040; Linhares DVBR, 2014, PEDIAT ALLERG IMM-UK, V25, P173, DOI [10.1111/pai.12218, 10.1111/pai.12187]; Frei T, 2008, INT J BIOMETEOROL, V52, P667, DOI 10.1007/s00484-008-0159-2; Samolinski B, 2012, LANCET, V379, pE45, DOI 10.1016/S0140-6736(12)60514-5; Behrendt H, 1997, INT ARCH ALLERGY IMM, V113, P69; Bernardo TM, 2013, J MED INTERNET RES, V15, P239, DOI 10.2196/jmir.2740; Beuscart-Zéphir M-C, 2007, Yearb Med Inform, P109; Boehm G, 1987, Experientia Suppl, V51, P87; Borrego LM, 2014, BMC PEDIATR, V14, DOI 10.1186/1471-2431-14-34; Bousquet J, 2007, GLOBAL SURVEILLANCE, P148; Bousquet J, 2014, EUR GERIATR MED, V5, P361, DOI 10.1016/j.eurger.2014.09.010; Bousquet J, 2011, GENOME MED, V3, DOI 10.1186/gm259; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Broniatowski DA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083672; Bruhn S, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007410; Burnay E, 2013, TELEMED E-HEALTH, V19, P13, DOI 10.1089/tmj.2012.0020; Caillaud D, 2014, INT ARCH ALLERGY IMM, V163, P43, DOI 10.1159/000355630; Caillaud DM, 2015, ALLERGY, V70, P99, DOI 10.1111/all.12522; Canonica Giorgio Walter, 2014, World Allergy Organ J, V7, P6, DOI 10.1186/1939-4551-7-6; Cassagne E, 2007, Eur Ann Allergy Clin Immunol, V39, P262; Davies R. J., 1993, Rhinology (Utrecht), V31, P159; De Jongh T, 2012, COCHRANE DB SYST REV, V12, DOI DOI 10.1002/14651858.CD007459.PUB2]; de WL, 2009, NED TIJDSCHR GENEES, V153, pA1410; Deak AJ, 2012, SCI TOTAL ENV C, V442C, P36; Deliu M, 2014, ALLERGY, V69, P1515, DOI 10.1111/all.12467; Devillier P, 2014, ALLERGY, V69, P1689, DOI 10.1111/all.12518; Dubey G., 2014, ANN MINES, P82; Dugas AF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056176; Dunton Genevieve Fridlund, 2014, Front Public Health, V2, P12, DOI 10.3389/fpubh.2014.00012; Bousquet J, 2014, EUR RESPIR J, V44, P304, DOI 10.1183/09031936.00014614; Fokkens WJ, 2012, RHINOL S, V23, P3; Frew AJ, 2012, ANN ALLERG ASTHMA IM, V109, P342, DOI 10.1016/j.anai.2012.08.013; Galan C, 2013, ALLERGY, V68, P809, DOI 10.1111/all.12144; Gurol-Urganci I, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007458.pub3; Integrated Care Pathways users in Scotland (ICPUS), WORKB PEOPL START DE; Klimek L, 2015, ALLERGY ASTHMA PROC, V36, P40, DOI 10.2500/aap.2015.36.3823; Konig V, 2014, J ALLERGY, V2014; Lahdensuo A, 1996, BRIT MED J, V312, P748; Larenas-Linnemann D, 2013, AM J RHINOL ALLERGY, V27, P495, DOI 10.2500/ajra.2013.27.3957; Clavel R, 1998, ALLERGY, V53, P493, DOI 10.1111/j.1398-9995.1998.tb04086.x; Lechner U., 2014, HLTH TECHNOLOGY, V4, P31; Lluch M., 2012, STRATEGIC INTELLIGEN; Manuel-Keenoy de- E, 2014, EUR GERIATR MED, V5, P342; Marsh D, 1987, ALLERG IMMUNOL PARIS, V1, P43; Bousquet J, 2004, ALLERGY, V59, P373; Myszkowska D, 2014, ANN AGR ENV MED, V21, P681, DOI 10.5604/12321966.1129914; Nogueira-Silva L, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-52; Nuti SV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109583; Overill S, 1998, J INTEGRATED CARE, V2, P93; Samoliński Bolesław, 2009, Otolaryngol Pol, V63, P324, DOI 10.1016/S0030-6657(09)70135-0; van der Leeuw S, 2015, NPJ PRIM CARE RESP M, V25, DOI 10.1038/npjpcrm.2014.107; Vijan Sandeep, 2010, Ann Intern Med, V152, pITC31, DOI 10.7326/0003-4819-152-5-201003020-01003; Voukantsis D, 2015, INT J BIOMETEOROL, V59, P889, DOI 10.1007/s00484-014-0905-6; Wang KJ, 2014, INT ARCH ALLERGY IMM, V163, P51, DOI 10.1159/000356317; Westman M, 2015, J ALLERGY CLIN IMMUN, V135, P1199, DOI 10.1016/j.jaci.2014.10.042; Yamamoto Hideyuki, 2012, Allergy Asthma Proc, V33, pe17, DOI 10.2500/aap.2012.33.3514; Zuberbier T, 2014, ALLERGY, V69, P1275, DOI 10.1111/all.12470	156	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0105-4538	1398-9995		ALLERGY	Allergy	NOV	2015	70	11					1372	1392		10.1111/all.12686		21	Allergy; Immunology	Allergy; Immunology	CU2CJ	WOS:000363329400003		
J	Patil, DT; Ma, S; Konishi, M; Carver, PD; Pukay, M; Beadling, C; Corless, CL; Rubin, BP				Patil, Deepa T.; Ma, Shuang; Konishi, Mai; Carver, Paula D.; Pukay, Marina; Beadling, Carol; Corless, Christopher L.; Rubin, Brian P.			Utility of BRAF V600E Mutation-Specific Immunohistochemistry in Detecting BRAF V600E-Mutated Gastrointestinal Stromal Tumors	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						BRAF V600E; Immunohistochemistry; Gastrointestinal stromal tumor	PAPILLARY THYROID-CARCINOMA; METASTATIC COLORECTAL-CANCER; LYNCH SYNDROME; BRAF(V600E) MUTATION; DIAGNOSTIC-VALUE; IMATINIB; EXPRESSION; MELANOMA; ADENOCARCINOMA; RESISTANCE	Objectives: As patients with BRAF V600E mutation respond to BRAF inhibitors, it is important to identify these mutations to stratify patients for the appropriate therapy. In this study, we evaluated the utility of a BRAF V600E allele-specific antibody in gastrointestinal stromal tumors (GISTs). Methods: BRAF V600E mutation-specific immunohistochemistry (negative, weak, or moderate/strong expression) and BRAF sequencing were performed on 38 consecutive GISTs diagnosed between January 2013 and April 2014. Results: GISTs from a cohort of 25 men and 13 women (mean age, 61 years; range, 39-88 years) were localized to the stomach (18), small bowel (10), colon (three), rectum (two), and pelvis/omentum (five). Strong and diffuse cytoplasmic BRAF expression was noted in two (5%) of 38 cases, while eight (21%) of 38 cases showed weak staining, and 28 (74%) of 38 cases were negative. Both of the strongly positive cases arose in the stomach, occurring in a 42-year-old and a 47-year-old woman, respectively. The lesions measured 0.8 and 1 cm, showed spindle cell morphology, and had no risk of progressive disease by Miettinen criteria. Both cases showed heterozygous BRAF V600E, while no BRAF mutations were detected in cases with weak or negative BRAF expression. Conclusions: BRAF V600E mutation-specific immunohistochemistry is a highly sensitive and specific method for detecting BRAF-mutated GISTs.	[Patil, Deepa T.; Ma, Shuang; Carver, Paula D.; Rubin, Brian P.] Cleveland Clin, Dept Pathol, Robert J Tomsich Pathol & Lab Med Inst, Cleveland, OH 44195 USA; [Konishi, Mai] Shiga Univ Med Sci, Div Mol & Diagnost Pathol, Dept Pathol, Otsu, Shiga, Japan; [Pukay, Marina; Beadling, Carol; Corless, Christopher L.] Oregon Hlth & Sci Univ, Knight Diagnost Labs, Portland, OR 97201 USA	Patil, DT (reprint author), Cleveland Clin, Dept Pathol, 9500 Euclid Ave,L-25, Cleveland, OH 44195 USA.	patild@ccf.org; rubinb2@ccf.org					Adackapara CA, 2013, HISTOPATHOLOGY, V63, P187, DOI 10.1111/his.12154; Ilie M, 2013, ANN ONCOL, V24, P742, DOI 10.1093/annonc/mds534; Colomba E, 2013, J MOL DIAGN, V15, P94, DOI 10.1016/j.jmoldx.2012.09.001; Demetri GD, 2009, CLIN CANCER RES, V15, P5902, DOI 10.1158/1078-0432.CCR-09-0482; Hostein I, 2010, AM J CLIN PATHOL, V133, P141, DOI 10.1309/AJCPPCKGA2QGBJ1R; Ilie MI, 2014, THYROID, V24, P858, DOI 10.1089/thy.2013.0302; Falchook GS, 2013, ONCOTARGET, V4, P310; Gill AJ, 2011, AM J SURG PATHOL, V35, P1245, DOI 10.1097/PAS.0b013e3182217b93; Capper D, 2013, INT J CANCER, V133, P1624, DOI 10.1002/ijc.28183; Demetri GD, 2006, LANCET, V368, P1329, DOI 10.1016/S0140-6736(06)69446-4; Miettinen M, 2001, VIRCHOWS ARCH, V438, P1, DOI 10.1007/s004280000338; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Affolter K, 2013, GENE CHROMOSOME CANC, V52, P748, DOI 10.1002/gcc.22070; Miettinen M, 2013, AM J SURG PATHOL, V37, P234, DOI 10.1097/PAS.0b013e3182671178; Long GV, 2013, AM J SURG PATHOL, V37, P61, DOI 10.1097/PAS.0b013e31826485c0; Rege TA, 2011, AM J SURG PATHOL, V35, P495, DOI 10.1097/PAS.0b013e31820e5f7d; Koperek O, 2012, AM J SURG PATHOL, V36, P844, DOI 10.1097/PAS.0b013e318246b527; Bullock M, 2012, ENDOCR-RELAT CANCER, V19, P779, DOI 10.1530/ERC-12-0239; Busam KJ, 2013, AM J SURG PATHOL, V37, P413, DOI 10.1097/PAS.0b013e318271249e; Daniels M, 2011, CANCER LETT, V312, P43, DOI 10.1016/j.canlet.2011.07.029; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Thiel A, 2013, VIRCHOWS ARCH, V463, P613, DOI 10.1007/s00428-013-1470-9; Corless CL, 2014, J CLIN ONCOL, V32, P1563, DOI 10.1200/JCO.2013.51.2046; Miranda C, 2012, CLIN CANCER RES, V18, P1769, DOI 10.1158/1078-0432.CCR-11-2230; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Lasota J, 2014, AM J SURG PATHOL, V38, P1235, DOI 10.1097/PAS.0000000000000229; Agaram NP, 2008, GENE CHROMOSOME CANC, V47, P853, DOI 10.1002/gcc.20589; Curry JL, 2012, SEMIN CUTAN MED SURG, V31, P267, DOI 10.1016/j.sder.2012.07.007; Wagner AJ, 2013, MODERN PATHOL, V26, P289, DOI 10.1038/modpathol.2012.153; Capper D, 2011, ACTA NEUROPATHOL, V122, P11, DOI 10.1007/s00401-011-0841-z; Blank PR, 2011, CLIN CANCER RES, V17, P6338, DOI 10.1158/1078-0432.CCR-10-2267; Rubin BP, 2007, LANCET, V369, P1731, DOI 10.1016/S0140-6736(07)60780-6; Agaimy A, 2009, J CLIN PATHOL, V62, P613, DOI 10.1136/jcp.2009.064550; Demetri GD, 2013, LANCET, V381, P295, DOI 10.1016/S0140-6736(12)61857-1; Miettinen M, 2006, SEMIN DIAGN PATHOL, V23, P70, DOI 10.1053/j.semdp.2006.09.001; Sinicrope FA, 2013, CANCER-AM CANCER SOC, V119, P2765, DOI 10.1002/cncr.28133; Calonge N, 2013, GENET MED, V15, P517, DOI 10.1038/gim.2012.184; Shaib Walid, 2013, J Gastrointest Oncol, V4, P308, DOI 10.3978/j.issn.2078-6891.2013.029; Toon CW, 2013, AM J SURG PATHOL, V37, P1592, DOI 10.1097/PAS.0b013e31828f233d	39	0	0	AMER SOC CLINICAL PATHOLOGY	CHICAGO	2100 W HARRISON ST, CHICAGO, IL 60612 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	NOV	2015	144	5					782	789		10.1309/AJCPRK3V2EIIUPQZ		8	Pathology	Pathology	CU0RL	WOS:000363226300013		
J	Kawada, T				Kawada, Tomoyuki			Cardiometabolic risk prediction by job stress and sleep deficiency	AMERICAN JOURNAL OF INDUSTRIAL MEDICINE			English	Letter							CARE		Nippon Med Sch, Dept Hyg & Publ Hlth, Bunkyo Ku, Tokyo 1138602, Japan	Kawada, T (reprint author), Nippon Med Sch, Dept Hyg & Publ Hlth, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138602, Japan.	kawada@nms.ac.jp					D'Agostino RB, 2008, CIRCULATION, V117, P743, DOI 10.1161/CIRCULATIONAHA.107.699579; Jacobsen HB, 2014, AM J IND MED, V57, P940, DOI 10.1002/ajim.22340; Marino M, 2014, AM J PREV MED, V47, P131, DOI 10.1016/j.amepre.2014.03.006	3	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0271-3586	1097-0274		AM J IND MED	Am. J. Ind. Med.	NOV	2015	58	11					1229	1229		10.1002/ajim.22521		1	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	CU1ZN	WOS:000363321000010		
J	Imai, K; Uchiyama, A; Okamura, T; Ago, M; Suenaga, H; Sugita, E; Ono, H; Shuri, K; Masumoto, K; Totsu, S; Nakanishi, H; Kusuda, S				Imai, Ken; Uchiyama, Atsushi; Okamura, Tomoka; Ago, Mako; Suenaga, Hideyo; Sugita, Eri; Ono, Hideko; Shuri, Kyoko; Masumoto, Kenichi; Totsu, Satsuki; Nakanishi, Hidehiko; Kusuda, Satoshi			Differences in mortality and morbidity according to gestational ages and birth weights in infants with trisomy 18	AMERICAN JOURNAL OF MEDICAL GENETICS PART A			English	Article						trisomy 18; very-low-birth-weight infant; preterm; mortality; prognosis	NATURAL-HISTORY; SURVIVAL; MANAGEMENT; TEXAS	The aim of this study was to clarify the effects of gestational age and birth weight on outcomes of the infants. Medical records of 36 infants with trisomy 18 admitted to Tokyo Women's Medical University Hospital from 1991 to 2012 were reviewed retrospectively. We compared clinical characteristics between term infants (n=15) and preterm infants (n=21). There were one very-low-birth-weight (VLBW) term infant (5%) and 12 VLBW preterm infants (80%). Although there were no significant differences in clinical characteristics and provided management between the two groups, none of the preterm infants achieved survival to discharge. On the other hand, 6 of 21 term infants (29%) achieved survival to discharge (P<0.05). Similar results were obtained for comparisons between the VLBW infants and non-VLBW infants. Multiple logistic regression analysis revealed that shorter gestational age had a more negative impact than lower birth weight to survival to discharge in infants with trisomy 18. In both preterm and term groups, the infants who died before 30 days commonly died of respiratory failure or apnea. Whereas, the infants who survived more than 30 days mostly died of heart failure. (c) 2015 The Authors. American Journal of Medical Genetics Part A Published by Wiley Periodicals, Inc.	[Imai, Ken; Uchiyama, Atsushi; Okamura, Tomoka; Ago, Mako; Suenaga, Hideyo; Sugita, Eri; Ono, Hideko; Shuri, Kyoko; Masumoto, Kenichi; Totsu, Satsuki; Nakanishi, Hidehiko; Kusuda, Satoshi] Tokyo Womens Med Univ, Dept Neonatol, Maternal & Perinatal Ctr, Tokyo 1628666, Japan	Imai, K (reprint author), Tokyo Womens Med Univ, Dept Neonatol, Maternal & Perinatal Ctr, Shinjyuku Ku, 8-1 Kawada Cho, Tokyo 1628666, Japan.	imai.ken@twmu.ac.jp					Embleton ND, 1996, ARCH DIS CHILD, V75, pF38, DOI 10.1136/fn.75.1.F38; EDWARDS JH, 1960, LANCET, V1, P787; Irving C, 2011, J MATERN-FETAL NEO M, V24, P137, DOI 10.3109/14767051003758879; Rasmussen SA, 2003, PEDIATRICS, V111, P777, DOI 10.1542/peds.111.4.777; Kosho T, 2013, AM J MED GENET A, V161A, P1531, DOI 10.1002/ajmg.a.35990; McGraw MP, 2008, PEDIATRICS, V121, P1106, DOI 10.1542/peds.2007-1869; Carey JC, 2012, CURR OPIN PEDIATR, V24, P672, DOI 10.1097/MOP.0b013e3283595031; Wu JH, 2013, AM J MED GENET A, V161, P2512, DOI 10.1002/ajmg.a.36127; ROOT S, 1994, AM J MED GENET, V49, P170, DOI 10.1002/ajmg.1320490203; Boghossian NS, 2014, PEDIATRICS, V133, P226, DOI 10.1542/peds.2013-1702; Niedrist D, 2006, AM J MED GENET A, V140A, P952, DOI 10.1002/ajmg.a.31172; Nembhard WN, 2001, TERATOLOGY, V64, P267, DOI 10.1002/tera.1073; Vendola C, 2010, AM J MED GENET A, V152A, P360, DOI 10.1002/ajmg.a.33156; CARTER PE, 1985, CLIN GENET, V27, P59; Naguib KK, 1999, INT J EPIDEMIOL, V28, P711, DOI 10.1093/ije/28.4.711; Kosho T, 2006, AM J MED GENET A, V140A, P937, DOI 10.1002/ajmg.a.31175; Hsiao CC, 2009, PEDIATR NEONATOL, V50, P147, DOI 10.1016/S1875-9572(09)60053-X; YOUNG ID, 1986, ARCH DIS CHILD, V61, P1035; Lin HY, 2006, AM J MED GENET A, V140A, P945, DOI 10.1002/ajmg.a.31173; Brewer C M, 2002, J Med Genet, V39, pe54, DOI 10.1136/jmg.39.9.e54; Guon J, 2013, AM J MED GENET A, V164A, P308; Itabashi K, 2010, ACTA PEDIAT JPN, V114, P1271; Jones KL, 2006, SMITHS RECOGNIZABLE, P13; Nielsen KG, 1985, CLIN GENET, V27, P59	24	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1552-4825	1552-4833		AM J MED GENET A	Am. J. Med. Genet. A	NOV	2015	167	11					2610	2617		10.1002/ajmg.a.37246		8	Genetics & Heredity	Genetics & Heredity	CU1LB	WOS:000363281900021		
J	Takenouchi, T; Kosaki, R; Niizuma, T; Hata, K; Kosaki, K				Takenouchi, Toshiki; Kosaki, Rika; Niizuma, Takahiro; Hata, Kenichiro; Kosaki, Kenjiro			Macrothrombocytopenia and developmental delay with a de novo CDC42 mutation: Yet another locus for thrombocytopenia and developmental delay	AMERICAN JOURNAL OF MEDICAL GENETICS PART A			English	Article						CDC42; thrombocytopenia; developmental delay; Wiskott-Aldrich syndrome; cytoskeleton; exome sequencing	ALDRICH-SYNDROME PROTEIN; CDC42 GTPASES; RHO; COMPLEX; MICRODELETION; PHENOTYPE; REGION; RAC	The combinatory phenotype of thrombocytopenia and developmental delay has been described for two genetic conditions: a chromosome 11q deletion that is referred to as Jacobsen syndrome, and a 21q22 microdeletion syndrome. Herein, we report a young girl who presented with persistent macrothrombocytopenia and a developmental delay. Whole exome sequencing revealed a de novo amino acid substitution in CDC42, a critical regulator of the cytoskeleton. Our observation recapitulates observations in mice lacking Cdc42. We suggest that this CDC42 mutation may represent yet another mechanism leading to the combinatory phenotype of persistent macrothrombocytopenia and developmental delay. (c) 2015 Wiley Periodicals, Inc.	[Takenouchi, Toshiki] Keio Univ, Sch Med, Dept Pediat, Tokyo 1608582, Japan; [Takenouchi, Toshiki; Kosaki, Kenjiro] Keio Univ, Sch Med, Ctr Med Genet, Tokyo 1608582, Japan; [Kosaki, Rika] Natl Ctr Child Hlth & Dev, Div Med Genet, Tokyo, Japan; [Niizuma, Takahiro] Tokyo Rinkai Hosp, Dept Pediat, Tokyo, Japan; [Hata, Kenichiro] Natl Ctr Child Hlth & Dev, Dept Maternal Fetal Biol, Tokyo, Japan	Kosaki, K (reprint author), Keio Univ, Sch Med, Ctr Med Genet, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	kkosaki@z3.keio.jp			Ministry of Health, Labour and Welfare, Japan; Japan Agency for Medical Research and Development; Kawano Masanori Memorial Public Interest Incorporated Foundation for Promotion of Pediatric Health; Keio University Research Grants for Life Science and Medicine; Japan Foundation for Pediatric Research [14-002]	Grant sponsor: Ministry of Health, Labour and Welfare, Japan; Grant sponsor: IRUD grant from Japan Agency for Medical Research and Development; Grant sponsor: Kawano Masanori Memorial Public Interest Incorporated Foundation for Promotion of Pediatric Health; Grant sponsor: Keio University Research Grants for Life Science and Medicine; Grant sponsor: Japan Foundation for Pediatric Research; Grant number: No14-002.	Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; Linder S, 1999, P NATL ACAD SCI USA, V96, P9648, DOI 10.1073/pnas.96.17.9648; Yamaguchi H, 2005, J CELL BIOL, V168, P441, DOI 10.1083/jcb.200407076; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Cappello S, 2006, NAT NEUROSCI, V9, P1099, DOI 10.1038/nn1744; Pleines I, 2010, BLOOD, V115, P3364, DOI 10.1182/blood-2009-09-242271; Fujita H, 2010, AM J MED GENET A, V152A, P1033, DOI 10.1002/ajmg.a.33151; Kang SHL, 2007, CLIN GENET, V72, P329, DOI 10.1111/j.1399-0004.2007.00876.x; D'Amico G, 2009, DEVELOPMENT, V136, P4043, DOI 10.1242/dev.035014; Abdul-Manan N, 1999, NATURE, V399, P379; Izumi K, 2012, AM J MED GENET A, V158A, P1535, DOI 10.1002/ajmg.a.35368; Fujita H, 2010, AM J MED GENET A, V152A, P950, DOI 10.1002/ajmg.a.33228; Song WJ, 1999, NAT GENET, V23, P166; Braddock S R, 1994, Clin Dysmorphol, V3, P75; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Grossfeld PD, 2004, AM J MED GENET A, V129A, P51, DOI 10.1002/ajmg.a.30090; Maruoka R, 2014, GENET TEST MOL BIOMA, V18, P722, DOI 10.1089/gtmb.2014.0109; Takenouchi T, 2015, J PEDIATR-US, V166, P483, DOI 10.1016/j.jpeds.2014.10.015	19	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1552-4825	1552-4833		AM J MED GENET A	Am. J. Med. Genet. A	NOV	2015	167	11					2822	2825		10.1002/ajmg.a.37275		4	Genetics & Heredity	Genetics & Heredity	CU1LB	WOS:000363281900053		
J	Chinen, Y; Kaneshi, T; Kamiya, T; Hata, K; Nishimura, G; Kaname, T				Chinen, Yasutsugu; Kaneshi, Takuya; Kamiya, Takeshi; Hata, Kenichiro; Nishimura, Gen; Kaname, Tadashi			Progressive hip joint subluxation in Saul-Wilson syndrome	AMERICAN JOURNAL OF MEDICAL GENETICS PART A			English	Article						Saul-Wilson syndrome; short stature; hip joint subluxation	SPONDYLOEPIPHYSEAL DYSPLASIA TARDA	Saul-Wilson syndrome (SWS) is a rare congenital skeletal syndrome characterized by postnatal onset of short stature, relative microcephaly, frontal bossing, prominent eyes with shallow orbits, midface hypoplasia, cataract, and generalized skeletal changes, including spondylar dysplasia, overtubulation of the long bones with metaphyseal flaring and megaepiphyses, coxa valga, elbow deformity, and brachydactyly. We describe a boy with the overall clinical and radiological features fitting the characteristics of SWS, although cataract, elbow deformity, and overt brachydactyly were not seen. He presented with painful hip joint due to hip subluxation in late childhood, which exacerbated with age and ultimately, required surgical intervention. Awareness of this orthopedic complication in SWS is essential in the management of patients with SWS. (c) 2015 Wiley Periodicals, Inc.	[Chinen, Yasutsugu; Kaneshi, Takuya] Univ Ryukyus, Fac Med, Dept Pediat, Nishihara, Okinawa 9030125, Japan; [Kamiya, Takeshi] Univ Ryukyus, Fac Med, Dept Orthoped Surg, Nishihara, Okinawa 9030125, Japan; [Hata, Kenichiro] Natl Res Inst Child Hlth & Dev, Dept Maternal Fetal Biol, Tokyo, Japan; [Nishimura, Gen] Tokyo Metropolitan Childrens Med Ctr, Dept Pediat Imaging, Fuchu, Tokyo, Japan; [Kaname, Tadashi] Univ Ryukyus, Grad Sch Med, Dept Adv Genom, Nishihara, Okinawa 9030125, Japan; [Kaname, Tadashi] Univ Ryukyus, Grad Sch Med, Dept Lab Med, Nishihara, Okinawa 9030125, Japan; [Kaname, Tadashi] Natl Res Inst Child Hlth & Dev, Dept Genome Med, Tokyo, Japan	Chinen, Y (reprint author), Univ Ryukyus, Fac Med, Dept Pediat, 207 Uehara, Nishihara, Okinawa 9030125, Japan.	ychinen@med.u-ryukyu.ac.jp					Whyte MP, 1999, MEDICINE, V78, P9, DOI 10.1097/00005792-199901000-00002; HERSH JH, 1994, AM J MED GENET, V51, P194, DOI 10.1002/ajmg.1320510304; SAUL RA, 1990, AM J MED GENET, V35, P388, DOI 10.1002/ajmg.1320350315; Gedeon AK, 1999, NAT GENET, V22, P400	4	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1552-4825	1552-4833		AM J MED GENET A	Am. J. Med. Genet. A	NOV	2015	167	11					2834	2838		10.1002/ajmg.a.37278		5	Genetics & Heredity	Genetics & Heredity	CU1LB	WOS:000363281900056		
J	Takagi, M; Kouwaki, M; Kawase, K; Shinohara, H; Hasegawa, Y; Yamada, T; Fujiwara, I; Sawai, H; Nishimura, G; Hasegawa, T				Takagi, Masaki; Kouwaki, Masanori; Kawase, Koya; Shinohara, Hiroyuki; Hasegawa, Yukihiro; Yamada, Takahiro; Fujiwara, Ikuma; Sawai, Hideaki; Nishimura, Gen; Hasegawa, Tomonobu			A novel mutation Ser344Cys in FGFR3 causes achondroplasia with severe platyspondyly	AMERICAN JOURNAL OF MEDICAL GENETICS PART A			English	Letter							GROWTH-FACTOR RECEPTOR-3; DYSPLASIA TYPE-I; ACANTHOSIS NIGRICANS; EXTRACELLULAR DOMAIN; SKELETAL DYSPLASIAS; DEVELOPMENTAL DELAY; LYS650MET MUTATION; CYSTEINE RESIDUES; HYPOCHONDROPLASIA; SUBSTITUTION		[Takagi, Masaki; Hasegawa, Tomonobu] Keio Univ, Sch Med, Dept Pediat, Tokyo 1608582, Japan; [Takagi, Masaki; Shinohara, Hiroyuki; Hasegawa, Yukihiro] Tokyo Metropolitan Childrens Med Ctr, Dept Endocrinol & Metab, Tokyo, Japan; [Kouwaki, Masanori] Toyohashi Municipal Hosp, Dept Pediat Neonates, Aichi, Japan; [Kawase, Koya] Nagoya City Univ, Grad Sch Med Sci, Dept Neonatol & Pediat, Aichi, Japan; [Yamada, Takahiro] Hokkaido Univ, Grad Sch Med, Dept Obstet & Gynecol, Sapporo, Hokkaido 060, Japan; [Fujiwara, Ikuma] Tohoku Univ, Sch Med, Dept Pediat, Sendai, Miyagi 980, Japan; [Sawai, Hideaki] Hyogo Coll Med, Dept Obstet & Gynecol, Nishinomiya, Hyogo, Japan; [Nishimura, Gen] Tokyo Metropolitan Childrens Med Ctr, Dept Radiol, Tokyo, Japan	Hasegawa, T (reprint author), Keio Univ, Sch Med, Dept Pediat, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	thaseg@a6.keio.jp					TAVORMINA PL, 1995, HUM MOL GENET, V4, P2175, DOI 10.1093/hmg/4.11.2175; Rousseau F, 1996, HUM MOL GENET, V5, P509, DOI 10.1093/hmg/5.4.509; IKEGAWA S, 1995, HUM GENET, V96, P309; Camera G, 2001, AM J MED GENET, V104, P277, DOI 10.1002/ajmg.10092; Wang H, 2013, CLIN CHIM ACTA, V423, P62, DOI 10.1016/j.cca.2013.04.015; SUPERTIFURGA A, 1995, EUR J PEDIATR, V154, P215, DOI 10.1007/BF01954274; Takagi M, 2012, AM J MED GENET A, V158A, P247, DOI 10.1002/ajmg.a.34358; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; Tavormina PL, 1999, AM J HUM GENET, V64, P722; Heuertz S, 2006, EUR J HUM GENET, V14, P1240, DOI 10.1038/sj.ejhg.5201700; Vajo Z, 2000, ENDOCR REV, V21, P23, DOI 10.1210/er.21.1.23; Zankl A, 2008, AM J MED GENET A, V146A, P212, DOI 10.1002/ajmg.a.32085; Baujat G, 2008, BEST PRACT RES CL RH, V22, P3, DOI 10.1016/j.berh.2007.12.008; Bonaventure J, 2007, FEBS J, V274, P3078, DOI 10.1111/j.1742-4658.2007.05835.x; Zhang SR, 2007, CHINESE MED J-PEKING, V120, P1017; Foldynova-Trantirkova S, 2012, HUM MUTAT, V33, P29, DOI 10.1002/humu.21636; Hyland VJ, 2003, AM J MED GENET A, V120A, P57	17	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1552-4825	1552-4833		AM J MED GENET A	Am. J. Med. Genet. A	NOV	2015	167	11					2851	2854		10.1002/ajmg.a.37231		4	Genetics & Heredity	Genetics & Heredity	CU1LB	WOS:000363281900060		
J	Stephen, J; Shukla, A; Dalal, A; Girisha, KM; Shah, H; Gupta, N; Kabra, M; Dabadghao, P; Hasegawa, K; Tanaka, H; Phadke, SR				Stephen, Joshi; Shukla, Anju; Dalal, Ashwin; Girisha, Katta Mohan; Shah, Hitesh; Gupta, Neerja; Kabra, Madhulika; Dabadghao, Preeti; Hasegawa, Kosei; Tanaka, Hiroyuki; Phadke, Shubha R.			Mutation spectrum of COL1A1 and COL1A2 genes in Indian patients with osteogenesis imperfecta (vol 164, pg 1482, 2014)	AMERICAN JOURNAL OF MEDICAL GENETICS PART A			English	Correction									[Stephen, Joshi; Shukla, Anju; Phadke, Shubha R.] Sanjay Gandhi Postgrad Inst Med Sci, Dept Med Genet, Lucknow, Uttar Pradesh, India; [Dalal, Ashwin] Ctr DNA Fingerprinting & Diagnost, Div Diagnost, Hyderabad, Andhra Pradesh, India; [Girisha, Katta Mohan] Manipal Univ, Dept Pediat, Kasturba Med Coll, Div Med Genet, Manipal, Karnataka, India; [Shah, Hitesh] Manipal Univ, Kasturba Med Coll, Pediat Orthopaed Serv, Dept Orthopaed, Manipal, Karnataka, India; [Gupta, Neerja; Kabra, Madhulika] All India Inst Med Sci, Dept Paediat, Genet Unit, New Delhi, India; [Dabadghao, Preeti] Sanjay Gandhi Postgrad Inst Med Sci, Dept Endocrinol, Lucknow, Uttar Pradesh, India; [Hasegawa, Kosei] Okayama Univ Hosp, Dept Pediat, Okayama, Japan; [Tanaka, Hiroyuki] Okayama Saiseikai Gen Hosp, Dept Pediat, Okayama, Japan	Phadke, SR (reprint author), Sanjay Gandhi Postgrad Inst Med Sci, Dept Med Genet, Lucknow, Uttar Pradesh, India.	shubharaophadke@gmail.com					Stephen J, 2014, AM J MED GENET A, V164, P1482, DOI 10.1002/ajmg.a.36481	1	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1552-4825	1552-4833		AM J MED GENET A	Am. J. Med. Genet. A	NOV	2015	167	11					2868	2868		10.1002/ajmg.a.37272		1	Genetics & Heredity	Genetics & Heredity	CU1LB	WOS:000363281900067		
J	Kamiya, K; Masuda, T; Tanaka, S; Hamazaki, N; Matsue, Y; Mezzani, A; Matsuzawa, R; Nozaki, K; Maekawa, E; Noda, C; Yamaoka-Tojo, M; Arai, Y; Matsunaga, A; Izumi, T; Ako, J				Kamiya, Kentaro; Masuda, Takashi; Tanaka, Shinya; Hamazaki, Nobuaki; Matsue, Yuya; Mezzani, Alessandro; Matsuzawa, Ryota; Nozaki, Kohei; Maekawa, Emi; Noda, Chiharu; Yamaoka-Tojo, Minako; Arai, Yasuo; Matsunaga, Atsuhiko; Izumi, Tohru; Ako, Junya			Quadriceps Strength as a Predictor of Mortality in Coronary Artery Disease	AMERICAN JOURNAL OF MEDICINE			English	Article						Coronary artery disease; Muscle strength; Prognosis	HAND-HELD DYNAMOMETRY; ELEVATION MYOCARDIAL-INFARCTION; EXTREMITY MUSCLE STRENGTH; CONGESTIVE-HEART-FAILURE; ALL-CAUSE MORTALITY; RESISTANCE EXERCISE; OLDER-ADULTS; CARDIOVASCULAR-DISEASE; ISOMETRIC STRENGTH; JAPANESE PATIENTS	BACKGROUND: The purpose of this study was to investigate the prognostic value of quadriceps isometric strength (QIS) in coronary artery disease (CAD). METHODS: The study population consisted of 1314 patients aged >30 years (64.7 +/- 10.6 years, 1051 male) with CAD who were hospitalized for acute coronary syndrome or coronary artery bypass grafting. Maximal QIS was evaluated as a marker of leg strength and expressed relative to body weight (% body weight). The primary and secondary endpoints were all-cause death and cardiovascular (CV) death, respectively. RESULTS: During a mean follow-up of 5.0 +/- 3.5 years, corresponding to 6537 person-years, there were 118 all-cause deaths and 63 CV deaths. A higher QIS remained associated with decreased all-cause mortality and CV mortality risks (hazard ratio for increasing 10% body weight of QIS 0.77, 95% confidence interval 0.67-0.89, P < .001 for all-cause death; hazard ratio 0.66, 95% confidence interval 0.54-0.82, P < .001 for CV death) after adjustment for other prognostic factors. The inclusion of QIS significantly increased both continuous net reclassification improvement (cNRI) and integrated discrimination improvement (IDI) for all-cause death (cNRI: 0.25, P = .009; IDI: 0.007, P = .030) and CV death (cNRI: 0.34, P = .008; IDI: 0.013, P = .008). CONCLUSIONS: A high level of quadriceps strength was strongly associated with a lower risk of both all-cause and CV mortality in patients with CAD. Evaluation of QIS offered incremental prognostic information beyond pre-existing risk factors. (C) 2015 Elsevier Inc. All rights reserved.	[Kamiya, Kentaro; Hamazaki, Nobuaki; Matsuzawa, Ryota; Nozaki, Kohei] Kitasato Univ Hosp, Dept Rehabil, Sagamihara, Kanagawa 2520375, Japan; [Arai, Yasuo] Kitasato Univ Hosp, Dept Hlth Informat Management, Sagamihara, Kanagawa 2520375, Japan; [Masuda, Takashi; Tanaka, Shinya; Hamazaki, Nobuaki; Yamaoka-Tojo, Minako; Matsunaga, Atsuhiko] Kitasato Univ, Grad Sch Med Sci, Dept Cardiovasc Med, Sagamihara, Kanagawa 228, Japan; [Masuda, Takashi; Yamaoka-Tojo, Minako; Matsunaga, Atsuhiko] Kitasato Univ, Sch Allied Hlth Sci, Dept Rehabil, Sagamihara, Kanagawa 228, Japan; [Matsue, Yuya] Kameda Med Ctr, Dept Cardiol, Chiba, Japan; [Mezzani, Alessandro] Salvatore Maugeri Fdn IRCCS, Sci Inst Veruno, Cardiac Rehabil Div, Exercise Pathophysiol Lab, Pavia, Italy; [Maekawa, Emi; Noda, Chiharu; Izumi, Tohru; Ako, Junya] Kitasato Univ, Sch Med, Dept Cardiovasc Med, Sagamihara, Kanagawa 228, Japan	Kamiya, K (reprint author), Kitasato Univ Hosp, Dept Rehabil, Minami Ku, 1-15-1 Kitasato, Sagamihara, Kanagawa 2520375, Japan.	k-kamiya@kitasato-u.ac.jp		Yamaoka-Tojo, Minako/0000-0003-3890-3777	Japanese Physical Therapy Association; Japanese Society of Cardiovascular Disease Prevention - AstraZeneca; Japan Heart Foundation	This study was supported by the grant from the Japanese Physical Therapy Association and the grant for Clinical and Epidemiologic Research of the Joint Project of Japan Heart Foundation and the Japanese Society of Cardiovascular Disease Prevention Sponsored by AstraZeneca.	Afilalo J, 2014, J AM COLL CARDIOL, V63, P747, DOI 10.1016/j.jacc.2013.09.070; Anderson JL, 2007, CIRCULATION, V116, pE148, DOI 10.1161/CIRCULATIONAHA.107.181940; Shamsi MM, 2014, ENDOCRINE, V46, P60, DOI 10.1007/s12020-013-0038-4; Visser M, 2002, J GERONTOL A-BIOL, V57, pM326; Artero EG, 2011, J AM COLL CARDIOL, V57, P1831, DOI 10.1016/j.jacc.2010.12.025; Beenakker KGM, 2010, AGEING RES REV, V9, P431, DOI 10.1016/j.arr.2010.05.005; Harrington D, 1997, J AM COLL CARDIOL, V30, P1758, DOI 10.1016/S0735-1097(97)00381-1; Bohannon Richard W., 2012, Physiotherapy Theory and Practice, V28, P562, DOI 10.3109/09593985.2011.640385; Hulsmann M, 2004, EUR J HEART FAIL, V6, P101, DOI 10.1016/j.jeheart.2003.07.008; HAYES KW, 1992, J ORTHOP SPORT PHYS, V16, P145; Afilalo J, 2009, AM J CARDIOL, V103, P1616, DOI 10.1016/j.amjcard.2009.01.375; Barbat-Artigas S, 2013, J GERONTOL A-BIOL, V68, P811, DOI 10.1093/gerona/gls254; Fried LP, 2001, J GERONTOL A-BIOL, V56, pM146; Newman AB, 2006, J GERONTOL A-BIOL, V61, P72; Matsuzawa R, 2014, PHYS THER, V94, P947, DOI 10.2522/ptj.20130270; RANTANEN T, 1994, AGE AGEING, V23, P132, DOI 10.1093/ageing/23.2.132; Moraes C, 2014, INT UROL NEPHROL, V46, P1655, DOI 10.1007/s11255-014-0712-3; Lawson A, 1997, PERCEPT MOTOR SKILL, V84, P539; Swallow EB, 2007, THORAX, V62, P115, DOI 10.1136/thx.2006.062026; Katoh M, 2009, J PHYS THER SCI, V21, P37; BOHANNON RW, 1986, PHYS THER, V66, P206; Purser JL, 2006, J AM GERIATR SOC, V54, P1674, DOI 10.1111/j.1532-5415.2006.00914.x; Martin HJ, 2006, GERONTOLOGY, V52, P154, DOI 10.1159/000091824; Williams MA, 2007, CIRCULATION, V116, P572, DOI 10.1161/CIRCULATIONAHA.107.185214; Singh M, 2011, CIRC-CARDIOVASC QUAL, V4, P496, DOI 10.1161/CIRCOUTCOMES.111.961375; Pencina MJ, 2008, STAT MED, V27, P157, DOI 10.1002/sim.2929; Izawa KP, 2009, EUR J CARDIOV PREV R, V16, P21, DOI 10.1097/HJR.0b013e32831269a3; Boden WE, 2014, AM J MED, V127, P905, DOI 10.1016/j.amjmed.2014.05.007; Bohannon RW, 1997, ARCH PHYS MED REHAB, V78, P26, DOI 10.1016/S0003-9993(97)90005-8; Ekerstad N, 2014, EUR J PREV CARDIOL, V21, P1216, DOI 10.1177/2047487313490257; Forti LN, 2014, AGE, V36, DOI 10.1007/s11357-014-9704-6; Gerber Y, 2013, AM J MED, V126; Heitmann BL, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b3292; Kamiya K, 2014, EUR J PREV CARDIOL, V21, P1285, DOI 10.1177/2047487313492252; Landers KA, 2001, J GERONTOL A-BIOL, V56, pB443; Leong DP, 2015, LANCET, V836, P266; Rodriguez-Miguelez P, 2014, AGE, V36, DOI 10.1007/s11357-014-9734-0; Ruiz JR, 2008, BMJ-BRIT MED J, V337, P92; Schaap LA, 2006, AM J MED, V119; Vaara JP, 2014, INT J SPORTS MED, V35, P1229, DOI 10.1055/s-0034-1375615	40	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9343	1555-7162		AM J MED	Am. J. Med.	NOV	2015	128	11					1212	1219		10.1016/j.amjmed.2015.06.035		8	Medicine, General & Internal	General & Internal Medicine	CU3VI	WOS:000363453500036		
J	Fumi, Y; Mizuno, A; Niwa, K				Fumi, Yamagami; Mizuno, Atsushi; Niwa, Koichiro			Brugada Phenocopy Is an Important Differential Diagnosis in Patients with Type 1 Brugada ECG Patterns Reply	AMERICAN JOURNAL OF MEDICINE			English	Letter							RIGHT-VENTRICULAR INFARCTION; PULMONARY-EMBOLISM		[Fumi, Yamagami; Mizuno, Atsushi; Niwa, Koichiro] St Lukes Int Hosp, Dept Cardiol, Tokyo, Japan	Fumi, Y (reprint author), St Lukes Int Hosp, Dept Cardiol, Tokyo, Japan.						Yamagami F, 2014, AM J MED, V127, P820, DOI 10.1016/j.amjmed.2014.04.031; Priori SG, 2013, HEART RHYTHM, V10, P1932, DOI 10.1016/j.hrthm.2013.05.014; Anselm DD, 2014, CAN J CARDIOL, V30, P1511, DOI 10.1016/j.cjca.2014.09.023; Zhan ZQ, 2014, INT J CARDIOL, V177, pE153, DOI 10.1016/j.ijcard.2014.09.046; Manohar S, 2015, AM J MED, V128, pE25, DOI 10.1016/j.amjmed.2014.10.048; Baranchuk A, 2012, ANN NONINVAS ELECTRO, V17, P299, DOI 10.1111/j.1542-474X.2012.00525.x; Yamagami F, 2015, AM J MED, V128, pE27, DOI 10.1016/j.amjmed.2014.10.059; Zhan ZQ, 2015, CARDIOL J	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9343	1555-7162		AM J MED	Am. J. Med.	NOV	2015	128	11					E35	E35		10.1016/j.amjmed.2015.06.042		1	Medicine, General & Internal	General & Internal Medicine	CU3VI	WOS:000363453500014		
J	Mizuno, A; Fumi, Y; Niwa, K				Mizuno, Atsushi; Fumi, Yamagami; Niwa, Koichiro			Fever-induced Brugada Pattern Reply	AMERICAN JOURNAL OF MEDICINE			English	Letter									[Mizuno, Atsushi; Fumi, Yamagami; Niwa, Koichiro] St Lukes Int Hosp, Dept Cardiol, Tokyo, Japan	Mizuno, A (reprint author), St Lukes Int Hosp, Dept Cardiol, Tokyo, Japan.						Yamagami F, 2014, AM J MED, V127, P820, DOI 10.1016/j.amjmed.2014.04.031; Anselm DD, 2014, CAN J CARDIOL, V30, P1511, DOI 10.1016/j.cjca.2014.09.023; Dumaine R, 1999, CIRC RES, V85, P803; Junttila MJ, 2008, CIRCULATION, V117, P1890, DOI 10.1161/CIRCULATIONAHA.107.746495; Baranchuk A, 2012, ANN NONINVAS ELECTRO, V17, P299, DOI 10.1111/j.1542-474X.2012.00525.x; Yamagami F, 2015, AM J MED, V128, pE27, DOI 10.1016/j.amjmed.2014.10.059; Adler A, 2013, HEART RHYTHM, V10, P1375, DOI 10.1016/j.hrthm.2013.07.030	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9343	1555-7162		AM J MED	Am. J. Med.	NOV	2015	128	11					E31	E31		10.1016/j.amjmed.2015.06.041		1	Medicine, General & Internal	General & Internal Medicine	CU3VI	WOS:000363453500012		
J	Duboscq, J; Romano, V; MacIntosh, A; Sueur, C				Duboscq, J.; Romano, V.; MacIntosh, A.; Sueur, C.			A SOCIAL NETWORK PERSPECTIVE ON MACAQUE SOCIAL STYLES	AMERICAN JOURNAL OF PRIMATOLOGY			English	Meeting Abstract	38th Annual Meeting of the American-Society-of-Primatologists	JUN 18-21, 2015	Bend, OR	Amer Soc Primatologists, Chimps Inc, Primate Conservat Inc, Purina LabDiet, Res Diets Inc, Carter 2 Syst Inc, S Karger Publishers Inc, Cambridge Univ Press, Unifab Corp, Van Hoang Dao					[Duboscq, J.; Romano, V.; Sueur, C.] Univ Strasbourg, Inst Pluridisciplinaire Hubert Curien, F-67087 Strasbourg, France; [Duboscq, J.; Romano, V.; Sueur, C.] Ctr Natl Rech Sci, Dept Ecol Physiol & Ethol, Strasbourg, France; [MacIntosh, A.] Kyoto Univ, Primate Res Inst, Inuyama, Aichi 484, Japan; [MacIntosh, A.] Kyoto Univ, Wildlife Res Ctr, Kyoto, Japan; [Sueur, C.] Univ Libre Bruxelles, Unit Social Ecol, Brussels, Belgium								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0275-2565	1098-2345		AM J PRIMATOL	Am. J. Primatol.	NOV	2015	77			1		28	42	42				1	Zoology	Zoology	CU5GQ	WOS:000363560500013		
J	Duboscq, J; Romano, V; Sueur, C; MacIntosh, A				Duboscq, J.; Romano, V.; Sueur, C.; MacIntosh, A.			INVESTIGATING INFECTION RISK AND SOCIALITY: CENTRALITY INTERACTS WITH SEASONALITY TO PREDICT LICE LOAD IN FREE-RANGING FEMALE JAPANESE MACAQUES, MACACA FUSCATA	AMERICAN JOURNAL OF PRIMATOLOGY			English	Meeting Abstract	38th Annual Meeting of the American-Society-of-Primatologists	JUN 18-21, 2015	Bend, OR	Amer Soc Primatologists, Chimps Inc, Primate Conservat Inc, Purina LabDiet, Res Diets Inc, Carter 2 Syst Inc, S Karger Publishers Inc, Cambridge Univ Press, Unifab Corp, Van Hoang Dao					[Duboscq, J.; Romano, V.; Sueur, C.] Univ Strasbourg, Inst Pluridisciplinaire Hubert Curien, F-67087 Strasbourg, France; [Duboscq, J.; Romano, V.; Sueur, C.] CNRS, Dept Ecol Physiol & Ethol, Strasbourg, France; [Sueur, C.] Univ Libre Bruxelles, Unit Social Ecol, Brussels, Belgium; [MacIntosh, A.] Kyoto Univ, Primate Res Inst, Inuyama, Aichi 484, Japan; [MacIntosh, A.] Kyoto Univ, Wildlife Res Ctr, Kyoto, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0275-2565	1098-2345		AM J PRIMATOL	Am. J. Primatol.	NOV	2015	77			1		249	143	144				2	Zoology	Zoology	CU5GQ	WOS:000363560500208		
J	Karamurzin, YS; Kiyokawa, T; Parkash, V; Jotwani, AR; Patel, P; Pike, MC; Soslow, RA; Park, KJ				Karamurzin, Yevgeniy S.; Kiyokawa, Takako; Parkash, Vinita; Jotwani, Anjali R.; Patel, Prusha; Pike, Malcolm C.; Soslow, Robert A.; Park, Kay J.			Gastric-type Endocervical Adenocarcinoma An Aggressive Tumor With Unusual Metastatic Patterns and Poor Prognosis	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						cervix; carcinoma; adenocarcinoma; HPV; gastric; lobular endocervical glandular hyperplasia; minimal deviation; clinical outcomes; metastasis	MINIMAL DEVIATION ADENOCARCINOMA; HUMAN-PAPILLOMAVIRUS INFECTION; PEUTZ-JEGHERS SYNDROME; PYLORIC GLAND METAPLASIA; ADENOMA MALIGNUM; CERVICAL ADENOCARCINOMA; UTERINE CERVIX; IMMUNOHISTOCHEMICAL ANALYSIS; HYPERPLASIA; CANCER	Gastric-type adenocarcinoma of the uterine cervix (GAS) is a rare variant of mucinous endocervical adenocarcinoma not etiologically associated with human papillomavirus (HPV) infection, with minimal deviation adenocarcinoma (MDA) at the well-differentiated end of the morphologic spectrum. These tumors are reported to have worse prognosis than usual HPV associated endocervical adenocarcinoma (UEA). A retrospective review of GAS was performed from the pathology databases of 3 institutions spanning 20 years. Stage, metastatic patterns, and overall survival were documented. Forty GAS cases were identified, with clinical follow-up data available for 38. The tumors were subclassified as MDA (n=13) and non-MDA GAS (n=27). Two patients were syndromic (1 Li-Fraumeni, 1 Peutz-Jeghers). At presentation, 59% were advanced stage (FIGO II to IV), 50% had lymph node metastases, 35% had ovarian involvement, 20% had abdominal disease, 39% had at least 1 site of metastasis at the time of initial surgery, and 12% of patients experienced distant recurrence. The metastatic sites included lymph nodes, adnexa, omentum, bowel, peritoneum, diaphragm, abdominal wall, bladder, vagina, appendix, and brain. Follow-up ranged from 1.4 to 136.0 months (mean, 33.9 mo); 20/38 (52.6%) had no evidence of disease, 3/38 (7.9%) were alive with disease, and 15/38 (39.5%) died of disease. Disease-specific survival at 5 years was 42% for GAS versus 91% for UEA. There were no survival differences between MDA and non-MDA GAS. GAS represents a distinct, biologically aggressive type of endocervical adenocarcinoma. The majority of patients present at advanced stage and pelvic, abdominal, and distant metastases are not uncommon.	[Karamurzin, Yevgeniy S.] North Western State Med Univ, Dept Pathol, St Petersburg, Russia; [Kiyokawa, Takako] Jikei Univ, Dept Pathol, Sch Med, Tokyo 105, Japan; [Parkash, Vinita] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; [Jotwani, Anjali R.; Patel, Prusha; Pike, Malcolm C.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10065 USA; [Soslow, Robert A.; Park, Kay J.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA; [Soslow, Robert A.] Weill Cornell Med Coll, New York, NY USA	Park, KJ (reprint author), Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10065 USA.	parkk@mskcc.org					Takatsu A, 2013, VIRCHOWS ARCH, V462, P645, DOI 10.1007/s00428-013-1417-1; Ishii K, 1998, VIRCHOWS ARCH, V432, P315, DOI 10.1007/s004280050172; Quint KD, 2009, GYNECOL ONCOL, V114, P390, DOI 10.1016/j.ygyno.2009.05.013; Smith HO, 2000, GYNECOL ONCOL, V78, P97, DOI 10.1006/gyno.2000.5826; Tsuji T, 2011, HISTOPATHOLOGY, V59, P55, DOI 10.1111/j.1365-2559.2011.03886.x; Pirog EC, 2000, AM J PATHOL, V157, P1055, DOI 10.1016/S0002-9440(10)64619-6; ARRAIZ GA, 1990, CAN J PUBLIC HEALTH, V81, P396; Nucci MR, 1999, AM J SURG PATHOL, V23, P886, DOI 10.1097/00000478-199908000-00005; KAMINSKI PF, 1983, INT J GYNECOL PATHOL, V2, P141, DOI 10.1097/00004347-198302000-00005; Kusanagi Y, 2010, AM J PATHOL, V177, P2169, DOI 10.2353/ajpath.2010.100323; Mikami Y, 2004, MODERN PATHOL, V17, P962, DOI 10.1038/modpathol.3800148; Xu JY, 2005, INT J GYNECOL PATHOL, V24, P296, DOI 10.1097/01.PGP.0000157918.36354.C1; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; MCGOWAN L, 1980, GYNECOL ONCOL, V10, P125, DOI 10.1016/0090-8258(80)90074-8; Houghton O, 2010, HISTOPATHOLOGY, V57, P342, DOI 10.1111/j.1365-2559.2010.03632.x; Kondo T, 2005, MODERN PATHOL, V18, P1199, DOI 10.1038/modpathol.3800403; YOUNG RH, 1982, CANCER, V50, P1384, DOI 10.1002/1097-0142(19821001)50:7<1384::AID-CNCR2820500726>3.0.CO;2-5; Andersson S, 2001, EUR J CANCER, V37, P246, DOI 10.1016/S0959-8049(00)00376-2; Mikami Y, 1999, GYNECOL ONCOL, V74, P504, DOI 10.1006/gyno.1999.5462; CHILVERS C, 1987, BRIT MED J, V295, P1446; Bergstrom R, 1999, BRIT J CANCER, V81, P159, DOI 10.1038/sj.bjc.6690666; Mikami Y, 2001, HISTOPATHOLOGY, V39, P364, DOI 10.1046/j.1365-2559.2001.01239.x; Park KJ, 2011, AM J SURG PATHOL, V35, P633, DOI 10.1097/PAS.0b013e31821534b9; Mikami Y, 2013, ADV ANAT PATHOL, V20, P227, DOI 10.1097/PAP.0b013e31829c2d66; McCluggage WG, 2010, J CLIN PATHOL, V63, P935, DOI 10.1136/jcp.2010.080150; EIDE TJ, 1987, J NATL CANCER I, V79, P199; GILKS CB, 1989, AM J SURG PATHOL, V13, P717, DOI 10.1097/00000478-198909000-00001; Park SB, 2011, ULTRASOUND OBST GYN, V38, P716, DOI 10.1002/uog.9078; Nara M, 2007, GYNECOL ONCOL, V106, P289, DOI 10.1016/j.ygyno.2007.03.044; Kojima A, 2007, AM J SURG PATHOL, V31, P664, DOI 10.1097/01.pas.0000213434.91868.b0; KAKU T, 1983, INT J GYNECOL PATHOL, V2, P28; Kawauchi S, 2008, AM J SURG PATHOL, V32, P1807, DOI 10.1097/PAS.0b013e3181883722; Takatsu A, 2011, INT J GYNECOL CANCER, V21, P1287, DOI 10.1097/IGC.0b013e31821f746c; Collett D, 2003, MODELLING SURVIVAL D; Conlon N, 2015, MOD PATHOL S2, V28, p280A; Fisher RA, 1922, J ROY STAT SOC, V85, P8; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kurman RJ, 2014, WHO CLASSIFICATION T; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Mikami Y, 2000, AM J SURG PATHOL, V24, P323, DOI 10.1097/00000478-200002000-00042; Mikami Y, 2000, AM J SURG PATHOL, V24, P5; Moeschberger M. L., 2003, SURVIVAL ANAL TECHNI	42	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	NOV	2015	39	11					1449	1457		10.1097/PAS.0000000000000532		9	Pathology; Surgery	Pathology; Surgery	CU2TH	WOS:000363375900001		
J	Ishibashi, K; Ito, Y; Masaki, A; Fujii, K; Beppu, S; Sakakibara, T; Takino, H; Takase, H; Ijichi, K; Shimozato, K; Inagaki, H				Ishibashi, Kenichiro; Ito, Yohei; Masaki, Ayako; Fujii, Kana; Beppu, Shintaro; Sakakibara, Takeo; Takino, Hisashi; Takase, Hiroshi; Ijichi, Kei; Shimozato, Kazuo; Inagaki, Hiroshi			Warthin-like Mucoepidermoid Carcinoma A Combined Study of Fluorescence In Situ Hybridization and Whole-slide Imaging	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						Warthin tumor; metaplastic; CRTC1-MAML2 gene fusions; mucoepidermoid carcinoma; fluorescence in situ hybridization; whole-slide imaging	CRTCI/MAML2 FUSION TRANSCRIPT; CLINICOPATHOLOGICAL SIGNIFICANCE; TUMORS; SALIVARY; GLAND; CLASSIFICATION; TRANSLOCATION; MICROSCOPY; ONCOGENE	There has been some debate as to whether a subset of metaplastic Warthin tumors (mWTs) harbor the mucoepidermoid carcinoma (MEC)-associated CRTC1-MAML2 fusion. We analyzed 15 tumors originally diagnosed as mWT (mWT-like tumors), 2 of which had concurrent MECs. We looked for the CRTC1/3-MAML2 fusion transcripts and performed immunohistochemistry for p63 and fluorescence in situ hybridization (FISH) for the MAML2 split. To localize MAML2 split-positive cells at the cellular level, whole tumor tissue sections were digitalized (whole-slide imaging [WSI]). The CRTC1-MAML2, but not CRTC3-MAML2 was detected in 5/15 mWT-like tumors. FISH-WSI results showed that all epithelial cells harbored the MAML2 split in fusion-positive mWT-like tumors and were totally negative in fusion-negative mWT-like tumors. A review of the hematoxylin and eosin-stained slides showed that morphology of the metaplastic epithelium was virtually indistinguishable between fusion-positive and fusion-negative tumors. However, oncocytic bilayered tumor epithelium, characteristic to typical WT, was always found somewhere in the fusion-negative tumors but not in the fusion-positive tumors. This distinguishing histologic finding enabled 5 pathologists to easily differentiate the 2 tumor groups with 100% accuracy. The age and sex distribution of fusion-positive mWT-like tumor cases was similar to that of fusion-positive MEC cases and significantly different from those of fusion-negative mWT-like tumor and typical WT cases. In addition, only fusion-positive mWT-like tumors possessed concurrent low-grade MECs. In conclusion, a subset of mWT-like tumors were positive for the CRTC1-MAML2 fusion and had many features that are more in accord with MEC than with WT. The term Warthin-like MEC should be considered for fusion-positive mWT-like tumors.	[Ishibashi, Kenichiro; Ito, Yohei; Masaki, Ayako; Fujii, Kana; Beppu, Shintaro; Sakakibara, Takeo; Takino, Hisashi; Inagaki, Hiroshi] Nagoya City Univ, Dept Pathol & Mol Diagnost, Grad Sch Med Sci, Nagoya, Aichi 4678601, Japan; [Beppu, Shintaro; Ijichi, Kei] Nagoya City Univ, Dept Otolaryngol Head & Neck Surg, Grad Sch Med Sci, Nagoya, Aichi 4678601, Japan; [Takase, Hiroshi] Nagoya City Univ, Core Lab, Grad Sch Med Sci, Nagoya, Aichi 4678601, Japan; [Ishibashi, Kenichiro; Ito, Yohei; Shimozato, Kazuo] Aichi Gakuin Univ, Sch Dent, Dept Maxillofacial Surg, Nagoya, Aichi 464, Japan	Inagaki, H (reprint author), Nagoya City Univ, Dept Pathol & Mol Diagnost, Grad Sch Med Sci, Mizuho Ku, 1 Kawasumi,Mizuho Cho, Nagoya, Aichi 4678601, Japan.	hinagaki@med.nagoya-cu.ac.jp			Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of Japan [15K08351]	Conflicts of Interest and Source of Funding: Supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of Japan (15K08351 to H.I.). The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Seethala RR, 2012, MODERN PATHOL, V25, P26, DOI 10.1038/modpathol.2011.135; Enlund F, 2004, EXP CELL RES, V292, P21, DOI 10.1016/j.yexcr.2003.09.007; Behboudi A, 2006, GENE CHROMOSOME CANC, V45, P470, DOI 10.1002/gcc.20306; Sauter G, 2009, J CLIN ONCOL, V27, P1323, DOI 10.1200/JCO.2007.14.8197; MARK J, 1989, ANTICANCER RES, V9, P1565; BULLERDIEK J, 1988, CANCER GENET CYTOGEN, V35, P129, DOI 10.1016/0165-4608(88)90131-8; Laurent C, 2013, HUM PATHOL, V44, P1544, DOI 10.1016/j.humpath.2012.12.009; Bell D, 2008, GENE CHROMOSOME CANC, V47, P309, DOI 10.1002/gcc.20534; Garcia JJ, 2011, HUM PATHOL, V42, P2001, DOI 10.1016/j.humpath.2011.02.028; Noda H, 2013, CANCER SCI, V104, P85, DOI 10.1111/cas.12039; Okabe M, 2006, CLIN CANCER RES, V12, P3902, DOI 10.1158/1078-0432.CCR-05-2376; Fehr A, 2008, GENE CHROMOSOME CANC, V47, P203, DOI 10.1002/gec.20522; Preibisch S, 2009, BIOINFORMATICS, V25, P1463, DOI 10.1093/bioinformatics/btp184; Tonon G, 2003, NAT GENET, V33, P208, DOI 10.1038/ng1083; Pinkston JA, 1999, OTOLARYNG HEAD NECK, V120, P834, DOI 10.1016/S0194-5998(99)70323-2; Okumura Y, 2011, HISTOPATHOLOGY, V59, P90, DOI 10.1111/j.1365-2559.2011.03890.x; Coxon A, 2005, CANCER RES, V65, P7137, DOI 10.1158/0008-5472.CAN-05-1125; Fehr A, 2008, CANCER GENET CYTOGEN, V180, P135, DOI 10.1016/j.cancergencyto.2007.10.007; Tirado Y, 2007, GENE CHROMOSOME CANC, V46, P708, DOI 10.1002/gcc.20458; Xia HJ, 2011, HUM PATHOL, V42, P1297, DOI 10.1016/j.humpath.2010.11.022; DARDICK I, 1984, J ORAL PATHOL MED, V13, P342, DOI 10.1111/j.1600-0714.1984.tb01433.x; Rotellini M, 2012, J ORAL PATHOL MED, V41, P615, DOI 10.1111/j.1600-0714.2012.01159.x; Nakayama T, 2009, MODERN PATHOL, V22, P1575, DOI 10.1038/modpathol.2009.126; Azevedo Rebeca Souza, 2008, Head Neck Pathol, V2, P257, DOI 10.1007/s12105-008-0074-1; Bell Diana, 2013, Head Neck Pathol, V7, P23, DOI 10.1007/s12105-013-0432-5; Deftos C., 1996, Archives d'Anatomie et de Cytologie Pathologiques, V44, P180; Ellis GL, 2007, TUMORS SALIVARY GLAN; Goode R. K., 2005, WHO CLASSIFICATION T, P219; Pantanowitz L., 2010, J PATHOL INFORM, V1, P15, DOI DOI 10.4103/2153-3539.68332; Simpson RHW, 2005, WHO CLASSIFICATION T, P263; Skalova A, 2013, AM J SURG PATHOL, V37, P1743, DOI 10.1097/PAS.0000000000000065; Wienert S, 2009, DIAGN PATHOL, V4, DOI 10.1186/1746-1596-4-3	32	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	NOV	2015	39	11					1479	1487		10.1097/PAS.0000000000000507		9	Pathology; Surgery	Pathology; Surgery	CU2TH	WOS:000363375900004		
J	Kang, JH; Asai, D; Toita, R; Kawano, T; Murata, M				Kang, Jeong-Hun; Asai, Daisuke; Toita, Riki; Kawano, Takahito; Murata, Masaharu			Monitoring of phosphorylated peptides by radioactive assay and matrix-assisted laser desorption-ionization time-of-flight mass spectrometry	AMINO ACIDS			English	Article						MALDI-TOF-MS; Negative mode; Phosphorylation; Protein kinase; Counts per minute; Radioactive assay	PROTEIN-COUPLED RECEPTOR; KINASE 2; TOF MS; BETA; GRK2; IDENTIFICATION; PHOSPHOPEPTIDES; ANTAGONIST; ACTIVATION; PROTOCOL	Matrix-assisted laser desorption-ionization time-of-flight mass spectrometry (MALDI-TOF-MS) is frequently used to monitor phosphorylated peptides or protein kinase activities. However, few reports have compared a radioactivity assay with MALDI-TOF-MS analysis. We analyzed the phosphorylation ratios of 23 peptide substrates for G protein-coupled receptor kinase 2 (GRK2) with different lengths and numbers of negatively charged amino acids by MALDI-TOF-MS. We then examined the correlations between the phosphorylation ratios determined by MALDI-TOF-MS and the radioactivity levels (counts per minute, CPM) determined using a radioactive assay. Using MALDI-TOF-MS, the phosphorylation ratios were greater in the negative mode than in the positive mode. The phosphorylation ratio measured in the negative mode was strongly correlated with the CPM (r = 0.86). The number of acidic amino acids was related to the phosphorylation of peptide substrates by GRK2 (r = 0.53 and 0.46 for the phosphorylation ratio and CPM, respectively). These results suggest that MALDI-TOF-MS is an alternative to radioactive assays for monitoring phosphorylated peptides.	[Kang, Jeong-Hun] Natl Cerebral & Cardiovasc Ctr Res Inst, Dept Biomed Engn, Div Biopharmaceut & Pharmacokinet, Suita, Osaka 5658565, Japan; [Asai, Daisuke] St Marianna Univ, Sch Med, Dept Microbiol, Kawasaki, Kanagawa 2168511, Japan; [Toita, Riki] Kyushu Univ, Fac Dent Sci, Dept Biomat, Higashi Ku, Fukuoka 8128582, Japan; [Kawano, Takahito; Murata, Masaharu] Kyushu Univ, Fac Med Sci, Dept Adv Med Initiat, Higashi Ku, Fukuoka 8128582, Japan	Kang, JH (reprint author), Natl Cerebral & Cardiovasc Ctr Res Inst, Dept Biomed Engn, Div Biopharmaceut & Pharmacokinet, 5-7-1 Fujishirodai, Suita, Osaka 5658565, Japan.	jrjhkang@ncvc.go.jp			Health Labour Sciences Research Grant (Research on Publicly Essential Drugs and Medical Devices) from the Ministry of Health, Labour and Welfare of Japan; Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan [24245015, 23310085]	This work was supported by a Health Labour Sciences Research Grant (Research on Publicly Essential Drugs and Medical Devices) from the Ministry of Health, Labour and Welfare of Japan, and a grant-in-aid for Scientific Research (A) (KAKENHI Grant Number 24245015) and (B) (KAKENHI Grant Number 23310085) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan.	Rykx A, 2007, ASSAY DRUG DEV TECHN, V5, P637, DOI 10.1089/adt.2007.081; OHGURO H, 1994, BIOCHEMISTRY-US, V33, P1023, DOI 10.1021/bi00170a022; Wan KF, 2001, J BIOL CHEM, V276, P37802; Asai D, 2014, FEBS LETT, V588, P2129, DOI 10.1016/j.febslet.2014.04.038; Ho J, 2005, EMBO J, V24, P3247, DOI 10.1038/sj.emboj.7600794; McLachlin DT, 2001, CURR OPIN CHEM BIOL, V5, P591, DOI 10.1016/S1367-5931(00)00250-7; Kang JH, 2008, EUR J MASS SPECTROM, V14, P261, DOI 10.1255/ejms.916; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796; Ma YL, 2001, RAPID COMMUN MASS SP, V15, P1693, DOI 10.1002/rcm.426; Ruiz-Gomez A, 2000, J BIOL CHEM, V275, P29724, DOI 10.1074/jbc.M001864200; Gainetdinov RR, 2004, ANNU REV NEUROSCI, V27, P107, DOI 10.1146/annurev.neuro.27.070203.144206; Penela P, 2010, BRIT J PHARMACOL, V160, P821, DOI 10.1111/j.1476-5381.2010.00727.x; Xu CF, 2005, MOL CELL PROTEOMICS, V4, P809, DOI 10.1074/mcp.T400019-MCP200; Hildreth KL, 2004, J BIOL CHEM, V279, P41775, DOI 10.1074/jbc.M403274200; Kang JH, 2012, BIOTECHNOL ADV, V30, P1662, DOI 10.1016/j.biotechadv.2012.07.004; Janek K, 2001, RAPID COMMUN MASS SP, V15, P1593, DOI 10.1002/rcm.417; Woodall MC, 2014, CIRC RES, V114, P1661, DOI 10.1161/CIRCRESAHA.114.300513; Kang JH, 2008, J AM CHEM SOC, V130, P14906, DOI 10.1021/ja805364s; Kahsai AW, 2010, BBA-MOL CELL RES, V1803, P300, DOI 10.1016/j.bbamcr.2009.11.002; Dinudom A, 2004, P NATL ACAD SCI USA, V101, P11886, DOI 10.1073/pnas.0402178101; Yoshida N, 2003, EUR J BIOCHEM, V270, P1154, DOI 10.1046/j.1432-1033.2003.03465.x; Hastie CJ, 2006, NAT PROTOC, V1, P968, DOI 10.1038/nprot.2006.149; Asai D, 2009, J GENE MED, V11, P624, DOI 10.1002/jgm.1342; Smith FD, 2011, BIOCHEM J, V438, P103, DOI 10.1042/BJ20110720; Ruiz-Gomez A, 2007, J BIOL CHEM, V282, P1205, DOI 10.1074/jbc.M607166200; Peregrin S, 2006, CURR BIOL, V16, P2042, DOI 10.1016/j.cub.2006.08.083; Sanchez-Perez A, 2007, BIOCHEM BIOPH RES CO, V359, P611, DOI 10.1016/j.bbrc.2007.0'.134; Cant SH, 2005, MOL BIOL CELL, V16, P3088, DOI 10.1091/mbc.E04-10-0877; Hoozemans JJM, 2012, NEURODEGENER DIS, V10, P46, DOI 10.1159/000335914; Pronin AN, 2000, J BIOL CHEM, V275, P26515, DOI 10.1074/jbc.M003542200; Freeman JLR, 2002, BIOCHEMISTRY-US, V41, P12850, DOI 10.1021/bi020145d; Kang JH, 2007, J AM SOC MASS SPECTR, V18, P1925, DOI 10.1016/j.jasms.2007.08.002; Irungu J, 2008, J AM SOC MASS SPECTR, V19, P1209, DOI 10.1016/j.jasms.2008.05.010; Duncan Mark W., 2008, Briefings in Functional Genomics & Proteomics, V7, P355, DOI 10.1093/bfgp/eln041; Bowley Erin, 2005, BMC Biochem, V6, P29, DOI 10.1186/1471-2091-6-29; Kang JH, 2008, PROTEOMICS, V8, P2006, DOI 10.1002/pmic.200701045; Kang JH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022699; Kozlov IA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037441	38	0	0	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0939-4451	1438-2199		AMINO ACIDS	Amino Acids	NOV	2015	47	11					2377	2383		10.1007/s00726-015-2025-y		7	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	CU4EY	WOS:000363481100012		
J	Kuroda, M; Kumakura, M; Sato, T; Saito, S				Kuroda, Masataka; Kumakura, Minami; Sato, Tomonobu; Saito, Shigeru			The Usefulness of Three-Dimensional Transesophageal Echocardiography for a Primum Atrial Septal Defect	ANESTHESIA AND ANALGESIA			English	Editorial Material									[Kuroda, Masataka; Kumakura, Minami; Sato, Tomonobu; Saito, Shigeru] Gunma Univ, Grad Sch Med, Dept Anesthesiol, Maebashi, Gumma 3718511, Japan	Kuroda, M (reprint author), Gunma Univ, Grad Sch Med, Dept Anesthesiol, 3-39-22 Showa Machi, Maebashi, Gumma 3718511, Japan.	m.kurohyou@gmail.com					Lang RM, 2012, J AM SOC ECHOCARDIOG, V25, P3, DOI 10.1016/j.echo.2011.11.010; Vegas A, 2010, ANESTH ANALG, V110, P1548, DOI 10.1213/ANE.0b013e3181d41be7; Roberson DA, 2011, J AM SOC ECHOCARDIOG, V24, P600, DOI 10.1016/j.echo.2011.02.008; Saric M, 2010, J AM SOC ECHOCARDIOG, V23, P1128, DOI 10.1016/j.echo.2010.08.008; Taniguchi M, 2009, J AM SOC ECHOCARDIOG, V22, P1114, DOI 10.1016/j.echo.2009.06.008; Franke A, 1997, CIRCULATION, V96, P323; Burch TM, 2012, ANESTH ANALG, V115, P772, DOI 10.1213/ANE.0b013e3182649696; Acar P, 2000, EUR HEART J, V21, P573, DOI 10.1053/euhj.1999.1855	8	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	NOV	2015	121	5					1151	1154		10.1213/ANE.0000000000000958		4	Anesthesiology	Anesthesiology	CU1QG	WOS:000363295800005		
J	Hori, D; Hogue, CW; Shah, A; Brown, C; Neufeld, KJ; Conte, JV; Price, J; Sciortino, C; Max, L; Laflam, A; Adachi, H; Cameron, DE; Mandal, K				Hori, Daijiro; Hogue, Charles W., Jr.; Shah, Ashish; Brown, Charles; Neufeld, Karin J.; Conte, John V.; Price, Joel; Sciortino, Christopher; Max, Laura; Laflam, Andrew; Adachi, Hideo; Cameron, Duke E.; Mandal, Kaushik			Cerebral Autoregulation Monitoring with Ultrasound-Tagged Near-Infrared Spectroscopy in Cardiac Surgery Patients	ANESTHESIA AND ANALGESIA			English	Article							BLOOD-FLOW AUTOREGULATION; HEAD-INJURED PATIENTS; CARDIOPULMONARY BYPASS; CEREBROVASCULAR REACTIVITY; PRESSURE AUTOREGULATION; STROKE; THRESHOLD; LIMITS	BACKGROUND: Individualizing mean arterial blood pressure (MAP) based on cerebral blood flow (CBF) autoregulation monitoring during cardiopulmonary bypass (CPB) holds promise as a strategy to optimize organ perfusion. The purpose of this study was to evaluate the accuracy of cerebral autoregulation monitoring using microcirculatory flow measured with innovative ultrasound-tagged near-infrared spectroscopy (UT-NIRS) noninvasive technology compared with transcranial Doppler (TCD). METHODS: Sixty-four patients undergoing CPB were monitored with TCD and UT-NIRS (CerOx). The mean velocity index (Mx) was calculated as a moving, linear correlation coefficient between slow waves of TCD-measured CBF velocity and MAP. The cerebral flow velocity index (CFVx) was calculated as a similar coefficient between slow waves of cerebral flow index measured using UT-NIRS and MAP. When MAP is outside the autoregulation range, Mx is progressively more positive. Optimal blood pressure was defined as the MAP with the lowest Mx and CFVx. The right- and left-sided optimal MAP values were averaged to define the individual optimal MAP and were the variables used for analysis. RESULTS: The Mx for the left side was 0.31 0.17 and for the right side was 0.32 +/- 0.17. The mean CFVx for the left side was 0.33 +/- 0.19 and for the right side was 0.35 +/- 0.19. Time-averaged Mx and CFVx during CPB had a statistically significant among-subject correlation (r = 0.39; 95% confidence interval [CI], 0.22-0.53; P < 0.001) but had only a modest agreement within subjects (bias 0.03 +/- 0.20; 95% prediction interval for the difference between Mx and CFVx, -0.37 to 0.42). The MAP with the lowest Mx and CFVx (optimal blood pressure) was correlated (r = 0.71; 95% CI, 0.56-0.81; P < 0.0001) and was in modest within-subject agreement (bias -2.85 +/- 8.54; 95% limits of agreement for MAP predicted by Mx and CFVx, -19.60 to 13.89). Coherence between ipsilateral middle CBF velocity and cerebral flow index values averaged 0.61 +/- 0.07 (95% CI, 0.59-0.63). CONCLUSIONS: There was a statistically significant correlation and agreement between CBF autoregulation monitored by CerOx compared with TCD-based Mx.	[Hori, Daijiro; Shah, Ashish; Conte, John V.; Price, Joel; Sciortino, Christopher; Cameron, Duke E.; Mandal, Kaushik] Johns Hopkins Univ, Sch Med, Dept Surg, Div Cardiac Surg, Baltimore, MD 21205 USA; [Hogue, Charles W., Jr.; Brown, Charles; Max, Laura; Laflam, Andrew] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205 USA; [Neufeld, Karin J.] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA; [Adachi, Hideo] Jichi Med Univ, Saitama Med Ctr, Div Cardiovasc Surg, Saitama, Japan	Mandal, K (reprint author), Johns Hopkins Univ Hosp, Div Cardiac Surg, Sheikh Zayed Tower,Suite 7107,1800 Orleans St, Baltimore, MD 21287 USA.	kmandal2@jhmi.edu			Ornim, Inc., Kfar Saba, Israel; Japan Heart Association/Bayer Yakuhin Grant for Abroad; National Institutes of Health [RO1 095529]	Funded, in part, by grant from Ornim, Inc., Kfar Saba, Israel (Kaushik Mandal, Karin Neufeld) and Japan Heart Association/Bayer Yakuhin Grant for Abroad (Daijiro Hori). Dr. Hogue is the principal investigator on a grant from the National Institutes of Health (RO1 095529).	Ono M, 2012, J CARDIOTHOR VASC AN, V26, P1022, DOI 10.1053/j.jvca.2012.07.014; SCHELL RM, 1993, ANESTH ANALG, V76, P849; Brady KM, 2010, STROKE, V41, P1957, DOI 10.1161/STROKEAHA.109.575167; Joshi B, 2010, ANESTH ANALG, V110, P321, DOI 10.1213/ANE.0b013e3181c6fd12; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Boston US, 2001, ANN THORAC SURG, V71, P260, DOI 10.1016/S0003-4975(00)01883-X; Mahan GD, 1998, P NATL ACAD SCI USA, V95, P14015, DOI 10.1073/pnas.95.24.14015; Joshi B, 2012, ANESTH ANALG, V114, P503, DOI 10.1213/ANE.0b013e31823d292a; SMIELEWSKI P, 1995, STROKE, V26, P2285; Reinhard M, 2005, STROKE, V36, P1684, DOI 10.1161/01.STR.0000173183.36331.ee; Schytz HW, 2012, NEUROCRIT CARE, V17, P139, DOI 10.1007/s12028-012-9720-2; Ono M, 2012, BRIT J ANAESTH, V109, P391, DOI 10.1093/bja/aes148; Easley RB, 2013, NEUROL RES, V35, P344, DOI 10.1179/1743132812Y.0000000145; Rhee CJ, 2012, J APPL PHYSIOL, V113, P307, DOI 10.1152/japplphysiol.00024.2012; Czosnyka M, 1996, STROKE, V27, P1829; Ono M, 2014, J THORAC CARDIOV SUR, V147, P483, DOI 10.1016/j.jtcvs.2013.07.069; Brady K, 2010, STROKE, V41, P1951, DOI 10.1161/STROKEAHA.109.575159; Plochl W, 1999, BRIT J ANAESTH, V82, P237; Steiner LA, 2003, STROKE, V34, P2404, DOI 10.1161/01.STR.0000089014.59668.04; Minhas PS, 2004, NEUROSURGERY, V55, P63, DOI 10.1227/01.NEU.0000126876.10254.05; Ono M, 2013, CRIT CARE MED, V41, P464, DOI 10.1097/CCM.0b013e31826ab3a1; Steiner LA, 2009, NEUROCRIT CARE, V10, P122, DOI 10.1007/s12028-008-9140-5; Bratton SL, 2007, J NEUROTRAUMA S1, V24, pS59, DOI DOI 10.1089/NEU.2007.9990; Hori D, 2014, BRIT J ANAESTH, V113, P1009, DOI 10.1093/bja/aeu319; BLAND JM, 1986, LANCET, V1, P307; Ron A, 2012, PROC SPIE, V8223, DOI 10.1117/12.906349	26	1	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	NOV	2015	121	5					1187	1193		10.1213/ANE.0000000000000930		7	Anesthesiology	Anesthesiology	CU1QK	WOS:000363296200001		
J	Kuzukawa, Y; Nakahira, J; Sawai, T; Minami, T				Kuzukawa, Yosuke; Nakahira, Junko; Sawai, Toshiyuki; Minami, Toshiaki			A Perioperative Evaluation of Respiratory Mechanics Using the Forced Oscillation Technique	ANESTHESIA AND ANALGESIA			English	Article							IMPULSE OSCILLOMETRY; IMPEDANCE; VENTILATION; RESISTANCE; REACTANCE; ASTHMA; COPD	BACKGROUND: The forced oscillation technique is a new approach for assessing perioperative respiratory function. METHODS: This study enrolled 40 patients undergoing general anesthesia: 20 for 2 hours and 20 for <2 hours. Respiratory parameters were measured the day before and after surgery using forced oscillation during normal tidal breathing. RESULTS: Respiratory resistance at 5 Hz (P = 0.029 with the Student t test with unequal variances and P = 0.033 with analysis of covariance) changed significantly in the patients who underwent procedures for which they were anesthetized for >2 hours. CONCLUSIONS: The forced oscillation technique is a clinical tool that can be used to assess the effects of perioperative ventilation strategies on respiratory mechanics.	[Kuzukawa, Yosuke; Nakahira, Junko; Sawai, Toshiyuki; Minami, Toshiaki] Osaka Med Coll, Dept Anesthesiol, Osaka, Japan	Nakahira, J (reprint author), Osaka Med Coll, Dept Anesthesiol, 2-7 Daigakumachi, Takatsuki, Osaka 5698686, Japan.	ane052@poh.osaka-med.ac.jp					Kanda S, 2010, INTERNAL MED, V49, P23, DOI 10.2169/internalmedicine.49.2191; Carvalho AR, 2013, ANESTH ANALG, V116, P677, DOI 10.1213/ANE.0b013e318254230b; Oostveen E, 2003, EUR RESPIR J, V22, P1026, DOI 10.1183/09031936.03.00089403; Futier E, 2013, NEW ENGL J MED, V369, P428, DOI 10.1056/NEJMoa1301082; Wang MQ, 1999, CHINESE MED J-PEKING, V112, P982; Slutsky AS, 2013, NEW ENGL J MED, V369, P2126, DOI 10.1056/NEJMra1208707; Johnson MK, 2005, EUR RESPIR J, V25, P1061, DOI 10.1183/09031936.05.00082504; Borrill ZL, 2005, BRIT J CLIN PHARMACO, V59, P379, DOI 10.1111/j.1365-2125.2004.02261.x; PESLIN R, 1993, EUR RESPIR J, V6, P772; Carvalho AR, 2013, ANESTH ANALG, V116, P627, DOI 10.1213/ANE.0b013e31824a95ca; VANNOORD JA, 1991, AM REV RESPIR DIS, V143, P922; MacLeod D, 2001, MED BIOL ENG COMPUT, V39, P505, DOI 10.1007/BF02345140; Al-Mutairi SS, 2007, CLIN EXP MED, V7, P56, DOI 10.1007/s10238-007-0126-y; Global Initiative for Chronic Obstructive Lung Disease Global Strategy for the Diagnosis, 2006, GLOB STRAT DIAGN MAN; Ohishi J, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2011-000184	15	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	NOV	2015	121	5					1202	1206		10.1213/ANE.0000000000000720		5	Anesthesiology	Anesthesiology	CU1QK	WOS:000363296200003		
J	Asai, T				Asai, Takashi			Emergency Cricothyrotomy	ANESTHESIOLOGY			English	Article							MANAGEMENT		Dokkyo Med Univ, Koshigaya Hosp, Dept Anesthesiol, Koshigaya, Saitama, Japan	Asai, T (reprint author), Dokkyo Med Univ, Koshigaya Hosp, Dept Anesthesiol, Koshigaya, Saitama, Japan.	asaita@dokkyomed.ac.jp					Hofmann HS, 2002, EUR J CARDIO-THORAC, V21, P649, DOI 10.1016/S1010-7940(02)00037-4; Henderson JJ, 2004, ANAESTHESIA, V59, P675, DOI 10.1111/j.1365-2044.2004.03831.x; Asai T, 2013, J ANESTH, V27, P157, DOI 10.1007/s00540-012-1521-4; Hubble MW, 2010, PREHOSP EMERG CARE, V14, P515, DOI 10.3109/10903127.2010.497903; Apfelbaum Jeffrey L, 2013, Anesthesiology, V118, P251, DOI 10.1097/ALN.0b013e31827773b2; Japanese Society of Anesthesiologists, 2014, J ANESTH, V28, P482; Langvad S, 2013, SCAND J TRAUMA RESUS, V21, DOI 10.1186/1757-7241-21-43; Siddiqui N, 2015, ANESTHESIOLOGY, V123, P1033, DOI 10.1097/ALN.0000000000000848	8	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	NOV	2015	123	5					995	996		10.1097/ALN.0000000000000849		2	Anesthesiology	Anesthesiology	CT7RG	WOS:000363011600005		
J	Kiyose, K; Katsuki, M; Suzaki, Y; Okada, K				Kiyose, Katsuya; Katsuki, Masako; Suzaki, Yu; Okada, Kensuke			Competitive males but not attractive males reduce female fitness in Gnatocerus cornutus	ANIMAL BEHAVIOUR			English	Article						female mate choice; Fisherian process; horned beetle; male-male competition; sexually antagonistic coevolution	HORNED FLOUR BEETLE; FLY SEPSIS-CYNIPSEA; DROSOPHILA-MELANOGASTER FEMALES; MALE BODY-SIZE; SEXUAL SELECTION; MATE CHOICE; ARMED BEETLE; AGGREGATION PHEROMONE; MATING PREFERENCES; GENETIC BENEFITS	General concepts of sexual selection assume that females benefit from mating with more competitive or attractive males. By contrast, sexual conflict theory assumes that females suffer greater costs from mating with such males. To understand how mate choice evolves, it is necessary to examine these different predictions regarding costs and benefits. Moreover, environmental factors may play an important role in the consequences of mate choice benefits. Here, we examined how mate choice benefits and sexual conflict costs are affected by an environmental condition (single or repeated interaction with a mate) in Gnatocerus cornutus (Coleoptera: Tenebrionidae). The males have enlarged mandibles to fight rivals and for courtship display to attract mates, and these characters provide a mating advantage to males. In G. cornutus, compared with a single mating, continuous housing with a male directly enhances female fitness due to increased mating frequency and sperm replenishment. In a single mating situation, there were neither direct benefits nor costs from competitive and attractive males. By contrast, when females were continuously housed with a competitively superior male, female fitness was reduced, probably because of misdirected attacks by the competitive male. Thus, our result suggests that females suffer direct costs from competitive males in G. cornutus but this cost is not incurred when there are few sexual interactions. (C) 2015 The Association for the Study of Animal Behaviour. Published by Elsevier Ltd. All rights reserved.	[Kiyose, Katsuya; Okada, Kensuke] Okayama Univ, Grad Sch Environm & Life Sci, Okayama 7008530, Japan; [Katsuki, Masako] Univ Tsukuba, Fac Life & Environm Sci, Ibaraki, Japan; [Suzaki, Yu] Kyoto Univ, Grad Sch Sci, Kyoto, Japan	Okada, K (reprint author), Okayama Univ, Grad Sch Environm & Life Sci, Tsushima Naka 1-1-1, Okayama 7008530, Japan.	okaken@cc.okayama-u.ac.jp			Japan Society for the Promotion of Science [KAKENHI 25840157, 251662]	We thank Dr Wolf U. Blanckenhorn for helpful comments on the manuscript. This study was supported by a Grant-in-Aid for Scientific Research (KAKENHI 25840157) to K.O. and Grant-in-Aid for JSPS Fellows (251662) to M.K., both from the Japan Society for the Promotion of Science.	Alcock J., 1983, EVOLUTION INSECT MAT; Andersson M., 2006, ESSAYS ANIMAL BEHAV, P255; Andersson M.B., 1994, SEXUAL SELECTION; RICE WR, 1989, EVOLUTION, V43, P223, DOI 10.2307/2409177; Holland B, 1998, EVOLUTION, V52, P1, DOI 10.2307/2410914; Dukas R, 2008, ANNU REV ENTOMOL, V53, P145, DOI 10.1146/annurev.ento.53.103106.093343; Andersson M, 2006, TRENDS ECOL EVOL, V21, P296, DOI 10.1016/j.tree.2006.03.015; Arnqvist G, 2000, ANIM BEHAV, V60, P145, DOI 10.1006/anbe.2000.1446; Berglund A, 1996, BIOL J LINN SOC, V58, P385, DOI 10.1111/j.1095-8312.1996.tb01442.x; Hasson O, 2009, BIOL REV, V84, P225, DOI 10.1111/j.1469-185X.2008.00068.x; Kraus FB, 2004, BEHAV ECOL SOCIOBIOL, V55, P494, DOI 10.1007/s00265-003-0706-0; Shackleton MA, 2005, BEHAV ECOL SOCIOBIOL, V58, P1, DOI 10.1007/s00265-004-0907-1; Okada K, 2015, ANIM BEHAV, V106, P11, DOI 10.1016/j.anbehav.2015.05.008; Hoffmann AA, 1999, HEREDITY, V82, P158, DOI 10.1038/sj.hdy.6884640; CHAPMAN T, 1995, NATURE, V373, P241, DOI 10.1038/373241a0; Tebayashi S, 1998, J STORED PROD RES, V34, P99, DOI 10.1016/S0022-474X(98)00004-6; Sakurai G, 2008, ANIM BEHAV, V75, P1367, DOI 10.1016/j.anbehav.2007.09.010; Croft DP, 2006, AM NAT, V167, P867, DOI 10.1086/504853; Cornwallis CK, 2010, TRENDS ECOL EVOL, V25, P145, DOI 10.1016/j.tree.2009.09.008; Slatyer RA, 2012, BIOL REV, V87, P1, DOI 10.1111/j.1469-185X.2011.00182.x; Okada K, 2009, ANIM BEHAV, V77, P1057, DOI 10.1016/j.anbehav.2009.01.008; Moore AJ, 2001, P ROY SOC B-BIOL SCI, V268, P517, DOI 10.1098/rspb.2000.1399; Hunt J, 2009, J EVOLUTION BIOL, V22, P13, DOI 10.1111/j.1420-9101.2008.01633.x; Okada K, 2010, BEHAV ECOL SOCIOBIOL, V64, P361, DOI 10.1007/s00265-009-0852-0; Okada K, 2014, P ROY SOC B-BIOL SCI, V281, DOI 10.1098/rspb.2014.0281; Kokko H, 2003, P ROY SOC B-BIOL SCI, V270, P653, DOI 10.1098/rspb.2002.2235; Bonduriansky Russell, 2009, Trends Ecol Evol, V24, P280, DOI 10.1016/j.tree.2008.12.005; PALOKANGAS P, 1992, ANIM BEHAV, V43, P659, DOI 10.1016/0003-3472(92)90087-P; Harano T, 2010, CURR BIOL, V20, P2036, DOI 10.1016/j.cub.2010.10.023; Hosken DJ, 2005, CURR BIOL, V15, pR836, DOI 10.1016/j.cub.2005.10.005; Emlen DJ, 2008, ANNU REV ECOL EVOL S, V39, P387, DOI 10.1146/annurev.ecolsys.39.110707.173502; Okada K, 2010, EVOL ECOL, V24, P1339, DOI 10.1007/s10682-010-9370-9; LANDE R, 1981, P NATL ACAD SCI-BIOL, V78, P3721, DOI 10.1073/pnas.78.6.3721; Moore AJ, 2003, J EVOLUTION BIOL, V16, P523, DOI 10.1046/j.1420-9101.2003.00527.x; Bateman PW, 2006, J ZOOL, V268, P341, DOI 10.1111/j.1469-7998.2006.00054.x; Rice WR, 1997, BEHAV ECOL SOCIOBIOL, V41, P1, DOI 10.1007/s002650050357; Kirkpatrick M, 1997, P NATL ACAD SCI USA, V94, P1282, DOI 10.1073/pnas.94.4.1282; FOX CW, 1993, FUNCT ECOL, V7, P203, DOI 10.2307/2389888; Bonduriansky R, 2003, EVOLUTION, V57, P2046; Moore AJ, 1999, P ROY SOC B-BIOL SCI, V266, P711, DOI 10.1098/rspb.1999.0694; TSUDA Y, 1984, APPL ENTOMOL ZOOL, V19, P129; Avila FW, 2011, ANNU REV ENTOMOL, V56, P21, DOI 10.1146/annurev-ento-120709-144823; Dadda M, 2005, ANIM BEHAV, V70, P463, DOI 10.1016/j.anbehav.2004.12.010; Jennions MD, 2000, BIOL REV, V75, P21, DOI 10.1017/S0006323199005423; Kokko H, 2006, PHILOS T R SOC B, V361, P319, DOI 10.1098/rstb.2005.1784; Kokko H, 2006, ANNU REV ECOL EVOL S, V37, P43, DOI 10.1146/annurev.ecolsys.37.091305.110259; Vahed K, 1998, BIOL REV, V73, P43, DOI 10.1017/S0006323197005112; Rowe L, 1996, P ROY SOC B-BIOL SCI, V263, P1415, DOI 10.1098/rspb.1996.0207; Okada K, 2006, J INSECT BEHAV, V19, P457, DOI 10.1007/s10905-006-9038-z; Tashiro T, 2004, BIOSCI BIOTECH BIOCH, V68, P663, DOI 10.1271/bbb.68.663; PITNICK S, 1991, ANIM BEHAV, V41, P735, DOI 10.1016/S0003-3472(05)80340-9; Martin OY, 2004, CURR BIOL, V14, P906, DOI 10.1016/j.cub.2004.04.043; Miller CW, 2014, ANNU REV ENTOMOL, V59, P427, DOI 10.1146/annurev-ento-011613-162044; Dukas R, 2005, BEHAV ECOL, V16, P800, DOI 10.1093/beheco/ari057; SOUROUKIS K, 1995, J INSECT BEHAV, V8, P269; Pitnick S, 2002, P ROY SOC B-BIOL SCI, V269, P1821, DOI 10.1098/rspb.2002.2090; Katsuki M, 2012, ECOL LETT, V15, P193, DOI 10.1111/j.1461-0248.2011.01725.x; Okada K, 2010, BIOL LETTERS, V6, P593, DOI 10.1098/rsbl.2010.0225; Warren I, 2007, BIOESSAYS, V29, P300, DOI 10.1002/bies.20543; Gavrilets S, 2001, P ROY SOC B-BIOL SCI, V268, P531; Rice WR, 1998, P NATL ACAD SCI USA, V95, P6217, DOI 10.1073/pnas.95.11.6217; Edvardsson M, 2007, ANIM BEHAV, V74, P183, DOI 10.1016/j.anbehav.2006.07.018; GWYNNE DT, 1984, EVOLUTION, V38, P1011, DOI 10.2307/2408435; Katsuki M, 2012, ECOL ENTOMOL, V37, P463, DOI 10.1111/j.1365-2311.2012.01390.x; Taylor ML, 2008, ANIM BEHAV, V76, P963, DOI 10.1016/j.anbehav.2008.05.015; Cordero C, 2003, J EVOLUTION BIOL, V16, P1, DOI 10.1046/j.1420-9101.2003.00506.x; Kirkpatrick M, 1996, EVOLUTION, V50, P2125, DOI 10.2307/2410684; Hotzy C, 2009, CURR BIOL, V19, P404, DOI 10.1016/j.cub.2009.01.045; Friberg U, 2003, J EVOLUTION BIOL, V16, P797, DOI 10.1046/j.1420-9101.2003.00597.x; KIRKPATRICK M, 1985, AM NAT, V125, P788, DOI 10.1086/284380; LEBOEUF BJ, 1991, BEHAVIOUR, V116, P143, DOI 10.1163/156853990X00400; Watson PJ, 1998, AM NAT, V151, P46, DOI 10.1086/286101; Wigby S, 2005, CURR BIOL, V15, P316, DOI 10.1016/j.cub.2005.01.051; Moller AP, 2001, NATURWISSENSCHAFTEN, V88, P401; Yamane T, 2010, P ROY SOC B-BIOL SCI, V277, P1705, DOI 10.1098/rspb.2009.2017; Sharma MD, 2012, BIOL J LINN SOC, V106, P295, DOI 10.1111/j.1095-8312.2012.01883.x; Hunt J, 2004, TRENDS ECOL EVOL, V19, P329, DOI 10.1016/j.tree.2004.03.035; Okada K, 2011, J EVOLUTION BIOL, V24, P363, DOI 10.1111/j.1420-9101.2010.02170.x; Muhlhauser C, 2002, BEHAV ECOL, V13, P359, DOI 10.1093/beheco/13.3.359; Hosken DJ, 2009, ANNU REV ENTOMOL, V54, P361, DOI 10.1146/annurev.ento.54.110807.090608; South A, 2011, BIOL REV, V86, P299, DOI 10.1111/j.1469-185X.2010.00145.x; Blanckenhorn WU, 2002, BEHAV ECOL, V13, P353, DOI 10.1093/beheco/13.3.353; Rice WR, 1996, NATURE, V381, P232, DOI 10.1038/381232a0; Hongo Y, 2012, ACTA ETHOL, V15, P195, DOI 10.1007/s10211-012-0128-y; Gay L, 2009, PHYSIOL ENTOMOL, V34, P86, DOI 10.1111/j.1365-3032.2008.00656.x; Arnqvist G., 2005, SEXUAL CONFLICT; Arnqvist G, 2005, AM NAT, V165, pS26, DOI 10.1086/429350; Grafen A., 2002, MODERN STAT LIFE SCI; Hosken D. J., 2004, TRENDS ECOL EVOL, V19, P224; Hunt J, 2014, GENOTYPE-BY-ENVIRONMENT INTERACTIONS AND SEXUAL SELECTION, P1, DOI 10.1002/9781118912591; Ingleby FC, 2010, J EVOLUTION BIOL, V23, P2031, DOI 10.1111/j.1420-9101.2010.02080.x; Kokko H., 2012, ENTOMOL EXP APPL, V146, P26; Parker G.A., 1979, P123; PARTRIDGE L, 1990, J INSECT PHYSIOL, V36, P419, DOI 10.1016/0022-1910(90)90059-O; Roff D. A., 2002, LIFE HIST EVOLUTION; Shuster SM, 2003, MATING SYSTEM STRATE; Suzaki Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083278; Teuschl Y, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-194; Wong B. B. M., 2005, BIOL REV, V80, P558; Yoshida T, 1958, PLANT PROTECTION, V12, P59	100	0	0	ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	0003-3472	1095-8282		ANIM BEHAV	Anim. Behav.	NOV	2015	109						265	272		10.1016/j.anbehav.2015.09.002		8	Behavioral Sciences; Zoology	Behavioral Sciences; Zoology	CU1GK	WOS:000363268300031		
J	Kitaji, H; Ookutsu, S; Sato, M; Miyoshi, K				Kitaji, Hideki; Ookutsu, Shoji; Sato, Masahiro; Miyoshi, Kazuchika			Preincubation with green tea polyphenol extract is beneficial for attenuating sperm injury caused by freezing-thawing in swine	ANIMAL SCIENCE JOURNAL			English	Article						anti-oxidants; boar; cryopreservation; polyphenol; sperm quality	LONG-TERM PRESERVATION; BOAR SEMEN; PHYSIOLOGICAL CONDITIONS; MITOCHONDRIAL-FUNCTION; ACROSOMAL INTEGRITY; LIPID-PEROXIDATION; PROPIDIUM IODIDE; FLOW-CYTOMETRY; BOVINE SPERM; CANINE SEMEN	Polyphenols (PFs) extracted from green tea, known to be potent anti-oxidants, have been reported to be effective in increasing the motility and viability of mammalian sperm, preserved in a liquid form. Therefore, we tested whether PFs might also be effective for maintaining the integrity of frozen-thawed boar spermatozoa. Ejaculates, collected from Clawn miniature pigs, were diluted in a semen extender containing various amounts of PFs (0, 0.01, 0.05, 0.1 and 0.2% w/v) and then stored at 15 degrees C overnight. The semen samples were processed, using the straw freezing procedure, and then frozen in liquid nitrogen. After rapid thawing at 40 degrees C, the spermatozoa were subjected to several assays to evaluate semen quality. Spermatozoa frozen in a medium containing 0.01% w/v PFs exhibited significantly (P<0.05) higher degrees of post-thawed viability and acrosomal integrity than those stored in the absence of PFs. However, no change in the mitochondrial activity was noted between the two groups. The inclusion of 0.01% PFs in the semen extender was significantly (P<0.05) effective in increasing both the rates of monospermic oocyte formation and of blastocyst formation. These findings indicate that preincubation with the semen extender, containing 0.01% PFs prior to freezing, exerts a protective effect on boar sperm by preventing injuries associated with freezing-thawing.	[Kitaji, Hideki; Ookutsu, Shoji; Miyoshi, Kazuchika] Kagoshima Univ, Fac Agr, Lab Anim Reprod, Kagoshima, Kagoshima 8908544, Japan; [Sato, Masahiro] Kagoshima Univ, Sect Gene Express Regulat, Frontier Sci Res Ctr, Kagoshima, Kagoshima 8908544, Japan	Sato, M (reprint author), Kagoshima Univ, Sect Gene Express Regulat, Frontier Sci Res Ctr, 8-35-1 Sakuragaoka, Kagoshima, Kagoshima 8908544, Japan.	masasato@ms.kagoshima-u.ac.jp					Almlid T, 1996, REPROD DOMEST ANIM, V31, P169; GRAHAM JK, 1990, BIOL REPROD, V43, P55, DOI 10.1095/biolreprod43.1.55; Agarwal A, 2004, REPROD BIOMED ONLINE, V8, P616; Kaedei Y, 2012, REPROD DOMEST ANIM, V47, P880, DOI 10.1111/j.1439-0531.2012.01984.x; Garner DL, 1997, BIOL REPROD, V57, P1401, DOI 10.1095/biolreprod57.6.1401; PARKS JE, 1992, THERIOGENOLOGY, V38, P209, DOI 10.1016/0093-691X(92)90231-F; GARNER DL, 1994, J ANDROL, V15, P620; Storey BT, 2008, INT J DEV BIOL, V52, P427, DOI 10.1387/ijdb.072522bs; HUANG MT, 1992, CARCINOGENESIS, V13, P947, DOI 10.1093/carcin/13.6.947; Han DW, 2005, TISSUE ENG, V11, P1054, DOI 10.1089/ten.2005.11.1054; Hyon SH, 2006, CELL TRANSPLANT, V15, P881, DOI 10.3727/000000006783981422; Holt WV, 1997, REPROD FERT DEVELOP, V9, P309, DOI 10.1071/R96082; Baumber J, 2000, J ANDROL, V21, P895; Yoshioka K, 2002, BIOL REPROD, V66, P112, DOI 10.1095/biolreprod66.1.112; Cheng FP, 1996, J ANDROL, V17, P674; GARNER DL, 1995, BIOL REPROD, V53, P276, DOI 10.1095/biolreprod53.2.276; Hyon SH, 2004, YONSEI MED J, V45, P1025; Roca J, 2005, J ANDROL, V26, P15; Wittayarat M, 2012, CRYOLETTERS, V33, P318; Abeydeera LR, 1998, BIOL REPROD, V58, P1316, DOI 10.1095/biolreprod58.5.1316; Han DW, 2005, BIOTECHNOL LETT, V27, P655, DOI 10.1007/s10529-005-3677-6; Zhang GM, 2004, CELL TRANSPLANT, V13, P145; BAVISTER BD, 1977, BIOL REPROD, V16, P228, DOI 10.1095/biolreprod16.2.228; Ikeguchi R, 2005, TRANSPLANTATION, V79, P688, DOI 10.1097/01.TP.0000155417.87823.17; Bailey JL, 2008, THERIOGENOLOGY, V70, P1251, DOI 10.1016/j.theriogenology.2008.06.014; SHIRAKI M, 1994, MUTAT RES, V323, P29, DOI 10.1016/0165-7992(94)90041-8; Grossfeld R, 2008, THERIOGENOLOGY, V70, P1225, DOI 10.1016/j.theriogenology.2008.07.017; HO CT, 1992, PREV MED, V21, P520, DOI 10.1016/0091-7435(92)90059-Q; Johnson LA, 2000, ANIM REPROD SCI, V62, P143, DOI 10.1016/S0378-4320(00)00157-3; PARRISH JJ, 1988, BIOL REPROD, V38, P1171, DOI 10.1095/biolreprod38.5.1171; METEZEAU P, 1991, MOL REPROD DEV, V30, P250, DOI 10.1002/mrd.1080300313; Hyon SH, 2001, J BIOTECHNOL, V85, P241, DOI 10.1016/S0168-1656(00)00336-9; HALLIWELL B, 1984, LANCET, V1, P1396; Scorrano L, 1999, J BIOL CHEM, V274, P24657, DOI 10.1074/jbc.274.35.24657; Cerolini S, 2000, ANIM REPROD SCI, V58, P99, DOI 10.1016/S0378-4320(99)00035-4; Vizler C, 2002, CYTOMETRY, V47, P158, DOI 10.1002/cyto.10066; Kitaji H, 2014, ANIM SCI J, V86, P494; Watoson PF., 1995, REPROD FERT DEVELOP, V7, P871; Westendorf P, 1975, Dtsch Tierarztl Wochenschr, V82, P261; Wittayarat M, 2013, REPROD BIOL, V13, P251, DOI 10.1016/j.repbio.2013.07.006; YANG CS, 1993, J NATL CANCER I, V85, P1038, DOI 10.1093/jnci/85.13.1038	41	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1344-3941	1740-0929		ANIM SCI J	Anim. Sci. J.	NOV	2015	86	11					922	928		10.1111/asj.12379		7	Agriculture, Dairy & Animal Science	Agriculture	CU2DK	WOS:000363332800002		
J	Kim, DH; Choi, KC; Ichinohe, T; Song, SH				Kim, Da-Hye; Choi, Ki-Choon; Ichinohe, Toshiyoshi; Song, Sang-Houn			Effects of different roughage sources and feeding levels on adipogenesis of ovine adipocytes	ANIMAL SCIENCE JOURNAL			English	Article						adipocyte differentiation; lipid accumulation; serum treatment	STEAROYL-COA DESATURASE; INDUCED GENE-EXPRESSION; FATTY-ACIDS; PPAR-GAMMA; 3T3-L1 PREADIPOCYTES; CHEMERIN ANALOG; GROWTH-HORMONE; ADIPOSE-TISSUE; WAGYU STEERS; SHEEP	The objective of the present study was to conduct an adipogenic evaluation of different roughage sources and feeding levels during ruminant adipocyte differentiation in vitro. Six wether sheep were divided into a timothy hay feeding group (TFG, n=3) and an Italian ryegrass straw feeding group (IFG, n=3). The sheep were fed high-roughage (HR), medium roughage (MR) and low-roughage (LR) diets in a one-way layout design each over a 6-day period. Sheep serum samples collected on the last day of each dietary treatment were added to an adipogenic induction medium for differentiation of preadipocytes derived from sheep subcutaneous adipose tissue. The cytoplasmic lipid accumulations in the TFG serum-treated preadipocytes were significantly higher than those of the IFG-serum treated preadipocytes on day 12. Messenger RNA expression of CCAAT/enhancer-binding protein (C/EBP)-, C/EBP-, C/EBP-, fatty-acid-binding protein (aP2) and stearoyl-coenzyme A desaturase (SCD) were regulated by each serum treatment. This study shows that different roughage source diets and roughage-to-concentrate ratio diets can regulate adipocyte differentiation via ruminant blood composition.	[Kim, Da-Hye; Ichinohe, Toshiyoshi; Song, Sang-Houn] Shimane Univ, Fac Life & Environm Sci, Matsue, Shimane 6908504, Japan; [Kim, Da-Hye] Tottori Univ, United Grad Sch Agr Sci, Tottori 680, Japan; [Choi, Ki-Choon] RDA, Natl Inst Anim Sci, Grassland & Forage Div, Chungnam, South Korea	Song, SH (reprint author), Shimane Univ, Fac Life & Environm Sci, Matsue, Shimane 6908504, Japan.	sanghoun_song@life.shimane-u.ac.jp			Rural Development Administration, Republic of Korea [PJ008502032014]	This work was carried out with the support of "Cooperative Research Program for Agriculture Science & Technology Development (Project title: Technique Development for Evaluation of Nutrient Distribution in Forage-Fed Ruminant, Project No. PJ008502032014) "Rural Development Administration, Republic of Korea.	Atti N, 2004, SMALL RUMINANT RES, V54, P89, DOI 10.1016/j.smallrumres.2003.09.010; Roh SG, 2006, ANIM SCI J, V77, P472, DOI 10.1111/j.1740-0929.2006.00374.x; Schoonjans K, 1996, J LIPID RES, V37, P907; NTAMBI JM, 1988, J BIOL CHEM, V263, P17291; AMRI EZ, 1991, J LIPID RES, V32, P1449; Suzuki Y, 2012, ASIAN AUSTRAL J ANIM, V25, P1316, DOI 10.5713/ajas.2012.12083; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; Bajaj M, 2007, DIABETOLOGIA, V50, P1723, DOI 10.1007/s00125-007-0698-9; Pannier L, 2010, MEAT SCI, V85, P515, DOI 10.1016/j.meatsci.2010.02.025; Suzuki Y, 2012, ANIM SCI J, V83, P263, DOI 10.1111/j.1740-0929.2011.01002.x; Yamada T, 2012, MEAT SCI, V90, P807, DOI 10.1016/j.meatsci.2011.11.019; Yamada T, 2009, MEAT SCI, V83, P775, DOI 10.1016/j.meatsci.2009.08.023; Yamamoto M, 2010, J ANIM VET ADV, V9, P1639; WAGHORN GC, 1987, ANIM PROD, V44, P143; Rosen ED, 2001, J BIOL CHEM, V276, P37731; BASSETT JM, 1971, AUST J BIOL SCI, V24, P321; Wang JH, 2003, ASIAN AUSTRAL J ANIM, V16, P1604; EVANS E, 1975, J ANIM SCI, V41, P1474; Taniguchi M, 2004, LIVEST PROD SCI, V87, P215, DOI 10.1016/j.livprodsci.2003.07.008; BALLARD FJ, 1972, BIOCHEM J, V126, P193; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736; CHILLIARD Y, 1993, J DAIRY SCI, V76, P3897, DOI 10.3168/jds.S0022-0302(93)77730-9; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224	24	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1344-3941	1740-0929		ANIM SCI J	Anim. Sci. J.	NOV	2015	86	11					943	951		10.1111/asj.12380		9	Agriculture, Dairy & Animal Science	Agriculture	CU2DK	WOS:000363332800005		
J	Horikawa, A; Ogasawara, H; Okada, K; Kobayashi, M; Muroya, S; Hojito, M				Horikawa, Akihiko; Ogasawara, Hideki; Okada, Kaito; Kobayashi, Misato; Muroya, Susumu; Hojito, Masayuki			Grazing-induced changes in muscle microRNA-206 and-208b expression in association with myogenic gene expression in cattle	ANIMAL SCIENCE JOURNAL			English	Article						grazing; microRNA; muscle type; myogenic regulatory factors; myosin heavy chain isoform	RAT SKELETAL-MUSCLE; MYOD; DIFFERENTIATION; MICE; EXERCISE; MIR-206; QUALITY; FIBERS; MYF5; MEAT	To investigate the roles of microRNAs (miRNAs) in muscle type conversion, the effects of 4 months of grazing on the expression levels of miRNAs and mRNAs associated with skeletal muscle development were analyzed by quantitative RT-PCR using the Biceps femoris muscle of Japanese Shorthorn cattle. After 4 months of grazing, the expression of muscle fiber type-associated miR-208b was higher in the grazed cattle than in the housed. In concordance with the pattern in miR-208b expression, the expression of MyoD, a myogenic regulatory factor associated with the shifting of muscle property to the fast type, was lower in the grazed cattle after 4 months of grazing than in the housed cattle. In addition, the expression of MyHC-2x (a fast type) was higher in the housed cattle than in the grazed, after 4 months of grazing. During the grazing period, miR-206 expression decreased in the housed cattle, whereas expression in the grazed cattle did not change, but rather remained higher than that of the housed cattle even at 3 months after the grazing ended. These miRNAs including miR-206 persisting with muscles of grazed cattle may be associated with regulation of muscle gene expression during skeletal muscle adaptation to grazing.	[Horikawa, Akihiko] Fukui Livestock Expt Stn, Livestock Res Div, Sakai, Osaka, Japan; [Ogasawara, Hideki; Okada, Kaito; Kobayashi, Misato; Hojito, Masayuki] Kitasato Univ, Sch Vet Med, Field Sci Ctr, Yakumo, Japan; [Muroya, Susumu] NARO Inst Livestock & Grassland Sci, Anim Prod Res Div, Tsukuba, Ibaraki 3050901, Japan	Muroya, S (reprint author), NARO Inst Livestock & Grassland Sci, Anim Prod Res Div, Tsukuba, Ibaraki 3050901, Japan.	muros@affrc.go.jp			Japan Society for the Promotion of Science (JSPS KAKENHI) [22580326]	This work was supported by the Japan Society for the Promotion of Science (JSPS KAKENHI 22580326 to S.M.). The authors thank the staff of the Field Science Center of the School of Veterinary Medicine at Kitasato University for their great support to manage and feed cattle.	Muroya S, 2002, ZOOL SCI, V19, P755, DOI 10.2108/zsj.19.755; Wang X, 2013, ANIMAL, V7, P1567, DOI 10.1017/S1751731113001183; Rao PK, 2006, P NATL ACAD SCI USA, V103, P8721, DOI 10.1073/pnas.0602831103; Muroya S, 2005, DEV GROWTH DIFFER, V47, P483; Lefaucheur L, 2010, MEAT SCI, V84, P257, DOI 10.1016/j.meatsci.2009.05.004; Jeng SF, 2009, J NEUROTRAUM, V26, P2345, DOI 10.1089/neu.2009.0960; HUGHES SM, 1993, DEVELOPMENT, V118, P1137; Hughes SM, 1999, J CELL BIOL, V145, P633, DOI 10.1083/jcb.145.3.633; KOVANEN V, 1984, EUR J APPL PHYSIOL O, V52, P235, DOI 10.1007/BF00433399; Jurie C, 2006, LIVEST SCI, V104, P182, DOI 10.1016/j.livsci.2006.04.016; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; Shibata M, 2009, J ANIM SCI, V87, P2700, DOI 10.2527/jas.2008-1486; Lamas L, 2010, SCAND J MED SCI SPOR, V20, P216, DOI 10.1111/j.1600-0838.2009.00905.x; Kim HK, 2006, J CELL BIOL, V174, P677, DOI 10.1083/jcb.200603008; Chikuni K, 2004, MEAT SCI, V67, P87, DOI 10.1016/j.meatsci.2003.09.011; SCHLUTER JM, 1994, AM J PHYSIOL, V266, pC1699; Endo K, 2013, BIOMED RES-TOKYO, V34, P289; Vestergaard M, 2000, MEAT SCI, V54, P187, DOI 10.1016/S0309-1740(99)00098-4; Miyake M, 2007, CELL BIOL INT, V31, P1274, DOI 10.1016/j.cellbi.2007.05.007; Chen JF, 2006, NAT GENET, V38, P228, DOI 10.1038/ng1725; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Seward DJ, 2001, AM J PHYSIOL-CELL PH, V280, pC408; Muroya S, 2013, J ANIM SCI, V91, P90, DOI 10.2527/jas.2012-5371; Sweetman D, 2008, DEV BIOL, V321, P491, DOI 10.1016/j.ydbio.2008.06.019; KIENS B, 1993, J PHYSIOL-LONDON, V469, P459; Goljanek-Whysall K, 2011, P NATL ACAD SCI USA, V108, P11936, DOI 10.1073/pnas.1105362108; Goto Takafumi, 1995, Animal Science and Technology, V66, P62; Muroya S., 2002, Animal Science Journal, V73, P375, DOI 10.1046/j.1344-3941.2002.t01-1-00052.x; vansRooij E, 2008, TRENDS GENET, V24, P159; vansRooij E, 2009, DEV CELL, V17, P662	30	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1344-3941	1740-0929		ANIM SCI J	Anim. Sci. J.	NOV	2015	86	11					952	960		10.1111/asj.12381		9	Agriculture, Dairy & Animal Science	Agriculture	CU2DK	WOS:000363332800006		
J	Nakashima, M				Nakashima, Makoto			Branching random walks in random environment and super-Brownian motion in random environment	ANNALES DE L INSTITUT HENRI POINCARE-PROBABILITES ET STATISTIQUES			English	Article						Superprocesses in a random environment; Branching random walks in a random environment; Stochastic heat equations; Uniqueness	PARTIAL-DIFFERENTIAL-EQUATIONS; CENTRAL-LIMIT-THEOREM; LOCALIZATION; DIFFUSIONS; SUPPORT	We focus on the existence and characterization of the limit for a certain critical branching random walks in time-space random environment in one dimension which was introduced by Birkner, Geiger and Kersting in (In Interacting Stochastic Systems (2005) 269-291 Springer). Each particle performs simple random walk on Z and branching mechanism depends on the time-space site. The limit of this measure-valued processes is characterized as the unique solution to the non-trivial martingale problem and called super-Brownian motion in a random environment by Mytnik in (Ann. Probab. 24 (1996) 1953-1978).	Univ Tsukuba, Grad Sch Pure & Appl Sci, Div Math, Tsukuba, Ibaraki, Japan	Nakashima, M (reprint author), Univ Tsukuba, Grad Sch Pure & Appl Sci, Div Math, 1-1-1 Ten Noudai, Tsukuba, Ibaraki, Japan.	nakamako@math.tsukuba.ac.jp			JSPS [24840007]	The author is very grateful to the referees for their suggestions, especially on the explicit form on the dual processes. Also, he thanks the associated editor for his fruitful comments. He thanks Prof. Yoshida for his careful reading of this paper. He thanks Prof. Mytnik for the fruitful discussion. This work was partially supported by JSPS Grant-in-Aid for Young Scientists (Start-up) 24840007.	PERKINS E, 1989, ANN I H POINCARE-PR, V25, P205; Shiozawa Y, 2009, J STAT PHYS, V136, P145, DOI 10.1007/s10955-009-9774-5; PERKINS EA, 1988, T AM MATH SOC, V305, P743; LEGALL JF, 1995, STOCH PROC APPL, V59, P1, DOI 10.1016/0304-4149(95)00033-4; Mytnik L, 1996, ANN PROBAB, V24, P1953; Yoshida N, 2008, ANN APPL PROBAB, V18, P1619, DOI 10.1214/07-AAP500; Mytnik L, 2011, PROBAB THEORY REL, V149, P1, DOI 10.1007/s00440-009-0241-7; Heil H, 2011, ELECTRON COMMUN PROB, V16, P323; Shiozawa Y, 2009, TOHOKU MATH J, V61, P483; Nakashima M, 2011, ANN APPL PROBAB, V21, P351, DOI 10.1214/10-AAP699; Bertini L, 1997, COMMUN MATH PHYS, V183, P571, DOI 10.1007/s002200050044; REIMERS M, 1989, PROBAB THEORY REL, V81, P319, DOI 10.1007/BF00340057; Mytnik L, 1998, ANN PROBAB, V26, P968; Birkner M, 2005, INTERACTING STOCHASTIC SYSTEMS, P269, DOI 10.1007/3-540-27110-4_12; BURKHOLD.DL, 1973, ANN PROBAB, V1, P19, DOI 10.1214/aop/1176997023; Dawson D. A., 1993, LECT NOTES MATH, V1541, P1, DOI DOI 10.1007/BFB0084190.MR1242575; Dawson D. A., 1975, J MULTIVARIATE ANAL, V5, P1, DOI 10.1016/0047-259X(75)90054-8; Dawson D. A., 1991, MEM AM MATH SOC, V93; Dawson D. A., 1978, CANAD J STATIST, V6, P143, DOI 10.2307/3315044; Dynkin E. B., 2002, AM MATH SOC C PUBLIC, V50; Dynkin E. B., 2004, U LECT SERIES, V34; Etheridge Alison, 2000, U LECT SERIES, V20; Ethier S. N., 2009, MARKOV PROCESSES CHA; Heil H., 2011, ELECTRON J PROBAB, V16, P1318; KONNO N, 1988, PROBAB THEORY REL, V79, P201, DOI 10.1007/BF00320919; LeGall J., 1999, LECT MATH ETH ZURICH; Mueller C, 2014, ANN PROBAB, V42, P2032, DOI 10.1214/13-A00870; Mueller C., 1992, PROBAB THEORY REL, V44, P325; Perkins E. A., 2002, LECT PROBABILITY THE; SHIGA T, 1994, CAN J MATH, V46, P415, DOI 10.4153/CJM-1994-022-8; Watanabe S., 1968, KYOTO J MATH, V8, P141	31	0	0	INST MATHEMATICAL STATISTICS	CLEVELAND	3163 SOMERSET DR, CLEVELAND, OH 44122 USA	0246-0203			ANN I H POINCARE-PR	Ann. Inst. Henri Poincare-Probab. Stat.	NOV	2015	51	4					1251	1289		10.1214/14-AIHP620		39	Statistics & Probability	Mathematics	CU3IQ	WOS:000363418300002		
J	Kobayashi, J; Mabuchi, H				Kobayashi, Junji; Mabuchi, Hiroshi			Lipoprotein lipase and atherosclerosis	ANNALS OF CLINICAL BIOCHEMISTRY			English	Review						Atherosclerosis; lipoprotein lipase	LOW-DENSITY-LIPOPROTEIN; TRIGLYCERIDE-RICH LIPOPROTEINS; CORONARY-ARTERY-DISEASE; HEPATIC LIPASE; ACCELERATED ATHEROSCLEROSIS; SEVERE HYPERTRIGLYCERIDEMIA; PREMATURE ATHEROSCLEROSIS; MONOCYTE ADHESION; CHOLESTEROL; GENE	Lipoprotein lipase has long been known to hydrolyse triglycerides from triglycerides-rich lipoproteins. More recently, it has been shown to promote the binding of lipoproteins to various lipoprotein receptors. Evidence is also presented regarding the possible atherogenic role of lipoprotein lipase. In theory, lipoprotein lipase deficiency should help to clarify this question. However, the rarity of this condition means that it has not been possible to conduct epidemiological studies. An alternative approach is to investigate the correlation of lipoprotein lipase with onset of cardiovascular disease in prospective studies in large population-based cohorts. Complementary with this approach, animal models have been used to explore the atherogenicity of lipoprotein lipase expressed by macrophages.	[Kobayashi, Junji] Kanazawa Med Univ, Gen Internal Med, Uchinada, Ishikawa, Japan; [Mabuchi, Hiroshi] Kanazawa Univ, Grad Sch Pharmaceut, Lipid Res Course, Hlth Sci, Kanazawa, Ishikawa, Japan	Kobayashi, J (reprint author), Kanazawa Med Univ, Gen Internal Med, Uchinada Daigaku 1-1, Uchinada, Ishikawa, Japan.	mary@kanazawa-med.ac.jp					Kawashiri M, 2005, J CLIN ENDOCR METAB, V90, P6541, DOI 10.1210/jc.2005-1098; Ebara T, 2001, ATHEROSCLEROSIS, V159, P375, DOI 10.1016/S0021-9150(01)00510-X; OBRIEN KD, 1992, J CLIN INVEST, V89, P1544, DOI 10.1172/JCI115747; DICHEK HL, 1993, J LIPID RES, V34, P1393; Kobayashi J, 2007, CLIN CHIM ACTA, V378, P7, DOI 10.1016/j.cca.2006.12.003; WION KL, 1987, SCIENCE, V235, P1638, DOI 10.1126/science.3823907; Choi SY, 2002, J LIPID RES, V43, P1763, DOI 10.1197/jlr.R200011-JLR200; KIRCHGESSNER TG, 1989, P NATL ACAD SCI USA, V86, P9647, DOI 10.1073/pnas.86.24.9647; Hanyu O, 2004, ATHEROSCLEROSIS, V174, P385, DOI 10.1016/j.atherosclerosis.2004.01.034; Auerbach BJ, 1996, J BIOL CHEM, V271, P1329; Hu YM, 2006, J LIPID RES, V47, P1908, DOI 10.1194/jlr.M600108-JLR200; Benlian P, 1996, NEW ENGL J MED, V335, P848, DOI 10.1056/NEJM199609193351203; Okazaki M, 2000, CLIN CHIM ACTA, V296, P135, DOI 10.1016/S0009-8981(00)00213-8; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P10143, DOI 10.1073/pnas.88.22.10143; ZILVERSMIT DB, 1995, CLIN CHEM, V41, P153; Zhang XH, 2008, CIRC RES, V102, P250, DOI 10.1161/CIRCRESAHA.107.156554; Saika Y, 2003, EUR J CLIN INVEST, V33, P216, DOI 10.1046/j.1365-2362.2003.01129.x; Wittrup HH, 1997, J CLIN INVEST, V99, P1606, DOI 10.1172/JCI119323; Babaev VR, 1999, J CLIN INVEST, V103, P1697, DOI 10.1172/JCI6117; KOBAYASHI J, 1993, CLIN CHIM ACTA, V216, P113, DOI 10.1016/0009-8981(93)90144-S; Kaplan M, 1997, BIOCHEM BIOPH RES CO, V237, P271, DOI 10.1006/bbrc.1997.7130; Gotoda T, 2012, J ATHEROSCLER THROMB, V19, P1; Sagoo GS, 2008, AM J EPIDEMIOL, V168, P1233, DOI 10.1093/aje/kwn235; Hitsumoto T, 2000, ATHEROSCLEROSIS, V153, P391, DOI 10.1016/S0021-9150(00)00413-5; REYMER PWA, 1995, NAT GENET, V10, P28, DOI 10.1038/ng0595-28; Obunike JC, 1997, ARTERIOSCL THROM VAS, V17, P1414; AVIRAM M, 1988, J BIOL CHEM, V263, P15416; TSUTSUMI K, 1993, J CLIN INVEST, V92, P411, DOI 10.1172/JCI116582; LINDQVIST P, 1983, J BIOL CHEM, V258, P9086; Ebara T, 2007, CLIN CHIM ACTA, V386, P100, DOI 10.1016/j.cca.2007.08.011; SHIMADA M, 1993, J BIOL CHEM, V268, P17924; RENIER G, 1993, ARTERIOSCLER THROMB, V13, P190; DAVIS RC, 1992, J BIOL CHEM, V267, P21499; BENAVRAM CM, 1986, P NATL ACAD SCI USA, V83, P4185, DOI 10.1073/pnas.83.12.4185; Ichikawa T, 2005, ATHEROSCLEROSIS, V179, P87, DOI 10.1016/j.atherosclerosis.2004.10.044; Takahashi M, 2013, J LIPID RES, V54, P1124, DOI 10.1194/jlr.M035568; Mamputu JC, 1997, J LIPID RES, V38, P1722; Shirakawa T, 2015, CLIN CHIM ACTA, V440, P193, DOI 10.1016/j.cca.2014.07.020; BABIRAK SP, 1989, ARTERIOSCLEROSIS, V9, P326; Fan JL, 2001, J BIOL CHEM, V276, P40071, DOI 10.1074/jbc.M105456200; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; TAKAHASHI S, 1995, J BIOL CHEM, V270, P15747; OLIVECRONA G, 1995, CURR OPIN LIPIDOL, V6, P291, DOI 10.1097/00041433-199510000-00009; Shimada M, 1996, P NATL ACAD SCI USA, V93, P7242, DOI 10.1073/pnas.93.14.7242; Rip J, 2006, ARTERIOSCL THROM VAS, V26, P637, DOI 10.1161/01.ATV.0000201038.47949.56; Kobayashi J, 2001, HORM METAB RES, V33, P412, DOI 10.1055/s-2001-16230; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; Brunzell JD, 2000, METABOLIC MOL BASES, P2789; Deeb S S, 1989, Biochemistry, V28, P4131, DOI 10.1021/bi00436a001; Dugi KA, 1997, ARTERIOSCL THROM VAS, V17, P354; Hitsumoto Takashi, 2002, J Atheroscler Thromb, V9, P163; Martin-Campos JM, 2014, CLIN CHIM ACTA, V429, P61, DOI 10.1016/j.cca.2013.11.025	52	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0004-5632	1758-1001		ANN CLIN BIOCHEM	Ann. Clin. Biochem.	NOV	2015	52	6					632	637		10.1177/0004563215590451		6	Medical Laboratory Technology	Medical Laboratory Technology	CU3JF	WOS:000363420100002		
J	Manita, D; Hirowatari, Y; Yoshida, H				Manita, Daisuke; Hirowatari, Yuji; Yoshida, Hiroshi			A rapid anion-exchange chromatography for measurement of cholesterol concentrations in five lipoprotein classes and estimation of lipoprotein profiles in male volunteers without overt diseases	ANNALS OF CLINICAL BIOCHEMISTRY			English	Article						Lipoprotein; anion-exchange chromatography; dyslipidemia	CORONARY-HEART-DISEASE; HIGH-DENSITY LIPOPROTEIN; HDL CHOLESTEROL; SERUM; FRAMINGHAM; ATHEROSCLEROSIS	Background Analysis of lipoprotein profile gives important clinical information for lipid-lowering therapy which prevents atherosclerotic diseases. The lipoprotein classes can be isolated from serum with ultracentrifugation, which inevitably consumes a long time and needs large serum volume. We have established a method with anion-exchange chromatography with 1.0 mu L of the injected volume in 5.2min for assay of one sample. Methods One-hundred-forty-one male volunteers without overt diseases were divided three groups (Group 1, non-dyslipidemia with LDL-cholesterol [LDL-C] <120mg/dL and HDL-cholesterol (HDL-C) 40mg/dL; Group 2, borderline dyslipidemia with 120LDL-C<140mg/dL and HDL-C 40mg/dL; Group 3, dyslipidemia with LDL-C140mg/dL or HDL-C<40mg/dL). Their lipoprotein profiles were evaluated by rapid anion-exchange chromatography, which measured concentrations of HDL-C, LDL-C, IDL-cholesterol, VLDL-cholesterol, and other fraction (chylomicron + lipoprotein [a])-cholesterol (other-C). Results The within-day and between-day assay coefficients of variation of lipoprotein cholesterol values were 0.33-4.31% and 2.37-9.19%, respectively. The correlation coefficients between values of HDL-C, LDL-C, IDL-C and VLDL-C by the anion-exchange chromatography and those by ultracentrifugal method were 0.97, 0.92, 0.58 and 0.94, respectively. Group 3 had significantly lower HDL-C and higher concentrations of IDL-C, VLDL-C and other-C than did Group 1. Group 2, borderline dyslipidemia, had significantly higher concentrations of IDL-C and VLDL-C than did Group 1. Conclusion The rapid anion-exchange chromatography assay may be sufficiently applied to the assessment of borderline dyslipidemia.	[Manita, Daisuke] Tosoh Corp, Biosci Div, Ayase, Kanagawa, Japan; [Hirowatari, Yuji] Saitama Prefectural Univ, Dept Hlth Sci, Lab Sci, Kosigaya, Saitama, Japan; [Yoshida, Hiroshi] Jikei Univ, Kashiwa Hosp, Dept Lab Med, Chiba, Japan	Hirowatari, Y (reprint author), Saitama Prefectural Univ, Dept Hlth Sci, Lab Sci, 820 San Nomiya, Kosigaya, Saitama, Japan.	hirowatari-yuji@spu.ac.jp			Jikei University; Tosoh Research Fund	Research funds were provided in part by the Jikei University Research Fund (to HY) and in part by the Tosoh Research Fund (to DM and YH).	ANDERSON KM, 1987, JAMA-J AM MED ASSOC, V257, P2176, DOI 10.1001/jama.257.16.2176; Hirowatari Y, 2010, J LIPID RES, V51, P1237, DOI 10.1194/jlr.D003624; Karpe F, 1999, J INTERN MED, V246, P341, DOI 10.1046/j.1365-2796.1999.00548.x; Takeichi S, 1999, ATHEROSCLEROSIS, V142, P309, DOI 10.1016/S0021-9150(98)00246-9; Todo Y, 2004, CLIN CHIM ACTA, V348, P35, DOI 10.1016/j.cccn.2004.04.018; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; NOBLE RP, 1968, J LIPID RES, V9, P693; Imano H, 2011, PREV MED, V52, P381, DOI 10.1016/j.ypmed.2011.02.019; Arai H, 2005, J ATHEROSCLER THROMB, V12, P98; Liu J, 2006, AM J CARDIOL, V98, P1363, DOI 10.1016/j.amjcard.2006.06.032; Ito K, 2013, INT J CARDIOL, V168, P3853, DOI 10.1016/j.ijcard.2013.06.023; Nakajima K, 2001, ARTERIOSCL THROM VAS, V21, P1238, DOI 10.1161/hq0701.092246; Hirowatari Y, 2003, J LIPID RES, V44, P1404, DOI 10.1194/jlr.D300003-JLR200; Barter P, 2007, NEW ENGL J MED, V357, P1301, DOI 10.1056/NEJMoa064278; BEAUMONT J L, 1970, Bulletin of the World Health Organization, V43, P891; Carlson K, 1973, J Clin Pathol Suppl (Assoc Clin Pathol), V5, P32; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9	17	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0004-5632	1758-1001		ANN CLIN BIOCHEM	Ann. Clin. Biochem.	NOV	2015	52	6					638	646		10.1177/0004563215584405		9	Medical Laboratory Technology	Medical Laboratory Technology	CU3JF	WOS:000363420100003		
J	Takeda, S; Subagyo, A; Hui, SP; Fuda, H; Shrestha, R; Sueoka, K; Chiba, H				Takeda, Seiji; Subagyo, Agus; Hui, Shu-Ping; Fuda, Hirotoshi; Shrestha, Rojeet; Sueoka, Kazuhisa; Chiba, Hitoshi			Elastic modulus of low-density lipoprotein as potential indicator of its oxidation	ANNALS OF CLINICAL BIOCHEMISTRY			English	Article						AFM; nanoparticles; biological samples; bioanalytical methods; lipids	ATOMIC-FORCE MICROSCOPY; OXIDIZED-LDL; MONOCLONAL-ANTIBODIES; MEMBRANE; PROTEIN; CELLS; ELECTRODE	Background Evaluation of low-density lipoprotein oxidation is important in the risk assessment of cardiovascular disease. Atomic force microscope is widely used to evaluate the physical properties including stiffness on a single-particle scale. In this study, the effect of low-density lipoprotein oxidation on the low-density lipoprotein stiffness was investigated using an atomic force microscope. Methods Isolated low-density lipoprotein particles with or without oxidation were densely bound to an Au substrate on mica, and then pressed and deformed by the atomic force microscope tip. The stiffness of each low-density lipoprotein particle was estimated as the elastic modulus obtained by the force curve analysis. Biochemical change of low-density lipoprotein due to oxidation was studied by electrophoresis. Results and conclusion The elastic modulus of low-density lipoprotein particles ranged between 0.1 and 2MPa. The oxidation of low-density lipoprotein increased the number of low-density lipoprotein particles with smaller elastic moduli, indicating the decrease in low-density lipoprotein stiffness. The elastic modulus of low-density lipoprotein might be potentially useful to evaluate low-density lipoprotein oxidation.	[Takeda, Seiji; Hui, Shu-Ping; Fuda, Hirotoshi; Shrestha, Rojeet; Chiba, Hitoshi] Hokkaido Univ, Fac Hlth Sci, Sapporo, Hokkaido 0600812, Japan; [Subagyo, Agus; Sueoka, Kazuhisa] Hokkaido Univ, Grad Sch Informat Sci & Technol, Sapporo, Hokkaido 0600812, Japan	Hui, SP (reprint author), Hokkaido Univ, Fac Hlth Sci, Sapporo, Hokkaido 0600812, Japan.	keino@hs.hokudai.ac.jp			JSPS KAKENHI [23590655]; Ministry of Education, Culture, Sports, Sciences and Technology, Japan	This work was supported by a JSPS Grant-in-Aid for Scientific Research (C) KAKENHI (23590655), and partly by the Regional Innovation Strategy Support Program, Sapporo Health Innovation "Smart-H", of the Ministry of Education, Culture, Sports, Sciences and Technology, Japan.	Dieluweit S, 2010, LANGMUIR, V26, P11041, DOI 10.1021/la1005242; Takeda S, 2013, IEEE SENS J, V13, P3449, DOI 10.1109/JSEN.2013.2265014; GONEN B, 1987, ATHEROSCLEROSIS, V65, P265, DOI 10.1016/0021-9150(87)90042-6; Chouinard JA, 2008, EXP CELL RES, V314, P3007, DOI 10.1016/j.yexcr.2008.07.020; Takeda S, 2013, J BIOMED NANOTECHNOL, V9, P303, DOI 10.1166/jbn.2013.1518; Hui SP, 2012, ANAL BIOANAL CHEM, V403, P1831, DOI 10.1007/s00216-012-5833-x; Itabe H, 1996, J LIPID RES, V37, P45; Kato Y, 1996, BIOCHEM BIOPH RES CO, V226, P923, DOI 10.1006/bbrc.1996.1451; Lu MX, 2012, J LIPID RES, V53, P2175, DOI 10.1194/jlr.M029629; Takeda S, 2012, SENSOR ACTUAT B-CHEM, V166, P833, DOI 10.1016/j.snb.2012.02.064; Nakajima K, 2006, CLIN CHIM ACTA, V367, P36, DOI 10.1016/j.cca.2005.12.013; Engel A, 2008, ANNU REV BIOCHEM, V77, P127, DOI 10.1146/annurev.biochem.77.062706.154450; Maciaszek JL, 2011, J STRAIN ANAL ENG, V46, P368, DOI 10.1177/0309324711398809; Sakurai T, 2013, ANN CLIN BIOCHEM, V50, P564, DOI 10.1177/0004563213481586; MALLE E, 1995, ARTERIOSCL THROM VAS, V15, P982; STOCKER R, 1991, P NATL ACAD SCI USA, V88, P1646, DOI 10.1073/pnas.88.5.1646; ARDLIE NG, 1989, ATHEROSCLEROSIS, V76, P117, DOI 10.1016/0021-9150(89)90094-4; Tanaka K, 1999, J BIOCHEM-TOKYO, V125, P173; RADMACHER M, 1994, BIOPHYS J, V66, P2159; Heu C, 2012, J STRUCT BIOL, V178, P1, DOI 10.1016/j.jsb.2012.02.007; Stefanutti C, 2001, CLIN SCI, V100, P191, DOI 10.1042/CS20000128; Kawai Y, 2004, BIOCHEM BIOPH RES CO, V313, P271, DOI 10.1016/j.bbrc.2003.11.123; Milne GL, 2005, J LIPID RES, V46, P307, DOI 10.1194/jlr.M400311-JLR200; Adamcik J, 2011, APPL PHYS LETT, V98, DOI 10.1063/1.3589369; Siitonen AM, 2008, APPL SURF SCI, V254, P7877, DOI 10.1016/j.apsusc.2008.03.009; Frankel EN, 2005, LIPID OXIDATION, P99; Frankel EN, 2005, LIPID OXIDATION, P25; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; OHTSUKI M, 1980, ULTRAMICROSCOPY, V5, P317, DOI 10.1016/0304-3991(80)90035-2; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; Oliveira CLP, 2014, BIOPHYS J, V102, P2595; Picas L, 2012, BIOPHYS J, V102, pL1, DOI 10.1016/j.bpj.2011.11.4001; Sneddon I.N., 1965, INT J ENG SCI, V3, P47, DOI DOI 10.1016/0020-7225(65)90019-4; Vance DE, 1996, BIOCH LIPIDS LIPOPRO, P473	34	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0004-5632	1758-1001		ANN CLIN BIOCHEM	Ann. Clin. Biochem.	NOV	2015	52	6					647	653		10.1177/0004563215584958		7	Medical Laboratory Technology	Medical Laboratory Technology	CU3JF	WOS:000363420100004		
J	Yamaguchi, K; Imai, K; Fujimoto, T; Takahashi, M; Maruyama, Y				Yamaguchi, Kazuaki; Imai, Keisuke; Fujimoto, Takuya; Takahashi, Makoto; Maruyama, Yoko			Cosmetic Comparison Between the Modified Uchida Method and the Mustarde Method for Blepharophimosis-Ptosis-Epicanthus Inversus Syndrome	ANNALS OF PLASTIC SURGERY			English	Article						blepharophimosis-ptosis-epicanthus inversus syndrome (BPES); Asian; Mustarde; modified Uchida	ASIAN EYELIDS; FOXL2	Purpose Blepharophimosis-ptosis-epicanthus inversus syndrome (BPES) is a rare, congenital, surgically challenging disease. We undertook an objective, functional, and cosmetic comparison between the modified Uchida procedure and the Mustarde procedure on Asian patients with BPES. Design This is a retrospective, comparative, interventional case series with the description of 2 surgical techniques. Participants Twenty consecutive Japanese patients with BPES were studied. Methods The patients were assigned to either the modified Uchida or the Mustarde procedure on the basis of preoperative intercanthal distance (ICD) ratio (ICD/palpebral fissure width). Intercanthal distance and margin reflex distance were measured from photographs before and after surgery. Classifications were made according to epicanthal fold score and cosmetic score using a visual analog scale (VAS). Main Outcome Measures The main outcome measures were postoperative improvement in ICD ratio and the VAS. Results Of the 20 patients, 5 underwent the modified Uchida procedure and the other 15 underwent the Mustarde procedure. The preoperative median ICD ratio was 2.0 (range, 1.9-2.5) and 2.5 (range, 2.0-3.4) for the modified Uchida and Mustarde procedures, respectively, and decreased to 1.5 (range, 1.5-1.7) and 1.6 (range, 1.5-1.8) postoperatively. The mean ICD reduction rate was 35.7% (SD, 1.0%) in the Mustarde group and 22.1% (SD, 1.3%) in the modified Uchida group (P < 0.001). The mean VAS for the modified Uchida and Mustarde procedures was 5.9 (SD, 1.3) and 2.8 (SD, 1.1), respectively, which was statistically significant (P = 0.0166). Conclusions Both the modified Uchida and Mustarde procedures could effectively shorten the ICD; however, cosmetic results were significantly superior using the modified Uchida method.	[Yamaguchi, Kazuaki; Imai, Keisuke; Fujimoto, Takuya; Takahashi, Makoto; Maruyama, Yoko] Osaka City Gen Hosp, Dept Plast & Reconstruct Surg, Osaka, Osaka 5340021, Japan	Yamaguchi, K (reprint author), Osaka City Gen Hosp, Dept Plast & Reconstruct Surg, Miyakojima Ku, 22-13-2 Miyakojimahondori, Osaka, Osaka 5340021, Japan.	kuru3641@gmail.com					ANDERSON RL, 1989, ARCH OPHTHALMOL-CHIC, V107, P448; Sebastia R, 2011, AESTHET PLAST SURG, V35, P820, DOI 10.1007/s00266-011-9702-3; Park DH, 2008, PLAST RECONSTR SURG, V121, P1405, DOI 10.1097/01.prs.0000304608.33432.67; Crisponi L, 2001, NAT GENET, V27, P159, DOI 10.1038/84781; Fujiwara T, 2006, PLAST RECONSTR SURG, V118, P635, DOI 10.1097/01.prs.0000232998.97479.91; Le TT, 2002, AESTHET PLAST SURG, V26, P64, DOI 10.1007/s00266-001-0033-7; Lee CK, 2013, CLIN PLAST SURG, V40, P167, DOI 10.1016/j.cps.2012.07.004; Wu SY, 2008, EYE, V22, P380, DOI 10.1038/sj.eye.6702644; De Baere E, 2001, HUM MOL GENET, V10, P1591, DOI 10.1093/hmg/10.15.1591; Taylor A, 2007, CLIN EXP OPHTHALMOL, V35, P262, DOI 10.1111/j.1442-9071.2006.01448.x; Quinn JV, 1998, ACAD EMERG MED, V5, P583; Batniji Rami K, 2010, Facial Plast Surg Clin North Am, V18, P19, DOI 10.1016/j.fsc.2009.11.015; JOHNSON CC, 1964, ARCH OPHTHALMOL-CHIC, V71, P510; Lee JR, 1999, J KOREAN SOC AESTHET, V5, P364; OLEY C, 1988, J MED GENET, V25, P47, DOI 10.1136/jmg.25.1.47; Park SG, 2007, J KOREAN SOC PLAST R, V34, P807; Uchida J, 1967, Keisei Geka, V10, P120; Vilray P, 1932, ARCH OPHTHALMOL-CHIC, V7, P831; ZLOTOGORA J, 1983, AM J HUM GENET, V35, P1020	19	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0148-7043	1536-3708		ANN PLAS SURG	Ann. Plast. Surg.	NOV	2015	75	5					518	521		10.1097/SAP.0000000000000198		4	Surgery	Surgery	CU1ZS	WOS:000363321600008		
J	Yamamoto, K; Asano, Y				Yamamoto, Kazunori; Asano, Yasuhisa			Efficient Production of Lumichrome by Microbacterium sp Strain TPU 3598	APPLIED AND ENVIRONMENTAL MICROBIOLOGY			English	Article							ACETIC-ACID; COMB. NOV; RIBOFLAVIN; PHOTOTAUTOMERISM; DERIVATIVES; ALLOXAZINES; METHYL	Lumichrome is a photodegradation product of riboflavin and is available as a photosensitizer and fluorescent dye. To develop new efficient methods of lumichrome production, we isolated bacterial strains with high lumichrome productivity from soil. The strain with highest productivity was identified as Microbacterium sp. strain TPU 3598. Since this strain inductively produced lumichrome when cultivated with riboflavin, we developed two different methods, a cultivation method and a resting cell method, for the production of large amounts of lumichrome using the strain. In the cultivation method, 2.4 g (9.9 mmol) of lumichrome was produced from 3.8 g (10.1 mmol) of riboflavin at the 500-ml scale (98% yield). The strain also produced 4.7 g (19.4 mmol) of lumichrome from 7.6 g (20.2 mmol) of riboflavin (96% yield) by addition of riboflavin during cultivation at the 500-ml scale. In the resting cell method, 20 g of cells (wet weight) in 100 ml of potassium phosphate buffer, pH 7.0, produced 2.4 g of lumichrome from 3.8 g of riboflavin (98% yield). Since the lumichrome production by these methods was carried out in suspension, the resulting lumichrome was easily purified from the cultivation medium or reaction mixture by centrifugation and crystallization. Thus, the biochemical methods we describe here are a significant improvement in terms of simplicity and yield over the existing chemical, photolytic, and other biochemical methods of lumichrome production.	[Asano, Yasuhisa] Toyama Prefectural Univ, Biotechnol Res Ctr, Imizu, Toyama, Japan; Toyama Prefectural Univ, Dept Biotechnol, Imizu, Toyama, Japan; JST, ERATO, Asano Active Enzyme Mol Project, Imizu, Toyama, Japan	Asano, Y (reprint author), Toyama Prefectural Univ, Biotechnol Res Ctr, Imizu, Toyama, Japan.	asano@pu-toyama.ac.jp			Exploratory Research for Advanced Technology (ERATO) program of the Japan Science and Technology Agency (JST)	This work was supported by the Exploratory Research for Advanced Technology (ERATO) program of the Japan Science and Technology Agency (JST).	SENG F, 1972, ANGEW CHEM INT EDIT, V11, P1010, DOI 10.1002/anie.197210101; Takeuchi M, 1998, INT J SYST BACTERIOL, V48, P973; Schumann P, 1999, INT J SYST BACTERIOL, V49, P175; Sikorska E, 2004, J PHYS CHEM A, V108, P1501, DOI 10.1021/jp037048u; Koziolowa A, 1996, J PHOTOCH PHOTOBIO A, V93, P157, DOI 10.1016/1010-6030(95)04198-2; Ahmad I, 2004, J PHOTOCH PHOTOBIO B, V75, P13, DOI 10.1016/j.jphotobiol.2004.04.001; Huang R, 2006, J AGR FOOD CHEM, V54, P2359, DOI 10.1021/jf05248v; Massey V, 2000, BIOCHEM SOC T, V28, P283, DOI 10.1042/0300-5127:0280283; Sikorska E, 1996, J PHOTOCH PHOTOBIO A, V95, P215, DOI 10.1016/1010-6030(95)04258-X; Rajamani S, 2008, MOL PLANT MICROBE IN, V21, P1184, DOI 10.1094/MPMI-21-9-1184; YANAGITA T, 1956, J BIOL CHEM, V221, P593; Kino K, 2009, BIOORG MED CHEM LETT, V19, P2070, DOI 10.1016/j.bmcl.2009.01.112; Bairi P, 2014, SENSOR ACTUAT B-CHEM, V193, P349, DOI 10.1016/j.snb.2013.11.119; KOZIOLOWA A, 1979, PHOTOCHEM PHOTOBIOL, V29, P459, DOI 10.1111/j.1751-1097.1979.tb07076.x; Miskolczy Z, 2005, CHEM PHYS LETT, V411, P238, DOI 10.1016/j.cplett.2005.06.049; Prukala D, 2012, J PHYS CHEM A, V116, P7474, DOI 10.1021/jp300522h; Coffman ER, 1996, J PHARM SCI, V85, P951; Foster WE, 1992, US patent, Patent No. [5,120,655, 5120655]; Foster WJ, 1944, J BACTERIOL, V47, P27; Goodrich PR Jr, 2006, US patent, Patent No. [7,094,378, 7094378]; HAMADA K, 1956, J Vitaminol (Kyoto), V2, P307; Laser N, 1977, PHOTOCHEM PHOTOBIOL, V25, P451, DOI 10.1111/j.1751-1097.1977.tb09170.x; Platz SM, 2004, US patent, Patent No. [6,828,323, 6828323]; Remucal KC, 2011, ENVIRON SCI TECHNOL, V45, P5223; Suzuki TA, 1979, J CHROMATOGR A, V169, P459; Yang SC, 1967, BIOCHIM BIOPHYS ACTA, V132, P511; Yukawa M, 2011, US patent, Patent No. [7,935,957, 7935957]	27	0	0	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	0099-2240	1098-5336		APPL ENVIRON MICROB	Appl. Environ. Microbiol.	NOV	2015	81	21					7360	7367		10.1128/AEM.02166-15		8	Biotechnology & Applied Microbiology; Microbiology	Biotechnology & Applied Microbiology; Microbiology	CU3YP	WOS:000363462900002		
J	Hida, A; Oku, S; Kawasaki, T; Nakashimada, Y; Tajima, T; Kato, J				Hida, Akiko; Oku, Shota; Kawasaki, Takeru; Nakashimada, Yutaka; Tajima, Takahisa; Kato, Junichi			Identification of the mcpA and mcpM Genes, Encoding Methyl-Accepting Proteins Involved in Amino Acid and L-Malate Chemotaxis, and Involvement of McpM-Mediated Chemotaxis in Plant Infection by Ralstonia pseudosolanacearum (Formerly Ralstonia solanacearum Phylotypes I and III)	APPLIED AND ENVIRONMENTAL MICROBIOLOGY			English	Article							TOMATO ROOT COLONIZATION; PSEUDOMONAS-AERUGINOSA; ORGANIC-ACIDS; SENSORY PROTEINS; FLUORESCENS; CHEMORECEPTORS; PHOSPHATE; TRANSDUCERS; COMPONENTS; PLASMIDS	Sequence analysis has revealed the presence of 22 putative methyl-accepting chemotaxis protein (mcp) genes in the Ralstonia pseudosolanacearum GMI1000 genome. PCR analysis and DNA sequencing showed that the highly motile R. pseudosolanacearum strain Ps29 possesses homologs of all 22 R. pseudosolanacearum GMI1000 mcp genes. We constructed a complete collection of single mcp gene deletion mutants of R. pseudosolanacearum Ps29 by unmarked gene deletion. Screening of the mutant collection revealed that R. pseudosolanacearum Ps29 mutants of RSp0507 and RSc0606 homologs were defective in chemotaxis to L-malate and amino acids, respectively. RSp0507 and RSc0606 homologs were designated mcpM and mcpA. While wild-type R. pseudosolanacearum strain Ps29 displayed attraction to 16 amino acids, the mcpA mutant showed no response to 12 of these amino acids and decreased responses to 4 amino acids. We constructed mcpA and mcpM deletion mutants of highly virulent R. pseudosolanacearum strain MAFF106611 to investigate the contribution of chemotaxis to L-malate and amino acids to tomato plant infection. Neither single mutant exhibited altered virulence for tomato plants when tested by root dip inoculation assays. In contrast, the mcpM mutant (but not the mcpA mutant) was significantly less infectious than the wild type when tested by a sand soak inoculation assay, which requires bacteria to locate and invade host roots from sand. Thus, McpM-mediated chemotaxis, possibly reflecting chemotaxis to L-malate, facilitates R. pseudosolanacearum motility to tomato roots in sand.	[Hida, Akiko; Oku, Shota; Kawasaki, Takeru; Nakashimada, Yutaka; Tajima, Takahisa; Kato, Junichi] Hiroshima Univ, Grad Sch Adv Sci Matter, Dept Mol Biotechnol, Hiroshima, Japan	Kato, J (reprint author), Hiroshima Univ, Grad Sch Adv Sci Matter, Dept Mol Biotechnol, Hiroshima, Japan.	jun@hiroshima-u.ac.jp			Program for Promotion of Basic and Applied Researches for Innovations in Bio-Oriented Industry of the Bio-Oriented Technology Research Advancement Institution (BRAIN), Japan; Science and Technology Research Promotion Program for Agriculture, Forestry, Fisheries and Food Industry of the Ministry of Agriculture, Forestry and Fisheries of Japan; Japan Society for Promotion of Science (JSPS) [15H04478]; JSPS KAKENHI [15J05572]	J.K. was supported by the Program for Promotion of Basic and Applied Researches for Innovations in Bio-Oriented Industry of the Bio-Oriented Technology Research Advancement Institution (BRAIN), Japan; the Science and Technology Research Promotion Program for Agriculture, Forestry, Fisheries and Food Industry of the Ministry of Agriculture, Forestry and Fisheries of Japan; and grant-in-aid for scientific research (B) 15H04478 from the Japan Society for Promotion of Science (JSPS). A.H. was supported by JSPS KAKENHI grant number 15J05572.	MOULTON RC, 1979, J BACTERIOL, V137, P274; KURODA A, 1995, J BACTERIOL, V177, P7019; MOENCH TT, 1978, J BACTERIOL, V133, P427; KATO J, 1992, J BACTERIOL, V174, P5149; Monteiro F, 2012, MOL PLANT MICROBE IN, V25, P557, DOI 10.1094/MPMI-07-11-0201; Yao J, 2006, J BACTERIOL, V188, P3697, DOI 10.1128/JB.188.10-3697-3708.2006; Wu H, 2000, J BACTERIOL, V182, P3400, DOI 10.1128/JB.182.12.3400-3404.2000; HOFFLAND E, 1989, PLANT SOIL, V113, P161, DOI 10.1007/BF02280176; Oku S, 2012, MICROBES ENVIRON, V27, P462, DOI 10.1264/jsme2.ME12005; SCHAFER A, 1994, GENE, V145, P69, DOI 10.1016/0378-1119(94)90324-7; Safni I, 2014, INT J SYST EVOL MICR, V64, P3087, DOI 10.1099/ijs.0.066712-0; Zhang Z, 2010, J MOL BIOL, V400, P335, DOI 10.1016/j.jmb.2010.04.049; Fegan M, 2006, AUSTRALAS PLANT PATH, V35, P93, DOI 10.1071/AP05105; Ortega A, 2014, PROTEIN SCI, V23, P332, DOI 10.1002/pro.2410; Kamilova F, 2006, MOL PLANT MICROBE IN, V19, P250, DOI 10.1094/MPMI-19-0250; Ulrich LE, 2005, BIOINFORMATICS, V21, P45, DOI 10.1093/bioinformatics/bti1204; Miller LD, 2007, MOL MICROBIOL, V63, P348, DOI 10.1111/j.1365-2958.2006.05515.x; Porter SL, 2011, NAT REV MICROBIOL, V9, P153, DOI 10.1038/nrmicro2505; Falke JJ, 2001, TRENDS BIOCHEM SCI, V26, P257, DOI 10.1016/S0968-0004(00)01770-9; Kelley LA, 2015, NAT PROTOC, V10, P845, DOI 10.1038/nprot.2015.053; de Weert S, 2002, MOL PLANT MICROBE IN, V15, P1173, DOI 10.1094/MPMI.2002.15.11.1173; Yamada T, 2007, MICROBIOL-SGM, V153, P2630, DOI 10.1099/mic.0.2006/001453-0; SCHWEIZER HP, 1991, GENE, V97, P109, DOI 10.1016/0378-1119(91)90016-5; Simons M, 1997, MOL PLANT MICROBE IN, V10, P102, DOI 10.1094/MPMI.1997.10.1.102; Lacal J, 2010, ENVIRON MICROBIOL, V12, P2873, DOI 10.1111/j.1462-2920.2010.02325.x; NIKATA T, 1992, APPL ENVIRON MICROB, V58, P2250; Anantharaman V, 2000, TRENDS BIOCHEM SCI, V25, P535, DOI 10.1016/S0968-0004(00)01672-8; Taguchi K, 1997, MICROBIOL-UK, V143, P3223; HAYWARD AC, 1991, ANNU REV PHYTOPATHOL, V29, P65, DOI 10.1146/annurev.py.29.090191.000433; HENDRICK CA, 1984, APPL ENVIRON MICROB, V48, P94; Reyes-Darias JA, 2015, MOL MICROBIOL, V96, P513, DOI 10.1111/mmi.12953; ADLER J, 1966, SCIENCE, V153, P708, DOI 10.1126/science.153.3737.708; Parales RE, 2013, MICROBIOL-SGM, V159, P1086, DOI 10.1099/mic.0.065698-0; Alvarez-Ortega C, 2007, APPL ENVIRON MICROB, V73, P7793, DOI 10.1128/AEM.01898-07; CHET I, 1976, ANNU REV MICROBIOL, V30, P221, DOI 10.1146/annurev.mi.30.100176.001253; Genin S, 2010, NEW PHYTOL, V187, P920, DOI 10.1111/j.1469-8137.2010.03397.x; STEWART RC, 1987, CHEM REV, V87, P997, DOI 10.1021/cr00081a007; GILLINGS MR, 1994, BACTERIAL WILT, P95; Guidot A, 2007, J BACTERIOL, V189, P377, DOI 10.1128/JB.00999-06; Hayward AC, 2000, ENCY MICROBIOLOGY, V4, P32; Lefeuvre P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063155; Lacal J, 2010, J BIOL CHEM, V285, P23124, DOI 10.1074/jbc.M110.110403; Oku S, 2014, MICROBES ENVIRON, V29, P413, DOI 10.1264/jsme2.ME14128; SAMBROOK J, 1989, MOL CLONING LAB MANU; Simon R, 1983, NAT BIOTECHNOL, V1, P784, DOI DOI 10.1038/NBT1183-784; Stock JB, 1996, ESCHERICHIA COLI SAL, P1103; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; Yao J, 2007, J BACTERIOL, V189, P6415, DOI 10.1128/JB.00398-07	48	0	0	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	0099-2240	1098-5336		APPL ENVIRON MICROB	Appl. Environ. Microbiol.	NOV	2015	81	21					7420	7430		10.1128/AEM.01870-15		11	Biotechnology & Applied Microbiology; Microbiology	Biotechnology & Applied Microbiology; Microbiology	CU3YP	WOS:000363462900009		
J	Kobayashi, J; Tanabiki, M; Doi, S; Kondo, A; Ohshiro, T; Suzuki, H				Kobayashi, Jyumpei; Tanabiki, Misaki; Doi, Shohei; Kondo, Akihiko; Ohshiro, Takashi; Suzuki, Hirokazu			Unique Plasmids Generated via pUC Replicon Mutagenesis in an Error-Prone Thermophile Derived from Geobacillus kaustophilus HTA426	APPLIED AND ENVIRONMENTAL MICROBIOLOGY			English	Article							ACETYLTRANSFERASE CAT GENE; MEGATERIUM QM B1551; COPY-NUMBER MUTANT; DEEPEST SEA MUD; ESCHERICHIA-COLI; CHLORAMPHENICOL ACETYLTRANSFERASE; PRIMER FORMATION; BACILLUS-STEAROTHERMOPHILUS; SHUTTLE VECTOR; ROM PROTEIN	The plasmid pGKE75-cat(A138T), which comprises pUC18 and the cat(A138T) gene encoding thermostable chloramphenicol acetyltransferase with an A138T amino acid replacement (CAT(A138T)), serves as an Escherichia coli-Geobacillus kaustophilus shuttle plasmid that confers moderate chloramphenicol resistance on G. kaustophilus HTA426. The present study examined the thermoadaptation-directed mutagenesis of pGKE75-cat(A138T) in an error-prone thermophile, generating the mutant plasmid pGKE75(alpha beta)-cat(A138T) responsible for substantial chloramphenicol resistance at 65 degrees C. pGKE75(alpha beta)-cat(A138T) contained no mutation in the cat(A138T) gene but had two mutations in the pUC replicon, even though the replicon has no apparent role in G. kaustophilus. Biochemical characterization suggested that the efficient chloramphenicol resistance conferred by pGKE75(alpha beta)-cat(A138T) is attributable to increases in intracellular CAT(A138T) and acetyl-coenzyme A following a decrease in incomplete forms of pGKE75(alpha beta)-cat(A138)T. The decrease in incomplete plasmids may be due to optimization of plasmid replication by RNA species transcribed from the mutant pUC replicon, which were actually produced in G. kaustophilus. It is noteworthy that G. kaustophilus was transformed with pGKE75(alpha beta)-cat(A138T) using chloramphenicol selection at 60 degrees C. In addition, a pUC18 derivative with the two mutations propagated in E. coli at a high copy number independently of the culture temperature and high plasmid stability. Since these properties have not been observed in known plasmids, the outcomes extend the genetic toolboxes for G. kaustophilus and E. coli.	[Tanabiki, Misaki; Ohshiro, Takashi; Suzuki, Hirokazu] Tottori Univ, Grad Sch Engn, Dept Chem & Biotechnol, Tottori 680, Japan; [Kobayashi, Jyumpei; Suzuki, Hirokazu] Kyushu Univ, Fac Agr, Grad Sch, Funct Genom Extremophiles, Fukuoka 812, Japan; [Doi, Shohei] Tottori Univ, Fac Engn, Dept Biotechnol, Tottori 680, Japan; [Kondo, Akihiko] Kobe Univ, Dept Chem Sci & Engn, Grad Sch Engn, Kobe, Hyogo 657, Japan	Suzuki, H (reprint author), Tottori Univ, Grad Sch Engn, Dept Chem & Biotechnol, Tottori 680, Japan.	hirokap@xpost.plala.or.jp			Programme for Promotion of Basic and Applied Researches for Innovations in Bio-oriented Industry, Japan; Science and Technology Research Promotion Program for Agriculture, Forestry, Fisheries and Food Industry, Japan; JSPS KAKENHI [25450105]; Institute for Fermentation, Osaka, Japan	This work was supported by the following organizations: Programme for Promotion of Basic and Applied Researches for Innovations in Bio-oriented Industry, Japan; the Science and Technology Research Promotion Program for Agriculture, Forestry, Fisheries and Food Industry, Japan; JSPS KAKENHI (grant number 25450105); and the Institute for Fermentation, Osaka, Japan.	HELLING RB, 1981, J GEN MICROBIOL, V123, P129; FIGURSKI DH, 1979, P NATL ACAD SCI USA, V76, P1648, DOI 10.1073/pnas.76.4.1648; TOMIZAWA J, 1984, CELL, V38, P871, DOI 10.1016/0092-8674(84)90282-4; BENNETT PM, 1977, MOL GEN GENET, V154, P205, DOI 10.1007/BF00330839; Suzuki H, 2013, BIOSCI BIOTECH BIOCH, V77, P2316, DOI 10.1271/bbb.1304921; SHAW WV, 1968, J BACTERIOL, V95, P28; WONG EM, 1982, P NATL ACAD SCI-BIOL, V79, P3570, DOI 10.1073/pnas.79.11.3570; Taylor MP, 2008, PLASMID, V60, P45, DOI 10.1016/j.plasmid.2008.04.001; NARUMI I, 1993, BIOTECHNOL LETT, V15, P815; LUPSKI JR, 1986, P NATL ACAD SCI USA, V83, P7381, DOI 10.1073/pnas.83.19.7381; ITOH T, 1980, P NATL ACAD SCI-BIOL, V77, P2450, DOI 10.1073/pnas.77.5.2450; MASUKATA H, 1986, CELL, V44, P125, DOI 10.1016/0092-8674(86)90491-5; Takami H, 2004, EXTREMOPHILES, V8, P351, DOI 10.1007/s00792-004-0394-3; LIAO H, 1986, P NATL ACAD SCI USA, V83, P576, DOI 10.1073/pnas.83.3.576; Takami H, 2004, NUCLEIC ACIDS RES, V32, P6292, DOI 10.1093/nar/gkh970; Kunnimalaiyaan M, 2005, APPL ENVIRON MICROB, V71, P3068, DOI 10.1128/AEM.71.6.3068-3076.2005; Takami H, 1997, FEMS MICROBIOL LETT, V152, P279, DOI 10.1016/S0378-1097(97)00211-5; CESARENI G, 1984, EMBO J, V3, P1365; MANKIN AS, 1991, J BACTERIOL, V173, P3559; Stevenson DM, 1998, PLASMID, V40, P175, DOI 10.1006/plas.1998.1359; IMANAKA T, 1982, J BACTERIOL, V149, P824; TOMIZAWA J, 1981, P NATL ACAD SCI-BIOL, V78, P1421, DOI 10.1073/pnas.78.3.1421; Kobayashi J, 2015, APPL MICROBIOL BIOT, V99, P5563, DOI 10.1007/s00253-015-6522-4; Ow DSW, 2006, ENZYME MICROB TECH, V39, P391, DOI 10.1016/j.enzmictec.2005.11.048; EGUCHI Y, 1990, CELL, V60, P199, DOI 10.1016/0092-8674(90)90736-X; WU LJ, 1989, J GEN MICROBIOL, V135, P1315; Shimizu E, 2008, J AGR FOOD CHEM, V56, P5521, DOI 10.1021/jf073348n; Suzuki H, 2012, APPL ENVIRON MICROB, V78, P7376, DOI 10.1128/AEM.01669-12; GELFAND DH, 1978, P NATL ACAD SCI USA, V75, P5869, DOI 10.1073/pnas.75.12.5869; Lin-Chao S, 1992, MOL MICROBIOL, V6, P3385, DOI 10.1111/j.1365-2958.1992.tb02206.x; Potrykus J, 2003, ARCH MICROBIOL, V180, P362, DOI 10.1007/s00203-003-0592-x; Jones KL, 2000, METAB ENG, V2, P328, DOI 10.1006/mben.2000.0161; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; TAJIRI T, 1995, MUTAT RES-DNA REPAIR, V336, P257, DOI 10.1016/0921-8777(94)00062-B; Dwyer DJ, 2009, CURR OPIN MICROBIOL, V12, P482, DOI 10.1016/j.mib.2009.06.018; ANDERSON AJ, 1990, MICROBIOL REV, V54, P450; TOMIZAWA J, 1990, J MOL BIOL, V212, P695, DOI 10.1016/0022-2836(90)90231-A; Suzuki H, 2012, J MICROBIOL BIOTECHN, V22, P1279, DOI 10.4014/jmb.1203.03023; Suzuki H, 2013, APPL ENVIRON MICROB, V79, P5151, DOI 10.1128/AEM.01506-13; TOMIZAWA J, 1986, CELL, V47, P89, DOI 10.1016/0092-8674(86)90369-7; MCMURRY LM, 1994, ANTIMICROB AGENTS CH, V38, P542; Potrykus J, 2001, ANTIMICROB AGENTS CH, V45, P3610, DOI 10.1128/AAC.45.12.3610-3612.2001; SEO J-H, 1985, Biotechnology and Bioengineering, V27, P1668, DOI 10.1002/bit.260271207; Suzuki H, 2015, APPL ENVIRON MICROB, V81, P149, DOI 10.1128/AEM.02577-14	44	0	0	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	0099-2240	1098-5336		APPL ENVIRON MICROB	Appl. Environ. Microbiol.	NOV	2015	81	21					7625	7632		10.1128/AEM.01574-15		8	Biotechnology & Applied Microbiology; Microbiology	Biotechnology & Applied Microbiology; Microbiology	CU3YP	WOS:000363462900029		
J	Kasai, D; Araki, N; Motoi, K; Yoshikawa, S; Iino, T; Imai, S; Masai, E; Fukuda, M				Kasai, Daisuke; Araki, Naoto; Motoi, Kota; Yoshikawa, Shota; Iino, Toju; Imai, Shunsuke; Masai, Eiji; Fukuda, Masao			gamma-Resorcylate Catabolic-Pathway Genes in the Soil Actinomycete Rhodococcus jostii RHA1	APPLIED AND ENVIRONMENTAL MICROBIOLOGY			English	Article							SP STRAIN RHA1; PROTOCATECHUATE 4,5-CLEAVAGE PATHWAY; EPSILON-SEMIALDEHYDE DECARBOXYLASE; PSEUDOMONAS-PUTIDA; 2-AMINO-3-CARBOXYMUCONATE-6-SEMIALDEHYDE DECARBOXYLASE; HYDROXYQUINOL 1,2-DIOXYGENASE; CORYNEBACTERIUM-GLUTAMICUM; MALEYLACETATE REDUCTASE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI	The Rhodococcus jostii RHA1 gene cluster required for gamma-resorcylate (GRA) catabolism was characterized. The cluster includes tsdA, tsdB, tsdC, tsdD, tsdR, tsdT, and tsdX, which encode GRA decarboxylase, resorcinol 4-hydroxylase, hydroxyquinol 1,2-dioxygenase, maleylacetate reductase, an IclR-type regulator, a major facilitator superfamily transporter, and a putative hydrolase, respectively. The tsdA gene conferred GRA decarboxylase activity on Escherichia coli. Purified TsdB oxidized NADH in the presence of resorcinol, suggesting that tsdB encodes a unique NADH-specific single-component resorcinol 4-hydroxylase. Mutations in either tsdA or tsdB resulted in growth deficiency on GRA. The tsdC and tsdD genes conferred hydroxyquinol 1,2-dioxygenase and maleylacetate reductase activities, respectively, on E. coli. Inactivation of tsdT significantly retarded the growth of RHA1 on GRA. The growth retardation was partially suppressed under acidic conditions, suggesting the involvement of tsdT in GRA uptake. Reverse transcription-PCR analysis revealed that the tsd genes constitute three transcriptional units, the tsdBADC and tsdTX operons and tsdR. Transcription of the tsdBADC and tsdTX operons was induced during growth on GRA. Inactivation of tsdR derepressed transcription of the tsdBADC and tsdTX operons in the absence of GRA, suggesting that tsd gene transcription is negatively regulated by the tsdR-encoded regulator. Binding of TsdR to the tsdR-tsdB and tsdT-tsdR intergenic regions was inhibited by the addition of GRA, indicating that GRA interacts with TsdR as an effector molecule.	[Kasai, Daisuke; Araki, Naoto; Motoi, Kota; Yoshikawa, Shota; Iino, Toju; Imai, Shunsuke; Masai, Eiji; Fukuda, Masao] Nagaoka Univ Technol, Dept Bioengn, Nagaoka, Niigata 94021, Japan	Fukuda, M (reprint author), Nagaoka Univ Technol, Dept Bioengn, Nagaoka, Niigata 94021, Japan.	masao@vos.nagaokaut.ac.jp			Japan Society for the Promotion of Science (JSPS) [24780068]	This work was supported in part by Grant-in-Aid for Young Scientists (B) 24780068 from the Japan Society for the Promotion of Science (JSPS).	Vesely M, 2007, APPL MICROBIOL BIOT, V76, P159, DOI 10.1007/s00253-007-0997-6; RUSCHIG H, 1973, ARZNEIMITTEL-FORSCH, V23, P1745; Ishii Y, 2004, BIOCHEM BIOPH RES CO, V324, P611, DOI 10.1016/j.bbrc.2004.09.091; Navarro I, 2009, J ORG CHEM, V74, P8139, DOI 10.1021/jo9015858; Guo Z, 1999, MOL MICROBIOL, V32, P253, DOI 10.1046/j.1365-2958.1999.01342.x; DIMARCO AA, 1994, J BACTERIOL, V176, P4277; SCHAFER A, 1994, GENE, V145, P69, DOI 10.1016/0378-1119(94)90324-7; Armengaud J, 1999, J BACTERIOL, V181, P3452; Fukuhara Y, 2010, APPL ENVIRON MICROB, V76, P519, DOI 10.1128/AEM.01270-09; Daubaras DL, 1996, APPL ENVIRON MICROB, V62, P4276; Yoshida M, 2007, J BACTERIOL, V189, P1573, DOI 10.1128/JB.01675-06; Xu Y, 2012, APPL ENVIRON MICROB, V78, P6113, DOI 10.1128/AEM.01511-12; Pieper DH, 2002, J BACTERIOL, V184, P1466, DOI 10.1128/JB.184.5.1466-1470.2002; Collier LS, 1997, J BACTERIOL, V179, P5943; Ditty JL, 2002, J BACTERIOL, V184, P1444, DOI 10.1128/JB.184.5.1444-1448.2002; CHAPMAN PJ, 1976, J BACTERIOL, V125, P985; Sharp JO, 2007, APPL ENVIRON MICROB, V73, P6930, DOI 10.1128/AEM.01697-07; Araki N, 2011, J MOL MICROB BIOTECH, V20, P125, DOI 10.1159/000324330; Molina-Henares AJ, 2006, FEMS MICROBIOL REV, V30, P157, DOI 10.1111/j.1574-6976.2005.00008.x; Yamamoto K, 2011, J BIOSCI BIOENG, V111, P687, DOI 10.1016/j.jbiosc.2011.01.016; Masai E, 2000, J BACTERIOL, V182, P6651, DOI 10.1128/JB.182.23.6651-6658.2000; Ferraroni M, 2005, J BIOL CHEM, V280, P21144, DOI 10.1074/jbc.M500666200; Matsui T, 2006, APPL MICROBIOL BIOT, V73, P95, DOI 10.1007/s00253-006-0437-z; ARMSTRONG SM, 1993, J BASIC MICROB, V33, P75, DOI 10.1002/jobm.3620330202; SEIBERT V, 1993, J BACTERIOL, V175, P6745; Yoshida M, 2004, J BACTERIOL, V186, P6855, DOI 10.1128/JB.186.20.6855-6863.2004; Ditty JL, 1999, J BACTERIOL, V181, P5068; SETO M, 1995, APPL ENVIRON MICROB, V61, P3353; Huang Y, 2006, APPL ENVIRON MICROB, V72, P7238, DOI 10.1128/AEM.01494-06; Kasai D, 2009, J BACTERIOL, V191, P6758, DOI 10.1128/JB.00840-09; van der Geize R, 2001, FEMS MICROBIOL LETT, V205, P197, DOI 10.1016/S0378-1097(01)00464-5; Fukuoka SI, 2002, J BIOL CHEM, V277, P35162, DOI 10.1074/jbc.M200819200; Kitagawa W, 2001, J BACTERIOL, V183, P6598, DOI 10.1128/JB.183.22.6598-6606.2001; Tanabe A, 2002, BIOCHEM J, V361, P567, DOI 10.1042/0264-6021:3610567; SETO M, 1995, APPL ENVIRON MICROB, V61, P4510; Muraki T, 2003, APPL ENVIRON MICROB, V69, P1564, DOI 10.1128/AEM.69.3.1564-1572.2003; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; Liu AM, 2006, BIOCHEMISTRY-US, V45, P10407, DOI 10.1021/bi061031v; MASAI E, 1995, APPL ENVIRON MICROB, V61, P2079; Kamimura N, 2010, J BACTERIOL, V192, P3394, DOI 10.1128/JB.00215-10; Berrow NS, 2007, NUCLEIC ACIDS RES, V35, pE45, DOI 10.1093/nar/gkm047; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Martynowski D, 2006, BIOCHEMISTRY-US, V45, P10412, DOI 10.1021/bi060903q; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Zhou H, 2008, P NATL ACAD SCI USA, V105, P6249, DOI 10.1073/pnas.0800657105	46	0	0	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	0099-2240	1098-5336		APPL ENVIRON MICROB	Appl. Environ. Microbiol.	NOV	2015	81	21					7656	7665		10.1128/AEM.02422-15		10	Biotechnology & Applied Microbiology; Microbiology	Biotechnology & Applied Microbiology; Microbiology	CU3YP	WOS:000363462900032		
J	Sato'o, Y; Hisatsune, J; Nagasako, Y; Ono, HK; Omoe, K; Sugai, M				Sato'o, Yusuke; Hisatsune, Junzo; Nagasako, Yuria; Ono, Hisaya K.; Omoe, Katsuhiko; Sugai, Motoyuki			Positive Regulation of Staphylococcal Enterotoxin H by Rot (Repressor of Toxin) Protein and Its Importance in Clonal Complex 81 Subtype 1 Lineage-Related Food Poisoning	APPLIED AND ENVIRONMENTAL MICROBIOLOGY			English	Article							VIRULENCE DETERMINANTS; COMPREHENSIVE ANALYSIS; AUREUS; EXPRESSION; OUTBREAK; IDENTIFICATION; AGR; STRAINS; GENES; JAPAN	We previously demonstrated the clonal complex 81 (CC81) subtype 1 lineage is the major staphylococcal food poisoning (SFP)-associated lineage in Japan (Y. Sato'o et al., J Clin Microbiol 52:2637-2640, 2014, http://dx.doi.org/10.1128/JCM.00661-14). Strains of this lineage produce staphylococcal enterotoxin H (SEH) in addition to SEA. However, an evaluation of the risk for the recently reported SEH has not been sufficiently conducted. We first searched for staphylococcal enterotoxin (SE) genes and SE proteins in milk samples that caused a large SFP outbreak in Japan. Only SEA and SEH were detected, while there were several SE genes detected in the samples. We next designed an experimental model using a meat product to assess the productivity of SEs and found that only SEA and SEH were detectably produced in situ. Therefore, we investigated the regulation of SEH production using a CC81 subtype 1 isolate. Through mutant analysis of global regulators, we found the repressor of toxin (Rot) functioned oppositely as a stimulator of SEH production. SEA production was not affected by Rot. seh mRNA expression correlated with rot both in media and on the meat product, and the Rot protein was shown to directly bind to the seh promoter. The seh promoter sequence was predicted to form a loop structure and to hide the RNA polymerase binding sequences. We propose Rot binds to the promoter sequence of seh and unfolds the secondary structure that may lead the RNA polymerase to bind the promoter, and then seh mRNA transcription begins. This alternative Rot regulation for SEH may contribute to sufficient toxin production by the CC81 subtype 1 lineage in foods to induce SFP.	[Sato'o, Yusuke; Hisatsune, Junzo; Sugai, Motoyuki] Hiroshima Univ, Dept Bacteriol, Grad Sch Biomed & Hlth Sci, Hiroshima, Hiroshima, Japan; [Sato'o, Yusuke; Omoe, Katsuhiko] Gifu Univ, United Grad Sch Vet Sci, Gifu, Gifu, Japan; [Sato'o, Yusuke; Nagasako, Yuria; Omoe, Katsuhiko] Iwate Univ, Fac Agr, Dept Vet Med, Morioka, Iwate 020, Japan; [Ono, Hisaya K.] Hirosaki Univ, Grad Sch Med, Dept Microbiol & Immunol, Hirosaki, Aomori, Japan	Sugai, M (reprint author), Hiroshima Univ, Dept Bacteriol, Grad Sch Biomed & Hlth Sci, Hiroshima, Hiroshima, Japan.	sugai@hiroshima-u.ac.jp					Cheung AL, 2008, INT J BIOCHEM CELL B, V40, P355, DOI 10.1016/j.biocel.2007.10.032; Sato'o Y, 2014, J CLIN MICROBIOL, V52, P2637, DOI 10.1128/JCM.00661-14; Sato'o Y, 2013, MICROBIOL IMMUNOL, V57, P91, DOI 10.1111/1348-0421.12007; KADAN RS, 1963, APPL MICROBIOL, V11, P45; FREA JI, 1963, J BACTERIOL, V86, P1308; Omoe K, 2005, FEMS MICROBIOL LETT, V246, P191, DOI 10.1016/j.femsle.2005.04.007; Omoe K, 2002, J CLIN MICROBIOL, V40, P857, DOI 10.1128/JCM.40.3.857-862.2002; Baba T, 2002, LANCET, V359, P1819, DOI 10.1016/S0140-6736(02)08713-5; Li DM, 2008, INFECT IMMUN, V76, P1068, DOI 10.1128/IAI.01069-07; Benson MA, 2012, J BACTERIOL, V194, P4355, DOI 10.1128/JB.00706-12; Omoe K, 2013, INFECT IMMUN, V81, P3627, DOI 10.1128/IAI.00550-13; Jorgensen HJ, 2005, FEMS MICROBIOL LETT, V252, P267, DOI 10.1016/j.femsle.2005.09.005; Fetsch A, 2014, INT J FOOD MICROBIOL, V187, P1, DOI 10.1016/j.ijfoodmicro.2014.06.017; Said-Salim B, 2003, J BACTERIOL, V185, P610, DOI 10.1128/JB.185.2.610-619.2003; Tseng CW, 2005, J BACTERIOL, V187, P5301, DOI 10.1128/JB.187.15.5301-5309.2005; Traber K, 2006, MOL MICROBIOL, V59, P1519, DOI 10.1111/j.1365-2958.2005.04986.x; Cha JO, 2006, J APPL MICROBIOL, V101, P864, DOI 10.1111/j.1365-2672.2006.02957.x; Kerouanton A, 2007, INT J FOOD MICROBIOL, V115, P369, DOI 10.1016/j.ijfoodmicro.2006.10.050; BERGDOLL MS, 1988, METHOD ENZYMOL, V165, P324, DOI 10.1016/S0076-6879(88)65048-8; Cheung AL, 2004, FEMS IMMUNOL MED MIC, V40, P1, DOI 10.1016/S0928-8244(03)00309-2; Tseng CW, 2004, J BACTERIOL, V186, P1793, DOI 10.1128/JB.186.6.1793-1801.2004; Ikeda T, 2005, APPL ENVIRON MICROB, V71, P2793, DOI 10.1128/AEM.71.5.2793-2795.2005; Ono HK, 2008, INFECT IMMUN, V76, P4999, DOI 10.1128/IAI.00045-08; Yan XM, 2012, APPL ENVIRON MICROB, V78, P6637, DOI 10.1128/AEM.01165-12; Dumitrescu O, 2011, ANTIMICROB AGENTS CH, V55, P3261, DOI 10.1128/AAC.01401-10; Hennekinne JA, 2012, FEMS MICROBIOL REV, V36, P815, DOI 10.1111/j.1574-6976.2011.00311.x; Geisinger E, 2006, MOL MICROBIOL, V61, P1038, DOI 10.1111/j.1365-2958.2006.05292.x; Hu DL, 2014, EUR J PHARMACOL, V722, P95, DOI 10.1016/j.ejphar.2013.08.050; Kato F, 2011, J MICROBIOL METH, V87, P76, DOI 10.1016/j.mimet.2011.07.010; Omoe K, 2005, INFECT IMMUN, V73, P5540, DOI 10.1128/IAI.73.9.5540.5546.2005; Kato F, 2011, INFECT IMMUN, V79, P1660, DOI 10.1128/IAI.00872-10; Boisset S, 2007, GENE DEV, V21, P1353, DOI 10.1101/gad.423507; Omoe K, 2003, INFECT IMMUN, V71, P6088, DOI 10.1128/IAI.71.10.6088-6094.2003; Lis E, 2012, J FOOD PROTECT, V75, P238, DOI 10.4315/0362-028X.JFP-11-336; EVENSON ML, 1988, INT J FOOD MICROBIOL, V7, P311, DOI 10.1016/0168-1605(88)90057-8; Derzelle S, 2009, FOOD MICROBIOL, V26, P896, DOI 10.1016/j.fm.2009.06.007; Frees D, 2005, INFECT IMMUN, V73, P8100, DOI 10.1128/IAI.73.12.8100-8108.2005; Asao T, 2003, EPIDEMIOL INFECT, V130, P33, DOI 10.1017/S0950268802007951; TREMAINE MT, 1993, INFECT IMMUN, V61, P356; Xue T, 2012, MED MICROBIOL IMMUN, V201, P81, DOI 10.1007/s00430-011-0208-z; REGASSA LB, 1991, INFECT IMMUN, V59, P955; Masuda S, 2007, J MOL BIOL, V368, P1223, DOI 10.1016/j.jmb.2007.02.087; Fechter P, 2014, FEBS LETT, V588, P2523, DOI 10.1016/j.febslet.2014.05.037; McNamara PJ, 2000, J BACTERIOL, V182, P3197, DOI 10.1128/JB.182.11.3197-3203.2000; Hu DL, 2003, INFECT IMMUN, V71, P567, DOI 10.1128/IAI.71.1.567-570.2003; Purrello SM, 2014, J GLOB ANTIMICROB RE, V2, P61, DOI 10.1016/j.jgar.2014.02.003; Suzuki Y, 2014, MICROBIOL IMMUNOL, V58, P570, DOI 10.1111/1348-0421.12188	47	0	0	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	0099-2240	1098-5336		APPL ENVIRON MICROB	Appl. Environ. Microbiol.	NOV	2015	81	22					7782	7790		10.1128/AEM.01936-15		9	Biotechnology & Applied Microbiology; Microbiology	Biotechnology & Applied Microbiology; Microbiology	CU3YY	WOS:000363463800011		
J	Kumagai, T; Ozawa, T; Tanimoto, M; Noda, M; Matoba, Y; Sugiyama, M				Kumagai, Takanori; Ozawa, Tomoki; Tanimoto, Momoko; Noda, Masafumi; Matoba, Yasuyuki; Sugiyama, Masanori			High-Level Heterologous Production of D-Cycloserine by Escherichia coli	APPLIED AND ENVIRONMENTAL MICROBIOLOGY			English	Article							D-ALANINE RACEMASE; ALANYL-D-ALANINE; STREPTOMYCES-LAVENDULAE; MYCOBACTERIUM-SMEGMATIS; SUBSTRATE-SPECIFICITY; BIOSYNTHETIC-PATHWAY; MOLECULAR-CLONING; GLYCINE SITE; GENE; RESISTANCE	Previously, we successfully cloned a D-cycloserine (D-CS) biosynthetic gene cluster consisting of 10 open reading frames (designated dcsA to dcsJ) from D-CS-producing Streptomyces lavendulae ATCC 11924. In this study, we put four D-CS biosynthetic genes (dcsC, dcsD, dcsE, and dcsG) in tandem under the control of the T7 promoter in an Escherichia coli host. SDS-PAGE analysis demonstrated that the 4 gene products were simultaneously expressed in host cells. When L-serine and hydroxyurea (HU), the precursors of D-CS, were incubated together with the E. coli resting cell suspension, the cells produced significant amounts of D-CS (350 +/- 20 mu M). To increase the productivity of D-CS, the dcsJ gene, which might be responsible for the D-CS excretion, was connected downstream of the four genes. The E. coli resting cells harboring the five genes produced D-CS at 660 +/- 31 mu M. The dcsD gene product, DcsD, forms O-ureido-L-serine from O-acetyl-L-serine (OAS) and HU, which are intermediates in D-CS biosynthesis. DcsD also catalyzes the formation of L-cysteine from OAS and H2S. To repress the side catalytic activity of DcsD, the E. coli chromosomal cysJ and cysK genes, encoding the sulfite reductase alpha subunit and OAS sulfhydrylase, respectively, were disrupted. When resting cells of the double-knockout mutant harboring the four D-CS biosynthetic genes, together with dcsJ, were incubated with L-serine and HU, the D-CS production was 980 +/- 57 mu M, which is comparable to that of D-CS-producing S. lavendulae ATCC 11924 (930 +/- 36 mu M).	[Kumagai, Takanori; Noda, Masafumi; Matoba, Yasuyuki; Sugiyama, Masanori] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Mol Microbiol & Biotechnol, Hiroshima, Japan; [Ozawa, Tomoki; Tanimoto, Momoko] Hiroshima Univ, Dept Pharmaceut Sci, Hiroshima, Japan	Sugiyama, M (reprint author), Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Mol Microbiol & Biotechnol, Hiroshima, Japan.	sugi@hiroshima-u.ac.jp			JSPS [25460119]	Part of this work was supported by JSPS KAKENHI grant number 25460119.	Zhang YM, 1998, NAT GENET, V20, P123, DOI 10.1038/2417; LAMBERT MP, 1972, J BACTERIOL, V110, P978; Matsuo H, 2003, J ANTIBIOT, V56, P762; Hindson VJ, 2003, BIOCHEM J, V375, P745, DOI 10.1042/BJ20030429; Kumagai T, 2012, ANTIMICROB AGENTS CH, V56, P3682, DOI 10.1128/AAC.00614-12; BOLIVAR F, 1977, GENE, V2, P95; Caceres NE, 1997, J BACTERIOL, V179, P5046; LEESON PD, 1994, J MED CHEM, V37, P4053, DOI 10.1021/jm00050a001; Feng ZY, 2003, ANTIMICROB AGENTS CH, V47, P283, DOI 10.1128/AAC.47.1.283-291.2003; Kitani S, 2001, J BACTERIOL, V183, P4357, DOI 10.1128/JB.183.14.4357-4363.2001; HERBERG LJ, 1990, PHARMACOL BIOCHEM BE, V36, P735, DOI 10.1016/0091-3057(90)90069-T; YANAGIMOTO M, 1983, J FERMENT TECHNOL, V61, P545; Humma LM, 1996, AM J HEALTH-SYST PH, V53, P2291; Goff DC, 1999, ARCH GEN PSYCHIAT, V56, P21, DOI 10.1001/archpsyc.56.1.21; NEUHAUS FC, 1964, BIOCHEMISTRY-US, V3, P471, DOI 10.1021/bi00892a001; Noda M, 2004, J BIOL CHEM, V279, P46143, DOI 10.1074/jbc.M404603200; Uda N, 2013, ANTIMICROB AGENTS CH, V57, P2603, DOI 10.1128/AAC.02291-12; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Dietrich D, 2012, ORG BIOMOL CHEM, V10, P2248, DOI 10.1039/c2ob06864h; Oda K, 2013, J BACTERIOL, V195, P1741, DOI 10.1128/JB.02085-12; Kumagai T, 2010, ANTIMICROB AGENTS CH, V54, P1132, DOI 10.1128/AAC.01226-09; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HARRIS DALE A., 1955, ANTIBIOT AND CHEMOTHER, V5, P183; Ikeda K, 1996, APPL MICROBIOL BIOT, V45, P80; Kieser T., 2000, PRACTICAL STREPTOMYC; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Sambrook J., 2001, MOL CLONING LAB MANU; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	28	0	0	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	0099-2240	1098-5336		APPL ENVIRON MICROB	Appl. Environ. Microbiol.	NOV	2015	81	22					7881	7887		10.1128/AEM.02187-15		7	Biotechnology & Applied Microbiology; Microbiology	Biotechnology & Applied Microbiology; Microbiology	CU3YY	WOS:000363463800021		
J	Park, CA; Kang, D; Son, YD; Kim, HK; Kang, CK				Park, Chan-A; Kang, Daehun; Son, Young-Don; Kim, Hang-Keun; Kang, Chang-Ki			Microvascular Imaging Using Compressed Sensing at 7T MRI: A Preliminary Study	APPLIED MAGNETIC RESONANCE			English	Article							HIGH-RESOLUTION MRI; T MRI; 4T	The aim of this study was to obtain high-resolution images with a short acquisition time using a compressed sensing (CS) technique for microvascular imaging, especially of the lenticulostriate arteries (LSAs), with 7T magnetic resonance imaging (MRI). Initially, two different radio frequency (RF) coils, birdcage and multi-channel phased array, were tested to compare images of micro-vessels acquired using the CS technique with those acquired using conventional magnetic resonance angiography (MRA) at 7T MRI. High-resolution CS MRA as well as low- and high-resolution conventional time-of-flight MRA images obtained with a multi-channel RF coil was compared to evaluate the feasibility of the CS technique for microvascular imaging. Signal intensities were then used to quantitatively estimate vessel sizes. Compared to low-resolution MRA, the CS technique improved the depiction of the LSAs and provided a substantially reduced partial volume effect of the vessels. Despite the short acquisition time of the CS technique, it clearly depicted the LSA morphology almost as well as the high-resolution MRA. The measured size difference between micro-vessels that were analyzed using the CS technique and those analyzed using high-resolution MRA was about 20 %; however, the difference between the high-resolution and the low-resolution MRA was as high as 100 %. This study evaluated the feasibility of the CS technique for microvascular imaging with 7T MRI. A CS technique that combines high-resolution imaging with a short acquisition time would be a very effective method for microvascular imaging in both research and clinical studies.	[Park, Chan-A] Korea Basic Sci Inst, Bioimaging Res Team, Ochang, Chungbuk, South Korea; [Kang, Daehun] Tohoku Univ, Grad Sch Informat Sci, Sendai, Miyagi 980, Japan; [Kang, Daehun] Tohoku Univ, Kansei Fukushi Res Inst, Sendai, Miyagi 980, Japan; [Son, Young-Don; Kim, Hang-Keun; Kang, Chang-Ki] Gachon Univ, Neurosci Res Inst, Inchon, South Korea; [Son, Young-Don; Kim, Hang-Keun] Gachon Univ, Coll Hlth Sci, Dept Biomed Engn, Inchon, South Korea; [Kang, Chang-Ki] Gachon Univ, Coll Hlth Sci, Dept Radiol Sci, Inchon, South Korea	Kang, CK (reprint author), Gachon Univ, Neurosci Res Inst, Inchon, South Korea.	ckkang@gachon.ac.kr			Gachon University, Incheon, Republic of Korea [GCU-2015-0061, GCU-2015-5030]	This work was supported by Gachon University, Incheon, Republic of Korea (Grant Number: GCU-2015-0061 & GCU-2015-5030).	Griswold MA, 2002, MAGNET RESON MED, V47, P1202, DOI 10.1002/mrm.10171; Madelin G, 2012, J MAGN RESON, V214, P360, DOI 10.1016/j.jmr.2011.12.005; Bourekas EC, 1999, J COMPUT ASSIST TOMO, V23, P867, DOI 10.1097/00004728-199911000-00009; Worz S, 2007, IEEE T IMAGE PROCESS, V16, P1994, DOI 10.1109/TIP.2007.901204; Thurling M, 2011, NEUROIMAGE, V57, P1184, DOI 10.1016/j.neuroimage.2011.05.045; Klein IF, 2006, NEUROLOGY, V67, P327, DOI 10.1212/01.wnl.0000225074.47396.71; Vaughan JT, 2001, MAGNET RESON MED, V46, P24, DOI 10.1002/mrm.1156; Otazo R, 2010, MAGN RESON MED, V64, P767, DOI 10.1002/mrm.22463; Lee YB, 2013, VASC MED, V18, P314, DOI 10.1177/1358863X13507991; Cho ZH, 2010, J NUCL MED, V51, P1545, DOI 10.2967/jnumed.110.076182; Akcakaya M, 2014, MAGN RESON MED, V71, P815, DOI 10.1002/mrm.24683; Kang CK, 2014, INT J IMAG SYST TECH, V24, P121, DOI 10.1002/ima.22085; Weiger M, 2005, MAGNET RESON MED, V53, P177, DOI 10.1002/mrm.20322; Mueller SG, 2007, NEUROBIOL AGING, V28, P719, DOI 10.1016/j.neurobiolaging.2006.03.007; Cho ZH, 2013, J NEUROL, V260, P144, DOI 10.1007/s00415-012-6604-5; Cho ZH, 2008, STROKE, V39, P1604, DOI 10.1161/STROKEAHA.107.508002; Walters NB, 2003, P NATL ACAD SCI USA, V100, P2981, DOI 10.1073/pnas.0437891600; Ohliger MA, 2003, MAGNET RESON MED, V50, P1018, DOI 10.1002/mrm.10597; Lustig M, 2007, MAGN RESON MED, V58, P1182, DOI 10.1002/mrm.21391; Kang CK, 2014, MAGN RESON IMAGING, V32, P1133, DOI 10.1016/j.mri.2014.07.006; Milles J., 2010, 10 IEEE INT C INF TE, V2010, P1; Nakada T, 2007, BRAIN DEV-JPN, V29, P325, DOI 10.1016/j.braindev.2006.10.005; Pruessmann KP, 1999, MAGNET RESON MED, V42, P952, DOI 10.1002/(SICI)1522-2594(199911)42:5<952::AID-MRM16>3.0.CO;2-S; Sharma S.D., 2013, INVEST RADIOL, V2013, P638	24	0	0	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0937-9347	1613-7507		APPL MAGN RESON	Appl. Magn. Reson.	NOV	2015	46	11					1189	1197		10.1007/s00723-015-0713-0		9	Physics, Atomic, Molecular & Chemical; Spectroscopy	Physics; Spectroscopy	CU1HC	WOS:000363270300001		
J	Matsuzawa, T; Kaneko, S; Yaoi, K				Matsuzawa, Tomohiko; Kaneko, Satoshi; Yaoi, Katsuro			Screening, identification, and characterization of a GH43 family beta-xylosidase/alpha-arabinofuranosidase from a compost microbial metagenome	APPLIED MICROBIOLOGY AND BIOTECHNOLOGY			English	Article						beta-xylosidase; alpha-arabinofuranosidase; Biomass; Metagenome; Glycoside hydrolase family 43	TRICHODERMA-REESEI; GEOBACILLUS-STEAROTHERMOPHILUS; BIOCHEMICAL-CHARACTERIZATION; TRANSGLYCOSYLATION ACTIVITY; BIFUNCTIONAL PROTEIN; NUCLEOTIDE-SEQUENCE; CATALYTIC RESIDUES; ASPERGILLUS-NIGER; BOVINE RUMEN; L-SORBOSE	A putative glycoside hydrolase family 43 beta-xylosidase/alpha-arabinofuranosidase (CoXyl43) that promotes plant biomass saccharification was isolated via functional screening of a compost microbial metagenomic library and characterized. CoXyl43 promoted the saccharification of plant biomasses, including xylans (xylan and arabinoxylan), rice straw, and Erianthus, by degrading xylooligosaccharide residues to monosaccharide residues. The recombinant CoXyl43 protein exhibited both beta-xylosidase and alpha-arabinofuranosidase activities for chromogenic substrates, with optimal activity at pH 7.5 and 55 A degrees C. Both of these activities were inactivated by ethanol, dimethylsulfoxide, and zinc and copper ions but were activated by manganese ions. Only the beta-xylosidase activity of recombinant CoXyl43 was enhanced in the presence of calcium ions. These results indicate that CoXyl43 exhibits unique enzymatic properties useful for biomass saccharification.	[Matsuzawa, Tomohiko; Yaoi, Katsuro] Natl Inst Adv Ind Sci & Technol, Bioprod Res Inst, Tsukuba, Ibaraki 3058566, Japan; [Kaneko, Satoshi] Natl Food Res Inst, Food Biotechnol Div, Tsukuba, Ibaraki 3058642, Japan; [Kaneko, Satoshi] Univ Ryukyus, Fac Agr, Dept Subtrop Biochem & Biotechnol, Nishihara, Okinawa 9030213, Japan	Yaoi, K (reprint author), Natl Inst Adv Ind Sci & Technol, Bioprod Res Inst, Tsukuba Cent 6,1-1-1 Higashi, Tsukuba, Ibaraki 3058566, Japan.	k-yaoi@aist.go.jp			New Energy and Industrial Technology Development Organization (NEDO)	We thank Dr. Y. Kobayashi (Japan Bioindustry Association) for provision of the biomass materials and helpful discussion. This work was supported in part by grants from the New Energy and Industrial Technology Development Organization (NEDO).	Alvarez TM, 2013, PLOS ONE, V8; PENTTILA M, 1986, GENE, V45, P253, DOI 10.1016/0378-1119(86)90023-5; Brux C, 2006, J MOL BIOL, V359, P97, DOI 10.1016/j.jmb.2006.03.005; Uchiyama T, 2013, J BIOL CHEM, V288, P18325, DOI 10.1074/jbc.M113.471342; [Anonymous], 1983, NAT BIOTECHNOL, DOI DOI 10.1038/NBT1083-696; SHAO WL, 1992, J BACTERIOL, V174, P5848; Zhou J, 2012, LETT APPL MICROBIOL, V54, P79, DOI 10.1111/j.1472-765X.2011.03175.x; Zhou JG, 2012, J IND MICROBIOL BIOT, V39, P143, DOI 10.1007/s10295-011-1009-5; Whitehead TR, 2001, CURR MICROBIOL, V43, P293, DOI 10.1007/s002840010304; Lee CM, 2008, BIOCHEM BIOPH RES CO, V370, P322, DOI 10.1016/j.bbrc.2008.03.102; Pang H, 2009, CURR MICROBIOL, V58, P404, DOI 10.1007/s00284-008-9346-y; GRUPPEN H, 1992, J CEREAL SCI, V16, P53; GASPARIC A, 1995, APPL ENVIRON MICROB, V61, P2958; Fujimoto Z, 2004, J BIOL CHEM, V279, P9606, DOI 10.1074/jbc.M312293200; Kim YA, 2010, J MICROBIOL BIOTECHN, V20, P1711, DOI 10.4014/jmb.1010.10040; FLIPPHI MJA, 1993, APPL MICROBIOL BIOT, V40, P318; Okada H, 1998, APPL ENVIRON MICROB, V64, P555; Peterson R, 2012, MICROBIOL-SGM, V158, P58, DOI 10.1099/mic.0.054031-0; Nogawa M, 2001, CURR GENET, V38, P329, DOI 10.1007/s002940000165; Okamura Y, 2010, MAR BIOTECHNOL, V12, P395, DOI 10.1007/s10126-009-9226-x; Shallom D, 2005, BIOCHEMISTRY-US, V44, P387, DOI 10.1021/bi048059w; Yang XZ, 2014, FOOD CHEM, V148, P381, DOI 10.1016/j.foodchem.2013.10.062; Beloqui A, 2006, J BIOL CHEM, V281, P22933, DOI 10.1074/jbc.M600577200; Lynd LR, 2002, MICROBIOL MOL BIOL R, V66, P506, DOI 10.1128/MMBR.66.3.506-577.2002; Lee CC, 2013, ENZYME MICROB TECH, V52, P84, DOI 10.1016/j.enzmictec.2012.10.010; Suenaga H, 2007, ENVIRON MICROBIOL, V9, P2289, DOI 10.1111/j.1462-2920.2007.01342.x; McAndrew RP, 2013, J BIOL CHEM, V288, P14985, DOI 10.1074/jbc.M113.458356; Bao L, 2012, APPL BIOCHEM BIOTECH, V166, P72, DOI 10.1007/s12010-011-9405-x; Gong X, 2013, APPL MICROBIOL BIOT, V97, P2423, DOI 10.1007/s00253-012-4088-y; Gupta R, 2012, APPL BIOCHEM BIOTECH, V168, P1681, DOI 10.1007/s12010-012-9889-z; Handelsman J, 1998, CHEM BIOL, V5, pR245, DOI 10.1016/S1074-5521(98)90108-9; SAKKA K, 1993, BIOSCI BIOTECH BIOCH, V57, P268; Saha BC, 2003, J IND MICROBIOL BIOT, V30, P279, DOI 10.1007/s10295-003-0049-x; Wagschal K, 2009, APPL MICROBIOL BIOT, V81, P855, DOI 10.1007/s00253-008-1662-4; FLIPPHI MJA, 1993, APPL MICROBIOL BIOT, V39, P335; Kimura N, 2010, MICROBES ENVIRON, V25, P133, DOI 10.1264/jsme2.ME10110; McIlvaine TC, 1921, J BIOL CHEM, V49, P183; Torsvik V, 2002, CURR OPIN MICROBIOL, V5, P240, DOI 10.1016/S1369-5274(02)00324-7; KAWAMORI M, 1986, APPL MICROBIOL BIOT, V24, P449; WHITEHEAD TR, 1995, BBA-GEN SUBJECTS, V1244, P239, DOI 10.1016/0304-4165(95)00051-C; Jordan DB, 2013, APPL MICROBIOL BIOT, V97, P4415, DOI 10.1007/s00253-012-4475-4; TEERI TT, 1987, GENE, V51, P43, DOI 10.1016/0378-1119(87)90472-0; Nakazawa H, 2012, BIOTECHNOL BIOENG, V109, P92, DOI 10.1002/bit.23296; Kawai T, 2012, J IND MICROBIOL BIOT, V39, P1741, DOI 10.1007/s10295-012-1195-9; UTT EA, 1991, APPL ENVIRON MICROB, V57, P1227; Xu J, 1998, APPL MICROBIOL BIOT, V49, P718, DOI 10.1007/s002530051237; Dougherty MJ, 2012, BMC BIOTECHNOL, V12, DOI 10.1186/1472-6750-12-38; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; Ferrer M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038134; KORMELINK FJM, 1993, APPL MICROBIOL BIOT, V38, P688; MILLER GL, 1959, ANAL CHEM, V31, P426, DOI 10.1021/ac60147a030; SALOHEIMO M, 1988, GENE, V63, P11, DOI 10.1016/0378-1119(88)90541-0; TENKANEN M, 1992, ENZYME MICROB TECH, V14, P566, DOI 10.1016/0141-0229(92)90128-B; Viborg AH, 2013, AMB EXPRESS, V3, DOI 10.1186/2191-0855-3-56	54	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0175-7598	1432-0614		APPL MICROBIOL BIOT	Appl. Microbiol. Biotechnol.	NOV	2015	99	21					8943	8954		10.1007/s00253-015-6647-5		12	Biotechnology & Applied Microbiology	Biotechnology & Applied Microbiology	CU4FB	WOS:000363481400011		
J	Hwang, IW; Makishima, Y; Suzuki, T; Kato, T; Park, S; Terzic, A; Chung, SK; Park, EY				Hwang, In-Wook; Makishima, Yu; Suzuki, Tomohiro; Kato, Tatsuya; Park, Sungjo; Terzic, Andre; Chung, Shin-kyo; Park, Enoch Y.			Phosphorylation of Ser-204 and Tyr-405 in human malonyl-CoA decarboxylase expressed in silkworm Bombyx mori regulates catalytic decarboxylase activity	APPLIED MICROBIOLOGY AND BIOTECHNOLOGY			English	Article						Human malonyl-CoA decarboxylase (hMCD); Site-directed mutagenesis; Phosphorylation/dephosphorylation; Lipid metabolism; Silkworm; Bombyx mori nucleopolyhedrovirus	COENZYME-A DECARBOXYLASE; ACTIVATED PROTEIN-KINASE; HUMAN SKELETAL-MUSCLE; RAT-LIVER; FUSION PROTEIN; CARBOXYLASE 2; LARVAE; DEFICIENCY; PURIFICATION; METABOLISM	Decarboxylation of malonyl-CoA to acetyl-CoA by malonyl-CoA decarboxylase (MCD; EC 4.1.1.9) is a vital catalytic reaction of lipid metabolism. While it is established that phosphorylation of MCD modulates the enzymatic activity, the specific phosphorylation sites associated with the catalytic function have not been documented due to lack of sufficient production of MCD with proper post-translational modifications. Here, we used the silkworm-based Bombyx mori nucleopolyhedrovirus (BmNPV) bacmid system to express human MCD (hMCD) and mapped phosphorylation effects on enzymatic function. Purified MCD from silkworm displayed post-translational phosphorylation and demonstrated coherent enzymatic activity with high yield (-200 mu g/silkworm). Point mutations in putative phosphorylation sites, Ser-204 or Tyr-405 of hMCD, identified by bioinformatics and proteomics analyses reduced the catalytic activity, underscoring the functional significance of phosphorylation in modulating decarboxylase-based catalysis. Identified phosphorylated residues are distinct from the decarboxylation catalytic site, implicating a phosphorylation-induced global conformational change of MCD as responsible in altering catalytic function. We conclude that phosphorylation of Ser-204 and Tyr-405 regulates the decarboxylase function of hMCD leveraging the silkworm-based BmNPV bacmid expression system that offers a fail-safe eukaryotic production platform implementing proper post-translational modification such as phosphorylation.	[Hwang, In-Wook; Park, Enoch Y.] Shizuoka Univ, Grad Sch Sci & Technol, Integrated Biosci Sect, Biotechnol Lab,Suruga Ku, Shizuoka 4228529, Japan; [Makishima, Yu; Kato, Tatsuya; Park, Enoch Y.] Shizuoka Univ, Dept Appl Biol Chem, Biotechnol Lab, Fac Agr,Suruga Ku, Shizuoka 4228529, Japan; [Suzuki, Tomohiro] Shizuoka Univ, Res Inst Green Sci & Technol, Suruga Ku, Shizuoka 4228529, Japan; [Kato, Tatsuya; Park, Enoch Y.] Shizuoka Univ, Res Inst Green Sci & Technol, Green Chem Res Div, Biotechnol Lab,Suruga Ku, Shizuoka 4228529, Japan; [Park, Sungjo; Terzic, Andre] Mayo Clin, Ctr Regenerat Med, Rochester, MN 55905 USA; [Park, Sungjo; Terzic, Andre] Mayo Clin, Marriott Heart Dis Res Program, Div Cardiovasc Med, Dept Med, Rochester, MN 55905 USA; [Park, Sungjo; Terzic, Andre] Mayo Clin, Marriott Heart Dis Res Program, Div Cardiovasc Med, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55905 USA; [Park, Sungjo; Terzic, Andre] Mayo Clin, Marriott Heart Dis Res Program, Div Cardiovasc Med, Dept Med Genet, Rochester, MN 55905 USA; [Chung, Shin-kyo] Kyungpook Natl Univ, Sch Food Sci & Biotechnol, Taegu 702701, South Korea	Park, EY (reprint author), Shizuoka Univ, Grad Sch Sci & Technol, Integrated Biosci Sect, Biotechnol Lab,Suruga Ku, 836 Ohya, Shizuoka 4228529, Japan.	gunryung21@hanmail.net; mmm.yu@live.jp; atsuzuk@ipc.shizuoka.ac.jp; atkato@ipc.shizuoka.ac.jp; park.sungjo@mayo.edu; terzic.andre@mayo.edu; kchung@knu.ac.kr; park.enoch@shizuoka.ac.jp	Kato, Tatsuya/E-3095-2010		Japan Society for the Promotion of Science (JSPS), Japan; National Institute of Health; Marriott Heart Disease Research Program at the Mayo Clinic	This work was supported partly by the Strategic Young Researcher Overseas Visits Program for Accelerating Brain Circulation from Japan Society for the Promotion of Science (JSPS), Japan, National Institute of Health, and Marriott Heart Disease Research Program at the Mayo Clinic. A.T. holds the Marriott Family Professorship in Cardiovascular Diseases Research.	KIM YS, 1978, ARCH BIOCHEM BIOPHYS, V190, P234, DOI 10.1016/0003-9861(78)90273-4; Folmes CDL, 2013, CELL METAB, V17, P153, DOI 10.1016/j.cmet.2013.01.010; Park EY, 2007, J BIOTECHNOL, V129, P681, DOI 10.1016/j.jbiotec.2007.01.028; Dyck JRB, 1998, AM J PHYSIOL-HEART C, V275, pH2122; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Park H, 2002, J BIOL CHEM, V277, P32571, DOI 10.1074/jbc.M201692200; Kato T, 2010, APPL MICROBIOL BIOT, V85, P459, DOI 10.1007/s00253-009-2267-2; Aparicio D, 2013, J BIOL CHEM, V288, P11907, DOI 10.1074/jbc.M112.443846; Kamionka M, 2011, CURR PHARM BIOTECHNO, V12, P268, DOI 10.2174/138920111794295693; Laurent G, 2013, MOL CELL, V50, P686, DOI 10.1016/j.molcel.2013.05.012; Zhou DM, 2004, PROTEIN EXPRES PURIF, V34, P261, DOI 10.1016/j.pep.2003.11.023; Saha AK, 2000, J BIOL CHEM, V275, P24279, DOI 10.1074/jbc.C000291200; KIM KH, 1989, FASEB J, V3, P2250; An J, 2004, NAT MED, V10, P268, DOI 10.1038/nm995; Bouzakri K, 2008, DIABETES, V57, P1508, DOI 10.2337/db07-0583; Dyck JRB, 2000, BIOCHEM J, V350, P599, DOI 10.1042/0264-6021:3500599; MACPHEE GB, 1993, ARCH DIS CHILD, V69, P433; KRAWINKEL MB, 1994, J INHERIT METAB DIS, V17, P636, DOI 10.1007/BF00711609; Motohashi T, 2005, BIOCHEM BIOPH RES CO, V326, P564, DOI 10.1016/j.bbrc.2004.11.060; Park S, 2008, J PROTEOME RES, V7, P1721, DOI 10.1021/pr7007847; Hwang IW, 2014, APPL MICROBIOL BIOT, V98, P8201, DOI 10.1007/s00253-014-5715-6; MATALON R, 1993, J INHERIT METAB DIS, V16, P571, DOI 10.1007/BF00711684; SCHOLTE HR, 1969, BIOCHIM BIOPHYS ACTA, V178, P137, DOI 10.1016/0005-2744(69)90140-5; Froese DS, 2013, STRUCTURE, V21, P1182, DOI 10.1016/j.str.2013.05.001; Karger AB, 2008, J GEN PHYSIOL, V131, P185, DOI 10.1085/jgp.200709852; Xue JJ, 2012, MOL GENET METAB, V105, P79, DOI 10.1016/j.ymgme.2011.09.007; Yano S, 1997, EUR J PEDIATR, V156, P382, DOI 10.1007/s004310050619; Park S, 2013, J MOL RECOGNIT, V26, P679, DOI 10.1002/jmr.2313; Dojima T, 2009, J BIOTECHNOL, V143, P27, DOI 10.1016/j.jbiotec.2009.06.013; Dyck JRB, 2006, CIRCULATION, V114, P1721, DOI 10.1161/CIRCULATIONAHA.106.642009; Ishikiriyama M, 2009, J BIOSCI BIOENG, V107, P67, DOI 10.1016/j.jbiosc.2008.11.001; Sambandam N, 2004, EUR J BIOCHEM, V271, P2831, DOI 10.1111/j.1432-1033.2004.04218.x; Saggerson D, 2008, ANNU REV NUTR, V28, P253, DOI 10.1146/annurev.nutr.28.061807.155434; Park EY, 2008, BIOTECHNOL APPL BIOC, V49, P135, DOI 10.1042/BA20070098; HAAN EA, 1986, EUR J PEDIATR, V144, P567, DOI 10.1007/BF00496037; Otsuki T, 2013, VET PARASITOL, V192, P284, DOI 10.1016/j.vetpar.2012.09.038; BUCKNER JS, 1976, ARCH BIOCHEM BIOPHYS, V177, P539, DOI 10.1016/0003-9861(76)90465-3; KIM YS, 1979, INT J BIOCHEM, V10, P551; Pender C, 2006, J CELL BIOCHEM, V99, P860, DOI 10.1002/jcb.20944; Nam HW, 2006, J PROTEOME RES, V5, P1398, DOI 10.1021/pr050487g; Du DN, 2009, MOL BIOTECHNOL, V43, P154, DOI 10.1007/s12033-009-9183-7; Voilley N, 1999, BIOCHEM J, V340, P213, DOI 10.1042/0264-6021:3400213; BROWN GK, 1984, J INHERIT METAB DIS, V7, P21, DOI 10.1007/BF01805615; Ogata M, 2009, BMC BIOTECHNOL, V9, DOI 10.1186/1472-6750-9-54	44	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0175-7598	1432-0614		APPL MICROBIOL BIOT	Appl. Microbiol. Biotechnol.	NOV	2015	99	21					8977	8986		10.1007/s00253-015-6687-x		10	Biotechnology & Applied Microbiology	Biotechnology & Applied Microbiology	CU4FB	WOS:000363481400014		
J	Tanaka, U; Kitanaka, T; Hayasaka, K; Urabe, S				Tanaka, Utako; Kitanaka, Tomohiro; Hayasaka, Kazuhiro; Urabe, Shinji			Sideband cooling of a Ca+-In+ ion chain toward the quantum logic spectroscopy of In+	APPLIED PHYSICS B-LASERS AND OPTICS			English	Article							ABSOLUTE FREQUENCY-MEASUREMENT; TRAPPED IONS; LASER; CLOCK; TRANSITION; LEVEL	Indium ions (In-115(+)) are a promising candidate for an optical clock with a frequency inaccuracy below 10(-17). Quantum logic spectroscopy (QLS) plays a fundamental role in realizing such a clock by supplying a high-fidelity fast quantum state detection method. Initializing a phonon mode of an ion chain consisting of In+ and an ancillary ion to the ground state is a fundamental step toward the implementation of QLS. We report experimental results of the sideband cooling and heating rate measurements of a Ca-40(+)-In-115(+) chain using optical transitions in Ca+. The sideband cooling of the out-of-phase mode of the axial motion down to an estimated phonon number of 0.096 is demonstrated.	[Tanaka, Utako; Kitanaka, Tomohiro; Urabe, Shinji] Osaka Univ, Grad Sch Engn Sci, Toyonaka, Osaka 5608531, Japan; [Hayasaka, Kazuhiro] Natl Inst Informat & Commun Technol, Nishi Ku, Kobe, Hyogo 6512492, Japan	Tanaka, U (reprint author), Osaka Univ, Grad Sch Engn Sci, 1-3 Machikaneyama Cho, Toyonaka, Osaka 5608531, Japan.	utako@ee.es.osaka-u.ac.jp					Morigi G, 2001, EUR PHYS J D, V13, P261, DOI 10.1007/s100530170275; Chou CW, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.070802; Schmidt PO, 2005, SCIENCE, V309, P749, DOI 10.1126/science.1114375; King SA, 2012, NEW J PHYS, V14, DOI 10.1088/1367-2630/14/1/013045; Bloom BJ, 2014, NATURE, V506, P71, DOI 10.1038/nature12941; Noguchi A, 2012, PHYS REV LETT, V109, DOI 10.1103/PhysRevLett.109.260502; Epstein RJ, 2007, PHYS REV A, V76, DOI 10.1103/PhysRevA.76.033411; Marquet C, 2003, APPL PHYS B-LASERS O, V76, P199, DOI 10.1007/s00340-003-1097-7; Chwalla M, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.023002; Uetake S, 2009, APPL PHYS B-LASERS O, V97, P413, DOI 10.1007/s00340-009-3619-4; Wang YH, 2007, OPT COMMUN, V273, P526, DOI 10.1016/j.optcom.2007.01.068; Huntemann N, 2012, PHYS REV LETT, V108, DOI 10.1103/PhysRevLett.108.090801; DEHMELT HG, 1982, IEEE T INSTRUM MEAS, V31, P83; Lin Y, 2013, PHYS REV LETT, V110, DOI 10.1103/PhysRevLett.110.153002; Rosenband T, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.220801; Safronova MS, 2011, PHYS REV LETT, V107, DOI 10.1103/PhysRevLett.107.143006; Margolis HS, 2004, SCIENCE, V306, P1355, DOI 10.1126/science.1105497; Nie XR, 2009, PHYS LETT A, V373, P422, DOI 10.1016/j.physleta.2008.11.045; Herschbach N, 2012, APPL PHYS B-LASERS O, V107, P891, DOI 10.1007/s00340-011-4790-y; Madej AA, 2012, PHYS REV LETT, V109, DOI 10.1103/PhysRevLett.109.203002; Noguchi A, 2012, PHYS REV LETT, V108, DOI 10.1103/PhysRevLett.108.060503; Berkeland DJ, 1998, J APPL PHYS, V83, P5025, DOI 10.1063/1.367318; von Zanthier J, 2000, OPT LETT, V25, P1729; Matsubara K, 2008, APPL PHYS EXPRESS, V1, DOI 10.1143/APEX.1067011; Wubbena JB, 2012, PHYS REV A, V85, DOI 10.1103/PhysRevA.85.043412; Sawamura H, 2008, APPL PHYS B-LASERS O, V93, P381, DOI 10.1007/s00340-008-3162-8; Labaziewicz J, 2007, OPT LETT, V32, P572, DOI 10.1364/OL.32.000572; Savard TA, 1997, PHYS REV A, V56, pR1095; Toyoda K, 2013, PHYS REV LETT, V111, DOI 10.1103/PhysRevLett.111.160501; Pyka K, 2014, APPL PHYS B-LASERS O, V114, P231, DOI 10.1007/s00340-013-5580-5; Barrett MD, 2003, PHYS REV A, V68, DOI 10.1103/PhysRevA.68.042302; Goldstein H., 1962, CLASSICAL MECH; Hayasaka K, 2012, APPL PHYS B-LASERS O, V107, P965, DOI 10.1007/s00340-012-4909-9; Huang Y, 2012, PHYS REV A, V85, DOI 10.1103/PhysRevA.85.030503; James DFV, 1998, APPL PHYS B-LASERS O, V66, P181, DOI 10.1007/s003400050373; Kielpinski D, 2000, PHYS REV A, V61, part. no., DOI 10.1103/PhysRevA.61.032310; Poulsen G., 2011, THESIS U AARHUS; Ushijima I, 2015, NAT PHOTONICS, V9, P185, DOI 10.1038/NPHOTON.2015.5; Wakui K, 2014, APPL PHYS B-LASERS O, V117, P957, DOI 10.1007/s00340-014-5914-y	39	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0946-2171	1432-0649		APPL PHYS B-LASERS O	Appl. Phys. B-Lasers Opt.	NOV	2015	121	2					147	153		10.1007/s00340-015-6212-z		7	Optics; Physics, Applied	Optics; Physics	CU0YD	WOS:000363244300006		
J	Kawai, Y; Tanaka, U; Hayasaka, K; Urabe, S				Kawai, Yuji; Tanaka, Utako; Hayasaka, Kazuhiro; Urabe, Shinji			Mode-hop-free operation of a distributed Bragg reflector diode laser in an external fiber-cavity configuration	APPLIED PHYSICS B-LASERS AND OPTICS			English	Article							PRECISION SPECTROSCOPY; INTRINSIC-LINEWIDTH; OPTICAL FEEDBACK; CA+	We report on the mode-hop-free operation of a distributed Bragg reflector (DBR) diode laser with an external cavity consisting of an optical fiber. A simple method is implemented, using feedback to the DBR drive current, to suppress mode hops due to frequency mismatch between the intrinsic mode of the DBR laser and the resonant mode of the fiber cavity. The error signal is derived from the change in the output power of the whole system. The feedback allows long-term operation over hours without mode hops, as well as continuous frequency scans of about 1 GHz with a reduced short-term linewidth.	[Kawai, Yuji; Tanaka, Utako; Urabe, Shinji] Osaka Univ, Grad Sch Engn Sci, Toyonaka, Osaka 5608531, Japan; [Hayasaka, Kazuhiro] Natl Inst Informat & Commun Technol, Nishi Ku, Kobe, Hyogo 6512492, Japan	Hayasaka, K (reprint author), Natl Inst Informat & Commun Technol, Nishi Ku, 588-2 Iwaoka,Iwaoka Cho, Kobe, Hyogo 6512492, Japan.	hayasaka@nict.go.jp					Prevedelli M, 1996, OPT COMMUN, V125, P231, DOI 10.1016/0030-4018(96)00053-3; Zhao Y, 2011, OPT LETT, V36, P34, DOI 10.1364/OL.36.000034; Lin Q, 2012, OPT LETT, V37, P1989, DOI 10.1364/OL.37.001989; Samutpraphoot P, 2014, OPT EXPRESS, V22, P11592, DOI 10.1364/OE.22.011592; Huntemann N, 2012, PHYS REV LETT, V108, DOI 10.1103/PhysRevLett.108.090801; Thompson DJ, 2012, REV SCI INSTRUM, V83, DOI 10.1063/1.3687441; Repasky KS, 2006, APPL OPTICS, V45, P9013, DOI 10.1364/AO.45.009013; Matsubara K, 2012, OPT EXPRESS, V20, P22034, DOI 10.1364/OE.20.022034; Hayasaka K, 2000, JPN J APPL PHYS 2, V39, pL687, DOI 10.1143/JJAP.39.L687; Hayasaka K, 2011, OPT LETT, V36, P2188, DOI 10.1364/OL.36.002188; Labaziewicz J, 2007, OPT LETT, V32, P572, DOI 10.1364/OL.32.000572; Kostylev N, 2015, APPL PHYS B-LASERS O, V118, P517, DOI 10.1007/s00340-015-6018-z; Mroziewicz B, 2008, OPTO-ELECTRON REV, V16, P347, DOI 10.2478/s11772-008-0045-9; Poli N., 2015, APPL PHYS B, V117, P1107; Siegman A. E., 1986, LASERS	15	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0946-2171	1432-0649		APPL PHYS B-LASERS O	Appl. Phys. B-Lasers Opt.	NOV	2015	121	2					213	219		10.1007/s00340-015-6222-x		7	Optics; Physics, Applied	Optics; Physics	CU0YD	WOS:000363244300014		
J	Oishi, S; Saeki, M; Axt, J				Oishi, Shigehiro; Saeki, Masao; Axt, Jordan			Are People Living in Walkable Areas Healthier and More Satisfied with Life?	APPLIED PSYCHOLOGY-HEALTH AND WELL BEING			English	Article						health; life satisfaction; social ecology; walkability	BODY-MASS INDEX; QUALITY-OF-LIFE; BUILT-ENVIRONMENT; PHYSICAL-ACTIVITY; NEIGHBORHOOD WALKABILITY; INCOME INEQUALITY; SOCIAL ECOLOGY; LEVEL ANALYSIS; ASSOCIATION; MORTALITY	Are people who live in more walkable areas healthier and more satisfied with life? This study investigates that question by using the 2005 Behavioral Risk Factors Surveillance System (BRFSS) survey, the largest telephone survey on health in the US (302,841 respondents from 989 metropolitan and micropolitan statistical areas [MSA]; 177,524 respondents from 703 MSAs had complete data). Using multilevel random coefficient modeling, we found that people living in walkable areas reported being generally healthier than people living in less walkable areas. In addition, aside from higher self-reported health, people living in walkable areas also had a lower body mass index (BMI). However, contrary to our prediction, people in more walkable areas were less satisfied with their lives than people in less walkable areas after controlling for various individual-level variables (age, gender, race, education, marital status, income, and unemployment). People who live in walkable areas are healthier but not happier than those living in less walkable areas.	[Oishi, Shigehiro; Axt, Jordan] Univ Virginia, Charlottesville, VA 22904 USA; [Saeki, Masao] Keio Univ, Tokyo 108, Japan	Oishi, S (reprint author), Univ Virginia, Dept Psychol, POB 400400, Charlottesville, VA 22904 USA.	soishi@virginia.edu					Calle EE, 1999, NEW ENGL J MED, V341, P1097, DOI 10.1056/NEJM199910073411501; Must A, 1999, JAMA-J AM MED ASSOC, V282, P1523, DOI 10.1001/jama.282.16.1523; Duncan DT, 2011, INT J ENV RES PUB HE, V8, P4160, DOI 10.3390/ijerph8114160; Diener E, 2013, J PERS SOC PSYCHOL, V104, P267, DOI 10.1037/a0030487; COSTA PT, 1987, J PERS, V55, P299, DOI 10.1111/j.1467-6494.1987.tb00438.x; Berke EM, 2007, J AM GERIATR SOC, V55, P526, DOI 10.1111/j.1532-5415.2007.01108.x; Troiano RP, 2008, MED SCI SPORT EXER, V40, P181, DOI 10.1249/mss.0b013e31815a51b3; Norman GJ, 2013, AM J HEALTH BEHAV, V37, P277, DOI 10.5993/AJHB.37.2.15; McGrath LJ, 2015, SPORTS MED, V45, P841, DOI 10.1007/s40279-015-0301-3; Flegal KM, 2013, JAMA-J AM MED ASSOC, V309, P71, DOI 10.1001/jama.2012.113905; Kawachi I, 1997, AM J PUBLIC HEALTH, V87, P1491, DOI 10.2105/AJPH.87.9.1491; Haselwandter EM, 2015, J AGING PHYS ACTIV, V23, P323, DOI 10.1123/japa.2013-0151; Sallis JF, 2009, SOC SCI MED, V68, P1285, DOI 10.1016/j.socscimed.2009.01.017; Patterson PK, 2004, AM J HEALTH PROMOT, V19, P45; Oishi S, 2012, PSYCHOL SCI, V23, P86, DOI 10.1177/0956797611420882; Christian H, 2015, HEALTH PLACE, V33, P25, DOI 10.1016/j.healthplace.2015.01.005; Carlson JA, 2015, HEALTH PLACE, V32, P1, DOI 10.1016/j.healthplace.2014.12.008; Diener E, 2003, ANNU REV PSYCHOL, V54, P403, DOI 10.1146/annurev.psych.54.101601.145056; STOKOLS D, 1992, AM PSYCHOL, V47, P6, DOI 10.1037/0003-066X.47.1.6; Oishi S, 2014, ANNU REV PSYCHOL, V65, P581, DOI 10.1146/annurev-psych-030413-152156; Powell KE, 2003, AM J PUBLIC HEALTH, V93, P1519, DOI 10.2105/AJPH.93.9.1519; Lucas RE, 2012, SOC INDIC RES, V105, P323, DOI 10.1007/s11205-011-9783-z; Sampson RJ, 1997, SCIENCE, V277, P918, DOI 10.1126/science.277.5328.918; Rogers SH, 2011, APPL RES QUAL LIFE, V6, P201, DOI 10.1007/s11482-010-9132-4; Lawless NM, 2011, SOC INDIC RES, V101, P341, DOI 10.1007/s11205-010-9667-7; Diener E, 1999, PSYCHOL BULL, V125, P276, DOI 10.1037/0033-2909.125.2.276; Carr LJ, 2011, BRIT J SPORT MED, V45, P1144, DOI 10.1136/bjsm.2009.069609; Stommel M, 2010, OBESITY, V18, P1821, DOI 10.1038/oby.2009.472; Leyden KM, 2003, AM J PUBLIC HEALTH, V93, P1546, DOI 10.2105/AJPH.93.9.1546; Hirsch JA, 2013, AM J PREV MED, V45, P158, DOI 10.1016/j.amepre.2013.03.018; Renalds A, 2010, FAM COMMUNITY HEALTH, V33, P68, DOI 10.1097/FCH.0b013e3181c4e2e5; Sallis JE, 2006, ANNU REV PUBL HEALTH, V27, P297, DOI 10.1146/annurev.publhealth.27.021405.102100; Oswald AJ, 2010, SCIENCE, V327, P576, DOI 10.1126/science.1180606; Helliwell JF, 2004, PHILOS T ROY SOC B, V359, P1435, DOI 10.1098/rstb.2004.1522; Steel P, 2008, PSYCHOL BULL, V134, P138, DOI 10.1037/0033-2909.134.1.138; Frank L D, 2010, Br J Sports Med, V44, P924, DOI 10.1136/bjsm.2009.058701; Maher JP, 2013, HEALTH PSYCHOL, V32, P647, DOI 10.1037/a0030129; Oishi S, 2011, PSYCHOL SCI, V22, P1095, DOI 10.1177/0956797611417262; Rentfrow PJ, 2009, J RES PERS, V43, P1073, DOI 10.1016/j.jrp.2009.08.005; Diener E, 2000, AM PSYCHOL, V55, P34, DOI 10.1037/0003-066X.55.1.34; Stevens J, 1998, NEW ENGL J MED, V338, P1, DOI 10.1056/NEJM199801013380101; OKUN MA, 1984, INT J AGING HUM DEV, V19, P111, DOI 10.2190/QGJN-0N81-5957-HAQD; DeSalvo KB, 2006, QUAL LIFE RES, V15, P191, DOI 10.1007/s11136-005-0887-2; Berke EM, 2007, AM J PUBLIC HEALTH, V97, P486, DOI 10.2105/AJPH.2006.085837; Lucas RE, 2004, PSYCHOL SCI, V15, P8, DOI 10.1111/j.0963-7214.2004.01501002.x; Oishi S, 2010, PERSPECT PSYCHOL SCI, V5, P356, DOI 10.1177/1745691610374588; Chetty R., 2014, WORKING PAPER; Ferdinand AO, 2012, RELATIONSHIP BUILT E, V102, P7, DOI DOI 10.2105/AJPH.2012; Lucas R. E., 2014, GEOGRAPHICAL PSYCHOL, P161; Luttmer EFP, 2005, Q J ECON, V120, P963, DOI 10.1162/003355305774268255; MICHALOS AC, 1985, SOC INDIC RES, V16, P347, DOI 10.1007/BF00333288; Oishi S., 2015, PSYCHOL DESIRE, P286; Oishi S., 2012, PSYCHOL WEALTH NATIO; Sallis JF, 2008, HLTH BEHAV HLTH ED T, V4, P465; Schwartz B, 2004, PARADOX CHOICE WHY M; Schwarz N., 1999, WELL BEING FDN HEDON, P61; Siedlecki K. L., 2008, J POSIT PSYCHOL, V<IT>3</IT>, P153, DOI DOI 10.1080/17439760701834602; Stiglitz J., 2009, REPORT COMMISSION ME; US Public Health Service Office of the Surgeon General, 1996, PHYS ACT HLTH REP SU; Zick CD, 2013, INT J BEHAV NUTR PHY, V10, DOI 10.1186/1479-5868-10-27	60	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1758-0846	1758-0854		APPL PSYCHOL-HLTH WE	Appl. Psychol.-Health Well Being	NOV	2015	7	3					365	386		10.1111/aphw.12058		22	Psychology, Applied	Psychology	CU4OM	WOS:000363509300006		
J	Fujiwara, M; Ishihara, H; Nemoto, T				Fujiwara, Makoto; Ishihara, Hajime; Nemoto, Takako			Some principles weaker than Markov's principle	ARCHIVE FOR MATHEMATICAL LOGIC			English	Article						Markov's principle; Disjunctive Markov's principle; Weak Markov's principle; Independence of premiss schema; Church's thesis		We systematically study several principles and give a principle which is weaker than disjunctive Markov's principle (MPa). We also show that the principle is underivable and strictly weaker than MPa in certain extensions of the system EL of elementary analysis.	[Fujiwara, Makoto; Ishihara, Hajime; Nemoto, Takako] Japan Adv Inst Sci & Technol, Sch Informat Sci, Nomi, Ishikawa 9231292, Japan	Ishihara, H (reprint author), Japan Adv Inst Sci & Technol, Sch Informat Sci, Nomi, Ishikawa 9231292, Japan.	ishihara@jaist.ac.jp			Japan Society for the Promotion of Science (JSPS)	The authors thank the Japan Society for the Promotion of Science (JSPS), Core-to-Core Program (A. Advanced Research Networks) for supporting the research. The first author has been supported by Grant-in-Aid for JSPS Fellows.	MANDELKERN M, 1988, Z MATH LOGIK, V34, P97, DOI 10.1002/malq.19880340202; ISHIHARA H, 1993, INDAGAT MATH NEW SER, V4, P321, DOI 10.1016/0019-3577(93)90005-J; Kohlenbach U, 2015, STUD LOGICA, V103, P1313, DOI 10.1007/s11225-015-9627-y; Kohlenbach U, 2008, SPRINGER MONOGR MATH, P1; Luckhardt H., 1977, ARCH MATH LOGIC, V18, P73, DOI 10.1007/BF02007259; Troelstra A.S., 1973, METAMATHEMATICAL INV; Troelstra A.S., 1988, CONSTRUCTIVISM MATH	7	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0933-5846	1432-0665		ARCH MATH LOGIC	Arch. Math. Log.	NOV	2015	54	7-8					861	870		10.1007/s00153-015-0444-9		10	Mathematics; Logic	Mathematics; Science & Technology - Other Topics	CU4XX	WOS:000363535900007		
J	Ohnuma, T; Anzai, E; Suzuki, Y; Shimoda, M; Saito, S; Nishiyama, T; Ogura, K; Hiratsuka, A				Ohnuma, Tomokazu; Anzai, Eri; Suzuki, Yohei; Shimoda, Mai; Saito, Shin; Nishiyama, Takahito; Ogura, Kenichiro; Hiratsuka, Akira			Selective antagonization of activated Nrf2 and inhibition of cancer cell proliferation by procyanidins from Cinnamomi Cortex extract	ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS			English	Article						Nrf2; Cinnamomi Cortex; Cancer cells; Antiproliferation; Procyanidin; Suppression	HUMAN BREAST-CANCER; HUMAN LUNG-CANCER; TUMOR-GROWTH; ANTICANCER DRUGS; KEAP1; EXPRESSION; PATHWAY; ANTIOXIDANT; MUTATIONS; INDUCTION	Nuclear factor-E2-related factor 2 (Nrf2) is an important transcription factor and plays a central role in inducible expression of many cytoprotective genes. Recent studies have reported that various cancer cells having unrestrained Nrf2 due to its overexpression exhibit increased proliferation and resistance to chemotherapy. Suppression of abnormal Nrf2 activation is needed for a new therapeutic approach against these cancers. Our previous study found that procyanidins prepared from Cinnamomi Cortex extract (CCE) have an ability to suppress Nrf2-regulated enzyme activity and Nrf2 expression in human lung cancer A549 cells. In the present study, we investigated the effect of CCE procyanidins on Nrf2 activity and cell proliferation in several cancer cells, which have normal or constitutively active Nrf2. Interestingly, CCE procyanidin treatment selectively reduced Nrf2 expression and inhibited cell proliferation in cancer cells that overexpress Nrf2, but these phenomena were not seen in cells with low Nrf2 expression. Moreover, transfection assay demonstrated that CCE procyanidins had selective inhibition of activated Nrf2. These results suggest that CCE procyanidins might be an effective cancer therapeutic agent to selectively suppress abnormal Nrf2 activation responsible for enhanced proliferation. (C) 2015 Elsevier Inc. All rights reserved.	[Ohnuma, Tomokazu; Anzai, Eri; Suzuki, Yohei; Shimoda, Mai; Saito, Shin; Nishiyama, Takahito; Ogura, Kenichiro; Hiratsuka, Akira] Tokyo Univ Pharm & Life Sci, Dept Drug Metab & Mol Toxicol, Sch Pharm, Hachioji, Tokyo 1920392, Japan	Hiratsuka, A (reprint author), Tokyo Univ Pharm & Life Sci, Dept Drug Metab & Mol Toxicol, Sch Pharm, 1432-1 Horinouchi, Hachioji, Tokyo 1920392, Japan.	hiratuka@toyaku.ac.jp					Takahashi T, 2010, J SURG ONCOL, V101, P500, DOI 10.1002/jso.21520; Shibata T, 2008, P NATL ACAD SCI USA, V105, P13568, DOI 10.1073/pnas.0806268105; Yanagida A, 2007, J CHROMATOGR A, V1143, P153, DOI 10.1016/j.chroma.2007.01.004; Chian S, 2014, BIOCHEM BIOPH RES CO, V447, P602, DOI 10.1016/j.bbrc.2014.04.039; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; CANCE WG, 1995, BREAST CANCER RES TR, V35, P105, DOI 10.1007/BF00694751; Ramljak D, 2005, MOL CANCER THER, V4, P537, DOI 10.1158/1535-7163.MCT-04-0286; Yang EB, 1997, CANCER J, V10, P319; McMahon M, 2006, J BIOL CHEM, V281, P24756, DOI 10.1074/jbc.M601119200; Homma S, 2009, CLIN CANCER RES, V15, P3423, DOI 10.1158/1078-0432.CCR-08-2822; Zhang P, 2010, MOL CANCER THER, V9, P336, DOI 10.1158/1535-7163.MCT-09-0589; Cao HP, 2007, ARCH BIOCHEM BIOPHYS, V459, P214, DOI 10.1016/j.abb.2006.12.034; Thimmulappa RK, 2002, CANCER RES, V62, P5196; Ohnuma T, 2009, ARCH BIOCHEM BIOPHYS, V488, P34, DOI 10.1016/j.abb.2009.06.006; Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046; Ohta T, 2008, CANCER RES, V68, P1303, DOI 10.1158/0008-5472.CAN-07-5003; Ohnuma T, 2011, BIOCHEM BIOPH RES CO, V413, P623, DOI 10.1016/j.bbrc.2011.09.014; Wang R, 2008, BIOCHEM BIOPH RES CO, V373, P151, DOI 10.1016/j.bbrc.2008.06.004; Mitsuishi Y, 2012, CANCER CELL, V22, P66, DOI 10.1016/j.ccr.2012.05.016; Kobayashi A, 2006, MOL CELL BIOL, V26, P221, DOI 10.1128/MCB.26.1.221-229.2006; Singh A, 2008, CANCER RES, V68, P7975, DOI 10.1158/0008-5472.CAN-08-1401; HAGERMAN AE, 1981, J BIOL CHEM, V256, P4494; Singh A, 2006, PLOS MED, V3, P1865, DOI 10.1371/journal.pmed.0030420	23	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0003-9861	1096-0384		ARCH BIOCHEM BIOPHYS	Arch. Biochem. Biophys.	NOV 1	2015	585						17	24		10.1016/j.abb.2015.09.007		8	Biochemistry & Molecular Biology; Biophysics	Biochemistry & Molecular Biology; Biophysics	CU2NR	WOS:000363360700003		
